PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Liu, BR; Lo, SY; Liu, CC; Chyan, CL; Huang, YW; Aronstam, RS; Lee, HJ				Liu, Betty R.; Lo, Shih-Yen; Liu, Chia-Chin; Chyan, Chia-Lin; Huang, Yue-Wern; Aronstam, Robert S.; Lee, Han-Jung			Endocytic Trafficking of Nanoparticles Delivered by Cell-penetrating Peptides Comprised of Nona-arginine and a Penetration Accelerating Sequence	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; QUANTUM DOTS; INTRACELLULAR DELIVERY; PROTEIN TRANSDUCTION; RICH PEPTIDES; PLASMA-MEMBRANE; GENE; INTERNALIZATION; TRANSPORT; SYSTEM	Cell-penetrating peptides (CPPs) can traverse cellular membranes and deliver biologically active molecules into cells. In this study, we demonstrate that CPPs comprised of nona-arginine (R9) and a penetration accelerating peptide sequence (Pas) that facilitates escape from endocytic lysosomes, denoted as PR9, greatly enhance the delivery of noncovalently associated quantum dots (QDs) into human A549 cells. Mechanistic studies, intracellular trafficking analysis and a functional gene assay reveal that endocytosis is the main route for intracellular delivery of PR9/QD complexes. Endocytic trafficking of PR9/QD complexes was monitored using both confocal and transmission electron microscopy (TEM). Zeta-potential and size analyses indicate the importance of electrostatic forces in the interaction of PR9/QD complexes with plasma membranes. Circular dichroism (CD) spectroscopy reveals that the secondary structural elements of PR9 have similar conformations in aqueous buffer at pH 7 and 5. This study of nontoxic PR9 provides a basis for the design of optimized cargo delivery that allows escape from endocytic vesicles.	[Liu, Betty R.; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien, Taiwan; [Lo, Shih-Yen] Tzu Chi Univ, Dept Lab Med & Biotechnol, Hualien, Taiwan; [Liu, Chia-Chin] Tzu Chi Univ, Dept Life Sci, Hualien, Taiwan; [Chyan, Chia-Lin] Natl Dong Hwa Univ, Dept Chem, Hualien, Taiwan; [Huang, Yue-Wern; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO USA	National Dong Hwa University; Tzu Chi University; Tzu Chi University; National Dong Hwa University; University of Missouri System; Missouri University of Science & Technology	Lee, HJ (corresponding author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien, Taiwan.	hjlee@mail.ndhu.edu.tw	Liu, Betty Revon/GLU-3300-2022	Liu, Betty Revon/0000-0002-5152-8687	National Science Council of Taiwan [NSC 101-2811-B-259-001, NSC 101-2320-B-259-002-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by the Postdoctoral Fellowship NSC 101-2811-B-259-001 (to BRL) and the Grant Number NSC 101-2320-B-259-002-MY3 from the National Science Council of Taiwan (HJL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamczyk Z, 2011, ADV COLLOID INTERFAC, V168, P3, DOI 10.1016/j.cis.2011.04.002; [Anonymous], 2013, ADV STUD BIOL; Chan M. H., 2013, PHARM NANOTECHNOL, V1, P151; Chang JC, 2009, BIOMATERIALS, V30, P1937, DOI 10.1016/j.biomaterials.2008.12.039; Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x; Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q; Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060; Choi Y, 2011, BIOCONJUGATE CHEM, V22, P1576, DOI 10.1021/bc200126k; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011; Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4; Depalo N, 2008, J COLLOID INTERF SCI, V325, P558, DOI 10.1016/j.jcis.2008.06.018; Doane TL, 2012, ACCOUNTS CHEM RES, V45, P317, DOI 10.1021/ar200113c; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; Fonseca SB, 2009, ADV DRUG DELIVER REV, V61, P953, DOI 10.1016/j.addr.2009.06.001; Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808; Gautam A, 2012, DATABASE-OXFORD, DOI 10.1093/database/bas015; Gauthier NC, 2005, MOL BIOL CELL, V16, P4852, DOI 10.1091/mbc.E05-05-0398; Gauthier NC, 2007, J CELL BIOL, V177, P343, DOI 10.1083/jcb.200609061; Hirose H, 2012, MOL THER, V20, P984, DOI 10.1038/mt.2011.313; Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006; Huang Yue-Wern, 2013, Methods Mol Biol, V991, P249, DOI 10.1007/978-1-62703-336-7_23; Irene D, 2013, J BIOMOL STRUCT DYN, V31, P414, DOI 10.1080/07391102.2012.703069; Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Koren E, 2012, TRENDS MOL MED, V18, P385, DOI 10.1016/j.molmed.2012.04.012; Koshman YE, 2008, J MOL CELL CARDIOL, V45, P853, DOI 10.1016/j.yjmcc.2008.08.006; Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w; Lee CY, 2011, BIOMATERIALS, V32, P6264, DOI 10.1016/j.biomaterials.2011.05.012; Lei Y, 2008, BIOCONJUGATE CHEM, V19, P421, DOI 10.1021/bc0700685; Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019; Liu BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064205; Liu BR, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-57; Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041; Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012; Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637; Liu BR, 2013, MAR BIOTECHNOL, V15, P584, DOI 10.1007/s10126-013-9509-0; Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053; LIU MJ, 2013, ADV STUD BIOL, V5, P71; Madani Fatemeh, 2011, J Biophys, V2011, P414729, DOI 10.1155/2011/414729; Mattoussi H, 2012, ADV DRUG DELIVER REV, V64, P138, DOI 10.1016/j.addr.2011.09.011; MEGO JL, 1971, BIOCHEM J, V122, P445, DOI 10.1042/bj1220445; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Nakase I, 2010, BIOPOLYMERS, V94, P763, DOI 10.1002/bip.21487; Padari K, 2011, METHODS MOL BIOL, V683, P181, DOI 10.1007/978-1-60761-919-2_13; Perevedentseva E, 2011, LANGMUIR, V27, P1085, DOI 10.1021/la103155c; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Raagel H, 2010, BBA-BIOMEMBRANES, V1798, P2240, DOI 10.1016/j.bbamem.2010.02.013; Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046; Shu SJ, 2009, CARBOHYD RES, V344, P1197, DOI 10.1016/j.carres.2009.04.018; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; Takayama K, 2012, MOL PHARMACEUT, V9, P1222, DOI 10.1021/mp200518n; Takayama K, 2009, J CONTROL RELEASE, V138, P128, DOI 10.1016/j.jconrel.2009.05.019; Takechi Y, 2011, LANGMUIR, V27, P7099, DOI 10.1021/la200917y; Ueda Y, 2012, BIOMATERIALS, V33, P9061, DOI 10.1016/j.biomaterials.2012.09.003; van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871; Walrant A, 2011, BBA-BIOMEMBRANES, V1808, P382, DOI 10.1016/j.bbamem.2010.09.009; Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205; Webster A, 2005, ANALYST, V130, P163, DOI 10.1039/b413725f; Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777; Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543; Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2; Yang S, 2009, J CONTROL RELEASE, V135, P159, DOI 10.1016/j.jconrel.2008.12.015; Yasuda Y, 1999, J BIOCHEM-TOKYO, V125, P1137, DOI 10.1093/oxfordjournals.jbchem.a022396; Yukawa H, 2010, BIOMATERIALS, V31, P4094, DOI 10.1016/j.biomaterials.2010.01.134	69	50	56	1	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2013	8	6							e67100	10.1371/journal.pone.0067100	http://dx.doi.org/10.1371/journal.pone.0067100			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	178DN	23840594	gold, Green Published, Green Submitted			2023-01-03	WOS:000321424400071
J	Davies, E				Davies, Edward			ASSISTED DYING Assisted dying: what happens after Vermont?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material								\				edavies@bmj.com						[Anonymous], 2012, BOSTON GLOBE; Canadian Press, 2012, NATIONAL POST   0613; Giglio C., 2013, LIFENEWS; Gram D, 2013, BURLINGTON FREE PRES; Johnson K., 2009, NY TIMES; Leffler SM, 2013, PATIENT CHOICE END L; McCarthy M, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3210; Montana Legislature, 2013, DET BILL INF; State of Connecticut, 2013, ACT DEATH DIGN; Turner D, 2012, LA TIMES        1106	10	1	1	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 24	2013	346								f4041	10.1136/bmj.f4041	http://dx.doi.org/10.1136/bmj.f4041			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175QH	23798734				2023-01-03	WOS:000321245800005
J	Wild, AT; Gandhi, N; Chettiar, ST; Aziz, K; Gajula, RP; Williams, RD; Kumar, R; Taparra, K; Zeng, J; Cades, JA; Velarde, E; Menon, S; Geschwind, JF; Cosgrove, D; Pawlik, TM; Maitra, A; Wong, J; Hales, RK; Torbenson, MS; Herman, JM; Tran, PT				Wild, Aaron T.; Gandhi, Nishant; Chettiar, Sivarajan T.; Aziz, Khaled; Gajula, Rajendra P.; Williams, Russell D.; Kumar, Rachit; Taparra, Kekoa; Zeng, Jing; Cades, Jessica A.; Velarde, Esteban; Menon, Siddharth; Geschwind, Jean F.; Cosgrove, David; Pawlik, Timothy M.; Maitra, Anirban; Wong, John; Hales, Russell K.; Torbenson, Michael S.; Herman, Joseph M.; Tran, Phuoc T.			Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma	PLOS ONE			English	Article							PHASE-II; TRANSARTERIAL CHEMOEMBOLIZATION; RAF/MEK/ERK PATHWAY; TUMOR PROGRESSION; UNITED-STATES; RAF KINASE; GROWTH; BAY-43-9006; INHIBITOR; ANGIOGENESIS	Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC). However, SOR prolongs survival by less than 3 months and does not alter symptomatic progression. To improve outcomes, several phase I-II trials are currently examining SOR with radiation (RT) for HCC utilizing heterogeneous concurrent and sequential treatment regimens. Our study provides preclinical data characterizing the effects of concurrent versus sequential RT-SOR on HCC cells both in vitro and in vivo. Concurrent and sequential RT-SOR regimens were tested for efficacy among 4 HCC cell lines in vitro by assessment of clonogenic survival, apoptosis, cell cycle distribution, and gamma-H2AX foci formation. Results were confirmed in vivo by evaluating tumor growth delay and performing immunofluorescence staining in a hind-flank xenograft model. In vitro, concurrent RT-SOR produced radioprotection in 3 of 4 cell lines, whereas sequential RT-SOR produced decreased colony formation among all 4. Sequential RT-SOR increased apoptosis compared to RT alone, while concurrent RT-SOR did not. Sorafenib induced reassortment into less radiosensitive phases of the cell cycle through G(1)-S delay and cell cycle slowing. More double-strand breaks (DSBs) persisted 24 h post-irradiation for RT alone versus concurrent RT-SOR. In vivo, sequential RT-SOR produced the greatest tumor growth delay, while concurrent RT-SOR was similar to RT alone. More persistent DSBs were observed in xenografts treated with sequential RT-SOR or RT alone versus concurrent RT-SOR. Sequential RT-SOR additionally produced a greater reduction in xenograft tumor vascularity and mitotic index than either concurrent RT-SOR or RT alone. In conclusion, sequential RT-SOR demonstrates greater efficacy against HCC than concurrent RT-SOR both in vitro and in vivo. These results may have implications for clinical decision-making and prospective trial design.	[Wild, Aaron T.; Gandhi, Nishant; Chettiar, Sivarajan T.; Aziz, Khaled; Gajula, Rajendra P.; Williams, Russell D.; Kumar, Rachit; Taparra, Kekoa; Zeng, Jing; Velarde, Esteban; Menon, Siddharth; Wong, John; Hales, Russell K.; Herman, Joseph M.; Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA; [Cades, Jessica A.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Geschwind, Jean F.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; [Cosgrove, David; Herman, Joseph M.; Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21205 USA; [Pawlik, Timothy M.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Maitra, Anirban; Torbenson, Michael S.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Tran, Phuoc T.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Herman, JM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA.	jherma15@jhmi.edu; tranp@jhmi.edu	Pawlik, Timothy/AAO-9335-2020; Chettiar, Sivarajan T/K-2766-2014; Aziz, Khaled/AAZ-7061-2021; Tran, Phuoc/W-2084-2019	Chettiar, Sivarajan T/0000-0002-6864-7308; Tran, Phuoc/0000-0002-0147-0376; Taparra, Kekoa/0000-0001-8493-3868	RSNA Research Medical Student Grant; National Institutes of Health (NIH) [1R01CA158100, P30 CA006973]; ASTRO; Parker B. Francis Fellowship; Phyllis and Brian L. Harvey Scholar Award from the Patrick C. Walsh Cancer Research Fund; DoD [W81XWH-11-1-0272]; NATIONAL CANCER INSTITUTE [P50CA103175, T32CA121937, R01CA158100, P30CA006973] Funding Source: NIH RePORTER	RSNA Research Medical Student Grant; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ASTRO; Parker B. Francis Fellowship; Phyllis and Brian L. Harvey Scholar Award from the Patrick C. Walsh Cancer Research Fund; DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	AT Wild was funded by an RSNA Research Medical Student Grant (https://www.rsna.org/Research_Medical_Student_Grant.aspx). RD Williams was a Johns Hopkins Laboratory Radiation Oncology Training Fellow (NIH-T32CA121937) (http://www.nih.gov/). J Wong was funded by the National Institutes of Health (NIH) (1R01CA158100) (http://www.nih.gov/). PT Tran was funded by an ASTRO Junior Faculty Career Research Training Award (https://www.astro.org/Research/Funding-Opportunities/ASTRO-Supported-Grants/Junior-Faculty/Index.aspx), Parker B. Francis Fellowship (http://www.francisfellowships.org/), the Phyllis and Brian L. Harvey Scholar Award from the Patrick C. Walsh Cancer Research Fund (http://prostatecancerprogram.onc.jhmi.edu/PCW/) and a DoD Cancer Physician Research Training Award (W81XWH-11-1-0272) (http://www.grants.gov/search/search.do?mode = VIEW&oppId = 88953). The Sidney Kimmel Comprehensive Cancer Center was funded by the NIH (P30 CA006973) (http://www.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Alfa GK, 2010, JAMA-J AM MED ASSOC, V304, P2154, DOI 10.1001/jama.2010.1672; ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; Armstrong GL, 2006, ANN INTERN MED, V144, P705, DOI 10.7326/0003-4819-144-10-200605160-00004; Biade S, 1997, RADIAT RES, V147, P416, DOI 10.2307/3579497; Cao ZW, 2011, CANCER RES, V71, P2286, DOI 10.1158/0008-5472.CAN-10-3367; Chang YS, 2007, CANCER CHEMOTH PHARM, V59, P561, DOI 10.1007/s00280-006-0393-4; Chen HH, 2011, RADIAT RES, V175, P214, DOI 10.1667/RR2323.1; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Choi BI, 2010, J HEPATO-BIL-PAN SCI, V17, P369, DOI 10.1007/s00534-009-0227-y; Clark JW, 2005, CLIN CANCER RES, V11, P5472, DOI 10.1158/1078-0432.CCR-04-2658; Degos F, 2000, GUT, V47, P131, DOI 10.1136/gut.47.1.131; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; FERTIL B, 1984, RADIAT RES, V99, P73, DOI 10.2307/3576448; GERDES J, 1985, INT J CANCER, V35, P169, DOI 10.1002/ijc.2910350205; Heim M, 2005, ANTI-CANCER DRUG, V16, P129, DOI 10.1097/00001813-200502000-00003; Hill AA, 1999, INT J RADIAT BIOL, V75, P1395, DOI 10.1080/095530099139269; Hsu CH, 2010, J HEPATOL, V53, P126, DOI 10.1016/j.jhep.2010.01.035; Huynh H, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-19; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim S, 2007, MOL CANCER THER, V6, P1785, DOI 10.1158/1535-7163.MCT-06-0595; Li QQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-485; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; London WT, 2006, CANC EPIDEMIOLOGY PR, P763, DOI DOI 10.1093/ACPROF:OSO/9780195149616.003.0039; Milas L, 2000, CLIN CANCER RES, V6, P701; Morgan MA, 2008, CLIN CANCER RES, V14, P5142, DOI 10.1158/1078-0432.CCR-07-4072; Murphy DA, 2006, AM J PATHOL, V169, P1875, DOI 10.2353/ajpath.2006.050711; Park JW, 2012, J HEPATOL, V56, P1336, DOI 10.1016/j.jhep.2012.01.006; Pawlik TM, 2011, J CLIN ONCOL, V29, P3960, DOI 10.1200/JCO.2011.37.1021; Petrini I, 2012, CANCER CHEMOTH PHARM, V69, P773, DOI 10.1007/s00280-011-1753-2; Plastaras JP, 2007, CANCER RES, V67, P9443, DOI 10.1158/0008-5472.CAN-07-1473; Plaza-Menacho I, 2007, J BIOL CHEM, V282, P29230, DOI 10.1074/jbc.M703461200; Qu XD, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-263; Rynn L., 2008, Morbidity and Mortality Weekly Report, V57, P1; Sanoff Hanna K, 2011, Gastrointest Cancer Res, V4, P78; Stobbe CC, 2002, INT J RADIAT BIOL, V78, P1149, DOI 10.1080/09553000210166570; Sugimoto K, 2012, EUR RADIOL, V22, P1205, DOI 10.1007/s00330-011-2372-3; Surveillance Epidemiology and End Results (SEER) Program, SEER STAT DAT INC SE; TERASIMA T, 1963, SCIENCE, V140, P490, DOI 10.1126/science.140.3566.490; TERASIMA T, 1961, NATURE, V190, P1210, DOI 10.1038/1901210a0; Wilhelm SM, 2008, MOL CANCER THER, V7, P3129, DOI 10.1158/1535-7163.MCT-08-0013; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Wong J, 2008, INT J RADIAT ONCOL, V71, P1591, DOI 10.1016/j.ijrobp.2008.04.025; Xie BR, 2012, DIGEST DIS SCI, V57, P1122, DOI 10.1007/s10620-012-2136-1; Zaidi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035436	46	31	32	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2013	8	6							e65726	10.1371/journal.pone.0065726	http://dx.doi.org/10.1371/journal.pone.0065726			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173SK	23762417	Green Published, gold, Green Submitted			2023-01-03	WOS:000321099000098
J	Rosenau, AM				Rosenau, Alex M.			Guidelines for Opioid Prescription: The Devil Is in the Details	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Lehigh Valley Hlth Network, Allentown, PA 18103 USA	Lehigh Valley Health Network	Rosenau, AM (corresponding author), Lehigh Valley Hlth Network, JDMCC 214,I-78 & Cedar Crest Blvd, Allentown, PA 18103 USA.	alex.rosenau@gmail.com						American College of Emergency Physicians, 2013, POL COMP EL PRESCR M; American College of Emergency Physicians, 2013, POL COMP OPT TREATM; American College of Emergency Physicians, 2013, POL COMP EM PHYS RIG; Benard A, 2013, AM MED ASS STAT LEG; Cantrill SV, 2012, ANN EMERG MED, V60, P499, DOI 10.1016/j.annemergmed.2012.06.013; Chu J, 2013, NEW YORK CITY EMERGE; Governale L., 2010, JOINT M AN LIF SUPP; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Warner Margaret, 2011, NCHS Data Brief, P1	9	6	6	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2013	158	11					843	+		10.7326/0003-4819-158-11-201306040-00632	http://dx.doi.org/10.7326/0003-4819-158-11-201306040-00632			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164AA	23567867				2023-01-03	WOS:000320379800009
J	Sinnott, SJ; Buckley, C; O'Riordan, D; Bradley, C; Whelton, H				Sinnott, Sarah-Jo; Buckley, Claire; O'Riordan, David; Bradley, Colin; Whelton, Helen			The Effect of Copayments for Prescriptions on Adherence to Prescription Medicines in Publicly Insured Populations; A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							D COVERAGE GAP; MEDICATION ADHERENCE; CO-PAYMENT; VULNERABLE POPULATIONS; HEALTH-STATUS; DRUG-THERAPY; IMPACT; PERSISTENCE; COSTS; POOR	Introduction: Copayments are intended to decrease third party expenditure on pharmaceuticals, particularly those regarded as less essential. However, copayments are associated with decreased use of all medicines. Publicly insured populations encompass some vulnerable patient groups such as older individuals and low income groups, who may be especially susceptible to medication non-adherence when required to pay. Non-adherence has potential consequences of increased morbidity and costs elsewhere in the system. Objective: To quantify the risk of non-adherence to prescribed medicines in publicly insured populations exposed to copayments. Methods: The population of interest consisted of cohorts who received public health insurance. The intervention was the introduction of, or an increase, in copayment. The outcome was non-adherence to medications, evaluated using objective measures. Eight electronic databases and the grey literature were systematically searched for relevant articles, along with hand searches of references in review articles and the included studies. Studies were quality appraised using modified EPOC and EHPPH checklists. A random effects model was used to generate the meta-analysis in RevMan v5.1. Statistical heterogeneity was assessed using the I-2 test; p>0.1 indicated a lack of heterogeneity. Results: Seven out of 41 studies met the inclusion criteria. Five studies contributed more than 1 result to the meta-analysis. The meta-analysis included 199, 996 people overall; 74, 236 people in the copayment group and 125,760 people in the non-copayment group. Average age was 71.75years. In the copayment group, (verses the non-copayment group), the odds ratio for non-adherence was 1.11 (95% CI 1.09-1.14; P = <0.00001). An acceptable level of heterogeneity at I-2 = 7%, (p = 0.37) was observed. Conclusion: This meta-analysis showed an 11% increased odds of non-adherence to medicines in publicly insured populations where copayments for medicines are necessary. Policy-makers should be wary of potential negative clinical outcomes resulting from non-adherence, and also possible knock-on economic repercussions.	[Sinnott, Sarah-Jo; O'Riordan, David] Natl Univ Ireland Univ Coll Cork, Dept Epidemiol & Publ Hlth, Cork, Ireland; [Buckley, Claire; Bradley, Colin] Natl Univ Ireland Univ Coll Cork, Dept Gen Practice, Cork, Ireland; [Whelton, Helen] Natl Univ Ireland Univ Coll Cork, Sch Dent, Oral Hlth Serv Res Ctr, Cork, Ireland	University College Cork; University College Cork; University College Cork	Sinnott, SJ (corresponding author), Natl Univ Ireland Univ Coll Cork, Dept Epidemiol & Publ Hlth, Cork, Ireland.	s.sinnott@ucc.ie			Health Research Board in Ireland [PHD/2007/16]	Health Research Board in Ireland	This work was funded by the Health Research Board in Ireland under Grant No. PHD/2007/16. (http://www.hrb.ie/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams AS, 2001, ANNU REV PUBL HEALTH, V22, P49, DOI 10.1146/annurev.publhealth.22.1.49; Andrade SE, 2006, PHARMACOEPIDEM DR S, V15, P565, DOI 10.1002/pds.1230; [Anonymous], 1977, WHO TECHN REP SER; Atella V, 2006, HEALTH ECON, V15, P875, DOI 10.1002/hec.1135; Austvoll-Dahlgren A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007017; Balkrishnan R, 2003, CLIN THER, V25, P2958, DOI 10.1016/S0149-2918(03)80347-8; Barry M, 2010, EXPERT REV PHARM OUT, V10, P239, DOI [10.1586/erp.10.23, 10.1586/ERP.10.23]; BRIAN EW, 1974, MED CARE, V12, P1; Bryson CL, 2007, MED CARE, V45, P497, DOI 10.1097/MLR.0b013e3180329368; Cherry SB, 2009, VALUE HEALTH, V12, P489, DOI 10.1111/j.1524-4733.2008.00447.x; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Cohen J, 2012, POPUL HEALTH MANAG, V15, P20, DOI 10.1089/pop.2011.0020; Cramer JA, 2008, VALUE HEALTH, V11, P44, DOI 10.1111/j.1524-4733.2007.00213.x; Doshi JA, 2009, CIRCULATION, V119, P390, DOI 10.1161/CIRCULATIONAHA.108.783944; Eaddy Michael T, 2012, P T, V37, P45; Farley JF, 2010, MED CARE, V48, P440, DOI 10.1097/MLR.0b013e3181d502bd; Fau Jha Ak, 2012, HLTH AFFAIRS PROJECT; Flaskerud JH, 1998, NURS RES, V47, P69, DOI 10.1097/00006199-199803000-00005; Fung V, 2010, HEALTH SERV RES, V45, P355, DOI 10.1111/j.1475-6773.2009.01071.x; Gemmill MC, 2008, INT J EQUITY HEALTH, V7, DOI 10.1186/1475-9276-7-12; Gibson TB, 2005, AM J MANAG CARE, V11, P730; Gilmer TP, 1997, DIABETES CARE, V20, P1847, DOI 10.2337/diacare.20.12.1847; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Gu QA, 2010, AM J MANAG CARE, V16, P911; HARRIS BL, 1990, MED CARE, V28, P907, DOI 10.1097/00005650-199010000-00005; Haynes R. B., 1979, COMPLIANCE HLTH CARE; Hess LM, 2006, ANN PHARMACOTHER, V40, P1280, DOI 10.1345/aph.1H018; Hill MN, 2010, J CLIN HYPERTENS, V12, P757, DOI 10.1111/j.1751-7176.2010.00356.x; Ho PM, 2006, ARCH INTERN MED, V166, P1836, DOI 10.1001/archinte.166.17.1836; Hynd A, 2008, PHARMACOEPIDEM DR S, V17, P1091, DOI 10.1002/pds.1670; Hynd A, 2009, AUST NZ J PUBL HEAL, V33, P246, DOI 10.1111/j.1753-6405.2009.00383.x; Jha AK, 2012, HEALTH AFFAIR, V31, P1836, DOI 10.1377/hlthaff.2011.1198; Karve S, 2009, CURR MED RES OPIN, V25, P2303, DOI 10.1185/03007990903126833; Karve S, 2009, VALUE HEALTH, V12, P989, DOI 10.1111/j.1524-4733.2009.00543.x; Lee IH, 2012, HEALTH POLICY, V104, P40, DOI 10.1016/j.healthpol.2011.09.003; Lexchin J, 2004, INT J HEALTH SERV, V34, P101, DOI 10.2190/4M3E-L0YF-W1TD-EKG0; Li P, 2012, ANN INTERNAL MED, V156, pW; Li P, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4773183; Li PX, 2012, ANN INTERN MED, V156, P776, DOI 10.7326/0003-4819-156-11-201206050-00004; Maciejewski ML, 2010, AM J MANAG CARE, V16, pE20; MCCOMBS JS, 1994, MED CARE, V32, P214, DOI 10.1097/00005650-199403000-00003; McManus P, 1996, Pharmacoepidemiol Drug Saf, V5, P385, DOI 10.1002/(SICI)1099-1557(199611)5:6<385::AID-PDS246>3.0.CO;2-8; McPake B., 2020, HLTH EC INT PERSPECT, VFourth; Metge C, 1999, MED CARE, V37, pJS42, DOI 10.1097/00005650-199906001-00008; OECD, 2011, HLTH GLANC 2011 OECD; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Peters J, 2008, EVAL HEALTH PROF, V31, P370, DOI 10.1177/0163278708324438; Polinski JM, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001075; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; Repetto L, 2006, J CLIN ONCOL, V24, pE62, DOI 10.1200/JCO.2006.09.3039; Review Manager (RevMan). [Computer program], 2011, REV MAN REVMAN COMP; Rice T, 2004, MED CARE RES REV, V61, P415, DOI 10.1177/1077558704269498; Schneeweiss S, 2007, AM J MANAG CARE, V13, P445; Schneeweiss S, 2007, CIRCULATION, V115, P2128, DOI 10.1161/CIRCULATIONAHA.106.665992; Smith D G, 1992, Pharmacoeconomics, V2, P335, DOI 10.2165/00019053-199202040-00008; Sokol MC, 2005, MED CARE, V43, P521, DOI 10.1097/01.mlr.0000163641.86870.af; Soumerai S, 1994, NEW ENGLAND J MED, V331; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Stuart B, 2011, HEALTH SERV RES, V46, P1180, DOI 10.1111/j.1475-6773.2011.01250.x; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Vrijens B, 2008, BMJ-BRIT MED J, V336, P1114, DOI 10.1136/bmj.39553.670231.25; Wang CZ, 2012, ANN INTERN MED, V156, P166, DOI 10.7326/0003-4819-156-2-201201170-00018; Wang V, 2011, HEALTH SERV RES, V46, P1963, DOI 10.1111/j.1475-6773.2011.01286.x; World Health Organization, 2020, TOP 10 CAUS DEATH	65	89	90	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e64914	10.1371/journal.pone.0064914	http://dx.doi.org/10.1371/journal.pone.0064914			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	155FM	23724105	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000319733000104
J	Zoerner, F; Wiklund, L; Miclescu, A; Martijn, C				Zoerner, Frank; Wiklund, Lars; Miclescu, Adriana; Martijn, Cecile			Therapeutic Hypothermia Activates the Endothelin and Nitric Oxide Systems after Cardiac Arrest in a Pig Model of Cardiopulmonary Resuscitation	PLOS ONE			English	Article							INTERNATIONAL LIAISON COMMITTEE; METHYLENE-BLUE; FREE-RADICALS; REPERFUSION; CARDIOMYOCYTES; DYSFUNCTION; EXPRESSION; STATEMENT; SURVIVAL; SYNTHASE	Post-cardiac arrest myocardial dysfunction is a major cause of mortality in patients receiving successful cardiopulmonary resuscitation (CPR). Mild therapeutic hypothermia (MTH) is the recommended treatment after resuscitation from cardiac arrest (CA) and is known to exert neuroprotective effects and improve short-term survival. Yet its cytoprotective mechanisms are not fully understood. In this study, our aim was to determine the possible effect of MTH on vasoactive mediators belonging to the endothelin/ nitric oxide axis in our porcine model of CA and CPR. Pigs underwent either untreated CA or CA with subsequent CPR. After state-of-the-art resuscitation, the animals were either left untreated, cooled between 32-34 degrees C after ROSC or treated with a bolus injection of S-PBN (sodium 4-[(tert-butylimino) methyl]benzene-3-sulfonate N-oxide) until 180 min after ROSC, respectively. The expression of endothelin 1 (ET-1), endothelin converting enzyme 1 (ECE-1), and endothelin A and B receptors (ETAR and ETBR) transcripts were measured using quantitative real-time PCR while protein levels for the ETAR, ETBR and nitric oxide synthases (NOS) were assessed using immunohistochemistry and Western Blot. Our results indicated that the endothelin system was not upregulated at 30, 60 and 180 min after ROSC in untreated postcardiac arrest syndrome. Post-resuscitative 3 hour-long treatments either with MTH or S-PBN stimulated ET-1, ECE-1, ETAR and ETBR as well as neuronal NOS and endothelial NOS in left ventricular cardiomyocytes. Our data suggests that the endothelin and nitric oxide pathways are activated by MTH in the heart.	[Zoerner, Frank; Wiklund, Lars; Miclescu, Adriana; Martijn, Cecile] Uppsala Univ, Dept Surg Sci Anesthesiol & Intens Care, Uppsala, Sweden; [Zoerner, Frank] Hallands Hosp Halmstad, Dept Operat & Intens Care Med, Halmstad, Sweden; [Martijn, Cecile] Sci Life Lab, Uppsala, Sweden; [Martijn, Cecile] Uppsala Univ, Dept Chem BMC, Uppsala, Sweden	Uppsala University; Uppsala University	Martijn, C (corresponding author), Uppsala Univ, Dept Surg Sci Anesthesiol & Intens Care, Uppsala, Sweden.	cecile.martijn@surgsci.uu.se		Zoerner, Frank/0000-0001-9610-1225	Laerdal Foundation for Acute Medicine	Laerdal Foundation for Acute Medicine	Financial support was provided by the Laerdal Foundation for Acute Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beiser DG, 2011, RESUSCITATION, V82, P115, DOI 10.1016/j.resuscitation.2010.08.038; Burkard N, 2010, CIRCULATION, V122, P1588, DOI 10.1161/CIRCULATIONAHA.109.933630; Chalkias A, 2012, HEART FAIL REV, V17, P117, DOI 10.1007/s10741-011-9255-1; Forni M, 2005, REGUL PEPTIDES, V131, P89, DOI 10.1016/j.regpep.2005.07.001; HAYNES WG, 1994, RESUSCITATION, V27, P117, DOI 10.1016/0300-9572(94)90003-5; HEARSE DJ, 1987, CIRC RES, V60, P375, DOI 10.1161/01.RES.60.3.375; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; Kolettis TM, 2011, HYPERTENS RES, V34, P170, DOI 10.1038/hr.2010.215; Lindner KH, 1996, HEART, V75, P145, DOI 10.1136/hrt.75.2.145; Liu XL, 2003, ACTA ANAESTH SCAND, V47, P958, DOI 10.1034/j.1399-6576.2003.00189.x; Massion PB, 2003, J PHYSIOL-LONDON, V546, P63, DOI 10.1113/jphysiol.2002.025973; Meybohm P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007588; Miclescu A, 2007, RESUSCITATION, V75, P88, DOI 10.1016/j.resuscitation.2007.03.014; Miclescu A, 2010, CRIT CARE MED, V38, P2199, DOI 10.1097/CCM.0b013e3181f26b0c; MOLENAAR P, 1993, CIRC RES, V72, P526, DOI 10.1161/01.RES.72.3.526; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Oikonomidis DL, 2010, J INTERV CARD ELECTR, V28, P157, DOI 10.1007/s10840-010-9493-5; Rapoport RM, 2011, J PHARM PHARMACOL, V63, P1373, DOI 10.1111/j.2042-7158.2011.01334.x; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Seddon M, 2007, CARDIOVASC RES, V75, P315, DOI 10.1016/j.cardiores.2007.04.031; SHARMA HS, 1990, ACT NEUR S, V51, P383; Tawa M, 2011, J CARDIOVASC PHARM, V57, P575, DOI 10.1097/FJC.0b013e31821325ad; TONNESSEN T, 1995, CIRC RES, V76, P767; Vrbjar N, 1998, MOL CELL BIOCHEM, V186, P107, DOI 10.1023/A:1006875515357; Wainwright Cherry L., 2005, Current Vascular Pharmacology, V3, P333, DOI 10.2174/157016105774329417; Walters JH, 2011, RESUSCITATION, V82, P508, DOI 10.1016/j.resuscitation.2011.01.021; Wiklund L, 2005, ANN NY ACAD SCI, V1053, P205, DOI 10.1196/annals.1344.019; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yamamoto S, 2005, CIRCULATION, V111, P302, DOI 10.1161/01.CIR.0000153351.86708.F7; Zhao XS, 2006, CIRCULATION, V114, P830, DOI 10.1161/CIRCULATIONAHA.105.577288	31	10	15	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2013	8	5							e64792	10.1371/journal.pone.0064792	http://dx.doi.org/10.1371/journal.pone.0064792			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151BM	23717659	gold, Green Submitted, Green Published			2023-01-03	WOS:000319435600076
J	Brew, N; Hooper, SB; Zahra, V; Wallace, M; Harding, R				Brew, Nadine; Hooper, Stuart B.; Zahra, Valerie; Wallace, Megan; Harding, Richard			Mechanical Ventilation Injury and Repair in Extremely and Very Preterm Lungs	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; BRONCHOPULMONARY DYSPLASIA; PREMATURE-INFANTS; METALLOTHIONEIN; EXPRESSION; CYTOKINES; EXPOSURE; ELASTIN; INFLAMMATION; MATURATION	Background: Extremely preterm infants often receive mechanical ventilation (MV), which can contribute to bronchopulmonary dysplasia (BPD). However, the effects of MV alone on the extremely preterm lung and the lung's capacity for repair are poorly understood. Aim: To characterise lung injury induced by MV alone, and mechanisms of injury and repair, in extremely preterm lungs and to compare them with very preterm lungs. Methods: Extremely preterm lambs (0.75 of term) were transiently exposed by hysterotomy and underwent 2 h of injurious MV. Lungs were collected 24 h and at 15 d after MV. Immunohistochemistry and morphometry were used to characterise injury and repair processes. qRT-PCR was performed on extremely and very preterm (0.85 of term) lungs 24 h after MV to assess molecular injury and repair responses. Results: 24 h after MV at 0.75 of term, lung parenchyma and bronchioles were severely injured; tissue space and myofibroblast density were increased, collagen and elastin fibres were deformed and secondary crest density was reduced. Bronchioles contained debris and their epithelium was injured and thickened. 24 h after MV at 0.75 and 0.85 of term, mRNA expression of potential mediators of lung repair were significantly increased. By 15 days after MV, most lung injury had resolved without treatment. Conclusions: Extremely immature lungs, particularly bronchioles, are severely injured by 2 h of MV. In the absence of continued ventilation these injured lungs are capable of repair. At 24 h after MV, genes associated with injurious MV are unaltered, while potential repair genes are activated in both extremely and very preterm lungs.	[Brew, Nadine; Harding, Richard] Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia; [Hooper, Stuart B.; Zahra, Valerie; Wallace, Megan] Monash Univ, Monash Inst Med Res, Ritchie Ctr, Clayton, Vic, Australia; [Hooper, Stuart B.; Wallace, Megan] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia	Monash University; Monash University; Monash University	Brew, N (corresponding author), Monash Univ, Dept Anat & Dev Biol, Clayton, Vic, Australia.	Nadine.brew@monash.edu		Hooper, Stuart/0000-0003-1676-4825; Wallace, Megan/0000-0001-5785-5120	National Health and Medical research Council of Australia; Victorian Government's Operational Infrastructure Support Program	National Health and Medical research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational Infrastructure Support Program	This work is supported by the National Health and Medical research Council of Australia and the Victorian Government's Operational Infrastructure Support Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albertine KH, 1999, AM J RESP CRIT CARE, V159, P945, DOI 10.1164/ajrccm.159.3.9804027; Allison BJ, 2008, PEDIATR RES, V64, P387, DOI 10.1203/PDR.0b013e318181e05e; Allison BJ, 2010, PEDIATR RES, V67, P238, DOI 10.1203/PDR.0b013e3181cde9b3; Ambalavanan N, 2009, PEDIATRICS, V123, P1132, DOI 10.1542/peds.2008-0526; Bach KP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047044; BHUTANI VK, 1981, RESP PHYSIOL, V43, P221, DOI 10.1016/0034-5687(81)90104-3; Bland RD, 2008, AM J PHYSIOL-LUNG C, V294, pL3, DOI 10.1152/ajplung.00362.2007; Bose C, 2011, PEDIATR RES, V69, P347, DOI 10.1203/PDR.0b013e31820a58f3; Brass DM, 2008, IMMUNOGENETICS, V60, P353, DOI 10.1007/s00251-008-0293-3; Brew N, 2011, AM J PHYSIOL-LUNG C, V301, pL917, DOI 10.1152/ajplung.00207.2011; Capoluongo E, 2005, EUR CYTOKINE NETW, V16, P199; Chen ZM, 2007, FREE RADICAL BIO MED, V43, P628, DOI 10.1016/j.freeradbiomed.2007.05.024; Coalson JJ, 2006, SEMIN PERINATOL, V30, P179, DOI 10.1053/j.semperi.2006.05.004; COALSON JJ, 1992, AM REV RESPIR DIS, V145, P872, DOI 10.1164/ajrccm/145.4_Pt_1.872; Courtade M, 1998, CHEST, V113, P371, DOI 10.1378/chest.113.2.371; Cullen AB, 2006, BIOL NEONATE, V90, P17, DOI 10.1159/000091742; Doyle LW, 2006, PEDIATR PULM, V41, P570, DOI 10.1002/ppul.20412; Fakhoury KF, 2010, PEDIATRICS, V125, pE1441, DOI 10.1542/peds.2009-0668; Fanaroff Avroy A, 2007, Am J Obstet Gynecol, V196, DOI 10.1016/j.ajog.2006.09.014; Farstad T, 2011, ACTA PAEDIATR, V100, P53, DOI 10.1111/j.1651-2227.2010.01959.x; Hennessy EM, 2008, ARCH DIS CHILD, V93, P1037, DOI 10.1136/adc.2008.140830; Hillman NH, 2007, AM J RESP CRIT CARE, V176, P575, DOI 10.1164/rccm.200701-051OC; Hillman NH, 2011, AM J PHYSIOL-LUNG C, V300, pL232, DOI 10.1152/ajplung.00294.2010; Hillman NH, 2010, PEDIATR RES, V67, P60, DOI 10.1203/PDR.0b013e3181c1b09e; Husain AN, 1998, HUM PATHOL, V29, P710, DOI 10.1016/S0046-8177(98)90280-5; Inoue K, 2008, FREE RADICAL BIO MED, V45, P1714, DOI 10.1016/j.freeradbiomed.2008.09.008; Inoue KI, 2005, EXP BIOL MED, V230, P75; Kaarteenaho-Wiik R, 2002, J HISTOCHEM CYTOCHEM, V50, P423, DOI 10.1177/002215540205000313; KAGI JHR, 1960, J BIOL CHEM, V235, P3460; Kallapur SG, 2011, AM J PHYSL LUNG CELL; Kroon AA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016910; Laughon MM, 2011, AM J RESP CRIT CARE, V183, P1715, DOI 10.1164/rccm.201101-0055OC; LEE RMKW, 1988, AM REV RESPIR DIS, V137, P450, DOI 10.1164/ajrccm/137.2.450; MARTIN C, 1995, CHEST, V107, P196, DOI 10.1378/chest.107.1.196; MOTOYAMA EK, 1987, AM REV RESPIR DIS, V136, P50, DOI 10.1164/ajrccm/136.1.50; Nie J, 2011, J SURG RES, V168, P281, DOI 10.1016/j.jss.2009.10.020; NORTHWAY WH, 1990, NEW ENGL J MED, V323, P1793, DOI 10.1056/NEJM199012273232603; O'Reilly M, 2009, AM J PHYSIOL-LUNG C, V297, pL992, DOI 10.1152/ajplung.00099.2009; Oh JH, 2009, INHAL TOXICOL, V21, P347, DOI [10.1080/08958370802464281, 10.1080/08958370802464281 ]; PIEDBOEUF B, 1994, AM J RESP CELL MOL, V10, P123, DOI 10.1165/ajrcmb.10.2.8110467; Pierce RA, 1997, AM J PHYSIOL-LUNG C, V272, pL452, DOI 10.1152/ajplung.1997.272.3.L452; Pierce RA, 2007, PEDIATR RES, V61, P703, DOI 10.1203/pdr.0b013e318053661d; PITT BR, 1992, PEDIATR RES, V32, P424, DOI 10.1203/00006450-199210000-00011; Rijken DC, 2009, J THROMB HAEMOST, V7, P4, DOI 10.1111/j.1538-7836.2008.03220.x; Sarafidis K, 2011, J PERINATOL, V31, P104, DOI 10.1038/jp.2010.78; Singhal KK, 1996, PEDIATR RES, V39, P229, DOI 10.1203/00006450-199602000-00007; Stoll BJ, 2010, PEDIATRICS, V126, P443, DOI 10.1542/peds.2009-2959; Takano H, 2004, THORAX, V59, P1057, DOI 10.1136/thx.2004.024232; Thibeault DW, 2003, PEDIATRICS, V111, P766, DOI 10.1542/peds.111.4.766; Thibeault DW, 2000, PEDIATRICS, V106, P1452, DOI 10.1542/peds.106.6.1452; Thirumoorthy N, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-54; Tiddens HAWM, 2008, PEDIATR PULM, V43, P1206, DOI 10.1002/ppul.20928; Toti P, 1997, PEDIATR PULM, V24, P22, DOI 10.1002/(SICI)1099-0496(199707)24:1<22::AID-PPUL4>3.0.CO;2-L; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Wallace MJ, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-19; Wilson A, 2000, PEDIATRICS, V105, P822, DOI 10.1542/peds.105.4.822	56	14	18	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2013	8	5							e63905	10.1371/journal.pone.0063905	http://dx.doi.org/10.1371/journal.pone.0063905			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	149OK	23704953	Green Published, gold, Green Submitted			2023-01-03	WOS:000319330200084
J	Kaida, A; Matthews, LT; Kanters, S; Kabakyenga, J; Muzoora, C; Mocello, AR; Martin, JN; Hunt, P; Haberer, J; Hogg, RS; Bangsberg, DR				Kaida, Angela; Matthews, Lynn T.; Kanters, Steve; Kabakyenga, Jerome; Muzoora, Conrad; Mocello, A. Rain; Martin, Jeffrey N.; Hunt, Peter; Haberer, Jessica; Hogg, Robert S.; Bangsberg, David R.			Incidence and Predictors of Pregnancy among a Cohort of HIV-Positive Women Initiating Antiretroviral Therapy in Mbarara, Uganda	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REPRODUCTIVE HEALTH-CARE; INFECTED WOMEN; FERTILITY INTENTIONS; MALE CIRCUMCISION; PREEXPOSURE PROPHYLAXIS; MISSED OPPORTUNITIES; DISCORDANT COUPLES; EXPANDING ACCESS; RISK BEHAVIOR	Objective: Many people living with HIV in sub-Saharan Africa desire biological children. Implementation of HIV prevention strategies that support the reproductive goals of people living with HIV while minimizing HIV transmission risk to sexual partners and future children requires a comprehensive understanding of pregnancy in this population. We analyzed prospective cohort data to determine pregnancy incidence and predictors among HIV-positive women initiating antiretroviral therapy (ART) in a setting with high HIV prevalence and fertility. Methods: Participants were enrolled in the Uganda AIDS Rural Treatment Outcomes (UARTO) cohort of HIV-positive individuals initiating ART in Mbarara. Bloodwork (including CD4 cells/mm(3), HIV viral load) and questionnaires (including socio-demographics, health status, sexual behavior, partner dynamics, HIV history, and self-reported pregnancy) were completed at baseline and quarterly. Our analysis includes 351 HIV-positive women (18-49 years) who enrolled between 2005-2011. We measured pregnancy incidence by proximal and distal time relative to ART initiation and used multivariable Cox proportional hazards regression analysis (with repeated events) to identify baseline and time-dependent predictors of pregnancy post-ART initiation. Results: At baseline (pre-ART initiation), median age was 33 years [IQR: 27-37] and median prior livebirths was four [IQR: 2-6]. 38% were married with 61% reporting HIV-positive spouses. 73% of women had disclosed HIV status to a primary sexual partner. Median baseline CD4 was 137 cells/mm(3) [IQR: 81-207]. At enrolment, 9.1% (31/342) reported current pregnancy. After ART initiation, 84 women experienced 105 pregnancies over 3.8 median years of follow-up, yielding a pregnancy incidence of 9.40 per 100 WYs. Three years post-ART initiation, cumulative probability of at least one pregnancy was 28% and independently associated with younger age (Adjusted Hazard Ratio (AHR): 0.89/year increase; 95% CI: 0.86-0.92) and HIV serostatus disclosure to primary sexual partner (AHR: 2.45; 95% CI: 1.29-4.63). Conclusions: Nearly one-third of women became pregnant within three years of initiating ART, highlighting the need for integrated services to prevent unintended pregnancies and reduce periconception-related risks for HIV-infected women choosing to conceive. Association with younger age and disclosure suggests a role for early and couples-based safer conception counselling.	[Kaida, Angela; Hogg, Robert S.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada; [Matthews, Lynn T.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Matthews, Lynn T.; Haberer, Jessica; Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA USA; [Matthews, Lynn T.; Haberer, Jessica; Bangsberg, David R.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Kanters, Steve] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Kabakyenga, Jerome; Muzoora, Conrad; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda; [Mocello, A. Rain; Martin, Jeffrey N.; Hunt, Peter] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Hogg, Robert S.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada	Simon Fraser University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of British Columbia; Mbarara University of Science & Technology; University of California System; University of California San Francisco; B.C. Centre for Excellence in HIV/AIDS	Kaida, A (corresponding author), Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada.	kangela@sfu.ca	Haberer, Jessica/AAH-7976-2019; Hunt, Peter W./P-2976-2017; Muzoora, Conrad/AAV-7023-2021	Haberer, Jessica/0000-0001-5845-3190; Hunt, Peter W./0000-0002-4571-4870; Muzoora, Conrad/0000-0002-7866-5198; Hogg, Robert/0000-0003-3463-5488	National Institute of Child Health and Human Development [NICHD R21-HD069194]; National Institute of Mental Health [NIMH R01-MH54907]; Sullivan Family Foundation;  [K-23 MH095655];  [K-24 MH87227]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD069194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH087227, R01MH054907, K23MH095655] Funding Source: NIH RePORTER	National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Sullivan Family Foundation; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Funding for this study was provided by grants from the National Institute of Child Health and Human Development (NICHD R21-HD069194), the National Institute of Mental Health (NIMH R01-MH54907), and the Sullivan Family Foundation. LTM received support from K-23 MH095655 and DRB received support from K-24 MH87227. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Andia I, 2009, AM J PUBLIC HEALTH, V99, P340, DOI 10.2105/AJPH.2007.129528; Auvert B, 2005, PLOS MED, V2, P1112, DOI 10.1371/journal.pmed.0020298; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Bailey RC, 2007, LANCET, V369, P643, DOI 10.1016/S0140-6736(07)60312-2; Bekker L. G., 2011, Southern African Journal of HIV Medicine, V12, P31; Beyeza-Kashesya J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-247; Blair JM, 2004, OBSTET GYNECOL, V103, P663, DOI 10.1097/01.AOG.0000117083.33239.b5; Brubaker SG, 2011, HIV MED, V12, P316, DOI 10.1111/j.1468-1293.2010.00884.x; Bujan L, 2007, AIDS, V21, P1909, DOI 10.1097/QAD.0b013e3282703879; Bussmann H, 2007, JAIDS-J ACQ IMM DEF, V45, P269; Chadwick Rachelle J, 2011, Top Antivir Med, V19, P148; Chen JL, 2001, FAM PLANN PERSPECT, V33, P144, DOI 10.2307/2673717; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cooper D, 2007, SOC SCI MED, V65, P274, DOI 10.1016/j.socscimed.2007.03.019; Cooper D, 2009, AIDS BEHAV, V13, pS38, DOI 10.1007/s10461-009-9550-1; DECHERNEY AH, 1982, NEW ENGL J MED, V306, P424, DOI 10.1056/NEJM198202183060712; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Desgrees-du-Lou A, 2002, INT J STD AIDS, V13, P462, DOI 10.1258/09564620260079617; Farrell B, 2007, FAMILY PLANNING INTE; Frodsham LCG, 2006, FERTIL STERIL, V85, P285, DOI 10.1016/j.fertnstert.2005.07.1326; Geng EH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014098; Giaquinto C, 2005, BJOG-INT J OBSTET GY, V112, P881, DOI 10.1111/j.1471-0528.2005.00569.x; Gibb DM, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001217; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Gruskin S, 2007, REPROD HEALTH MATTER, V15, P4, DOI 10.1016/S0968-8080(07)29028-7; Guthrie BL, 2010, AIDS BEHAV, V14, P1066, DOI 10.1007/s10461-010-9716-x; Heard I, 2007, AIDS, V21, pS77, DOI 10.1097/01.aids.0000255089.44297.6f; Heffron R, 2010, SEX TRANSM DIS, V37, P621, DOI 10.1097/OLQ.0b013e3181e1a162; Homsy J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004149; Kabami J, 2011, 6 INT AIDS SOC IAS C; Kaida A, 2012, INFECT DIS OBSTET GY, V2012, P9; Kaida A, 2011, AM J PUBLIC HEALTH, V101, P350, DOI 10.2105/AJPH.2009.177469; Kaida A, 2009, AIDS BEHAV, V13, pS1, DOI 10.1007/s10461-009-9568-4; Karim QA, 2010, SCIENCE, V329, P1168, DOI 10.1126/science.1193748; Kastner J, 2013, AFR FOR ENT UG JAN 1; Kharsany ABM, 2010, HIV MED, V11, P661, DOI 10.1111/j.1468-1293.2010.00838.x; King R, 2008, AIDS BEHAV, V12, P232, DOI 10.1007/s10461-007-9307-7; King R, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-530; Kisakye P, 2010, CULT HEALTH SEX, V12, P445, DOI 10.1080/13691051003628922; Lewis JJC, 2004, AIDS, V18, pS35, DOI 10.1097/00002030-200406002-00005; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Linas BS, 2011, AIDS, V25, P707, DOI 10.1097/QAD.0b013e3283445811; Maier M, 2009, AIDS BEHAV, V13, pS28, DOI 10.1007/s10461-008-9371-7; Makumbi FE, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/519492; Mantell JE, 2009, J PUBLIC HEALTH POL, V30, P367, DOI 10.1057/jphp.2009.35; Martinez P, 2008, AIDS BEHAV, V12, P605, DOI 10.1007/s10461-007-9312-x; Matthews LT, 2013, AIDS BEHAV, V17, P461, DOI 10.1007/s10461-011-0068-y; Matthews LT, 2012, CURR OPIN HIV AIDS, V7, P569, DOI 10.1097/COH.0b013e328358bac9; Matthews LT, 2009, AIDS BEHAV, V13, pS5, DOI 10.1007/s10461-009-9551-0; [Ministry of Health Uganda ORC Macro], 2006, UG HIV AIDS SER SURV; Mmeje Okeoma, 2012, Infect Dis Obstet Gynecol, V2012, P587651, DOI 10.1155/2012/587651; Moodley D, 2009, AIDS, V23, P1255, DOI 10.1097/QAD.0b013e32832a5934; Mugo NR, 2011, AIDS, V25, P1887, DOI 10.1097/QAD.0b013e32834a9338; Muyindike W, 2012, INFECT DIS OBSTET GY, V2012; Myer L, 2007, TROP MED INT HEALTH, V12, P1484, DOI 10.1111/j.1365-3156.2007.01955.x; Myer L, 2007, AIDS PATIENT CARE ST, V21, P278, DOI 10.1089/apc.2006.0108; Myer L, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000229; Myer L, 2009, JAIDS-J ACQ IMM DEF, V52, pS52, DOI 10.1097/QAI.0b013e3181bbc818; Nakayiwa S, 2006, AIDS BEHAV, V10, pS95, DOI 10.1007/s10461-006-9126-2; Ogilvie GS, 2007, AIDS, V21, pS83, DOI 10.1097/01.aids.0000255090.51921.60; Panozzo L, 2003, SWISS MED WKLY, V133, P124; Polis CB, 2011, CONTRACEPTION, V83, P549, DOI 10.1016/j.contraception.2010.10.002; Revicki DA, 1998, MED CARE, V36, P126, DOI 10.1097/00005650-199802000-00003; SAS, 2011, SAS VERS 9 3; Schwartz SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036039; Schwartz SR, 2012, AIDS BEHAV, V16, P69, DOI 10.1007/s10461-011-9981-3; Sharma A, 2007, AM J OBSTET GYNECOL, V196, P541, DOI 10.1016/j.ajog.2007.01.005; Simbayi LC, 2007, SEX TRANSM INFECT, V83, P29, DOI 10.1136/sti.2006.019893; Snow RC, 2013, AM J PUBLIC HEALTH, V103, P278, DOI 10.2105/AJPH.2012.300892; Taulo F, 2009, AIDS BEHAV, V13, pS20, DOI 10.1007/s10461-009-9547-9; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Tweya H, 2012, AIDS BEHAV; Uganda Bureau of Statistics Macro International Inc, 2007, UG DEM HLTH SURV 200; Uganda Ministry of Health, 2008, NAT ANT TREATM CAR G; Uganda Ministry of Health, 2003, NAT ANT TREATM CAR G; Ugandan Ministry of Health, 2009, NAT ANT TREATM GUID; Ujiji OA, 2010, BMC WOMENS HEALTH, V10, DOI 10.1186/1472-6874-10-13; UNAIDS, 2010, REP GLOB AIDS EP; United Nations Population Division, 2009, WORLD FERT DAT 2008; US Census Bureau International Programs, 2008, GLOB POP PROF 2008 I; van Benthem BHB, 2000, AIDS, V14, P2171, DOI 10.1097/00002030-200009290-00014; Van Damme L, 2012, NEW ENGL J MED, V367, P411, DOI 10.1056/NEJMoa1202614; Vitorino RL, 2011, FERTIL STERIL, V95, P1684, DOI 10.1016/j.fertnstert.2011.01.127; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; Wilcher R, 2009, AIDS, V23, pS1, DOI 10.1097/01.aids.0000363772.45635.35; World Health Organization,, 2020, UNDERSTANDING SEXUAL; World Vision, 2017, INT LIV ASS TARG REF; Wu AW., 1999, MOS HIV HLTH SURVEY; Zaba B, 1998, AIDS, V12, pS41	90	43	43	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2013	8	5							e63411	10.1371/journal.pone.0063411	http://dx.doi.org/10.1371/journal.pone.0063411			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	149OK	23704906	Green Submitted, Green Published, gold			2023-01-03	WOS:000319330200036
J	Burns, T; Rugkasa, J; Molodynski, A; Dawson, J; Yeeles, K; Vazquez-Montes, M; Voysey, M; Sinclair, J; Priebe, S				Burns, Tom; Rugkasa, Jorun; Molodynski, Andrew; Dawson, John; Yeeles, Ksenija; Vazquez-Montes, Maria; Voysey, Merryn; Sinclair, Julia; Priebe, Stefan			Community treatment orders for patients with psychosis (OCTET): a randomised controlled trial	LANCET			English	Article							INVOLUNTARY OUTPATIENT COMMITMENT	Background Compulsory supervision outside hospital has been developed internationally for the treatment of mentally ill people following widespread deinstitutionalisation but its efficacy has not yet been proven. Community treatment orders (CTOs) for psychiatric patients became available in England and Wales in 2008. We tested whether CTOs reduce admissions compared with use of Section 17 leave when patients in both groups receive equivalent levels of clinical contact but different lengths of compulsory supervision. Methods OCTET is a non-blinded, parallel-arm randomised controlled trial. We postulated that patients with a diagnosis of psychosis discharged from hospital on CTOs would have a lower rate of readmission over 12 months than those discharged on the pre-existing Section 17 leave of absence. Eligible patients were those involuntarily admitted to hospital with a diagnosis of psychosis, aged 18-65 years, who were deemed suitable for supervised outpatient care by their clinicians. Consenting patients were randomly assigned (1:1 ratio) to be discharged from hospital either on CTO or Section 17 leave. Randomisation used random permuted blocks with lengths of two, four, and six, and stratified for sex, schizophrenic diagnosis, and duration of illness. Research assistants, treating clinicians, and patients were aware of assignment to randomisation group. The primary outcome measure was whether or not the patient was admitted to hospital during the 12-month follow-up period, analysed with a log-binomial regression model adjusted for stratification factors. We did all analyses by intention to treat. This trial is registered, number ISRCTN73110773. Findings Of 442 patients assessed, 336 patients were randomly assigned to be discharged from hospital either on CTO (167 patients) or Section 17 leave (169 patients). One patient withdrew directly after randomisation and two were ineligible, giving a total sample of 333 patients (166 in the CTO group and 167 in the Section 17 group). At 12 months, despite the fact that the length of initial compulsory outpatient treatment differed significantly between the two groups (median 183 days CTO group vs 8 days Section 17 group, p<0.001) the number of patients readmitted did not differ between groups (59 [36%] of 166 patients in the CTO group vs 60 [36%] of 167 patients in the Section 17 group; adjusted relative risk 1.0 [95% CI 0.75-1.33]). Interpretation In well coordinated mental health services the imposition of compulsory supervision does not reduce the rate of readmission of psychotic patients. We found no support in terms of any reduction in overall hospital admission to justify the significant curtailment of patients' personal liberty.	[Burns, Tom; Rugkasa, Jorun; Yeeles, Ksenija] Univ Oxford, Dept Psychiat, Oxford OX3 7JX, England; [Vazquez-Montes, Maria] Univ Oxford, Dept Primary Hlth Care Sci, Oxford OX3 7JX, England; [Voysey, Merryn] Univ Oxford, Ctr Stat Med, Oxford OX3 7JX, England; [Rugkasa, Jorun] Akershus Univ Hosp, Hlth Serv Res Unit, Lorenskog, Norway; [Molodynski, Andrew] Oxford Hlth NHS Fdn Trust, Oxford, England; [Dawson, John] Univ Otago, Fac Law, Otago, New Zealand; [Sinclair, Julia] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Priebe, Stefan] Queen Mary Univ London, Unit Social & Community Psychiat, London, England	University of Oxford; University of Oxford; University of Oxford; University of Oslo; University of Otago; University of Southampton; University of London; Queen Mary University London	Burns, T (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.	tom.burns@psych.ox.ac.uk	Rugkåsa, Jorun/ABI-6495-2020; Dawson, John/HDM-6702-2022; Sinclair, Julia/AAD-8049-2019	Sinclair, Julia/0000-0002-1905-2025; Yeeles, Ksenija/0000-0002-7757-0154; Priebe, Stefan/0000-0001-9864-3394; Rugkasa, Jorun/0000-0001-5842-2845; Houston, Mary/0000-0002-8837-4503; molodynski, andrew/0000-0002-3820-5955; Voysey, Merryn/0000-0001-6324-6559	National Institute of Health Research [RP-PG-0606-1006]; National Institute for Health Research [RP-PG-0606-1006] Funding Source: researchfish	National Institute of Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	The trial is funded by a Programme Grant for Applied Research from the National Institute of Health Research (RP-PG-0606-1006). It is adopted into the UKCRN and MHRN portfolios, and is registered with ISRCTN [ISRCTN73110773]. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.	Appelbaum PS, 2001, PSYCHIATR SERV, V52, P347, DOI 10.1176/appi.ps.52.3.347; Burns T, 2009, PSYCHOL MED, V39, P1583, DOI 10.1017/S0033291709005352; Burns T, 2010, PSYCHIATR BULL, V34, P361, DOI 10.1192/pb.bp.110.030254; Churchill R, 2007, INT EXPERIENCES USIN; Dawson J, 2011, MED LAW REV, V19, P1, DOI 10.1093/medlaw/fwq030; Dawson J., 2005, COMMUNITY TREATMENT; Dawson John, 2002, Med Law Rev, V10, P308, DOI 10.1093/medlaw/10.3.308; Gledhill K., 2007, J MENT HEALTH, VL, P149; GOLDMAN HH, 1992, AM J PSYCHIAT, V149, P1148; Kisely S, 2005, COCHRANE DB SYST REV, V3; Lukoff D, 1986, SCHIZOPHRENIA B, V12, P594, DOI DOI 10.1093/SCHBUL/12.4.578; Munetz MR, 2003, J AM ACAD PSYCHIATRY, V31, P173; Priebe S, 2005, BMJ-BRIT MED J, V330, P123, DOI 10.1136/bmj.38296.611215.AE; Romans S, 2004, AUST NZ J PSYCHIAT, V38, P836, DOI 10.1080/j.1440-1614.2004.01470.x; Royal College of Psychiatrists, 1993, CR18 ROYAL COLL PSYC; Steadman HJ, 2001, PSYCHIATR SERV, V52, P330, DOI 10.1176/appi.ps.52.3.330; Swartz MS, 1997, J MENT HEALTH ADMIN, V24, P35; Swartz MS, 1999, AM J PSYCHIAT, V156, P1968; Torrey E, 2008, SHORTAGE PUBLIC HOSP	19	232	234	0	43	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 11	2013	381	9878					1627	1633		10.1016/S0140-6736(13)60107-5	http://dx.doi.org/10.1016/S0140-6736(13)60107-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	146SX	23537605	Green Published			2023-01-03	WOS:000319112400029
J	Chen, JS; Chan, WK; Tsai, KT; Hsu, HH; Lin, CY; Yuan, A; Chen, WJ; Lai, HS; Yang, PC				Chen, Jin-Shing; Chan, Wing-Kai; Tsai, Kung-Tsao; Hsu, Hsao-Hsun; Lin, Chien-Yu; Yuan, Ang; Chen, Wen-Jone; Lai, Hong-Shiee; Yang, Pan-Chyr			Simple aspiration and drainage and intrapleural minocycline pleurodesis versus simple aspiration and drainage for the initial treatment of primary spontaneous pneumothorax: an open-label, parallel-group, prospective, randomised, controlled trial	LANCET			English	Article							TUBE DRAINAGE; TETRACYCLINE PLEURODESIS; MANAGEMENT; PHYSICIANS; SURGERY	Background Simple aspiration and drainage is a standard initial treatment for primary spontaneous pneumothorax, but the rate of pneumothorax recurrence is substantial. We investigated whether additional minocycline pleurodesis after simple aspiration and drainage reduces the rate of recurrence. Methods In our open-label, parallel-group, prospective, randomised, controlled trial at two hospitals in Taiwan, patients were aged 15-40 years and had a first episode of primary spontaneous pneumothorax with a rim of air greater than 2 cm on chest radiographs, complete lung expansion without air leakage after pigtail catheter drainage, adequate haematological function, and normal renal and hepatic function. After simple aspiration and drainage via a pigtail catheter, patients were randomly assigned (1:1) to receive 300 mg of minocycline pleurodesis or no further treatment (control group). Randomisation was by computer-generated random numbers in sealed envelopes. Our primary endpoint was rate of pneumothorax recurrence at 1 year. This trial is registered with ClinicalTrials.gov (NCT00418392). Findings Between Dec 31, 2006, and June 30, 2012, 214 patients were randomly assigned-106 to the minocycline group and 108 to the control group (intention-to-treat population). Treatment was unsuccessful within 7 days of randomisation in 14 patients in the minocycline group and 20 patients in the control group. At 1 year, pneumothoraces had recurred in 31 of 106 (29.2%) patients in the minocycline group compared with 53 of 108 (49.1%) in the control group (p=0.003). We noted no procedure-related complications in either group. Interpretation Simple aspiration and drainage followed by minocycline pleurodesis is a safe and more effective treatment for primary spontaneous pneumothorax than is simple aspiration and drainage only. Minocycline pleurodesis should be an adjunct to standard treatment for primary spontaneous pneumothorax.	[Chen, Jin-Shing; Hsu, Hsao-Hsun; Lai, Hong-Shiee] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Yuan, Ang] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Chen, Wen-Jone] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Yang, Pan-Chyr] Natl Taiwan Univ, Coll Med, Taipei 100, Taiwan; [Chan, Wing-Kai] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan; [Tsai, Kung-Tsao] Far Eastern Mem Hosp, Dept Emergency Med, New Taipei City, Taiwan; [Lin, Chien-Yu] Natl Taiwan Univ, Acad Sinica, Inst Stat Sci, Taipei 100, Taiwan; [Lin, Chien-Yu] Natl Taiwan Univ, Ctr Genom Med, Microarray Core Facil, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Far Eastern Memorial Hospital; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University	Yang, PC (corresponding author), Natl Taiwan Univ, Coll Med, 1,Sect 1,Ren Ai Rd, Taipei 100, Taiwan.	pcyang@ntu.edu.tw		Lai, Hong-Shiee/0000-0002-7958-2183; CHEN, JIN-SHING/0000-0001-5077-4483; Chan, Wing-Kai/0000-0002-5328-548X; YANG, PAN-CHYR/0000-0001-6330-6048; CHEN, WEN-JONE/0000-0002-2098-5922; YUAN, ANG/0000-0002-5664-1339; HSU, HSAO-HSUN/0000-0002-0376-1206	Department of Health; National Science Council, Taiwan [NSC 100-2325-B-002-072]; Department of Health, Taiwan [DOH95-TD-I-111-012]	Department of Health; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); Department of Health, Taiwan	Department of Health and National Science Council, Taiwan.; We would like to acknowledge the contribution of Yung-Chie Lee, who was the principal investigator of this study before his death on Dec 30, 2010. This study was supported by research grants from the Department of Health, Taiwan (DOH95-TD-I-111-012) and National Science Council, Taiwan (NSC 100-2325-B-002-072).	ALFAGEME I, 1994, CHEST, V106, P347, DOI 10.1378/chest.106.2.347; ALMIND M, 1989, THORAX, V44, P627, DOI 10.1136/thx.44.8.627; ANDRIVET P, 1995, CHEST, V108, P335, DOI 10.1378/chest.108.2.335; Ayed AK, 2006, EUR RESPIR J, V27, P477, DOI 10.1183/09031936.06.00091505; Baumann MH, 2001, CHEST, V119, P590, DOI 10.1378/chest.119.2.590; British Thoracic Society Research Committee, 1993, THORAX, V48, P430; Chan L, 1997, AM J EMERG MED, V15, P368, DOI 10.1016/S0735-6757(97)90127-3; Chen JS, 2008, RESP MED, V102, P1004, DOI 10.1016/j.rmed.2008.02.006; Chen JS, 2006, AM J RESP CRIT CARE, V173, P548, DOI 10.1164/rccm.200509-1414OC; Chen JS, 2004, CHEST, V125, P50, DOI 10.1378/chest.125.1.50; Chen JS, 2003, ANN THORAC SURG, V75, P1080, DOI 10.1016/S0003-4975(02)04649-0; GOBBEL WG, 1963, J THORAC CARDIOV SUR, V46, P331, DOI 10.1016/S0022-5223(19)33666-9; HARVEY J, 1994, BRIT MED J, V309, P1338, DOI 10.1136/bmj.309.6965.1338; Henry M, 2003, THORAX S2, V58, pii39, DOI DOI 10.1136/TH0RAX.58.SUPPL_21I39; Lichter J, 1971, THORAX, V25, P409; LIGHT RW, 1994, CHEST, V106, P577, DOI 10.1378/chest.106.2.577; LIGHT RW, 1990, JAMA-J AM MED ASSOC, V264, P2224, DOI 10.1001/jama.264.17.2224; LIGHT RW, 1993, AM REV RESPIR DIS, V148, P245, DOI 10.1164/ajrccm/148.1.245; MacDuff A, 2010, THORAX, V65, P18, DOI 10.1136/thx.2010.136986; Margolis M, 2003, ANN THORAC SURG, V76, P1661, DOI 10.1016/S0003-4975(02)04816-6; Noppen M, 2002, AM J RESP CRIT CARE, V165, P1240, DOI 10.1164/rccm.200111-078OC; Noppen M, 2001, RESPIRATION, V68, P396, DOI 10.1159/000050533; Packham S, 2003, POSTGRAD MED J, V79, P345, DOI 10.1136/pmj.79.932.345; Sahn SA, 2000, NEW ENGL J MED, V342, P868, DOI 10.1056/NEJM200003233421207; SEREMETIS MG, 1970, CHEST, V57, P65, DOI 10.1378/chest.57.1.65; Sodikot RT, 1997, THORAX, V52, P805; Tschopp JM, 2006, EUR RESPIR J, V28, P637, DOI 10.1183/09031936.06.00014206; Tschopp JM, 2002, EUR RESPIR J, V20, P1003, DOI 10.1183/09031936.02.00278202; VOGE VM, 1986, AVIAT SPACE ENVIR MD, V57, P939; Wakai A, 2007, COCHRANE DB SYST REV	30	65	74	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 13	2013	381	9874					1277	1282		10.1016/S0140-6736(12)62170-9	http://dx.doi.org/10.1016/S0140-6736(12)62170-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122XD	23489754	Green Submitted			2023-01-03	WOS:000317351000030
J	Chen, XL; Chen, XZ; Yang, C; Liao, YB; Li, H; Wang, L; Yang, K; Li, K; Hu, JK; Zhang, B; Chen, ZX; Chen, JP; Zhou, ZG				Chen, Xiao-Long; Chen, Xin-Zu; Yang, Chen; Liao, Yan-Biao; Li, He; Wang, Li; Yang, Kun; Li, Ka; Hu, Jian-Kun; Zhang, Bo; Chen, Zhi-Xin; Chen, Jia-Ping; Zhou, Zong-Guang			Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; S-1 COMBINATION THERAPY; QUALITY-OF-LIFE; PHASE-III TRIAL; PLUS FLUOROURACIL; 1ST-LINE THERAPY; G-CSF; CANCER; EPIRUBICIN; LEUCOVORIN	Background: Gastric carcinoma (GC) is one of the highest cancer-mortality diseases with a high incidence rate in Asia. For surgically unfit but medically fit patients, palliative chemotherapy is the main treatment. The chemotherapy regimen of docetaxel, cisplatin and 5-fluorouracil (DCF) has been used to treat the advanced stage or metastatic GC. It is necessary to compare effectiveness and toxicities of DCF regimen with non-taxane-containing palliative chemotherapy for GC. Methods: PubMed, EmBase, Cochrane Central Register of Controlled Trials and China National Knowledge Infrastructure databases were searched to select relative randomized controlled trials (RCTs) comparing DCF to non-taxane-containing chemotherapy for patients with palliatively resected, unresectable, recurrent or metastatic GC. Primary outcome measures were 1-year and 2-year overall survival (OS) rates. Secondary outcome measures were median survival time (MST), median time to progression (TTP), response rate and toxicities. Results: Twelve RCTs were eligible and 1089 patients were analyzed totally (549 in DCF and 540 in control). DCF regimen increased partial response rate (38.8% vs 27.9%, p = 0.0003) and reduced progressive disease rate (18.9% vs 33.3%, p = 0.0005) compared to control regimen. Significant improvement of 2-year OS rate was found in DCF regimen (RR = 2.03, p = 0.006), but not of 1-year OS rate (RR = 1.22, p = 0.08). MST was significantly prolonged by DCF regimen (p = 0.039), but not median TTP (p = 0.054). Both 1-year OS rate and median TTP had a trend of prolongation by DCF regimen. Chemotherapy-related mortality was comparable (RR = 1.23, p = 0.49) in both regimens. In grade I-IV toxicities, DCF regimen showed a major raise of febrile neutropenia (RR = 2.33, p<0.0001) and minor raises of leucopenia (RR = 1.25, p<0.00001), neutropenia (RR = 1.19, p<0.00001), and diarrhea (RR = 1.59, p<0.00001), while in other toxicities there were no significant differences. Conclusion: DCF regimen has better response than non-taxane containing regimen and could potentially improve the survival outcomes. The chemotherapy-related toxicity of DCF regimen is acceptable to some extent.	[Chen, Xiao-Long; Chen, Xin-Zu; Yang, Kun; Li, Ka; Hu, Jian-Kun; Zhang, Bo; Chen, Zhi-Xin; Chen, Jia-Ping; Zhou, Zong-Guang] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610064, Sichuan, Peoples R China; [Chen, Xiao-Long; Yang, Chen; Liao, Yan-Biao; Li, He] Sichuan Univ, West China Sch Med, Fac Med, Chengdu 610064, Sichuan, Peoples R China; [Wang, Li] Sichuan Univ, West China Hosp, Chinese Cochrane Ctr, Chengdu 610064, Sichuan, Peoples R China	Sichuan University; Sichuan University; Sichuan University	Hu, JK (corresponding author), Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610064, Sichuan, Peoples R China.	hujkwch@126.com	Chen, Xin-Zu/K-2988-2019; Yang, Kun/A-4293-2010; Chen, Xin-Zu/C-2515-2009; Chen, Xin-Zu/G-6579-2014	Chen, Xin-Zu/0000-0002-7619-6244; , Zongguang/0000-0002-7616-1199	National Natural Science Foundation of China [81071777]; Outstanding Young Scientific Scholarship Foundation of Sichuan University, from the Fundamental Research Funds for the Central Universities of China [2011SCU04B19]; New Century Excellent Talents in University support program, Ministry of Education of China [2012SCU-NCET-11-0343]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Young Scientific Scholarship Foundation of Sichuan University, from the Fundamental Research Funds for the Central Universities of China; New Century Excellent Talents in University support program, Ministry of Education of China(Program for New Century Excellent Talents in University (NCET))	This research was funded by these sources: 1) National Natural Science Foundation of China (No. 81071777); 2) Outstanding Young Scientific Scholarship Foundation of Sichuan University, from the Fundamental Research Funds for the Central Universities of China (No.2011SCU04B19); 3) New Century Excellent Talents in University support program, Ministry of Education of China (2012SCU-NCET-11-0343). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajani JA, 1998, ONCOLOGY-NY, V12, P44; Ajani JA, 2002, ONCOLOGY-NY, V16, P89; Ajani JA, 2007, J CLIN ONCOL, V25, P3210, DOI 10.1200/JCO.2006.08.3956; Ajani JA, 2007, J CLIN ONCOL, V25, P3205, DOI 10.1200/JCO.2006.10.4968; Ajani JA, 2010, J NATL COMPR CANC NE, V8, P378, DOI 10.6004/jnccn.2010.0030; Bang YJ, 2002, JPN J CLIN ONCOL, V32, P248, DOI 10.1093/jjco/hyf057; Bittoni A, 2010, EUR REV MED PHARMACO, V14, P309; Catalano V, 2009, CRIT REV ONCOL HEMAT, V71, P127, DOI 10.1016/j.critrevonc.2009.01.004; Chen XZ, 2008, WORLD J GASTROENTERO, V14, P2715, DOI 10.3748/wjg.14.2715; Chen XZ, 2011, WORLD J GASTROENTERO, V17, P4542, DOI 10.3748/wjg.v17.i40.4542; Chen XZ, 2010, J AM COLL SURGEONS, V210, P100, DOI 10.1016/j.jamcollsurg.2009.09.033; Chu JH, 2006, CHIN J CLIN ONCOL, V11, P541; CORTES JE, 1995, J CLIN ONCOL, V13, P2643, DOI 10.1200/JCO.1995.13.10.2643; Das P, 2005, EXPERT OPIN PHARMACO, V6, P2805, DOI 10.1517/14656566.6.16.2805; Gao H, 2010, CHIN J CLIN ONCOL, V15, P529; Giuliani F, 2003, ANTICANCER RES, V23, P4219; Haller DG, 2002, ANTI-CANCER DRUG, V13, P451, DOI 10.1097/00001813-200206000-00003; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Hou AnJi, 2009, Tumor, V29, P160; Hu JK, 2007, J CHEMOTHERAPY, V19, P359, DOI 10.1179/joc.2007.19.4.359; Hu JK, 2009, SURG TODAY, V39, P207, DOI 10.1007/s00595-008-3856-x; Hu JK, 2002, WORLD J GASTROENTERO, V8, P1023, DOI 10.3748/wjg.v8.i6.1023; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kakeji Y, 2009, ONCOLOGY-BASEL, V77, P49, DOI 10.1159/000226111; Li CP, 2010, BRIT J CANCER, V103, P1343, DOI 10.1038/sj.bjc.6605928; Li XQ, 2007, MODERN ONCOL, V15, P659; Liang B, 2010, CHIN J CLIN ONCOL RE, V17, P59; Lorenzen S, 2007, ANN ONCOL, V18, P1673, DOI 10.1093/annonc/mdm269; Makatsoris T, 2007, MED ONCOL, V24, P301, DOI 10.1007/s12032-007-0004-1; Mavroudis D, 2000, AM J CLIN ONCOL-CANC, V23, P341, DOI 10.1097/00000421-200008000-00005; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Oh DY, 2005, JPN J CLIN ONCOL, V35, P380, DOI 10.1093/jjco/hyi107; Oh SC, 2005, BRIT J CANCER, V92, P827, DOI 10.1038/sj.bjc.6602446; Ohtsu Atsushi, 2005, Gastric Cancer, V8, P95, DOI 10.1007/s10120-005-0324-9; Park SR, 2005, AM J CLIN ONCOL-CANC, V28, P433, DOI 10.1097/01.coc.0000162424.69631.79; Rino Y, 2006, ANTICANCER RES, V26, P1455; Roth AD, 2003, ANN ONCOL, V14, P41, DOI 10.1093/annonc/mdg728; Roth AD, 2000, ANN ONCOL, V11, P301, DOI 10.1023/A:1008342013224; Roth AD, 2007, J CLIN ONCOL, V25, P3217, DOI 10.1200/JCO.2006.08.0135; Sadighi S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-274; Sato Y, 2010, CANCER CHEMOTH PHARM, V66, P721, DOI 10.1007/s00280-009-1215-2; Shah MA, 2011, J CLIN ONCOL, V29, P868, DOI 10.1200/JCO.2010.32.0770; Shen YC, 2009, J BASIC CLIN ONCOL, V22, P318; Sun WJ, 2010, J CLIN ONCOL, V28, P2947, DOI 10.1200/JCO.2009.27.7988; Takayama T, 2007, BRIT J CANCER, V97, P851, DOI 10.1038/sj.bjc.6603957; Tsai James Y, 2003, Curr Oncol Rep, V5, P210, DOI 10.1007/s11912-003-0112-9; Van Cutsem E, 2004, EJC SUPPL, V2, P52, DOI 10.1016/j.ejcsup.2004.04.016; Van Cutsem E, 2004, ONCOLOGIST, V9, P9, DOI 10.1634/theoncologist.9-suppl_2-9; Van Cutsem E, 2008, EUR J CANCER, V44, P182, DOI 10.1016/j.ejca.2007.11.001; Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429; Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3; Wagner AD, 2009, DRUG AGING, V26, P627, DOI 10.2165/11315740-000000000-00000; Wu GC, 2008, J SHANDONG MED, V48, P73; Yamaguchi K, 2006, BRIT J CANCER, V94, P1803, DOI 10.1038/sj.bjc.6603196; Yamamoto K, 2009, ANTICANCER RES, V29, P4211; Yang K, 2009, WORLD J GASTROENTERO, V15, P5352, DOI 10.3748/wjg.15.5352; Yoshida K, 2004, ANTICANCER RES, V24, P1843; Yoshida K, 2006, CLIN CANCER RES, V12, P3402, DOI 10.1158/1078-0432.CCR-05-2425; Zhang FL, 2008, CHIN J CLIN ONCOL, V35, p[1397, 1406]; 赵帆, 2009, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V29, P237	61	34	45	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 4	2013	8	4							e60320	10.1371/journal.pone.0060320	http://dx.doi.org/10.1371/journal.pone.0060320			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146RK	23593191	Green Published, gold, Green Submitted			2023-01-03	WOS:000319108100031
J	Collins, M; Latimer, N				Collins, Marissa; Latimer, Nicholas			NICE's end of life decision making scheme: impact on population health	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Collins, Marissa] Glasgow Caledonian Univ, Yunus Ctr Social Business & Hlth, Glasgow G4 0BA, Lanark, Scotland; [Latimer, Nicholas] Univ Sheffield, ScHARR, Sheffield, S Yorkshire, England	Glasgow Caledonian University; University of Sheffield	Collins, M (corresponding author), Glasgow Caledonian Univ, Yunus Ctr Social Business & Hlth, Glasgow G4 0BA, Lanark, Scotland.	marissa.collins@gcu.ac.uk		Collins, Marissa/0000-0002-0896-6673; Latimer, Nicholas/0000-0001-5304-5585				[Anonymous], 2010, NICE TECHN APPR GUID; [Anonymous], 2010, NICE TECHN APPR GUID; [Anonymous], 2009, NICE TECHN APPR GUID; [Anonymous], 2009, NICE TECHN APPR GUID; [Anonymous], 2011, NICE TECHN APPR GUID; [Anonymous], 2010, NICE TECHN APPR GUID; [Anonymous], 2011, NICE TECHN APPR GUID; [Anonymous], 2009, NICE TECHN APPR GUID; [Anonymous], 2009, NIC TECHN APPR GUID; Claxton K, 2013, 81 CHE; Department of Health, 2011, GUID SUPP OP CANC DR; Kerr M, 2012, CHRONIC KIDNEY DIS E; Linley WG, 2012, HLTH EC; National Institute for Health and Clinical Excellence (NICE), 2008, GUID METH TECHN APPR; NICE, 2004, GUID METH TECHN APPR; NICE, 2009, APPR LIF EXT END LIF; Raftery JP, 2009, BMJ-BRIT MED J, V338, P271; Shah K, 2012, VALUING HLTH END LIF, P56	18	36	37	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 21	2013	346								f1363	10.1136/bmj.f1363	http://dx.doi.org/10.1136/bmj.f1363			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	113MJ	23518274				2023-01-03	WOS:000316671800004
J	Abe, T; Ishimatsu, S; Tokuda, Y				Abe, Toshikazu; Ishimatsu, Shinichi; Tokuda, Yasuharu			Descriptive Analysis of Patients' EMS Use Related to Severity in Tokyo: A Population-Based Observational Study	PLOS ONE			English	Article							AMBULANCE TRANSPORTS; HEALTH-CARE; TRAUMA; SYSTEM; JAPAN; COST	Introduction: Few studies are available on the clinical characteristics of patients using emergency medical transports in Japan. In this study, we aimed to investigate reasons for emergency medical transports and their relation to clinical severity. Methods: We conducted a 3-year population-based observational study of patients transported by ambulance to emergency departments (ED) in the capital of Japan, Tokyo, which has a population of about 13 million. Demographic data, reasons for transport, and the severity of initial assessment at ED were recorded. Logistic regression was used to determine the odds of the clinical severity of each reason for transport. Results: The number of emergency medical transports in the three-year study period was 1,832,637. Mean age was 53 +/- 26. Males were 976,142 (53%). Overall, 92% of all transported patients were in a mild or moderate medical state and patients with the 17 most frequent reasons for transport occupied 82% (1,506,017) of all transports. Pain was the most frequent reason for transport, followed by traffic accident. Considering all the patients and their reasons for transport, patients whose reason was pain or a traffic accident (29% of all patients) were in a relatively mild state compared with patients with other reasons for transport. Patients in an altered mental state in the prehospital setting (6.8% of all patients) were in a more severe medical state than other patients. Conclusions: In Tokyo, Japan, 92% of transported patients were in a mild or moderate medical state. In particular, most patients from traffic accidents were in a mild state, even though traffic accidents were the second most frequent reason for transport. Patients in an altered mental state were most likely to be in a severe medical state.	[Abe, Toshikazu] Univ Tsukuba, Dept Emergency Med, Mito Kyodo Gen Hosp, Mito, Ibaraki, Japan; [Ishimatsu, Shinichi] St Lukes Int Hosp, Dept Emergency & Crit Care Med, Tokyo, Japan; [Tokuda, Yasuharu] Univ Tsukuba, Inst Clin Med, Grad Sch Comprehens Human Sci, Mito, Ibaraki, Japan	University of Tsukuba; St. Luke's International Hospital; University of Tsukuba	Abe, T (corresponding author), Univ Tsukuba, Dept Emergency Med, Mito Kyodo Gen Hosp, Mito, Ibaraki, Japan.	mican-philia@sunny.ocn.ne.jp	Abe, Toshikazu/ABH-1639-2021		St. Luke's Life Science Institute Research grant, Japan	St. Luke's Life Science Institute Research grant, Japan	We are supported by St. Luke's Life Science Institute Research grant, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Abe T, 2008, EMERG MED J, V25, P769, DOI 10.1136/emj.2007.056960; Billittier AJ, 1996, ACAD EMERG MED, V3, P1046; Burt CW, 2006, ANN EMERG MED, V47, P317, DOI 10.1016/j.annemergmed.2005.12.001; CamassoRichardson K, 1997, ACAD EMERG MED, V4, P1137, DOI 10.1111/j.1553-2712.1997.tb03696.x; Chernew ME, 2008, AM J MANAG CARE, V14, P412; Koenig KL, 1996, ACAD EMERG MED, V3, P989, DOI 10.1111/j.1553-2712.1996.tb03339.x; Kondo Y, 2011, CRIT CARE, V15, DOI 10.1186/cc10348; Ministry of Education Culture S Science and Technology of Japan/Ministry of Health Labour and Welfare of Japan, 2006, GUIDELINE EPIDEMIOLO; Ohshige K, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-21; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Shibuya K, 2011, LANCET, V378, P1265, DOI 10.1016/S0140-6736(11)61098-2; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; Tanigawa K, 2006, RESUSCITATION, V69, P365, DOI 10.1016/j.resuscitation.2006.04.001; Tokuda Y, 2010, J EPIDEMIOL, V20, P468, DOI 10.2188/jea.JE20090210	14	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2013	8	3							e59738	10.1371/journal.pone.0059738	http://dx.doi.org/10.1371/journal.pone.0059738			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SW	23527262	gold, Green Published, Green Submitted			2023-01-03	WOS:000317562600091
J	Chan, PS; Nallamothu, BK; Krumholz, HM; Spertus, JA; Li, Y; Hammill, BG; Curtis, LH				Chan, Paul S.; Nallamothu, Brahmajee K.; Krumholz, Harlan M.; Spertus, John A.; Li, Yan; Hammill, Bradley G.; Curtis, Lesley H.		Amer Heart Assoc Get Guidelines	Long-Term Outcomes in Elderly Survivors of In-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AUSTRALIAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE-PROFESSIONALS; CAUSE READMISSION RATES; CARDIOPULMONARY-RESUSCITATION; STROKE-FOUNDATION; SOUTHERN-AFRICA; PERFORMANCE; STATEMENT; REGISTRY	BACKGROUND Little is known about the long-term outcomes in elderly survivors of in-hospital cardiac arrest. We determined rates of long-term survival and readmission among survivors of in-hospital cardiac arrest and examined whether these outcomes differed according to demographic characteristics and neurologic status at discharge. METHODS We linked data from a national registry of inpatient cardiac arrests with Medicare files and identified 6972 adults, 65 years of age or older, who were discharged from the hospital after surviving an in-hospital cardiac arrest between 2000 and 2008. Predictors of 1-year survival and of readmission to the hospital were examined. RESULTS One year after hospital discharge, 58.5% of the patients were alive, and 34.4% had not been readmitted to the hospital. The risk-adjusted rate of 1-year survival was lower among older patients than among younger patients (63.7%, 58.6%, and 49.7% among patients 65 to 74, 75 to 84, and >= 85 years of age, respectively; P<0.001), among men than among women (58.6% vs. 60.9%, P = 0.03), and among black patients than among white patients (52.5% vs. 60.4%, P = 0.001). The risk-adjusted rate of 1-year survival was 72.8% among patients with mild or no neurologic disability at discharge, as compared with 61.1% among patients with moderate neurologic disability, 42.2% among those with severe neurologic disability, and 10.2% among those in a coma or vegetative state (P<0.001 for all comparisons). Moreover, 1-year readmission rates were higher among patients who were black, those who were women, and those who had substantial neurologic disability (P<0.05 for all comparisons). These differences in survival and readmission rates persisted at 2 years. At 3 years, the rate of survival among survivors of in-hospital cardiac arrest was similar to that of patients who had been hospitalized with heart failure and were discharged alive (43.5% and 44.9%, respectively; risk ratio, 0.98; 95% confidence interval, 0.95 to 1.02; P = 0.35). CONCLUSIONS Among elderly survivors of in-hospital cardiac arrest, nearly 60% were alive at 1 year, and the rate of 3-year survival was similar to that among patients with heart failure. Survival and readmission rates differed according to the demographic characteristics of the patients and neurologic status at discharge. (Funded by the American Heart Association and the National Heart, Lung, and Blood Institute.)	[Chan, Paul S.; Spertus, John A.; Li, Yan] St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO 64111 USA; [Nallamothu, Brahmajee K.] Univ Michigan, VA Ann Arbor Healthcare Syst, Vet Affairs VA Hlth Serv Res & Dev Ctr, Ann Arbor, MI 48109 USA; [Nallamothu, Brahmajee K.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Nallamothu, Brahmajee K.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Hammill, Bradley G.; Curtis, Lesley H.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA; [Curtis, Lesley H.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA	Saint Luke's Hospital - Missouri; Saint Luke's Mid America Heart Institute; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Yale University; Yale University; Yale University; Yale University; Duke University; Duke University	Chan, PS (corresponding author), St Lukes Hosp, Mid Amer Heart Inst, 5th Fl,4401 Wornall Rd, Kansas City, MO 64111 USA.	pchan@cc-pc.com	Spertus, John/ABD-3075-2021; , Harlan/AAI-2875-2020		American Heart Association; National Heart, Lung, and Blood Institute [K23HL102224, 1U01HL105270-02]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL102224, U01HL105270] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by the American Heart Association and by a Career Development Grant Award (K23HL102224, to Dr. Chan) from the National Heart, Lung, and Blood Institute. Dr. Krumholz was supported, in part, by a grant (1U01HL105270-02) from the National Heart, Lung, and Blood Institute to the Center for Cardiovascular Outcomes Research at Yale University.	Becker LB, 2011, CIRCULATION, V124, P2158, DOI 10.1161/CIR.0b013e3182340239; Bloom HL, 2007, AM HEART J, V153, P831, DOI 10.1016/j.ahj.2007.02.011; Chan PS, 2008, NEW ENGL J MED, V358, P9, DOI 10.1056/NEJMoa0706467; Cummins RO, 1997, CIRCULATION, V95, P2213, DOI 10.1161/01.CIR.95.8.2213; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Hammill BG, 2009, AM HEART J, V157, P995, DOI 10.1016/j.ahj.2009.04.002; Herlitz J, 2000, RESUSCITATION, V45, P167, DOI 10.1016/S0300-9572(00)00187-8; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JENNETT B, 1975, LANCET, V1, P480; Kalbag A, 2006, RESUSCITATION, V68, P79, DOI 10.1016/j.resuscitation.2005.06.003; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Kutsogiannis DJ, 2011, CAN MED ASSOC J, V183, P1589, DOI 10.1503/cmaj.100034; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Peberdy MA, 2008, JAMA-J AM MED ASSOC, V299, P785, DOI 10.1001/jama.299.7.785; Raghunathan T. E., 2002, IVEWARE IMPUTATION V; Team R.C., 2021, R FOUN DATION STAT C; Topjian AA, 2010, CRIT CARE MED, V38, P1254, DOI 10.1097/CCM.0b013e3181d8ca43; Zoch TW, 2000, ARCH INTERN MED, V160, P1969, DOI 10.1001/archinte.160.13.1969; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	21	112	113	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	2013	368	11					1019	1026		10.1056/NEJMoa1200657	http://dx.doi.org/10.1056/NEJMoa1200657			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104HF	23484828	Green Accepted			2023-01-03	WOS:000315982100008
J	Downar, J; Kritek, PA				Downar, James; Kritek, Patricia A.			Family Presence during Cardiac Resuscitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Downar, James] Univ Hlth Network, Toronto, ON, Canada; [Kritek, Patricia A.] Univ Washington, Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98195 USA	University of Toronto; University Health Network Toronto; University of Washington; University of Washington Seattle	Downar, J (corresponding author), Univ Hlth Network, Toronto, ON, Canada.							Aidman EV, 2006, PSYCHOL REP, V99, P569, DOI 10.2466/PR0.99.2.569-580; Compton S, 2011, J PALLIAT MED, V14, P715, DOI 10.1089/jpm.2010.0463; Curley MAQ, 2012, AM J RESP CRIT CARE, V186, P1133, DOI 10.1164/rccm.201205-0915OC; Dudley NC, 2009, ANN EMERG MED, V53, P777, DOI 10.1016/j.annemergmed.2008.10.002; Itzhaki M, 2012, J ADV NURS, V68, P1967, DOI 10.1111/j.1365-2648.2011.05883.x; Jabre P, 2013, NEW ENGL J MED, V368, P1008, DOI 10.1056/NEJMoa1203366; Kotler M, 2001, J NERV MENT DIS, V189, P162, DOI 10.1097/00005053-200103000-00004; O'Connell KJ, 2007, PEDIATRICS, V120, pE565, DOI 10.1542/peds.2006-2914	8	8	8	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 14	2013	368	11					1060	1062		10.1056/NEJMclde1301020	http://dx.doi.org/10.1056/NEJMclde1301020			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	104HF	23484836				2023-01-03	WOS:000315982100016
J	Park, MJ; Green, J; Ishikawa, H; Yamazaki, Y; Kitagawa, A; Ono, M; Yasukata, F; Kiuchi, T				Park, M. J.; Green, Joseph; Ishikawa, Hirono; Yamazaki, Yoshihiko; Kitagawa, Akira; Ono, Miho; Yasukata, Fumiko; Kiuchi, Takahiro			Decay of Impact after Self-Management Education for People with Chronic Illnesses: Changes in Anxiety and Depression over One Year	PLOS ONE			English	Article							QUALITY-OF-LIFE; LONG-TERM OUTCOMES; CHRONIC DISEASE; HEALTH-STATUS; CLINICAL-SIGNIFICANCE; FOLLOW-UP; PROGRAM; ARTHRITIS; CHINESE; IMPLEMENTATION	Background: In people with chronic illnesses, self-management education can reduce anxiety and depression. Those benefits, however, decay over time. Efforts have been made to prevent or minimize that "decay of impact", but they have not been based on information about the decay's characteristics, and they have failed. Here we show how the decay's basic characteristics (prevalence, timing, and magnitude) can be quantified. Regarding anxiety and depression, we also report the prevalence, timing, and magnitude of the decay. Methods: Adults with various chronic conditions participated in a self-management educational program (n = 369). Data were collected with the Hospital Anxiety and Depression Scale four times over one year. Using within-person effect sizes, we defined decay of impact as a decline of >= 0.5 standard deviations after improvement by at least the same amount. We also interpret the results using previously-set criteria for non-cases, possible cases, and probable cases. Results: Prevalence: On anxiety, decay occurred in 19% of the participants (70/369), and on depression it occurred in 24% (90/369). Timing: In about one third of those with decay, it began 3 months after the baseline measurement (6 weeks after the educational program ended). Magnitude: The median magnitudes of decay on anxiety and on depression were both 4 points, which was about 1 standard deviation. Early in the follow-up year, many participants with decay moved into less severe clinical categories (e.g., becoming non-cases). Later, many of them moved into more severe categories (e.g., becoming probable cases). Conclusions: Decay of impact can be identified and quantified from within-person effect sizes. This decay occurs in about one fifth or more of this program's participants. It can start soon after the program ends, and it is large enough to be clinically important. These findings can be used to plan interventions aimed at preventing or minimizing the decay of impact.	[Park, M. J.; Ishikawa, Hirono; Kiuchi, Takahiro] Univ Tokyo, Grad Sch Med, Dept Hlth Commun, Tokyo, Japan; [Green, Joseph] Univ Tokyo, Grad Sch Med, Tokyo, Japan; [Yamazaki, Yoshihiko] Nihon Fukushi Univ, Fac Social Welf, Nagoya, Aichi, Japan; [Kitagawa, Akira; Yasukata, Fumiko] Fukuoka Prefectural Univ, Dept Fundamental Nursing, Tagawa, Fukuoka, Japan; [Ono, Miho] Kawasaki Univ Med Welf, Dept Hlth Sci & Nursing, Kurashiki, Okayama, Japan	University of Tokyo; University of Tokyo	Park, MJ (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hlth Commun, Tokyo, Japan.	mjpark417@gmail.com			Japanese Ministry of Health, Labor and Welfare Aids for Scientific Research (health disease prevention, treatment and research projects for allergy and immunology)	Japanese Ministry of Health, Labor and Welfare Aids for Scientific Research (health disease prevention, treatment and research projects for allergy and immunology)	This work was supported by the Japanese Ministry of Health, Labor and Welfare Aids for Scientific Research (health disease prevention, treatment and research projects for allergy and immunology). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed S, 2009, J CLIN EPIDEMIOL, V62, P1165, DOI 10.1016/j.jclinepi.2009.03.015; [Anonymous], 2008, IMPL MAN STANF SELF; Barlow J, 2009, RHEUMATOLOGY, V48, P128, DOI 10.1093/rheumatology/ken429; Barlow JH, 2005, BRIT J HEALTH PSYCH, V10, P589, DOI 10.1348/135910705X26317; Barlow JH, 1998, BRIT J RHEUMATOL, V37, P1315; Barlow J, 2009, PATIENT EDUC COUNS, V77, P81, DOI 10.1016/j.pec.2009.02.009; Barth J., 2005, HEALTH QUAL LIFE OUT, V3, P15, DOI DOI 10.1186/1477-7525-3-15; Bennette C, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-21; BJELLAND I, 2002, J PSYCHOSOM RES, V0052; Campbell D.T., 1999, PRIMER REGRESSION AR; Caplin DL, 2001, J ASTHMA, V38, P343, DOI 10.1081/JAS-100000263; Cappellery JC, 2013, STAT METHODS MED RES; Chan SCC, 2005, INT J REHABIL RES, V28, P351, DOI 10.1097/00004356-200512000-00008; Clark NM, 2003, ANNU REV PUBL HEALTH, V24, P289, DOI 10.1146/annurev.publhealth.24.100901.141021; Cohen J., 2013, STAT POWER ANAL BEHA; Damush TM, 2003, ARCH INTERN MED, V163, P2632, DOI 10.1001/archinte.163.21.2632; Edwards PJ, 2009, COCHRANE DB SYST REV, V3, P1; Elzen H, 2007, SOC SCI MED, V64, P1832, DOI 10.1016/j.socscimed.2007.02.008; Foster G, 2007, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD005108.PUB2; Franks P, 2009, BRIT J HEALTH PSYCH, V14, P473, DOI 10.1348/135910708X360700; Fu DB, 2003, B WORLD HEALTH ORGAN, V81, P174; Gitlin LN, 2008, GERONTOLOGIST, V48, P698, DOI 10.1093/geront/48.5.698; Glasgow RE, 2002, PATIENT EDUC COUNS, V48, P115, DOI 10.1016/S0738-3991(02)00025-3; Goeppinger J, 2007, ARTHRIT RHEUM-ARTHR, V57, P1081, DOI 10.1002/art.22896; GREEN LW, 1977, AM J PUBLIC HEALTH, V67, P155, DOI 10.2105/AJPH.67.2.155; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; Gwaltney CJ, 2005, J ABNORM PSYCHOL, V114, P661, DOI 10.1037/0021-843X.114.4.661; Haas M, 2005, J MANIP PHYSIOL THER, V28, P228, DOI 10.1016/j.jmpt.2005.03.010; Hennessy M, 1999, STRUCT EQU MODELING, V6, P322, DOI 10.1080/10705519909540139; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jerant A, 2008, MED CARE, V46, P523, DOI 10.1097/MLR.0b013e31815f53a4; Jerant A, 2009, ANN FAM MED, V7, P319, DOI 10.1370/afm.996; Jordan JE, 2009, J CLIN EPIDEMIOL, V62, P642, DOI 10.1016/j.jclinepi.2008.07.019; KENNY DA, 1995, J CONSULT CLIN PSYCH, V63, P52, DOI 10.1037/0022-006X.63.1.52; Krebs P, 2010, PREV MED, V51, P214, DOI 10.1016/j.ypmed.2010.06.004; Linden M, 2013, CLIN PSYCHOL PSYCHOT, V20, P286, DOI 10.1002/cpp.1765; LORIG K, 1989, SOC SCI MED, V29, P221, DOI 10.1016/0277-9536(89)90170-6; Lorig K., 2020, LIVING HLTHY LIFE CH, V5th ed.; Lorig K, 2001, LIVING HLTH LIFE CHR; Lorig K, 2000, LIVING HLTH LIFE CHR; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lorig K, 2008, DIABETES CARE, V31, P408, DOI 10.2337/dc07-1313; Lorig K, 2010, DIABETES CARE, V33, P1275, DOI 10.2337/dc09-2153; Lorig KR, 2006, MED CARE, V44, P964, DOI 10.1097/01.mlr.0000233678.80203.c1; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lorig KR, 2005, DIABETES EDUCATOR, V31, P401, DOI 10.1177/0145721705276574; Lorig KR, 2004, MED CARE, V42, P346, DOI 10.1097/01.mlr.0000118709.74348.65; Matsudaira T, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-42; McArdle JJ, 2002, DEV PSYCHOL, V38, P115, DOI 10.1037//0012-1649.38.1.115; McDowell I, 2006, MEASURING HLTH GUIDE, P294; McLeod LD, 2011, EXPERT REV PHARM OUT, V11, P163, DOI [10.1586/ERP.11.12, 10.1586/erp.11.12]; Mulligan K, 2007, CAMBRIDGE HANDBOOK OF PSYCHOLOGY, HEALTH AND MEDICINE, 2ND EDITION, P393; Muschalla B, 2011, REHABILITATION, V50, P103, DOI 10.1055/s-0030-1265182; Newman S, 2009, CHRONIC PHYS ILLNESS, P72; Nguyen HQ, 2005, HEART LUNG, V34, P51, DOI 10.1016/j.hrtlng.2004.06.005; Nolte S, 2007, PATIENT EDUC COUNS, V65, P351, DOI 10.1016/j.pec.2006.08.016; Norman Geoffrey R, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P581, DOI 10.1586/14737167.4.5.581; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Osborne RH, 2007, PATIENT EDUC COUNS, V66, P192, DOI 10.1016/j.pec.2006.12.002; Osborne RH, 2006, ARTHRIT RHEUM-ARTHR, V55, P458, DOI 10.1002/art.21982; Park MJ, 2013, CHRONIC ILLN, V9, P73, DOI 10.1177/1742395312453351; Park MJ, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-145; Puhan MA, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-46; Riemsma RP, 2003, ARTHRIT RHEUM-ARTHR, V49, P556, DOI 10.1002/art.11207; Schwartz C, 2006, QUAL LIFE RES, V15, P1503, DOI 10.1007/s11136-006-0008-x; Siu AMH, 2007, PATIENT EDUC COUNS, V65, P42, DOI 10.1016/j.pec.2006.04.013; Smith L, 2007, SOC SCI MED, V64, P1501, DOI 10.1016/j.socscimed.2006.11.006; Swerissen H, 2006, PATIENT EDUC COUNS, V64, P360, DOI 10.1016/j.pec.2006.04.003; Tousman S, 2010, CLIN NURS RES, V19, P71, DOI 10.1177/1054773809354290; Wyrwich KW, 2013, QUAL LIFE RES, V22, P475, DOI 10.1007/s11136-012-0175-x; Wyrwich KW, 2005, QUAL LIFE RES, V14, P285, DOI 10.1007/s11136-004-0705-2; Yip Yin-Bing, 2008, Psychol Health Med, V13, P402, DOI 10.1080/13548500701584030	73	1	1	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2013	8	6							e65316	10.1371/journal.pone.0065316	http://dx.doi.org/10.1371/journal.pone.0065316			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	172XB	23785418	Green Published, Green Submitted, gold			2023-01-03	WOS:000321038800102
J	Chlan, LL; Weinert, CR; Heiderscheit, A; Tracy, MF; Skaar, DJ; Guttormson, JL; Savik, K				Chlan, Linda L.; Weinert, Craig R.; Heiderscheit, Annie; Tracy, Mary Fran; Skaar, Debra J.; Guttormson, Jill L.; Savik, Kay			Effects of Patient-Directed Music Intervention on Anxiety and Sedative Exposure in Critically Ill Patients Receiving Mechanical Ventilatory Support A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; NEUROMUSCULAR BLOCKING-AGENTS; RELAXATION; ANALGESICS; DECREASES; PROTOCOL; DELIRIUM; THERAPY	Importance Alternatives to sedative medications, such as music, may alleviate the anxiety associated with ventilatory support. Objective To test whether listening to self-initiated patient-directed music (PDM) can reduce anxiety and sedative exposure during ventilatory support in critically ill patients. Design, Setting, and Patients Randomized clinical trial that enrolled 373 patients from 12 intensive care units (ICUs) at 5 hospitals in the Minneapolis-St Paul, Minnesota, area receiving acute mechanical ventilatory support for respiratory failure between September 2006 and March 2011. Of the patients included in the study, 86% were white, 52% were female, and the mean (SD) age was 59 (14) years. The patients had a mean (SD) Acute Physiology, Age and Chronic Health Evaluation III score of 63 (21.6) and a mean (SD) of 5.7 (6.4) study days. Interventions Self-initiated PDM (n=126) with preferred selections tailored by a music therapist whenever desired while receiving ventilatory support, self-initiated use of noise-canceling headphones (NCH; n=122), or usual care (n=125). Main Outcomes and Measures Daily assessments of anxiety (on 100-mm visual analog scale) and 2 aggregate measures of sedative exposure (intensity and frequency). Results Patients in the PDM group listened to music for a mean (SD) of 79.8 (126) (median [range], 12 [0-796]) minutes/day. Patients in the NCH group wore the noise-abating headphones for a mean(SD) of 34.0 (89.6) (median [range], 0 [0-916]) minutes/day. The mixed-models analysis showed that at any time point, patients in the PDM group had an anxiety score that was 19.5 points lower(95% CI, -32.2 to -6.8) than patients in the usual care group (P=.003). By the fifth study day, anxiety was reduced by 36.5% in PDM patients. The treatment x time interaction showed that PDM significantly reduced both measures of sedative exposure. Compared with usual care, the PDM group had reduced sedation intensity by -0.18 (95% CI, -0.36 to -0.004) points/day (P=.05) and had reduced frequency by -0.21 (95% CI, -0.37 to -0.05) points/day (P=.01). The PDM group had reduced sedation frequency by -0.18(95% CI, -0.36 to -0.004) points/day vs the NCH group (P=.04). By the fifth study day, the PDM patients received 2 fewer sedative doses (reduction of 38%) and had a reduction of 36% in sedation intensity. Conclusions and Relevance Among ICU patients receiving acute ventilatory support for respiratory failure, PDM resulted in greater reduction in anxiety compared with usual care, but not compared with NCH. Concurrently, PDM resulted in greater reduction in sedation frequency compared with usual care or NCH, and greater reduction in sedation intensity compared with usual care, but not compared with NCH.	[Chlan, Linda L.] Ohio State Univ, Coll Nursing, Columbus, OH 43210 USA; [Weinert, Craig R.] Univ Minnesota, Sch Med, Dept Pulm Allergy Crit Care & Sleep Med, Minneapolis, MN 55455 USA; [Heiderscheit, Annie] Univ Minnesota, Ctr Spiritual & Healing, Minneapolis, MN USA; [Skaar, Debra J.] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA; [Savik, Kay] Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA; [Weinert, Craig R.; Tracy, Mary Fran] Univ Minnesota, Med Ctr, Fairview, MN USA; [Guttormson, Jill L.] Marquette Univ, Coll Nursing, Milwaukee, WI 53233 USA	University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; Marquette University	Chlan, LL (corresponding author), Ohio State Univ, Coll Nursing, 398 Newton Hall,1585 Neil Ave, Columbus, OH 43210 USA.	chlan.1@osu.edu			National Institutes of Health, National Institute of Nursing Research [R01-NR009295]; National Institutes of Health; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR009295] Funding Source: NIH RePORTER	National Institutes of Health, National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	This study was funded by grant R01-NR009295 from the National Institutes of Health, National Institute of Nursing Research (Dr Chlan was the principal investigator of the grant). A portion of Dr Chlan's salary was paid by the National Institutes of Health to her institution for the work performed. Drs Weinert, Heiderscheit, Tracy, Skaar, and Ms Savik had a portion of their salaries paid by the National Institutes of Health to their institutions for work performed on the grant. Dr Guttormson was a paid project coordinator on this study funded by the National Institutes of Health.	Arroliga AC, 2008, CRIT CARE MED, V36, P1083, DOI 10.1097/CCM.0B013E3181653895; BARR J, 1995, CRIT CARE CLIN, V11, P827, DOI 10.1016/S0749-0704(18)30041-1; Chakraborty H, MIXED MODEL APPROACH; Chlan L, 1998, HEART LUNG, V27, P169, DOI 10.1016/S0147-9563(98)90004-8; Chlan L L, 2000, AACN Clin Issues, V11, P128, DOI 10.1097/00044067-200002000-00014; Chlan L L, 1995, Am J Crit Care, V4, P233; Chlan L, 2011, CONTEMP CLIN TRIALS, V32, P544, DOI 10.1016/j.cct.2011.03.005; Chlan L, 2011, NURS RES, V60, pS50, DOI 10.1097/NNR.0b013e318216009c; Chlan L, 2009, MUSIC THER PERSPECT, V27, P42, DOI 10.1093/mtp/27.1.42; Chlan LL, 2004, J ADV NURS, V48, P493, DOI 10.1111/j.1365-2648.2004.03231.x; Conti G, 2002, Minerva Anestesiol, V68, P240; Hwang J, 2005, ACTA ANAESTH SCAND, V49, P1334, DOI 10.1111/j.1399-6576.2005.00842.x; Johnson M M, 1990, Crit Care Nurse, V10, P48; Lee DWH, 2002, GASTROINTEST ENDOSC, V55, P33, DOI 10.1067/mge.2002.120387; Lepage C, 2001, ANESTH ANALG, V93, P912, DOI 10.1097/00000539-200110000-00022; Li DT, 2006, APPL NURS RES, V19, P216, DOI 10.1016/j.apnr.2006.01.003; Maranto C. D., 1993, MUSIC THERAPY HLTH E, P153; MAZZEO AJ, 1995, CRIT CARE CLIN, V11, P937, DOI 10.1016/S0749-0704(18)30047-2; MCCARTNEY JR, 1994, CRIT CARE CLIN, V10, P673, DOI 10.1016/S0749-0704(18)30099-X; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Riker RR, 2009, CRIT CARE CLIN, V25, P527, DOI 10.1016/j.ccc.2009.05.004; Sikes P J, 1992, AACN Clin Issues Crit Care Nurs, V3, P379; STOLTZFUS DP, 1995, CRIT CARE CLIN, V11, P903, DOI 10.1016/S0749-0704(18)30045-9; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; THAUT MH, 1993, J MUSIC THER, V30, P210, DOI 10.1093/jmt/30.4.210; TUNG A, 1995, CRIT CARE CLIN, V11, P791, DOI 10.1016/S0749-0704(18)30039-3; Vogelsang J, 1988, J Post Anesth Nurs, V3, P235; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D; Wong HLC, 2001, HEART LUNG, V30, P376, DOI 10.1067/mhl.2001.118302	31	137	140	0	64	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2013	309	22					2335	2344		10.1001/jama.2013.5670	http://dx.doi.org/10.1001/jama.2013.5670			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161EV	23689789	Green Accepted			2023-01-03	WOS:000320176000023
J	Kainz, KP; Krenn, L; Erdem, Z; Kaehlig, H; Zehl, M; Bursch, W; Berger, W; Marian, B				Kainz, Kerstin P.; Krenn, Liselotte; Erdem, Zeynep; Kaehlig, Hanspeter; Zehl, Martin; Bursch, Wilfried; Berger, Walter; Marian, Brigitte			2-Deprenyl-Rheediaxanthone B Isolated from Metaxya rostrata Induces Active Cell Death in Colorectal Tumor Cells	PLOS ONE			English	Article							INDUCED MITOTIC CATASTROPHE; ALPHA-MANGOSTIN; CANCER-CELLS; COLON-CANCER; IN-VITRO; APOPTOSIS; EXPRESSION; XANTHONES; MITOCHONDRIA; PROGRESSION	Metaxya rostrata C. Presl (Metaxyaceae) is a common tree fern in Central and South America that is used for the treatment of intestinal ulcers and tumours in ethnic medicine. Using a bioactivity-guided strategy 2-deprenyl-rheediaxanthone B (XB) has been isolated as one of the active principles in this plant. XB induced loss of cell viability in colorectal cancer cell lines at IC50 concentrations of 11-23 mu M. This was caused by both accumulation of cells in the G2- and S-phase as well as by induction of active cell death in a time and concentration-dependent manner. Cells exposed to XB were incapable of undergoing regular mitosis due to down-regulation of FoxM1 and absence of chromosome condensation. The apoptosis-related proteins Bcl(2) and Bcl(xl) were up-regulated so that Caspase 3 was not activated and classical apoptosis was not observed. However, XB triggered damage pathways down-stream of ATR and activated Caspase 2 causing cell death by a mechanism similar to mitotic catastrophe. Our observations are the first to show the cytotoxic activity of 2-deprenyl-rheediaxanthone B and indicate that XB is an interesting new lead compound for cancer therapy that merits further development.	[Kainz, Kerstin P.; Erdem, Zeynep; Bursch, Wilfried; Berger, Walter; Marian, Brigitte] Med Univ Vienna, Dept Med 1, Inst Canc Res, Vienna, Austria; [Kainz, Kerstin P.; Krenn, Liselotte; Zehl, Martin] Univ Vienna, Dept Pharmacognosy, Vienna, Austria; [Kaehlig, Hanspeter] Univ Vienna, Dept Organ Chem, Vienna, Austria	Medical University of Vienna; University of Vienna; University of Vienna	Marian, B (corresponding author), Med Univ Vienna, Dept Med 1, Inst Canc Res, Vienna, Austria.	brigitte.marian@meduniwien.ac.at	Zehl, Martin/B-5901-2008	Zehl, Martin/0000-0001-9685-0373; Berger, Walter/0000-0003-0014-1658; Krenn, Liselotte/0000-0002-9526-4396; Kaehlig, Hanspeter/0000-0002-3898-6501	Austrian Science Foundation [P20354]	Austrian Science Foundation(Austrian Science Fund (FWF))	The study was suppported by the Austrian Science Foundation (P20354). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akao Y, 2008, INT J MOL SCI, V9, P355, DOI 10.3390/ijms9030355; Batova A, 2010, MOL CANCER THER, V9, P2869, DOI 10.1158/1535-7163.MCT-10-0517; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Castanheiro RAP, 2009, PHARMACEUTICALS, V2, P33, DOI 10.3390/ph2020033; Chao AC, 2011, J AGR FOOD CHEM, V59, P2086, DOI 10.1021/jf1042757; Cheng JH, 2011, EUR J MED CHEM, V46, P1222, DOI 10.1016/j.ejmech.2011.01.043; de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001; Ding L, 2009, TOXICOL IN VITRO, V23, P408, DOI 10.1016/j.tiv.2009.01.010; Eng C, 2010, ONCOLOGIST, V15, P73, DOI 10.1634/theoncologist.2009-0167; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Garcia-Rivera D, 2011, CANCER LETT, V305, P21, DOI 10.1016/j.canlet.2011.02.011; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hausott B, 2004, INT J CANCER, V109, P933, DOI 10.1002/ijc.20033; Hay AE, 2004, LIFE SCI, V75, P3077, DOI 10.1016/j.lfs.2004.07.009; Hinoshita E, 2000, CLIN CANCER RES, V6, P2401; Ianzini F, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-11; Kalabis J, 2003, FASEB J, V17, P1115, DOI 10.1096/fj.02-0852fje; Kim Jinwoong, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P485; Krajarng A, 2011, J AGR FOOD CHEM, V59, P5746, DOI 10.1021/jf200620n; Krajewska M, 1996, CANCER RES, V56, P2422; Lavaud A, 2012, BIOCHEM PHARMACOL, V83, P514, DOI 10.1016/j.bcp.2011.12.002; Lim CK, 2011, LETT DRUG DES DISCOV, V8, P523; Macdonald JS, 2001, SEMIN ONCOL, V28, P30, DOI 10.1053/sonc.2001.20750; Matsumoto K, 2004, BIOORGAN MED CHEM, V12, P5799, DOI 10.1016/j.bmc.2004.08.034; Monache FD, 1981, J CHEM SOC, V1, P484; Nakagawa Y, 2007, BIOORGAN MED CHEM, V15, P5620, DOI 10.1016/j.bmc.2007.04.071; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Niu SL, 2012, PHYTOCHEMISTRY, V77, P280, DOI 10.1016/j.phytochem.2012.01.010; Palmeira A, 2010, CHEM BIOL DRUG DES, V76, P43, DOI 10.1111/j.1747-0285.2010.00978.x; Partik G, 1998, VIRCHOWS ARCH, V432, P415, DOI 10.1007/s004280050185; Pekarek B, 2003, THESIS U NATURAL RES; Peng KC, 1999, J HISTOCHEM CYTOCHEM, V47, P757, DOI 10.1177/002215549904700605; Peterson C, 2011, EUR J CLIN PHARMACOL, V67, P437, DOI 10.1007/s00228-011-1011-x; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Ragnhammar P, 2001, ACTA ONCOL, V40, P282, DOI 10.1080/02841860151116367; Rath G, 1996, PHYTOCHEMISTRY, V43, P513, DOI 10.1016/0031-9422(96)00284-1; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Shen R, 2010, J FLUORESC, V20, P1287, DOI 10.1007/s10895-010-0680-7; Singh R, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-4; Virtbauer J, 2008, Z NATURFORSCH C, V63, P469; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Watanapokasin R, 2011, WORLD J GASTROENTERO, V17, P2086, DOI 10.3748/wjg.v17.i16.2086; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7	44	14	14	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2013	8	6							e65745	10.1371/journal.pone.0065745	http://dx.doi.org/10.1371/journal.pone.0065745			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169CU	23776538	Green Published, gold, Green Submitted			2023-01-03	WOS:000320755400064
J	Alcaide, ML; Parmigiani, A; Pallikkuth, S; Roach, M; Freguja, R; Della Negra, M; Bolivar, H; Fischl, MA; Pahwa, S				Alcaide, Maria L.; Parmigiani, Anita; Pallikkuth, Suresh; Roach, Margaret; Freguja, Riccardo; Della Negra, Marina; Bolivar, Hector; Fischl, Margaret A.; Pahwa, Savita			Immune Activation in HIV-Infected Aging Women on Antiretrovirals-Implications for Age-Associated Comorbidities: A Cross-Sectional Pilot Study	PLOS ONE			English	Article							T-CELL-ACTIVATION; MICROBIAL TRANSLOCATION; CARDIOVASCULAR-DISEASE; FLOW-CYTOMETRY; SOLUBLE CD163; PLASMA-LEVELS; THERAPY; AIDS; DYSREGULATION; PROGRESSION	Background: Persistent immune activation and microbial translocation associated with HIV infection likely place HIV-infected aging women at high risk of developing chronic age-related diseases. We investigated immune activation and microbial translocation in HIV-infected aging women in the post-menopausal ages. Methods: Twenty-seven post-menopausal women with HIV infection receiving antiretroviral treatment with documented viral suppression and 15 HIV-negative age-matched controls were enrolled. Levels of immune activation markers (T cell immune phenotype, sCD25, sCD14, sCD163), microbial translocation (LPS) and biomarkers of cardiovascular disease and impaired cognitive function (sVCAM-1, sICAM-1 and CXCL10) were evaluated. Results: T cell activation and exhaustion, monocyte/macrophage activation, and microbial translocation were significantly higher in HIV-infected women when compared to uninfected controls. Microbial translocation correlated with T cell and monocyte/macrophage activation. Biomarkers of cardiovascular disease and impaired cognition were elevated in women with HIV infection and correlated with immune activation. Conclusions: HIV-infected antiretroviral-treated aging women who achieved viral suppression are in a generalized status of immune activation and therefore are at an increased risk of age-associated end-organ diseases compared to uninfected age-matched controls.	[Alcaide, Maria L.] Univ Miami, Miller Sch Med, Div Infect Dis, Miami, FL 33136 USA; [Parmigiani, Anita; Pallikkuth, Suresh; Roach, Margaret; Pahwa, Savita] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; [Freguja, Riccardo] Univ Padua, Sect Oncol & Immunol, Dept Surg Oncol & Gastroenterol, Unit Viral Oncol, I-35100 Padua, Italy; [Freguja, Riccardo] Univ Padua, AIDS Reference Ctr, I-35100 Padua, Italy; [Della Negra, Marina] Inst Infectol Emilio Ribas, Sao Paulo, Brazil; [Bolivar, Hector; Fischl, Margaret A.] Univ Miami, Miller Sch Med, AIDS Clin Res Unit, Div Infect Dis, Miami, FL 33136 USA	University of Miami; University of Miami; University of Padua; University of Padua; University of Miami	Pahwa, S (corresponding author), Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.	Spahwa@med.miami.edu	Pahwa, Savita/AAA-4900-2019	Pahwa, Savita/0000-0002-4470-4216; Alcaide, Maria/0000-0003-4648-0145	University of Miami CFAR (United States National Institutes of Health) [P30 AI073961]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI073961] Funding Source: NIH RePORTER	University of Miami CFAR (United States National Institutes of Health); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded through a developmental award from the University of Miami CFAR (United States National Institutes of Health P30 AI073961). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alimonti JB, 2003, J GEN VIROL, V84, P1649, DOI 10.1099/vir.0.19110-0; Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brockman MA, 2009, BLOOD, V114, P346, DOI 10.1182/blood-2008-12-191296; Burdo T. H., 2013, AIDS; Burdo TH, 2011, J INFECT DIS, V204, P1227, DOI 10.1093/infdis/jir520; Burdo TH, 2011, J INFECT DIS, V204, P154, DOI 10.1093/infdis/jir214; Cao W, 2009, JAIDS-J ACQ IMM DEF, V50, P137, DOI 10.1097/QAI.0b013e3181926c28; Catalfamo M, 2008, P NATL ACAD SCI USA, V105, P19851, DOI 10.1073/pnas.0810032105; Desai Seema, 2010, Curr HIV/AIDS Rep, V7, P4, DOI 10.1007/s11904-009-0038-4; Dhillon NK, 2008, FRONT BIOSCI, V13, P3913, DOI 10.2741/2979; Douek Daniel, 2007, Top HIV Med, V15, P114; Engelmann F, 2011, AGE, V33, P275, DOI 10.1007/s11357-010-9178-0; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Gameiro CM, 2010, MATURITAS, V67, P316, DOI 10.1016/j.maturitas.2010.08.003; Hatano H, 2012, J INFECT DIS; Hazenberg MD, 2003, AIDS, V17, P1881, DOI 10.1097/00002030-200309050-00006; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hearps AC, 2012, AGING CELL, V11, P867, DOI 10.1111/j.1474-9726.2012.00851.x; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476; Kaplan RC, 2012, JAIDS-J ACQ IMM DEF, V60, P359, DOI 10.1097/QAI.0b013e31825b03be; Kaplan RC, 2011, J INFECT DIS, V203, P452, DOI 10.1093/infdis/jiq071; Kiazyk SAK, 2008, TRENDS MICROBIOL, V16, P567, DOI 10.1016/j.tim.2008.08.011; Kolb SA, 1999, J NEUROIMMUNOL, V93, P172, DOI 10.1016/S0165-5728(98)00223-9; Lederman MM, 2011, J INFECT DIS, V204, P1217, DOI 10.1093/infdis/jir507; Lyons JL, 2011, JAIDS-J ACQ IMM DEF, V57, P371, DOI 10.1097/QAI.0b013e3182237e54; Maecker HT, 2006, CYTOM PART A, V69A, P1037, DOI 10.1002/cyto.a.20333; Marchetti G, 2008, AIDS, V22, P2035, DOI 10.1097/QAD.0b013e3283112d29; Marchetti G, 2006, AIDS, V20, P1727, DOI 10.1097/01.aids.0000242819.72839.db; Marchetti G, 2013, CLIN MICROBIOL REV, V26, P2, DOI 10.1128/CMR.00050-12; Marchetti G, 2011, AIDS, V25, P1385, DOI 10.1097/QAD.0b013e3283471d10; Massanella M, 2010, AIDS, V24, P959, DOI 10.1097/QAD.0b013e328337b957; Mavigner M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007658; Moore RD, 2012, CLIN INFECT DIS, V55, P1242, DOI 10.1093/cid/cis654; Ockene IS, 1997, CIRCULATION, V96, P3243, DOI 10.1161/01.CIR.96.9.3243; Perfetto SP, 2006, NAT PROTOC, V1, P1522, DOI 10.1038/nprot.2006.250; Piconi S, 2010, AIDS, V24, P1991, DOI 10.1097/QAD.0b013e32833c93ce; RHOADS GG, 1983, LANCET, V1, P492; Ross AC, 2009, CLIN INFECT DIS, V49, P1119, DOI 10.1086/605578; Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848; Sandler NG, 2011, J INFECT DIS, V203, P780, DOI 10.1093/infdis/jiq118; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Shaw AC, 2010, CURR OPIN IMMUNOL, V22, P507, DOI 10.1016/j.coi.2010.05.003; Sui YJ, 2006, EUR J NEUROSCI, V23, P957, DOI 10.1111/j.1460-9568.2006.04631.x; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tilling R, 2002, AIDS, V16, P589, DOI 10.1097/00002030-200203080-00010; Triant VA, 2011, J INFECT DIS, V203, P439, DOI 10.1093/infdis/jiq084; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9	50	55	55	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e63804	10.1371/journal.pone.0063804	http://dx.doi.org/10.1371/journal.pone.0063804			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155FM	23724003	Green Published, gold, Green Submitted			2023-01-03	WOS:000319733000026
J	Lai, LY; Qian, J; Yang, YJ; Xie, QH; You, HZ; Zhou, Y; Ma, S; Hao, CM; Gu, Y; Ding, F				Lai, Lingyun; Qian, Jing; Yang, Yanjiao; Xie, Qionghong; You, Huaizhou; Zhou, Ying; Ma, Shuai; Hao, Chuanming; Gu, Yong; Ding, Feng			Is the Serum Vitamin D Level at the Time of Hospital-Acquired Acute Kidney Injury Diagnosis Associated with Prognosis?	PLOS ONE			English	Article							D DEFICIENCY; 25-HYDROXYVITAMIN-D; MORTALITY	Background: Low circulating vitamin D levels have been suggested to potentially contribute to acute complications in critically ill patients. However, in patients with acute kidney injury (AKI), whether vitamin D deficiency occurs and is a potential contributor to worse early outcomes at the time of AKI diagnosis remains unclear. Methodology/Principal Findings: Two hundred patients with AKI were enrolled in our study. Healthy subjects and critically ill patients without AKI served as controls. Serum vitamin D concentrations were measured in the three groups. The patients with AKI were followed up for 90 days and grouped according to median serum vitamin D concentrations. In addition, vitamin D receptor polymorphisms (BsmI and FokI) were measured in these patients; they were also followed up for 90 days and grouped according to vitamin D receptor gene mutations. Low serum 1,25-dihydroxyvitamin D levels (59.56 +/- 53.00 pmol/L) were detected in patients with AKI and decreased with increasing severity of AKI. There were no significant findings with respect to 25-hydroxyvitamin D. The 90-day survival curves of individuals with high vitamin D concentrations showed no significant differences compared with the curves of individuals with low concentrations. The survival curves of patients with BB/Bb or FF/Ff genotypes also showed no significant differences compared with patients with bb or ff genotypes. In Cox regression analysis, the vitamin D status in patients with AKI was not an independent prognostic factor as adjusted by age, sex, Sequential Organ Failure Assessment score, or vitamin D receptor polymorphisms. Conclusions/Significance: Patients with AKI manifested a marked decrease in the 1,25-dihydroxyvitamin D level at the time of AKI diagnosis, and the degree of 1,25-dihydroxyvitamin D deficiency increased with the severity of AKI. No association between the serum vitamin D level at the time of AKI diagnosis and 90-day all-cause mortality was found in patients with AKI.	[Lai, Lingyun; Qian, Jing; Yang, Yanjiao; Xie, Qionghong; You, Huaizhou; Zhou, Ying; Ma, Shuai; Hao, Chuanming; Gu, Yong; Ding, Feng] Fudan Univ, Div Nephrol, Huashan Hosp, Shanghai 200433, Peoples R China	Fudan University	Ding, F (corresponding author), Fudan Univ, Div Nephrol, Huashan Hosp, Shanghai 200433, Peoples R China.	dingfeng@fudan.edu.cn			National Natural Science Foundation of China [81070609, 30800526]; Science and Technology Commission of Shanghai Municipality [09411961500]; Shanghai Pujiang Program	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Pujiang Program(Shanghai Pujiang Program)	This study was funded in part by grants from National Natural Science Foundation of China (No: 81070609), the Science and Technology Commission of Shanghai Municipality (No: 09411961500), Shanghai Pujiang Program (to FD) and National Natural Science Foundation of China (No. 30800526) (to HY). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnson Y, 2012, QJM-INT J MED, V105, P633, DOI 10.1093/qjmed/hcs014; Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Braun A, 2011, CRIT CARE MED, V39, P671, DOI 10.1097/CCM.0b013e318206ccdf; Braun AB, 2012, CRIT CARE MED, V40, P63, DOI 10.1097/CCM.0b013e31822d74f3; COBURN JW, 1974, WESTERN J MED, V121, P22; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P8, DOI 10.1177/014860718701100108; Dobnig H, 2008, ARCH INTERN MED, V168, P1340, DOI 10.1001/archinte.168.12.1340; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Hagenau T, 2009, OSTEOPOROSIS INT, V20, P133, DOI 10.1007/s00198-008-0626-y; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Lee P, 2009, INTENS CARE MED, V35, P2028, DOI 10.1007/s00134-009-1642-x; Lee P, 2009, NEW ENGL J MED, V360, P1912, DOI 10.1056/NEJMc0809996; Li M, 2011, SHANGHAI MED J, V34; Lucidarme O, 2010, INTENS CARE MED, V36, P1609, DOI 10.1007/s00134-010-1875-8; Melamed ML, 2008, ARCH INTERN MED, V168, P1629, DOI 10.1001/archinte.168.15.1629; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; Valdivielso JM, 2006, CLIN CHIM ACTA, V371, P1, DOI 10.1016/j.cca.2006.02.016; Venkatram S, 2011, CRIT CARE, V15, DOI 10.1186/cc10585; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; World Health Organization International Agency for Research on Cancer, 2008, IARC WORK GROUP REP; Zittermann A, 2009, CURR OPIN CLIN NUTR, V12, P634, DOI 10.1097/MCO.0b013e3283310767	22	20	20	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2013	8	5							e64964	10.1371/journal.pone.0064964	http://dx.doi.org/10.1371/journal.pone.0064964			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163UP	23717679	Green Submitted, Green Published, gold			2023-01-03	WOS:000320362700185
J	Ji, WT; Lee, CI; Chen, JYF; Cheng, YP; Yang, SR; Chen, JH; Chen, HR				Ji, Wen-Tsai; Lee, Cheng-I; Chen, Jeff Yi-Fu; Cheng, Ya-Ping; Yang, Sheng-Ru; Chen, Jung-Hua; Chen, Hau-Ren			Areca Nut Extract Induces Pyknotic Necrosis in Serum-Starved Oral Cells via Increasing Reactive Oxygen Species and Inhibiting GSK3 beta: An Implication for Cytopathic Effects in Betel Quid Chewers	PLOS ONE			English	Article							CANCER CELLS; CYCLE ARREST; AUTOPHAGY; CARCINOMA; APOPTOSIS; EXPRESSION; STRESS; TAIWAN; DEATH; DNA	Areca nut has been proven to be correlated with various pathologic alterations in oral cavity. However, the mechanisms for such cytopathic effects are still elusive due mostly to the limitations of cell culture systems. Here we discovered that areca nut extract (ANE) induced production of autophagosome vacuoles in cells cultured with rich medium but induced pyknosis and ballooning, two morphological alterations frequently observed in betel quid chewers, in cells under a serum-free culture condition. Permeability of the serum-starved cells to propidium iodide (PI) confirmed ANE induced novel necrosis with pyknosis (pyknotic necrosis), providing a possible explanation for inflammatory infiltration in chewers' mucosa. In these serum-starved cells, ANE strongly induced reactive oxygen species (ROS), which acted as a key switch for the initiation of pyknotic necrosis. Calcium flux was also involved in the morphological alterations. Besides, inhibition of GSK3 beta by SB216763 significantly exacerbated the pyknotic necrosis either induced by ANE or H2O2 in serum-starved cells, suggesting that GSK3 beta is a critical regulator for ANE/ROS-mediated pyknotic necrosis. Interestingly, LC3-II transition and PARP cleavage were still detected in the serum-starved cells after ANE treatment, suggesting concurrent activation of apoptotic and autophagic pathways. Finally, insulin could counteract the effect of ANE-induced pyknotic necrosis. Taken together, these data provide a platform for studying ANE-induced cytopathogenesis and the first clinical implication for several pathological alterations, such as ballooning and inflammatory infiltration, in betel quid chewers.	[Ji, Wen-Tsai; Lee, Cheng-I; Cheng, Ya-Ping; Yang, Sheng-Ru; Chen, Jung-Hua; Chen, Hau-Ren] Natl Chung Cheng Univ, Coll Sci, Inst Mol Biol, Dept Life Sci, Chiayi, Taiwan; [Ji, Wen-Tsai; Lee, Cheng-I; Cheng, Ya-Ping; Yang, Sheng-Ru; Chen, Jung-Hua; Chen, Hau-Ren] Natl Chung Cheng Univ, Coll Sci, Inst Biomed Sci, Chiayi, Taiwan; [Chen, Jeff Yi-Fu] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung, Taiwan	National Chung Cheng University; National Chung Cheng University; Kaohsiung Medical University	Chen, HR (corresponding author), Natl Chung Cheng Univ, Coll Sci, Inst Mol Biol, Dept Life Sci, Chiayi, Taiwan.	biohrc@ccu.edu.tw			National Science Council [97-2311-B-194-001-MY3]	National Science Council(Ministry of Science and Technology, Taiwan)	This work was partially supported by National Science Council (97-2311-B-194-001-MY3). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chang MC, 2001, CARCINOGENESIS, V22, P1527, DOI 10.1093/carcin/22.9.1527; Chen JYF, 2008, NEOPLASIA, V10, P1393, DOI 10.1593/neo.08854; Chen SH, 2011, HEALTH POLICY PLANN, V26, P266, DOI 10.1093/heapol/czq041; Cheng HL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-126; Cheng YP, 2012, J BIOMEDICAL SCI, P19; Chiu CT, 2008, J DENT SCI, V3, P75; Festjens N, 2006, BBA-BIOENERGETICS, V1757, P1371, DOI 10.1016/j.bbabio.2006.06.014; Fimia GM, 1996, J BIOL CHEM, V271, P15575, DOI 10.1074/jbc.271.26.15575; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Huang LW, 2012, TOXICOL APPL PHARM, V258, P199, DOI 10.1016/j.taap.2011.11.001; Huang TT, 2010, J FORMOS MED ASSOC, V109, P326, DOI 10.1016/S0929-6646(10)60060-5; Ji WT, 2012, CANCER SCI, V103, P1221, DOI 10.1111/j.1349-7006.2012.02294.x; Lin MH, 2010, ORAL ONCOL, V46, P822, DOI 10.1016/j.oraloncology.2010.08.002; Liu TY, 1996, MUTAT RES-GENET TOX, V367, P25, DOI 10.1016/S0165-1218(96)90018-X; Lu HH, 2010, AUTOPHAGY, V6, P725, DOI 10.4161/auto.6.6.12423; Lu SY, 2006, CARCINOGENESIS, V27, P1273, DOI 10.1093/carcin/bgi357; Reichart PA, 1998, J ORAL PATHOL MED, V27, P239, DOI 10.1111/j.1600-0714.1998.tb01949.x; Richard V, 2010, BBA-REV CANCER, V1806, P146, DOI 10.1016/j.bbcan.2010.06.004; Rusten TE, 2010, NAT CELL BIOL, V12, P207, DOI 10.1038/ncb0310-207; Soderlund G, 2004, NEOPLASMA, V51, P1; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Trivedy CR, 2002, ADDICT BIOL, V7, P115, DOI 10.1080/13556210120091482; Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234; Wang CC, 2009, TOXICOL IN VITRO, V23, P1234, DOI 10.1016/j.tiv.2009.07.033; Yang J, 2010, J CELL SCI, V123, P861, DOI 10.1242/jcs.060475; Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506	26	11	11	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2013	8	5							e63295	10.1371/journal.pone.0063295	http://dx.doi.org/10.1371/journal.pone.0063295			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	149OK	23704899	Green Submitted, Green Published, gold			2023-01-03	WOS:000319330200028
J	Zhou, W; Wang, HD; Zhu, XX; Shan, JJ; Yin, AL; Cai, BC; Di, LQ				Zhou, Wei; Wang, Haidan; Zhu, Xuanxuan; Shan, Jinjun; Yin, Ailing; Cai, Baochang; Di, Liuqing			Improvement of Intestinal Absorption of Forsythoside A and Chlorogenic Acid by Different Carboxymethyl Chitosan and Chito-oligosaccharide, Application to Flos Lonicerae - Fructus Forsythiae Herb Couple Preparations	PLOS ONE			English	Article							IN-SITU; DELIVERY-SYSTEMS; DRUG-DELIVERY; ENHANCERS; RATS; TRANSPORT; INSULIN; ANTIOXIDANT; MECHANISM; PERFUSION	The current study aims to investigate the effect of chitosan derivatives on the intestinal absorption and bioavailabilities of forsythoside A (FTA) and Chlorogenic acid (CHA), the major active components in Flos Lonicerae - Fructus Forsythiae herb couple. Biopharmaceutics and pharmacokinetics properties of the two compounds have been characterized in vitro, in situ as well as in rats. Based on the identified biopharmaceutics characteristics of the two compounds, the effect of chitosan derivatives as an absorption enhancer on the intestinal absorption and pharmacokinetics of FTA and CHA in pure compound form as well as extract form were investigated in vitro, in situ and in vivo. Both FTA and CHA demonstrated very limited intestinal permeabilities, leading to oral bioavailabilities being only 0.50% and 0.13% in rats, respectively. Results from both in vitro, in situ as well as in vivo studies consistently indicated that Chito-oligosaccharide (COS) at dosage of 25 mg/kg could enhance intestinal permeabilities significantly as well as the in vivo bioavailabilities of both FTA and CHA than CMCs in Flos Lonicerae - Fructus Forsythiae herb couple preparations, and was safe for gastrointestine from morphological observation. Besides, treatment with Flos Lonicerae - Fructus Forsythiae herb couple preparations with COS at the dosage of 25 mg/kg prevented MDCK damage after influenza virus propagation, which was significantly better than control. The current findings not only identified the usefulness of COS for the improved delivery of Flos Lonicerae - Fructus Forsythiae preparations but also demonstrated the importance of biopharmaceutical characterization in the dosage form development of traditional Chinese medicine.	[Zhou, Wei; Yin, Ailing; Cai, Baochang; Di, Liuqing] Nanjing Univ Chinese Med, Coll Pharm, Nanjing, Jiangsu, Peoples R China; [Zhou, Wei; Di, Liuqing] Jiangsu Engn Res Ctr Efficient Delivery Syst TCM, Nanjing, Jiangsu, Peoples R China; [Zhou, Wei; Di, Liuqing] Nanjing Engn Res Ctr Industrializat Chinese Med P, Nanjing, Jiangsu, Peoples R China; [Wang, Haidan; Zhu, Xuanxuan] Nanjing Univ Chinese Med, Dept Pharmacol, Affiliated Hosp, Nanjing, Jiangsu, Peoples R China; [Shan, Jinjun] Nanjing Univ Chinese Med, Med Coll 1, Nanjing, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Di, LQ (corresponding author), Nanjing Univ Chinese Med, Coll Pharm, Nanjing, Jiangsu, Peoples R China.	diliuqing@hotmail.com	wang, haidan/HGC-7982-2022; Zhou, Wei/I-5964-2014		National Natural Science Foundation of China [81073071, 81273655]; "Qing Lan" Project from Jiangsu Provincial Technology Innovation Team Support Scheme; priority Academic Program Development of Jiangsu Higher Education Institution [ysxk-2010]; program sponsored for scientific innovation research of college graduate in the Jiangsu province [623]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Qing Lan" Project from Jiangsu Provincial Technology Innovation Team Support Scheme; priority Academic Program Development of Jiangsu Higher Education Institution; program sponsored for scientific innovation research of college graduate in the Jiangsu province	The present study is supported financially by the National Natural Science Foundation of China (81073071, 81273655), "Qing Lan" Project from Jiangsu Provincial Technology Innovation Team Support Scheme, the priority Academic Program Development of Jiangsu Higher Education Institution (No.ysxk-2010) and a 2012 program sponsored for scientific innovation research of college graduate in the Jiangsu province (623). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Artursson P, 1994, PHARM RES, V11, P358; BARRY BW, 1983, DERMATOLOGICAL FORMU, P127; Bernkop-Schnurch A, 2012, EUR J PHARM BIOPHARM, V81, P463, DOI 10.1016/j.ejpb.2012.04.007; Du Qiu, 2009, Yaoxue Xuebao, V44, P922; Fetih G, 2005, J CONTROL RELEASE, V106, P287, DOI 10.1016/j.jconrel.2005.05.017; Gao Y, 2008, INT J PHARM, V359, P70, DOI 10.1016/j.ijpharm.2008.03.016; Hejazi R, 2003, J CONTROL RELEASE, V89, P151, DOI 10.1016/S0168-3659(03)00126-3; Hu K. J., 2001, J HARBIN MED U, V35, P430; ILLUM L, 1994, PHARMACEUT RES, V11, P1186, DOI 10.1023/A:1018901302450; Jonker C, 2002, INT J PHARMACEUT, V238, P205, DOI 10.1016/S0378-5173(02)00068-6; Konishi Y, 2004, J AGR FOOD CHEM, V52, P2518, DOI 10.1021/jf035407c; Kuang Hai-Xue, 2009, Chinese Journal of Natural Medicines, V7, P278, DOI 10.3724/SP.J.1009.2009.00278; [刘碧源 Liu Biyuan], 2003, [中国生化药物杂志, Chinese Journal of Biochemical Pharmaceutics], V24, P73; Ma YuanYuan, 2010, Scientia Agricultura Sinica, V43, P3237; Mehrbod P, 2009, DARU, V17, P88; Qu HH, 2008, J PHARM PHARMACOL, V60, P261, DOI 10.1211/jpp.60.2.0016; RAFTER JJ, 1986, GUT, V27, P1320, DOI 10.1136/gut.27.11.1320; Salama NN, 2006, ADV DRUG DELIVER REV, V58, P15, DOI 10.1016/j.addr.2006.01.003; Schipper NGM, 1997, PHARMACEUT RES, V14, P923, DOI 10.1023/A:1012160102740; Shang XF, 2011, J ETHNOPHARMACOL, V138, P1, DOI 10.1016/j.jep.2011.08.016; THOMSON ABR, 1986, J CLIN INVEST, V77, P279, DOI 10.1172/JCI112288; Uchiyama T, 1999, J PHARM PHARMACOL, V51, P1241, DOI 10.1211/0022357991776976; Wang GN, 2010, J CHROMATOGR B, V878, P102, DOI 10.1016/j.jchromb.2009.11.029; Yamamoto A, 1996, J PHARM PHARMACOL, V48, P1285, DOI 10.1111/j.2042-7158.1996.tb03937.x; Ye JX, 2010, J PHARMACEUT BIOMED, V52, P625, DOI 10.1016/j.jpba.2010.01.035; Yuan W., 2007, FOOD RES DEV, V28, P185; Zhang LW, 2002, EXTRACTION METHOD BI; Zhou W, 2012, PHYTOMEDICINE, V20, P47, DOI 10.1016/j.phymed.2012.09.014; Zhou W, 2012, ACTA PHARMACOL SIN, V33, P1069, DOI 10.1038/aps.2012.58; Zou YX, 2012, INT J MOL SCI, V13, P16544, DOI 10.3390/ijms131216544	30	22	25	2	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2013	8	5							e63348	10.1371/journal.pone.0063348	http://dx.doi.org/10.1371/journal.pone.0063348			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145RZ	23675483	Green Submitted, Green Published, gold			2023-01-03	WOS:000319036100041
J	Grupp, SA; Kalos, M; Barrett, D; Aplenc, R; Porter, DL; Rheingold, SR; Teachey, DT; Chew, A; Hauck, B; Wright, JF; Milone, MC; Levine, BL; June, CH				Grupp, Stephan A.; Kalos, Michael; Barrett, David; Aplenc, Richard; Porter, David L.; Rheingold, Susan R.; Teachey, David T.; Chew, Anne; Hauck, Bernd; Wright, J. Fraser; Milone, Michael C.; Levine, Bruce L.; June, Carl H.			Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; ACUTE LYMPHOCYTIC-LEUKEMIA; DONOR LEUKOCYTE INFUSIONS; ADOPTIVE IMMUNOTHERAPY; CLINICAL-TRIAL; CHEMOTHERAPY; PERSISTENCE; MALIGNANCY; CHILDREN	Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whether chimeric antigen receptor T cells have clinical activity in acute lymphoblastic leukemia (ALL). Two children with relapsed and refractory pre-B-cell ALL received infusions of T cells transduced with anti-CD19 antibody and a T-cell signaling molecule (CTL019 chimeric antigen receptor T cells), at a dose of 1.4x10(6) to 1.2x10(7) CTL019 cells per kilogram of body weight. In both patients, CTL019 T cells expanded to a level that was more than 1000 times as high as the initial engraftment level, and the cells were identified in bone marrow. In addition, the chimeric antigen receptor T cells were observed in the cerebrospinal fluid (CSF), where they persisted at high levels for at least 6 months. Eight grade 3 or 4 adverse events were noted. The cytokine-release syndrome and B-cell aplasia developed in both patients. In one child, the cytokine-release syndrome was severe; cytokine blockade with etanercept and tocilizumab was effective in reversing the syndrome and did not prevent expansion of chimeric antigen receptor T cells or reduce anti-leukemic efficacy. Complete remission was observed in both patients and is ongoing in one patient at 11 months after treatment. The other patient had a relapse, with blast cells that no longer expressed CD19, approximately 2 months after treatment. Chimeric antigen receptor-modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. The emergence of tumor cells that no longer express the target indicates a need to target other molecules in addition to CD19 in some patients with ALL.	[Grupp, Stephan A.; Barrett, David; Aplenc, Richard; Rheingold, Susan R.; Teachey, David T.; Hauck, Bernd; Wright, J. Fraser] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Grupp, Stephan A.; Barrett, David; Aplenc, Richard; Rheingold, Susan R.; Teachey, David T.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; [Grupp, Stephan A.; Kalos, Michael; Aplenc, Richard; Porter, David L.; Rheingold, Susan R.; Teachey, David T.; Milone, Michael C.; Levine, Bruce L.; June, Carl H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Kalos, Michael; Chew, Anne; Hauck, Bernd; Wright, J. Fraser; Milone, Michael C.; Levine, Bruce L.; June, Carl H.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Porter, David L.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Grupp, SA (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Oncol BMT CTRB 3006,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	grupp@email.chop.edu		Teachey, David/0000-0001-7373-8987; June, Carl/0000-0003-0241-3557	National Institutes of Health [1R01CA165206, R01CA102646, R01CA116660]; Leukemia and Lymphoma Society; NATIONAL CANCER INSTITUTE [P30CA016520, R01CA165206, R01CA102646, R01CA116660] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported in part by grants from the National Institutes of Health (1R01CA165206, to Dr. June; and R01CA102646 and R01CA116660, to Dr. Grupp) and the Leukemia and Lymphoma Society.	Bargou R, 2008, SCIENCE, V321, P974, DOI 10.1126/science.1158545; BARRETT AJ, 1994, NEW ENGL J MED, V331, P1253, DOI 10.1056/NEJM199411103311902; Behrens EM, 2011, J CLIN INVEST, V121, P2264, DOI 10.1172/JCI43157; Brentjens RJ, 2011, BLOOD, V118, P4817, DOI 10.1182/blood-2011-04-348540; Collins RH, 2000, BONE MARROW TRANSPL, V26, P511, DOI 10.1038/sj.bmt.1702555; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Huu DL, 2012, J INVEST DERMATOL, V132, P2752, DOI 10.1038/jid.2012.226; Drobyski WR, 2011, BIOL BLOOD MARROW TR, V17, P1862, DOI 10.1016/j.bbmt.2011.07.001; Garcia-Manero G, 2001, HEMATOL ONCOL CLIN N, V15, P163, DOI 10.1016/S0889-8588(05)70204-5; Gokbuget N, 2012, BLOOD, V120, P2032, DOI 10.1182/blood-2011-12-399287; Hotfilder M, 2005, CANCER RES, V65, P1442, DOI 10.1158/0008-5472.CAN-04-1356; Janka GE, 2012, ANNU REV MED, V63, P233, DOI 10.1146/annurev-med-041610-134208; Jensen MC, 2010, BIOL BLOOD MARROW TR, V16, P1245, DOI 10.1016/j.bbmt.2010.03.014; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388; Kochenderfer JN, 2010, BLOOD, V116, P4099, DOI 10.1182/blood-2010-04-281931; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; le Viseur C, 2008, CANCER CELL, V14, P47, DOI 10.1016/j.ccr.2008.05.015; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; PULLEN J, 1993, J CLIN ONCOL, V11, P839, DOI 10.1200/JCO.1993.11.5.839; Savoldo B, 2011, J CLIN INVEST, V121, P1822, DOI 10.1172/JCI46110; Tang YM, 2008, BRIT J HAEMATOL, V143, P84, DOI 10.1111/j.1365-2141.2008.07298.x; Tawara I, 2011, CLIN CANCER RES, V17, P77, DOI 10.1158/1078-0432.CCR-10-1198; Till BG, 2008, BLOOD, V112, P2261, DOI 10.1182/blood-2007-12-128843; Till BG, 2012, BLOOD, V119, P3940, DOI 10.1182/blood-2011-10-387969	26	2374	2709	90	725	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2013	368	16					1509	1518		10.1056/NEJMoa1215134	http://dx.doi.org/10.1056/NEJMoa1215134			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126HC	23527958	Green Accepted, Bronze			2023-01-03	WOS:000317603300008
J	Higgins, J; Hagman, J; Pan, ZX; MacLean, P				Higgins, Janine; Hagman, Jennifer; Pan, Zhaoxing; MacLean, Paul			Increased Physical Activity Not Decreased Energy Intake Is Associated with Inpatient Medical Treatment for Anorexia Nervosa in Adolescent Females	PLOS ONE			English	Article							EATING DISORDERS; MACRONUTRIENT; WOMEN; FOOD; EXERCISE; WEIGHT; EXPENDITURE; VALIDATION; ACCURACY; EFFICACY	There is a dearth of data regarding changes in dietary intake and physical activity over time that lead to inpatient medical treatment for anorexia nervosa (AN). Without such data, more effective nutritional therapies for patients cannot be devised. This study was undertaken to describe changes in diet and physical activity that precede inpatient medical hospitalization for AN in female adolescents. This data can be used to understand factors contributing to medical instability in AN, and may advance rodent models of AN to investigate novel weight restoration strategies. It was hypothesized that hospitalization for AN would be associated with progressive energy restriction and increased physical activity over time. 20 females, 11-19 years (14.3 +/- 1.8 years), with restricting type AN, completed retrospective, self-report questionnaires to assess dietary intake and physical activity over the 6 month period prior to inpatient admission (food frequency questionnaire, Pediatric physical activity recall) and 1 week prior (24 hour food recall, modifiable activity questionnaire). Physical activity increased acutely prior to inpatient admission without any change in energy or macronutrient intake. However, there were significant changes in reported micronutrient intake causing inadequate intake of Vitamin A, Vitamin D, and pantothenic acid at 1 week versus high, potentially harmful, intake of Vitamin A over 6 months prior to admission. Subject report of significantly increased physical activity, not decreased energy intake, were associated with medical hospitalization for AN. Physical activity and Vitamin A and D intake should be carefully monitored following initial AN diagnosis, as markers of disease progression as to potentially minimize the risk of medical instability.	[Higgins, Janine] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Hagman, Jennifer] Univ Colorado, Sch Med, Dept Psychiat, Aurora, CO USA; [Pan, Zhaoxing] Childrens Hosp Colorado, Res Inst, Aurora, CO USA; [MacLean, Paul] Univ Colorado, Sch Med, Div Endocrinol Diabet & Metab, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Higgins, J (corresponding author), Univ Colorado, Sch Med, Dept Pediat, Anschutz Med Campus, Aurora, CO USA.	janine.higgins@childrenscolorado.org	Hagman, Jennifer/R-8240-2017; Zamora, Cristina Cuesta/E-2864-2016; MacLean, Paul/A-7887-2008	Hagman, Jennifer/0000-0002-7770-3092; Zamora, Cristina Cuesta/0000-0003-1121-9561; MacLean, Paul/0000-0002-1123-6612; Higgins, Janine/0000-0002-4273-194X	National Institutes of Health/National Center for Research Resources (NIH/NCRR) Colorado CTSI Grant [UL1 RR025780]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048520] Funding Source: NIH RePORTER	National Institutes of Health/National Center for Research Resources (NIH/NCRR) Colorado CTSI Grant; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health/National Center for Research Resources (NIH/NCRR) Colorado CTSI Grant UL1 RR025780 (Independent Investigator Pilot and Feasibility Award). Contents are the authors' sole responsibility and do not necessarily represent official NIH views. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AARON DJ, 1995, AM J EPIDEMIOL, V142, P191, DOI 10.1093/oxfordjournals.aje.a117618; Affenito SG, 2002, J PEDIATR-US, V141, P701, DOI 10.1067/mpd.2002.129840; American Association of Psychiatrists, 2000, DIAGN STAT MAN MENT; [Anonymous], DRI TABL; ARAVICH PF, 1994, APPETITE, V23, P196, DOI 10.1006/appe.1994.1049; Baxter SD, 2009, EUR J CLIN NUTR, V63, pS19, DOI 10.1038/ejcn.2008.61; Beasley J, 2005, NUTRITION, V21, P672, DOI 10.1016/j.nut.2004.11.006; BENDICH A, 1989, AM J CLIN NUTR, V49, P358, DOI 10.1093/ajcn/49.2.358; BENEKE WM, 1995, PHYSIOL BEHAV, V58, P451, DOI 10.1016/0031-9384(95)00083-U; CASPER RC, 1991, AM J CLIN NUTR, V53, P1143, DOI 10.1093/ajcn/53.5.1143; Davis C, 1997, COMPR PSYCHIAT, V38, P321, DOI 10.1016/S0010-440X(97)90927-5; DAVIS C, 1990, J PSYCHOSOM RES, V34, P563, DOI 10.1016/0022-3999(90)90031-X; Dellava JE, 2011, INT J EAT DISORDER, V44, P376, DOI 10.1002/eat.20865; Dixon DP, 2003, PHYSIOL BEHAV, V80, P273, DOI 10.1016/j.physbeh.2003.08.008; FERNSTROM MH, 1994, BIOL PSYCHIAT, V36, P696, DOI 10.1016/0006-3223(94)91179-7; FRENCH SA, 1994, J ADOLESCENT HEALTH, V15, P286, DOI 10.1016/1054-139X(94)90601-7; Gardner RM, 1996, J CLIN PSYCHOL, V52, P3, DOI 10.1002/(SICI)1097-4679(199601)52:1<3::AID-JCLP1>3.0.CO;2-X; Gentile MG, 2008, EAT WEIGHT DISORD-ST, V13, P191; GWIRTSMAN HE, 1989, J AM DIET ASSOC, V89, P54; Hadigan CM, 2000, INT J EAT DISORDER, V28, P284, DOI 10.1002/1098-108X(200011)28:3&lt;284::AID-EAT5&gt;3.0.CO;2-G; Halmi Katherine A, 2009, Dialogues Clin Neurosci, V11, P100; Hechler T, 2008, ADAPT PHYS ACT Q, V25, P159, DOI 10.1123/apaq.25.2.159; Hill RJ, 2001, BRIT J NUTR, V85, P415, DOI 10.1079/BJN2000281; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; KRON L, 1978, COMPR PSYCHIAT, V19, P433, DOI 10.1016/0010-440X(78)90072-X; Misra M, 2006, AM J CLIN NUTR, V84, P698, DOI 10.1093/ajcn/84.4.698; Neumarker KJ, 1997, INT J EAT DISORDER, V21, P205, DOI 10.1002/(SICI)1098-108X(199704)21:3<205::AID-EAT1>3.0.CO;2-O; Nogal P, 2009, NEUROENDOCRINOL LETT, V30, P32; Nova E, 2001, EUR J CLIN NUTR, V55, P547, DOI 10.1038/sj.ejcn.1601181; PIRKE KM, 1991, BIOL PSYCHIAT, V30, P711, DOI 10.1016/0006-3223(91)90016-F; Rockett HRH, 1997, PREV MED, V26, P808, DOI 10.1006/pmed.1997.0200; Schebendach JE, 2012, INT J EAT DISORDER, V45, P570, DOI 10.1002/eat.20973; Schwartz BI, 2008, J ADOLESCENT HEALTH, V43, P425, DOI 10.1016/j.jadohealth.2008.04.010; Soh NLW, 2008, EUR EAT DISORD REV, V16, P427, DOI 10.1002/erv.876; United States Department of Agriculture FaNIC, 2007, NAT HLTH NUTR EX SUR; WALLIN GV, 1995, J AM COLL NUTR, V14, P271; Weston AT, 1997, MED SCI SPORT EXER, V29, P138, DOI 10.1097/00005768-199701000-00020	37	9	9	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2013	8	4							e61559	10.1371/journal.pone.0061559	http://dx.doi.org/10.1371/journal.pone.0061559			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	130IU	23637854	Green Submitted, Green Published, gold			2023-01-03	WOS:000317908700045
J	Li, XM; Li, ZP; Xue, M; Ou, ZM; Liu, M; Yang, MX; Liu, SH; Yang, SY; Li, XJ				Li, Xiumin; Li, Zhipeng; Xue, Mei; Ou, Zhimin; Liu, Ming; Yang, Mingxing; Liu, Suhuan; Yang, Shuyu; Li, Xuejun			Fructus Xanthii Attenuates Hepatic Steatosis in Rats Fed on High-Fat Diet	PLOS ONE			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; LIVER-X-RECEPTOR; ELEMENT-BINDING PROTEIN; GLUCOSE-METABOLISM; ACID-METABOLISM; ALPHA; LXR; OBESITY; CHREBP; GENE	Fructus Xanthii (FX) has been widely used as a traditional herbal medicine for rhinitis, headache, cold, etc. Modern pharmacological studies revealed that FX possesses anti-inflammatory, anti-oxidative, and anti-hyperglycemic properties. The present study was designed to investigate the effects of FX on glucose and insulin tolerance, and hepatic lipid metabolism in rats fed on high-fat diet (HFD). Hepatic steatosis was induced by HFD feeding. Aqueous extraction fractions of FX or vehicle were orally administered by gavage for 6 weeks. Body weight and blood glucose were monitored. Glucose and insulin tolerance test were performed. Liver morphology was visualized by hematoxylin and eosin, and oil red O staining. Expression of liver lipogenic and lipolytic genes was measured by real-time PCR. We showed here that FX improved glucose tolerance and insulin sensitivity in HFD rats. FX significantly decreased the expression of lipogenic genes and increased the expression of lipolytic genes, ameliorated lipid accumulation and decreased the total liver triglyceride (TG) content, and thus attenuated HFD-induced hepatic steatosis. In conclusion, FX improves glucose tolerance and insulin sensitivity, decreases lipogenesis and increases lipid oxidation in the liver of HFD rats, implying a potential application in the treatment of non-alcoholic fatty liver disease.	[Li, Xiumin; Li, Zhipeng; Xue, Mei; Ou, Zhimin; Liu, Ming; Yang, Mingxing; Liu, Suhuan; Yang, Shuyu; Li, Xuejun] Xiamen Univ, Affiliated Hosp 1, Xiamen Diabet Inst, Xiamen, Peoples R China; [Yang, Shuyu; Li, Xuejun] Xiamen Univ, Affiliated Hosp 1, Div Endocrinol & Diabet, Xiamen, Peoples R China; [Liu, Suhuan] Xiamen Univ, Affiliated Hosp 1, Cent Lab, Xiamen, Peoples R China	Xiamen University; Xiamen University; Xiamen University	Yang, SY (corresponding author), Xiamen Univ, Affiliated Hosp 1, Xiamen Diabet Inst, Xiamen, Peoples R China.	yang.shuyu@yahoo.com.cn; lixuejun@yahoo.com.cn	li, xiu/GXV-1745-2022		Xiamen Science and Technology Bureau (Xiamen Research Platform for Systems Biology of Metabolic Disease) [3502Z20100001]; National Natural Science Foundation [30973912, 81073113, 81270901]	Xiamen Science and Technology Bureau (Xiamen Research Platform for Systems Biology of Metabolic Disease); National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	This work was supported by Xiamen Science and Technology Bureau (Xiamen Research Platform for Systems Biology of Metabolic Disease, 3502Z20100001), National Natural Science Foundation to Shuyu Yang (30973912), Xuejun Li (81073113), and Suhuan Liu (81270901). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson SP, 2004, MOL PHARMACOL, V66, P1440, DOI 10.1124/mol.104.005496; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; Browning JD, 2004, J CLIN INVEST, V114, P147, DOI 10.1172/JCI200422422; Cha JY, 2007, J BIOL CHEM, V282, P743, DOI 10.1074/jbc.M605023200; Chakravarthy MV, 2009, J LIPID RES, V50, P630, DOI 10.1194/jlr.M800379-JLR200; de Alwis NMW, 2008, J HEPATOL, V48, pS104, DOI 10.1016/j.jhep.2008.01.009; Dentin R, 2006, DIABETES, V55, P2159, DOI 10.2337/db06-0200; Endo M, 2007, EXP BIOL MED, V232, P614; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Huang MH, 2011, J ETHNOPHARMACOL, V135, P545, DOI 10.1016/j.jep.2011.03.057; Hulsmans M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030414; Iizuka K, 2008, ENDOCR J, V55, P617, DOI 10.1507/endocrj.K07E-110; Jaskiewicz K, 2008, DIGEST DIS SCI, V53, P785, DOI 10.1007/s10620-007-9942-x; Jeong HW, 2011, DIABETES, V60, P496, DOI 10.2337/db09-1145; Lazo M, 2008, SEMIN LIVER DIS, V28, P339, DOI 10.1055/s-0028-1091978; Lumeng CN, 2011, J CLIN INVEST, V121, P2111, DOI 10.1172/JCI57132; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; Nagle CA, 2009, J LIPID RES, V50, pS74, DOI 10.1194/jlr.R800053-JLR200; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Song MY, 2009, INT J MOL MED, V23, P547, DOI 10.3892/ijmm_00000163; Stienstra R, 2010, HEPATOLOGY, V51, P511, DOI 10.1002/hep.23337; Tacer KF, 2011, J LIPIDS, V2011, DOI 10.1155/2011/783976; Talukdar S, 2006, J LIPID RES, V47, P2451, DOI 10.1194/jlr.M600276-JLR200; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; Yoshikawa T, 2003, MOL ENDOCRINOL, V17, P1240, DOI 10.1210/me.2002-0190; Zhou J, 2008, GASTROENTEROLOGY, V134, P556, DOI 10.1053/j.gastro.2007.11.037	29	9	9	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e61499	10.1371/journal.pone.0061499	http://dx.doi.org/10.1371/journal.pone.0061499			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23585904	Green Submitted, Green Published, gold			2023-01-03	WOS:000317909600119
J	Horwitz, RI; Cullen, MR; Abell, J; Christian, JB				Horwitz, Ralph I.; Cullen, Mark R.; Abell, Jill; Christian, Jennifer B.			(De)Personalized Medicine	SCIENCE			English	Editorial Material							GENOMICS		[Horwitz, Ralph I.] GlaxoSmithKline, Clin Evaluat Sci, King Of Prussia, PA 19406 USA; [Cullen, Mark R.] Stanford Univ, Sch Med, Div Gen Med Disciplines, Stanford, CA 94305 USA; [Abell, Jill] GlaxoSmithKline, Clin Effectiveness & Safety, King Of Prussia, PA 19406 USA; [Christian, Jennifer B.] GlaxoSmithKline, Clin Effectiveness & Safety, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; Stanford University; GlaxoSmithKline; GlaxoSmithKline	Horwitz, RI (corresponding author), GlaxoSmithKline, Clin Evaluat Sci, King Of Prussia, PA 19406 USA.	mrcullen@stanford.edu		cullen, mark/0000-0001-7996-1864				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Burke W, 2007, JAMA-J AM MED ASSOC, V298, P1682, DOI 10.1001/jama.298.14.1682; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Goodman SN, 1999, ANN INTERN MED, V130, P604, DOI 10.7326/0003-4819-130-7-199904060-00022; Guttmacher AE, 2007, NAT REV GENET, V8, P151, DOI 10.1038/nrg2007; Idaghdour Y, 2010, NAT GENET, V42, P62, DOI 10.1038/ng.495; 1982, JAMA, V247, P1707	7	35	36	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 8	2013	339	6124					1155	1156		10.1126/science.1234106	http://dx.doi.org/10.1126/science.1234106			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	100OG	23471391				2023-01-03	WOS:000315709900030
J	Cuypers, K; Leenus, DJF; den Berg, FE; Nitsche, MA; Thijs, H; Wenderoth, N; Meesen, RLJ				Cuypers, Koen; Leenus, Daphnie J. F.; van den Berg, Femke E.; Nitsche, Michael A.; Thijs, Herbert; Wenderoth, Nicole; Meesen, Raf L. J.			Is Motor Learning Mediated by tDCS Intensity?	PLOS ONE			English	Article							DIRECT-CURRENT STIMULATION; NONINVASIVE CORTICAL STIMULATION; PARKINSONS-DISEASE; BRAIN POLARIZATION; CHRONIC STROKE; CORTEX; PLASTICITY; EXCITABILITY; CONSOLIDATION; IMPLICIT	Although tDCS has been shown to improve motor learning, previous studies reported rather small effects. Since physiological effects of tDCS depend on intensity, the present study evaluated this parameter in order to enhance the effect of tDCS on skill acquisition. The effect of different stimulation intensities of anodal tDCS (atDCS) was investigated in a double blind, sham controlled crossover design. In each condition, thirteen healthy subjects were instructed to perform a unimanual motor (sequence) learning task. Our results showed (1) a significant increase in the slope of the learning curve and (2) a significant improvement in motor performance at retention for 1.5 mA atDCS as compared to sham tDCS. No significant differences were reported between 1 mA atDCS and sham tDCS; and between 1.5 mA atDCS and 1 mA atDCS.	[Cuypers, Koen; Leenus, Daphnie J. F.; Meesen, Raf L. J.] Hasselt Univ, BIOMED Biomed Res Inst, Diepenbeek, Belgium; [Cuypers, Koen; Leenus, Daphnie J. F.; Thijs, Herbert; Meesen, Raf L. J.] PHL Univ Coll, REVAL Res Inst, Diepenbeek, Belgium; [Cuypers, Koen; van den Berg, Femke E.; Wenderoth, Nicole; Meesen, Raf L. J.] Katholieke Univ Leuven, Dept Biomed Kinesiol, Motor Control Lab, B-3001 Heverlee, Belgium; [Nitsche, Michael A.] Univ Gottingen, Dept Clin Neurophysiol, D-37073 Gottingen, Germany; [Thijs, Herbert] Hasselt Univ, I BioStat Interuniv Inst Biostat & Stat Bioinfir, Diepenbeek, Belgium; [Thijs, Herbert] Katholieke Univ Leuven, Louvain, Belgium; [Wenderoth, Nicole; Meesen, Raf L. J.] ETH, Neural Control Movement Lab, Dept Hlth Sci & Technol, Zurich, Switzerland	Hasselt University; KU Leuven; University of Gottingen; Hasselt University; KU Leuven; Swiss Federal Institutes of Technology Domain; ETH Zurich	Meesen, RLJ (corresponding author), Hasselt Univ, BIOMED Biomed Res Inst, Diepenbeek, Belgium.	raf.meesen@uhasselt.be	Nitsche, Michael A/B-6755-2012; Wenderoth, Nicole/D-7262-2015; Cuypers, Koen/N-9918-2018; Meesen, Raf L/F-2582-2019	Wenderoth, Nicole/0000-0002-3246-9386; Meesen, Raf L/0000-0002-7938-3758	Flanders Fund for Scientific Research [G075810]; Special Research Fund UHasselt	Flanders Fund for Scientific Research(FWO); Special Research Fund UHasselt	This work was supported by the Flanders Fund for Scientific Research [G075810]. Koen Cuypers is supported by the Special Research Fund UHasselt. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antal A, 2007, EUR J NEUROSCI, V26, P2687, DOI 10.1111/j.1460-9568.2007.05896.x; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Cheeran B, 2008, J PHYSIOL-LONDON, V586, P5717, DOI 10.1113/jphysiol.2008.159905; Fregni F, 2006, MOVEMENT DISORD, V21, P1693, DOI 10.1002/mds.21012; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Hummel F, 2005, BRAIN, V128, P490, DOI 10.1093/brain/awh369; Hummel FC, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-73; Iyer MB, 2005, NEUROLOGY, V64, P872, DOI 10.1212/01.WNL.0000152986.07469.E9; Kang Eun Kyoung, 2011, Exp Transl Stroke Med, V3, P4, DOI 10.1186/2040-7378-3-4; Kantak SS, 2012, EUR J NEUROSCI, V36, P2710, DOI 10.1111/j.1460-9568.2012.08175.x; KARNI A, 1995, NATURE, V377, P155; Muellbacher W, 2002, NATURE, V415, P640, DOI 10.1038/nature712; Nitsche MA, 2007, J NEUROPHYSIOL, V97, P3109, DOI 10.1152/jn.01312.2006; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Reis J, 2009, P NATL ACAD SCI USA, V106, P1590, DOI 10.1073/pnas.0805413106; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Tanaka S, 2011, NEUROREHAB NEURAL RE, V25, P565, DOI 10.1177/1545968311402091; Teo Florence, 2011, Front Psychiatry, V2, P45, DOI 10.3389/fpsyt.2011.00045; Ungerleider LG, 2002, NEUROBIOL LEARN MEM, V78, P553, DOI 10.1006/nlme.2002.4091	24	65	69	2	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2013	8	6							e67344	10.1371/journal.pone.0067344	http://dx.doi.org/10.1371/journal.pone.0067344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JP	23826272	Green Published, gold			2023-01-03	WOS:000321738400136
J	Tang, JLW; Nicolle, A; Pantelic, J; Klettner, CA; Su, R; Kalliomaki, P; Saarinen, P; Koskela, H; Reijula, K; Mustakallio, P; Cheong, DKW; Sekhar, C; Tham, KW				Tang, Julian W.; Nicolle, Andre; Pantelic, Jovan; Klettner, Christian A.; Su, Ruikun; Kalliomaki, Petri; Saarinen, Pekka; Koskela, Hannu; Reijula, Kari; Mustakallio, Panu; Cheong, David K. W.; Sekhar, Chandra; Tham, Kwok Wai			Different Types of Door-Opening Motions as Contributing Factors to Containment Failures in Hospital Isolation Rooms	PLOS ONE			English	Article							ACUTE RESPIRATORY SYNDROME; INFECTION-CONTROL; TUBERCULOSIS; VENTILATION; MODEL; SARS	Hospital isolation rooms are vital for the containment (when under negative pressure) of patients with, or the protection (when under positive pressure) of patients, from airborne infectious agents. Such facilities were essential for the management of highly contagious patients during the 2003 severe acute respiratory syndrome (SARS) outbreaks and the more recent 2009 A/H1N1 influenza pandemic. Many different types of door designs are used in the construction of such isolation rooms, which may be related to the space available and affordability. Using colored food dye as a tracer, the qualitative effects of door-opening motions on the dissemination of potentially contaminated air into and out of a single isolation room were visualized and filmed using Reynolds-number-equivalent, small-scale, water-tank models fitted with programmable door-opening and moving human figure motions. Careful scaling considerations involved in the design and construction of these water-tank models enabled these results to be accurately extrapolated to the full-scale situation. Four simple types of door design were tested: variable speed single and double, sliding and hinged doors, in combination with the moving human figure. The resulting video footage was edited, synchronized and presented in a series of split-screen formats. From these experiments, it is clear that double-hinged doors pose the greatest risk of leakage into or out of the room, followed by (in order of decreasing risk) single-hinged, double-sliding and single-sliding doors. The relative effect of the moving human figure on spreading any potential contamination was greatest with the sliding doors, as the bulk airflows induced were large relative to those resulting from these door-opening motions. However, with the hinged doors, the airflows induced by these door-opening motions were significantly greater. Further experiments involving a simulated ventilated environment are required, but from these findings alone, it appears that sliding-doors are far more effective for hospital isolation room containment.	[Tang, Julian W.; Nicolle, Andre; Klettner, Christian A.; Su, Ruikun] Natl Univ Singapore Hosp, Dept Lab Med, Singapore, Singapore; [Tang, Julian W.] Alberta Prov Lab Publ Hlth, Edmonton, AB, Canada; [Tang, Julian W.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada; [Pantelic, Jovan; Cheong, David K. W.; Sekhar, Chandra; Tham, Kwok Wai] Natl Univ Singapore, Sch Design & Environm, Dept Bldg, Singapore 117548, Singapore; [Kalliomaki, Petri; Saarinen, Pekka; Koskela, Hannu; Reijula, Kari] Finnish Inst Occupat Hlth, Helsinki, Finland; [Mustakallio, Panu] Oy Halton Grp Ltd, Vantaa, Finland	National University of Singapore; University of Alberta; National University of Singapore; Finnish Institute of Occupational Health	Tang, JLW (corresponding author), Natl Univ Singapore Hosp, Dept Lab Med, Singapore, Singapore.	jwtang49@hotmail.com	THAM, Kwok Wai/B-6541-2009; Sekhar, Chandra/F-3253-2017	THAM, Kwok Wai/0000-0002-2957-1152; Sekhar, Chandra/0000-0002-0814-8662; Mustakallio, Panu/0000-0002-9042-8240; Tang, Julian/0000-0002-4963-1028; Pantelic, Jovan/0000-0001-7541-8274; Saarinen, Pekka/0000-0003-0152-7237; Cheong, David/0000-0001-7680-4281	Agency for Science, Technology and Research (A*STAR) in Singapore [SERC 1021290099]	Agency for Science, Technology and Research (A*STAR) in Singapore(Agency for Science Technology & Research (A*STAR))	Funding for this study (and support for post-doctoral research fellow, C.A. Klettner) was provided by a grant to JWT from the Agency for Science, Technology and Research (A*STAR grant no.: SERC 1021290099) in Singapore. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams NJ, 2011, AM J INFECT CONTROL, V39, P91, DOI 10.1016/j.ajic.2010.05.025; Beauchene C, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-58; Eames I, 2009, J R SOC INTERFACE, V6, pS757, DOI 10.1098/rsif.2009.0319.focus; Eames I, 2009, J R SOC INTERFACE, V6, pS697, DOI 10.1098/rsif.2009.0407.focus; Ferguson JK, 2009, MED J AUSTRALIA, V191, P454, DOI 10.5694/j.1326-5377.2009.tb02886.x; Fung CP, 2004, INFECT CONT HOSP EP, V25, P1026, DOI 10.1086/502339; Fusco FM, 2009, J HOSP INFECT, V73, P15, DOI 10.1016/j.jhin.2009.06.009; Harries AD, 1997, B WORLD HEALTH ORGAN, V75, P477; Harrison JP, 2010, HEALTH CARE MANAG, V29, P11, DOI 10.1097/HCM.0b013e3181cd8ab1; Hayden CS, 2007, J OCCUP ENVIRON HYG, V4, P198, DOI 10.1080/15459620601177370; Humphreys H, 2007, J HOSP INFECT, V66, P1, DOI 10.1016/j.jhin.2007.01.007; Jensen Paul A., 2005, Morbidity and Mortality Weekly Report, V54, P1; Johnson DL, 2009, AM J INFECT CONTROL, V37, P94, DOI 10.1016/j.ajic.2008.05.011; Lee NE, 2004, AM J INFECT CONTROL, V32, P377, DOI 10.1016/j.ajic.2004.03.005; Lee S, 2010, J THEOR BIOL, V265, P136, DOI 10.1016/j.jtbi.2010.04.003; Leung TF, 2004, J HOSP INFECT, V56, P215, DOI 10.1016/j.jhin.2003.11.004; Liu JW, 2006, INFECT CONT HOSP EP, V27, P466, DOI 10.1086/504501; Rice N, 2001, INFECT CONT HOSP EP, V22, P19, DOI 10.1086/501819; Rydock James P, 2002, Appl Occup Environ Hyg, V17, P486, DOI 10.1080/10473220290035688; Rydock JP, 2004, J HOSP INFECT, V57, P228, DOI 10.1016/j.jhin.2004.01.032; Saravia SA, 2007, AM J INFECT CONTROL, V35, P324, DOI 10.1016/j.ajic.2006.10.012; Sehulster Lynne, 2003, MMWR Recomm Rep, V52, P1; Tang JW, 2006, J HOSP INFECT, V64, P100, DOI 10.1016/j.jhin.2006.05.022; Tang JW, 2005, J HOSP INFECT, V61, P283, DOI 10.1016/j.jhin.2005.05.017; Wojgani H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040171	25	38	38	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2013	8	6							e66663	10.1371/journal.pone.0066663	http://dx.doi.org/10.1371/journal.pone.0066663			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JP	23826109	Green Submitted, Green Published, gold			2023-01-03	WOS:000321738400029
J	Cohen, JC; Hobbs, HH				Cohen, Jonathan C.; Hobbs, Helen H.			Simple Genetics for a Complex Disease	SCIENCE			English	Editorial Material							MOLECULAR CHARACTERIZATION; PCSK9; CHOLESTEROL; MUTATIONS		[Cohen, Jonathan C.; Hobbs, Helen H.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Cohen, Jonathan C.; Hobbs, Helen H.] Univ Texas SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; [Cohen, Jonathan C.] Univ Texas SW Med Ctr Dallas, Ctr Human Nutr, Dallas, TX 75390 USA; [Hobbs, Helen H.] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Res Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Cohen, JC (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.	jonathan.cohen@utsouthwestern.edu; helen.hobbs@utsouthwestern.edu			NHLBI NIH HHS [P01 HL020948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chen XW, 2013, ELIFE, V2, DOI 10.7554/eLife.00444; Cohen JC, 2006, NEW ENGL J MED, V354, P1264, DOI 10.1056/NEJMoa054013; Hooper AJ, 2007, ATHEROSCLEROSIS, V193, P445, DOI 10.1016/j.atherosclerosis.2006.08.039; Horton JD, 2009, J LIPID RES, V50, pS172, DOI 10.1194/jlr.R800091-JLR200; Stein EA, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0310-3; Wang Y, 2012, J LIPID RES, V53, P1932, DOI 10.1194/jlr.M028563; Zhao ZZ, 2006, AM J HUM GENET, V79, P514, DOI 10.1086/507488	9	38	39	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 10	2013	340	6133					689	690		10.1126/science.1239101	http://dx.doi.org/10.1126/science.1239101			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	139XR	23661745	Green Accepted			2023-01-03	WOS:000318619000021
J	Wu, PH; Lin, YT; Lee, TC; Lin, MY; Kuo, MC; Chiu, YW; Hwang, SJ; Chen, HC				Wu, Ping-Hsun; Lin, Yi-Ting; Lee, Tzu-Chi; Lin, Ming-Yen; Kuo, Mei-Chuan; Chiu, Yi-Wen; Hwang, Shang-Jyh; Chen, Hung-Chun			Predicting Mortality of Incident Dialysis Patients in Taiwan - A Longitudinal Population-Based Study	PLOS ONE			English	Article							CHARLSON COMORBIDITY INDEX; STAGE RENAL-DISEASE; MAINTENANCE HEMODIALYSIS-PATIENTS; PERITONEAL-DIALYSIS; CARDIOVASCULAR-DISEASE; REPLACEMENT THERAPY; BLOOD-PRESSURE; SURVIVAL; OUTCOMES; ESRD	Background: Comorbid conditions are highly prevalent among patients with end-stage renal disease (ESRD) and index score is a predictor of mortality in dialysis patients. The aim of this study is to perform a population-based cohort study to investigate the survival rate by age and Charlson comorbidity index (CCI) in incident dialysis patients. Methods: Using the catastrophic illness registration of the Taiwan National Health Insurance Research Database for all patients from 1 January 1998 to 31 December 2008, individuals newly diagnosed with ESRD and receiving dialysis for more than 90 days were eligible for our study. Individuals younger than 18 years or renal transplantation patients either before or after dialysis were excluded. We calculated the CCI, age-weighted CCI by Deyo-Charlson method according to ICD-9 code and categorized CCI into six groups as index scores < 3, 4-6, 7-9, 10-12, 13-15, > 15. Cox regression models were used to analyze the association between age, CCI and survival, and the risk markers of survival. Results: There were 79,645 incident dialysis patients, whose mean age (+/- SD) was 60.96 (+/- 13.92) years; 51.43% of patients were women and 51.2% were diabetic. In cox proportional hazard models and stratifying by age, older patients had significantly higher mortality than younger patients. The mortality risk was higher in persons with higher CCI as compared with low CCI. Mortality increased steadily with higher age or comorbidity both for unadjusted and for adjusted models. For all age groups, mortality rates increased in different CCI groups with the highest rates occurring in the oldest age groups. Conclusions: Age and CCI are both strong predictors of survival in Taiwan. The older age or higher comorbidity index in incident dialysis patient is associated with lower long-term survival rates. These population-based estimates may assist clinicians who make decisions when patients need long-term dialysis.	[Wu, Ping-Hsun; Lin, Ming-Yen; Kuo, Mei-Chuan; Chiu, Yi-Wen; Hwang, Shang-Jyh; Chen, Hung-Chun] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Lin, Yi-Ting; Lee, Tzu-Chi] Kaohsiung Med Univ Hosp, Dept Family Med, Kaohsiung, Taiwan; [Lin, Yi-Ting] Kaohsiung Med Univ, Coll Med, Dept Publ Hlth, Kaohsiung, Taiwan; [Wu, Ping-Hsun] Kaohsiung Med Univ, Coll Med, Dept Internal Med, Kaohsiung, Taiwan; [Kuo, Mei-Chuan; Chiu, Yi-Wen; Hwang, Shang-Jyh; Chen, Hung-Chun] Kaohsiung Med Univ, Coll Med, Fac Renal Care, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University	Kuo, MC (corresponding author), Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan.	mechku@kmu.edu.tw	Lin, Ming Yen/A-8637-2010; Wu, Ping-Hsun/S-8746-2017; LIN, YI-TING/S-8855-2017	Lin, Ming Yen/0000-0002-8194-4833; Wu, Ping-Hsun/0000-0003-1021-8161; LIN, YI-TING/0000-0002-5833-0040				Athienites NV, 2000, SEMIN DIALYSIS, V13, P320, DOI 10.1046/j.1525-139x.2000.00095.x; Beddhu S, 2000, AM J MED, V108, P609, DOI 10.1016/S0002-9343(00)00371-5; Bradbury BD, 2007, CLIN J AM SOC NEPHRO, V2, P89, DOI 10.2215/CJN.01170905; Chae JW, 2011, NEPHRON CLIN PRACT, V117, pC379, DOI 10.1159/000321525; Chang YK, 2012, MEDICINE, V91, P144, DOI 10.1097/MD.0b013e318256538e; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Collins AJ, 2009, AM J KIDNEY DIS, V53, pS1, DOI 10.1053/j.ajkd.2008.10.005; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; DAVIES SJ, 1995, AM J KIDNEY DIS, V26, P353, DOI 10.1016/0272-6386(95)90657-6; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Fried L, 2001, AM J KIDNEY DIS, V37, P337, DOI 10.1053/ajkd.2001.21300; Geddes CC, 2006, NEPHROL DIAL TRANSPL, V21, P945, DOI 10.1093/ndt/gfi326; Hall SF, 2006, J CLIN EPIDEMIOL, V59, P849, DOI 10.1016/j.jclinepi.2005.11.013; Hemmelgarn BR, 2003, AM J KIDNEY DIS, V42, P125, DOI 10.1016/S0272-6386(03)00415-3; Honda H, 2006, AM J KIDNEY DIS, V47, P139, DOI 10.1053/j.ajkd.2005.09.014; Huang CC, 2008, PERITON DIALYSIS INT, V28, pS15; Hwang SJ, 2010, NEPHROL DIAL TRANSPL, V25, P2616, DOI 10.1093/ndt/gfq308; KHAN IH, 1993, LANCET, V341, P415, DOI 10.1016/0140-6736(93)93003-J; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P1002, DOI 10.1016/S0272-6386(12)81075-4; Kopple JD, 1999, KIDNEY INT, V56, P1136, DOI 10.1046/j.1523-1755.1999.00615.x; Lee CC, 2009, PERITON DIALYSIS INT, V29, P182; Lee CC, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-100; Luo JC, 2011, CAN MED ASSOC J, V183, pE1345, DOI 10.1503/cmaj.110299; Ma JZ, 1999, J AM SOC NEPHROL, V10, P610; Mazzuchi N, 2000, KIDNEY INT, V58, P2147; Miskulin D, 2009, CLIN J AM SOC NEPHRO, V4, P1818, DOI 10.2215/CJN.00640109; Miskulin DC, 2004, NEPHROL DIAL TRANSPL, V19, P413, DOI 10.1093/ndt/gfg571; Miskulin DC, 2003, AM J KIDNEY DIS, V41, P149, DOI 10.1053/ajkd.2003.50034; Ng YY, 2012, NEPHROL DIAL TRANSPL; Nicolucci A, 1992, ASAIO J, V38, pM291, DOI 10.1097/00002480-199207000-00040; Port FK, 1999, AM J KIDNEY DIS, V33, P507, DOI 10.1016/S0272-6386(99)70188-5; Ueshima H, 2003, J HUM HYPERTENS, V17, P631, DOI 10.1038/sj.jhh.1001606; van Manen JG, 2002, AM J KIDNEY DIS, V40, P82, DOI 10.1053/ajkd.2002.33916; Yang WC, 2008, NEPHROL DIAL TRANSPL, V23, P3977, DOI 10.1093/ndt/gfn406	34	24	25	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e61930	10.1371/journal.pone.0061930	http://dx.doi.org/10.1371/journal.pone.0061930			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131QH	23626754	Green Submitted, Green Published, gold			2023-01-03	WOS:000318008400118
J	Kesavan, R; Potunuru, UR; Nastasijevic, B; Avaneesh, T; Joksic, G; Dixit, M				Kesavan, Rushendhiran; Potunuru, Uma Rani; Nastasijevic, Branislav; Avaneesh, T.; Joksic, Gordana; Dixit, Madhulika			Inhibition of Vascular Smooth Muscle Cell Proliferation by Gentiana lutea Root Extracts	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; ERK1/2 MAP KINASES; ACTIVATION; MIGRATION; PHOSPHORYLATION; MYELOPEROXIDASE; LYMPHOCYTES; PREVENTION; AUSTRIACA; MECHANISM	Gentiana lutea belonging to the Gentianaceae family of flowering plants are routinely used in traditional Serbian medicine for their beneficial gastro-intestinal and anti-inflammatory properties. The aim of the study was to determine whether aqueous root extracts of Gentiana lutea consisting of gentiopicroside, gentisin, bellidifolin-8-O-glucoside, demethylbellidifolin-8-O-glucoside, isovitexin, swertiamarin and amarogentin prevents proliferation of aortic smooth muscle cells in response to PDGF-BB. Cell proliferation and cell cycle analysis were performed based on alamar blue assay and propidium iodide labeling respectively. In primary cultures of rat aortic smooth muscle cells (RASMCs), PDGF-BB (20 ng/ml) induced a two-fold increase in cell proliferation which was significantly blocked by the root extract (1 mg/ml). The root extract also prevented the S-phase entry of synchronized cells in response to PDGF. Furthermore, PDGF-BB induced ERK1/2 activation and consequent increase in cellular nitric oxide (NO) levels were also blocked by the extract. These effects of extract were due to blockade of PDGF-BB induced expression of iNOS, cyclin D1 and proliferating cell nuclear antigen (PCNA). Docking analysis of the extract components on MEK1, the upstream ERK1/2 activating kinase using AutoDock4, indicated a likely binding of isovitexin to the inhibitor binding site of MEK1. Experiments performed with purified isovitexin demonstrated that it successfully blocks PDGF-induced ERK1/2 activation and proliferation of RASMCs in cell culture. Thus, Gentiana lutea can provide novel candidates for prevention and treatment of atherosclerosis.	[Kesavan, Rushendhiran; Potunuru, Uma Rani; Avaneesh, T.; Dixit, Madhulika] Indian Inst Technol, Dept Biotechnol, Lab Vasc Biol, Chennai 600036, Tamil Nadu, India; [Nastasijevic, Branislav; Joksic, Gordana] Vinca Inst Nucl Sci, Dept Phys Chem, Belgrade, Serbia	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Madras; University of Belgrade	Dixit, M (corresponding author), Indian Inst Technol, Dept Biotechnol, Lab Vasc Biol, Chennai 600036, Tamil Nadu, India.	mdixit@iitm.ac.in	Kesavan, Rushendhiran/AAD-6783-2021; Nastasijevic, Branislav/AAV-1763-2021; Kesavan, Rushendhiran/GLS-9475-2022	Nastasijevic, Branislav/0000-0002-4529-1599; Joksic, Gordana/0000-0002-7186-301X; Kesavan, Rushendhiran/0000-0002-8540-8093	Council of Scientific and Industrial Research (CSIR), Government of India; Department of Biotechnology (DBT), Government of India; Indo-EU 'FUNCFOOD' project;  [BT/IN/EU/17/SN/2009]	Council of Scientific and Industrial Research (CSIR), Government of India(Council of Scientific & Industrial Research (CSIR) - India); Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India); Indo-EU 'FUNCFOOD' project; 	Uma Rani Potunuru acknowledges Council of Scientific and Industrial Research (CSIR), Government of India for her Senior Research Fellowship and Madhulika Dixit acknowledges Department of Biotechnology (DBT), Government of India for her 'IYBA Fellowship'.; This was funded by Department of Biotechnology (DBT), Government of India sponsored joint Indo-EU 'FUNCFOOD' project. The grant number for the same is BT/IN/EU/17/SN/2009 and the website address is http://www.gmt.su.se/english/funcfood/main. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aberham A, 2007, J PHARMACEUT BIOMED, V45, P437, DOI 10.1016/j.jpba.2007.07.001; AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; Akileshwari C, 2012, EXP DIABETES RES, DOI 10.1155/2012/147965; AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S; Baba SP, 2009, DIABETES, V58, P2486, DOI 10.2337/db09-0375; Brahmachari G, 2004, CHEM BIODIVERS, V1, P1627, DOI 10.1002/cbdv.200490123; Brown C, 1999, CIRC RES, V84, P655, DOI 10.1161/01.RES.84.6.655; Calmels S, 1997, CANCER RES, V57, P3365; Cao DD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021071; Chang WC, 2008, BRIT J NUTR, V99, P709, DOI 10.1017/S0007114507831734; Chen SY, 2012, FOOD CHEM TOXICOL, V50, P3025, DOI 10.1016/j.fct.2012.06.006; Choi BM, 2002, J BIOCHEM MOL BIOL, V35, P116; Chyu KY, 2004, VASC MED, V9, P177, DOI 10.1191/1358863x04vm545oa; Chyu KY, 1999, CIRC RES, V85, P1192; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Dan Q, 2004, LIFE SCI, V76, P445, DOI 10.1016/j.lfs.2004.09.010; Di Pietro N, 2013, ATHEROSCLEROSIS, V226, P88, DOI 10.1016/j.atherosclerosis.2012.10.062; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dumesic PA, 2009, J CELL BIOL, V185, P409, DOI 10.1083/jcb.200804038; Fischmann TO, 2009, BIOCHEMISTRY-US, V48, P2661, DOI 10.1021/bi801898e; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Golias CH, 2004, INT J CLIN PRACT, V58, P1134, DOI 10.1111/j.1742-1241.2004.00284.x; Guo J, 2005, J BIOL CHEM, V280, P35992, DOI 10.1074/jbc.M504583200; Hu YH, 2000, ARTERIOSCL THROM VAS, V20, P18, DOI 10.1161/01.ATV.20.1.18; Hudecova A, 2012, FOOD CHEM TOXICOL, V50, P3352, DOI 10.1016/j.fct.2012.06.017; Jankovic T, 2008, PLANTA MED, V74, P736, DOI 10.1055/s-2008-1074524; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Jiang ZL, 2009, WOUND REPAIR REGEN, V17, P224, DOI 10.1111/j.1524-475X.2009.00459.x; Kappert K, 2006, ARTERIOSCL THROM VAS, V26, P2644, DOI 10.1161/01.ATV.0000246777.30819.85; Kreuzer J, 2002, FASEB J, V16, P38, DOI 10.1096/fj.01-1036fje; Lang YS, 2012, J PHARM PHARMACOL, V64, P597, DOI 10.1111/j.2042-7158.2011.01438.x; Leskovac A, 2007, PLANTA MED, V73, P1169, DOI 10.1055/s-2007-981586; Lo HM, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-18; Maejima Y, 2005, J MOL CELL CARDIOL, V38, P163, DOI 10.1016/j.yjmcc.2004.10.012; Matsukawa K, 2006, BIOSCI BIOTECH BIOCH, V70, P1046, DOI 10.1271/bbb.70.1046; Menkovic N, 2010, PHYTOTHER RES, V24, P1693, DOI 10.1002/ptr.3225; Miyoshi T, 2006, LIFE SCI, V79, P525, DOI 10.1016/j.lfs.2006.01.043; Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256; Myagmar BE, 2000, PHYTOMEDICINE, V7, P221, DOI 10.1016/S0944-7113(00)80007-0; Myllarniemi M, 1999, CARDIOVASC DRUG THER, V13, P159, DOI 10.1023/A:1007700629728; Nadinic E, 1999, FITOTERAPIA, V70, P166, DOI 10.1016/S0367-326X(99)00020-9; Nastasijevic B, 2012, J PHARMACEUT BIOMED, V66, P191, DOI 10.1016/j.jpba.2012.03.052; Nickel T, 2009, MICROVASC RES, V78, P364, DOI 10.1016/j.mvr.2009.07.008; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Ramana KV, 2002, J BIOL CHEM, V277, P32063, DOI 10.1074/jbc.M202126200; Rojas A, 2000, PLANTA MED, V66, P765, DOI 10.1055/s-2000-9774; Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005; Sanchez I, 2005, SEMIN CELL DEV BIOL, V16, P311, DOI 10.1016/j.semcdb.2005.02.007; Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096; Schindhelm RK, 2009, CLIN CHEM, V55, P1462, DOI 10.1373/clinchem.2009.126029; Schmieder A, 2007, ATHEROSCLEROSIS, V194, P317, DOI 10.1016/j.atherosclerosis.2006.10.019; Sezik E, 2005, LIFE SCI, V76, P1223, DOI 10.1016/j.lfs.2004.07.024; Shaul YD, 2009, GENE DEV, V23, P1779, DOI 10.1101/gad.523909; Srivastava S, 2009, CIRC RES, V105, P793, DOI 10.1161/CIRCRESAHA.109.200568; Tammali R, 2010, ENDOCRINOLOGY, V151, P2140, DOI 10.1210/en.2010-0160; Toriumi Y, 2003, CHEM PHARM BULL, V51, P89, DOI 10.1248/cpb.51.89; Villalobo A, 2006, FEBS J, V273, P2329, DOI 10.1111/j.1742-4658.2006.05250.x; Waltenberger J, 1997, CIRCULATION, V96, P4083; Wortzel Inbal, 2011, Genes Cancer, V2, P195, DOI 10.1177/1947601911407328; Wu QX, 2006, J ASIAN NAT PROD RES, V8, P391, DOI 10.1080/10286020500172368; Yang JL, 2010, NAT PROD COMMUN, V5, P649	64	37	39	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2013	8	4							e61393	10.1371/journal.pone.0061393	http://dx.doi.org/10.1371/journal.pone.0061393			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IU	23637826	Green Submitted, Green Published, gold			2023-01-03	WOS:000317908700029
J	Chai-Coetzer, CL; Antic, NA; Rowland, LS; Reed, RL; Esterman, A; Catcheside, PG; Eckermann, S; Vowles, N; Williams, H; Dunn, S; McEvoy, RD				Chai-Coetzer, Ching Li; Antic, Nick A.; Rowland, L. Sharn; Reed, Richard L.; Esterman, Adrian; Catcheside, Peter G.; Eckermann, Simon; Vowles, Norman; Williams, Helena; Dunn, Sandra; McEvoy, R. Doug			Primary Care vs Specialist Sleep Center Management of Obstructive Sleep Apnea and Daytime Sleepiness and Quality of Life A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITIVE AIRWAY PRESSURE; POLYSOMNOGRAPHY; DIAGNOSIS; MODERATE; AUTOTITRATION; ASSOCIATION; OUTCOMES; SCALE; RISK; MEN	Importance Due to increasing demand for sleep services, there has been growing interest in ambulatory models of care for patients with obstructive sleep apnea. With appropriate training and simplified management tools, primary care physicians are ideally positioned to take on a greater role in diagnosis and treatment. Objective To compare the clinical efficacy and within-trial costs of a simplified model of diagnosis and care in primary care relative to that in specialist sleep centers. Design, Setting, and Patients A randomized, controlled, noninferiority study involving 155 patients with obstructive sleep apnea that was treated at primary care practices (n=81) in metropolitan Adelaide, 3 rural regions of South Australia or at a university hospital sleep medicine center in Adelaide, Australia (n=74), between September 2008 and June 2010. Interventions Primary care management of obstructive sleep apnea vs usual care in a specialist sleep center; both plans included continuous positive airway pressure, mandibular advancement splints, or conservative measures only. Main Outcome and Measures The primary outcome was 6-month change in Epworth Sleepiness Scale (ESS) score, which ranges from 0 (no daytime sleepiness) to 24 points (high level of daytime sleepiness). The noninferiority margin was < 2.0. Secondary outcomes included disease-specific and general quality of life measures, obstructive sleep apnea symptoms, adherence to using continuous positive airway pressure, patient satisfaction, and health care costs. Results There were significant improvements in ESS scores from baseline to 6 months in both groups. In the primary care group, the mean baseline score of 12.8 decreased to 7.0 at 6 months (P < .001), and in the specialist group, the score decreased from a mean of 12.5 to 7.0 (P < .001). Primary care management was noninferior to specialist management with a mean change in ESS score of 5.8 vs 5.4 (adjusted difference, -0.13; lower bound of 1-sided 95% CI, -1.5; P=. 43). There were no differences in secondary outcome measures between groups. Seventeen patients (21%) withdrew from the study in the primary care group vs 6 patients (8%) in the specialist group. Conclusions and Relevance Among patients with obstructive sleep apnea, treatment under a primary care model compared with a specialist model did not result in worse sleepiness scores, suggesting that the 2 treatment modes may be comparable.	[Chai-Coetzer, Ching Li; Antic, Nick A.; Rowland, L. Sharn; Catcheside, Peter G.; Vowles, Norman; McEvoy, R. Doug] Repatriat Gen Hosp, Adelaide Inst Sleep Hlth, Adelaide, SA, Australia; [Chai-Coetzer, Ching Li; Antic, Nick A.; Rowland, L. Sharn; Reed, Richard L.; Catcheside, Peter G.; McEvoy, R. Doug] Flinders Univ S Australia, Dept Med, Adelaide, SA 5001, Australia; [Eckermann, Simon] Univ S Australia, Div Hlth Sci, Adelaide, SA 5001, Australia; [Williams, Helena] Southern Adelaide Fleurieu Kangaroo Isl Medicare, Adelaide, SA, Australia; [Eckermann, Simon] Univ Wollongong, Australian Hlth Serv Res Inst, Wollongong, NSW, Australia; [Dunn, Sandra] Charles Darwin Univ, Sch Hlth, Darwin, NT 0909, Australia	Flinders University South Australia; Flinders University South Australia; University of South Australia; University of Wollongong; Charles Darwin University	Chai-Coetzer, CL (corresponding author), Repatriat Gen Hosp, Adelaide Inst Sleep Hlth, Daws Rd, Daw Pk, SA 5041, Australia.	chingli.chai-coetzer@health.sa.gov.au	McEvoy, Doug/ABB-8052-2020; Esterman, Adrian J/D-1042-2009	McEvoy, Doug/0000-0002-5759-0094; Catcheside, Peter/0000-0002-9372-6788; Reed, Richard/0000-0002-5115-4726; Esterman, Adrian/0000-0001-7324-9171	National Health and Medical Research Council of Australia; Flinders Medical Centre Clinicians Trust; Flinders Medical Centre Foundation; ResMed; Philips Respironics; SomnoMed; Fisher and Paykel; Gorman Promed Pty Ltd.; National Health and Medical Research Council of Australia [426744]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Flinders Medical Centre Clinicians Trust; Flinders Medical Centre Foundation; ResMed; Philips Respironics; SomnoMed; Fisher and Paykel; Gorman Promed Pty Ltd.; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Chai-Coetzer reported that she has received research funding from the National Health and Medical Research Council of Australia, Flinders Medical Centre Clinicians Trust and Flinders Medical Centre Foundation, and equipment donations from ResMed, Philips Respironics, and SomnoMed. Dr Antic reported that he has received research funding from the National Health and Medical Research Council of Australia, Philips Respironics, and Fisher and Paykel, equipment donations from ResMed, Philips Respironics and SomnoMed, and lecture fees and payment for development of educational presentations from ResMed. Ms Rowland has reported that she has received research funding from the National Health and Medical Research Council of Australia and equipment donations from ResMed, Philips Respironics and SomnoMed. Dr Reed reported that he has received research funding from the National Health and Medical Research Council of Australia. Dr Catcheside has reported that he has received research funding from the National Health and Medical Research Council of Australia, and equipment support from Philips Respironics, Apnex Medical, and Gorman Promed Pty Ltd. Dr Williams has reported that she is Director on the Board of the Australian Commission for Safety and Quality in Health Care and Chair of the Primary Care Clinical Committee, is employed by the SAFKI Medicare Local as Executive Clinical Director, Southern Adelaide Local Health Network as the Presiding Member of the Governing Council, and the Russell Clinic where she is practicing as a general practitioner, and she has previously been employed by the Royal District Nursing Society of South Australia as the Chair of the Clinical Governance Committee. In addition, the National Prescribing Service has paid for her accommodation to attend the National Medicines Symposium 2012. Dr Dunn has reported that she has received research funding from the National Health and Medical Research Council of Australia and equipment donations from ResMed, Philips Respironics and SomnoMed. Dr McEvoy has reported that he has received research funding from the National Health and Medical Research Council of Australia, Philips Respironics, and Fisher and Paykel, equipment donations from ResMed, Philips Respironics and SomnoMed, and lecture fees from Philips Respironics. Drs Esterman, Eckermann, and Vowles have reported no conflicts of interest.; This study was funded by Project Grant 426744 from the National Health and Medical Research Council of Australia and a small grant from the Flinders Medical Centre Foundation. Research scholarship support was provided to Dr ChaiCoetzer by the Flinders Medical Centre Clinicians Trust. Equipment donations were received from ResMed (oximetry monitors and CPAP machines), Philips Respironics (CPAP machines), and SomnoMed (mandibular advancement splints).	Andreu AL, 2012, EUR RESPIR J, V39, P305, DOI 10.1183/09031936.00013311; Antic NA, 2009, AM J RESP CRIT CARE, V179, P501, DOI 10.1164/rccm.200810-1558OC; Association AMG, VIS SPEC SAT QUEST V; Ayas NT, 2011, SLEEP, V34, P691, DOI 10.5665/SLEEP.1026; BEARPARK H, 1995, AM J RESP CRIT CARE, V151, P1459, DOI 10.1164/ajrccm.151.5.7735600; Berry RB, 2008, SLEEP, V31, P1423; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Chai-Coetzer CL, 2011, THORAX, V66, P213, DOI 10.1136/thx.2010.152801; Dixon T, 2003, GROWING PROBLEM TREN, P8; Engleman HM, 2004, THORAX, V59, P618, DOI 10.1136/thx.2003.015867; Goudge R, 2001, AM J RESP CRIT CARE, V163, pA933; Hukins CA, 2005, AM J RESP CRIT CARE, V171, P500, DOI 10.1164/rccm.200401-019OC; Jenkinson C, 1999, LANCET, V353, P2100, DOI 10.1016/S0140-6736(98)10532-9; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kuna ST, 2011, AM J RESP CRIT CARE, V183, P1238, DOI 10.1164/rccm.201011-1770OC; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Massie CA, 2003, AM J RESP CRIT CARE, V167, P20, DOI 10.1164/rccm.200201-022OC; Mulgrew AT, 2007, ANN INTERN MED, V146, P157, DOI 10.7326/0003-4819-146-3-200702060-00004; Netzer NC, 2003, CHEST, V124, P1406, DOI 10.1378/chest.124.4.1406; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Pietzsch JB, 2011, SLEEP, V34, P695, DOI 10.5665/SLEEP.1030; Rosen CL, 2012, SLEEP, V35, P757, DOI 10.5665/sleep.1870; Siccoli MM, 2008, SLEEP, V31, P1551, DOI 10.1093/sleep/31.11.1551; Teran-Santos J, 1999, NEW ENGL J MED, V340, P847, DOI 10.1056/NEJM199903183401104; Weaver TE, 1997, SLEEP, V20, P835; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	28	136	139	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	2013	309	10					997	1004		10.1001/jama.2013.1823	http://dx.doi.org/10.1001/jama.2013.1823			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103SH	23483174	Bronze			2023-01-03	WOS:000315938700028
J	Szymanski, CR; Chiha, W; Morellini, N; Cummins, N; Bartlett, CA; Doig, RLO; Savigni, DL; Payne, SC; Harvey, AR; Dunlop, SA; Fitzgerald, M				Szymanski, Charis R.; Chiha, Wissam; Morellini, Natalie; Cummins, Nadia; Bartlett, Carole A.; Doig, Ryan L. O'Hare; Savigni, Donna L.; Payne, Sophie C.; Harvey, Alan R.; Dunlop, Sarah A.; Fitzgerald, Melinda			Paranode Abnormalities and Oxidative Stress in Optic Nerve Vulnerable to Secondary Degeneration: Modulation by 670 nm Light Treatment	PLOS ONE			English	Article							SPINAL-CORD-INJURY; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; CYTOCHROME-C-OXIDASE; NEAR-INFRARED LIGHT; REACTIVE OXYGEN; ABSORPTION-MEASUREMENTS; OLIGODENDROCYTES; CALCIUM; DEATH	Secondary degeneration of nerve tissue adjacent to a traumatic injury results in further loss of neurons, glia and function, via mechanisms that may involve oxidative stress. However, changes in indicators of oxidative stress have not yet been demonstrated in oligodendrocytes vulnerable to secondary degeneration in vivo. We show increases in the oxidative stress indicator carboxymethyl lysine at days 1 and 3 after injury in oligodendrocytes vulnerable to secondary degeneration. Dihydroethidium staining for superoxide is reduced, indicating endogenous control of this particular reactive species after injury. Concurrently, node of Ranvier/paranode complexes are altered, with significant lengthening of the paranodal gap and paranode as well as paranode disorganisation. Therapeutic administration of 670 nm light is thought to improve oxidative metabolism via mechanisms that may include increased activity of cytochrome c oxidase. Here, we show that light at 670 nm, delivered for 30 minutes per day, results in in vivo increases in cytochrome c oxidase activity co-localised with oligodendrocytes. Short term (1 day) 670 nm light treatment is associated with reductions in reactive species at the injury site. In optic nerve vulnerable to secondary degeneration superoxide in oligodendrocytes is reduced relative to handling controls, and is associated with reduced paranode abnormalities. Long term (3 month) administration of 670 nm light preserves retinal ganglion cells vulnerable to secondary degeneration and maintains visual function, as assessed by the optokinetic nystagmus visual reflex. Light at a wavelength of 670 nm may serve as a therapeutic intervention for treatment of secondary degeneration following neurotrauma.	[Szymanski, Charis R.; Chiha, Wissam; Morellini, Natalie; Cummins, Nadia; Bartlett, Carole A.; Doig, Ryan L. O'Hare; Savigni, Donna L.; Payne, Sophie C.; Dunlop, Sarah A.; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA, Australia; [Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA, Australia	University of Western Australia; University of Western Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Sch Anim Biol, Crawley, WA, Australia.	lindy.fitzgerald@uwa.edu.au	Fitzgerald, Melinda/C-4235-2011; Dunlop, Sarah A/G-9357-2013; Doig, Ryan O'Hare/AAG-7585-2019	Fitzgerald, Melinda/0000-0002-4823-8179; Dunlop, Sarah/0000-0002-1306-3962; Cummins, Nadia/0000-0002-4494-2345; , Alan/0000-0002-2590-831X	Neurotrauma Research Program (Western Australia); National Health and Medical Research Council (NHMRC), Australia [572550]; NHMRC, Australia [APP1002347]	Neurotrauma Research Program (Western Australia); National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC, Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the Neurotrauma Research Program (Western Australia) and National Health and Medical Research Council (NH&MRC), Australia (Grant ID: 572550). Prof. Dunlop is a Principal Research Fellow of the NH&MRC, Australia (Grant ID: APP1002347). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arvanian VL, 2009, EXP NEUROL, V216, P471, DOI 10.1016/j.expneurol.2009.01.004; Back SA, 1998, J NEUROSCI, V18, P6241; Balabanov R, 2005, NAT NEUROSCI, V8, P262, DOI 10.1038/nn0305-262; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Buffo A, 2005, P NATL ACAD SCI USA, V102, P18183, DOI 10.1073/pnas.0506535102; Buttermore ED, 2011, J NEUROSCI, V31, P8013, DOI 10.1523/JNEUROSCI.1015-11.2011; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Chan YC, 2009, J PHARMACOL EXP THER, V329, P450, DOI 10.1124/jpet.108.148353; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; DANNENBERG AM, 1994, J LEUKOCYTE BIOL, V56, P436, DOI 10.1002/jlb.56.4.436; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Fu MX, 1996, J BIOL CHEM, V271, P9982, DOI 10.1074/jbc.271.17.9982; Fu Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006705; Funfschilling U, 2012, NATURE, V485, P517, DOI 10.1038/nature11007; Fuss B, 2000, DEV BIOL, V218, P259, DOI 10.1006/dbio.1999.9574; Giaume C, 2007, CELL DEATH DIFFER, V14, P1324, DOI 10.1038/sj.cdd.4402144; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Griselda CM, 2011, NEUROSCI BIOBEHAV R, V35, P1353, DOI 10.1016/j.neubiorev.2011.02.009; Haynes RL, 2003, J NEUROPATH EXP NEUR, V62, P441, DOI 10.1093/jnen/62.5.441; Howell OW, 2006, BRAIN, V129, P3173, DOI 10.1093/brain/awl290; Jia Z, 2012, SPINAL CORD, V50, P264, DOI 10.1038/sc.2011.111; Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030; Karadottir R, 2005, NATURE, V438, P1162, DOI 10.1038/nature04302; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2008, PHOTOMED LASER SURG, V26, P593, DOI 10.1089/pho.2008.2246; Kitada M, 2006, GLIA, V54, P35, DOI 10.1002/glia.20354; Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014; Komel'kova L V, 2004, Patol Fiziol Eksp Ter, P15; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Lasiene J, 2008, J NEUROSCI, V28, P3887, DOI 10.1523/JNEUROSCI.4756-07.2008; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Li ZS, 2010, FEBS LETT, V584, P2291, DOI 10.1016/j.febslet.2010.03.040; McLellan ME, 2003, J NEUROSCI, V23, P2212; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Nickells RW, 2004, BRAIN RES BULL, V62, P439, DOI 10.1016/j.brainresbull.2003.07.007; Othman A, 2011, GLIA, V59, P914, DOI 10.1002/glia.21163; Owusu-Ansah E, 2008, PROTOCOL IN VIVO DET; Pacak K, 2001, ENDOCR REV, V22, P502, DOI 10.1210/er.22.4.502; Payne SC, 2012, INVEST OPHTHALMOL VI; Payne SC, 2011, J NEUROTRAUM, V28, P1077, DOI 10.1089/neu.2010.1665; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Reyes RC, 2012, J NEUROSCI, V32, P12973, DOI 10.1523/JNEUROSCI.1597-12.2012; Rinholm JE, 2012, NATURE, V487, P435, DOI 10.1038/487435a; Robinson KM, 2006, P NATL ACAD SCI USA, V103, P15038, DOI 10.1073/pnas.0601945103; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Rosenbluth J, 2009, J NEUROSCI RES, V87, P3250, DOI 10.1002/jnr.22013; Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-257; Saggu SK, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-97; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Schlieve CR, 2006, INVEST OPHTH VIS SCI, V47, P3878, DOI 10.1167/iovs.05-1010; Sharikabad MN, 2001, AM J PHYSIOL-HEART C, V280, pH344, DOI 10.1152/ajpheart.2001.280.1.H344; Shen SL, 1999, NEURON, V23, P285, DOI 10.1016/S0896-6273(00)80780-1; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Tretter L, 2007, J NEUROSCI RES, V85, P3471, DOI 10.1002/jnr.21405; Wells J, 2012, J NEUROSCI RES, V90, P606, DOI 10.1002/jnr.22784; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011; Ziabreva I, 2010, GLIA, V58, P1827, DOI 10.1002/glia.21052	65	28	28	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2013	8	6							e66448	10.1371/journal.pone.0066448	http://dx.doi.org/10.1371/journal.pone.0066448			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190ST	23840470	Green Published, gold			2023-01-03	WOS:000322361200080
J	Zemp, FJ; McKenzie, BA; Lun, XQ; Maxwell, L; Reilly, KM; McFadden, G; Yong, VW; Forsyth, PA				Zemp, Franz J.; McKenzie, Brienne A.; Lun, Xueqing; Maxwell, Lori; Reilly, Karlyne M.; McFadden, Grant; Yong, V. Wee; Forsyth, Peter A.			Resistance to Oncolytic Myxoma Virus Therapy in Nf1(-/-)/Trp53(-/-) Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon	PLOS ONE			English	Article							HERPES-SIMPLEX-VIRUS; CENTRAL-NERVOUS-SYSTEM; IMMUNOCOMPETENT ANIMAL-MODELS; MALIGNANT GLIOMAS; PANCREATIC-CANCER; GLIOBLASTOMA; CELLS; MUTANT; MICE; VIROTHERAPY	Despite promising preclinical studies, oncolytic viral therapy for malignant gliomas has resulted in variable, but underwhelming results in clinical evaluations. Of concern are the low levels of tumour infection and viral replication within the tumour. This discrepancy between the laboratory and the clinic could result from the disparity of xenograft versus syngeneic models in determining in vivo viral infection, replication and treatment efficacy. Here we describe a panel of primary mouse glioma lines derived from Nf1(+/-)Trp53(+/-) mice in the C57Bl/6J background for use in the preclinical testing of the oncolytic virus Myxoma (MYXV). These lines show a range of susceptibility to MYXV replication in vitro, but all succumb to viral-mediated cell death. Two of these lines orthotopically grafted produced aggressive gliomas. Intracranial injection of MYXV failed to result in sustained viral replication or treatment efficacy, with minimal tumour infection that was completely resolved by 7 days post-infection. We hypothesized that the stromal production of Type-I interferons (IFN alpha/beta) could explain the resistance seen in these models; however, we found that neither the cell lines in vitro nor the tumours in vivo produce any IFN alpha/beta in response to MYXV infection. To confirm IFN alpha/beta did not play a role in this resistance, we ablated the ability of tumours to respond to IFN alpha/beta via IRF9 knockdown, and generated identical results. Our studies demonstrate that these syngeneic cell lines are relevant preclinical models for testing experimental glioma treatments, and show that IFN alpha/beta is not responsible for the MYXV treatment resistance seen in syngeneic glioma models.	[Zemp, Franz J.; McKenzie, Brienne A.; Lun, Xueqing; Maxwell, Lori; Forsyth, Peter A.] Univ Calgary, Southern Alberta Canc Res Inst, Tom Baker Canc Ctr, Clark H Smith Brain Tumor Ctr,Dept Oncol, Calgary, AB, Canada; [Zemp, Franz J.; McKenzie, Brienne A.; Lun, Xueqing; Maxwell, Lori; Forsyth, Peter A.] Univ Calgary, Clark H Smith Brain Tumor Ctr, Calgary, AB, Canada; [Reilly, Karlyne M.] NCI, Mouse Canc Genet Program, Frederick, MD 21701 USA; [McFadden, Grant] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA; [Yong, V. Wee] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB, Canada; [Yong, V. Wee] Univ Calgary, Dept Oncol, Hotchkiss Brain Inst, Calgary, AB, Canada; [Forsyth, Peter A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Forsyth, Peter A.] Univ S Florida, Tampa, FL USA	Tom Baker Cancer Clinic; University of Calgary; University of Calgary; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida; University of Calgary; University of Calgary; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Forsyth, PA (corresponding author), Univ Calgary, Southern Alberta Canc Res Inst, Tom Baker Canc Ctr, Clark H Smith Brain Tumor Ctr,Dept Oncol, Calgary, AB, Canada.	Peter.Forsyth@moffitt.org	McKenzie, Brienne/AAY-6533-2020; Reilly, Karlyne/V-4475-2019	Reilly, Karlyne/0000-0001-9109-4409; McFadden, Grant/0000-0002-2556-3526; McKenzie, Brienne/0000-0001-6829-9828; Yong, V. Wee/0000-0002-2600-3563	Canadian Cancer Society Research Institute (CCSRI); Canadian Cancer Society (PAF); Terry Fox Foundation; V Foundation; Canadian Institutes of Health Research (CIHR); Alberta Innovates Health Solutions; Izaak Walton Killam scholarship; NIH [R01 AI080607, R21 CA149869, R01 CA138541]; Bankhead Coley Foundation [1BT02]; NIH, NCI [ZIA BC 010541]; NATIONAL CANCER INSTITUTE [ZIABC010541, R21CA149869, R01CA138541, ZIABC010540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080607] Funding Source: NIH RePORTER	Canadian Cancer Society Research Institute (CCSRI)(Canadian Cancer Society (CCS)); Canadian Cancer Society (PAF); Terry Fox Foundation; V Foundation; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates Health Solutions; Izaak Walton Killam scholarship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bankhead Coley Foundation; NIH, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by the Canadian Cancer Society Research Institute (CCSRI) with funds raised by the Canadian Cancer Society (PAF), a Program Project Grant from the Terry Fox Foundation (PAF), the V Foundation (PAF), and the Canadian Institutes of Health Research (CIHR) (VWY). During this work FJZ was funded by Alberta Innovates Health Solutions, Vanier Scholarship from CIHR, and the Izaak Walton Killam scholarship. BAM was funded by CIHR. GM's lab is funded by NIH grants (R01 AI080607, R21 CA149869 and R01 CA138541) and by the Bankhead Coley Foundation (1BT02). KMR's lab is funded by the Intramural Research Program of NIH, NCI (ZIA BC 010541). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alain T, 2010, P NATL ACAD SCI USA, V107, P1576, DOI 10.1073/pnas.0912344107; [Anonymous], 2009, ASTR SEC GLIOBL DISS, P93; [Anonymous], 2008, NATURE, V455, P1061; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Barth RF, 2009, J NEURO-ONCOL, V94, P299, DOI 10.1007/s11060-009-9875-7; Bossen C, 2006, J BIOL CHEM, V281, P13964, DOI 10.1074/jbc.M601553200; Cantin E, 1999, J VIROL, V73, P3418, DOI 10.1128/JVI.73.4.3418-3423.1999; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Christensen JE, 2012, J VIROL, V86, P7384, DOI 10.1128/JVI.07090-11; Collins SE, 2004, J VIROL, V78, P1706, DOI 10.1128/JVI.78.4.1706-1717.2004; France MR, 2011, J GEN VIROL, V92, P195, DOI 10.1099/vir.0.026690-0; Gold R, 2006, BRAIN, V129, P1953, DOI 10.1093/brain/awl075; GRAY PW, 1983, P NATL ACAD SCI-BIOL, V80, P5842, DOI 10.1073/pnas.80.19.5842; Gursel DB, 2011, NEURO-ONCOLOGY, V13, P610, DOI 10.1093/neuonc/nor035; Hamilton SR, WHO CLASSIFICATION T; Hellums EK, 2005, NEURO-ONCOLOGY, V7, P213, DOI 10.1215/S1152851705000074; Kastrukoff Lorne F, 2012, Herpesviridae, V3, P4, DOI 10.1186/2042-4280-3-4; Kelly JJP, 2009, STEM CELLS, V27, P1722, DOI 10.1002/stem.98; LANDO Z, 1980, NATURE, V287, P551, DOI 10.1038/287551a0; Lasner TM, 1996, J NEUROPATH EXP NEUR, V55, P1259, DOI 10.1097/00005072-199612000-00010; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lun XQ, 2005, CANCER RES, V65, P9982, DOI 10.1158/0008-5472.CAN-05-1201; Lun XQ, 2007, CANCER RES, V67, P8818, DOI 10.1158/0008-5472.CAN-07-1214; Lun XQ, 2010, MOL THER, V18, P1927, DOI 10.1038/mt.2010.183; Lun XQ, 2010, CANCER RES, V70, P598, DOI 10.1158/0008-5472.CAN-09-1510; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; MCKEEVER PE, 1991, CRIT REV NEUROBIOL, V6, P119; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Motomura K, 2011, CANCER-AM CANCER SOC, V117, P1721, DOI 10.1002/cncr.25637; Noyce RS, 2011, J VIROL, V85, P10926, DOI 10.1128/JVI.00862-11; Oertel Joachim, 2005, Neurosurg Focus, V18, pe12; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Papanastassiou V, 2002, GENE THER, V9, P398, DOI 10.1038/sj.gt.3301664; Paul S, 2007, BIOCHIMIE, V89, P770, DOI 10.1016/j.biochi.2007.02.009; PAULUS W, 1994, INT J CANCER, V58, P841, DOI 10.1002/ijc.2910580616; Qin XQ, 2001, MOL THER, V4, P356, DOI 10.1006/mthe.2001.0464; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Savarin C, 2008, CURR OPIN PHARMACOL, V8, P472, DOI 10.1016/j.coph.2008.05.002; Smallwood Sherin E, 2010, Curr Protoc Microbiol, VChapter 14, DOI 10.1002/9780471729259.mc14a01s17; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tada H, 2001, J CLIN INVEST, V108, P83, DOI 10.1172/JCI9841; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang F, 2004, NAT IMMUNOL, V5, P1266, DOI 10.1038/ni1132; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wennier S, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001876; Wennier ST, 2012, MOL THER, V20, P759, DOI 10.1038/mt.2011.293; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wollmann G, 2012, CANCER J, V18, P69, DOI 10.1097/PPO.0b013e31824671c9; Yoshino A, 2005, J NEURO-ONCOL, V74, P249, DOI 10.1007/s11060-004-7316-1; Yuki K, 2009, CANCER LETT, V284, P71, DOI 10.1016/j.canlet.2009.04.020; Zemp F, 2013, NEURO-ONCOLOGY, DOI [10.1093/neuonc/not035, DOI 10.1093/NEU0NC/N0T035]; Zemp FJ, 2010, CYTOKINE GROWTH F R, V21, P103, DOI 10.1016/j.cytogfr.2010.04.001	56	12	13	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2013	8	6							e65801	10.1371/journal.pone.0065801	http://dx.doi.org/10.1371/journal.pone.0065801			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173SK	23762429	Green Published, gold, Green Submitted			2023-01-03	WOS:000321099000107
J	Karim, AM; Admassu, K; Schellenberg, J; Alemu, H; Getachew, N; Ameha, A; Tadesse, L; Betemariam, W				Karim, Ali Mehryar; Admassu, Kesetebirhane; Schellenberg, Joanna; Alemu, Hibret; Getachew, Nebiyu; Ameha, Agazi; Tadesse, Luche; Betemariam, Wuleta			Effect of Ethiopia's Health Extension Program on Maternal and Newborn Health Care Practices in 101 Rural Districts: A Dose-Response Study	PLOS ONE			English	Article							NEONATAL-MORTALITY; IMPACT; INTERVENTIONS; SERVICES; OUTCOMES; WORKERS	Background: Improving newborn survival is essential if Ethiopia is to achieve Millennium Development Goal 4. The national Health Extension Program (HEP) includes community-based newborn survival interventions. We report the effect of these interventions on changes in maternal and newborn health care practices between 2008 and 2010 in 101 districts, comprising 11.6 million people, or 16% of Ethiopia's population. Methods and Findings: Using data from cross-sectional surveys in December 2008 and December 2010 from a representative sample of 117 communities (kebeles), we estimated the prevalence of maternal and newborn care practices, and a program intensity score in each community. Women with children aged 0 to 11 months reported care practices for their most recent pregnancy and childbirth. The program intensity score ranged between zero and ten and was derived from four outreach activities of the HEP front-line health workers. Dose-response relationships between changes in program intensity and the changes in maternal and newborn health were investigated using regression methods, controlling for secular trend, respondents' background characteristics, and community-level factors. Between 2008 and 2010, median program intensity score increased 2.4-fold. For every unit increase in the score, the odds of receiving antenatal care increased by 1.13 times (95% CI 1.03-1.23); the odds of birth preparedness increased by 1.31 times (1.19-1.44); the odds of receiving postnatal care increased by 1.60 times (1.34-1.91); and the odds of initiating breastfeeding immediately after birth increased by 1.10 times (1.02-1.20). Program intensity score was not associated with skilled deliveries, nor with some of the other newborn health care indicators. Conclusions: The results of our analysis suggest that Ethiopia's HEP platform has improved maternal and newborn health care practices at scale. However, implementation research will be required to address the maternal and newborn care practices that were not influenced by the HEP outreach activities.	[Karim, Ali Mehryar; Alemu, Hibret; Getachew, Nebiyu; Ameha, Agazi; Tadesse, Luche; Betemariam, Wuleta] JSI Res & Training Inst Inc, Last Kilometers Project 10, Addis Ababa, Ethiopia; [Admassu, Kesetebirhane] Minist Hlth, Fed Democrat Republ Ethiopia, Addis Ababa, Ethiopia; [Schellenberg, Joanna] London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Karim, AM (corresponding author), JSI Res & Training Inst Inc, Last Kilometers Project 10, Addis Ababa, Ethiopia.	akarim@jsi.com	Karim, Ali/AAX-4495-2021; Ejeta, Luche Tadesse/J-8021-2019	Ejeta, Luche Tadesse/0000-0003-3529-8516; Schellenberg, Joanna/0000-0002-0708-3676	Bill & Melinda Gates Foundation; Regional Health Bureaus of Amhara; Oromia; Tigray; Southern Nations and Nationalities People's Regions	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Regional Health Bureaus of Amhara; Oromia; Tigray; Southern Nations and Nationalities People's Regions	Work was funded by the Bill & Melinda Gates Foundation. However, the views expressed in this study do not necessarily reflect the views of the foundation. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank the health extension workers, community health promoters, and the women in the L10K areas for making this research possible. The supports from the Regional Health Bureaus of Amhara, Oromia, Tigray, and Southern Nations and Nationalities People's Regions, and the L10K implementing partners, i.e., Amhara Development Association, Bench Maji Development Association, Ethiopian Kale Hiwot Church, Fayyaa Integrated Development Organization, Illu Women and Children Integrated Development Association, Oromia Development Association, Relief Society of Tigray, Sheka Peoples' Development Association, Siltie Development Association, Southern Region's Women's Association, and Women's Association of Tigray were critical for the data collection. Logistics, supervision, and management supports throughout the study period by the L10K central and regional team members were fundamental for conducting the study. We are thankful to Mary Taylor for her support. The review of the paper by W Brown, S Hodgins and E Allen were very useful for finalizing the manuscript. Comments from S Cousens on an early analysis of the L10K baseline and follow-up survey data were very helpful. A Becker helped us with the illustrations.	Admassie A, 2009, J DEV EFFECT, V1, P430, DOI 10.1080/19439340903375724; Angeles G, 2005, SOCIOL METHOD RES, V34, P76, DOI 10.1177/0049124104273069; Bhutta Z.A., 2010, GLOB HLTH WORKFORCE, V1, P61; Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441; Birhanu Z, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-74; Central Statistical Agency of Ethiopia, 2011, ETH DEM HLTH SURV 20; Croft T, 1991, DEMOGRAPHIC HLTH SUR, VII, P1337; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Edmond KM, 2006, PEDIATRICS, V117, pE380, DOI 10.1542/peds.2005-1496; Federal Democratic Republic of Ethiopia Ministry of Health, 2012, HLTH EXT PROGR IMPL; Federal Democratic Republic of Ethiopia Ministry of Health, 2010, HLTH SECT DEV PROGR, p[26, 58]; Federal Democratic Republic of Ethiopia Ministry of Health, 2008, HLTH SECT DEV PROGR; Federal Democratic Republic of Ethiopia Ministry of Health, 2010, ANN PERF REP 2009 20; Federal Democratic Republic of Ethiopia Ministry of Health, 2011, HLTH HLTH REL IND 20; Feysia B, 2012, HLTH WORKFORCE ETHIO, DOI [10.1596/978-0-8213-8984-3, DOI 10.1596/978-0-8213-8984-3.ACCESSED]; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Friberg IK, 2010, INT J EPIDEMIOL, V39, P11, DOI 10.1093/ije/dyq017; Habicht JP, 1999, INT J EPIDEMIOL, V28, P10, DOI 10.1093/ije/28.1.10; Karim AM, 2010, ETHIOP J HEALTH DEV, V24, P92; Koblinsky M, 2010, ETHIOP J HEALTH DEV, V24, P105; Lawn JE, 2010, INT J EPIDEMIOL, V39, P144, DOI 10.1093/ije/dyq031; Lemeshow S, 1985, World Health Stat Q, V38, P65; Marsh David R, 2002, J Perinatol, V22, P572, DOI 10.1038/sj.jp.7210793; Medhanyie A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-352; Morgenstern H, 1999, MODERN EPIDEMIOLOGY, P459; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; Oestergaard MZ, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001080; Seward N, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001180; Shiffman J, 2010, LANCET, V375, P2045, DOI 10.1016/S0140-6736(10)60710-6; Soofi S, 2012, LANCET, V379, P1029, DOI 10.1016/S0140-6736(11)61877-1; StataCorp, 2011, STATA STAT SOFTWARE; StataCorp, 2011, LONG DAT PAN DAT REF, P11; The Partnership for Maternal Newborn & Child Health, 2011, ESS INT COMM GUID RE, P17; Victora CG, 2011, LANCET, V377, P85, DOI 10.1016/S0140-6736(10)60810-0; Wakabi W, 2008, LANCET, V372, P880, DOI 10.1016/S0140-6736(08)61381-1; Wooldridge JM, 2003, INTRO ECONOMETRICS M, P461	36	76	76	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2013	8	6							e65160	10.1371/journal.pone.0065160	http://dx.doi.org/10.1371/journal.pone.0065160			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	158IE	23750240	gold, Green Submitted, Green Published			2023-01-03	WOS:000319961900042
J	Yang, L; Price, ET; Chang, CW; Li, Y; Huang, Y; Guo, LW; Guo, YL; Kaput, J; Shi, LM; Ning, BT				Yang, Lun; Price, Elvin T.; Chang, Ching-Wei; Li, Yan; Huang, Ying; Guo, Li-Wu; Guo, Yongli; Kaput, Jim; Shi, Leming; Ning, Baitang			Gene Expression Variability in Human Hepatic Drug Metabolizing Enzymes and Transporters	PLOS ONE			English	Article							HUMAN LIVER; CYTOCHROME-P450 ENZYMES; HUMAN HEPATOCYTES; POLYMORPHISMS; BIOTRANSFORMATION; PHARMACOGENETICS; HEPATOTOXICITY; RECEPTORS; NETWORKS	Interindividual variability in the expression of drug-metabolizing enzymes and transporters (DMETs) in human liver may contribute to interindividual differences in drug efficacy and adverse reactions. Published studies that analyzed variability in the expression of DMET genes were limited by sample sizes and the number of genes profiled. We systematically analyzed the expression of 374 DMETs from a microarray data set consisting of gene expression profiles derived from 427 human liver samples. The standard deviation of interindividual expression for DMET genes was much higher than that for non-DMET genes. The 20 DMET genes with the largest variability in the expression provided examples of the interindividual variation. Gene expression data were also analyzed using network analysis methods, which delineates the similarities of biological functionalities and regulation mechanisms for these highly variable DMET genes. Expression variability of human hepatic DMET genes may affect drug-gene interactions and disease susceptibility, with concomitant clinical implications.	[Yang, Lun; Chang, Ching-Wei; Li, Yan; Guo, Li-Wu; Guo, Yongli; Kaput, Jim; Shi, Leming; Ning, Baitang] US FDA, Div Syst Biol, Natl Ctr Toxicol Res, Jefferson, AR USA; [Price, Elvin T.] Univ Arkansas Med Sci, Dept Pharmaceut Sci, Little Rock, AR 72205 USA; [Huang, Ying] Western Univ Hlth Sci, Coll Pharm, Dept Pharmaceut Sci, Pomona, CA USA	US Food & Drug Administration (FDA); University of Arkansas System; University of Arkansas Medical Sciences; Western University of Health Sciences	Shi, LM (corresponding author), US FDA, Div Syst Biol, Natl Ctr Toxicol Res, Jefferson, AR USA.	leming.shi@fda.hhs.gov; baitang.ning@fda.hhs.gov	Shi, Leming/B-3150-2010; Kaput, Jim/GSD-5978-2022; Kaput, Jim/AAJ-1386-2020	Shi, Leming/0000-0002-7143-2033; Ning, Baitang/0000-0003-0798-0331	Postgraduate Research Program at the National Center for Toxicological Research	Postgraduate Research Program at the National Center for Toxicological Research	LY, YL and LG were supported by appointments to the Postgraduate Research Program at the National Center for Toxicological Research administered by Oak Ridge Institute for Science Education through an interagency agreement between the United States Department of Energy and the Federal Drug Administration. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amaral LAN, 2000, P NATL ACAD SCI USA, V97, P11149, DOI 10.1073/pnas.200327197; Burk O, 2005, BIOL CHEM, V386, P503, DOI 10.1515/BC.2005.060; Chrostek L, 2003, J CLIN LAB ANAL, V17, P93, DOI 10.1002/jcla.10076; Constable S, 2006, EXPERT REV MOL DIAGN, V6, P193, DOI 10.1586/14737159.6.2.193; Daniel WC, 1996, AM J CARDIOL, V78, P288, DOI 10.1016/S0002-9149(96)00279-2; Garcia-Martin E, 2002, CLIN PHARMACOL THER, V71, P196, DOI 10.1067/mcp.2002.121371; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Guo L, 2011, DRUG METAB DISPOS, V39, P528, DOI 10.1124/dmd.110.035873; Hagenbuch B, 2010, CLIN PHARMACOL THER, V87, P39, DOI 10.1038/clpt.2009.235; Horvath S, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000117; Ieiri I, 2009, EXPERT OPIN DRUG MET, V5, P703, DOI 10.1517/17425250902976854; Kajinami K, 2004, AM J CARDIOL, V93, P104, DOI 10.1016/j.amjcard.2003.08.078; Kroetz DL, 2010, CLIN PHARMACOL THER, V87, P109, DOI 10.1038/clpt.2009.226; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Li DS, 2011, ECOTOXICOLOGY, V20, P1018, DOI 10.1007/s10646-011-0693-2; Liguori MJ, 2005, HEPATOLOGY, V41, P177, DOI 10.1002/hep.20514; Ma MK, 2002, AM J HEALTH-SYST PH, V59, P2061, DOI 10.1093/ajhp/59.21.2061; Ning BT, 2008, J BIOMOL SCREEN, V13, P194, DOI 10.1177/1087057108315513; Ning BT, 2005, PHARMACOGENET GENOM, V15, P465, DOI 10.1097/01.fpc.0000166823.74378.79; Ning BT, 2004, PHARMACOGENETICS, V14, P35, DOI 10.1097/00008571-200401000-00004; Novembre J, 2008, NATURE, V456, P98, DOI 10.1038/nature07331; Omiecinski CJ, 2011, TOXICOL SCI, V120, pS49, DOI 10.1093/toxsci/kfq338; Owens IS, 2005, METHOD ENZYMOL, V400, P1, DOI 10.1016/S0076-6879(05)00001-7; Park BK, 2005, ANNU REV PHARMACOL, V45, P177, DOI 10.1146/annurev.pharmtox.45.120403.100058; Pirmohamed M, 2001, TRENDS PHARMACOL SCI, V22, P298, DOI 10.1016/S0165-6147(00)01717-X; Ravasz E, 2002, SCIENCE, V297, P1551, DOI 10.1126/science.1073374; Rodriguez-Antona C, 2001, ARCH BIOCHEM BIOPHYS, V393, P308, DOI 10.1006/abbi.2001.2499; Schadt EE, 2008, PLOS BIOL, V6, P1020, DOI 10.1371/journal.pbio.0060107; Shay NF, 2005, ANNU REV NUTR, V25, P297, DOI 10.1146/annurev.nutr.25.050304.092639; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; Spear BB, 2001, TRENDS MOL MED, V7, P201, DOI 10.1016/S1471-4914(01)01986-4; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tirona RG, 2005, J PHARM SCI-US, V94, P1169, DOI 10.1002/jps.20324; Tolson AH, 2010, ADV DRUG DELIVER REV, V62, P1238, DOI 10.1016/j.addr.2010.08.006; Tomalik-Scharte D, 2008, PHARMACOGENOMICS J, V8, P4, DOI 10.1038/sj.tpj.6500462; Wauthier V, 2007, CURR MED CHEM, V14, P745, DOI 10.2174/092986707780090981; Waxman DJ, 2009, MOL PHARMACOL, V76, P215, DOI 10.1124/mol.109.056705; Wilkinson GR, 2005, NEW ENGL J MED, V352, P2211, DOI 10.1056/NEJMra032424; Yang L, 2012, J DRUG METAB TOXICOL, V3, P1, DOI DOI 10.4172/2157-7609.1000119; Yang X, 2010, GENOME RES, V20, P1020, DOI 10.1101/gr.103341.109; Zanger UM, 2008, ANAL BIOANAL CHEM, V392, P1093, DOI 10.1007/s00216-008-2291-6; Zanger UM, 2013, PHARM THER; Zhou SF, 2009, DRUG METAB REV, V41, P89, DOI 10.1080/03602530902843483	43	37	37	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e60368	10.1371/journal.pone.0060368	http://dx.doi.org/10.1371/journal.pone.0060368			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131QH	23637747	Green Published, Green Submitted, gold			2023-01-03	WOS:000318008400004
J	Wang, J; Yang, YG; Zhou, M; Xu, JY; Zhang, QG; Zhou, RF; Chen, B; Ouyang, J				Wang, Jing; Yang, Yong-Gong; Zhou, Min; Xu, Jing-Yan; Zhang, Qi-Guo; Zhou, Rong-Fu; Chen, Bing; Ouyang, Jian			Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin plus Cytarabine with Daunorubicin plus Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia	PLOS ONE			English	Article							ACUTE MYELOGENOUS LEUKEMIA; 1ST COMPLETE REMISSION; HIGH-DOSE DAUNORUBICIN; PUBLICATION BIAS; ADULT PATIENTS; THERAPY; MULTICENTER; COMBINATION; RECOMMENDATIONS; FLUDARABINE	Background: To determine whether the use of idarubicin+cytarabine (IA) is more effective than the use of daunorubicin+cytarabine (DA) as induction chemotherapy for patients with newly diagnosed acute myeloid leukaemia. Methods: A computer-based search was performed. Randomised trials comparing IA with DA as induction therapy for newly diagnosed AML were included in this meta-analysis. The primary outcome of interest for our analysis was survival (disease-free survival, event-free survival and overall survival); the secondary endpoint was complete remission. Results: Ten trials with 4,060 patients were eligible for this meta-analysis. Our pooled results suggest that IA is associated with a significant advantage in CR (RR = 1.23; 95% CI = 1.07-1.41, p = 0.004), EFS (HR = 0.64; 95% CI = 0.45-0.91, p = 0.013), and OS (HR = 0.88; 95% CI = 0.81-0.95, p = 0.02) but not in DFS (HR = 0.90; 95% CI = 0.80-1.00, p = 0.06). In the subgroup analysis, age had a significant interaction with OS and CR benefits. Conclusion: Our analysis indicated that IA could improve the duration of overall survival compared to DA as induction therapy for young patients with newly diagnosed AML. Further study is needed to determine whether IA can produce clinical benefits in selected genetic or molecular subgroups of young AML patients.	[Wang, Jing; Yang, Yong-Gong; Zhou, Min; Xu, Jing-Yan; Zhang, Qi-Guo; Zhou, Rong-Fu; Chen, Bing; Ouyang, Jian] Nanjing Univ, Dept Hematol, Affiliated DrumTower Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China	Nanjing University	Ouyang, J (corresponding author), Nanjing Univ, Dept Hematol, Affiliated DrumTower Hosp, Sch Med, Nanjing 210008, Jiangsu, Peoples R China.	ouyang211@hotmail.com	zhou, rongfu/L-1743-2016	zhou, rongfu/0000-0002-3217-9194; Yang, Yonggong/0000-0002-6475-2696; Wang, Jing/0000-0001-9981-5530				Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BERMAN E, 1991, BLOOD, V77, P1666; Burnett AK, 2011, J CLIN ONCOL, V29, P369, DOI 10.1200/JCO.2010.31.4310; Candoni A, 2008, LEUKEMIA RES, V32, P1800, DOI 10.1016/j.leukres.2008.05.011; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Chevallier P, 2010, LEUKEMIA, V24, P1380, DOI 10.1038/leu.2010.111; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Creutzig U, 2001, LEUKEMIA, V15, P348, DOI 10.1038/sj.leu.2402046; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Fernandez HF, 2009, NEW ENGL J MED, V361, P1249, DOI 10.1056/NEJMoa0904544; Ferrara F, 2008, CRIT REV ONCOL HEMAT, V66, P181, DOI 10.1016/j.critrevonc.2007.09.008; Gardin C, 2007, BLOOD, V109, P5129, DOI 10.1182/blood-2007-02-069666; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P783, DOI 10.1093/oxfordjournals.aje.a117326; Holowiecki J, 2004, LEUKEMIA, V18, P989, DOI 10.1038/sj.leu.2403336; Holowiecki J, 2012, J CLIN ONCOL, V30, P2441, DOI 10.1200/JCO.2011.37.1286; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Lee JH, 2011, BLOOD, V118, P3832, DOI 10.1182/blood-2011-06-361410; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Liddle J., 1996, METHOD EVALUATING RE; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Lowenberg B, 2009, NEW ENGL J MED, V361, P1235, DOI 10.1056/NEJMoa0901409; MANDELLI F, 1991, EUR J CANCER, V27, P750, DOI 10.1016/0277-5379(91)90181-C; Mandelli F, 2009, J CLIN ONCOL, V27, P5397, DOI 10.1200/JCO.2008.20.6490; MANTEL N, 1959, J NATL CANCER I, V22, P719; Ohtake S, 2011, BLOOD, V117, P2358, DOI 10.1182/blood-2010-03-273243; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Pautas C, 2010, J CLIN ONCOL, V28, P808, DOI 10.1200/JCO.2009.23.2652; Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010; Poole C, 1999, AM J EPIDEMIOL, V150, P469, DOI 10.1093/oxfordjournals.aje.a010035; Reiffers J, 1996, LEUKEMIA, V10, P389; Roboz GJ, 2011, HEMATOL-AM SOC HEMAT, P43, DOI 10.1182/asheducation-2011.1.43; Rowe JM, 2004, BLOOD, V103, P479, DOI 10.1182/blood-2003-05-1686; Rowe JM, 1997, BLOOD, V90, P2121; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; VOGLER WR, 1992, J CLIN ONCOL, V10, P1103, DOI 10.1200/JCO.1992.10.7.1103; Wheatley D, 1998, BRIT J HAEMATOL, V103, P100; WIERNIK PH, 1992, BLOOD, V79, P313	43	20	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2013	8	4							e60699	10.1371/journal.pone.0060699	http://dx.doi.org/10.1371/journal.pone.0060699			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146RZ	23593285	Green Submitted, Green Published, gold			2023-01-03	WOS:000319109800092
J	Williams, M; Villarreal, A; Bozhilov, K; Lin, S; Talbot, P				Williams, Monique; Villarreal, Amanda; Bozhilov, Krassimir; Lin, Sabrina; Talbot, Prue			Metal and Silicate Particles Including Nanoparticles Are Present in Electronic Cigarette Cartomizer Fluid and Aerosol	PLOS ONE			English	Article							TRACE-ELEMENTS; TOXICITY; TOBACCO; NICOTINE; SMOKE	Background: Electronic cigarettes (EC) deliver aerosol by heating fluid containing nicotine. Cartomizer EC combine the fluid chamber and heating element in a single unit. Because EC do not burn tobacco, they may be safer than conventional cigarettes. Their use is rapidly increasing worldwide with little prior testing of their aerosol. Objectives: We tested the hypothesis that EC aerosol contains metals derived from various components in EC. Methods: Cartomizer contents and aerosols were analyzed using light and electron microscopy, cytotoxicity testing, x-ray microanalysis, particle counting, and inductively coupled plasma optical emission spectrometry. Results: The filament, a nickel-chromium wire, was coupled to a thicker copper wire coated with silver. The silver coating was sometimes missing. Four tin solder joints attached the wires to each other and coupled the copper/silver wire to the air tube and mouthpiece. All cartomizers had evidence of use before packaging (burn spots on the fibers and electrophoretic movement of fluid in the fibers). Fibers in two cartomizers had green deposits that contained copper. Centrifugation of the fibers produced large pellets containing tin. Tin particles and tin whiskers were identified in cartridge fluid and outer fibers. Cartomizer fluid with tin particles was cytotoxic in assays using human pulmonary fibroblasts. The aerosol contained particles > 1 mu m comprised of tin, silver, iron, nickel, aluminum, and silicate and nanoparticles (<100 nm) of tin, chromium and nickel. The concentrations of nine of eleven elements in EC aerosol were higher than or equal to the corresponding concentrations in conventional cigarette smoke. Many of the elements identified in EC aerosol are known to cause respiratory distress and disease. Conclusions: The presence of metal and silicate particles in cartomizer aerosol demonstrates the need for improved quality control in EC design and manufacture and studies on how EC aerosol impacts the health of users and bystanders.	[Williams, Monique; Villarreal, Amanda; Lin, Sabrina; Talbot, Prue] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; [Bozhilov, Krassimir] Univ Calif Riverside, Cent Facil Adv Microscopy & Microanal, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Talbot, P (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA.	talbot@ucr.edu	Talbot, Prue/AAY-3896-2021		Tobacco-Related Disease Research Program (TRDRP); MARC National Institutes of Health (NIH); TRDRP; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM062756] Funding Source: NIH RePORTER	Tobacco-Related Disease Research Program (TRDRP)(University of California System); MARC National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); TRDRP; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the Tobacco-Related Disease Research Program (TRDRP) to PT, a Cornelius Hopper Award to MW, a MARC National Institutes of Health (NIH) fellowship to AV, and a TRDRP Postdoctoral Fellowship to SL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Administration FaD Services DoHaP], 2012, HAMF POT HARMF CONST; Agency for Toxic Substances and Disease Registry (ATSDR), 2007, TOX PROF LEAD; Agency for Toxic Substances and Disease Registry ATSDR, 2010, TOX PROF BOR; Agency for Toxic Substances and Disease Registry (ATSDR), 2004, INT PROF BENZ TOL ET; [ATSDR Services DoHaH], 2008, TOX PROF MAN; ATSDR, 2004, TOX PROF STRONT; ATSDR, 2005, TOXICOLOGICAL PROFIL; ATSDR, 2004, TOX PROF COPP; [ATSDR Agency for Toxic Substances & Disease Registry CfDCaP], 2005, TOX PROF ZINC; ATSDR, 2008, TOX PROF AL; ATSDR, 2007, TOX PROF BAR BAR COM; ATSDR (Agency for Toxic Substances and Disease Registry), 2008, TOX PROF CHROM; ATSDR (Agency for Toxic Substances and Disease Registry), 2005, TOX PROF NICK; Ayers JW, 2011, AM J PREV MED, V40, P448, DOI 10.1016/j.amepre.2010.12.007; Bakand S, 2012, INHAL TOXICOL, V24, P125, DOI 10.3109/08958378.2010.642021; Behar RZ, 2012, J PHARMACOL TOX MET, V66, P238, DOI 10.1016/j.vascn.2012.07.003; Bernhard D, 2005, IUBMB LIFE, V57, P805, DOI 10.1080/15216540500459667; Bhabra G, 2009, NAT NANOTECHNOL, V4, P876, DOI [10.1038/nnano.2009.313, 10.1038/NNANO.2009.313]; Bian L, 2011, MED ONCOL, V28, pS560, DOI 10.1007/s12032-010-9655-4; Caponnetto Pasquale, 2011, J Med Case Rep, V5, P585, DOI 10.1186/1752-1947-5-585; Caponnetto P, 2012, EXPERT REV RESP MED, V6, P63, DOI [10.1586/ers.11.92, 10.1586/ERS.11.92]; Chen IL, 2013, NICOTINE TOB RES, V15, P615, DOI 10.1093/ntr/nts145; Chen Wei-hong, 2005, Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, V23, P366; CHIBA M, 1992, B WORLD HEALTH ORGAN, V70, P269; Etter JF, 2011, EUR RESPIR J, V38, P1219, DOI 10.1183/09031936.00066011; Etter JF, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-231; Flouris AD, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c311; Goniewicz ML, 2013, NICOTINE TOB RES, V15, P158, DOI 10.1093/ntr/nts103; Horie M., 2011, ENVIRON TOXICOL, V28, P61, DOI [10.1002/tox.20695, DOI 10.1002/TOX.20695]; Hua M, 2011, TOBACCO CONTROL; Kang GS, 2011, ENVIRON HEALTH PERSP, V119, P176, DOI 10.1289/ehp.1002508; Laugesen M., 2008, SAFETY REPORT RUYAN, P1; Lee NC, 2009, LEAD FREE SOLDERING; Liu SH, 2004, J APPL PHYS, V95, P7742, DOI 10.1063/1.1712019; McCauley L, 2012, CHEST, V141, P1110, DOI 10.1378/chest.11-1334; [NJDHSS Services NJDoHS], 2007, HAZ SUBST FACT SHEET; Noel JK, 2011, TOB CONTROL, V20, P81, DOI 10.1136/tc.2010.038562; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Odum Lauren E, 2012, J Pharm Pract, V25, P611, DOI 10.1177/0897190012451909; [RTKHS Services NJDoHS], 2009, RIGHT KNOW HAZ SUBST; [RTKHS Services NJDoHS], 2010, RIGHT KNOW HAZ SUBST; [RTKHS Services NJDoHS], 2008, RIGHT KNOW HAZ SUBST; [RTKHS Services NJDoHS], 2011, RIGHT KNOW HAZ SUBST; Schrand AM, 2010, WIRES NANOMED NANOBI, V2, P544, DOI 10.1002/wnan.103; SCHULER P, 1958, Ind Med Surg, V27, P432; Smith CJ, 1997, FOOD CHEM TOXICOL, V35, P1107, DOI 10.1016/S0278-6915(97)00063-X; SMITH RA, 1986, J NON-CRYST SOLIDS, V84, P421, DOI 10.1016/0022-3093(86)90805-7; Stohs SJ, 1997, INHAL TOXICOL, V9, P867; Takenaka S, 2001, ENVIRON HEALTH PERSP, V109, P547, DOI 10.2307/3454667; Terzano C, 2010, EUR REV MED PHARMACO, V14, P809; Trehy ML, 2011, J LIQ CHROMATOGR R T, V34, P1442, DOI 10.1080/10826076.2011.572213; Trtchounian A, 2011, TOB CONTROL, V20, P47, DOI 10.1136/tc.2010.037259; Trtchounian A, 2010, NICOTINE TOB RES, V12, P905, DOI 10.1093/ntr/ntq114; U.S. Food and Drug Administration, 2012, HARMF POT HARMF CONS; van Dijk WD, 2011, ANAL BIOANAL CHEM, V399, P3573, DOI 10.1007/s00216-011-4701-4; Vansickel AR, 2013, NICOTINE TOB RES, V15, P267, DOI 10.1093/ntr/ntr316; Westenberger B., 2009, EVALUATION E CIGARET, P1; Williams M, 2011, NICOTINE TOB RES, V13, P1276, DOI 10.1093/ntr/ntr164; Yang W, 2008, INT J PHARMACEUT, V356, P239, DOI 10.1016/j.ijpharm.2008.02.011; Young JA, 2008, J CHEM EDUC, V85, P193; Young JA, 2004, J CHEM EDUC, V81, P1562	61	420	439	10	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2013	8	3							e57987	10.1371/journal.pone.0057987	http://dx.doi.org/10.1371/journal.pone.0057987			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SW	23526962	Green Published, gold			2023-01-03	WOS:000317562600011
J	Katragadda, U; Fan, W; Wang, YZ; Teng, Q; Tan, C				Katragadda, Usha; Fan, Wei; Wang, Yingzhe; Teng, Quincy; Tan, Chalet			Combined Delivery of Paclitaxel and Tanespimycin via Micellar Nanocarriers: Pharmacokinetics, Efficacy and Metabolomic Analysis	PLOS ONE			English	Article							IN-VIVO; INDOCYANINE GREEN; CELL METABOLISM; PHASE-I; CANCER; DRUG; TUMORS; THERAPEUTICS; CHEMOTHERAPY; MALIGNANCIES	Background: Despite the promising anticancer efficacy observed in preclinical studies, paclitaxel and tanespimycin (17-AAG) combination therapy has yielded meager responses in a phase I clinical trial. One serious problem associated with paclitaxel/17-AAG combination therapy is the employment of large quantities of toxic organic surfactants and solvents for drug solubilization. The goal of this study was to evaluate a micellar formulation for the concurrent delivery of paclitaxel and 17-AAG in vivo. Methodology/Principal Findings: Paclitaxel/17-AAG-loaded micelles were assessed in mice bearing human ovarian tumor xenografts. Compared with the free drugs at equivalent doses, intravenous administration of paclitaxel/17-AAG-loaded micelles led to 3.5- and 1.7-fold increase in the tumor concentrations of paclitaxel and 17-AAG, respectively, without significant altering drug levels in normal organs. The enhanced tumor accumulation of the micellar drugs was further confirmed by the whole-body near infrared imaging using indocyanine green-labeled micelles. Subsequently, the anticancer efficacy of paclitaxel/17-AAG-loaded micelles was examined in comparison with the free drugs (weekly 20 mg/kg paclitaxel, twice-weekly 37.5 mg/kg 17-AAG). We found that paclitaxel/17-AAG-loaded micelles caused near-complete arrest of tumor growth, whereas the free drug-treated tumors experienced rapid growth shortly after the 3-week treatment period ended. Furthermore, comparative metabolomic profiling by proton nuclear magnetic resonance revealed significant decrease in glucose, lactate and alanine with simultaneous increase in glutamine, glutamate, aspartate, choline, creatine and acetate levels in the tumors of mice treated with paclitaxel/17-AAG-loaded micelles. Conclusions/Significance: We have demonstrated in the current wok a safe and efficacious nano-sized formulation for the combined delivery of paclitaxel and 17-AAG, and uncovered unique metabolomic signatures in the tumor that correlate with the favorable therapeutic response to paclitaxel/17-AAG combination therapy.	[Katragadda, Usha; Fan, Wei; Wang, Yingzhe; Tan, Chalet] Mercer Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Canc Nanomed Lab, Atlanta, GA USA; [Teng, Quincy] Univ Georgia, Coll Pharm, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA	Mercer University; University System of Georgia; University of Georgia	Tan, C (corresponding author), Mercer Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Canc Nanomed Lab, Atlanta, GA USA.	tan_c@mercer.edu	Wang, Yingzhe/AAA-4340-2020	Wang, Yingzhe/0000-0002-7382-9683; Fan, Wei/0000-0001-5893-6045	National Institutes of Health [R15CA152860]; Georgia Cancer Coalition Cancer Research Award; NATIONAL CANCER INSTITUTE [R15CA152860] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Georgia Cancer Coalition Cancer Research Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health grant R15CA152860 (CT) and the Georgia Cancer Coalition Cancer Research Award (CT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aryal S, 2010, SMALL, V6, P1442, DOI 10.1002/smll.201000631; Chen H, 2008, LANGMUIR, V24, P5213, DOI 10.1021/la703570m; Collette TW, 2010, ENVIRON SCI TECHNOL, V44, P6881, DOI 10.1021/es1011884; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Dicko A, 2010, EXPERT OPIN DRUG DEL, V7, P1329, DOI 10.1517/17425247.2010.538678; Egorin MJ, 2001, CANCER CHEMOTH PHARM, V47, P291, DOI 10.1007/s002800000242; Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Katragadda U, 2011, INT J PHARMACEUT, V419, P281, DOI 10.1016/j.ijpharm.2011.07.033; Kim SC, 2001, J CONTROL RELEASE, V72, P191, DOI 10.1016/S0168-3659(01)00275-9; Kim TY, 2004, CLIN CANCER RES, V10, P3708, DOI 10.1158/1078-0432.CCR-03-0655; Kolishetti N, 2010, P NATL ACAD SCI USA, V107, P17939, DOI 10.1073/pnas.1011368107; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Mordon S, 1998, MICROVASC RES, V55, P146, DOI 10.1006/mvre.1998.2068; Munster PN, 2001, CLIN CANCER RES, V7, P2228; Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000; Nishiyama N, 2006, PHARMACOL THERAPEUT, V112, P630, DOI 10.1016/j.pharmthera.2006.05.006; Ramalingam SS, 2008, CLIN CANCER RES, V14, P3456, DOI 10.1158/1078-0432.CCR-07-5088; Sawai A, 2008, CANCER RES, V68, P589, DOI 10.1158/0008-5472.CAN-07-1570; Shin HC, 2009, J CONTROL RELEASE, V140, P294, DOI 10.1016/j.jconrel.2009.04.024; Solit DB, 2003, CANCER RES, V63, P2139; Spaareboom A, 1996, CANCER RES, V56, P2112; Tang N, 2007, JNCI-J NATL CANCER I, V99, P1004, DOI 10.1093/jnci/djm027; Teng Q, 2012, ANALYST, V137, P2226, DOI 10.1039/c2an16251b; Teng Q, 2009, METABOLOMICS, V5, P199, DOI 10.1007/s11306-008-0137-z; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; WHEELER HO, 1958, P SOC EXP BIOL MED, V99, P11	30	36	38	0	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2013	8	3							e58619	10.1371/journal.pone.0058619	http://dx.doi.org/10.1371/journal.pone.0058619			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136BN	23505544	gold, Green Submitted, Green Published			2023-01-03	WOS:000318334500108
J	Courtin, A; Richards, FM; Bapiro, TE; Bramhall, JL; Neesse, A; Cook, N; Krippendorff, BF; Tuveson, DA; Jodrell, DI				Courtin, Aurelie; Richards, Frances M.; Bapiro, Tashinga E.; Bramhall, Jo L.; Neesse, Albrecht; Cook, Natalie; Krippendorff, Ben-Fillippo; Tuveson, David A.; Jodrell, Duncan I.			Anti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer	PLOS ONE			English	Article							ORAL FLUOROPYRIMIDINE CARBAMATE; GEMCITABINE PLUS CAPECITABINE; CYTIDINE DEAMINASE; NUCLEOSIDE TRANSPORTER; CELLULAR PHARMACOLOGY; RANDOMIZED-TRIAL; IN-VITRO; CHEMOTHERAPY; CELLS; XENOGRAFTS	Capecitabine (CAP) is a 5-FU pro-drug approved for the treatment of several cancers and it is used in combination with gemcitabine (GEM) in the treatment of patients with pancreatic adenocarcinoma (PDAC). However, limited pre-clinical data of the effects of CAP in PDAC are available to support the use of the GEMCAP combination in clinic. Therefore, we investigated the pharmacokinetics and the efficacy of CAP as a single agent first and then in combination with GEM to assess the utility of the GEMCAP therapy in clinic. Using a model of spontaneous PDAC occurring in Kras(G12D); p53(R172H); Pdx1-Cre (KPC) mice and subcutaneous allografts of a KPC PDAC-derived cell line (K8484), we showed that CAP achieved tumour concentrations (similar to 25 mu M) of 5-FU in both models, as a single agent, and induced survival similar to GEM in KPC mice, suggesting similar efficacy. In vitro studies performed in K8484 cells as well as in human pancreatic cell lines showed an additive effect of the GEMCAP combination however, it increased toxicity in vivo and no benefit of a tolerable GEMCAP combination was identified in the allograft model when compared to GEM alone. Our work provides pre-clinical evidence of 5-FU delivery to tumours and anti-tumour efficacy following oral CAP administration that was similar to effects of GEM. Nevertheless, the GEMCAP combination does not improve the therapeutic index compared to GEM alone. These data suggest that CAP could be considered as an alternative to GEM in future, rationally designed, combination treatment strategies for advanced pancreatic cancer.	[Courtin, Aurelie; Richards, Frances M.; Bapiro, Tashinga E.; Bramhall, Jo L.; Krippendorff, Ben-Fillippo; Jodrell, Duncan I.] Canc Res UK Cambridge Res Inst, Pharmacol & Drug Dev Grp, Cambridge, England; [Neesse, Albrecht; Cook, Natalie; Tuveson, David A.] Canc Res UK Cambridge Res Inst, Tumour Modelling & Expt Med Grp, Cambridge, England; [Courtin, Aurelie; Richards, Frances M.; Bapiro, Tashinga E.; Bramhall, Jo L.; Neesse, Albrecht; Cook, Natalie; Krippendorff, Ben-Fillippo; Tuveson, David A.; Jodrell, Duncan I.] Univ Cambridge, Dept Oncol, Cambridge, England	Cancer Research UK; CRUK Cambridge Institute; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Richards, FM (corresponding author), Canc Res UK Cambridge Res Inst, Pharmacol & Drug Dev Grp, Cambridge, England.	fran.richards@cruk.cam.ac.uk	Cook, Natalie/O-4871-2015	Cook, Natalie/0000-0003-2606-1082; Bramhall, Jo/0000-0002-0996-1583	Cancer Research UK [C96/A8333]; CRUK Cambridge Institute Group Leader funding; University of Cambridge; Li Ka Shing Foundation; Hutchison-Whampoa Ltd.; NIHR Cambridge Biomedical Research Centre; Cancer Research UK [15678] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); CRUK Cambridge Institute Group Leader funding; University of Cambridge(University of Cambridge); Li Ka Shing Foundation; Hutchison-Whampoa Ltd.; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK)	This work was funded by Cancer Research UK (www.cancerresearchuk.org) via Programme Grant C96/A8333 to DJ and via CRUK Cambridge Institute Group Leader funding to DJ and DT. This work was also supported by The University of Cambridge, the Li Ka Shing Foundation and by a charitable donation to the University of Cambridge from Hutchison-Whampoa Ltd. The work was also supported by funding from the NIHR Cambridge Biomedical Research Centre (www.nihr.ac.uk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Aresvik DM, 2010, ANTICANCER RES, V30, P3879; Blanquicett C, 2005, CLIN CANCER RES, V11, P8773, DOI 10.1158/1078-0432.CCR-05-0627; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cartwright TH, 2002, J CLIN ONCOL, V20, P160, DOI 10.1200/JCO.20.1.160; Ciccolini J, 2010, J CLIN ONCOL, V28, P160, DOI 10.1200/JCO.2009.24.4491; Cook N, 2008, METHOD ENZYMOL, V439, P73, DOI 10.1016/S0076-6879(07)00406-5; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817; Frese KK, 2012, CANCER DISCOV, V2, P260, DOI 10.1158/2159-8290.CD-11-0242; Guichard SM, 2005, J CHROMATOGR B, V826, P232, DOI 10.1016/j.jchromb.2005.09.010; Guichard SM, 2008, EUR J CANCER, V44, P310, DOI 10.1016/j.ejca.2007.10.023; Heinemann V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-82; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Hubner RA, 2013, PANCREAS, V42, P511, DOI 10.1097/MPA.0b013e31826c6aee; Hwang IT, 2007, BIOCHEM BIOPH RES CO, V359, P304, DOI 10.1016/j.bbrc.2007.05.088; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Ishikawa T, 1998, BIOCHEM PHARMACOL, V55, P1091, DOI 10.1016/S0006-2952(97)00682-5; Ishitsuka H, 2000, INVEST NEW DRUG, V18, P343, DOI 10.1023/A:1006497231579; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Lin Y, 2012, BRIT J CANCER, V107, P1692, DOI 10.1038/bjc.2012.450; Mackey JR, 1998, CANCER RES, V58, P4349; Mercier C, 2009, CANCER CHEMOTH PHARM, V63, P1177, DOI 10.1007/s00280-008-0889-1; Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941; Miwa M, 1998, EUR J CANCER, V34, P1274, DOI 10.1016/S0959-8049(98)00058-6; Morita T, 2003, ONCOLOGY-BASEL, V65, P267, DOI 10.1159/000074480; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Ninomiya I, 2004, INT J CANCER, V112, P135, DOI 10.1002/ijc.20360; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; PRESSACCO J, 1995, BRIT J CANCER, V72, P939, DOI 10.1038/bjc.1995.437; PRESSACCO J, 1995, CANCER RES, V55, P1505; Quinney SK, 2005, J PHARMACOL EXP THER, V313, P1011, DOI 10.1124/jpet.104.081265; Rauchwerger DR, 2000, CANCER RES, V60, P6075; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Reigner B, 2001, CLIN PHARMACOKINET, V40, P85, DOI 10.2165/00003088-200140020-00002; Schreiber FS, 2004, GASTROENTEROLOGY, V127, P250, DOI 10.1053/j.gastro.2004.03.058; Shindoh H, 2011, J TOXICOL SCI, V36, P411, DOI 10.2131/jts.36.411; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Yoshida T, 2010, DRUG METAB DISPOS, V38, P1814, DOI 10.1124/dmd.110.034397	43	24	24	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e67330	10.1371/journal.pone.0067330	http://dx.doi.org/10.1371/journal.pone.0067330			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IH	23840665	Green Submitted, Green Published, gold			2023-01-03	WOS:000321148400058
J	Berdot, S; Gillaizeau, F; Caruba, T; Prognon, P; Durieux, P; Sabatier, B				Berdot, Sarah; Gillaizeau, Florence; Caruba, Thibaut; Prognon, Patrice; Durieux, Pierre; Sabatier, Brigitte			Drug Administration Errors in Hospital Inpatients: A Systematic Review	PLOS ONE			English	Review							BAR-CODE TECHNOLOGY; MEDICATION ERRORS; INTENSIVE-CARE; INTRAVENOUS MEDICATION; DISPENSING SYSTEM; PRESCRIPTION; FREQUENCY; SEVERITY; IMPACT; NURSES	Context: Drug administration in the hospital setting is the last barrier before a possible error reaches the patient. Objectives: We aimed to analyze the prevalence and nature of administration error rate detected by the observation method. Data Sources: Embase, MEDLINE, Cochrane Library from 1966 to December 2011 and reference lists of included studies. Study Selection: Observational studies, cross-sectional studies, before-and-after studies, and randomized controlled trials that measured the rate of administration errors in inpatients were included. Data Extraction: Two reviewers (senior pharmacists) independently identified studies for inclusion. One reviewer extracted the data; the second reviewer checked the data. The main outcome was the error rate calculated as being the number of errors without wrong time errors divided by the Total Opportunity for Errors (TOE, sum of the total number of doses ordered plus the unordered doses given), and multiplied by 100. For studies that reported it, clinical impact was reclassified into four categories from fatal to minor or no impact. Due to a large heterogeneity, results were expressed as median values (interquartile range, IQR), according to their study design. Results: Among 2088 studies, a total of 52 reported TOE. Most of the studies were cross-sectional studies (N=46). The median error rate without wrong time errors for the cross-sectional studies using TOE was 10.5% [IQR: 7.3%-21.7%]. No fatal error was observed and most errors were classified as minor in the 18 studies in which clinical impact was analyzed. We did not find any evidence of publication bias. Conclusions: Administration errors are frequent among inpatients. The median error rate without wrong time errors for the cross-sectional studies using TOE was about 10%. A standardization of administration error rate using the same denominator (TOE), numerator and types of errors is essential for further publications.	[Berdot, Sarah; Caruba, Thibaut; Prognon, Patrice; Sabatier, Brigitte] Hop Europeen Georges Pompidou, AP HP, Dept Pharm, Paris, France; [Berdot, Sarah; Durieux, Pierre; Sabatier, Brigitte] INSERM, Ctr Rech Cordeliers, Equipe 22, UMR S 872, Paris, France; [Gillaizeau, Florence; Durieux, Pierre] INSERM, Ctr Invest Epidemiol 4, Paris, France; [Caruba, Thibaut] Univ Paris 05, Lab Interdisciplinaire Rech Econ Sante, Sorbonne Paris Cite, EA4410, Paris, France; [Prognon, Patrice] Univ Paris 11, Chatenay Malabry, France; [Durieux, Pierre] Univ Paris 05, Sorbonne Paris Cite, Fac Med, Paris, France; [Durieux, Pierre] Hop Europeen Georges Pompidou, AP HP, Dept Med Informat, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Durieux, P (corresponding author), INSERM, Ctr Rech Cordeliers, Equipe 22, UMR S 872, Paris, France.	pierre.durieux@egp.aphp.fr	Berdot, Sarah/I-9913-2019	Berdot, Sarah/0000-0001-6607-4318; Sabatier, Brigitte/0000-0003-1643-2070				ALLAN BL, 1987, AM J HOSP PHARM, V44, P1046, DOI 10.1093/ajhp/44.5.1044; ALLAN EL, 1990, AM J HOSP PHARM, V47, P555, DOI 10.1093/ajhp/47.3.555; Teixeira TCA, 2010, REV ESC ENFERM USP, V44, P139, DOI 10.1590/S0080-62342010000100020; [Anonymous], 2008, MED ERR NAT COORD CO; [Anonymous], 1993, AM J HOSP PHARM, V50, P305, DOI DOI 10.1093/AJHP/50.2.305; Anselmi ML, 2007, J CLIN NURS, V16, P1839, DOI 10.1111/j.1365-2702.2007.01834.x; Aspden P, 2007, PREVENTING MED ERROR; Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; BARKER KN, 1984, AM J HOSP PHARM, V41, P1352, DOI 10.1093/ajhp/41.7.1352; BARKER KN, 1984, AM J HOSP PHARM, V41, P2009, DOI 10.1093/ajhp/41.10.2009; BARKER KN, 1982, AM J HOSP PHARM, V39, P987, DOI 10.1093/ajhp/39.6.987; BARKER KN, 1969, AM J HOSP PHARM, V26, P324, DOI 10.1093/ajhp/26.6.324; Barker KN, 1962, AM J HOSP PHARM, V19, P361; BOREL JM, 1995, AM J HEALTH-SYST PH, V52, P1875, DOI 10.1093/ajhp/52.17.1875; Bourlon S., 2006, Journal de Pharmacie Clinique, V25, P23; Bruce J, 2001, DRUG SAFETY, V24, P855, DOI 10.2165/00002018-200124110-00006; Calabrese AD, 2001, INTENS CARE MED, V27, P1592, DOI 10.1007/s001340101065; Chapuis C, 2010, CRIT CARE MED, V38, P2275, DOI 10.1097/CCM.0b013e3181f8569b; Chua SS, 2009, J CLIN PHARM THER, V34, P215, DOI 10.1111/j.1365-2710.2008.00997.x; Chua SS, 2010, EUR J PEDIATR, V169, P603, DOI 10.1007/s00431-009-1084-z; CONROY S, 2007, PAEDIATR PERINAT DRU, V8, P18; Dean B, 2000, INT J PHARM PRACT, V8, P209, DOI [10.1111/j.2042-7174.2000.tb01007.x, DOI 10.1111/J.2042-7174.2000.TB01007.X]; DEAN BS, 1995, AM J HEALTH-SYST PH, V52, P2543, DOI 10.1093/ajhp/52.22.2543; DeYoung JL, 2009, AM J HEALTH-SYST PH, V66, P1110, DOI 10.2146/ajhp080355; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2001, SYSTEMATIC REV HLTH; Fahimi Fanak, 2008, Aust Crit Care, V21, P110, DOI 10.1016/j.aucc.2007.10.004; Flynn EA, 2002, AM J HEALTH-SYST PH, V59, P436, DOI 10.1093/ajhp/59.5.436; Fontan JE, 2003, PHARM WORLD SCI, V25, P112, DOI 10.1023/A:1024053514359; Ford DG, 2010, INTENS CARE MED, V36, P1526, DOI 10.1007/s00134-010-1860-2; Franklin BD, 2006, QUAL SAF HEALTH CARE, V15, P329, DOI 10.1136/qshc.2005.017608; Franklin BD, 2007, QUAL SAF HEALTH CARE, V16, P279, DOI 10.1136/qshc.2006.019497; Ghaleb MA, 2006, ANN PHARMACOTHER, V40, P1766, DOI 10.1345/aph.1G717; Ghaleb MA, 2010, ARCH DIS CHILD, V95, P113, DOI 10.1136/adc.2009.158485; Gokhman R, 2012, RESUSCITATION, V83, P482, DOI 10.1016/j.resuscitation.2011.10.001; Greengold NL, 2003, ARCH INTERN MED, V163, P2359, DOI 10.1001/archinte.163.19.2359; Rodriguez-Gonzalez CG, 2012, J AM MED INFORM ASSN, V19, P72, DOI 10.1136/amiajnl-2011-000332; Han PY, 2005, QUAL SAF HEALTH CARE, V14, P179, DOI 10.1136/qshc.2004.010728; Hartley GM, 1998, INT J PHARM PRACT, V6, P38, DOI [10.1111/j.2042-7174.1998.tb00914.x, DOI 10.1111/J.2042-7174.1998.TB00914.X]; Haw C, 2007, INT J QUAL HEALTH C, V19, P210, DOI 10.1093/intqhc/mzm019; Helmons PJ, 2009, AM J HEALTH-SYST PH, V66, P1202, DOI 10.2146/ajhp080357; Hicks RW, 2004, AM J HEALTH-SYST PH, V61, P993, DOI 10.1093/ajhp/61.10.993; Ho C., 1997, INT J PHARM PRACT, V5, P91, DOI DOI 10.1111/J.2042-7174.1997.TB00891.X; HYNNIMAN CE, 1970, AM J HOSP PHARM, V27, P802, DOI 10.1093/ajhp/27.10.802; Kelly J, 2011, J ADV NURS, V67, P2615, DOI 10.1111/j.1365-2648.2011.05700.x; Lam Judit, 2011, Orvosi Hetilap, V152, P1391, DOI 10.1556/OH.2011.29198; Le Grognec C, 2005, THERAPIE, V60, P391, DOI 10.2515/therapie:2005057; Font Noguera I, 2008, Farm Hosp, V32, P274; Lisby M, 2005, INT J QUAL HEALTH C, V17, P15, DOI 10.1093/intqhc/mzi015; McKibbon K, 2011, AHRQ PUBLICATION, V11-E008-EF; MEANS BJ, 1975, AM J HOSP PHARM, V32, P186, DOI 10.1093/ajhp/32.2.186; Meyer-Massetti C, 2011, AM J HEALTH-SYST PH, V68, P227, DOI 10.2146/ajhp100019; Miller MR, 2007, QUAL SAF HEALTH CARE, V16, P116, DOI 10.1136/qshc.2006.019950; Montesi G, 2009, BRIT J CLIN PHARMACO, V67, P651, DOI 10.1111/j.1365-2125.2009.03422.x; O'Brodovich M, 1991, Can J Hosp Pharm, V44, P5; Ozkan S, 2011, J NURS CARE QUAL, V26, P136, DOI 10.1097/NCQ.0b013e3182031006; Paoletti RD, 2007, AM J HEALTH-SYST PH, V64, P536, DOI 10.2146/ajhp060140; Pasto-Cardona Lourdes, 2009, Farm Hosp, V33, P257; PEPPER GA, 1995, AM J HEALTH-SYST PH, V52, P390, DOI 10.1093/ajhp/52.4.390; Perras C, 2009, 121 CAN AG DRUGS TEC; Poon EG, 2010, NEW ENGL J MED, V362, P1698, DOI 10.1056/NEJMsa0907115; Pourrat X, 2003, PRESSE MED, V32, P876; Prot S, 2005, INT J QUAL HEALTH C, V17, P381, DOI 10.1093/intqhc/mzi066; Raja LRJ, 2009, SINGAP MED J, V50, P68; Reifsteck Mark, 2006, J Healthc Inf Manag, V20, P35; Ridge K W, 1995, Qual Health Care, V4, P240, DOI 10.1136/qshc.4.4.240; Ros H, 2009, EUR J HOSP PHARM SCI, V15, P86; Rosati JR, 1983, QUAL REV B, V9, P34; Schneider MP, 1998, PHARM WORLD SCI, V20, P178, DOI 10.1023/A:1012087727393; Schneider PJ, 2006, AM J HEALTH-SYST PH, V63, P59, DOI 10.2146/ajhp040609; Schnell B R, 1976, Can J Hosp Pharm, V29, P85; Taxis K, 2004, EUR J CLIN PHARMACOL, V59, P815, DOI 10.1007/s00228-003-0689-9; Taxis K, 2003, BMJ-BRIT MED J, V326, P684, DOI 10.1136/bmj.326.7391.684; Taylor JA, 2008, PEDIATRICS, V121, P123, DOI 10.1542/peds.2007-0919; THUR MP, 1972, AM J HOSP PHARM, V72, P298, DOI 10.1093/ajhp/29.4.298; TISDALE JE, 1986, AM J HOSP PHARM, V43, P368, DOI 10.1093/ajhp/43.2.368; Tissot E, 2003, PHARM WORLD SCI, V25, P264, DOI 10.1023/B:PHAR.0000006519.44483.a0; Tissot E, 1999, INTENS CARE MED, V25, P353, DOI 10.1007/s001340050857; van den Bemt PMLA, 2002, CRIT CARE MED, V30, P846, DOI 10.1097/00003246-200204000-00022; van Gijssel-Wiersma DG, 2005, DRUG SAFETY, V28, P1119, DOI 10.2165/00002018-200528120-00006; Westbrook JI, 2011, BMJ QUAL SAF, V20, P1027, DOI 10.1136/bmjqs-2011-000089; Westbrook JI, 2010, ARCH INTERN MED, V170, P683, DOI 10.1001/archinternmed.2010.65; Wirtz V, 2003, PHARM WORLD SCI, V25, P104, DOI 10.1023/A:1024009000113; Zribi Triki E, 2011, PHARMACIEN HOSPITALI, V46, P226, DOI [10.1016/j.phclin.2011.05.022, DOI 10.1016/J.PHCLIN.2011.05.022]	84	48	49	1	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2013	8	6							e68856	10.1371/journal.pone.0068856	http://dx.doi.org/10.1371/journal.pone.0068856			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	190LY	23818992	Green Published, gold, Green Submitted			2023-01-03	WOS:000322342800149
J	Hirsch, C				Hirsch, Calvin			Review: Case management does not reduce unplanned hospital admissions compared with usual care in older persons	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							RANDOMIZED-TRIAL; PROGRAM		Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA	University of California System; University of California Davis	Hirsch, C (corresponding author), Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA.			Purdy, Sarah/0000-0002-3445-986X	National Institute for Health Research [PB-PG-1208-18013] Funding Source: researchfish; Department of Health [PB-PG-1208-18013] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Department of Health		Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Dunagan WC, 2005, J CARD FAIL, V11, P358, DOI 10.1016/j.cardfail.2004.12.004; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Wier L., 2006, HEALTHCARE COST UTIL	4	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2013	158	12							JC13	10.7326/0003-4819-158-12-201306180-02013	http://dx.doi.org/10.7326/0003-4819-158-12-201306180-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	167PW	23778925				2023-01-03	WOS:000320645000012
J	Etter, JF				Etter, Jean-Francois			Should electronic cigarettes be as freely available as tobacco? Yes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DEPENDENCE		Univ Geneva, Fac Med, Inst Social & Prevent Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Etter, JF (corresponding author), Univ Geneva, Fac Med, Inst Social & Prevent Med, CH-1211 Geneva 4, Switzerland.	Jean-Francois.Etter@unige.ch		ETTER, Jean-Francois/0000-0002-1426-3157				Etter JF, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015487; Etter JF, 2011, ADDICTION, V106, P2017, DOI 10.1111/j.1360-0443.2011.03505.x; European Union, 2012, PROP DIR EUR PARL CO; Goniewicz M. L, 2013, TOB CONTROL; Harris JE, 2004, BMJ-BRIT MED J, V328, P72, DOI 10.1136/bmj.37936.585382.44; Hughes JR, 2004, NICOTINE TOB RES, V6, P79, DOI 10.1080/14622200310001656894; HUGHES JR, 1989, BIOMED PHARMACOTHER, V43, P11, DOI 10.1016/0753-3322(89)90185-6; Koch W., 2012, US TODAY; Sparks I., 2013, DAILY MAIL	9	50	50	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2013	346								f3845	10.1136/bmj.f3845	http://dx.doi.org/10.1136/bmj.f3845			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	166XQ	23771039				2023-01-03	WOS:000320593900011
J	Mwitari, PG; Ayeka, PA; Ondicho, J; Matu, EN; Bii, CC				Mwitari, Peter G.; Ayeka, Peter A.; Ondicho, Joyce; Matu, Esther N.; Bii, Christine C.			Antimicrobial Activity and Probable Mechanisms of Action of Medicinal Plants of Kenya: Withania somnifera, Warbugia ugandensis, Prunus africana and Plectrunthus barbatus	PLOS ONE			English	Article							T-CELLS; EXPRESSION; IL-7; PROLIFERATION; ANTIBACTERIAL; SECRETION	Withania somnifera, Warbugia ugandensis, Prunus africana and Plectrunthus barbatus are used traditionally in Kenya for treatment of microbial infections and cancer. Information on their use is available, but scientific data on their bioactivity, safety and mechanisms of action is still scanty. A study was conducted on the effect of organic extracts of these plants on both bacterial and fungal strains, and their mechanisms of action. Extracts were evaluated through the disc diffusion assay. Bacteria and yeast test strains were cultured on Mueller-Hinton agar and on Sabouraud dextrose agar for the filamentous fungi. A 0.5 McFarland standard suspension was prepared. Sterile paper discs 6 mm in diameter impregnated with 10 ml of the test extract (100 mg/ml) were aseptically placed onto the surface of the inoculated media. Chloramphenicol (30 mu g) and fluconazole (25 mu g) were used as standards. Discs impregnated with dissolution medium were used as controls. Activity of the extracts was expressed according to zone of inhibition diameter. MIC was determined at 0.78-100 mg/ml. Safety studies were carried using Cell Counting Kit 8 cell proliferation assay protocol. To evaluate extracts mechanisms of action, IEC-6 cells and RT-PCR technique was employed in vitro to evaluate Interleukin 7 cytokine. Investigated plants extracts have both bactericidal and fungicidal activity. W. ugandensis is cytotoxic at IC50<50 mu g/ml with MIC values of less than 0.78 mg/ml. Prunus africana shuts down expression of IL 7 mRNA at 50 mu g/ml. W. somnifera has the best antimicrobial (1.5625 mg/ml), immunopotentiation (2 times IL 7 mRNA expression) and safety level (IC50>200 mu g/ml). Fractions from W. ugandensis and W. somnifera too demonstrated antimicrobial activity. Mechanisms of action can largely be attributed to cytotoxicity, Gene silencing and immunopotentiation. Use of medicinal plants in traditional medicine has been justified and possible mechanisms of action demonstrated. Studies to isolate and characterize the bioactive constituents continue.	[Mwitari, Peter G.; Ondicho, Joyce; Matu, Esther N.] Kenya Govt Med Res Ctr, Ctr Tradit Med & Drug Res, Nairobi, Kenya; [Mwitari, Peter G.; Ayeka, Peter A.] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China; [Ayeka, Peter A.] Egerton Univ, Egerton, Kenya; [Bii, Christine C.] Kenya Govt Med Res Ctr, Ctr Microbiol Res, Nairobi, Kenya	Kenya Medical Research Institute; Tianjin University of Traditional Chinese Medicine; Egerton University; Kenya Medical Research Institute	Mwitari, PG (corresponding author), Kenya Govt Med Res Ctr, Ctr Tradit Med & Drug Res, Nairobi, Kenya.	pmwitari67@yahoo.com	Ayeka, Peter/AAE-7421-2020					Abu-Shanab Bassam, 2004, Turkish Journal of Biology, V28, P99; Akwatulira F, 2011, J MED PLANTS RES, V5, P6615, DOI 10.5897/JMPR11.160; Beentje H.J., 1994, KENYA TREES SHRUBS L; Bii C, 2010, J MED PLANTS RES, V4, P995; Comber JD, 2012, VACCINE, V30, P2140, DOI 10.1016/j.vaccine.2012.01.037; Davis L, 2002, J EXP CLIN CANC RES, V21, P115; Dorman HJD, 2000, J APPL MICROBIOL, V88, P308, DOI 10.1046/j.1365-2672.2000.00969.x; Foster S., 2006, DESK REFERENCE NATUR, Vfirst; Gagnon J, 2010, IMMUNOL CELL BIOL, V88, P451, DOI 10.1038/icb.2009.109; Ichikawa H, 2006, MOL CANCER THER, V14, P34; ICRAF, 2009, AGR TREE DAT TREE SP; Ivana BS, 2006, BRAZILIAN J INFECT D, V10; Kariba RM, 2001, J ETHNOPHARMACOL, V74, P41, DOI 10.1016/S0378-8741(00)00337-8; Kobayashi H, 2005, BLOOD, V105, P721, DOI 10.1182/blood-2003-12-4187; Kokwaro J.O., 1993, MED PLANTS E AFRICA; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Lukhoba CW, 2006, J ETHNOPHARMACOL, V103, P1, DOI 10.1016/j.jep.2005.09.011; Matu EN, 2003, J ETHNOPHARMACOL, V87, P35, DOI 10.1016/S0378-8741(03)00107-7; McGee DW, 1996, CLIN EXP IMMUNOL, V105, P274, DOI 10.1046/j.1365-2249.1996.d01-750.x; Mishra L C, 2000, Altern Med Rev, V5, P334; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mwangi JW, 2005, J ESSENTIAL OIL RES; Noor A, 2013, CURRENT SCI, V104; Olila D, 2002, J AFR HLTH SCI, V210, P2; Pellegrini M, 2011, CELL, V144, P601, DOI 10.1016/j.cell.2011.01.011; Phillipson J D, 1994, Trans R Soc Trop Med Hyg, V88 Suppl 1, pS17; Rasoanaivo P, 1993, IFS NAPLECA WORKSH B; Ray AB, 2004, MED PROPERTIES PLANT; Rios JL, 2005, J ETHNOPHARMACOL, V100, P80, DOI 10.1016/j.jep.2005.04.025; Rozen S, 2000, Methods Mol Biol, V132, P365; Runyoro D. K., 2006, BMC COMPLEM ALTERN M, V30, P6, DOI DOI 10.1186/1472-6882-6-11; Schmelzer GH, 2008, PLANTS RESOURCES TRO; Singh G., 2010, Annals of Biological Research, V1, P56; Suzuki S, 2007, INT ARCH ALLERGY IMM, V143, P89, DOI 10.1159/000101413; Vlientink J, 1995, J ETHNOPHARMACOL, V46, P31; Wamalwa NL., 2006, GENETIC VARIATION WA; Yoshioka A, 2008, CYTOKINE, V44, P57, DOI 10.1016/j.cyto.2008.06.004	37	45	49	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2013	8	6							e65619	10.1371/journal.pone.0065619	http://dx.doi.org/10.1371/journal.pone.0065619			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	172XB	23785437	Green Published, gold, Green Submitted			2023-01-03	WOS:000321038800083
J	Bonato, FOB; Lemos, MM; Cassiolato, JL; Canziani, MEF				Bastos Bonato, Fabiana Oliveira; Lemos, Marcelo Montebello; Cassiolato, Jose Luiz; Fernandes Canziani, Maria Eugenia			Prevalence of Ventricular Arrhythmia and Its Associated Factors in Nondialyzed Chronic Kidney Disease Patients	PLOS ONE			English	Article							SUDDEN CARDIAC DEATH; HEART-RATE-VARIABILITY; STAGE RENAL-DISEASE; HEMODIALYSIS-PATIENTS; VASCULAR CALCIFICATION; CORONARY CALCIFICATION; PARATHYROID-HORMONE; GENDER-DIFFERENCES; RISK-FACTORS; HEMOGLOBIN	Background and Objectives: Sudden cardiac death is the most common cause of mortality in chronic kidney disease patients, and it occurs mostly due to ventricular arrhythmias. In this study, we aimed at investigating the prevalence of ventricular arrhythmia and the factors associated with its occurrence in nondialyzed chronic kidney disease patients. Design, Setting, Participants and Measurements: This cross-sectional study evaluated 111 chronic kidney disease patients (estimated glomerular filtration rate 34.7 +/- 16.1 mL/min/1.73 m(2), 57 +/- 11.4 years, 60% male, 24% diabetics). Ventricular arrhythmia was assessed by 24-hour electrocardiogram. Left ventricular hypertrophy (echocardiogram), 24-hour ambulatory blood pressure monitoring, and coronary artery calcification (multi-slice computed tomography) and laboratory parameters were also evaluated. Results: Ventricular arrhythmia was found in 35% of the patients. Non-controlled hypertension was observed in 21%, absence of systolic decency in 29%, left ventricular hypertrophy in 27%, systolic dysfunction in 10%, and coronary artery calcification in 49%. Patients with ventricular arrhythmia were older (p<0.001), predominantly men (p = 0.009), had higher estimated glomerular filtration rate (p = 0.03) and hemoglobin (p = 0.005), and lower intact parathyroid hormone (p = 0.024) and triglycerides (p = 0.011) when compared to patients without ventricular arrhythmia. In addition, a higher left ventricular mass index (p = 0.002) and coronary calcium score (p = 0.002), and a lower ejection fraction (p = 0.001) were observed among patients with ventricular arrhythmia. In the multiple logistic regression analysis, aging, increased hemoglobin levels and reduced ejection fraction were independently related to the presence of ventricular arrhythmia. Conclusions: Ventricular arrhythmia is prevalent in nondialyzed chronic kidney disease patients. Age, hemoglobin levels and ejection fraction were the factors associated with ventricular arrhythmia in these patients.	[Bastos Bonato, Fabiana Oliveira; Lemos, Marcelo Montebello; Fernandes Canziani, Maria Eugenia] Univ Fed Sao Paulo, Dept Internal Med, Div Nephrol, Sao Paulo, Brazil; [Cassiolato, Jose Luiz] Cardiol Res Inst, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP)	Canziani, MEF (corresponding author), Univ Fed Sao Paulo, Dept Internal Med, Div Nephrol, Sao Paulo, Brazil.	dialisefor@uol.com.br	Canziani, Maria E F/AGI-3240-2022; Bonato, Fabiana O Bastos/K-1253-2014	Bonato, Fabiana O Bastos/0000-0003-1566-4224				AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827, DOI 10.1016/0735-1097(90)90282-T; Barreto DV, 2005, KIDNEY INT, V67, P1576, DOI 10.1111/j.1523-1755.2005.00239.x; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; Bleyer AJ, 2006, KIDNEY INT, V69, P2268, DOI 10.1038/sj.ki.5000446; Busari O, 2010, CARDIOL J, V17, P281; Canziani M E, 1993, Perit Dial Int, V13 Suppl 2, pS409; Chen SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060008; Cheung AK, 2004, KIDNEY INT, V65, P2380, DOI 10.1111/j.1523-1755.2004.00657.x; Chugh SS, 2008, PROG CARDIOVASC DIS, V51, P213, DOI 10.1016/j.pcad.2008.06.003; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Eloot S, 2011, CLIN J AM SOC NEPHRO, V6, P1266, DOI 10.2215/CJN.09981110; Floege J, 2004, NEPHROL DIAL TRANSPL, V19, P59, DOI 10.1093/ndt/gfh1058; Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131; Gottdiener JS, 2004, J AM SOC ECHOCARDIOG, V17, P1086, DOI 10.1016/j.echo.2004.07.013; GOWDA R.M., 2006, CARDIOLOGY, V15, P296; Herzog CA, 2008, SEMIN DIALYSIS, V21, P300, DOI 10.1111/j.1525-139X.2008.00455.x; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Kalantar-Zadeh K, 2009, J AM SOC NEPHROL, V20, P479, DOI 10.1681/ASN.2007070728; Kleiger RE, 2005, ANN NONINVAS ELECTRO, V10, P88, DOI 10.1111/j.1542-474X.2005.10101.x; Kong MH, 2011, CARDIOL J, V18, P503, DOI 10.5603/CJ.2011.0005; Lampert R, 2004, J AM COLL CARDIOL, V43, P2293, DOI 10.1016/j.jacc.2004.03.031; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Marcassi AP, 2011, TRANSPL INT, V24, P67, DOI 10.1111/j.1432-2277.2010.01149.x; McCullough PA, 2011, AM J KIDNEY DIS, V57, pS1, DOI 10.1053/j.ajkd.2010.11.011; Moe SM, 2004, NEPHROL DIAL TRANSPL, V19, P2387, DOI 10.1093/ndt/gfh303; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; Neirynck N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044201; OBRIEN E, 1988, LANCET, V2, P397; Oxenham H, 2003, EUR J HEART FAIL, V5, P427, DOI 10.1016/S1388-9842(03)00011-4; Paoletti E, 2004, NEPHROL DIAL TRANSPL, V19, P1829, DOI 10.1093/ndt/gfh288; Parfrey PS, 2005, J AM SOC NEPHROL, V16, P2180, DOI 10.1681/ASN.2004121039; Pun PH, 2012, BLOOD PURIFICAT, V33, P183, DOI 10.1159/000334154; Pun PH, 2009, KIDNEY INT, V76, P652, DOI 10.1038/ki.2009.219; Raggi P, 2002, J AM COLL CARDIOL, V39, P695, DOI 10.1016/S0735-1097(01)01781-8; Ranpuria R, 2008, NEPHROL DIAL TRANSPL, V23, P444, DOI 10.1093/ndt/gfm634; Reed MJ, 2005, QJM-INT J MED, V98, P87, DOI 10.1093/qjmed/hci018; Regidor DL, 2006, J AM SOC NEPHROL, V17, P1181, DOI 10.1681/ASN.2005090997; Rivero A, 2010, CURR OPIN CARDIOL, V25, P8, DOI 10.1097/HCO.0b013e328333f95f; Roberts MA, 2011, AM J KIDNEY DIS, V58, P64, DOI 10.1053/j.ajkd.2011.01.024; Royal College of Physicians (The National Collaborating Centre for Chronic Conditions - UK), 2008, NATL I HLTH CLIN EXC, V73, P1; Russo D, 2004, AM J KIDNEY DIS, V44, P1024, DOI 10.1053/j.ajkd.2004.07.022; SARAGOCA MA, 1991, J CARDIOVASC PHARM, V17, pS136, DOI 10.1097/00005344-199117002-00032; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Slinin Y, 2005, J AM SOC NEPHROL, V16, P1788, DOI 10.1681/ASN.2004040275; Tomiyama C, 2006, NEPHROL DIAL TRANSPL, V21, P2464, DOI 10.1093/ndt/gfl291; Verrier RL, 2004, CURR OPIN CARDIOL, V19, P2, DOI 10.1097/00001573-200401000-00003; Wang AYM, 2010, HYPERTENSION, V56, P210, DOI 10.1161/HYPERTENSIONAHA.110.151167; Watanabe R, 2010, CLIN J AM SOC NEPHRO, V5, P189, DOI 10.2215/CJN.06240909; WEBB JG, 1986, CAN MED ASSOC J, V135, P753; Wolbrette D, 2002, CLIN CARDIOL, V25, P49, DOI 10.1002/clc.4950250203; Yang W, 2007, J AM SOC NEPHROL, V18, P3164, DOI 10.1681/ASN.2007010058; Zoccali C, 2010, HYPERTENSION, V56, P187, DOI 10.1161/HYPERTENSIONAHA.110.151829	54	24	25	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2013	8	6							e66036	10.1371/journal.pone.0066036	http://dx.doi.org/10.1371/journal.pone.0066036			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173QU	23762460	Green Published, Green Submitted, gold			2023-01-03	WOS:000321094800084
J	Williamson, LM; Devine, DV				Williamson, Lorna M.; Devine, Dana V.			Challenges in the management of the blood supply	LANCET			English	Article							PLATELET TRANSFUSIONS; DONATION; STRATEGIES; TRIAL; RISK; INVENTORY; THERAPY; MONITOR; PATIENT; STORAGE	Although blood suppliers are seeing short-term reductions in blood demand as a result of initiatives in patient blood management, modelling suggests that during the next 5-10 years, blood availability in developed countries will need to increase again to meet the demands of ageing populations. Increasing of the blood supply raises many challenges; new approaches to recruitment and retainment of future generations of blood donors will be needed, and care will be necessary to avoid taking too much blood from these donors. Integrated approaches in blood stock management between transfusion services and hospitals will be important to minimise wastage-eg, by use of supply chain solutions from industry. Cross-disciplinary systems for patient blood management need to be developed to lessen the need for transfusion-eg, by early identification and reversal of anaemia with haematinics or by reversal of the underlying cause. Personalised medicine could be applied to match donors to patients, not only with extended blood typing, but also by using genetically determined storage characteristics of blood components. Growing of red cells or platelets in large quantities from stem cells is a possibility in the future, but challenges of cost, scaling up, and reproducibility remain to be solved.	[Williamson, Lorna M.] Natl Hlth Serv Blood & Transplant, Watford, England; [Devine, Dana V.] Canadian Blood Serv, Vancouver, BC, Canada	NHS Blood & Transplant (NHSBT); Canadian Blood Services	Devine, DV (corresponding author), UBC Ctr Blood Res, Canadian Blood Serv, Vancouver, BC V6T 1Z3, Canada.	dana.devine@blood.ca			TerumoBCT; Macopharma	TerumoBCT; Macopharma	LMW declares that she has no conflicts of interest. DVD receives research funding from TerumoBCT and Macopharma. She is a member of the scientific advisory committee of Fresenius-Kabi Transfusion Technologies and has received speaker fees or travel reimbursement for speaking at various conferences including the International Society for Blood Transfusion, the International Association for Biological Standards, the US FDA Blood Products Advisory Committee, Cellular Therapeutics in Trauma and Clinical Care, and the Fresenius-Kabi Advanced Course on Transfusion Technology as well as a number of visiting professorships.	[Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; [Anonymous], REC CHANG ACC CRIT U; AuBuchon JP, 2011, TRANSFUSION, V51, P2750, DOI 10.1111/j.1537-2995.2011.03443.x; Baart AM, 2012, TRANSFUSION, V52, P2559, DOI 10.1111/j.1537-2995.2012.03655.x; Bercovitz RS, 2012, VOX SANG, V102, P345, DOI 10.1111/j.1423-0410.2011.01559.x; Blake JT, 2013, TRANSFUSION, V53, P1544, DOI 10.1111/j.1537-2995.2012.03947.x; Blake JT, 2009, TRANSFUSION, V49, P396, DOI 10.1111/j.1537-2995.2008.02061.x; Boralessa H, 2009, ANN ROY COLL SURG, V91, P599, DOI 10.1308/003588409X432464; Bryant BJ, 2012, TRANSFUSION, V52, P1566, DOI 10.1111/j.1537-2995.2011.03488.x; Cable RG, 2012, TRANSFUSION, V52, P702, DOI 10.1111/j.1537-2995.2011.03401.x; Cap AP, 2011, J TRAUMA, V70, pS59, DOI 10.1097/TA.0b013e31821a606d; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Chapman J, 2007, TRANSFUSION, V47, p190S, DOI 10.1111/j.1537-2995.2007.01384.x; Cid J, 2012, VOX SANG, V103, P322, DOI 10.1111/j.1423-0410.2012.01614.x; Curry N, 2012, INJURY, V43, P1021, DOI 10.1016/j.injury.2012.03.014; de Kort W, 2011, TRANSFUSION, V51, P2295, DOI 10.1111/j.1537-2995.2011.03190.x; Department of Health the National Blood Transfusion Committee NHS Blood and Transplant, 2012, PAT BLOOD MAN FUT BL; Devine DV, 2010, VOX SANG, V98, pe295, DOI 10.1111/j.1423-0410.2009.1252.x; Drackley A, 2012, TRANSFUSION, V52, P366, DOI 10.1111/j.1537-2995.2011.03280.x; Dumont LJ, 2009, TRANSFUSION, V49, P458, DOI 10.1111/j.1537-2995.2008.02038.x; Eder A, 2010, J CLIN APHERESIS, V25, P331, DOI 10.1002/jca.20257; Eder AF, 2008, TRANSFUSION, V48, P1809, DOI 10.1111/j.1537-2995.2008.01811.x; Eder AF, 2008, JAMA-J AM MED ASSOC, V299, P2279, DOI 10.1001/jama.299.19.2279; Ehling M, 2010, TRANSFUS MED HEMOTH, V37, P131, DOI 10.1159/000314281; Estcourt LJ, 2012, VOX SANG, V103, P284, DOI 10.1111/j.1423-0410.2012.01627.x; Estcourt L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004269.pub3; Fan W, 2012, TRANSFUSION MED, V22, P395, DOI 10.1111/j.1365-3148.2012.01184.x; Fergusson DA, 2012, JAMA-J AM MED ASSOC, V308, P1443, DOI 10.1001/2012.jama.11953; Fontaine MJ, 2012, TRANSFUSION, V50, P1685; Foukaneli T, 2010, REAUDIT USE GROUP O; France CR, 2011, TRANSFUSION, V51, P1796, DOI 10.1111/j.1537-2995.2010.03033.x; Giarratana MC, 2011, BLOOD, V118, P5071, DOI 10.1182/blood-2011-06-362038; Goldman M, 2007, TRANSFUSION, V47, P1595, DOI 10.1111/j.1537-2995.2007.01329.x; Goodnough LT, 2011, BRIT J ANAESTH, V106, P13, DOI 10.1093/bja/aeq361; Hearnshaw SA, 2011, GUT, V60, P1327, DOI 10.1136/gut.2010.228437; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hohberger C, 2012, BIOLOGICALS, V40, P209, DOI 10.1016/j.biologicals.2011.10.008; Karam O, 2010, CRIT CARE, V14, DOI 10.1186/cc8953; Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054; Kolins J, 2003, TRANSFUSION, V43, P1634, DOI 10.1046/j.1537-2995.2003.00560.x; LaSalle-Williams M, 2011, TRANSFUSION, V51, P1732, DOI 10.1111/j.1537-2995.2010.03045.x; Locatelli F, 2010, NEPHROL DIAL TRANSPL, V25, P2846, DOI 10.1093/ndt/gfq336; McCullough PA, 2010, AM J KIDNEY DIS, V55, pS1, DOI 10.1053/j.ajkd.2009.12.017; Moran L, GINGER CURRY COPIOUS; Mountford J, 2010, BRIT J HAEMATOL, V149, P22, DOI 10.1111/j.1365-2141.2010.08079.x; Murphy MF, 2012, TRANSFUSION, V52, P2502, DOI 10.1111/j.1537-2995.2011.03509.x; Nessen SC, 2013, TRANSFUSION, V53, p107S, DOI 10.1111/trf.12044; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Pinkerton PH, 2010, CAN MED ASSOC J, V182, P1019, DOI 10.1503/cmaj.081933; Pisoni RL, 2012, AM J KIDNEY DIS, V60, P160, DOI 10.1053/j.ajkd.2012.04.001; Potter M, 2012, REPORT CYTOMEGALOVIR; Prensky M., 2001, HORIZON, DOI [10.1108/10748120110424816, DOI 10.1108/10748120110424816]; Prowse CV, 2013, VOX SANG, V104, P183, DOI 10.1111/j.1423-0410.2012.01662.x; Raval JS, 2011, VOX SANG, V100, P418, DOI 10.1111/j.1423-0410.2010.01439.x; Reems JA, 2010, TRANSFUS MED REV, V24, P33, DOI 10.1016/j.tmrv.2009.09.003; Reesink HW, 2013, VOX SANG, V104, P350, DOI 10.1111/vox.12003; Riddington C, 2002, COCHRANE DB SYST REV, V1; Schubert P, 2012, J PROTEOMICS, V76, P329, DOI 10.1016/j.jprot.2012.06.023; Seed CR, 2010, TRANSFUSION, V50, P2722, DOI 10.1111/j.1537-2995.2010.02793.x; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; Stainsby D, 2010, VOX SANG, V98, P431, DOI 10.1111/j.1423-0410.2009.01275.x; Stanger SHW, 2012, TRANSFUS MED REV, V26, P153, DOI 10.1016/j.tmrv.2011.09.001; Stanworth SJ, 2012, BLOOD, V120; Tinegate H, 2013, TRANSFUSION, V53, P483, DOI 10.1111/j.1537-2995.2012.03782.x; Tomasulo P, 2011, TRANSFUSION, V51, P1511, DOI 10.1111/j.1537-2995.2011.03074.x; Tuinman PR, 2011, CLIN EXP IMMUNOL, V165, P278, DOI 10.1111/j.1365-2249.2011.04422.x; UK Blood Transfusion and Tissue Transplantation Services, GUID UK BLOOD TRANSF; UK Departments of Health advisory committee on safety of blood tissues and organs, 2011, DON SEL CRIT REV 201; van der Schoot CE, 2009, VOX SANG, V96, P167, DOI 10.1111/j.1423-0410.2008.01131.x; van Dijk N, 2009, TRANSFUSION, V49, P411, DOI 10.1111/j.1537-2995.2008.01996.x; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Vraets A, 2011, TRANSFUS MED REV, V25, P184, DOI 10.1016/j.tmrv.2011.01.006; Yazer M, 2007, TRANSFUSION, V47, p164S, DOI 10.1111/j.1537-2995.2007.01378.x; Yuan S, 2011, TRANSFUSION, V51, P2438, DOI 10.1111/j.1537-2995.2011.03174.x; Zou SM, 2012, TRANSFUS MED REV, V26, P119, DOI 10.1016/j.tmrv.2011.07.007	75	167	175	1	48	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2013	381	9880					1866	1875		10.1016/S0140-6736(13)60631-5	http://dx.doi.org/10.1016/S0140-6736(13)60631-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151EO	23706803				2023-01-03	WOS:000319443700033
J	Mangin, D				Mangin, Dee			Review: Cranberry products do not reduce urinary tract infections in susceptible populations	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Otago, Christchurch, New Zealand	University of Otago	Mangin, D (corresponding author), Univ Otago, Christchurch, New Zealand.		Craig, Jonathan/E-2813-2013	Craig, Jonathan/0000-0002-2548-4035				Buitrago-Lopez A, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4488; Epp A, 2010, J OBSTET GYNAECOL CA, V32, P1082, DOI 10.1016/S1701-2163(16)34717-X; Jepson RG, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001321.pub4; Mangin D, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c657	4	0	0	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 21	2013	158	10							JC11	10.7326/0003-4819-158-10-201305210-02011	http://dx.doi.org/10.7326/0003-4819-158-10-201305210-02011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	154HY	23689778				2023-01-03	WOS:000319666200010
J	Young, I; Li, J; McDaid, L				Young, Ingrid; Li, Jessica; McDaid, Lisa			Awareness and Willingness to Use HIV Pre-Exposure Prophylaxis amongst Gay and Bisexual Men in Scotland: Implications for Biomedical HIV Prevention	PLOS ONE			English	Article							ANTIRETROVIRAL PROPHYLAXIS; LIMITED KNOWLEDGE; CONDOM USE; SEX; POSTEXPOSURE	Objectives: To investigate the awareness of, and willingness to use, HIV Pre-Exposure Prophylaxis (PrEP), and willingness to take part in a PrEP study among gay and bisexual men in Scotland. Methods: Cross-sectional survey of 17 gay commercial venues in Glasgow and Edinburgh in May 2011 (N = 1515, 65.2% response rate); 1393 are included in the analyses. Results: Just under one-third of participants had heard of PrEP (n = 434; 31.2%), with awareness associated with being aged older than 35 years, talking to UAI partners about HIV, and with having had an HIV or STI test in the previous 12 months. Around half were willing to take part in a PrEP study (n = 695; 49.9%) or to take PrEP on a daily basis (n = 756; 54.3%). In multivariate analysis, willingness to take PrEP was associated with lower levels of education, regular gay scene attendance, 'high-risk' unprotected anal intercourse (UAI) and testing for HIV or STI in the previous 12 months. Reasons for not wanting to participate in a PrEP study or take PrEP included perceptions of low personal risk of HIV and concerns with using medication as an HIV prevention method. Conclusions: There is a willingness to engage in new forms of HIV prevention and research amongst a significant number of gay and bisexual men in Scotland. Future biomedical HIV interventions need to consider the links between sexual risk behaviour, testing, and potential PrEP use.	[Young, Ingrid; Li, Jessica; McDaid, Lisa] MRC, Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT	Young, I (corresponding author), MRC, Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland.	i.young@sphsu.mrc.ac.uk		Young, Ingrid/0000-0002-1242-5992; McDaid, Lisa/0000-0002-7711-8723	UK Medical Research Council; Gay Men's Survey as part of the Sexual Health programme at the MRC/CSO Social and Public Health Sciences Unit [MC_A540_5TK60]; Medical Research Council [MC_UU_12017/2, MC_U130031238] Funding Source: researchfish; MRC [MC_U130031238, MC_UU_12017/2] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Gay Men's Survey as part of the Sexual Health programme at the MRC/CSO Social and Public Health Sciences Unit; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The UK Medical Research Council (http://www.mrc.ac.uk/index.htm) funds IY, JL, LMD and the Gay Men's Survey as part of the Sexual Health programme (MC_A540_5TK60) at the MRC/CSO Social and Public Health Sciences Unit. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aghaizu A, 2012, SEX TRANSM INFECT; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Barash EA, 2010, AIDS PATIENT CARE ST, V24, P689, DOI 10.1089/apc.2010.0173; Brooks RA, 2011, AIDS CARE, V23, P1136, DOI 10.1080/09540121.2011.554528; Ezzy D., 2002, QUALITATIVE ANAL PRA; FDA, 2012, FDA APPR 1 DRUG RED; Gay Men's Health (GMH), 2011, GAY MENS HLTH 2010 2; Gibbs G.R., 2007, ANAL QUALITATIVE DAT; Golub SA, 2010, JAIDS-J ACQ IMM DEF, V54, P548, DOI 10.1097/QAI.0b013e3181e19a54; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Holt M, 2012, SEX TRANSM INFECT, V88, P258, DOI 10.1136/sextrans-2011-050312; Jackson T, 2012, AIDS BEHAV, V16, P1853, DOI 10.1007/s10461-012-0188-z; Kashuba ADM, 2012, LANCET, V379, P2409, DOI 10.1016/S0140-6736(11)61852-7; Krakower DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033119; Leonardi M, 2011, INT J STD AIDS, V22, P738, DOI 10.1258/ijsa.2011.011057; Liu AY, 2008, JAIDS-J ACQ IMM DEF, V47, P241, DOI 10.1097/QAI.0b013e31815e4041; Lorente N, 2011, AIDS CARE; Mansergh G, 2010, JAIDS-J ACQ IMM DEF, V55, pE14, DOI 10.1097/QAI.0b013e3181f27616; McCormack S, 2012, INT J STD AIDS, V23, P1, DOI 10.1258/ijsa.2011.051211; McDaid LM, 2011, SEX TRANSM INFECT, V87, P221, DOI 10.1136/sti.2010.044560; McDaid LM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-798; Mimiaga MJ, 2009, JAIDS-J ACQ IMM DEF, V50, P77, DOI 10.1097/QAI.0b013e31818d5a27; Sigma Research, 2011, SIGM PAN INS BLAST 6; Smith D. K., 2011, Morbidity and Mortality Weekly Report, V60, P65; Smith D. K., 2012, Morbidity and Mortality Weekly Report, V61, P586; THNG C, 2012, HIV MED S1, V13, P84; Thomas DR, 2006, AM J EVAL, V27, P237, DOI 10.1177/1098214005283748; van Griensven F, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-13	28	51	52	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2013	8	5							e64038	10.1371/journal.pone.0064038	http://dx.doi.org/10.1371/journal.pone.0064038			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	146RJ	23691143	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000319107900074
J	Vanzelli, AS; Medeiros, A; Rolim, N; Bartholomeu, JB; Cunha, TF; Bechara, LG; Gomes, ERM; Mattos, KC; Sirvente, R; Salemi, V; Mady, C; Negrao, CE; Guatimosim, S; Brum, PC				Vanzelli, Andrea S.; Medeiros, Alessandra; Rolim, Natale; Bartholomeu, Jan B.; Cunha, Telma F.; Bechara, Luiz G.; Gomes, Eneas R. M.; Mattos, Katt C.; Sirvente, Raquel; Salemi, Vera; Mady, Charles; Negrao, Carlos E.; Guatimosim, Silvia; Brum, Patricia C.			Integrative Effect of Carvedilol and Aerobic Exercise Training Therapies on Improving Cardiac Contractility and Remodeling in Heart Failure Mice	PLOS ONE			English	Article							SYMPATHETIC-NERVE ACTIVITY; OXIDATIVE STRESS; BETA-BLOCKERS; HYPERACTIVITY; ABNORMALITIES; DYSFUNCTION; MORTALITY; SYSTEM; IMPACT	The use of b-blockers is mandatory for counteracting heart failure (HF)-induced chronic sympathetic hyperactivity, cardiac dysfunction and remodeling. Importantly, aerobic exercise training, an efficient nonpharmacological therapy to HF, also counteracts sympathetic hyperactivity in HF and improves exercise tolerance and cardiac contractility; the latter associated with changes in cardiac Ca2+ handling. This study was undertaken to test whether combined b-blocker and aerobic exercise training would integrate the beneficial effects of isolated therapies on cardiac structure, contractility and cardiomyocyte Ca2+ handling in a genetic model of sympathetic hyperactivity-induced HF (alpha(2A)/alpha 2C(-)adrenergic receptor knockout mice, KO). We used a cohort of 5-7 mo male wild-type (WT) and congenic mice (KO) with C57Bl6/J genetic background randomly assigned into 5 groups: control (WT), saline-treated KO (KOS), exercise trained KO (KOT), carvedilol-treated KO (KOC) and, combined carvedilol-treated and exercise-trained KO (KOCT). Isolated and combined therapies reduced mortality compared with KOS mice. Both KOT and KOCT groups had increased exercise tolerance, while groups receiving carvedilol had increased left ventricular fractional shortening and reduced cardiac collagen volume fraction compared with KOS group. Cellular data confirmed that cardiomyocytes from KOS mice displayed abnormal Ca2+ handling. KOT group had increased intracellular peak of Ca2+ transient and reduced diastolic Ca2+ decay compared with KOS group, while KOC had increased Ca2+ decay compared with KOS group. Notably, combined therapies re-established cardiomyocyte Ca2+ transient paralleled by increased SERCA2 expression and SERCA2: PLN ratio toward WT levels. Aerobic exercise trained increased the phosphorylation of PLN at Ser16 and Thr17 residues in both KOT and KOCT groups, but carvedilol treatment reduced lipid peroxidation in KOC and KOCT groups compared with KOS group. The present findings provide evidence that the combination of carvedilol and aerobic exercise training therapies lead to a better integrative outcome than carvedilol or exercise training used in isolation.	[Vanzelli, Andrea S.; Bartholomeu, Jan B.; Cunha, Telma F.; Bechara, Luiz G.; Mattos, Katt C.; Negrao, Carlos E.; Brum, Patricia C.] Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil; [Medeiros, Alessandra] Univ Fed Sao Paulo, Dept Biosci, Santos, Brazil; [Rolim, Natale] Dept Circulat & Med Imaging, Trondheim, Norway; [Rolim, Natale] KG Jebsen Ctr Exercise Med, Trondheim, Norway; [Gomes, Eneas R. M.; Guatimosim, Silvia] Univ Fed Minas Gerais, Dept Physiol & Biophys, Belo Horizonte, MG, Brazil; [Sirvente, Raquel; Salemi, Vera; Mady, Charles; Negrao, Carlos E.] Univ Sao Paulo, Heart Inst InCor, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Minas Gerais; Universidade de Sao Paulo	Brum, PC (corresponding author), Univ Sao Paulo, Sch Phys Educ & Sport, Sao Paulo, Brazil.	pcbrum@usp.br	Guatimosim, Silvia/AAN-7441-2021; Bechara, Luiz R G/K-4095-2012; Negrao, Carlos E/C-4281-2012; Brum, Patricia C/E-6605-2011; Salemi, Vera MC/C-9104-2013; Medeiros, Alessandra/E-8132-2012; Cunha, Telma F/I-5222-2016; Salemi, Vera/AAY-5024-2020; Medeiros, Alessandra/F-6149-2014; Gomes, Eneas RM/G-3153-2010; Mady, Charles/C-8870-2012	Guatimosim, Silvia/0000-0001-8386-3722; Brum, Patricia C/0000-0002-4750-6506; Salemi, Vera MC/0000-0002-7152-1810; Medeiros, Alessandra/0000-0002-7962-7185; Medeiros, Alessandra/0000-0002-7962-7185; Gomes, Eneas RM/0000-0001-8528-8741; Mady, Charles/0000-0002-8838-199X; Bechara, Luiz/0000-0002-1642-1008; Negrao, Carlos Eduardo/0000-0003-4652-1226	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo [FAPESP:2010/50048-1]; FAPEMIG and Instituto Milenio (S.G.); Conselho Nacional de Pesquisa e Desenvolvimento; FAPESP [06/56123-0]; CNPq [302201/2011-4]	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); FAPEMIG and Instituto Milenio (S.G.); Conselho Nacional de Pesquisa e Desenvolvimento(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo. SP (FAPESP:2010/50048-1), FAPEMIG and Instituto Milenio (S.G.), Conselho Nacional de Pesquisa e Desenvolvimento (CNPq, S.G. and P.C.B.) for funding the present investigation, and Laboratories Baldacci S.A. for donating carvedilol. A.S.V. held a scholarship from FAPESP (06/56123-0). P.C.B. holds a scholarship from CNPq (302201/2011-4). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamopoulos S, 2003, INT J CARDIOL, V90, P1, DOI 10.1016/S0167-5273(02)00504-1; Barretto ACP, 2009, INT J CARDIOL, V135, P302, DOI 10.1016/j.ijcard.2008.03.056; Bartholomeu JB, 2008, J MOL CELL CARDIOL, V45, P240, DOI 10.1016/j.yjmcc.2008.05.011; Brum PC, 2011, BRAZ J MED BIOL RES, V44, P827, DOI 10.1590/S0100-879X2011000900002; Brum PC, 2002, AM J PHYSIOL-HEART C, V283, pH1838, DOI 10.1152/ajpheart.01063.2001; Burger AJ, 2001, J CARD FAIL, V7, P122, DOI 10.1054/jcaf.2001.24964; Chung CJ, 2011, PHYSICIAN SPORTSMED, V39, P37, DOI 10.3810/psm.2011.11.1937; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; De Matos LDNJ, 2004, J CARD FAIL, V10, P496, DOI 10.1016/j.cardfail.2004.03.006; Flesch M, 1999, CIRCULATION, V100, P346, DOI 10.1161/01.CIR.100.4.346; Fraga R, 2007, EUR J HEART FAIL, V9, P630, DOI 10.1016/j.ejheart.2007.03.003; GRASSI G, 1995, CIRCULATION, V92, P3206, DOI 10.1161/01.CIR.92.11.3206; Guatimosim S, 2001, AM J PHYSIOL-CELL PH, V280, pC1327, DOI 10.1152/ajpcell.2001.280.5.C1327; Johns C, 1996, HYPERTENSION, V28, P1064, DOI 10.1161/01.HYP.28.6.1064; Khattar R S, 2003, Minerva Cardioangiol, V51, P143; Koitabashi N, 2005, BIOCHEM BIOPH RES CO, V328, P116, DOI 10.1016/j.bbrc.2004.12.139; LIKOFF MJ, 1987, AM J CARDIOL, V59, P634; Mahon Niall G., 2002, Eur J Intern Med, V13, P96, DOI 10.1016/S0953-6205(02)00010-9; Medeiros A, 2008, BRAZ J MED BIOL RES, V41, P812, DOI 10.1590/S0100-879X2008000900012; Medeiros A, 2008, J APPL PHYSIOL, V104, P103, DOI 10.1152/japplphysiol.00493.2007; Myers J, 2002, NEW ENGL J MED, V346, P793, DOI 10.1056/NEJMoa011858; Nakahira A, 2010, CIRC J, V74, P1711, DOI 10.1253/circj.CJ-10-0149; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; Rolim NPL, 2007, PHYSIOL GENOMICS, V29, P246, DOI 10.1152/physiolgenomics.00188.2006; Vanzelli AS, 2010, ARQ BRAS CARDIOL, V95, P373, DOI 10.1590/S0066-782X2010005000098; Zhuang XF, 2009, J INT MED RES, V37, P1354, DOI 10.1177/147323000903700510; Zucker IH, 2012, HEART FAIL CLIN, V8, P87, DOI 10.1016/j.hfc.2011.08.007	27	26	27	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2013	8	5							e62452	10.1371/journal.pone.0062452	http://dx.doi.org/10.1371/journal.pone.0062452			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147KY	23658728	Green Submitted, Green Published, gold			2023-01-03	WOS:000319167000045
J	Kong, FJ; Chen, SP; Cheng, Y; Ma, LL; Lu, HS; Zhang, HH; Hu, WW				Kong, Feijuan; Chen, Shuping; Cheng, Yuan; Ma, Leilei; Lu, Huishun; Zhang, Honghai; Hu, Wenwen			Minocycline Attenuates Cognitive Impairment Induced by Isoflurane Anesthesia in Aged Rats	PLOS ONE			English	Article							HUNTINGTONS-DISEASE; GENERAL-ANESTHESIA; POSTNATAL MEMORY; ALZHEIMERS-DISEASE; NONCARDIAC SURGERY; LEARNING-DEFICITS; OXIDE ANESTHESIA; FETAL EXPOSURE; DYSFUNCTION; INJURY	Postoperative cognitive dysfunction (POCD) is a clinical phenomenon characterized by cognitive deficits in patients after anesthesia and surgery, especially in geriatric surgical patients. Although it has been documented that isoflurane exposure impaired cognitive function in several aged animal models, there are few clinical interventions and treatments available to prevent this disorder. Minocycline has been well established to exert neuroprotective effects in various experimental animal models and neurodegenerative diseases. Therefore, we hypothesized that pretreatment with minocycline attenuates isoflurane-induced cognitive decline in aged rats. In the present study, twenty-month-old rats were administered minocycline or an equal volume of saline by intraperitoneal injection 12 h before exposure to isoflurane. Then the rats were exposed to 1.3% isoflurane for 4 h. Two weeks later, spatial learning and memory of the rats were examined using the Morris Water Maze. We found that pretreatment with minocycline mitigated isoflurane-induced cognitive deficits and suppressed the isoflurane-induced excessive release of IL-1 beta and caspase-3 in the hippocampal CA1 region at 4 h after isoflurane exposure, as well as the number of TUNEL-positive nuclei. In addition, minocycline treatment also prevented the changes of synaptic ultrastructure in the hippocampal CA1 region induced by isoflurane. In conclusion, pretreatment with minocycline attenuated isoflurane-induced cognitive impairment in aged rats.	[Kong, Feijuan; Chen, Shuping; Cheng, Yuan; Zhang, Honghai] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China; [Ma, Leilei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Anesthesiol, Hangzhou 310003, Zhejiang, Peoples R China; [Lu, Huishun; Hu, Wenwen] Zhejiang Univ, Sch Med, Womens Hosp, Dept Anesthesiol, Hangzhou 310003, Zhejiang, Peoples R China	Nanjing Medical University; Zhejiang University; Zhejiang University	Kong, FJ (corresponding author), Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China.	kongfeijuan@163.com; lig08010915@163.com			Medical and Health Research Fund of Health Department of Zhejiang Provincial, China [2010KYA129]	Medical and Health Research Fund of Health Department of Zhejiang Provincial, China	The work was supported by Medical and Health Research Fund of Health Department of Zhejiang Provincial, China (NO. 2010KYA129). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abildstrom H, 2000, ACTA ANAESTH SCAND, V44, P1246, DOI 10.1034/j.1399-6576.2000.441010.x; ARONSON AL, 1980, J AM VET MED ASSOC, V176, P1061; Baranov D, 2009, ANESTH ANALG, V108, P1627, DOI 10.1213/ane.0b013e318199dc72; Bekker Alex Y, 2003, Best Pract Res Clin Anaesthesiol, V17, P259, DOI 10.1016/S1521-6896(03)00005-3; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bonelli RM, 2003, NEUROLOGY, V60, P883, DOI 10.1212/01.WNL.0000049936.85487.7A; Choi Y, 2007, NEUROPSYCHOPHARMACOL, V32, P2393, DOI 10.1038/sj.npp.1301377; Clergue F, 1999, ANESTHESIOLOGY, V91, P1509, DOI 10.1097/00000542-199911000-00045; Culley DJ, 2004, ANESTHESIOLOGY, V100, P309, DOI 10.1097/00000542-200402000-00020; Culley DJ, 2003, ANESTH ANALG, V96, P1004, DOI 10.1213/01.ANE.0000052712.67573.12; Diguet E, 2004, EXP NEUROL, V189, P1, DOI 10.1016/j.expneurol.2004.05.016; Fang M, 2003, J BIOL CHEM, V278, P36669, DOI 10.1074/jbc.M303520200; Grasshoff C, 2007, TOXICOLOGY, V229, P206, DOI 10.1016/j.tox.2006.10.017; Gruart A, 2006, J NEUROSCI, V26, P1077, DOI 10.1523/JNEUROSCI.2834-05.2006; Izquierdo I, 1999, BEHAV BRAIN RES, V103, P1, DOI 10.1016/S0166-4328(99)00036-4; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Kong FJ, 2012, BIOCHEM PHARMACOL, V84, P558, DOI 10.1016/j.bcp.2012.06.001; Kong FJ, 2011, EUR J PHARMACOL, V670, P168, DOI 10.1016/j.ejphar.2011.08.050; Li YJ, 2007, NEUROPHARMACOLOGY, V53, P942, DOI 10.1016/j.neuropharm.2007.09.005; Lin DW, 2011, NEUROPHARMACOLOGY, V61, P1354, DOI 10.1016/j.neuropharm.2011.08.011; Lunardi N, 2010, NEUROTOX RES, V17, P179, DOI 10.1007/s12640-009-9088-z; Mawhinney LJ, 2012, BRAIN RES, V1431, P23, DOI 10.1016/j.brainres.2011.11.004; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Nicholson DA, 2004, J NEUROSCI, V24, P7648, DOI 10.1523/JNEUROSCI.1725-04.2004; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Ramaiah Ramesh, 2009, Anesthesiol Clin, V27, P485, DOI 10.1016/j.anclin.2009.07.011; Rasmussen LS, 2003, ACTA ANAESTH SCAND, V47, P260, DOI 10.1034/j.1399-6576.2003.00057.x; Sametsky EA, 2010, NEUROBIOL AGING, V31, P813, DOI 10.1016/j.neurobiolaging.2008.05.029; Sanderson DJ, 2009, BEHAV BRAIN RES, V201, P103, DOI 10.1016/j.bbr.2009.01.038; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Szymanska A, 2006, EXP NEUROL, V197, P189, DOI 10.1016/j.expneurol.2005.09.011; Tao YX, 2004, MOL INTERV, V4, P215, DOI 10.1124/mi.4.4.5; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Terrando N, 2010, CRIT CARE, V14, DOI 10.1186/cc9019; Thompson JV, 2008, BRAIN RES, V1200, P58, DOI 10.1016/j.brainres.2008.01.057; Valentim AM, 2010, ANESTHESIOLOGY, V113, P1099, DOI 10.1097/ALN.0b013e3181f79c7c; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wu X, 2012, NEUROBIOL AGING, V33, P1364, DOI 10.1016/j.neurobiolaging.2010.11.002; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zhang YY, 2012, ANN NEUROL, V71, P687, DOI 10.1002/ana.23536; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	47	51	53	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e61385	10.1371/journal.pone.0061385	http://dx.doi.org/10.1371/journal.pone.0061385			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IK	23613842	Green Published, Green Submitted, gold			2023-01-03	WOS:000317907200052
J	Joynt, KE; Orav, EJ; Jha, AK				Joynt, Karen E.; Orav, E. John; Jha, Ashish K.			Mortality Rates for Medicare Beneficiaries Admitted to Critical Access and Non-Critical Access Hospitals, 2002-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							30-DAY MORTALITY; MYOCARDIAL-INFARCTION; QUALITY; CARE; OUTCOMES; COSTS	Importance Critical access hospitals (CAHs) provide inpatient care to Americans living in rural communities. These hospitals are at high risk of falling behind with respect to quality improvement, owing to their limited resources and vulnerable patient populations. How they have fared on patient outcomes during the past decade is unknown. Objective To evaluate trends in mortality for patients receiving care at CAHs and compare these trends with those for patients receiving care at non-CAHs. Design, Setting, and Patients Retrospective observational study using data from Medicare fee-for-service patients admitted to US acute care hospitals with acute myocardial infarction (1 902 586 admissions), congestive heart failure (4 488 269 admissions), and pneumonia (3 891 074 admissions) between 2002 and 2010. Main Outcome Measures Trends in risk-adjusted 30-day mortality rates for CAHs and other acute care US hospitals. Results Accounting for differences in patient, hospital, and community characteristics, CAHs had mortality rates comparable with those of non-CAHs in 2002 (composite mortality across all 3 conditions, 12.8% vs 13.0%; difference, -0.3% [95% CI, -0.7% to 0.2%]; P=.25). Between 2002 and 2010, mortality rates increased 0.1% per year in CAHs but decreased 0.2% per year in non-CAHs, for an annual difference in change of 0.3% (95% CI, 0.2% to 0.3%; P<.001). Thus, by 2010, CAHs had higher mortality rates compared with non-CAHs (13.3% vs 11.4%; difference, 1.8% [95% CI, 1.4% to 2.2%]; P<.001). The patterns were similar when each individual condition was examined separately. Comparing CAHs with other small, rural hospitals, similar patterns were found. Conclusions and Relevance Among Medicare beneficiaries with acute myocardial infarction, congestive heart failure, or pneumonia, 30-day mortality rates for those admitted to CAHs, compared with those admitted to other acute care hospitals, increased from 2002 to 2010. New efforts may be needed to help CAHs improve. JAMA. 2013;309(13):1379-1387 www.jama.com	[Joynt, Karen E.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Orav, E. John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Joynt, Karen E.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; [Orav, E. John; Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; [Joynt, Karen E.; Jha, Ashish K.] VA Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Joynt, KE (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	kjoynt@partners.org			National Heart, Lung, and Blood Institute, National Institutes of Health [1K23HL109177-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL109177] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Joynt was supported by grant 1K23HL109177-01 from the National Heart, Lung, and Blood Institute, National Institutes of Health.	Ambardekar AV, 2010, AM J CARDIOL, V105, P139, DOI 10.1016/j.amjcard.2009.09.003; Bodenheimer T, 2005, ANN INTERN MED, V142, P932, DOI 10.7326/0003-4819-142-11-200506070-00012; Bratzler DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017401; Desai MM, 2009, 2009 MEASURES MAINTE; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Institute of Medicine Committee on the Future of Rural Health Care Quality Board on Health Care Services., 2005, QUAL COLL FUT RUR HL; James PA, 2007, ANN FAM MED, V5, P105, DOI 10.1370/afm.625; Joynt KE, 2011, JAMA-J AM MED ASSOC, V306, P45, DOI 10.1001/jama.2011.902; Krumholz HM, 2006, CIRCULATION, V113, P1683, DOI 10.1161/CIRCULATIONAHA.105.611186; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Li P, 2007, HEALTH SERV RES, V42, P2294; Li PX, 2007, HEALTH SERV RES, V42, P2089, DOI 10.1111/j.1475-6773.2007.00731.x; Li PX, 2009, J RURAL HEALTH, V25, P70, DOI 10.1111/j.1748-0361.2009.00201.x; Li PX, 2009, INQUIRY-J HEALTH CAR, V46, P46, DOI 10.5034/inquiryjrnl_46.01.46; Lichtman JH, 2012, STROKE, V43, P2741, DOI 10.1161/STROKEAHA.112.665646; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Lindenauer PK, 2012, JAMA-J AM MED ASSOC, V307, P1405, DOI 10.1001/jama.2012.384; Medicare Payment Advisory Commission, 2008, C PAYM BAS CRIT ACC; MedPAC, 2005, C ISS MOD MED PROGR; Rosko MD, 2010, J HEALTH POLIT POLIC, V35, P95, DOI 10.1215/03616878-2009-042; Ross JS, 2008, HEALTH AFFAIR, V27, P1707, DOI 10.1377/hlthaff.27.6.1707; Share DA, 2011, HEALTH AFFAIR, V30, P636, DOI 10.1377/hlthaff.2010.0526; Snyder C, 2005, JAMA-J AM MED ASSOC, V293, P2900, DOI 10.1001/jama.293.23.2900; Stensland J, 2004, 44 U MINN RUR HLTH R; United States Department of Agriculture (USDA) Economic Research Service, 2005, MEAS RUR RUR URB COM; Wang M, 2012, URBAN STUD, V49, P563, DOI 10.1177/0042098011404932; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694; Werner RM, 2010, HEALTH AFFAIR, V29, P1319, DOI 10.1377/hlthaff.2008.0770; Yeh RW, 2012, CIRC-CARDIOVASC QUAL, V5, P197, DOI 10.1161/CIRCOUTCOMES.111.962456	29	60	60	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2013	309	13					1379	1387		10.1001/jama.2013.2366	http://dx.doi.org/10.1001/jama.2013.2366			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	117EC	23549583	Bronze			2023-01-03	WOS:000316934500027
J	Adams, LV; Craig, SR; Mmbaga, EJ; Naburi, H; Lahey, T; Nutt, CT; Kisenge, R; Noel, GJ; Spielberg, SP				Adams, Lisa V.; Craig, Sienna R.; Mmbaga, Elia John; Naburi, Helga; Lahey, Timothy; Nutt, Cameron T.; Kisenge, Rodrick; Noel, Gary J.; Spielberg, Stephen P.			Children's Medicines in Tanzania: A National Survey of Administration Practices and Preferences	PLOS ONE			English	Article							DEVELOPING-WORLD; PHARMACOLOGY; INITIATIVES; FORMULATION; ADHERENCE; HEALTH	Objective: The dearth of age-appropriate formulations of many medicines for children poses a major challenge to pediatric therapeutic practice, adherence, and health care delivery worldwide. We provide information on current administration practices of pediatric medicines and describe key stakeholder preferences for new formulation characteristics. Patients and Methods: We surveyed children aged 6-12 years, parents/caregivers over age 18 with children under age 12, and healthcare workers in 10 regions of Tanzania to determine current pediatric medicine prescription and administration practices as well as preferences for new formulations. Analyses were stratified by setting, pediatric age group, parent/caregiver education, and healthcare worker cadre. Results: Complete data were available for 206 children, 202 parents/caregivers, and 202 healthcare workers. Swallowing oral solid dosage forms whole or crushing/dissolving them and mixing with water were the two most frequently reported methods of administration. Children frequently reported disliking medication taste, and many had vomited doses. Healthcare workers reported medicine availability most significantly influences prescribing practices. Most parents/caregivers and children prefer sweet-tasting medicine. Parents/caregivers and healthcare workers prefer oral liquid dosage forms for young children, and had similar thresholds for the maximum number of oral solid dosage forms children at different ages can take. Conclusions: There are many impediments to acceptable and accurate administration of medicines to children. Current practices are associated with poor tolerability and the potential for under-or over-dosing. Children, parents/caregivers, and healthcare workers in Tanzania have clear preferences for tastes and formulations, which should inform the development, manufacturing, and marketing of pediatric medications for resource-limited settings.	[Adams, Lisa V.; Lahey, Timothy] Audrey & Theodor Geisel Sch Med Dartmouth, Hanover, NH USA; [Craig, Sienna R.] Dartmouth Coll, Hanover, NH 03755 USA; [Mmbaga, Elia John; Naburi, Helga; Kisenge, Rodrick] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania; [Nutt, Cameron T.] Dartmouth Ctr Hlth Care Delivery Sci, Hanover, NH USA; [Noel, Gary J.] Inst Pediat Innovat, Cambridge, MA USA; [Noel, Gary J.] Weill Cornell Med Coll, New York, NY USA; [Noel, Gary J.] AstraZeneca, Waltham, MA USA; [Spielberg, Stephen P.] US FDA, Washington, DC 20204 USA	Dartmouth College; Muhimbili University of Health & Allied Sciences; Dartmouth College; Cornell University; AstraZeneca; US Food & Drug Administration (FDA)	Adams, LV (corresponding author), Audrey & Theodor Geisel Sch Med Dartmouth, Hanover, NH USA.	Lisa.V.Adams@Dartmouth.edu		Naburi, Helga/0000-0003-1659-5224	World Health Organization (WHO), Better Medicines for Children project	World Health Organization (WHO), Better Medicines for Children project	This research was supported by a grant from the World Health Organization (WHO) as part of the Better Medicines for Children project. The funders had no role in the data collection, decision to publish, or preparation of the manuscript. Technical advice on the study design and data analysis was provided by appropriate experts at WHO. The named authors alone are responsible for the views expressed in this publication.	Access to Medicine Foundation, 2010, ACC MED IND 2010; [Anonymous], SOURC PRIC SEL MED C; Ansah EK, 2001, TROP MED INT HEALTH, V6, P496, DOI 10.1046/j.1365-3156.2001.00740.x; Baguley D, 2012, ARCH DIS CHILD, V97, P293, DOI 10.1136/archdischild-2011-300909; Beggs SA, 2005, ARCH DIS CHILD, V90, P1091, DOI 10.1136/adc.2005.076703; Breitkreutz J., 1999, PAEDIAT PERINAT DRUG, V3, P25; Craig SR, 2009, SOC SCI MED, V69, P1681, DOI 10.1016/j.socscimed.2009.08.024; Gazarian Madlen, 2009, Paediatr Drugs, V11, P41; Hill S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038055; Hill SR, 2012, B WORLD HEALTH ORGAN, V90, P236, DOI 10.2471/BLT.11.088658; Hoppu K, 2008, EUR J CLIN PHARMACOL, V64, P201, DOI 10.1007/s00228-007-0390-5; Hoppu K, 2012, EUR J CLIN PHARMACOL, V68, P1, DOI 10.1007/s00228-011-1089-1; Hoppu K, 2011, ARCH DIS CHILD, V96, P764, DOI 10.1136/adc.2009.180000; Knoppert David C, 2009, Paediatr Drugs, V11, P55; MacLeod Stuart, 2007, Paediatr Drugs, V9, P215, DOI 10.2165/00148581-200709040-00002; Mennella JA, 2008, CLIN THER, V30, P2120, DOI 10.1016/j.clinthera.2008.11.018; Nahirya-Ntege P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036186; NOTTERMAN DA, 1986, PEDIATRICS, V77, P850; Nunn T, 2005, BRIT J CLIN PHARMACO, V59, P674, DOI 10.1111/j.1365-2125.2005.02410.x; Peacock G, 2010, J AM PHARM ASSOC, V50, P84, DOI 10.1331/JAPhA.2010.09006; Rodriguez W, 2008, PEDIATRICS, V121, P530, DOI 10.1542/peds.2007-1529; Sachs AN, 2012, JAMA-J AM MED ASSOC, V307, P1914, DOI 10.1001/jama.2012.3435; Taylor DM, 2009, J PAEDIATR CHILD H, V45, P304, DOI 10.1111/j.1440-1754.2008.01462.x; Teng Jaja, 2002, J Am Pharm Assoc (Wash), V42, P195; United Nations, 2012, CONC NOT EST UN COMM; United Nations Children's Fund, 2012, LEV TRENDS CHILD MOR; World Health Organization, 2012, WORLD HLTH STAT 2012; Zucker H, 2007, CLIN PHARMACOL THER, V82, P503, DOI 10.1038/sj.clpt.6100395	28	18	19	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2013	8	3							e58303	10.1371/journal.pone.0058303	http://dx.doi.org/10.1371/journal.pone.0058303			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	117EP	23484012	Green Submitted, gold, Green Published			2023-01-03	WOS:000316936100102
J	Wu, MP; Weng, SF; Hsu, YW; Wang, JJ; Kuo, HC				Wu, Ming-Ping; Weng, Shih-Feng; Hsu, Ya-Wen; Wang, Jhi-Joung; Kuo, Hann-Chorng			Medical Attendance for Lower Urinary Tract Symptoms Is Associated with Subsequent Increased Risk of Outpatient Visits and Hospitalizations Based on a Nationwide Population-Based Database	PLOS ONE			English	Article							QUALITY-OF-LIFE; OVERACTIVE BLADDER; CARDIOVASCULAR RISK; INCONTINENCE; PREVALENCE; MEN; IMPACT; BOTHER; CONTINENCE; COMMITTEE	Introduction: Lower urinary tract symptoms (LUTS), which encompass storage, voiding, and postmicturition symptoms, are highly prevalent and recognized globally. Based on a nationwide population-based database, this study tests the hypothesis that medical attendance for LUTS is associated with a subsequent increase in the number of outpatient visits and hospitalizations, with differences among medical specialties and age groups. Methods: Participants were selected from a random population sample of approximately one million people as a representative cohort of National Health Insurance (NHI) enrollees in Taiwan. Participants had at least three outpatient service claims with a coding of LUTS during the recruitment period 2001-2004. Both the LUTS group and non-LUTS control group were monitored for subsequent outpatient visits and hospitalizations, excluding LUTS-related healthcare services, for 2 years following the index date. The results were categorized based on medical specialty and age group. Results: The outpatient visit rates (no. per person-year) and adjusted incidence rate ratios (IRRs) (95% confidence interval (CI) were significantly higher in urology (4.51, 95% CI 4.15-4.91) and gynecology (1.82, 95% CI 1.76-1.89) for the LUTS group. They were also significantly high in other departments, including internal medicine (1.25), general practice (1.13), Chinese medicine (1.77), family medicine (1.19), surgery (1.38), and psychiatry (1.98). Similarly, the hospitalization rate (no. per 1000 person-year) and adjusted IRRs (95% CI) were significantly higher in urology (5.50, 95% CI = 4.60-6.50) and gynecology (1.60, 95% CI = 1.35-1.90), as well as in internal medicine (1.55) and surgery (1.56), but not in psychiatry (1.12). Furthermore, the IRRs differed among 3 age groups. Conclusions: A significantly higher number of outpatient visits and hospitalizations were observed for individuals with LUTS, compared to the control group, and the effects differed with the advancement of age. This study broadens understanding of LUTS by viewing their impact on healthcare services with multiple and overlapping systems, rather than considering them exclusively as symptoms of traditional diseases of the bladder and urethra.	[Wu, Ming-Ping] Chi Mei Fdn Hosp, Dept Obstet & Gynecol, Div Urogynecol, Tainan, Taiwan; [Wu, Ming-Ping] Chia Nan Univ Pharm & Sci, Ctr Gen Educ, Tainan, Taiwan; [Weng, Shih-Feng; Hsu, Ya-Wen] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan; [Weng, Shih-Feng; Hsu, Ya-Wen; Wang, Jhi-Joung] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Kuo, Hann-Chorng] Buddhist Tzu Chi Gen Hosp, Dept Urol, Hualien, Taiwan; [Kuo, Hann-Chorng] Tzu Chi Univ, Hualien, Taiwan	Chi Mei Hospital; Chia Nan University of Pharmacy & Science; Chia Nan University of Pharmacy & Science; Chi Mei Hospital; Buddhist Tzu Chi General Hospital; Hualien Tzu Chi Hospital; Tzu Chi University	Kuo, HC (corresponding author), Buddhist Tzu Chi Gen Hosp, Dept Urol, Hualien, Taiwan.	hck@tzuchi.com.tw		Weng, Shih-Feng/0000-0001-8684-3487				Abrams P, 2010, NEUROUROL URODYNAM, V29, P213, DOI 10.1002/nau.20870; Abrams P, 2003, UROLOGY, V61, P37, DOI 10.1016/S0090-4295(02)02243-4; Chapple CR, 2008, EUR UROL, V54, P563, DOI 10.1016/j.eururo.2008.03.109; Charness N, 2008, HUM FACTORS, V50, P548, DOI 10.1518/001872008X312161; Chen GD, 2003, NEUROUROL URODYNAM, V22, P109, DOI 10.1002/nau.10010; Chung SD, 2011, NEUROUROL URODYNAM, V30, P417, DOI 10.1002/nau.20938; Coyne KS, 2008, BJU INT, V101, P1388, DOI 10.1111/j.1464-410X.2008.07601.x; Coyne KS, 2011, BJU INT, V108, P1459, DOI 10.1111/j.1464-410X.2010.10013.x; Coyne KS, 2009, BJU INT, V103, P4, DOI 10.1111/j.1464-410X.2009.08371.x; Girman CJ, 1998, UROLOGY, V51, P428, DOI 10.1016/S0090-4295(97)00717-6; Heaton JPW, 2006, BRIT J PHARMACOL, V147, pS2, DOI 10.1038/sj.bjp.0706620; Hsiao SM, 2012, INT UROGYNECOL J, V23, P935, DOI 10.1007/s00192-012-1715-1; Hu TW, 2005, BJU INT, V96, P43, DOI 10.1111/j.1464-410X.2005.05654.x; Irwin DE, 2006, BJU INT, V97, P96, DOI 10.1111/j.1464-410X.2005.05889.x; Irwin DE, 2008, EUR UROL, V53, P1029, DOI 10.1016/j.eururo.2008.01.027; Irwin DE, 2011, BJU INT, V108, P1132, DOI 10.1111/j.1464-410X.2010.09993.x; Irwin DE, 2009, EUR UROL, V56, P14, DOI 10.1016/j.eururo.2009.02.026; Kannan H, 2009, UROLOGY, V74, P34, DOI 10.1016/j.urology.2008.12.077; Karatas OF, 2010, INT J CARDIOL, V144, P452, DOI 10.1016/j.ijcard.2009.03.099; Lee YS, 2011, WORLD J UROL, V29, P185, DOI 10.1007/s00345-009-0490-1; Liao CH, 2011, UROLOGY, V78, P1373, DOI 10.1016/j.urology.2011.04.076; Liu HT, 2011, NEUROUROL URODYNAM, V30, P1525, DOI 10.1002/nau.21118; Lunenfeld B, 2008, GYNECOL ENDOCRINOL, V24, P1, DOI 10.1080/09513590701718364; Malmsten UGH, 2010, EUR UROL, V58, P149, DOI 10.1016/j.eururo.2010.03.014; McVary KT, 2011, J UROLOGY, V185, P1793, DOI 10.1016/j.juro.2011.01.074; Michel MC, 2004, J UROLOGY, V172, P1390, DOI 10.1097/01.ju.0000139995.85780.d8; Ng C. F., 2007, Hong Kong Medical Journal, V13, P421; Parsons JK, 2010, CURR BLADDER DYSFUNC, V5, P212, DOI 10.1007/s11884-010-0067-2; Ponholzer A, 2006, EUR UROL, V50, P581, DOI 10.1016/j.eururo.2006.01.031; Rotar M, 2011, NEUROUROL URODYNAM, V30, P1315, DOI 10.1002/nau.21013; Stewart WF, 2002, WORLD J UROL, V20, P327, DOI 10.1007/s00345-002-0301-4; Tai HC, 2010, J CLIN ENDOCR METAB, V95, P1143, DOI 10.1210/jc.2009-1492; Terai A, 2004, UROLOGY, V63, P487, DOI 10.1016/j.urology.2003.09.070; Wehrberger C, 2011, UROLOGY, V78, P1063, DOI 10.1016/j.urology.2011.05.065; Wu MP, 2008, INT UROGYNECOL J, V19, P1639, DOI 10.1007/s00192-008-0697-5; Wu MP, 2013, UROLOGY, V81, P61, DOI 10.1016/j.urology.2012.08.033; Yazici H, 2012, BULL HOSP JT DIS, V70, P95	37	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2013	8	3							e57825	10.1371/journal.pone.0057825	http://dx.doi.org/10.1371/journal.pone.0057825			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099RC	23472108	Green Published, Green Submitted, gold			2023-01-03	WOS:000315637900047
J	Kearns, T; Clucas, D; Connors, C; Currie, BJ; Carapetis, JR; Andrews, RM				Kearns, Therese; Clucas, Danielle; Connors, Christine; Currie, Bart J.; Carapetis, Jonathan R.; Andrews, Ross M.			Clinic Attendances during the First 12 Months of Life for Aboriginal Children in Five Remote Communities of Northern Australia	PLOS ONE			English	Article							DISEASE; TERRITORY	Background: The vast majority (>75%) of Aboriginal people in the Northern Territory (NT) live in remote or very remote locations. Children in these communities have high attendance rates at local Primary Health Care (PHC) centres but there is a paucity of studies documenting the reason and frequency of attendance. Such data can be used to help guide public health policy and practice. Methods and Findings: Clinic presentations during the first year of life were reviewed for 320 children born from 1 January 2001-31 December 2006. Data collected included reason for infectious presentation, antibiotic prescription and referral to hospital. The median number of presentations per child in the first year of life was 21 (IQR 15-29) with multiple reasons for presentation. The most prominent infectious presentations per child during the first year of life were upper respiratory tract infections (median 6, IQR 3-10); diarrhoea (median 3, IQR 1-5); ear disease (median 3, IQR 1-5); lower respiratory tract infection (median 3, IQR 2-5); scabies (median 3, IQR 1-5); and skin sores (median 3, IQR 2-5). Conclusions: Infectious diseases of childhood are strongly linked with poverty, poor living conditions and overcrowding. The data reported in our study were collected through manual review, however many remote communities now have established electronic health record systems, use the Key Performance Indicator System and are engaged in CQI (continuous quality improvement) processes. Building on these recent initiatives, there is an opportunity to incorporate routine monitoring of a range of infectious conditions (we suggest diarrhoea, LRTI, scabies and skin sores) using both the age at first presentation and the median number of presentations per child during the first year of life as potential indicators of progress in addressing health inequities in remote communities.	[Kearns, Therese; Currie, Bart J.; Andrews, Ross M.] Charles Darwin Univ, Menzies Sch Hlth Res, Child Hlth Div, Darwin, NT 0909, Australia; [Clucas, Danielle] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Connors, Christine; Currie, Bart J.] No Terr Dept Hlth & Families, Darwin, NT, Australia; [Carapetis, Jonathan R.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia	Charles Darwin University; Menzies School of Health Research; University of Melbourne; Telethon Kids Institute; University of Western Australia	Kearns, T (corresponding author), Charles Darwin Univ, Menzies Sch Hlth Res, Child Hlth Div, Darwin, NT 0909, Australia.	therese.kearns@menzies.edu.au	Carapetis, Jonathan R/H-8933-2014; Kearns, Therese/N-2308-2013	Carapetis, Jonathan R/0000-0002-1182-9792; Kearns, Therese/0000-0003-0862-7572	Cooperative Research Council for Aboriginal Health; Rio Tinto Aboriginal Foundation; Ian Potter Foundation; Australian Government Office of Aboriginal and Torres Strait Islander Health	Cooperative Research Council for Aboriginal Health; Rio Tinto Aboriginal Foundation; Ian Potter Foundation; Australian Government Office of Aboriginal and Torres Strait Islander Health(Australian Government)	This work was supported by the Cooperative Research Council for Aboriginal Health (http://www.lowitja.org.au/), Rio Tinto Aboriginal Foundation (http://www.riotinto.com/), Ian Potter Foundation (http://www.ianpotter.org.au/), and the Australian Government Office of Aboriginal and Torres Strait Islander Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin TT, 2011, RURAL REMOTE HEALTH, V11; Andrews RM, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000554; Austrailian Institute of Health and Welfare, 2015, AB TORR STRAIT ISL H; Australian Government, 2012, CLOS GAP MIN REP; Carapetis JR, 1996, MED J AUSTRALIA, V164, P146, DOI 10.5694/j.1326-5377.1996.tb122012.x; Carville KS, 2007, PEDIATR INFECT DIS J, V26, P210, DOI 10.1097/01.inf.0000254148.09831.7f; Clucas DB, 2008, B WORLD HEALTH ORGAN, V86, P241; Fischer K, 2012, ADV PARASIT, V79, P339, DOI 10.1016/B978-0-12-398457-9.00005-6; Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4; McMeniman E, 2011, AUSTRALAS J DERMATOL, V52, P270, DOI 10.1111/j.1440-0960.2011.00806.x; MUNOZ E, 1992, MED J AUSTRALIA, V156, P529, DOI 10.5694/j.1326-5377.1992.tb121412.x; StataCorpLP, 2012, STAT IC 12 1 WIND	12	51	51	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2013	8	3							e58231	10.1371/journal.pone.0058231	http://dx.doi.org/10.1371/journal.pone.0058231			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103EI	23469270	Green Published, gold			2023-01-03	WOS:000315897100067
J	Wing, R; Bolin, P; Brancati, FL; Bray, GA; Clark, JM; Coday, M; Crow, RS; Curtis, JM; Egan, CM; Espeland, MA; Evans, M; Foreyt, JP; Ghazarian, S; Gregg, EW; Harrison, B; Hazuda, HP; Hill, JO; Horton, ES; Hubbard, V; Jakicic, JM; Jeffery, RW; Johnson, KC; Kahn, SE; Kitabchi, AE; Knowler, WC; Lewis, CE; Maschak-Carey, BJ; Montez, MG; Murillo, A; Nathan, DM; Patricio, J; Peters, A; Pi-Sunyer, X; Pownall, H; Reboussin, D; Regensteiner, JG; Rickman, AD; Ryan, DH; Safford, M; Wadden, TA; Wagenknecht, LE; West, DS; Williamson, DF; Yanovski, SZ				Wing, Rena; Bolin, Paula; Brancati, Frederick L.; Bray, George A.; Clark, Jeanne M.; Coday, Mace; Crow, Richard S.; Curtis, Jeffrey M.; Egan, Caitlin M.; Espeland, Mark A.; Evans, Mary; Foreyt, John P.; Ghazarian, Siran; Gregg, Edward W.; Harrison, Barbara; Hazuda, Helen P.; Hill, James O.; Horton, Edward S.; Hubbard, Van S.; Jakicic, John M.; Jeffery, Robert W.; Johnson, Karen C.; Kahn, Steven E.; Kitabchi, Abbas E.; Knowler, William C.; Lewis, Cora E.; Maschak-Carey, Barbara J.; Montez, Maria G.; Murillo, Anne; Nathan, David M.; Patricio, Jennifer; Peters, Anne; Pi-Sunyer, Xavier; Pownall, Henry; Reboussin, David; Regensteiner, Judith G.; Rickman, Amy D.; Ryan, Donna H.; Safford, Monika; Wadden, Thomas A.; Wagenknecht, Lynne E.; West, Delia S.; Williamson, David F.; Yanovski, Susan Z.		Look AHEAD Res Grp	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEIGHT-LOSS; OBESE ADULTS; MORTALITY; INDIVIDUALS; PREVENTION; MELLITUS; HEALTH; DIET	Background Weight loss is recommended for overweight or obese patients with type 2 diabetes on the basis of short-term studies, but long-term effects on cardiovascular disease remain unknown. We examined whether an intensive lifestyle intervention for weight loss would decrease cardiovascular morbidity and mortality among such patients. Methods In 16 study centers in the United States, we randomly assigned 5145 overweight or obese patients with type 2 diabetes to participate in an intensive lifestyle intervention that promoted weight loss through decreased caloric intake and increased physical activity (intervention group) or to receive diabetes support and education (control group). The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for angina during a maximum follow-up of 13.5 years. Results The trial was stopped early on the basis of a futility analysis when the median follow- up was 9.6 years. Weight loss was greater in the intervention group than in the control group throughout the study (8.6% vs. 0.7% at 1 year; 6.0% vs. 3.5% at study end). The intensive lifestyle intervention also produced greater reductions in glycated hemoglobin and greater initial improvements in fitness and all cardiovascular risk factors, except for low-density-lipoprotein cholesterol levels. The primary outcome occurred in 403 patients in the intervention group and in 418 in the control group (1.83 and 1.92 events per 100 person-years, respectively; hazard ratio in the intervention group, 0.95; 95% confidence interval, 0.83 to 1.09; P = 0.51). Conclusions An intensive lifestyle intervention focusing on weight loss did not reduce the rate of cardiovascular events in overweight or obese adults with type 2 diabetes.	[Wing, Rena; Curtis, Jeffrey M.] Brown Univ, Warren Alpert Med Sch, Weight Control & Diabet Res Ctr, Providence, RI 02903 USA; [Bolin, Paula; Evans, Mary; Harrison, Barbara; Hubbard, Van S.] NIDDK, NIH, Bethesda, MD 20892 USA; [Brancati, Frederick L.; Clark, Jeanne M.] Johns Hopkins Sch Med, Baltimore, MD USA; [Bray, George A.] Pennington Biomed Res Ctr, Baton Rouge, LA USA; [Coday, Mace; Johnson, Karen C.; Kitabchi, Abbas E.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA; [Crow, Richard S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Curtis, Jeffrey M.] NIDDK, NIH, Phoenix, AZ USA; [Egan, Caitlin M.] Miriam Hosp, Providence, RI 02906 USA; [Espeland, Mark A.] Wake Forest Univ, Dept Biostat Sci, Sch Med, Winston Salem, NC 27109 USA; [Foreyt, John P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Ghazarian, Siran; Peters, Anne] Roybal Comprehens Hlth Ctr, Los Angeles, CA USA; [Gregg, Edward W.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Hazuda, Helen P.; Montez, Maria G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Clin Epidemiol, San Antonio, TX 78229 USA; [Hill, James O.] Univ Colorado, Hlth Sci Ctr, Ctr Human Nutr, Aurora, CO USA; [Horton, Edward S.] Joslin Diabet Ctr, Boston, MA 02215 USA; [Jakicic, John M.] Univ Pittsburgh, Dept Hlth & Phys Act, Pittsburgh, PA USA; [Jeffery, Robert W.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Kahn, Steven E.; Murillo, Anne] Univ Washington, Dept Med, Seattle, WA USA; [Knowler, William C.] NIDDK, NIH, Southwest Amer Indian Ctr, Phoenix, AZ USA; [Lewis, Cora E.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA; [Maschak-Carey, Barbara J.] Univ Penn, Weight & Eating Disorder Program, Philadelphia, PA 19104 USA; [Nathan, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Patricio, Jennifer] St Lukes Roosevelt Hosp, Dept Med, New York, NY 10025 USA; [Pi-Sunyer, Xavier] St Lukes Roosevelt Hosp, Dept Med, New York, NY 10025 USA; [Pownall, Henry] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Reboussin, David] Wake Forest Univ, Sch Med, Dept Biostat Sci, Winston Salem, NC 27109 USA; [Regensteiner, Judith G.] Univ Colorado, Hlth Sci Ctr, Ctr Womens Hlth Res, Aurora, CO USA; [Rickman, Amy D.] Univ Pittsburgh, Dept Hlth & Phys Act, Pittsburgh, PA USA; [Ryan, Donna H.] Pennington Biomed Res Ctr, Baton Rouge, LA USA; [Safford, Monika] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA; [Wadden, Thomas A.] Univ Penn, Weight & Eating Disorder Program, Philadelphia, PA 19104 USA; [Wagenknecht, Lynne E.] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27109 USA; [West, Delia S.] Univ Arkansas Med Sci, Coll Publ Hlth, Dept Hlth Behav & Hlth Educ, Little Rock, AR 72205 USA; [Williamson, David F.] Ctr Dis Control & Prevent, Atlanta, GA USA; [Yanovski, Susan Z.] NIDDK, NIH, Bethesda, MD USA	Brown University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Johns Hopkins University; Johns Hopkins Medicine; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Tennessee System; University of Tennessee Health Science Center; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Lifespan Health Rhode Island; Miriam Hospital; Wake Forest University; Baylor College of Medicine; Centers for Disease Control & Prevention - USA; University of Texas System; University of Texas Health San Antonio; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Joslin Diabetes Center, Inc.; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Massachusetts General Hospital; Mount Sinai St. Luke's; Mount Sinai West; Mount Sinai St. Luke's; Mount Sinai West; Baylor College of Medicine; Wake Forest University; University of Colorado System; University of Colorado Anschutz Medical Campus; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Alabama System; University of Alabama Birmingham; University of Pennsylvania; Pennsylvania Medicine; Wake Forest University; University of Arkansas System; University of Arkansas Medical Sciences; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wing, R (corresponding author), Brown Univ, Warren Alpert Med Sch, Weight Control & Diabet Res Ctr, 196 Richmond St, Providence, RI 02903 USA.	rwing@lifespan.org	Clark, Jeanne/AGG-8199-2022; West, Delia Smith/GWV-5839-2022; Soliman, Elsayed Z/AAD-7135-2020	Clark, Jeanne/0000-0003-1194-0092; West, Delia Smith/0000-0002-4375-2785; Soliman, Elsayed Z/0000-0001-5632-8150; Hill, James/0000-0003-4690-2264; Kahn, Steven/0000-0001-7307-9002; Gregg, Edward/0000-0003-2381-6822; Ryan, Donna/0000-0001-8374-2277; Peters, Anne/0000-0003-0520-0776; Pownall, Henry/0000-0001-8412-506X	National Institutes of Health (NIH); Department of Health and Human Services agencies; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, DK56992]; Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Nursing Research; National Center on Minority Health and Health Disparities; NIH Office of Research on Women's Health; Centers for Disease Control and Prevention; Johns Hopkins Medical Institutions Bayview General Clinical Research Center [M01RR02719]; Massachusetts General Hospital Mallinckrodt General Clinical Research Center; Massachusetts Institute of Technology General Clinical Research Center [M01RR01066]; University of Colorado Health Sciences Center General Clinical Research Center [M01RR00051]; Clinical Nutrition Research Unit [P30 DK48520]; University of Tennessee at Memphis General Clinical Research Center [M01RR0021140]; University of Pittsburgh General Clinical Research Center [M01RR000056]; Clinical Translational Research Center; Clinical and Translational Science Award [UL1 RR 024153]; NIH [DK 046204]; VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter General Clinical Research Center [M01RR01346]; FedEx; Health Management Resources; Johnson Johnson; Nestle HealthCare Nutrition; Hoffmann-La Roche; Abbott Nutrition; Unilever North America; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051, M01RR000056, M01RR002719, M01RR001346, M01RR001066, UL1RR024153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL109235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK057219, U01DK057131, U01DK057136, U01DK057151, P30DK048520, U01DK056992, P30DK079637, U01DK057154, U01DK057177, ZIADK075077, U01DK057008, U01DK057171, U01DK057178, U01DK057135, U01DK057078, U01DK056990, P30DK017047, U01DK057149, U01DK057182] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services agencies; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Center on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NIH Office of Research on Women's Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Office of Research on Women's Health (ORWH)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Johns Hopkins Medical Institutions Bayview General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Massachusetts General Hospital Mallinckrodt General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Massachusetts Institute of Technology General Clinical Research Center; University of Colorado Health Sciences Center General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Clinical Nutrition Research Unit; University of Tennessee at Memphis General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); University of Pittsburgh General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Clinical Translational Research Center; Clinical and Translational Science Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; Frederic C. Bartter General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); FedEx; Health Management Resources; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Nestle HealthCare Nutrition(Nestle SA); Hoffmann-La Roche(Hoffmann-La Roche); Abbott Nutrition(Abbott Laboratories); Unilever North America(Unilever); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the National Institutes of Health (NIH) and other Department of Health and Human Services agencies through cooperative agreements with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (DK57136, DK57149, DK56990, DK57177, DK57171, DK57151, DK57182, DK57131, DK57002, DK57078, DK57154, DK57178, DK57219, DK57008, DK57135, and DK56992). Additional funding was provided by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases; the National Heart, Lung, and Blood Institute; the National Institute of Nursing Research; the National Center on Minority Health and Health Disparities; the NIH Office of Research on Women's Health; and the Centers for Disease Control and Prevention. The Indian Health Service (IHS) provided personnel, medical oversight, and use of facilities. Additional support was provided by the Johns Hopkins Medical Institutions Bayview General Clinical Research Center (M01RR02719); the Massachusetts General Hospital Mallinckrodt General Clinical Research Center and the Massachusetts Institute of Technology General Clinical Research Center (M01RR01066); the University of Colorado Health Sciences Center General Clinical Research Center (M01RR00051) and Clinical Nutrition Research Unit (P30 DK48520); the University of Tennessee at Memphis General Clinical Research Center (M01RR0021140); the University of Pittsburgh General Clinical Research Center(M01RR000056) and Clinical Translational Research Center (funded by a Clinical and Translational Science Award [UL1 RR 024153] and an NIH grant [DK 046204]); the VA Puget Sound Health Care System Medical Research Service, Department of Veterans Affairs; and the Frederic C. Bartter General Clinical Research Center (M01RR01346); and by FedEx, Health Management Resources, Johnson & Johnson, Nestle HealthCare Nutrition, Hoffmann-La Roche, Abbott Nutrition, and Unilever North America.	Ali MK, 2013, NEW ENGL J MED, V368, P1613, DOI 10.1056/NEJMsa1213829; [Anonymous], 2013, CLIN PRACT REC; Brancati F, 2003, CONTROL CLIN TRIALS, V24, P610, DOI 10.1016/S0197-2456(03)00064-3; Brancati FL, 2012, CLIN TRIALS, V9, P113, DOI 10.1177/1740774511432726; Bray GA, 2009, LANCET, V374, P1677, DOI 10.1016/S0140-6736(09)61457-4; Buse JB, 2007, AM J CARDIOL, V99, p21I, DOI 10.1016/j.amjcard.2007.03.003; DiabetesPrev D. Prog Res. Group, 2002, NEW ENGL J MED, V346, P393, DOI [10.1056/NEJMoa012512, DOI 10.1056/NEJMOA012512]; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Faulconbridge LF, 2012, OBESITY, V20, P783, DOI 10.1038/oby.2011.315; Foster GD, 2009, ARCH INTERN MED, V169, P1619, DOI 10.1001/archinternmed.2009.266; Foy CG, 2011, OBESITY, V19, P83, DOI 10.1038/oby.2010.120; Gregg EW, 2012, JAMA-J AM MED ASSOC, V308, P2489, DOI 10.1001/jama.2012.67929; Harrington M, 2009, NUTR RES REV, V22, P93, DOI 10.1017/S0954422409990035; ing R. R., 2004, HDB OBESITY CLIN APP, V2nd, P147; Look Ahead Research Group, 2006, Diab Vasc Dis Res, V3, P202, DOI 10.3132/dvdr.2006.031; Phelan S, 2012, J UROLOGY, V187, P939, DOI 10.1016/j.juro.2011.10.139; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rejeski WJ, 2012, NEW ENGL J MED, V366, P1209, DOI 10.1056/NEJMoa1110294; Romeo S, 2012, DIABETES CARE, V35, P2613, DOI 10.2337/dc12-0193; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Wadden TA, 2007, OBESITY, V15, P1339; Wadden TA, 2006, OBESITY, V14, P737; Wadden TA, 2012, CIRCULATION, V125, P1157, DOI 10.1161/CIRCULATIONAHA.111.039453; Williamson DF, 1998, EXP CLIN ENDOCR DIAB, V106, P14, DOI 10.1055/s-0029-1212031; Williamson DF, 2000, DIABETES CARE, V23, P1499, DOI 10.2337/diacare.23.10.1499; Williamson DA, 2009, ARCH INTERN MED, V169, P163, DOI 10.1001/archinternmed.2008.544	26	1615	1647	15	257	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2013	369	2					145	154		10.1056/NEJMoa1212914	http://dx.doi.org/10.1056/NEJMoa1212914			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180BH	23796131	Green Accepted			2023-01-03	WOS:000321567300010
J	van der Meer, JWM; Netea, MG				van der Meer, Jos W. M.; Netea, Mihai G.			A Salty Taste to Autoimmunity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[van der Meer, Jos W. M.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Inst Infect Inflammat & Immun, NL-6525 ED Nijmegen, Netherlands; Radboud Univ Nijmegen, Med Ctr, Dept Med, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	van der Meer, JWM (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Inst Infect Inflammat & Immun, NL-6525 ED Nijmegen, Netherlands.		Netea, Mihai/N-5155-2014; van der Meer, Jos W.M./C-8521-2013	van der Meer, Jos W.M./0000-0001-5120-3690				Charalambous MP, 2008, SURG INFECT, V9, P67, DOI 10.1089/sur.2005.069; delaSierra A, 1996, CLIN SCI, V91, P155, DOI 10.1042/cs0910155; Kleinewietfeld M, 2013, NATURE; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Wu C, 2013, NATURE	5	39	39	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2013	368	26					2520	2521		10.1056/NEJMcibr1303292	http://dx.doi.org/10.1056/NEJMcibr1303292			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	171KQ	23802520				2023-01-03	WOS:000320926900017
J	Moore, W				Moore, Wendy			Ether frolics	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												wendymoore@ntlworld.com							0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	2013	346								f3861	10.1136/bmj.f3861	http://dx.doi.org/10.1136/bmj.f3861			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166WQ	23766494				2023-01-03	WOS:000320590800002
J	Genther, DJ; Frick, KD; Chen, D; Betz, J; Lin, FR				Genther, Dane J.; Frick, Kevin D.; Chen, David; Betz, Joshua; Lin, Frank R.			Association of Hearing Loss With Hospitalization and Burden of Disease in Older Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Genther, Dane J.; Chen, David; Lin, Frank R.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; [Frick, Kevin D.] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA; [Betz, Joshua] Johns Hopkins Univ, Dept Biostat, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Genther, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.	flin1@jhmi.edu		Betz, Joshua/0000-0003-4488-9799; Frick, Kevin/0000-0002-0178-5319; Genther, Dane/0000-0002-7925-012X	NIDCD NIH HHS [1K23DC011279, T32 DC000027, T32DC000027-24, K23 DC011279] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [T32DC000027, K23DC011279] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Berkman LF, 2000, SOC SCI MED, V51, P843, DOI 10.1016/S0277-9536(00)00065-4; Centers for Disease Control and Prevention, NAT HLTH NUTR EX SUR; Lin FR, 2011, J GERONTOL A-BIOL, V66, P582, DOI 10.1093/gerona/glr002; Lin FR, 2011, ARCH NEUROL-CHICAGO, V68, P214, DOI 10.1001/archneurol.2010.362; Viljanen A, 2009, J AM GERIATR SOC, V57, P2282, DOI 10.1111/j.1532-5415.2009.02553.x; WHO, PREV DEAFN HEAR IMP	6	106	115	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 12	2013	309	22					2322	2324		10.1001/jama.2013.5912	http://dx.doi.org/10.1001/jama.2013.5912			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	161EV	23757078	Bronze, Green Accepted			2023-01-03	WOS:000320176000017
J	Huang, H; Cao, Y; Wei, W; Liu, W; Lu, SY; Chen, YB; Wang, Y; Yan, H; Wu, YL				Huang, He; Cao, Yang; Wei, Wei; Liu, Wei; Lu, Shao-Yong; Chen, Yu-Bao; Wang, Yan; Yan, Hua; Wu, Ying-Li			Targeting Poly (ADP-Ribose) Polymerase Partially Contributes to Bufalin-Induced Cell Death in Multiple Myeloma Cells	PLOS ONE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; HUMAN LEUKEMIA-CELLS; POLY(ADP-RIBOSE) POLYMERASE; CANCER-CELLS; TOPOISOMERASE-II; OVARIAN-CANCER; LUNG-CANCER; APOPTOSIS; INHIBITORS; INDUCTION	Despite recent pharmaceutical advancements in therapeutic drugs, multiple myeloma (MM) remains an incurable disease. Recently, ploy(ADP-ribose) polymerase 1 (PARP1) has been shown as a potentially promising target for MM therapy. A previous report suggested bufalin, a component of traditional Chinese medicine ("Chan Su''), might target PARP1. However, this hypothesis has not been verified. We here showed that bufalin could inhibit PARP1 activity in vitro and reduce DNA-damage-induced poly(ADP-ribosyl)ation in MM cells. Molecular docking analysis revealed that the active site of bufalin interaction is within the catalytic domain of PAPR1. Thus, PARP1 is a putative target of bufalin. Furthermore, we showed, for the first time that the proliferation of MM cell lines (NCI-H929, U266, RPMI8226 and MM. 1S) and primary CD138(+) MM cells could be inhibited by bufalin, mainly via apoptosis and G(2)-M phase cell cycle arrest. MM cell apoptosis was confirmed by apoptotic cell morphology, Annexin-V positive cells, and the caspase3 activation. We further evaluated the role of PARP1 in bufalin-induced apoptosis, discovering that PARP1 overexpression partially suppressed bufalin-induced cell death. Moreover, bufalin can act as chemosensitizer to enhance the cell growth-inhibitory effects of topotecan, camptothecin, etoposide and vorinostat in MM cells. Collectively, our data suggest that bufalin is a novel PARP1 inhibitor and a potentially promising therapeutic agent against MM alone or in combination with other drugs.	[Huang, He; Cao, Yang; Wei, Wei; Chen, Yu-Bao; Wang, Yan; Yan, Hua] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Hematol, Shanghai 200030, Peoples R China; [Liu, Wei; Lu, Shao-Yong; Wu, Ying-Li] Shanghai Jiao Tong Univ, Shanghai Univ E Inst, Sch Med,Key Lab Cell Differentiat & Apoptos, Chem Biol,Chinese Minist Educ,Dept Pathoph, Shanghai 200030, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yan, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Hematol, Shanghai 200030, Peoples R China.	yanhua_candy@yahoo.com.cn; wuyingli@shsmu.edu.cn	Wei, Weijun/AAZ-3551-2021		National Basic Research Program of China (973 Program) [2010CB912104]; National Natural Science Foundation of China [91013008, 81070433, 81170509, 81272886]; Science and Technology Committee of Shanghai [11JC1406500]; SMC Program of Shanghai Jiao Tong University	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Committee of Shanghai(Shanghai Science & Technology Committee); SMC Program of Shanghai Jiao Tong University	This work was supported partly by grants from National Basic Research Program of China (973 Program) (No. 2010CB912104), National Natural Science Foundation of China (91013008, 81070433, 81170509, 81272886), Science and Technology Committee of Shanghai (11JC1406500), SMC Program of Shanghai Jiao Tong University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aghajan M, 2010, NAT BIOTECHNOL, V28, P738, DOI 10.1038/nbt.1645; Arnaud-Batista FJ, 2012, AM J PHYSIOL-RENAL, V302, pF959, DOI 10.1152/ajprenal.00130.2011; Banasik M, 2004, ACTA NEUROBIOL EXP, V64, P467; Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; Chen AL, 2009, BIOTECHNOL LETT, V31, P487, DOI 10.1007/s10529-008-9888-x; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Han KQ, 2007, WORLD J GASTROENTERO, V13, P3374, DOI 10.3748/wjg.v13.i24.3374; Hashimoto S, 1997, LEUKEMIA RES, V21, P875, DOI 10.1016/S0145-2126(97)00061-1; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; HONG Z, 1992, J PHARM PHARMACOL, V44, P1023, DOI 10.1111/j.2042-7158.1992.tb07086.x; Javle M, 2011, Ther Adv Med Oncol, V3, P257, DOI 10.1177/1758834011417039; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; Kameoka M, 2004, J VIROL, V78, P8931, DOI 10.1128/JVI.78.16.8931-8934.2004; Kawazoe N, 1999, J BIOCHEM-TOKYO, V126, P278, DOI 10.1093/oxfordjournals.jbchem.a022446; Krishnakumar R, 2010, MOL CELL, V39, P8, DOI 10.1016/j.molcel.2010.06.017; Li D, 2009, ANTI-CANCER DRUG, V20, P59, DOI 10.1097/CAD.0b013e3283160fd6; Lomenick B, 2011, ACS CHEM BIOL, V6, P34, DOI 10.1021/cb100294v; Lu SY, 2011, J COMPUT CHEM, V32, P1907, DOI 10.1002/jcc.21775; Ma HY, 2009, J NANJING U TRADITIO, V25, P370; Marchetti C, 2012, EXPERT OPIN INV DRUG, V21, P1575, DOI 10.1517/13543784.2012.707189; Meng ZQ, 2009, CANCER-AM CANCER SOC, V115, P5309, DOI 10.1002/cncr.24602; Meyer-Ficca ML, 2005, INT J BIOCHEM CELL B, V37, P920, DOI 10.1016/j.biocel.2004.09.011; MORISHITA S, 1986, FOLIA PHARMACOL JPN, V87, P361, DOI 10.1254/fpj.87.361; Neri P, 2011, BLOOD, V118, P6368, DOI 10.1182/blood-2011-06-363911; Pastor N, 2003, DNA REPAIR, V2, P1353, DOI 10.1016/j.dnarep.2003.08.001; Penning TD, 2010, J MED CHEM, V53, P3142, DOI 10.1021/jm901775y; Petruccelli LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020987; Premkumar DR, 2013, MOL CARCINOGEN, V52, P118, DOI 10.1002/mc.21835; Pyndiah S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001556; Qi FH, 2010, J ETHNOPHARMACOL, V128, P654, DOI 10.1016/j.jep.2010.02.022; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Takai N, 2008, INT J MOL MED, V21, P637; Takai N, 2012, ASIAN PAC J CANCER P, V13, P399, DOI 10.7314/APJCP.2012.13.1.399; Watabe M, 1997, CELL GROWTH DIFFER, V8, P871; WIELCKENS K, 1983, J BIOL CHEM, V258, P4098; Yeh JY, 2003, PROSTATE, V54, P112, DOI 10.1002/pros.10172; Zhang JX, 2012, HEPATOLOGY, V55, P1840, DOI 10.1002/hep.25566; ZHANG L, 1991, BIOCHEM BIOPH RES CO, V178, P686, DOI 10.1016/0006-291X(91)90162-Z; ZHANG LS, 1992, CANCER RES, V52, P4634; Zhao Y, 2009, J NAT PROD, V72, P988, DOI 10.1021/np9000366; Zhu ZT, 2012, INT J MOL SCI, V13, P2025, DOI 10.3390/ijms13022025	44	11	12	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2013	8	6							e66130	10.1371/journal.pone.0066130	http://dx.doi.org/10.1371/journal.pone.0066130			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173QU	23762475	gold, Green Published, Green Submitted			2023-01-03	WOS:000321094800092
J	Shimizu, N; Chikahisa, S; Nishi, Y; Harada, S; Iwaki, Y; Fujihara, H; Kitaoka, K; Shiuchi, T; Sei, H				Shimizu, Noriyuki; Chikahisa, Sachiko; Nishi, Yuina; Harada, Saki; Iwaki, Yohei; Fujihara, Hiroaki; Kitaoka, Kazuyoshi; Shiuchi, Tetsuya; Sei, Hiroyoshi			Maternal Dietary Restriction Alters Offspring's Sleep Homeostasis	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; PPAR-ALPHA; FOOD-INTAKE; AMP-KINASE; SYNTHASE; TRANSCRIPTION; METABOLISM; ADENOSINE; NUTRIENT; ENZYME	Nutritional state in the gestation period influences fetal growth and development. We hypothesized that undernutrition during gestation would affect offspring sleep architecture and/or homeostasis. Pregnant female mice were assigned to either control (fed ad libitum; AD) or 50% dietary restriction (DR) groups from gestation day 12 to parturition. After parturition, dams were fed AD chow. After weaning, the pups were also fed AD into adulthood. At adulthood (aged 8-9 weeks), we carried out sleep recordings. Although offspring mice displayed a significantly reduced body weight at birth, their weights recovered three days after birth. Enhancement of electroencephalogram (EEG) slow wave activity (SWA) during non-rapid eye movement (NREM) sleep was observed in the DR mice over a 24-hour period without changing the diurnal pattern or amounts of wake, NREM, or rapid eye movement (REM) sleep. In addition, DR mice also displayed an enhancement of EEG-SWA rebound after a 6-hour sleep deprivation and a higher threshold for waking in the face of external stimuli. DR adult offspring mice exhibited small but significant increases in the expression of hypothalamic peroxisome proliferator-activated receptor alpha (Ppar alpha) and brain-specific carnitine palmitoyltransferase 1 (Cpt1c) mRNA, two genes involved in lipid metabolism. Undernutrition during pregnancy may influence sleep homeostasis, with offspring exhibiting greater sleep pressure.	[Shimizu, Noriyuki; Chikahisa, Sachiko; Nishi, Yuina; Harada, Saki; Iwaki, Yohei; Fujihara, Hiroaki; Kitaoka, Kazuyoshi; Shiuchi, Tetsuya; Sei, Hiroyoshi] Univ Tokushima, Dept Integrat Physiol, Inst Hlth Biosci, Grad Sch, Tokushima 770, Japan; [Nishi, Yuina; Harada, Saki] Univ Tokushima, Student Lab, Fac Med, Tokushima 770, Japan	Tokushima University; Tokushima University	Sei, H (corresponding author), Univ Tokushima, Dept Integrat Physiol, Inst Hlth Biosci, Grad Sch, Tokushima 770, Japan.	sei@tokushima-u.ac.jp	Shiuchi, Tetsuya/AAG-7620-2020	Shiuchi, Tetsuya/0000-0002-3027-5465	Japan Society for the Promotion of Science (JSPS) [332 (22590224), 2373070600, 333]	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grants-in-Aid for Scientific Research (C) 332 (22590224) to H. S. and Grants-in-Aid for Young Scientists (B) (2373070600) to S. C. 333 from Japan Society for the Promotion of Science (JSPS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alamy M, 2012, NEUROSCI BIOBEHAV R, V36, P1463, DOI 10.1016/j.neubiorev.2012.03.009; Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200; Bensinger SJ, 2008, NATURE, V454, P470, DOI 10.1038/nature07202; Bjorness TE, 2009, CURR NEUROPHARMACOL, V7, P238, DOI 10.2174/157015909789152182; Borbely AA, 2001, ARCH ITAL BIOL, V139, P53; Brown RE, 2012, PHYSIOL REV, V92, P1087, DOI 10.1152/physrev.00032.2011; Bushey D, 2011, SCIENCE, V332, P1576, DOI 10.1126/science.1202839; Chakravarthy MV, 2007, J CLIN INVEST, V117, P2539, DOI 10.1172/JCI31183; Chikahisa S, 2008, ENDOCRINOLOGY, V149, P5262, DOI 10.1210/en.2008-0285; Chikahisa S, 2009, NEUROPHARMACOLOGY, V57, P369, DOI 10.1016/j.neuropharm.2009.07.015; DAAN S, 1984, AM J PHYSIOL, V246, pR161, DOI 10.1152/ajpregu.1984.246.2.R161; Dworak M, 2010, J NEUROSCI, V30, P9007, DOI 10.1523/JNEUROSCI.1423-10.2010; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; Huang ZL, 2007, CURR OPIN PHARMACOL, V7, P33, DOI 10.1016/j.coph.2006.09.004; Huang ZL, 2005, NAT NEUROSCI, V8, P858, DOI 10.1038/nn1491; Isganaitis E, 2009, DIABETES, V58, P1192, DOI 10.2337/db08-1266; Jimenez-Chillaron JC, 2006, DIABETOLOGIA, V49, P1974, DOI 10.1007/s00125-006-0311-7; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kostiuk MA, 2010, FASEB J, V24, P1914, DOI 10.1096/fj.09-149765; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Maret S, 2005, SCIENCE, V310, P111, DOI 10.1126/science.1117623; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Minokoshi Y, 2008, NUTRITION, V24, P786, DOI 10.1016/j.nut.2008.06.002; Porkka-Heiskanen T, 2011, SLEEP MED REV, V15, P123, DOI 10.1016/j.smrv.2010.06.005; Poulsen LL, 2012, SEMIN CELL DEV BIOL, V23, P631, DOI 10.1016/j.semcdb.2012.01.003; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Stenberg D, 2007, CELL MOL LIFE SCI, V64, P1187, DOI 10.1007/s00018-007-6530-3; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Tononi Giulio, 2009, J Clin Sleep Med, V5, pS16; Varga T, 2011, BBA-MOL BASIS DIS, V1812, P1007, DOI 10.1016/j.bbadis.2011.02.014; Wigren HKM, 2009, NEUROREPORT, V20, P97, DOI 10.1097/WNR.0b013e32831af03d	35	6	6	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2013	8	5							e64263	10.1371/journal.pone.0064263	http://dx.doi.org/10.1371/journal.pone.0064263			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	156DC	23741310	gold, Green Published, Green Submitted			2023-01-03	WOS:000319799900022
J	Njuguna, C; Orrell, C; Kaplan, R; Bekker, LG; Wood, R; Lawn, SD				Njuguna, Christine; Orrell, Catherine; Kaplan, Richard; Bekker, Linda-Gail; Wood, Robin; Lawn, Stephen D.			Rates of Switching Antiretroviral Drugs in a Primary Care Service in South Africa before and after Introduction of Tenofovir	PLOS ONE			English	Article							PROGRAMMATIC OUTCOMES; THERAPY; SAFETY; ADULTS; COMBINATION; TOXICITY; EFFICACY; DF	Introduction: Antiretroviral changes (single drug substitutions and regimen switches) limit treatment options and introduce challenges such as increased cost, monitoring and adherence difficulties. Patterns of drug substitutions and regimen switches from stavudine (d4T) and zidovudine (AZT) regimens have been well described but data on tenofovir (TDF) are more limited. This study describes the patterns and risk factors for drug changes of these antiretroviral drugs in adults. Method: This retrospective cohort study included HIV positive, antiretroviral treatment (ART) naive adults aged >= 18 years who started ART with two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor. Follow-up was censored at first drug change and analysis focused on NRTI changes only. Results: Between September 2002 and April 2011, 5095 adults initiated ART in Gugulethu. This comprised 948 subjects on TDF, 3438 on d4T and 709 subjects on AZT. Virological suppression rates at 1 year, regimen switching due to virological failure and overall losses to the programme were similar across the three groups. TDF had the lowest incidence rate of drug substitutions (2.6 per 100 P/Ys) compared to 17.9 for d4T and 8.5 per 100 P/Ys for AZT. Adverse drug reactions (ADRs) accounted for the majority of drug substitutions of d4T. Multivariate analysis showed that increasing age, female sex and d4T exposure were associated with increased hazard of drug substitution due to ADRs. Conversely, TDF exposure was associated with a substantially lower risk of substitution (adjusted hazards ratio 0.38; 95% CI 0.20-0.72). Conclusion: Regimen switches and virological suppression were similar for patients exposed to TDF, d4T and AZT, suggesting all regimens were equally effective. However, TDF was better tolerated with a substantially lower rate of drug substitutions due to ADRs.	[Njuguna, Christine; Orrell, Catherine; Kaplan, Richard; Bekker, Linda-Gail; Wood, Robin; Lawn, Stephen D.] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa; [Lawn, Stephen D.] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1E 7HT, England	University of Cape Town; University of London; London School of Hygiene & Tropical Medicine	Njuguna, C (corresponding author), Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa.	christine_njuguna@yahoo.co.uk	Bekker, Linda-Gail/AAZ-8929-2020; Orrell, Catherine/AAF-3405-2019	Orrell, Catherine/0000-0003-1134-7475; BEKKER, LINDA-GAIL/0000-0002-0755-4386; Kaplan, Richard/0000-0003-1565-4704	Fogarty International Grant [5D43TW007115-06]; Wellcome Trust; FOGARTY INTERNATIONAL CENTER [D43TW007115] Funding Source: NIH RePORTER	Fogarty International Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Wellcome Trust(Wellcome TrustEuropean Commission); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	Funding was provided by Fogarty International Grant, grant number 5D43TW007115-06. Dr. Stephen D. Lawn is funded by the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bendavid E, 2011, AIDS, V25, P211, DOI 10.1097/QAD.0b013e328340fdf8; Boulle A, 2007, ANTIVIR THER, V12, P753; BOYLE A, 2012, 11 INT C DRUG THER H; BRENNAN A, 2013, CROI C ATL; BRENNAN A, 2012, IMPACT CHANGE STAVUD; Bygrave H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017609; Cassetti I, 2007, HIV CLIN TRIALS, V8, P164, DOI 10.1310/hct0803-164; Castelnuovo B, 2011, JAIDS-J ACQ IMM DEF, V56, P59, DOI 10.1097/QAI.0b013e3181f5bd03; Chi BH, 2010, JAIDS-J ACQ IMM DEF, V54, P63, DOI 10.1097/QAI.0b013e3181c6c65c; Davidson I, 2010, ANTIVIR RES, V86, P227, DOI 10.1016/j.antiviral.2010.03.001; *DESM TUT HIV FDN, 2011, ANN REV 2010 2011 DE; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; Gupta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034156; Hawkins C, 2007, JAIDS-J ACQ IMM DEF, V45, P304; Landier J, 2011, AIDS CARE, V23, P75, DOI 10.1080/09540121.2010.498867; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; National Department of Health, 2004, NAT ANT TREATM GUID; Nelson MR, 2007, AIDS, V21, P1273, DOI 10.1097/QAD.0b013e3280b07b33; Nglazi MD, 2011, JAIDS-J ACQ IMM DEF, V56, pE1, DOI 10.1097/QAI.0b013e3181ff0bdc; Orrell C, 2007, ANTIVIR THER, V12, P83; Prosperi MCF, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-296; South African National Department of Health, 2010, S AFR ANT TREATM GUI; Statistics South Africa, 2010, MID POP EST; Subbaraman R, 2007, CLIN INFECT DIS, V45, P1093, DOI 10.1086/521150; TAKUVA S, 2012, J ANTIVIR ANTIRETROV, V4; WHO, 2010, ANT THER HIV INF AD	26	25	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2013	8	5							e63596	10.1371/journal.pone.0063596	http://dx.doi.org/10.1371/journal.pone.0063596			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163UP	23717451	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000320362700037
J	Gossett, DR; Kiley, JW; Hammond, C				Gossett, Dana R.; Kiley, Jessica W.; Hammond, Cassing			Contraception Is a Fundamental Primary Care Service	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNINTENDED PREGNANCY; UNITED-STATES		[Gossett, Dana R.; Kiley, Jessica W.; Hammond, Cassing] Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; [Kiley, Jessica W.; Hammond, Cassing] Northwestern Univ, Feinberg Sch Med, Sect Family Planning, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Gossett, DR (corresponding author), Northwestern Univ, Feinberg Sch Med, 680 N Lake Shore Dr,Ste 1015, Chicago, IL 60611 USA.	dana.gossett@nmff.org	Gossett, Dana/AAI-2929-2021	Gossett, Dana/0000-0002-7306-3606				Berg CJ, 2010, OBSTET GYNECOL, V116, P1302, DOI 10.1097/AOG.0b013e3181fdfb11; Finer LB, 2011, CONTRACEPTION, V84, P478, DOI 10.1016/j.contraception.2011.07.013; Frost JJ, 2013, CONTRACEPTION, V87, P465, DOI 10.1016/j.contraception.2012.08.012; HealthyPeople.gov, 2020 TOPICS AND OBJE; Jones R.K., 2011, COUNTERING CONVENTIO; Monea E, 2011, PERSPECT SEX REPRO H, V43, P88, DOI 10.1363/4308811; Peipert JF, 2012, OBSTET GYNECOL, V120, P1291, DOI [10.1097/AOG.0b013e318273eb56, http://10.1097/AOG.0b013e318273eb56]; Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x; Trussell J, 2006, CONTRACEPTION, V73, P437, DOI 10.1016/j.contraception.2006.01.008; US Dept of Health and Human Services Health Resources and Services Administration, WOMENS PREVENTIVE SE	10	9	9	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	2013	309	19					1997	1998		10.1001/jama.2013.4262	http://dx.doi.org/10.1001/jama.2013.4262			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	143GQ	23677310				2023-01-03	WOS:000318855500019
J	Zimmer, EA; Welie, JVM; Rendell, MS				Zimmer, Eric A.; Welie, Jos V. M.; Rendell, Marc S.			Contraceptives and the Law A View From a Catholic Medical Institution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VENOUS THROMBOEMBOLISM; ORAL-CONTRACEPTIVES; HEALTH		Creighton Univ, Sch Med, Omaha, NE USA; Creighton Ctr Hlth Policy Eth, Omaha, NE USA	Creighton University	Rendell, MS (corresponding author), Creighton Diabet Ctr, 601 N 30th St, Omaha, NE 68131 USA.	Rendell@asndi.com						[Anonymous], FAST FACTS CAR PROV; Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6; Jost TS, 2013, NEW ENGL J MED, V368, P4, DOI 10.1056/NEJMp1214605; Paul VI, 1968, HUMANAE VITAE ENCYCL; Pear Robert, NY TIMES; Samuelsson E, 2005, EUR J EPIDEMIOL, V20, P509, DOI 10.1007/s10654-005-4266-7; United States Conference of Catholic Bishops, 2009, ETH REL DIR CATH HLT, V5th; Wu O, 2005, THROMB HAEMOSTASIS, V94, P17, DOI 10.1160/TH04-11-0759	8	4	4	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 15	2013	309	19					1999	2000		10.1001/jama.2013.3730	http://dx.doi.org/10.1001/jama.2013.3730			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	143GQ	23677311				2023-01-03	WOS:000318855500020
J	Kim, B; Fatayer, H; Hanby, AM; Horgan, K; Perry, SL; Valleley, EMA; Verghese, ET; Williams, BJ; Thorne, JL; Hughes, TA				Kim, Baek; Fatayer, Hiba; Hanby, Andrew M.; Horgan, Kieran; Perry, Sarah L.; Valleley, Elizabeth M. A.; Verghese, Eldo T.; Williams, Bethany J.; Thorne, James L.; Hughes, Thomas A.			Neoadjuvant Chemotherapy Induces Expression Levels of Breast Cancer Resistance Protein That Predict Disease-Free Survival in Breast Cancer	PLOS ONE			English	Article							P-GLYCOPROTEIN EXPRESSION; MULTIDRUG-RESISTANCE; SYSTEMIC THERAPY; ABC TRANSPORTERS; DRUG-RESISTANCE; GENE-EXPRESSION; CARCINOMA; MDR1; EFFLUX; MRP1	Three main xenobiotic efflux pumps have been implicated in modulating breast cancer chemotherapy responses. These are P-glycoprotein (Pgp), Multidrug Resistance-associated Protein 1 (MRP1), and Breast Cancer Resistance Protein (BCRP). We investigated expression of these proteins in breast cancers before and after neoadjuvant chemotherapy (NAC) to determine whether their levels define response to NAC or subsequent survival. Formalin-fixed paraffin-embedded tissues were collected representing matched pairs of core biopsy (pre-NAC) and surgical specimen (post-NAC) from 45 patients with invasive ductal carcinomas. NAC regimes were anthracyclines +/- taxanes. Immunohistochemistry was performed for Pgp, MRP1 and BCRP and expression was quantified objectively using computer-aided scoring. Pgp and MRP1 were significantly up-regulated after exposure to NAC (Wilcoxon signed-rank p = 0.0024 and p < 0.0001), while BCRP showed more variation in response to NAC, with frequent up- (59% of cases) and down-regulation (41%) contributing to a lack of significant difference overall. Pre-NAC expression of all markers, and post-NAC expression of Pgp and MRP1 did not correlate with NAC response or with disease-free survival (DFS). Post-NAC expression of BCRP did not correlate with NAC response, but correlated significantly with DFS (Log rank p = 0.007), with longer DFS in patients with low post-NAC BCRP expression. In multivariate Cox regression analyses, post-NAC BCRP expression levels proved to predict DFS independently of standard prognostic factors, with high expression associated with a hazard ratio of 4.04 (95% confidence interval 1.3-12.2; p = 0.013). We conclude that NAC-induced expression levels of BCRP predict survival after NAC for breast cancer, while Pgp and MRP1 expression have little predictive value.	[Kim, Baek; Perry, Sarah L.; Valleley, Elizabeth M. A.; Thorne, James L.; Hughes, Thomas A.] Univ Leeds, Leeds Inst Mol Med, Leeds, W Yorkshire, England; [Kim, Baek; Fatayer, Hiba; Horgan, Kieran] Leeds Gen Infirm, Dept Breast Surg, Leeds, W Yorkshire, England; [Hanby, Andrew M.; Verghese, Eldo T.; Williams, Bethany J.] St James Univ Hosp, Dept Histopathol, Leeds LS9 7TF, W Yorkshire, England	University of Leeds; Leeds General Infirmary; University of Leeds; Saint James's University Hospital	Hughes, TA (corresponding author), Univ Leeds, Leeds Inst Mol Med, Leeds, W Yorkshire, England.	t.hughes@leeds.ac.uk	horgan, kieran/I-3892-2016; Horgan, Kieran/AAM-1280-2020; Hughes, Thomas/M-7063-2019; thorne, james/R-9878-2019; Hughes, Thomas A/O-8031-2015	Hughes, Thomas A/0000-0003-1169-3386; Kim, Baek/0000-0001-9759-7533; Williams, Bethany/0000-0002-6641-5503; Thorne, James/0000-0002-3037-8528	Breast Cancer Research Action Group; Leeds Teaching Hospitals Charitable Foundation; Yorkshire Cancer Research; Medical Research Council; Medical Research Council [G0902032] Funding Source: researchfish; MRC [G0902032] Funding Source: UKRI	Breast Cancer Research Action Group; Leeds Teaching Hospitals Charitable Foundation; Yorkshire Cancer Research; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funding for this work was received from the Breast Cancer Research Action Group (http://www.bcrag.org/), the Leeds Teaching Hospitals Charitable Foundation (http://www.leedshospitalsfundraising.org.uk), Yorkshire Cancer Research (http://www.yorkshirecancerresearch.org.uk), and the Medical Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amiri-Kordestani L, 2012, DRUG RESIST UPDATE, V15, P50, DOI 10.1016/j.drup.2012.02.002; Aomatsu N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045865; Bark H, 2008, FEBS LETT, V582, P2595, DOI 10.1016/j.febslet.2008.06.036; Barry WT, 2010, J CLIN ONCOL, V28, P2198, DOI 10.1200/JCO.2009.26.7245; Burger H, 2003, CLIN CANCER RES, V9, P827; Chintamani, 2005, World J Surg Oncol, V3, P61; Clarke R, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.09.009; Darb-Esfahani S, 2012, BRIT J CANC; Dexter DW, 1998, CLIN CANCER RES, V4, P1533; Doyle LA, 2003, ONCOGENE, V22, P7340, DOI 10.1038/sj.onc.1206938; Filipits M, 1996, CLIN CANCER RES, V2, P1231; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Hanrahan EO, 2005, EXPERT OPIN PHARMACO, V6, P1477, DOI 10.1517/14656566.6.9.1477; Kaufmann M, 2012, ANN SURG ONCOL, V19, P1508, DOI 10.1245/s10434-011-2108-2; Larkin A, 2004, INT J CANCER, V112, P286, DOI 10.1002/ijc.20369; Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411; Leonessa F, 2003, ENDOCR-RELAT CANCER, V10, P43, DOI 10.1677/erc.0.0100043; Marinovich ML, 2012, BREAST, V21, P669, DOI 10.1016/j.breast.2012.07.006; Mechetner E, 1998, CLIN CANCER RES, V4, P389; MECHETNER EB, 1992, P NATL ACAD SCI USA, V89, P5824, DOI 10.1073/pnas.89.13.5824; Mieog JSD, 2007, BRIT J SURG, V94, P1189, DOI 10.1002/bjs.5894; Mo Wei, 2012, Int J Biochem Mol Biol, V3, P1; Morrow CS, 2006, MOL PHARMACOL, V69, P1499, DOI 10.1124/mol.105.017988; Moureau-Zabotto L, 2006, BRIT J CANCER, V94, P473, DOI 10.1038/sj.bjc.6602958; Nakanishi T, 2012, CHIN J CANCER, V31, P73, DOI 10.5732/cjc.011.10320; Rivera E, 2010, BREAST J, V16, P252, DOI 10.1111/j.1524-4741.2009.00896.x; Rudas M, 2003, BREAST CANCER RES TR, V81, P149, DOI 10.1023/A:1025751631115; Shukla S, 2011, CURR DRUG TARGETS, V12, P621, DOI 10.2174/138945011795378540; Tamura A, 2007, CANCER SCI, V98, P231, DOI 10.1111/j.1349-7006.2006.00371.x; Tanei T, 2011, EJSO-EUR J SURG ONC, V37, P155, DOI 10.1016/j.ejso.2010.10.009; Tsukamoto, 1997, Breast Cancer, V4, P259, DOI 10.1007/BF02966518; van Nes JGH, 2012, BREAST CANCER RES TR, V133, P49, DOI 10.1007/s10549-011-1684-y; Xiang L, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-90	33	30	31	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2013	8	5							e62766	10.1371/journal.pone.0062766	http://dx.doi.org/10.1371/journal.pone.0062766			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175AF	23658771	Green Published, gold, Green Submitted			2023-01-03	WOS:000321200500038
J	Sartain, K				Sartain, Kate			An outstanding example of hospital care for patients with dementia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												katesartain@btinternet.com			Department of Health [RP-PG-0407-10147] Funding Source: Medline; National Institute for Health Research [RP-PG-0407-10147] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))			0	0	0	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 19	2013	346								f2513	10.1136/bmj.f2513	http://dx.doi.org/10.1136/bmj.f2513			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131BG	23604085				2023-01-03	WOS:000317965000011
J	Perez-Lozano, ML; Sandoval, P; Rynne-Vidal, A; Aguilera, A; Jimenez-Heffernan, JA; Albar-Vizcaino, P; Majano, PL; Sanchez-Tomero, JA; Selgas, R; Lopez-Cabrera, M				Luisa Perez-Lozano, Maria; Sandoval, Pilar; Rynne-Vidal, Angela; Aguilera, Abelardo; Antonio Jimenez-Heffernan, Jose; Albar-Vizcaino, Patricia; Majano, Pedro L.; Antonio Sanchez-Tomero, Jose; Selgas, Rafael; Lopez-Cabrera, Manuel			Functional Relevance of the Switch of VEGF Receptors/Co-Receptors during Peritoneal Dialysis-Induced Mesothelial to Mesenchymal Transition	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; SOLUTE TRANSPORT RATE; EX-VIVO; NEUROPILIN-1 OVEREXPRESSION; EXTRACELLULAR-MATRIX; MEMBRANE FAILURE; PROGENITOR CELLS; SEMAPHORIN-III; INDUCED DAMAGE; CANCER-CELLS	Vascular endothelial growth factor (VEGF) is up-regulated during mesothelial to mesenchymal transition (MMT) and has been associated with peritoneal membrane dysfunction in peritoneal dialysis (PD) patients. It has been shown that normal and malignant mesothelial cells (MCs) express VEGF receptors (VEGFRs) and co-receptors and that VEGF is an autocrine growth factor for mesothelioma. Hence, we evaluated the expression patterns and the functional relevance of the VEGF/VEGFRs/co-receptors axis during the mesenchymal conversion of MCs induced by peritoneal dialysis. Omentum-derived MCs treated with TGF-beta 1 plus IL-1 beta (in vitro MMT) and PD effluent-derived MCs with non-epithelioid phenotype (ex vivo MMT) showed down-regulated expression of the two main receptors Flt-1/VEGFR-1 and KDR/VEGFR-2, whereas the coreceptor neuropilin-1 (Nrp-1) was up-regulated. The expression of the Nrp-1 ligand semaphorin-3A (Sema-3A), a functional VEGF competitor, was repressed throughout the MMT process. These expression pattern changes were accompanied by a reduction of the proliferation capacity and by a parallel induction of the invasive capacity of MCs that had undergone an in vitro or ex vivo MMT. Treatment with neutralizing anti-VEGF or anti-Nrp-1 antibodies showed that these molecules played a relevant role in cellular proliferation only in naive omentum-derived MCs. Conversely, treatment with these blocking antibodies, as well as with recombinant Sema-3A, indicated that the switched VEGF/VEGFRs/co-receptors axis drove the enhanced invasion capacity of MCs undergoing MMT. In conclusion, the expression patterns of VEGFRs and co-receptors change in MCs during MMT, which in turn would determine their behaviour in terms of proliferation and invasion in response to VEGF.	[Luisa Perez-Lozano, Maria; Sandoval, Pilar; Rynne-Vidal, Angela; Lopez-Cabrera, Manuel] CSIC UAM, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [Aguilera, Abelardo; Albar-Vizcaino, Patricia; Majano, Pedro L.; Antonio Sanchez-Tomero, Jose] Hosp Univ Princesa, Unidad Biol Mol, Inst Invest Sanitaria Princesa IP, Madrid, Spain; [Aguilera, Abelardo; Albar-Vizcaino, Patricia; Majano, Pedro L.; Antonio Sanchez-Tomero, Jose; Lopez-Cabrera, Manuel] Hosp Univ Princesa, Serv Nefrol, Inst Invest Sanitaria Princesa IP, Madrid, Spain; [Antonio Jimenez-Heffernan, Jose] Hosp Univ Princesa, Serv Anat Patol, Inst Invest Sanitaria Princesa IP, Madrid, Spain; [Selgas, Rafael] Hosp Univ La Paz, Serv Nefrol, Inst Invest Sanitaria la Paz IdiPAZ, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Hospital Universitario La Paz	Lopez-Cabrera, M (corresponding author), CSIC UAM, Ctr Biol Mol Severo Ochoa, Madrid, Spain.	mlcabrera@cbm.uam.es	Cabrera, Manuel López/AAA-5463-2019; SANCHEZ TOMERO, JOSE ANTONIO/Q-9346-2017; Sandoval, Pilar/GVS-6463-2022; Lozano, Maria Luisa Pérez/J-9840-2017	Sandoval, Pilar/0000-0002-5893-7037; Lozano, Maria Luisa Pérez/0000-0002-6473-3823; Lopez Cabrera, Manuel/0000-0002-0976-9719; Rynne-Vidal, Angela/0000-0002-6316-530X; Majano, Pedro Lorenzo/0000-0002-5495-1413	Ministerio de Economia y Competitividad [SAF2010-21249]; Comunidad Autonoma de Madrid [S2010/BMD-2321]; Fondo de Investigaciones Sanitarias [PI 09/0776]; REDinREN, Fondos FEDER, EU [RETICS 06/0016]	Ministerio de Economia y Competitividad(Spanish Government); Comunidad Autonoma de Madrid(Comunidad de Madrid); Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); REDinREN, Fondos FEDER, EU	This work was supported by grant SAF2010-21249 from the "Ministerio de Economia y Competitividad'' to M.L.C. and by grant S2010/BMD-2321 from "Comunidad Autonoma de Madrid'' to M.L.C. and R.S. This work was also partially supported by grants PI 09/0776 from "Fondo de Investigaciones Sanitarias'' to A.A., and RETICS 06/0016 (REDinREN, Fondos FEDER, EU) to R.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Appleton BA, 2007, EMBO J, V26, P4902, DOI 10.1038/sj.emboj.7601906; Aroeira LS, 2005, AM J KIDNEY DIS, V46, P938, DOI 10.1053/j.ajkd.2005.08.011; Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Aroeira LS, 2009, J AM SOC NEPHROL, V20, P582, DOI 10.1681/ASN.2008020211; Bajo MA, 2011, NEPHROL DIAL TRANSPL, V26, P282, DOI 10.1093/ndt/gfq357; Baba T, 2007, GYNECOL ONCOL, V105, P703, DOI 10.1016/j.ygyno.2007.02.005; Bachelder RE, 2002, CANCER RES, V62, P7203; Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagri A, 2009, CLIN CANCER RES, V15, P1860, DOI 10.1158/1078-0432.CCR-08-0563; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Berge M, 2011, J HEPATOL, V55, P866, DOI 10.1016/j.jhep.2011.01.033; Boulanger E, 2007, KIDNEY INT, V71, P126, DOI 10.1038/sj.ki.5002016; Cai HB, 1999, J NEUROSCI, V19, P6519; Cariboni A, 2011, DEVELOPMENT, V138, P3723, DOI 10.1242/dev.063362; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Catalano A, 2004, FASEB J, V18, P1740, DOI 10.1096/fj.04-2258fje; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; del Peso G, 2008, KIDNEY INT, V73, pS26, DOI 10.1038/sj.ki.5002598; Ding HX, 2011, CELL BIOCHEM BIOPHYS, V59, P39, DOI 10.1007/s12013-010-9109-9; Fernandez-Perpen A, 2012, PERITON DIALYSIS INT, V32, P292, DOI 10.3747/pdi.2010.00315; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Fukasawa M, 2007, CANCER BIOL THER, V6, P1173; Glinka Y, 2008, J LEUKOCYTE BIOL, V84, P302, DOI 10.1189/jlb.0208090; Glinka Y, 2011, CARCINOGENESIS, V32, P613, DOI 10.1093/carcin/bgq281; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; Ha H, 2002, PERITON DIALYSIS INT, V22, P171; Hansel DE, 2004, AM J SURG PATHOL, V28, P347, DOI 10.1097/00000478-200403000-00007; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HodacPannekeet MM, 1997, PERITON DIALYSIS INT, V17, P144; Jubb AM, 2012, J PATHOL, V226, P50, DOI 10.1002/path.2989; Kihm LP, 2011, J AM SOC NEPHROL, V22, P914, DOI 10.1681/ASN.2010070750; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Krediet RT, 2000, PERITON DIALYSIS INT, V20, pS19; Kurschat P, 2006, J BIOL CHEM, V281, P2721, DOI 10.1074/jbc.M507860200; Lai KN, 2000, AM J KIDNEY DIS, V35, P644, DOI 10.1016/S0272-6386(00)70011-4; Latil A, 2000, INT J CANCER, V89, P167, DOI 10.1002/(SICI)1097-0215(20000320)89:2<167::AID-IJC11>3.0.CO;2-9; Li M, 2004, CANCER-AM CANCER SOC, V101, P2341, DOI 10.1002/cncr.20634; Liang WC, 2007, J MOL BIOL, V366, P815, DOI 10.1016/j.jmb.2006.11.021; Liu WB, 2005, CYTOKINE, V32, P206, DOI 10.1016/j.cyto.2005.09.009; Lopez-Cabrera M, 2006, PERITON DIALYSIS INT, V26, P26; Loureiro J, 2011, J AM SOC NEPHROL, V22, P1682, DOI 10.1681/ASN.2010111197; Loureiro J, 2010, NEPHROL DIAL TRANSPL, V25, P1098, DOI 10.1093/ndt/gfp618; Margetts PJ, 2003, PERITON DIALYSIS INT, V23, P530; Matsushita A, 2007, CANCER RES, V67, P10309, DOI 10.1158/0008-5472.CAN-07-3256; Medici D, NATURE MED, V16, P1400; Mizutani M, 2010, AM J PHYSIOL-RENAL, V298, pF721, DOI 10.1152/ajprenal.00368.2009; Murga M, 2005, BLOOD, V105, P1992, DOI 10.1182/blood-2004-07-2598; Narazaki M, 2006, BLOOD, V107, P3892, DOI 10.1182/blood-2005-10-4113; Numata M, 2003, PERITON DIALYSIS INT, V23, P116; Pallaoro A, 2011, P NATL ACAD SCI USA, V108, P16559, DOI 10.1073/pnas.1109490108; Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; Paruchuri S, 2006, CIRC RES, V99, P861, DOI 10.1161/01.RES.0000245188.41002.2c; Pecoits-Filho R, 2002, NEPHROL DIAL TRANSPL, V17, P1480, DOI 10.1093/ndt/17.8.1480; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; Sandoval P, 2010, LAB INVEST, V90, P1517, DOI 10.1038/labinvest.2010.111; SELGAS R, 1994, AM J KIDNEY DIS, V23, P64, DOI 10.1016/S0272-6386(12)80814-6; Selgas R, 2000, PERITON DIALYSIS INT, V20, P798; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Strippoli R, 2010, J CELL SCI, V123, P4321, DOI 10.1242/jcs.071647; Strippoli R, 2008, DIS MODEL MECH, V1, P264, DOI 10.1242/dmm.001321; STYLIANOU E, 1990, KIDNEY INT, V37, P1563, DOI 10.1038/ki.1990.150; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wang L, 2003, J BIOL CHEM, V278, P48848, DOI 10.1074/jbc.M310047200; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Williams JD, 2002, J AM SOC NEPHROL, V13, P470, DOI 10.1681/ASN.V132470; Yamada Y, 2003, BLOOD, V101, P1801, DOI 10.1182/blood-2002-01-0119; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yang WS, 1999, PERITON DIALYSIS INT, V19, P211; Yu MA, 2009, J AM SOC NEPHROL, V20, P567, DOI 10.1681/ASN.2008040424; Zweers MM, 1999, J LAB CLIN MED, V134, P124, DOI 10.1016/S0022-2143(99)90116-6	75	32	32	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e60776	10.1371/journal.pone.0060776	http://dx.doi.org/10.1371/journal.pone.0060776			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23585849	Green Published, gold, Green Submitted			2023-01-03	WOS:000317909600046
J	Grinsztejn, B; Luz, PM; Pacheco, AG; Santos, DVG; Velasque, L; Moreira, RI; Guimaraes, MRC; Nunes, EOP; Lemos, AS; Ribeiro, SR; Campos, DP; Vitoria, MAA; Veloso, VG				Grinsztejn, Beatriz; Luz, Paula M.; Pacheco, Antonio G.; Santos, Desiree V. G.; Velasque, Luciane; Moreira, Ronaldo I.; Guimaraes, Maria Regina C.; Nunes, Esteva O. P.; Lemos, Alberto S.; Ribeiro, Sayonara R.; Campos, Dayse P.; Vitoria, Marco A. A.; Veloso, Valdilea G.			Changing Mortality Profile among HIV-Infected Patients in Rio de Janeiro, Brazil: Shifting from AIDS to Non-AIDS Related Conditions in the HAART Era	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1-INFECTED PATIENTS; COLLABORATIVE ANALYSIS; CLINICAL CARE; IMMUNE STATUS; DEATH; RISK; PEOPLE; CANCER	Introduction: We describe temporal trends in the mortality rates and factors associated with AIDS and non-AIDS related mortality at the Evandro Chagas Clinical Research Institute (IPEC), Oswaldo Cruz Foundation (FIOCRUZ). Methods: Adult patients enrolling from 1986 through 2009 with a minimum follow up of 60 days were included. Vital status was exhaustively checked using patients' medical charts, through active contact with individuals and family members and by linkage with the Rio de Janeiro Mortality database using a previously validated algorithm. The CoDe protocol was used to establish the cause of death. Extended Cox proportional hazards models were used for multivariate modeling. Results: A total of 3530 individuals met the inclusion criteria, out of which 868 (24.6%) deceased; median follow up per patient was 3.9 years (interquartile range 1.7-9.2 years). The dramatic decrease in the overall mortality rates was driven by AIDS-related causes that decreased from 9.19 deaths/100PYs n 1986-1991 to 1.35/100PYs in 2007-2009. Non-AIDS related mortality rates remained stable overtime, at around 1 death/100PYs. Immunodeficiency significantly increased the hazard of both AIDS-related and non-AIDS-related causes of death, while HAART use was strongly associated with a lower hazard of death from either cause. Conclusions: Our results confirm the remarkable decrease in AIDS-related mortality as the HIV epidemic evolved and alerts to the conditions not traditionally related to HIV/AIDS which are now becoming more frequent, needing careful monitoring.	[Grinsztejn, Beatriz; Luz, Paula M.; Santos, Desiree V. G.; Velasque, Luciane; Moreira, Ronaldo I.; Guimaraes, Maria Regina C.; Nunes, Esteva O. P.; Lemos, Alberto S.; Ribeiro, Sayonara R.; Campos, Dayse P.; Veloso, Valdilea G.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil; [Pacheco, Antonio G.] Fundacao Oswaldo Cruz, Programa Comp Cient, Rio De Janeiro, Brazil; [Velasque, Luciane] Univ Fed Estado Rio de Janeiro, Dept Matemat & Estat, Rio De Janeiro, Brazil; [Vitoria, Marco A. A.] WHO, HIV Dept, CH-1211 Geneva, Switzerland	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; Universidade Federal do Estado do Rio de Janeiro; World Health Organization	Grinsztejn, B (corresponding author), Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.	gbeatriz@ipec.fiocruz.br	de Lemos, Alberto dos Santos/M-4246-2013; Pacheco, Antonio Guilherme/E-6378-2013	de Lemos, Alberto dos Santos/0000-0003-0138-6577; Pacheco, Antonio Guilherme/0000-0003-3095-1774; Luz, Paula/0000-0001-9746-719X	National Council of Technological and Scientific Development (CNPq); Research Funding Agency of the State of Rio de Janeiro (FAPERJ)	National Council of Technological and Scientific Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Research Funding Agency of the State of Rio de Janeiro (FAPERJ)(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ))	B.G. acknowledges funding from the National Council of Technological and Scientific Development (CNPq) and the Research Funding Agency of the State of Rio de Janeiro (FAPERJ). A.G.P. acknowledges funding from the National Council of Technological and Scientific Development (CNPq) and the Research Funding Agency of the State of Rio de Janeiro (FAPERJ). P.M.L. acknowledges funding from the National Council of Technological and Scientific Development (CNPq). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beral V, 2004, AIDS, V18, P51, DOI [10.1097/00002030-200401020-00006, 10.1097/01.aids.0000096908.73209.5d]; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Cain LE, 2011, ANN INTERN MED, V154, P509, DOI 10.7326/0003-4819-154-8-201104190-00001; Crum NF, 2006, JAIDS-J ACQ IMM DEF, V41, P194, DOI 10.1097/01.qai.0000179459.31562.16; Diamond C, 2006, LEUKEMIA LYMPHOMA, V47, P1822, DOI 10.1080/10428190600658688; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Engels EA, 2008, INT J CANCER, V123, P187, DOI 10.1002/ijc.23487; Funk MJ, 2011, ARCH INTERN MED, V171, P1560, DOI 10.1001/archinternmed.2011.401; Gill J, 2010, CLIN INFECT DIS, V50, P1387, DOI 10.1086/652283; Grinsztejn B, 2009, AIDS, V23, P2107, DOI 10.1097/QAD.0b013e32832ec494; Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a; Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Kowalska JD, 2012, AIDS, V26, P315, DOI 10.1097/QAD.0b013e32834e8805; Kowalska JD, 2011, EPIDEMIOLOGY, V22, P516, DOI 10.1097/EDE.0b013e31821b5332; Lang S, 2012, CLIN INFECT DIS, V55, P600, DOI 10.1093/cid/cis489; Lewden C, 2012, INT J EPIDEMIOL, V41, P433, DOI 10.1093/ije/dyr164; Lichtenstein KA, 2010, CLIN INFECT DIS, V51, P435, DOI 10.1086/655144; Martinson NA, 2007, AIDS, V21, P2043, DOI 10.1097/QAD.0b013e3282eea47f; Moreira RI, 2011, JAIDS-J ACQ IMM DEF, V57, pS171, DOI 10.1097/QAI.0b013e31821e9d59; Pacheco AG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001531; Pacheco AG, 2009, JAIDS-J ACQ IMM DEF, V51, P624, DOI 10.1097/QAI.0b013e3181a4ecf5; Pacheco AG, 2008, AM J EPIDEMIOL, V168, P1326, DOI 10.1093/aje/kwn249; Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003; Schramm Joyce Mendes de Andrade, 2004, Ciênc. saúde coletiva, V9, P897, DOI 10.1590/S1413-81232004000400011; Simard EP, 2010, CLIN INFECT DIS, V51, P957, DOI 10.1086/656416; Smit C, 2006, AIDS, V20, P741, DOI 10.1097/01.aids.0000216375.99560.a2; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; Triant VA, 2010, J ACQUIRED IMMUNODEF; Weller I, 2009, AIDS, V23, P2029, DOI 10.1097/QAD.0b013e32832e531c; WHO, 2012, WHO POL COLL TB HIV; Worm SW, 2010, AIDS, V24, P1537, DOI 10.1097/QAD.0b013e32833a0918	32	96	99	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2013	8	4							e59768	10.1371/journal.pone.0059768	http://dx.doi.org/10.1371/journal.pone.0059768			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146RZ	23577074	Green Published, gold			2023-01-03	WOS:000319109800018
J	McNabb-Baltar, J; Trinh, QD; Barkun, AN				McNabb-Baltar, Julia; Quoc-Dien Trinh; Barkun, Alan N.			Disparities in Outcomes following Admission for Cholangitis	PLOS ONE			English	Article							IN-HOSPITAL MORTALITY; LENGTH-OF-STAY; RACIAL DISPARITIES; COLORECTAL-CARCINOMA; PORTAL-HYPERTENSION; COMORBIDITY INDEX; INSURANCE STATUS; HEALTH-CARE; WEEKEND; QUALITY	Introduction: Few have examined determinants of adverse outcomes in patients presenting with ascending cholangitis. The objective of this study was to examine factors associated with in-hospital mortality, prolonged length of stay (LOS) and increased hospital charges (HC) in patients presenting with acute cholangitis. Methods: Within the Health Care Utilization Project Nationwide Inpatient Sample (NIS), we focused on patients, 18 years and older, admitted to the emergency department with cholangitis as primary diagnosis (1998-2009). Models were fitted to predict likelihood of in-hospital mortality, prolonged LOS and increased HC. Covariates included race, day of admission, insurance status, socio-economical status and other patient and hospital characteristics. Results: Overall, weighted estimates of 248,942 patients were admitted with acute cholangitis between 1998 and 2009, of which 13,534 (5.4%) died during the admission. Multivariable analyses revealed that relative to Caucasian patients, African American, Hispanic and Asian and Pacific Islander patients were more likely to die (OR = 1.61, p<0.001, OR = 1.20, p = 0.01 and OR = 1.26, p = 0.008), to experience a prolonged LOS (OR = 1.77, p<0.001, OR = 1.30, p<0.001, 1.34, p<0.001), and to incur high HC (OR = 1.83, p<0.001, OR = 1.51, p<0.001, OR = 1.56, p<0.001). Moreover, Medicaid and Medicare patients were more likely to die (OR = 1.64, p<0.001, OR = 1.24, p<0.001), to experience a prolonged LOS (1.74, p<0.001, OR = 1.25, p<0.001) and to incur high HC (OR = 1.23, p = 0.002, OR = 1.12, p = 0.002) compared to privately insured patients. In subgroup analysis, there were no differences for Medicare patients age 65 years and over. However, those under 65, most of whom have disability or end stage renal disease, were more likely to experience the negative outcomes. Conclusion: Race and insurance status represent independent predictors of in-hospital mortality and adverse outcomes in patients presenting with cholangitis. Whether these disparities are due to biological predisposition or unequal quality of care requires further investigation. Regardless, efforts should be made to reduce these outcome disparities.	[McNabb-Baltar, Julia; Barkun, Alan N.] McGill Univ, Div Gastroenterol, Montreal, PQ, Canada; [Quoc-Dien Trinh] Henry Ford Hlth Syst, Dept Surg, Detroit, MI USA; [Quoc-Dien Trinh] Univ Montreal, Canc Prognost & Hlth Outcomes Unit, Ctr Hlth, Montreal, PQ, Canada	McGill University; Henry Ford Health System; Henry Ford Hospital; Universite de Montreal	McNabb-Baltar, J (corresponding author), McGill Univ, Div Gastroenterol, Montreal, PQ, Canada.	julia.mcnabb-baltar@mail.mcgill.ca						Ananthakrishnan AN, 2009, CLIN GASTROENTEROL H, V7, P296, DOI 10.1016/j.cgh.2008.08.013; Anger JT, 2007, J UROLOGY, V177, P1846, DOI 10.1016/j.juro.2007.01.035; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; BOEY JH, 1980, ANN SURG, V191, P264, DOI 10.1097/00000658-198003000-00002; Carr BG, 2011, ARCH SURG-CHICAGO, V146, P810, DOI 10.1001/archsurg.2011.60; Crowley RW, 2009, STROKE, V40, P2387, DOI 10.1161/STROKEAHA.108.546572; DARLING DA, 1957, ANN MATH STAT, V28, P823, DOI 10.1214/aoms/1177706788; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Downing SR, 2010, ARCH SURG-CHICAGO, V145, P785, DOI 10.1001/archsurg.2010.131; Fang JM, 2010, NEUROLOGY, V75, P1589, DOI 10.1212/WNL.0b013e3181fb84bc; Glenn LL, 1999, J RURAL HEALTH, V15, P94, DOI 10.1111/j.1748-0361.1999.tb00603.x; Halpern MT, 2008, LANCET ONCOL, V9, P222, DOI 10.1016/S1470-2045(08)70032-9; Hoh BL, 2010, STROKE, V41, P2323, DOI 10.1161/STROKEAHA.110.591081; Janssen-Heijnen MLG, 2007, EUR J CANCER, V43, P2179, DOI 10.1016/j.ejca.2007.06.008; Katz JN, 2001, JAMA-J AM MED ASSOC, V286, P1506, DOI 10.1001/jama.286.12.1506; Kelz RR, 2004, CANCER-AM CANCER SOC, V101, P2187, DOI 10.1002/cncr.20624; Khuri SF, 2001, ANN SURG, V234, P370, DOI 10.1097/00000658-200109000-00011; Lee CC, 2007, AM J GASTROENTEROL, V102, P563, DOI 10.1111/j.1572-0241.2007.01095.x; Luyt CE, 2007, CRIT CARE MED, V35, P3, DOI 10.1097/01.CCM.0000249832.36518.11; Mayberry RM, 2000, MED CARE RES REV, V57, P108, DOI 10.1177/107755800773743628; Mayumi T, 2007, J HEPATO-BILIARY-PAN, V14, P114, DOI 10.1007/s00534-006-1163-8; Nathan H, 2008, J AM COLL SURGEONS, V207, P312, DOI 10.1016/j.jamcollsurg.2008.04.015; Nguyen GC, 2008, CLIN GASTROENTEROL H, V6, P1146, DOI 10.1016/j.cgh.2008.05.024; Nguyen GC, 2007, HEPATOLOGY, V45, P1282, DOI 10.1002/hep.21580; Ouellette JR, 2004, J GASTROINTEST SURG, V8, P1061, DOI 10.1016/j.gassur.2004.09.045; Perelman J, 2008, SOC SCI MED, V66, P88, DOI 10.1016/j.socscimed.2007.07.013; Ren Z, 2011, HEPATOGASTROENTEROLO, V59; REYNOLDS BM, 1959, ANN SURG, V150, P299, DOI 10.1097/00000658-195908000-00013; Saha S, 2003, AM J PUBLIC HEALTH, V93, P1713, DOI 10.2105/AJPH.93.10.1713; Schneider EC, 2002, JAMA-J AM MED ASSOC, V287, P1288, DOI 10.1001/jama.287.10.1288; Schyve PM, 2007, J GEN INTERN MED, V22, P360, DOI 10.1007/s11606-007-0365-3; Shao YH, 2009, JNCI-J NATL CANCER I, V101, P1280, DOI 10.1093/jnci/djp262; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.1093/biomet/52.3-4.591; Trivedi AN, 2006, JAMA-J AM MED ASSOC, V296, P1998, DOI 10.1001/jama.296.16.1998; WELCH HG, 1993, HEALTH SERV RES, V28, P441	36	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2013	8	3							e59487	10.1371/journal.pone.0059487	http://dx.doi.org/10.1371/journal.pone.0059487			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121SG	23555680	Green Published, Green Submitted, gold			2023-01-03	WOS:000317263900013
J	Wright, AA; Stieglitz, H; Kupersztoch, YM; Paulk, ME; Kim, Y; Katz, IT; Munoz, F; Jimenez, RB; Mutchler, J; Rivera, L; Back, AL; Prigerson, HG				Wright, Alexi A.; Stieglitz, Heather; Kupersztoch, Yankel M.; Paulk, M. Elizabeth; Kim, Yookyung; Katz, Ingrid T.; Munoz, Francisco; Jimenez, Rachel B.; Mutchler, Jan; Rivera, Lorna; Back, Anthony L.; Prigerson, Holly G.			United States Acculturation and Cancer Patients' End-of-Life Care	PLOS ONE			English	Article							STAGE LUNG-CANCER; ETHNIC-DIFFERENCES; SOCIOECONOMIC-STATUS; RACIAL-DIFFERENCES; MEXICAN-AMERICANS; AFRICAN-AMERICAN; CLINICAL-TRIALS; CULTURAL ISSUES; PALLIATIVE CARE; THE-LITERATURE	Background: Culture shapes how people understand illness and death, but few studies examine whether acculturation influences patients' end-of-life treatment preferences and medical care. Methods and Findings: In this multi-site, prospective, longitudinal cohort study of terminally-ill cancer patients and their caregivers (n = 171 dyads), trained interviewers administered the United States Acculturation Scale (USAS). The USAS is a 19-item scale developed to assess the degree of "Americanization" in first generation or non-US born caregivers of terminally-ill cancer patients. We evaluated the internal consistency, concurrent, criterion, and content validity of the USAS. We also examined whether caregivers' USAS scores predicted patients' communication, treatment preferences, and end-of-life medical care in multivariable models that corrected for significant confounding influences (e.g. education, country of origin, English proficiency). The USAS measure was internally consistent (Cronbach alpha = 0.98); and significantly associated with US birthplace (r = 0.66, P < 0.0001). USAS scores were predictive of patients' preferences for prognostic information (AOR = 1.31, 95% CI: 1.00-1.72), but not comfort asking physicians' questions about care (AOR 1.23, 95% CI: 0.87-1.73). They predicted patients' preferences for feeding tubes (AOR = 0.68, 95% CI: 0.49-0.99) and wish to avoid dying in an intensive care unit (AOR = 1.36, 95% CI: 1.05-1.76). Scores indicating greater acculturation were also associated with increased odds of patient participation in clinical trials (AOR = 2.20, 95% CI: 1.28-3.78), compared with lower USAS scores, and greater odds of patients receiving chemotherapy (AOR = 1.59, 95% CI: 1.20-2.12). Conclusion: The USAS is a reliable and valid measure of "Americanization" associated with advanced cancer patients' end-of-life preferences and care. USAS scores indicating greater caregiver acculturation were associated with increased odds of patient participation in cancer treatment (chemotherapy, clinical trials) compared with lower scores. Future studies should examine the effects of acculturation on end-of-life care to identify patient and provider factors that explain these effects and targets for future interventions to improve care (e.g., by designing more culturally-competent health education materials).	[Wright, Alexi A.; Prigerson, Holly G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Wright, Alexi A.; Jimenez, Rachel B.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA; [Wright, Alexi A.; Katz, Ingrid T.; Jimenez, Rachel B.; Prigerson, Holly G.] Harvard Univ, Sch Med, Boston, MA USA; [Wright, Alexi A.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; [Stieglitz, Heather] Parkland Ctr Clin Innovat, Dallas, TX USA; [Kupersztoch, Yankel M.; Paulk, M. Elizabeth] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Kim, Yookyung] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Katz, Ingrid T.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Munoz, Francisco] Pomona Valley Hosp Med Ctr, Pomona, CA USA; [Jimenez, Rachel B.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; [Mutchler, Jan; Rivera, Lorna] Univ Massachusetts, Boston, MA 02125 USA; [Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; [Prigerson, Holly G.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; University of Massachusetts System; University of Massachusetts Boston; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital	Prigerson, HG (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.	Holly_Prigerson@dfci.harvard.edu	Wright, Alexi/T-5793-2019; Prigerson, Holly/GWV-3283-2022; Prigerson, Holly/L-3800-2019	Prigerson, Holly/0000-0002-7075-4268; Katz, Ingrid/0000-0002-3014-238X	National Institute of Mental Health [MH63892]; National Cancer Institute [CA 106370, CA 156732]; Conquer Cancer Foundation of the American Society of Clinical Oncology; National Palliative Care Research Center; American Cancer Society; Center for Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute; NATIONAL CANCER INSTITUTE [U54CA156732, R01CA106370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH097667, R01MH063892] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Conquer Cancer Foundation of the American Society of Clinical Oncology; National Palliative Care Research Center; American Cancer Society(American Cancer Society); Center for Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This research was supported in part by the following grants to Dr. Prigerson: MH63892 from the National Institute of Mental Health and CA 106370 and CA 156732 from the National Cancer Institute; by Career Development Awards sponsored by the Conquer Cancer Foundation of the American Society of Clinical Oncology, the National Palliative Care Research Center, and the American Cancer Society to Dr. Wright; and by the Center for Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraido-Lanza AF, 2004, AM J PUBLIC HEALTH, V94, P1393, DOI 10.2105/AJPH.94.8.1393; Bach PB, 2002, JAMA-J AM MED ASSOC, V287, P2106, DOI 10.1001/jama.287.16.2106; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; Blackhall LJ, 2001, J URBAN HEALTH, V78, P59, DOI 10.1093/jurban/78.1.59; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Braun UK, 2008, J NATL MED ASSOC, V100, P1041, DOI 10.1016/S0027-9684(15)31442-5; Brown DR, 2000, ANN EPIDEMIOL, V10, pS13, DOI 10.1016/S1047-2797(00)00197-6; Brusamolino E, 1997, ANN NY ACAD SCI, V809, P411, DOI 10.1111/j.1749-6632.1997.tb48104.x; Butow PN, 2011, J CLIN ONCOL, V29, P2801, DOI 10.1200/JCO.2010.34.3335; Butow PN, 2011, SUPPORT CARE CANCER, V19, P281, DOI 10.1007/s00520-010-0817-x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clegg LX, 2002, ARCH INTERN MED, V162, P1985, DOI 10.1001/archinte.162.17.1985; Cohen LL, 2008, J PALLIAT MED, V11, P763, DOI 10.1089/jpm.2007.0216; Cohen SR, 1997, PALLIATIVE MED, V11, P3; Cortes DE, 2003, J PSYCHOACTIVE DRUGS, V35, P197, DOI 10.1080/02791072.2003.10400001; CUELLAR I, 1995, HISPANIC J BEHAV SCI, V17, P275, DOI 10.1177/07399863950173001; Cykert S, 2010, JAMA-J AM MED ASSOC, V303, P2368, DOI 10.1001/jama.2010.793; Derose KP, 2009, MED CARE RES REV, V66, P355, DOI 10.1177/1077558708330425; DeSanto-Madeya S, 2009, J PALLIAT MED, V12, P1143, DOI 10.1089/jpm.2009.0063; DEYO RA, 1985, AM J PUBLIC HEALTH, V75, P51, DOI 10.2105/AJPH.75.1.51; Equity OoMHaH, 2012, RAC ETHN MIN POP; Fernandez A, 2004, J GEN INTERN MED, V19, P167, DOI 10.1111/j.1525-1497.2004.30266.x; Freedman RA, 2009, J CLIN ONCOL, V27, P713, DOI 10.1200/JCO.2008.17.9234; Gessert Charles E., 2001, Ethnicity and Disease, V11, P97; Gordon HS, 2006, CANCER-AM CANCER SOC, V107, P1313, DOI 10.1002/cncr.22122; Grieco EM, 2010, AM COMMUNITY SURVEY; Hanchate A, 2009, ARCH INTERN MED, V169, P493, DOI 10.1001/archinternmed.2008.616; Hoffman HJ, 2011, CANCER-AM CANCER SOC, V117, P3824, DOI 10.1002/cncr.25970; Howerton MW, 2007, CANCER-AM CANCER SOC, V109, P465, DOI 10.1002/cncr.22436; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; KARNOFSKY DA, 1968, CANCER-AM CANCER SOC, V22, P730, DOI 10.1002/1097-0142(196810)22:4<730::AID-CNCR2820220407>3.0.CO;2-H; Kazdaglis G. A., 2010, Eastern Mediterranean Health Journal, V16, P442; Kouri EM, 2010, BREAST CANCER RES TR, V121, P743, DOI 10.1007/s10549-009-0643-3; Lackan NA, 2009, MED CARE, V47, P138, DOI 10.1097/MLR.0b013e3181844dba; Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI 10.1146/annurev.publhealth.26.021304.144615; Lin SS, 2002, CANCER, V94, P1175, DOI 10.1002/cncr.10319; Loggers ET, 2009, J CLIN ONCOL, V27, P5559, DOI 10.1200/JCO.2009.22.4733; Mack JW, 2010, ARCH INTERN MED, V170, P1533, DOI 10.1001/archinternmed.2010.322; Marin G, 1996, HISPANIC J BEHAV SCI, V18, P297, DOI 10.1177/07399863960183002; MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005; Matsumura S, 2002, J GEN INTERN MED, V17, P531, DOI 10.1046/j.1525-1497.2002.10734.x; Medicine Io, 1999, UN BURD CANC ASS NIH; Morrison RS, 1998, ARCH INTERN MED, V158, P2493, DOI 10.1001/archinte.158.22.2493; Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720; Nielsen SS, 2010, CANCER-AM CANCER SOC, V116, P5497, DOI 10.1002/cncr.25546; Ortega AN, 2007, ARCH INTERN MED, V167, P2354, DOI 10.1001/archinte.167.21.2354; Phipps E, 2003, J CLIN ONCOL, V21, P549, DOI 10.1200/JCO.2003.12.080; Schenker Y, 2007, J GEN INTERN MED, V22, P294, DOI 10.1007/s11606-007-0359-1; Schouten BC, 2006, PATIENT EDUC COUNS, V64, P21, DOI 10.1016/j.pec.2005.11.014; Sheikh A, 2006, PLOS MED, V3, P166, DOI 10.1371/journal.pmed.0030049; Shi LY, 2011, J HEALTH CARE POOR U, V22, P945, DOI 10.1353/hpu.2011.0079; Smith AK, 2008, J CLIN ONCOL, V26, P4131, DOI 10.1200/JCO.2007.14.8452; Smith AK, 2009, JAMA-J AM MED ASSOC, V301, P1047, DOI 10.1001/jama.2009.308; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; Sudore RL, 2006, J GEN INTERN MED, V21, P806, DOI 10.1111/j.1525-1497.2006.00539.x; Thornton JD, 2009, CRIT CARE MED, V37, P89, DOI 10.1097/CCM.0b013e3181926430; Ward E, 2004, CA-CANCER J CLIN, V54, P78, DOI 10.3322/canjclin.54.2.78; Wendler D, 2006, PLOS MED, V3, P201, DOI 10.1371/journal.pmed.0030019; Willems S, 2005, PATIENT EDUC COUNS, V56, P139, DOI 10.1016/j.pec.2004.02.011; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863	61	10	10	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2013	8	3							e58663	10.1371/journal.pone.0058663	http://dx.doi.org/10.1371/journal.pone.0058663			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	107WI	23536809	Green Published, Green Accepted, gold			2023-01-03	WOS:000316251100076
J	Yang, FW; Zhang, XJ; Sun, Y; Wang, BY; Zhou, CB; Luo, YA; Ge, PF				Yang, Fuwei; Zhang, Xiaojie; Sun, Ying; Wang, Boyu; Zhou, Chuibing; Luo, Yinan; Ge, Pengfei			Ischemic Postconditioning Decreases Cerebral Edema and Brain Blood Barrier Disruption Caused by Relief of Carotid Stenosis in a Rat Model of Cerebral Hypoperfusion	PLOS ONE			English	Article							REDUCES INFARCT SIZE; REPERFUSION INJURY; MATRIX METALLOPROTEINASES; OXIDATIVE STRESS; MATRIX-METALLOPROTEINASE-9 EXPRESSION; FOCAL ISCHEMIA; FREE-RADICALS; PROTECTS; ARTERY; INHIBITOR	Background and Purpose: Complications due to brain edema and breakdown of blood brain barrier are an important factor affecting the treatment effects of patients with severe carotid stenosis. In this study, we investigated the protective effects of ischemic postconditioning on brain edema and disruption of blood brain barrier via establishing rat model of hypoperfusion due to severe carotid stenosis. Methods: Wistar rat model of hypoperfusion due to severe carotid stenosis was established by binding a stainless microtube to both carotid arteries. Ischemic postconditioning procedure consisted of three cycles of 30 seconds ischemia and 30 seconds reperfusion. Brain edema was evaluated by measuring cerebral water content, and blood brain barrier permeability was assayed by examining cerebral concentration of Evans' Blue (EB) and fluorescein sodium (NaF). ELISA was used to analyze the expression of MMP-9, claudin-5 and occludin. The activity and location of MMP-9 was analyzed by gelatin zymography and in situ zymography, respectively. The distribution of tight junction proteins claudin-5 and occludin was observed by immunohistochemistry. Results: The increased brain water content and cerebral concentration of EB and NaF were suppressed by administration of ischemic postconditioning prior to relief of carotid stenosis. Zymographic studies showed that MMP-9 was mainly located in the cortex and its activity was significantly improved by relief of carotid stenosis and, but the elevated MMP-9 activity was inhibited markedly by ischemic postconditioning. Immunohistochemistry revealed that ischemic postconditioning improved the discontinuous distribution of claudin-5 and occludin. ELISA detected that the expression of up-regulated MMP-9 and down-regulated claudin-5 and occludin caused by carotid relief were all attenuated by ischemic postconditioning. Conclusions: Ischemic postconditioning is an effective method to prevent brain edema and improve BBB permeability and could be used during relief of severe carotid stenosis.	[Yang, Fuwei; Wang, Boyu; Luo, Yinan; Ge, Pengfei] Jilin Univ, Bethune Hosp 1, Dept Neurosurg, Changchun 130023, Peoples R China; [Zhang, Xiaojie; Zhou, Chuibing] Changchun Children Hosp, Dept Neurosurg, Changchun, Peoples R China; [Sun, Ying] Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin, Peoples R China	Jilin University; Harbin Medical University	Ge, PF (corresponding author), Jilin Univ, Bethune Hosp 1, Dept Neurosurg, Changchun 130023, Peoples R China.	pengfeige@gmail.com			National Nature and Science Foundation of China [81171234, 30973110]	National Nature and Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Nature and Science Foundation of China (Nos. 81171234 and 30973110). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Annambhotla S, 2012, J VASC SURG, V56, P1296, DOI 10.1016/j.jvs.2012.05.070; Chen F, 2009, HEPATOLOGY, V50, P1914, DOI 10.1002/hep.23203; Chen YH, 2012, INT J CARDIOL, V157, P104, DOI 10.1016/j.ijcard.2011.10.086; Cho AH, 2009, EUR J NEUROL, V16, P1066, DOI 10.1111/j.1468-1331.2009.02650.x; Dong X, 2009, CURR NEUROPHARMACOL, V7, P269, DOI 10.2174/157015909790031157; Duan W, 2011, ACTA NEUROBIOL EXP, V71, P233; Feng CS, 2012, INT J MOL SCI, V13, P13338, DOI 10.3390/ijms131013338; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Guo JY, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-79; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Ivens S, 2010, J NEUROL, V257, P615, DOI 10.1007/s00415-009-5384-z; Jiao HX, 2011, J MOL NEUROSCI, V44, P130, DOI 10.1007/s12031-011-9496-4; Karapanayiotides T, 2005, STROKE, V36, P21, DOI 10.1161/01.STR.0000149946.86087.e5; Kokuzawa J, 2010, NEUROL MED-CHIR, V50, P250, DOI 10.2176/nmc.50.250; Landgraff NC, 2010, J NEUROL, V257, P982, DOI 10.1007/s00415-009-5449-z; Lee CZ, 2004, STROKE, V35, P1715, DOI 10.1161/01.STR.0000129334.05181.b6; Lee H, 2009, NEUROBIOL DIS, V34, P189, DOI 10.1016/j.nbd.2008.12.012; Lee SR, 2004, J NEUROSCI, V24, P671, DOI 10.1523/JNEUROSCI.4243-03.2004; Li ZY, 2012, J INT MED RES, V40, P954, DOI 10.1177/147323001204000314; Liu H, 2012, CURR NEUROVASC RES, V9, P152, DOI 10.2174/156720212801619027; Liu KX, 2009, INTENS CARE MED, V35, P933, DOI 10.1007/s00134-009-1428-1; Liu KH, 2005, FREE RADICAL BIO MED, V39, P71, DOI 10.1016/j.freeadbiomed.2005.03.033; Liu XR, 2012, CNS NEUROSCI THER, V18, P855, DOI 10.1111/j.1755-5949.2012.00366.x; Liu XH, 2007, BIOCHEM BIOPH RES CO, V359, P628, DOI 10.1016/j.bbrc.2007.05.129; Lok J, 2012, TRANSL STROKE RES, V3, pS119, DOI 10.1007/s12975-012-0157-x; Loukogeorgakis SP, 2006, CIRCULATION, V113, P1015, DOI 10.1161/CIRCULATIONAHA.105.590398; Lukic-Panin V, 2010, CURR NEUROVASC RES, V7, P319, DOI 10.2174/156720210793180747; Ma XJ, 2006, SCAND CARDIOVASC J, V40, P327, DOI 10.1080/14017430601047864; Marnane M, 2011, NEUROLOGY, V77, P738, DOI 10.1212/WNL.0b013e31822b00cf; Meng FR, 2011, BRAIN RES, V1391, P93, DOI 10.1016/j.brainres.2011.03.010; Moulakakis KG, 2009, J VASC SURG, V49, P1060, DOI 10.1016/j.jvs.2008.11.026; Panickar KS, 2011, INT J MOL SCI, V12, P8181, DOI 10.3390/ijms12118181; Penna C, 2009, BBA-BIOENERGETICS, V1787, P781, DOI 10.1016/j.bbabio.2009.02.008; Rehni AK, 2012, CYTOKINE, V60, P83, DOI 10.1016/j.cyto.2012.05.009; Roach DM, 2002, EUR J VASC ENDOVASC, V23, P260, DOI 10.1053/ejvs.2002.1598; Switzer JA, 2011, STROKE, V42, P2633, DOI 10.1161/STROKEAHA.111.618215; Taussky P, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11222; Thuny F, 2012, J AM COLL CARDIOL, V59, P2175, DOI 10.1016/j.jacc.2012.03.026; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang JY, 2008, STROKE, V39, P983, DOI 10.1161/STROKEAHA.107.499079; Wang Q, 2011, ANESTH ANALG, V113, P1180, DOI 10.1213/ANE.0b013e31822b885f; Wu TY, 2012, J NEUROL NEUROSUR PS, V83, P543, DOI 10.1136/jnnp-2011-301162; Xu B, 2011, J SURG RES, V166, pE157, DOI 10.1016/j.jss.2010.11.902; Yan JH, 2011, EXP NEUROL, V230, P240, DOI 10.1016/j.expneurol.2011.04.022; Yang CM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-12; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Young KC, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.3.FOCUS1143; Yuan YJ, 2011, BRAIN RES, V1367, P85, DOI 10.1016/j.brainres.2010.10.017; Zhang WQ, 2011, J CLIN NEUROSCI, V18, P685, DOI 10.1016/j.jocn.2010.08.027; Zhao H, 2006, J CEREBR BLOOD F MET, V26, P1114, DOI 10.1038/sj.jcbfm.9600348; Zhou CF, 2011, NEUROCHEM INT, V59, P749, DOI 10.1016/j.neuint.2011.08.008; Zhou Z, 2012, NEUROSCIENCE, V219, P137, DOI 10.1016/j.neuroscience.2012.05.060	52	16	17	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57869	10.1371/journal.pone.0057869	http://dx.doi.org/10.1371/journal.pone.0057869			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469092	Green Published, Green Submitted, gold			2023-01-03	WOS:000315524900188
J	Zhang, Y; Chen, MB; Zhou, XY; Hong, XN				Zhang, Yan; Chen, Min-Bin; Zhou, Xiao-Yan; Hong, Xiao-Nan			Lymphotoxin Alpha (LTA) Polymorphism Is Associated with Prognosis of Non-Hodgkin's Lymphoma in a Chinese Population	PLOS ONE			English	Article							TUMOR-NECROSIS-FACTOR; B-CELL LYMPHOMA; RANDOMIZED CONTROLLED-TRIAL; GENETIC POLYMORPHISMS; CHOP CHEMOTHERAPY; ELDERLY-PATIENTS; DES-LYMPHOMES; RITUXIMAB; PATHWAY; RISK	Background: Non-Hodgkin's lymphoma (NHL) has been widely reported to be associated with autoimmune and pro-inflammatory response, and genetic polymorphisms of candidate genes involved in autoimmune and pro-inflammatory response may influence the survival and prognosis of NHL patients. To evaluate the role of such genetic variations in prognosis of NHL, we conducted this study in a Chinese population. Methods: We used the TaqMan assay to genotype six single nucleotide polymorphisms (SNPs) (TNF rs1799964T>C, LTA rs1800683G>A, IL-10 rs1800872T>G, LEP rs2167270G>A, LEPR rs1327118C>G, TNFAIP8 rs1045241C>T) for 215 NHL cases. Kaplan-Meier analysis was performed to compare progression free survival among two common genotypes. Cox proportional hazard models were used to identify independent risk factors. Results: We observed that LTA rs1800683G>A was significantly associated with risk of progression or relapse in NHL patients (HR = 1.63, 95% CI = 1.06-2.51; P = 0.028), particularly in Diffuse large B cell lymphoma (DLBCL) cases (HR = 1.50, 95% CI = 1.10-2.04, P = 0.01). Both univariate and multivariate Cox regression analysis showed that in DLBCL patients, Ann Arbor stage III/IV, elevated LDH level before treatment and LTA rs1800683 AA genotype carrier were independent risk factors for progression or relapse. While in NK/T cell lymphoma, Ann Arbor stage III/IV and elevated beta(2)-MG level before treatment indicated poorer prognosis. Conclusions: The polymorphism of LTA rs1800683G>A contributes to NHL prognosis in a Chinese population. Further large-scale and well-designed studies are needed to confirm these results.	[Zhang, Yan; Chen, Min-Bin] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Med Oncol, Zhenjiang, Jiangsu, Peoples R China; [Zhou, Xiao-Yan] Fudan Univ, Shanghai Canc Ctr, Canc Res Lab, Shanghai 200433, Peoples R China; [Hong, Xiao-Nan] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai 200433, Peoples R China	Jiangsu University; Fudan University; Fudan University	Zhang, Y (corresponding author), Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Med Oncol, Zhenjiang, Jiangsu, Peoples R China.	zy-zl-126@126.com			National Natural Science Foundation of China [30870985]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by a grant from National Natural Science Foundation of China (30870985). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelhamid T, 2011, J EGYPT NATL CANCER, V23, P17, DOI 10.1016/j.jnci.2011.07.003; Aschebrook-Kilfoy B, 2011, J CANCER SURVIV, V6, P102; AVILES A, 1993, LEUKEMIA LYMPHOMA, V9, P377, DOI 10.3109/10428199309148537; Cabanillas Fernando, 2011, Clin Lymphoma Myeloma Leuk, V11 Suppl 1, pS87, DOI 10.1016/j.clml.2011.03.029; Chae YS, 2010, CANCER CHEMOTH PHARM, V65, P571, DOI 10.1007/s00280-009-1066-x; Chen WL, 2010, ANN HEMATOL, V89, P553, DOI 10.1007/s00277-009-0870-z; Coiffier B, 2010, BLOOD, V116, P2040, DOI 10.1182/blood-2010-03-276246; Fernberg P, 2010, CANCER CAUSE CONTROL, V21, P759, DOI 10.1007/s10552-010-9504-y; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Jost PJ, 2007, BLOOD, V109, P2700, DOI 10.1182/blood-2006-07-025809; Kuppers R, 2004, NEW ENGL J MED, V351, P2152, DOI 10.1056/NEJMp048257; Lan Q, 2006, BLOOD, V107, P4101, DOI 10.1182/blood-2005-10-4160; Lan Q, 2011, BRIT J HAEMATOL, V153, P341, DOI 10.1111/j.1365-2141.2010.08424.x; Lech-Maranda E, 2004, BLOOD, V103, P3529, DOI 10.1182/blood-2003-06-1850; Luminari S, 2007, HEMATOL ONCOL, V25, P189, DOI 10.1002/hon.826; Nogai H, 2011, J CLIN ONCOL, V29, P1803, DOI 10.1200/JCO.2010.33.3252; Pfreundschuh M, 2008, LANCET ONCOL, V9, P105, DOI 10.1016/S1470-2045(08)70002-0; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Purdue MP, 2007, CARCINOGENESIS, V28, P704, DOI 10.1093/carcin/bgl200; Seidemann K, 2005, J CLIN ONCOL, V23, P8414, DOI 10.1200/JCO.2005.01.2179; Seki R, 2010, INT J HEMATOL, V91, P258, DOI 10.1007/s12185-009-0475-2; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Skibola CF, 2010, AM J EPIDEMIOL, V171, P267, DOI 10.1093/aje/kwp383; Swerdlow S.H., 2008, WHO CLASSIFICATION T; Warzocha K, 1998, BLOOD, V91, P3574; Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037846	27	11	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2013	8	6							e66411	10.1371/journal.pone.0066411	http://dx.doi.org/10.1371/journal.pone.0066411			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190LY	23840460	Green Published, Green Submitted, gold			2023-01-03	WOS:000322342800058
J	Rajabali, A; Caton, H				Rajabali, Alefiyah; Caton, Harmony			BOSTON MARATHON BOMBING A tale of two physicians: reflections on the Boston Marathon bombing	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Rajabali, Alefiyah; Caton, Harmony] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Rajabali, A (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.	arajabali@partners.org							0	0	0	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 10	2013	346								f2993	10.1136/bmj.f2993	http://dx.doi.org/10.1136/bmj.f2993			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	144BV	23667127				2023-01-03	WOS:000318915300006
J	Anders, CK; Adamo, B; Karginova, O; Deal, AM; Rawal, S; Darr, D; Schorzman, A; Santos, C; Bash, R; Kafri, T; Carey, L; Miller, CR; Perou, CM; Sharpless, N; Zamboni, WC				Anders, Carey K.; Adamo, Barbara; Karginova, Olga; Deal, Allison M.; Rawal, Sumit; Darr, David; Schorzman, Allison; Santos, Charlene; Bash, Ryan; Kafri, Tal; Carey, Lisa; Miller, C. Ryan; Perou, Charles M.; Sharpless, Norman; Zamboni, William C.			Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer	PLOS ONE			English	Article							NERVOUS-SYSTEM METASTASES; WHOLE-BRAIN RADIOTHERAPY; POLY(ADP-RIBOSE) POLYMERASE; ANTICANCER AGENTS; CKD-602 S-CKD602; TUMOR MODEL; IN-VITRO; INHIBITOR; CHEMOTHERAPY; XENOGRAFTS	Introduction: Breast cancer brain metastases (BCBM) are a challenging consequence of advanced BC. Nanoparticle agents, including liposomes, have shown enhanced delivery to solid tumors and brain. We compared pharmacokinetics (PK) and efficacy of PEGylated liposomal doxorubicin (PLD) with non-liposomal doxorubicin (NonL-doxo) in an intracranial model of BC. Methods: Athymic mice were inoculated intracerebrally with MDA-MB-231-BR-luciferase-expressing cells. Tumor-bearing mice were administered PLD or NonL-doxo at 6mg/kg IVx1 and were euthanized prior to and 0.083, 1, 3, 6, 24, 72 and 96 h post-treatment. Samples were processed to measure sum total doxorubicin via HPLC. PLD and NonL-doxo were administered IV weekly as single agents (6 mg/kg) or in combination (4.5 mg/kg) with the PARP inhibitor, ABT-888, PO 25 mg/kg/day. Efficacy was assessed by survival and bioluminescence. Results: Treatment with PLD resulted in approximately 1,500-fold higher plasma and 20-fold higher intracranial tumor sum total doxorubicin AUC compared with NonL-doxo. PLD was detected at 96 h; NonL-doxo was undetectable after 24 h in plasma and tumor. Median survival of PLD-treated animals was 32 days (d, [CI] 31-38), which was significantly longer than controls (26d [CI 25-28]; p = 0.0012) or NonL-doxo treatment (23.5d [CI 18-28], p = 0.0002). Combination treatment with PLD/ABT-888 yielded improved survival compared to NonL-doxo/ABT-888 (35d [CI 31-38] versus 29.5d [CI 25-34]; p = 0.006). Conclusions: PLD provides both PK and efficacy advantage over NonL-doxo in the treatment of an in vivo model of BCBM. The results provide preclinical rationale to translate findings into early phase trials of PLD, with or without ABT-888, for	[Anders, Carey K.; Carey, Lisa; Sharpless, Norman] Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA; [Anders, Carey K.; Adamo, Barbara; Karginova, Olga; Deal, Allison M.; Rawal, Sumit; Darr, David; Schorzman, Allison; Santos, Charlene; Bash, Ryan; Kafri, Tal; Carey, Lisa; Miller, C. Ryan; Perou, Charles M.; Sharpless, Norman; Zamboni, William C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Adamo, Barbara] Univ Messina, Integrated Therapies Oncol Unit, Dept Human Pathol, Messina, Italy; [Deal, Allison M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biostat, Chapel Hill, NC 27599 USA; [Rawal, Sumit; Schorzman, Allison; Zamboni, William C.] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA; [Rawal, Sumit; Zamboni, William C.] Univ N Carolina, Translat Oncol & Nanoparticle Drug Dev Initiat TO, Chapel Hill, NC USA; [Kafri, Tal] Univ N Carolina, Gene Therapy Ctr, Chapel Hill, NC USA; [Kafri, Tal] Univ N Carolina, Dept Microbiol & Immnunol, Chapel Hill, NC USA; [Miller, C. Ryan] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Sharpless, Norman] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Zamboni, William C.] Univ N Carolina, Carolina Ctr Canc Nanotechnol Excellence, Chapel Hill, NC USA; [Zamboni, William C.] Univ N Carolina, Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Messina; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Anders, CK (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27515 USA.	carey_anders@med.unc.edu	Miller, Ryan/B-9365-2008; , Animal Studies Core/ADK-4234-2022; Perou, Charles M/H-9934-2014; , Animal Studies Core/AAF-4432-2022; , Pathology Services Core/CEZ-2246-2022	Miller, Ryan/0000-0002-0096-8762; Perou, Charles M/0000-0001-9827-2247; Sharpless, Norman/0000-0001-7078-9455	National Cancer Institute [K23CA157728]; Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research [10-60-26-ANDE]; Damon Runyon Cancer Research Foundation [CI-64-12]; University Cancer Research Fund; Lineberger Cancer Center; University of North Carolina at Chapel Hill; Lineberger Comprehensive Cancer Center; University of North Carolina SPORE Career Development Award [5P50CA058223]; NATIONAL CANCER INSTITUTE [U54CA151652, K23CA157728, P50CA058223, P30CA016086] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research; Damon Runyon Cancer Research Foundation; University Cancer Research Fund; Lineberger Cancer Center; University of North Carolina at Chapel Hill; Lineberger Comprehensive Cancer Center; University of North Carolina SPORE Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding Sources: The project described was supported by Grant Number K23CA157728 (CKA) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health. Research supported by the 2010 Breast Cancer Research Foundation-AACR Grant for Translational Breast Cancer Research, Grant Number 10-60-26-ANDE (CKA). Carey Anders, MD is a Damon Runyon Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-64-12). Funding also came from The University Cancer Research Fund, Lineberger Cancer Center, University of North Carolina at Chapel Hill (BZ and Mouse Phase I Unit) and Lineberger Comprehensive Cancer Center, University of North Carolina SPORE Career Development Award, 5P50CA058223 (SPORE, CKA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali M, 2011, MOL CANCER THER, V10, P2320, DOI 10.1158/1535-7163.MCT-11-0356; AMSELEM S, 1990, J PHARM SCI, V79, P1045, DOI 10.1002/jps.2600791202; Baschnagel A, 2009, MOL CANCER THER, V8, P1589, DOI 10.1158/1535-7163.MCT-09-0038; Beijnen J, 1985, PDA J PHARM SCI TECH, V39, P220; Bendell JC, 2003, CANCER-AM CANCER SOC, V97, P2972, DOI 10.1002/cncr.11436; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Coombes RC, 1996, J CLIN ONCOL, V14, P35, DOI 10.1200/JCO.1996.14.1.35; Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039; Ewend Matthew G, 2008, J Natl Compr Canc Netw, V6, P505; FORNARI FA, 1994, MOL PHARMACOL, V45, P649; GABIZON A, 1989, JNCI-J NATL CANCER I, V81, P1484, DOI 10.1093/jnci/81.19.1484; GABIZON AA, 1993, PHARMACEUT RES, V10, P703, DOI 10.1023/A:1018907715905; Gerstner ER, 2007, J CLIN ONCOL, V25, P2306, DOI 10.1200/JCO.2006.10.0677; Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Koukourakis MI, 2000, BRIT J CANCER, V83, P1281, DOI 10.1054/bjoc.2000.1459; Lay JC, 2009, THORAX, V64, P313, DOI 10.1136/thx.2008.096222; Lin NU, 2008, CANCER-AM CANCER SOC, V113, P2638, DOI 10.1002/cncr.23930; Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175; Lockman PR, 2010, CLIN CANCER RES, V16, P5664, DOI 10.1158/1078-0432.CCR-10-1564; Madhankumar AB, 2009, MOL CANCER THER, V8, P648, DOI 10.1158/1535-7163.MCT-08-0853; Mason KA, 2008, INVEST NEW DRUG, V26, P1, DOI 10.1007/s10637-007-9072-5; Muldoon LL, 2007, J CLIN ONCOL, V25, P2295, DOI 10.1200/JCO.2006.09.9861; Niwinska A, 2010, ANN ONCOL, V21, P942, DOI 10.1093/annonc/mdp407; Niwinska A, 2010, CANCER-AM CANCER SOC, V116, P4238, DOI 10.1002/cncr.25391; O'Brien MER, 2004, ANN ONCOL, V15, P440, DOI 10.1093/annonc/mdh097; Park JW, 2004, SEMIN ONCOL, V31, P196, DOI 10.1053/j.seminoncol.2004.08.009; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; Sharma US, 1997, PHARM RES-DORDR, V14, P992, DOI 10.1023/A:1012136925030; Shroff K, 2012, LANGMUIR, V28, P4729, DOI 10.1021/la204466g; SIEGAL T, 1995, J NEUROSURG, V83, P1029, DOI 10.3171/jns.1995.83.6.1029; van Rooijen N, 2007, LIPOSOME TECHNOLOGY, V3, P303; Walsh MD, 2012, CLIN CANCER RES, V18, P2591, DOI 10.1158/1078-0432.CCR-11-1554; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Zamboni WC, 2005, CLIN CANCER RES, V11, P8230, DOI 10.1158/1078-0432.CCR-05-1895; Zamboni WC, 2010, DRUG DELIV SYST, V25, P58; Zamboni WC, 2008, ONCOLOGIST, V13, P248, DOI 10.1634/theoncologist.2007-0180; Zamboni WC, 2007, CLIN CANCER RES, V13, P7217, DOI 10.1158/1078-0432.CCR-07-1035; Zamboni WC, 2011, J LIPOSOME RES, V21, P158, DOI 10.3109/08982104.2010.496085; Zamboni WC, 2009, CLIN CANCER RES, V15, P1466, DOI 10.1158/1078-0432.CCR-08-1405	41	73	76	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2013	8	5							e61359	10.1371/journal.pone.0061359	http://dx.doi.org/10.1371/journal.pone.0061359			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147KY	23650496	gold, Green Published			2023-01-03	WOS:000319167000011
J	Sumpter, C; Torondel, B				Sumpter, Colin; Torondel, Belen			A Systematic Review of the Health and Social Effects of Menstrual Hygiene Management	PLOS ONE			English	Article							BACTERIAL VAGINOSIS; TRACT-INFECTIONS; PANTY LINERS; AGE; MORBIDITY; MENARCHE; WOMEN	Background: Differing approaches to menstrual hygiene management (MHM) have been associated with a wide range of health and psycho-social outcomes in lower income settings. This paper systematically collates, summarizes and critically appraises the available evidence. Methods: Following the PRISMA guidelines a structured search strategy was used to identify articles investigating the effects of MHM on health and psycho-social outcomes. The search was conducted in May 2012 and had no date limit. Data was extracted and quality of methodology was independently assessed by two researchers. Where no measure of effect was provided, but sufficient data were available to calculate one, this was undertaken. Meta-analysis was conducted where sufficient data were available. Results: 14 articles were identified which looked at health outcomes, primarily reproductive tract infections (RTI). 11 articles were identified investigating associations between MHM, social restrictions and school attendance. MHM was found to be associated with RTI in 7 papers. Methodologies however varied greatly and overall quality was low. Meta-analysis of a subset of studies found no association between confirmed bacterial vaginosis and MHM (OR: 1.07, 95% CI: 0.52-2.24). No other substantial associations with health outcomes were found. Although there was good evidence that educational interventions can improve MHM practices and reduce social restrictions there was no quantitative evidence that improvements in management methods reduce school absenteeism. Conclusion: The management of menstruation presents significant challenges for women in lower income settings; the effect of poor MHM however remains unclear. It is plausible that MHM can affect the reproductive tract but the specific infections, the strength of effect, and the route of transmission, remain unclear. There is a gap in the evidence for high quality randomised intervention studies which combine hardware and software interventions, in particular for better understanding the nuanced effect improving MHM may have on girls' attendance at school.	[Sumpter, Colin; Torondel, Belen] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Sumpter, C (corresponding author), London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England.	colin.sumpter@lshtm.ac.uk		Sumpter, Colin/0000-0002-6776-1774	SHARE Research Consortium	SHARE Research Consortium	The SHARE Research Consortium (http://www.shareresearch.org/) provided funding for this review. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adinma Echendu Dolly, 2008, Afr J Reprod Health, V12, P74; Ali TS, 2007, J HEALTH POPUL NUTR, V25, P189; Ali TS, 2010, J ADOLESCENCE, V33, P531, DOI 10.1016/j.adolescence.2009.05.013; Allah E. S. A., 2011, The Journal of American Science, V7, P737; Anandalakshmy S, 1994, GIRL CHILD FAMILY AC; Aniebue Uzochukwu Uzoma, 2009, Pan Afr Med J, V2, P9; Atashili J, 2008, AIDS, V22, P1493, DOI 10.1097/QAD.0b013e3283021a37; Bahram Amini, 2009, Oman Med J, V24, P288, DOI 10.5001/omj.2009.58; Baisley K, 2009, SEX TRANSM INFECT, V85, P370, DOI 10.1136/sti.2008.035543; Balamurugan Sangeetha S, 2012, Indian J Community Med, V37, P34, DOI 10.4103/0970-0218.94020; BHATIA JC, 1995, STUD FAMILY PLANN, V26, P203, DOI 10.2307/2137846; Bhatti LI, 2002, SOC SCI MED, V54, P105, DOI 10.1016/S0277-9536(01)00012-0; Bility K, 2000, WATER USE SANITATION; Birdthistle I., 2011, WHAT IMPACT DOES PRO; Bulut A, 1997, STUD FAMILY PLANN, V28, P35, DOI 10.2307/2137969; Carrard N, 2011, MENSTRUAL HYGIENE MA; Crofts T, 2012, J WATER SANIT HYG DE, V2, P50, DOI 10.2166/washdev.2012.067; Dasgupta A, 2008, Indian J Community Med, V33, P77, DOI 10.4103/0970-0218.40872; Demba E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-12; Dipali Nemade, 2009, Health and Population - Perspectives and Issues, V32, P167; Dongre A R, 2007, World Health Popul, V9, P48; Fakhri M, 2012, BMC PUBLIC HLTH, V12; Farage M, 2007, EUR J OBSTET GYN R B, V132, P8, DOI 10.1016/j.ejogrb.2006.11.015; Fetohy Ebtisam M, 2007, J Egypt Public Health Assoc, V82, P105; Gillet E, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-10; Giraldo PC, 2011, INT J GYNECOL OBSTET, V115, P61, DOI 10.1016/j.ijgo.2011.04.016; Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102; Johnson LF, 2008, SEX TRANSM DIS, V35, P946, DOI 10.1097/OLQ.0b013e3181812d15; Jones LL, 2009, AM J HUM BIOL, V21, P130, DOI 10.1002/ajhb.20836; Kanyemba A, 2011, GROWING SCH GUIDE ME; McMahon SA, 2011, BMC INT HEALTH HUM R, V11, DOI 10.1186/1472-698X-11-7; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Morison L, 2005, SEX TRANSM INFECT, V81, P242, DOI 10.1136/sti.2004.011684; Narayan K. A., 2001, AP POP J, V16, P225, DOI DOI 10.18356/65D467C6-EN; Neelofar S, 2012, PLOS ONE, V7; Oster E, 2011, AM EC J APPL EC, V3; Patkar, 2004, MENSTRUAL HYGIENE MA; Piper-Pillitteri S, 2011, SCH MENSTRUAL HYGIEN; Posner J, 2009, GLOB PUBLIC HEALTH, V4, P284, DOI 10.1080/17441690902783157; Scott L, 2009, IMPACT PROVIDING SAN; SHARMA K, 1990, ANN HUM BIOL, V17, P159, DOI 10.1080/03014469000000912; Singh M M, 2001, Indian J Med Sci, V55, P209; Sommer M, 2010, J ADOLESCENCE, V33, P521, DOI 10.1016/j.adolescence.2009.03.008; Sweet R L, 2000, Infect Dis Obstet Gynecol, V8, P184, DOI 10.1155/S1064744900000260; Ugwumadu AHN, 2002, CURR OPIN OBSTET GYN, V14, P115, DOI 10.1097/00001703-200204000-00003; UNICEF, 2004, STAT WORLDS CHILDR 2; WALKER ARP, 1984, BRIT J OBSTET GYNAEC, V91, P797, DOI 10.1111/j.1471-0528.1984.tb04853.x; WASSERHEIT JN, 1989, STUD FAMILY PLANN, V20, P69, DOI 10.2307/1966461; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307/2939232	49	150	149	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2013	8	4							e62004	10.1371/journal.pone.0062004	http://dx.doi.org/10.1371/journal.pone.0062004			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	136EF	23637945	Green Published, gold, Green Accepted			2023-01-03	WOS:000318343700026
J	Tracy, SW				Tracy, Sarah W.			HISTORY OF MEDICINE Something New under the Sun? The Mediterranean Diet and Cardiovascular Health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Oklahoma, McClendon Honors Coll, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Tracy, SW (corresponding author), Univ Oklahoma, McClendon Honors Coll, Norman, OK 73019 USA.							Allbaugh LG, 1953, CRETE CASE STUDY UND; Datz T., 2011, HARVARD SERVES ITS O; GOFMAN H, 1951, LOW FAT LOW CHOLESTE; Gofman J. W., 1958, DIETARY PREVENTION T; Jacobs DR, 2007, NUTR REV, V65, P439, DOI 10.1301/nr.2007.oct.439-450; NESTLE M, 1995, AM J CLIN NUTR, V61, p1313S, DOI 10.1093/ajcn/61.6.1313S; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673	7	18	18	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 4	2013	368	14					1274	1276		10.1056/NEJMp1302616	http://dx.doi.org/10.1056/NEJMp1302616			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	117YT	23550666				2023-01-03	WOS:000316989900003
J	Roher, AE; Cribbs, DH; Kim, RC; Maarouf, CL; Whiteside, CM; Kokjohn, TA; Daugs, ID; Head, E; Liebsack, C; Serrano, G; Belden, C; Sabbagh, MN; Beach, TG				Roher, Alex E.; Cribbs, David H.; Kim, Ronald C.; Maarouf, Chera L.; Whiteside, Charisse M.; Kokjohn, Tyler A.; Daugs, Ian D.; Head, Elizabeth; Liebsack, Carolyn; Serrano, Geidy; Belden, Christine; Sabbagh, Marwan N.; Beach, Thomas G.			Bapineuzumab Alters A beta Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy	PLOS ONE			English	Article							BRAIN-BARRIER BREAKDOWN; ALZHEIMERS-DISEASE; CHEMICAL-CHARACTERIZATION; IMAGING ABNORMALITIES; PASSIVE IMMUNOTHERAPY; PEPTIDE REMNANTS; RISK-FACTORS; IMMUNIZATION; PATHOLOGY; DEPOSITS	The characteristic neuropathological changes associated with Alzheimer's disease (AD) and other lines of evidence support the amyloid cascade hypothesis. Viewing amyloid deposits as the prime instigator of dementia has now led to clinical trials of multiple strategies to remove or prevent their formation. We performed neuropathological and biochemical assessments of 3 subjects treated with bapineuzumab infusions. Histological analyses were conducted to quantify amyloid plaque densities, Braak stages and the extent of cerebral amyloid angiopathy (CAA). Amyloid-beta (A beta) species in frontal and temporal lobe samples were quantified by ELISA. Western blots of amyloid-beta precursor protein (A beta PP) and its C-terminal (CT) fragments as well as tau species were performed. Bapineuzumab-treated (Bapi-AD) subjects were compared to non-immunized age-matched subjects with AD (NI-AD) and non-demented control (NDC) cases. Our study revealed that Bapi-AD subjects exhibited overall amyloid plaque densities similar to those of NI-AD cases. In addition, CAA was moderate to severe in NI-AD and Bapi-AD patients. Although histologically-demonstrable leptomeningeal, cerebrovascular and neuroparenchymal-amyloid densities all appeared unaffected by treatment, A beta peptide profiles were significantly altered in Bapi-AD subjects. There was a trend for reduction in total A beta(42) levels as well as an increase in A beta(40) which led to a corresponding significant decrease in A beta(42):A beta(40) ratio in comparison to NI-AD subjects. There were no differences in the levels of A beta PP, CT99 and CT83 or tau species between Bapi-AD and NI-AD subjects. The remarkable alteration in A beta profiles reveals a dynamic amyloid production in which removal and depositional processes were apparently perturbed by bapineuzumab therapy. Despite the alteration in biochemical composition, all 3 immunized subjects exhibited continued cognitive decline.	[Roher, Alex E.; Maarouf, Chera L.; Whiteside, Charisse M.; Kokjohn, Tyler A.; Daugs, Ian D.] Banner Sun Hlth Res Inst, Longtine Ctr Neurodegenerat Biochem, Sun City, AZ USA; [Cribbs, David H.] Univ Calif Irvine, Dept Neurol, Irvine, CA 92717 USA; [Cribbs, David H.] Univ Calif Irvine, UCI MIND, Irvine, CA 92717 USA; [Kim, Ronald C.] Univ Calif Irivine, Dept Pathol, Irivine, CA USA; [Kokjohn, Tyler A.] Midwestern Univ, Sch Med, Dept Microbiol, Glendale, AZ USA; [Head, Elizabeth] Univ Kentucky, Sanders Brown Ctr Aging, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA; [Liebsack, Carolyn; Belden, Christine; Sabbagh, Marwan N.] Banner Sun Hlth Res Inst, Roberts Clin Ctr, Sun City, AZ USA; [Serrano, Geidy; Beach, Thomas G.] Banner Sun Hlth Res Inst, Civin Lab Neuropathol, Sun City, AZ USA	Banner Research; Banner Health; Banner Sun Health Research Institute; University of California System; University of California Irvine; University of California System; University of California Irvine; Midwestern University; University of Kentucky; Banner Research; Banner Health; Banner Sun Health Research Institute; Banner Research; Banner Health; Banner Sun Health Research Institute	Roher, AE (corresponding author), Banner Sun Hlth Res Inst, Longtine Ctr Neurodegenerat Biochem, Sun City, AZ USA.	alex.roher@bannerhealth.com			National Institute on Aging (NIA) [R01 AG-19795]; NIA Arizona Alzheimer's Disease Core Center [P30 AG-19610]; State of Arizona Alzheimer's Research Consortium; University of California (Irvine) - ADRC NIH/NIA [P50 AG-16573]; National Institute of Neurological Disorders and Stroke [U24 NS072026]; Arizona Department of Health Services [211002]; Arizona Biomedical Research Commission [4001, 0011, 05-901, 1001]; Michael J. Fox Foundation for Parkinson's Research; Celgene; Quintiles/Genentech; AVID; Lilly; GE; Wyeth; Bayer; Pfizer; BMS; Baxter; Janssen; Medivation; Amerisciences; Wiley; AVID-Radiopharmaceuticals; Schering-Bayer Pharmaceuticals; GE Healthcare; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U24NS072026] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019795, P50AG016573, P30AG019610] Funding Source: NIH RePORTER	National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA Arizona Alzheimer's Disease Core Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); State of Arizona Alzheimer's Research Consortium; University of California (Irvine) - ADRC NIH/NIA; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Arizona Department of Health Services; Arizona Biomedical Research Commission; Michael J. Fox Foundation for Parkinson's Research; Celgene(Bristol-Myers SquibbCelgene Corporation); Quintiles/Genentech; AVID; Lilly(Eli Lilly); GE; Wyeth(Wyeth); Bayer(Bayer AG); Pfizer(Pfizer); BMS(Bristol-Myers Squibb); Baxter; Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Medivation; Amerisciences; Wiley; AVID-Radiopharmaceuticals; Schering-Bayer Pharmaceuticals; GE Healthcare(General ElectricGE Healthcare); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by the National Institute on Aging (NIA) grant R01 AG-19795, the NIA Arizona Alzheimer's Disease Core Center P30 AG-19610, the State of Arizona Alzheimer's Research Consortium and by the University of California (Irvine) - ADRC NIH/NIA Grant P50 AG-16573. The Brain Donation Program at Banner Sun Health Research Institute is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's Research. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.; CB's salary is supported, in part, by Celgene, Quintiles/Genentech, AVID, Lilly, GE, Wyeth, Bayer, and Pfizer. MNS receives grant support from BMS, Avid, GE, Bayer, Baxter, Wyeth, Janssen, Lilly and Medivation, and is in the consultant/advisory board for Janssen/Pfizer, Amerisciences, Eisai and GSK, and receives royalties from Amerisciences and Wiley. TGB receives funding from AVID-Radiopharmaceuticals, Schering-Bayer Pharmaceuticals and GE Healthcare. None of the above funding was for this specific study. The bapineuzumab used in this study is a Pfizer/Johnson & Johnson/Elan product. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.	Abraham CR, 2000, ANN NY ACAD SCI, V920, P245; ABRAHAM CR, 1989, ANN MED, V21, P77, DOI 10.3109/07853898909149188; Ahn HJ, 2010, P NATL ACAD SCI USA, V107, P21812, DOI 10.1073/pnas.1010373107; Atwood CS, 2003, BRAIN RES REV, V43, P164, DOI 10.1016/S0165-0173(03)00206-6; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Beach TG, 2008, CELL TISSUE BANK, V9, P229, DOI 10.1007/s10561-008-9067-2; Biere AL, 1996, J BIOL CHEM, V271, P32916, DOI 10.1074/jbc.271.51.32916; Black RS, 2010, ALZ DIS ASSOC DIS, V24, P198, DOI 10.1097/WAD.0b013e3181c53b00; Blennow K, 2012, ARCH NEUROL-CHICAGO, V69, P1002, DOI 10.1001/archneurol.2012.90; Boche D, 2008, BRAIN, V131, P3299, DOI 10.1093/brain/awn261; Boche D, 2010, ACTA NEUROPATHOL, V120, P369, DOI 10.1007/s00401-010-0719-5; Bohrmann B, 1999, J BIOL CHEM, V274, P15990, DOI 10.1074/jbc.274.23.15990; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Carlson C, 2011, ALZHEIMERS DEMENT, V7, P396, DOI 10.1016/j.jalz.2011.05.2353; Chaney MO, 1998, PROTEIN ENG, V11, P761, DOI 10.1093/protein/11.9.761; Cheng-te Chou P, 2012, ALZHEIMERS DEMENT, V8, pP11, DOI DOI 10.1016/J.JALZ.2012.05.035; Chuang JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033120; Cortes-Canteli M, 2010, NEURON, V66, P695, DOI 10.1016/j.neuron.2010.05.014; Craft S, 2009, ARCH NEUROL-CHICAGO, V66, P300, DOI 10.1001/archneurol.2009.27; Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016; Cullen KM, 2005, J CEREBR BLOOD F MET, V25, P1656, DOI 10.1038/sj.jcbfm.9600155; de la Torre JC, 2012, J ALZHEIMERS DIS; Dickstein DL, 2010, MT SINAI J MED, V77, P82, DOI 10.1002/msj.20155; Fagan T, 2012, CLIN TRIALS INTRAVEN; Fagan T, 2011, PFIZER HALTS DEV ASS; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Gingrich MB, 2000, TRENDS NEUROSCI, V23, P399, DOI 10.1016/S0166-2236(00)01617-9; Giulian D, 1996, J NEUROSCI, V16, P6021; Goodman J, 2012, ALZHEIMERS DEMENT, V8, pP153; GOWING E, 1994, J BIOL CHEM, V269, P10987; Grammas P, 2004, J ALZHEIMERS DIS, V6, P275; Hachinski V, 2012, NEUROLOGY, V79, P107, DOI 10.1212/01.wnl.0000416262.36658.49; Head E, 2001, NEUROBIOL DIS, V8, P252, DOI 10.1006/nbdi.2000.0380; Head E, 2006, ACTA NEUROPATHOL, V112, P217, DOI 10.1007/s00401-006-0098-0; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Jack CR, 2010, BRAIN, V133, P3336, DOI 10.1093/brain/awq277; Kalaria RN, 2012, J NEUROL SCI, V322, P141, DOI 10.1016/j.jns.2012.07.032; Kalaria RN, 2010, NUTR REV, V68, pS74, DOI 10.1111/j.1753-4887.2010.00352.x; Kenche VB, 2011, BRIT J PHARMACOL, V163, P211, DOI 10.1111/j.1476-5381.2011.01221.x; Kerchner GA, 2010, EXPERT OPIN BIOL TH, V10, P1121, DOI 10.1517/14712598.2010.493872; Kim BH, 2011, BIOCHEMISTRY-US, V50, P5154, DOI 10.1021/bi200147a; Kokjohn TA, 2012, ALZHEIMERS DEMENT, V8, P574, DOI 10.1016/j.jalz.2011.05.2429; Kokjohn TA, 2009, CNS NEUROL DISORD-DR, V8, P88, DOI 10.2174/187152709787847315; Kumar-Singh S, 2005, AM J PATHOL, V167, P527, DOI 10.1016/S0002-9440(10)62995-1; Kuo YM, 1997, BIOCHEM BIOPH RES CO, V237, P188, DOI 10.1006/bbrc.1997.7083; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; Kuo YM, 2000, BIOCHEM BIOPH RES CO, V268, P750, DOI 10.1006/bbrc.2000.2222; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lin PY, 2012, ALZHEIMERS DEMENT, V8, pP651; Lleo A, 2004, AM J GERIAT PSYCHIAT, V12, P146, DOI 10.1176/appi.ajgp.12.2.146; Luo F, 2010, J PHARMACOL EXP THER, V335, P580, DOI 10.1124/jpet.110.172932; Lyubchenko Y, 2012, ALZHEIMERS DEMENT, V8, pP659; Lyubchenko YL, 2010, WIRES NANOMED NANOBI, V2, P526, DOI 10.1002/wnan.102; Maarouf CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027291; Maarouf CL, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-39; Maarouf CL, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-20; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; Matsuoka H, 2002, CNS DRUGS, V16, P509, DOI 10.2165/00023210-200216080-00001; Melchor JP, 2003, J NEUROSCI, V23, P8867; Melchor JP, 2003, J MOL NEUROSCI, V20, P287, DOI 10.1385/JMN:20:3:287; Milojevic J, 2011, BIOPHYS J, V100, P183, DOI 10.1016/j.bpj.2010.11.037; Mirra SS, 1997, NEUROBIOL AGING, V18, pS91, DOI 10.1016/S0197-4580(97)00058-4; Morgan D, 2011, J INTERN MED, V269, P54, DOI 10.1111/j.1365-2796.2010.02315.x; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Patton RL, 2006, AM J PATHOL, V169, P1048, DOI 10.2353/ajpath.2006.060269; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Pul R, 2011, EXPERT OPIN BIOL TH, V11, P343, DOI 10.1517/14712598.2011.552884; Racke MM, 2005, J NEUROSCI, V25, P629, DOI 10.1523/JNEUROSCI.4337-04.2005; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0; Roberts BR, 2012, J NEUROCHEM, V120, P149, DOI 10.1111/j.1471-4159.2011.07500.x; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Roher AE, 2003, ARTERIOSCL THROM VAS, V23, P2055, DOI 10.1161/01.ATV.0000095973.42032.44; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Roher AE, 2011, J ALZHEIMERS DIS, V24, P315, DOI 10.3233/JAD-2011-101809; Sabbagh MN, 2010, CURR ALZHEIMER RES, V7, P280, DOI 10.2174/156720510791162340; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Salloway S, 2009, NEUROLOGY, V73, P2061, DOI 10.1212/WNL.0b013e3181c67808; Serrano-Pozo A, 2010, BRAIN, V133, P1312, DOI 10.1093/brain/awq056; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Sosa MAG, 2010, AM J PATHOL, V176, P353, DOI 10.2353/ajpath.2010.090482; Sperling R, 2012, LANCET NEUROL, V11, P241, DOI 10.1016/S1474-4422(12)70015-7; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P367, DOI 10.1016/j.jalz.2011.05.2351; Strobel G, 2012, EXPANDING NETWORK DI; Tougu V, 2011, METALLOMICS, V3, P250, DOI 10.1039/c0mt00073f; Van Vickle GD, 2008, MOL MED, V14, P184, DOI [10.2119/2007-00094.VanVickle, 10.2119/2007-00094.Van Vickle]; VANNOSTRAND WE, 1991, ANN NY ACAD SCI, V640, P140; VANNOSTRAND WE, 1992, ANN NY ACAD SCI, V674, P243; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Wolfe MS, 2007, EMBO REP, V8, P136, DOI 10.1038/sj.embor.7400896; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Yin XL, 2010, AM J PATHOL, V176, P1600, DOI 10.2353/ajpath.2010.090406; Zakaib GD, 2012, PHASE 3 SOLANEZUMAB; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	98	29	30	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2013	8	3							e59735	10.1371/journal.pone.0059735	http://dx.doi.org/10.1371/journal.pone.0059735			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	111UM	23555764	Green Published, gold			2023-01-03	WOS:000316546400059
J	Wang, X; Dong, Y; Han, X; Qi, XQ; Huang, CG; Hou, LJ				Wang, Xiang; Dong, Yan; Han, Xi; Qi, Xiang-Qian; Huang, Cheng-Guang; Hou, Li-Jun			Nutritional Support for Patients Sustaining Traumatic Brain Injury: A Systematic Review and Meta-Analysis of Prospective Studies	PLOS ONE			English	Article							TOTAL PARENTERAL-NUTRITION; EARLY ENTERAL NUTRITION; CONTROLLED-TRIAL; HEAD; HYPERALIMENTATION; SUPPLEMENTATION; GLUTAMINE; BENEFITS; MODERATE	Background: In traumatic brain injury (TBI), the appropriate timing and route of feeding, and the efficacy of immune-enhancing formulae have not been well established. We performed this meta-analysis aiming to compare the effects of different nutritional support modalities on clinical outcomes of TBI patients. Methods: We systematically searched Pubmed, Embase, and the Cochrane Library until October, 2012. All randomized controlled trials (RCTs) and non-randomized prospective studies (NPSs) that compared the effects of different routes, timings, or formulae of feeding on outcomes in TBI patients were selected. The primary outcomes included mortality and poor outcome. The secondary outcomes included the length of hospital stay, the length of ventilation days, and the rate of infectious or feeding-related complications. Findings: 13 RCTs and 3 NPSs were included. The pooled data demonstrated that, compared with delayed feeding, early feeding was associated with a significant reduction in the rate of mortality (relative risk [RR] = 0.35; 95% CI, 0.24-0.50), poor outcome (RR = 0.70; 95% CI, 0.54-0.91), and infectious complications (RR = 0.77; 95% CI, 0.59-0.99). Compared with enteral nutrition, parenteral nutrition showed a slight trend of reduction in the rate of mortality (RR = 0.61; 95% CI, 0.34-1.09), poor outcome (RR = 0.73; 95% CI, 0.51-1.04), and infectious complications (RR = 0.89; 95% CI, 0.66-1.22), whereas without statistical significances. The immune-enhancing formula was associated with a significant reduction in infection rate compared with the standard formula (RR = 0.54; 95% CI, 0.35-0.82). Small-bowel feeding was found to be with a decreasing rate of pneumonia compared with nasogastric feeding (RR = 0.41; 95% CI, 0.22-0.76). Conclusion: After TBI, early initiation of nutrition is recommended. It appears that parenteral nutrition is superior to enteral nutrition in improving outcomes. Our results lend support to the use of small-bowel feeding and immune-enhancing formulae in reducing infectious complications.	[Wang, Xiang; Dong, Yan; Qi, Xiang-Qian; Huang, Cheng-Guang; Hou, Li-Jun] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Dong, Yan] Second Mil Med Univ, Changzheng Hosp, Ctr Neurosci, Shanghai, Peoples R China; [Han, Xi] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China	Naval Medical University; Naval Medical University; Fudan University	Huang, CG (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.	huang64@163.com; lj_hou@hotmail.com		Wang, Xiang/0000-0001-7465-606X	Natural Science Foundation of China [81171130/H0908]; Natural Science Foundation from Science and Technology Commission of Shanghai Municipality [11ZR1448700]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation from Science and Technology Commission of Shanghai Municipality	This study was supported by Natural Science Foundation of China (81171130/H0908) and Natural Science Foundation from Science and Technology Commission of Shanghai Municipality (11ZR1448700). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta-Escribano J, 2010, INTENS CARE MED, V36, P1532, DOI 10.1007/s00134-010-1908-3; Berg A, 2008, CLIN NUTR, V27, P816, DOI 10.1016/j.clnu.2008.06.006; Bistrian BR, 2011, JPEN-PARENTER ENTER, V35, P556, DOI 10.1177/0148607111416122; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Boselli M, 2012, NUTR CLIN PRACT, V27, P99, DOI 10.1177/0884533611431068; Bratton S.L., 2007, J NEUROTRAUMA S, V24, pS37, DOI DOI 10.1089/NEU.2007.9999; Briassoulis G, 2006, PEDIATR CRIT CARE ME, V7, P56, DOI 10.1097/01.PCC.0000192339.44871.26; CALON B, 1990, INFUSIONSTHERAPIE, V17, P246; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Chiang YH, 2012, J NEUROTRAUM, V29, P75, DOI 10.1089/neu.2011.1801; Chourdakis M, 2012, JPEN-PARENTER ENTER, V36, P108, DOI 10.1177/0148607110397878; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060; de Arruda ISF, 2004, CLIN SCI, V106, P287, DOI 10.1042/CS20030251; Dhandapani Sivashanmugam, 2012, Surg Neurol Int, V3, P31, DOI 10.4103/2152-7806.93858; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Foley N, 2008, J NEUROTRAUM, V25, P1415, DOI 10.1089/neu.2008.0628; GADISSEUX P, 1984, J NEUROSURG, V60, P219, DOI 10.3171/jns.1984.60.2.0219; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; Griffiths RD, 2006, LANCET, V368, P1868, DOI 10.1016/S0140-6736(06)69771-7; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; HAUSMANN D, 1985, INTENS CARE MED, V11, P80; Heidegger CP, 2013, LANCET, V381, P385, DOI 10.1016/S0140-6736(12)61351-8; Higgins J. P., 2011, COCHRANE HDB SYST RE, V4, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Meirelles CMJ, 2011, NUTR HOSP, V26, P1120, DOI [10.1590/S0212-16112011000500030, 10.3305/nh.2011.26.5.5133]; Khorana Jiraporn, 2009, Journal of the Medical Association of Thailand, V92, P188; Kostadima E, 2005, EUR RESPIR J, V26, P106, DOI 10.1183/09031936.05.00096104; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Maurya I, 2011, SAUDI J ANAESTH, V5, P195, DOI 10.4103/1658-354X.82800; Minard G, 2000, JPEN-PARENTER ENTER, V24, P145, DOI 10.1177/0148607100024003145; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nataloni S, 1999, CLIN NUTR, V18, P247, DOI 10.1016/S0261-5614(99)80077-6; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; Suchner U, 1996, NUTRITION, V12, P13, DOI 10.1016/0899-9007(95)00016-X; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; Vincent JL, 2013, LANCET, V381, P354, DOI 10.1016/S0140-6736(12)61893-5; Vizzini A, 2011, NUTRITION, V27, P129, DOI 10.1016/j.nut.2010.05.004; Wells G., 2009, VIS COMMUN Q; Worthington ML, 2011, NUTR CLIN PRACT, V26, P650, DOI 10.1177/0884533611425799; YOUNG B, 1987, J NEUROSURG, V67, P76, DOI 10.3171/jns.1987.67.1.0076; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; Zaloga GP, 2006, LANCET, V367, P1101, DOI 10.1016/S0140-6736(06)68307-4; Ziegler TR, 2009, NEW ENGL J MED, V361, P1088, DOI 10.1056/NEJMct0806956	51	54	66	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e58838	10.1371/journal.pone.0058838	http://dx.doi.org/10.1371/journal.pone.0058838			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SR	23527035	Green Published, gold, Green Submitted			2023-01-03	WOS:000317562100050
J	Aleksinskaya, MA; van Faassen, EEH; Nelissen, J; Janssen, BJA; De Mey, JGR; Hanemaaijer, R; Rabelink, T; van Zonneveld, AJ				Aleksinskaya, Marina A.; van Faassen, Ernst E. H.; Nelissen, Jelly; Janssen, Ben J. A.; De Mey, Jo G. R.; Hanemaaijer, Roeland; Rabelink, Ton; van Zonneveld, Anton Jan			Identification of Free Nitric Oxide Radicals in Rat Bone Marrow: Implications for Progenitor Cell Mobilization in Hypertension	PLOS ONE			English	Article							SYNTHASE ENHANCER AVE9488; DOCA-SALT; ENDOTHELIAL DYSFUNCTION; NO; ISOFORMS; STEM; EXPRESSION; BIOLOGY; BLOOD	Nitric oxide (NO) has been implicated in matrix metallopeptidase 9 (MMP9)-dependent mobilization of hematopoietic stem and progenitor cells from bone marrow (BM). However, direct measurement of NO in the BM remained elusive due to its low in situ concentration and short lifetime. Using NO spin trapping and electron paramagnetic resonance (EPR) spectroscopy we give the first experimental confirmation of free NO radicals in rodent BM. NO production was quantified and attributed to enzymatic activity of NO synthases (NOS). Although endothelial NOS (eNOS) accounts for most (66%) of basal NO, we identified a significant contribution (23%) from inducible NOS (iNOS). Basal NO levels closely correlate with MMP9 bioavailability in BM of both hypertensive and control rats. Our observations support the hypothesis that inadequate mobilization of BM-derived stem and progenitor cells in hypertension results from impaired NOS/NO/MMP9 signalling in BM, a condition that may be corrected with pharmacological intervention.	[Aleksinskaya, Marina A.; van Faassen, Ernst E. H.; Rabelink, Ton; van Zonneveld, Anton Jan] Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; [Aleksinskaya, Marina A.; van Faassen, Ernst E. H.; Rabelink, Ton; van Zonneveld, Anton Jan] Leiden Univ, Med Ctr, Einthoven Lab Expt Vasc Med, Leiden, Netherlands; [Nelissen, Jelly; Janssen, Ben J. A.; De Mey, Jo G. R.] Maastricht Univ, Dept Pharmacol, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands; [Hanemaaijer, Roeland] TNO, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Maastricht University; Netherlands Organization Applied Science Research	Aleksinskaya, MA (corresponding author), Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands.	m.a.aleksinskaya@lumc.nl	Rabelink, Ton J./A-5316-2008; van Zonneveld, Anton Jan/D-8060-2018	Rabelink, Ton J./0000-0001-6780-5186; van Zonneveld, Anton Jan/0000-0002-1676-7738; De Mey, Jo G. R./0000-0001-6274-8071	Dutch Top Institute Pharma [T2-108]; Dutch government [FES0908]	Dutch Top Institute Pharma; Dutch government	This research was performed within the framework of project T2-108 of the Dutch Top Institute Pharma and a grant from the Dutch government to the Netherlands Institute for Regenerative Medicine (NIRM, grant No. FES0908). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aicher A, 2004, TRENDS MOL MED, V10, P421, DOI 10.1016/j.molmed.2004.07.007; Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Aicher A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004879; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bae EH, 2009, REGUL PEPTIDES, V157, P76, DOI 10.1016/j.regpep.2009.04.015; Brooks VL, 2006, AM J PHYSIOL-REG I, V291, pR1825, DOI 10.1152/ajpregu.00068.2006; Butler AR, 2001, CHEM COMMUN, P1732, DOI 10.1039/b105460k; Case J, 2008, ANTIOXID REDOX SIGN, V10, P1895, DOI 10.1089/ars.2008.2118; Crabos M, 1997, J MOL CELL CARDIOL, V29, P55, DOI 10.1006/jmcc.1996.0251; Daff S, 2010, NITRIC OXIDE-BIOL CH, V23, P1, DOI 10.1016/j.niox.2010.03.001; Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859; Dimmeler S, 2004, J MOL MED, V82, P671, DOI 10.1007/s00109-004-0580-x; Ergun S, 2011, ANTIOXID REDOX SIGN, V15, P981, DOI 10.1089/ars.2010.3507; Everaert BR, 2010, INT J CARDIOL, V144, P350, DOI 10.1016/j.ijcard.2010.04.018; Fraccarollo D, 2008, CIRCULATION, V118, P818, DOI 10.1161/CIRCULATIONAHA.107.717702; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Hanemaaijer R, 1998, MATRIX BIOL, V17, P657, DOI 10.1016/S0945-053X(98)90116-0; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108; Iwakura A, 2006, CIRCULATION, V113, P1605, DOI 10.1161/CIRCULATIONAHA.105.553925; Iyer A, 2010, CURR CARDIOL REV, V6, P291, DOI 10.2174/157340310793566109; Johnson FK, 2004, AM J PHYSIOL-HEART C, V286, pH1681, DOI 10.1152/ajpheart.00409.2003; Kleschyov AL, 2007, J CHROMATOGR B, V851, P12, DOI 10.1016/j.jchromb.2006.10.006; Kumar S, 2010, CYTOM PART A, V77A, P467, DOI 10.1002/cyto.a.20852; Kurz DJ, 2004, J CELL SCI, V117, P2417, DOI 10.1242/jcs.01097; Liu ZJ, 2008, ANTIOXID REDOX SIGN, V10, P1869, DOI 10.1089/ars.2008.2121; Mur LAJ, 2011, PLANT SCI, V181, P509, DOI 10.1016/j.plantsci.2011.04.003; Op den Buijs J, 2004, AM J PHYSIOL-HEART C, V287, pH2651, DOI 10.1152/ajpheart.00332.2004; Rosti V, 2007, HAEMATOLOGICA, V92, P1291, DOI 10.3324/haematol.11455; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Sasaki K, 2006, P NATL ACAD SCI USA, V103, P14537, DOI 10.1073/pnas.0604144103; Saura M, 2010, THESCIENTIFICWORLDJO, V10, P624, DOI 10.1100/tsw.2010.58; Savoia C, 2011, INT J HYPERTENS, V2011, DOI 10.4061/2011/281240; Suzuki Y, 1997, BBA-GEN SUBJECTS, V1335, P242, DOI 10.1016/S0304-4165(97)00027-5; Taddei S, 2002, J HYPERTENS, V20, P1671, DOI 10.1097/00004872-200209000-00001; van Faassen E., 2007, RADICALS LIFE VARIOU; van Faassen EE, 2008, NITRIC OXIDE-BIOL CH, V18, P279, DOI 10.1016/j.niox.2008.02.003; van Faassen EE, 2009, MED RES REV, V29, P683, DOI 10.1002/med.20151; van Zonneveld AJ, 2006, CURR OPIN NEPHROL HY, V15, P167, DOI 10.1097/01.mnh.0000214774.42103.ec; Vanin AF, 2007, CELL MOL LIFE SCI, V64, P96, DOI 10.1007/s00018-006-6374-2; Vanin AF, 2007, NITRIC OXIDE-BIOL CH, V16, P71, DOI 10.1016/j.niox.2006.06.009; Vanin Anatoly F., 2007, P383, DOI 10.1016/B978-044452236-8/50018-6; Werner N, 2006, ARTERIOSCL THROM VAS, V26, P257, DOI 10.1161/01.ATV.0000198239.41189.5d	43	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2013	8	3							e57761	10.1371/journal.pone.0057761	http://dx.doi.org/10.1371/journal.pone.0057761			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107WV	23554866	Green Published, gold			2023-01-03	WOS:000316252500006
J	De Cecco, L; Berardi, M; Sommariva, M; Cataldo, A; Canevari, S; Mezzanzanica, D; Iorio, MV; Tagliabue, E; Balsari, A				De Cecco, Loris; Berardi, Martina; Sommariva, Michele; Cataldo, Alessandra; Canevari, Silvana; Mezzanzanica, Delia; Iorio, Marilena V.; Tagliabue, Elda; Balsari, Andrea			Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation	PLOS ONE			English	Article							HISTONE DEACETYLASE INHIBITORS; DNA-DAMAGE RESPONSE; OVARIAN-CANCER; IMMUNE-SYSTEM; TLR9 AGONISTS; REPAIR GENES; CELLS; EXPRESSION; TUMOR; RESISTANCE	We recently reported that peritumoral CpG-ODN treatment, activating TLR-9 expressing cells in tumor microenvironment, induces modulation of genes involved in DNA repair and sensitizes cancer cells to DNA-damaging cisplatin treatment. Here, we investigated whether this treatment induces modulation of miRNAs in tumor cells and their relevance to chemotherapy response. Array analysis identified 20 differentially expressed miRNAs in human IGROV-1 ovarian tumor cells from CpG-ODN-treated mice versus controls (16 down-and 4 up-regulated). Evaluation of the role of the 3 most differentially expressed miRNAs on sensitivity to cisplatin of IGROV-1 cells revealed significantly increased cisplatin cytotoxicity upon ectopic expression of hsa-miR-302b (up-modulated in our array), but no increased effect upon reduced expression of hsa-miR-424 or hsa-miR-340 (down-modulated in our array). Accordingly, hsa-miR-302b expression was significantly associated with time to relapse or overall survival in two data sets of platinum-treated ovarian cancer patients. Use of bio-informatics tools identified 19 mRNAs potentially targeted by hsa-miR-302b, including HDAC4 gene, which has been reported to mediate cisplatin sensitivity in ovarian cancer. Both HDAC4 mRNA and protein levels were significantly reduced in IGROV-1 cells overexpressing hsa-miR-302b. Altogether, these findings indicate that hsa-miR-302b acts as a "chemosensitizer" in human ovarian carcinoma cells and may represent a biomarker able to predict response to cisplatin treatment. Moreover, the identification of miRNAs that improve sensitivity to chemotherapy provides the experimental underpinning for their possible future clinical use.	[De Cecco, Loris] Fdn Ist Ricovero & Cura Carattere Sci, Ist Nazl Tumori, Funct Genom Core Facil, Milan, Italy; [Berardi, Martina; Sommariva, Michele; Tagliabue, Elda; Balsari, Andrea] Fdn Ist Ricovero & Cura Carattere Sci, Ist Nazl Tumori, Mol Targeting Unit, Milan, Italy; [Sommariva, Michele; Cataldo, Alessandra; Balsari, Andrea] Univ Milan, Dept Biomed Sci Hlth, Milan, Italy; [Canevari, Silvana; Mezzanzanica, Delia] Fdn Ist Ricovero & Cura Carattere Sci, Ist Nazl Tumori, Mol Therapies Unit, Milan, Italy; [Iorio, Marilena V.] Fdn Ist Ricovero & Cura Carattere Sci, Ist Nazl Tumori, Start Unit, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Balsari, A (corresponding author), Fdn Ist Ricovero & Cura Carattere Sci, Ist Nazl Tumori, Mol Targeting Unit, Milan, Italy.	andrea.balsari@unimi.it	balsari, andrea/M-5657-2016; Tagliabue, Elda/B-9377-2017; De Cecco, Loris/K-7036-2016; Iorio, Marilena V/K-5446-2016; Cataldo, Alessandra/C-6204-2017; Mezzanzanica, Delia/C-2607-2017; Sommariva, Michele/C-1174-2017	balsari, andrea/0000-0002-3250-2668; Tagliabue, Elda/0000-0001-9877-2903; De Cecco, Loris/0000-0002-7066-473X; Iorio, Marilena V/0000-0002-6058-1527; Cataldo, Alessandra/0000-0002-1882-9410; Mezzanzanica, Delia/0000-0002-9664-6871; Sommariva, Michele/0000-0002-7622-0996	Associazione Italiana per la Ricerca sul Cancro (AIRC); "Dote ricerca": FSE, Regione Lombardia; Start Up AIRC Grant	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); "Dote ricerca": FSE, Regione Lombardia(Regione Lombardia); Start Up AIRC Grant(Fondazione AIRC per la ricerca sul cancro)	This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC). MS was supported by "Dote ricerca": FSE, Regione Lombardia. MVI is supported by Start Up AIRC Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu MT, 2005, J IMMUNOL, V174, P4453, DOI 10.4049/jimmunol.174.8.4453; Allen KE, 2010, MOL CANCER THER, V9, P3126, DOI 10.1158/1535-7163.MCT-10-0397; Bagnoli M, 2011, ONCOTARGET, V2, P1265, DOI 10.18632/oncotarget.401; Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; BENARD J, 1985, CANCER RES, V45, P4970; Berezikov E, 2006, NAT GENET, V38, P1375, DOI 10.1038/ng1914; De Cesare M, 2008, CLIN CANCER RES, V14, P5512, DOI 10.1158/1078-0432.CCR-08-0445; Dolezalova D, 2012, STEM CELLS, V30, P1362, DOI 10.1002/stem.1108; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/FMC.12.3, 10.4155/fmc.12.3]; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Hu HL, 2011, J MOL CELL BIOL, V3, P151, DOI 10.1093/jmcb/mjq042; Jackson AL, 2012, NUCLEIC ACID THER, V22, P213, DOI 10.1089/nat.2012.0356; Jin KL, 2010, J GYNECOL ONCOL, V21, P262, DOI 10.3802/jgo.2010.21.4.262; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Kim TH, 2010, HISTOPATHOLOGY, V57, P734, DOI 10.1111/j.1365-2559.2010.03686.x; Krieg Arthur M, 2007, Proc Am Thorac Soc, V4, P289, DOI 10.1513/pats.200701-021AW; Landau DA, 2011, SEMIN ONCOL, V38, P743, DOI 10.1053/j.seminoncol.2011.08.003; Lodish HF, 2008, NAT REV IMMUNOL, V8, P120, DOI 10.1038/nri2252; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Nahid MA, 2011, CELL MOL IMMUNOL, V8, P388, DOI 10.1038/cmi.2011.26; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Ozaki K, 2008, CANCER SCI, V99, P376, DOI 10.1111/j.1349-7006.2007.00669.x; Sales G, 2010, NUCLEIC ACIDS RES, V38, pW352, DOI 10.1093/nar/gkq423; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shih KK, 2011, GYNECOL ONCOL, V121, P444, DOI 10.1016/j.ygyno.2011.01.025; Sommariva M, 2012, ONCOIMMUNOLOGY, V1, P258, DOI 10.4161/onci.1.2.18343; Sommariva M, 2011, CANCER RES, V71, P6382, DOI 10.1158/0008-5472.CAN-11-1285; Stiborova M, 2012, CURR MED CHEM; Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111; Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI 10.2217/FON.11.2; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34	39	16	17	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2013	8	3							e58849	10.1371/journal.pone.0058849	http://dx.doi.org/10.1371/journal.pone.0058849			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	117EP	23484053	gold, Green Published, Green Submitted			2023-01-03	WOS:000316936100139
J	Kornfield, R; Donohue, J; Berndt, ER; Alexander, GC				Kornfield, Rachel; Donohue, Julie; Berndt, Ernst R.; Alexander, G. Caleb			Promotion of Prescription Drugs to Consumers and Providers, 2001-2010	PLOS ONE			English	Article							OF-INTEREST; QUALITY	Background: Pharmaceutical firms heavily promote their products and may have changed marketing strategies in response to reductions in new product approvals, restrictions on some forms of promotion, and the expanding role of biologic therapies. Methods: We used descriptive analyses of annual cross-sectional data from 2001 through 2010 to examine direct-to-consumer advertising (DTCA) (Kantar Media) and provider-targeted promotion (IMS Health and SDI), including: (1) inflation-adjusted total promotion spending ($ and percent of sales); (2) distribution by channel (consumer v. provider); and (3) provider specialty both for the industry as a whole and for top-selling biologic and small molecule therapies. Results: Total promotion peaked in 2004 at US$36.1 billion (13.4% of sales). By 2010 it had declined to $27.7B (9.0% of sales). Between 2006 and 2010, similar declines were seen for promotion to providers and DTCA (both by 25%). DTCA's share of total promotion increased from 12% in 2002 to 18% in 2006, but then declined to 16% and remains highly concentrated. Number of products promoted to providers peaked in 2004 at over 3000, and then declined 20% by 2010. In contrast to top-selling small molecule therapies having an average of $ 370 million (8.8% of sales) spent on promotion, top biologics were promoted less, with only $ 33 million (1.4% of sales) spent per product. Little change occurred in the composition of promotion between primary care physicians and specialists from 2001-2010. Conclusions: These findings suggest that pharmaceutical companies have reduced promotion following changes in the pharmaceutical pipeline and patent expiry for several blockbuster drugs. Promotional strategies for biologic drugs differ substantially from small molecule therapies.	[Kornfield, Rachel; Alexander, G. Caleb] Univ Chicago, Dept Med, Gen Internal Med Sect, Chicago, IL 60637 USA; [Donohue, Julie] Univ Pittsburgh, Dept Hlth Policy & Management, Pittsburgh, PA USA; [Donohue, Julie] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Berndt, Ernst R.] MIT, Alfred P Sloan Sch Management, Cambridge, MA 02139 USA; [Berndt, Ernst R.] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Alexander, G. Caleb] Johns Hopkins Med, Dept Med, Baltimore, MD USA; [Alexander, G. Caleb] Univ Illinois, Chicago Sch Pharm, Dept Pharm Practice, Chicago, IL USA	University of Chicago; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Massachusetts Institute of Technology (MIT); National Bureau of Economic Research; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Alexander, GC (corresponding author), Univ Chicago, Dept Med, Gen Internal Med Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.	galexand@jhsph.edu	Kornfield, Rachel/Q-4992-2019	Donohue, Julie/0000-0003-2418-6017	Agency for Healthcare Research and Quality [RO1 HS0189960]	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Ms. Kornfield and Dr. Alexander were supported by the Agency for Healthcare Research and Quality (RO1 HS0189960). The funding sources had no role in study design or conduct; collection, management, analysis, or interpretation of the data; or preparation, review, or final manuscript approval.	Aggarwal S, 2010, NAT BIOTECHNOL, V28, P1165, DOI 10.1038/nbt1110-1165; Aitken M, 2009, HEALTH AFFAIR, V28, pW151, DOI 10.1377/hlthaff.28.1.w151; American Association of Medical Colleges, 2008, PROT PAT PRES INT AD; Brennan TA, 2006, JAMA-J AM MED ASSOC, V295, P429, DOI 10.1001/jama.295.4.429; Campbell EG, 2010, ARCH INTERN MED, V170, P1820, DOI 10.1001/archinternmed.2010.383; Campbell S, 2009, PROMOTIONAL SPENDING; Chimonas S, 2010, HEALTH SERV RES, V45, P98, DOI 10.1111/j.1475-6773.2009.01048.x; Donohue JM, 2004, J PUBLIC POLICY MARK, V23, P115, DOI 10.1509/jppm.23.2.115.51395; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; Eichler HG, 2008, NAT REV DRUG DISCOV, V7, P818, DOI 10.1038/nrd2664; Fugh-Berman A, 2011, ACAD MED, V86, P649, DOI 10.1097/ACM.0b013e318212e8d4; Gagnon MA, 2008, PLOS MED, V5, P29, DOI 10.1371/journal.pmed.0050001; Groves KEM, 2003, J CLIN PHARM THER, V28, P259, DOI 10.1046/j.1365-2710.2003.00481.x; Hensley Scott, 2005, Wall St J (East Ed); Iizuka T, 2005, J ECON MANAGE STRAT, V14, P701, DOI 10.1111/j.1530-9134.2005.00079.x; IMS Institute for Healthcare Informatics, 2011, US MED US REV 2010; Institute of Medicine, 2009, CONFL INT MED RES ED; Kolata G., 2008, NY TIMES; Korenstein D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023336; Liang BA, 2011, JAMA-J AM MED ASSOC, V305, P824, DOI 10.1001/jama.2011.203; Mullins CD, 2005, HEALTH AFFAIR, V24, P1117, DOI 10.1377/hlthaff.24.4.1117; O'Reilly K, 2009, AM MED NEWS     0323; Othman N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006350; Rader RA, 2011, TOP 50 BIOPHARMA PRO; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Rosenthal MB, 2003, FRONTIERS HLTH POLIC, V6, P1; Rothman DJ, 2008, JAMA-J AM MED ASSOC, V300, P1067, DOI 10.1001/jama.300.9.1067; Rothman DJ, 2010, JAMA-J AM MED ASSOC, V304, P2294, DOI 10.1001/jama.2010.1714; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Trusheim MR, 2010, 16014 NAT BUR EC RES; United States Food and Drug Administration, 2011, SUMM NDA APPR REC 19; United States Food and Drug Administration, 2011, CTR DRUG EV RES DRUG	32	62	62	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2013	8	3							e55504	10.1371/journal.pone.0055504	http://dx.doi.org/10.1371/journal.pone.0055504			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	099PY	23469165	gold, Green Submitted, Green Accepted, Green Published			2023-01-03	WOS:000315634900003
J	Pei, LX; Bao, YW; Liu, S; Zheng, J; Chen, XP				Pei, Lixia; Bao, Yuanwu; Liu, Sheng; Zheng, Jin; Chen, Xiuping			Material Basis of Chinese Herbal Formulas Explored by Combining Pharmacokinetics with Network Pharmacology	PLOS ONE			English	Article							PSORALEA-CORYLIFOLIA L.; MASS-SPECTROMETRY; DRUG CANDIDATES; MEDICINE; PHARMACODYNAMICS; COMBINATIONS; COMPONENTS; PLASMA; CELLS	The clinical application of Traditional Chinese medicine (TCM), using several herbs in combination (called formulas), has a history of more than one thousand years. However, the bioactive compounds that account for their therapeutic effects remain unclear. We hypothesized that the material basis of a formula are those compounds with a high content in the decoction that are maintained at a certain level in the system circulation. Network pharmacology provides new methodological insights for complicated system studies. In this study, we propose combining pharmacokinetic (PK) analysis with network pharmacology to explore the material basis of TCM formulas as exemplified by the Bushen Zhuanggu formula (BZ) composed of Psoralea corylifolia L., Aconitum carmichaeli Debx., and Cnidium monnieri (L.) Cuss. A sensitive and credible liquid chromatography tandem mass spectrometry (LC-MS/MS) method was established for the simultaneous determination of 15 compounds present in the three herbs. The concentrations of these compounds in the BZ decoction and in rat plasma after oral BZ administration were determined. Up to 12 compounds were detected in the BZ decoction, but only 5 could be analyzed using PK parameters. Combined PK results, network pharmacology analysis revealed that 4 compounds might serve as the material basis for BZ. We concluded that a sensitive, reliable, and suitable LC-MS/MS method for both the composition and pharmacokinetic study of BZ has been established. The combination of PK with network pharmacology might be a potent method for exploring the material basis of TCM formulas.	[Pei, Lixia; Bao, Yuanwu; Liu, Sheng; Zheng, Jin] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Pharmacol Lab Tradit Chinese Med, Shanghai, Peoples R China; [Chen, Xiuping] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China	Shanghai University of Traditional Chinese Medicine; University of Macau	Chen, XP (corresponding author), Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.	xpchen@umac.mo	Chen, Xiuping/O-8927-2017; Chen, Xiuping/AAG-3086-2020	Chen, Xiuping/0000-0003-2675-7645; 	Foundation of Shanghai Municipal Health Bureau [20114060]; Higher Education Institutions of Shanghai [shzy019]; Major Science and Technology Project for the 12th National Five-Year Plan-Clinical Evaluation and Research Technology Platform for TCM New Drug Research [2011ZX09302-006-04]; Macao Science and Technology Development Fund [045/2011/A]	Foundation of Shanghai Municipal Health Bureau; Higher Education Institutions of Shanghai; Major Science and Technology Project for the 12th National Five-Year Plan-Clinical Evaluation and Research Technology Platform for TCM New Drug Research; Macao Science and Technology Development Fund	The study was supported by the Foundation of Shanghai Municipal Health Bureau (No. 20114060), the Young Teachers Program of the Higher Education Institutions of Shanghai (No. shzy019), the Major Science and Technology Project for the 12th National Five-Year Plan-Clinical Evaluation and Research Technology Platform for TCM New Drug Research (Cancer and Related Diseases; No. 2011ZX09302-006-04), and the Macao Science and Technology Development Fund (No. 045/2011/A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Rahman SM, 2004, ANNU REV PHARMACOL, V44, P111, DOI 10.1146/annurev.pharmtox.44.101802.121347; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Borgatti SP, 2009, SCIENCE, V323, P892, DOI 10.1126/science.1165821; [陈修平 CHEN Xiu-ping], 2010, [中草药, Chinese Traditional and Herbal Drugs], V41, P1; COLBURN WA, 1988, J CLIN PHARMACOL, V28, P769, DOI 10.1002/j.1552-4604.1988.tb03215.x; Di Wang, 2008, Zhongguo Zhong Yao Za Zhi, V33, P1687; Dingemanse J, 2007, CLIN PHARMACOKINET, V46, P713, DOI 10.2165/00003088-200746090-00001; Feng L, 2010, ARCH PHARM RES, V33, P225, DOI 10.1007/s12272-010-0206-5; Fujimura Takashi, 2007, J Gastrointest Cancer, V38, P78, DOI 10.1007/s12029-008-9035-x; Graziose Rocky, 2010, Curr Drug Discov Technol, V7, P2; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; IWASA JUNZO, 1966, YAKUGAKU ZASSHI, V86, P585; Ji L, 1995, Zhongguo Zhong Yao Za Zhi, V20, P120; Kang YJ, 2008, EXP BIOL MED, V233, P1059, DOI 10.3181/0802-MR-47; Kao SJ, 2012, TOXICOL APPL PHARM, V261, P105, DOI 10.1016/j.taap.2012.03.020; Kwoh CK, 2007, CELL MOL LIFE SCI, V64, P1739, DOI 10.1007/s00018-007-7053-7; Lan K, 2010, CURR DRUG METAB, V11, P105, DOI 10.2174/138920010791110926; Li Q, 2010, ACTA U TRADITIONIS M, V24, P6; Li S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-S1-S10; Li S, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S11-S6; Li XM, 2009, CURR OPIN ALLERGY CL, V9, P161, DOI 10.1097/ACI.0b013e328329226f; Lin JH, 2002, E SCHERING RES FDN W, V37, P33; Liu Chang-xiao, 2005, Yao Xue Xue Bao, V40, P395; Liu S, 2011, CHIN J INTEGR MED, V31, P6; Lu T, 2008, DRUG METAB DISPOS, V36, P1578, DOI 10.1124/dmd.108.021592; Luo KW, 2011, CHEMOTHERAPY, V57, P449, DOI 10.1159/000331641; Okamura N, 1999, J PHARMACEUT BIOMED, V20, P363, DOI 10.1016/S0731-7085(99)00065-5; Okamura N, 1999, J PHARMACEUT BIOMED, V19, P603, DOI 10.1016/S0731-7085(98)00262-3; Ruan B, 2007, J ASIAN NAT PROD RES, V9, P41, DOI 10.1080/10286020500289618; Ruiz-Garcia A, 2008, J PHARM SCI-US, V97, P654, DOI 10.1002/jps.21009; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; SUN W J, 1990, Yaoxue Xuebao, V25, P530; Tang W, 2009, CURR PHARM DESIGN, V15, P2170, DOI 10.2174/138161209788682451; Todorovic N, 2011, BIOMARK MED, V5, P855, DOI [10.2217/BMM.11.59, 10.2217/bmm.11.59]; Wang J, 2009, J CHROMATOGR A, V1216, P2169, DOI 10.1016/j.chroma.2008.11.077; Wang JF, 2008, CURR TOP MED CHEM, V8, P1656, DOI 10.2174/156802608786786633; Wang Steven, 2010, Curr Drug Discov Technol, V7, P67; Wang XJ, 2011, ANALYST, V136, P5068, DOI 10.1039/c1an15752c; Xu XM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-33; Yan DM, 2009, PHYTOTHER RES, V23, P317, DOI 10.1002/ptr.2622; Yang Xian, 2007, Yaoxue Xuebao, V42, P877; Yue H, 2009, TALANTA, V77, P1800, DOI 10.1016/j.talanta.2008.10.022; Zhang AH, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-20; Zhang N, 2013, J NAT MED-TOKYO, V67, P36, DOI 10.1007/s11418-012-0641-3; Zhao J, 2010, BRIEF BIOINFORM, V11, P417, DOI 10.1093/bib/bbp063; Zhao LH, 2005, CHEM PHARM BULL, V53, P1054, DOI 10.1248/cpb.53.1054	46	28	30	1	68	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57414	10.1371/journal.pone.0057414	http://dx.doi.org/10.1371/journal.pone.0057414			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23468985	gold, Green Submitted, Green Published			2023-01-03	WOS:000315524900085
J	Wang, ZY; Zhang, PX; Kou, YH; Yin, XF; Han, N; Jiang, BG				Wang, Zhiyong; Zhang, Peixun; Kou, Yuhui; Yin, Xiaofeng; Han, Na; Jiang, Baoguo			Hedysari Extract Improves Regeneration after Peripheral Nerve Injury by Enhancing the Amplification Effect	PLOS ONE			English	Article							GROWTH-FACTOR DELIVERY; SPINAL-CORD; AXON GROWTH; SCHWANN; CONDUITS; CELLS; RATS	Radix Hedysari is an herbal preparation frequently used in traditional Chinese medicine. It can promote regeneration after peripheral nerve injury, but its effect on the amplification ratio (the ratio of distal to proximal fibers) during peripheral nerve regeneration has not yet been examined. In this study, we explored the effect of Hedysari extract on the amplification ratio in the peripheral nerve. Male Sprague-Dawley rats were separated into three groups at random: normal group (without surgery), model group (given sleeve nerve bridging surgery, but without adjuvant treatment) and treatment group (given sleeve nerve bridging surgery and then given Hedysari extract as adjuvant treatment). Twelve weeks after surgery, general observations, electrophysiological examination, histological analysis, morphometric measurements, and amplification ratio calculations were made. The results showed that nerve conduction velocity, the fiber and axon diameter, the g-ratio, the number of regenerating nerve fibers and the amplification ratio were better in the treatment group than in the model group, suggesting that Hedysari extract can effectively promote the growth of lateral buds in the proximal nerve stump and substantially improve the amplification effect during peripheral nerve regeneration.	[Wang, Zhiyong; Zhang, Peixun; Kou, Yuhui; Yin, Xiaofeng; Han, Na; Jiang, Baoguo] Peking Univ, Dept Trauma & Orthoped, Peoples Hosp, Beijing 100871, Peoples R China	Peking University	Zhang, PX (corresponding author), Peking Univ, Dept Trauma & Orthoped, Peoples Hosp, Beijing 100871, Peoples R China.	zhangpeixun@126.com; jiangbaoguo@vip.sina.com		Jiang, Baoguo/0000-0001-8436-5266; Kou, Yuhui/0000-0003-1523-825X; Han, Na/0000-0002-2472-8245; Yin, Xiaofeng/0000-0001-9932-642X	National Natural Science Fund [31171150, 31271284, 81171146, 30971526, 30801169]; Beijing City Science and Technology New Star Classification [A-2008-10]; Educational Ministry New Century Excellent Talents Support Project [BMU 20110270]; National Eleven Five State Science and Technology Support Program [2007BAI04B06]; National Natural Science Youth Science Fund [31100860]	National Natural Science Fund(National Natural Science Foundation of China (NSFC)); Beijing City Science and Technology New Star Classification; Educational Ministry New Century Excellent Talents Support Project; National Eleven Five State Science and Technology Support Program; National Natural Science Youth Science Fund	This study was supported by National Natural Science Fund (31171150, 31271284, 81171146, 30971526, 30801169), Beijing City Science and Technology New Star Classification (A-2008-10), Educational Ministry New Century Excellent Talents Support Project (BMU 20110270), National Eleven Five State Science and Technology Support Program (2007BAI04B06) and National Natural Science Youth Science Fund (31100860). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Berger A, 1999, UNFALLCHIRURG, V102, P59, DOI 10.1007/s001130050373; Blesch A, 1999, J NEUROSCI, V19, P3556; Cui XM, 1998, TCM PHARM CLIN, V14, P19; Ide C, 1996, NEUROSCI RES, V25, P101; IDE C, 1983, ARCH HISTOL JAPON, V46, P243, DOI 10.1679/aohc.46.243; Jiang BG, 2007, EUR NEUROL, V58, P12, DOI 10.1159/000102161; [姜保国 Jiang Baoguo], 2002, [中华显微外科杂志, Chinese Journal of Microsurgery], V25, P38; Jiang BG, 2006, ARTIF CELL BLOOD SUB, V34, P55, DOI 10.1080/10731190500430149; Jin Z.S., 2004, CHIN J TCM WM CRIT C, V11, P141; Madduri S, 2012, J CONTROL RELEASE, V161, P274, DOI 10.1016/j.jconrel.2011.11.036; RUTISHAUSER U, 1985, J NEUROSCI RES, V13, P123, DOI 10.1002/jnr.490130109; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Song QH, 2000, J ETHNOPHARMACOL, V73, P111, DOI 10.1016/S0378-8741(00)00273-7; Su KX, 2005, J YOUJIANG MINZU COL, V4, P445; Sun HY, 2012, NEUROL RES, V34, P491, DOI 10.1179/1743132812Y.0000000037; Torigoe K, 1996, EXP NEUROL, V137, P301, DOI 10.1006/exnr.1996.0030; Tuszynski MH, 1996, EXP NEUROL, V137, P157, DOI 10.1006/exnr.1996.0016; [魏光如 Wei Guangru], 2004, [中华手外科杂志, Chinese Journal of Hand Surgery], V20, P177; Wei SY, 2009, AM J CHINESE MED, V37, P57, DOI 10.1142/S0192415X09006618; Wei SY, 2009, J ETHNOPHARMACOL, V123, P51, DOI 10.1016/j.jep.2009.02.030; [杨德梅 Yang Demei], 2006, [中华手外科杂志, Chinese Journal of Hand Surgery], V22, P308; Ye JH, 1997, EXP NEUROL, V143, P70, DOI 10.1006/exnr.1996.6353; Yu CS, 2009, NEUROIMAGE, V47, P451, DOI 10.1016/j.neuroimage.2009.04.066; Zhang J. P., 1998, CHIN J INT MED, V18, P76; Zhang PX, 2011, ARTIF CELL BLOOD SUB, V39, P39, DOI 10.3109/10731199.2010.494583; Zhang PX, 2005, J RECONSTR MICROSURG, V21, P565, DOI 10.1055/s-2005-922437; Zhang ZH, 2005, J JILIN MED, V26, P132; Zheng HJ, 1991, J LANZHOU U, V37, P82	29	21	24	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2013	8	7							e67921	10.1371/journal.pone.0067921	http://dx.doi.org/10.1371/journal.pone.0067921			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182HT	23844128	Green Submitted, Green Published, gold			2023-01-03	WOS:000321733000115
J	Sugiyama, T; Asai, T; Nedachi, YM; Katanasaka, Y; Shimizu, K; Maeda, N; Oku, N				Sugiyama, Tomoki; Asai, Tomohiro; Nedachi, Yuki Murase; Katanasaka, Yasufumi; Shimizu, Kosuke; Maeda, Noriyuki; Oku, Naoto			Enhanced Active Targeting via Cooperative Binding of Ligands on Liposomes to Target Receptors	PLOS ONE			English	Article							ANTI-NEOVASCULAR THERAPY; ANGIOGENIC VESSELS; TUMOR VASCULATURE; CANCER; DRUG; DELIVERY; IMMUNOLIPOSOMES; CHEMOTHERAPY; PEPTIDES; GROWTH	To achieve effective active targeting in a drug delivery system, we previously developed dual-targeting (DT) liposomes decorated with both vascular endothelial growth factor receptor-1 (VEGFR-1)-targeted APRPG and CD13-targeted GNGRG peptide ligands for tumor neovessels, and observed the enhanced suppression of tumor growth in Colon26 NL-17 tumor-bearing mice by the treatment with the DT liposomes encapsulating doxorubicin. In this present study, we examined the binding characteristics of DT liposomes having a different couple of ligands, namely, APRPG and integrin alpha(v)beta(3)-targeted GRGDS peptides. These DT liposomes synergistically associated to stimulated human umbilical vein endothelial cells compared with single-targeting (ST) liposomes decorated with APRPG or GRGDS. The results of a surface plasmon resonance assay showed that ST liposomes modified with APRPG or GRGDS peptide selectively bound to immobilized VEGFR-1 or integrin alpha(v)beta(3), respectively. DT liposomes showed a higher affinity for a mixture of VEGFR-1 and integrin alpha(v)beta(3) compared with ST liposomes, suggesting the cooperative binding of these 2 kinds of ligand on the liposomal surface. In a biodistribution assay, the DT liposomes accumulated to a significantly greater extent in the tumors of Colon26 NL-17 tumor-bearing mice compared with other liposomes. Moreover, the intratumoral distribution of the liposomes examined by confocal microscopy suggested that the DT liposomes targeted not only angiogenic endothelial cells but also tumor cells due to GRGDS-decoration. These findings suggest that "dual-targeting" augmented the affinity of the liposomes for the target cells and would thus be useful for active-targeting drug delivery for cancer treatment.	[Sugiyama, Tomoki; Asai, Tomohiro; Nedachi, Yuki Murase; Katanasaka, Yasufumi; Shimizu, Kosuke; Oku, Naoto] Univ Shizuoka, Sch Pharmaceut Sci, Dept Med Biochem, Suruga Ku, Shizuoka 4228526, Japan; [Maeda, Noriyuki] Nippon Fine Chem Co Ltd, Takasago, Hyogo, Japan	University of Shizuoka	Oku, N (corresponding author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Med Biochem, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	oku@u-shizuoka-ken.ac.jp		Shimizu, Kosuke/0000-0003-3789-2447	 [17016064]		This research was supported by Grant-in-Aid for Scientific Research on Priority Areas (17016064) http://www.mext.go.jp/english/. The funders had no role in study design, data collection and analysis, decision to publish.	Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Asai T, 2002, FEBS LETT, V520, P167, DOI 10.1016/S0014-5793(02)02821-1; Fay F, 2011, IMMUNOTHERAPY-UK, V3, P381, DOI 10.2217/IMT.11.5; Giordano RJ, 2001, NAT MED, V7, P1249, DOI 10.1038/nm1101-1249; Hatakeyama H, 2011, ADV DRUG DELIVER REV, V63, P152, DOI 10.1016/j.addr.2010.09.001; Ichikawa K, 2004, BIOL PHARM BULL, V27, P443, DOI 10.1248/bpb.27.443; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Koide H, 2011, BIOL PHARM BULL, V34, P602, DOI 10.1248/bpb.34.602; Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063; Maeda H, 2011, ADV DRUG DELIVER REV, V63, P129, DOI 10.1016/j.addr.2010.05.001; Maeda N, 2004, J CONTROL RELEASE, V100, P41, DOI 10.1016/j.jconrel.2004.07.033; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Murase Y, 2010, CANCER LETT, V287, P165, DOI 10.1016/j.canlet.2009.06.008; Nishikawa K, 2012, J CONTROL RELEASE, V160, P274, DOI 10.1016/j.jconrel.2011.10.010; Oku N, 2002, ONCOGENE, V21, P2662, DOI 10.1038/sj.onc.1205347; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; Park JW, 1997, CANCER LETT, V118, P153, DOI 10.1016/S0304-3835(97)00326-1; Pasqualini R, 2000, CANCER RES, V60, P722; Pastorino F, 2003, CANCER RES, V63, P7400; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Shimizu K, 2005, INT J PHARMACEUT, V296, P133, DOI 10.1016/j.ijpharm.2005.02.030; TSURUO T, 1984, GANN, V75, P193; Xiong XB, 2005, J PHARM SCI-US, V94, P1782, DOI 10.1002/jps.20397; Yonezawa S, 2007, J CONTROL RELEASE, V118, P303, DOI 10.1016/j.jconrel.2006.12.024	24	20	20	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e67550	10.1371/journal.pone.0067550	http://dx.doi.org/10.1371/journal.pone.0067550			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IH	23840738	gold, Green Published, Green Submitted			2023-01-03	WOS:000321148400105
J	Johannsen, NM; Sparks, LM; Zhang, ZY; Earnest, CP; Smith, SR; Church, TS; Ravussin, E				Johannsen, Neil M.; Sparks, Lauren M.; Zhang, Zhengyu; Earnest, Conrad P.; Smith, Steven R.; Church, Timothy S.; Ravussin, Eric			Determinants of the Changes in Glycemic Control with Exercise Training in Type 2 Diabetes: A Randomized Trial	PLOS ONE			English	Article							HUMAN SKELETAL-MUSCLE; INSULIN-RESISTANCE; PGC-1-ALPHA; ADIPONECTIN; ACTIVATION; METABOLISM; OXIDATION; GENE	Aims: To assess the determinants of exercise training-induced improvements in glucose control (HbA(1C)) including changes in serum total adiponectin and FFA concentrations, and skeletal muscle peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1 alpha) protein content. Methods: A sub-cohort (n = 35; 48% men; 74% Caucasian) from the HART-D study undertaking muscle biopsies before and after 9 months of aerobic (AT), resistance (RT), or combination training (ATRT). Results: Changes in HbA(1C) were associated with changes in adiponectin (r = -0.45, P = 0.007). Participants diagnosed with type 2 diabetes for a longer duration had the largest increase in PGC-1 alpha (r = 0.44, P = 0.008). Statistical modeling examining changes in HbA(1C) suggested that male sex (P = 0.05), non-Caucasian ethnicity (P = 0.02), duration of type 2 diabetes (r = 0.40; P<0.002) and changes in FFA (r = 0.36; P<0.004), adiponectin (r = -0.26; P<0.03), and PGC-1 alpha (r = -0.28; P = 0.02) explain, similar to 65% of the variability in the changes in HbA(1C). Conclusions: Decreases in HbA(1C) after 9 months of exercise were associated with shorter duration of diabetes, lowering of serum FFA concentrations, increasing serum adiponectin concentrations and increasing skeletal muscle PGC-1 alpha protein expression.	[Johannsen, Neil M.; Zhang, Zhengyu; Church, Timothy S.; Ravussin, Eric] Pennington Biomed Res Ctr, Baton Rouge, LA USA; [Johannsen, Neil M.] Louisiana State Univ, Baton Rouge, LA 70803 USA; [Sparks, Lauren M.] Translat Res Inst Metab & Diabet, Orlando, FL USA; [Earnest, Conrad P.] Univ Bath, Dept Hlth, Bath BA2 7AY, Avon, England; [Smith, Steven R.] Sanford Burnham Med Res Inst, Orlando, FL USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; University of Bath; Sanford Burnham Prebys Medical Discovery Institute	Ravussin, E (corresponding author), Pennington Biomed Res Ctr, Baton Rouge, LA USA.	eric.ravussin@pbrc.edu	Smith, Steven/HDM-9496-2022; Ravussin, Eric/N-1985-2017; Earnest, Conrad P./M-6849-2017	Ravussin, Eric/0000-0003-2129-547X; Earnest, Conrad P./0000-0002-6546-1268; Smith, Steven/0000-0002-5098-8147	NORC Center Grant [2P30DK072476]; Coca-Cola Company; Pennington Biomedical Research Center Clinical and Translational Research Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER	NORC Center Grant; Coca-Cola Company; Pennington Biomedical Research Center Clinical and Translational Research Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was partially funded by an institutional grant to ER and by a NORC Center Grant (#2P30DK072476; PI-ER). Cost of analyses was partially supported by an unrestricted research funding grant from The Coca-Cola Company. Further funding was contributed by Dr. Donna Ryan from the Pennington Biomedical Research Center Clinical and Translational Research Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; A commercial funding source is acknowledged in the manuscript: The Coca-Cola Company. The authors have no declarations for this funding source relating to employment, consultancy, patents, products in development or marketed products and the funding source does not alter their adherence to the PLOS ONE policies on sharing data and materials, as detailed in the online guide for authors.	Alexander-Bridges M., 1992, ADV ENZYME REGUL, V32, P149; American College of Sports Medicine, 2006, ACSMS GUID EX TEST P; Benton CR, 2008, APPL PHYSIOL NUTR ME, V33, P843, DOI 10.1139/H08-074; Church TS, 2010, JAMA-J AM MED ASSOC, V304, P2253, DOI 10.1001/jama.2010.1710; Civitarese AE, 2006, CELL METAB, V4, P75, DOI 10.1016/j.cmet.2006.05.002; Heilbronn LK, 2007, J CLIN ENDOCR METAB, V92, P1467, DOI 10.1210/jc.2006-2210; Holland WL, 2011, NAT MED, V17, P55, DOI 10.1038/nm.2277; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Koves TR, 2008, CELL METAB, V7, P45, DOI 10.1016/j.cmet.2007.10.013; Layne AS, 2011, J CLIN ENDOCR METAB, V96, P1815, DOI 10.1210/jc.2010-2532; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Ravussin E, 2002, ANN NY ACAD SCI, V967, P363; Ritov VB, 2005, DIABETES, V54, P8, DOI 10.2337/diabetes.54.1.8; Services USDoHaH, 2008, 2008 PHYS ACT GUID A	17	11	11	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2013	8	6							e62973	10.1371/journal.pone.0062973	http://dx.doi.org/10.1371/journal.pone.0062973			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	170JP	23805175	gold, Green Published, Green Submitted			2023-01-03	WOS:000320846500003
J	O'Mahony, AM; Ogier, J; Darcy, R; Cryan, JF; O'Driscoll, CM				O'Mahony, Aoife M.; Ogier, Julien; Darcy, Raphael; Cryan, John F.; O'Driscoll, Caitriona M.			Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna Delivery	PLOS ONE			English	Article							SMALL INTERFERING RNA; GENE DELIVERY; INTRACELLULAR TRAFFICKING; TRANSFECTION; COMPLEXES; NANOPARTICLES; DNA; CONJUGATE; BARRIERS; VECTORS	Optimising non-viral vectors for neuronal siRNA delivery presents a significant challenge. Here, we investigate a co-formulation, consisting of two amphiphilic cyclodextrins (CDs), one cationic and the other PEGylated, which were blended together for siRNA delivery to a neuronal cell culture model. Co-formulated CD-siRNA complexes were characterised in terms of size, charge and morphology. Stability in salt and serum was also examined. Uptake was determined by flow cytometry and toxicity was measured by MTT assay. Knockdown of a luciferase reporter gene was used as a measure of gene silencing efficiency. Incorporation of a PEGylated CD in the formulation had significant effects on the physical and biological properties of CD. siRNA complexes. Co-formulated complexes exhibited a lower surface charge and greater stability in a high salt environment. However, the inclusion of the PEGylated CD also dramatically reduced gene silencing efficiency due to its effects on neuronal uptake. The co-formulation strategy for cationic and PEGylated CDs improved the stability of the CD. siRNA delivery systems, although knockdown efficiency was impaired. Future work will focus on the addition of targeting ligands to the co-formulated complexes to restore transfection capabilities.	[O'Mahony, Aoife M.; O'Driscoll, Caitriona M.] Univ Coll Cork, Sch Pharm, Pharmacodelivery Grp, Cork, Ireland; [Ogier, Julien; Darcy, Raphael] Univ Coll Dublin, Sch Chem & Chem Biol, Dublin 2, Ireland; [Cryan, John F.] Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland	University College Cork; University College Dublin; University College Cork	O'Driscoll, CM (corresponding author), Univ Coll Cork, Sch Pharm, Pharmacodelivery Grp, Cork, Ireland.	caitriona.odriscoll@ucc.ie	Cryan, John F./A-6950-2013	Cryan, John F./0000-0001-5887-2723; OGIER, Julien/0000-0002-2093-1617; O'Driscoll, Caitriona/0000-0002-6915-6201	Science Foundation Ireland [07/SRC/B1154]; Irish Drug Delivery Network; Irish Research Council of Science, Engineering and Technology	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Irish Drug Delivery Network(Science Foundation Ireland); Irish Research Council of Science, Engineering and Technology(Irish Research Council for Science, Engineering and Technology)	This work was supported by Science Foundation Ireland (Grant no. 07/SRC/B1154), the Irish Drug Delivery Network and by a scholarship to AO'M from the Irish Research Council of Science, Engineering and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bartlett DW, 2007, BIOCONJUGATE CHEM, V18, P456, DOI 10.1021/bc0603539; Belsham DD, 2004, ENDOCRINOLOGY, V145, P393, DOI 10.1210/en.2003-0946; Bergen JM, 2008, PHARM RES-DORDR, V25, P983, DOI 10.1007/s11095-007-9439-5; Bergen JM, 2008, J GENE MED, V10, P187, DOI 10.1002/jgm.1137; Beyerle A, 2010, TOXICOL APPL PHARM, V242, P146, DOI 10.1016/j.taap.2009.10.001; Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839; Cardoso ALC, 2010, J CONTROL RELEASE, V142, P392, DOI 10.1016/j.jconrel.2009.11.004; Cheng TL, 1999, BIOCONJUGATE CHEM, V10, P520, DOI 10.1021/bc980143z; Cryan SA, 2004, J DRUG DELIV SCI TEC, V14, P57, DOI 10.1016/S1773-2247(04)50006-0; Cryan SA, 2004, EUR J PHARM SCI, V21, P625, DOI 10.1016/j.ejps.2004.01.001; Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004; Davis ME, 2009, MOL PHARMACEUT, V6, P659, DOI 10.1021/mp900015y; Desigaux L, 2007, P NATL ACAD SCI USA, V104, P16534, DOI 10.1073/pnas.0707431104; Diaz-Moscoso A, 2011, BIOMATERIALS, V32, P7263, DOI 10.1016/j.biomaterials.2011.06.025; Donohue R, 2002, CHEM COMMUN, P2864, DOI 10.1039/b207238f; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Godinho BMDC, 2013, MOL PHARMACEUT, V10, P640, DOI 10.1021/mp3003946; Guo JF, 2012, BIOMATERIALS, V33, P7775, DOI 10.1016/j.biomaterials.2012.07.012; Guo JF, 2012, EUR J PHARM SCI, V45, P521, DOI 10.1016/j.ejps.2011.11.024; Guo JF, 2010, MOL BIOSYST, V6, P1143, DOI 10.1039/c001050m; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; Jung S, 2010, J CONTROL RELEASE, V144, P306, DOI 10.1016/j.jconrel.2010.03.002; Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006; Kong WH, 2009, J CONTROL RELEASE, V138, P141, DOI 10.1016/j.jconrel.2009.04.034; Kostarelos K, 2005, CHEM SOC REV, V34, P970, DOI 10.1039/b307062j; Krichevsky AM, 2002, P NATL ACAD SCI USA, V99, P11926, DOI 10.1073/pnas.182272699; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Lee SH, 2007, BIOCHEM BIOPH RES CO, V357, P511, DOI 10.1016/j.bbrc.2007.03.185; Lingor P, 2004, BIOCHEM BIOPH RES CO, V315, P1126, DOI 10.1016/j.bbrc.2004.01.170; McMahon A, 2008, J DRUG DELIV SCI TEC, V18, P303, DOI 10.1016/S1773-2247(08)50060-8; McMahon A, 2012, J PHARM PHARMACOL, V64, P1063, DOI 10.1111/j.2042-7158.2012.01497.x; Mendez-Ardoy A, 2011, NANOMEDICINE-UK, V6, P1697, DOI [10.2217/nnm.11.59, 10.2217/NNM.11.59]; Mendonca LS, 2010, BIOCONJUGATE CHEM, V21, P157, DOI 10.1021/bc9004365; Mishra S, 2004, EUR J CELL BIOL, V83, P97, DOI 10.1078/0171-9335-00363; Morille M, 2011, BIOMATERIALS, V32, P2327, DOI 10.1016/j.biomaterials.2010.11.063; O'Mahony AM, 2012, EUR J PHARM SCI, V47, P896, DOI 10.1016/j.ejps.2012.08.020; O'Mahony AM, 2012, ACS CHEM NEUROSCI, V3, P744, DOI 10.1021/cn3000372; O'Mahony AM, 2013, PHARM NANOTECHNOL, V1, P6, DOI DOI 10.2174/2211738511301010006; O'Mahony AM, 2013, PHARM RES-DORDR, V30, P1086, DOI 10.1007/s11095-012-0945-8; O'Mahony AM, 2012, ORG BIOMOL CHEM, V10, P4954, DOI 10.1039/c2ob25490e; O' Neill MJ, 2011, INT J PHARMACEUT, V413, P174, DOI 10.1016/j.ijpharm.2011.04.021; Ohki EC, 2001, J NEUROSCI METH, V112, P95, DOI 10.1016/S0165-0270(01)00441-1; Mellet CO, 2011, CHEM SOC REV, V40, P1586, DOI 10.1039/c0cs00019a; Perez-Martinez FC, 2011, PHARM RES-DORDR, V28, P1843, DOI 10.1007/s11095-010-0364-7; Ping Y, 2011, BIOMATERIALS, V32, P8328, DOI 10.1016/j.biomaterials.2011.07.038; Pun SH, 2002, BIOCONJUGATE CHEM, V13, P630, DOI 10.1021/bc0155768; Rettig GR, 2012, MOL THER, V20, P483, DOI 10.1038/mt.2011.263; Schafer J, 2010, BIOMATERIALS, V31, P6892, DOI 10.1016/j.biomaterials.2010.05.043; Tsutsumi T, 2008, J PHARM SCI-US, V97, P3022, DOI 10.1002/jps.21206; Vader P, 2012, PHARM RES-DORDR, V29, P352, DOI 10.1007/s11095-011-0545-z	50	30	32	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2013	8	6							e66413	10.1371/journal.pone.0066413	http://dx.doi.org/10.1371/journal.pone.0066413			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	170JP	23805220	Green Published, gold, Green Submitted			2023-01-03	WOS:000320846500048
J	Spence, D				Spence, Des			Saying no to chemotherapy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410	1	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2013	346								f4023	10.1136/bmj.f4023	http://dx.doi.org/10.1136/bmj.f4023			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	171RC	23794158				2023-01-03	WOS:000320945700005
J	Myburgh, J				Myburgh, John			Review: Hydroxyethyl starch increases mortality and acute kidney injury in critically ill patients	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							FLUID RESUSCITATION; METAANALYSIS		Univ New S Wales, St George Clin Sch, George Inst Global Hlth, Sydney, NSW, Australia	George Institute for Global Health; University of New South Wales Sydney; University of Sydney	Myburgh, J (corresponding author), Univ New S Wales, St George Clin Sch, George Inst Global Hlth, Sydney, NSW, Australia.			Zarychanski, Ryan/0000-0001-9455-6138				Gattas DJ, 2013, INTENS CARE MED, V39, P558, DOI 10.1007/s00134-013-2840-0; Haase N, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f839; Myburgh J, 2013, INTENS CARE MED, V39, P998, DOI 10.1007/s00134-013-2890-3; Patel A, 2013, INTENS CARE MED, V39, P811, DOI 10.1007/s00134-013-2863-6	4	0	0	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2013	158	12							JC4	10.7326/0003-4819-158-12-201306180-02004	http://dx.doi.org/10.7326/0003-4819-158-12-201306180-02004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	167PW	23778928				2023-01-03	WOS:000320645000003
J	Li, JY; Yu, T; Chen, GC; Yuan, YH; Zhong, W; Zhao, LN; Chen, QK				Li, Jie-Yao; Yu, Tao; Chen, Guang-Cheng; Yuan, Yu-Hong; Zhong, Wa; Zhao, Li-Na; Chen, Qi-Kui			Enteral Nutrition within 48 Hours of Admission Improves Clinical Outcomes of Acute Pancreatitis by Reducing Complications: A Meta-Analysis	PLOS ONE			English	Article							TOTAL PARENTERAL-NUTRITION; BACTERIAL TRANSLOCATION; INTESTINAL PERMEABILITY; GUT BARRIER; GUIDELINES; SUPPORT; TRIAL; MECHANISMS; REDUCTION; MORTALITY	Background: Enteral nutrition is increasingly advocated in the treatment of acute pancreatitis, but its timing is still controversial. The aim of this meta-analysis was to find out the feasibility of early enteral nutrition within 48 hours of admission and its possible advantages. Methods and Findings: We searched PubMed, EMBASE Databases, Web of Science, the Cochrane library, and scholar.google.com for all the relevant articles about the effect of enteral nutrition initiated within 48 hours of admission on the clinical outcomes of acute pancreatitis from inception to December 2012. Eleven studies containing 775 patients with acute pancreatitis were analyzed. Results from a pooled analysis of all the studies demonstrated that early enteral nutrition was associated with significant reductions in all the infections as a whole (OR 0.38; 95% CI 0.21-0.68, P<0.05), in catheter-related septic complications (OR 0.26; 95% CI 0.11-0.58, P<0.05), in pancreatic infection (OR 0.49; 95% CI 0.31-0.78, P<0.05), in hyperglycemia (OR 0.24; 95% CI 0.11-0.52, P<0.05), in the length of hospitalization (mean difference 22.18; 95% CI -3.48-(-0.87); P<0.05), and in mortality (OR 0.31; 95% CI 0.14-0.71, P<0.05), but no difference was found in pulmonary complications (P>0.05). The stratified analysis based on the severity of disease revealed that, even in predicted severe or severe acute pancreatitis patients, early enteral nutrition still showed a protective power against all the infection complications as a whole, catheter-related septic complications, pancreatic infection complications, and organ failure that was only reported in the severe attack of the disease (all P<0.05). Conclusion: Enteral nutrition within 48 hours of admission is feasible and improves the clinical outcomes in acute pancreatitis as well as in predicted severe or severe acute pancreatitis by reducing complications.	[Li, Jie-Yao; Yu, Tao; Chen, Guang-Cheng; Yuan, Yu-Hong; Zhong, Wa; Zhao, Li-Na; Chen, Qi-Kui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Chen, QK (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China.	qikuichen@yahoo.com	YUAN, YUHONG/ABC-5917-2020; Zhao, Lina/GVR-7716-2022		National Natural Science Foundation of China [81270442, 81000152]; Youthful Teacher Foster Plan of Sun Yat-Sen University [09ykpy10]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youthful Teacher Foster Plan of Sun Yat-Sen University	This study was supported by National Natural Science Foundation of China (No. 81270442 and No. 81000152) and Youthful Teacher Foster Plan of Sun Yat-Sen University (No. 09ykpy10). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Assi S, 2002, AM J GASTROENTEROL, V97, P2255, DOI 10.1111/j.1572-0241.2002.05979.x; Al-Omran M, 2010, COCHRANE DB SYST REV, V20; Ammori BJ, 2003, PANCREAS, V26, P122, DOI 10.1097/00006676-200303000-00006; Ammori BJ, 2003, PANCREAS, V26, P18, DOI 10.1097/00006676-200301000-00004; [ASPEN Board of Directors Clinical Guidelines Task Force], 2002, JPEN J PARENTER E S1, V26, p1SA; Bakker OJ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-73; Bakker OJ, 2009, GASTROENTEROLOGY, V136, pA75; Balzan S, 2007, J GASTROEN HEPATOL, V22, P464, DOI 10.1111/j.1440-1746.2007.04933.x; Laguna LB, 2011, NUTR HOSP, V26, P32, DOI 10.1590/S0212-16112011000800007; Cao YF, 2008, ANN NUTR METAB, V53, P268, DOI 10.1159/000189382; Capurso G, 2012, J CLIN GASTROENTEROL, V46, pS46, DOI 10.1097/MCG.0b013e3182652096; Casas M, 2007, REV ESP ENFERM DIG, V99, P264; Chen Jie, 2004, Zhonghua Yi Xue Za Zhi, V84, P1726; Eckerwall GE, 2006, ANN SURG, V244, P959, DOI 10.1097/01.sla.0000246866.01930.58; Elder ASF, 2012, PANCREATOLOGY, V12, P49, DOI 10.1016/j.pan.2011.12.012; Feng YJ, 2010, AM J PHYSIOL-GASTR L, V298, pG833, DOI 10.1152/ajpgi.00030.2010; FOITZIK T, 1994, ANN SURG, V220, P193, DOI 10.1097/00000658-199408000-00011; Fritz S, 2010, AM J SURG, V200, P111, DOI 10.1016/j.amjsurg.2009.08.019; Gupta R, 2003, PANCREATOLOGY, V3, P406, DOI 10.1159/000073657; Hajdu Nora, 2012, Magy Seb, V65, P44, DOI 10.1556/MaSeb.65.2012.2.2; Hegazi R, 2011, JPEN-PARENTER ENTER, V35, P91, DOI 10.1177/0148607110376196; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Jacobi J, 2012, CRIT CARE MED, V40, P3251, DOI 10.1097/CCM.0b013e3182653269; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665, DOI 10.1002/bjs.1800841207; Koh YY, 2012, GUT LIVER, V6, P505, DOI 10.5009/gnl.2012.6.4.505; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; Mikaeili H, 2012, BRATISL MED J, V113, P616, DOI 10.4149/BLL_2012_139; Mirtallo JM, 2012, JPEN-PARENTER ENTER, V36, P284, DOI 10.1177/0148607112440823; Olah A, 2002, NUTRITION, V18, P259, DOI 10.1016/S0899-9007(01)00755-9; Olah A, 1996, NUTRITION, V12, P580; Ong JPL, 2012, J DIGEST DIS, V13, P445, DOI 10.1111/j.1751-2980.2012.00611.x; Petrov M, 2012, GASTROENTEROLOGY, V142, pS94; Petrov MS, 2006, DIGEST SURG, V23, P336, DOI 10.1159/000097949; Petrov MS, 2010, GASTROENTEROLOGY, V139, P813, DOI 10.1053/j.gastro.2010.06.010; Petrov MS, 2009, BRIT J NUTR, V101, P787, DOI 10.1017/S0007114508123443; Pezzilli R, 2008, DIGEST LIVER DIS, V40, P803, DOI 10.1016/j.dld.2008.02.019; Pupelis G, 2001, NUTRITION, V17, P91, DOI 10.1016/S0899-9007(00)00508-6; Qin HL, 2008, EUR J CLIN NUTR, V62, P923, DOI 10.1038/sj.ejcn.1602792; Qin HL, 2002, CLIN NUTR, V21, P469, DOI 10.1054/clnu.2002.0574; Qin Huan-Long, 2002, Hepatobiliary Pancreat Dis Int, V1, P150; SAX HC, 1987, AM J SURG, V153, P117, DOI 10.1016/0002-9610(87)90211-X; Vieira JP, 2010, ACTA CIR BRAS, V25, P449, DOI 10.1590/S0102-86502010000500012; [吴大成 WU Dacheng], 2008, [肠外与肠内营养, Parenteral & Enteral Nutrition], V15, P285; Xu Chun-fang, 2011, Zhonghua Nei Ke Za Zhi, V50, P370; Yubero S, 2012, PULM PHARMACOL THER, V25, P319, DOI 10.1016/j.pupt.2012.05.009	45	62	74	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2013	8	6							e64926	10.1371/journal.pone.0064926	http://dx.doi.org/10.1371/journal.pone.0064926			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173SK	23762266	gold, Green Published, Green Submitted			2023-01-03	WOS:000321099000028
J	Lin, CY; Chang, CH; Fan, PC; Tian, YC; Chang, MY; Jenq, CC; Hung, CC; Fang, JT; Yang, CW; Chen, YC				Lin, Chan-Yu; Chang, Chih-Hsiang; Fan, Pei-Chun; Tian, Ya-Chung; Chang, Ming-Yang; Jenq, Chang-Chyi; Hung, Cheng-Chieh; Fang, Ji-Tseng; Yang, Chih-Wei; Chen, Yung-Chang			Serum Interleukin-18 at Commencement of Renal Replacement Therapy Predicts Short-Term Prognosis in Critically Ill Patients with Acute Kidney Injury	PLOS ONE			English	Article							HOSPITAL MORTALITY; OUTCOME PREDICTION; CYSTATIN-C; SEPSIS; FAILURE; DISEASE; RISK; CARE; CLASSIFICATION; SYSTEM	Background: Acute kidney injury (AKI) requiring renal replacement therapy (RRT) in critically ill patients results in a high hospital mortality. Outcome prediction in this selected high-risk collective is challenging due to the lack of appropriate biomarkers. The aim of this study was to identify outcome-specific biomarkers in this patient population. Methodology/Principal Findings: Serum samples were collected from 101 critically ill patients with AKI at the initiation of RRT in intensive care units (ICUs) of a tertiary care university hospital between August 2008 and March 2011. Measurements of serum levels of cystatin C (CysC), neutrophil gelatinase-associated lipocalin, and interleukin-18 (IL-18) were performed. The primary outcome measure was hospital mortality. The observed overall mortality rate was 56.4% (57/101). Multiple logistic regression analysis indicated that the serum IL-18 and CysC concentrations and Acute Physiology and Chronic Health Evaluation III (ACPACHE III) scores determined on the first day of RRT were independent predictors of hospital mortality. The APACHE III score had the best discriminatory power (0.872 +/- 0.041, p<0.001), whereas serum IL-18 had the best Youden index (0.65) and the highest correctness of prediction (83%). Cumulative survival rates at 6-month follow-up following hospital discharge differed significantly (p<0.001) for serum IL-18 <1786 pg/ml vs. >= 1786 pg/ml in these critically ill patients. Conclusions: In this study, we confirmed the grave prognosis for critically ill patients at the commencement of RRT and found a strong correlation between serum IL-18 and the hospital mortality of ICU patients with dialysis-dependent AKI. In addition, we demonstrated that the APACHE III score has the best discriminative power for predicting hospital mortality in these critically ill patients.	[Lin, Chan-Yu; Chang, Chih-Hsiang; Fan, Pei-Chun; Tian, Ya-Chung; Chang, Ming-Yang; Jenq, Chang-Chyi; Hung, Cheng-Chieh; Fang, Ji-Tseng; Yang, Chih-Wei; Chen, Yung-Chang] Chang Gung Univ Coll Med, Chang Gung Mem Hosp, Dept Nephrol, Kidney Res Ctr, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Chen, YC (corresponding author), Chang Gung Univ Coll Med, Chang Gung Mem Hosp, Dept Nephrol, Kidney Res Ctr, Taipei, Taiwan.	cyc2356@adm.cgmh.org.tw	Chang, Jason Chih-Hsiang/P-8662-2017; Chang, Ming-Yang/AGH-5397-2022	Chang, Jason Chih-Hsiang/0000-0002-7342-335X; Chang, Ming-Yang/0000-0001-8899-0376	Chang Gung Medical Research Fund [CMRPG-370591]; Chang Gung Memorial Hospital, Linkou, Taiwan	Chang Gung Medical Research Fund; Chang Gung Memorial Hospital, Linkou, Taiwan(Chang Gung Memorial Hospital)	This work was supported by the Chang Gung Medical Research Fund CMRPG-370591, Chang Gung Memorial Hospital, Linkou, Taiwan. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Blankenberg S, 2003, CIRCULATION, V108, P2453, DOI 10.1161/01.CIR.0000099509.76044.A2; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Chen TH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032328; Chen YC, 2009, SHOCK, V31, P139, DOI 10.1097/SHK.0b013e31817d419e; Coca SG, 2008, KIDNEY INT, V73, P1008, DOI 10.1038/sj.ki.5002729; Davenport A, 2008, CLIN J AM SOC NEPHRO, V3, P869, DOI 10.2215/CJN.04821107; Fan PC, 2012, AM J MED SCI, V344, P83, DOI 10.1097/MAJ.0b013e3182373d36; Gracie JA, 2003, J LEUKOCYTE BIOL, V73, P213, DOI 10.1189/jlb.0602313; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kumpers P, 2010, CRIT CARE, V14, DOI 10.1186/cc8861; Lin CY, 2009, RESPIRATION, V77, P398, DOI 10.1159/000183756; Lin YF, 2009, AM J SURG, V198, P325, DOI 10.1016/j.amjsurg.2008.10.021; Mallat Z, 2001, CIRCULATION, V104, P1598, DOI 10.1161/hc3901.096721; Nejat M, 2010, CRIT CARE, V14, DOI 10.1186/cc9014; Ostermann M, 2009, CRIT CARE, V13, DOI 10.1186/cc8154; Perianayagam MC, 2009, AM J KIDNEY DIS, V54, P1025, DOI 10.1053/j.ajkd.2009.05.022; Ricci Z, 2009, BLOOD PURIFICAT, V27, P127, DOI 10.1159/000167019; Rocha E, 2009, NEPHROL DIAL TRANSPL, V24, P1925, DOI 10.1093/ndt/gfn750; Tiret L, 2005, CIRCULATION, V112, P643, DOI 10.1161/CIRCULATIONAHA.104.519702; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Westhuyzen J, 2006, ANN CLIN LAB SCI, V36, P387; Whitman SC, 2002, CIRC RES, V90, pE34, DOI 10.1161/hh0202.105292; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zimmerman JE, 2008, CURR OPIN CRIT CARE, V14, P491, DOI 10.1097/MCC.0b013e32830864c0	27	6	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2013	8	5							e66028	10.1371/journal.pone.0066028	http://dx.doi.org/10.1371/journal.pone.0066028			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	156DC	23741523	gold, Green Published, Green Submitted			2023-01-03	WOS:000319799900236
J	Peterson, DC; Martin-Gill, C; Guyette, FX; Tobias, AZ; McCarthy, CE; Harrington, ST; Delbridge, TR; Yealy, DM				Peterson, Drew C.; Martin-Gill, Christian; Guyette, Francis X.; Tobias, Adam Z.; McCarthy, Catherine E.; Harrington, Scott T.; Delbridge, Theodore R.; Yealy, Donald M.			Outcomes of Medical Emergencies on Commercial Airline Flights	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIRCRAFT; AIR; DIVERSIONS; EXPERIENCE	BACKGROUND Worldwide, 2.75 billion passengers fly on commercial airlines annually. When in-flight medical emergencies occur, access to care is limited. We describe in-flight medical emergencies and the outcomes of these events. METHODS We reviewed records of in-flight medical emergency calls from five domestic and international airlines to a physician-directed medical communications center from January 1, 2008, through October 31, 2010. We characterized the most common medical problems and the type of on-board assistance rendered. We determined the incidence of and factors associated with unscheduled aircraft diversion, transport to a hospital, and hospital admission, and we determined the incidence of death. RESULTS There were 11,920 in-flight medical emergencies resulting in calls to the center (1 medical emergency per 604 flights). The most common problems were syncope or presyncope (37.4% of cases), respiratory symptoms (12.1%), and nausea or vomiting (9.5%). Physician passengers provided medical assistance in 48.1% of in-flight medical emergencies, and aircraft diversion occurred in 7.3%. Of 10,914 patients for whom postflight follow-up data were available, 25.8% were transported to a hospital by emergency-medical-service personnel, 8.6% were admitted, and 0.3% died. The most common triggers for admission were possible stroke (odds ratio, 3.36; 95% confidence interval [CI], 1.88 to 6.03), respiratory symptoms (odds ratio, 2.13; 95% CI, 1.48 to 3.06), and cardiac symptoms (odds ratio, 1.95; 95% CI, 1.37 to 2.77). CONCLUSIONS Most in-flight medical emergencies were related to syncope, respiratory symptoms, or gastrointestinal symptoms, and a physician was frequently the responding medical volunteer. Few in-flight medical emergencies resulted in diversion of aircraft or death; one fourth of passengers who had an in-flight medical emergency underwent additional evaluation in a hospital.	[Peterson, Drew C.; Martin-Gill, Christian; Guyette, Francis X.; Tobias, Adam Z.; McCarthy, Catherine E.; Harrington, Scott T.; Yealy, Donald M.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA; [Delbridge, Theodore R.] E Carolina Univ, Brody Sch Med, Dept Emergency Med, Greenville, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; East Carolina University	Martin-Gill, C (corresponding author), Iroquois Bldg,Suite 400A,3600 Forbes Ave, Pittsburgh, PA 15261 USA.	martingillc2@upmc.edu	, Francis/AAE-1586-2022	Guyette, Francis/0000-0002-9151-4896	National Institutes of Health [UL1 RR024153, UL1 TR000005]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by grants from the National Institutes of Health (UL1 RR024153 and UL1 TR000005).; Funded by the National Institutes of Health.	[Anonymous], 2012, PASS NUMB REACH 2 75; [Anonymous], 2006, POL AC 121 33B EM ME; [Anonymous], 2009, OBSTET GYNECOL, V114, P954; Baltsezak S, 2008, J TRAVEL MED, V15, P391, DOI 10.1111/j.1708-8305.2008.00233.x; Brown AM, 2010, PREHOSP EMERG CARE, V14, P235, DOI 10.3109/10903120903572319; CUMMINS RO, 1989, JAMA-J AM MED ASSOC, V261, P1295, DOI 10.1001/jama.261.9.1295; DeJohn CA, 2000, EVALUATION IN FLIGHT; Delaune EF, 2003, AVIAT SPACE ENVIR MD, V74, P62; HORDINSKY JR, 1989, AVIAT SPACE ENVIR MD, V60, P1211; Hung KKC, 2010, ARCH INTERN MED, V170, P1401, DOI 10.1001/archinternmed.2010.267; Moore BR, 2005, PEDIATR EMERG CARE, V21, P725, DOI 10.1097/01.pec.0000186424.84764.94; ORourke MF, 1997, CIRCULATION, V96, P2849, DOI 10.1161/01.CIR.96.9.2849; RODENBERG H, 1987, ANN EMERG MED, V16, P1373, DOI 10.1016/S0196-0644(87)80422-5; Sand M, 2009, CRIT CARE, V13, DOI 10.1186/cc7690; Shepherd B, 2006, J ROY SOC MED, V99, P628, DOI 10.1258/jrsm.99.12.628; Szmajer M, 2001, RESUSCITATION, V50, P147, DOI 10.1016/S0300-9572(01)00347-1; TranStats: Research and Innovative Technology Administration Bureau of Transportation Statistics, LOAD FACT PASS MIL P	17	144	145	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	2013	368	22					2075	2083		10.1056/NEJMoa1212052	http://dx.doi.org/10.1056/NEJMoa1212052			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153AT	23718164	Bronze, Green Accepted			2023-01-03	WOS:000319574200005
J	Stenson, BJ; Tarnow-Mordi, WO; Darlow, BA; Simes, J; Juszczak, E; Askie, L; Battin, M; Bowler, U; Broadbent, R; Cairns, P; Davis, PG; Deshpande, S; Donoghoe, M; Doyle, L; Fleck, BW; Ghadge, A; Hague, W; Halliday, HL; Hewson, M; King, A; Kirby, A; Marlow, N; Meyer, M; Morley, C; Simmer, K; Tin, W; Wardle, SP; Brocklehurst, P				Stenson, Ben J.; Tarnow-Mordi, William O.; Darlow, Brian A.; Simes, John; Juszczak, Edmund; Askie, Lisa; Battin, Malcolm; Bowler, Ursula; Broadbent, Roland; Cairns, Pamela; Davis, Peter Graham; Deshpande, Sanjeev; Donoghoe, Mark; Doyle, Lex; Fleck, Brian W.; Ghadge, Alpana; Hague, Wendy; Halliday, Henry L.; Hewson, Michael; King, Andrew; Kirby, Adrienne; Marlow, Neil; Meyer, Michael; Morley, Colin; Simmer, Karen; Tin, Win; Wardle, Stephen P.; Brocklehurst, Peter		Boost II United Kingdom; Boost II; Boost II New Zealand	Oxygen Saturation and Outcomes in Preterm Infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE RETINOPATHY; PULSE OXIMETRY; TARGET RANGES; PREMATURITY; GESTATION; CROSSOVER; TRIAL	BACKGROUND The clinically appropriate range for oxygen saturation in preterm infants is unknown. Previous studies have shown that infants had reduced rates of retinopathy of prematurity when lower targets of oxygen saturation were used. METHODS In three international randomized, controlled trials, we evaluated the effects of targeting an oxygen saturation of 85 to 89%, as compared with a range of 91 to 95%, on disability-free survival at 2 years in infants born before 28 weeks' gestation. Halfway through the trials, the oximeter-calibration algorithm was revised. Recruitment was stopped early when an interim analysis showed an increased rate of death at 36 weeks in the group with a lower oxygen saturation. We analyzed pooled data from patients and now report hospital-discharge outcomes. RESULTS A total of 2448 infants were recruited. Among the 1187 infants whose treatment used the revised oximeter-calibration algorithm, the rate of death was significantly higher in the lower-target group than in the higher-target group (23.1% vs. 15.9%; relative risk in the lower-target group, 1.45; 95% confidence interval [CI], 1.15 to 1.84; P = 0.002). There was heterogeneity for mortality between the original algorithm and the revised algorithm (P = 0.006) but not for other outcomes. In all 2448 infants, those in the lower-target group for oxygen saturation had a reduced rate of retinopathy of prematurity (10.6% vs. 13.5%; relative risk, 0.79; 95% CI, 0.63 to 1.00; P = 0.045) and an increased rate of necrotizing enterocolitis (10.4% vs. 8.0%; relative risk, 1.31; 95% CI, 1.02 to 1.68; P = 0.04). There were no significant between-group differences in rates of other outcomes or adverse events. CONCLUSIONS Targeting an oxygen saturation below 90% with the use of current oximeters in extremely preterm infants was associated with an increased risk of death.	[Stenson, Ben J.] Univ Edinburgh, Dept Child Life & Hlth, Royal Infirm Edinburgh, Neonatal Unit, Edinburgh, Midlothian, Scotland; [Tarnow-Mordi, William O.] Univ Sydney, Westmead Hosp, Westmead Int Network Neonatal Educ & Res WINNER C, Natl Hlth & Med Res Council NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia; [Darlow, Brian A.] Univ Otago, Christchurch, New Zealand; [Simes, John; Askie, Lisa; Donoghoe, Mark; Ghadge, Alpana; Hague, Wendy; Kirby, Adrienne] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia; [Juszczak, Edmund; Bowler, Ursula; King, Andrew] Univ Oxford, Clin Trials Unit, NPEU, Oxford, England; [Battin, Malcolm] Univ Auckland, Auckland City Hosp, Newborn Serv, Auckland 1, New Zealand; [Battin, Malcolm] Univ Auckland, Dept Paediat, Auckland, New Zealand; [Broadbent, Roland] Univ Otago, Dunedin Sch Med, Dept Womens & Childrens Hlth, Dunedin, New Zealand; [Cairns, Pamela] Univ Hosp Bristol Natl Hlth Serv NHS Trust, Bristol, Avon, England; [Davis, Peter Graham] Univ Melbourne, Royal Melbourne Hosp, Melbourne, Vic 3050, Australia; [Davis, Peter Graham] Univ Melbourne, Dept Obstet & Gynaecol, Melbourne, Vic, Australia; [Deshpande, Sanjeev] Shrewsbury & Telford Hosp NHS Trust, Shrewsbury, Salop, England; [Doyle, Lex] Univ Melbourne, Royal Womens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Fleck, Brian W.] Princess Alexandra Eye Pavil, NHS Lothian, Edinburgh, Midlothian, Scotland; [Halliday, Henry L.] Queens Univ Belfast, Belfast, Antrim, North Ireland; [Hewson, Michael] Wellington Hosp, Neonatal Intens Care Unit, Wellington, New Zealand; [Marlow, Neil] UCL, Inst Womens Hlth, London WC1E 6BT, England; [Meyer, Michael] Univ Auckland, Middlemore Hosp, Auckland, New Zealand; [Morley, Colin] Royal Womens Hosp, Dept Neonatal Res, Melbourne, Vic, Australia; [Simmer, Karen] Univ Western Australia, Ctr Neonatal Res & Educ, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Tin, Win] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [Wardle, Stephen P.] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Brocklehurst, Peter] UCL Med Sch, Inst Womens Hlth, London, England	Royal Infirmary of Edinburgh; University of Edinburgh; University of Sydney; University of Otago; University of Sydney; University of Oxford; Auckland City Hospital; University of Auckland; University of Auckland; University of Otago; Royal Melbourne Hospital; University of Melbourne; University of Melbourne; Murdoch Children's Research Institute; University of Melbourne; Queens University Belfast; University of London; University College London; University of Auckland; University of Western Australia; James Cook University Hospital; Nottingham University Hospital NHS Trust; University of London; University College London	Stenson, BJ (corresponding author), Royal Infirm Edinburgh NHS Trust, Dept Neonatol, Edinburgh EH16 4SA, Midlothian, Scotland.	ben.stenson@luht.scot.nhs.uk	Marlow, Neil/D-2918-2009; Simes, Robert John/P-1497-2014; D'ESTE, CATHERINE ANNE/G-7392-2013; Doyle, Lex/AAJ-5205-2021; Colditz, Paul B/F-6772-2010; Simmer, Karen N/H-5834-2014	Marlow, Neil/0000-0001-5890-2953; Doyle, Lex/0000-0002-7667-7312; Colditz, Paul B/0000-0002-6408-8238; Morley, Colin/0000-0001-5388-0214; Simmer, Karen/0000-0003-4777-9069; Couper, Jennifer/0000-0003-4448-8629; Wright, Ian/0000-0001-5337-0134; Wardle, Stephen/0000-0001-5727-3315; Broadbent, Roland/0000-0002-4628-7276; Halliday, Henry/0000-0001-7978-4992; Jamieson, Nina/0000-0002-8776-5000	Australian National Health and Medical Research Council [352386]; Medical Research Council [73460]; New Zealand Health Research Council [05-145]; United Kingdom's Biomedical Research Centres of the National Institute for Health Research; MRC [G0400415] Funding Source: UKRI; Medical Research Council [G0400415] Funding Source: researchfish; National Institute for Health Research [NF-SI-0512-10034] Funding Source: researchfish	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); New Zealand Health Research Council(Health Research Council of New Zealand); United Kingdom's Biomedical Research Centres of the National Institute for Health Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	Funded by the Australian National Health and Medical Research Council and others; BOOST II Current Controlled Trials number, ISRCTN00842661, and Australian New Zealand Clinical Trials Registry numbers, ACTRN12605000055606 and ACTRN12605000253606.; Supported by the National Health and Medical Research Council (project grant 352386, to the Australian trial), the Medical Research Council (grant number 73460, to the United Kingdom trial), and the New Zealand Health Research Council (project grant number 05-145, to the New Zealand trial); and by a grant from the United Kingdom's Biomedical Research Centres of the National Institute for Health Research (to Dr. Marlow). Masimo supplied the study oximeters under lease.	American Academy of Pediatrics American College of Obstetricans and Gynecologists, 2007, GUID PER CAR; Anderson Christina G, 2004, J Perinatol, V24, P164, DOI 10.1038/sj.jp.7211067; Askie LM, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-6; Askie LM, 2003, NEW ENGL J MED, V349, P959, DOI 10.1056/NEJMoa023080; Askie LM, 2009, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001077.PUB2; Bancalari E, 2012, EARLY HUM DEV, V88, pS78, DOI 10.1016/S0378-3782(12)70021-X; Carlo WA, 2010, NEW ENGL J MED, V362, P1959, DOI 10.1056/NEJMoa0911781; Chow LC, 2003, PEDIATRICS, V111, P339, DOI 10.1542/peds.111.2.339; Claure N, 2011, PEDIATRICS, V127, pE76, DOI 10.1542/peds.2010-0939; Darlow BA, 2008, CLIN EXP OPHTHALMOL, V36, P43, DOI 10.1111/j.1442-9071.2007.01652.x; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991, DOI 10.1001/archopht.123.7.991; Good WV, 2003, ARCH OPHTHALMOL-CHIC, V121, P1684; Johnston ED, 2011, ARCH DIS CHILD-FETAL, V96, pF429, DOI 10.1136/adc.2010.206011; Myers Timothy R, 2002, Respir Care, V47, P707; Quine D, 2008, ARCH DIS CHILD-FETAL, V93, pF347, DOI 10.1136/adc.2007.132282; Quine D, 2009, ARCH DIS CHILD-FETAL, V94, pF51, DOI 10.1136/adc.2007.135285; Quinn GE, 2013, PEDIAT OPHTHALMOLOGY, P432; Stenson B, 2011, NEW ENGL J MED, V364, P1680, DOI 10.1056/NEJMc1101319; Tarnow-Mordi WO, 2010, NEW ENGL J MED, V363, P1285, DOI 10.1056/NEJMc1007912; Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106; Vaucher YE, 2012, NEW ENGL J MED, V367, P2495, DOI 10.1056/NEJMoa1208506; Yusuf S, 2000, AM HEART J, V139, pS136, DOI 10.1016/S0002-8703(00)90061-9	22	299	309	0	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	2013	368	22					2094	2104		10.1056/NEJMoa1302298	http://dx.doi.org/10.1056/NEJMoa1302298			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	153AT	23642047	Green Published			2023-01-03	WOS:000319574200007
J	Talbott, EO; Rager, JR; Brink, LL; Benson, SM; Bilonick, RA; Wu, WC; Han, YY				Talbott, Evelyn O.; Rager, Judith R.; Brink, LuAnn L.; Benson, Stacey M.; Bilonick, Richard A.; Wu, Wen Chi; Han, Yueh-Ying			Trends in Acute Myocardial Infarction Hospitalization Rates for US States in the CDC Tracking Network	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; UNITED-STATES; MINNESOTA; MORTALITY; OUTCOMES	Objective: We examined temporal trends, spatial variation, and gender differences in rates of hospitalization due to acute myocardial infarction. Methods: We used data from the Centers for Disease Control National Environmental Public Health Tracking Network to evaluate temporal trends, geographic variation, and gender differences in 20 Environmental Public Health Tracking Network states from 2000 to 2008. A longitudinal linear mixed effects model was fitted to the acute myocardial infarction hospitalization rates for the states and counties within each state to examine the overall temporal trend. Results: There was a significant overall decrease in age-adjusted acute myocardial infarction hospitalization rates between 2000 and 2008, with most states showing over a 20% decline during the period. The ratio of male/female rates for acute myocardial infarction hospitalization rates remained relatively consistent over time, approximately two-fold higher in men compared to women. A large geographic variability was found for age-adjusted acute myocardial infarction hospitalization rates, with the highest rates found in the Northeastern states. Results of two ecological analyses revealed that the NE region remained significantly associated with increased AMI hospitalization rates after adjustment for socio-demographic factors. Conclusions: This investigation is one of the first to explore geographic differences in AMI age adjusted hospital rates in individuals 35+ years of age for 2000-2008. We showed a decreasing trend in AMI hospitalization rates in men and women. A large geographic variability in rates was found with particularly higher rates in the New England/Mid-Atlantic region of the US and lower rates in the mountain and Pacific states of the tracking network. It appeared that over time this disparity in rates became less notable.	[Talbott, Evelyn O.; Rager, Judith R.; Brink, LuAnn L.; Benson, Stacey M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA; [Bilonick, Richard A.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Pittsburgh, PA 15261 USA; [Wu, Wen Chi] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Han, Yueh-Ying] Univ Pittsburgh, Childrens Hosp Pittsburgh, UPMC, Div Pediat Pulm Med Allergy & Immunol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Talbott, EO (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA.	eot1@pitt.edu		Talbott, Evelyn/0000-0002-5198-7939	Centers for Disease Control and Prevention [BAA2010-N-11993]	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This work was supported by the Centers for Disease Control and Prevention contract number BAA2010-N-11993. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bates D., 2011, PACKAGE LME4 LINEAR; Bell ML, 2007, ENVIRON HEALTH PERSP, V115, P989, DOI 10.1289/ehp.9621; Centers for Disease Control and Prevention, 1999, COMPR MORT 1999 2007; Chen J, 2010, CIRCULATION, V121, P1322, DOI 10.1161/CIRCULATIONAHA.109.862094; Conolly DC, 1981, MAYO CLIN P, V56, P661; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; ESRI (Environmental Systems Resource Institute), 2009, ARCMAP 9 2 ESRI; Fang J, 2002, AM J MED, V113, P208, DOI 10.1016/S0002-9343(02)01172-5; Fang J, 2010, AM J MED, V123, P259, DOI 10.1016/j.amjmed.2009.08.018; GILLUM RF, 1983, NEW ENGL J MED, V309, P1353, DOI 10.1056/NEJM198312013092203; Goff David C. Jr., 1993, Ethnicity and Disease, V3, P64; Goff DC, 1997, CIRCULATION, V95, P1433; KEIL JE, 1989, AM HEART J, V117, P1022, DOI 10.1016/0002-8703(89)90857-0; KEYFITZ N, 1966, HUM BIOL, V38, P309; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; R Development Core Team, 2005, R LANG ENV STAT COMP; Wang OJ, 2012, AM J CARDIOL, V109, P1589, DOI 10.1016/j.amjcard.2012.01.381; Yeh RW, 2012, CIRC-CARDIOVASC QUAL, V5, P197, DOI 10.1161/CIRCOUTCOMES.111.962456; Yeh RW, 2010, NEW ENGL J MED, V362, P2155, DOI 10.1056/NEJMoa0908610	20	26	26	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2013	8	5							e64457	10.1371/journal.pone.0064457	http://dx.doi.org/10.1371/journal.pone.0064457			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163UP	23717617	Green Submitted, Green Published, gold			2023-01-03	WOS:000320362700150
J	Johnson, NR; Wang, YD				Johnson, Noah Ray; Wang, Yadong			Controlled Delivery of Sonic Hedgehog Morphogen and Its Potential for Cardiac Repair	PLOS ONE			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST GROWTH FACTOR-2; AMERICAN-HEART-ASSOCIATION; GENE-THERAPY; MYOCARDIAL-INFARCTION; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; SIGNALING PATHWAYS; BONE-MARROW; ANGIOGENESIS	The morphogen Sonic hedgehog (Shh) holds great promise for repair or regeneration of tissues suffering ischemic injury, however clinical translation is limited by its short half-life in the body. Here, we describe a coacervate delivery system which incorporates Shh, protects it from degradation, and sustains its release for at least 3 weeks. Shh released from the coacervate stimulates cardiac fibroblasts to upregulate the expression of multiple trophic factors including VEGF, SDF-1 alpha, IGF-1, and Shh itself, for at least 48 hours. Shh coacervate also demonstrates cytoprotective effects for cardiomyocytes in a hydrogen peroxide-induced oxidative stress environment. In each of these studies the bioactivity of the Shh coacervate is enhanced compared to free Shh. These results warrant further investigation of the in vivo efficacy of Shh coacervate for cardiac repair.	[Johnson, Noah Ray; Wang, Yadong] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA; [Johnson, Noah Ray; Wang, Yadong] McGowan Inst Regenerat Med, Pittsburgh, PA USA; [Wang, Yadong] Univ Pittsburgh, Dept Chem & Petr Engn, Pittsburgh, PA 15261 USA; [Wang, Yadong] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, YD (corresponding author), Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15260 USA.	yaw20@pitt.edu	Wang, Yadong/AAC-3381-2020	Wang, Yadong/0000-0003-2067-382X	National Science Foundation [DMR 1005766]; American Heart Association [12EIA9020016]	National Science Foundation(National Science Foundation (NSF)); American Heart Association(American Heart Association)	This work was supported by grants from the National Science Foundation (#DMR 1005766) and the American Heart Association (#12EIA9020016). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed RPH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008576; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Asai J, 2006, CIRCULATION, V113, P2413, DOI 10.1161/CIRCULATIONAHA.105.603167; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Cencioni C, 2012, CARDIOVASC RES, V94, P400, DOI 10.1093/cvr/cvs132; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chang H, 2010, INT J BIOCHEM CELL B, V42, P1462, DOI 10.1016/j.biocel.2010.04.016; Chang SC, 2011, J BIOL CHEM, V286, P44391, DOI 10.1074/jbc.M111.285361; Charrier JB, 2001, DEVELOPMENT, V128, P4011; Chinchilla P, 2010, CELL CYCLE, V9, P570, DOI 10.4161/cc.9.3.10591; Chu HH, 2013, BIOMATERIALS, V34, P1747, DOI 10.1016/j.biomaterials.2012.11.019; Chu HH, 2012, BIOTECHNOL PROGR, V28, P257, DOI 10.1002/btpr.728; Chu HH, 2011, P NATL ACAD SCI USA, V108, P13444, DOI 10.1073/pnas.1110121108; Chu HH, 2011, J CONTROL RELEASE, V150, P157, DOI 10.1016/j.jconrel.2010.11.025; Dong F, 2012, CIRCULATION, V126, P314, DOI 10.1161/CIRCULATIONAHA.111.082453; Fu JR, 2006, ACTA PHARMACOL SIN, V27, P685, DOI 10.1111/j.1745-7254.2006.00335.x; Gritli-Linde A, 2001, DEV BIOL, V236, P364, DOI 10.1006/dbio.2001.0336; Gupta R, 2009, CIRC RES, V105, P724, DOI 10.1161/CIRCRESAHA.109.200386; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Houser SR, 2012, CIRC RES, V111, P131, DOI 10.1161/RES.0b013e3182582523; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jiang ZS, 2004, CARDIOVASC RES, V62, P154, DOI 10.1016/j.cardiores.2004.01.009; Johnson NR, 2013, J CONTROL RELEASE, V166, P124, DOI 10.1016/j.jconrel.2012.11.004; Kajstura J, 2001, DIABETES, V50, P1414, DOI 10.2337/diabetes.50.6.1414; Kicheva A, 2012, CURR OPIN GENET DEV, V22, P527, DOI 10.1016/j.gde.2012.08.004; Kucia M, 2004, CIRC RES, V95, P1191, DOI 10.1161/01.RES.0000150856.47324.5b; Kusano KF, 2005, NAT MED, V11, P1197, DOI 10.1038/nm1313; Kusano KF, 2004, ARTERIOSCL THROM VAS, V24, P2102, DOI 10.1161/01.ATV.0000144813.44650.75; Lavine KJ, 2008, TRENDS GENET, V24, P33, DOI 10.1016/j.tig.2007.10.007; Lin XH, 2004, DEVELOPMENT, V131, P6009, DOI 10.1242/dev.01522; Mark RJ, 1997, BRAIN RES, V756, P205, DOI 10.1016/S0006-8993(97)00196-0; Nakamura K, 2010, J SYN ORG CHEM JPN, V68, P1, DOI 10.5059/yukigoseikyokaishi.68.1; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Palladino M, 2011, MOL THER, V19, P658, DOI 10.1038/mt.2010.292; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Pola R, 2003, CIRCULATION, V108, P479, DOI 10.1161/01.CIR.0000080338.60981.FA; Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708; Renault MA, 2010, J MOL CELL CARDIOL, V49, P490, DOI 10.1016/j.yjmcc.2010.05.003; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Roncalli J, 2011, J AM COLL CARDIOL, V57, P2444, DOI 10.1016/j.jacc.2010.11.069; Soleti R, 2012, FREE RADICAL BIO MED, V53, P2159, DOI 10.1016/j.freeradbiomed.2012.09.021; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Unzek S, 2007, CELL TRANSPLANT, V16, P879, DOI 10.3727/096368907783338271; Wang ZG, 2012, TOXICOL LETT, V212, P137, DOI 10.1016/j.toxlet.2012.05.006; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Zernecke A, 2005, CIRC RES, V96, P784, DOI 10.1161/01.RES.0000162100.52009.38	49	38	40	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2013	8	5							e63075	10.1371/journal.pone.0063075	http://dx.doi.org/10.1371/journal.pone.0063075			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146RE	23690982	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000319107400030
J	Qu, S; Olafsrud, SM; Meza-Zepeda, LA; Saatcioglu, F				Qu, Su; Olafsrud, Solveig Mjelstad; Meza-Zepeda, Leonardo A.; Saatcioglu, Fahri			Rapid Gene Expression Changes in Peripheral Blood Lymphocytes upon Practice of a Comprehensive Yoga Program	PLOS ONE			English	Article							PRACTITIONERS; EXERCISE; MEDICINE; HEALTH	One of the most common integrative medicine (IM) modalities is yoga and related practices. Previous work has shown that yoga may improve wellness in healthy people and have benefits for patients. However, the mechanisms of how yoga may positively affect the mind-body system are largely unknown. Here we have assessed possible rapid changes in global gene expression profiles in the peripheral blood mononuclear cells (PBMCs) in healthy people that practiced either a comprehensive yoga program or a control regimen. The experimental sessions included gentle yoga postures, breathing exercises, and meditation (Sudarshan Kriya and Related Practices - SK&P) compared with a control regimen of a nature walk and listening to relaxing music. We show that the SK&P program has a rapid and significantly greater effect on gene expression in PBMCs compared with the control regimen. These data suggest that yoga and related practices result in rapid gene expression alterations which may be the basis for their longer term cell biological and higher level health effects.	[Qu, Su; Saatcioglu, Fahri] Univ Oslo, Dept Biosci, Oslo, Norway; [Olafsrud, Solveig Mjelstad; Meza-Zepeda, Leonardo A.] Oslo Univ Hosp, Inst Canc Res, Dept Tumor Biol, Oslo, Norway; [Olafsrud, Solveig Mjelstad; Meza-Zepeda, Leonardo A.] Univ Oslo, Genom Core Facil, Dept Biosci, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Saatcioglu, F (corresponding author), Univ Oslo, Dept Biosci, Oslo, Norway.	fahris@ibv.uio.no	Meza-Zepeda, Leonardo Andres/CAG-5229-2022	Meza-Zepeda, Leonardo Andres/0000-0003-3056-212X	Norwegian Cancer Society; Coffral Ltd	Norwegian Cancer Society(Norwegian Cancer Society); Coffral Ltd	This work was supported by grants from the Norwegian Cancer Society and Coffral Ltd to FS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Astin JA, 2003, J AM BOARD FAM PRACT, V16, P131, DOI 10.3122/jabfm.16.2.131; Barnes Patricia M, 2008, Natl Health Stat Report, P1; Bhatia M., 2003, Indian Journal of Physiology and Pharmacology, V47, P157; Black D.S., 2012, PSYCHONEUROENDOCRINO; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; Cole SW, 2010, PSYCHONEUROENDOCRINO, V35, P955, DOI 10.1016/j.psyneuen.2010.06.008; Dusek JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002576; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Garland EL, 2009, HEALTH SOC WORK, V34, P191, DOI 10.1093/hsw/34.3.191; GLASER R, 1986, BEHAV NEUROSCI, V100, P675, DOI 10.1037/0735-7044.100.5.675; Janakiramaiah N, 2000, J AFFECT DISORDERS, V57, P255, DOI 10.1016/S0165-0327(99)00079-8; Kim J, 2010, NATURE, V464, P1048, DOI 10.1038/nature08895; Kjellgren Anette, 2007, BMC Complement Altern Med, V7, P43, DOI 10.1186/1472-6882-7-43; Klokk TI, 2007, CANCER RES, V67, P5221, DOI 10.1158/0008-5472.CAN-06-4728; Kuntsevich V, 2010, MT SINAI J MED, V77, P559, DOI 10.1002/msj.20214; Li QZ, 2005, J ALTERN COMPLEM MED, V11, P29, DOI 10.1089/acm.2005.11.29; Marks PW, 1998, J CELL SCI, V111, P2129; Nahin Richard L, 2009, Natl Health Stat Report, P1; NIEMAN DC, 1995, INT J SPORTS MED, V16, P404, DOI 10.1055/s-2007-973028; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Pilkington K, 2005, J AFFECT DISORDERS, V89, P13, DOI 10.1016/j.jad.2005.08.013; Pullen PR, 2008, J CARD FAIL, V14, P407, DOI 10.1016/j.cardfail.2007.12.007; Ross A, 2010, J ALTERN COMPLEM MED, V16, P3, DOI 10.1089/acm.2009.0044; Shankar SSR, 2010, PATANJALI YOGA SUTRA; Sharma H, 2003, BIOL PSYCHOL, V63, P281, DOI 10.1016/S0301-0511(03)00071-1; Sharma H, 2008, J PSYCHOSOM RES, V64, P213, DOI 10.1016/j.jpsychores.2007.07.003; SHINKAI S, 1992, INT J SPORTS MED, V13, P452, DOI 10.1055/s-2007-1021297; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Shivdasani RA, 2001, STEM CELLS, V19, P397, DOI 10.1634/stemcells.19-5-397; Snyderman R, 2002, ARCH INTERN MED, V162, P395, DOI 10.1001/archinte.162.4.395; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Yeung KY, 2001, BIOINFORMATICS, V17, P763, DOI 10.1093/bioinformatics/17.9.763	32	48	48	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e61910	10.1371/journal.pone.0061910	http://dx.doi.org/10.1371/journal.pone.0061910			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IK	23613970	Green Published, gold			2023-01-03	WOS:000317907200102
J	McLeod, HL				McLeod, Howard L.			Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed	SCIENCE			English	Review							GENOME-WIDE ASSOCIATION; PLASMA-CONCENTRATIONS; LUNG-CANCER; TAMOXIFEN; CYP2D6; CHEMOTHERAPY; WOMEN	The past decade has brought together substantial advances in human genome analysis and a maturation of understanding of tumor biology. Although there is much progress still to be made, there are now several prominent examples in which tumor-associated somatic mutations have been used to identify cellular signaling pathways in tumors. This in turn has led to the development of targeted therapies, with somatic mutations serving as genomic predictors of tumor response and providing new leads for drug development. There is also a realization that germline DNA variants can help optimize cancer drug dosing and predict the susceptibility of patients to the adverse side effects of these drugs-knowledge that ultimately can be used to improve the benefit: risk ratio of cancer treatment for individual patients.	[McLeod, Howard L.] Univ N Carolina, Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC 27599 USA; [McLeod, Howard L.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [McLeod, Howard L.] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA; [McLeod, Howard L.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	McLeod, HL (corresponding author), Univ N Carolina, Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC 27599 USA.	hmcleod@unc.edu	McLeod, Howard/ABD-8364-2021	McLeod, Howard/0000-0002-9004-9232	NIH [UL1 RR025747, P01CA142538, R01 CA161608, R01HL110380]; NATIONAL CANCER INSTITUTE [R01CA161608, P01CA142538] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025747] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL110380] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported in part by NIH grants UL1 RR025747, P01CA142538, R01 CA161608, and R01HL110380. The author serves on the NIH NHGRI Advisory Council, FDA Clinical Pharmacology Committee, and Coriell Institute Pharmacogenomics Advisory Committee and is a scientific advisor to Gentris Corporation.	Ahmad A, 2010, CLIN PHARMACOL THER, V88, P814, DOI 10.1038/clpt.2010.196; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Baldwin RM, 2012, CLIN CANCER RES, V18, P5099, DOI 10.1158/1078-0432.CCR-12-1590; Berg JS, 2013, GENET MED, V15, P36, DOI 10.1038/gim.2012.112; Brown CC, 2012, PHARMACOGENET GENOM, V22, P796, DOI 10.1097/FPC.0b013e3283589c50; Cox NJ, 2012, CLIN PHARMACOL THER, V92, P425, DOI 10.1038/clpt.2012.115; Eechoute K, 2012, CLIN CANCER RES, V18, P5780, DOI 10.1158/1078-0432.CCR-12-0490; Engstrom PF, 2011, J NATL COMPR CANC NE, V9, pS1; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hertz DL, 2012, BREAST CANCER RES TR, V134, P401, DOI 10.1007/s10549-012-2054-0; Hertz DL, 2012, ONCOLOGIST, V17, P620, DOI 10.1634/theoncologist.2011-0418; Innocenti F, 2012, CLIN CANCER RES, V18, P577, DOI 10.1158/1078-0432.CCR-11-1387; Irvin WJ, 2011, J CLIN ONCOL, V29, P3232, DOI 10.1200/JCO.2010.31.4427; KALOW W, 1956, LANCET, V271, P576; Kelly CM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c693; Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670; Lee SY, 2011, J PATHOL, V223, P15, DOI 10.1002/path.2766; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; McWhinney SR, 2009, MOL CANCER THER, V8, P10, DOI 10.1158/1535-7163.MCT-08-0840; Meyer UA, 2000, LANCET, V356, P1667, DOI 10.1016/S0140-6736(00)03167-6; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Peters EJ, 2011, PHARMACOGENOMICS, V12, P1407, DOI [10.2217/PGS.11.92, 10.2217/pgs.11.92]; Ratain MJ, 2006, CLIN CANCER RES, V12, p3612S, DOI 10.1158/1078-0432.CCR-06-9008; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; Ross CJD, 2009, NAT GENET, V41, P1345, DOI 10.1038/ng.478; Stearns V, 2003, JNCI-J NATL CANCER I, V95, P1758, DOI 10.1093/jnci/djg108; Visscher H, 2012, J CLIN ONCOL, V30, P1422, DOI 10.1200/JCO.2010.34.3467; Walko CM, 2012, PHARMACOGENOMICS, V13, P691, DOI [10.2217/PGS.12.27, 10.2217/pgs.12.27]; Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600	30	107	110	0	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 29	2013	339	6127					1563	1566		10.1126/science.1234139	http://dx.doi.org/10.1126/science.1234139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114HL	23539596	Green Submitted, Green Accepted			2023-01-03	WOS:000316731600038
J	Pang, WH; Wang, HF; Shi, L; Sun, YQ; Wang, XT; Wang, MM; Li, JF; Wang, HB; Shi, GG				Pang, Wenhui; Wang, Hefeng; Shi, Lei; Sun, Yueqi; Wang, Xiaoting; Wang, Mingming; Li, Jianfeng; Wang, Haibo; Shi, Guanggang			Immunomodulatory Effects of Escherichia coli ATCC 25922 on Allergic Airway Inflammation in a Mouse Model	PLOS ONE			English	Article							HYGIENE HYPOTHESIS; STEM-CELLS; EARLY-LIFE; RHINITIS; ASTHMA; IMMUNOLOGY; MECHANISMS; MICROBIOTA; SYMPTOMS; IMPACT	Background: Hygiene hypothesis demonstrates that the lack of microbial exposure would promote the development of allergic airway disease (AAD). Therefore, the gut microbiota, including Escherichia coli (E. coli), would probably offer a potential strategy for AAD. Objective: To investigate whether E. coli infection is able to suppress the induction of AAD and to elucidate the underlying mechanisms. Methods: Nonpathogenic E. coli ATCC 25922 was infected by gavage before AAD phase in three patterns: 10(8) or 10(6) CFU in neonates or 10(8) CFU in adults. Then mice were sensitized and challenged with ovalbumin (OVA) to induce allergic inflammation in both the upper and lower airways. Hallmarks of AAD, in terms of eosinophil infiltration and goblet cell metaplasia in subepithelial mucosa, Th2 skewing of the immune response, and levels of T regulate cells (Tregs), were examined by histological analysis, ELISA, and flow cytometry, respectively. Results: E. coli, especially neonatally infected with an optimal dose, attenuated allergic responses, including a decrease in nasal rubbing and sneezing, a reduction in eosinophil inflammation and goblet cell metaplasia in subepithelial mucosa, decreased serum levels of OVA-specific IgE, and reduced Th2 (IL-4) cytokines. In contrast, this effect came with an increase of Th1 (IFN-r and IL-2) cytokines, and an enhancement of IL-10-secreting Tregs in paratracheal lymph nodes (PTLN). Conclusion: E. coli suppresses allergic responses in mice, probably via a shift from Th1 to Th2 and/or induction of Tregs. Moreover, this infection is age-and dose-dependent, which may open up novel possibilities for new therapeutic interventions.	[Pang, Wenhui; Shi, Lei; Wang, Xiaoting; Wang, Mingming; Li, Jianfeng; Wang, Haibo; Shi, Guanggang] Shandong Univ, Prov Hosp, Dept Otorhinolaryngol Head & Neck Surg, Inst Eye & Otorhinolaryngol, Jinan 250100, Peoples R China; [Wang, Hefeng] Shandong Univ, Qilu Hosp, Jinan 250100, Peoples R China; [Sun, Yueqi] Sun Yat Sen Univ, Affiliated Hosp 1, Otorhinolaryngol Hosp, Guangzhou 510275, Guangdong, Peoples R China	Shandong University; Shandong University; Sun Yat Sen University	Shi, GG (corresponding author), Shandong Univ, Prov Hosp, Dept Otorhinolaryngol Head & Neck Surg, Inst Eye & Otorhinolaryngol, Jinan 250100, Peoples R China.	shiguangangent@hotmail.com	Shi, Lei/AAR-5350-2020; Sun, Yueqi/N-4528-2018	Sun, Yueqi/0000-0002-2382-0429	Science and Technology Foundation of Shandong Province, China [2007HW104]; Shandong Provincial Natural Science Foundation, China [Y2006C73]; National Natural Science Foundation of China (NSFC) [30801279]	Science and Technology Foundation of Shandong Province, China; Shandong Provincial Natural Science Foundation, China(Natural Science Foundation of Shandong Province); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	The authors thank each named author for their contributions to this work. This study was supported by grants from the Science and Technology Foundation of Shandong Province, China (2007HW104), the Shandong Provincial Natural Science Foundation, China (Y2006C73), and the National Natural Science Foundation of China (NSFC, 30801279). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Blaser MJ, 2009, NAT REV MICROBIOL, V7, P887, DOI 10.1038/nrmicro2245; Boudeau J, 2003, ALIMENT PHARM THER, V18, P45, DOI 10.1046/j.1365-2036.2003.01638.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Cho KS, 2009, STEM CELLS, V27, P259, DOI 10.1634/stemcells.2008-0283; Compalati E, 2010, EXPERT REV CLIN IMMU, V6, P413, DOI [10.1586/ECI.10.15, 10.1586/eci.10.15]; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Hellings PW, 2001, CLIN EXP ALLERGY, V31, P782, DOI 10.1046/j.1365-2222.2001.01081.x; Henderson WR, 2005, J ALLERGY CLIN IMMUN, V116, P332, DOI 10.1016/j.jaci.2005.04.013; Hill DA, 2012, NAT MED, V18, P538, DOI 10.1038/nm.2657; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Jenerowicz D, 2012, ANN AGR ENV MED, V19, P475; Kang JH, 2009, AM J RESP CRIT CARE, V179, P875, DOI 10.1164/rccm.200806-893OC; Leavy O, 2012, NAT REV IMMUNOL, V12, P319, DOI 10.1038/nri3213; Ley RE, 2008, NAT REV MICROBIOL, V6, P776, DOI 10.1038/nrmicro1978; LOBRY JR, 1992, J ANTIMICROB CHEMOTH, V29, P121, DOI 10.1093/jac/29.2.121; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S, DOI 10.1093/ajcn/69.5.1035s; Nauta AJ, 2008, EUR J PHARMACOL, V585, P354, DOI 10.1016/j.ejphar.2008.02.094; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Qiu HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022004; Renz H, 2012, NAT REV IMMUNOL, V12, P9, DOI 10.1038/nri3112; Robinson CJ, 2010, MICROBIOL MOL BIOL R, V74, P453, DOI 10.1128/MMBR.00014-10; Robinson DS, 2009, CLIN EXP ALLERGY, V39, P1314, DOI 10.1111/j.1365-2222.2009.03301.x; Rose MA, 2011, BMC COMPLEM ALTERN M, V3, P11; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Sauer A, 2009, J FOOD PROTECT, V72, P937, DOI 10.4315/0362-028X-72.5.937; Savilahti EM, CLIN EXP ALLERGY, V405- 411; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; SHARMA V, 1992, J BACTERIOL, V174, P5057, DOI 10.1128/JB.174.15.5057-5062.1992; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Skapenko Alla, 2007, V136, P87; Smit JJ, 2003, CLIN EXP ALLERGY, V33, P1083, DOI 10.1046/j.1365-2222.2003.01727.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Sun YQ, 2012, STEM CELLS, V30, P2692, DOI 10.1002/stem.1241; Thorburn AN, 2010, THORAX, V65, P1053, DOI 10.1136/thx.2009.131508; Uri J V, 1994, Acta Microbiol Immunol Hung, V41, P215; Wang DY, 2000, AM J RHINOL, V14, P325, DOI 10.2500/105065800781329483; Wold AE, 1998, ALLERGY, V53, P20, DOI 10.1111/j.1398-9995.1998.tb04953.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yokota E, 2008, INT IMMUNOPHARMACOL, V8, P1083, DOI 10.1016/j.intimp.2008.03.018; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	47	11	12	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2013	8	3							e59174	10.1371/journal.pone.0059174	http://dx.doi.org/10.1371/journal.pone.0059174			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123NP	23536867	Green Published, gold, Green Submitted			2023-01-03	WOS:000317397200017
J	Dormuth, CR; Hemmelgarn, BR; Paterson, JM; James, MT; Teare, GF; Raymond, CB; Lafrance, JP; Levy, A; Garg, AX; Ernst, P				Dormuth, Colin R.; Hemmelgarn, Brenda R.; Paterson, J. Michael; James, Matthew T.; Teare, Gary F.; Raymond, Colette B.; Lafrance, Jean-Philippe; Levy, Adrian; Garg, Amit X.; Ernst, Pierre		CNODES	Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ROSUVASTATIN; METAANALYSIS; CHOLESTEROL; VALIDITY; OUTCOMES; FAILURE; DISEASE; WOMEN; MEN	Objective To quantify an association between acute kidney injury and use of high potency statins versus low potency statins. Design Retrospective observational analysis of administrative databases, using nine population based cohort studies and meta-analysis. We performed as treated analyses in each database with a nested case-control design. Rate ratios for different durations of current and past statin exposure to high potency or low potency statins were estimated using conditional logistic regression. Ratios were adjusted for confounding by high dimensional propensity scores. Meta-analytic methods estimated overall effects across participating sites. Setting Seven Canadian provinces and two databases in the United Kingdom and the United States. Participants 2 067 639 patients aged 40 years or older and newly treated with statins between 1 January 1997 and 30 April 2008. Each person hospitalized for acute kidney injury was matched with ten controls. Intervention A dispensing event was new if no cholesterol lowering drug or niacin prescription was dispensed in the previous year. High potency statin treatment was defined as >= 10 mg rosuvastatin, >= 20 mg atorvastatin, and >= 40 mg simvastatin; all other statin treatments were defined as low potency. Statin potency groups were further divided into cohorts with or without chronic kidney disease. Main outcome measure Relative hospitalization rates for acute kidney injury. Results Of more than two million statin users (2 008 003 with non-chronic kidney disease; 59 636 with chronic kidney disease), patients with similar propensity scores were comparable on measured characteristics. Within 120 days of current treatment, there were 4691 hospitalizations for acute kidney injury in patients with non-chronic kidney injury, and 1896 hospitalizations in those with chronic kidney injury. In patients with non-chronic kidney disease, current users of high potency statins were 34% more likely to be hospitalized with acute kidney injury within 120 days after starting treatment (fixed effect rate ratio 1.34, 95% confidence interval 1.25 to 1.43). Users of high potency statins with chronic kidney disease did not have as large an increase in admission rate (1.10, 0.99 to 1.23). chi(2) tests for heterogeneity confirmed that the observed association was robust across participating sites. Conclusions Use of high potency statins is associated with an increased rate of diagnosis for acute kidney injury in hospital admissions compared with low potency statins. The effect seems to be strongest in the first 120 days after initiation of statin treatment.	[Dormuth, Colin R.] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Victoria, BC V8W 1Y2, Canada; [Hemmelgarn, Brenda R.; James, Matthew T.] Univ Calgary, Dept Med, Calgary, AB, Canada; [Paterson, J. Michael] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Teare, Gary F.] Hlth Qual Council, Saskatoon, SK, Canada; [Raymond, Colette B.] Univ Manitoba, Manitoba Ctr Hlth Policy, Winnipeg, MB, Canada; [Lafrance, Jean-Philippe] Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; [Levy, Adrian] Dalhousie Univ, Halifax, NS, Canada; [Garg, Amit X.] Univ Western Ontario, Div Nephrol, London, ON, Canada; [Ernst, Pierre] McGill Univ, Jewish Gen Hosp, Ctr Clin Epidemiol, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada	University of British Columbia; University of Calgary; University of Toronto; University of Manitoba; Universite de Montreal; Dalhousie University; Western University (University of Western Ontario); Lady Davis Institute; McGill University	Dormuth, CR (corresponding author), Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Victoria, BC V8W 1Y2, Canada.	colin.dormuth@ti.ubc.ca	Garg, Amit X/G-3295-2011; Lafrance, Jean-Philippe/C-9113-2013	Lafrance, Jean-Philippe/0000-0001-7876-0446; Platt, Robert/0000-0002-5981-8443; Dormuth, Colin/0000-0001-8577-8783	Health Canada; Drug Safety and Effectiveness Network; Canadian Institutes for Health Research; Zeneca; Boehringer Ingelheim; Merck; Nycomed; Icon	Health Canada; Drug Safety and Effectiveness Network; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Zeneca; Boehringer Ingelheim(Boehringer Ingelheim); Merck(Merck & Company); Nycomed; Icon	CNODES is funded by a grant from Health Canada, the Drug Safety and Effectiveness Network, and the Canadian Institutes for Health Research that oversaw the peer review and funding process.; All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from Health Canada, the Drug Safety and Effectiveness Network, and the Canadian Institutes for Health Research for the submitted work; PE receives consultancy and speaker's fees from Astra Zeneca, Boehringer Ingelheim, Merck, and Nycomed, and a research grant from Boehringer Ingelheim; AL receives consultancy fees from Oxford Outcomes (now Icon), a company that carries out contracted work for pharmaceutical companies; no other relationships or activities that could appear to have influenced the submitted work.	Alsheikh-Ali AA, 2005, CIRCULATION, V111, P3051, DOI 10.1161/CIRCULATIONAHA.105.555482; [Anonymous], 2010, HIGH DIMENSIONAL PRO; Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5; *CAN PHARM ASS, 2004, COMP PHARM SPEC; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Essebag Vidal, 2005, BMC Med Res Methodol, V5, P5, DOI 10.1186/1471-2288-5-5; Rodriguez LAG, 2010, PHARMACOEPIDEM DR S, V19, P1218, DOI 10.1002/pds.2032; Hippisley-Cox J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2197; Hwang YJ, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001821; Ishikawa A, 2011, CLIN EXP NEPHROL, V15, P30, DOI 10.1007/s10157-010-0350-8; Kheterpal S, 2007, ANESTHESIOLOGY, V107, P892, DOI 10.1097/01.anes.0000290588.29668.38; Kiortsis DN, 2007, ATHEROSCLEROSIS, V195, P7, DOI 10.1016/j.atherosclerosis.2006.10.001; Law MR, 2003, BRIT MED J, V326, P1423, DOI 10.1136/bmj.326.7404.1423; McMurray JJV, 2010, J AM COLL CARDIOL, V56, P1196, DOI 10.1016/j.jacc.2010.02.075; Molnar AO, 2011, J AM SOC NEPHROL, V22, P939, DOI 10.1681/ASN.2010050442; Murugan R, 2012, CLIN J AM SOC NEPHRO, V7, P895, DOI 10.2215/CJN.07100711; Ouattara A, 2009, J CARDIOTHOR VASC AN, V23, P633, DOI 10.1053/j.jvca.2009.02.008; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Roberts MD, 2009, CRESTOR ROSUVASTATIN; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; Singh Ram B., 2000, Journal of Nutritional and Environmental Medicine (Abingdon), V10, P281, DOI 10.1080/13590840020013266; Sniderman A, 2012, J CLIN LIPIDOL, V6, P303, DOI 10.1016/j.jacl.2012.05.004; Suissa Samy, 2012, Open Med, V6, pe134; Vlasschaert MEO, 2011, AM J KIDNEY DIS, V57, P29, DOI 10.1053/j.ajkd.2010.08.031; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1688, DOI 10.1681/ASN.2006010073; Wolfe SM, 2004, LANCET, V363, P2189, DOI 10.1016/S0140-6736(04)16513-6	26	162	166	0	29	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 19	2013	346								f880	10.1136/bmj.f880	http://dx.doi.org/10.1136/bmj.f880			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LX	23511950	hybrid			2023-01-03	WOS:000316670500002
J	Vehling, S; Oechsle, K; Koch, U; Mehnert, A				Vehling, Sigrun; Oechsle, Karin; Koch, Uwe; Mehnert, Anja			Receiving Palliative Treatment Moderates the Effect of Age and Gender on Demoralization in Patients with Cancer	PLOS ONE			English	Article							QUALITY-OF-LIFE; BREAST-CANCER; PSYCHOLOGICAL DISTRESS; PSYCHOSOMATIC RESEARCH; PSYCHOSOCIAL DISTRESS; DEPRESSIVE SYMPTOMS; DIAGNOSTIC-CRITERIA; SOCIAL SUPPORT; ERROR VARIANCE; CARE	Background: Existential distress is an important factor affecting psychological well-being in cancer patients. We studied occurrence and predictors of demoralization, a syndrome of existential distress, in particular the interaction of age, gender, and curative vs. palliative treatment phase. Methods: A cross-sectional sample of N = 750 patients with different tumor sites was recruited from in-and outpatient treatment facilities. Patients completed the following self-report questionnaires: Demoralization Scale, Patient Health Questionnaire-9, Illness-Specific Social Support Scale Short Version-8, and physical problems list of the NCCN Distress Thermometer. Moderated multiple regression analyses were conducted. Results: We found high demoralization in 15% and moderate demoralization in 8% of the sample. Curative vs. palliative treatment phase moderated the impact of age and gender on demoralization (three-way interaction: b = 1.30, P = 0.2): the effect of age on demoralization was negative for women receiving palliative treatment (b = -2.6, P = 0.2) and positive for men receiving palliative treatment (b = 2.5, P = 0.3). Effects of age and gender were not significant among patients receiving curative treatment. Female gender was associated with higher demoralization among younger patients receiving palliative treatment only. Analyses were controlled for significant effects of the number of physical problems (b = 6.10, P < 0.01) and social support (b = -3.17, P<0.01). Conclusions: Existential distress in terms of demoralization is a relevant problem within the spectrum of cancer-related distress. It is associated with a complex interaction of demographic and medical patient characteristics; existential challenges related to palliative treatment may exacerbate the impact of age-and gender-related vulnerability factors on demoralization. Psychosocial interventions should acknowledge this interaction in order to address the individual nature of existential distress in subgroups of cancer patients.	[Vehling, Sigrun; Koch, Uwe; Mehnert, Anja] Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany; [Oechsle, Karin] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol Pneumol, Hamburg, Germany; [Koch, Uwe] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Mehnert, Anja] Univ Med Ctr Leipzig, Div Psychosocial Oncol, Dept Med Psychol & Med Sociol, Leipzig, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leipzig University	Vehling, S (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Med Psychol, Hamburg, Germany.	s.vehling@uke.de	Koch, Uwe/A-5825-2009; Vehling, Sigrun/AAD-2861-2021; tan, janie/AAH-9283-2021; Mehnert-Theuerkauf, Anja/A-1177-2008	Vehling, Sigrun/0000-0001-9314-4326; Mehnert-Theuerkauf, Anja/0000-0002-6872-9805	German Cancer Aid (Deutsche Krebshilfe) [107465]	German Cancer Aid (Deutsche Krebshilfe)(Deutsche Krebshilfe)	This study was supported by the German Cancer Aid (Deutsche Krebshilfe, Grant number 107465). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguinis H, 1998, ORGAN RES METHODS, V1, P296, DOI 10.1177/109442819813002; Aiken L. S., 1991, MULTIPLE REGRESSION; ALEXANDER RA, 1994, PSYCHOL BULL, V115, P308, DOI 10.1037/0033-2909.115.2.308; Angelino AF, 2001, SUPPORT CARE CANCER, V9, P344, DOI 10.1007/s005200000195; Arden-Close E, 2008, PSYCHO-ONCOLOGY, V17, P1061, DOI 10.1002/pon.1363; Blank TO, 2008, CANCER-AM CANCER SOC, V112, P2569, DOI 10.1002/cncr.23444; Boscaglia N, 2007, PSYCHO-ONCOL, V16, P189, DOI 10.1002/pon.1044; Breitbart W, 2012, J CLIN ONCOL, V30, P1304, DOI 10.1200/JCO.2011.36.2517; Brothers BM, 2009, PSYCHO-ONCOLOGY, V18, P267, DOI 10.1002/pon.1394; Chochinov HM, 2009, J PAIN SYMPTOM MANAG, V38, P641, DOI 10.1016/j.jpainsymman.2009.04.021; Chochinov HM, 2006, CA-CANCER J CLIN, V56, P84, DOI 10.3322/canjclin.56.2.84; Clarke David M, 2005, World Psychiatry, V4, P96; Clarke DM, 2002, AUST NZ J PSYCHIAT, V36, P733, DOI 10.1046/j.1440-1614.2002.01086.x; Cockram CA, 2009, PSYCHOTHER PSYCHOSOM, V78, P342, DOI 10.1159/000235737; Connor MJ, 2011, NURS INQ, V18, P2, DOI 10.1111/j.1440-1800.2010.00501.x; Dawson JF, 2006, J APPL PSYCHOL, V91, P917, DOI 10.1037/0021-9010.91.4.917; DEFIGUEIREDO JM, 1993, COMPR PSYCHIAT, V34, P308, DOI 10.1016/0010-440X(93)90016-W; Fox J, 2008, APPL REGRESSION ANAL; Giese-Davis J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-441; Grassi L, 2005, PSYCHOTHER PSYCHOSOM, V74, P100, DOI 10.1159/000083168; Grassi L, 2004, PSYCHOSOMATICS, V45, P483, DOI 10.1176/appi.psy.45.6.483; Hagedoorn M, 2008, PSYCHOL BULL, V134, P1, DOI 10.1037/0033-2909.134.1.1; Jacobsen JC, 2006, INDIAN J PALLIAT CAR, V12, P8, DOI 10.4103/0973-1075.25913; Jacobsen Juliet C, 2007, Prim Care Companion J Clin Psychiatry, V9, P139; Jones JM, 2003, J PSYCHOSOM RES, V55, P411, DOI 10.1016/S0022-3999(03)00526-9; Kissane D, 2009, HDB PSYCHIAT PALLIAT, P324; Kissane DW, 2012, ARCH INTERN MED, V172, P1501, DOI 10.1001/archinternmed.2012.3633; Kissane DW, 2004, J PALLIATIVE CARE, V20, P269, DOI 10.1177/082585970402000402; Kissane DW, 2001, J PALLIAT CARE, V17, P12, DOI 10.1177/082585970101700103; Kuehner C, 2003, ACTA PSYCHIAT SCAND, V108, P163, DOI 10.1034/j.1600-0447.2003.00204.x; Lee CY, 2012, SUPPORT CARE CANCER, V20, P2259, DOI 10.1007/s00520-011-1332-4; Lemay K, 2008, CLIN PSYCHOL REV, V28, P472, DOI 10.1016/j.cpr.2007.07.013; Lo C, 2010, AGEING SOC, V30, P325, DOI 10.1017/S0144686X09990201; Lowe B, 2004, J AFFECT DISORDERS, V81, P61, DOI 10.1016/S0165-0327(03)00198-8; Mehnert A, 2010, EUR J CANCER CARE, V19, P736, DOI 10.1111/j.1365-2354.2009.01117.x; Mehnert A, 2006, PSYCHOTHER PSYCH MED, V56, P462, DOI 10.1055/s-2006-951828; Mehnert A, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-70; Mehnert A, 2011, J PAIN SYMPTOM MANAG, V42, P768, DOI 10.1016/j.jpainsymman.2011.02.013; Miller S, 2011, SOC PSYCH PSYCH EPID, V46, P767, DOI 10.1007/s00127-010-0246-7; Monforte-Royo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037117; Mosher CE, 2005, J PSYCHOSOC ONCOL, V23, P101, DOI 10.1300/J077v23n02_07; Nelson CJ, 2009, ONCOLOGIST, V14, P891, DOI 10.1634/theoncologist.2009-0059; Nissim R, 2012, PALLIATIVE MED, V26, P713, DOI 10.1177/0269216311425096; Nolen-Hoeksema S, 2012, ANNU REV CLIN PSYCHO, V8, P161, DOI 10.1146/annurev-clinpsy-032511-143109; REVENSON TA, 1991, SOC SCI MED, V33, P807, DOI 10.1016/0277-9536(91)90385-P; Rodin Gary, 2008, J Am Acad Psychoanal Dyn Psychiatry, V36, P181, DOI 10.1521/jaap.2008.36.1.181; Rodin G, 2009, SOC SCI MED, V68, P562, DOI 10.1016/j.socscimed.2008.10.037; Rosenfeld B, 2004, PSYCHO-ONCOL, V13, P800, DOI 10.1002/pon.797; Ryan D, 2012, PALLIATIVE MED, V26, P162, DOI 10.1177/0269216311399663; Sachs E, 2012, AM J HOSP PALLIAT CA; Scheier MF, 2006, J CLIN ONCOL, V24, P2407, DOI 10.1200/JCO.2005.05.5244; Siegel K, 1999, J PSYCHOSOC ONCOL, V17, P1, DOI 10.1300/J077v17n01_01; Tamres LK, 2002, PERS SOC PSYCHOL REV, V6, P2, DOI 10.1207/S15327957PSPR0601_1; Ullrich A., 2010, KLIN DIAGNOSTIK EVAL, V3, P359; Vehling S, 2011, SUPPORT CARE CANCER, V19, P513, DOI 10.1007/s00520-010-0845-6; Vehling S, 2012, PSYCHO-ONCOLOGY, V21, P54, DOI 10.1002/pon.1866; Whisman MA, 2005, J FAM PSYCHOL, V19, P111, DOI 10.1037/0893-3200.19.1.111	57	28	31	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2013	8	3							e59417	10.1371/journal.pone.0059417	http://dx.doi.org/10.1371/journal.pone.0059417			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	109ZC	23555030	Green Published, Green Submitted, gold			2023-01-03	WOS:000316409800088
J	Nguyen, NP; Smith-Raymond, L; Vinh-Hung, V; Vos, P; Davis, R; Desai, A; Sroka, T; Abraham, D; Krafft, SP; Stevie, M; Modarresifar, H; Jo, BH; Ceizyk, M				Nguyen, Nam P.; Smith-Raymond, Lexie; Vinh-Hung, Vincent; Vos, Paul; Davis, Rick; Desai, Anand; Sroka, Thomas; Abraham, Dave; Krafft, Shane P.; Stevie, Michelle; Modarresifar, Homayoun; Jo, Beng-Hoey; Ceizyk, Misty			Feasibility of Tomotherapy-Based Image-Guided Radiotherapy to Reduce Aspiration Risk in Patients with Non-Laryngeal and Non-Pharyngeal Head and Neck Cancer	PLOS ONE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; LOCALLY ADVANCED HEAD; RADIATION-THERAPY; DYSPHAGIA SEVERITY; CHEMORADIOTHERAPY; CHEMORADIATION; IMPACT	Purpose: The study aims to assess the feasibility of Tomotherapy-based image-guided radiotherapy (IGRT) to reduce the aspiration risk in patients with non-laryngeal and non-hypopharyngeal cancer. A retrospective review of 48 patients undergoing radiation for non-laryngeal and non-hypopharyngeal head and neck cancers was conducted. All patients had a modified barium swallow (MBS) prior to treatment, which was repeated one month following radiotherapy. Mean middle and inferior pharyngeal dose was recorded and correlated with the MBS results to determine aspiration risk. Results: Mean pharyngeal dose was 23.2 Gy for the whole group. Two patients (4.2%) developed trace aspiration following radiotherapy which resolved with swallowing therapy. At a median follow-up of 19 months (1-48 months), all patients were able to resume normal oral feeding without aspiration. Conclusion and Clinical Relevance: IGRT may reduce the aspiration risk by decreasing the mean pharyngeal dose in the presence of large cervical lymph nodes. Further prospective studies with IGRT should be performed in patients with non-laryngeal and non-hypopharyngeal head and neck cancers to verify this hypothesis.	[Nguyen, Nam P.; Smith-Raymond, Lexie; Davis, Rick; Abraham, Dave; Stevie, Michelle; Jo, Beng-Hoey; Ceizyk, Misty] Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA; [Vinh-Hung, Vincent] Univ Hosp Geneva, Dept Radiat Oncol, Geneva, Switzerland; [Vos, Paul] E Carolina Univ, Greenville, NC USA; [Desai, Anand; Krafft, Shane P.] Univ Texas MD Anderson, Dept Radiat Oncol, Houston, TX USA; [Sroka, Thomas] Dartmouth Coll, Dept Radiat Oncol, Hanover, NH 03755 USA; [Modarresifar, Homayoun] Univ Arizona, Dept Radiol, Tucson, AZ 85724 USA	University of Arizona; University of Geneva; University of North Carolina; East Carolina University; University of Texas System; UTMD Anderson Cancer Center; Dartmouth College; University of Arizona	Nguyen, NP (corresponding author), Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA.	NamPhong.Nguyen@yahoo.com	Vinh-Hung, Vincent/A-5762-2008	Vinh-Hung, Vincent/0000-0002-6403-6120; Krafft, Shane/0000-0002-4582-8587				Amdur RJ, 2007, INT J RADIAT ONCOL, V69, pS46, DOI 10.1016/j.ijrobp.2007.04.091; Caglar HB, 2008, INT J RADIAT ONCOL, V72, P1110, DOI 10.1016/j.ijrobp.2008.02.048; Chao KSC, 2003, INT J RADIAT ONCOL, V55, P312, DOI 10.1016/S0360-3016(02)03940-8; Dirix P, 2009, INT J RADIAT ONCOL, V78, P1356; Eisbruch A, 2004, INT J RADIAT ONCOL, V60, P1425, DOI 10.1016/j.ijrobp.2004.05.050; Feng FY, 2007, INT J RADIAT ONCOL, V68, P1289, DOI 10.1016/j.ijrobp.2007.02.049; Feng FY, 2010, J CLIN ONCOL, V28, P2732, DOI 10.1200/JCO.2009.24.6199; Fua TF, 2007, INT J RADIAT ONCOL, V67, P976, DOI 10.1016/j.ijrobp.2006.10.028; Gokhale AS, 2010, ANN ONCOL, V21, P145, DOI 10.1093/annonc/mdp268; Kamprad F, 2008, STRAHLENTHER ONKOL, V184, P157, DOI 10.1007/s00066-008-1780-z; Langerman A, 2007, ARCH OTOLARYNGOL, V133, P1289, DOI 10.1001/archotol.133.12.1289; Lee N, 2007, INT J RADIAT ONCOL, V68, P1299, DOI 10.1016/j.ijrobp.2006.11.019; Levendag PC, 2007, RADIOTHER ONCOL, V85, P64, DOI 10.1016/j.radonc.2007.07.009; Logemann JA, 2006, HEAD NECK-J SCI SPEC, V28, P64, DOI 10.1002/hed.20299; Nguyen NP, 2008, BRIT J RADIOL, V81, P706, DOI 10.1259/bjr/98862877; Nguyen NP, 2009, BRIT J RADIOL, V82, P675, DOI 10.1259/bjr/72852974; Nguyen NP, 2008, ANTICANCER RES, V28, P431; Nguyen NP, 2007, ORAL ONCOL, V43, P352, DOI 10.1016/j.oraloncology.2006.04.002; Nguyen NP, 2006, RADIOTHER ONCOL, V80, P302, DOI 10.1016/j.radonc.2006.07.031; Nguyen NP, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-253; Nguyen NP, 2011, ORAL ONCOL, V47, P900, DOI 10.1016/j.oraloncology.2011.06.004; Nguyen NP, 2010, ORAL ONCOL, V46, P283, DOI 10.1016/j.oraloncology.2010.01.010; Schwartz DL, 2010, INT J RADIAT ONCOL, V78, P1356, DOI 10.1016/j.ijrobp.2009.10.002	23	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2013	8	3							e56290	10.1371/journal.pone.0056290	http://dx.doi.org/10.1371/journal.pone.0056290			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136BN	23505414	Green Published, Green Submitted, gold			2023-01-03	WOS:000318334500007
J	Li, H; Lui, N; Cheng, T; Tseng, HHK; Yue, DS; Giroux-Leprieur, E; Do, HT; Sheng, Q; Jin, JQ; Luh, TW; Jablons, DM; He, BA				Li, Hui; Lui, Natalie; Cheng, Tiffany; Tseng, Hsin-Hui K.; Yue, Dongsheng; Giroux-Leprieur, Etienne; Do, Hanh T.; Sheng, Qing; Jin, Joy Q.; Luh, Thomas W.; Jablons, David M.; He, Biao			Gli as a Novel Therapeutic Target in Malignant Pleural Mesothelioma	PLOS ONE			English	Article							HEDGEHOG SIGNALING PATHWAY; TGF-BETA; ACTIVATION; MECHANISMS; GENE	Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with poor prognosis. Current treatment is rarely curative, thus novel meaningful therapies are urgently needed. Inhibition of Hedgehog (Hh) signaling at the cell membrane level in several cancers has shown anti-cancer activity in recent clinical studies. Evidence of Hh-independent Gli activation suggests Gli as a more potent therapeutic target. The current study is aimed to evaluate the potential of Gli as a therapeutic target to treat MPM. The expression profiles of Gli factors and other Hh signaling components were characterized in 46 MPM patient tissue samples by RT-PCR and immunohistochemistry. Cultured cell lines were employed to investigate the requirement of Gli activation in tumor cell growth by inhibiting Gli through siRNA or a novel small molecule Gli inhibitor (Gli-I). A xenograft model was used to evaluate Gli-I in vivo. In addition, a side by side comparison between Gli and Smoothened (Smo) inhibition was conducted in vitro using siRNA and small molecule inhibitors. Our study reported aberrant Gli1 and Gli2 activation in a large majority of tissues. Inhibition of Gli by siRNAs or Gli-I suppressed cell growth dramatically both in vitro and in vivo. Inhibition of Gli exhibited better cytotoxicity than that of Smo by siRNA and small molecule inhibitors vismodegib and cyclopamine. Combination of Gli-I and pemetrexed, as well as Gli-I and vismodegib demonstrated synergistic effects in suppression of MPM proliferation in vitro. In summary, Gli activation plays a critical role in MPM. Inhibition of Gli function holds strong potential to become a novel, clinically effective approach to treat MPM.	[Li, Hui; Lui, Natalie; Cheng, Tiffany; Tseng, Hsin-Hui K.; Yue, Dongsheng; Giroux-Leprieur, Etienne; Do, Hanh T.; Sheng, Qing; Jin, Joy Q.; Luh, Thomas W.; Jablons, David M.; He, Biao] Univ Calif San Francisco, Dept Surg, Thorac Oncol Program, San Francisco, CA 94143 USA; [Sheng, Qing] Zhejiang Sci Tech Univ, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China; [Yue, Dongsheng] TianJin Med Univ, Dept Lung Canc, Lung Canc Ctr, Canc Inst & Hosp, Tianjin, Peoples R China	University of California System; University of California San Francisco; Zhejiang Sci-Tech University; Tianjin Medical University	He, BA (corresponding author), Univ Calif San Francisco, Dept Surg, Thorac Oncol Program, San Francisco, CA 94143 USA.	biao.he@ucsfmedctr.org	Leprieur, Etienne Giroux/H-6345-2015; Tseng, Hsin-Hui Katty/AAG-1941-2019	Giroux Leprieur, Etienne/0000-0001-8441-1701; Jin, Joy/0000-0002-1283-4665	NIH/NCI [R01CA125030, R01CA132566]; Eileen D. Ludwig Endowed for Thoracic Oncology Research; Bonnie J. Addario Lung Cancer Foundation; Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation; Paul and Michelle Zygielbaum; Honeywell Foundation; Jeffrey and Karen Peterson Family Foundation; NATIONAL CANCER INSTITUTE [R01CA132566, R01CA125030] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Eileen D. Ludwig Endowed for Thoracic Oncology Research; Bonnie J. Addario Lung Cancer Foundation; Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation; Paul and Michelle Zygielbaum; Honeywell Foundation; Jeffrey and Karen Peterson Family Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH/NCI grant R01CA125030; the Eileen D. Ludwig Endowed for Thoracic Oncology Research (to BH); NIH/NCI grant R01CA132566; the Bonnie J. Addario Lung Cancer Foundation; the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley & Oberman Foundation; Paul and Michelle Zygielbaum; the Honeywell Foundation; and the Jeffrey and Karen Peterson Family Foundation (to DMJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bigelow RLH, 2005, J INVEST DERMATOL, V124, P457, DOI 10.1111/j.0022-202X.2004.23590.x; Carbone M, 2012, CLIN CANCER RES, V18, P598, DOI 10.1158/1078-0432.CCR-11-2259; Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724; Chi SM, 2006, CANCER LETT, V244, P53, DOI 10.1016/j.canlet.2005.11.036; Crispi S, 2010, CURR CANCER DRUG TAR, V10, P19, DOI 10.2174/156800910790980232; Dennler S, 2009, J INVEST DERMATOL, V129, pS85; Dlugosz A, 2012, NAT REV DRUG DISCOV, V11, P437, DOI 10.1038/nrd3753; Dodge ME, 2011, ANNU REV PHARMACOL, V51, P289, DOI 10.1146/annurev-pharmtox-010510-100558; Greillier L, 2011, ANTI-CANCER DRUG, V22, P199, DOI 10.1097/CAD.0b013e328341ccdd; He BNF, 2010, United States patent, Patent No. [US 6,885,550, 6885550]; Hui CC, 2011, ANNU REV CELL DEV BI, V27, P513, DOI 10.1146/annurev-cellbio-092910-154048; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Lauth M, 2007, CURR OPIN INVEST DR, V8, P457; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Mimeault M, 2010, PHARMACOL REV, V62, P497, DOI 10.1124/pr.109.002329; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Sekido Y, 2010, CANCER SCI, V101, P1, DOI 10.1111/j.1349-7006.2009.01336.x; Sekulic A, 2012, NEW ENGL J MED, V366, P2171, DOI 10.1056/NEJMoa1113713; Seto M, 2009, MOL CARCINOGEN, V48, P703, DOI 10.1002/mc.20516; Shi YD, 2012, CLIN CANCER RES, V18, P4646, DOI 10.1158/1078-0432.CCR-12-0599; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Stanton BZ, 2010, MOL BIOSYST, V6, P44, DOI 10.1039/b910196a; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Thompson MC, 2006, J CLIN ONCOL, V24, P1924, DOI 10.1200/JCO.2005.04.4974; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Tsao AS, 2009, J CLIN ONCOL, V27, P2081, DOI 10.1200/JCO.2008.19.8523; Zucali PA, 2011, CANCER TREAT REV, V37, P543, DOI 10.1016/j.ctrv.2011.01.001	35	26	29	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2013	8	3							e57346	10.1371/journal.pone.0057346	http://dx.doi.org/10.1371/journal.pone.0057346			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	117EP	23483902	Green Published, Green Submitted, gold			2023-01-03	WOS:000316936100019
J	Hosseinzadeh, R; Khorsandi, K; Hemmaty, S				Hosseinzadeh, Reza; Khorsandi, Khatereh; Hemmaty, Syavash			Study of the Effect of Surfactants on Extraction and Determination of Polyphenolic Compounds and Antioxidant Capacity of Fruits Extracts	PLOS ONE			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; PHENOLIC-COMPOUNDS; SEPARATION; MICELLES; RADICALS; BROMIDE; TANNINS	Micelle/water mixed solutions of different surface active agents were studied for their effectiveness in the extraction of polyphenolic compounds from various varieties of apples from west Azerbaijan province in Iran. The total content of polyphenolic compound in fruit extracts were determined using ferrous tartrate and Folin-Ciocalteu assays methods and chromatographic methods and compared with theme. High performance liquid chromatography is one of the most common and important methods in biochemical compound identification. The effect of pH, ionic strength, surfactant type, surfactant concentration, extraction time and common organic solvent in the apple polyphenolics extractions was studied using HPLC-DAD. Mixtures of surfactants, water and methanol at various ratios were examined and micellar-water solutions of Brij surfactant showed the highest polyphenol extraction efficiency. Optimum conditions for the extraction of polyphenolic compounds from apple occurred at 7 mM Brij35, pH 3. Effect of ionic strength on extraction was determined and 2% (W/V) potassium Chloride was determined to be the optimum salt concentration. The procedure worked well with an ultrasound bath. Total antioxidant capacity also was determined in this study. The method can be safely scaled up for pharmaceutical applications.	[Hosseinzadeh, Reza; Hemmaty, Syavash] Univ Urmia, Urmia Branch, Acad Ctr Educ Culture & Res, Food & Chem Anal Res Lab, Orumiyeh, Iran; [Hosseinzadeh, Reza; Khorsandi, Khatereh] Univ Tehran, Inst Biochem & Biophys, Tehran, Iran	Academic Center for Education, Culture & Research (ACECR); Urmia University; University of Tehran	Hosseinzadeh, R (corresponding author), Univ Urmia, Urmia Branch, Acad Ctr Educ Culture & Res, Food & Chem Anal Res Lab, Orumiyeh, Iran.	chem.reza@gmail.com	Hosseinzadeh, Reza/N-5330-2017	Hosseinzadeh, Reza/0000-0003-2524-176X; Hemmaty, Syavash/0000-0002-7944-0118				Alonso-Salces RM, 2001, J CHROMATOGR A, V933, P37, DOI 10.1016/S0021-9673(01)01212-2; Alvarez-Suarez JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025878; Antolovich M, 2000, ANALYST, V125, P989, DOI 10.1039/b000080i; Berthod A, 2000, CHROMATOGR SCI SERIE; Bordbar AK, 2007, J THERM ANAL CALORIM, V87, P453, DOI 10.1007/s10973-005-6906-2; Bordbar AK, 2006, COLLOID SURFACE B, V53, P288, DOI 10.1016/j.colsurfb.2006.09.019; Cam M, 2010, FOOD CHEM, V123, P878, DOI 10.1016/j.foodchem.2010.05.011; Cao DD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021071; COSETENG MY, 1987, J FOOD SCI, V52, P985, DOI 10.1111/j.1365-2621.1987.tb14257.x; Cudina O, 2005, COLLOID SURFACE A, V256, P225, DOI 10.1016/j.colsurfa.2005.01.023; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; DESHPANDE SS, 1986, CRC CR REV FOOD SCI, V24, P401, DOI 10.1080/10408398609527441; Escarpa A, 1998, J CHROMATOGR A, V823, P331, DOI 10.1016/S0021-9673(98)00294-5; German J B, 1999, Adv Exp Med Biol, V459, P23; Guyot S, 1997, PHYTOCHEMISTRY, V44, P351, DOI 10.1016/S0031-9422(96)00480-3; Guyot S, 1998, J AGR FOOD CHEM, V46, P1698, DOI 10.1021/jf970832p; Hagerman AE, 1997, ACS SYM SER, V662, P209, DOI 10.1021/bk-1997-0662.ch012; Hosseinzadeh R, 2011, COLLOID SURFACE B, V84, P13, DOI 10.1016/j.colsurfb.2010.11.036; Hosseinzadeh R, 2009, COLLECT CZECH CHEM C, V74, P503, DOI 10.1135/cccc2008021; Hosseinzadeh R, 2009, COLLOID SURFACE B, V68, P213, DOI 10.1016/j.colsurfb.2008.10.012; JACKMAN RL, 1987, J FOOD BIOCHEM, V11, P279, DOI 10.1111/j.1745-4514.1987.tb00128.x; Khaledi MG, 1997, J CHROMATOGR A, V780, P3, DOI 10.1016/S0021-9673(97)00610-9; Kulikov A., 2007, METHODS OBJECTS CH 1, V92, P92; MAKKAR HPS, 1989, J AGR FOOD CHEM, V37, P1197, DOI 10.1021/jf00088a083; Markham K., 1975, FLAVONOIDS, P1; McBain TW, 1912, J CHEM SOC, V101, P2042; Ozyurt D, 2007, TALANTA, V71, P1155, DOI 10.1016/j.talanta.2006.06.015; Perez Ilzarbe J, 1997, Z UNTERS FORSCH, V204, P52; Porter L J., 1989, METHODS PLANT BIOCH, P389; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rosen MJ, 2004, SURFACTANTS INTERFAC, V3, DOI DOI 10.1002/0471670561.CH11; SCALBERT A, 1989, J AGR FOOD CHEM, V37, P1324, DOI 10.1021/jf00089a026; SCALBERT A, 1992, BASIC LIFE SCI, V59, P259; Seoud OA, 1989, ADV COLLOID INTERFAC, V30, P1; Shahidi F., 2004, PHENOLICS FOOD NUTRA; Sies H, 1997, EXP PHYSIOL, V82, P291, DOI 10.1113/expphysiol.1997.sp004024; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Sulaiman SF, 2001, J FOOD COMPOS ANAL, V24, P506; TEMPEL AS, 1982, J CHEM ECOL, V8, P1289, DOI 10.1007/BF00987762; Texter J, 1999, SURFACTANTS: A PRACTICAL HANDBOOK, P1; Tsao R, 2003, J AGR FOOD CHEM, V51, P6347, DOI 10.1021/jf0346298; Valko M, 2004, MOL CELL BIOCHEM, V266, P37, DOI 10.1023/B:MCBI.0000049134.69131.89; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Vermerris W, 2006, PHENOLIC COMPOUND BI; Vertuani S, 2004, CURR PHARM DESIGN, V10, P1677, DOI 10.2174/1381612043384655; Wu T, 2012, FOOD CHEM, V133, P1292, DOI 10.1016/j.foodchem.2011.08.002; Zarena AS, 2012, FOOD CHEM, V130, P203, DOI 10.1016/j.foodchem.2011.07.007; Zhang GW, 2011, INNOV FOOD SCI EMERG, V12, P18, DOI 10.1016/j.ifset.2010.12.003	48	49	50	3	53	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2013	8	3							e57353	10.1371/journal.pone.0057353	http://dx.doi.org/10.1371/journal.pone.0057353			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099RC	23472082	Green Published, Green Submitted, gold			2023-01-03	WOS:000315637900020
J	Chen, KJ; Tseng, CK; Chang, FR; Yang, JL; Yeh, CC; Chen, WC; Wu, SF; Chang, HW; Lee, JC				Chen, Kuan-Jen; Tseng, Chin-Kai; Chang, Fang-Rong; Yang, Jin-long; Yeh, Chi-Chen; Chen, Wei-Chun; Wu, Shou-Fang; Chang, Hsueh-Wei; Lee, Jin-Ching			Aqueous Extract of the Edible Gracilaria tenuistipitata Inhibits Hepatitis C Viral Replication via Cyclooxygenase-2 Suppression and Reduces Virus-Induced Inflammation	PLOS ONE			English	Article							NF-KAPPA-B; ORAL-CANCER CELLS; HUMAN CYTOMEGALOVIRUS; ANTIVIRAL ACTIVITY; RNA REPLICATION; DNA-DAMAGE; EXPRESSION; COX-2; INFECTION; ALGAE	Hepatitis C virus (HCV) is an important human pathogen leading to hepatocellular carcinoma. Using an in vitro cell-based HCV replicon and JFH-1 infection system, we demonstrated that an aqueous extract of the seaweed Gracilaria tenuistipitata (AEGT) concentration-dependently inhibited HCV replication at nontoxic concentrations. AEGT synergistically enhanced interferon-alpha (IFN-alpha) anti-HCV activity in a combination treatment. We found that AEGT also significantly suppressed virus-induced cyclooxygenase-2 (COX-2) expression at promoter transactivation and protein levels. Notably, addition of exogenous COX-2 expression in AEGT-treated HCV replicon cells gradually abolished AEGT anti-HCV activity, suggesting that COX-2 down-regulation was responsible for AEGT antiviral effects. Furthermore, we highlighted the inhibitory effect of AEGT in HCV-induced pro-inflammatory gene expression such as the expression of tumour necrosis factor-alpha, interleukin-1 beta, inducible nitrite oxide synthase and COX-2 in a concentration-dependent manner to evaluate the potential therapeutic supplement in the management of patients with chronic HCV infections.	[Chen, Kuan-Jen; Tseng, Chin-Kai; Chen, Wei-Chun; Lee, Jin-Ching] Kaohsiung Med Univ, Coll Life Sci, Dept Biotechnol, Kaohsiung, Taiwan; [Chang, Fang-Rong; Yeh, Chi-Chen; Wu, Shou-Fang; Lee, Jin-Ching] Kaohsiung Med Univ, Grad Inst Nat Prod, Coll Pharm, Kaohsiung, Taiwan; [Yang, Jin-long] Natl Kaohsiung Marine Univ, Dept Seafood Sci, Kaohsiung, Taiwan; [Chang, Hsueh-Wei] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Ctr Canc, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; National Kaohsiung University of Science & Technology; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Chang, HW (corresponding author), Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Ctr Canc, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan.	changhw@kmu.edu.tw; jclee@kmu.edu.tw	Chang, Hsueh-Wei/C-9654-2009	Chang, Hsueh-Wei/0000-0003-0068-2366; Chang, Fang-Rong/0000-0003-2549-4193; Lee, Jin-Ching/0000-0003-0729-9589	National Science Council of Taiwan [NSC 101-2311-B-037-002-MY3, NSC 101-2622-B-037-001-CC3]; Kaohsiung Medical University Research Foundation, Taiwan [KMUER014]; Department of Health, Executive Yuan, Taiwan [DOH102-TD-C-111-002]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Kaohsiung Medical University Research Foundation, Taiwan; Department of Health, Executive Yuan, Taiwan	National Science Council of Taiwan (NSC 101-2311-B-037-002-MY3; NSC 101-2622-B-037-001-CC3) http://web1.nsc.gov.tw/, Kaohsiung Medical University Research Foundation, Taiwan (KMUER014) http://www2.kmu.edu.tw/index.phtml and Department of Health, Executive Yuan, Taiwan (DOH102-TD-C-111-002) http://www.doh.gov.tw/EN2006/index_EN.aspx. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrantes JL, 2010, PLANTA MED, V76, P339, DOI 10.1055/s-0029-1186144; Alter MJ, 2007, WORLD J GASTROENTERO, V13, P2436, DOI 10.3748/wjg.v13.i17.2436; Baryawno N, 2011, J CLIN INVEST, V121, P4043, DOI 10.1172/JCI57147; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dang HT, 2008, J NAT PROD, V71, P232, DOI 10.1021/np070452q; de Almeida CLF, 2011, INT J MOL SCI, V12, P4550, DOI 10.3390/ijms12074550; Domitrovic R, 2011, TOXICOLOGY, V280, P33, DOI 10.1016/j.tox.2010.11.005; Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082; Ferreira SD, 2010, BRAZ J INFECT DIS, V14, P330, DOI 10.1590/S1413-86702010000400003; Freudenburg W, 2010, J GEN VIROL, V91, P2278, DOI 10.1099/vir.0.022665-0; Ganesan P, 2008, BIORESOURCE TECHNOL, V99, P2717, DOI 10.1016/j.biortech.2007.07.005; Gee J, 2008, UROL ONCOL-SEMIN ORI, V26, P641, DOI 10.1016/j.urolonc.2007.05.015; Ghosh N, 2010, PHARMACOL REP, V62, P233, DOI 10.1016/S1734-1140(10)70262-0; Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121; Gretton S, 2010, J GEN VIROL, V91, P671, DOI 10.1099/vir.0.016899-0; Halfon P, 2012, LIVER INT, V32, P79, DOI 10.1111/j.1478-3231.2011.02716.x; Jiang YF, 2011, CELL BIOL INT, V35, P1225, DOI 10.1042/CBI20110102; Kato T, 2006, NAT PROTOC, V1, P2334, DOI 10.1038/nprot.2006.395; Lee HJ, 2009, ARCH PHARM RES, V32, P453, DOI 10.1007/s12272-009-1320-0; Lee JC, 2011, J VIRAL HEPATITIS, V18, pE315, DOI 10.1111/j.1365-2893.2010.01424.x; Lee JC, 2011, ANTIVIR RES, V89, P35, DOI 10.1016/j.antiviral.2010.11.003; Lee SMY, 2011, INFLUENZA OTHER RESP, V5, P230, DOI 10.1111/j.1750-2659.2011.00218.x; Levrero M, 2006, ONCOGENE, V25, P3834, DOI 10.1038/sj.onc.1209562; Liu TS, 2005, VIROLOGY, V343, P12, DOI 10.1016/j.virol.2005.08.012; Makarenkova I. D., 2010, Voprosy Virusologii, V55, P41; Morinaga S, 2007, J GASTROEN HEPATOL, V22, P1249, DOI 10.1111/j.1440-1746.2006.04367.x; Nunez O, 2004, GUT, V53, P1665, DOI 10.1136/gut.2003.038364; Okamoto Mika, 2009, Antivir Chem Chemother, V20, P47, DOI 10.3851/IMP1372; Ozeki I, 2011, J GASTROENTEROL, V46, P929, DOI 10.1007/s00535-011-0411-0; Park CM, 2010, FOOD CHEM TOXICOL, V48, P1255, DOI 10.1016/j.fct.2010.02.019; Reynolds AE, 2006, REV MED VIROL, V16, P393, DOI 10.1002/rmv.519; Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10; Sarrazin C, 2012, J HEPATOL, V56, pS88, DOI 10.1016/S0168-8278(12)60010-5; Steer P, 2003, LIPIDS, V38, P15, DOI 10.1007/s11745-003-1025-9; Strader DB, 2004, HEPATOLOGY, V39, P1147, DOI 10.1002/hep.20119; Trujillo-Murillo K, 2007, J VIRAL HEPATITIS, V14, P608, DOI 10.1111/j.1365-2893.2006.00837.x; Trujillo-Murillo K, 2008, HEPATOLOGY, V47, P1462, DOI 10.1002/hep.22215; Tung WH, 2010, CELL SIGNAL, V22, P234, DOI 10.1016/j.cellsig.2009.09.018; Verma S, 2011, J GEN VIROL, V92, P507, DOI 10.1099/vir.0.026716-0; Vijayavel K, 2010, J MED FOOD, V13, P1494, DOI 10.1089/jmf.2009.0287; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Ward SM, 2007, J HEPATOL, V47, P316, DOI 10.1016/j.jhep.2007.03.023; Yang JI, 2012, MOLECULES, V17, P7241, DOI 10.3390/molecules17067241; Yangthong M, 2009, PLANT FOOD HUM NUTR, V64, P218, DOI 10.1007/s11130-009-0127-y; Yeh CC, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-142; Yeh CC, 2012, MOLECULES, V17, P10916, DOI 10.3390/molecules170910916; Yeh ST, 2010, FISH SHELLFISH IMMUN, V28, P887, DOI 10.1016/j.fsi.2010.02.005; Zhu H, 2002, P NATL ACAD SCI USA, V99, P3932, DOI 10.1073/pnas.052713799	49	54	56	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57704	10.1371/journal.pone.0057704	http://dx.doi.org/10.1371/journal.pone.0057704			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469054	Green Published, Green Submitted, gold			2023-01-03	WOS:000315524900153
J	Scott, CA; Iyer, H; Bwalya, DL; McCoy, K; Meyer-Rath, G; Moyo, C; Bolton-Moore, C; Larson, B; Rosen, S				Scott, Callie A.; Iyer, Hari; Bwalya, Deophine Lembela; McCoy, Kelly; Meyer-Rath, Gesine; Moyo, Crispin; Bolton-Moore, Carolyn; Larson, Bruce; Rosen, Sydney			Retention in Care and Outpatient Costs for Children Receiving Antiretroviral Therapy in Zambia: A Retrospective Cohort Analysis	PLOS ONE			English	Article							SOUTH-AFRICA; HIV/AIDS; HEALTH; FACILITIES; DELIVERY; OUTCOMES; HIV	Background: There are few published estimates of the cost of pediatric antiretroviral therapy (ART) in Africa. Our objective was to estimate the outpatient cost of providing ART to children remaining in care at six public sector clinics in Zambia during the first three years after ART initiation, stratified by service delivery site and time on treatment. Methods: Data on resource utilization (drugs, diagnostics, outpatient visits, fixed costs) and treatment outcomes (in care, died, lost to follow up) were extracted from medical records for 1,334 children at six sites who initiated ART at <15 years of age between 2006 and 2011. Fixed and variable unit costs (reported in 2011 USD) were estimated from the provider's perspective using site level data. Results: Median age at ART initiation was 4.0 years; median CD4 percentage was 14%. One year after ART initiation, 73% of patients remained in care, ranging from 60% to 91% depending on site. The average annual outpatient cost per patient remaining in care was $209 (95% CI, $199-$219), ranging from $116 (95% CI, $107-$126) to $516 (95% CI, $499-$533) depending on site. Average annual costs decreased as time on treatment increased. Antiretroviral drugs were the largest component of all outpatient costs (>50%) at four sites. At the two remaining sites, outpatient visits and fixed costs together accounted for >50% of outpatient costs. The distribution of costs is slightly skewed, with median costs 3% to 13% lower than average costs during the first year after ART initiation depending on site. Conclusions: Outpatient costs for children initiating ART in Zambia are low and comparable to reported outpatient costs for adults. Outpatient costs and retention in care vary widely by site, suggesting opportunities for efficiency gains. Taking advantage of such opportunities will help ensure that targets for pediatric treatment coverage can be met.	[Scott, Callie A.; McCoy, Kelly; Meyer-Rath, Gesine; Larson, Bruce; Rosen, Sydney] Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA; [Scott, Callie A.; Iyer, Hari; Bwalya, Deophine Lembela] Zambia Ctr Appl Hlth Res & Dev, Lusaka, Zambia; [Meyer-Rath, Gesine; Rosen, Sydney] Univ Witwatersrand, Hlth Econ & Epidemiol Res Off, Wits Hlth Consortium, Fac Hlth Sci, Johannesburg, South Africa; [Moyo, Crispin] Zambian Minist Hlth, Lusaka, Zambia; [Bolton-Moore, Carolyn] Univ N Carolina, Dept Obstet & Gynecol, Chapel Hill, NC USA; [Bolton-Moore, Carolyn] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Larson, Bruce] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA USA	Boston University; University of Zambia; University of Witwatersrand; University of North Carolina; University of North Carolina Chapel Hill; Boston University	Scott, CA (corresponding author), Boston Univ, Ctr Global Hlth & Dev, Boston, MA 02215 USA.	callie@bu.edu	Iyer, Hari S./AAZ-1563-2020	Larson, Bruce/0000-0002-9322-2387; Rosen, Sydney/0000-0002-6560-2964; Meyer-Rath, Gesine/0000-0003-0439-381X; Bolton Moore, Carolyn/0000-0001-9103-7746	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention [5U2GPS001418-00]	President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This research was funded by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (5U2GPS001418-00). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888; Bratt JH, 2011, TROP MED INT HEALTH, V16, P110, DOI 10.1111/j.1365-3156.2010.02640.x; Ciaranello AL, 2009, CLIN INFECT DIS, V49, P1915, DOI 10.1086/648079; Marques HHD, 2007, CAD SAUDE PUBLICA, V23, pS402, DOI 10.1590/S0102-311X2007001500008; Galarraga O, 2011, PHARMACOECONOMICS, V29, P579, DOI 10.2165/11586120-000000000-00000; Government of the Republic of Zambia Ministry of Health, 2007, ZAMB GUID ANT THER H; International Monetary Fund [Internet], 2012, WORLD EC OUTL DAT AP; Long L, 2010, AIDS, V24, P915, DOI 10.1097/QAD.0b013e3283360976; Marseille E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051993; Menzies NA, 2011, AIDS, V25, P1753, DOI 10.1097/QAD.0b013e3283463eec; Meyer-Rath G, 2013, AIDS, V27, P243, DOI 10.1097/QAD.0b013e32835a5b92; Oanda Corporation, 2012, HIST EXCH RAT DAIL M; Rosen S, 2008, TROP MED INT HEALTH, V13, P1005, DOI 10.1111/j.1365-3156.2008.02114.x; Tagar E, 2012, 19 INT AIDS C 22 27; van Dijk JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019006; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; WHO UNAIDS Unicef, 2011, GLOB HIV AIDS RESP E; World Health Organization, 2011, GLOB PRIC REP MECH	18	16	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e67910	10.1371/journal.pone.0067910	http://dx.doi.org/10.1371/journal.pone.0067910			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IH	23840788	Green Published, gold, Green Submitted			2023-01-03	WOS:000321148400143
J	Picq, CA; Clarencon, D; Sinniger, VE; Bonaz, BL; Mayol, JFS				Picq, Chloe A.; Clarencon, Didier; Sinniger, Valerie E.; Bonaz, Bruno L.; Mayol, Jean-Francois S.			Impact of Anesthetics on Immune Functions in a Rat Model of Vagus Nerve Stimulation	PLOS ONE			English	Article							CHOLINERGIC ANTIINFLAMMATORY PATHWAY; ISCHEMIA-REPERFUSION INJURY; VOLATILE ANESTHETICS; ENDOTOXEMIC RATS; ISOFLURANE; INFLAMMATION; CELLS; LUNG; ACTIVATION; EXPRESSION	Vagus nerve stimulation (VNS) has been successfully performed in animals for the treatment of different experimental models of inflammation. The anti-inflammatory effect of VNS involves the release of acetylcholine by vagus nerve efferent fibers inhibiting pro-inflammatory cytokines (e.g. TNF-alpha) produced by macrophages. Moreover, it has recently been demonstrated that splenic lymphocytic populations may also be involved. As anesthetics can modulate the inflammatory response, the current study evaluated the effect of two different anesthetics, isoflurane and pentobarbital, on splenic cellular and molecular parameters in a VNS rat model. Spleens were collected for the characterization of lymphocytes sub-populations by flow cytometry and quantification of cytokines secretion after in vitro activation. Different results were observed depending on the anesthetic used. The use of isoflurane displayed a non-specific effect of VNS characterized by a decrease of most splenic lymphocytes sub-populations studied, and also led to a significantly lower TNF-a secretion by splenocytes. However, the use of pentobarbital brought to light immune modifications in non-stimulated animals that were not observed with isoflurane, and also revealed a specific effect of VNS, notably at the level of T lymphocytes' activation. These differences between the two anesthetics could be related to the anti-inflammatory properties of isoflurane. In conclusion, pentobarbital is more adapted than isoflurane in the study of the anti-inflammatory effect of VNS on an anesthetized rat model in that it allows more accurate monitoring of subtle immunomodulatory processes.	[Picq, Chloe A.; Clarencon, Didier; Mayol, Jean-Francois S.] Ctr Rech Serv Sante Armees, Antenne La Tronche, Inst Rech Biomed Armees, La Tronche, France; [Picq, Chloe A.; Clarencon, Didier; Sinniger, Valerie E.; Bonaz, Bruno L.] Ctr Rech INSERM 836 UJF CEA CHU, Stress & Interact Neurodigest Grenoble Inst Neuro, La Tronche, France; [Bonaz, Bruno L.] CHU Grenoble, Clin Univ Hepatogastroenterol, F-38043 Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA)	Picq, CA (corresponding author), Ctr Rech Serv Sante Armees, Antenne La Tronche, Inst Rech Biomed Armees, La Tronche, France.	picq.chloe@gmail.com			Direction Generale de l'Armement, France [10co601]	Direction Generale de l'Armement, France	Funding was provided by Direction Generale de l'Armement, France. Number of contract: 10co601. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], BRAIN BEHAV IMMUN, V24, P316; Barbulescu K, 1998, J IMMUNOL; Bedirli N, 2012, J SURG RES, V178, pE17, DOI 10.1016/j.jss.2011.12.037; Bonaz B, 2007, GASTROENTEROLOGY, V133, P1370, DOI 10.1053/j.gastro.2007.08.061; Boost KA, 2009, INT J MOL MED, V23, P665, DOI 10.3892/ijmm_00000178; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Chiang N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001879; Chung IS, 2013, ANESTH ANALG, V116, P327, DOI 10.1213/ANE.0b013e31827aec06; de Rossi LW, 2004, ANESTH ANALG, V98, P1007, DOI 10.1213/01.ANE.0000106860.27791.44; Flondor M, 2008, EUR SURG RES, V40, P1, DOI 10.1159/000107614; Hofstetter C, 2005, INT IMMUNOPHARMACOL, V5, P1519, DOI 10.1016/j.intimp.2005.04.008; Hofstetter C, 2007, INT J MOL MED, V20, P597; Hotta H, 2009, AUTON NEUROSCI-BASIC, V151, P98, DOI 10.1016/j.autneu.2009.07.008; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Karimi K, 2010, BRAIN BEHAV IMMUN, V24, P316, DOI 10.1016/j.bbi.2009.10.016; Kawaguchi M, 1996, ANESTHESIOLOGY, V85, P1176, DOI 10.1097/00000542-199611000-00027; Kim M, 2012, ANN SURG, V255, P492, DOI 10.1097/SLA.0b013e3182441767; Lee HT, 2004, ANESTHESIOLOGY, V101, P1313; Meregnani J, 2011, AUTON NEUROSCI-BASIC, V160, P82, DOI 10.1016/j.autneu.2010.10.007; Mu JL, 2010, SHOCK, V34, P183, DOI 10.1097/SHK.0b013e3181cffc3f; Olofsson PS, 2012, IMMUNOL REV, V248, P188, DOI 10.1111/j.1600-065X.2012.01138.x; Park WR, 2004, INT IMMUNOL, V16, P295, DOI 10.1093/intimm/dxh034; Pavlov VA, 2005, BRAIN BEHAV IMMUN, V19, P493, DOI 10.1016/j.bbi.2005.03.015; Pavlov VA, 2003, MOL MED, V9, P125, DOI 10.1007/BF03402177; Plachinta RV, 2003, ANESTHESIOLOGY, V98, P89, DOI 10.1097/00000542-200301000-00017; Reyt S, 2010, NEUROIMAGE, V52, P1456, DOI 10.1016/j.neuroimage.2010.05.021; Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C; Saad MM, 2010, CAN J ANAESTH, V57, P50, DOI 10.1007/s12630-009-9205-8; Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566; Tschaikowsky K, 2000, ANESTHESIOLOGY, V92, P1093, DOI 10.1097/00000542-200004000-00028; Yamamoto M, 1998, ANESTH ANALG, V86, P552, DOI 10.1097/00000539-199803000-00021; Zaaimi B, 2008, AUTON NEUROSCI-BASIC, V143, P20, DOI 10.1016/j.autneu.2008.07.002	33	17	18	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2013	8	6							e67086	10.1371/journal.pone.0067086	http://dx.doi.org/10.1371/journal.pone.0067086			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	178DN	23840592	Green Published, gold			2023-01-03	WOS:000321424400070
J	Fillafer, C; Schneider, MF				Fillafer, Christian; Schneider, Matthias F.			On the Temperature Behavior of Pulse Propagation and Relaxation in Worms, Nerves and Gels	PLOS ONE			English	Article							SPREADING DEPRESSION; CONDUCTION-VELOCITY; ACTION-POTENTIALS; CHEMICAL WAVES; DEPENDENCE; AXON; MEMBRANE; NITELLA; RETINA	The effect of temperature on pulse propagation in biological systems has been an important field of research. Environmental temperature not only affects a host of physiological processes e.g. in poikilotherms but also provides an experimental means to investigate the thermodynamic phenomenology of nerves and muscle. In the present work, the temperature dependence of blood vessel pulsation velocity and frequency was studied in the annelid Lumbriculus variegatus. The pulse velocity was found to vary linearily between 0 degrees C and 30 degrees C. In contrast, the pulse frequency increased non-linearly in the same temperature range. A heat block ultimately resulted in complete cessation of vessel pulsations at 37.2 +/- 2.7 degrees C (lowest: 33 degrees C, highest: 43 degrees C). However, quick cooling of the animal led to restoration of regularly propagating pulses. This experimentally observed phenomenology of pulse propagation and frequency is interpreted without any assumptions about molecules in the excitable membrane (e.g. ion channels) or their temperature-dependent behaviour. By following Einstein's approach to thermodynamics and diffusion, a relation between relaxation time tau and compressibility kappa of the excitable medium is derived that can be tested experimentally (for k(T) similar to k(S)). Without fitting parameters this theory predicts the temperature dependence of the limiting (i.e. highest) pulse frequency in good agreement with experimental data. The thermodynamic approach presented herein is neither limited to temperature nor to worms nor to living systems. It describes the coupling between pulse propagation and relaxation equally well in nerves and gels. The inherent consistency and universality of the concept underline its potential to explain the dependence of pulse propagation and relaxation on any thermodynamic observable.	[Fillafer, Christian; Schneider, Matthias F.] Boston Univ, Dept Mech Engn, Biol Phys Grp, Boston, MA 02215 USA	Boston University	Schneider, MF (corresponding author), Boston Univ, Dept Mech Engn, Biol Phys Grp, Boston, MA 02215 USA.	mfs@bu.edu		/0000-0002-6124-4899	Max Kade Foundation; Austrian Academy of Sciences; BU-ENG-ME; German Science Foundation (DFG); research unit SHENC	Max Kade Foundation; Austrian Academy of Sciences; BU-ENG-ME; German Science Foundation (DFG)(German Research Foundation (DFG)); research unit SHENC	CF is grateful for funding by the Max Kade Foundation (http://maxkadefoundation.org/) and the Austrian Academy of Sciences (www.oeaw.ac.at/). Furthermore, financial support by BU-ENG-ME (www.bu.edu/me/) is acknowledged. MFS would also like to recognize funding through the German Science Foundation (DFG) and the research unit SHENC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersen SSL, 2009, PROG NEUROBIOL, V88, P104, DOI 10.1016/j.pneurobio.2009.03.002; BEILBY M J, 1976, Australian Journal of Plant Physiology, V3, P275; BLATT FJ, 1974, BIOCHIM BIOPHYS ACTA, V339, P382, DOI 10.1016/0005-2736(74)90165-5; Castro G de O, 1970, J Neurophysiol, V33, P891; CHAPMAN RA, 1967, NATURE, V213, P1143, DOI 10.1038/2131143a0; COHEN LB, 1972, J PHYSIOL-LONDON, V224, P727, DOI 10.1113/jphysiol.1972.sp009920; Engelhardt A, 1951, J COMP PHYSL NEUROET, V128, P125; Fernandes De Lima VM, 1997, PROGR RETINAL EYE RE, V16, P657; FRANZ DN, 1968, J PHYSIOL-LONDON, V199, P319, DOI 10.1113/jphysiol.1968.sp008656; Grabitz P, 2002, BIOPHYS J, V82, P299, DOI 10.1016/S0006-3495(02)75395-2; Griesbauer J, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.198103; Griesbauer J, 2009, BIOPHYS J, V97, P2710, DOI 10.1016/j.bpj.2009.07.049; Hamilton M.F, 1998, NONLINEAR ACOUSTICS; Heimburg T, 2005, P NATL ACAD SCI USA, V102, P9790, DOI 10.1073/pnas.0503823102; HODGKIN AL, 1949, J PHYSIOL-LONDON, V109, P240, DOI 10.1113/jphysiol.1949.sp004388; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HUTCHINSON NA, 1970, J PHYSIOL-LONDON, V208, P279, DOI 10.1113/jphysiol.1970.sp009119; INOUE I, 1973, BIOCHIM BIOPHYS ACTA, V307, P471, DOI 10.1016/0005-2736(73)90294-0; IWASA K, 1980, SCIENCE, V210, P338, DOI 10.1126/science.7423196; Jaffe LF, 2002, CELL CALCIUM, V32, P217, DOI 10.1016/S0143416002001574; Kaufmann K., 1989, ACTION POTENTIALS; Lesiuk NM, 1999, AM BIOL TEACH, V61, P48, DOI 10.2307/4450609; LOWITZSCH K, 1977, J NEUROL, V216, P181, DOI 10.1007/BF00313619; LUDIN HP, 1977, J NEUROL, V216, P173, DOI 10.1007/BF00313618; MARTINSFERREIRA H, 1974, J NEUROPHYSIOL, V37, P773, DOI 10.1152/jn.1974.37.4.773; Miyakawa K, 2000, PHYS REV E, V62, P793, DOI 10.1103/PhysRevE.62.793; RITCHIE JM, 1985, Q REV BIOPHYS, V18, P451, DOI 10.1017/S0033583500005382; ROOTS BI, 1962, J EXP BIOL, V39, P617; SANDLIN R, 1968, NATURE, V217, P575, DOI 10.1038/217575b0; TASAKI I, 1969, SCIENCE, V163, P683, DOI 10.1126/science.163.3868.683; TASAKI I, 1949, BIOCHIM BIOPHYS ACTA, V3, P494, DOI 10.1016/0006-3002(49)90121-3; TASAKI I, 1989, BIOPHYS J, V55, P1033, DOI 10.1016/S0006-3495(89)82902-9; TASAKI I, 1991, BIOCHEM BIOPH RES CO, V174, P293, DOI 10.1016/0006-291X(91)90519-D; TASAKI I, 1948, J NEUROPHYSIOL, V11, P311, DOI 10.1152/jn.1948.11.4.311; UEDA T, 1974, J MEMBRANE BIOL, V18, P177, DOI 10.1007/BF01870110; Weimer M, 2005, EXP BRAIN RES, V161, P201, DOI 10.1007/s00221-004-2060-5; Wilke E, 1912, PFLUGERS ARCH EUROPE, P35; WOOD PM, 1985, J CHEM PHYS, V82, P1924, DOI 10.1063/1.448376	38	12	12	3	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2013	8	6							e66773	10.1371/journal.pone.0066773	http://dx.doi.org/10.1371/journal.pone.0066773			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	170JP	23805275	Green Published, Green Submitted, gold			2023-01-03	WOS:000320846500103
J	Kostova, D; Reed, C; Finelli, L; Cheng, PY; Gargiullo, PM; Shay, DK; Singleton, JA; Meltzer, MI; Lu, PJ; Bresee, JS				Kostova, Deliana; Reed, Carrie; Finelli, Lyn; Cheng, Po-Yung; Gargiullo, Paul M.; Shay, David K.; Singleton, James A.; Meltzer, Martin I.; Lu, Peng-Jun; Bresee, Joseph S.			Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011	PLOS ONE			English	Article							COST-EFFECTIVENESS; SEASONAL INFLUENZA; EFFICACY; VACCINES; PNEUMONIA; FAILURE; NETWORK; ADULTS; IMPACT	Context: The goal of influenza vaccination programs is to reduce influenza-associated disease outcomes. Therefore, estimating the reduced burden of influenza as a result of vaccination over time and by age group would allow for a clear understanding of the value of influenza vaccines in the US, and of areas where improvements could lead to greatest benefits. Objective: To estimate the direct effect of influenza vaccination in the US in terms of averted number of cases, medically-attended cases, and hospitalizations over six recent influenza seasons. Design: Using existing surveillance data, we present a method for assessing the impact of influenza vaccination where impact is defined as either the number of averted outcomes or as the prevented disease fraction (the number of cases estimated to have been averted relative to the number of cases that would have occurred in the absence of vaccination). Results: We estimated that during our 6-year study period, the number of influenza illnesses averted by vaccination ranged from a low of approximately 1.1 million (95% confidence interval (CI) 0.6-1.7 million) during the 2006-2007 season to a high of 5 million (CI 2.9-8.6 million) during the 2010-2011 season while the number of averted hospitalizations ranged from a low of 7,700 (CI 3,700-14,100) in 2009-2010 to a high of 40,400 (CI 20,800-73,000) in 2010-2011. Prevented fractions varied across age groups and over time. The highest prevented fraction in the study period was observed in 2010-2011, reflecting the post-pandemic expansion of vaccination coverage. Conclusions: Influenza vaccination programs in the US produce a substantial health benefit in terms of averted cases, clinic visits and hospitalizations. Our results underscore the potential for additional disease prevention through increased vaccination coverage, particularly among nonelderly adults, and increased vaccine effectiveness, particularly among the elderly.	[Kostova, Deliana; Reed, Carrie; Finelli, Lyn; Cheng, Po-Yung; Gargiullo, Paul M.; Shay, David K.; Bresee, Joseph S.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA; [Singleton, James A.; Lu, Peng-Jun] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA; [Meltzer, Martin I.] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Natl Ctr Enter & Zoonot Infect Dis, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Kostova, D (corresponding author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA.	kiv0@cdc.gov	Finelli, Lyn/AAK-2360-2020; Meltzer, Martin/AAT-3235-2021	Meltzer, Martin/0000-0002-7250-0472; Shay, David/0000-0001-9619-4820				BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BARKER WH, 1980, JAMA-J AM MED ASSOC, V244, P2547, DOI 10.1001/jama.244.22.2547; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; Belongia EA, 2011, VACCINE, V29, P6558, DOI 10.1016/j.vaccine.2011.07.002; Belongia EA, 2009, J INFECT DIS, V199, P159, DOI 10.1086/595861; Biggerstaff M, 2012, AM J PUBLIC HEALTH, V102, pE21, DOI 10.2105/AJPH.2012.300651; Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655; DALESSIO DJ, 1969, J AMER MED ASSOC, V210, P485, DOI 10.1001/jama.210.3.485; Frey S, 2010, CLIN INFECT DIS, V51, P997, DOI 10.1086/656578; Griffin MR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023085; Kamimoto L, 2010, 27 ANN BEH RISK FACT; KEREN G, 1988, J MED VIROL, V25, P85, DOI 10.1002/jmv.1890250112; Maciosek MV, 2006, AM J PREV MED, V31, P72, DOI 10.1016/j.amepre.2006.03.008; Meltzer MI, 2005, VACCINE, V23, P1004, DOI 10.1016/j.vaccine.2004.07.040; Monto AS, 2009, NEW ENGL J MED, V361, P1260, DOI 10.1056/NEJMoa0808652; National Center for Immunization and Respiratory Diseases CDC, 2009, MMWR Recomm Rep, V58, P1; Nichol KL, 2003, VACCINE, V21, P1769, DOI 10.1016/S0264-410X(03)00070-7; Ohmit SE, 2008, J INFECT DIS, V198, P312, DOI 10.1086/589885; Prosser LA, 2006, EMERG INFECT DIS, V12, P1548, DOI 10.3201/eid1210.051015; Reed C, 2011, P 49 ANN M IDSA OCT; Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413; Roberts S, 2006, OBSTET GYNECOL, V107, P1323, DOI 10.1097/01.AOG.0000210225.45986.99; Salo H, 2006, VACCINE, V24, P4934, DOI 10.1016/j.vaccine.2006.03.057; Shay D, 2011, WORKING PAPER UNPUB; Singleton JA, 2011, M ADV COMM IMM PRACT; Skowronski DM, 2007, VACCINE, V25, P2842, DOI 10.1016/j.vaccine.2006.10.002; Skowronski DM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000258; Skowronski DM, 2009, J INFECT DIS, V199, P168, DOI 10.1086/595862; Staples J. Erin, 2010, Morbidity and Mortality Weekly Report, V59, P1; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Treanor JJ, 2012, CLIN INFECT DIS, V55, P951, DOI 10.1093/cid/cis574	32	147	151	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2013	8	6							e66312	10.1371/journal.pone.0066312	http://dx.doi.org/10.1371/journal.pone.0066312			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190ST	23840439	Green Submitted, Green Published, gold			2023-01-03	WOS:000322361200067
J	Lombardo, F; Maggini, M; Gruden, G; Bruno, G				Lombardo, Flavia; Maggini, Marina; Gruden, Gabriella; Bruno, Graziella			Temporal Trend in Hospitalizations for Acute Diabetic Complications: A Nationwide Study, Italy, 2001-2010	PLOS ONE			English	Article							CARDIOVASCULAR EVENTS; TIME TRENDS; KETOACIDOSIS; MORTALITY; CHILDREN; HYPOGLYCEMIA; RISK; ASSOCIATION; ONTARIO; ACCORD	Background: We investigated temporal trends and geographic variations in both hospitalizations and in-hospital mortality rates for acute diabetic complications (ADC) in the Italian universal health care system. Methods and Findings: A retrospective review of the medical records of patients with either primary or secondary discharge diagnosis of hyperglycaemic acute complications (ICD-9-CM codes 250.1, 250.2, 250.3) or hypoglycemic coma (ICD-9-CM code 251.0) was performed in period 2001-2010. Standardized rates by age and gender on 2001 Italian population and by diabetic population were calculated. We identified 7,601.883 diabetes-related hospital discharges. Out of them, 266,374 (3.5%) were due to ADC, either ketoacidosis/hyperosmolarity (94.4%) or hypoglycemic coma (5.6%). The rate of discharge for ADC decreased by 51.1% from 2001 to 2010 (14.4 vs. 7.1 discharge rate/1,000 diabetic people; 5.7% decrease per year, test for trend, p<0.001) with a similar trend for both hyperglycemic and hypoglycemic complications. Diabetic people in the younger age groups (<= 19 and 20-44 years old) had a significantly greater rate of discharge for ADC than people aged 65 years and over (<= 19 10-fold increase; 20-44: 2-fold increase). In-hospital mortality rate was 7.6%, with 211 preventable deaths in younger diabetic people (<= 44 years old). There was a large variability among Italian Regions and the ratio between the highest and the lowest regional discharge rate reached 300% in 2010. Conclusions: Decreasing temporal trend in hospitalizations for preventable ADC suggests improving outpatient care. In younger diabetic patients, however, both hospitalization rates and in-hospital mortality are still a matter of concern.	[Lombardo, Flavia; Maggini, Marina] Natl Inst Hlth, Rome, Italy; [Gruden, Gabriella; Bruno, Graziella] Univ Turin, Dept Med Sci, Turin, Italy	Istituto Superiore di Sanita (ISS); University of Turin	Bruno, G (corresponding author), Univ Turin, Dept Med Sci, Turin, Italy.	graziella.bruno@unito.it	Oliveira, Claudia DL/G-8618-2011; Lombardo, Flavia/AAA-9723-2021	BRUNO, Graziella/0000-0002-3011-8304; Lombardo, Flavia Lucia/0000-0001-6183-0735	Piedmont Region, Diabetes Prevention	Piedmont Region, Diabetes Prevention	This work was supported by the Piedmont Region, Diabetes Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagdure D, 2013, PEDIATR DIABETES, V14, P18, DOI 10.1111/j.1399-5448.2012.00897.x; BILD D, 1988, J CLIN EPIDEMIOL, V41, P999, DOI 10.1016/0895-4356(88)90039-X; Booth GL, 2005, DIABETES CARE, V28, P1045, DOI 10.2337/diacare.28.5.1045; Brodovicz KG, 2013, CURR MED RES OPIN, V29, P101, DOI 10.1185/03007995.2012.754744; Bruno G, 2012, NUTR METAB CARDIOVAS, V22, P684, DOI 10.1016/j.numecd.2011.04.007; Bruno G, 2009, NUTR METAB CARDIOVAS, V19, P340, DOI 10.1016/j.numecd.2008.03.010; Bruno G, 2008, NUTR METAB CARDIOVAS, V18, P39, DOI 10.1016/j.numecd.2006.08.007; Chen HF, 2010, INTERNAL MED, V49, P729, DOI 10.2169/internalmedicine.49.2965; Curtis JR, 2002, DIABETES CARE, V25, P1591, DOI 10.2337/diacare.25.9.1591; Fadini GP, 2009, DIABETES RES CLIN PR, V84, P267, DOI 10.1016/j.diabres.2009.01.019; Gaede P, 2008, NEW ENGL J MED, V358, P580, DOI 10.1056/NEJMoa0706245; Govan L, 2012, DIABETOLOGIA, V55, P2356, DOI 10.1007/s00125-012-2601-6; Harjutsalo V, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5364; Hirasing RA, 1996, DIABETES CARE, V19, P431, DOI 10.2337/diacare.19.5.431; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; Hsu PF, 2013, DIABETES CARE, V36, P894, DOI 10.2337/dc12-0916; Jiang HJ, 2003, DIABETES CARE, V26, P1421, DOI 10.2337/diacare.26.5.1421; Johnston SS, 2011, DIABETES CARE, V34, P1164, DOI 10.2337/dc10-1915; Liu CC, 2010, J FORMOS MED ASSOC, V109, P725, DOI 10.1016/S0929-6646(10)60117-9; Marchesini G, 2011, NUTR METAB CARDIOVAS, V21, P339, DOI 10.1016/j.numecd.2009.10.009; Nathan DM, 2005, NEW ENGL J MED, V353, P2643, DOI 10.1056/nejmoa052187; Punthakee Z, 2012, DIABETES CARE, V35, P787, DOI 10.2337/dc11-1855; Randall L, 2011, DIABETES CARE, V34, P1891, DOI 10.2337/dc11-0701; Rosenbauer J, 2002, J PEDIATR ENDOCR MET, V15, P1137; Seaquist ER, 2012, DIABETES CARE, V35, P409, DOI 10.2337/dc11-0996; Wang J, 2009, DIABETES CARE, V32, P1213, DOI 10.2337/dc08-2211	26	39	40	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2013	8	5							e63675	10.1371/journal.pone.0063675	http://dx.doi.org/10.1371/journal.pone.0063675			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151BM	23717464	Green Submitted, Green Published, gold			2023-01-03	WOS:000319435600028
J	Carey, TS				Carey, Timothy S.			Corticosteroid injection worsened recovery and recurrence of tennis elbow; physiotherapy had no effect	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ N Carolina, Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	Carey, TS (corresponding author), Univ N Carolina, Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27515 USA.		Coombes, Brooke/D-3456-2015; Bisset, Leanne/AAS-8947-2021	Coombes, Brooke/0000-0002-6163-1047; Bisset, Leanne/0000-0001-8807-7093					0	1	1	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 21	2013	158	10							JC8	10.7326/0003-4819-158-10-201305210-02008	http://dx.doi.org/10.7326/0003-4819-158-10-201305210-02008			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	154HY	23689787				2023-01-03	WOS:000319666200007
J	Wang, H; Li, NN; Zhu, HD; Xu, SM; Lu, H; Feng, ZC				Wang, Heng; Li, NianNian; Zhu, Haidi; Xu, Shuman; Lu, Hua; Feng, ZhanChun			Prescription Pattern and Its Influencing Factors in Chinese County Hospitals: A Retrospective Cross-Sectional Study	PLOS ONE			English	Article							RATIONAL DRUG-USE; FACILITIES; CARE	Objective: This study aimed to investigate prescription patterns and influencing factors in Chinese county hospitals. Methods: Prescription quality was evaluated by five indicators proposed by WHO/INRUD. A questionnaire for doctors was designed by our research group. All internists, surgeons, obstetricians, gynecologists and pediatricians from 10 county hospitals in Anhui province were asked to fill the questionnaire. Their prescriptions from May 2011 to April 2012 were analyzed. Results: Three-hundred and thirty-seven doctors completed valid questionnaires, and 5099 prescriptions were analyzed. The average number of drugs per prescription was 3.52+/-2.31; the average percentage of generic drugs, antibiotic usage, injection drug usage, and drugs prescribed from the national essential drug list were 96.12%, 29.90%, 20.02% and 48.85%, respectively. Differences in final academic degree and specialty led to differences in all of the five prescription quality indicators. The older doctors tended to use more antibiotics. Doctors with more education, more training on rational drug use, and better acquisition of medicine knowledge prescribe a lower percentage of generic drugs. Moreover, the more supportive the doctor's attitude to national essential medicine policy, the higher the percentage of generic drugs were prescribed. A higher level of medical knowledge was associated with a higher percentage of drugs prescribed from the essential drugs list. Conclusions: Promoting the education of medical knowledge on doctors, reinforcing the publicity of rational drug use to doctors, and initiating the performance evaluation for doctors are effective ways for improving prescription quality in Chinese county hospitals.	[Wang, Heng; Zhu, Haidi; Feng, ZhanChun] Huazhong Univ Sci & Technol, Wuhan 430074, Hubei, Peoples R China; [Wang, Heng; Li, NianNian] Anhui Med Univ, Affiliated Hosp 1, Hefei, Anhui, Peoples R China; [Xu, Shuman; Lu, Hua] Anhui Med Univ, Social Sci & Hlth Management Sch, Hefei, Anhui, Peoples R China	Huazhong University of Science & Technology; Anhui Medical University; Anhui Medical University	Feng, ZC (corresponding author), Huazhong Univ Sci & Technol, Wuhan 430074, Hubei, Peoples R China.	zcfeng@mails.tjmu.edu.cn			soft science planning project of Anhui province [12020503084]; Humanities Social Science Planning Project of Ministry of Education [12YJA630121]	soft science planning project of Anhui province; Humanities Social Science Planning Project of Ministry of Education	This study was supported by grants from soft science planning project of Anhui province (12020503084) (http://www.ahkjt.gov.cn/) and the Humanities Social Science Planning Project of Ministry of Education (12YJA630121), (http://www.moe.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adebayo ET, 2010, ANN AFR MED, V9, P152, DOI 10.4103/1596-3519.68366; Andersen M, 2006, JAMA-J AM MED ASSOC, V295, P2759, DOI 10.1001/jama.295.23.2759; Bashrahil K. A., 2010, Eastern Mediterranean Health Journal, V16, P151; Daohai C, 2012, EVALUATION ANAL DRUG, V12, P373; Figueiras A, 2001, J EVAL CLIN PRACT, V7, P223, DOI 10.1046/j.1365-2753.2001.00234.x; GREENHALGH T, 1987, SOC SCI MED, V25, P307, DOI 10.1016/0277-9536(87)90233-4; HOGERZEIL HV, 1995, BRIT J CLIN PHARMACO, V39, P1; HOGERZEIL HV, 1993, LANCET, V342, P1408, DOI 10.1016/0140-6736(93)92760-Q; Hua L, 2009, EVALUATION ANAL DRUG, V9, P280; Irshaid YM, 2004, SAUDI MED J, V25, P1864; Keohavong B, 2006, PHARMACOEPIDEM DR S, V15, P344, DOI 10.1002/pds.1169; Kun Y, 2002, CHIN J HOSP ADM, V18, P92; Lianzhen C, 2003, CHINA PHARM, V14, P156; Mahajan R, 2010, J PHARM BIOALLIED SC, V2, P132, DOI 10.4103/0975-7406.67008; MELVILLE A, 1980, SOC SCI MED-MED SOC, V14, P495, DOI 10.1016/0160-7979(80)90050-8; Menik HL, 2011, J PHARM BIOALLIED SC, V3, P165, DOI 10.4103/0975-7406.76502; Orzella L, 2010, HEALTH POLICY, V95, P236, DOI 10.1016/j.healthpol.2009.12.005; Trap B, 2002, HEALTH POLICY PLANN, V17, P288, DOI 10.1093/heapol/17.3.288; Uzochukwu BS, 2002, HEALTH POLICY PLANN, V17, P378, DOI 10.1093/heapol/17.4.378; Vallano A, 2004, EUR J CLIN PHARMACOL, V60, P725, DOI 10.1007/s00228-004-0802-8; Weihui D, 2009, ANAL INFLUENCE FACTO; WHO, 1993, ACT PROGR ESS DRUGS, P1; WHO, 2003, WHO TECH REP SER, V914; WHO Website, 2010, WHO WEBS 10 FACTS ES; World Health Organization, 2004, EQ ACC ESS MED FRAM; World Health Organization, 2011, WORLD MED SIT 2011 M; Xinyi Z, 2010, CHINESE J PHARMACOVI, V7, P755; Younis MZ, 2009, PHARMACOECONOMICS OU, V9, P243	28	33	34	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2013	8	5							e63225	10.1371/journal.pone.0063225	http://dx.doi.org/10.1371/journal.pone.0063225			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	143FO	23675465	Green Submitted, Green Published, gold			2023-01-03	WOS:000318852400031
J	Xing, H; Wang, X; Liao, LJ; Ma, YL; Su, B; Fu, JH; He, JM; Chen, L; Pan, XH; Dong, YH; Liu, W; Hsi, JH; Yang, LT; Ruan, YH; Shao, YM				Xing, Hui; Wang, Xia; Liao, Lingjie; Ma, Yanling; Su, Bin; Fu, Jihua; He, Jianmei; Chen, Lin; Pan, Xiaohong; Dong, Yonghui; Liu, Wei; Hsi, Jenny H.; Yang, Liting; Ruan, Yuhua; Shao, Yiming			Incidence and Associated Factors of HIV Drug Resistance in Chinese HIV-Infected Patients Receiving Antiretroviral Treatment	PLOS ONE			English	Article							THERAPY; ADULTS; PREVALENCE; MORTALITY; SURVIVAL; COHORT	Background: A critical indicator of the future success of highly active antiretroviral therapy (HAART) is the incidence of HIV drug resistance, which has not been studied in China on the national scale. Methods: HIV drug resistance baseline survey was conducted in the eight provinces with the largest numbers of patients on HAART in 2009, and a prospective cohort study with 12-month follow-up was completed in 2010. Patients completed an interviewer-administrated questionnaire and provided blood for CD4+ T-lymphocyte count (CD4 count), HIV viral load (VL), and HIV drug resistance genotyping. Factors associated with incidence of HIVDR were identified by Cox regression analysis. Results: The overall prevalence of HIV RNA >= 1000 copies/ml and HIVDR at baseline was 12.4% and 5.6%, respectively. Incidence of HIVDR in the one year follow-up was 3.5 per 100 person years. Independently associated factors were started treatment with a didanosine-based regimen, received care at township hospital or village clinic, low baseline CD4 counts, and high baseline VL. Conclusions: The incidence of HIVDR in China was higher than that of some developed countries. China urgently needs to provide comprehensive education and training to doctors at village clinics and township hospitals to improve quality community-based care and treatment.	[Xing, Hui; Wang, Xia; Liao, Lingjie; Hsi, Jenny H.; Yang, Liting; Ruan, Yuhua; Shao, Yiming] Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China; [Xing, Hui; Wang, Xia; Liao, Lingjie; Hsi, Jenny H.; Yang, Liting; Ruan, Yuhua; Shao, Yiming] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Ma, Yanling] Yunnan Ctr Dis Control & Prevent, Kunming, Peoples R China; [Su, Bin] Anhui Ctr Dis Control & Prevent, Hefei, Peoples R China; [Fu, Jihua] Shandong Ctr Dis Control & Prevent, Jinan, Peoples R China; [He, Jianmei] Hunan Ctr Dis Control & Prevent, Changcha, Peoples R China; [Chen, Lin] Shenzheng Ctr Dis Control & Prevent, Shenzheng, Peoples R China; [Pan, Xiaohong] Zhejiang Ctr Dis Control & Prevent, Hangzhou, Zhejiang, Peoples R China; [Dong, Yonghui] Xinjiang Ctr Dis Control & Prevent, Urumqi, Peoples R China; [Liu, Wei] Guangxi Ctr Dis Control & Prevent, Nanning, Peoples R China	Chinese Center for Disease Control & Prevention; Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention	Shao, YM (corresponding author), Chinese Ctr Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China.	yshao08@gmail.com	MA, YAN/HHN-2912-2022; Wang, Xia/C-3298-2018	Wang, Xia/0000-0002-1684-7076	Ministry of Science and Technology of China [2012ZX10001-002, 2009DFB30420]; International Development Research Center of Canada [104519-010]; Chinese State Key Laboratory for Infectious Disease Develop Grant [2012SKLID103]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); International Development Research Center of Canada; Chinese State Key Laboratory for Infectious Disease Develop Grant	This work was supported by grants from the Ministry of Science and Technology of China (2012ZX10001-002 and 2009DFB30420) and the International Development Research Center of Canada (#104519-010), and Chinese State Key Laboratory for Infectious Disease Develop Grant (2012SKLID103). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Audelin AM, 2009, ANTIVIR THER, V14, P995, DOI 10.3851/IMP1412; Chang HM, 2012, JPN J INFECT DIS, V65, P61; Gill VS, 2010, CLIN INFECT DIS, V50, P98, DOI 10.1086/648729; Gong Jian, 2011, Virologica Sinica, V26, P386, DOI 10.1007/s12250-011-3210-0; Gupta RK, 2009, LANCET INFECT DIS, V9, P409, DOI 10.1016/S1473-3099(09)70136-7; Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192; Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Johannessen A, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-108; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Liao LJ, 2010, JAIDS-J ACQ IMM DEF, V53, pS10, DOI 10.1097/QAI.0b013e3181c7d363; Liu TF, 2006, CLIN INFECT DIS, V42, P1608, DOI 10.1086/503914; Ma Y, 2010, CLIN INFECT DIS, V50, P264, DOI 10.1086/649215; Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7; Ruan YH, 2010, TROP MED INT HEALTH, V15, P1357, DOI 10.1111/j.1365-3156.2010.02621.x; Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370; Vercauteren J, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-12; Wang Hui, 2010, Zhonghua Yi Xue Za Zhi, V90, P584; WANG X, 2012, J ANTIVIRALS ANTIRET, V4, P5; *WORLD HE ORG, 2011, ANT THER HIV INF AD; Xing H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054917; Yuan Yuan, 2011, Zhonghua Yu Fang Yi Xue Za Zhi, V45, P619; Zhang Y, 2012, JAIDS-J ACQ IMM DEF, V60, P59, DOI 10.1097/QAI.0b013e31824c3d9f; Zhong P, 2007, AIDS RES HUM RETROV, V23, P847, DOI 10.1089/aid.2006.0196	26	24	33	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62408	10.1371/journal.pone.0062408	http://dx.doi.org/10.1371/journal.pone.0062408			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23638072	Green Published, Green Submitted, gold			2023-01-03	WOS:000319077300053
J	Atanasov, AG; Blunder, M; Fakhrudin, N; Liu, X; Noha, SM; Malainer, C; Kramer, MP; Cocic, A; Kunert, O; Schinkovitz, A; Heiss, EH; Schuster, D; Dirsch, VM; Bauer, R				Atanasov, Atanas G.; Blunder, Martina; Fakhrudin, Nanang; Liu, Xin; Noha, Stefan M.; Malainer, Clemens; Kramer, Matthias P.; Cocic, Amina; Kunert, Olaf; Schinkovitz, Andreas; Heiss, Elke H.; Schuster, Daniela; Dirsch, Verena M.; Bauer, Rudolf			Polyacetylenes from Notopterygium incisum-New Selective Partial Agonists of Peroxisome Proliferator-Activated Receptor-Gamma	PLOS ONE			English	Article							PPAR-GAMMA; INSIGHTS; AFFINITY; LIGAND; EXPRESSION; COMPLEX; FAMILY; FAT	Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a key regulator of glucose and lipid metabolism and therefore an important pharmacological target to combat metabolic diseases. Since the currently used full PPAR gamma agonists display serious side effects, identification of novel ligands, particularly partial agonists, is highly relevant. Searching for new active compounds, we investigated extracts of the underground parts of Notopterygium incisum, a medicinal plant used in traditional Chinese medicine, and observed significant PPAR gamma activation using a PPAR gamma-driven luciferase reporter model. Activity-guided fractionation of the dichloromethane extract led to the isolation of six polyacetylenes, which displayed properties of selective partial PPAR gamma agonists in the luciferase reporter model. Since PPAR gamma activation by this class of compounds has so far not been reported, we have chosen the prototypical polyacetylene falcarindiol for further investigation. The effect of falcarindiol (10 mu M) in the luciferase reporter model was blocked upon co-treatment with the PPAR gamma antagonist T0070907 (1 mu M). Falcarindiol bound to the purified human PPAR gamma receptor with a K-i of 3.07 mu M. In silico docking studies suggested a binding mode within the ligand binding site, where hydrogen bonds to Cys285 and Glu295 are predicted to be formed in addition to extensive hydrophobic interactions. Furthermore, falcarindiol further induced 3T3-L1 preadipocyte differentiation and enhanced the insulin-induced glucose uptake in differentiated 3T3-L1 adipocytes confirming effectiveness in cell models with endogenous PPAR gamma expression. In conclusion, we identified falcarindiol-type polyacetylenes as a novel class of natural partial PPAR gamma agonists, having potential to be further explored as pharmaceutical leads or dietary supplements.	[Atanasov, Atanas G.; Fakhrudin, Nanang; Malainer, Clemens; Kramer, Matthias P.; Cocic, Amina; Heiss, Elke H.; Dirsch, Verena M.] Univ Vienna, Dept Pharmacognosy, Vienna, Austria; [Blunder, Martina; Liu, Xin; Schinkovitz, Andreas; Bauer, Rudolf] Karl Franzens Univ Graz, Dept Pharmacognosy, Inst Pharmaceut Sci, Graz, Austria; [Noha, Stefan M.; Schuster, Daniela] Univ Innsbruck, Inst Pharm Pharmaceut Chem, A-6020 Innsbruck, Austria; [Noha, Stefan M.; Schuster, Daniela] Univ Innsbruck, CMBI, A-6020 Innsbruck, Austria; [Fakhrudin, Nanang] Gadjah Mada Univ, Fac Pharm, Dept Pharmaceut Biol, Yogyakarta, Indonesia; [Kunert, Olaf] Karl Franzens Univ Graz, Dept Pharmaceut Chem, Inst Pharmaceut Sci, Graz, Austria	University of Vienna; University of Graz; University of Innsbruck; University of Innsbruck; Gadjah Mada University; University of Graz	Atanasov, AG (corresponding author), Univ Vienna, Dept Pharmacognosy, Vienna, Austria.	atanas.atanasov@univie.ac.at	Schuster, Daniela/C-1024-2014; Kramer, Matthias/L-1782-2016; Bauer, Rudolf/F-8468-2010; Heiss, Elke/B-6086-2015; Blunder, Martina/I-5948-2013; Atanasov, Atanas G./C-5535-2013; Fakhrudin, Nanang/AED-3803-2022; Kramer, Matthias P/A-6224-2009	Schuster, Daniela/0000-0002-9933-8938; Kramer, Matthias/0000-0002-0289-5261; Bauer, Rudolf/0000-0002-0057-5547; Heiss, Elke/0000-0001-7618-5505; Blunder, Martina/0000-0002-0066-8217; Atanasov, Atanas G./0000-0003-2545-0967; Kunert, Olaf/0000-0002-7091-5973; Dirsch, Verena/0000-0002-9261-5293; fakhrudin, nanang/0000-0001-7954-9503	Austrian Science Fund (FWF-NFN) [S10704, S10705, S10711]; Austrian Federal Ministry for Science and Research [ACM-2007-00178, ACM-2008-00857, ACM-2009-01206]	Austrian Science Fund (FWF-NFN)(Austrian Science Fund (FWF)); Austrian Federal Ministry for Science and Research	This work was financed by the Austrian Science Fund (FWF-NFN; project "Drugs from Nature Targeting Inflammation" (DNTI), project parts S10704, S10705, and S10711), and the Austrian Federal Ministry for Science and Research (ACM-2007-00178, ACM-2008-00857, and ACM-2009-01206). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott BD, 2009, REPROD TOXICOL, V27, P246, DOI 10.1016/j.reprotox.2008.10.001; Agrawal R, 2012, MINI-REV MED CHEM, V12, P87, DOI 10.2174/138955712798995048; Anghel SI, 2007, CELL RES, V17, P486, DOI 10.1038/cr.2007.48; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Bhalla K, 2011, J BIOL CHEM, V286, P41626, DOI 10.1074/jbc.M111.257915; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chandalia A, 2009, PPAR RES, V2009, DOI 10.1155/2009/706852; Chang F, 2007, ANN PHARMACOTHER, V41, P973, DOI 10.1345/aph.1K013; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chien SC, 2009, PHYTOCHEMISTRY, V70, P1246, DOI 10.1016/j.phytochem.2009.07.011; Christensen KB, 2010, PHYTOTHER RES, V24, pS129, DOI 10.1002/ptr.3005; Christensen LP, 2006, J PHARMACEUT BIOMED, V41, P683, DOI 10.1016/j.jpba.2006.01.057; Christensen Lars P, 2011, Recent Pat Food Nutr Agric, V3, P64; Chung JY, 2009, J CHEM INF MODEL, V49, P2382, DOI 10.1021/ci900231p; Copland JA, 2006, ONCOGENE, V25, P2304, DOI 10.1038/sj.onc.1209267; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Fakhrudin N, 2010, MOL PHARMACOL, V77, P559, DOI 10.1124/mol.109.062141; Fredenrich A, 2005, DIABETES METAB, V31, P23, DOI 10.1016/S1262-3636(07)70162-3; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Guasch L, 2011, J COMPUT AID MOL DES, V25, P717, DOI 10.1007/s10822-011-9446-9; Hansen MK, 2008, CURR OPIN INVEST DR, V9, P247; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Lalloyer F, 2010, ARTERIOSCL THROM VAS, V30, P894, DOI 10.1161/ATVBAHA.108.179689; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Liu X, 2009, J ETHNOPHARMACOL, V126, P474, DOI 10.1016/j.jep.2009.09.011; Marion-Letellier R, 2009, GUT, V58, P586, DOI 10.1136/gut.2008.162859; Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5; Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s; Patsouris David, 2004, Curr Opin Investig Drugs, V5, P1045; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Pochetti G, 2007, J BIOL CHEM, V282, P17314, DOI 10.1074/jbc.M702316200; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Rubenstrunk A, 2007, BBA-MOL CELL BIOL L, V1771, P1065, DOI 10.1016/j.bbalip.2007.02.003; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; Soltoft M, 2010, J AGR FOOD CHEM, V58, P7673, DOI 10.1021/jf101921v; Subramanian V, 2010, CIRC RES, V107, P953, DOI 10.1161/CIRCRESAHA.110.219089; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Waku T, 2010, EMBO J, V29, P3395, DOI 10.1038/emboj.2010.197; Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yumuk VD, 2006, ANN NY ACAD SCI, V1083, P306, DOI 10.1196/annals.1367.019; Zhang HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028253; Ziouzenkova O, 2004, CURR OPIN CLIN NUTR, V7, P369, DOI 10.1097/01.mco.0000134358.46159.61; Vincent ZA, 2007, BBA-MOL CELL BIOL L, V1771, P915, DOI 10.1016/j.bbalip.2007.01.007; Zschocke S, 1997, PLANTA MED, V63, P203, DOI 10.1055/s-2006-957653	51	51	55	4	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2013	8	4							e61755	10.1371/journal.pone.0061755	http://dx.doi.org/10.1371/journal.pone.0061755			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JR	23630612	Green Published, gold, Green Submitted			2023-01-03	WOS:000317911500065
J	Bhaumik, S				Bhaumik, Soumyadeep			India's rejection of Novartis's patent is but a small step in the right direction	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												soumyadeepbhaumik@rediffmail.com		Bhaumik, Soumyadeep/0000-0001-9579-4453				Ardal C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001827; Arie S, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2099; D'Silva J, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1605; Hitchings AW, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7941; Jain A., 2013, BRIT MED J, V346, pf2218; Kumar Raman, 2012, J Family Med Prim Care, V1, P10, DOI 10.4103/2249-4863.94442; Mudur G., 2012, BMJ-BRIT MED J, V344; Planning Commission, FAST SUST MOR INCL G; World Health Organization (WHO), 2012, WORLD HLTH STAT 2012	9	2	2	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	2013	346								f2412	10.1136/bmj.f2412	http://dx.doi.org/10.1136/bmj.f2412			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131AT	23596223				2023-01-03	WOS:000317963400015
J	Tuckson, RV; Newcomer, L; De Sa, JM				Tuckson, Reed V.; Newcomer, Lee; De Sa, Jeanne M.			Accessing Genomic Medicine Affordability, Diffusion, and Disparities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Tuckson, Reed V.] UnitedHlth Grp, Minnetonka, MN 55343 USA; [Newcomer, Lee] UnitedHealthcare, Minnetonka, MN USA; [De Sa, Jeanne M.] UnitedHlth Ctr Hlth Reform & Modernizat, Washington, DC USA		Tuckson, RV (corresponding author), UnitedHlth Grp, 9900 Bren Rd E,MN008-T902, Minnetonka, MN 55343 USA.	reed.v.tuckson@uhg.com						Congressional Budget Office, 2008, TECHN CHANG GROWTH H; *DEP HLTH HUM SERV, 2008, US SYST OV GEN TEST; Express Scripts, 2011, 2011 DRUG TREND REP; FederalReserve BankofStLouis, 2022, CAS SHILL US NAT HOM; Khoury MJ, 2012, AM J PREV MED, V42, P639, DOI 10.1016/j.amepre.2012.02.012; Smith M, 2012, BEST CARE LOWER COST; UnitedHealth, 2010, US DIAB CHALL OPP DE	7	22	22	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2013	309	14					1469	1470		10.1001/jama.2013.1468	http://dx.doi.org/10.1001/jama.2013.1468			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VD	23571584				2023-01-03	WOS:000317271700023
J	Bishop, TF				Bishop, Tara F.			Pushing the Outpatient Quality Envelope	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Bishop, Tara F.] Weill Cornell Med Coll, Dept Publ Hlth, Div Outcomes & Effectiveness, New York, NY 10021 USA; [Bishop, Tara F.] Weill Cornell Med Coll, Dept Med, New York, NY 10021 USA	Cornell University; Cornell University	Bishop, TF (corresponding author), Weill Cornell Med Coll, Dept Publ Hlth, 402 E 67th St,Room LA 218, New York, NY 10021 USA.	tlfernan@med.cornell.edu			NATIONAL INSTITUTE ON AGING [K23AG043499] Funding Source: NIH RePORTER; NIA NIH HHS [K23 AG043499, K23AG043499] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Casalino LP, 1999, NEW ENGL J MED, V341, P1147, DOI 10.1056/NEJM199910073411511; Cassel CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/jama.2012.476; Insitute of Medicine, 2008, FUT NURS LEAD CHANG; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Kupfer JM, 2012, JAMA-J AM MED ASSOC, V308, P139, DOI 10.1001/jama.2012.7381; The Joint Commission, 2012 NAT PAT SAF GOA; Volpp KG, 2012, JAMA-J AM MED ASSOC, V308, P1635, DOI 10.1001/jama.2012.13616; Workgroup ACQA, 2005, REC START SET CLIN P	8	9	9	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 3	2013	309	13					1353	1354		10.1001/jama.2013.1220	http://dx.doi.org/10.1001/jama.2013.1220			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EC	23519384	Green Accepted			2023-01-03	WOS:000316934500022
J	Howick, J; Bishop, FL; Heneghan, C; Wolstenholme, J; Stevens, S; Hobbs, FDR; Lewith, G				Howick, Jeremy; Bishop, Felicity L.; Heneghan, Carl; Wolstenholme, Jane; Stevens, Sarah; Hobbs, F. D. Richard; Lewith, George			Placebo Use in the United Kingdom: Results from a National Survey of Primary Care Practitioners	PLOS ONE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CLINICAL-PRACTICE; QUESTIONNAIRE SURVEY; GENERAL-PRACTICE; RESPONSE BIAS; INTERVENTIONS; MEDICINE	Objectives: Surveys in various countries suggest 17% to 80% of doctors prescribe 'placebos' in routine practice, but prevalence of placebo use in UK primary care is unknown. Methods: We administered a web-based questionnaire to a representative sample of UK general practitioners. Following surveys conducted in other countries we divided placebos into 'pure' and 'impure'. 'Impure' placebos are interventions with clear efficacy for certain conditions but are prescribed for ailments where their efficacy is unknown, such as antibiotics for suspected viral infections. 'Pure' placebos are interventions such as sugar pills or saline injections without direct pharmacologically active ingredients for the condition being treated. We initiated the survey in April 2012. Two reminders were sent and electronic data collection closed after 4 weeks. Results: We surveyed 1715 general practitioners and 783 (46%) completed our questionnaire. Our respondents were similar to those of all registered UK doctors suggesting our results are generalizable. 12% (95% CI 10 to 15) of respondents used pure placebos while 97% (95% CI 96 to 98) used impure placebos at least once in their career. 1% of respondents used pure placebos, and 77% (95% CI 74 to 79) used impure placebos at least once per week. Most (66% for pure, 84% for impure) respondents stated placebos were ethical in some circumstances. Conclusion and implications: Placebo use is common in primary care but questions remain about their benefits, harms, costs, and whether they can be delivered ethically. Further research is required to investigate ethically acceptable and cost-effective placebo interventions.	[Howick, Jeremy; Heneghan, Carl; Stevens, Sarah; Hobbs, F. D. Richard] Univ Oxford, Dept Primary Care Hlth Sci, Oxford, England; [Bishop, Felicity L.] Univ Southampton, Fac Social & Human Sci, Ctr Applicat Hlth Psychol, Southampton, Hants, England; [Wolstenholme, Jane] Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford, England; [Lewith, George] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England	University of Oxford; University of Southampton; University of Oxford; University of Southampton	Howick, J (corresponding author), Univ Oxford, Dept Primary Care Hlth Sci, Oxford, England.	Jeremy.howick@phc.ox.ac.uk	Howick, Jeremy/ADP-7644-2022	Wolstenholme, Jane/0000-0001-7493-1850; Howick, Jeremy/0000-0003-0280-7206; Lay-Flurrie, Sarah/0000-0003-1094-8455; Lewith, George/0000-0002-2364-3960; hobbs, richard/0000-0001-7976-7172; Bishop, Felicity/0000-0002-8737-6662	University of Oxford Department of Primary Care Health Sciences; Southampton Complementary Medical Research Trust [1094802]	University of Oxford Department of Primary Care Health Sciences; Southampton Complementary Medical Research Trust	Jeremy Howick is an NSPCR-NIHR Fellow. The University of Oxford Department of Primary Care Health Sciences and The Southampton Complementary Medical Research Trust (Registered Charity No: 1094802) funded part of the research. No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benedetti F, 2007, Handb Exp Pharmacol, P393; Benedetti F, 1998, PAIN, V75, P313, DOI 10.1016/S0304-3959(98)00010-4; Benedetti F., 2020, PLACEBO EFFECTS, DOI [10.1093/oso/9780198843177.001.0001, DOI 10.1093/OSO/9780198843177.001.0001]; Benedetti F, 2011, PSYCHOPHARMACOLOGY, V213, P791, DOI 10.1007/s00213-010-2037-y; Benedetti F, 2011, NEUROPSYCHOPHARMACOL, V36, P339, DOI 10.1038/npp.2010.81; Berger JT, 1999, WESTERN J MED, V170, P93; Bostick NA, 2008, J CLIN ETHIC, V19, P58; Colloca L, 2012, JAMA-J AM MED ASSOC, V307, P567, DOI 10.1001/jama.2012.115; COMAROFF J, 1976, SOCIOL REV, V24, P79, DOI 10.1111/j.1467-954X.1976.tb00574.x; COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; Cunha BA, 2001, MED CLIN N AM, V85, P149, DOI 10.1016/S0025-7125(05)70309-6; de Craen AJM, 1999, J ROY SOC MED, V92, P511, DOI 10.1177/014107689909201005; de Jong V, 2011, J MIND BODY REGULATI, P1; Department of Health, 2011, 2010 11 REF COSTS PU; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Enck P, 2008, NEURON, V59, P195, DOI 10.1016/j.neuron.2008.06.030; Ernst E, 2000, BMJ-BRIT MED J, V321, P1133, DOI 10.1136/bmj.321.7269.1133; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Fassler M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-144; Foddy B, 2009, AM J BIOETHICS, V9, P4, DOI 10.1080/15265160903318350; Gill P, 1996, BRIT MED J, V312, P819; GMC, 2012, LIST REG MED PRACT S; Golomb B, 2002, JAMA; GOODWIN JS, 1979, ANN INTERN MED, V91, P106, DOI 10.7326/0003-4819-91-1-106; GOTZSCHE PC, 1994, LANCET, V344, P925; GRUNBAUM A, 1986, PSYCHOL MED, V16, P19, DOI 10.1017/S0033291700002506; Health and Social Care Information Centre, 2012, PRESCR COST AN ENGL; Heneghan C, 2007, BRIT J GEN PRACT, V57, P948, DOI 10.3399/096016407782604965; Howick J, 2008, PHILOS ISSUES EVIDEN; Howick J, PHILOS EVIDENCE BASE; Howick J, 2009, AM J BIOETHICS, V9, P34, DOI 10.1080/15265160903090041; Hrobjartsson A, 2003, EVAL HEALTH PROF, V26, P153, DOI 10.1177/0163278703026002002; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; Imrie R, 2000, COMPLEMENT THER MED, V8, P123, DOI 10.1054/ctim.2000.0370; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; Kumar S, 2003, BMJ-BRIT MED J, V326, P138, DOI 10.1136/bmj.326.7381.138; Makris UE, 2010, J RHEUMATOL, V37, P1236, DOI 10.3899/jrheum.090935; Mayr A, 2012, J CLIN EPIDEMIOL, V65, P970, DOI 10.1016/j.jclinepi.2012.03.005; Meissner K, 2012, FAM PRACT, V29, P79, DOI 10.1093/fampra/cmr045; Moerman Daniel E., 2002, CAMBRIDGE STUDIES ME; Murray E, 2007, BRIT J GEN PRACT, V57, P939, DOI 10.3399/096016407782605045; Nitzan U, 2004, BMJ-BRIT MED J, V329, P944, DOI 10.1136/bmj.38236.646678.55; Nunn R., 2009, BMJ-BRIT MED J, V338, P1015; Reame NK, 2005, MENOPAUSE, V12, P4, DOI 10.1097/00042192-200512010-00003; Roelofs PDDM, 2008, SPINE, V33, P1766, DOI 10.1097/BRS.0b013e31817e69d3; Shapiro AK, 1978, HDB PSYCHOTHERAPY BE, P369; Shermon R, 2008, J GEN INTERN MED, V23, P7, DOI 10.1007/s11606-007-0332-z; SMITH R, 1991, BRIT MED J, V303, P798, DOI 10.1136/bmj.303.6806.798; Strandvik GF, 2009, ANAESTHESIA, V64, P990, DOI 10.1111/j.1365-2044.2009.05986.x; Tilburt JC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1938; Ward KE, 2010, AM J HEALTH-SYST PH, V67, P206, DOI 10.2146/ajhp080603; World Medical Association (WMA), 2008, DECL HELS; WORSLEY A, 1984, HUM NUTR-APPL NUTR, V38A, P29	53	96	96	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2013	8	3							e58247	10.1371/journal.pone.0058247	http://dx.doi.org/10.1371/journal.pone.0058247			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	125SW	23526969	Green Published, gold, Green Accepted			2023-01-03	WOS:000317562600014
J	Ferreira, R; Artali, R; Benoit, A; Gargallo, R; Eritja, R; Ferguson, DM; Sham, YY; Mazzini, S				Ferreira, Ruben; Artali, Roberto; Benoit, Adam; Gargallo, Raimundo; Eritja, Ramon; Ferguson, David M.; Sham, Yuk Y.; Mazzini, Stefania			Structure and Stability of Human Telomeric G-Quadruplex with Preclinical 9-Amino Acridines	PLOS ONE			English	Article							PROXIMAL PROMOTER REGION; FORCE-FIELD; DNA; BINDING; TARGET; RECOGNITION; SELECTIVITY; DYNAMICS; GENE; NMR	G-quadruplexes are higher-order DNA structures formed from guanine-rich sequences, and have been identified as attractive anticancer drug targets. Elucidating the three-dimensional structure of G-quadruplex with 9-amino acridines and the specific interactions involved in binding selectivity are the key to understanding their mechanism of action. Fluorescence titration assays, competitive dialysis and NMR studies have been used to study the binding specificity of 9-amino acridines to DNA. Structural models of the complexes with the telomeric DNA G-quadruplex based on NMR measurements were developed and further examined by molecular dynamics simulations and free energy calculations. Selective binding of 9-amino acridines for G-quadruplex sequences were observed. These compounds bind between A and G-tetrads, involving significant pi-pi interactions and several strong hydrogen bonds. The specific interactions between different moieties of the 9-amino acridines to the DNA were examined and shown to play a significant role in governing the overall stabilities of DNA G-quadruplex complexes. Both 9-amino acridines, with similar binding affinities to the G-quadruplex, were shown to induce different level of structural stabilization through intercalation. This unique property of altering structural stability is likely a contributing factor for affecting telomerase function and, subsequently, the observed differences in the anticancer activities between the two 9-amino acridines.	[Ferreira, Ruben; Eritja, Ramon] CIBER BBN Networking Ctr Bioengn Biomat & Nanomed, IQAC CSIC, Inst Res Biomed, Barcelona, Spain; [Benoit, Adam; Ferguson, David M.] Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; [Gargallo, Raimundo] Univ Barcelona, Dept Analyt Chem, E-08028 Barcelona, Spain; [Sham, Yuk Y.] Univ Minnesota, Acad Hlth Ctr, Ctr Drug Design, Minneapolis, MN USA; [Mazzini, Stefania] Univ Milan, Dept Organ Chem, Dept Food Environm & Nutr Sci DEFENS, Milan, Italy	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); CSIC - Instituto de Quimica Avanzada de Cataluna (IQAC); University of Minnesota System; University of Minnesota Twin Cities; University of Barcelona; University of Minnesota System; University of Minnesota Twin Cities; University of Milan	Mazzini, S (corresponding author), Univ Milan, Dept Organ Chem, Dept Food Environm & Nutr Sci DEFENS, Milan, Italy.	stefania.mazzini@unimi.it	Sham, Yuk Y/A-6472-2011; Gargallo, Raimundo/A-6084-2017; Eritja, Ramon/B-5613-2008	Sham, Yuk Y/0000-0003-2601-8930; Gargallo, Raimundo/0000-0001-8716-8356; Eritja, Ramon/0000-0001-5383-9334; Scaglioni, Leonardo/0000-0002-9971-100X; Ferguson, David/0000-0001-6294-8057	Spanish Ministerio de Ciencia e Innovacion MICINN [CTQ2008-00177, CTQ2010-20541]; Generalitat de Catalunya [2009/SGR/208]; EU [MP0802]; University of Milano [PUR09]; MIUR [PRIN09]	Spanish Ministerio de Ciencia e Innovacion MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Generalitat de Catalunya(Generalitat de Catalunya); EU(European Commission); University of Milano; MIUR(Ministry of Education, Universities and Research (MIUR))	This work was partially supported by grants from Spanish Ministerio de Ciencia e Innovacion MICINN (CTQ2008-00177, CTQ2010-20541), Generalitat de Catalunya, (2009/SGR/208), the EU COST action (MP0802), the University of Milano (PUR09) and by MIUR (Funds PRIN09). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arimondo P. B., 2001, Current Medicinal Chemistry - Anti-Cancer Agents, V1, P219, DOI 10.2174/1568011013354642; Balasubramanian S, 2011, NAT REV DRUG DISCOV, V10, P261, DOI 10.1038/nrd3428; Belmont P, 2007, ANTI-CANCER AGENT ME, V7, P139, DOI 10.2174/187152007780058669; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BORTOLINI R, 1994, APPL MAGN RESON, V7, P71, DOI 10.1007/BF03162548; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Campbell NH, 2009, BIOCHEMISTRY-US, V48, P1675, DOI 10.1021/bi802233v; Cheng MK, 2008, J MED CHEM, V51, P963, DOI 10.1021/jm070587t; Cogoi S, 2006, NUCLEIC ACIDS RES, V34, P2536, DOI 10.1093/nar/gkl286; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Dai JX, 2006, J AM CHEM SOC, V128, P1096, DOI 10.1021/ja055636a; Denny WA, 2002, CURR MED CHEM, V9, P1655; Dyson RM, 1997, ANAL CHIM ACTA, V353, P381, DOI 10.1016/S0003-2670(97)87800-2; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fernando H, 2006, BIOCHEMISTRY-US, V45, P7854, DOI 10.1021/bi0601510; Ferreira R, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/489060; Franceschin M, 2006, BIOORG MED CHEM LETT, V16, P1707, DOI 10.1016/j.bmcl.2005.12.001; Frisch M., 2016, GAUSSIAN 16, P3; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Goddard T. D., 2004, SPARKY, V3; Goodell JR, 2008, J MED CHEM, V51, P179, DOI 10.1021/jm701228e; Goodell JR, 2006, BIOORGAN MED CHEM, V14, P5467, DOI 10.1016/j.bmc.2006.04.044; GORENSTEIN DG, 1994, CHEM REV, V94, P1315, DOI 10.1021/cr00029a007; Granotier C, 2005, NUCLEIC ACIDS RES, V33, P4182, DOI 10.1093/nar/gki722; Gros J, 2007, NUCLEIC ACIDS RES, V35, P3064, DOI 10.1093/nar/gkm111; Guo K, 2007, J AM CHEM SOC, V129, P10220, DOI 10.1021/ja072185g; Han HY, 2000, TRENDS PHARMACOL SCI, V21, P136, DOI 10.1016/S0165-6147(00)01457-7; Hounsou C, 2007, CHEMMEDCHEM, V2, P655, DOI 10.1002/cmdc.200600286; Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634; Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kumari S, 2007, NAT CHEM BIOL, V3, P218, DOI 10.1038/nchembio864; Larsen AK, 2003, PHARMACOL THERAPEUT, V99, P167, DOI 10.1016/S0163-7258(03)00058-5; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Mazzini S, 2004, ORG BIOMOL CHEM, V2, P505, DOI 10.1039/b312780j; Mazzini S, 1998, J CHEM SOC PERK T 2, P1983, DOI 10.1039/a802350f; Mazzini S, 2010, BIOORGAN MED CHEM, V18, P1497, DOI 10.1016/j.bmc.2010.01.012; Mergny JL, 1998, NAT MED, V4, P1366, DOI 10.1038/3949; Monchaud D, 2008, ORG BIOMOL CHEM, V6, P627, DOI 10.1039/b714772b; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Naasani I, 1999, CANCER RES, V59, P4004; Neidle S, 2002, NAT REV DRUG DISCOV, V1, P383, DOI 10.1038/nrd793; Oostenbrink C, 2005, EUR BIOPHYS J BIOPHY, V34, P273, DOI 10.1007/s00249-004-0448-6; Oppegard LM, 2009, EUR J PHARMACOL, V602, P223, DOI 10.1016/j.ejphar.2008.11.044; Palchaudhuri R, 2007, CURR OPIN BIOTECH, V18, P497, DOI 10.1016/j.copbio.2007.09.006; Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k; Ragazzon P, 2007, METHODS, V43, P313, DOI 10.1016/j.ymeth.2007.08.003; Ragg E, 1998, J CHEM SOC P2, V2, P149; Rao L, 2011, J PHYS CHEM B, V115, P13701, DOI 10.1021/jp207265s; Ren JS, 1999, BIOCHEMISTRY-US, V38, P16067, DOI 10.1021/bi992070s; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799; Sponer J, METHODS; Stewart JJP, 2007, J MOL MODEL, V13, P1173, DOI 10.1007/s00894-007-0233-4; Sun D, 2008, MOL CANCER THER, V7, P880, DOI 10.1158/1535-7163.MCT-07-2119; Sun DY, 2005, NUCLEIC ACIDS RES, V33, P6070, DOI 10.1093/nar/gki917; Topcu Z, 2001, J CLIN PHARM THER, V26, P405, DOI 10.1046/j.1365-2710.2001.00368.x; WANG Y, 1993, J MOL BIOL, V234, P1171, DOI 10.1006/jmbi.1993.1668; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; White EW, 2007, BIOPHYS CHEM, V126, P140, DOI 10.1016/j.bpc.2006.06.006; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0	65	25	26	0	59	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2013	8	3							e57701	10.1371/journal.pone.0057701	http://dx.doi.org/10.1371/journal.pone.0057701			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	109ZC	23554865	Green Published, gold			2023-01-03	WOS:000316409800009
J	Hung, SC; Lin, YP; Huang, HL; Pu, HF; Tarng, DC				Hung, Szu-Chun; Lin, Yao-Ping; Huang, Hsin-Lei; Pu, Hsiao-Fung; Tarng, Der-Cherng			Aldosterone and Mortality in Hemodialysis Patients: Role of Volume Overload	PLOS ONE			English	Article							PLASMA-ALDOSTERONE; CHRONIC KIDNEY; AORTIC STIFFNESS; HEART-FAILURE; SPIRONOLACTONE; EPLERENONE; SURVIVAL; RENIN; DEATH; RISK	Background: Elevated aldosterone is associated with increased mortality in the general population. In patients on dialysis, however, the association is reversed. This paradox may be explained by volume overload, which is associated with lower aldosterone and higher mortality. Methods: We evaluated the relationship between aldosterone and outcomes in a prospective cohort of 328 hemodialysis patients stratified by the presence or absence of volume overload (defined as extracellular water/total body water >48%, as measured with bioimpedance). Baseline plasma aldosterone was measured before dialysis and categorized as low (<140 pg/mL), middle (140 to 280 pg/mL) and high (>280 pg/mL). Results: Overall, 36% (n = 119) of the hemodialysis patients had evidence of volume overload. Baseline aldosterone was significantly lower in the presence of volume overload than in its absence. During a median follow-up of 54 months, 83 deaths and 70 cardiovascular events occurred. Cox multivariate analysis showed that by using the low aldosterone as the reference, high aldosterone was inversely associated with decreased hazard ratios for mortality (0.49; 95% confidence interval, 0.25-0.76) and first cardiovascular event (0.70; 95% confidence interval, 0.3320.78) in the presence of volume overload. In contrast, high aldosterone was associated with an increased risk for mortality (1.97; 95% confidence interval, 1.69-3.75) and first cardiovascular event (2.01; 95% confidence interval, 1.2824.15) in the absence of volume overload. Conclusions: The inverse association of aldosterone with adverse outcomes in hemodialysis patients is due to the confounding effect of volume overload. These findings support treatment of hyperaldosteronemia in hemodialysis patients who have achieved strict volume control.	[Hung, Szu-Chun] Buddhist Tzu Chi Gen Hosp, Taipei Branch, Div Nephrol, Taipei, Taiwan; [Lin, Yao-Ping; Tarng, Der-Cherng] Taipei Vet Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan; [Lin, Yao-Ping; Tarng, Der-Cherng] Taipei Vet Gen Hosp, Immunol Res Ctr, Taipei, Taiwan; [Huang, Hsin-Lei; Pu, Hsiao-Fung; Tarng, Der-Cherng] Natl Yang Ming Univ, Sch Med, Dept & Inst Physiol, Taipei 112, Taiwan	Buddhist Tzu Chi General Hospital; Taipei Veterans General Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University	Tarng, DC (corresponding author), Taipei Vet Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan.	dctarng@vghtpe.gov.tw			National Science Council [NSC 96-2628-B-010-001-MY3, 99-2314-B-010-004-MY3]; Taipei City Hospital [97001-62-002]; National Yang-Ming University Hospital [RD2011-025]; Ministry of Education	National Science Council(Ministry of Science and Technology, Taiwan); Taipei City Hospital; National Yang-Ming University Hospital; Ministry of Education	This study was supported by grants from the National Science Council (NSC 96-2628-B-010-001-MY3 and 99-2314-B-010-004-MY3), Taipei City Hospital (97001-62-002), National Yang-Ming University Hospital (RD2011-025), and Ministry of Education's aim for the Top University Plan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2010, HYPERTENSION, V56, P512, DOI 10.1161/HYPERTENSIONAHA.110.154815; BARENBROCK M, 1994, KIDNEY INT, V45, P1397, DOI 10.1038/ki.1994.182; BERL T, 1978, KIDNEY INT, V14, P228, DOI 10.1038/ki.1978.114; Beygui F, 2006, CIRCULATION, V114, P2604, DOI 10.1161/CIRCULATIONAHA.106.634626; Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434; Bomback AS, 2009, J RENIN-ANGIO-ALDO S, V10, P230, DOI 10.1177/1470320309352353; Cice G, 2010, J AM COLL CARDIOL, V56, P1701, DOI 10.1016/j.jacc.2010.03.105; Contreras G, 2010, J AM SOC NEPHROL, V21, P2131, DOI 10.1681/ASN.2009121285; Covic A, 2006, NEPHROL DIAL TRANSPL, V21, P854, DOI 10.1093/ndt/gfk086; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Diskin CJ, 2004, NEPHROL DIAL TRANSPL, V19, P1331, DOI 10.1093/ndt/gfh081; Edwards NC, 2009, J AM COLL CARDIOL, V54, P505, DOI 10.1016/j.jacc.2009.03.066; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Green D, 2011, AM J KIDNEY DIS, V57, P921, DOI 10.1053/j.ajkd.2011.02.376; Guder G, 2007, CIRCULATION, V115, P1754, DOI 10.1161/CIRCULATIONAHA.106.653964; HENE RJ, 1982, KIDNEY INT, V21, P98, DOI 10.1038/ki.1982.14; Hostetter TH, 2003, J AM SOC NEPHROL, V14, P2395, DOI 10.1097/01.ASN.0000086472.65806.73; Ibrahim HN, 1998, J AM SOC NEPHROL, V9, P72; Juknevicius I, 2004, AM J PHYSIOL-RENAL, V286, pF1059, DOI 10.1152/ajprenal.00202.2003; Kalantar-Zadeh K, 2009, CIRCULATION, V119, P671, DOI 10.1161/CIRCULATIONAHA.108.807362; Klemmer PJ, 2009, BLOOD PURIFICAT, V27, P92, DOI 10.1159/000167016; Kohagura K, 2006, HYPERTENS RES, V29, P597, DOI 10.1291/hypres.29.597; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; London GM, 1996, J HYPERTENS, V14, P1139, DOI 10.1097/00004872-199609000-00015; London GM, 2001, J AM SOC NEPHROL, V12, P2759, DOI 10.1681/ASN.V12122759; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; McLaughlin N, 2004, CURR HYPERTENS REP, V6, P327, DOI 10.1007/s11906-004-0029-1; PARMAR M, 1995, SURVIVAL ANAL PRACTI; Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; RATGE D, 1983, INT J ARTIF ORGANS, V6, P255, DOI 10.1177/039139888300600508; Ritz E, 2010, BLOOD PURIFICAT, V29, P111, DOI 10.1159/000245635; Rossignol P, 2011, J AM COLL CARDIOL, V58, P1958, DOI 10.1016/j.jacc.2011.04.049; Sato A, 2004, HYPERTENS RES, V27, P303, DOI 10.1291/hypres.27.303; Tomaschitz A, 2011, AM J KIDNEY DIS, V57, P403, DOI 10.1053/j.ajkd.2010.10.047; Tomaschitz A, 2010, EUR HEART J, V31, P1237, DOI 10.1093/eurheartj/ehq019; Vuurmans JLT, 2002, J AM SOC NEPHROL, V13, P177, DOI 10.1681/ASN.V131177; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; Young M, 2004, ENDOCRINOLOGY, V145, P3153, DOI 10.1210/en.2004-0005	39	20	20	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57511	10.1371/journal.pone.0057511	http://dx.doi.org/10.1371/journal.pone.0057511			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469009	Green Published, gold, Green Submitted			2023-01-03	WOS:000315524900109
J	Teno, JM; Gozalo, P; Mitchell, SL; Tyler, D; Mor, V				Teno, Joan M.; Gozalo, Pedro; Mitchell, Susan L.; Tyler, Denise; Mor, Vincent			Survival After Multiple Hospitalizations for Infections and Dehydration in Nursing Home Residents With Advanced Cognitive Impairment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							MINIMUM DATA SET		[Teno, Joan M.; Gozalo, Pedro; Tyler, Denise; Mor, Vincent] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA; [Mitchell, Susan L.] Hebrew SeniorLife, Inst Aging Res, Boston, MA USA	Brown University; Harvard University; Hebrew SeniorLife	Teno, JM (corresponding author), Brown Univ, Ctr Gerontol & Hlth Care Res, 121 S Main St,Room 612, Providence, RI 02912 USA.	joan_teno@brown.edu		Tyler, Denise/0000-0001-8555-9011	NIA NIH HHS [P01AG027296, P01 AG027296, K24 AG033640] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K24AG033640, P01AG027296] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Loeb M, 2006, JAMA-J AM MED ASSOC, V295, P2503, DOI 10.1001/jama.295.21.2503; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Mor V, 2004, MED CARE, V42, P50, DOI 10.1097/01.mlr.0000120104.01232.5e; Mor V, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-78; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174	5	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2013	310	3					319	320		10.1001/jama.2013.8392	http://dx.doi.org/10.1001/jama.2013.8392			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183RU	23860991	Green Accepted, Bronze			2023-01-03	WOS:000321835700020
J	Gellad, WF; Donohue, JM; Zhao, XH; Mor, MK; Thorpe, CT; Smith, J; Good, CB; Fine, MJ; Morden, NE				Gellad, Walid F.; Donohue, Julie M.; Zhao, Xinhua; Mor, Maria K.; Thorpe, Carolyn T.; Smith, Jeremy; Good, Chester B.; Fine, Michael J.; Morden, Nancy E.			Brand-Name Prescription Drug Use Among Veterans Affairs and Medicare Part D Patients With Diabetes A National Cohort Comparison	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-CARE-SYSTEM; QUALITY-OF-CARE; GEOGRAPHIC-VARIATION; OLDER-ADULTS; COST; PRICES; IMPLEMENTATION; HYPERTENSION; MEDICATIONS; PHYSICIANS	Background: Medicare Part D and the U.S. Department of Veterans Affairs (VA) use different approaches to manage prescription drug benefits, with implications for spending. Medicare relies on private plans with distinct formularies, whereas the VA administers its own benefit using a national formulary. Objective: To compare overall and regional rates of brand-name drug use among older adults with diabetes in Medicare and the VA. Design: Retrospective cohort. Setting: Medicare and the VA, 2008. Patients: 1 061 095 Medicare Part D beneficiaries and 510 485 veterans aged 65 years or older with diabetes. Measurements: Percentage of patients taking oral hypoglycemics, statins, and angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) who filled brand-name drug prescriptions and percentage of patients taking long-acting insulins who filled analogue prescriptions. Sociodemographic-and health status-adjusted hospital referral region (HRR) brand-name drug use was compared, and changes in spending were calculated if use of brand-name drugs in 1 system mirrored the other. Results: Brand-name drug use in Medicare was 2 to 3 times that in the VA: 35.3% versus 12.7% for oral hypoglycemics, 50.7% versus 18.2% for statins, 42.5% versus 20.8% for ACE inhibitors or ARBs, and 75.1% versus 27.0% for insulin analogues. Adjusted HRR-level brand-name statin use ranged (from the 5th to 95th percentiles) from 41.0% to 58.3% in Medicare and 6.2% to 38.2% in the VA. For each drug group, the 95th-percentile HRR in the VA had lower brand-name drug use than the 5th-percentile HRR in Medicare. Medicare spending in this population would have been $1.4 billion less if brand-name drug use matched that of the VA. Limitation: This analysis cannot fully describe the factors underlying differences in brand-name drug use. Conclusion: Medicare beneficiaries with diabetes use 2 to 3 times more brand-name drugs than a comparable group within the VA, at substantial excess cost.	Univ Pittsburgh, RAND Corp, Vet Affairs Pittsburgh Healthcare Syst, Grad Sch Publ Hlth,Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA; Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA; [Smith, Jeremy; Morden, Nancy E.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA; US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA; Geisel Sch Med Dartmouth, Hanover, NH USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dartmouth College; US Department of Veterans Affairs; Dartmouth College	Gellad, WF (corresponding author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 7180 Highland Dr, Pittsburgh, PA 15206 USA.	walid.gellad@va.gov	Good, Chester B/K-2818-2019	Good, Chester B/0000-0003-4388-4558; Donohue, Julie/0000-0003-2418-6017	U.S. Department of Veterans Affairs; National Institutes of Health; Robert Wood Johnson Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS017695] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG019783, K23AG035030] Funding Source: NIH RePORTER	U.S. Department of Veterans Affairs(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Primary Funding Source: U.S. Department of Veterans Affairs, National Institutes of Health, and Robert Wood Johnson Foundation.	Alexander GC, 2008, ARCH INTERN MED, V168, P2088, DOI 10.1001/archinte.168.19.2088; [Anonymous], 2011, TREATMENT GUIDELINES, V9, P47; Antos JR, 2012, NEW ENGL J MED, V367, P954, DOI 10.1056/NEJMsb1207996; Asch SM, 2004, ANN INTERN MED, V141, P938, DOI 10.7326/0003-4819-141-12-200412210-00010; Barnett ML, 2012, MED CARE, V50, P152, DOI 10.1097/MLR.0b013e31822dcef7; Berwick DM, 2012, JAMA-J AM MED ASSOC, V307, P1513, DOI 10.1001/jama.2012.362; Cassel CK, 2012, JAMA-J AM MED ASSOC, V307, P1801, DOI 10.1001/jama.2012.476; Choudhry NK, 2010, NEW ENGL J MED, V363, P1885, DOI 10.1056/NEJMp1006189; Congressional Budget Office, 2010, EFF US GEN DRUGS MED; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Donohue JM, 2012, NEW ENGL J MED, V366, P530, DOI 10.1056/NEJMsa1104816; Donohue JM, 2011, AM J GERIAT PSYCHIAT, V19, P989, DOI 10.1097/JGP.0b013e3182051a9b; Donohue JM, 2010, AM HEART J, V160, P159, DOI 10.1016/j.ahj.2010.04.023; Emanuel E, 2012, NEW ENGL J MED, V367, P949, DOI 10.1056/NEJMsb1205901; Frakt AB, 2012, HEALTH ECON, V21, P485, DOI 10.1002/hec.1733; Frank RG, 2008, HEALTH AFFAIR, V27, P33, DOI 10.1377/hlthaff.27.1.33; Gabow P, 2012, JAMA-J AM MED ASSOC, V308, P239, DOI 10.1001/jama.2012.7081; Gellad W, 2012, ARCH INTERN MED, V172, P1608, DOI 10.1001/archinternmed.2012.4482; Gellad WF, 2008, J GEN INTERN MED, V23, P1435, DOI 10.1007/s11606-008-0689-7; Gellad WF, 2010, AM J MANAG CARE, V16, P741; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; Green JB, 2013, JAMA INTERN MED, V173, P229, DOI 10.1001/jamainternmed.2013.1529; Hargrave E, 2010, MEANINGFUL QUALITY D; Horvath K, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005613.pub3; Huskamp HA, 2003, HEALTH AFFAIR, V22, P149, DOI 10.1377/hlthaff.22.3.149; Jacobson GA, 2007, PHARM COSTS COMP DEP; Jha AK, 2003, NEW ENGL J MED, V348, P2218, DOI 10.1056/NEJMsa021899; Kerr EA, 2004, ANN INTERN MED, V141, P272, DOI 10.7326/0003-4819-141-4-200408170-00007; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Kronick R, 2012, HEALTH AFFAIR, V31, P948, DOI 10.1377/hlthaff.2009.1065; Laine C, 2012, ANN INTERN MED, V156, P162, DOI 10.7326/0003-4819-156-2-201201170-00016; Madden JM, 2008, JAMA-J AM MED ASSOC, V299, P1922, DOI 10.1001/jama.299.16.1922; Matchar DB, 2008, ANN INTERN MED, V148, P16, DOI 10.7326/0003-4819-148-1-200801010-00189; Miller DR, 2004, DIABETES CARE, V27, pB10, DOI 10.2337/diacare.27.suppl_2.B10; Polinski JM, 2011, J AM GERIATR SOC, V59, P1922, DOI 10.1111/j.1532-5415.2011.03537.x; Polinski JM, 2010, J AM GERIATR SOC, V58, P1764, DOI 10.1111/j.1532-5415.2010.03025.x; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Smith CD, 2012, ANN INTERN MED, V157, P284, DOI 10.7326/0003-4819-157-4-201208210-00496; The Henry J. Kaiser Family Foundation, 2009, MED PRESCR DRUG BEN; The Henry J. Kaiser Family Foundation, 2011, AN MED PRESCR DRUG P; Trivedi AN, 2011, MED CARE, V49, P76, DOI 10.1097/MLR.0b013e3181f53575; U.S. Department of Health and Human Services Office of the Inspector General, 2011, HIGH REB BRAND NAM D; US Census Bureau, AM FACTFINDER; Wilt TJ, 2012, ARCH INTERN MED, V172, P1610, DOI 10.1001/2013.jamainternmed.203; Young BA, 2008, AM J MANAG CARE, V14, P15; Zhang YT, 2012, ARCH INTERN MED, V172, P1465, DOI 10.1001/archinternmed.2012.3717; Zhang YT, 2012, J GEN INTERN MED, V27, P1251, DOI 10.1007/s11606-012-1993-9; Zhang YT, 2011, HEALTH SERV RES, V46, P185, DOI 10.1111/j.1475-6773.2010.01183.x; Zhang YT, 2010, NEW ENGL J MED, V363, P1985, DOI 10.1056/NEJMp1010220	49	30	30	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2013	159	2					105	W39		10.7326/0003-4819-159-2-201307160-00664	http://dx.doi.org/10.7326/0003-4819-159-2-201307160-00664			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	187IX	23752663	Green Accepted			2023-01-03	WOS:000322112000016
J	Hirst, J; Jeffery, H				Hirst, Jane; Jeffery, Heather			Education, audit, and outreach to prevent maternal mortality	LANCET			English	Editorial Material									[Hirst, Jane] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England; [Hirst, Jane; Jeffery, Heather] Univ Sydney, Sch Publ Hlth, Sydney Med Sch, Sydney, NSW 2006, Australia; [Jeffery, Heather] Royal Prince Alfred Hosp, Dept Neonatol, Camperdown, NSW 2050, Australia	University of Oxford; University of Sydney; University of Sydney	Hirst, J (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.	jane.hirst@obs-gyn.ox.ac.uk	Hirst, Jane Elizabeth/L-8863-2019; Hirst, Jane/AAM-9891-2020	Hirst, Jane/0000-0002-0176-2651				[Anonymous], 2012, AHRC2122 UN; Bradshaw D, 2008, LANCET, V371, P1294, DOI 10.1016/S0140-6736(08)60564-4; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Dumont A, 2006, B WORLD HEALTH ORGAN, V84, P218, DOI 10.2471/BLT.05.023903; Dumont A, 2013, LANCET; HILL DA, 1992, MED TEACH, V14, P37, DOI 10.3109/01421599209044013; Jeffery HE, 2004, MED EDUC, V38, P435, DOI 10.1046/j.1365-2923.2004.01785.x; Pattinson RC, 2005, COCHRANE DB SYST REV, V4; Peterson HB, 2012, OBSTET GYNECOL, V120, P636, DOI 10.1097/AOG.0b013e3182632cc1; van den Akker T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020776; World Health Organization, 2004, NUMB REV MAT DEATHS; World Health Organization (WHO), 2012, TRENDS MAT MORT 1990	12	1	1	1	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2013	382	9887					108	110		10.1016/S0140-6736(13)60906-X	http://dx.doi.org/10.1016/S0140-6736(13)60906-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	187JY	23721754				2023-01-03	WOS:000322115300007
J	Liu, ZX; Huang, SY; Zhang, DS				Liu, Zhenxing; Huang, Shengyun; Zhang, Dongsheng			High Dose Rate versus Low Dose Rate Brachytherapy for Oral Cancer - A Meta-Analysis of Clinical Trials	PLOS ONE			English	Article							RATE INTERSTITIAL BRACHYTHERAPY; CARCINOMA; RADIOTHERAPY; FRACTIONS; HEAD	Objective: To compare the efficacy and safety of high dose rate (HDR) and low dose rate (LDR) brachytherapy in treating early-stage oral cancer. Data Sources: A systematic search of MEDLINE, EMBASE and Cochrane Library databases, restricted to English language up to June 1, 2012, was performed to identify potentially relevant studies. Study Selection: Only randomized controlled trials (RCT) and controlled trials that compared HDR to LDR brachytherapy in treatment of early-stage oral cancer (stages I, II and III) were of interest. Data Extraction and Synthesis: Two investigators independently extracted data from retrieved studies and controversies were solved by discussion. Meta-analysis was performed using RevMan 5.1. One RCT and five controlled trials (607 patients: 447 for LDR and 160 for HDR) met the inclusion criteria. The odds ratio showed no statistically significant difference between LDR group and HDR group in terms of local recurrence (OR = 1.12, CI 95% 0.62-2.01), overall mortality (OR = 1.01, CI 95% 0.61-1.66) and Grade 3/4 complications (OR = 0.86, CI 95% 0.52-1.42). Conclusions: This meta-analysis indicated that HDR brachytherapy was a comparable alternative to LDR brachytherapy in treatment of oral cancer. HDR brachytherapy might become a routine choice for early-stage oral cancer in the future.	[Liu, Zhenxing; Huang, Shengyun; Zhang, Dongsheng] Shandong Univ, Dept Oral & Maxillofacial Surg, Prov Hosp, Jinan 250100, Peoples R China	Shandong University	Zhang, DS (corresponding author), Shandong Univ, Dept Oral & Maxillofacial Surg, Prov Hosp, Jinan 250100, Peoples R China.	ds63zhang@sdu.edu.cn			Shandong Provincial Science and Technology Development Plan [2006GG2202034]; Science and Technology Foundation of Shandong Province [2006GG20002046]; Shandong Provincial Natural Science Foundation [ZR2012HQ022]	Shandong Provincial Science and Technology Development Plan; Science and Technology Foundation of Shandong Province; Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province)	This study is supported by Shandong Provincial Science and Technology Development Plan (2006GG2202034), the Science and Technology Foundation of Shandong Province (2006GG20002046) and Shandong Provincial Natural Science Foundation (ZR2012HQ022). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akiyama H, 2012, J RADIAT RES, V53, P722, DOI 10.1093/jrr/rrs027; Ayerra Arrate Querejeta, 2010, J Contemp Brachytherapy, V2, P9, DOI 10.5114/jcb.2010.13717; Deng H, 2011, AUST DENT J, V56, P244, DOI 10.1111/j.1834-7819.2011.01349.x; Erickson BA, 2011, INT J RADIAT ONCOL, V79, P641, DOI 10.1016/j.ijrobp.2010.08.046; Genden EM, 2010, EUR ARCH OTO-RHINO-L, V267, P1001, DOI 10.1007/s00405-010-1206-2; Ghadjar P, 2012, INT J RADIAT ONCOL, V83, P1205, DOI 10.1016/j.ijrobp.2011.09.038; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Inoue T, 1998, INT J RADIAT ONCOL, V41, P53, DOI 10.1016/S0360-3016(98)00041-8; Inoue T, 2001, INT J RADIAT ONCOL, V51, P171, DOI 10.1016/S0360-3016(01)01561-9; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Katimoto N, 2003, RADIOTHER ONCOL, V68, P123, DOI 10.1016/S0167-8140(03)00055-0; Lau HY, 1996, RADIOTHER ONCOL, V39, P15, DOI 10.1016/0167-8140(95)01686-4; Leung TW, 2002, HEAD NECK-J SCI SPEC, V24, P274, DOI 10.1002/hed.10021; Leung TW, 1997, INT J RADIAT ONCOL, V39, P1113, DOI 10.1016/S0360-3016(97)00376-3; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Guinot JL, 2010, BRACHYTHERAPY, V9, P227, DOI 10.1016/j.brachy.2009.10.003; MANTEL N, 1959, J NATL CANCER I, V22, P719; Martinez A, 1997, PRINCIPLES PRACTICE, P569; Mazeron JJ, 2009, RADIOTHER ONCOL, V91, P150, DOI 10.1016/j.radonc.2009.01.005; Mikami M, 2011, BRACHYTHERAPY, V10, P318, DOI 10.1016/j.brachy.2010.11.006; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nag S, 2004, TECHNOL CANCER RES T, V3, P269, DOI 10.1177/153303460400300305; National Comprehensive Cancer Network, 2011, NCCN GUID HEAD NECK; Oxford Centre for Evidence-Based Medicine, 2009, LEVELS EVIDENCE; Petera J, 2009, NEOPLASMA, V56, P163, DOI 10.4149/neo_2009_02_163; Shibuya H, 2009, INT J CLIN ONCOL, V14, P2, DOI 10.1007/s10147-008-0859-y; Umeda M, 2000, ORAL SURG ORAL MED O, V90, P667, DOI 10.1067/moe.2000.110087; Umeda M, 2005, INT J ORAL MAX SURG, V34, P739, DOI 10.1016/j.ijom.2005.02.015; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002; Wells GA., 2012, NEWCASTLE OTTAWA SCA; Yamazaki H, 2007, ANTICANCER RES, V27, P491; Yamazaki H, 2013, J RADIAT RES, V54, P1, DOI 10.1093/jrr/rrs103; Yoshida K, 2010, INT J RADIAT ONCOL, V77, P765, DOI 10.1016/j.ijrobp.2009.05.027	34	8	8	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2013	8	6							e65423	10.1371/journal.pone.0065423	http://dx.doi.org/10.1371/journal.pone.0065423			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164VY	23762369	Green Published, gold, Green Submitted			2023-01-03	WOS:000320440500038
J	Miyamoto, DT; Viswanathan, AN				Miyamoto, David T.; Viswanathan, Akila N.			Concurrent Chemoradiation for Vaginal Cancer	PLOS ONE			English	Article							SQUAMOUS-CELL CARCINOMA; GYNECOLOGIC-ONCOLOGY-GROUP; HIGH-DOSE-RATE; CERVICAL-CANCER; PREOPERATIVE CHEMORADIATION; INTERSTITIAL BRACHYTHERAPY; RADIATION-THERAPY; CHEMOTHERAPY; VULVA; OUTCOMES	Background: It is not known whether the addition of chemotherapy to radiation therapy improves outcomes in primary vaginal cancer. Here, we review clinical outcomes in patients with primary vaginal cancer treated with radiation therapy (RT) or concurrent chemoradiation therapy (CRT). Methods: Seventy-one patients with primary vaginal cancer treated with definitive RT with or without concurrent chemotherapy at a single institution were identified and their records reviewed. A total of 51 patients were treated with RT alone; 20 patients were treated with CRT. Recurrences were analyzed. Overall survival (OS) and disease-free survival (DFS) rates were estimated using the Kaplan-Meier method. Cox regression analysis was performed. Results: The median age at diagnosis was 61 years (range, 18-92 years) and the median follow-up time among survivors was 3.0 years. Kaplan-Meier estimates for OS and DFS differed significantly between the RT and CRT groups (3-yr OS = 56% vs. 79%, log-rank p=0.037; 3-yr DFS = 43% vs. 73%, log-rank p=0.011). Twenty-three patients (45%) in the RT group had a relapse at any site compared to 3 (15%) in the CRT group (p=0.027). With regard to the sites of first relapse, 10 patients (14%) had local only, 4 (6%) had local and regional, 9 (13%) had regional only, 1 (1%) had regional and distant, and 2 (3%) had distant only relapse. On univariate analysis, the use of concurrent chemotherapy, FIGO stage, tumor size, and date of diagnosis were significant predictors of DFS. On multivariate analysis, the use of concurrent chemotherapy remained a significant predictor of DFS (hazard ratio 0.31 (95% CI, 0.10-0.97; p = 0.04)). Conclusions: Vaginal cancer results in poor outcomes. Adequate radiation dose is essential to ensure curative management. Concurrent chemotherapy should be considered for vaginal cancer patients.	[Miyamoto, David T.] Harvard Univ, Sch Med, Harvard Radiat Oncol Program, Boston, MA USA; [Viswanathan, Akila N.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute	Viswanathan, AN (corresponding author), Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.	aviswanathan@lroc.harvard.edu		viswaanathan, akila/0000-0002-1896-2924	St. Laurent Family Fund	St. Laurent Family Fund	This research was supported by a donation to Dr Viswanathan by the St. Laurent Family Fund. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Beriwal S, 2012, BRACHYTHERAPY, V11, P68, DOI 10.1016/j.brachy.2011.06.008; Cardenes H, 2007, PRINCIPLES PRACTICE, P1657; Creasman WT, 1998, CANCER, V83, P1033, DOI 10.1002/(SICI)1097-0142(19980901)83:5<1033::AID-CNCR30>3.0.CO;2-6; Dalrymple JL, 2004, INT J GYNECOL CANCER, V14, P110, DOI 10.1111/j.1048-891x.2004.014066.x; Frank SJ, 2005, INT J RADIAT ONCOL, V62, P138, DOI 10.1016/j.ijrobp.2004.09.032; Hellman K, 2004, INT J GYNECOL CANCER, V14, P491, DOI 10.1111/j.1048-891x.2004.014310.x; Kapur T, 2012, MAGN RESON IMAGING, V30, P1279, DOI 10.1016/j.mri.2012.06.003; Landrum LM, 2008, GYNECOL ONCOL, V108, P584, DOI 10.1016/j.ygyno.2007.11.010; Lee LJ, 2012, INT J RADIAT ONCOL, V84, P1192, DOI 10.1016/j.ijrobp.2012.01.085; Mak RH, 2011, GYNECOL ONCOL, V120, P101, DOI 10.1016/j.ygyno.2010.09.004; Montana GS, 2000, INT J RADIAT ONCOL, V48, P1007, DOI 10.1016/S0360-3016(00)00762-8; Moore DH, 1998, INT J RADIAT ONCOL, V42, P79, DOI 10.1016/S0360-3016(98)00193-X; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Nashiro T, 2008, INT J CLIN ONCOL, V13, P335, DOI 10.1007/s10147-007-0758-7; PEREZ CA, 1988, INT J RADIAT ONCOL, V15, P1283, DOI 10.1016/0360-3016(88)90222-2; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Samant R, 2007, INT J RADIAT ONCOL, V69, P746, DOI 10.1016/j.ijrobp.2007.04.015; Shah CA, 2009, OBSTET GYNECOL, V113, P1038, DOI 10.1097/AOG.0b013e31819fe844; Stewart AJ, 2006, CANCER, V107, P908, DOI 10.1002/cncr.22054; Tran PT, 2007, GYNECOL ONCOL, V105, P641, DOI 10.1016/j.ygyno.2007.01.033; Viswanathan AN, 2006, INT J RADIAT ONCOL, V66, P91, DOI 10.1016/j.ijrobp.2006.04.037; Viswanathan AN, 2011, GYNECOLOGIC RADIATION THERAPY: NOVEL APPROACHES TO IMAGE-GUIDANCE AND MANAGEMENT, P1	22	35	36	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2013	8	6							e65048	10.1371/journal.pone.0065048	http://dx.doi.org/10.1371/journal.pone.0065048			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173QU	23762284	gold, Green Published, Green Submitted			2023-01-03	WOS:000321094800016
J	Britton, J; McNeill, A				Britton, John; McNeill, Ann			Nicotine regulation and tobacco harm reduction in the UK	LANCET			English	Editorial Material							CIGARETTES; SMOKING		[Britton, John] Univ Nottingham, UK Ctr Tobacco Control Studies, Nottingham NG5 1PB, England; [McNeill, Ann] Kings Coll London, Inst Psychiat, UK Ctr Tobacco Control Studies, London WC2R 2LS, England	University of Nottingham; University of London; King's College London	Britton, J (corresponding author), Univ Nottingham, UK Ctr Tobacco Control Studies, Nottingham NG5 1PB, England.	j.britton@virgin.net		McNeill, Ann/0000-0002-6223-4000				Department of Health (DoH), 2011, HLTH LIV HLTH PEOPL; Etter JF, 2011, ADDICTION, V106, P2017, DOI 10.1111/j.1360-0443.2011.03505.x; Gartner CE, 2007, LANCET, V369, P2010, DOI 10.1016/S0140-6736(07)60677-1; Medicines and Healthcare Products Regulatory Agency (MHRA), 2005, REP COMM SAF MED WOR; Moore D, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1024; *ROYAL COLL PHYS T, 2007, HARM RED NIC ADD; RUSSELL MAH, 1976, BRIT MED J, V1, P1430, DOI 10.1136/bmj.1.6023.1430; Scientific Committee on Emerging and Newly Identified Health Risks, 2008, HLTH EFF SMOK TOB PR; Vansickel AR, 2013, NICOTINE TOB RES, V15, P267, DOI 10.1093/ntr/ntr316; West R, 2013, MONTHL TRACK KEY PER	10	5	7	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 1	2013	381	9881					1879	1880		10.1016/S0140-6736(13)61122-8	http://dx.doi.org/10.1016/S0140-6736(13)61122-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	163EV	23725716				2023-01-03	WOS:000320319500005
J	Wake, S; Kitchiner, D				Wake, Sarah; Kitchiner, Deborah			Post-traumatic stress disorder after intensive care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Wake, Sarah] Univ Wales Hosp, Cardiff CF14 4XW, S Glam, Wales; [Kitchiner, Deborah] CBT Cardiff, Cardiff, S Glam, Wales	Cardiff University	Wake, S (corresponding author), Univ Wales Hosp, Cardiff CF14 4XW, S Glam, Wales.	sarah.wake@doctors.org.uk							0	10	11	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2013	346								f3232	10.1136/bmj.f3232	http://dx.doi.org/10.1136/bmj.f3232			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	153AV	23697673	Bronze			2023-01-03	WOS:000319574400020
J	Katz, JN; Brophy, RH; Chaisson, CE; de Chaves, L; Cole, BJ; Dahm, DL; Donnell-Fink, LA; Guermazi, A; Haas, AK; Jones, MH; Levy, BA; Mandl, LA; Martin, SD; Marx, RG; Miniaci, A; Matava, MJ; Palmisano, J; Reinke, EK; Richardson, BE; Rome, BN; Safran-Norton, CE; Skoniecki, DJ; Solomon, DH; Smith, MV; Spindler, KP; Stuart, MJ; Wright, J; Wright, RW; Losina, E				Katz, Jeffrey N.; Brophy, Robert H.; Chaisson, Christine E.; de Chaves, Leigh; Cole, Brian J.; Dahm, Diane L.; Donnell-Fink, Laurel A.; Guermazi, Ali; Haas, Amanda K.; Jones, Morgan H.; Levy, Bruce A.; Mandl, Lisa A.; Martin, Scott D.; Marx, Robert G.; Miniaci, Anthony; Matava, Matthew J.; Palmisano, Joseph; Reinke, Emily K.; Richardson, Brian E.; Rome, Benjamin N.; Safran-Norton, Clare E.; Skoniecki, Debra J.; Solomon, Daniel H.; Smith, Matthew V.; Spindler, Kurt P.; Stuart, Michael J.; Wright, John; Wright, Rick W.; Losina, Elena			Surgery versus Physical Therapy for a Meniscal Tear and Osteoarthritis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OUTCOME SCORE KOOS; KNEE OSTEOARTHRITIS; ARTHROSCOPIC SURGERY; LOWER-EXTREMITIES; RANDOMIZED-TRIAL; ELDERLY PERSONS; CLINICAL-TRIALS; UNITED-STATES; MENISCECTOMY; VALIDATION	BACKGROUND Whether arthroscopic partial meniscectomy for symptomatic patients with a meniscal tear and knee osteoarthritis results in better functional outcomes than nonoperative therapy is uncertain. METHODS We conducted a multicenter, randomized, controlled trial involving symptomatic patients 45 years of age or older with a meniscal tear and evidence of mild-to-moderate osteoarthritis on imaging. We randomly assigned 351 patients to surgery and postoperative physical therapy or to a standardized physical-therapy regimen (with the option to cross over to surgery at the discretion of the patient and surgeon). The patients were evaluated at 6 and 12 months. The primary outcome was the difference between the groups with respect to the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) physical-function score (ranging from 0 to 100, with higher scores indicating more severe symptoms) 6 months after randomization. RESULTS In the intention-to-treat analysis, the mean improvement in the WOMAC score after 6 months was 20.9 points (95% confidence interval [CI], 17.9 to 23.9) in the surgical group and 18.5 (95% CI, 15.6 to 21.5) in the physical-therapy group (mean difference, 2.4 points; 95% CI, -1.8 to 6.5). At 6 months, 51 active participants in the study who were assigned to physical therapy alone (30%) had undergone surgery, and 9 patients assigned to surgery (6%) had not undergone surgery. The results at 12 months were similar to those at 6 months. The frequency of adverse events did not differ significantly between the groups. CONCLUSIONS In the intention-to-treat analysis, we did not find significant differences between the study groups in functional improvement 6 months after randomization; however, 30% of the patients who were assigned to physical therapy alone underwent surgery within 6 months. (Funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases; METEOR ClinicalTrials.gov number, NCT00597012.)	[Katz, Jeffrey N.; de Chaves, Leigh; Donnell-Fink, Laurel A.; Martin, Scott D.; Rome, Benjamin N.; Safran-Norton, Clare E.; Skoniecki, Debra J.; Solomon, Daniel H.; Wright, John; Losina, Elena] Brigham & Womens Hosp, Boston, MA 02115 USA; [Chaisson, Christine E.; Guermazi, Ali; Palmisano, Joseph] Boston Univ, Boston, MA 02215 USA; [Brophy, Robert H.; Haas, Amanda K.; Matava, Matthew J.; Smith, Matthew V.; Wright, Rick W.] Washington Univ, St Louis, MO 63130 USA; [Cole, Brian J.] Rush Univ, Chicago, IL 60612 USA; [Dahm, Diane L.; Levy, Bruce A.; Stuart, Michael J.] Mayo Clin, Rochester, MN USA; [Jones, Morgan H.; Miniaci, Anthony] Cleveland Clin, Cleveland, OH 44106 USA; [Mandl, Lisa A.; Marx, Robert G.] Hosp Special Surg, New York, NY 10021 USA; [Reinke, Emily K.; Richardson, Brian E.; Spindler, Kurt P.] Vanderbilt Univ, Nashville, TN USA	Harvard University; Brigham & Women's Hospital; Boston University; Washington University (WUSTL); Rush University; Mayo Clinic; Cleveland Clinic Foundation; Vanderbilt University	Katz, JN (corresponding author), Brigham & Womens Hosp, Dept Orthoped Surg, Orthoped & Arthrit Ctr Outcomes Res, 75 Francis St,BC-4016, Boston, MA 02115 USA.	jnkatz@partners.org	Brophy, Robert H/AAX-8562-2021; Jones, Morgan H/ABG-3503-2021; Cole, Brian/K-4268-2019	Brophy, Robert H/0000-0002-2912-8265; Jones, Morgan H/0000-0002-5466-0624; Reinke, Emily/0000-0001-7629-8067; Rome, Benjamin/0000-0001-5776-3293; Losina, ELENA/0000-0002-3424-0892; Chaisson, Christine/0000-0002-3207-9257	National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [R01AR055557, K24AR057827, P60AR047782]; Orthopaedic Research and Education Foundation; Arthrex; Carticept; DJ Orthopedics; Genzyme; Johnson Johnson; DePuy Orthopedics; Regentis; Zimmer; Major League Baseball; Arthrosurface; Ossur; Smith and Nephew; Merck Serono; Pfizer; Allergan; Stryker; Breg; ISTO Technologies; Schwartz Biomedical; Ostesys; Arthrex and Breg; Arthrosurface and Stryker; DonJoy; National Football League; Flexion Therapeutics; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR047782, R01AR055557, K24AR057827] Funding Source: NIH RePORTER	National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Orthopaedic Research and Education Foundation; Arthrex; Carticept; DJ Orthopedics; Genzyme(Sanofi-AventisGenzyme Corporation); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); DePuy Orthopedics; Regentis; Zimmer; Major League Baseball; Arthrosurface; Ossur; Smith and Nephew; Merck Serono(Merck & Company); Pfizer(Pfizer); Allergan(AbbVieAllergan); Stryker; Breg; ISTO Technologies; Schwartz Biomedical; Ostesys; Arthrex and Breg; Arthrosurface and Stryker; DonJoy; National Football League; Flexion Therapeutics; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Supported by grants (R01AR055557, K24AR057827, and P60AR047782) from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.; Dr. Brophy reports receiving fees for providing expert testimony on behalf of Genzyme on the use of Synvisc and grant support through his institution from the Orthopaedic Research and Education Foundation. Dr. Cole reports receiving consulting fees from Arthrex, Carticept, DJ Orthopedics, Genzyme, Johnson & Johnson, DePuy Orthopedics, Regentis, and Zimmer, lecture fees from Genzyme, fees for providing expert testimony for medical malpractice defense and third-party liability cases on personal injury and product liability, and royalties from Arthrex, DJ Orthopedics, Elsevier, and W.B. Saunders, holding equity in Carticept and Regentis, receiving grant support through his institution from Major League Baseball, Arthrex, Zimmer, Arthrosurface, Johnson & Johnson, and Medipost and fellowship support through his institution from DJ Orthopedics, Ossur, and Smith and Nephew. Dr. Guermazi reports receiving consulting fees from Merck Serono, Pfizer, and Genzyme, and holding stock in Boston Imaging Core Lab. Dr. Jones reports receiving consulting fees from Allergan and grant support through his institution from DJ Orthopedics, Stryker, Smith and Nephew, Breg, and Arthrex. Dr. Levy reports receiving consulting fees from Arthrex and royalties from VOT Solutions and Arthrex. Dr. Matava reports receiving consulting fees from ISTO Technologies, Schwartz Biomedical, and Ostesys, and grant support through his institution from Arthrex and Breg. Dr. Miniaci reports receiving consulting fees from Arthrosurface and Stryker and lecture fees, payment for the development of educational presentations, and travel support from Arthrosurface, holding stock in Arthrosurface, and receiving royalties from Arthrosurface for granted and pending patents regarding retrograde delivery of resurfacing devices, an articular surface implant and delivery system, and a system and method for a retrograde procedure and grant support through his institution from DJ Orthopedics, Stryker, and Arthrex. Dr. Reinke reports receiving grant support through her institution from Smith and Nephew, DonJoy, and the National Football League. Dr. Smith reports receiving consulting fees from ISTO Technologies. Dr. Spindler reports receiving consulting fees from the National Football League and payment for patents from Connective Orthopedics on a biologic replacement for fibrin clots. Dr. Stuart reports receiving consulting fees and royalties from Arthrex and grant support through his institution from Stryker. Dr. J. Wright reports receiving consulting fees from DePuy Orthopedics. Dr. R. Wright reports receiving consulting fees from Flexion Therapeutics and ISTO Technologies, and grant support through his institution from Smith and Nephew. No other potential conflict of interest relevant to this article was reported.	Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; Angst F, 2002, J RHEUMATOL, V29, P131; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bhattacharyya T, 2003, J BONE JOINT SURG AM, V85A, P4, DOI 10.2106/00004623-200301000-00002; Englund M, 2004, ARTHRITIS RHEUM-US, V50, P2811, DOI 10.1002/art.20489; Englund M, 2008, NEW ENGL J MED, V359, P1108, DOI 10.1056/NEJMoa0800777; Englund M, 2009, ARTHRITIS RHEUM-US, V60, P831, DOI 10.1002/art.24383; Fransen M, 2008, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD004376.PUB2; Fransen M, 2009, J RHEUMATOL, V36, P1109, DOI 10.3899/jrheum.090058; Frobell RB, 2010, NEW ENGL J MED, V363, P893; Frobell RB, 2010, NEW ENGL J MED, V363, P331, DOI 10.1056/NEJMoa0907797; Guermazi A, 2012, SKELETAL RADIOL, V41, P179, DOI 10.1007/s00256-011-1142-2; Herrlin S, 2007, KNEE SURG SPORT TR A, V15, P393, DOI 10.1007/s00167-006-0243-2; Herrlin SV, 2013, KNEE SURG SPORT TR A, V21, P358, DOI 10.1007/s00167-012-1960-3; Katz JN, 2012, CONTEMP CLIN TRIALS, V33, P1189, DOI 10.1016/j.cct.2012.08.010; Katz JN, 2011, J CLIN EPIDEMIOL, V64, P280, DOI 10.1016/j.jclinepi.2010.04.008; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Kim S, 2011, J BONE JOINT SURG AM, V93A, P994, DOI 10.2106/JBJS.I.01618; Kirkley A, 2009, NEW ENGL J MED, V361, P2004; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; Mills PM, 2008, OSTEOARTHR CARTILAGE, V16, P1526, DOI 10.1016/j.joca.2008.04.014; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Niu NNN, 2011, ARTHRIT CARE RES, V63, P208, DOI 10.1002/acr.20354; Papalia R, 2011, BRIT MED BULL, V99, P89, DOI 10.1093/bmb/ldq043; Roos EM, 1998, J ORTHOP SPORT PHYS, V28, P88, DOI 10.2519/jospt.1998.28.2.88; Roos EM, 1998, SCAND J MED SCI SPOR, V8, P439, DOI 10.1111/j.1600-0838.1998.tb00465.x; Sowers M, 2011, J BONE JOINT SURG AM, V93A, P241, DOI 10.2106/JBJS.I.00667; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinstein JN, 2008, NEW ENGL J MED, V358, P794, DOI 10.1056/NEJMoa0707136	31	404	411	9	112	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	2013	368	18					1675	1684		10.1056/NEJMoa1301408	http://dx.doi.org/10.1056/NEJMoa1301408			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134MN	23506518	Green Accepted			2023-01-03	WOS:000318214400001
J	Mendelsohn, BA				Mendelsohn, Bryce A.			What Is Natural?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Mendelsohn, BA (corresponding author), Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.	mendelsohnb@peds.ucsf.edu							0	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2013	309	17					1783	1784		10.1001/jama.2012.205105	http://dx.doi.org/10.1001/jama.2012.205105			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134SU	23632721				2023-01-03	WOS:000318235600025
J	Noronha, V; Prabhash, K; Thavamani, A; Chougule, A; Purandare, N; Joshi, A; Sharma, R; Desai, S; Jambekar, N; Dutt, A; Mulherkar, R				Noronha, Vanita; Prabhash, Kumar; Thavamani, Abhishek; Chougule, Anuradha; Purandare, Nilendu; Joshi, Amit; Sharma, Rashmi; Desai, Saral; Jambekar, Nirmala; Dutt, Amit; Mulherkar, Rita			EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy	PLOS ONE			English	Article							ACTIVATING MUTATIONS; NEVER-SMOKERS; GEFITINIB; CHEMOTHERAPY	Screening for EGFR mutation is a key molecular test for management of lung cancer patients. Outcome of patients with mutation receiving EGFR tyrosine kinase inhibitor is known to be better across different ethnic populations. However, frequency of EGFR mutations and the clinical response in most other ethnic populations, including India, remains to be explored. We conducted a retrospective analysis of Indian lung cancer patients who were managed with oral tyrosine kinase inhibitors. Majority of the patients in the study had adenocarcinoma and were non-smokers. 39/111 patients tested positive for EGFR kinase domain mutations determined by Taqman based real time PCR. The overall response to oral TKI therapy was 30%. Patients with an activating mutation of EGFR had a response rate of 74%, while the response rate in patients with wild type EGFR was 5%, which was a statistically significant difference. Progression free survival of patients with EGFR mutations was 10 months compared to 2 months for EGFR mutation negative patients. Overall survival was 19 months for EGFR mutation patients and 13 months for mutation negative patients. This study emphasizes EGFR mutation as an important predictive marker for response to oral tyrosine kinase inhibitors in the Indian population.	[Noronha, Vanita; Prabhash, Kumar; Thavamani, Abhishek; Chougule, Anuradha; Joshi, Amit; Sharma, Rashmi] Tata Mem Hosp, Tata Mem Ctr, Dept Med Oncol, Bombay 400012, Maharashtra, India; [Purandare, Nilendu] Tata Mem Hosp, Tata Mem Ctr, Dept Radiol, Bombay 400012, Maharashtra, India; [Desai, Saral; Jambekar, Nirmala] Tata Mem Hosp, Tata Mem Ctr, Dept Pathol, Bombay 400012, Maharashtra, India; [Dutt, Amit; Mulherkar, Rita] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Navi Mumbai, India	Tata Memorial Centre (TMC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Hospital	Prabhash, K (corresponding author), Tata Mem Hosp, Tata Mem Ctr, Dept Med Oncol, Bombay 400012, Maharashtra, India.	kprabhash1@gmail.com; adutt@actrec.gov.in	Dutt, Amit/I-1911-2013; Thavamani, Abhishek/I-3207-2018	Dutt, Amit/0000-0002-1119-4774; Thavamani, Abhishek/0000-0001-7187-9188	Wellcome Trust/Department of Biotechnology India Alliance	Wellcome Trust/Department of Biotechnology India Alliance	A.D. is supported by an Intermediate fellowship from the Wellcome Trust/Department of Biotechnology India Alliance. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cortes-Funes H, 2005, ANN ONCOL, V16, P1081, DOI 10.1093/annonc/mdi221; Dong J, 2012, NAT GENET, V44, P895, DOI 10.1038/ng.2351; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Han JY, 2012, J CLIN ONCOL, V30, P1122, DOI 10.1200/JCO.2011.36.8456; Krishnamurthy A, 2012, INDIAN J CANCER, V49, P82, DOI 10.4103/0019-509X.98928; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Noronha V, 2012, INDIAN J CANCER, V49, P74, DOI 10.4103/0019-509X.98925; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Reinersman JM, 2011, J THORAC ONCOL, V6, P28, DOI 10.1097/JTO.0b013e3181fb4fe2; Sahoo R, 2011, LUNG CANCER, V73, P316, DOI 10.1016/j.lungcan.2011.01.004; Yang CH, 2008, J CLIN ONCOL, V26, P2745, DOI 10.1200/JCO.2007.15.6695; Zhang XT, 2005, ANN ONCOL, V16, P1334, DOI 10.1093/annonc/mdi340	16	47	47	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2013	8	4							e61561	10.1371/journal.pone.0061561	http://dx.doi.org/10.1371/journal.pone.0061561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JA	23620765	Green Published, Green Submitted, gold			2023-01-03	WOS:000317909500045
J	Berent, I; Dupuis, A; Brentari, D				Berent, Iris; Dupuis, Amanda; Brentari, Diane			Amodal Aspects of Linguistic Design	PLOS ONE			English	Article							AMERICAN SIGN-LANGUAGE; VISUAL WORD RECOGNITION; PHONOLOGICAL UNIVERSALS; GESTURAL COMMUNICATION; CATEGORICAL PERCEPTION; DEAF-CHILDREN; SYLLABLES; UNITS; CONSTRAINTS; COMPUTATION	All spoken languages encode syllables and constrain their internal structure. But whether these restrictions concern the design of the language system, broadly, or speech, specifically, remains unknown. To address this question, here, we gauge the structure of signed syllables in American Sign Language (ASL). Like spoken languages, signed syllables must exhibit a single sonority/energy peak (i.e., movement). Four experiments examine whether this restriction is enforced by signers and nonsigners. We first show that Deaf ASL signers selectively apply sonority restrictions to syllables (but not morphemes) in novel ASL signs. We next examine whether this principle might further shape the representation of signed syllables by nonsigners. Absent any experience with ASL, nonsigners used movement to define syllable-like units. Moreover, the restriction on syllable structure constrained the capacity of nonsigners to learn from experience. Given brief practice that implicitly paired syllables with sonority peaks (i.e., movement)-a natural phonological constraint attested in every human language-nonsigners rapidly learned to selectively rely on movement to define syllables and they also learned to partly ignore it in the identification of morpheme-like units. Remarkably, nonsigners failed to learn an unnatural rule that defines syllables by handshape, suggesting they were unable to ignore movement in identifying syllables. These findings indicate that signed and spoken syllables are subject to a shared phonological restriction that constrains phonological learning in a new modality. These conclusions suggest the design of the phonological system is partly amodal.	[Berent, Iris; Dupuis, Amanda] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA; [Brentari, Diane] Univ Chicago, Dept Linguist, Chicago, IL 60637 USA	Northeastern University; University of Chicago	Berent, I (corresponding author), Northeastern Univ, Dept Psychol, Boston, MA 02115 USA.	i.berent@neu.edu			National Institute on Deafness and Other Communication Disorders (NIDCD) grant [R01DC003277]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003277] Funding Source: NIH RePORTER	National Institute on Deafness and Other Communication Disorders (NIDCD) grant; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This research was supported by National Institute on Deafness and Other Communication Disorders (NIDCD) grant R01DC003277 to IB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2004, PHONETICALLY BASED P; Aronoff M, 2005, LANGUAGE, V81, P301, DOI 10.1353/lan.2005.0043; Ashby J, 2004, LANG COGNITIVE PROC, V19, P391, DOI 10.1080/01690960344000233; Baker SA, 2005, MEM COGNITION, V33, P887, DOI 10.3758/BF03193083; Baker SA, 2006, LANG LEARN DEV, V2, P147, DOI 10.1207/s15473341lld0203_1; Berent I, 2005, J MEM LANG, V53, P342, DOI 10.1016/j.jml.2005.05.002; Berent I, 1997, COGNITION, V64, P39, DOI 10.1016/S0010-0277(97)00016-4; Berent I, 2001, COGNITIVE PSYCHOL, V42, P1, DOI 10.1006/cogp.2000.0742; Berent I, 2001, J MEM LANG, V44, P644, DOI 10.1006/jmla.2000.2760; Berent I., 2013, PHONOLOGICAL MIND; Berent I, 2008, P NATL ACAD SCI USA, V105, P5321, DOI 10.1073/pnas.0801469105; Berent I, 2007, COGNITION, V104, P591, DOI 10.1016/j.cognition.2006.05.015; Berent I, 2012, MENT LEX, V7, P275, DOI 10.1075/ml.7.3.02ber; Berent I, 2011, BRILL HANDB LINGUIST, V1, P373; Berent I, 2012, LANG SPEECH, V55, P311, DOI 10.1177/0023830911417804; Berent I, 2011, LANG ACQUIS, V18, P281, DOI 10.1080/10489223.2011.580676; Berent I, 2007, MENT LEX, V2, P129, DOI 10.1075/ml.2.2.03ber; Berent I, 2010, J EXP PSYCHOL GEN, V139, P418, DOI 10.1037/a0020094; Berent I, 2006, MENT LEX, V1, P201, DOI 10.1075/ml.1.2.03ber; Berent I, 2010, J EXP PSYCHOL HUMAN, V36, P212, DOI 10.1037/a0017638; Berent I, 2009, PHONOLOGY, V26, P75, DOI 10.1017/S0952675709001729; BERTONCINI J, 1981, INFANT BEHAV DEV, V4, P247, DOI 10.1016/S0163-6383(81)80027-6; Best CT, 2010, ATTEN PERCEPT PSYCHO, V72, P747, DOI 10.3758/APP.72.3.747; Brentari D, 2012, NATURAL LANGUAGE LIN, V30; Brentari D., 1993, PHONOLOGY, V10, P281, DOI [10.1017/S0952675700000063, DOI 10.1017/S0952675700000063]; Brentari D, 2010, SIGN LANGUAGES; Brentari D, 1994, SIGN LANGUAGE RES, P39; BRENTARI D., 2006, PAPERS LAB PHONOLOGY, P155; Brentari D, 1998, PROSODIC MODEL SIGN, Vxviii; Brentari D, 2011, LANG SPEECH, V54, P49, DOI 10.1177/0023830910388011; CARREIRAS M, 1993, J MEM LANG, V32, P766, DOI 10.1006/jmla.1993.1038; Cholin J, 2011, BRILL HANDB LINGUIST, V1, P225; Clements G.N., 1990, PAPERS LAB PHONOLOGY, P283, DOI [10.1017/CBO9780511627736.017, DOI 10.1017/CBO9780511627736.017]; Coetzee AW, 2011, BRILL HANDB LINGUIST, V1, P295; Conrad M, 2009, J EXP PSYCHOL HUMAN, V35, P461, DOI 10.1037/a0013480; Corina D., 1993, PHONOLOGY, V10, P165, DOI [10.1017/S0952675700000038, DOI 10.1017/S0952675700000038]; Corina D. P., 1990, 26 ANN REG M CHIC LI, V2, P33; Corina DP, 2003, J COGNITIVE NEUROSCI, V15, P718, DOI 10.1162/jocn.2003.15.5.718; Corina DP, 1999, NEUROIMAGE, V10, P570, DOI 10.1006/nimg.1999.0499; De Lacy P, 2006, CAMB STUD LINGUIST, V112, pXI, DOI 10.1017/CBO9780511486388.001; Emmorey K, 2003, LANG COGNITIVE PROC, V18, P21, DOI 10.1080/01690960143000416; Emmorey K., 2002, LANGUAGE COGNITION B; Emmorey K, 2007, NEUROIMAGE, V36, P202, DOI 10.1016/j.neuroimage.2007.02.040; Fitch WT, 2005, COGNITION, V97, P179, DOI 10.1016/j.cognition.2005.02.005; Goldin-Meadow S, 1998, NATURE, V391, P279, DOI 10.1038/34646; Goldin-Meadow S., 2003, RESILIENCE LANGUAGE; GOLDINMEADOW S, 1983, SCIENCE, V221, P372, DOI 10.1126/science.6867713; Hildebrandt U, 2002, LANG COGNITIVE PROC, V17, P593, DOI 10.1080/01690960143000371; HOCKETT CF, 1960, SCI AM, V203, P88, DOI 10.1038/scientificamerican0960-88; Jaeger TF, 2008, J MEM LANG, V59, P434, DOI 10.1016/j.jml.2007.11.007; Jantunen T., 2010, SIGN LANGUAGES, P312, DOI [10.1017/CBO9780511712203.015, DOI 10.1017/CBO9780511712203.015]; Klima E.S., 1979, SIGNS LANGUAGE; LANE H, 1976, COGNITIVE PSYCHOL, V8, P263, DOI 10.1016/0010-0285(76)90027-X; LIDDELL SK, 1986, NAT LANG LINGUIST TH, V4, P445, DOI 10.1007/BF00134470; MacNeilage P. F., 2008, ORIGIN SPEECH, pxi; MacSweeney M, 2004, NEUROIMAGE, V22, P1605, DOI 10.1016/j.neuroimage.2004.03.015; MacSweeney M, 2008, NEUROIMAGE, V40, P1369, DOI 10.1016/j.neuroimage.2007.12.047; Mathur G, 2011, DEAF WORLD IMPACT LA, P54; McCarthy JJ., 1998, HDB MORPHOLOGY, P283; Newman AJ, 2010, NEUROIMAGE, V52, P669, DOI 10.1016/j.neuroimage.2010.03.055; Newport E. L, 1982, LANG ACQUIS, P450; Nishimura H, 1999, NATURE, V397, P116, DOI 10.1038/16376; Ohala DK, 1999, J COMMUN DISORD, V32, P397, DOI 10.1016/S0021-9924(99)00018-0; OHALA JJ, 1990, CLS 26, V2, P319; Orfanidou E, 2010, J MEM LANG, V62, P272, DOI 10.1016/j.jml.2009.12.001; Palmer SB, 2012, CHILD DEV, V83, P543, DOI 10.1111/j.1467-8624.2011.01715.x; Parker Stephen, 2002, THESIS U MASSACHUSET; PERLMUTTER DM, 1992, LINGUIST INQ, V23, P407; PERTZ DL, 1975, LANGUAGE, V51, P149, DOI 10.2307/413156; Petitto LA, 2000, P NATL ACAD SCI USA, V97, P13961, DOI 10.1073/pnas.97.25.13961; Petitto LA, 2001, NATURE, V413, P35, DOI 10.1038/35092613; Pfau R., 2012, SIGN LANGUAGE INT HD, DOI [10.1515/9783110261325, DOI 10.1515/9783110261325]; Pinker S, 2005, COGNITION, V95, P201, DOI 10.1016/j.cognition.2004.08.004; Pinker S, 1997, NATURE, V387, P547, DOI 10.1038/42347; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Prince Alan., 2004, OPTIMALITY THEORY CO; Sandler W, 2005, P NATL ACAD SCI USA, V102, P2661, DOI 10.1073/pnas.0405448102; Sandler W, 2006, SIGN LANGUAGE AND LINGUISTIC UNIVERSALS, P1, DOI 10.2277/ 0521483956; Sandler W, 2008, SYLLABLE SPEECH PROD, P379; Sandler W, 2011, NAT LANG LINGUIST TH, V29, P503, DOI 10.1007/s11049-011-9128-2; Senghas A, 2004, SCIENCE, V305, P1779, DOI 10.1126/science.1100199; Singleton JL, 2004, COGNITIVE PSYCHOL, V49, P370, DOI 10.1016/j.cogpsych.2004.05.001; Smolensky Paul, 2006, HARMONIC MIND NEURAL, P27; Steriade D, 1988, PHONOLOGY, V5, P37; Stokoe WC, 2005, J DEAF STUD DEAF EDU, V10, P3, DOI 10.1093/deafed/eni001; Supalla T.R., 1982, THESIS U SAN DIEGO S; TREIMAN R, 1995, J MEM LANG, V34, P132, DOI 10.1006/jmla.1995.1007; Wilbur R, 2012, BLACKWELL COMPANION, P1309; WILBUR RB, 1986, LANG SPEECH, V29, P263, DOI 10.1177/002383098602900306; WILBUR RB, 1991, LANG SPEECH, V34, P27, DOI 10.1177/002383099103400102; Wilbur RB, 1997, LANG SPEECH, V40, P63, DOI 10.1177/002383099704000104; Zec D, 2007, CAMBRIDGE HANDBOOK OF PHONOLOGY, P161	92	23	23	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2013	8	4							e60617	10.1371/journal.pone.0060617	http://dx.doi.org/10.1371/journal.pone.0060617			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	143BA	23573272	Green Published, Green Submitted, gold			2023-01-03	WOS:000318840100091
J	Silverman, E				Silverman, Ed			DRUG COMPANIES Big brand pharma on the hook for generic problems	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												pharmalot@gmail.com							0	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 28	2013	346								f1978	10.1136/bmj.f1978	http://dx.doi.org/10.1136/bmj.f1978			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	117XI	23538929				2023-01-03	WOS:000316986200013
J	Corcoran, MJ; Wetherbee, BM; Shivji, MS; Potenski, MD; Chapman, DD; Harvey, GM				Corcoran, Mark J.; Wetherbee, Bradley M.; Shivji, Mahmood S.; Potenski, Matthew D.; Chapman, Demian D.; Harvey, Guy M.			Supplemental Feeding for Ecotourism Reverses Diel Activity and Alters Movement Patterns and Spatial Distribution of the Southern Stingray, Dasyatis americana	PLOS ONE			English	Article							HOME-RANGE SIZE; BEHAVIOR; WILDLIFE; DENSITY; ORGANIZATION; POPULATION; RESPONSES; RESOURCE; TOURISM; BIOMASS	Southern stingrays, Dasyatis americana, have been provided supplemental food in ecotourism operations at Stingray City Sandbar (SCS), Grand Cayman since 1986, with this site becoming one of the world's most famous and heavily visited marine wildlife interaction venues. Given expansion of marine wildlife interactive tourism worldwide, there are questions about the effects of such activities on the focal species and their ecosystems. We used a combination of acoustic telemetry and tag-recapture efforts to test the hypothesis that human-sourced supplemental feeding has altered stingray activity patterns and habitat use at SCS relative to wild animals at control sites. Secondarily, we also qualitatively estimated the population size of stingrays supporting this major ecotourism venue. Tag-recapture data indicated that a population of at least 164 stingrays, over 80% female, utilized the small area at SCS for prolonged periods of time. Examination of comparative movements of mature female stingrays at SCS and control sites revealed strong differences between the two groups: The fed animals demonstrated a notable inversion of diel activity, being constantly active during the day with little movement at night compared to the nocturnally active wild stingrays; The fed stingrays utilized significantly (p<0.05) smaller 24 hour activity spaces compared to wild conspecifics, staying in close proximity to the ecotourism site; Fed stingrays showed a high degree of overlap in their core activity spaces compared to wild stingrays which were largely solitary in the spaces utilized (72% vs. 3% overlap respectively). Supplemental feeding has strikingly altered movement behavior and spatial distribution of the stingrays, and generated an atypically high density of animals at SCS which could have downstream fitness costs for individuals and potentially broader ecosystem effects. These findings should help environmental managers plan mitigating measures for existing operations, and develop precautionary policies regarding proposed feeding sites.	[Corcoran, Mark J.; Wetherbee, Bradley M.; Shivji, Mahmood S.; Potenski, Matthew D.; Chapman, Demian D.; Harvey, Guy M.] Nova SE Univ, Guy Harvey Res Inst, Dania, FL USA; [Wetherbee, Bradley M.] Univ Rhode Isl, Dept Biol Sci, Kingston, RI 02881 USA	Nova Southeastern University; University of Rhode Island	Shivji, MS (corresponding author), Nova SE Univ, Guy Harvey Res Inst, Dania, FL USA.	mahmood@nova.edu			Guy Harvey Research Institute; Guy Harvey Ocean Foundation; PADI Project Aware; Nova Southeastern University Oceanographic Center; Honda Marine; Digital Angel Corporation	Guy Harvey Research Institute; Guy Harvey Ocean Foundation; PADI Project Aware; Nova Southeastern University Oceanographic Center; Honda Marine; Digital Angel Corporation	This research was supported by the Guy Harvey Research Institute, the Guy Harvey Ocean Foundation, PADI Project Aware and Nova Southeastern University Oceanographic Center. Additional equipment was provided by Honda Marine and Digital Angel Corporation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors declare that some funding (equipment) for this study was received from commercial sources (Honda Marine and Digital Angel Corporation), and confirm that this commercial funding does not alter their adherence to all the PLOS ONE policies on sharing data and materials.	[Anonymous], 2004, ANAL TIME SERIES INT, DOI DOI 10.20950/1678-2305.2018.187; [Anonymous], 2000, ECOTOURISM STAT FACT; ASQUITH PJ, 1989, YEARB PHYS ANTHROPOL, V32, P129; Bejder L, 2006, CONSERV BIOL, V20, P1791, DOI 10.1111/j.1523-1739.2006.00540.x; Bjorge A, 2002, MAR MAMMAL SCI, V18, P438, DOI 10.1111/j.1748-7692.2002.tb01047.x; BOUTIN S, 1990, CAN J ZOOL, V68, P203, DOI 10.1139/z90-031; Carpenter KE., 2002, SPECIAL PUBLICATION, P508; Cartamil DP, 2003, MAR BIOL, V142, P841, DOI 10.1007/s00227-003-1014-y; Chapman DD, 2003, ENVIRON BIOL FISH, V68, P241, DOI 10.1023/A:1027332113894; Clua E, 2010, MAR ECOL PROG SER, V414, P257, DOI 10.3354/meps08746; COLE RG, 1994, BIOL CONSERV, V70, P93, DOI 10.1016/0006-3207(94)90276-3; D'Andrea AF, 2004, J MAR RES, V62, P67, DOI 10.1357/00222400460744627; Dill LM, 2003, MAR MAMMAL SCI, V19, P650, DOI 10.1111/j.1748-7692.2003.tb01122.x; DUFFUS DA, 1990, BIOL CONSERV, V53, P213, DOI 10.1016/0006-3207(90)90087-6; Eifler DA, 1996, HERPETOLOGICA, V52, P477; Ewer RF, 1968, ETHNOLOGY MAMMALS; Ferguson A, 2007, AQUAT MICROB ECOL, V48, P175, DOI 10.3354/ame048175; Ferreras P, 1997, J ZOOL, V243, P163, DOI 10.1111/j.1469-7998.1997.tb05762.x; Fitzpatrick R, 2011, CORAL REEFS, V30, P569, DOI 10.1007/s00338-011-0769-8; Gaspar C, 2008, CYBIUM, V32, P153; GILLIAM D, 1993, B MAR SCI, V52, P1007; Guttridge TL, 2013, ANIM COGN, V16, P55, DOI 10.1007/s10071-012-0550-6; Hawkins JP, 1999, CONSERV BIOL, V13, P888, DOI 10.1046/j.1523-1739.1999.97447.x; Herfindal I, 2005, J ZOOL, V265, P63, DOI 10.1017/S0952836904006053; Higham J, 2008, MARINE WILDLIFE AND TOURISM MANAGEMENT: INSIGHTS FROM THE NATURAL AND SOCIAL SCIENCES, P1, DOI 10.1079/9781845933456.0001; Hines AH, 1997, J EXP MAR BIOL ECOL, V216, P191, DOI 10.1016/S0022-0981(97)00096-8; HOLLAND KN, 1993, COPEIA, P495, DOI 10.2307/1447150; IMS RA, 1987, J ANIM ECOL, V56, P585, DOI 10.2307/5070; KOFORD RR, 1992, J MAMMAL, V73, P930, DOI 10.2307/1382218; Kronfeld-Schor N, 2003, ANNU REV ECOL EVOL S, V34, P153, DOI 10.1146/annurev.ecolsys.34.011802.132435; Laroche RK, 2007, MAR ECOL PROG SER, V338, P199, DOI 10.3354/meps338199; Linares F, 2006, J EXP MAR BIOL ECOL, V330, P469, DOI 10.1016/j.jembe.2005.09.012; Loveridge AJ, 2009, ECOGRAPHY, V32, P953, DOI 10.1111/j.1600-0587.2009.05745.x; Lyndaker S, 1987, THESIS COLORADO STAT; Maljkovic A, 2011, BIOL CONSERV, V144, P859, DOI 10.1016/j.biocon.2010.11.019; Metcalfe NB, 1999, J ANIM ECOL, V68, P371, DOI 10.1046/j.1365-2656.1999.00289.x; Milazzo M, 2005, MAR BIOL, V146, P1213, DOI 10.1007/s00227-004-1527-z; Milazzo M, 2006, MAR ECOL PROG SER, V310, P165, DOI 10.3354/meps310165; Mitchell MS, 2004, ECOL MODEL, V177, P209, DOI 10.1016/j.ecolmodel.2004.01.015; MONAGHAN P, 1985, ANIM BEHAV, V33, P993, DOI 10.1016/S0003-3472(85)80033-6; Moreau MA, 2004, MAR FRESHWATER RES, V55, P231, DOI 10.1071/MF03159; NELSON M, 1995, SWIM RAYS GUIDE STIN; Newsome D., 2004, International Journal of Tourism Research, V6, P305, DOI 10.1002/jtr.491; Newsome D, 2008, TOO CLOSE FOR COMFORT : CONTENTIOUS ISSUES IN HUMAN-WILDLIFE ENCOUNTERS, P255; Orams MB, 2002, TOURISM MANAGE, V23, P281, DOI 10.1016/S0261-5177(01)00080-2; OSTFELD RS, 1986, J ANIM ECOL, V55, P691, DOI 10.2307/4748; Ryan C., 1998, Journal of Sustainable Tourism, V6, P314, DOI 10.1080/09669589808667319; Samson C, 2001, CAN J ZOOL, V79, P633, DOI 10.1139/cjz-79-4-633; SAMUEL MD, 1985, J ANIM ECOL, V54, P711, DOI 10.2307/4373; Semeniuk CAD, 2008, MAR ECOL PROG SER, V357, P271, DOI 10.3354/meps07299; Semeniuk CAD, 2007, ENVIRON MANAGE, V40, P665, DOI 10.1007/s00267-006-0321-8; Semeniuk CAD, 2009, BIOL CONSERV, V142, P1818, DOI 10.1016/j.biocon.2009.03.022; Shackley M., 1998, Journal of Sustainable Tourism, V6, P328, DOI 10.1080/09669589808667320; SNELSON FF, 1988, COPEIA, P729; STRONG WR, 1990, COPEIA, P836, DOI 10.2307/1446449; SULLIVAN TP, 1990, J MAMMAL, V71, P579, DOI 10.2307/1381797; THRUSH SF, 1991, MAR ECOL PROG SER, V69, P245, DOI 10.3354/meps069245; Wetherbee BM, 2001, REV METHODS TECHNOLO, V1, P249; Youth H, 2000, WORLD WATCH, P12	59	79	80	0	98	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2013	8	3							e59235	10.1371/journal.pone.0059235	http://dx.doi.org/10.1371/journal.pone.0059235			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	109ZS	23527144	Green Published, Green Submitted, gold			2023-01-03	WOS:000316411600053
J	Hong, SY; Jerger, L; Jonas, A; Badi, A; Cohen, S; Nachega, JB; Parienti, JJ; Tang, AM; Wanke, C; Terrin, N; Pereko, D; Blom, A; Trotter, AB; Jordan, MR				Hong, Steven Y.; Jerger, Logan; Jonas, Anna; Badi, Alfons; Cohen, Steven; Nachega, Jean B.; Parienti, Jean-Jacques; Tang, Alice M.; Wanke, Christine; Terrin, Norma; Pereko, Dawn; Blom, Abraham; Trotter, Andrew B.; Jordan, Michael R.			Medication Possession Ratio Associated with Short-Term Virologic Response in Individuals Initiating Antiretroviral Therapy in Namibia	PLOS ONE			English	Article							HIV-INFECTED ADULTS; VIRAL LOAD; ASSESS ADHERENCE; SOUTH-AFRICA; SELF-REPORT; BASE-LINE; RESISTANCE; FAILURE; SUPPRESSION; PREDICTORS	The visual-analogue scale (VAS), Likert item (rating scale), pills identification test (PIT), and medication possession ratio (MPR) provide estimates of antiretroviral therapy (ART) adherence which correlate with HIV viral suppression. These simple adherence measures are inexpensive and easy to administer; however, require validation and adjustment prior to implementation. The objective of this study was to define the optimal adherence assessment measure in Namibia to identify patients at risk for sub-optimal adherence and poor virologic response 6 months after ART initiation. We conducted a cross-sectional survey in HIV-infected adults receiving ART for 6-12 months prior to the adherence assessment. Adherence measures included 30-day VAS, 30-day Likert item, self-reported treatment interruptions, PIT, and MPR. Association of adherence measures with 6-month HIV-1 RNA level was assessed using two thresholds (1000 copies/mL and 5000 copies/mL). Adherence was assessed in 236 patients, mean age 37.3 years, 54% female. Mean adherence was 98.1% by 30-day VAS, 84.7% by 30-day Likert item, 97.0% by self-reported treatment interruptions, 90.6% by PIT, and 98.8% by MPR. Agreement between adherence measures was poor using kappa statistic. 76% had HIV-1 RNA <1000 copies/ml, and 88% had HIV-1 RNA <5000 copies/ml. MPR (continuous) was associated with viral suppression <5000 copies/ml (p = 0.036). MPR <75% was associated with virologic failure at >= 5000 copies/ml with OR 3.89 (1.24, 12.21), p = 0.013. Adherence was high with all measures. Only MPR, was associated with short-term virologic response, suggesting its cross-culturally utility for early identification of patients at high risk for virologic failure.	[Hong, Steven Y.; Wanke, Christine; Trotter, Andrew B.; Jordan, Michael R.] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA USA; [Hong, Steven Y.; Jerger, Logan; Cohen, Steven; Tang, Alice M.; Wanke, Christine; Trotter, Andrew B.; Jordan, Michael R.] Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA; [Jonas, Anna; Badi, Alfons; Blom, Abraham] Republ Namibia Minist Hlth & Social Serv, Directorate Special Programmes, Windhoek, Namibia; [Nachega, Jean B.] Johns Hopkins Univ, Ctr Global Hlth, Baltimore, MD USA; [Nachega, Jean B.] Univ Stellenbosch, Fac Hlth Sci, Ctr Infect Dis, Cape Town, South Africa; [Parienti, Jean-Jacques] Univ Hosp Ctr, Dept Biostat & Clin Res, Caen, France; [Terrin, Norma] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA USA; [Pereko, Dawn] ABT Associates Inc, Strengthening Hlth Outcomes Private Sector, Windhoek, Namibia	Tufts Medical Center; Massachusetts Department of Public Health; Tufts University; Johns Hopkins University; Stellenbosch University; CHU de Caen NORMANDIE; Tufts Medical Center; ABT Associates	Hong, SY (corresponding author), Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA USA.	shong@tuftsmedicalcenter.org	Parienti, Jean-Jacques/AAD-1701-2021	Parienti, Jean-Jacques/0000-0002-4774-5590; Trotter, Andrew/0000-0001-7069-2979; Nachega, Jean/0000-0002-2862-4443	National Institutes of Health (NIH) [K23 AI074423-05, L30 AI080268-02, 1K23AI097010-01A1];  [T32 AI007438-18]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007438, K23AI097010, K23AI074423, P30AI042853] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by T32 AI007438-18 (ABT), National Institutes of Health (NIH) K23 AI074423-05 (MRJ), and NIH L30 AI080268-02 (SYH), and NIH 1K23AI097010-01A1 (SYH). Publication expenses for this manuscript were supported in part by a gift from the Christine E. Driscoll O'Neill and James M. Driscoll, Driscoll-O'Neill Charitable Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], WORLD FACTB; Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201; Bangsberg DR, 2006, AIDS, V20, P223, DOI 10.1097/01.aids.0000199825.34241.49; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Bisson GP, 2008, PLOS MED, V5, P777, DOI 10.1371/journal.pmed.0050109; Goldman JD, 2008, AIDS RES HUM RETROV, V24, P1031, DOI 10.1089/aid.2008.0035; Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Jordan MR, 2008, ANTIVIR THER, V13, P15; Low-Beer S, 2000, J ACQ IMMUN DEF SYND, V23, P360; Luca D, 2011, J ACQUIR IMMUNE DEFI; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Maneesriwongul WL, 2006, JAIDS-J ACQ IMM DEF, V43, pS119, DOI 10.1097/01.qai.0000248346.79888.78; Martin M, 2008, AIDS RES HUM RETROV, V24, P1263, DOI 10.1089/aid.2008.0141; McMahon JH, 2011, CLIN INFECT DIS, V52, P493, DOI 10.1093/cid/ciq167; Messou E, 2011, JAIDS-J ACQ IMM DEF, V56, P356, DOI 10.1097/QAI.0b013e3182084b5a; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Nachega JB, 2004, AIDS RES HUM RETROV, V20, P1053, DOI 10.1089/aid.2004.20.1053; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, P78, DOI 10.1097/01.qai.0000225015.43266.46; Orrell C, 2003, AIDS, V17, P1369, DOI 10.1097/00002030-200306130-00011; Oyugi JH, 2007, AIDS, V21, P965, DOI 10.1097/QAD.0b013e32802e6bfa; Oyugi JH, 2004, JAIDS-J ACQ IMM DEF, V36, P1100, DOI 10.1097/00126334-200408150-00014; Parienti JJ, 2004, CLIN INFECT DIS, V38, P1311, DOI 10.1086/383572; Parienti JJ, 2001, JAMA-J AM MED ASSOC, V285, P412, DOI 10.1001/jama.285.4.412; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Republic of Namibia Ministry of Health and Social Services Directorate of Special Programmes, 2010, NAT GUID ANT THER; ROTH HP, 1978, CLIN PHARMACOL THER, V23, P361; Shuter J, 2007, JAIDS-J ACQ IMM DEF, V45, P4, DOI 10.1097/QAI.0b013e318050d8c2; Simoni JM, 2006, AIDS BEHAV, V10, P227, DOI 10.1007/s10461-006-9078-6; The Republic of Namibia Ministry of Health and Social Services, 2010, REP 2010 NAT HIV SEN; UNAIDS, 2012, TOG WE WILL END AIDS; WHO, 2010, ANT THER HIV INF AD; WHO UNAIDS, 2011, UN ACC SCAL PRIOR HI; Wood E, 2006, AIDS, V20, P1117, DOI 10.1097/01.aids.0000226951.49353.ed	35	26	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e56307	10.1371/journal.pone.0056307	http://dx.doi.org/10.1371/journal.pone.0056307			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23509605	Green Published, gold			2023-01-03	WOS:000315524900022
J	Longbottom, D; Livingstone, M; Maley, S; van der Zon, A; Rocchi, M; Wilson, K; Wheelhouse, N; Dagleish, M; Aitchison, K; Wattegedera, S; Nath, M; Entrican, G; Buxton, D				Longbottom, David; Livingstone, Morag; Maley, Stephen; van der Zon, Arjan; Rocchi, Mara; Wilson, Kim; Wheelhouse, Nicholas; Dagleish, Mark; Aitchison, Kevin; Wattegedera, Sean; Nath, Mintu; Entrican, Gary; Buxton, David			Intranasal Infection with Chlamydia abortus Induces Dose-Dependent Latency and Abortion in Sheep	PLOS ONE			English	Article							OVINE ENZOOTIC ABORTION; BLOOD MONONUCLEAR-CELLS; CHLAMYDOPHILA-ABORTUS; PSITTACI INFECTION; PLACENTAL TISSUES; IMMUNE-RESPONSES; PREGNANT SHEEP; PATHOGENESIS; IDENTIFICATION; KINETICS	Background: Latency is a key feature of the animal pathogen Chlamydia abortus, where infection remains inapparent in the non-pregnant animal and only becomes evident during a subsequent pregnancy. Often the first sign that an animal is infected is abortion occurring late in gestation. Despite this, little is understood of the underlying mechanisms that control latency or the recrudescence of infection that occurs during subsequent pregnancy. The aim of this study was to develop an experimental model of latency by mimicking the natural route of infection through the intranasal inoculation of nonpregnant sheep with C. abortus. Methodology/Principal Findings: Three groups of sheep (groups 1, 2 and 3) were experimentally infected with different doses of C. abortus (5x10(3), 5x10(5) and 5x10(7) inclusion forming units (IFU), respectively) prior to mating and monitored over 2 breeding cycles for clinical, microbiological, pathological, immunological and serological outcomes. Two further groups received either negative control inoculum (group 4a,b) or were inoculated subcutaneously on day 70 of gestation with 2x10(6) IFU C. abortus (group 5). Animals in groups 1, 2 and 5 experienced an abortion rate of 50-67%, while only one animal aborted in group 3 and none in group 4a, b. Pathological, microbiological, immunological and serological analyses support the view that the maternal protective immune response is influenced by initial exposure to the bacterium. Conclusions/Significance: The results show that intranasal administration of non-pregnant sheep with a low/medium dose of C. abortus results in a latent infection that leads in a subsequent pregnancy to infection of the placenta and abortion. In contrast a high dose stimulates protective immunity, resulting in a much lower abortion rate. This model will be useful in understanding the mechanisms of infection underlying latency and onset of disease, as well as in the development of novel therapeutics and vaccines for controlling infection.	[Longbottom, David; Livingstone, Morag; Maley, Stephen; Rocchi, Mara; Wilson, Kim; Wheelhouse, Nicholas; Dagleish, Mark; Aitchison, Kevin; Wattegedera, Sean; Entrican, Gary; Buxton, David] Moredun Res Inst, Edinburgh EH17 7JH, Midlothian, Scotland; [van der Zon, Arjan] Univ Utrecht, Fac Vet Med, Utrecht, Netherlands; [Nath, Mintu] Biomath & Stat Scotland, Edinburgh, Midlothian, Scotland	Moredun Research Institute; Utrecht University; James Hutton Institute	Longbottom, D (corresponding author), Moredun Res Inst, 408 Gilmerton Rd, Edinburgh EH17 7JH, Midlothian, Scotland.	david.longbottom@moredun.ac.uk	Nath, M/J-3777-2013; Longbottom, David/GWZ-8448-2022	Longbottom, David/0000-0003-0086-8443; Wattegedera, Sean/0000-0002-2218-5144; Wheelhouse, Nick/0000-0002-2803-0055	Scottish Government Rural and Environment Science and Analytical Services Division; Biotechnology and Biological Sciences Research Council [BB/E018939/1]; BBSRC [BB/E018939/1] Funding Source: UKRI	Scottish Government Rural and Environment Science and Analytical Services Division; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by the Scottish Government Rural and Environment Science and Analytical Services Division (http://www.scotland.gov.uk) and by grant number BB/E018939/1 from the Biotechnology and Biological Sciences Research Council (http://www.bbsrc.ac.uk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aitken ID., 2007, DIS SHEEP, V4, P105, DOI [10.1002/9780470753316.ch16, DOI 10.1002/9780470753316.CH16]; ANDERSON IE, 1986, VET MICROBIOL, V12, P213, DOI 10.1016/0378-1135(86)90050-7; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Buxton D, 2002, J COMP PATHOL, V127, P133, DOI 10.1053/jcpa.2002.0573; Buxton D, 1996, J COMP PATHOL, V114, P221, DOI 10.1016/S0021-9975(96)80044-2; Buxton D., 2001, Research in Veterinary Science, V70, P22; BUXTON D, 1990, J COMP PATHOL, V102, P221, DOI 10.1016/S0021-9975(08)80127-2; Caro MR, 2009, VET MICROBIOL, V135, P103, DOI 10.1016/j.vetmic.2008.09.029; DAWSON M, 1986, RES VET SCI, V40, P59, DOI 10.1016/S0034-5288(18)30487-9; Entrican G, 2012, COMP IMMUNOL MICROB, V35, P271, DOI 10.1016/j.cimid.2011.12.001; Gutierrez J, 2011, VET MICROBIOL, V147, P119, DOI 10.1016/j.vetmic.2010.06.015; JONES GE, 1988, RES VET SCI, V44, P260, DOI 10.1016/S0034-5288(18)30852-X; Kerr K, 2005, RES VET SCI, V78, P1, DOI 10.1016/j.rvsc.2004.08.004; LITTLEJOHN A I, 1950, Vet Rec, V62, P571; Livingstone M, 2005, CLIN DIAGN LAB IMMUN, V12, P770, DOI 10.1128/CDLI.12.6.770-777.2005; Livingstone M, 2009, VET MICROBIOL, V135, P134, DOI 10.1016/j.vetmic.2008.09.033; Longbottom D, 2003, J COMP PATHOL, V128, P217, DOI 10.1053/jcpa.2002.0629; Maley SW, 2009, VET MICROBIOL, V135, P122, DOI 10.1016/j.vetmic.2008.09.031; MCCLENAGHAN M, 1984, INFECT IMMUN, V45, P384, DOI 10.1128/IAI.45.2.384-389.1984; McEWEN A. D., 1951, VET REC, V63, P197; McEWEN A. D., 1951, VET REC, V63, P489; Navarro JA, 2004, VET PATHOL, V41, P498, DOI 10.1354/vp.41-5-498; NOVILLA MN, 1970, AM J VET RES, V31, P1983; Papp JR, 1996, INFECT IMMUN, V64, P1116, DOI 10.1128/IAI.64.4.1116-1125.1996; Rocchi MS, 2009, VET MICROBIOL, V135, P112, DOI 10.1016/j.vetmic.2008.09.030; Sammin DJ, 2006, J COMP PATHOL, V135, P83, DOI 10.1016/j.jcpa.2006.04.005; SPENCER WN, 1983, VET REC, V113, P535; STAMP J. T., 1950, VET REC, V62, P251; Stanley AC, 2004, VACCINE, V22, P3929, DOI 10.1016/j.vaccine.2004.04.022; Stanley AC, 2001, J COMP PATHOL, V125, P262, DOI 10.1053/jcpa.2001.0506; STUDDERT MJ, 1968, RES VET SCI, V9, P57; Wattegedera S, 2008, J REPROD IMMUNOL, V77, P171, DOI 10.1016/j.jri.2007.07.003; Wattegedera S, 2004, VET IMMUNOL IMMUNOP, V102, P67, DOI 10.1016/j.vetimm.2004.06.006; Wattegedera SR, 2010, VET IMMUNOL IMMUNOP, V136, P34, DOI 10.1016/j.vetimm.2010.02.004; WILSMORE AJ, 1984, BRIT VET J, V140, P380, DOI 10.1016/0007-1935(84)90130-1; Wilson K, 2009, VET MICROBIOL, V135, P38, DOI 10.1016/j.vetmic.2008.09.043	36	48	50	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57950	10.1371/journal.pone.0057950	http://dx.doi.org/10.1371/journal.pone.0057950			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469113	Green Published, Green Submitted, gold			2023-01-03	WOS:000315524900208
J	Underwood, M; Lamb, SE; Eldridge, S; Sheehan, B; Slowther, AM; Spencer, A; Thorogood, M; Atherton, N; Bremner, SA; Devine, A; Diaz-Ordaz, K; Ellard, DR; Potter, R; Spanjers, K; Taylor, SJC				Underwood, Martin; Lamb, Sarah E.; Eldridge, Sandra; Sheehan, Bart; Slowther, Anne-Marie; Spencer, Anne; Thorogood, Margaret; Atherton, Nicky; Bremner, Stephen A.; Devine, Angela; Diaz-Ordaz, Karla; Ellard, David R.; Potter, Rachel; Spanjers, Kathleen; Taylor, Stephanie J. C.			Exercise for depression in elderly residents of care homes: a cluster-randomised controlled trial	LANCET			English	Article								Background Depression is common and is associated with poor outcomes among elderly care-home residents. Exercise is a promising low-risk intervention for depression in this population. We tested the hypothesis that a moderate intensity exercise programme would reduce the burden of depressive symptoms in residents of care homes. Methods We did a cluster-randomised controlled trial in care homes in two regions in England; northeast London, and Coventry and Warwickshire. Residents aged 65 years or older were eligible for inclusion. A statistician independent of the study randomised each home (1 to 1.5 ratio, stratified by location, minimised by type of home provider [ local authority, voluntary, private and care home, private and nursing home] and size of home [<32 or >= 32 residents]) into intervention and control groups. The intervention package included depression awareness training for care-home staff, 45 min physiotherapist-led group exercise sessions for residents (delivered twice weekly), and a whole home component designed to encourage more physical activity in daily life. The control consisted of only the depression awareness training. Researchers collecting follow-up data from individual participants and the participants themselves were inevitably aware of home randomisation because of the physiotherapists' activities within the home. A researcher masked to study allocation coded NHS routine data. The primary outcome was number of depressive symptoms on the geriatric depression scale-15 (GDS-15). Follow-up was for 12 months. This trial is registered with ISRCTN Register, number ISRCTN43769277. Findings Care homes were randomised between Dec 15, 2008, and April 9, 2010. At randomisation, 891 individuals in 78 care homes (35 intervention, 43 control) had provided baseline data. We delivered 3191 group exercise sessions attended on average by five study participants and five non-study residents. Of residents with a GDS-15 score, 374 of 765 (49%) were depressed at baseline; 484 of 765 (63%) provided 12 month follow-up scores. Overall the GDS-15 score was 0.13 (95% CI -0.33 to 0.60) points higher (worse) at 12 months for the intervention group compared with the control group. Among residents depressed at baseline, GDS-15 score was 0.22 (95% CI -0.52 to 0.95) points higher at 6 months in the intervention group than in the control group. In an end of study cross-sectional analysis, including 132 additional residents joining after randomisation, the odds of being depressed were 0.76 (95% CI 0.53 to 1.09) for the intervention group compared with the control group. Interpretation This moderately intense exercise programme did not reduce depressive symptoms in residents of care homes. In this frail population, alternative strategies to manage psychological symptoms are required.	[Underwood, Martin; Lamb, Sarah E.; Slowther, Anne-Marie; Atherton, Nicky; Ellard, David R.; Potter, Rachel; Spanjers, Kathleen] Univ Warwick, Warwick Med Sch, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England; [Thorogood, Margaret] Univ Warwick, Warwick Med Sch, Div Hlth Sci, Coventry CV4 7AL, W Midlands, England; [Sheehan, Bart] Univ Warwick, Warwick Med Sch, Div Mental Hlth & Wellbeing, Coventry CV4 7AL, W Midlands, England; [Eldridge, Sandra; Bremner, Stephen A.; Devine, Angela; Diaz-Ordaz, Karla; Taylor, Stephanie J. C.] Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England; [Spencer, Anne] Univ Exeter, Sch Med, Exeter, Devon, England	University of Warwick; University of Warwick; University of Warwick; University of London; Queen Mary University London; University of Exeter	Underwood, M (corresponding author), Univ Warwick, Div Hlth Sci, Warwick Med Sch, Warwick Clin Trials Unit, Coventry CV4 7AL, W Midlands, England.	m.underwood@warwick.ac.uk	TAYLOR, STEPHANIE/GYV-4768-2022; Bremner, Stephen/R-4038-2016; Underwood, Martin/D-6364-2015; Devine, Angela/A-6295-2012	Bremner, Stephen/0000-0003-0790-7070; Underwood, Martin/0000-0002-0309-1708; Devine, Angela/0000-0002-3321-8706; Eldridge, Sandra/0000-0001-5638-2317; Lamb, Sarah/0000-0003-4349-7195; Spencer, Anne/0000-0002-8163-3103; DiazOrdaz, Karla/0000-0003-3155-1561; Ellard, David/0000-0002-2992-048X; Taylor, Stephanie/0000-0001-7454-6354	National Institute for Health Research Health Technology Assessment; National Institute for Health Research [NF-SI-0512-10103, 06/02/01] Funding Source: researchfish	National Institute for Health Research Health Technology Assessment; National Institute for Health Research(National Institute for Health Research (NIHR))	National Institute for Health Research Health Technology Assessment.		0	77	82	0	66	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 6	2013	382	9886					41	49		10.1016/S0140-6736(13)60649-2	http://dx.doi.org/10.1016/S0140-6736(13)60649-2			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	177AD	23643112	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000321347000027
J	Sawyers, CL				Sawyers, Charles L.			PERSPECTIVE Combined forces	NATURE			English	Editorial Material							CHRONIC MYELOID-LEUKEMIA; MUTATIONS; IMATINIB		[Sawyers, Charles L.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA; [Sawyers, Charles L.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Sawyers, CL (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.		Sawyers, Charles/G-5327-2016					Cortes JE, 2012, NEW ENGL J MED, V367, P2075, DOI 10.1056/NEJMoa1205127; Experts in Chronic Myeloid Leukemia, 2013, BLOOD, V121, P4439; Mahon FX, 2010, LANCET ONCOL, V11, P1029, DOI 10.1016/S1470-2045(10)70233-3; Marin D, 2012, J CLIN ONCOL, V30, P232, DOI 10.1200/JCO.2011.38.6565; Shah NP, 2007, J CLIN INVEST, V117, P2562, DOI 10.1172/JCI30890; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X	6	11	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 27	2013	498	7455					S7	S7		10.1038/498S7a	http://dx.doi.org/10.1038/498S7a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171LH	23803949	Bronze			2023-01-03	WOS:000320929400004
J	Haider, BA; Olofin, I; Wang, ML; Spiegelman, D; Ezzati, M; Fawzi, WW				Haider, Batool A.; Olofin, Ibironke; Wang, Molin; Spiegelman, Donna; Ezzati, Majid; Fawzi, Wafaie W.		Nutr Impact Model Study Grp Anaemi	Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; LOW-DOSE IRON; MATERNAL HEMOGLOBIN; FOLIC-ACID; PRETERM DELIVERY; SERUM FERRITIN; PERINATAL-MORTALITY; NUTRITIONAL ANEMIA; PROSPECTIVE COHORT; RANDOMIZED-TRIAL	Objectives To summarise evidence on the associations of maternal anaemia and prenatal iron use with maternal haematological and adverse pregnancy outcomes; and to evaluate potential exposure-response relations of dose of iron, duration of use, and haemoglobin concentration in prenatal period with pregnancy outcomes. Design Systematic review and meta-analysis Data sources Searches of PubMed and Embase for studies published up to May 2012 and references of review articles. Study selection criteria Randomised trials of prenatal iron use and prospective cohort studies of prenatal anaemia; cross sectional and case-control studies were excluded. Results 48 randomised trials (17 793 women) and 44 cohort studies (1 851 682 women) were included. Iron use increased maternal mean haemoglobin concentration by 4.59 (95% confidence interval 3.72 to 5.46) g/L compared with controls and significantly reduced the risk of anaemia (relative risk 0.50, 0.42 to 0.59), iron deficiency (0.59, 0.46 to 0.79), iron deficiency anaemia (0.40, 0.26 to 0.60), and low birth weight (0.81, 0.71 to 0.93). The effect of iron on preterm birth was not significant (relative risk 0.84, 0.68 to 1.03). Analysis of cohort studies showed a significantly higher risk of low birth weight (adjusted odds ratio 1.29, 1.09 to 1.53) and preterm birth (1.21, 1.13 to 1.30) with anaemia in the first or second trimester. Exposure-response analysis indicated that for every 10 mg increase in iron dose/day, up to 66 mg/day, the relative risk of maternal anaemia was 0.88 (0.84 to 0.92) (P for linear trend<0.001). Birth weight increased by 15.1 (6.0 to 24.2) g (P for linear trend=0.005) and risk of low birth weight decreased by 3% (relative risk 0.97, 0.95 to 0.98) for every 10 mg increase in dose/day (P for linear trend<0.001). Duration of use was not significantly associated with the outcomes after adjustment for dose. Furthermore, for each 1 g/L increase in mean haemoglobin, birth weight increased by 14.0 (6.8 to 21.8) g (P for linear trend=0.002); however, mean haemoglobin was not associated with the risk of low birth weight and preterm birth. No evidence of a significant effect on duration of gestation, small for gestational age births, and birth length was noted. Conclusions Daily prenatal use of iron substantially improved birth weight in a linear dose-response fashion, probably leading to a reduction in risk of low birth weight. An improvement in prenatal mean haemoglobin concentration linearly increased birth weight.	[Haider, Batool A.; Olofin, Ibironke; Wang, Molin; Spiegelman, Donna; Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Haider, Batool A.; Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Wang, Molin] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Wang, Molin; Spiegelman, Donna] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London SW7 2AZ, England; [Fawzi, Wafaie W.] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Imperial College London; Harvard University; Harvard T.H. Chan School of Public Health	Haider, BA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	bah201@mail.harvard.edu	Lucas, Maria Tamires Barroso/H-9587-2015		Bill and Melinda Gates Foundation; Saving Brains Program, Grand Challenges Canada [0073-03]; Medical Research Council [G0801056B] Funding Source: researchfish	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Saving Brains Program, Grand Challenges Canada; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The Nutrition Impact Model Study was funded by the Bill and Melinda Gates Foundation. Additional support came from the Saving Brains Program, Grand Challenges Canada Grant Number 0073-03. The funding sources had no role in the study design; in the collection, analysis, and interpretation of results; in the writing of the manuscript; or in the submission of the manuscript for publication. No author has any affiliation with the funding agency.	Agarwal D K, 1998, Indian Pediatr, V35, P733; Al Mamun A, 2006, PAEDIATR PERINAT EP, V20, P482, DOI 10.1111/j.1365-3016.2006.00752.x; Allen LH, 2001, J NUTR, V131, p581S, DOI 10.1093/jn/131.2.581S; Allen LH, 2000, AM J CLIN NUTR, V71, p1280S, DOI 10.1093/ajcn/71.5.1280s; Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337; Andrews NC, 2000, NAT REV GENET, V1, P208, DOI 10.1038/35042073; Andrews NC, 2000, ANNU REV GENOM HUM G, V1, P75, DOI 10.1146/annurev.genom.1.1.75; [Anonymous], 2009, GLOBAL HEALTH RISKS: MORTALITY AND BURDEN OF DISEASE ATTRIBUTABLE TO SELECTED MAJOR RISKS, P1; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], WORLD BANK LIST EC; [Anonymous], SPAT LIM MAL TRANSM; [Anonymous], IR DEF AN GUID PREV; [Anonymous], LANCET GLOB IN PRESS; [Anonymous], BR J OBSTET GYNAECOL; [Anonymous], IR FOL SUPPL STAND M; [Anonymous], ANN TROP MED PARASIT; [Anonymous], WHOMCHMSM92 DIV FAM; [Anonymous], IR DIET REF INT VIT; [Anonymous], MICR DEF IR DEF AN; Arbuckle T E, 1989, Paediatr Perinat Epidemiol, V3, P115, DOI 10.1111/j.1365-3016.1989.tb00503.x; AUNGTHANBATU, 1976, ISRAEL J MED SCI, V12, P1410; Banhidy F, 2011, NUTRITION, V27, P65, DOI 10.1016/j.nut.2009.12.005; BARTON DPJ, 1994, AM J OBSTET GYNECOL, V170, P896, DOI 10.1016/S0002-9378(94)70305-1; Bastin J, 2006, BRIT J HAEMATOL, V134, P532, DOI 10.1111/j.1365-2141.2006.06216.x; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; BLOXAM DL, 1989, CLIN SCI, V76, P59, DOI 10.1042/cs0760059; Bondevik GT, 2001, ACTA OBSTET GYN SCAN, V80, P402, DOI 10.1034/j.1600-0412.2001.080005402.x; BRABIN BJ, 1990, ANN TROP MED PARASIT, V84, P11, DOI 10.1080/00034983.1990.11812429; BUTLER E B, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P497; BUYTAERT G, 1983, EUR J OBSTET GYN R B, V15, P11, DOI 10.1016/0028-2243(83)90291-5; CANTLIE GSD, 1971, AM J CLIN NUTR, V24, P637; Chan KKL, 2009, BJOG-INT J OBSTET GY, V116, P789, DOI 10.1111/j.1471-0528.2008.02014.x; Chang SC, 2003, J NUTR, V133, P2348, DOI 10.1093/jn/133.7.2348; CHAROENLARP P, 1988, AM J CLIN NUTR, V47, P280, DOI 10.1093/ajcn/47.2.280; CHISHOLM M., 1966, Journal of Obstetrics and Gynaecology of the British Commonwealth, V73, P191; Christian P, 2003, BMJ-BRIT MED J, V326, P571, DOI 10.1136/bmj.326.7389.571; Cogswell ME, 2003, AM J CLIN NUTR, V78, P773, DOI 10.1093/ajcn/78.4.773; Conde-Agudelo A, 2000, ACTA OBSTET GYN SCAN, V79, P371, DOI 10.1034/j.1600-0412.2000.079005371.x; DAWSON EB, 1989, AM J CLIN NUTR, V50, P848, DOI 10.1093/ajcn/50.4.848; DEBENAZE C, 1989, REV EPIDEMIOL SANTE, V37, P109; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; El Guindi W, 2004, J Gynecol Obstet Biol Reprod (Paris), V33, P506; Eskeland B, 1997, ACTA OBSTET GYN SCAN, V76, P822, DOI 10.3109/00016349709024359; Fareh O I, 2005, J Obstet Gynaecol, V25, P440, DOI 10.1080/01443610500160451; Feldman RE, 2011, MAGN RESON MED, V66, P1798, DOI 10.1002/mrm.22971; Feresu SA, 2004, INT J EPIDEMIOL, V33, P1194, DOI 10.1093/ije/dyh120; FINCH C, 1994, BLOOD, V84, P1697; FLEMING AF, 1986, ANN TROP MED PARASIT, V80, P211, DOI 10.1080/00034983.1986.11812006; FREIRE WB, 1989, AM J CLIN NUTR, V50, P1442, DOI 10.1093/ajcn/50.6.1442; Gambling L, 2009, AM J PHYSIOL-REG I, V296, pR1063, DOI 10.1152/ajpregu.90793.2008; Gonzales GF, 2009, AM J PHYSIOL-REG I, V297, pR1477, DOI 10.1152/ajpregu.00275.2009; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Hamalainen H, 2003, CLIN NUTR, V22, P271, DOI 10.1016/S0261-5614(02)00209-1; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; Harvey LJ, 2007, AM J CLIN NUTR, V85, P131, DOI 10.1093/ajcn/85.1.131; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hoa P. Thuy, 2005, Food and Nutrition Bulletin, V26, P32; HOLLY RG, 1955, OBSTET GYNECOL, V5, P562; Hwang HS, 2010, J PERINAT MED, V38, P467, DOI [10.1515/JPM.2010.047, 10.1515/jpm.2010.047]; Imdad A, 2012, PAEDIATR PERINAT EP, V26, P168, DOI 10.1111/j.1365-3016.2012.01312.x; Jehan I, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.07.012; KLEBANOFF MA, 1989, JAMA-J AM MED ASSOC, V262, P511, DOI 10.1001/jama.262.4.511; KNOTTNERUS JA, 1990, J CLIN EPIDEMIOL, V43, P461, DOI 10.1016/0895-4356(90)90134-B; Lao TT, 2002, OBSTET GYNECOL, V99, P807, DOI 10.1016/S0029-7844(02)01941-5; Lee HS, 2006, EUR J CLIN NUTR, V60, P1130, DOI 10.1038/sj.ejcn.1602429; Lee JI, 2005, AM J CLIN NUTR, V82, P843, DOI 10.1093/ajcn/82.4.843; Levy A, 2005, EUR J OBSTET GYN R B, V122, P182, DOI 10.1016/j.ejogrb.2005.02.015; Lipinski P, 2013, CELL MOL LIFE SCI, V70, P23, DOI 10.1007/s00018-012-1018-1; Little MP, 2005, AM J OBSTET GYNECOL, V193, P220, DOI 10.1016/j.ajog.2004.11.053; Liu X N, 1996, Biomed Environ Sci, V9, P341; Lone FW, 2004, TROP MED INT HEALTH, V9, P486, DOI 10.1111/j.1365-3156.2004.01222.x; Ma AG, 2010, BRIT J NUTR, V104, P1655, DOI 10.1017/S000711451000259X; Makrides M, 2003, AM J CLIN NUTR, V78, P145, DOI 10.1093/ajcn/78.1.145; Malhotra M, 2002, INT J GYNECOL OBSTET, V79, P93, DOI 10.1016/S0020-7292(02)00225-4; MANTEL N, 1959, J NATL CANCER I, V22, P719; Marahatta R, 2007, Nepal Med Coll J, V9, P270; MAU G, 1977, J PERINAT MED, V5, P172, DOI 10.1515/jpme.1977.5.4.172; McArdle HJ, 2011, NUTR REV, V69, pS17, DOI 10.1111/j.1753-4887.2011.00428.x; McKenna D, 2003, CLIN LAB HAEMATOL, V25, P99, DOI 10.1046/j.1365-2257.2003.00501.x; Meier Paul R, 2003, Clin Med Res, V1, P29; MENENDEZ C, 1994, T ROY SOC TROP MED H, V88, P590, DOI 10.1016/0035-9203(94)90176-7; MILMAN N, 1991, DAN MED BULL, V38, P471; Milman N, 2005, ACTA OBSTET GYN SCAN, V84, P238, DOI 10.1111/j.0001-6349.2005.00610.x; Mola G, 1999, AUST NZ J OBSTET GYN, V39, P31, DOI 10.1111/j.1479-828X.1999.tb03439.x; MURPHY JF, 1986, LANCET, V1, P992; Nacher M, 2003, T ROY SOC TROP MED H, V97, P273, DOI 10.1016/S0035-9203(03)90140-4; Ndyomugyenyi R, 2000, ANN TROP MED PARASIT, V94, P759, DOI 10.1080/00034980020015189; NORDENVALL M, 1990, ACTA OBSTET GYN SCAN, V69, P127, DOI 10.3109/00016349009006157; OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P603, DOI 10.1016/0035-9203(86)90154-9; OPPENHEIMER SJ, 1986, T ROY SOC TROP MED H, V80, P818, DOI 10.1016/0035-9203(86)90393-7; Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265; Pena-Rosas JP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004736.pub3; Preziosi P, 1997, AM J CLIN NUTR, V66, P1178, DOI 10.1093/ajcn/66.5.1178; PRITCHARD JA, 1958, SURG GYNECOL OBSTET, V106, P516; Puolakka J, 1980, Acta Obstet Gynecol Scand Suppl, V95, P43; Ren A, 2007, INT J GYNECOL OBSTET, V98, P124, DOI 10.1016/j.ijgo.2007.05.011; Rohlfs EM, 2011, CLIN CHEM, V57, P841, DOI 10.1373/clinchem.2010.159285; ROMSLO I, 1983, BRIT J OBSTET GYNAEC, V90, P101, DOI 10.1111/j.1471-0528.1983.tb08891.x; Rush D, 2000, AM J CLIN NUTR, V72, p212S, DOI 10.1093/ajcn/72.1.212S; Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; Scanlon KS, 2000, OBSTET GYNECOL, V96, P741, DOI 10.1016/S0029-7844(00)00982-0; Scholl TO, 2011, NUTR REV, V69, pS23, DOI 10.1111/j.1753-4887.2011.00429.x; SCHOLL TO, 1992, AM J CLIN NUTR, V55, P985, DOI 10.1093/ajcn/55.5.985; Shobeiri F, 2006, NUTR RES, V26, P209, DOI 10.1016/j.nutres.2006.05.008; Siega-Riz AM, 1998, AM J PERINAT, V15, P515, DOI 10.1055/s-2007-993976; Siega-Riz AM, 2006, AM J OBSTET GYNECOL, V194, P512, DOI 10.1016/j.ajog.2005.08.011; SIMMONS WK, 1993, AM J CLIN NUTR, V58, P622, DOI 10.1093/ajcn/58.5.622; Sloan NL, 2002, AM J PUBLIC HEALTH, V92, P288, DOI 10.2105/AJPH.92.2.288; SOOD SK, 1975, Q J MED, V44, P241; Steer PJ, 2000, AM J CLIN NUTR, V71, p1285S, DOI 10.1093/ajcn/71.5.1285s; Stoltzfus RJ., 2004, COMP QUANTIFICATION, pp. 163; Stoltzfus RJ, 1998, GUIDELINES USE IRON; Stram DO, 1996, BIOMETRICS, V52, P536, DOI 10.2307/2532893; SUHARNO D, 1993, LANCET, V342, P1325, DOI 10.1016/0140-6736(93)92246-P; SVANBERG B, 1975, ACTA OBSTET GYN SCAN, P87; Tanumihardjo SA, 2002, J NUTR, V132, P1909, DOI 10.1093/jn/132.7.1909; TAYLOR DJ, 1982, BRIT J OBSTET GYNAEC, V89, P1011, DOI 10.1111/j.1471-0528.1982.tb04656.x; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; Torlesse H, 2000, LANCET, V356, P1083, DOI 10.1016/S0140-6736(00)02738-0; Tura S, 1989, Recenti Prog Med, V80, P607; VANEIJK HG, 1978, CLIN CHIM ACTA, V83, P81, DOI 10.1016/0009-8981(78)90210-3; Vijayalaxmi KG, 2009, INDIAN J CLIN BIOCHE, V24, P269, DOI 10.1007/s12291-009-0051-9; von Tempelhoff GF, 2008, CLIN APPL THROMB-HEM, V14, P19, DOI 10.1177/1076029607304748; WALLENBURG HCS, 1984, J PERINAT MED, V12, P7, DOI 10.1515/jpme.1984.12.1.7; Williams LA, 1997, BRIT MED J, V314, P1864, DOI 10.1136/bmj.314.7098.1864; Xiong X, 2000, AM J PERINAT, V17, P137, DOI 10.1055/s-2000-9508; Xiong X, 2003, INT J GYNECOL OBSTET, V83, P159, DOI [10.1016/S0020-7292(03)00214-5, 10.1016/s0020-7292(03)00214-5]; Yakoob MY, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S21; Zeng LX, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2001; Zhang QY, 2009, ANN EPIDEMIOL, V19, P793, DOI 10.1016/j.annepidem.2009.06.002; Zhou LM, 1998, AM J EPIDEMIOL, V148, P998; Zhou SJ, 2009, EUR J CLIN NUTR, V63, P183, DOI 10.1038/sj.ejcn.1602926; Zhou SJ, 2007, J PEDIATR-US, V151, P438, DOI 10.1016/j.jpeds.2007.06.001; Ziaei S, 2007, BJOG-INT J OBSTET GY, V114, P684, DOI 10.1111/j.1471-0528.2007.01325.x; Ziaei S, 2008, INT J GYNECOL OBSTET, V100, P133, DOI 10.1016/j.ijgo.2007.07.026	141	398	420	3	99	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 21	2013	346								f3443	10.1136/bmj.f3443	http://dx.doi.org/10.1136/bmj.f3443			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	171RC	23794316	hybrid, Green Published			2023-01-03	WOS:000320945700001
J	Paubelle, E; Zylbersztejn, F; Alkhaeir, S; Suarez, F; Callens, C; Dussiot, M; Isnard, F; Rubio, MT; Damaj, G; Gorin, NC; Marolleau, JP; Monteiro, RC; Moura, IC; Hermine, O				Paubelle, Etienne; Zylbersztejn, Florence; Alkhaeir, Sawsaneh; Suarez, Felipe; Callens, Celine; Dussiot, Michael; Isnard, Francoise; Rubio, Marie-Therese; Damaj, Gandhi; Gorin, Norbert-Claude; Marolleau, Jean-Pierre; Monteiro, Renato C.; Moura, Ivan C.; Hermine, Olivier			Deferasirox and Vitamin D Improves Overall Survival in Elderly Patients with Acute Myeloid Leukemia after Demethylating Agents Failure	PLOS ONE			English	Article							DIFFERENTIATING AGENTS; OLDER PATIENTS; AML; CYTOGENETICS; TRIAL; CELLS; CARE	The prognosis of acute myeloid leukemia (AML) in elderly (>= 65 years) patients is poor and treatment remains non-consensual especially for those who are not eligible for intensive therapies. Our group has shown that in vitro the iron chelator deferasirox (DFX) synergizes with vitamin D (VD) to promote monocyte differentiation in primary AML cells. Herein, we present results from a retrospective case-control study in which the association of DFX (1-2 g/d) and 25-hydroxycholecalciferol (100,000 IU/week) (DFX/VD) was proposed to patients following demethylating agents failure. Median survival of patients treated with DFX/VD combination (n = 17) was significantly increased in comparison with matched patients receiving best supportive care (BSC) alone (n = 13) (10.4 versus 4 months respectively). In addition, the only factor associated to an increased overall survival in DFX/VD-treated patients was serum VD levels. We conclude that DFX/VD treatment correlated with increased overall survival of AML patients in this retrospective cohort of elderly patients.	[Paubelle, Etienne; Zylbersztejn, Florence; Alkhaeir, Sawsaneh; Callens, Celine; Dussiot, Michael; Hermine, Olivier] Univ Paris 05, Fac Med, Hop Necker, CNRS UMR 8147, Paris, France; [Paubelle, Etienne; Zylbersztejn, Florence; Alkhaeir, Sawsaneh; Dussiot, Michael; Monteiro, Renato C.; Moura, Ivan C.] INSERM U699, Paris, France; [Paubelle, Etienne; Zylbersztejn, Florence; Alkhaeir, Sawsaneh; Suarez, Felipe; Dussiot, Michael; Moura, Ivan C.; Hermine, Olivier] Univ Sorbonne Paris Cite, Hop Necker, IHU Imagine, AP HP, Paris, France; [Paubelle, Etienne; Suarez, Felipe; Hermine, Olivier] Hop Necker Enfants Malad, AP HP, Serv Hematol Clin, Paris, France; [Dussiot, Michael; Hermine, Olivier] Lab Excellence Globules Rouges GR Ex, Paris, France; [Isnard, Francoise; Rubio, Marie-Therese] Univ Paris 06, Dept Hematol, AP HP Hop St Antoine, Paris, France; [Damaj, Gandhi; Marolleau, Jean-Pierre] CHU Sud, Amiens, France; [Monteiro, Renato C.] Hop Bichat Claude Bernard, AP HP, Serv Immunol, F-75877 Paris, France; [Monteiro, Renato C.; Moura, Ivan C.] Fac Med, Paris, France; [Monteiro, Renato C.; Moura, Ivan C.] Univ Paris 07, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Hermine, O (corresponding author), Univ Paris 05, Fac Med, Hop Necker, CNRS UMR 8147, Paris, France.	olivier.hermine@nck.aphp.fr	Moura, Ivan C/A-9510-2013; Monteiro, Renato C/U-8633-2017; Hermine, Olivier/Q-7072-2018; Cruz Moura, Ivan/A-9510-2013	Moura, Ivan C/0000-0002-2977-0354; Monteiro, Renato C/0000-0001-5202-5646; Cruz Moura, Ivan/0000-0002-8418-2803; Hermine, Olivier/0000-0003-2574-3874	Fondation pour la Recherche Medicale (FRM); fondation de France; Ligue contre le cancer, le canceropole; Institut National du Cancer (INCA); association Laurette Fugain; Association pour la Recherche contre le Cancer (ARC)	Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); fondation de France(Fondation de France); Ligue contre le cancer, le canceropole; Institut National du Cancer (INCA)(Institut National du Cancer (INCA) France); association Laurette Fugain; Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR))	The Fondation pour la Recherche Medicale (FRM), the fondation de France, Ligue contre le cancer, le canceropole, Institut National du Cancer (INCA), association Laurette Fugain and the Association pour la Recherche contre le Cancer (ARC) supported this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Callens C, 2010, J EXP MED, V207, P731, DOI 10.1084/jem.20091488; Estey E, 2009, BEST PRACT RES CL HA, V22, P529, DOI 10.1016/j.beha.2009.08.007; Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329; Ferrero D, 2004, HAEMATOLOGICA, V89, P619; Frohling S, 2006, BLOOD, V108, P3280, DOI 10.1182/blood-2006-04-014324; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Hughes PJ, 2010, LEUKEMIA RES, V34, P553, DOI 10.1016/j.leukres.2009.09.010; Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429; Lichtman SM, 1999, AM J HEMATOL, V61, P262, DOI 10.1002/(SICI)1096-8652(199908)61:4<262::AID-AJH7>3.0.CO;2-B; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Malcovati L, 2005, J CLIN ONCOL, V23, P7594, DOI 10.1200/JCO.2005.01.7038; Messa E, 2010, HAEMATOL-HEMATOL J, V95, P1308, DOI 10.3324/haematol.2009.016824; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Quintas-Cardama A, 2012, BLOOD; Rose C, 2010, LEUKEMIA RES, V34, P864, DOI 10.1016/j.leukres.2009.12.004	16	30	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2013	8	6							e65998	10.1371/journal.pone.0065998	http://dx.doi.org/10.1371/journal.pone.0065998			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190LY	23840388	Green Published, gold, Green Submitted			2023-01-03	WOS:000322342800026
J	Kunins, HV; Farley, TA; Dowell, D				Kunins, Hillary V.; Farley, Thomas A.; Dowell, Deborah			Guidelines for Opioid Prescription: Why Emergency Physicians Need Support	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PAIN; MANAGEMENT		[Kunins, Hillary V.; Farley, Thomas A.; Dowell, Deborah] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA	New York City Department of Health & Mental Hygiene	Kunins, HV (corresponding author), New York City Dept Hlth & Mental Hyg, 42-09 28th St,19th Floor, Queens, NY 11101 USA.							Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Boscarino JA, 2011, J ADDICT DIS, V30, P185, DOI 10.1080/10550887.2011.581961; Chu J, 2013, NEW YORK CITY EMERGE; Franklin GM, 2008, SPINE, V33, P199, DOI 10.1097/BRS.0b013e318160455c; Manchikanti L, 2011, PAIN PHYSICIAN, V14, P91; Mularski RA, 2006, J GEN INTERN MED, V21, P607, DOI 10.1111/j.1525-1497.2006.00415.x; Paone D, 2001, CITY HLTH INFORM, V30, P23; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; PORTER J, 1980, NEW ENGL J MED, V302, P123; Warner Margaret, 2011, NCHS Data Brief, P1; Zee AV, 2009, AM J PUBLIC HEALTH, V99, P221, DOI 10.2105/AJPH.2007.131714	11	21	21	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2013	158	11					841	+		10.7326/0003-4819-158-11-201306040-00631	http://dx.doi.org/10.7326/0003-4819-158-11-201306040-00631			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	164AA	23567824				2023-01-03	WOS:000320379800008
J	Haseneder, R; Starker, L; Berkmann, J; Kellermann, K; Jungwirth, B; Blobner, M; Eder, M; Kochs, E; Rammes, G				Haseneder, Rainer; Starker, Laura; Berkmann, Jasmin; Kellermann, Kristine; Jungwirth, Bettina; Blobner, Manfred; Eder, Matthias; Kochs, Eberhard; Rammes, Gerhard			Sevoflurane Anesthesia Improves Cognitive Performance in Mice, but Does Not Influence In Vitro Long-Term Potentation in Hippocampus CA1 Stratum Radiatum	PLOS ONE			English	Article							MODIFIED HOLE BOARD; NITROUS OXIDE ANESTHESIA; PROTEIN-KINASE-C; SYNAPTIC PLASTICITY; SPATIAL MEMORY; VOLATILE ANESTHETICS; GENERAL-ANESTHESIA; RAT HIPPOCAMPUS; AGED RATS; DDN MICE	Background: Whether the occurrence of postoperative cognitive dysfunction is a result of the effects of surgery or anesthesia is under debate. In this study, we investigated the impact of sevoflurane anesthesia on cognitive performance and cellular mechanisms involved in learning and memory. Methods: Male C57Bl6/J mice (4-5 months) were exposed to one minimum alveolar concentration sevoflurane for two hours. After 24 h, cognitive performance of mice was assessed using the modified hole board test. Additionally, we evaluated hippocampal long-term potentiation and expression levels of different receptor subunits by recording excitatory postsynaptic field potentials and using the western blot technique, respectively. Non-anesthetized mice served as controls. Results: In anesthetized mice, neither cognitive performance nor long-term potentiation was impaired 24 h after anesthesia. Interestingly, sevoflurane anesthesia induced even an improvement of cognitive performance and an elevation of the expression levels of N-methyl-D-aspartate (NMDA) receptor type 1 and 2B subunits in the hippocampus. Conclusions: Since NMDA receptor type 1 and 2B subunits play a crucial role in processes related to learning and memory, we hypothesize that sevoflurane-induced changes in NMDA receptor subunit composition might cause hippocampus-dependent cognitive improvement. The data of the present study are in favor of a minor role of anesthesia in mediating postoperative cognitive dysfunction.	[Haseneder, Rainer; Starker, Laura; Berkmann, Jasmin; Kellermann, Kristine; Jungwirth, Bettina; Blobner, Manfred; Kochs, Eberhard; Rammes, Gerhard] Tech Univ Munich, Klinikum Rechts Isar, Dept Anesthesiol, D-80290 Munich, Germany; [Eder, Matthias] Max Planck Inst Psychiat, Res Grp Neuronal Network Dynam, D-80804 Munich, Germany	Technical University of Munich; Max Planck Society	Haseneder, R (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Anesthesiol, D-80290 Munich, Germany.	r.haseneder@lrz.tum.de	Blobner, Manfred/R-4411-2017	Blobner, Manfred/0000-0002-0370-5247; Jungwirth, Bettina/0000-0001-9749-7460; Eder, Matthias/0000-0002-2579-2628				Alkire MT, 2005, ANESTHESIOLOGY, V103, P1167, DOI 10.1097/00000542-200512010-00010; Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Bianchi SL, 2008, NEUROBIOL AGING, V29, P1002, DOI 10.1016/j.neurobiolaging.2007.02.009; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Cain DP, 1997, CURR OPIN NEUROBIOL, V7, P235, DOI 10.1016/S0959-4388(97)80012-8; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Cheng VY, 2006, J NEUROSCI, V26, P3713, DOI 10.1523/JNEUROSCI.5024-05.2006; Clayton DA, 2002, J NEUROSCI, V22, P3628; Criswell HE, 2004, BRAIN RES, V1015, P107, DOI 10.1016/j.brainres.2004.04.050; Crosby C, 2005, ANESTH ANALG, V101, P1389, DOI 10.1213/01.ANE.0000180835.72669.AD; Culley DJ, 2006, EUR J PHARMACOL, V549, P71, DOI 10.1016/j.ejphar.2006.08.028; Culley DJ, 2004, ANESTH ANALG, V99, P1393, DOI 10.1213/01.ANE.0000135408.14319.CC; Culley DJ, 2004, ANESTHESIOLOGY, V100, P309, DOI 10.1097/00000542-200402000-00020; Culley DJ, 2003, ANESTH ANALG, V96, P1004, DOI 10.1213/01.ANE.0000052712.67573.12; Futterer CD, 2004, ANESTHESIOLOGY, V100, P302; Gordan ML, 2012, BEHAV BRAIN RES, V235, P7, DOI 10.1016/j.bbr.2012.07.027; Hirota K, 1998, TOXICOL LETT, V101, P203, DOI 10.1016/S0378-4274(98)00186-6; Holscher C, 1999, J NEUROSCI RES, V58, P62; HOPE BT, 1994, NEURON, V13, P1235, DOI 10.1016/0896-6273(94)90061-2; Ishizeki J, 2008, ANESTHESIOLOGY, V108, P447, DOI 10.1097/ALN.0b013e318164cfba; Jungwirth Bettina, 2008, Central Nervous System Agents in Medicinal Chemistry, V8, P37; Komatsu H, 1997, CLIN EXP PHARMACOL P, V24, P706, DOI 10.1111/j.1440-1681.1997.tb02116.x; KOMATSU H, 1993, ANESTH ANALG, V76, P609; KOMATSU H, 1991, ANESTH ANALG, V73, P295; Li YJ, 2007, NEUROPHARMACOLOGY, V53, P942, DOI 10.1016/j.neuropharm.2007.09.005; MACIVER MB, 1989, BRIT J ANAESTH, V62, P301, DOI 10.1093/bja/62.3.301; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Mawhinney LJ, 2012, BRAIN RES, V1431, P23, DOI 10.1016/j.brainres.2011.11.004; Moe MC, 2003, J NEUROSURG ANESTH, V15, P209, DOI 10.1097/00008506-200307000-00008; Nagashima K, 2005, ANESTHESIOLOGY, V103, P318, DOI 10.1097/00000542-200508000-00015; Newman S, 2007, ANESTHESIOLOGY, V106, P572, DOI 10.1097/00000542-200703000-00023; Nishikawa K, 2005, BRAIN RES, V1039, P153, DOI 10.1016/j.brainres.2005.01.060; Nishikawa K, 2001, ANESTHESIOLOGY, V94, P340, DOI 10.1097/00000542-200102000-00025; Ohl F, 2003, EUR J PHARMACOL, V480, P219, DOI 10.1016/j.ejphar.2003.08.108; Ohl F, 2003, EUR J NEUROSCI, V17, P128, DOI 10.1046/j.1460-9568.2003.02436.x; Ohl F, 2001, BEHAV RES METH INS C, V33, P392, DOI 10.3758/BF03195393; Ohl F, 2001, J PSYCHIAT RES, V35, P147, DOI 10.1016/S0022-3956(01)00017-6; Ramakers GMJ, 1997, PROG NEURO-PSYCHOPH, V21, P455, DOI 10.1016/S0278-5846(97)00013-4; Rammes G, 2009, NEUROPHARMACOLOGY, V56, P626, DOI 10.1016/j.neuropharm.2008.11.002; Rampil IJ, 2006, ANESTH ANALG, V102, P1431, DOI 10.1213/01.ane.0000202384.96269.51; Royse CF, 2011, ANAESTHESIA, V66, P455, DOI 10.1111/j.1365-2044.2011.06704.x; Sasaki R, 2002, ANESTHESIOLOGY, V96, P681, DOI 10.1097/00000542-200203000-00026; Scheller M, 1997, ANESTHESIOLOGY, V86, P118, DOI 10.1097/00000542-199701000-00016; Schoen J, 2011, BRIT J ANAESTH, V106, P840, DOI 10.1093/bja/aer091; Shin WJ, 2003, ANESTH ANALG, V96, P1340, DOI 10.1213/01.ANE.0000055365.31940.0A; Simon W, 2001, ANESTHESIOLOGY, V94, P1058, DOI 10.1097/00000542-200106000-00021; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Vinje ML, 2002, ACTA ANAESTH SCAND, V46, P103, DOI 10.1046/j.0001-5172.2001.00412.x; White TL, 2004, BRAIN RES, V1021, P1, DOI 10.1016/j.brainres.2004.05.114; Zhao X, 2009, NEUROSCIENCE, V162, P933, DOI 10.1016/j.neuroscience.2009.05.018	51	24	27	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e64732	10.1371/journal.pone.0064732	http://dx.doi.org/10.1371/journal.pone.0064732			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155FM	23724087	Green Published, gold			2023-01-03	WOS:000319733000088
J	Chadha, MS; Hirve, S; Dawood, FS; Lele, P; Deoshatwar, A; Sambhudas, S; Juvekar, S; LaFond, KE; Mott, JA; Lal, RB; Mishra, AC				Chadha, Mandeep S.; Hirve, Siddhivinayak; Dawood, Fatimah S.; Lele, Pallavi; Deoshatwar, Avinash; Sambhudas, Somnath; Juvekar, Sanjay; LaFond, Kathryn E.; Mott, Joshua A.; Lal, Renu B.; Mishra, Akhilesh C.			Burden of Seasonal and Pandemic Influenza-Associated Hospitalization during and after 2009 A(H1N1)pdm09 Pandemic in a Rural Community in India	PLOS ONE			English	Article							HONG-KONG; UNITED-STATES; PNEUMONIA; CHILDREN; MORTALITY; EPIDEMIOLOGY; IMPACT	Background: Influenza is vaccine-preventable; however, the burden of severe influenza in India remains unknown. We conducted a population-based study to estimate the incidence of laboratory confirmed influenza-associated hospitalizations in a rural community in western India. Methods: We conducted active surveillance for hospitalized patients with acute medical illnesses or acute chronic disease exacerbations in Pune during pandemic and post pandemic periods (May 2009-April 2011). Nasal and throat swabs were tested for influenza viruses. A community health utilization survey estimated the proportion of residents hospitalized with respiratory illness at non-study facilities and was used to adjust incidence estimates from facility-based surveillance. Results: Among 9,426 hospitalizations, 3,391 (36%) patients were enrolled; 665 of 3,179 (20.9%) tested positive for influenza. Of 665 influenza positives, 340 (51%) were pandemic A(H1N1)pdm09 and 327 (49%) were seasonal, including A/H3 (16%), A/H1 (3%) and influenza B (30%). The proportion of patients with influenza peaked during August 2009 (39%) and 2010 (42%). The adjusted annual incidence of influenza hospitalizations was 46.8/10,000 during pandemic and 40.5/10,000 during post-pandemic period with comparable incidence of A(H1N1) pdm09 during both periods (18.8 and 20.3, respectively). The incidence of both pH1N1 and seasonal hospitalized influenza disease was highest in the 5-29 year olds. Conclusions: We document the previously unrecognized burden of influenza hospitalization in a rural community following the emergence of influenza A(H1N1)pdm09 viruses in India. During peak periods of influenza activity circulation i.e during the monsoon period, 20% of all hospital admissions in the community had influenza positivity. These findings can inform development of influenza prevention and control strategies in India.	[Chadha, Mandeep S.; Deoshatwar, Avinash; Mishra, Akhilesh C.] Indian Council Med Res, Natl Inst Virol, Pune, Maharashtra, India; [Hirve, Siddhivinayak; Lele, Pallavi; Deoshatwar, Avinash; Sambhudas, Somnath; Juvekar, Sanjay] King Edward Mem Hosp Res Ctr, Vadu Rural Hlth Program, Pune, Maharashtra, India; [Dawood, Fatimah S.; LaFond, Kathryn E.; Mott, Joshua A.; Lal, Renu B.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA	Indian Council of Medical Research (ICMR); ICMR - National Institute of Virology (NIV); Centers for Disease Control & Prevention - USA	Chadha, MS (corresponding author), Indian Council Med Res, Natl Inst Virol, Pune, Maharashtra, India.	acm1750@rediffmail.com; mscniv@hotmail.com		Sambhudas, Somnath/0000-0003-0140-4931	Centers for Disease Control and Prevention [1U01IP000206]; National Center for Immunization and Respiratory Diseases (NCIRD) [U01IP000206] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center for Immunization and Respiratory Diseases (NCIRD)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The Influenza Disease Burden, India Study was supported by a Centers for Disease Control and Prevention co-operative agreement # 1U01IP000206. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475; ASSAAD F, 1973, B WORLD HEALTH ORGAN, V49, P219; BARKER WH, 1980, AM J EPIDEMIOL, V112, P798, DOI 10.1093/oxfordjournals.aje.a113052; BARKER WH, 1986, AM J PUBLIC HEALTH, V76, P761, DOI 10.2105/AJPH.76.7.761; Broor S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029129; CDC, 2009, CDC PROT REAL TIM RT; Census of India, 2012, RUR URB DISTR POP PR; Chadha MS, 2012, INFLUENZA OTHER RESP, V6, P196, DOI 10.1111/j.1750-2659.2011.00293.x; Chiu SS, 2002, NEW ENGL J MED, V347, P2097, DOI 10.1056/NEJMoa020546; Crighton EJ, 2004, EPIDEMIOL INFECT, V132, P1167, DOI 10.1017/S0950268804002924; Dawood FS, 2010, J PEDIATR-US, V157, P808, DOI 10.1016/j.jpeds.2010.05.012; Esposito S, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-271; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; Gregg MB, 1976, INFLUENZA VIRUS VACC, P79; Griffin Marie R, 2004, Pediatr Infect Dis J, V23, pS188, DOI 10.1097/01.inf.0000144660.53024.64; Li CK, 2006, PUBLIC HEALTH, V120, P517, DOI 10.1016/j.puhe.2006.03.004; Mishra AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010540; Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Ramamurty N, 2005, INDIAN J MED RES, V121, P776; RAO BL, 1993, B WORLD HEALTH ORGAN, V71, P177; Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769; Simmerman JM, 2009, PLOS ONE, V4, pA107, DOI 10.1371/journal.pone.0007776; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; *WHO, 2009, PRACT GUID HARM VIR; Wong CM, 2006, PLOS MED, V3, P485, DOI 10.1371/journal.pmed.0030121; World Health Organization, GLOB INFL SURV RESP; World Health Organization, 2009, PRACT GUID DES COND; Yap FHY, 2004, J MED VIROL, V73, P617, DOI 10.1002/jmv.20135	30	18	19	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2013	8	5							e55918	10.1371/journal.pone.0055918	http://dx.doi.org/10.1371/journal.pone.0055918			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145XK	23690913	gold, Green Published, Green Submitted			2023-01-03	WOS:000319052700001
J	Srivastava, A; Mohanty, SK				Srivastava, Akanksha; Mohanty, Sanjay K.			Age and Sex Pattern of Cardiovascular Mortality, Hospitalisation and Associated Cost in India	PLOS ONE			English	Article							PREVENTING CHRONIC DISEASES; MIDDLE-INCOME COUNTRIES; RISK-FACTORS; DETERMINANTS; OUTCOMES; CONTEXT; DEATH	Context: Though the cardiovascular diseases are the leading cause of mortality in India, little is known about the human and economic loss attributed to the disease. The aim of this paper is to account the age and sex pattern of mortality, hospitalisation and the cost of hospitalisation for cardiovascular diseases in India. Data and Methods: Data for the present study has been drawn from multiple sources; 52nd and 60th rounds of the National Sample Survey, Special Survey of Death, 2001-03 and the Sample Registration System 2004-2010. Under the changing demographics and constant assumptions of mortality, hospitalisation and cost of hospitalisation, we have estimated the deaths, hospitalisation and cost of hospitalisation for cardiovascular diseases in India during 2004 to 2021. Descriptive analyses and multivariate techniques were used to understand the socio-economic differentials in cost of hospitalisation for cardiovascular diseases in India. Findings: In India, the cardiovascular diseases accounted for an estimated 1.4 million deaths in 2004 and it is likely to be 2.1 million in 2021. An estimated 6.7 million people were hospitalised for cardiovascular diseases in 2004, and projected to be 10.9 million by 2021. Unlike mortality, majority of the hospitalisation due to cardiovascular diseases will be in the prime working age group (25-59). The estimated cost of hospitalisation for cardiovascular diseases was 94/- billion rupees in 2004 and expected to be 152/- billion rupees by 2021, at 2004 prices. The cost of hospitalisation for cardiovascular diseases was significantly high in private health centres, high fertility states and among high socio-economic groups. Conclusion: The cardiovascular mortality and hospitalisation will be largely concentrated in the prime working age group and the cost of hospitalisation is expected to increase substantially in coming years. This calls for mobilising resources, increasing access to health insurance and devising strategies for the prevention, control and treatment of cardiovascular diseases in India.	[Srivastava, Akanksha] Int Inst Populat Sci, Bombay, Maharashtra, India; [Mohanty, Sanjay K.] Int Inst Populat Sci, Dept Fertil Studies, Bombay, Maharashtra, India	International Institute for Population Sciences; International Institute for Population Sciences	Srivastava, A (corresponding author), Int Inst Populat Sci, Bombay, Maharashtra, India.	akankshaleo@gmail.com	Mohanty, Sanjay K/AAR-7658-2020	Mohanty, Sanjay K/0000-0001-9041-5952				Adeyi O, 2007, DIR DEV, P1, DOI 10.1596/978-0-8213-7044-5; Ala L, 2004, J HUM HYPERTENS, V18, P775, DOI 10.1038/sj.jhh.1001750; Alwan A, 2010, LANCET, V376, P1861, DOI 10.1016/S0140-6736(10)61853-3; [Anonymous], 2005, UPDATED PROJECTIONS; [Anonymous], 2011, CENSUS INDIA 2011 PR, P1; Asaria P, 2007, LANCET, V370, P2044, DOI 10.1016/S0140-6736(07)61698-5; AZAMBUJA MIR, 2008, EC BURDEN SEVERE CAR; Beaglehole R, 2007, LANCET, V370, P2152, DOI 10.1016/S0140-6736(07)61700-0; Bhutta ZA, 2006, PLOS MED, V3, P163, DOI 10.1371/journal.pmed.0030103; Cecchini M, 2010, LANCET, V376, P1775, DOI 10.1016/S0140-6736(10)61514-0; Chadha SL, 1997, B WORLD HEALTH ORGAN, V75, P31; Ezeamama AE, 2006, SOC SCI MED, V63, P2533, DOI 10.1016/j.socscimed.2006.06.023; Gaziano TA, 2007, LANCET, V370, P1939, DOI 10.1016/S0140-6736(07)61697-3; Geneau R, 2010, LANCET, V376, P1689, DOI 10.1016/S0140-6736(10)61414-6; Goyal A, 2006, INDIAN J MED RES, V124, P235; Gupta R, 1995, Indian Heart J, V47, P331; HEINDENREICH PA, FORECASTING FUTURE C; Huffman MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020821; Jeemon P, 2010, INDIAN J MED RES, V132, P617; Jha P, 2006, PLOS MED, V3, P191, DOI 10.1371/journal.pmed.0030018; JORDAN JEE, 2005, LANCET, V366, P1667; Joshi R, 2006, INT J EPIDEMIOL, V35, P1522, DOI 10.1093/ije/dyl168; Leeder S, 2004, RACE TIME CHALLENGE; Lim SS, 2007, LANCET, V370, P2054, DOI 10.1016/S0140-6736(07)61699-7; Ministry of Health and Family Welfare Government of India, NAT PROGR PREV CONTR; Miranda JJ, 2008, TROP MED INT HEALTH, V13, P1225, DOI 10.1111/j.1365-3156.2008.02116.x; Msyamboza KP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020316; *NSSO, 2006, 507602501 NSSO GOV I; *NSSO, 1998, 441522501 NSSO GOV I; Office of the Registrar General and Census Commissioner (ORGI), 2006, POP PROJ IND STAT 20; Office of the Registrar General (RGI) India, 2009, REP CAUS DEATH IND 2; *ORGI, 2006, SAMPL REG SYST STAT; *ORGI, 2012, SAMPL REG SYST STAT; Patel V, 2011, LANCET, V377, P413, DOI 10.1016/S0140-6736(10)61188-9; PEDNEKAR MS, 2011, ILLITERACY LOW ED ST; *PLANN COMM GOVT I, 2011, HIGH LEV EXP GROUP R; Rao KD, 2011, INDIAN J MED RES, V133, P57; Reddy KS, 2005, LANCET, V366, P1744, DOI [10.1016/s0140-6736(05)67343-6, 10.1016/S0140-6736(05)67343-6]; REDDY KS, 1998, CIRCULATION, V70, P945; Reddy N Krishna, 2002, Indian Heart J, V54, P697; *RGI, 1990, MED CERT CAUS DEATH; *RGI, 2004, MED CERT CAUS DEATH; RISSAM HS, 2001, INDIAN ACAD CLIN MED, V2, P128; Samb B, 2010, LANCET, V376, P1785, DOI 10.1016/S0140-6736(10)61353-0; SARVOTHHAM SG, 1968, CIRCULATION, V32; Stanciole A., 2006, ESTIMATION EC IMPACT; Strong K, 2005, LANCET, V366, P1578, DOI 10.1016/S0140-6736(05)67341-2; SUGATHAN TN, 2008, BEHAV RISK FACTORS N; SUHRCKE M, 2006, 1845 CESIFO; Taylor M., 2009, WHAT IS SENSITIVITY; United Nations Department of Economic and Social Affairs, 2010, WORLD POP PROSP; United Nations Department of Economic and Social Affairs Population Division, 2010, WORLD POP PROSP 2010; Vorster HH, 2002, PUBLIC HEALTH NUTR, V5, P239, DOI 10.1079/PHN2001299; Wang LD, 2005, LANCET, V366, P1821, DOI 10.1016/S0140-6736(05)67344-8; Whitehead M, 2001, LANCET, V358, P833, DOI 10.1016/S0140-6736(01)05975-X; WHO, 2011, NCD COUNTR PROF; Xavier D, 2008, LANCET, V371, P1435, DOI 10.1016/S0140-6736(08)60623-6; YANG L, 2012, ESTIMATES CANC INCID; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zhou BF, 2003, AM J PUBLIC HEALTH, V93, P2049, DOI 10.2105/AJPH.93.12.2049	60	15	16	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2013	8	5							e62134	10.1371/journal.pone.0062134	http://dx.doi.org/10.1371/journal.pone.0062134			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	154EP	23667455	Green Published, Green Submitted, gold			2023-01-03	WOS:000319654700023
J	Wichmann, J; Rosengren, A; Sjoberg, K; Barregard, L; Sallsten, G				Wichmann, Janine; Rosengren, Annika; Sjoberg, Karin; Barregard, Lars; Sallsten, Gerd			Association between Ambient Temperature and Acute Myocardial Infarction Hospitalisations in Gothenburg, Sweden: 1985-2010	PLOS ONE			English	Article							CASE-CROSSOVER ANALYSES; AIR-POLLUTION; CARDIOVASCULAR-DISEASE; SEASONAL-VARIATION; WEATHER; RISK; INFLAMMATION; ENVIRONMENT; ADMISSIONS; MORBIDITY	Cardiovascular disease (CVD) is the number one cause of death globally and evidence is steadily increasing on the role of non-traditional risk factors such as meteorology and air pollution. Nevertheless, many research gaps remain, such as the association between these non-traditional risk factors and subtypes of CVD, such as acute myocardial infarction (AMI). The objective of this study was to investigate the association between daily ambient temperature and AMI hospitalisations using a case-crossover design in Gothenburg, Sweden (1985-2010). A secondary analysis was also performed for out-of-hospital ischemic heart disease (IHD) deaths. Susceptible groups by age and sex were explored. The entire year as well as the warm (April-September) and cold periods (October-March) were considered. In total 28 215 AMI hospitalisations (of 22 475 people) and 21 082 out-of-hospital IHD deaths occurred during the 26-year study period. A linear exposure-response corresponding to a 3% and 7% decrease in AMI hospitalisations was observed for an inter-quartile range (IQR) increase in the 2-day cumulative average of temperature during the entire year (11 degrees C) and the warm period (6 degrees C), respectively, with and without adjustment for PM10, NO2, NOx or O-3. No heat waves occurred during the warm period. No evidence of an association in the cold period nor any association between temperature and IHD deaths in the entire year, warm or cold periods - with and without adjusting for PM10, NO2, NOx or O-3 was found. No susceptible groups, based on age or sex, were identified either. The inverse association between temperature and AMI hospitalisations (entire year and warm period) in Gothenburg is in accordance with the majority of the few other studies that investigated this subtype of CVD.	[Wichmann, Janine; Barregard, Lars; Sallsten, Gerd] Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden; [Wichmann, Janine; Rosengren, Annika; Barregard, Lars; Sallsten, Gerd] Univ Gothenburg, Gothenburg, Sweden; [Rosengren, Annika] Sahlgrens Univ Hosp, Dept Mol & Clin Med, Gothenburg, Sweden; [Sjoberg, Karin] IVL Swedish Environm Res Inst, Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; IVL Swedish Environmental Research Institute	Wichmann, J (corresponding author), Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden.	gerd.sallsten@amm.gu.se	Stefanadis, Christodoulos/ABH-2232-2020	Stefanadis, Christodoulos/0000-0001-5974-6454; Rosengren, Annika/0000-0002-5409-6605	Swedish Research Council Formas	Swedish Research Council Formas(Swedish Research CouncilSwedish Research Council Formas)	The Swedish Research Council Formas funded the study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrignani MG, 2009, INT J CARDIOL, V137, P123, DOI 10.1016/j.ijcard.2008.06.036; Analitis A, 2008, AM J EPIDEMIOL, V168, P1397, DOI 10.1093/aje/kwn266; Anderson H.R., 2004, METAANALYSIS TIME SE; Anderson H.R., 2007, QUANTITATIVE SYSTEMA; Barnett AG, 2010, ENVIRON RES, V110, P604, DOI 10.1016/j.envres.2010.05.006; Basu R, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-40; Bateson TF, 1999, EPIDEMIOLOGY, V10, P539, DOI 10.1097/00001648-199909000-00013; Bateson TF, 2001, EPIDEMIOLOGY, V12, P654, DOI 10.1097/00001648-200111000-00013; Bhaskaran K, 2009, HEART, V95, P1760, DOI 10.1136/hrt.2009.175000; Bhaskaran K, 2009, HEART, V95, P1746, DOI 10.1136/hrt.2009.175018; Bhaskaran K, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3823; BOKENES L, 2009, EUROPEAN J PUBLIC HL, V21, P526, DOI DOI 10.1003/EURPUB/CKPL; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Danet S, 1999, Circulation, V100, pE1; Dudas K, 2011, CIRCULATION, V123, P46, DOI 10.1161/CIRCULATIONAHA.110.964999; Ebi KL, 2004, INT J BIOMETEOROL, V49, P48, DOI 10.1007/s00484-004-0207-5; ELWOOD PC, 1993, BRIT HEART J, V70, P520; Green RS, 2010, INT J PUBLIC HEALTH, V55, P113, DOI 10.1007/s00038-009-0076-0; Hanninen O, 2011, AIR QUAL ATMOS HLTH, V4, P221, DOI 10.1007/s11869-010-0076-5; IPCC, 2007, AR4 CLIMATE CHANGE 2; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; Kociol RD, 2012, JAMA-J AM MED ASSOC, V307, P66, DOI 10.1001/jama.2011.1926; Kovats RS, 2008, ANNU REV PUBL HEALTH, V29, P41, DOI 10.1146/annurev.publhealth.29.020907.090843; Lee JH, 2010, INT J CARDIOL, V144, P16, DOI 10.1016/j.ijcard.2009.03.122; Levy D, 2001, EPIDEMIOLOGY, V12, P186, DOI 10.1097/00001648-200103000-00010; Lloyd-Jones DM, 2006, CIRCULATION, V113, P791, DOI 10.1161/CIRCULATIONAHA.105.548206; Lucas RM, 2005, B WORLD HEALTH ORGAN, V83, P792; Ludvigsson JF, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-450; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Matthews CE, 2001, AM J EPIDEMIOL, V153, P172, DOI 10.1093/aje/153.2.172; Michelozzi P, 2009, AM J RESP CRIT CARE, V179, P383, DOI 10.1164/rccm.200802-217OC; Miller KA, 2007, NEW ENGL J MED, V356, P447, DOI 10.1056/NEJMoa054409; Misailidou M, 2006, EUR J CARDIOV PREV R, V13, P846, DOI 10.1097/01.hjr.0000221857.04168.06; Mustafic H, 2012, JAMA-J AM MED ASSOC, V307, P713, DOI 10.1001/jama.2012.126; O'Neill MS, 2007, OCCUP ENVIRON MED, V64, P373, DOI 10.1136/oem.2006.030023; Ostro B, 2010, AM J EPIDEMIOL, V172, P1053, DOI 10.1093/aje/kwq231; Panagiotakos DB, 2004, INT J CARDIOL, V94, P229, DOI 10.1016/j.ijcard.2003.04.050; Park SK, 2006, CIRCULATION, V114, P2798, DOI 10.1161/CIRCULATIONAHA.106.643197; Rayner M, 2009, EUR J CARDIOV PREV R, V16, pS43, DOI 10.1097/01.hjr.0000359235.59808.ba; Schauble CL, 2012, OCCUP ENVIRON MED, V69, P670, DOI 10.1136/oemed-2011-100469; Scheer FAJL, 2010, P NATL ACAD SCI USA, V107, P20541, DOI 10.1073/pnas.1006749107; Sher L, 1999, J AM COLL CARDIOL, V33, P2088; TENG HC, 1955, AM HEART J, V49, P9, DOI 10.1016/0002-8703(55)90049-1; Turner LR, 2012, EPIDEMIOLOGY, V23, P594, DOI 10.1097/EDE.0b013e3182572795; Wichmann J, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-19; Wolf K, 2009, CIRCULATION, V120, P735, DOI 10.1161/CIRCULATIONAHA.108.815860; World Health Organization, 2006, AIR QUAL GUID GLOB U; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	48	40	40	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62059	10.1371/journal.pone.0062059	http://dx.doi.org/10.1371/journal.pone.0062059			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23646115	Green Submitted, gold, Green Published			2023-01-03	WOS:000319077300025
J	Blackhall, LJ				Blackhall, Leslie J.			Do patients need to know they are terminally ill? No	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARE; SURVIVAL; ILLNESS; HOSPICE		Univ Virginia, Sch Med, Charlottesville, VA 22908 USA	University of Virginia	Blackhall, LJ (corresponding author), Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.	LB9X@hscmail.mcc.virginia.edu						Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Blackhall LJ, 2001, J URBAN HEALTH, V78, P59, DOI 10.1093/jurban/78.1.59; Christakis NA, 2000, WESTERN J MED, V172, P310, DOI 10.1136/ewjm.172.5.310; Connor SR, 2007, J PAIN SYMPTOM MANAG, V33, P238, DOI 10.1016/j.jpainsymman.2006.10.010; Curtis JR, 2003, J CRIT CARE, V18, P22, DOI 10.1053/jcrc.2003.YJCRC5; Fried TR, 2003, J AM GERIATR SOC, V51, P1398, DOI 10.1046/j.1532-5415.2003.51457.x; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; Hui D, 2012, J PAIN SYMPTOM MANAG, V43, P582, DOI 10.1016/j.jpainsymman.2011.04.016; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Saito AM, 2011, J PALLIAT MED, V14, P929, DOI 10.1089/jpm.2010.0522; Smith TJ, 2011, NEW ENGL J MED, V364, P2060, DOI 10.1056/NEJMsb1013826; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	12	6	6	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2013	346								f2560	10.1136/bmj.f2560	http://dx.doi.org/10.1136/bmj.f2560			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	134PM	23615595				2023-01-03	WOS:000318224900017
J	Moore, W				Moore, Wendy			Flower power	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												wendymoore@ntlworld.com						Oakeley H, 2012, DOCTORS IN THE MEDIC	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2013	346								f2525	10.1136/bmj.f2525	http://dx.doi.org/10.1136/bmj.f2525			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	134PM	23615592				2023-01-03	WOS:000318224900013
J	Shizu, R; Benoki, S; Numakura, Y; Kodama, S; Miyata, M; Yamazoe, Y; Yoshinari, K				Shizu, Ryota; Benoki, Satoshi; Numakura, Yuki; Kodama, Susumu; Miyata, Masaaki; Yamazoe, Yasushi; Yoshinari, Kouichi			Xenobiotic-Induced Hepatocyte Proliferation Associated with Constitutive Active/Androstane Receptor (CAR) or Peroxisome Proliferator-Activated Receptor alpha (PPAR alpha) Is Enhanced by Pregnane X Receptor (PXR) Activation in Mice	PLOS ONE			English	Article							ANDROSTANE RECEPTOR; MOUSE-LIVER; DRUG-METABOLISM; CELL; HEPATOCARCINOGENESIS; EXPRESSION; PROTEIN; ROLES	Xenobiotic-responsive nuclear receptors pregnane X receptor (PXR), constitutive active/androstane receptor (CAR) and peroxisome proliferator-activated receptor alpha (PPAR alpha) play pivotal roles in the metabolic functions of the liver such as xenobiotics detoxification and energy metabolism. While CAR or PPAR alpha activation induces hepatocyte proliferation and hepatocarcinogenesis in rodent models, it remains unclear whether PXR activation also shows such effects. In the present study, we have investigated the role of PXR in the xenobiotic-induced hepatocyte proliferation with or without CAR activation by 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP) and phenobarbital, or PPAR alpha activation by Wy-14643 in mice. Treatment with TCPOBOP or phenobarbital increased the percentage of Ki-67-positive nuclei as well as mRNA levels of cell proliferation-related genes in livers as expected. On the other hand, treatment with the PXR activator pregnenolone 16 alpha-carbonitrile (PCN) alone showed no such effects. Surprisingly, PCN co-treatment significantly augmented the hepatocyte proliferation induced by CAR activation with TCPOBOP or phenobarbital in wild-type mice but not in PXR-deficient mice. Intriguingly, PXR activation also augmented the hepatocyte proliferation induced by Wy-14643 treatment. Moreover, PCN treatment increased the RNA content of hepatocytes, suggesting the induction of G0/G1 transition, and reduced mRNA levels of Cdkn1b and Rbl2, encoding suppressors of cell cycle initiation. Our present findings indicate that xenobiotic-induced hepatocyte proliferation mediated by CAR or PPAR alpha is enhanced by PXR co-activation despite that PXR activation alone does not cause the cell proliferation in mouse livers. Thus PXR may play a novel and unique role in the hepatocyte/ liver hyperplasia upon exposure to xenobiotics.	[Shizu, Ryota; Benoki, Satoshi; Numakura, Yuki; Kodama, Susumu; Miyata, Masaaki; Yamazoe, Yasushi; Yoshinari, Kouichi] Tohoku Univ, Grad Sch Pharmaceut Sci, Div Drug Metab & Mol Toxicol, Aoba Ku, Sendai, Miyagi 980, Japan	Tohoku University	Yoshinari, K (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Div Drug Metab & Mol Toxicol, Aoba Ku, Sendai, Miyagi 980, Japan.	yoshinari@m.tohoku.ac.jp	Yoshinari, Kouichi/X-8070-2019; Shizu, Ryota/ACP-9957-2022; Yoshinari, Kouichi/V-8156-2019	Yoshinari, Kouichi/0000-0002-2027-2017; Shizu, Ryota/0000-0002-0465-5077	Japan Society for the Promotion of Science (JSPS) [22390027, 24659061]; Japan Chemical Industry Association (JCIA) Long-range Research Initiative (LRI)	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japan Chemical Industry Association (JCIA) Long-range Research Initiative (LRI)	This work was supported in part by Grant-in-Aid for Scientific Research (KAKENHI: #22390027, #24659061) from Japan Society for the Promotion of Science (JSPS) and a grant from the Japan Chemical Industry Association (JCIA) Long-range Research Initiative (LRI). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barton KM, 2008, DEV DYNAM, V237, P672, DOI 10.1002/dvdy.21449; Blanco-Bose WE, 2008, HEPATOLOGY, V48, P1302, DOI 10.1002/hep.22475; BUTLER WH, 1978, BRIT J CANCER, V37, P418, DOI 10.1038/bjc.1978.62; CATTLEY RC, 1989, CANCER RES, V49, P3246; Columbano A, 2005, HEPATOLOGY, V42, P1118, DOI 10.1002/hep.20883; DARZYNKIEWICZ Z, 1980, CYTOMETRY, V1, P98, DOI 10.1002/cyto.990010203; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Gao J, 2010, DRUG METAB DISPOS, V38, P2091, DOI 10.1124/dmd.110.035568; Gonzalez FJ, 2008, TOXICOLOGY, V246, P2, DOI 10.1016/j.tox.2007.09.030; Handschin C, 2003, PHARMACOL REV, V55, P649, DOI 10.1124/pr.55.4.2; Hays T, 2005, CARCINOGENESIS, V26, P219, DOI 10.1093/carcin/bgh285; Huynh H, 2004, CARCINOGENESIS, V25, P1485, DOI 10.1093/carcin/bgh154; Klaunig JE, 2003, CRIT REV TOXICOL, V33, P655, DOI 10.1080/713608372; Konno Y, 2008, DRUG METAB PHARMACOK, V23, P8, DOI 10.2133/dmpk.23.8; Lehmann K, 2012, GASTROENTEROLOGY, V143, P1609, DOI 10.1053/j.gastro.2012.08.043; Liu W, 2011, PROTEOMICS, V11, P3556, DOI 10.1002/pmic.201100157; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Osabe M, 2008, BIOCHEM BIOPH RES CO, V369, P1027, DOI 10.1016/j.bbrc.2008.02.140; Ouyang N, 2010, BRIT J CANCER, V102, P1753, DOI 10.1038/sj.bjc.6605677; Peffer RC, 2007, TOXICOL SCI, V99, P315, DOI 10.1093/toxsci/kfm154; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Ross PK, 2009, TOXICOL APPL PHARM, V235, P199, DOI 10.1016/j.taap.2008.12.011; Schaffer BE, 2010, CANCER RES, V70, P3877, DOI 10.1158/0008-5472.CAN-09-4228; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Sun A, 2007, J CELL BIOCHEM, V102, P1400, DOI 10.1002/jcb.21609; Sun D, 2008, MOL CARCINOGEN, V47, P47, DOI 10.1002/mc.20360; THATCHER NJ, 1994, BIOCHEM SOC T, V22, pS132, DOI 10.1042/bst022132s; Timsit YE, 2007, STEROIDS, V72, P231, DOI 10.1016/j.steroids.2006.12.006; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Williams GM, 1996, EXP TOXICOL PATHOL, V48, P189, DOI 10.1016/S0940-2993(96)80041-8; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Yamamoto Y, 2004, CANCER RES, V64, P7197, DOI 10.1158/0008-5472.CAN-04-1459; Yamamoto Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010121	37	36	36	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e61802	10.1371/journal.pone.0061802	http://dx.doi.org/10.1371/journal.pone.0061802			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131QH	23626729	Green Published, Green Submitted, gold			2023-01-03	WOS:000318008400093
J	Wang, Y; Liu, BY; Yu, JN; Wu, JN; Wang, J; Liu, ZS				Wang, Yang; Liu, Baoyan; Yu, Jinna; Wu, Jiani; Wang, Jing; Liu, Zhishun			Electroacupuncture for Moderate and Severe Benign Prostatic Hyperplasia: A Randomized Controlled Trial	PLOS ONE			English	Article							URINARY-TRACT SYMPTOMS; ACUPUNCTURE; MANAGEMENT	Purpose: To evaluate the effects of electroacupuncture (EA) on the International Prostate Symptom Score (IPSS), postvoid residual urine (PVR), and maximum urinary flow rate (Qmax), and explore the difference between EA at acupoints and non-acupoints in patients with moderate to severe benign prostate hyperplasia (BPH). Subjects and Methods: Men with BPH and IPSS >= 8 were enrolled. Participants were randomly allocated to receive EA at acupoint (treatment group, n = 50) and EA at non-acupoint (control group, n = 50). The primary outcome measure includes the change of IPSS at the 6th week and the secondary outcome measures include changes of PVR and Qmax at the 6th week and change of IPSS at the 18th week. Results: 100/192 patients were included. At the 6th week, treatment group patients had a 4.51 (p<0.001) and 4.12 (p<0.001) points greater decline in IPSS than the control group in the intention to treat (ITT) and per-protocol (PP) populations. At the 18th week, a 3.2 points (p = 0.001) greater decline was found in IPSS for the treatment. No significant differences were found between the two groups in Qmax at the 6th week (p = 0.819). No significant difference was observed in PVR (P = 0.35). Conclusion: Acupoint EA at BL 33 had better effects on IPSS, but no difference on PVR and Qmax as compared with non-acupoint EA. The results indicate that EA is effective in improving patient's quality of life and acupoint may have better therapeutic effects than non-acupoints in acupuncture treatments of BPH.	[Wang, Yang; Yu, Jinna; Wu, Jiani; Wang, Jing; Liu, Zhishun] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China; [Liu, Baoyan] China Acad Chinese Med Sci, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; Guang'anmen Hospital, CACMS; China Academy of Chinese Medical Sciences	Liu, ZS (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Beijing, Peoples R China.	liuzhishun@yahoo.com.cn			"Twelfth Five-Year Plan" of National Science and Technology Support Program [2012BAI24B01]; Guang'anmen Hospital [2009S208]	"Twelfth Five-Year Plan" of National Science and Technology Support Program; Guang'anmen Hospital	This study is supported by a grant from the "Twelfth Five-Year Plan" of National Science and Technology Support Program (Project Number: 2012BAI24B01) and Guang'anmen Hospital (2009S208). No other potential conflict of interest related to this trial. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamowicz W.L., 2011, J CLIN ACUPUNCTURE M, V27, P1; Alraek T, 2002, AM J PUBLIC HEALTH, V92, P1609, DOI 10.2105/AJPH.92.10.1609; American Urology Association, 2012, GUID MAN BEN PROST H; Aune A, 1998, SCAND J PRIM HEALTH, V16, P37; Bruskewitz Reginald C, 2003, Rev Urol, V5, P72; Capodice Jillian L, 2007, Chin Med, V2, P1, DOI 10.1186/1749-8546-2-1; Chapple CR, 2011, EUR UROL, V59, P342, DOI 10.1016/j.eururo.2010.10.046; [程凯 Cheng Kai], 2004, [针刺研究, Acupuncture Research], V29, P204; Chung IM, 2008, NEUROSCI LETT, V439, P18, DOI 10.1016/j.neulet.2008.04.100; Diracoglu D, 2012, J BACK MUSCULOSKELET, V25, P285, DOI 10.3233/BMR-2012-0338; Fang JL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/515893; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; Hino K, 2010, UROLOGY, V75, P730, DOI 10.1016/j.urology.2009.04.025; Hong SK, 2010, BJU INT, V105, P1424, DOI 10.1111/j.1464-410X.2009.08975.x; Johnstone PAS, 2003, J UROLOGY, V169, P1037, DOI 10.1097/01.ju.0000044925.03113.ab; Kalichman L, 2010, J AM BOARD FAM MED, V23, P640, DOI 10.3122/jabfm.2010.05.090296; Karaman MI, 2011, J UROLOGY, V185, P1852, DOI 10.1016/j.juro.2010.12.071; KUBISTA E, 1976, American Journal of Chinese Medicine, V4, P177, DOI 10.1142/S0192415X76000226; Liu ZS, 2011, ACUPUNCT MED, V29, P188, DOI 10.1136/aim.2010.003913; Napadow V, 2012, HUM BRAIN MAPP, DOI 10.1002/hbm.22091; Nickel JC, 2006, CURR OPIN UROL, V16, P5, DOI 10.1097/01.mou.0000193365.46081.cd; PHILP T, 1988, BRIT J UROL, V61, P490, DOI 10.1111/j.1464-410X.1988.tb05086.x; Ricci L, 2004, NEUROUROL URODYNAM, V23, P58, DOI 10.1002/nau.10105; Shuran J, 1987, ACUPUNCTURE REAEARCH, V1, P73; Tanguay S, 2009, CUAJ-CAN UROL ASSOC, V3, pS92; Vignes Jr, 2005, ADV TECH STAND NEUR, V30, P177, DOI 10.1007/3-211-27208-9_5; Wang J, 2001, CLIN EPIDEMIOLOGY DE, P41; Wang QC, 2003, ACUPUNCTURE THERAPEU; Wang Y, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-211; Wendy WL, 2005, UROLCLIN N AM, V32, P11; Xu Bin, 2010, Zhen Ci Yan Jiu, V35, P422; [杨涛 YANG Tao], 2008, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V23, P1028; Yang Tao, 2008, Zhongguo Zhong Xi Yi Jie He Za Zhi, V28, P998; Yu HJ, 2011, BJU INT, V108, P1843, DOI 10.1111/j.1464-410X.2011.10233.x; Yu JS, 2011, EVID-BASED COMPL ALT, V20	35	98	103	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2013	8	4							e59449	10.1371/journal.pone.0059449	http://dx.doi.org/10.1371/journal.pone.0059449			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123JP	23593139	Green Submitted, Green Published, gold			2023-01-03	WOS:000317385300007
J	Rondy, M; Puig-Barbera, J; Launay, O; Duval, X; Castilla, J; Guevara, M; Costanzo, S; Donati, KD; Moren, A				Rondy, Marc; Puig-Barbera, Joan; Launay, Odile; Duval, Xavier; Castilla, Jesus; Guevara, Marcela; Costanzo, Simona; de Gaetano Donati, Katleen; Moren, Alain			2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study	PLOS ONE			English	Article							PREVENTING INFLUENZA; VACCINATION; INFECTIONS; EFFICACY; ENGLAND; COHORT; VIRUS	Background: Influenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estimating the effectiveness of seasonal vaccines against influenza related hospitalisation is important to guide these strategies. Large sample size is needed to have precise estimate of influenza vaccine effectiveness (IVE) against severe outcomes. We assessed the feasibility of measuring seasonal IVE against hospitalisation with laboratory confirmed influenza through a network of 21 hospitals in the European Union. Methods: We conducted a multicentre study in France (seven hospitals), Italy (one hospital), and Navarra (four hospitals) and Valencia (nine hospitals) regions in Spain. All >= 18 years hospitalised patients presenting an influenza-like illness within seven days were swabbed. Cases were patients RT-PCR positive for influenza A (H3N2); controls were patients negative for any influenza virus. Using logistic regression with study site as a fixed effect we calculated IVE adjusted for potential confounders. We restricted the analyses to those swabbed within four days. Results: We included, 375 A(H3N2) cases and 770 controls. The overall adjusted IVE was 24.9% (95% CI-1.8; 44.6). Among the target group for vaccination (N = 1058) the adjusted IVE was 28.8% (95% CI: 2.8; 47.9); it was respectively 36.8% (95% CI: 248.8; 73.1), 42.6% (95% CI: 216.5; 71.7), 17.8%(95% CI: 240.8; 52.1) and 37.5% (95% CI: 222.8;68.2) in the age groups 18-64, 65-74, 75-84 and more than 84 years. Discussion: Estimation of IVE based on the pooling of data obtained through a European network of hospitals was feasible. Our results suggest a low IVE against hospitalised confirmed influenza in 2011-12. The low IVE may be explained by a poor immune response in the high-risk population, imperfect match between vaccine and circulating strain or waning immunity due to a late season. Increased sample size within this network would allow more precise estimates and stratification of the IVE by time since vaccination and vaccine types or brands.	[Rondy, Marc; Moren, Alain] EpiConcept, Paris, France; [Puig-Barbera, Joan] CSISP, Valencia, Spain; [Puig-Barbera, Joan] Ctr Salud Publ Castellon, Castellon de La Plana, Spain; [Launay, Odile; Duval, Xavier] INSERM, Reseau Natl Invest Clin Vaccinol REIVAC, Paris, France; [Launay, Odile] Univ Paris 05, Paris, France; [Launay, Odile] INSERM, Ctr Invest Clin CIC Vaccinol Cochin Pasteur BT505, Paris, France; [Launay, Odile] Hop Cochin, AP HP, F-75674 Paris, France; [Duval, Xavier] Hop Bichat Claude Bernard, AP HP, INSERM, CIC 007, F-75877 Paris 18, France; [Castilla, Jesus; Guevara, Marcela] Inst Salud Publ Navarra, Pamplona, Spain; [Castilla, Jesus; Guevara, Marcela] Ctr Invest Biomed Red CIBER, Barcelona, Spain; [Castilla, Jesus; Guevara, Marcela] Ctr Epidemiol, Barcelona, Spain; [Castilla, Jesus; Guevara, Marcela] Ctr Salud Publ, Barcelona, Spain; [Costanzo, Simona] Fdn Ric & Cura Giovanni Paolo II, Res Labs, Lab Genet & Environm Epidemiol, Campobasso, Italy; [de Gaetano Donati, Katleen] Catholic Univ, Dept Infect Dis, Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Public Health Institute of Navarra; CIBER - Centro de Investigacion Biomedica en Red; IRCCS Istituto Tumori Bari Giovanni Paolo II; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Rondy, M (corresponding author), EpiConcept, Paris, France.	m.rondy@epiconcept.fr	Puig-Barberà, Joan/F-1563-2015; Guevara, Marcela/B-4473-2015; Castilla, Jesus/B-9048-2008; Costanzo, Simona/K-5076-2016	Puig-Barberà, Joan/0000-0001-5783-0409; Guevara, Marcela/0000-0001-9242-6364; Castilla, Jesus/0000-0002-6396-7265; Costanzo, Simona/0000-0003-4569-1186	Sanofi Pasteur; Inserm (Institut national de la sante et de la recherche medicale); GlaxoSmithKline; Sanofi Pasteur MSD; Navarra Health Service; European Centre for Disease Prevention and Control (I-MOVE programme); Carlos III Institute of Health [PS09/01179]; Spanish Ministry of Health [EC11-302]; EpiConcept	Sanofi Pasteur; Inserm (Institut national de la sante et de la recherche medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); GlaxoSmithKline(GlaxoSmithKline); Sanofi Pasteur MSD; Navarra Health Service; European Centre for Disease Prevention and Control (I-MOVE programme); Carlos III Institute of Health(Instituto de Salud Carlos III); Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); EpiConcept	The French study site was funded by Sanofi Pasteur and Inserm (Institut national de la sante et de la recherche medicale). The Italian study was partially supported by GlaxoSmithKline. The Valencia study site was funded by grants from Sanofi Pasteur and Sanofi Pasteur MSD. The study of Navarre was supported by the Navarra Health Service, by the European Centre for Disease Prevention and Control (I-MOVE programme), by the Carlos III Institute of Health (PS09/01179), and by the Spanish Ministry of Health (EC11-302). The pooled analysis was co-funded by the Sanofi Pasteur, Sanofi Pasteur MSD, GlaxoSmithKline and EpiConcept. Vaccine producers had no role in the pooled study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], WHO INFL SEAS; [BEH Haut Conseil de la Sante Publique (HCPS)], 2011, CAL VACC REC VACC 20; Buxton JA, 2001, J INFECT DIS, V184, P188, DOI 10.1086/322013; Castilla J, 2012, EURO SURVEILL, V17; Castilla J, 2013, EURO SURVEILL, V18; Castilla J, 2012, VACCINE, V30, P195, DOI 10.1016/j.vaccine.2011.11.024; Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe, NEWS INFL CHAR SUMM; Conselleria de sanitat Generalitat valenciana, 2012, RED CENT SAN COM VAL; Demicheli V, 2001, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001269.PUB2, 10.1002/14651858.CD001269]; European Centre for Disease Prevention and Control (ECDC), 2012, MAIN SURV DEV WEEK 7; Hardelid P, 2012, VACCINE, V30, P1371, DOI 10.1016/j.vaccine.2011.12.038; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Institut de veille sanitaire, 2012, B HEBD GRIPP POINT 2; Istituto superiore di sanita, 2012, RAPP EP INFLUNET RET; Jimenez-Jorge S, 2012, EURO SURVEILL, V17; Jimenez-Jorge S, 2012, EURSURVEILLANCE, V17; Kissling E, 2013, EURO SURVEILL, V18; Kissling E, 2009, EURO SURVEILL, V14; Kissling E, 2012, EUROSURVEILLANCE, V17; Kissling E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027622; Leekha S, 2007, INFECT CONT HOSP EP, V28, P1071, DOI 10.1086/520101; Madrid: Ministry of Health and Social Policy, PREV GRIP VAC ANT; MAHONEY F I, 1965, Md State Med J, V14, P61; Muller-Pebody B, 2006, EPIDEMIOL INFECT, V134, P1150, DOI 10.1017/S0950268806006376; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Pebody R., 2013, EURO SURVEILL, V18; Petrie JG, 2011, J INFECT DIS, V203, P1309, DOI 10.1093/infdis/jir015; Pitman RJ, 2007, J INFECTION, V54, P530, DOI 10.1016/j.jinf.2006.09.017; Roma: Ministero della Salute, 2012, PREV CONTR INFL RACC; Simonsen L, 2007, LANCET INFECT DIS, V7, P658, DOI 10.1016/S1473-3099(07)70236-0; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Valenciano M, 2012, PROTOCOL HOSP BASED; Valenciano M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000388; Valenciano M, 2010, VACCINE, V28, P7381, DOI 10.1016/j.vaccine.2010.09.010; Van Lier A, 2007, EURO SURVEILL, V12; WHO, 2012, REC COMP INFL VIR VA; Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211	37	28	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2013	8	4							e59681	10.1371/journal.pone.0059681	http://dx.doi.org/10.1371/journal.pone.0059681			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127RY	23565159	Green Published, gold, Green Submitted			2023-01-03	WOS:000317717300028
J	Mayo, C; de los Santos, LF; Kruse, J; Blackwell, CR; McLemore, LB; Pafundi, D; Stoker, J; Herman, M				Mayo, Charles; de los Santos, Luis Fong; Kruse, Jon; Blackwell, Charles R.; McLemore, Luke B.; Pafundi, Deanna; Stoker, Joshua; Herman, Michael			Report on Use of a Methodology for Commissioning and Quality Assurance of a VMAT System	PLOS ONE			English	Article							PASSING RATES; RAPIDARC; QA; DOSIMETRY; DELIVERY	Introduction: Results of use of methodology for VMAT commissioning and quality assurance, utilizing both control point tests and dosimetric measurements are presented. Methods and Materials: A generalizable, phantom measurement approach is used to characterize the accuracy of the measurement system. Correction for angular response of the measurement system and inclusion of couch structures are used to characterize the full range gantry angles desirable for clinical plans. A dose based daily QA measurement approach is defined. Results: Agreement in the static vs. VMAT picket fence control point test was better than 0.5 mm. Control point tests varying gantry rotation speed, leaf speed and dose rate, demonstrated agreement with predicted values better than 1%. Angular dependence of the MatriXX array, varied over a range of 0.94-1.06, with respect to the calibration condition. Phantom measurements demonstrated central axis dose accuracy for un-modulated four field box plans was >= 2.5% vs. 1% with and without angular correction respectively with better results for VMAT (0.4%) vs. IMRT (1.6%) plans. Daily QA results demonstrated average agreement all three chambers within 0.4% over 9 month period with no false positives at a 3% threshold. Discussion: The methodology described is simple in design and characterizes both the inherit limitations of the measurement system as well at the dose based measurements that may be directly related to patient plan QA.	[Mayo, Charles; de los Santos, Luis Fong; Kruse, Jon; Blackwell, Charles R.; McLemore, Luke B.; Pafundi, Deanna; Stoker, Joshua; Herman, Michael] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA	Mayo Clinic	Mayo, C (corresponding author), Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA.	mayo.charles@mayo.edu		Stoker, Joshua/0000-0002-0486-1495				Bedford JL, 2009, INT J RADIAT ONCOL, V73, P537, DOI 10.1016/j.ijrobp.2008.08.055; Chandraraj V, 2011, J APPL CLIN MED PHYS, V12, P338, DOI 10.1120/jacmp.v12i2.3367; Clivio A, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-129; Dobler B, 2011, RADIOTHER ONCOL, V99, P86, DOI 10.1016/j.radonc.2011.01.024; Ezzell GA, 2009, MED PHYS, V36, P5359, DOI 10.1118/1.3238104; Gloi AM, 2011, J APPL CLIN MED PHYS, V12, P39, DOI 10.1120/jacmp.v12i2.3251; Iftimia I, 2010, J APPL CLIN MED PHYS, V11, P130, DOI 10.1120/jacmp.v11i4.3164; Klein EE, 2009, MED PHYS, V36, P4197, DOI 10.1118/1.3190392; Kruse JJ, 2010, MED PHYS, V37, P2516, DOI 10.1118/1.3425781; Ling CC, 2008, INT J RADIAT ONCOL, V72, P575, DOI 10.1016/j.ijrobp.2008.05.060; Masi L, 2011, MED PHYS, V38, P612, DOI 10.1118/1.3533900; Nelms BE, 2011, MED PHYS, V38, P1037, DOI 10.1118/1.3544657; Palta JR, 2003, INTENSITY MODULATED, V29, P593; Van Esch A, 2011, MED PHYS, V38, P5146, DOI 10.1118/1.3622672; Zhen HM, 2011, MED PHYS, V38, P5477, DOI 10.1118/1.3633904	15	0	0	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2013	8	3							e58877	10.1371/journal.pone.0058877	http://dx.doi.org/10.1371/journal.pone.0058877			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	109ZC	23554948	gold, Green Published, Green Submitted			2023-01-03	WOS:000316409800042
J	Kudgus, RA; Szabolcs, A; Khan, JA; Walden, CA; Reid, JM; Robertson, JD; Bhattacharya, R; Mukherjee, P				Kudgus, Rachel A.; Szabolcs, Annamaria; Khan, Jameel Ahmad; Walden, Chad A.; Reid, Joel M.; Robertson, J. David; Bhattacharya, Resham; Mukherjee, Priyabrata			Inhibiting the Growth of Pancreatic Adenocarcinoma In Vitro and In Vivo through Targeted Treatment with Designer Gold Nanotherapeutics	PLOS ONE			English	Article							PHASE-III TRIAL; FACTOR-RECEPTOR; NUCLEOSIDE TRANSPORTERS; COMPARING GEMCITABINE; CANCER NANOTECHNOLOGY; CLINICAL BENEFIT; NANOPARTICLES; SIZE; CHEMISTRY; MECHANISM	Background: Pancreatic cancer is one of the deadliest of all human malignancies with limited options for therapy. Here, we report the development of an optimized targeted drug delivery system to inhibit advanced stage pancreatic tumor growth in an orthotopic mouse model. Method/Principal Findings: Targeting specificity in vitro was confirmed by preincubation of the pancreatic cancer cells with C225 as well as Nitrobenzylthioinosine (NBMPR - nucleoside transporter (NT) inhibitor). Upon nanoconjugation functional activity of gemcitabine was retained as tested using a thymidine incorporation assay. Significant stability of the nanoconjugates was maintained, with only 12% release of gemcitabine over a 24-hour period in mouse plasma. Finally, an in vivo study demonstrated the inhibition of tumor growth through targeted delivery of a low dose of gemcitabine in an orthotopic model of pancreatic cancer, mimicking an advanced stage of the disease. Conclusion: We demonstrated in this study that the gold nanoparticle-based therapeutic containing gemcitabine inhibited tumor growth in an advanced stage of the disease in an orthotopic model of pancreatic cancer. Future work would focus on understanding the pharmacokinetics and combining active targeting with passive targeting to further improve the therapeutic efficacy and increase survival.	[Kudgus, Rachel A.; Szabolcs, Annamaria; Khan, Jameel Ahmad; Bhattacharya, Resham; Mukherjee, Priyabrata] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Walden, Chad A.; Reid, Joel M.; Mukherjee, Priyabrata] Mayo Clin, Coll Med, Dept Physiol & Biomed Engn, Rochester, MN USA; [Robertson, J. David] Univ Missouri, Dept Chem, Columbia, MO 65211 USA; [Robertson, J. David] Univ Missouri, Univ Missouri Res Reactor, Columbia, MO USA; [Mukherjee, Priyabrata] Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Rochester, MN USA	Mayo Clinic; Mayo Clinic; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Mayo Clinic	Mukherjee, P (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	Mukherjee.priyabrata@mayo.edu		Robertson, John/0000-0002-6675-8469	National Institutes of Health [CA135011, CA136494]; NATIONAL CANCER INSTITUTE [R01CA135011, R01CA136494] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by National Institutes of Health CA135011, CA136494 (PM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arvizo RR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033650; Arvizo RR, 2012, CHEM SOC REV, V41, P2943, DOI 10.1039/c2cs15355f; Arvizo RR, 2011, NANOMED-NANOTECHNOL, V7, P580, DOI 10.1016/j.nano.2011.01.011; Bayraktar S, 2010, WORLD J GASTROENTERO, V16, P673, DOI 10.3748/wjg.v16.i6.673; Bhattacharya R, 2008, ADV DRUG DELIVER REV, V60, P1289, DOI 10.1016/j.addr.2008.03.013; Bhattacharyya S, 2011, PHARM RES-DORDR, V28, P237, DOI 10.1007/s11095-010-0318-0; Bramhall SR, 2002, BRIT J CANCER, V87, P161, DOI 10.1038/sj.bjc.6600446; Brigger I, 2012, ADV DRUG DELIV REV; Burda C, 2005, CHEM REV, V105, P1025, DOI 10.1021/cr030063a; Burris H, 1997, EUR J CANCER, V33, pS18, DOI 10.1016/S0959-8049(96)00324-3; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cobley CM, 2011, CHEM SOC REV, V40, P44, DOI 10.1039/b821763g; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+; Dreaden EC, 2012, CHEM SOC REV, V41, P2740, DOI 10.1039/c1cs15237h; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; Giljohann DA, 2009, NATURE, V462, P461, DOI 10.1038/nature08605; Giovannetti E, 2006, CANCER RES, V66, P3928, DOI 10.1158/0008-5472.CAN-05-4203; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Han G, 2007, NANOMEDICINE-UK, V2, P113, DOI 10.2217/17435889.2.1.113; Herbst RS, 2001, EXPERT OPIN BIOL TH, V1, P719, DOI 10.1517/14712598.1.4.719; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Khan JA, 2007, CHEMBIOCHEM, V8, P1237, DOI 10.1002/cbic.200700165; Khan JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020347; Kim ES, 2001, LUNG CANCER-J IASLC, V34, P427, DOI 10.1016/S0169-5002(01)00278-1; Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014; Kindler HL, 2010, J CLIN ONCOL, V28, P3617, DOI 10.1200/JCO.2010.28.1386; Kleeff J, 2006, PANCREAS, V33, P111, DOI 10.1097/01.mpa.0000229010.62538.f2; Kudgus RA, 2011, ANTI-CANCER AGENT ME, V11, P965; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Liao HJ, 2009, CANCER RES, V69, P6179, DOI 10.1158/0008-5472.CAN-09-0049; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mangeney C, 2002, J AM CHEM SOC, V124, P5811, DOI 10.1021/ja010796h; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Mukherjee Priyabrata, 2007, Journal of Nanobiotechnology, V5, P4, DOI 10.1186/1477-3155-5-4; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Paciotti GF, 2004, DRUG DELIV, V11, P169, DOI 10.1080/10717540490433895; Paproski RJ, 2008, MOL PHARMACOL, V74, P1372, DOI 10.1124/mol.108.048900; Patra CR, 2008, CANCER RES, V68, P1970, DOI 10.1158/0008-5472.CAN-07-6102; Patra CR, 2010, ADV DRUG DELIVER REV, V62, P346, DOI 10.1016/j.addr.2009.11.007; Patra CR, 2010, J MATER CHEM, V20, P547, DOI 10.1039/b913224d; Perrault SD, 2009, NANO LETT, V9, P1909, DOI 10.1021/nl900031y; Philip PA, 2010, J CLIN ONCOL, V28, P3605, DOI 10.1200/JCO.2009.25.7550; Philip PA, 2010, SURG ONCOL CLIN N AM, V19, P419, DOI 10.1016/j.soc.2009.11.012; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; Qian XM, 2008, NAT BIOTECHNOL, V26, P83, DOI 10.1038/nbt1377; Rathos MJ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-161; Rocha-Lima Caio M, 2007, Cancer Control, V14, P295; Saha K, 2011, SMALL, V7, P1903, DOI 10.1002/smll.201100478; Sardar R, 2009, LANGMUIR, V25, P13840, DOI 10.1021/la9019475; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Shore S, 2004, SURG ONCOL, V13, P201, DOI 10.1016/j.suronc.2004.11.001; Walczyk D, 2010, J AM CHEM SOC, V132, P5761, DOI 10.1021/ja910675v; Whitesides GM, 2003, NAT BIOTECHNOL, V21, P1161, DOI 10.1038/nbt872; Wong A, 2009, DRUG METAB REV, V41, P77, DOI 10.1080/03602530902741828; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Young JD, 2008, XENOBIOTICA, V38, P995, DOI [10.1080/00498250801927427, 10.1080/00498250801927427 ]	60	28	29	1	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2013	8	3							e57522	10.1371/journal.pone.0057522	http://dx.doi.org/10.1371/journal.pone.0057522			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	117EP	23483913	Green Published, gold, Green Submitted			2023-01-03	WOS:000316936100029
J	Wang, ZL; Tang, XQ; Xu, W; Cao, Z; Sun, L; Li, WM; Li, QB; Zou, P; Zhao, ZG				Wang, Zhenling; Tang, Xiaoqiong; Xu, Wen; Cao, Zeng; Sun, Li; Li, Weiming; Li, Qiubai; Zou, Ping; Zhao, Zhigang			The Different Immunoregulatory Functions on Dendritic Cells between Mesenchymal Stem Cells Derived from Bone Marrow of Patients with Low-Risk or High-Risk Myelodysplastic Syndromes	PLOS ONE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; T-CELLS; INHIBIT; RESPONSES; CANCER; PROLIFERATION; MATURATION; LEUKEMIA; IMMUNITY	Myelodysplastic syndrome (MDS) is a group of progressive, clonal, neoplastic bone marrow disorders characterized by hematopoietic stem cell dysregulation and abnormalities in the immune system. Mesenchymal stem cells (MSC) appear to modulate the immune system at the very first step of the immune response through the inhibition of dendritic cells (DCs) differentiation and maturation. However, it is still unclear whether the effects of MSC on the development of DCs will be altered with disease state. In addition, it is not clear whether there are differences in the effects between low-risk and high-risk MDS-MSC on DCs development. In this study, our data confirm that MDS-MSC mediate a potent inhibition of DCs differentiation. Additionaly, MDS-MSC greatly alter DCs functions, including endocytosis, IL-12 secretion, their ability to inhibit T cell proliferation. Moreover, our results show that there are major differences in DCs development and function between low-risk and high-risk MDS-MSC. Compared to high-risk MDS-MSC, low-risk MDS-MSC is characterized by a poor ability to inhibit DCs differentiation and maturation; and correspondingly, less dysfunctional DC endocytosis, mildly decreased IL-12 secretion, and a reduction in DC-mediated inhibition of T cell proliferation. Finally, our results demonstrate that MDS-MSC derived TGF-beta 1 is largely responsible for the inhitory effects. These results elucidate the different immunoregulatory role of MSC in low-risk and high-risk MDS on DCs development, which may be important for understanding the pathogenesis of MDS and the development of novel immune therapies for the treatment of MDS.	[Wang, Zhenling; Xu, Wen; Zhao, Zhigang] Tianjin Med Univ, Oncol Hosp, Dept Hematol & Oncol, Tianjin, Peoples R China; [Tang, Xiaoqiong] Chongqing Med Univ, Dept Hematol, Inst Hematol, Chongqing, Peoples R China; [Cao, Zeng] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China; [Cao, Zeng] Chinese Acad Med Sci, Blood Dis Hosp, State Key Lab Expt Method Hematol, Tianjin, Peoples R China; [Cao, Zeng] Peking Union Med Coll, Tianjin, Peoples R China; [Sun, Li; Li, Weiming; Li, Qiubai; Zou, Ping] Huazhong Univ Sci & Technol, Dept Hematol, Inst Hematol, Tongji Med Coll, Wuhan 430074, Peoples R China	Tianjin Medical University; Chongqing Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Huazhong University of Science & Technology	Zhao, ZG (corresponding author), Tianjin Med Univ, Oncol Hosp, Dept Hematol & Oncol, Tianjin, Peoples R China.	zhaodor001@gmail.com	Li, Qiubai/GWQ-9911-2022		National Natural Science Foundation [30801051, 81172833]; Tianjin Application Foundation; Advanced Technology Research Program [08JCYBJC06500, 09JCYBJC11000]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Tianjin Application Foundation; Advanced Technology Research Program	This work is supported by grants from National Natural Science Foundation (30801051; 81172833) and Tianjin Application Foundation and Advanced Technology Research Program (08JCYBJC06500; 09JCYBJC11000). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Aggarwal S, 2011, BRIT J HAEMATOL, V153, P568, DOI 10.1111/j.1365-2141.2011.08683.x; Alfinito F, 2010, BRIT J HAEMATOL, V148, P90, DOI 10.1111/j.1365-2141.2009.07921.x; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Buck MB, 2006, ANN NY ACAD SCI, V1089, P119, DOI 10.1196/annals.1386.024; Chan AC, 2010, LEUKEMIA, V24, P592, DOI 10.1038/leu.2009.279; Chen Wanjun, 2002, Curr Dir Autoimmun, V5, P62; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Djouad F, 2007, STEM CELLS, V25, P2025, DOI 10.1634/stemcells.2006-0548; Epperson DE, 2001, LEUKEMIA RES, V25, P1075, DOI 10.1016/S0145-2126(01)00083-2; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Guo H, 2003, EXP HEMATOL, V31, P650, DOI 10.1016/S0301-472X(03)00087-0; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Kordasti SY, 2007, BLOOD, V110, P847, DOI 10.1182/blood-2007-01-067546; Kordasti SY, 2009, BRIT J HAEMATOL, V145, P64, DOI 10.1111/j.1365-2141.2009.07593.x; Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104; Maciejewski JP, 2007, FOLIA HISTOCHEM CYTO, V45, P5; Mantel PY, 2011, METHODS MOL BIOL, V677, P303, DOI 10.1007/978-1-60761-869-0_21; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997; Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943; Tauro S, 2002, LEUKEMIA, V16, P785, DOI 10.1038/sj.leu.2402440; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Wlodarski MW, 2005, BLOOD, V106, P2769, DOI 10.1182/blood-2004-10-4045; Zhang W, 2004, STEM CELLS DEV, V13, P263, DOI 10.1089/154732804323099190; Zhao ZG, 2008, IMMUNOL INVEST, V37, P726, DOI 10.1080/08820130802349940; Zhao ZG, 2012, CANCER LETT, V317, P136, DOI 10.1016/j.canlet.2011.08.030; Zou P, 2008, LEUKEMIA LYMPHOMA, V9, P2187	33	28	31	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2013	8	3							e57470	10.1371/journal.pone.0057470	http://dx.doi.org/10.1371/journal.pone.0057470			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099PY	23469196	Green Submitted, Green Published, gold			2023-01-03	WOS:000315634900023
J	Griffin, MR; Zhu, YW; Moore, MR; Whitney, CG; Grijalva, CG				Griffin, Marie R.; Zhu, Yuwei; Moore, Matthew R.; Whitney, Cynthia G.; Grijalva, Carlos G.			US Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; CHILDHOOD IMMUNIZATION; YOUNG-CHILDREN; DISEASE; IMPACT; PREVENTION; SEROTYPES; CARRIAGE; TRENDS	BACKGROUND The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) into the U. S. childhood immunization schedule in 2000 has substantially reduced the incidence of vaccine-serotype invasive pneumococcal disease in young children and in unvaccinated older children and adults. By 2004, hospitalizations associated with pneumonia from any cause had also declined markedly among young children. Because of concerns about increases in disease caused by nonvaccine serotypes, we wanted to determine whether the reduction in pneumonia-related hospitalizations among young children had been sustained through 2009 and whether such hospitalizations in older age groups had also declined. METHODS We estimated annual rates of hospitalization for pneumonia from any cause using the Nationwide Inpatient Sample database. The reason for hospitalization was classified as pneumonia if pneumonia was the first listed diagnosis or if it was listed after a first diagnosis of sepsis, meningitis, or empyema. Average annual rates of pneumonia-related hospitalizations from 1997 through 1999 (before the introduction of PCV7) and from 2007 through 2009 (well after its introduction) were used to estimate annual declines in hospitalizations due to pneumonia. RESULTS The annual rate of hospitalization for pneumonia among children younger than 2 years of age declined by 551.1 per 100,000 children (95% confidence interval [CI], 445.1 to 657.1), which translates to 47,000 fewer hospitalizations annually than expected on the basis of the rates before PCV7 was introduced. The rate for adults 85 years of age or older declined by 1300.8 per 100,000 (95% CI, 984.0 to 1617.6), which translates to 73,000 fewer hospitalizations annually. For the three age groups of 18 to 39 years, 65 to 74 years, and 75 to 84 years, the annual rate of hospitalization for pneumonia declined by 8.4 per 100,000 (95% CI, 0.6 to 16.2), 85.3 per 100,000 (95% CI, 7.0 to 163.6), and 359.8 per 100,000 (95% CI, 199.6 to 520.0), respectively. Overall, we estimated an age-adjusted annual reduction of 54.8 per 100,000 (95% CI, 41.0 to 68.5), or 168,000 fewer hospitalizations for pneumonia annually. CONCLUSIONS Declines in hospitalizations for childhood pneumonia were sustained during the decade after the introduction of PCV7. Substantial reductions in hospitalizations for pneumonia among adults were also observed. (Funded by the Centers for Disease Control and Prevention.)	[Griffin, Marie R.; Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; [Griffin, Marie R.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Griffin, Marie R.; Grijalva, Carlos G.] Vet Affairs Tennessee Valley Hlth Care Syst, Midsouth Geriatr Res Educ & Clin Ctr, Nashville, TN USA; [Moore, Matthew R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Centers for Disease Control & Prevention - USA	Griffin, MR (corresponding author), Village Vanderbilt, Dept Prevent Med, Suite 2600,1500 21st Ave S, Nashville, TN 37212 USA.	marie.griffin@vanderbilt.edu		Grijalva, Carlos/0000-0002-2329-7797	Centers for Disease Control and Prevention [11-IPA1110211, 12-IPA1210402]; Thrasher Research Fund [02832-9]; Glaxo-SmithKline; Pfizer	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Thrasher Research Fund; Glaxo-SmithKline(GlaxoSmithKline); Pfizer(Pfizer)	Supported in part by grants from the Centers for Disease Control and Prevention (11-IPA1110211, to Dr. Griffin, and 12-IPA1210402, to Dr. Grijalva) and the Thrasher Research Fund (02832-9, to Dr. Grijalva).; Dr. Grijalva reports receiving consulting fees from Glaxo-SmithKline and grant support through his institution from Pfizer; and Dr. Griffin, grant support through her institution from Pfizer. No other potential conflict of interest relevant to this article was reported.	Agency for Healthcare Research and Quality (US), 2009, FACTS FIG STAT HOSP; Bartlett JG, 2011, CLIN INFECT DIS, V52, pS296, DOI 10.1093/cid/cir045; Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816; Bewick T, 2012, THORAX, V67, P540, DOI 10.1136/thoraxjnl-2011-201092; Centers for Disease Control and Prevention, SEAS INFL FLU VACC T; Cohen AL, 2010, AIDS, V24, P2253, DOI 10.1097/QAD.0b013e32833d46fd; Feikin DR, 2005, CLIN INFECT DIS, V41, P481, DOI 10.1086/432015; French N, 2010, NEW ENGL J MED, V362, P812, DOI 10.1056/NEJMoa0903029; Fry AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/jama.294.21.2712; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9; Grijalva CG, 2006, PEDIATRICS, V118, P865, DOI 10.1542/peds.2006-0492; Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573; Grijalva CG, 2009, JAMA-J AM MED ASSOC, V302, P758, DOI 10.1001/jama.2009.1163; Hammitt LL, 2006, J INFECT DIS, V193, P1487, DOI 10.1086/503805; Hansen J, 2006, PEDIATR INFECT DIS J, V25, P779, DOI 10.1097/01.inf.0000232706.35674.2f; Huang SS, 2009, PEDIATRICS, V124, pE1, DOI 10.1542/peds.2008-3099; Jardine A, 2010, PEDIATR INFECT DIS J, V29, P607, DOI 10.1097/INF.0b013e3181d7d09c; Kayhty H, 2006, EXPERT REV VACCINES, V5, P651, DOI 10.1586/14760584.5.5.651; Klugman K P, 2001, Lancet Infect Dis, V1, P85, DOI 10.1016/S1473-3099(01)00063-9; Koshy E, 2010, THORAX, V65, P770, DOI 10.1136/thx.2010.137802; Lindenauer PK, 2012, JAMA-J AM MED ASSOC, V307, P1405, DOI 10.1001/jama.2012.384; Muhammad Riyadh D, 2013, Clin Infect Dis, V56, pe59, DOI 10.1093/cid/cis971; Musher DM, 2012, CLIN INFECT DIS, V55, P265, DOI 10.1093/cid/cis364; O'Brien KL, 2009, PEDIATR INFECT DIS J, V28, P463, DOI 10.1097/INF.0b013e31819b9085; Pelton SI, 2004, PEDIATR INFECT DIS J, V23, P1015, DOI 10.1097/01.inf.0000143645.58215.f0; Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593; Poehling KA, 2004, PEDIATRICS, V114, P755, DOI 10.1542/peds.2003-0592-F; Potter R., 2009, Morbidity and Mortality Weekly Report, V58, P1059; Rosen JB, 2011, CLIN INFECT DIS, V53, P137, DOI 10.1093/cid/cir326; Shapiro ED, 2012, JAMA-J AM MED ASSOC, V307, P847, DOI 10.1001/jama.2012.194; Simonsen L, 2011, MBIO, V2, DOI 10.1128/mBio.00309-10; Singleton RJ, 2007, JAMA-J AM MED ASSOC, V297, P1784, DOI 10.1001/jama.297.16.1784; Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Wroe PC, 2012, PEDIATR INFECT DIS J, V31, P249, DOI 10.1097/INF.0b013e31824214ac; Zhou FJ, 2007, ARCH PEDIAT ADOL MED, V161, P1162, DOI 10.1001/archpedi.161.12.1162	37	372	386	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2013	369	2					155	163		10.1056/NEJMoa1209165	http://dx.doi.org/10.1056/NEJMoa1209165			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180BH	23841730	Green Accepted			2023-01-03	WOS:000321567300011
J	Zhang, YM; Gao, B; Wang, JJ; Sun, XD; Liu, XW				Zhang, Yu-ming; Gao, Bo; Wang, Juan-juan; Sun, Xu-de; Liu, Xi-wen			Effect of Hypotensive Resuscitation with a Novel Combination of Fluids in a Rabbit Model of Uncontrolled Hemorrhagic Shock	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; HYPERTONIC SALINE; LUNG INJURY; INFLAMMATORY RESPONSE; HYPOVOLEMIC SHOCK; OXIDATIVE STRESS; TRAUMA; RATS; STRATEGIES; PREVENTS	Objective: The aim of this study was to compare the effects of hypotensive and normotensive resuscitation with a novel combination of fluids via lactate Ringer's solution (LRS), 6% hydroxyethyl starch 130/0.4 solution (HES), and 7.5% hypertonic saline solution (HSS) at early stage of uncontrolled hemorrhagic shock (UHS) before hemostasis. Methods: New Zealand white rabbits (n = 32) underwent UHS by transecting the splenic parenchyma, followed by blood withdrawal via the femoral artery to target mean arterial pressure (MAP) of 40-45 mmHg. Animals were distributed randomly into 4 groups (n = 8): in group Sham, sham operation was performed; in group HS, UHS was untreated; in group HS-HR, UHS was treated by hypotensive resuscitation with HSS and LRS+HES (ratio of 2:1) to MAP of 50-55 mmHg; in group HS-NR, UHS was treated by normotensive resuscitation with HSS and LRS+HES (ratio of 2:1) to MAP of 75-80 mmHg. Outcomes of hemodynamics, inflammatory and oxidative response, and other metabolic variables were measured and the histopathological studies of heart, lung and kidney were performed at the end of resusucitation. Results: Hypotensive resuscitation with the novel combination of fluids for UHS rabbits decreased blood loss, maintained better stabilization of hemodynamics, and resulted in relatively higher hematocrit and platelet count, superior outcomes of blood gas, and lower plasma lactate concentration. Besides, hypotensive resuscitation attenuated the inflammatory and oxidative response significantly in UHS rabbits. Conclusion: Hypotensive resuscitation with the novel combination of fluids via HSS and LRS+HES (ratio of 2:1) has an effective treatment at early stage of UHS before hemostasis.	[Zhang, Yu-ming; Sun, Xu-de] Fourth Mil Med Univ, Tangdu Hosp, Dept Anesthesiol, Xian 710032, Peoples R China; [Wang, Juan-juan] Yanan Univ, Affiliated Hosp, Dept Surg, Yanan, Peoples R China; [Gao, Bo] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped Surg, Xian 710032, Peoples R China; [Liu, Xi-wen] Fourth Mil Med Univ, Dept Nursing, Xian 710032, Peoples R China	Air Force Military Medical University; Yanan University; Air Force Military Medical University; Air Force Military Medical University	Sun, XD (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Anesthesiol, Xian 710032, Peoples R China.	sunxude@fmmu.edu.cn; liuwen@fmmu.edu.cn	wang, juanjuan/GYV-5540-2022; liu, xiwen/GSJ-3861-2022		Army Medical Health Research Fund of China [08G109]	Army Medical Health Research Fund of China	This study was supported by the Army Medical Health Research Fund of China 08G109. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bahrami S, 2006, SHOCK, V25, P283, DOI 10.1097/01.shk.0000208808.03148.ea; Beer KAS, 2013, JAVMA-J AM VET MED A, V242, P54, DOI 10.2460/javma.242.1.54; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Catrambone JE, 2008, EUR J TRAUMA EMERG S, V34, P397, DOI 10.1007/s00068-007-7068-7; Cherkas David, 2011, Emerg Med Pract, V13, P1; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Crimi E, 2006, AM J RESP CRIT CARE, V174, P178, DOI 10.1164/rccm.200507-1178OC; Curry N, 2012, INJURY, V43, P1021, DOI 10.1016/j.injury.2012.03.014; DEFELIPPE J, 1980, LANCET, V2, P1002; Frithiof R, 2011, AM J PHYSIOL-HEART C, V300, pH685, DOI 10.1152/ajpheart.00930.2010; Gecit I, 2011, BIOL TRACE ELEM RES, V144, P1069, DOI 10.1007/s12011-011-9124-8; Hashiguchi N, 2007, J TRAUMA, V62, P299, DOI 10.1097/01.ta.0000222956.88760.33; Hatanaka E, 2007, SHOCK, V27, P32, DOI 10.1097/01.shk.0000238061.69579.a5; Hauser CJ, 2005, SHOCK, V24, P24, DOI 10.1097/01.shk.0000191387.18818.43; Hussmann B, 2011, UNFALLCHIRURG, V114, P705, DOI 10.1007/s00113-010-1842-4; James MFM, 2011, BRIT J ANAESTH, V107, P693, DOI 10.1093/bja/aer229; Klein CL, 2008, KIDNEY INT, V74, P901, DOI 10.1038/ki.2008.314; Li T, 2011, J SURG RES, V169, P76, DOI 10.1016/j.jss.2010.02.001; Li T, 2011, ANESTHESIOLOGY, V114, P111, DOI 10.1097/ALN.0b013e3181fe3fe7; Matsuoka T, 1996, J TRAUMA, V40, P915, DOI 10.1097/00005373-199606000-00009; Montassier E, 2012, AM J EMERG MED, V30, P184, DOI 10.1016/j.ajem.2010.09.033; Moran A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021449; MORITA H, 1987, J AUTONOM NERV SYST, V20, P57, DOI 10.1016/0165-1838(87)90081-6; Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea; Park Marcelo, 2006, Clinics, V61, P47, DOI 10.1590/S1807-59322006000100009; Perkins JG, 2009, J TRAUMA, V66, pS77, DOI 10.1097/TA.0b013e31819d8936; Rossaint R, 2010, CRIT CARE, V14, DOI 10.1186/cc8943; Santry HP, 2010, SHOCK, V33, P229, DOI 10.1097/SHK.0b013e3181c30f0c; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Shah SK, 2011, J SURG RES, V166, P120, DOI 10.1016/j.jss.2009.09.010; Solomonov E, 2000, CRIT CARE MED, V28, P749, DOI 10.1097/00003246-200003000-00024; Wang PF, 2009, INT IMMUNOPHARMACOL, V9, P347, DOI 10.1016/j.intimp.2008.12.014; Watters JM, 2006, J TRAUMA, V61, P75, DOI 10.1097/01.ta.0000222723.54559.47; White NJ, 2010, RESUSCITATION, V81, P111, DOI 10.1016/j.resuscitation.2009.09.017; White SA, 1997, ANAESTHESIA, V52, P422, DOI 10.1111/j.1365-2044.1997.090-az0082.x; Wohlauer M, 2012, CRIT CARE MED, V40, P2647, DOI 10.1097/CCM.0b013e3182592006; Wu BU, 2011, CLIN GASTROENTEROL H, V9, P710, DOI 10.1016/j.cgh.2011.04.026; Yu GF, 2012, PULM PHARMACOL THER, V25, P27, DOI 10.1016/j.pupt.2011.10.003; Yu YH, 2009, RESUSCITATION, V80, P1424, DOI 10.1016/j.resuscitation.2009.08.024	40	5	9	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2013	8	6							e66916	10.1371/journal.pone.0066916	http://dx.doi.org/10.1371/journal.pone.0066916			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	170JP	23805284	Green Published, gold, Green Submitted			2023-01-03	WOS:000320846500112
J	Parker, MJ				Parker, Martyn J.			PERSONAL VIEW We need an alternative to the Liverpool care pathway for patients who might recover	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Peterborough & Stamford Hosp NHS Fdn Trust, Peterborough City Hosp, Dept Orthopaed, Peterborough PE3 9GZ, Cambs, England		Parker, MJ (corresponding author), Peterborough & Stamford Hosp NHS Fdn Trust, Peterborough City Hosp, Dept Orthopaed, Peterborough PE3 9GZ, Cambs, England.	Martyn.Parker@pbh-tr.nhs.uk						Chinthapalli K, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1184; National Institute for Health and Care Excellence, 2011, GUID COMM END LIF CA; Royal Brompton and Harefield NHS Foundation Trust, QUAL ACC 2010 11	3	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 11	2013	346								f3702	10.1136/bmj.f3702	http://dx.doi.org/10.1136/bmj.f3702			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166VQ	23757741				2023-01-03	WOS:000320587600003
J	Sharma, N; Sequea, DA; Castorena, CM; Arias, EB; Qi, NR; Cartee, GD				Sharma, Naveen; Sequea, Donel A.; Castorena, Carlos M.; Arias, Edward B.; Qi, Nathan R.; Cartee, Gregory D.			Heterogeneous Effects of Calorie Restriction on In Vivo Glucose Uptake and Insulin Signaling of Individual Rat Skeletal Muscles	PLOS ONE			English	Article							BRIEF DIETARY RESTRICTION; INCREASES INSULIN; AKT2 PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; FOOD RESTRICTION; TRANSPORT; SENSITIVITY; EXERCISE; PROTEIN; GLUT4	Calorie restriction (CR) (consuming,60% of ad libitum, AL, intake) improves whole body insulin sensitivity and enhances insulin-stimulated glucose uptake by isolated skeletal muscles. However, little is known about CR-effects on in vivo glucose uptake and insulin signaling in muscle. Accordingly, 9-month-old male AL and CR (initiated when 3-months-old) Fischer 344xBrown Norway rats were studied using a euglycemic-hyperinsulinemic clamp with plasma insulin elevated to a similar level (similar to 140 mu U/ml) in each diet group. Glucose uptake (assessed by infusion of [C-14]-2-deoxyglucose, 2-DG), phosphorylation of key insulin signaling proteins (insulin receptor, Akt and Akt substrate of 160kDa, AS160), abundance of GLUT4 and hexokinase proteins, and muscle fiber type composition (myosin heavy chain, MHC, isoform percentages) were determined in four predominantly fast-twitch (epitrochlearis, gastrocnemius, tibialis anterior, plantaris) and two predominantly slow-twitch (soleus, adductor longus) muscles. CR did not result in greater GLUT4 or hexokinase abundance in any of the muscles, and there were no significant diet-related effects on percentages of MHC isoforms. Glucose infusion was greater for CR versus AL rats (P<0.05) concomitant with significantly (P<0.05) elevated 2-DG uptake in 3 of the 4 fast-twitch muscles (epitrochlearis, gastrocnemius, tibialis anterior), without a significant diet-effect on 2-DG uptake by the plantaris or either slow-twitch muscle. Each of the muscles with a CR-related increase in 2-DG uptake was also characterized by significant (P<0.05) increases in phosphorylation of both Akt and AS160. Among the 3 muscles without a CR-related increase in glucose uptake, only the soleus had significant (P<0.05) CR-related increases in Akt and AS160 phosphorylation. The current data revealed that CR leads to greater whole body glucose disposal in part attributable to elevated in vivo insulin-stimulated glucose uptake by fast-twitch muscles. The results also demonstrated that CR does not uniformly enhance either insulin signaling or insulin-stimulated glucose uptake in all muscles in vivo.	[Sharma, Naveen; Castorena, Carlos M.; Arias, Edward B.; Cartee, Gregory D.] Univ Michigan, Sch Kinesiol, Muscle Biol Lab, Ann Arbor, MI 48109 USA; [Sequea, Donel A.; Cartee, Gregory D.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Qi, Nathan R.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Cartee, Gregory D.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Cartee, GD (corresponding author), Univ Michigan, Sch Kinesiol, Muscle Biol Lab, Ann Arbor, MI 48109 USA.	gcartee@umich.edu	Sharma, Naveen/K-6672-2015	Sharma, Naveen/0000-0003-4705-5116; Cartee, Gregory/0000-0001-5311-1722	National Institutes of Health [AG-010026, AG-013283, T32-AG000114, DK-089503]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020572, P30DK089503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114, R01AG010026, P30AG013283, R29AG010026] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institutes of Health grants AG-010026, AG-013283, T32-AG000114, and DK-089503. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arciero PJ, 1999, J APPL PHYSIOL, V86, P1930, DOI 10.1152/jappl.1999.86.6.1930; CARTEE GD, 1994, AM J PHYSIOL, V266, pR1443, DOI 10.1152/ajpregu.1994.266.5.R1443; CARTEE GD, 1994, AM J PHYSIOL, V266, pE946, DOI 10.1152/ajpendo.1994.266.6.E946; Cartee GD, 2007, APPL PHYSIOL NUTR ME, V32, P557, DOI 10.1139/H07-026; Cartee GD, 2009, EXERC SPORT SCI REV, V37, P188, DOI 10.1097/JES.0b013e3181b7b7c5; Davidson RT, 2002, AM J PHYSIOL-ENDOC M, V282, pE270, DOI 10.1152/ajpendo.00232.2001; Dean DJ, 1996, J GERONTOL A-BIOL, V51, pB208, DOI 10.1093/gerona/51A.3.B208; Dean DJ, 1998, AM J PHYSIOL-ENDOC M, V275, pE957, DOI 10.1152/ajpendo.1998.275.6.E957; Dean DJ, 1998, AGING-CLIN EXP RES, V10, P303, DOI 10.1007/BF03339792; Dean DJ, 2000, ACTA PHYSIOL SCAND, V169, P133, DOI 10.1046/j.1365-201x.2000.00723.x; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Escriva F, 2007, J ENDOCRINOL, V194, P131, DOI 10.1677/joe.1.07043; Feuers RJ, 1995, DIETARY RESTRICTION, P181; Gazdag AC, 2000, J GERONTOL A-BIOL, V55, pB44; Gazdag AC, 2000, AM J PHYSIOL-REG I, V278, pR504, DOI 10.1152/ajpregu.2000.278.2.R504; Gazdag AC, 1999, DIABETES, V48, P1930, DOI 10.2337/diabetes.48.10.1930; Gazdag AC, 1998, BIOCHEM BIOPH RES CO, V252, P733, DOI 10.1006/bbrc.1998.9713; Geiger PC, 2003, J APPL PHYSIOL, V95, P611, DOI 10.1152/japplphysiol.00862.2002; Gupta G, 2000, AM J PHYSIOL-REG I, V278, pR111, DOI 10.1152/ajpregu.2000.278.1.R111; Halseth AE, 1999, AM J PHYSIOL-ENDOC M, V276, pE70, DOI 10.1152/ajpendo.1999.276.1.E70; Halseth AE, 2001, AM J PHYSIOL-ENDOC M, V280, pE994, DOI 10.1152/ajpendo.2001.280.6.E994; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; IVY JL, 1991, MECH AGEING DEV, V61, P123, DOI 10.1016/0047-6374(91)90011-N; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540; Kramer HF, 2006, J BIOL CHEM, V281, P31478, DOI 10.1074/jbc.M605461200; Lang G., 1974, METHODS ENZYMATIC AN, P1238; Lawler DF, 2008, BRIT J NUTR, V99, P793, DOI 10.1017/S0007114507871686; McCurdy CE, 2005, DIABETES, V54, P1349, DOI 10.2337/diabetes.54.5.1349; McCurdy CE, 2005, AM J PHYSIOL-ENDOC M, V288, pE996, DOI 10.1152/ajpendo.00566.2004; McCurdy CE, 2003, AM J PHYSIOL-ENDOC M, V285, pE693, DOI 10.1152/ajpendo.00224.2003; Petersen HA, 2003, AM J PHYSIOL-ENDOC M, V284, pE541, DOI 10.1152/ajpendo.00323.2002; Petersen KF, 2012, P NATL ACAD SCI US; Sakamoto K, 2008, AM J PHYSIOL-ENDOC M, V295, pE29, DOI 10.1152/ajpendo.90331.2008; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Schenk S, 2011, J CLIN INVEST, V121, P4281, DOI 10.1172/JCI58554; Sequea DA, 2012, J GERONTOL A; Sharma N, 2012, AM J PHYSL REGUL INT; Sharma N, 2012, BBA-MOL BASIS DIS, V1822, P1735, DOI 10.1016/j.bbadis.2012.07.012; Sharma N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038835; Sharma N, 2011, AM J PHYSIOL-ENDOC M, V300, pE966, DOI 10.1152/ajpendo.00659.2010; TALMADGE RJ, 1993, J APPL PHYSIOL, V75, P2337, DOI 10.1152/jappl.1993.75.5.2337; Tonge DP, 2010, OSTEOARTHR CARTILAGE, V18, P555, DOI 10.1016/j.joca.2009.11.014; WING RR, 1994, DIABETES CARE, V17, P30, DOI 10.2337/diacare.17.1.30	45	8	8	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2013	8	6							e65118	10.1371/journal.pone.0065118	http://dx.doi.org/10.1371/journal.pone.0065118			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157CD	23755179	gold, Green Published, Green Submitted			2023-01-03	WOS:000319872300049
J	Huang, YT; Wen, CC; Chen, YH; Huang, WC; Huang, LT; Lin, WC; Arulselvan, P; Liao, JW; Lin, SH; Hsiao, PW; Kuo, SC; Yang, NS				Huang, Yuh-Ting; Wen, Chih-Chun; Chen, Yung-Hsiang; Huang, Wen-Ching; Huang, Li-Ting; Lin, Wen-Ching; Arulselvan, Palanisamy; Liao, Jiunn-Wang; Lin, Shu-Hui; Hsiao, Pei-Wen; Kuo, Sheng-Chu; Yang, Ning-Sun			Dietary Uptake of Wedelia chinensis Extract Attenuates Dextran Sulfate Sodium-Induced Colitis in Mice	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; TNBS-INDUCED COLITIS; MATRIX METALLOPROTEINASES; INTESTINAL INFLAMMATION; ANTIOXIDANT ACTIVITY; COLORECTAL-CANCER; NITRIC-OXIDE; MOUSE MODEL; EXPRESSION; ARTICLE	Scope: Traditional medicinal herbs are increasingly used as alternative therapies in patients with inflammatory diseases. Here we evaluated the effect of Wedelia chinensis, a medicinal herb commonly used in Asia, on the prevention of dextran sulfate sodium (DSS)-induced acute colitis in mice. General safety and the effect of different extraction methods on the bioactivity of W. chinensis were also explored. Methods and Results: C57BL/6 mice were administrated hot water extract of fresh W. chinensis (WCHF) orally for one week followed by drinking water containing 2% DSS for nine days. WCHF significantly attenuated the symptoms of colitis including diarrhea, rectal bleeding and loss of body weight; it also reduced the shortening of colon length and histopathological damage caused by colonic inflammation. Among four W. chinensis extracts prepared using different extraction techniques, WCHF showed the highest anti-colitis efficacy. Analyses of specific T-cell regulatory cytokines (TNF-alpha, IL-4, IFN-gamma, IL-17, TGF-beta, IL-12) revealed that WCHF treatment can suppress the Th1 and Th17, but not Th2, responses in colon tissues and dendritic cells of DSS-induced colitis mice. A 28-day subacute toxicity study showed that daily oral administration of WCHF (100, 500, 1000 mg/kg body weight) was not toxic to mice. Conclusion: Together, our findings suggest that specific extracts of W. chinensis have nutritional potential for future development into nutraceuticals or dietary supplements for treatment of inflammatory bowel disease.	[Huang, Yuh-Ting; Chen, Yung-Hsiang; Huang, Wen-Ching; Huang, Li-Ting; Lin, Wen-Ching; Arulselvan, Palanisamy; Hsiao, Pei-Wen; Yang, Ning-Sun] Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan; [Kuo, Sheng-Chu] China Med Univ, Grad Inst Pharmaceut Chem, Taichung, Taiwan; [Liao, Jiunn-Wang] Natl Chung Hsing Univ, Grad Inst Vet Pathol, Taichung 40227, Taiwan; [Wen, Chih-Chun; Lin, Shu-Hui] One Power Bio Technol Co Ltd, Taipei, Taiwan	Academia Sinica - Taiwan; China Medical University Taiwan; National Chung Hsing University	Yang, NS (corresponding author), Acad Sinica, Agr Biotechnol Res Ctr, Taipei 115, Taiwan.	nsyang@gate.sinica.edu.tw	Arulselvan, Palanisamy/M-6388-2014; Hsiao, Pei-Wen/V-5653-2018	Arulselvan, Palanisamy/0000-0002-1835-9738; Liao, Jiunn-Wang/0000-0001-7374-1203; Hsiao, Pei-Wen/0000-0002-3589-6754	National Science Council, Taiwan, R.O.C [NSC-97-2317-B-001-010-CC2, NSC-98-2324-B-001-002-CC2, NSC-99-2324-B-001-003-CC2]	National Science Council, Taiwan, R.O.C(Ministry of Science and Technology, Taiwan)	This work was supported by grants (NSC-97-2317-B-001-010-CC2, NSC-98-2324-B-001-002-CC2 and NSC-99-2324-B-001-003-CC2) from the National Science Council, Taiwan, R.O.C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alex P, 2009, INFLAMM BOWEL DIS, V15, P341, DOI 10.1002/ibd.20753; Amin I, 2006, FOOD CHEM, V94, P47, DOI 10.1016/j.foodchem.2004.10.048; BABCOCK MB, 1975, AM J ANAT, V143, P399, DOI 10.1002/aja.1001430402; Berndt BE, 2007, J IMMUNOL, V179, P6255, DOI 10.4049/jimmunol.179.9.6255; Capecka E, 2005, FOOD CHEM, V93, P223, DOI 10.1016/j.foodchem.2004.09.020; Chen HM, 2012, CANCER IMMUNOL IMMUN, V61, P1989, DOI 10.1007/s00262-012-1258-9; Choi YA, 2005, INT J MOL MED, V16, P667; COOPER HS, 1993, LAB INVEST, V69, P238; Dijkstra G, 2007, INFLAMM BOWEL DIS, V13, P1467, DOI 10.1002/ibd.20262; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Garg P, 2009, AM J PHYSIOL-GASTR L, V296, pG175, DOI 10.1152/ajpgi.90454.2008; Grisham MB, 2002, J INVEST MED, V50, P272, DOI 10.2310/6650.2002.33281; HAMMAD ESF, 1982, DIGEST DIS SCI, V27, P680, DOI 10.1007/BF01393762; Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68; Hanauer SB, 2004, ALIMENT PHARM THER, V20, P60, DOI 10.1111/j.1365-2036.2004.02048.x; Huang T. C., 1998, FLORA TAIWAN; Huang TC, 2010, WORLD J GASTROENTERO, V16, P4193, DOI 10.3748/wjg.v16.i33.4193; Jackson LN, 2008, AM J CHINESE MED, V36, P953, DOI 10.1142/S0192415X08006375; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kawada M, 2007, WORLD J GASTROENTERO, V13, P5581, DOI 10.3748/wjg.v13.i42.5581; Krakauer T, 2002, IMMUNOPHARM IMMUNOT, V24, P113, DOI 10.1081/IPH-120003407; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; Kretzmann NA, 2008, INFLAMM BOWEL DIS, V14, P1504, DOI 10.1002/ibd.20543; Kunnumakkara AB, 2009, INT J CANCER, V125, P2187, DOI 10.1002/ijc.24593; Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270; Langmead L, 2006, ALIMENT PHARM THER, V23, P341, DOI 10.1111/j.1365-2036.2006.02761.x; LEVIN B, 1992, CANCER-AM CANCER SOC, V70, P1313, DOI 10.1002/1097-0142(19920901)70:3+<1313::AID-CNCR2820701518>3.0.CO;2-B; LIN SC, 1994, AM J CHINESE MED, V22, P155, DOI 10.1142/S0192415X9400019X; Lin WC, 2011, GENETIC DIVERSITY RE; Lin WY, 2008, PLANTA MED, V74, P464, DOI 10.1055/s-2008-1034325; Lin Y. L., 2008, J CHIN MED, V19, P135; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Munkholm P, 2003, ALIMENT PHARM THER, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x; O'Connor Mortimer B, 2009, Cases J, V2, P173, DOI 10.1186/1757-1626-2-173; Pizarro TT, 2007, ANNU REV MED, V58, P433, DOI 10.1146/annurev.med.58.121205.100607; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Raina K, 2013, CANCER PREV RES, V6, P40, DOI 10.1158/1940-6207.CAPR-12-0387; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Shackelford C, 2002, TOXICOL PATHOL, V30, P93, DOI 10.1080/01926230252824761; Shan JH, 2009, INT IMMUNOPHARMACOL, V9, P1042, DOI 10.1016/j.intimp.2009.04.011; Shyur LF, 2008, CURR OPIN CHEM BIOL, V12, P66, DOI 10.1016/j.cbpa.2008.01.032; Staniforth V, 2012, J NUTR BIOCHEM, V23, P443, DOI 10.1016/j.jnutbio.2011.01.009; TARGAN SR, 1995, NAT MED, V1, P1241, DOI 10.1038/nm1295-1241; Toor RK, 2006, FOOD CHEM, V94, P90, DOI 10.1016/j.foodchem.2004.10.054; Tsai CH, 2009, CLIN CANCER RES, V15, P5435, DOI 10.1158/1078-0432.CCR-09-0298; von Lampe B, 2000, GUT, V47, P63, DOI 10.1136/gut.47.1.63; Wang XS, 2003, AM J CHINESE MED, V31, P927, DOI 10.1142/S0192415X0300165X; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Xu CT, 2004, WORLD J GASTROENTERO, V10, P2311	49	20	21	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 29	2013	8	5							e64152	10.1371/journal.pone.0064152	http://dx.doi.org/10.1371/journal.pone.0064152			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155DJ	23734189	Green Published, gold, Green Submitted			2023-01-03	WOS:000319725500079
J	Liu, BR; Liou, JS; Huang, YW; Aronstam, RS; Lee, HJ				Liu, Betty R.; Liou, Ji-Sing; Huang, Yue-Wern; Aronstam, Robert S.; Lee, Han-Jung			Intracellular Delivery of Nanoparticles and DNAs by IR9 Cell-penetrating Peptides	PLOS ONE			English	Article							ARGININE-RICH PEPTIDES; QUANTUM DOTS; PROTEIN TRANSDUCTION; PLASMA-MEMBRANE; MOLECULAR-MECHANISM; UPTAKE KINETICS; DRUG-DELIVERY; GENE-TRANSFER; LIVING CELLS; TAT PROTEIN	Cell-penetrating peptides (CPPs) comprised of basic amino residues are able to cross cytoplasmic membranes and are able to deliver biologically active molecules inside cells. However, CPP/cargo entrapment in endosome limits biomedical utility as cargoes are destroyed in the acidic environment. In this study, we demonstrate protein transduction of a novel CPP comprised of an INF7 fusion peptide and nona-arginine (designated IR9). IR9 noncovalently interacts with quantum dots (QDs) and DNAs to form stable IR9/QD and IR9/DNA complexes which are capable of entering human A549 cells. Zeta-potentials were a better predictor of transduction efficiency than gel shift analysis, emphasizing the importance of electrostatic interactions of CPP/cargo complexes with plasma membranes. Mechanistic studies revealed that IR9, IR9/QD and IR9/DNA complexes may enter cells by endocytosis. Further, IR9, IR9/QD and IR9/DNA complexes were not cytotoxic at concentrations below 30, 5 and 20.1 mu M, respectively. Without labor intensive production of fusion proteins from prokaryotes, these results indicate that IR9 could be a safe carrier of genes and drugs in biomedical applications.	[Liu, Betty R.; Liou, Ji-Sing; Lee, Han-Jung] Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien, Taiwan; [Huang, Yue-Wern; Aronstam, Robert S.] Missouri Univ Sci & Technol, Dept Biol Sci, Rolla, MO USA	National Dong Hwa University; University of Missouri System; Missouri University of Science & Technology	Lee, HJ (corresponding author), Natl Dong Hwa Univ, Dept Nat Resources & Environm Studies, Hualien, Taiwan.	hjlee@mail.ndhu.edu.tw	Liu, Betty Revon/GLU-3300-2022	Aronstam, Robert/0000-0001-7188-8412; Liu, Betty Revon/0000-0002-5152-8687	National Science Council of Taiwan [NSC 101-2811-B-259-001, NSC 101-2320-B-259-002-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	The financial support of this study was provided by the Postdoctoral Fellowship NSC 101-2811-B-259-001 (to Liu BR) and the Grant Number NSC 101-2320-B-259-002-MY3 from the National Science Council of Taiwan (to Lee HJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2013, ADV STUD BIOL; Bharali DJ, 2005, J AM CHEM SOC, V127, P11364, DOI 10.1021/ja051455x; Bolhassani A, 2011, BBA-REV CANCER, V1816, P232, DOI 10.1016/j.bbcan.2011.07.006; Chan M. H., 2013, PHARM NANOTECHNOL, V1, P151; Chang M, 2005, PLANT CELL PHYSIOL, V46, P482, DOI 10.1093/pcp/pci046; Chang M, 2007, NEW PHYTOL, V174, P46, DOI 10.1111/j.1469-8137.2007.01977.x; Chen CP, 2007, FEBS LETT, V581, P1891, DOI 10.1016/j.febslet.2007.03.076; Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q; Chen YJ, 2012, GENE, V493, P201, DOI 10.1016/j.gene.2011.11.060; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Dai YH, 2011, GENE, V489, P89, DOI 10.1016/j.gene.2011.08.011; Delehanty JB, 2009, ANAL BIOANAL CHEM, V393, P1091, DOI 10.1007/s00216-008-2410-4; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; EKIMOV AI, 1981, JETP LETT+, V34, P345; El-Sayed A, 2009, J CONTROL RELEASE, V138, P160, DOI 10.1016/j.jconrel.2009.05.018; El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2; Floren A, 2011, METHODS MOL BIOL, V683, P117, DOI 10.1007/978-1-60761-919-2_9; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Gautam A, 2012, DATABASE-OXFORD, DOI 10.1093/database/bas015; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002; Gurtovenko AA, 2007, J PHYS CHEM B, V111, P10453, DOI 10.1021/jp073113e; Hanaor D, 2012, J EUR CERAM SOC, V32, P235, DOI 10.1016/j.jeurceramsoc.2011.08.015; Hirose H, 2012, MOL THER, V20, P984, DOI 10.1038/mt.2011.313; Hou YW, 2007, EXP DERMATOL, V16, P999, DOI 10.1111/j.1600-0625.2007.00622.x; Hu JW, 2009, PEPTIDES, V30, P1669, DOI 10.1016/j.peptides.2009.06.006; Iversen TG, 2011, NANO TODAY, V6, P176, DOI 10.1016/j.nantod.2011.02.003; Jiao CY, 2009, J BIOL CHEM, V284, P33957, DOI 10.1074/jbc.M109.056309; Kilk K, 2009, TOXICOLOGY, V265, P87, DOI 10.1016/j.tox.2009.09.016; Koshman YE, 2008, J MOL CELL CARDIOL, V45, P853, DOI 10.1016/j.yjmcc.2008.08.006; Kosuge M, 2008, BIOCONJUGATE CHEM, V19, P656, DOI 10.1021/bc700289w; Lee CY, 2011, BIOMATERIALS, V32, P6264, DOI 10.1016/j.biomaterials.2011.05.012; Li JF, 2010, ANTICANCER RES, V30, P2193; Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1; Liou JS, 2012, PEPTIDES, V37, P273, DOI 10.1016/j.peptides.2012.07.019; Liu BR, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-57; Liu BR, 2011, BIOMATERIALS, V32, P3520, DOI 10.1016/j.biomaterials.2011.01.041; Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P7897, DOI 10.1166/jnn.2010.3012; Liu BR, 2010, J NANOSCI NANOTECHNO, V10, P6534, DOI 10.1166/jnn.2010.2637; Liu BR, 2008, J MEMBRANE BIOL, V222, P1, DOI 10.1007/s00232-008-9096-6; Liu BR, 2012, GENE, V505, P37, DOI 10.1016/j.gene.2012.05.053; Liu K, 2007, J PLANT GROWTH REGUL, V26, P278, DOI 10.1007/s00344-007-9015-6; LIU MJ, 2013, ADV STUD BIOL, V5, P71; Lu SW, 2010, J AGR FOOD CHEM, V58, P2288, DOI 10.1021/jf903039j; Madani Fatemeh, 2011, J Biophys, V2011, P414729, DOI 10.1155/2011/414729; Mager I, 2012, BBA-BIOMEMBRANES, V1818, P502, DOI 10.1016/j.bbamem.2011.11.020; Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010; Mattoussi H, 2012, ADV DRUG DELIVER REV, V64, P138, DOI 10.1016/j.addr.2011.09.011; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200; Nakase I, 2012, J CONTROL RELEASE, V159, P181, DOI 10.1016/j.jconrel.2012.01.016; Nakase I, 2010, BIOPOLYMERS, V94, P763, DOI 10.1002/bip.21487; Noguchi H, 2010, CELL TRANSPLANT, V19, P649, DOI 10.3727/096368910X508744; Odds FC, 2003, TRENDS MICROBIOL, V11, P272, DOI 10.1016/S0966-842X(03)00117-3; PLANK C, 1994, J BIOL CHEM, V269, P12918; Ruan G, 2007, J AM CHEM SOC, V129, P14759, DOI 10.1021/ja074936k; Rucevic M, 2011, ELECTROPHORESIS, V32, P1549, DOI 10.1002/elps.201100212; Schaeublin NM, 2011, NANOSCALE, V3, P410, DOI 10.1039/c0nr00478b; Schmidt N, 2010, FEBS LETT, V584, P1806, DOI 10.1016/j.febslet.2009.11.046; Schrand AM, 2009, CRIT REV SOLID STATE, V34, P18, DOI 10.1080/10408430902831987; Shao LJ, 2011, SENSORS-BASEL, V11, P11736, DOI 10.3390/s111211736; Siennicka Joanna, 2003, Medycyna Doswiadczalna i Mikrobiologia, V55, P157; Sugita T, 2007, BIOCHEM BIOPH RES CO, V363, P1027, DOI 10.1016/j.bbrc.2007.09.077; Suhorutsenko J, 2011, BIOCONJUGATE CHEM, V22, P2255, DOI 10.1021/bc200293d; Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m; Tuunnemann G, 2008, J PEPT SCI, V14, P469, DOI 10.1002/psc.968; Tunnemann G, 2006, FASEB J, V20, P1775, DOI 10.1096/fj.05-5523com; van den Berg A, 2011, CURR OPIN BIOTECH, V22, P888, DOI 10.1016/j.copbio.2011.03.008; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7; Wagstaff KM, 2006, CURR MED CHEM, V13, P1371, DOI 10.2174/092986706776872871; Wang YH, 2007, J BIOCHEM BIOPH METH, V70, P579, DOI 10.1016/j.jbbm.2007.01.010; Wang YH, 2006, BIOCHEM BIOPH RES CO, V346, P758, DOI 10.1016/j.bbrc.2006.05.205; Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777; Wender PA, 2008, ADV DRUG DELIVER REV, V60, P452, DOI 10.1016/j.addr.2007.10.016; Xu Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/948543; Xue FL, 2007, J FLUORESC, V17, P149, DOI 10.1007/s10895-006-0152-2; Yang S, 2009, J CONTROL RELEASE, V135, P159, DOI 10.1016/j.jconrel.2008.12.015; Ye SF, 2012, NANOMED-NANOTECHNOL, V8, P833, DOI 10.1016/j.nano.2011.10.003; Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604	81	27	34	0	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e64205	10.1371/journal.pone.0064205	http://dx.doi.org/10.1371/journal.pone.0064205			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155FM	23724035	Green Submitted, gold, Green Published			2023-01-03	WOS:000319733000048
J	Savic, R; He, XX; Fiel, I; Schuchman, EH				Savic, Radoslav; He, Xingxuan; Fiel, Isabel; Schuchman, Edward H.			Recombinant Human Acid Sphingomyelinase as an Adjuvant to Sorafenib Treatment of Experimental Liver Cancer	PLOS ONE			English	Article							HEPATOCELLULAR-CARCINOMA; QUANTITATIVE-ANALYSIS; TARGETED THERAPIES; ANTITUMOR-ACTIVITY; KUPFFER CELLS; RECEPTOR; INHIBITOR; CERAMIDE; DELIVERY; GENE	Background: Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the third leading cause of cancer death worldwide. The only approved systemic treatment for unresectable HCC is the oral kinase inhibitor, sorafenib. Recombinant human acid sphingomyelinase (rhASM), which hydrolyzes sphingomyelin to ceramide, is an orphan drug under development for the treatment of Type B Niemann-Pick disease (NPD). Due to the hepatotropic nature of rhASM and its ability to generate pro-apoptotic ceramide, this study evaluated the use of rhASM as an adjuvant treatment with sorafenib in experimental models of HCC. Methodology/Principal Findings: In vitro, rhASM/sorafenib treatment reduced the viability of Huh7 liver cancer cells more than sorafenib. In vivo, using a subcutaneous Huh7 tumor model, mouse survival was increased and proliferation in the tumors decreased to a similar extent in both sorafenib and rhASM/sorafenib treatment groups. However, combined rhASM/ sorafenib treatment significantly lowered tumor volume, increased tumor necrosis, and decreased tumor blood vessel density compared to sorafenib. These results were obtained despite poor delivery of rhASM to the tumors. A second (orthotopic) model of Huh7 tumors also was established, but modest ASM activity was similarly detected in these tumors compared to healthy mouse livers. Importantly, no chronic liver toxicity or weight loss was observed from rhASM therapy in either model. Conclusions/Significance: The rhASM/sorafenib combination exhibited a synergistic effect on reducing the tumor volume and blood vessel density in Huh7 xenografts, despite modest activity of rhASM in these tumors. No significant increases in survival were observed from the rhASM/sorafenib treatment. The poor delivery of rhASM to Huh7 tumors may be due, at least in part, to low expression of mannose receptors. The safety and efficacy of this approach, together with the novel findings regarding enzyme targeting, merits further investigation.	[Savic, Radoslav; He, Xingxuan; Schuchman, Edward H.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA; [Fiel, Isabel] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Schuchman, EH (corresponding author), Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA.	Edward.Schuchman@mssm.edu			NIH [HD28607]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Funding: NIH HD28607. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bao MY, 2012, LIVER INT, V32, P331, DOI 10.1111/j.1478-3231.2011.02666.x; Barth BM, 2011, ANTI-CANCER AGENT ME, V11, P911; Beljanski V, 2011, CANCER BIOL THER, V11, P524, DOI 10.4161/cbt.11.5.14677; Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s-2007-978725; Canals D, 2011, BRIT J PHARMACOL, V163, P694, DOI 10.1111/j.1476-5381.2011.01279.x; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Dhami R, 2004, J BIOL CHEM, V279, P1526, DOI 10.1074/jbc.M309465200; Draper JM, 2011, MOL CANCER THER, V10, P2052, DOI 10.1158/1535-7163.MCT-11-0365; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Garnacho C, 2008, J PHARMACOL EXP THER, V325, P400, DOI 10.1124/jpet.107.133298; Gentschev I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022069; Hakomori S, 1973, Adv Cancer Res, V18, P265, DOI 10.1016/S0065-230X(08)60755-1; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; He XX, 2005, ANAL BIOCHEM, V340, P113, DOI 10.1016/j.ab.2005.01.058; He XX, 2003, ANAL BIOCHEM, V314, P116, DOI 10.1016/S0003-2697(02)00629-2; Hikita H, 2010, HEPATOLOGY, V52, P1310, DOI 10.1002/hep.23836; Imai Y, 2000, HEPATOLOGY, V32, P205, DOI 10.1053/jhep.2000.9113; Killian JK, 2001, HUM MOL GENET, V10, P1721, DOI 10.1093/hmg/10.17.1721; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Lee YH, 2011, ONCOGENE, V30, P4175, DOI 10.1038/onc.2011.126; Liu K, 2003, WORLD J GASTROENTERO, V9, P1946, DOI 10.3748/wjg.v9.i9.1946; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; Mari M, 2007, LIVER INT, V27, P440, DOI 10.1111/j.1478-3231.2007.01475.x; Mas VR, 2009, MOL MED, V15, P85, DOI 10.2119/molmed.2008.00110; Muro S, 2006, MOL THER, V13, P135, DOI 10.1016/j.ymthe.2005.07.687; Osawa Y, 2013, J CLIN INVEST; Oskouian B, 2010, ADV EXP MED BIOL, V688, P185; Ponnusamy S, 2010, FUTURE ONCOL, V6, P1603, DOI 10.2217/FON.10.116; Puxbaum V, 2012, J HEPATOL, V57, P337, DOI 10.1016/j.jhep.2012.03.026; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sato S, 2011, HISTOL HISTOPATHOL, V26, P497, DOI 10.14670/HH-26.497; Savic R, 2006, J DRUG TARGET, V14, P343, DOI 10.1080/10611860600874538; Savic R, 2013, ADV CANCER RES, V117, P91, DOI 10.1016/B978-0-12-394274-6.00004-2; Schuchman EH, 2009, INT J CLIN PHARM TH, V47, pS48; Smith E. L., 2008, ACID SPHINGOMYELINAS; Smith EL, 2008, MOL THER, V16, P1565, DOI 10.1038/mt.2008.145; Tagaram HRS, 2011, GUT, V60, P695, DOI 10.1136/gut.2010.216671; TAGHIAN A, 1993, CANCER RES, V53, P5012; Takahashi K, 1998, CELL TISSUE RES, V292, P311, DOI 10.1007/s004410051062; Tanaka M, 1996, HEPATOLOGY, V24, P807; Thomas MB, 2005, J CLIN ONCOL, V23, P8093, DOI 10.1200/JCO.2004.00.1537; Toffanin S, 2011, GASTROENTEROLOGY, V140, P1618, DOI 10.1053/j.gastro.2011.02.009; Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05; Waxman S, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-243; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622; Yang J, 2000, ANTICANCER RES, V20, P1635; Zhang XS, 2011, J INHERIT METAB DIS, V34, P795, DOI 10.1007/s10545-011-9285-9; Zhu AX, 2010, EXPERT OPIN INV DRUG, V19, P663, DOI 10.1517/13543781003767426	55	24	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e65620	10.1371/journal.pone.0065620	http://dx.doi.org/10.1371/journal.pone.0065620			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155FM	23724146	gold, Green Published, Green Submitted			2023-01-03	WOS:000319733000135
J	McDonald, C				McDonald, Christine			Review: Nutritional supplementation has uncertain effects on patient-important outcomes in COPD	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Austin Hosp Dept Resp & Sleep Med, Heidelberg, Vic, Australia		McDonald, C (corresponding author), Austin Hosp Dept Resp & Sleep Med, Heidelberg, Vic, Australia.		McDonald, Christine Faye/AAU-9083-2021					Ferreira IM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000998.pub2	1	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 21	2013	158	10							JC5	10.7326/0003-4819-158-10-201305210-02005	http://dx.doi.org/10.7326/0003-4819-158-10-201305210-02005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	154HY	23689784				2023-01-03	WOS:000319666200004
J	Boccardi, V; Esposito, A; Rizzo, MR; Marfella, R; Barbieri, M; Paolisso, G				Boccardi, Virginia; Esposito, Antonietta; Rizzo, Maria Rosaria; Marfella, Raffaele; Barbieri, Michelangela; Paolisso, Giuseppe			Mediterranean Diet, Telomere Maintenance and Health Status among Elderly	PLOS ONE			English	Article							LIFE-STYLE FACTORS; CARDIOVASCULAR-DISEASE; CIGARETTE-SMOKING; LENGTH; ASSOCIATION; ADHERENCE; SURVIVAL; PATTERNS; STRESS; CANCER	Leukocyte telomere length (LTL) and rate of telomere shortening are known biomarkers of aging while, numerous studies showed that Mediterranean diet (MD) may boost longevity. We studied association between telomere length, telomerase activity and different adherence to MD and its effects on healthy status. The study was conducted in 217 elderly subjects stratified according Mediterranean diet score (MDS) in low adherence (MDS <= 3), medium adherence (MDS 4-5) and high adherence (MDS >= 6) groups. LTL was measured by quantitative polymerase chain reaction and telomerase activity by a PCR-ELISA protocol. High adherence group showed longer LTL (p = 0.003) and higher telomerase activity (p = 0.013) compared to others. Linear regression analysis including age, gender, smoking habit and MDS showed that MDS was independently associated with LTL (p = 0.024) and telomerase activity levels (p = 0.006). Telomerase activity was independently associated with LTL (p = 0.007) and negatively modulated by inflammation and oxidative stress. Indeed, telomerase levels were associated with healthy status independently of multiple covariates (p = 0.048). These results support a novel role of MD in promoting health-span suggesting that telomere maintenance, rather than LTL variability is the major determinant of healthy status among elderly.	[Boccardi, Virginia; Esposito, Antonietta; Rizzo, Maria Rosaria; Marfella, Raffaele; Barbieri, Michelangela; Paolisso, Giuseppe] Univ Naples 2, Dept Internal Med Surg Neurol Metab Dis & Geriatr, Naples, Italy	Universita della Campania Vanvitelli	Paolisso, G (corresponding author), Univ Naples 2, Dept Internal Med Surg Neurol Metab Dis & Geriatr, Naples, Italy.	giuseppe.paolisso@unina2.it	Boccardi, Virginia/K-2630-2016; rizzo, maria rosaria R/J-1968-2016; Rizzo, Maria Rosaria/AHH-3649-2022; Rizzo, Maria/HGD-6576-2022; paolisso, giuseppe/AAP-8516-2020; Marfella, Raffaele/AAH-2595-2019; Barbieri, Michelangela/K-2192-2016	Boccardi, Virginia/0000-0003-2134-1122; rizzo, maria rosaria R/0000-0002-1023-4260; Rizzo, Maria Rosaria/0000-0002-1023-4260; paolisso, giuseppe/0000-0002-2137-455X; Marfella, Raffaele/0000-0003-3960-9270; Barbieri, Michelangela/0000-0002-9223-5792				Anderson AL, 2011, J AM DIET ASSOC, V111, P84, DOI 10.1016/j.jada.2010.10.012; de Jesus BB, 2012, EMBO MOL MED, V4, P691, DOI 10.1002/emmm.201200245; de Jesus BB, 2011, AGING CELL, V10, P604, DOI 10.1111/j.1474-9726.2011.00700.x; Blackburn EH, 2005, FEBS LETT, V579, P859, DOI 10.1016/j.febslet.2004.11.036; Boccardi V, 2012, EMBO MOL MED, V4, P685, DOI 10.1002/emmm.201200246; Canela A, 2007, P NATL ACAD SCI USA, V104, P5300, DOI 10.1073/pnas.0609367104; Cassidy A, 2010, AM J CLIN NUTR, V91, P1273, DOI 10.3945/ajcn.2009.28947; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528; Dai J, 2008, CIRCULATION, V117, P169, DOI 10.1161/CIRCULATIONAHA.107.710699; Daubenmier J, 2012, PSYCHONEUROENDOCRINO, V37, P917, DOI 10.1016/j.psyneuen.2011.10.008; Donate LE, 2011, PHILOS T R SOC B, V366, P76, DOI 10.1098/rstb.2010.0291; Epel ES, 2006, PSYCHONEUROENDOCRINO, V31, P277, DOI 10.1016/j.psyneuen.2005.08.011; Garcia CK, 2007, NUCLEIC ACIDS RES, V35, P7406, DOI 10.1093/nar/gkm644; Gardner JP, 2005, CIRCULATION, V111, P2171, DOI 10.1161/01.CIR.0000163550.70487.0B; Haveman-Nies A, 2003, AGE AGEING, V32, P427, DOI 10.1093/ageing/32.4.427; Hu FB, 2003, AM J CLIN NUTR, V78, p544S, DOI 10.1093/ajcn/78.3.544S; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Kimura M, 2007, AM J PHYSIOL-REG I, V293, pR2210, DOI 10.1152/ajpregu.00615.2007; Kouris-Blazos A, 1999, BRIT J NUTR, V82, P57, DOI 10.1017/S0007114599001129; MAHONEY F I, 1965, Md State Med J, V14, P61; MARIN C, 2011, AGE DORDR, V34, P1309; Mirabello L, 2009, AGING CELL, V8, P405, DOI 10.1111/j.1474-9726.2009.00485.x; Nettleton JA, 2008, AM J CLIN NUTR, V88, P1405, DOI 10.3945/ajcn.2008.26429; Oeseburg H, 2010, PFLUG ARCH EUR J PHY, V459, P259, DOI 10.1007/s00424-009-0728-1; Ornish D, 2008, LANCET ONCOL, V9, P1048, DOI 10.1016/S1470-2045(08)70234-1; Paul L, 2011, J NUTR BIOCHEM, V22, P895, DOI 10.1016/j.jnutbio.2010.12.001; Serrano AL, 2004, CIRC RES, V94, P575, DOI 10.1161/01.RES.0000122141.18795.9C; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; Terry DF, 2008, J GERONTOL A-BIOL, V63, P809, DOI 10.1093/gerona/63.8.809; Terry DF, 2008, ARCH INTERN MED, V168, P277, DOI 10.1001/archinternmed.2007.75; Trichopoulou A, 2004, PUBLIC HEALTH NUTR, V7, P943, DOI 10.1079/PHN2004558; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Xu Q, 2009, AM J CLIN NUTR, V89, P1857, DOI 10.3945/ajcn.2008.26986; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	36	114	116	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62781	10.1371/journal.pone.0062781	http://dx.doi.org/10.1371/journal.pone.0062781			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23646142	gold, Green Published, Green Submitted			2023-01-03	WOS:000319077300095
J	Manish, M; Rahi, A; Kaur, M; Bhatnagar, R; Singh, S				Manish, Manish; Rahi, Amit; Kaur, Manpreet; Bhatnagar, Rakesh; Singh, Samer			A Single-Dose PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation Protects Mice against Bacillus anthracis Spore Challenge	PLOS ONE			English	Article							IMMUNE-RESPONSES; INHALATIONAL ANTHRAX; VACCINE; DELIVERY; MUCOSAL; NANOPARTICLES; INDUCTION; INFECTION; ADJUVANTS; BINDING	Bacillus anthracis, the etiological agent of anthrax, is a major bioterror agent. Vaccination is the most effective prophylactic measure available against anthrax. Currently available anthrax vaccines have issues of the multiple booster dose requirement, adjuvant-associated side effects and stability. Use of biocompatible and biodegradable nanoparticles to deliver the antigens to immune cells could solve the issues associated with anthrax vaccines. We hypothesized that the delivery of a stable immunogenic domain 4 of protective antigen (PAD4) of Bacillus anthracis encapsulated in a poly (lactide-co-glycolide) (PLGA) - an FDA approved biocompatible and biodegradable material, may alleviate the problems of booster dose, adjuvant toxicity and stability associated with anthrax vaccines. We made a PLGA based protective antigen domain 4 nanoparticle (PAD4-NP) formulation using water/oil/water solvent evaporation method. Nanoparticles were characterized for antigen content, morphology, size, polydispersity and zeta potential. The immune correlates and protective efficacy of the nanoparticle formulation was evaluated in Swiss Webster outbred mice. Mice were immunized with single dose of PAD4-NP or recombinant PAD4. The PAD4-NP elicited a robust IgG response with mixed IgG1 and IgG2a subtypes, whereas the control PAD4 immunized mice elicited low IgG response with predominant IgG1 subtype. The PAD4-NP generated mixed Th1/Th2 response, whereas PAD4 elicited predominantly Th2 response. When we compared the efficacy of this single-dose vaccine nanoformulation PAD4-NP with that of the recombinant PAD4 in providing protective immunity against a lethal challenge with Bacillus anthracis spores, the median survival of PAD4-NP immunized mice was 6 days as compared to 1 day for PAD4 immunized mice (p<0.001). Thus, we demonstrate, for the first time, the possibility of the development of a single-dose and adjuvant-free protective antigen based anthrax vaccine in the form of PAD4-NP. Further work in this direction may produce a better and safer candidate anthrax vaccine.	[Singh, Samer] Jawaharlal Nehru Univ, Special Ctr Nano Sci, New Delhi 110067, India; [Manish, Manish; Rahi, Amit; Kaur, Manpreet; Bhatnagar, Rakesh] Jawaharlal Nehru Univ, Sch Biotechnol, Lab Mol Biol & Genet Engn, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Jawaharlal Nehru University, New Delhi	Singh, S (corresponding author), Jawaharlal Nehru Univ, Special Ctr Nano Sci, New Delhi 110067, India.	samersingh@gmail.com	Singh, Samer/H-8468-2013; Manish, Manish/AAP-9469-2021	Singh, Samer/0000-0002-0921-1686; 	Department of Biotechnology (DBT), India; Department of Science and Technology (DST), India; DBT, India; Utrecht University Short Stay Fellowship; Fulbright fellowship; SBRI-India GID fellowship (NIH Research Grant) [D43 TW000924]; Fogarty International Center; FOGARTY INTERNATIONAL CENTER [D43TW000924] Funding Source: NIH RePORTER	Department of Biotechnology (DBT), India(Department of Biotechnology (DBT) India); Department of Science and Technology (DST), India(Department of Science & Technology (India)); DBT, India(Department of Biotechnology (DBT) India); Utrecht University Short Stay Fellowship; Fulbright fellowship; SBRI-India GID fellowship (NIH Research Grant); Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	The study was supported in part by funding from the Department of Biotechnology (DBT) and Department of Science and Technology (DST), India. SS is a Ramalingaswami Fellow supported by DBT, India. MM is the recipient of Utrecht University Short Stay Fellowship, Fulbright fellowship and SBRI-India GID fellowship (NIH Research Grant number D43 TW000924 funded by the Fogarty International Center). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abboud N, 2010, J EXP MED, V207, P2395, DOI 10.1084/jem.20100995; Akagi T, 2012, ADV POLYM SCI, V247, P31, DOI 10.1007/12_2011_150; Anderson JM, 2012, ADV DRUG DELIVER REV, V64, P72, DOI 10.1016/j.addr.2012.09.004; Baillie LW, 2009, HUM VACCINES, V5, P806, DOI 10.4161/hv.9777; Bielinska AU, 2007, INFECT IMMUN, V75, P4020, DOI 10.1128/IAI.00070-07; Borio L, 2001, JAMA-J AM MED ASSOC, V286, P2554, DOI 10.1001/jama.286.20.2554; Brey RN, 2005, ADV DRUG DELIVER REV, V57, P1266, DOI 10.1016/j.addr.2005.01.028; Brodzik R, 2005, BIOCHEM BIOPH RES CO, V338, P717, DOI 10.1016/j.bbrc.2005.09.196; Cote CK, 2005, MICROB PATHOGENESIS, V38, P209, DOI 10.1016/j.micpath.2005.02.001; Demento SL, 2012, BIOMATERIALS, V33, P4957, DOI 10.1016/j.biomaterials.2012.03.041; Flick-Smith HC, 2005, MICROB PATHOGENESIS, V38, P33, DOI 10.1016/j.micpath.2004.10.007; Flick-Smith HC, 2002, INFECT IMMUN, V70, P1653, DOI 10.1128/IAI.70.3.1653-1656.2002; Flick-Smith HC, 2002, INFECT IMMUN, V70, P2022, DOI 10.1128/IAI.70.4.2022-2028.2002; Franz DR, 2009, MOL ASPECTS MED, V30, P503, DOI 10.1016/j.mam.2009.07.002; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; FRIEDLANDER AM, 1993, J INFECT DIS, V167, P1239, DOI 10.1093/infdis/167.5.1239; Friedlander AM, 2009, VACCINE, V27, pD28, DOI 10.1016/j.vaccine.2009.08.102; Ganesan A, 2012, EUR J PHARM BIOPHARM, V82, P475, DOI 10.1016/j.ejpb.2012.05.019; Gorantala J, 2011, VACCINE, V29, P4521, DOI 10.1016/j.vaccine.2011.03.082; Hu L, 2012, J PHARM SCI-US, V101, P4118, DOI 10.1002/jps.23294; Jiang G, 2006, J PHARM SCI-US, V95, P80, DOI 10.1002/jps.20484; Kaur Manpreet, 2011, Recent Pat Biotechnol, V5, P148; Kaur M, 2009, MOL IMMUNOL, V46, P2107, DOI 10.1016/j.molimm.2008.12.031; Kumari A, 2010, COLLOID SURFACE B, V75, P1, DOI 10.1016/j.colsurfb.2009.09.001; Langley WA, 2010, J VIROL, V84, P8300, DOI 10.1128/JVI.00183-10; Lee Young-Ran, 2011, Immune Netw, V11, P163, DOI 10.4110/in.2011.11.3.163; Leggett HC, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002512; Leppla SH, 2002, J CLIN INVEST, V110, P141, DOI [10.1172/JCI200216204, 10.1172/JCI0216204]; Li XR, 2011, EUR J PHARM BIOPHARM, V78, P107, DOI 10.1016/j.ejpb.2010.12.017; Lutsiak MEC, 2006, J PHARM PHARMACOL, V58, P739, DOI 10.1211/jpp.58.6.0004; Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377; McBride B, 1998, VACCINE, V16, P810, DOI 10.1016/S0264-410X(97)00268-5; Merkel TJ, 2010, P NATL ACAD SCI USA, V107, P18091, DOI 10.1073/pnas.1013083107; Moon JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031472; Mourez M, 2005, REV PHYSIOL BIOCH P, V152, P135, DOI 10.1007/s10254-004-0028-2; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI [10.1586/erv.10.89, 10.1586/ERV.10.89]; Plaut RD, 2012, INFECT IMMUN, V80, P3189, DOI 10.1128/IAI.00515-12; Quinn CP, 2012, CLIN VACCINE IMMUNOL, V19, P1730, DOI 10.1128/CVI.00324-12; Radha C, 1996, J BIOTECHNOL, V50, P235, DOI 10.1016/0168-1656(96)01569-6; Ribeiro S, 2007, INT J PHARMACEUT, V331, P228, DOI 10.1016/j.ijpharm.2006.11.063; Santos Diego M, 2012, Int J Nanomedicine, V7, P2115, DOI 10.2147/IJN.S30093; Singh S, 2002, BIOCHEM BIOPH RES CO, V296, P1058, DOI 10.1016/S0006-291X(02)02049-1; Smith ME, 2006, VIROLOGY, V353, P344, DOI 10.1016/j.virol.2006.05.010; Tournier JN, 2009, EXPERT REV ANTI-INFE, V7, P219, DOI 10.1586/14787210.7.2.219; Wagner L, 2012, CLIN VACCINE IMMUNOL, V19, P1465, DOI 10.1128/CVI.00174-12; WELKOS SL, 1986, INFECT IMMUN, V51, P795, DOI 10.1128/IAI.51.3.795-800.1986; Williams AS, 2009, PROTEIN SCI, V18, P2277, DOI 10.1002/pro.238; Zomber G, 2005, J BIOL CHEM, V280, P39897, DOI 10.1074/jbc.M508569200	49	65	68	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2013	8	4							e61885	10.1371/journal.pone.0061885	http://dx.doi.org/10.1371/journal.pone.0061885			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	181JC	23637922	gold, Green Submitted, Green Published			2023-01-03	WOS:000321662800015
J	Bieuzen, F; Bleakley, CM; Costello, JT				Bieuzen, Francois; Bleakley, Chris M.; Costello, Joseph Thomas			Contrast Water Therapy and Exercise Induced Muscle Damage: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							MATCH RECOVERY STRATEGIES; COLD-WATER; ECCENTRIC EXERCISE; POSTEXERCISE RECOVERY; COMPRESSION THERAPY; POSITION SENSE; BLOOD-FLOW; IMMERSION; SYMPTOMS; PERFORMANCE	The aim of this systematic review was to examine the effect of Contrast Water Therapy (CWT) on recovery following exercise induced muscle damage. Controlled trials were identified from computerized literature searching and citation tracking performed up to February 2013. Eighteen trials met the inclusion criteria; all had a high risk of bias. Pooled data from 13 studies showed that CWT resulted in significantly greater improvements in muscle soreness at the five follow-up time points (<6, 24, 48, 72 and 96 hours) in comparison to passive recovery. Pooled data also showed that CWT significantly reduced muscle strength loss at each follow-up time (<6, 24, 48, 72 and 96 hours) in comparison to passive recovery. Despite comparing CWT to a large number of other recovery interventions, including cold water immersion, warm water immersion, compression, active recovery and stretching, there was little evidence for a superior treatment intervention. The current evidence base shows that CWT is superior to using passive recovery or rest after exercise; the magnitudes of these effects may be most relevant to an elite sporting population. There seems to be little difference in recovery outcome between CWT and other popular recovery interventions.	[Bieuzen, Francois] INSEP, Lab Sport Expertise & Performance, Paris, France; [Bleakley, Chris M.] Univ Ulster, Fac Life & Hlth Sci, Ulster Sports Acad, Newtownabbey, Antrim, North Ireland; [Costello, Joseph Thomas] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld, Australia; [Costello, Joseph Thomas] Univ Limerick, Dept Phys Educ & Sport Sci, Limerick, Ireland	Ulster University; Queensland University of Technology (QUT); University of Limerick	Bieuzen, F (corresponding author), INSEP, Lab Sport Expertise & Performance, Paris, France.	francois.bieuzen@insep.fr	Costello, Joseph/G-6294-2011; Costello, Joseph/J-1374-2012; Costello, Joseph/AAW-8764-2020; Bieuzen, Francois/F-8162-2013	Costello, Joseph/0000-0001-9510-7932; Costello, Joseph/0000-0001-9510-7932; Costello, Joseph/0000-0001-9510-7932; BIEUZEN, Francois/0000-0002-8073-8421; Bieuzen, Francois/0000-0002-9690-9168; Bleakley, Chris/0000-0001-9032-9691				Algafly AA, 2007, BRIT J SPORT MED, V41, P365, DOI 10.1136/bjsm.2006.031237; Aoi W, 2004, FREE RADICAL BIO MED, V37, P480, DOI 10.1016/j.freeradbiomed.2004.05.008; Bennett M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004713.pub2; Bleakley C, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008262.pub2; Brockett C, 1997, BRAIN RES, V771, P251, DOI 10.1016/S0006-8993(97)00808-1; Brown SJ, 1997, J SPORT SCI, V15, P215, DOI 10.1080/026404197367498; Burt DG, 2011, J STRENGTH COND RES, V25, P2185, DOI 10.1519/JSC.0b013e3181e86148; Cheung K, 2003, SPORTS MED, V33, P145, DOI 10.2165/00007256-200333020-00005; Clarkson PM, 2002, AM J PHYS MED REHAB, V81, pS52, DOI [10.1097/00002060-200211001-00007, 10.1097/01.PHM.0000029772.45258.43]; Cleak M J, 1992, Br J Sports Med, V26, P267; Cochrane DJ, 2004, PHYS THER SPORT, V5, P26, DOI 10.1016/j.ptsp.2003.10.002; Coffey V, 2004, J SCI MED SPORT, V7, P1, DOI 10.1016/S1440-2440(04)80038-0; Costello JT, 2012, SCAND J MED SCI SPOR, V22, P190, DOI 10.1111/j.1600-0838.2011.01292.x; Dawson B, 2005, J SCI MED SPORT, V8, P210, DOI 10.1016/S1440-2440(05)80012-X; EBBELING CB, 1989, SPORTS MED, V7, P207, DOI 10.2165/00007256-198907040-00001; Elias GP, 2012, INT J SPORT PHYSIOL, V7, P357, DOI 10.1123/ijspp.7.4.357; Elias GP, 2012, INT J SPORT PHYSIOL; Eston R, 1999, J SPORT SCI, V17, P231, DOI 10.1080/026404199366136; Fiscus KA, 2005, ARCH PHYS MED REHAB, V86, P1404, DOI 10.1016/j.apmr.2004.11.046; French DN, 2008, MED SCI SPORT EXER, V40, P1297, DOI 10.1249/MSS.0b013e31816b10d5; FRIDEN J, 1983, INT J SPORTS MED, V4, P170, DOI 10.1055/s-2008-1026030; Friesenbichler B, 2011, J BIOMECH, V44, P116, DOI 10.1016/j.jbiomech.2010.08.034; Gill ND, 2006, BRIT J SPORT MED, V40, P260, DOI 10.1136/bjsm.2005.022483; Goodall S, 2008, J SPORT SCI MED, V7, P235; Gregson W, 2011, AM J SPORT MED, V39, P1316, DOI 10.1177/0363546510395497; Gulick Dawn T., 1996, Journal of Athletic Training, V31, P145; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; Hausswirth C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027749; Herbert RD, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004577.pub3; Higgins D, 1998, J ATHL TRAINING, V33, P336; Higgins JPT, COCHRANE HDB SYSTEMA; Higgins Trevor, 2012, J Strength Cond Res; Higgins TR, 2013, J STRENGTH COND RES, V27, P2851, DOI 10.1519/JSC.0b013e31828151b6; Higgins TR, 2011, J STRENGTH COND RES, V25, P1046, DOI 10.1519/JSC.0b013e3181cc269f; Hing WA, 2008, PHYS THER SPORT, V9, P148, DOI 10.1016/j.ptsp.2008.06.001; Hough T, 1902, AM J PHYSIOL, V7, P76, DOI 10.1152/ajplegacy.1902.7.1.76; Howatson G, 2005, SCAND J MED SCI SPOR, V15, P416, DOI 10.1111/j.1600-0838.2005.00437.x; Howatson G, 2008, SPORTS MED, V38, P483, DOI 10.2165/00007256-200838060-00004; Howatson G, 2009, EUR J APPL PHYSIOL, V105, P615, DOI 10.1007/s00421-008-0941-1; Ingram J, 2009, J SCI MED SPORT, V12, P417, DOI 10.1016/j.jsams.2007.12.011; Ispirlidis I, 2008, CLIN J SPORT MED, V18, P423, DOI 10.1097/JSM.0b013e3181818e0b; JONES DA, 1986, J PHYSIOL-LONDON, V375, P435, DOI 10.1113/jphysiol.1986.sp016126; King M, 2009, J STRENGTH COND RES, V23, P1795, DOI 10.1519/JSC.0b013e3181b3f81f; Kinugasa T, 2009, J STRENGTH COND RES, V23, P1402, DOI 10.1519/JSC.0b013e3181a0226a; Kraemer WJ, 2001, J ORTHOP SPORT PHYS, V31, P282, DOI 10.2519/jospt.2001.31.6.282; Kuligowski LA, 1998, J ATHL TRAINING, V33, P222; Lee H, 2005, MED SCI SPORT EXER, V37, P1093, DOI 10.1249/01.mss.0000169611.21671.2e; Leeder J, 2012, BRIT J SPORT MED, V46, P233, DOI 10.1136/bjsports-2011-090061; Mackey AL, 2008, J APPL PHYSIOL, V105, P1620, DOI 10.1152/japplphysiol.90952.2008; Moher D., 2009, BMJ-BRIT MED J, V6, DOI [DOI 10.1023/B:MEDI.0000005484.26741.79, 10.1371/journal.pmed1000097.]; Morton JP, 2005, EUR J APPL PHYSIOL, V94, P541, DOI 10.1007/s00421-005-1373-9; Myrer J. William, 1994, Journal of Athletic Training, V29, P318; NEWHAM DJ, 1987, J APPL PHYSIOL, V63, P1381, DOI 10.1152/jappl.1987.63.4.1381; Paschalis V, 2007, MUSCLE NERVE, V35, P496, DOI 10.1002/mus.20723; Peake JM, 2005, MED SCI SPORT EXER, V37, P737, DOI 10.1249/01.MSS.0000161804.05399.3B; Pournot H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022748; Pournot H, 2011, EUR J APPL PHYSIOL, V111, P1287, DOI 10.1007/s00421-010-1754-6; Proske U, 2001, J PHYSIOL-LONDON, V537, P333, DOI 10.1111/j.1469-7793.2001.00333.x; Robey E, 2009, RES SPORTS MED, V17, P245, DOI 10.1080/15438620902901276; SAXTON JM, 1995, MED SCI SPORT EXER, V27, P1185; Sellwood KL, 2007, BRIT J SPORT MED, V41, P392, DOI 10.1136/bjsm.2006.033985; Stanley J, 2012, EUR J APPL PHYSIOL, V112, P951, DOI 10.1007/s00421-011-2052-7; STAUBER WT, 1989, EXERCISE SPORT SCI R, V17, P157; Stupka N, 2000, J APPL PHYSIOL, V89, P2325, DOI 10.1152/jappl.2000.89.6.2325; Tashjian RZ, 2009, J SHOULDER ELB SURG, V18, P927, DOI 10.1016/j.jse.2009.03.021; Thompson D, 2003, EUR J APPL PHYSIOL, V89, P393, DOI 10.1007/s00421-003-0816-4; Thorlacius H, 1998, J TRAUMA, V45, P715, DOI 10.1097/00005373-199810000-00016; Torres R, 2012, PHYS THER SPORT, V13, P101, DOI 10.1016/j.ptsp.2011.07.005; Twist C, 2009, EUR J APPL PHYSIOL, V105, P559, DOI 10.1007/s00421-008-0935-z; Vaile J, 2008, EUR J APPL PHYSIOL, V102, P447, DOI 10.1007/s00421-007-0605-6; Vaile JM, 2007, J STRENGTH COND RES, V21, P697; Versey N, 2011, EUR J APPL PHYSIOL, V111, P37, DOI 10.1007/s00421-010-1614-4; Versey NG, 2012, INT J SPORT PHYSIOL, V7, P130, DOI 10.1123/ijspp.7.2.130; Warren GL, 1999, SPORTS MED, V27, P43, DOI 10.2165/00007256-199927010-00004; Wilcock IM, 2006, SPORTS MED, V36, P747, DOI 10.2165/00007256-200636090-00003; Xu X, 2007, EUR J APPL PHYSIOL, V100, P79, DOI 10.1007/s00421-007-0393-z	76	54	58	4	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e62356	10.1371/journal.pone.0062356	http://dx.doi.org/10.1371/journal.pone.0062356			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131QH	23626806	Green Published, Green Submitted, gold			2023-01-03	WOS:000318008400170
J	Dumont, A; Fournier, P; Abrahamowicz, M; Traore, M; Haddad, S; Fraser, WD				Dumont, Alexandre; Fournier, Pierre; Abrahamowicz, Michal; Traore, Mamadou; Haddad, Slim; Fraser, William D.		QUARITE Res Grp	Quality of care, risk management, and technology in obstetrics to reduce hospital-based maternal mortality in Senegal and Mali (QUARITE): a cluster-randomised trial	LANCET			English	Article							DEATH REVIEWS	Background Maternal mortality is higher in west Africa than in most industrialised countries, so the development and validation of effective interventions is essential. We did a trial to assess the effect of a multifaceted intervention to promote maternity death reviews and onsite training in emergency obstetric care in referral hospitals with high maternal mortality rates in Senegal and Mali. Methods We did a pragmatic cluster-randomised controlled trial, with hospitals as the units of randomisation and patients as the unit of analysis. 46 public first-level and second-level referral hospitals with more than 800 deliveries a year were enrolled, stratified by country and hospital type, and randomly assigned to either the intervention group (n=23) or the control group with no external intervention (n=23). All women who delivered in each of the participating facilities during the baseline and post-intervention periods were included. The intervention, implemented over a period of 2 years at the hospital level, consisted of an initial interactive workshop and quarterly educational clinically-oriented and evidence-based outreach visits focused on maternal death reviews and best practices implementation. The primary outcome was reduction of risk of hospital-based mortality. Analysis was by intention-to-treat and relied on the generalised estimating equations extension of the logistic regression model to account for clustering of women within hospitals. This study is registered with ClinicalTrials.gov, number ISRCTN46950658. Findings 191 167 patients who delivered in the participating hospitals were analysed (95 931 in the intervention groups and 95 236 in the control groups). Overall, mortality reduction in intervention hospitals was significantly higher than in control hospitals (odds ratio [OR] 0.85, 95% CI 0.73-0.98, p=0.0299), but this effect was limited to capital and district hospitals, which mainly acted as first-level referral hospitals in this trial. There was no effect in second-level referral (regional) hospitals outside the capitals (OR 1.02, 95% CI 0.79-1.31, p=0.89). No hospitals were lost to follow-up. Concrete actions were implemented comprehensively to improve quality of care in intervention hospitals. Interpretation Regular visits by a trained external facilitator and onsite training can provide health-care professionals with the knowledge and confidence to make quality improvement suggestions during audit sessions. Maternal death reviews, combined with best practices implementation, are effective in reducing hospital-based mortality in first-level referral hospitals. Further studies are needed to determine whether the benefits of the intervention are generalisable to second-level referral hospitals.	[Dumont, Alexandre] Univ Paris 05, IRD, UMR 216, Sorbonne Paris Cite, F-75006 Paris, France; [Dumont, Alexandre; Fraser, William D.] Univ Montreal, CHU St Justine, Res Ctr, Montreal, PQ, Canada; [Fournier, Pierre; Haddad, Slim] Univ Montreal, CHUM CRCHUM, Res Ctr, Montreal, PQ, Canada; [Abrahamowicz, Michal] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; [Traore, Mamadou] URFOSAME, Referral Hlth Ctr Commune 5, Bamako, Mali; [Fraser, William D.] Univ Montreal, Dept Obstet & Gynaecol, Montreal, PQ, Canada	Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; McGill University; Universite de Montreal	Dumont, A (corresponding author), Univ Paris 05, IRD, UMR 216, 4 Ave Observ, F-75006 Paris, France.	alexandre.dumont@ird.fr	Dumont, Alexandre/I-9429-2016; Trajman, Anete/C-7679-2016	Dumont, Alexandre/0000-0003-3826-0193; Trajman, Anete/0000-0002-4000-4984; Abrahamowicz, Michal/0000-0002-3172-3952	Canadian Institutes of Health Research; QUARITE trial under Randomized Controlled Trials committee	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); QUARITE trial under Randomized Controlled Trials committee	Canadian Institutes of Health Research.; We thank all the medical and administrative staff of the 46 participating centres for their valuable contribution in this trial. We wish to thank the Canadian Institutes of Health Research (CIHR), which fully funded the QUARITE trial under the auspices of the Randomized Controlled Trials committee. The CIHR also provided a 2-year salary grant to AD for the development of this project in the context of the Randomized Controlled Trials Mentoring Program. Statistical analyses were also supported by the CIHR, grant 81275. We also thank the Fonds de Recherche en Sante du Quebec for providing a research fellowship and operating grant to support this research project. MA is a James McGill Professor at McGill University. WDF receives salary support from CIHR through a Canada Research Chair. The trial has been funded by the CIHR, grant number 200602MCT-157547-RFA-CFCF-100169.	Briand V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047352; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Dumont A, 2006, B WORLD HEALTH ORGAN, V84, P218, DOI 10.2471/BLT.05.023903; Dumont A, 2009, HUM RESOUR HEALTH, V7, DOI 10.1186/1478-4491-7-61; Dumont A, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-85; Flodgren G, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000125, 10.1002/14651858.CD000125.pub4]; Fournier P, 2009, B WORLD HEALTH ORGAN, V87, P30, DOI 10.2471/BLT.07.047076; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Jamtvedt G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000259.pub2; Kaye DK, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-65; Koblinsky M, 2006, LANCET, V368, P1377, DOI 10.1016/S0140-6736(06)69382-3; Kongnyuy E J, 2008, Women Birth, V21, P149, DOI 10.1016/j.wombi.2008.08.002; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; Liu XN, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-566; MARTEY JO, 1993, INT J GYNECOL OBSTET, V42, P237, DOI 10.1016/0020-7292(93)90217-K; MBARUKU G, 1995, HEALTH POLICY PLANN, V10, P71, DOI 10.1093/heapol/10.1.71; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; Santos C, 2006, INT J GYNECOL OBSTET, V94, P190, DOI 10.1016/j.ijgo.2006.05.024; Shah A, 2008, B WORLD HEALTH ORGAN, V86, P126, DOI 10.2471/BLT.06.039842; Society of Obstetricians and Gynaecologists of Canada, 2007, ALARM INT PROGR MAN; van den Akker T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020776; van Lonkhuijzen L, 2010, BJOG-INT J OBSTET GY, V117, P777, DOI 10.1111/j.1471-0528.2010.02561.x; Witter S, 2010, HEALTH POLICY PLANN, V25, P384, DOI 10.1093/heapol/czq013; World Health Organization, 2004, NUMB REV MAT DEATHS; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	27	89	89	1	31	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 13	2013	382	9887					146	157		10.1016/S0140-6736(13)60593-0	http://dx.doi.org/10.1016/S0140-6736(13)60593-0			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187JY	23721752				2023-01-03	WOS:000322115300030
J	Chapman, S				Chapman, Simon			Should electronic cigarettes be as freely available as tobacco cigarettes? No	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NICOTINE		Univ Sydney, Sydney, NSW 2006, Australia	University of Sydney	Chapman, S (corresponding author), Univ Sydney, Sydney, NSW 2006, Australia.	simon.chapman@sydney.edu.au	Chapman, Simon/D-4114-2009					Adkison SE, 2013, AM J PREV MED, V44, P207, DOI 10.1016/j.amepre.2012.10.018; Australian Bureau of Statistics, AUSTR HLTH SURV 1 RE; Chapman S, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001342; Chen RJ, 2008, TOXICOL SCI, V104, P283, DOI 10.1093/toxsci/kfn086; Moore M, 2012, REYNOLDS AM CEO HOST; Proctor RN, 2001, NAT REV CANCER, V1, P82, DOI 10.1038/35094091; Tobacco in Australia, FACTS ISS; Tverdal A, 2006, TOB CONTROL, V15, P472, DOI 10.1136/tc.2006.016246; Vassallo R, 2008, MOL IMMUNOL, V45, P3321, DOI 10.1016/j.molimm.2008.04.014; Zeidler R, 2007, APOPTOSIS, V12, P1927, DOI 10.1007/s10495-007-0102-8	10	48	49	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2013	346								f3840	10.1136/bmj.f3840	http://dx.doi.org/10.1136/bmj.f3840			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166XQ	23771038				2023-01-03	WOS:000320593900010
J	Dancer, SJ				Dancer, Stephanie J.			Put your ties back on: scruffy doctors damage our reputation and indicate a decline in hygiene	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INFECTION-CONTROL; WASH		Hairmyres Hosp, E Kilbride G75 8RG, Lanark, Scotland	University Hospital Hairmyres	Dancer, SJ (corresponding author), Hairmyres Hosp, E Kilbride G75 8RG, Lanark, Scotland.	stephanie.dancer@lanarkshire.scot.nhs.uk		Dancer, Stephanie/0000-0002-8777-2614				[Anonymous], 2007, LANCET, V370, P1102; [Anonymous], 2008, BMA NEWS        0927; Burden M, 2011, J HOSP MED, V6, P177, DOI 10.1002/jhm.864; Cubitt J, 2010, B ROYAL COLL SURG EN, V92, P242; Dancer SJ, 2012, J HOSP INFECT, V80, P189, DOI 10.1016/j.jhin.2011.12.003; Dancer SJ, 2010, J HOSP INFECT, V74, P10, DOI 10.1016/j.jhin.2009.10.012; Dancer SJ, 2008, BMJ; Horlock A, 2012, DAILY MAIL; Magee TR, 2008, B ROYAL COLL SURG EN, V90, P126; Mann CM, 2006, J HOSP INFECT, V64, P366, DOI 10.1016/j.jhin.2006.06.030; Mooney H., 2008, NURSING TIMES; Price EH, 2008, J HOSP INFECT, V69, P89, DOI 10.1016/j.jhin.2008.01.009; Rehman SU, 2005, AM J MED, V118, P1279, DOI 10.1016/j.amjmed.2005.04.026; Steinlechner C, 2002, ANN R COLL SURG EN S, V84, P307; Wellcome Collection, 2011, DIRT FILTH REAL EV L; Whitby M, 2006, INFECT CONT HOSP EP, V27, P484, DOI 10.1086/503335	16	12	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	2013	346								f3211	10.1136/bmj.f3211	http://dx.doi.org/10.1136/bmj.f3211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166WQ	23766481				2023-01-03	WOS:000320590800016
J	Silverman, E				Silverman, Ed			Pfizer versus Kaiser: insurers want their day in court	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Pharmalot, Millburn, NJ USA		Silverman, E (corresponding author), Pharmalot, Millburn, NJ USA.	pharmalot@gmail.com							0	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2013	346								f3738	10.1136/bmj.f3738	http://dx.doi.org/10.1136/bmj.f3738			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166WH	23760967				2023-01-03	WOS:000320589800008
J	Davies, M; Carter, P; Drake, L				Davies, Martin; Carter, Pam; Drake, Loreto			Spinal injury	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Carter, Pam] Univ Leicester, Dept Hlth Sci, Social Sci Appl Healthcare Improvement Res SAPPHI, Leicester LE1 6TP, Leics, England; [Drake, Loreto] Alsager Hlth Ctr, Stoke On Trent ST7 2LU, Staffs, England	University of Leicester	Carter, P (corresponding author), Univ Leicester, Dept Hlth Sci, Social Sci Appl Healthcare Improvement Res SAPPHI, Leicester LE1 6TP, Leics, England.	pc216@le.ac.uk						Cohen SP, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2718; Gibson JNA, 2005, SPINE, V30, P2312, DOI 10.1097/01.brs.0000182315.88558.9c	2	1	1	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ BRIT MED J	BMJ-British Medical Journal	JUN 7	2013	346								f3374	10.1136/bmj.f3374	http://dx.doi.org/10.1136/bmj.f3374			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161YM	23747969	Bronze			2023-01-03	WOS:000320230400004
J	Mizushima, D; Nishijima, T; Gatanaga, H; Tsukada, K; Teruya, K; Kikuchi, Y; Oka, S				Mizushima, Daisuke; Nishijima, Takeshi; Gatanaga, Hiroyuki; Tsukada, Kunihisa; Teruya, Katsuji; Kikuchi, Yoshimi; Oka, Shinichi			Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naive Patients with Advanced HIV-1 Infection in the HAART Era	PLOS ONE			English	Article							CMV DNA LOAD; ORAL GANCICLOVIR; ANTIRETROVIRAL THERAPY; RISK-FACTORS; AIDS; VALGANCICLOVIR; SURVIVAL; EFFICACY; SAFETY; PROPHYLAXIS	Background: The efficacy of preemptive therapy against cytomegalovirus (CMV) infection remains unknown in treatment naive patients with advanced HIV-1 infection in the HAART era. Methods: The subjects of this single-center observation study were126 treatment-naive HIV-1 infected patients with positive CMV viremia between January 1, 2000 and December 31, 2006. Inclusion criteria were age more than 17 years, CD4 count less than 100/ml, plasma CMV DNA positive, never having received antiretroviral therapy (ART) and no CMV end-organ disease (EOD) at first visit. The incidence of CMV-EOD was compared in patients with and without preemptive therapy against CMV-EOD. The effects of the CMV preemptive therapy were estimated in uni-and multivariate Cox hazards models. Results: CMV-EOD was diagnosed in 30 of the 96 patients of the non-preemptive therapy group (31%, 230.3 per 1000 person-years), compared with 3 of the 30 patients of the preemptive therapy group (10%, 60.9 per 1000 person-years). Univariate (HR = 0.286; 95% CI, 0.087-0.939; p = 0.039) and multivariate (adjusted HR = 0.170; 95% CI, 0.049-0.602; p = 0.005) analyses confirmed that CMV-EOD is significantly prevented by CMV preemptive therapy. Multivariate analysis showed that plasma CMV DNA level correlated significantly with CMV-EOD (per log10/ml, adjusted HR = 1.941; 95% CI, 1.266-2.975; p = 0.002). Among the 30 patients on preemptive therapy, 7 (23.3%) developed grade 3-4 leukopenia. The mortality rate was not significantly different between the two groups (p = 0.193, Log-rank test). Conclusions: The results indicate that preemptive therapy lowers the incidence of CMV-EOD by almost 25%. Preemptive therapy for treatment-naive patients with CMV viremia is effective, although monitoring of potential treatment-related side effects is required.	[Mizushima, Daisuke; Nishijima, Takeshi; Gatanaga, Hiroyuki; Tsukada, Kunihisa; Teruya, Katsuji; Kikuchi, Yoshimi; Oka, Shinichi] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan; [Mizushima, Daisuke; Nishijima, Takeshi; Gatanaga, Hiroyuki; Oka, Shinichi] Kumamoto Univ, Ctr AIDS Res, Kumamoto, Japan	National Center for Global Health & Medicine - Japan; Kumamoto University	Gatanaga, H (corresponding author), Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan.	higatana@acc.ncgm.go.jp		Oka, Shinichi/0000-0002-9283-2167	National Center for Global Health and Medicine [23-114]	National Center for Global Health and Medicine(National Center for Global Health & Medicine - Japan)	This work was supported by a Grant for National Center for Global Health and Medicine (23-114). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Biron KK, 2006, ANTIVIR RES, V71, P154, DOI 10.1016/j.antiviral.2006.05.002; Brosgart CL, 1998, AIDS, V12, P269, DOI 10.1097/00002030-199803000-00004; Deayton JR, 2004, LANCET, V363, P2116, DOI 10.1016/S0140-6736(04)16500-8; Erice A, 2003, CLIN INFECT DIS, V37, P567, DOI 10.1086/375843; Fielding K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025571; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Hodge WG, 2005, CAN J OPHTHALMOL, V40, P701, DOI 10.1016/S0008-4182(05)80086-9; Humar A, 2005, AM J TRANSPLANT, V5, P1462, DOI 10.1111/j.1600-6143.2005.00866.x; Jabs DA, 2007, OPHTHALMOLOGY, V114, P780, DOI 10.1016/j.ophtha.2006.11.008; Kalil AC, 2005, ANN INTERN MED, V143, P870, DOI 10.7326/0003-4819-143-12-200512200-00005; Kalil AC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005512; Kempen JH, 2003, OPHTHALMOLOGY, V110, P987, DOI 10.1016/S0161-6420(03)00089-7; Kute VB, 2012, TRANSPL P, V44, P706, DOI 10.1016/j.transproceed.2011.12.025; Micol R, 2009, JAIDS-J ACQ IMM DEF, V51, P486, DOI 10.1097/QAI.0b013e3181a254c2; Park JM, 2006, LIVER TRANSPLANT, V12, P112, DOI 10.1002/lt.20562; Pergam SA, 2012, BIOL BLOOD MARROW TR, V18, P1391, DOI 10.1016/j.bbmt.2012.02.008; Ray M, 2010, AIDS, V24, P123, DOI 10.1097/QAD.0b013e3283324283; Rose DN, 1997, AIDS, V11, P883, DOI 10.1097/00002030-199707000-00007; Spector SA, 1999, J VIROL, V73, P7027, DOI 10.1128/JVI.73.8.7027-7030.1999; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; Spector SA, 1998, J CLIN INVEST, V101, P497, DOI 10.1172/JCI1101; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; Wohl DA, 2009, HIV CLIN TRIALS, V10, P143, DOI 10.1310/hct1003-143; Yoshida A, 2001, CLIN INFECT DIS, V33, P1756, DOI 10.1086/323782	25	10	11	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e65348	10.1371/journal.pone.0065348	http://dx.doi.org/10.1371/journal.pone.0065348			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155FM	23724140	Green Submitted, gold, Green Published			2023-01-03	WOS:000319733000130
J	Schriner, SE; Lee, K; Truong, S; Salvadora, KT; Maler, S; Nam, A; Lee, T; Jafari, M				Schriner, Samuel E.; Lee, Kevin; Truong, Stephanie; Salvadora, Kathyrn T.; Maler, Steven; Nam, Alexander; Lee, Thomas; Jafari, Mahtab			Extension of Drosophila Lifespan by Rhodiola rosea through a Mechanism Independent from Dietary Restriction	PLOS ONE			English	Article							CALORIC RESTRICTION; STRESS RESISTANCE; OXIDATIVE STRESS; RHESUS-MONKEYS; FAT-BODY; MELANOGASTER; MICE; CELLS; OVEREXPRESSION; EXPRESSION	Rhodiola rosea has been extensively used to improve physical and mental performance and to protect against stress. We, and others, have reported that R. rosea can extend lifespan in flies, worms, and yeast. However, its molecular mechanism is currently unknown. Here, we tested whether R. rosea might act through a pathway related to dietary restriction (DR) that can extend lifespan in a range of model organisms. While the mechanism of DR itself is also unknown, three molecular pathways have been associated with it: the silent information regulator 2 (SIR2) proteins, insulin and insulin-like growth factor signaling (IIS), and the target of rapamycin (TOR). In flies, DR is implemented through a reduction in dietary yeast content. We found that R. rosea extract extended lifespan in both sexes independent of the yeast content in the diet. We also found that the extract extended lifespan when the SIR2, IIS, or TOR pathways were genetically perturbed. Upon examination of water and fat content, we found that R. rosea decreased water content and elevated fat content in both sexes, but did not sensitize flies to desiccation or protect them against starvation. There were some sex-specific differences in response to R. rosea. In female flies, the expression levels of glycolytic genes and dSir2 were down-regulated, and NADH levels were decreased. In males however, R. rosea provided no protection against heat stress and had no effect on the major heat shock protein HSP70 and actually down-regulated the mitochondrial HSP22. Our findings largely rule out an elevated general resistance to stress and DR-related pathways as mechanistic candidates. The latter conclusion is especially relevant given the limited potential for DR to improve human health and lifespan, and presents R. rosea as a potential viable candidate to treat aging and age-related diseases in humans.	[Schriner, Samuel E.; Lee, Kevin; Truong, Stephanie; Salvadora, Kathyrn T.; Maler, Steven; Nam, Alexander; Lee, Thomas; Jafari, Mahtab] Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA 92717 USA	University of California System; University of California Irvine	Jafari, M (corresponding author), Univ Calif Irvine, Dept Pharmaceut Sci, Irvine, CA 92717 USA.	mjafari@uci.edu			National Institutes of Health [AT004987]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT004987] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	This work was supported by an National Institutes of Health R21 grant, AT004987. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	Abidov M, 2003, B EXP BIOL MED+, V136, P585, DOI 10.1023/B:BEBM.0000020211.24779.15; Anderson RM, 2009, TOXICOL PATHOL, V37, P47, DOI 10.1177/0192623308329476; Archer MA, 2007, PHYSIOL BIOCHEM ZOOL, V80, P386, DOI 10.1086/518354; Bai H, 2012, AGING CELL, V11, P978, DOI 10.1111/acel.12000; Bayliak MM, 2011, PHYTOMEDICINE, V18, P1262, DOI 10.1016/j.phymed.2011.06.010; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Boon-Niermeijer EK, 2000, PHYTOMEDICINE, V7, P389, DOI 10.1016/S0944-7113(00)80060-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Broughton SJ, 2010, AGING CELL, V9, P336, DOI 10.1111/j.1474-9726.2010.00558.x; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Giannakou ME, 2008, AGING CELL, V7, P187, DOI 10.1111/j.1474-9726.2007.00362.x; Grandison RC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004067; Hagopian K, 2003, EXP GERONTOL, V38, P253, DOI 10.1016/S0531-5565(02)00203-6; Humphrey DM, 2009, EXP GERONTOL, V44, P316, DOI 10.1016/j.exger.2009.02.001; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Ingram DK, 2011, EXP GERONTOL, V46, P148, DOI 10.1016/j.exger.2010.12.001; Jafari M, 2007, REJUV RES, V10, P587, DOI 10.1089/rej.2007.0560; Jang YC, 2009, J GERONTOL A-BIOL, V64, P1114, DOI 10.1093/gerona/glp100; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kelly G S, 2001, Altern Med Rev, V6, P293; Kim SH, 2006, BIOFACTORS, V26, P209, DOI 10.1002/biof.5520260306; Lee KS, 2010, REJUV RES, V13, P561, DOI 10.1089/rej.2010.1031; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Magwere T, 2006, J GERONTOL A-BIOL, V61, P36, DOI 10.1093/gerona/61.1.36; MARTIN GM, 1989, GENOME, V31, P390, DOI 10.1139/g89-059; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Matsumura H., 1980, METHOD ENZYMOL, V69, P465, DOI DOI 10.1016/S0076-6879(80)69045-4; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; Mattson MP, 2008, AGEING RES REV, V7, P1, DOI 10.1016/j.arr.2007.08.007; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758; Orr WC, 2003, EXP GERONTOL, V38, P227, DOI 10.1016/S0531-5565(02)00263-2; Panossian A, 2010, PHYTOMEDICINE, V17, P481, DOI 10.1016/j.phymed.2010.02.002; Perez VI, 2009, AGING CELL, V8, P73, DOI 10.1111/j.1474-9726.2008.00449.x; Piper MDW, 2008, CELL METAB, V8, P99, DOI 10.1016/j.cmet.2008.06.012; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Schriner SE, 2012, BIOGERONTOLOGY, V13, P105, DOI 10.1007/s10522-011-9357-0; Schriner SE, 2009, FREE RADICAL RES, V43, P836, DOI 10.1080/10715760903089724; Schriner SE, 2009, FREE RADICAL BIO MED, V47, P577, DOI 10.1016/j.freeradbiomed.2009.05.025; Slack C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047699; Spindler SR, 2006, AGING CELL, V5, P39, DOI 10.1111/j.1474-9726.2006.00194.x; Tu MP, 2002, AGING CELL, V1, P75, DOI 10.1046/j.1474-9728.2002.00010.x; UDINTSEV SN, 1991, EUR J CANCER, V27, P1182, DOI 10.1016/0277-5379(91)90323-6; Wiegant FAC, 2009, BIOGERONTOLOGY, V10, P27, DOI 10.1007/s10522-008-9151-9	48	35	36	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2013	8	5							e63886	10.1371/journal.pone.0063886	http://dx.doi.org/10.1371/journal.pone.0063886			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	149OK	23704949	gold, Green Published, Green Submitted			2023-01-03	WOS:000319330200080
J	Davis, JC; Bryan, S; Marra, CA; Sharma, D; Chan, A; Beattie, BL; Graf, P; Liu-Ambrose, T				Davis, Jennifer C.; Bryan, Stirling; Marra, Carlo A.; Sharma, Devika; Chan, Alison; Beattie, B. Lynn; Graf, Peter; Liu-Ambrose, Teresa			An Economic Evaluation of Resistance Training and Aerobic Training versus Balance and Toning Exercises in Older Adults with Mild Cognitive Impairment	PLOS ONE			English	Article							NURSING-HOME PLACEMENT; PHYSICAL-ACTIVITY; CORTICAL PLASTICITY; RISK-FACTORS; TALK TEST; DEMENTIA; STRENGTH; WOMEN; REHABILITATION; INFERENCE	Background: Mild cognitive impairment (MCI) represents a critical window to intervene against dementia. Exercise training is a promising intervention strategy, but the efficiency (i.e., relationship of costs and consequences) of such types of training remains unknown. Thus, we estimated the incremental cost-effectiveness of resistance training or aerobic training compared with balance and tone exercises in terms of changes in executive cognitive function among senior women with probable MCI. Methods: Economic evaluation conducted concurrently with a six-month three arm randomized controlled trial including eighty-six community dwelling women aged 70 to 80 years living in Vancouver, Canada. Participants received twice-weekly resistance training (n = 28), twice weekly aerobic training (n = 30) or twice-weekly balance and tone (control group) classes (n = 28) for 6 months. The primary outcome measure of the Exercise for Cognition and Everyday Living (EXCEL) study assessed executive cognitive function, a test of selective attention and conflict resolution (i.e., Stroop Test). We collected healthcare resource utilization costs over six months. Results: Based on the bootstrapped estimates from our base case analysis, we found that both the aerobic training and resistance training interventions were less costly than twice weekly balance and tone classes. Compared with the balance and tone group, the resistance-training group had significantly improved performance on the Stroop Test (p = 0.04). Conclusions: Resistance training and aerobic training result in health care cost saving and are more effective than balance and tone classes after only 6 months of intervention. Resistance training is a promising strategy to alter the trajectory of cognitive decline in seniors with MCI.	[Davis, Jennifer C.; Bryan, Stirling] Univ British Columbia, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada; [Marra, Carlo A.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Sharma, Devika; Chan, Alison; Liu-Ambrose, Teresa] Univ British Columbia, Dept Phys Therapy, Vancouver, BC V5Z 1M9, Canada; [Beattie, B. Lynn; Graf, Peter] Univ British Columbia, Brain Res Ctr, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Davis, JC (corresponding author), Univ British Columbia, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada.	Jennifer.davis@ubc.ca; tlambrose@exchange.ubc.ca	Marra, Carlo/AAE-4904-2021; Liu-Ambrose, Teresa/W-2332-2019	Marra, Carlo/0000-0002-2625-2121; Liu-Ambrose, Teresa/0000-0002-8297-5308	The Pacific Alzheimer's Research Foundation; Michael Smith Foundation for Health Research Senior Graduate Studentship; Canadian Institute for Health Research Canada Graduate Scholarship; Canada Research Chair in Physical Activity, Mobility, and Cognitive Neuroscience; Michael Smith Foundation for Health Research Scholar Award; Canada Research Chair in Pharmaceutical Outcomes	The Pacific Alzheimer's Research Foundation; Michael Smith Foundation for Health Research Senior Graduate Studentship(Michael Smith Foundation for Health Research); Canadian Institute for Health Research Canada Graduate Scholarship(Canadian Institutes of Health Research (CIHR)); Canada Research Chair in Physical Activity, Mobility, and Cognitive Neuroscience; Michael Smith Foundation for Health Research Scholar Award(Michael Smith Foundation for Health Research); Canada Research Chair in Pharmaceutical Outcomes(Canada Research Chairs)	The Pacific Alzheimer's Research Foundation provided funding for this study (to TLA). JCD is funded by a Michael Smith Foundation for Health Research Senior Graduate Studentship, a Canadian Institute for Health Research Canada Graduate Scholarship. TLA is funded by a Canada Research Chair in Physical Activity, Mobility, and Cognitive Neuroscience and a Michael Smith Foundation for Health Research Scholar Award. CAM is funded by a Canada Research Chair in Pharmaceutical Outcomes and a Michael Smith Foundation for Health Research Scholar Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott RD, 2004, JAMA-J AM MED ASSOC, V292, P1447, DOI 10.1001/jama.292.12.1447; Baker LD, 2010, ARCH NEUROL-CHICAGO, V67, P71, DOI 10.1001/archneurol.2009.307; Balota DA, 2010, PSYCHOL AGING, V25, P208, DOI 10.1037/a0017474; Barrett C, 2002, AUST J PHYSIOTHER, V48, P215, DOI 10.1016/S0004-9514(14)60226-9; BORG G, 1982, INT J SPORTS MED, V3, P153, DOI 10.1055/s-2008-1026080; Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381; Canada TAsSo, 2010, RIS TID IMP DEM CAN; Cassilhas RC, 2007, MED SCI SPORT EXER, V39, P1401, DOI 10.1249/mss.0b013e318060111f; Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Davis JC, 2012, QUAL LIFE RES; Davis JC, 2010, OSTEOPO IN PRESS JUN; Davis JC, 2011, J AM GERIATR SOC, V59, P1232, DOI 10.1111/j.1532-5415.2011.03474.x; Davis JC, 2010, ARCH INTERN MED, V170, P2036, DOI 10.1001/archinternmed.2010.462; Delavande A, 2012, ALZHEIMERS DEMENT; Erickson K, 2008, BR J SPORTS MED; Feldman HH, 2005, AM J GERIAT PSYCHIAT, V13, P645, DOI 10.1176/appi.ajgp.13.8.645; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; Foster C, 2008, J CARDIOPULM REHABIL, V28, P24, DOI 10.1097/01.HCR.0000311504.41775.78; Glick H, 2007, EC EVALUATION CLIN T; GRAF P, 1995, J CLIN EXP NEUROPSYC, V17, P390, DOI 10.1080/01688639508405132; Hoenig H, 1997, J AM GERIATR SOC, V45, P1371, DOI 10.1111/j.1532-5415.1997.tb02939.x; Kramer AF, 2007, TRENDS COGN SCI, V11, P342, DOI 10.1016/j.tics.2007.06.009; Laska EM, 1997, HEALTH ECON, V6, P229, DOI 10.1002/(SICI)1099-1050(199705)6:3<229::AID-HEC268>3.3.CO;2-D; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Liu Ambrose T, 2009, ARCH INTERN IN PRESS; Liu-Ambrose T, 2009, BRIT J SPORT MED, V43, P25, DOI 10.1136/bjsm.2008.055616; Liu-Ambrose T, 2004, J AM GERIATR SOC, V52, P657, DOI 10.1111/j.1532-5415.2004.52200.x; Liu-Ambrose T, 2008, J AM GERIATR SOC, V56, P1821, DOI [10.1111/j.1532-5415.2008.01931.x, 10.1111/j.1532-5415.2008.01984.x]; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; MCCARTNEY N, 1995, J GERONTOL A-BIOL, V50, pB97, DOI 10.1093/gerona/50A.2.B97; Nagamatsu LS, 2012, ARCH INTERN MED, V172, P666, DOI 10.1001/archinternmed.2012.379; NELSON ME, 1994, JAMA-J AM MED ASSOC, V272, P1909, DOI 10.1001/jama.272.24.1909; Orr R, 2006, J GERONTOL A-BIOL, V61, P78, DOI 10.1093/gerona/61.1.78; Orr R, 2008, SPORTS MED, V38, P317, DOI 10.2165/00007256-200838040-00004; OSTBYE T, 1994, CAN MED ASSOC J, V151, P1457; Pedersen BK, 2006, SCAND J MED SCI SPOR, V16, P3, DOI 10.1111/j.1600-0838.2006.00520.x; Persinger R, 2004, MED SCI SPORT EXER, V36, P1632, DOI 10.1249/01.MSS.0000074690.03001.98; Petersen RC, 2005, ARCH NEUROL-CHICAGO, V62, P1160, DOI 10.1001/archneur.62.7.1160; Royall DR, 2007, J NEUROPSYCH CLIN N, V19, P249, DOI 10.1176/appi.neuropsych.19.3.249; Smith GE, 2001, NEUROLOGY, V57, P1467, DOI 10.1212/WNL.57.8.1467; Spreen O., 1998, COMPENDIUM NEUROLOGI, V2nd ed.; Timonen L, 2002, SCAND J MED SCI SPOR, V12, P186, DOI 10.1034/j.1600-0838.2002.120310.x; Trenerry M, 1988, PSYCHOLOGICAL ASSESS; Van der Elst W, 2006, ASSESSMENT, V13, P62, DOI 10.1177/1073191105283427; van Oijen M, 2007, ALZHEIMERS DEMENT, V3, P92, DOI 10.1016/j.jalz.2007.01.011; Verghese J, 2008, J AM GERIATR SOC, V56, P1244, DOI 10.1111/j.1532-5415.2008.01758.x; Wadley VG, 2007, J AM GERIATR SOC, V55, P1192, DOI 10.1111/j.1532-5415.2007.01245.x; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454; Yaffe K, 2002, JAMA-J AM MED ASSOC, V287, P2090, DOI 10.1001/jama.287.16.2090	52	33	36	1	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2013	8	5							e63031	10.1371/journal.pone.0063031	http://dx.doi.org/10.1371/journal.pone.0063031			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	146RE	23690976	gold, Green Published, Green Submitted			2023-01-03	WOS:000319107400028
J	Mitsnefes, MM; Laskin, BL; Dahhou, M; Zhang, X; Foster, BJ				Mitsnefes, Mark M.; Laskin, Benjamin L.; Dahhou, Mourad; Zhang, Xun; Foster, Bethany J.			Mortality Risk Among Children Initially Treated With Dialysis for End-Stage Kidney Disease, 1990-2010	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR-DISEASE; RENAL-DISEASE; YOUNG-ADULTS; SURVIVAL; HEMODIALYSIS; INFANTS; ANEMIA	Importance Most children with end-stage kidney disease (ESKD) are treated with dialysis prior to transplant. It is not known whether their outcomes have changed in recent years. Objective To determine if all-cause, cardiovascular, and infection-related mortality rates for children and adolescents beginning dialysis improved between 1990 and 2010. Design, Setting, and Participants Retrospective cohort study of patients younger than 21 years initially treated with dialysis for ESKD, recorded in the United States Renal Data System between 1990 and 2010. Children with a prior kidney transplant were excluded. We used Cox proportional hazard models to estimate the hazard ratios (HRs) for mortality associated with a 5-year increment in year of ESKD treatment initiation. Primary analyses censored observation at kidney transplant. Main Outcomes and Measures All-cause, cardiovascular, and infection-related mortality. Results A total of 23 401 children and adolescents who initiated ESKD treatment with dialysis at younger than 21 years between 1990 and 2010 were identified. Crude mortality rates during dialysis treatment were higher among children younger than 5 years at the start of dialysis compared with those who were 5 years and older. Mortality rates for both children and adolescents being treated for ESKD with dialysis decreased significantly between 1990 and 2010. [GRAPHICS] Conclusions and Relevance In the United States, there was a substantial decrease in mortality rates over time among children and adolescents initiating ESKD treatment with dialysis between 1990 and 2010. Further research is needed to determine the specific factors responsible for this decrease. JAMA. 2013;309(18):1921-1929 Published online May 4, 2013. doi:10.1001/jama.2013.4208 www.jama.com	[Mitsnefes, Mark M.] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH USA; [Laskin, Benjamin L.] Childrens Hosp Philadelphia, Div Nephrol, Philadelphia, PA 19104 USA; [Dahhou, Mourad; Zhang, Xun; Foster, Bethany J.] McGill Univ, Montreal Childrens Hosp, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; [Foster, Bethany J.] McGill Univ, Fac Med, Dept Pediat, Div Nephrol, Montreal, PQ, Canada; [Foster, Bethany J.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada	Cincinnati Children's Hospital Medical Center; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; McGill University; McGill University; McGill University	Foster, BJ (corresponding author), Montreal Childrens Hosp, 2300 Tupper St,E-222, Montreal, PQ H3H 1P3, Canada.	beth.foster@muhc.mcgill.ca	Zhang, Xun/HHM-9059-2022	Zhang, Xun/0000-0001-5411-2727	National Institutes of Health [R01DK07695, K24DK090070, U01DK-03-012]; Career Development Award in Comparative Effectiveness Research [1KM1CA156715-01]; Fonds de la recherche en sante du Quebec [FRSQ]; FRSQ; Health Resources and Services Administration [234-2005-370011C]; NATIONAL CANCER INSTITUTE [KM1CA156715] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK066143, K24DK090070] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Career Development Award in Comparative Effectiveness Research; Fonds de la recherche en sante du Quebec [FRSQ](Fonds de la Recherche en Sante du Quebec); FRSQ(Fonds de la Recherche en Sante du Quebec); Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Dr Mitsnefes is supported by the National Institutes of Health (R01DK07695, K24DK090070, and U01DK-03-012). Dr Laskin is supported by a Career Development Award in Comparative Effectiveness Research (1KM1CA156715-01). Dr Foster, a member of the McGill University Health Centre Research Institute (supported in part by the Fonds de la recherche en sante du Quebec [FRSQ]), received salary support from the FRSQ. This work was supported in part by Health Resources and Services Administration contract 234-2005-370011C. Data were supplied by the USRDS.	[Anonymous], 2006, AM J KIDNEY DIS, V48, pS4, DOI 10.1053/j.ajkd.2006.07.015; [Anonymous], DRUG APPR DAT DRUGS; [Anonymous], 2012 ANN DAT REP ATL; Balas EA, YB MED INFORM 2000 P; Bond TC, 2012, AM J KIDNEY DIS, V60, P959, DOI 10.1053/j.ajkd.2012.04.018; Borzych-Duzalka D, 2013, J AM SOC NEPHROL, V24, P665, DOI 10.1681/ASN.2012050433; Chavers BM, 2007, J AM SOC NEPHROL, V18, P952, DOI 10.1681/ASN.2006040406; Chavers BM, 2002, KIDNEY INT, V62, P648, DOI 10.1046/j.1523-1755.2002.00472.x; Dell'Aquila R, 2007, PERITON DIALYSIS INT, V27, pS130; DEVRIES JPPM, 1993, KIDNEY INT, V44, P851, DOI 10.1038/ki.1993.321; Eisenstein I, 2011, CLIN J AM SOC NEPHRO, V6, P793, DOI 10.2215/CJN.04810610; Fischbach M, 2005, PEDIATR NEPHROL, V20, P1054, DOI 10.1007/s00467-005-1876-y; Foley RN, 2013, CLIN J AM SOC NEPHRO, V8, P845, DOI 10.2215/CJN.06840712; Foster BJ, 2011, AM J TRANSPLANT, V11, P2432, DOI 10.1111/j.1600-6143.2011.03691.x; Groothoff JW, 2002, KIDNEY INT, V61, P621, DOI 10.1046/j.1523-1755.2002.00156.x; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hoyert D, 2012, NATL VITAL STAT REP, V61; Ing TS, 2012, DIALYSIS: HISTORY, DEVELOPMENT AND PROMISE, pVII; Kucirka LM, 2011, JAMA-J AM MED ASSOC, V306, P620, DOI 10.1001/jama.2011.1127; Leonard MB, 2003, KIDNEY INT, V63, P744, DOI 10.1046/j.1523-1755.2003.00788.x; Matas AJ, 2013, AM J TRANSPLANT, V13, P11, DOI 10.1111/ajt.12019; Mathews TJ, 2011, PEDIATRICS, V127, P146, DOI 10.1542/peds.2010-3175; McDonald SP, 2004, NEW ENGL J MED, V350, P2654, DOI 10.1056/NEJMoa031643; Miskulin DC, 2003, AM J KIDNEY DIS, V41, P149, DOI 10.1053/ajkd.2003.50034; Mitsnefes MM, 2012, J AM SOC NEPHROL, V23, P578, DOI 10.1681/ASN.2011111115; Oh J, 2002, CIRCULATION, V106, P100, DOI 10.1161/01.CIR.0000020222.63035.C0; Parekh RS, 2002, J PEDIATR-US, V141, P191, DOI 10.1067/mpd.2002.125910; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Schwartz GJ, 2009, J AM SOC NEPHROL, V20, P629, DOI 10.1681/ASN.2008030287; Sebestyen JF, 2011, ADV CHRONIC KIDNEY D, V18, P376, DOI 10.1053/j.ackd.2011.07.003; Tetta C, 2011, EXPERT REV CARDIOVAS, V9, P155, DOI [10.1586/erc.10.194, 10.1586/ERC.10.194]; Verrina E, 2009, PEDIATR NEPHROL, V24, P1453, DOI 10.1007/s00467-008-0848-4; Vidal E, 2012, NEPHROL DIAL TRANSPL, V27, P388, DOI 10.1093/ndt/gfr322; Warady BA, 2012, PEDIATRIC DIALYSIS, SECOND EDITION, P1, DOI 10.1007/978-1-4614-0721-8; Warady BA, 2003, PEDIATR NEPHROL, V18, P1055, DOI 10.1007/s00467-003-1214-1; Wedekin M, 2010, CLIN J AM SOC NEPHRO, V5, P18, DOI 10.2215/CJN.03670609; Woodward R S, 2008, Am J Transplant, V8, P2636, DOI 10.1111/j.1600-6143.2008.02422.x	37	119	119	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2013	309	18					1921	1929		10.1001/jama.2013.4208	http://dx.doi.org/10.1001/jama.2013.4208			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138AZ	23645144	Green Accepted, Bronze			2023-01-03	WOS:000318481900027
J	Moore, A; Derry, S; Eccleston, C; Kalso, E				Moore, Andrew; Derry, Sheena; Eccleston, Christopher; Kalso, Eija			Expect analgesic failure; pursue analgesic success	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; CHRONIC PAIN; POSTHERPETIC NEURALGIA; RANDOMIZED-TRIAL; FIBROMYALGIA; IMPROVEMENT; PREGABALIN; EFFICACY; ETORICOXIB; WITHDRAWAL		[Moore, Andrew; Derry, Sheena] Univ Oxford, Churchill Hosp, Oxford OX3 7LJ, England; [Moore, Andrew; Derry, Sheena] Univ Oxford, Churchill Hosp, Nuffield Div Anaesthet, Oxford OX3 7LJ, England; [Eccleston, Christopher] Univ Bath, Ctr Pain Res, Bath BA2 7AY, Avon, England; [Kalso, Eija] Univ Helsinki, Cent Hosp, Dept Anaesthesiol, Pain Clin, FIN-00014 Helsinki, Finland	University of Oxford; University of Oxford; University of Bath; University of Helsinki; Helsinki University Central Hospital	Moore, A (corresponding author), Univ Oxford, Churchill Hosp, S Parks Rd, Oxford OX3 7LJ, England.	andrew.moore@ndcn.ox.ac.uk		Kalso, Eija/0000-0002-4899-605X; Eccleston, Christopher/0000-0003-0698-1543				Arnold LM, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3359; CONNOR S, 2003, INDEPENDENT; Crofford LJ, 2008, PAIN, V136, P419, DOI 10.1016/j.pain.2008.02.027; Farmer K., 2010, EFFECT VOLUNATARY EX; Hoffman DL, 2010, PAIN, V149, P194, DOI 10.1016/j.pain.2009.09.017; Kroenke K, 2001, JAMA-J AM MED ASSOC, V286, P2947, DOI 10.1001/jama.286.23.2947; Lin HY, 2010, INT J RHEUM DIS, V13, P144, DOI 10.1111/j.1756-185X.2010.01468.x; McQuay HJ, 2008, PAIN, V135, P217, DOI 10.1016/j.pain.2008.01.014; Moore RA, 2013, ANAESTHESIA, V68, P400, DOI 10.1111/anae.12148; Moore RA, 2010, PAIN, V149, P173, DOI 10.1016/j.pain.2009.08.007; Moore RA, 2010, ANN RHEUM DIS, V69, P374, DOI 10.1136/ard.2009.107805; Moore RA, 2012, PAIN, V153, P265, DOI 10.1016/j.pain.2011.10.004; Moore RA, 2011, PAIN, V152, P982, DOI 10.1016/j.pain.2010.11.030; Moore RA, 2010, PAIN, V151, P592, DOI 10.1016/j.pain.2010.07.013; Moore RA, 2010, PAIN, V150, P386, DOI 10.1016/j.pain.2010.05.011; Moore RA, 2010, PAIN, V149, P360, DOI 10.1016/j.pain.2010.02.039; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; National Collaborating Centre for Chronic Conditions, 2008, OST NAT CLIN GUID CA; Simon G, 2001, JAMA-J AM MED ASSOC, V286, P3003, DOI 10.1001/jama.286.23.3003; Smith R., 2003, BRIT MED J, V327, P09; Stacey BR, 2008, J PAIN, V9, P1006, DOI 10.1016/j.jpain.2008.05.014; Straube S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-125; Wang FJ, 2011, J PAIN, V12, P1088, DOI 10.1016/j.jpain.2011.05.002; Watson CPN, 1998, NEUROLOGY, V51, P1166, DOI 10.1212/WNL.51.4.1166	24	162	163	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2013	346								f2690	10.1136/bmj.f2690	http://dx.doi.org/10.1136/bmj.f2690			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	139FC	23645858	Green Accepted, Green Published			2023-01-03	WOS:000318566200003
J	Okiro, EA; Kazembe, LN; Kabaria, CW; Ligomeka, J; Noor, AM; Ali, D; Snow, RW				Okiro, Emelda A.; Kazembe, Lawrence N.; Kabaria, Caroline W.; Ligomeka, Jeffrey; Noor, Abdisalan M.; Ali, Doreen; Snow, Robert W.			Childhood Malaria Admission Rates to Four Hospitals in Malawi between 2000 and 2010	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM TRANSMISSION; SCALE-UP; PEDIATRIC MALARIA; FEBRILE ILLNESS; MORBIDITY; MORTALITY; CHILDREN; BURDEN; TRENDS; IMPACT	Introduction: The last few years have witnessed rapid scaling-up of key malaria interventions in several African countries following increases in development assistance. However, there is only limited country-specific information on the health impact of expanded coverage of these interventions. Methods: Paediatric admission data were assembled from 4 hospitals in Malawi reflecting different malaria ecologies. Trends in monthly clinical malaria admissions between January 2000 and December 2010 were analysed using time-series models controlling for covariates related to climate and service use to establish whether changes in admissions can be related to expanded coverage of interventions aimed at reducing malaria infection. Results: In 3 of 4 sites there was an increase in clinical malaria admission rates. Results from time series models indicate a significant month-to-month increase in the mean clinical malaria admission rates at two hospitals (trend P<0.05). At these hospitals clinical malaria admissions had increased from 2000 by 41% to 100%. Comparison of changes in malaria risk and ITN coverage appear to correspond to a lack of disease declines over the period. Changes in intervention coverage within hospital catchments showed minimal increases in ITN coverage from <6% across all sites in 2000 to maximum of 33% at one hospital site by 2010. Additionally, malaria transmission intensity remained unchanged between 2000-2010 across all sites. Discussion: Despite modest increases in coverage of measures to reduce infection there has been minimal changes in paediatric clinical malaria cases in four hospitals in Malawi. Studies across Africa are increasingly showing a mixed set of impact results and it is important to assemble more data from more sites to understand the wider implications of malaria funding investment. We also caution that impact surveillance should continue in areas where intervention coverage is increasing with time, for example Malawi, as decline may become evident within a period when coverage reaches optimal levels.	[Okiro, Emelda A.; Kabaria, Caroline W.; Noor, Abdisalan M.; Snow, Robert W.] Kenya Med Res Inst Wellcome Trust Univ Oxford Col, Malaria Publ Hlth Dept, Nairobi, Kenya; [Okiro, Emelda A.; Noor, Abdisalan M.; Snow, Robert W.] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England; [Kazembe, Lawrence N.] Univ Malawi, Chancellor Coll, Dept Math Sci, Zomba, Malawi; [Kazembe, Lawrence N.] Univ Namibia, Dept Stat, Windhoek, Namibia; [Ligomeka, Jeffrey] Zomba Cent Hosp, Records Dept, Zomba, Malawi; [Ali, Doreen] Minist Hlth, Natl Malaria Control Programme, Lilongwe, Malawi	Kenya Medical Research Institute; University of Oxford; University of Malawi; University of Namibia	Okiro, EA (corresponding author), Kenya Med Res Inst Wellcome Trust Univ Oxford Col, Malaria Publ Hlth Dept, Nairobi, Kenya.	eokiro@nairobi.kemri-wellcome.org	Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088; Okiro, Emelda/0000-0001-9543-8360; Kabaria, Caroline/0000-0002-5641-5243	Wellcome Trust, UK; Kenyan Medical Research Institute; Wellcome Trust [086166, 079080]; Novartis; Pfizer	Wellcome Trust, UK(Wellcome Trust); Kenyan Medical Research Institute; Wellcome Trust(Wellcome TrustEuropean Commission); Novartis(Novartis); Pfizer(Pfizer)	This study received financial support from The Wellcome Trust, UK and The Kenyan Medical Research Institute. EAO is supported by the Wellcome Trust as a Research Training Fellow (#086166). RWS is supported by the Wellcome Trust as Principal Research Fellow (#079080) that also supports CWK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors' have read the journal's policy and have the following conflicts: RWS has received funding from Novartis for chairing meetings of national control programmes in Africa and EAO has received honoraria from Novartis at their regional best practice workshops. RWS has received a research grant from Pfizer. All other authors have no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	[Anonymous], TIME SERIES ANAL FOR; [Anonymous], ACC PROGR HLTH REL M; [Anonymous], NAT MAL CONTR PROGR; Arcury TA, 2005, HEALTH SERV RES, V40, P135, DOI 10.1111/j.1475-6773.2005.00346.x; Aregawi MW, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-46; Barat LM, 2006, AM J TROP MED HYG, V74, P12, DOI 10.4269/ajtmh.2006.74.12; Barnes KI, 2005, PLOS MED, V2, P1123, DOI 10.1371/journal.pmed.0020330; Bennett A, AM J TROPIC IN PRESS; Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; Cairns M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1879; Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2; Ceesay SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012242; Chizema-Kawesha E, 2010, AM J TROP MED HYG, V83, P480, DOI 10.4269/ajtmh.2010.10-0035; DICKEY DA, 1979, J AM STAT ASSOC, V74, P427, DOI 10.2307/2286348; Eisele TP, 2010, INT J EPIDEMIOL, V39, P88, DOI 10.1093/ije/dyq026; Eisele TP, 2009, AM J TROP MED HYG, V80, P209, DOI 10.4269/ajtmh.2009.80.209; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; Feikin DR, 2009, TROP MED INT HEALTH, V14, P54, DOI 10.1111/j.1365-3156.2008.02193.x; Gething PW, 2004, ACTA TROP, V91, P227, DOI 10.1016/j.actatropica.2004.05.002; GILL CA, 1938, SEASONAL PERIODICITY; Graves PM, 2008, TROP MED INT HEALTH, V13, P218, DOI 10.1111/j.1365-3156.2007.01993.x; Griffin JT, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000324; Hay SI, 2008, LANCET INFECT DIS, V8, P369, DOI 10.1016/S1473-3099(08)70069-0; IUCN and UNEP-WCMC, 2010, WORLD DAT PROT AR WD; Karema C, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-236; Kazembe Lawrence N, 2006, Int J Health Geogr, V5, P41, DOI 10.1186/1476-072X-5-41; Kleinschmidt I, 2009, AM J TROP MED HYG, V80, P882, DOI 10.4269/ajtmh.2009.80.882; KLOOS H, 1990, SOC SCI MED, V31, P101, DOI 10.1016/0277-9536(90)90052-T; Komatsu R, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-109; Linard Catherine, 2010, Int J Health Geogr, V9, P45, DOI 10.1186/1476-072X-9-45; Lozano R, 2011, LANCET, V378, P1139, DOI 10.1016/S0140-6736(11)61337-8; Mabiala-Babela JR, 2003, ARCH PEDIATRIE, V10, P650, DOI 10.1016/S0929-693X(03)00290-2; Maegga B T A, 2005, Tanzan Health Res Bull, V7, P125; Malawi National Malaria Control Programme, 2010, MAL NAT MAL IND SURV; Measure-DHS, 2004, MAL DEM HLTH SURV; Measure-DHS, 2000, MAL DEM HLTH SURV; Measure-DHS, 2010, MAL DEM HLTH SURV; Mufunda J, 2007, SAMJ S AFR MED J, V97, P46; Muller I, 1998, INT J EPIDEMIOL, V27, P878, DOI 10.1093/ije/27.5.878; Munier A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-270; National Statistical Office, 2008, 2008 POP HOUS CENS; Ndymugyenyi R, 2004, ANN TROP MED PARASIT, V98, P315, DOI 10.1179/000349804225003433; Noor AM, 2006, TROP MED INT HEALTH, V11, P188, DOI 10.1111/j.1365-3156.2005.01555.x; Noor AM, 2003, TROP MED INT HEALTH, V8, P917, DOI 10.1046/j.1365-3156.2003.01112.x; Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33; O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4; O'Meara WP, 2010, LANCET INFECT DIS, V10, P545, DOI 10.1016/S1473-3099(10)70096-7; Okiro EA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-151; Okiro EA, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-37; Okiro EA, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-285; Okiro Emelda A, 2009, BMC Med, V7, P75, DOI 10.1186/1741-7015-7-75; Okiro EA, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-4; Otten M, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-14; President's Malaria Initiative, 2009, MAL MAL OP PLAN FY 2; President's Malaria Initiative, 2007, MAL MAL OP PLAN FY 2; Reyburn H, 2004, BMJ-BRIT MED J, V329, P1212, DOI 10.1136/bmj.38251.658229.55; Roca-Feltrer A, 2012, EMERG INFECT DIS, V18, P272, DOI 10.3201/eid1802.111008; Rodrigues A, 2008, TROP MED INT HEALTH, V13, P410, DOI 10.1111/j.1365-3156.2008.02016.x; Roll Back Malaria, 2010, SAV LIV MAL CONTR CO; Roll Back Malaria Partnership, 2012, FOC SWAZ PROGR IMP S; Rose-Wood A, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-319; Sarrassat S, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-215; Sievers AC, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-167; Smith DL, 2009, TRENDS PARASITOL, V25, P511, DOI 10.1016/j.pt.2009.08.002; Snow RW, 2010, LANCET, V376, P1409, DOI 10.1016/S0140-6736(10)61340-2; Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6; Snow RW, 2002, ADV PARASIT, V52, P235, DOI 10.1016/S0065-308X(02)52013-3; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; STOCK R, 1983, SOC SCI MED, V17, P563, DOI 10.1016/0277-9536(83)90298-8; Tanser F, 2001, TROP MED INT HEALTH, V6, P826, DOI 10.1046/j.1365-3156.2001.00794.x; Teklehaimanot HD, 2009, AM J TROP MED HYG, V80, P133, DOI 10.4269/ajtmh.2009.80.133; UNDP, 2012, UNDP HUM DEV REP; USGS, 2006, SHUTTL RAD TOP MISS	73	31	31	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 26	2013	8	4							e62214	10.1371/journal.pone.0062214	http://dx.doi.org/10.1371/journal.pone.0062214			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136EF	23638008	Green Published, Green Submitted, gold			2023-01-03	WOS:000318343700040
J	Roberts, RA; Shen, T; Allen, IC; Hasan, W; DeSimone, JM; Ting, JPY				Roberts, Reid A.; Shen, Tammy; Allen, Irving C.; Hasan, Warefta; DeSimone, Joseph M.; Ting, Jenny P. Y.			Analysis of the Murine Immune Response to Pulmonary Delivery of Precisely Fabricated Nano- and Microscale Particles	PLOS ONE			English	Article							AMORPHOUS SILICA PARTICLES; NLRP3 INFLAMMASOME; DRUG-DELIVERY; NANOPARTICLES; ACTIVATION; CELLS; SIZE; RELEASE; NALP3; SHAPE	Nanomedicine has the potential to transform clinical care in the 21st century. However, a precise understanding of how nanomaterial design parameters such as size, shape and composition affect the mammalian immune system is a prerequisite for the realization of nanomedicine's translational promise. Herein, we make use of the recently developed Particle Replication in Non-wetting Template (PRINT) fabrication process to precisely fabricate particles across and the nano- and micro-scale with defined shapes and compositions to address the role of particle design parameters on the murine innate immune response in both in vitro and in vivo settings. We find that particles composed of either the biodegradable polymer poly(lactic-co-glycolic acid) (PLGA) or the biocompatible polymer polyethylene glycol (PEG) do not cause release of pro-inflammatory cytokines nor inflammasome activation in bone marrow-derived macrophages. When instilled into the lungs of mice, particle composition and size can augment the number and type of innate immune cells recruited to the lungs without triggering inflammatory responses as assayed by cytokine release and histopathology. Smaller particles (80x320 nm) are more readily taken up in vivo by monocytes and macrophages than larger particles (6 mu m diameter), yet particles of all tested sizes remained in the lungs for up to 7 days without clearance or triggering of host immunity. These results suggest rational design of nanoparticle physical parameters can be used for sustained and localized delivery of therapeutics to the lungs.	[Roberts, Reid A.; Ting, Jenny P. Y.] Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; [Shen, Tammy; DeSimone, Joseph M.] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Allen, Irving C.] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA; [Hasan, Warefta; DeSimone, Joseph M.] Univ N Carolina, Dept Chem, Chapel Hill, NC USA; [DeSimone, Joseph M.; Ting, Jenny P. Y.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [DeSimone, Joseph M.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC USA; [DeSimone, Joseph M.] Univ N Carolina, Carolina Ctr Canc Nanotechnol Excellence, Chapel Hill, NC USA; [DeSimone, Joseph M.] N Carolina State Univ, Dept Chem & Biomol Engn, Raleigh, NC 27695 USA; [DeSimone, Joseph M.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA; [DeSimone, Joseph M.] Univ N Carolina, Inst Adv Mat, Chapel Hill, NC USA; [DeSimone, Joseph M.] Univ N Carolina, Inst Nanomed, Chapel Hill, NC USA; [DeSimone, Joseph M.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst Canc Res, New York, NY 10021 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Virginia Polytechnic Institute & State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Memorial Sloan Kettering Cancer Center	DeSimone, JM (corresponding author), Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.	desimone@email.unc.edu; jpyting@gmail.com		Allen, Irving/0000-0001-9573-5250	National Institutes of Health [8-VP1-CA174425-04, U19-AI077437, U54 AI057157]; NC Tracs [100K1202]; NATIONAL CANCER INSTITUTE [P30CA016086, DP1CA174425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI077437, U54AI057157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK092355] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NC Tracs; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grants 8-VP1-CA174425-04 (awarded to Joseph M. DeSimone), U19-AI077437 and U54 AI057157 (Jenny P.Y. Ting) and NC Tracs 100K1202 (Joseph M. DeSimone and Jenny P.Y. Ting). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen IC, 2006, AM J PHYSIOL-LUNG C, V291, pL1005, DOI 10.1152/ajplung.00174.2006; Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Bershteyn A, 2012, J CONTROL RELEASE, V157, P354, DOI 10.1016/j.jconrel.2011.07.029; Canelas DA, 2009, WIRES NANOMED NANOBI, V1, P391, DOI 10.1002/wnan.40; Capriotti AL, 2012, J PROTEOMICS, V75, P1924, DOI 10.1016/j.jprot.2012.01.003; Chan JM, 2010, METHODS MOL BIOL, V624, P163, DOI 10.1007/978-1-60761-609-2_11; Chen K, 2012, BIOMACROMOLECULES, V13, P2748, DOI 10.1021/bm3007242; Choi HS, 2010, NAT BIOTECHNOL, V28, P1300, DOI 10.1038/nbt.1696; Chu KS, 2012, NANOMEDICINE; Dailey LA, 2006, TOXICOL APPL PHARM, V215, P100, DOI 10.1016/j.taap.2006.01.016; Danhier F, 2012, J CONTROL RELEASE, V161, P505, DOI 10.1016/j.jconrel.2012.01.043; Demento SL, 2010, J IMMUNOL, V185, P2989, DOI 10.4049/jimmunol.1000768; Demento SL, 2009, VACCINE, V27, P3013, DOI 10.1016/j.vaccine.2009.03.034; Dhar S, 2011, P NATL ACAD SCI USA, V108, P1850, DOI 10.1073/pnas.1011379108; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Dobrovolskaia MA, 2009, NAT NANOTECHNOL, V4, P411, DOI [10.1038/nnano.2009.175, 10.1038/NNANO.2009.175]; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Dunn SS, 2012, J AM CHEM SOC, V134, P7423, DOI 10.1021/ja300174v; Enlow EM, 2011, NANO LETT, V11, P808, DOI 10.1021/nl104117p; Fahmy TM, 2007, AAPS J, V9, pE171, DOI 10.1208/aapsj0902019; Garcia A, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/941243; Gebril A, 2012, EXPERT REV VACCINES, V11, P1139, DOI [10.1586/ERV.12.81, 10.1586/erv.12.81]; Getts DR, 2012, NAT BIOTECHNOL, V30, P1217, DOI 10.1038/nbt.2434; Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105; Guzman J, 1997, POLYMER, V38, P5227, DOI 10.1016/S0032-3861(97)00039-6; Hasan W, 2012, NANO LETT, V12, P287, DOI 10.1021/nl2035354; Holgado MA, 2011, CURR DRUG TARGETS, V12, P1096; Hubbell JA, 2009, NATURE, V462, P449, DOI 10.1038/nature08604; Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0; Jeong W, 2010, NANOMEDICINE-UK, V5, P633, DOI 10.2217/NNM.10.34; Karmali PP, 2011, EXPERT OPIN DRUG DEL, V8, P343, DOI 10.1517/17425247.2011.554818; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Kircher MF, 2012, NAT MED, V18, P829, DOI 10.1038/nm.2721; Leuschner F, 2011, NAT BIOTECHNOL, V29, P1005, DOI 10.1038/nbt.1989; Lu JM, 2009, EXPERT REV MOL DIAGN, V9, P325, DOI 10.1586/ERM.09.15; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Merkel TJ, 2011, P NATL ACAD SCI USA, V108, P586, DOI 10.1073/pnas.1010013108; Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109; Moon JJ, 2011, NAT MATER, V10, P243, DOI 10.1038/NMAT2960; Morishige T, 2010, PHARMAZIE, V65, P596, DOI 10.1691/ph.2010.9408; Morishige T, 2012, ARCH TOXICOL; Morishige T, 2010, BIOMATERIALS, V31, P6833, DOI 10.1016/j.biomaterials.2010.05.036; Nicolete R, 2011, INT IMMUNOPHARMACOL, V11, P1557, DOI 10.1016/j.intimp.2011.05.014; Park J, 2012, NAT MAT; Park J, 2011, MOL PHARMACEUT, V8, P143, DOI 10.1021/mp100203a; Parrott MC, 2012, J AM CHEM SOC, V134, P7978, DOI 10.1021/ja301710z; Parrott MC, 2010, J AM CHEM SOC, V132, P17928, DOI 10.1021/ja108568g; Perry JL, 2011, ACCOUNTS CHEM RES, V44, P990, DOI 10.1021/ar2000315; Petros RA, 2008, J AM CHEM SOC, V130, P5008, DOI 10.1021/ja801436j; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Qiao Y, 2012, FEBS LETT, V586, P1022, DOI 10.1016/j.febslet.2012.02.045; Rice-Ficht AC, 2010, CURR OPIN MICROBIOL, V13, P106, DOI 10.1016/j.mib.2009.12.001; Rolland JP, 2005, J AM CHEM SOC, V127, P10096, DOI 10.1021/ja051977c; Roy I, 2010, NANOMED-NANOTECHNOL, V6, P237, DOI 10.1016/j.nano.2009.07.001; Sayes CM, 2011, METHODS MOL BIOL, V726, P313, DOI 10.1007/978-1-61779-052-2_20; Schijns VEJC, 2011, EXPERT REV VACCINES, V10, P539, DOI [10.1586/erv.11.21, 10.1586/ERV.11.21]; Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106; Stephan MT, 2012, BIOMATERIALS, V33, P5776, DOI 10.1016/j.biomaterials.2012.04.029; Tsai SE, 2010, IMMUNITY, V32, P568, DOI 10.1016/j.immuni.2010.03.015; Vaine CA, 2013, J IMMUNOL; Wang J, 2010, J AM CHEM SOC, V132, P11306, DOI 10.1021/ja1043177; Willingham SB, 2009, J IMMUNOL, V183, P2008, DOI 10.4049/jimmunol.0900138; Yang W, 2008, INT J PHARMACEUT, V356, P239, DOI 10.1016/j.ijpharm.2008.02.011; Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107; Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009-1082	68	47	47	2	71	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2013	8	4							e62115	10.1371/journal.pone.0062115	http://dx.doi.org/10.1371/journal.pone.0062115			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123JP	23593509	Green Submitted, Green Published, gold			2023-01-03	WOS:000317385300093
J	Wei, GX; Xu, T; Fan, FM; Dong, HM; Jiang, LL; Li, HJ; Yang, Z; Luo, J; Zuo, XN				Wei, Gao-Xia; Xu, Ting; Fan, Feng-Mei; Dong, Hao-Ming; Jiang, Li-Li; Li, Hui-Jie; Yang, Zhi; Luo, Jing; Zuo, Xi-Nian			Can Taichi Reshape the Brain? A Brain Morphometry Study	PLOS ONE			English	Article							HUMAN CEREBRAL-CORTEX; EXERCISE INDUCES ANGIOGENESIS; LONG-TERM MEDITATION; PRIMARY MOTOR CORTEX; CORTICAL THICKNESS; GEOMETRICALLY ACCURATE; PHYSICAL-ACTIVITY; CHI CHUAN; GRAY; VOLUME	Although research has provided abundant evidence for Taichi-induced improvements in psychological and physiological well-being, little is known about possible links to brain structure of Taichi practice. Using high-resolution MRI of 22 Tai Chi Chuan (TCC) practitioners and 18 controls matched for age, sex and education, we set out to examine the underlying anatomical correlates of long-term Taichi practice at two different levels of regional specificity. For this purpose, parcel-wise and vertex-wise analyses were employed to quantify the difference between TCC practitioners and the controls based on cortical surface reconstruction. We also adopted the Attention Network Test (ANT) to explore the effect of TCC on executive control. TCC practitioners, compared with controls, showed significantly thicker cortex in precentral gyrus, insula sulcus and middle frontal sulcus in the right hemisphere and superior temporal gyrus and medial occipito-temporal sulcus and lingual sulcus in the left hemisphere. Moreover, we found that thicker cortex in left medial occipito-temporal sulcus and lingual sulcus was associated with greater intensity of TCC practice. These findings indicate that long-term TCC practice could induce regional structural change and also suggest TCC might share similar patterns of neural correlates with meditation and aerobic exercise.	[Wei, Gao-Xia; Xu, Ting; Fan, Feng-Mei; Dong, Hao-Ming; Jiang, Li-Li; Li, Hui-Jie; Yang, Zhi; Zuo, Xi-Nian] Chinese Acad Sci, Inst Psychol, Magnet Resonance Imaging Res Ctr, Lab Funct Connectome & Dev,Key Lab Behav Sci, Beijing 100101, Peoples R China; [Wei, Gao-Xia; Luo, Jing] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing 100101, Peoples R China; [Fan, Feng-Mei] Beijing Huilongguan Hosp, Psychiat Res Ctr, Beijing, Peoples R China; [Luo, Jing] Capital Normal Univ, Dept Psychol, Beijing Key Lab Learning & Cognit, Beijing, Peoples R China; [Dong, Hao-Ming] Univ Chinese Acad Sci, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Psychology, CAS; Chinese Academy of Sciences; Institute of Psychology, CAS; Capital Normal University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zuo, XN (corresponding author), Chinese Acad Sci, Inst Psychol, Magnet Resonance Imaging Res Ctr, Lab Funct Connectome & Dev,Key Lab Behav Sci, Beijing 100101, Peoples R China.	luoj@psych.ac.cn; zuoxn@psych.ac.cn	Zuo, Xi-Nian/A-7273-2009; Yang, Zhi/W-6459-2019	Zuo, Xi-Nian/0000-0001-9110-585X; Yang, Zhi/0000-0002-2222-2312; Wei, Gao-Xia/0000-0002-6350-9096	National Natural Science Foundation of China [31200794, 91132728, 81171409, 81030028]; Key Laboratory of Mental Health, the Knowledge Innovation Program from Institute of Psychology, Chinese Academy of Sciences (CAS) [KSCX2-EW-J-8]; Hundred Talents Program [Y2CX112006]; Key Research Program of CAS [KSZD-EW-TZ-002]; Major Joint Fund for International Cooperation and Exchange of the National Natural Science Foundation [81220108014]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Laboratory of Mental Health, the Knowledge Innovation Program from Institute of Psychology, Chinese Academy of Sciences (CAS); Hundred Talents Program(Chinese Academy of Sciences); Key Research Program of CAS; Major Joint Fund for International Cooperation and Exchange of the National Natural Science Foundation	This work was supported by the National Natural Science Foundation of China (31200794, 91132728, 81171409, 81030028) and the Open Research Fund of the Key Laboratory of Mental Health, the Knowledge Innovation Program (KSCX2-EW-J-8) from Institute of Psychology, Chinese Academy of Sciences (CAS). The senior author Prof. Xi-Nian Zuo acknowledges the Hundred Talents Program (Y2CX112006) and the Key Research Program (KSZD-EW-TZ-002) of CAS and the Major Joint Fund for International Cooperation and Exchange of the National Natural Science Foundation (81220108014). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Barbier EL, 2001, J MAGN RESON IMAGING, V13, P496, DOI 10.1002/jmri.1073; Bernal-Rusiel JL, 2010, NEUROIMAGE, V52, P158, DOI 10.1016/j.neuroimage.2010.03.074; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; Booth FW, 2006, MED SCI SPORT EXER, V38, P405, DOI 10.1249/01.mss.0000205117.11882.65; Caldwell K, 2009, J BODYW MOV THER, V13, P155, DOI 10.1016/j.jbmt.2007.12.001; Chang YK, 2010, J AGING PHYS ACTIV, V18, P451, DOI 10.1123/japa.18.4.451; Colcombe SJ, 2006, J GERONTOL A-BIOL, V61, P1166, DOI 10.1093/gerona/61.11.1166; Craig ADB, 2003, TRENDS NEUROSCI, V26, P303, DOI 10.1016/S0166-2236(03)00123-1; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Dechamps A, 2009, J AGING PHYS ACTIV, V17, P236, DOI 10.1123/japa.17.2.236; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Ekstrom AD, 2003, NATURE, V425, P184, DOI 10.1038/nature01964; Erickson KI, 2010, NEUROLOGY, V75, P1415, DOI 10.1212/WNL.0b013e3181f88359; Eskildsen SF, 2007, LECT NOTES COMPUT SC, V4791, P409; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Grant JA, 2010, EMOTION, V10, P43, DOI 10.1037/a0018334; Gron G, 2000, NAT NEUROSCI, V3, P404, DOI 10.1038/73980; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hari R, 1998, P NATL ACAD SCI USA, V95, P15061, DOI 10.1073/pnas.95.25.15061; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Holzel BK, 2008, SOC COGN AFFECT NEUR, V3, P55, DOI 10.1093/scan/nsm038; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Hogstrom LJ, 2013, CEREB CORTEX, V23, P2521, DOI 10.1093/cercor/bhs231; Holmes MM, 2004, J NEUROSCI RES, V76, P216, DOI 10.1002/jnr.20039; Jang JH, 2011, NEUROSCI LETT, V487, P358, DOI 10.1016/j.neulet.2010.10.056; Kang DH, 2013, SOC COGN AFFECT NEUR, V8, P27, DOI 10.1093/scan/nss056; Kleim JA, 2002, NEUROBIOL LEARN MEM, V77, P63, DOI 10.1006/nlme.2000.4004; Kleim JA, 2002, BRAIN RES, V934, P1, DOI 10.1016/S0006-8993(02)02239-4; Klein Penelope J, 2006, J Neurol Phys Ther, V30, P22; Kolb B, 2008, NEUROBIOL LEARN MEM, V90, P295, DOI 10.1016/j.nlm.2008.04.012; Lan C, 1998, MED SCI SPORT EXER, V30, P345, DOI 10.1097/00005768-199803000-00003; Lan C, 2000, ARCH PHYS MED REHAB, V81, P604, DOI 10.1053/mr.2000.3849; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Lee JK, 2006, NEUROIMAGE, V31, P572, DOI 10.1016/j.neuroimage.2005.12.044; Lee MS, 2008, PARKINSONISM RELAT D, V14, P589, DOI 10.1016/j.parkreldis.2008.02.003; Luders E, 2009, NEUROIMAGE, V45, P672, DOI 10.1016/j.neuroimage.2008.12.061; Makris N, 2006, NEUROIMAGE, V33, P139, DOI 10.1016/j.neuroimage.2006.04.220; Matthews Margaret M, 2008, J S C Med Assoc, V104, P255; Monda KL, 2007, SOC SCI MED, V64, P858, DOI 10.1016/j.socscimed.2006.10.019; Paw MJMCA, 2008, SPORTS MED, V38, P781, DOI 10.2165/00007256-200838090-00006; Pienaar R, 2008, INT J IMAG SYST TECH, V18, P42, DOI 10.1002/ima.20138; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, TRENDS NEUROSCI, V18, P383, DOI 10.1016/0166-2236(95)93934-P; Redick TS, 2006, APPL COGNITIVE PSYCH, V20, P713, DOI 10.1002/acp.1224; Rejbi Imen Ben Cheikh, 2010, Int J Chron Obstruct Pulmon Dis, V5, P209; Rogers CE, 2009, WESTERN J NURS RES, V31, P245, DOI 10.1177/0193945908327529; Sandlund ES, 2000, INT J STRESS MANAGE, V7, P139, DOI 10.1023/A:1009536319034; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Swain RA, 2003, NEUROSCIENCE, V117, P1037, DOI 10.1016/S0306-4522(02)00664-4; Tai'Wang Yong, 2008, V52, P135, DOI 10.1159/000134294; Taubert M, 2012, NEUROSCIENTIST, V18, P320, DOI 10.1177/1073858411419048; Taylor D, 2012, J AM GERIATR SOC, V60, P841, DOI 10.1111/j.1532-5415.2012.03928.x; Taylor-Piliae RE, 2006, J ADV NURS, V54, P313, DOI 10.1111/j.1365-2648.2006.03809.x; Taylor-Piliae Ruth E, 2004, J Cardiovasc Nurs, V19, P48; Tsang WWN, 2004, MED SCI SPORT EXER, V36, P648, DOI 10.1249/01.MSS.0000121941.57669.BF; Vaynman S, 2006, J NEUROSCI RES, V84, P699, DOI 10.1002/jnr.20979; Vestergaard-Poulsen P, 2009, NEUROREPORT, V20, P170, DOI 10.1097/WNR.0b013e328320012a; Wang WC, 2009, J ACUPUNCT MERIDIAN, V2, P171, DOI 10.1016/S2005-2901(09)60052-2; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P191, DOI 10.1089/acm.2007.7170B; Weinberg RS, 2007, EXERCISE BEHAV ADHER; Weinstein AM, 2012, BRAIN BEHAV IMMUN, V26, P811, DOI 10.1016/j.bbi.2011.11.008; Wong Alice M. K., 2008, V52, P115, DOI 10.1159/000134291; Xing XX, 2011, MAGN RESON IMAGING, V29, P731, DOI 10.1016/j.mri.2011.02.007; Zatorre RJ, 2012, NAT NEUROSCI, V15, P528, DOI 10.1038/nn.3045; Zhu WM, 2010, AM J LIFESTYLE MED, V4, P418, DOI 10.1177/1559827610368777; Zuo XN, 2013, NEUROIMAGE, V65, P374, DOI 10.1016/j.neuroimage.2012.10.017; Zuo XN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026703	76	92	101	4	96	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e61038	10.1371/journal.pone.0061038	http://dx.doi.org/10.1371/journal.pone.0061038			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23585869	Green Published, Green Submitted, gold			2023-01-03	WOS:000317909600076
J	Dhurandhar, EJ; Allison, DB; van Groen, T; Kadish, I				Dhurandhar, Emily J.; Allison, David B.; van Groen, Thomas; Kadish, Inga			Hunger in the Absence of Caloric Restriction Improves Cognition and Attenuates Alzheimer's Disease Pathology in a Mouse Model	PLOS ONE			English	Article							WEIGHT-LOSS; CHOLESTEROL LEVEL; TRANSGENIC MICE; STATIN USE; LIFE-SPAN; GHRELIN; RISK; INFLAMMATION; DYSFUNCTION; PREVENTION	It has been shown that caloric restriction (CR) delays aging and possibly delays the development of Alzheimer's disease (AD). We conjecture that the mechanism may involve interoceptive cues, rather than reduced energy intake per se. We determined that hunger alone, induced by a ghrelin agonist, reduces AD pathology and improves cognition in the APP-SwDI mouse model of AD. Long-term treatment with a ghrelin agonist was sufficient to improve the performance in the water maze. The treatment also reduced levels of amyloid beta (Ab) and inflammation (microglial activation) at 6 months of age compared to the control group, similar to the effect of CR. Thus, a hunger-inducing drug attenuates AD pathology, in the absence of CR, and the neuroendocrine aspects of hunger also prevent age-related cognitive decline.	[Dhurandhar, Emily J.; Allison, David B.] Univ Alabama Birmingham, Sch Publ Hlth, Off Energet, Nutr Obes Res Ctr, Birmingham, AL 35294 USA; [van Groen, Thomas; Kadish, Inga] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Nutr Obes Res Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kadish, I (corresponding author), Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Nutr Obes Res Ctr, Birmingham, AL USA.	ikadisha@uab.edu		Allison, David/0000-0003-3566-9399	Alzheimer's of Central Alabama; National Institutes of Health [P30 NS47466, T32DK062710]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079626, T32DK062710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047466] Funding Source: NIH RePORTER	Alzheimer's of Central Alabama; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by Alzheimer's of Central Alabama, and part of the work was supported by National Institutes of Health P30 NS47466 and T32DK062710. In addition, the ghrelin agonist was donated for the study by Eli Lilly. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Arab L, 2010, J ALZHEIMERS DIS, V20, P785, DOI 10.3233/JAD-2010-091573; Aziz NA, 2008, J NEUROL, V255, P1872, DOI 10.1007/s00415-009-0062-8; Bales KR, 2010, NEUROPHARMACOLOGY, V59, P295, DOI 10.1016/j.neuropharm.2010.01.005; Bonda DJ, 2011, LANCET NEUROL, V10, P275, DOI 10.1016/S1474-4422(11)70013-8; Bulgarelli I, 2009, J NEUROSCI RES, V87, P2718, DOI 10.1002/jnr.22088; Cai H, 2012, CURR ALZHEIMER RES, V9, P5, DOI 10.2174/156720512799015064; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Davidson TL, 2005, PEPTIDES, V26, P1602, DOI 10.1016/j.peptides.2005.02.014; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; Di Paolo G, 2011, NAT REV NEUROSCI, V12, P284, DOI 10.1038/nrn3012; Diano S, 2006, NAT NEUROSCI, V9, P381, DOI 10.1038/nn1656; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; FURST A, 1987, HEALTH PHYS, V52, P527, DOI 10.1097/00004032-198705000-00001; Furuya TK, 2012, NEUROCHEM INT; Giddings M, 2008, OB SOC ANN M OB PHOE, pS108; Gillette-Guyonnet S, 2007, J NUTR HEALTH AGING, V11, P38; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Hambly C, 2007, REJUV RES, V10, P533, DOI 10.1089/rej.2007.0555; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Inelmen EM, 2010, AGING CLIN EXP RES, V22, P192, DOI [10.3275/6677, 10.1007/BF03324796]; Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556; Libert S, 2007, SCIENCE, V315, P1133, DOI 10.1126/science.1136610; Lugar CW, 2004, BIOORG MED CHEM LETT, V14, P5873, DOI 10.1016/j.bmcl.2004.09.027; Minor RK, 2009, MOL CELL ENDOCRINOL, V299, P79, DOI 10.1016/j.mce.2008.10.044; Moon M, 2011, J ALZHEIMERS DIS, V23, P147, DOI 10.3233/JAD-2010-101263; Rattan SIS, 2004, J GERONTOL A-BIOL, V59, P705; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Rogers J, 2001, NEUROCHEM INT, V39, P333, DOI 10.1016/S0197-0186(01)00040-7; Seneff S, 2011, EUR J INTERN MED, V22, P134, DOI 10.1016/j.ejim.2010.12.017; Shepardson NE, 2011, ARCH NEUROL-CHICAGO, V68, P1385, DOI 10.1001/archneurol.2011.242; Shepardson NE, 2011, ARCH NEUROL-CHICAGO, V68, P1239, DOI 10.1001/archneurol.2011.203; Stalder M, 2001, NEUROBIOL AGING, V22, P427, DOI 10.1016/S0197-4580(01)00209-3; Tamura Bruce K., 2007, Journal of Nutrition for the Elderly, V26, P21, DOI 10.1300/J052v26n03_02; Tezapsidis N, 2009, J ALZHEIMERS DIS, V16, P731, DOI 10.3233/JAD-2009-1021; van Groen T, 2005, BRAIN RES REV, V48, P370, DOI 10.1016/j.brainresrev.2004.12.026; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Wang J, 2010, BBA-PROTEINS PROTEOM, V1804, P1690, DOI 10.1016/j.bbapap.2009.11.015; Weih M, 2007, J NEURAL TRANSM, V114, P1187, DOI 10.1007/s00702-007-0704-x; Whitmer RA, 2005, BMJ-BRIT MED J, V330, P1360, DOI 10.1136/bmj.38446.466238.E0	40	46	51	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2013	8	4							e60437	10.1371/journal.pone.0060437	http://dx.doi.org/10.1371/journal.pone.0060437			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127RY	23565247	Green Published, gold			2023-01-03	WOS:000317717300117
J	Yuan, YK; Zhao, YW; Xin, SC; Wu, N; Wen, JL; Li, S; Chen, LJ; Wei, YQ; Yang, HS; Lin, S				Yuan, Yike; Zhao, Yuwei; Xin, Shengchang; Wu, Ni; Wen, Jiaolin; Li, Song; Chen, Lijuan; Wei, Yuquan; Yang, Hanshuo; Lin, Shuo			A Novel PEGylated Liposome-Encapsulated SANT75 Suppresses Tumor Growth through Inhibiting Hedgehog Signaling Pathway	PLOS ONE			English	Article							BREAST-CANCER; SMOOTHENED ACTIVITY; OVARIAN CANCERS; DRUG-DELIVERY; PHASE-I; THERAPY; ACTIVATION; CARCINOMA; CELLS; THERAPEUTICS	The Hedgehog (Hh) pathway inhibitors have shown great promise in cancer therapeutics. SANT75, a novel compound we previously designed to specially inhibit the Smoothened (SMO) protein in the Hh pathway, has greater inhibitory potency than many of commonly used Hh inhibitors. However, preclinical studies of SANT75 revealed water insolubility and acute toxicity. To overcome these limitations, we developed a liposomal formulation of SANT75 and investigated its antitumor efficacy in vitro and in vivo. We encapsulated SANT75 into PEGylated liposome and the mean particle size distribution and zeta-potential (ZP) of liposomes were optimized. Using the Shh-light2 cell and Gli-GFP or Flk-GFP transgenic reporter zebrafish, we confirmed that liposome-encapsulated SANT75 inhibited Hh activity with similar potency as the original SANT75. SANT75 encapsulated into liposome exerted strong tumor growth-inhibiting effects in vitro and in vivo. In addition, the liposomal SANT75 therapy efficiently improved the survival time of tumor-bearing mice without obvious systemic toxicity. The pathological morphology and immunohistochemistry staining revealed that liposomal SANT75 induced tumor cell apoptosis, inhibited tumor angiogenesis as assessed by CD31 and down-regulated the expression of Hh target protein Gli-1 in tumor tissues. Our findings suggest that liposomal formulated SANT75 has improved solubility and bioavailability and should be further developed as a drug candidate for treating tumors with abnormally high Hh activity.	[Yuan, Yike; Zhao, Yuwei; Wu, Ni; Wen, Jiaolin; Chen, Lijuan; Wei, Yuquan; Yang, Hanshuo; Lin, Shuo] Sichuan Univ, State Key Lab Biotherapy, West China Hosp, West China Med Sch, Chengdu 610064, Sichuan, Peoples R China; [Yuan, Yike; Zhao, Yuwei; Wu, Ni; Wen, Jiaolin; Chen, Lijuan; Wei, Yuquan; Yang, Hanshuo; Lin, Shuo] Sichuan Univ, Ctr Canc, West China Hosp, West China Med Sch, Chengdu 610064, Sichuan, Peoples R China; [Xin, Shengchang; Li, Song] Peking Univ, Lab Chem Genom, Shenzhen Grad Sch, Shenzhen, Peoples R China; [Lin, Shuo] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA USA	Sichuan University; Sichuan University; Peking University; University Town of Shenzhen; University of California System; University of California Los Angeles	Yang, HS (corresponding author), Sichuan Univ, State Key Lab Biotherapy, West China Hosp, West China Med Sch, Chengdu 610064, Sichuan, Peoples R China.	yhansh@scu.edu.cn; shuolin@ucla.edu	Wen, Jiaolin/GZL-0162-2022		National ST Major project [2012ZX09501001-003]	National ST Major project	This work was supported by the National S&T Major project(2012ZX09501001-003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chen WW, 2011, P NATL ACAD SCI USA, V108, P9589, DOI 10.1073/pnas.1017945108; Cukierman E, 2010, BIOCHEM PHARMACOL, V80, P762, DOI 10.1016/j.bcp.2010.04.020; Dlugosz A, 2012, NAT REV DRUG DISCOV, V11, P437, DOI 10.1038/nrd3753; Dormoy V, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-123; Dritschilo A, 2006, CLIN CANCER RES, V12, P1251, DOI 10.1158/1078-0432.CCR-05-1260; El-Sayed A, 2009, AAPS J, V11, P13, DOI 10.1208/s12248-008-9071-2; Ferrandina G, 2010, THER CLIN RISK MANAG, V6, P463, DOI 10.2147/TCRM.S3348; Fetterly GJ, 2008, CLIN CANCER RES, V14, P5856, DOI 10.1158/1078-0432.CCR-08-1046; Harris L, 2002, CANCER, V94, P25, DOI 10.1002/cncr.10201; Hioki A, 2010, BIOL PHARM BULL, V33, P1466, DOI 10.1248/bpb.33.1466; Kameda C, 2009, ANTICANCER RES, V29, P871; Kasper M, 2009, CARCINOGENESIS, V30, P903, DOI 10.1093/carcin/bgp048; Kim JY, 2009, BIOMATERIALS, V30, P5751, DOI 10.1016/j.biomaterials.2009.07.021; Liao XY, 2009, CARCINOGENESIS, V30, P131, DOI 10.1093/carcin/bgn230; Markman Maurie, 2011, Cancer Manag Res, V3, P219, DOI 10.2147/CMR.S15558; Mukherjee S, 2006, CANCER BIOL THER, V5, P674, DOI 10.4161/cbt.5.6.2906; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Peukert S, 2010, CHEMMEDCHEM, V5, P500, DOI 10.1002/cmdc.201000011; Ruel L, 2009, GENE DEV, V23, P1843, DOI 10.1101/gad.1838109; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Sun DS, 2006, WORLD J GASTROENTERO, V12, P4741, DOI 10.3748/wjg.v12.i29.4741; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Torchilin V, 2012, ADV DEL SCI TECHNOL, P289, DOI 10.1007/978-1-4614-0881-9_11; Torchilin VP, 2005, ADV DRUG DELIVER REV, V57, P95, DOI 10.1016/j.addr.2004.06.002; Vasir JK, 2007, ADV DRUG DELIVER REV, V59, P718, DOI 10.1016/j.addr.2007.06.003; Wu Y, 2008, ACTA BIOCH BIOPH SIN, V40, P643, DOI 10.1111/j.1745-7270.2008.00443.x; Xie JW, 2008, ACTA BIOCH BIOPH SIN, V40, P670, DOI 10.1111/j.1745-7270.2008.00431.x; Xu Xuan-Fu, 2009, J Carcinog, V8, P13, DOI 10.4103/1477-3163.55429; Yang HB, 2009, J BIOL CHEM, V284, P20876, DOI 10.1074/jbc.M807648200; Yang L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-112; Yoshimoto AN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045332; You SH, 2010, UPSALA J MED SCI, V115, P169, DOI 10.3109/03009731003668316; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860; Yuan ZP, 2006, CLIN CANCER RES, V12, P3193, DOI 10.1158/1078-0432.CCR-05-2365; Zhang JA, 2005, EUR J PHARM BIOPHARM, V59, P177, DOI 10.1016/j.ejpb.2004.06.009	38	6	6	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2013	8	4							e60266	10.1371/journal.pone.0060266	http://dx.doi.org/10.1371/journal.pone.0060266			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	117CY	23560085	Green Submitted, Green Published, gold			2023-01-03	WOS:000316930900060
J	Bonomi, AG; Soenen, S; Goris, AHC; Westerterp, KR				Bonomi, Alberto G.; Soenen, Stijn; Goris, Annelies H. C.; Westerterp, Klaas R.			Weight-Loss Induced Changes in Physical Activity and Activity Energy Expenditure in Overweight and Obese Subjects before and after Energy Restriction	PLOS ONE			English	Article							DOUBLY-LABELED WATER; RESTING METABOLIC-RATE; BODY-WEIGHT; POSTURE ALLOCATION; PIMA-INDIANS; MOVEMENT; WOMEN; ADOLESCENTS; ACCELEROMETERS; WALKING	Activity energy expenditure (AEE) is the component of daily energy expenditure that is mainly influenced by the amount of physical activity (PA) and by the weight of the body displaced. This study aimed at analyzing the effect of weight loss on PA and AEE. The body weight and PA of 66 overweight and obese subjects were measured at baseline and after 12 weeks of 67% energy restriction. PA was measured using a tri-axial accelerometer for movement registration (Tracmor) and quantified in activity counts. Tracmor recordings were also processed using a classification algorithm to recognize 6 common activity types engaged in during the day. A doubly-labeled water validated equation based on Tracmor output was used to estimate AEE. After weight loss, body weight decreased by 13 +/- 4%, daily activity counts augmented by 9% (95% CI: +2%, +15%), and this increase was weakly associated with the decrease in body weight (R-2=7%; P<0.05). After weight loss subjects were significantly (P<0.05) less sedentary (-26 min/d), and increased the time spent walking (+11 min/d) and bicycling (+4 min/d). However, AEE decreased by 0.6 +/- 0.4 MJ/d after weight loss. On average, a 2-hour/day reduction of sedentary time by increasing ambulatory and generic activities was required to restore baseline levels of AEE. In conclusion, after weight loss PA increased but the related metabolic demand did not offset the reduction in AEE due to the lower body weight. Promoting physical activity according to the extent of weight loss might increase successfulness of weight maintenance.	[Bonomi, Alberto G.; Soenen, Stijn; Westerterp, Klaas R.] Maastricht Univ, Dept Human Biol, Maastricht, Netherlands; [Bonomi, Alberto G.] Philips Res, Personal Hlth Solut, Eindhoven, Netherlands; [Goris, Annelies H. C.] Philips Consumer Lifestyle, DirectLife, Amsterdam, Netherlands	Maastricht University; Philips; Philips Research; Philips	Bonomi, AG (corresponding author), Maastricht Univ, Dept Human Biol, Maastricht, Netherlands.	a.bonomi@maastrichtuniversity.nl		Soenen, Stijn/0000-0002-0196-128X				Assah FK, 2009, OBESITY, V17, P1588, DOI 10.1038/oby.2009.39; Ball K, 2001, INT J OBESITY, V25, P914, DOI 10.1038/sj.ijo.0801622; Bonomi AG, 2012, INT J OBESITY, V36, P167, DOI 10.1038/ijo.2011.99; Bonomi AG, 2009, J APPL PHYSIOL, V107, P655, DOI 10.1152/japplphysiol.00150.2009; Bonomi AG, 2010, OBESITY, V18, P1845, DOI 10.1038/oby.2010.34; Bonomi AG, 2009, MED SCI SPORT EXER, V41, P1770, DOI 10.1249/MSS.0b013e3181a24536; Bouten CVC, 1996, J APPL PHYSIOL, V81, P1019, DOI 10.1152/jappl.1996.81.2.1019; CHONG PKK, 1993, DIABETIC MED, V10, P729, DOI 10.1111/j.1464-5491.1993.tb00156.x; Crouter SE, 2006, EUR J APPL PHYSIOL, V98, P601, DOI 10.1007/s00421-006-0307-5; Ekelund U, 2004, AM J CLIN NUTR, V79, P851; Ekelund U, 2002, AM J CLIN NUTR, V76, P935, DOI 10.1093/ajcn/76.5.935; Esparza J, 2000, INT J OBESITY, V24, P55, DOI 10.1038/sj.ijo.0801085; Frankenfield DC, 2003, J AM DIET ASSOC, V103, P1152, DOI 10.1016/S0002-8223(03)00982-9; Harris AM, 2007, AM J PHYSIOL-ENDOC M, V292, pE1207, DOI 10.1152/ajpendo.00509.2006; Johannsen DL, 2008, OBESITY, V16, P34, DOI 10.1038/oby.2007.15; Leenders NY, 2006, MED SCI SPORT EXER, V38, P2165, DOI 10.1249/01.mss.0000235883.94357.95; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Levine JA, 2005, SCIENCE, V307, P584, DOI 10.1126/science.1106561; Levine JA, 2000, AM J CLIN NUTR, V72, P1451; Levine JA, 2008, DIABETES, V57, P548, DOI 10.2337/db07-0815; Luke A, 2009, AM J CLIN NUTR, V89, P169, DOI 10.3945/ajcn.2008.26630; Martin CK, 2007, OBESITY, V15, P2964, DOI 10.1038/oby.2007.354; Martinez JA, 1999, PUBLIC HEALTH NUTR, V2, P125, DOI 10.1017/S1368980099000178; MEIJER GAL, 1992, EUR J APPL PHYSIOL O, V65, P525, DOI 10.1007/BF00602359; Peyrot N, 2009, J APPL PHYSIOL, V106, P1763, DOI 10.1152/japplphysiol.91240.2008; Plasqui G, 2007, OBESITY, V15, P2371, DOI 10.1038/oby.2007.281; Prentice AM, 1996, EUR J CLIN NUTR, V50, P93; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; Prentice AM, 1996, INT J OBESITY, V20, P688; RAVUSSIN E, 1985, AM J CLIN NUTR, V41, P753, DOI 10.1093/ajcn/41.4.753; RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802; Redman LM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004377; Schoeller DA, 2002, INT J OBESITY, V26, P97, DOI 10.1038/sj.ijo.0801851; TAYLOR HL, 1950, SCIENCE, V112, P215, DOI 10.1126/science.112.2904.215; Wang XW, 2008, MED SCI SPORT EXER, V40, P1781, DOI 10.1249/MSS.0b013e31817d8176; Wearing SC, 2006, OBES REV, V7, P13, DOI 10.1111/j.1467-789X.2006.00215.x; Weinsier RL, 2000, AM J CLIN NUTR, V71, P1138; Weinsier RL, 2002, AM J CLIN NUTR, V75, P499, DOI 10.1093/ajcn/75.3.499; Weinsier RL, 1998, AM J MED, V105, P145, DOI 10.1016/S0002-9343(98)00190-9; Westerterp MR, 2008, PHYSIOL BEHAV, V93, P1039, DOI 10.1016/j.physbeh.2008.01.021; ZURLO F, 1992, AM J PHYSIOL, V263, pE296, DOI 10.1152/ajpendo.1992.263.2.E296	41	28	28	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2013	8	3							e59641	10.1371/journal.pone.0059641	http://dx.doi.org/10.1371/journal.pone.0059641			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	111UM	23555733	Green Submitted, Green Published, gold			2023-01-03	WOS:000316546400052
J	Gheorghiade, M; Bohm, M; Greene, SJ; Fonarow, GC; Lewis, EF; Zannad, F; Solomon, SD; Baschiera, F; Botha, J; Hua, TA; Gimpelewicz, CR; Jaumont, X; Lesogor, A; Maggioni, AP				Gheorghiade, Mihai; Boehm, Michael; Greene, Stephen J.; Fonarow, Gregg C.; Lewis, Eldrin F.; Zannad, Faiez; Solomon, Scott D.; Baschiera, Fabio; Botha, Jaco; Hua, Tsushung A.; Gimpelewicz, Claudio R.; Jaumont, Xavier; Lesogor, Anastasia; Maggioni, Aldo P.		ASTRONAUT Investigators Coordinato	Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure The ASTRONAUT Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENIN INHIBITOR ALISKIREN; CLINICAL-TRIALS; DOUBLE-BLIND; VASOPRESSIN ANTAGONISM; TASK-FORCE; OUTCOMES; EVEREST; ASSOCIATION; RATIONALE; TOLVAPTAN	Importance Hospitalizations for heart failure (HHF) represent a major health burden, with high rates of early postdischarge rehospitalization and mortality. Objective To investigate whether aliskiren, a direct renin inhibitor, when added to standard therapy, would reduce the rate of cardiovascular (CV) death or HF rehospitalization among HHF patients. Design, Setting, and Participants International, double-blind, placebo-controlled study that randomized hemodynamically stable HHF patients a median 5 days after admission. Eligible patients were 18 years or older with left ventricular ejection fraction (LVEF) 40% or less, elevated natriuretic peptides (brain natriuretic peptide [BNP] >= 400 pg/mL or N-terminal pro-BNP [NT-proBNP] >= 1600 pg/mL), and signs and symptoms of fluid overload. Patients were recruited from 316 sites across North and South America, Europe, and Asia between May 2009 and December 2011. The follow-up period ended in July 2012. Intervention All patients received 150mg(increased to 300 mg as tolerated) of aliskiren or placebo daily, in addition to standard therapy. The study drug was continued after discharge for a median 11.3 months. Main Outcome Measures Cardiovascular death or HF rehospitalization at 6 months and 12 months. Results In total, 1639 patients were randomized, with 1615 patients included in the final efficacy analysis cohort (808 aliskiren, 807 placebo). Mean age was 65 years; mean LVEF, 28%; 41% of patients had diabetes mellitus, mean estimated glomerular filtration rate, 67 mL/min/1.73 m(2). At admission and randomization, median NT-proBNP levels were 4239 pg/mL and 2718 pg/mL, respectively. At randomization, patients were receiving diuretics (95.9%), beta-blockers (82.5%), angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (84.2%), and mineralocorticoid receptor antagonists (57.0%). In total, 24.9% of patients receiving aliskiren (77 CV deaths, 153 HF rehospitalizations) and 26.5% of patients receiving placebo (85 CV deaths, 166 HF rehospitalizations) experienced the primary end point at 6 months (hazard ratio [HR], 0.92; 95% CI, 0.76-1.12; P=.41). At 12 months, the event rates were 35.0% for the aliskiren group (126 CV deaths, 212 HF rehospitalizations) and 37.3% for the placebo group (137 CV deaths, 224 HF rehospitalizations; HR, 0.93; 95% CI, 0.79-1.09; P=.36). The rates of hyperkalemia, hypotension, and renal impairment/renal failure were higher in the aliskiren group compared with placebo. Conclusion and Relevance Among patients hospitalized for HF with reduced LVEF, initiation of aliskiren in addition to standard therapy did not reduce CV death or HF rehospitalization at 6 months or 12 months after discharge. Trial Registration clinicaltrials.gov Identifier: NCT00894387 JAMA. 2013;309(11):1125-1135 Published online March 11, 2013. doi:10.1001/jama.2013.1954 www.jama.com	[Gheorghiade, Mihai; Greene, Stephen J.] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA; [Boehm, Michael] Univ Klinikum Saarlandes, Innere Med Klin 3, Homburg, Germany; [Fonarow, Gregg C.] Univ Calif Los Angeles, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA; [Lewis, Eldrin F.; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; [Zannad, Faiez] Hop Jeanne dArc, CHU Nancy, INSERM, Clin Invest Ctr, Dommartin Les Toul, France; [Baschiera, Fabio; Botha, Jaco; Gimpelewicz, Claudio R.; Jaumont, Xavier; Lesogor, Anastasia] Novartis Pharma AG, Basel, Switzerland; [Hua, Tsushung A.] Novartis Pharmaceut, E Hanover, NJ USA; [Maggioni, Aldo P.] Assoc Nazl Med Cardiol Osped, Res Ctr, Florence, Italy	Northwestern University; Feinberg School of Medicine; Universitatsklinikum des Saarlandes; University of California System; University of California Los Angeles; Harvard University; Brigham & Women's Hospital; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Novartis; Novartis; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO)	Gheorghiade, M (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 645 N Michigan Ave,Ste 1006, Chicago, IL 60611 USA.	m-gheorghiade@northwestern.edu	Maggioni, Aldo Pietro/AAL-5334-2020; Zannad, Faiez/K-4649-2019; Zadionchenko, Vladimir/A-7445-2016; Braun-Dullaeus, Ruediger C/G-1844-2013; Hradec, Jaromir/S-2388-2016; De Keulenaer, Gilles/D-9321-2017; Böhm, Michael/C-3638-2011; Boldueva, Svetlana/AAH-3862-2019; Fonarow, Gregg C/D-5988-2014; Solomon, Scott/I-5789-2013	Maggioni, Aldo Pietro/0000-0003-2764-6779; Zadionchenko, Vladimir/0000-0003-2377-5266; Braun-Dullaeus, Ruediger C/0000-0003-3888-6532; Hradec, Jaromir/0000-0001-7597-8239; De Keulenaer, Gilles/0000-0002-4238-4183; Boldueva, Svetlana/0000-0002-1898-084X; Fonarow, Gregg C/0000-0002-3192-8093; Kasprzak, Jaroslaw D/0000-0002-5850-8187; GALINIER, Michel/0000-0003-1735-3390; Volpe, Massimo/0000-0002-9642-8380; gosse, philippe/0000-0002-5840-7749; jourdain, patrick/0000-0002-5202-6902; Gomez-Bueno, Manuel/0000-0002-9764-7518; Jaramillo, Monica/0000-0003-0100-5682; URAL, DILEK/0000-0003-0224-1433; Isnard, Richard/0000-0002-3439-8104	Ahmanson Foundation; Novartis; BG Medicine; Roche Diagnostics; Novartis Pharma; Medtronic; Abbott	Ahmanson Foundation; Novartis(Novartis); BG Medicine; Roche Diagnostics; Novartis Pharma; Medtronic(Medtronic); Abbott(Abbott Laboratories)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Gheorghiade reported serving as a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma, Bayer HealthCare, Cardiorentis, CorThera, Cytokinetics, CytoPherx, DebioPharm, Errekappa Terapeutici, GlaxoSmithKline, Ikaria, Intersection Medical, INC, Johnson and Johnson, Medtronic, Merck, Novartis Pharma, Ono Pharma USA, Otsuka Pharmaceuticals, Palatin Technologies, Pericor Therapeutics, Protein Design Laboratories, sanofi-aventis, Sigma Tau, Solvay Pharmaceuticals, Sticares InterACT, Takeda Pharmaceuticals, and Trevena Therapeutics. Dr Bohm reported serving as a consultant for AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, sanofi-aventis, Servier, and Medtronic and on speakers' bureaus for AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, AWDDresden, Berlin-Chemie, MSD, Novartis, Pfizer, sanofi-aventis, and Servier. Dr Fonarow reported receiving grant funding from GlaxoSmithKline, the National Institutes of Health, and the Agency for Healthcare Research and Quality; serving on speakers' bureaus for Boston Scientific/Guidant, GlaxoSmithKline, Medtronic, Merck, Novartis, Pfizer, and St Jude Medical; and serving as a consultant for Amgen, Gambro, GlaxoSmithKline, Medtronic, Merck, Novartis, Pfizer, Relypsa, Scios, St Jude Medical, Medicines Company, Johnson and Johnson, and Takeda. Dr Fonarow holds the Eliot Corday Chair of Cardiovascular Medicine at UCLA and is also supported by the Ahmanson Foundation. Dr Lewis reported receiving grant funding and other support from Novartis. Dr Zannad reported receiving grant funding from Novartis, BG Medicine, and Roche Diagnostics; serving on speakers' bureaus for Pfizer and AstraZeneca; serving on a board for Boston Scientific; and serving as a consultant for Novartis, Takeda, AstraZeneca, Boehringer-Ingelheim, GEHealthcare, Relypsa, Servier, Boston Scientific, Bayer, Johnson and Johnson, and ResMed. Dr Solomon reported receiving grant funding, consulting fees, and travel support from Novartis. Dr Baschiera reported receiving consulting fees, travel support, stock options, and other funding from Novartis Pharma, where he is an employee. Mr Botha reported receiving consulting fees, travel support, and other funding from Novartis Pharma, where he is an employee. Dr Hua reported receiving travel support and stock options from Novartis Pharma, where he is an employee. Dr Gimpelewicz reported being an employee of Novartis and receiving stock and stock options from Novartis. Dr Jaumont reported receiving consulting fees, travel support, stock options, and other funding from Novartis Pharma, where he is an employee. Dr Lesogor reported receiving consulting fees, travel support, stock options, and other funding from Novartis Pharma, where she is an employee. Dr Maggioni reported serving as a consultant for Bayer, Amgen, Cardiorentis, and Johnson and Johnson; receiving grants from Novartis, Medtronic, and Abbott; and receiving consulting fees and travel support from Novartis Pharma. No other disclosures were reported.	Blair JEA, 2008, J AM COLL CARDIOL, V52, P1640, DOI 10.1016/j.jacc.2008.07.056; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; Felker GM, 2010, CIRC-HEART FAIL, V3, P314, DOI 10.1161/CIRCHEARTFAILURE.109.893222; Fisher NDL, 2008, CIRCULATION, V117, P3199, DOI 10.1161/CIRCULATIONAHA.108.767202; Gheorghiade M, 2005, J CARD FAIL, V11, P260, DOI 10.1016/j.cardfail.2005.03.009; Gheorghiade M, 2005, AM J CARDIOL, V96, p3L, DOI 10.1016/j.amjcard.2005.09.059; Gheorghiade M, 2006, JAMA-J AM MED ASSOC, V296, P2217, DOI 10.1001/jama.296.18.2217; Gheorghiade M, 2013, J AM COLL CARDIOL, V61, P391, DOI 10.1016/j.jacc.2012.09.038; Gheorghiade M, 2012, HEART FAIL REV, V17, P485, DOI 10.1007/s10741-011-9280-0; Gheorghiade M, 2011, EUR J HEART FAIL, V13, P100, DOI 10.1093/eurjhf/hfq209; Harjola VP, 2010, EUR J HEART FAIL, V12, P239, DOI 10.1093/eurjhf/hfq002; Hunt SA, 2009, CIRCULATION, V119, pE391, DOI 10.1161/CIRCULATIONAHA.109.192065; Konstam MA, 2007, JAMA-J AM MED ASSOC, V297, P1319, DOI 10.1001/jama.297.12.1319; Krum H, 2011, EUR J HEART FAIL, V13, P107, DOI 10.1093/eurjhf/hfq212; Latini R, 2006, AM J MED, V119; McMurray JJV, 2003, LANCET, V362, P767, DOI 10.1016/S0140-6736(03)14283-3; McMurray JJV, 2008, CIRC-HEART FAIL, V1, P17, DOI 10.1161/CIRCHEARTFAILURE.107.740704; McMurray JJV, 2012, EUR HEART J, V33, P1787, DOI 10.1093/eurheartj/ehs104; Parving HH, 2012, NEW ENGL J MED, V367, P2204, DOI 10.1056/NEJMoa1208799; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Sarma S, 2013, EUR J HEART FAIL, V15, P194, DOI 10.1093/eurjhf/hfs153; Schmieder RE, 2009, CIRCULATION, V119, P417, DOI 10.1161/CIRCULATIONAHA.107.750745; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Swedberg K, 2010, LANCET, V376, P875, DOI 10.1016/S0140-6736(10)61198-1; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Zannad F, 2011, NEW ENGL J MED, V364, P11, DOI 10.1056/NEJMoa1009492	27	275	289	1	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2013	309	11					1125	1135		10.1001/jama.2013.1954	http://dx.doi.org/10.1001/jama.2013.1954			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108FF	23478743	Green Published			2023-01-03	WOS:000316276500026
J	Jabre, P; Belpomme, V; Azoulay, E; Jacob, L; Bertrand, L; Lapostolle, F; Tazarourte, K; Bouilleau, G; Pinaud, V; Broche, C; Normand, D; Baubet, T; Ricard-Hibon, A; Istria, J; Beltramini, A; Alheritiere, A; Assez, N; Nace, L; Vivien, B; Turi, L; Launay, S; Desmaizieres, M; Borron, SW; Vicaut, E; Adnet, F				Jabre, Patricia; Belpomme, Vanessa; Azoulay, Elie; Jacob, Line; Bertrand, Lionel; Lapostolle, Frederic; Tazarourte, Karim; Bouilleau, Guillem; Pinaud, Virginie; Broche, Claire; Normand, Domitille; Baubet, Thierry; Ricard-Hibon, Agnes; Istria, Jacques; Beltramini, Alexandra; Alheritiere, Armelle; Assez, Nathalie; Nace, Lionel; Vivien, Benoit; Turi, Laurent; Launay, Stephane; Desmaizieres, Michel; Borron, Stephen W.; Vicaut, Eric; Adnet, Frederic			Family Presence during Cardiopulmonary Resuscitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; WITNESSED RESUSCITATION; INVASIVE PROCEDURES; MEMBERS; GUIDELINES; HEALTH; BEREAVEMENT; DEPRESSION; SYMPTOMS; COUNCIL	BACKGROUND The effect of family presence during cardiopulmonary resuscitation (CPR) on the family members themselves and the medical team remains controversial. METHODS We enrolled 570 relatives of patients who were in cardiac arrest and were given CPR by 15 prehospital emergency medical service units. The units were randomly assigned either to systematically offer the family member the opportunity to observe CPR (intervention group) or to follow standard practice regarding family presence (control group). The primary end point was the proportion of relatives with post-traumatic stress disorder (PTSD)-related symptoms on day 90. Secondary end points included the presence of anxiety and depression symptoms and the effect of family presence on medical efforts at resuscitation, the well-being of the health care team, and the occurrence of medicolegal claims. RESULTS In the intervention group, 211 of 266 relatives (79%) witnessed CPR, as compared with 131 of 304 relatives (43%) in the control group. In the intention-to-treat analysis, the frequency of PTSD-related symptoms was significantly higher in the control group than in the intervention group (adjusted odds ratio, 1.7; 95% confidence interval [CI], 1.2 to 2.5; P = 0.004) and among family members who did not witness CPR than among those who did (adjusted odds ratio, 1.6; 95% CI, 1.1 to 2.5; P = 0.02). Relatives who did not witness CPR had symptoms of anxiety and depression more frequently than those who did witness CPR. Family-witnessed CPR did not affect resuscitation characteristics, patient survival, or the level of emotional stress in the medical team and did not result in medicolegal claims. CONCLUSIONS Family presence during CPR was associated with positive results on psychological variables and did not interfere with medical efforts, increase stress in the health care team, or result in medicolegal conflicts. (Funded by Programme Hospitalier de Recherche Clinique 2008 of the French Ministry of Health; ClinicalTrials.gov number, NCT01009606.)	[Jabre, Patricia; Lapostolle, Frederic; Normand, Domitille; Alheritiere, Armelle; Desmaizieres, Michel; Adnet, Frederic] Hop Avicenne, AP HP, SAMU, F-93000 Bobigny, France; [Baubet, Thierry] Hop Avicenne, AP HP, Serv Psychiat, F-93000 Bobigny, France; [Jabre, Patricia] Univ Paris 05, INSERM, U970, Ctr Rech Cardiovasc Paris, Paris, France; [Jabre, Patricia; Vivien, Benoit] Hop Necker Enfants Malad, AP HP, SAMU Paris, Paris, France; [Azoulay, Elie] Hop St Louis, AP HP, Paris, France; [Broche, Claire] Hop Lariboisiere, AP HP, F-75475 Paris, France; [Vicaut, Eric] Hop Fernand Widal, AP HP, Unite Rech Clin, Paris, France; [Belpomme, Vanessa; Ricard-Hibon, Agnes] Hop Beaujon, AP HP, Clichy, France; [Jacob, Line] Hop Henri Mondor, AP HP, F-94010 Creteil, France; [Bertrand, Lionel] Hop Montauban, Montauban, France; [Tazarourte, Karim] Hop Melun, Melun, France; [Bouilleau, Guillem] Hop Chateauroux, Chateauroux, France; [Pinaud, Virginie] Hop Nantes, Nantes, France; [Istria, Jacques] Hop Toulon, Toulon, France; [Beltramini, Alexandra] Hop Dreux, Dreux, France; [Assez, Nathalie] Hop Lille, Lille, France; [Nace, Lionel] Hop Nancy, Nancy, France; [Turi, Laurent] Hop Comminges Pyrennees, St Gaudens, France; [Launay, Stephane] Hop Pontoise, Pontoise, France; [Borron, Stephen W.] Texas Tech Univ, Hlth Sci Ctr, Dept Emergency Med, El Paso, TX USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Nantes Universite; CHU de Nantes; Universite de Lille - ISITE; CHU Lille; CHU de Nancy; Centre Hospitalier Rene Dubos, Pontoise; Texas Tech University System; Texas Tech University	Adnet, F (corresponding author), Hop Avicenne, F-93000 Bobigny, France.	frederic.adnet@avc.aphp.fr	Tazarourte, karim/GQZ-6054-2022	tazarourte, karim/0000-0002-3376-1258; Baubet, Thierry/0000-0002-4112-1592	Programme Hospitalier de Recherche Clinique of the French Ministry of Health	Programme Hospitalier de Recherche Clinique of the French Ministry of Health	Supported by Programme Hospitalier de Recherche Clinique 2008 of the French Ministry of Health.	Adnet F, 2004, RESUSCITATION, V63, P7, DOI 10.1016/j.resuscitation.2004.04.001; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Boie ET, 1999, ANN EMERG MED, V34, P70, DOI 10.1016/S0196-0644(99)70274-X; Christakis NA, 2006, NEW ENGL J MED, V354, P719, DOI 10.1056/NEJMsa050196; Compton S, 2011, J PALLIAT MED, V14, P715, DOI 10.1089/jpm.2010.0463; Compton S, 2009, ACAD EMERG MED, V16, P226, DOI 10.1111/j.1553-2712.2008.00336.x; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DOYLE CJ, 1987, ANN EMERG MED, V16, P673, DOI 10.1016/S0196-0644(87)80069-0; Dudley NC, 2009, ANN EMERG MED, V53, P777, DOI 10.1016/j.annemergmed.2008.10.002; Fernandez R, 2009, CRIT CARE MED, V37, P1956, DOI 10.1097/CCM.0b013e3181a00818; Fulbrook Paul, 2007, Eur J Cardiovasc Nurs, V6, P255, DOI 10.1016/j.ejcnurse.2007.07.003; Gueugniaud PY, 2008, NEW ENGL J MED, V359, P21, DOI 10.1056/NEJMoa0706873; Helmer SD, 2000, J TRAUMA, V48, P1015, DOI 10.1097/00005373-200006000-00004; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Kristensen P, 2012, PSYCHIATRY, V75, P76, DOI 10.1521/psyc.2012.75.1.76; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Lippert FK, 2010, RESUSCITATION, V81, P1445, DOI 10.1016/j.resuscitation.2010.08.013; Lloyd-Jones, 2011, CIRCULATION, V124, pE425, DOI 10.1161/CIR.0b013e3182365a58; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; McClenathan BM, 2002, CHEST, V122, P2204, DOI 10.1378/chest.122.6.2204; Meyers T A, 1998, J Emerg Nurs, V24, P400, DOI 10.1016/S0099-1767(98)70005-4; Meyers TA, 2000, AM J NURS, V100, P32, DOI 10.2307/3521954; Mian P, 2007, CRIT CARE NURSE, V27, P52; Morrison LJ, 2010, CIRCULATION, V122, pS665, DOI 10.1161/CIRCULATIONAHA.110.970905; O'Connell KJ, 2007, PEDIATRICS, V120, pE565, DOI 10.1542/peds.2006-2914; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Robinson SM, 1998, LANCET, V352, P614, DOI 10.1016/S0140-6736(97)12179-1; Tsai E, 2002, NEW ENGL J MED, V346, P1019, DOI 10.1056/NEJM200203283461312; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	31	202	213	0	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	2013	368	11					1008	1018		10.1056/NEJMoa1203366	http://dx.doi.org/10.1056/NEJMoa1203366			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104HF	23484827				2023-01-03	WOS:000315982100007
J	Appleby, J				Appleby, John			The hospital bed: on its way out?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London, England		Appleby, J (corresponding author), Kings Fund, London, England.	j.appleby@kingsfund.org.uk						[Anonymous], 2012, GUARDIAN; *DEP HLTH, 2007, HOSP ORG SPEC MIX MR; Department of Health, 1992, STAT B, V2, P92; Department of Health, 2012, BED AV OCC OV TIM SE; King Edward's Hospital Fund for London, 1967, DES HOSP BEDST; Lawrence G., 2001, LANCET, DOI [10.1016/S0140-6736(01)05957-8, DOI 10.1016/S0140-6736(01)05957-8]; Lawrence G, 2001, THESIS U LONDON; Organisation for Economic Cooperation and Development, OECD HLTH DAT 2012 F	8	16	16	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	2013	346								f1563	10.1136/bmj.f1563	http://dx.doi.org/10.1136/bmj.f1563			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	108VM	23482956				2023-01-03	WOS:000316324300013
J	Duecker, F; Sack, AT				Duecker, Felix; Sack, Alexander T.			Pre-Stimulus Sham TMS Facilitates Target Detection	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; SIMPLE REACTION-TIME; OBJECTIVE MEASURES; SPATIAL ATTENTION; INFORMATION; NETWORK; MASKING; VISION	Transcranial magnetic stimulation (TMS) allows non-invasive manipulation of brain activity during active task performance. Because every TMS pulse is accompanied by non-neural effects such as a clicking sound and somato-sensation on the head, control conditions are required to ensure that changes in task behavior are indeed due to the induced neural effects. However, the non-neural effects of TMS in the context of a given task performance are largely unknown and, consequently, it is unclear what constitutes a valid control condition. We explored the non-neural effects of TMS on visual target detection. Participants received single pulse sham TMS to each hemisphere at different time points prior to target appearance during a visual target detection task. It was hypothesized that the clicking sound of a sham TMS pulse differentially affects performance depending on the location of the coil and the timing of the pulse. Our results show that, first, sham TMS caused a facilitation of reaction times when preceding the target stimulus by 150, 200, and 250 ms, whereas earlier and later time windows were not effective. Second, positioning the TMS coil ipsilateral instead of contralateral relative to the target stimulus improved reaction times. Third, infrequent noTMS trials that were interleaved with sham TMS trials had oddball-like properties resulting in increased reaction times during noTMS. The clicking sound produced by sham TMS influences task performance in multiple ways. These non-neural effects of TMS need to be controlled for in TMS research and the present findings provide an empirical basis for deciding what constitutes a valid control condition.	[Duecker, Felix; Sack, Alexander T.] Maastricht Univ, Fac Psychol & Neurosci, Dept Cognit Neurosci, Maastricht, Netherlands; [Duecker, Felix; Sack, Alexander T.] Maastricht Univ, Fac Psychol & Neurosci, Maastricht Brain Imaging Ctr, Maastricht, Netherlands	Maastricht University; Maastricht University	Duecker, F (corresponding author), Maastricht Univ, Fac Psychol & Neurosci, Dept Cognit Neurosci, Maastricht, Netherlands.	felix.duecker@maastrichtuniversity.nl		Sack, Alexander/0000-0002-1471-0885	European Research Council under the European Union [263472]; Netherlands Organization for Scientific Research (NWO) [400-07-230]	European Research Council under the European Union(European Research Council (ERC)); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO))	The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC Grant agreement no [263472]; granted to A. T. S.), and the Netherlands Organization for Scientific Research (NWO; grant number 400-07-230). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abler B, 2005, BRAIN TOPOGR, V17, P193, DOI 10.1007/s10548-005-6028-y; [Anonymous], [No title captured]; de Graaf TA, 2011, NEUROSCI BIOBEHAV R, V35, P871, DOI 10.1016/j.neubiorev.2010.10.006; de Graaf TA, 2011, CONSCIOUS COGN, V20, P1244, DOI 10.1016/j.concog.2011.04.012; de Graaf TA, 2011, EXP BRAIN RES, V209, P19, DOI 10.1007/s00221-010-2512-z; de Graaf TA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008307; FARAH MJ, 1989, NEUROPSYCHOLOGIA, V27, P461, DOI 10.1016/0028-3932(89)90051-1; Hackley SA, 2009, PSYCHOPHYSIOLOGY, V46, P225, DOI 10.1111/j.1469-8986.2008.00716.x; Jacobs C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048808; Jacobs C, 2012, NEUROIMAGE, V59, P616, DOI 10.1016/j.neuroimage.2011.07.090; Kirby N. H., 1980, REACTION TIMES, P129; Marzi CA, 1998, EXP BRAIN RES, V118, P435, DOI 10.1007/s002210050299; NIEMI P, 1981, PSYCHOL BULL, V89, P133, DOI 10.1037/0033-2909.89.1.133; Sawaki L, 1999, EXP BRAIN RES, V127, P402, DOI 10.1007/s002210050808; Schmitt M, 2000, Q J EXP PSYCHOL-A, V53, P105, DOI 10.1080/027249800390691; Schuhmann T, 2012, CEREB CORTEX, V22, P701, DOI 10.1093/cercor/bhr155; SIMON JR, 1967, J APPL PSYCHOL, V51, P300, DOI 10.1037/h0020586; Spence C, 1997, PERCEPT PSYCHOPHYS, V59, P1, DOI 10.3758/BF03206843; Terao Y, 1997, EXP BRAIN RES, V115, P541, DOI 10.1007/PL00005724	19	32	32	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2013	8	3							e57765	10.1371/journal.pone.0057765	http://dx.doi.org/10.1371/journal.pone.0057765			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099PY	23469232	Green Published, Green Submitted, gold			2023-01-03	WOS:000315634900042
J	Mastroeni, C; Bergmann, TO; Rizzo, V; Ritter, C; Klein, C; Pohlmann, I; Brueggemann, N; Quartarone, A; Siebner, HR				Mastroeni, Claudia; Bergmann, Til Ole; Rizzo, Vincenzo; Ritter, Christoph; Klein, Christine; Pohlmann, Ines; Brueggemann, Norbert; Quartarone, Angelo; Siebner, Hartwig Roman			Brain-Derived Neurotrophic Factor - A Major Player in Stimulation-Induced Homeostatic Metaplasticity of Human Motor Cortex?	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; THETA-BURST-STIMULATION; PAIRED-ASSOCIATIVE STIMULATION; BDNF VAL66MET POLYMORPHISM; CORTICAL PLASTICITY; SYNAPTIC PLASTICITY; CONSCIOUS HUMANS; CEREBRAL-CORTEX; UNIT RESPONSES; SURFACE EMG	Repetitive transcranial magnetic stimulation (rTMS) of the human motor hand area (M1(HAND)) can induce lasting changes in corticospinal excitability as indexed by a change in amplitude of the motor-evoked potential. The plasticity-inducing effects of rTMS in M1(HAND) show substantial inter-individual variability which has been partially attributed to the val(66)met polymorphism in the brain-derived neurotrophic factor (BDNF) gene. Here we used theta burst stimulation (TBS) to examine whether the BDNF val(66)met genotype can be used to predict the expression of TBS-induced homeostatic metaplasticity in human M1(HAND). TBS is a patterned rTMS protocol with intermittent TBS (iTBS) usually inducing a lasting increase and continuous TBS (cTBS) a lasting decrease in corticospinal excitability. In three separate sessions, healthy val(66)met (n = 12) and val(66)val (n = 17) carriers received neuronavigated cTBS followed by cTBS (n = 27), cTBS followed by iTBS (n = 29), and iTBS followed by iTBS (n = 28). Participants and examiner were blinded to the genotype at the time of examination. As expected, the first TBS intervention induced a decrease (cTBS) and increase (iTBS) in corticospinal excitability, respectively, at the same time priming the after effects caused by the second TBS intervention in a homeostatic fashion. Critically, val(66)met carriers and val(66)val carriers showed very similar response patterns to cTBS and iTBS regardless of the order of TBS interventions. Since none of the observed TBS effects was modulated by the BDNF val(66)met polymorphism, our results do not support the notion that the BDNF val(66)met genotype is a major player with regard to TBS-induced plasticity and metaplasticity in the human M1(HAND).	[Mastroeni, Claudia; Bergmann, Til Ole; Ritter, Christoph; Pohlmann, Ines; Siebner, Hartwig Roman] Univ Kiel, Dept Neurol, Kiel, Germany; [Mastroeni, Claudia; Rizzo, Vincenzo; Quartarone, Angelo] Univ Messina, Dept Neurosci Psychiat & Anaesthesiol Sci, Messina, Italy; [Bergmann, Til Ole] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Njmegen, Netherlands; [Klein, Christine; Brueggemann, Norbert] Med Univ Lubeck, Sect Clin & Mol Neurogenet, Dept Neurol, D-23538 Lubeck, Germany; [Quartarone, Angelo] NYU, Dept Neurol, Sch Med, New York, NY 10016 USA; [Ritter, Christoph] Univ Hamburg, Dept Neurol, Hamburg, Germany; [Brueggemann, Norbert; Siebner, Hartwig Roman] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark	University of Kiel; University of Messina; Radboud University Nijmegen; University of Lubeck; New York University; University of Hamburg; University of Copenhagen	Siebner, HR (corresponding author), Univ Kiel, Dept Neurol, Kiel, Germany.	hartwig.siebner@drcmr.dk	Bergmann, Til Ole/F-9453-2010; Siebner, Hartwig R/G-4052-2016; Klein, Christine/AGK-8003-2022; Mastroeni, Claudia/AAC-1001-2019; QUARTARONE, Angelo/G-3264-2017	Bergmann, Til Ole/0000-0002-2282-6618; Klein, Christine/0000-0003-2102-3431; QUARTARONE, Angelo/0000-0003-1485-6590; Ritter, Christoph/0000-0001-8899-6444	Lundbeck Foundation on "Mapping, Modulation & Modeling the Control of Actions (ContAct)" [R59 A5399]; Deutsche Forschungsgemeinschaft [SFB654/A6]; Dutch BrainGain Smart Mix Programme (NWO) [056-14-011]; Lundbeck Foundation [R59-2010-5399] Funding Source: researchfish	Lundbeck Foundation on "Mapping, Modulation & Modeling the Control of Actions (ContAct)"; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Dutch BrainGain Smart Mix Programme (NWO); Lundbeck Foundation(Lundbeckfonden)	HRS was supported by a Grant of Excellence sponsored by The Lundbeck Foundation on "Mapping, Modulation & Modeling the Control of Actions (ContAct)" (grant no. R59 A5399). TOB was supported by the Deutsche Forschungsgemeinschaft (grant no. SFB654/A6, "Plasticity and Sleep") and the Dutch BrainGain Smart Mix Programme (NWO grant no. 056-14-011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham WC, 2001, P NATL ACAD SCI USA, V98, P10924, DOI 10.1073/pnas.181342098; AMASSIAN VE, 1987, NEUROSURGERY, V20, P74; Antal A, 2010, BRAIN STIMUL, V3, P230, DOI 10.1016/j.brs.2009.12.003; Antal A, 2008, BRAIN STIMUL, V1, P97, DOI 10.1016/j.brs.2007.10.001; Bergmann TO, 2009, J NEUROPHYSIOL, V102, P2303, DOI 10.1152/jn.00437.2009; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Butefisch CM, 2004, NEUROSCIENTIST, V10, P163, DOI 10.1177/1073858403262152; Cheeran BJ, 2009, NEUROSCIENCE, V164, P156, DOI 10.1016/j.neuroscience.2009.01.054; Cheeran B, 2008, J PHYSIOL-LONDON, V586, P5717, DOI 10.1113/jphysiol.2008.159905; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; DAY BL, 1989, J PHYSIOL-LONDON, V412, P449, DOI 10.1113/jphysiol.1989.sp017626; Di Lazzaro V, 1998, J PHYSIOL-LONDON, V508, P625; Di Lazzaro V, 2001, EXP BRAIN RES, V141, P121; Doeltgen SH, 2011, EXP BRAIN RES, V215, P199, DOI 10.1007/s00221-011-2886-6; Edwards MJ, 2008, LANCET NEUROL, V7, P827, DOI 10.1016/S1474-4422(08)70190-X; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Florian J, 2007, EUR J NEUROSCI, V25, P3461, DOI 10.1111/j.1460-9568.2007.05603.x; Fricke K, 2011, J NEUROPHYSIOL, V105, P1141, DOI 10.1152/jn.00608.2009; Fritsch B, 2010, NEURON, V66, P198, DOI 10.1016/j.neuron.2010.03.035; Gamboa OL, 2011, BRAIN STIMUL, V4, P145, DOI 10.1016/j.brs.2010.09.008; Gentner R, 2008, CEREB CORTEX, V18, P2046, DOI 10.1093/cercor/bhm239; Granert O, 2011, NEUROIMAGE, V54, P32, DOI 10.1016/j.neuroimage.2010.08.013; Hamada M, 2012, CEREB CORTEX; Hamada M, 2008, J PHYSIOL-LONDON, V586, P3927, DOI 10.1113/jphysiol.2008.152793; Huang YZ, 2008, CEREB CORTEX, V18, P563, DOI 10.1093/cercor/bhm087; Huang YZ, 2007, CLIN NEUROPHYSIOL, V118, P1028, DOI 10.1016/j.clinph.2007.01.021; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Hummel FC, 2006, LANCET NEUROL, V5, P708, DOI 10.1016/S1474-4422(06)70525-7; Ilic TV, 2005, ANN NY ACAD SCI, V1048, P175, DOI 10.1196/annals.1342.016; Inghilleri M, 2004, CLIN NEUROPHYSIOL, V115, P1063, DOI 10.1016/j.clinph.2003.12.003; Iyer MB, 2003, J NEUROSCI, V23, P10867; Jayasekeran V, 2011, GASTROENTEROLOGY; Kamke MR, 2012, J NEUROSCI, V32, P7001, DOI 10.1523/JNEUROSCI.1028-12.2012; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P250, DOI 10.1016/S1388-2457(00)00513-7; Karabanov A, J PHYSL IN PRESS; Kleim JA, 2006, NAT NEUROSCI, V9, P735, DOI 10.1038/nn1699; Lang N, 2004, BIOL PSYCHIAT, V56, P634, DOI 10.1016/j.biopsych.2004.07.017; Lefaucheur JP, 2005, REV NEUROL-FRANCE, V161, P27, DOI 10.1016/S0035-3787(05)84971-9; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Mansur CG, 2005, NEUROLOGY, V64, P1802, DOI 10.1212/01.WNL.0000161839.38079.92; Missitzi J, 2011, J PHYSIOL-LONDON, V589, P297, DOI 10.1113/jphysiol.2010.200600; Mori F, 2012, J NEUROSCI, V32, P873, DOI 10.1523/JNEUROSCI.2531-11.2012; Murakami T, 2012, J PHYSL; Murase N, 2004, ANN NEUROL, V55, P400, DOI 10.1002/ana.10848; Nakamura K, 2011, NEUROSCI LETT, V487, P264, DOI 10.1016/j.neulet.2010.10.034; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; PASCUALLEONE A, 1995, J NEUROPHYSIOL, V74, P1037, DOI 10.1152/jn.1995.74.3.1037; Potter-Nerger M, 2009, J NEUROPHYSIOL; Ragert P, 2009, J NEUROPHYSIOL, V102, P766, DOI 10.1152/jn.00274.2009; Sale MV, 2008, J NEUROSCI, V28, P8285, DOI 10.1523/JNEUROSCI.1963-08.2008; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P1815, DOI 10.1016/j.clinph.2007.05.062; Terney D, 2008, J NEUROSCI, V28, P14147, DOI 10.1523/JNEUROSCI.4248-08.2008; Todd G, 2009, EXP BRAIN RES, V195, P307, DOI 10.1007/s00221-009-1791-8; Voti PL, 2011, EXP BRAIN RES, V212, P91, DOI 10.1007/s00221-011-2700-5; Wankerl K, 2010, J NEUROSCI, V30, P6197, DOI 10.1523/JNEUROSCI.4673-09.2010; Wassermann EM, 2002, CLIN NEUROPHYSIOL, V113, P1165, DOI 10.1016/S1388-2457(02)00144-X; WERHAHN KJ, 1994, ELECTROEN CLIN NEURO, V93, P138, DOI 10.1016/0168-5597(94)90077-9; Weyh T, 2005, CLIN NEUROPHYSIOL, V116, P1477, DOI 10.1016/j.clinph.2005.02.002; Witte AV, 2012, J NEUROSCI, V32, P4553, DOI 10.1523/JNEUROSCI.6010-11.2012; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002; Zafar N, 2008, CLIN NEUROPHYSIOL, V119, P1393, DOI 10.1016/j.clinph.2008.02.006; Ziemann U, 2008, BRAIN STIMUL, V1, P60, DOI 10.1016/j.brs.2007.08.003	69	51	53	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57957	10.1371/journal.pone.0057957	http://dx.doi.org/10.1371/journal.pone.0057957			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469118	Green Submitted, Green Published, gold			2023-01-03	WOS:000315524900212
J	Jiang, Y; Wang, H; Liu, ZY; Dong, YR; Dong, Y; Xiang, XH; Bai, LJ; Tian, J; Wu, LZ; Han, JS; Cui, CL				Jiang, Yin; Wang, Hong; Liu, Zhenyu; Dong, Yuru; Dong, Yue; Xiang, Xiaohui; Bai, Lijun; Tian, Jie; Wu, Liuzhen; Han, Jisheng; Cui, Cailian			Manipulation of and Sustained Effects on the Human Brain Induced by Different Modalities of Acupuncture: An fMRI Study	PLOS ONE			English	Article							ELECTRICAL ACUPOINT STIMULATION; DEFAULT-MODE; MANUAL ACUPUNCTURE; NETWORK; ELECTROACUPUNCTURE; CONNECTIVITY; PERCEPTION; ACTIVATION; CHINESE; GRAY	The javascript: void(0) manipulation and sustained effects of acupuncture have been investigated in multiple studies, but several findings are inconsistent with one another. One possible explanation for these discrepancies is that different modalities of acupuncture were utilized in these studies. In the present study, we investigated both the manipulation and sustained effects of acupuncture in different modalities, including manual acupuncture (MA), electroacupuncture (EA) and transcutaneous electrical acupoint stimulation (TEAS). MA, EA, TEAS and sensory control stimulation were applied to 18 healthy subjects, and combined block-designed and resting-state fMRI scans were performed. In analyzing these data, the block-designed datasets were used to assess the manipulation effect by employing a modified general linear model. The data from the resting states, before and after stimulation, were used to explore the brain networks involved in the sustained effect. The results showed that the two 1-min stimulation periods produced similar activation patterns in the sensory control with positive activation in the sensorimotor areas and negative activation in the default mode areas. Although similar patterns could be detected in the first stimulation period in MA, EA and TEAS, no positive activation result was observed in the second stimulation period, and EA showed a more extensive deactivation compared to MA and TEAS. Additionally, all three of the modalities of acupuncture stimulation could increase the instinct brain network in rest. A more secure and spatially extended connectivity of the default mode network was observed following MA and EA, and TEAS specifically increased the functional connectivity in the sensorimotor network. The present study suggested that different brain mechanisms might be recruited in different acupuncture modalities. In addition, the findings from our work could provide methodological information for further research into the mechanism of acupuncture.	[Jiang, Yin; Xiang, Xiaohui; Wu, Liuzhen; Han, Jisheng; Cui, Cailian] Peking Univ, Neurosci Res Inst, Beijing 100871, Peoples R China; [Jiang, Yin; Dong, Yue; Xiang, Xiaohui; Wu, Liuzhen; Han, Jisheng; Cui, Cailian] Peking Univ, Sch Basic Med Sci, Dept Neurobiol, Beijing 100871, Peoples R China; [Jiang, Yin; Xiang, Xiaohui; Wu, Liuzhen; Han, Jisheng; Cui, Cailian] Minist Educ Res, Key Lab Neurosci, Beijing, Peoples R China; [Jiang, Yin; Xiang, Xiaohui; Wu, Liuzhen; Han, Jisheng; Cui, Cailian] Minist Publ Hlth, Beijing, Peoples R China; [Wang, Hong; Dong, Yuru] Gen Hosp Armed Police Forces, Dept Magnet Resonance, Beijing, Peoples R China; [Liu, Zhenyu; Bai, Lijun; Tian, Jie] Chinese Acad Sci, Inst Automat, Beijing, Peoples R China	Peking University; Peking University; Chinese Academy of Sciences; Institute of Automation, CAS	Cui, CL (corresponding author), Peking Univ, Neurosci Res Inst, Beijing 100871, Peoples R China.	clcui@bjmu.edu.cn	Liu, Zhenyu/G-8444-2018; Tian, Jie/H-1190-2011; tian, jie/M-6336-2013; Bai, Lijun/C-5119-2015; Xiang, Xiaohui/D-8093-2015	Liu, Zhenyu/0000-0001-7559-8519; Tian, Jie/0000-0003-0498-0432; Bai, Lijun/0000-0001-8790-5424; Cui, Cailian/0000-0002-8638-8258; Xiang, Xiaohui/0000-0002-5762-5007	National Basic Research Program of China [2007CB512501, 2013CB531905, 2009CB522003]	National Basic Research Program of China(National Basic Research Program of China)	This work was supported by the National Basic Research Program of China (2007CB512501, 2013CB531905, 2009CB522003). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Bai LJ, 2009, HUM BRAIN MAPP, V30, P3445, DOI 10.1002/hbm.20769; Bai LJ, 2009, BRAIN RES, V1279, P37, DOI 10.1016/j.brainres.2009.04.056; Baliki MN, 2008, J NEUROSCI, V28, P1398, DOI 10.1523/JNEUROSCI.4123-07.2008; Beissner F., 2011, NEUROIMAGE; Cheng X, 1997, CHINESE ACUPUNCTURE; Cui CL, 2008, NEUROCHEM RES, V33, P2013, DOI 10.1007/s11064-008-9784-8; Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011; Fang JL, 2009, HUM BRAIN MAPP, V30, P1196, DOI 10.1002/hbm.20583; Franco AR, 2009, HUM BRAIN MAPP, V30, P2293, DOI 10.1002/hbm.20668; Han JS, 2011, PAIN, V152, pS41, DOI 10.1016/j.pain.2010.10.012; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Huang WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032960; Hui KKKS, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-2; Hui KKS, 2009, BRAIN RES, V1287, P84, DOI 10.1016/j.brainres.2009.06.061; Hui KK, 2010, AUTON NEUROSCI; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Hui KKS, 2000, HUM BRAIN MAPP, V9, P13, DOI 10.1002/(SICI)1097-0193(2000)9:1<13::AID-HBM2>3.0.CO;2-F; Jiang Y, 2012, BRAIN RES; Kong JA, 2002, J ALTERN COMPLEM MED, V8, P411, DOI 10.1089/107555302760253603; Kong J, 2007, J ALTERN COMPLEM MED, V13, P1059, DOI 10.1089/acm.2007.0524; Li G, 2003, NEUROREPORT, V14, P669, DOI 10.1097/00001756-200304150-00002; Liu B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039342; Liu JX, 2010, NEUROSCI LETT, V468, P353, DOI 10.1016/j.neulet.2009.11.031; Liu P, 2009, NEUROSCI LETT, V462, P183, DOI 10.1016/j.neulet.2009.07.015; Ma N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016560; Meesen RLJ, 2011, HUM BRAIN MAPP, V32, P872, DOI 10.1002/hbm.21075; Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081; Napadow V, 2012, HUM BRAIN MAPP, DOI 10.1002/hbm.22091; Napadow V, 2009, NEUROIMAGE, V47, P1055, DOI 10.1016/j.neuroimage.2009.05.079; Napadow V, 2009, NEUROIMAGE, V47, P289, DOI 10.1016/j.neuroimage.2009.03.060; PRICE DD, 1984, PAIN, V19, P27, DOI 10.1016/0304-3959(84)90062-9; Qin W, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-55; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Research Group Of Acupuncture Anesthesia PMC, 1973, CHIN MED J, P151; Schliessbach J, 2011, PAIN MED, V12, P268, DOI 10.1111/j.1526-4637.2010.01051.x; THOMPSON RF, 1966, PSYCHOL REV, V73, P16, DOI 10.1037/h0022681; Ulett GA, 1998, BIOL PSYCHIAT, V44, P129, DOI 10.1016/S0006-3223(97)00394-6; Unterrainer AF, 2010, J NEUROSURG ANESTH, V22, P1, DOI 10.1097/ANA.0b013e3181b7fef5; WANG JQ, 1992, INT J NEUROSCI, V65, P117, DOI 10.3109/00207459209003283; Wang ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042730; Wu MT, 2002, NEUROIMAGE, V16, P1028, DOI 10.1006/nimg.2002.1145; Xiang XH, 2012, PHYSIOL GENOMICS, V44, P318, DOI 10.1152/physiolgenomics.00162.2011; Zhang R, 2012, RES DEV DISABIL, V33, P1136, DOI 10.1016/j.ridd.2012.02.001; Zhang R, 2011, FERTIL STERIL, V96, P912, DOI 10.1016/j.fertnstert.2011.07.1093; Zhang WT, 2003, BRAIN RES, V982, P168, DOI 10.1016/S0006-8993(03)02983-4; Zhang Y, 2011, BRAIN RES, V1402, P46, DOI 10.1016/j.brainres.2011.05.054; Zhong C, 2011, J MAGN RESON IMAGING; Zyloney CE, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-80	48	19	25	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e66815	10.1371/journal.pone.0066815	http://dx.doi.org/10.1371/journal.pone.0066815			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IH	23840533	Green Published, gold, Green Submitted			2023-01-03	WOS:000321148400019
J	Leuenberger, N; Schumacher, YO; Pradervand, S; Sander, T; Saugy, M; Pottgiesser, T				Leuenberger, Nicolas; Schumacher, Yorck Olaf; Pradervand, Sylvain; Sander, Thomas; Saugy, Martial; Pottgiesser, Torben			Circulating microRNAs as Biomarkers for Detection of Autologous Blood Transfusion	PLOS ONE			English	Article							IRON STATUS; MARKERS; CELLS; ERYTHROPOIESIS	MicroRNAs (miRNAs) are small non-coding RNAs that regulate various biological processes. Cell-free miRNAs measured in blood plasma have emerged as specific and sensitive markers of physiological processes and disease. In this study, we investigated whether circulating miRNAs can serve as biomarkers for the detection of autologous blood transfusion, a major doping technique that is still undetectable. Plasma miRNA levels were analyzed using high-throughput quantitative real-time PCR. Plasma samples were obtained before and at several time points after autologous blood transfusion (blood bag storage time 42 days) in 10 healthy subjects and 10 controls without transfusion. Other serum markers of erythropoiesis were determined in the same samples. Our results revealed a distinct change in the pattern of circulating miRNAs. Ten miRNAs were upregulated in transfusion samples compared with control samples. Among these, miR-30b, miR-30c, and miR-26b increased significantly and showed a 3.9-, 4.0-, and 3.0-fold change, respectively. The origin of these miRNAs was related to pulmonary and liver tissues. Erythropoietin (EPO) concentration decreased after blood reinfusion. A combination of miRNAs and EPO measurement in a mathematical model enhanced the efficiency of autologous transfusion detection through miRNA analysis. Therefore, our results lay the foundation for the development of miRNAs as novel blood-based biomarkers to detect autologous transfusion.	[Leuenberger, Nicolas; Saugy, Martial] Univ Ctr Legal Med, Swiss Lab Doping Anal, Geneva, Switzerland; [Leuenberger, Nicolas; Saugy, Martial] Univ Ctr Legal Med, Swiss Lab Doping Anal, Lausanne, Switzerland; [Leuenberger, Nicolas; Saugy, Martial] CHU Vaudois, CH-1011 Lausanne, Switzerland; [Leuenberger, Nicolas; Saugy, Martial] Univ Lausanne, Lausanne, Switzerland; [Schumacher, Yorck Olaf; Sander, Thomas; Pottgiesser, Torben] Univ Hosp Freiburg, Dept Sports Med, Freiburg, Germany; [Schumacher, Yorck Olaf] Aspetar Orthoped & Sports Med Hosp, Doha, Qatar; [Pradervand, Sylvain] Univ Lausanne, Genom Technol Facil, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; University of Freiburg; Aspetar Orthopaedic & Sports Medicine Hospital; University of Lausanne	Leuenberger, N (corresponding author), Univ Ctr Legal Med, Swiss Lab Doping Anal, Geneva, Switzerland.	Nicolas.leuenberger@chuv.ch		Pottgiesser, Torben/0000-0003-4925-8478	Exiqon grant program; "Bundesinstitut fur Sportwissenschaft" based on a decision of "Deutscher Bundestag" [IIA1-070303/10-11]	Exiqon grant program; "Bundesinstitut fur Sportwissenschaft" based on a decision of "Deutscher Bundestag"	The authors are grateful to the Partnership for Clean Competition and Exiqon grant program for providing funds. In addition, the hematology and clinical chemistry analyses were in part funded by a grant of the "Bundesinstitut fur Sportwissenschaft" based on a decision of "Deutscher Bundestag" (IIA1-070303/10-11). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreasen D, 2010, METHODS, V50, pS6, DOI 10.1016/j.ymeth.2010.01.006; Ashenden M, 2011, VOX SANG, V101, P320, DOI 10.1111/j.1423-0410.2011.01493.x; Audran M, 1999, MED SCI SPORT EXER, V31, P639, DOI 10.1097/00005768-199905000-00003; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BETTS JC, 1991, SCAND J IMMUNOL, V34, P471, DOI 10.1111/j.1365-3083.1991.tb01570.x; Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; DellaValle DM, 2012, MED SCI SPORT EXER, V44, P1552, DOI 10.1249/MSS.0b013e3182517ceb; Duttagupta R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020769; Hod EA, 2011, BLOOD, V118, P6675, DOI 10.1182/blood-2011-08-371849; Hod EA, 2010, BLOOD, V115, P4284, DOI 10.1182/blood-2009-10-245001; Holley CL, 2011, CARDIOVASC DRUG THER, V25, P151, DOI 10.1007/s10557-011-6290-z; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kwiatkowski JL, 2011, J BLOOD MED, V2, P135, DOI 10.2147/JBM.S13065; Leuenberger N, 2011, DRUG TEST ANAL, V3, P771, DOI 10.1002/dta.370; Lewis PJS, 2011, HEPATOLOGY, V54, P1767, DOI 10.1002/hep.24538; Mangalmurti NS, 2009, BLOOD, V113, P1158, DOI 10.1182/blood-2008-07-166264; McClung JP, 2012, J TRACE ELEM MED BIO, V26, P124, DOI 10.1016/j.jtemb.2012.03.006; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Monfort N, 2012, TRANSFUSION, V52, P647, DOI 10.1111/j.1537-2995.2011.03331.x; Mossuz P, 2005, CLIN CHEM, V51, P1018, DOI 10.1373/clinchem.2004.047365; Parisotto R, 2000, HAEMATOLOGICA, V85, P564; Pottgiesser T, 2011, TRANSFUSION, V51, P1707, DOI 10.1111/j.1537-2995.2011.03076.x; Pritchard CC, 2012, CANCER PREV RES, V5, P492, DOI 10.1158/1940-6207.CAPR-11-0370; Ruvkun G, 2008, NAT MED, V14, P1041, DOI 10.1038/nm1008-1041; Schumacher YO, 2012, DRUG TEST ANAL, V4, P846, DOI 10.1002/dta.406; Sottas PE, 2012, BIOANALYSIS, V4, P1645, DOI [10.4155/BIO.12.130, 10.4155/bio.12.130]; Thevis M, 2012, DRUG TEST ANAL, V4, P2, DOI 10.1002/dta.415; Turchinovich A, 2012, TRENDS BIOCHEM SCI, V37, P460, DOI 10.1016/j.tibs.2012.08.003; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Tzouvelekis A, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-78; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vlaar APJ, 2012, TRANSFUS CLIN BIOL, V19, P117, DOI 10.1016/j.tracli.2012.03.001; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Zhang Y, 2010, CLIN CHEM, V56, P1830, DOI 10.1373/clinchem.2010.147850	35	36	37	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2013	8	6							e66309	10.1371/journal.pone.0066309	http://dx.doi.org/10.1371/journal.pone.0066309			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190LY	23840438	gold, Green Submitted, Green Published			2023-01-03	WOS:000322342800047
J	Gao, J; Zhou, LJ; Ge, YL; Lin, SY; Du, J				Gao, Ju; Zhou, Luojing; Ge, Yali; Lin, Shunyan; Du, Jin			Effects of Different Resuscitation Fluids on Pulmonary Expression of Aquaporin1 and Aquaporin5 in a Rat Model of Uncontrolled Hemorrhagic Shock and Infection	PLOS ONE			English	Article							KAPPA-B ACTIVATION; HYDROXYETHYL STARCH; DOWN-REGULATION; WATER CHANNELS; MOUSE LUNG; TRANSPORT; EPIDEMIOLOGY; SEPSIS; INJURY	Background: To investigate the effects of fluids resuscitation on pulmonary expression of aquaporin1 and aquaporin5 in a rat model of uncontrolled hemorrhagic shock and infection. Methods: Sixty Sprague-Dawley rats were randomly assigned to five groups, sham operation group (Group C) and four treated groups: no fluid resuscitation group (Group NF), groups resuscitated with Lactated Ringer's (LR), 7.5% NaCl (HTS) and Hydroxyl ethyl starch (HES) respectively. Three-phased uncontrolled hemorrhagic shock and infection model was used. Phase I: Massive hemorrhage with a mean arterial pressure of 35-40 mmHg for 60 min, and followed by infection of lipopolysaccharide. Then some animals were resuscitated with solutions mentioned above, until 90 min. Phase II: At hemorrhagic shock 90 minutes, phase II of 60 minutes began with hemostasis and returning of all the initial shed blood. Phase III: Observation phase for 3.5 hours. After phase III, arterial blood gas analysis and the survival rates of the rats were recorded, Wet-to-dry lung weight ratio, BALF protein, pulmonary permeability index, and expressions of aquaporin1 and aquaporin5 were tested. Results: The expressions of aquaporin1 and aquaporin5 were decreased in treatment groups comparing with sham operation group. Group HES and Group HTS decreased pulmonary vascular permeability and Wet-to-dry lung weight ratio, improved arterial blood gas analysis and survival rates, and attenuated the decreased pulmonary expression of aquaporin1 and aquaporin5 after the "two-hit'', comparing with groups NF and LR, but these beneficial effects were blunted in group HTS. Conclusion: The expression of aquaporin1 and aquaporin5 may play important roles in formation of pulmonary edema. Resuscitation with HTS and HES, especially HES can reduce lung injury after hemorrhagic shock, partly by up-regulating the expressions of aquaporin1 and aquaporin5.	[Gao, Ju; Ge, Yali; Lin, Shunyan; Du, Jin] Yangzhou Univ, Clin Med Coll, Subei Peoples Hosp, Dept Anesthesiol, Yangzhou, Jiangsu, Peoples R China; [Zhou, Luojing] Yangzhou Univ, Clin Med Coll, Subei Peoples Hosp, Dept Sci Res, Yangzhou, Jiangsu, Peoples R China	Yangzhou University; Yangzhou University	Gao, J (corresponding author), Yangzhou Univ, Clin Med Coll, Subei Peoples Hosp, Dept Anesthesiol, Yangzhou, Jiangsu, Peoples R China.	happygezi81@163.com			National Natural Science Fund, China [81171838]	National Natural Science Fund, China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Fund, China (81171838). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ablove RH, 2006, ORTHOPEDICS, V29, P443, DOI 10.3928/01477447-20060501-07; Auwerda JJA, 2002, ANN INTERN MED, V137, P1013, DOI 10.7326/0003-4819-137-12-200212170-00037; Bork K, 2005, BRIT J DERMATOL, V152, P3, DOI 10.1111/J.1365-2133.2004.06272.X; CAPONE AC, 1995, J AM COLL SURGEONS, V180, P49; Chen HZ, 2006, J TRAUMA, V60, P701, DOI 10.1097/01.ta.0000203699.91475.f6; Cheng IW, 2003, CRIT CARE CLIN, V19, P693, DOI 10.1016/S0749-0704(03)00050-2; Costantini TW, 2010, CLINICS, V65, P621, DOI 10.1590/S1807-59322010000600010; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Dart AB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007594.pub2; Feng XM, 2006, J SURG RES, V135, P129, DOI 10.1016/j.jss.2006.02.028; Gao J, 2009, J TRAUMA, V67, P1213, DOI 10.1097/TA.0b013e31818cc1e4; Gurfinkel V, 2003, J TRAUMA, V54, P1137, DOI 10.1097/01.TA.0000064452.37534.29; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kauvar DS, 2005, CRIT CARE, V9, P1, DOI 10.1186/cc3779; Lehmann GL, 2008, AM J PHYSIOL-GASTR L, V294, pG567, DOI 10.1152/ajpgi.00232.2007; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; MacCallum NS, 2005, CURR OPIN CRIT CARE, V11, P43, DOI 10.1097/00075198-200502000-00007; Madigan MC, 2008, J TRAUMA, V64, P280, DOI 10.1097/TA.0b013e3181622bb6; Saadia R, 1999, J ACCID EMERG MED, V16, P163; Santry HP, 2010, SHOCK, V33, P229, DOI 10.1097/SHK.0b013e3181c30f0c; Sato H, 2007, SHOCK, V28, P291, DOI 10.1097/SHK.0b013e3180326e3d; Song LL, 2000, J GEN PHYSIOL, V115, P17, DOI 10.1085/jgp.115.1.17; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818; Towne JE, 2001, J BIOL CHEM, V276, P18657, DOI 10.1074/jbc.M100322200; Tsai MC, 2007, SHOCK, V27, P527, DOI 10.1097/01.shk.0000245032.31859.f2; Verkman AS, 2000, AM J PHYSIOL-LUNG C, V278, pL867, DOI 10.1152/ajplung.2000.278.5.L867; Wang F, 2010, HEPATO-GASTROENTEROL, V57, P1553; WANG P, 2006, INT IMMUNOPHARMACOL, V9, P347; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Westphal M, 2009, ANESTHESIOLOGY, V111, P187, DOI 10.1097/ALN.0b013e3181a7ec82; Xie Yan-ping, 2005, Zhonghua Jiehe He Huxi Zazhi, V28, P385; Zarychanski Ryan, 2009, Open Med, V3, pe196; Zhang YW, 2009, CLIN EXP PHARMACOL P, V36, P734, DOI 10.1111/j.1440-1681.2009.05156.x	35	13	17	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2013	8	5							e64390	10.1371/journal.pone.0064390	http://dx.doi.org/10.1371/journal.pone.0064390			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	156DC	23741323	Green Submitted, Green Published, gold			2023-01-03	WOS:000319799900035
J	Conseil, M; Carr, J; Molinari, N; Coisel, Y; Cisse, M; Belafia, F; Delay, JM; Jung, B; Jaber, S; Chanques, G				Conseil, Mathieu; Carr, Julie; Molinari, Nicolas; Coisel, Yannael; Cisse, Moussa; Belafia, Fouad; Delay, Jean-Marc; Jung, Boris; Jaber, Samir; Chanques, Gerald			A Simple Widespread Computer Help Improves Nutrition Support Orders and Decreases Infection Complications in Critically Ill Patients	PLOS ONE			English	Article							ENTERAL NUTRITION; PARENTERAL-NUTRITION; ENERGY-EXPENDITURE; INFORMATION-SYSTEM; ADULT PATIENTS; CALORIC-INTAKE; CARE; GUIDELINES; IMPACT; IMPLEMENTATION	Aims: To assess the impact of a simple computer-based decision-support system (computer help) on the quality of nutrition support orders and patients' outcome in Intensive-Care Unit (ICU). Methods: This quality-improvement study was carried out in a 16-bed medical-surgical ICU in a French university hospital. All consecutive patients who stayed in ICU more than 10 days with non-oral feeding for more than 5 days were retrospectively included during two 12-month periods. Prescriptions of nutrition support were collected and compared to French national guidelines as a quality-improvement process. A computer help was constructed using a simple Excel-sheet (Microsoft(TM)) to guide physicians' prescriptions according to guidelines. This computer help was displayed in computers previously used for medical orders. Physicians were informed but no systematic protocol was implemented. Patients included during the first (control group) and second period (computer help group) were compared for achievement of nutrition goals and ICU outcomes. Results: The control and computer help groups respectively included 71 and 95 patients. Patients' characteristics were not significantly different between groups. In the computer help group, prescriptions achieved significantly more often 80% of nutrition goals for calorie (45% vs. 79% p<0.001) and nitrogen intake (3% vs. 37%, p<0.001). Incidence of nosocomial infections decreased significantly between the two groups (59% vs. 41%, p = 0.03). Mortality did not significantly differ between control (21%) and computer help groups (15%, p = 0.30). Conclusions: Use of a widespread inexpensive computer help is associated with significant improvements in nutrition support orders and decreased nosocomial infections in ICU patients. This computer-help is provided in electronic supplement.	[Conseil, Mathieu; Carr, Julie; Coisel, Yannael; Cisse, Moussa; Belafia, Fouad; Delay, Jean-Marc; Jung, Boris; Jaber, Samir; Chanques, Gerald] Univ Montpellier Hosp, St Eloi Hosp, Intens Care & Anesthesiol Dept, Montpellier, France; [Conseil, Mathieu; Coisel, Yannael; Jung, Boris; Jaber, Samir; Chanques, Gerald] Univ Montpellier 2, Univ Montpellier 1, INSERM, Unite U1046, Montpellier, France; [Molinari, Nicolas] Univ Montpellier, Lapeyronie Hosp, Dept Stat, F-34059 Montpellier, France	Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Chanques, G (corresponding author), Univ Montpellier Hosp, St Eloi Hosp, Intens Care & Anesthesiol Dept, Montpellier, France.	g-chanques@chu-montpellier.fr	Jung, Boris/AAK-5066-2021; molinari, nicolas/Y-9681-2019	Jung, Boris/0000-0003-2522-1531; 	University of Montpellier Hospitals	University of Montpellier Hospitals	This study is part of the authors' own work at the University of Montpellier Hospitals which had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Attof Y, 2007, ANN FR ANESTH, V26, P1031, DOI 10.1016/j.annfar.2007.09.026; Barr J, 2004, CHEST, V125, P1446, DOI 10.1378/chest.125.4.1446; Berger MM, 1997, NUTRITION, V13, P870, DOI 10.1016/S0899-9007(97)00270-0; Berger MM, 2006, NUTRITION, V22, P221, DOI 10.1016/j.nut.2005.04.017; Blaser AR, 2012, INTENS CARE MED, V38, P384, DOI 10.1007/s00134-011-2459-y; Bosman RJ, 2003, INTENS CARE MED, V29, P83, DOI 10.1007/s00134-002-1542-9; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Chambrier C, 2010, FRENCH CLIN GUIDELIN; Conference de Consensus, 1998, NUTR CLIN METAB, V12, P2; Conference de Consensus, 1995, NUTR CLIN METABOL S1, V9, P1; Conseil M, 2006, REANIMATION, V15, pS58; Correia MITD, 2003, CLIN NUTR, V22, P235, DOI 10.1016/S0261-5614(02)00215-7; De Jonghe B, 2001, CRIT CARE MED, V29, P8, DOI 10.1097/00003246-200101000-00002; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Fowler S, 2007, J ANTIMICROB CHEMOTH, V59, P990, DOI 10.1093/jac/dkm014; Giner M, 1996, NUTRITION, V12, P23, DOI 10.1016/0899-9007(95)00015-1; Glynn CC, 1999, JPEN-PARENTER ENTER, V23, P147, DOI 10.1177/0148607199023003147; Gramlich L, 2004, NUTRITION, V20, P843, DOI 10.1016/j.nut.2004.06.003; Heidegger CP, 2013, LANCET, V381, P385, DOI 10.1016/S0140-6736(12)61351-8; Heyland DK, 2011, CLIN NUTR, V30, P148, DOI 10.1016/j.clnu.2010.09.011; Heyland DK, 2004, CRIT CARE MED, V32, P2260, DOI 10.1097/01.CCM.0000145581.54571.32; Howard JP, 1999, CLIN NUTR, V18, P379, DOI 10.1016/S0261-5614(99)80020-X; Kiser Kim, 2011, Minn Med, V94, P22; Klein CJ, 1998, J AM DIET ASSOC, V98, P795, DOI 10.1016/S0002-8223(98)00179-5; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Krishnan JA, 2003, CHEST, V124, P297, DOI 10.1378/chest.124.1.297; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MacDonald A, 2003, NUTRITION, V19, P233, DOI 10.1016/S0899-9007(02)01033-X; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Mowe M, 2008, CLIN NUTR, V27, P196, DOI 10.1016/j.clnu.2007.10.014; Nightingale PG, 2000, BMJ-BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750; Pulcini C, 2011, MED MALADIES INFECT, V41, P546, DOI 10.1016/j.medmal.2011.07.003; ROZA AM, 1984, AM J CLIN NUTR, V40, P168, DOI 10.1093/ajcn/40.1.168; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Singer P, 2011, INTENS CARE MED, V37, P601, DOI 10.1007/s00134-011-2146-z; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; Societe francaise d'anesthesie et de reanimation, 2009, Ann Fr Anesth Reanim, V28, P912, DOI 10.1016/j.annfar.2009.09.007; Villet S, 2005, CLIN NUTR, V24, P502, DOI 10.1016/j.clnu.2005.03.006; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	41	13	13	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2013	8	5							e63771	10.1371/journal.pone.0063771	http://dx.doi.org/10.1371/journal.pone.0063771			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177SC	23737948	Green Published, gold			2023-01-03	WOS:000321394700011
J	Rise, MB; Pellerud, A; Rygg, LO; Steinsbekk, A				Rise, Marit B.; Pellerud, Anneli; Rygg, Lisbeth O.; Steinsbekk, Aslak			Making and Maintaining Lifestyle Changes after Participating in Group Based Type 2 Diabetes Self-Management Educations: A Qualitative Study	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CARE MANAGEMENT; PEOPLE; METAANALYSIS; MEDICATION; BEHAVIORS; MELLITUS.; STANDARDS; EXERCISE; PROGRAM	Background: Disease management is crucial in type 2 diabetes. Diabetes self-management education aims to provide the knowledge necessary to make and maintain lifestyle changes. However, few studies have investigated the processes after such courses. The aim of this study was to investigate how participants make and maintain lifestyle changes after participating in group-based type 2 diabetes self-management education. Methods: Data was collected through qualitative semi-structured interviews with 23 patients who attended educational group programs in Central Norway. The participants were asked how they had used the advice given and what they had changed after the course. Results: Knowledge was essential for making lifestyle changes following education. Three factors affected whether lifestyle changes were implemented: obtaining new knowledge, taking responsibility, and receiving confirmation of an already healthy lifestyle. Four factors motivated individuals to maintain changes: support from others, experiencing an effect, fear of complications, and the formation of new habits. Conclusion: Knowledge was used to make and maintain changes in diet, medication and physical activity. Knowledge also acted as confirmation of an already adequate lifestyle. Knowledge led to no changes if diabetes appeared "not that scary'' or if changes appeared too time consuming. Those involved in diabetes education need to be aware of the challenges in convincing asymptomatic patients about the benefits of adherence to self-management behaviour.	[Rise, Marit B.; Pellerud, Anneli; Rygg, Lisbeth O.; Steinsbekk, Aslak] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, N-7034 Trondheim, Norway; [Rygg, Lisbeth O.] Helse Nord Trondelag Hosp Trust, Levanger, Norway	Norwegian University of Science & Technology (NTNU)	Rise, MB (corresponding author), Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, N-7034 Trondheim, Norway.	marit.b.rise@ntnu.no	Steinsbekk, Aslak/E-9223-2012; Albertin, Paloma C/X-1093-2018	Steinsbekk, Aslak/0000-0001-9090-0739; Rygg, Lisbeth Ostgaard/0000-0002-8415-8715	Central Norway Health Authorities [46011600-47]	Central Norway Health Authorities	The study was funded by The Central Norway Health Authorities (grant number 46011600-47). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alm-Roijer Carin, 2004, Eur J Cardiovasc Nurs, V3, P321; Balcou-Debussche M, 2009, QUAL HEALTH RES, V19, P1100, DOI 10.1177/1049732309341642; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; Barlow JH, 2005, J HEALTH PSYCHOL, V10, P863, DOI 10.1177/1359105305057320; Blissmer B, 2010, J HEALTH PSYCHOL, V15, P205, DOI 10.1177/1359105309345555; Burge S, 2005, FAM MED, V37, P712; Eigenmann C, 2007, OUTCOMES INDICATORS; Farmer A, 2006, DIABETIC MED, V23, P265, DOI 10.1111/j.1464-5491.2005.01778.x; Fredrickson BL, 2005, AM PSYCHOL, V60, P678, DOI 10.1037/0003-066X.60.7.678; Funnell MM, 2012, DIABETES CARE, V35, pS101, DOI 10.2337/dc12-s101; Gazmararian JA, 2009, DIABETES EDUCATOR, V35, P778, DOI 10.1177/0145721709338527; Giorgi A., 2009, DESCRIPTIVE PHENOMEN; Hibbard JH, 2010, PATIENT EDUC COUNS, V78, P377, DOI 10.1016/j.pec.2009.12.015; HISCOCK J, 2001, LISTENING DIABETES S; HORTON ES, 1988, DIABETES CARE, V11, P201, DOI 10.2337/diacare.11.2.201; Khunti K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2333; Kvale S., 1996, INTERVIEWS INTRO QUA; Lawton J, 2005, SOC SCI MED, V60, P1423, DOI 10.1016/j.socscimed.2004.08.013; Malpass A, 2009, PATIENT EDUC COUNS, V74, P258, DOI 10.1016/j.pec.2008.08.018; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Malterud K, 2012, SCAND J PUBLIC HEALT, V40, P795, DOI 10.1177/1403494812465030; Manderson L, 2009, CHRONIC ILLN, V5, P21, DOI 10.1177/1742395309102243; Marks DF, 2008, J HEALTH PSYCHOL, V13, P977, DOI 10.1177/1359105308098002; Minet L, 2010, PATIENT EDUC COUNS, V80, P29, DOI 10.1016/j.pec.2009.09.033; Moser A, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-91; Mulcahy K, 2003, DIABETES EDUCATOR, V29, P768, DOI 10.1177/014572170302900509; MURPHY E, 1995, FAM PRACT, V12, P184, DOI 10.1093/fampra/12.2.184; Norris SL, 2002, DIABETES CARE, V25, P1159, DOI 10.2337/diacare.25.7.1159; Ockleford E, 2008, CHRONIC ILLN, V4, P28, DOI 10.1177/1742395307086673; Parry O, 2006, HEALTH EDUC RES, V21, P97, DOI 10.1093/her/cyh044; Peel E, 2004, PATIENT EDUC COUNS, V53, P269, DOI 10.1016/j.pec.2003.07.010; Peel E, 2010, BRIT J GEN PRACT, V60, P570, DOI 10.3399/bjgp10X515061; Polonsky WH, 2003, DIABETES CARE, V26, P3048, DOI 10.2337/diacare.26.11.3048; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Rygg LO, 2012, PATIENT EDUC COUNS, V86, P98, DOI 10.1016/j.pec.2011.04.008; Rygg LO, 2010, SCAND J PUBLIC HEALT, V38, P788, DOI 10.1177/1403494810382475; Shariff F, 2009, QUAL HEALTH RES, V19, P1037, DOI 10.1177/1049732309341189; Snoek FJ, 2002, INT J CLIN PRACT, P80; Steinsbekk A, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-213; Tucker M, 2002, J NUTR EDUC BEHAV, V34, pS14, DOI 10.1016/S1499-4046(06)60306-0; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Zimmerman GL, 2000, AM FAM PHYSICIAN, V61, P1409	42	43	44	1	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2013	8	5							e64009	10.1371/journal.pone.0064009	http://dx.doi.org/10.1371/journal.pone.0064009			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	155HD	23671705	Green Published, Green Submitted, gold			2023-01-03	WOS:000319737700063
J	Abdelhady, HG; Lin, YL; Sun, HP; ElSayed, MEH				Abdelhady, Hosam G.; Lin, Yen-Ling; Sun, Haiping; ElSayed, Mohamed E. H.			Visualizing the Attack of RNase Enzymes on Dendriplexes and Naked RNA Using Atomic Force Microscopy	PLOS ONE			English	Article							GENE DELIVERY; POLYAMIDOAMINE DENDRIMERS; STARBURST DENDRIMERS; DNA CONDENSATION; MAMMALIAN-CELLS; PLASMID DNA; IN-VITRO; SIRNA; INTERFERENCE; COMPLEXES	Cationic polymers such as poly(amidoamine), PAMAM, dendrimers have been used to electrostatically complex siRNA molecules forming dendriplexes for enhancing the cytoplasmic delivery of the encapsulated cargo. However, excess PAMAM dendrimers is typically used to protect the loaded siRNA against enzymatic attack, which results in systemic toxicity that hinders the in vivo use of these particles. In this paper, we evaluate the ability of G4 (flexible) and G5 (rigid) dendrimers to complex model siRNA molecules at low +/- ratio of 2/1 upon incubation for 20 minutes and 24 hours. We examine the ability of the formed G4 and G5 dendriplexes to shield the loaded siRNA molecules and protect them from degradation by RNase V1 enzymes using atomic force microscopy (AFM). Results show that G4 and G5 dendrimers form similar hexagonal complexes upon incubation with siRNA molecules for 20 minutes with average full width of 43 +/- 19.3 nm and 62 +/- 8.3 at half the maximum height, respectively. AFM images show that these G4 and G5 dendriplexes were attacked by RNase V1 enzyme leading to degradation of the exposed RNA molecules that increased with the increase in incubation time. In comparison, incubating G4 and G5 dendrimers with siRNA for 24 hours led to the formation of large particles with average full width of 263 +/- 60 nm and 48.3 +/- 2.5 nm at half the maximum height, respectively. Both G4 and G5 dendriplexes had a dense central core that proved to shield the loaded RNA molecules from enzymatic attack for up to 60 minutes. These results show the feasibility of formulating G4 and G5 dendriplexes at a low N/P (+/-) ratio that can resist degradation by RNase enzymes, which reduces the risk of inducing non-specific toxicity when used in vivo.	[Abdelhady, Hosam G.] Taibah Univ, Coll Pharm, Al Madinah Al Munawwarah, Saudi Arabia; [Abdelhady, Hosam G.] Natl Org Drug Control & Res, Cairo, Egypt; [Abdelhady, Hosam G.; Lin, Yen-Ling; ElSayed, Mohamed E. H.] Univ Michigan, Cellular Engn & Nanotherapeut Lab, Dept Biomed Engn, Ann Arbor, MI 48109 USA; [Sun, Haiping] Univ Michigan, Electron Microbeam Anal Lab, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA; [ElSayed, Mohamed E. H.] Univ Michigan, Macromol Sci & Engn Program, Ann Arbor, MI 48109 USA	Taibah University; National Organization for Drug Control & Research (NODCAR); University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	ElSayed, MEH (corresponding author), Univ Michigan, Cellular Engn & Nanotherapeut Lab, Dept Biomed Engn, Ann Arbor, MI 48109 USA.	melsayed@umich.edu		Gharib Abdelhady, Hosam/0000-0001-6653-3705	Science and Technology Unit at Taibah University; King Abdulaziz City for Science and Technology (KACST); National Science, Technology and Innovation Plan	Science and Technology Unit at Taibah University; King Abdulaziz City for Science and Technology (KACST); National Science, Technology and Innovation Plan	Hosam G. Abdelhady acknowledges the Science and Technology Unit at Taibah University, King Abdulaziz City for Science and Technology (KACST), and its National Science, Technology and Innovation Plan for their financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelhady HG, 2005, NANOTECHNOLOGY, V16, P966, DOI 10.1088/0957-4484/16/6/058; Abdelhady HG, 2003, NUCLEIC ACIDS RES, V31, P4001, DOI 10.1093/nar/gkg462; BEZANILLA M, 1994, BIOPHYS J, V67, P2454, DOI 10.1016/S0006-3495(94)80733-7; Bielinska AU, 1997, BBA-GENE STRUCT EXPR, V1353, P180, DOI 10.1016/S0167-4781(97)00069-9; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; Boeckle S, 2004, J GENE MED, V6, P1102, DOI 10.1002/jgm.598; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; Eccleston A, 2004, NATURE, V431, P337, DOI 10.1038/431337a; El-Sayed MEH, 2005, EXPERT OPIN BIOL TH, V5, P23, DOI 10.1517/14712598.5.1.23; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Ellis JS, 2004, J MICROSC-OXFORD, V215, P297, DOI 10.1111/j.0022-2720.2004.01379.x; FATTAL E, 1994, BIOCHEMISTRY-US, V33, P6721, DOI 10.1021/bi00187a044; Forrest ML, 2003, BIOCONJUGATE CHEM, V14, P934, DOI 10.1021/bc034014g; FRECHET JMJ, 1994, SCIENCE, V263, P1710, DOI 10.1126/science.8134834; Funhoff AM, 2005, J CONTROL RELEASE, V101, P233, DOI 10.1016/j.jconrel.2004.06.023; Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021; HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012; Hansma HG, 1996, BIOPHYS J, V70, P1933, DOI 10.1016/S0006-3495(96)79757-6; Hansma HG, 1998, NUCLEIC ACIDS RES, V26, P2481, DOI 10.1093/nar/26.10.2481; HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795; Hassan Ali, 2006, Recent Pat Cardiovasc Drug Discov, V1, P141, DOI 10.2174/157489006777442540; Henderson RM, 2000, AM J PHYSIOL-RENAL, V278, pF689, DOI 10.1152/ajprenal.2000.278.5.F689; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; Hori K, 1998, EUR BIOPHYS J BIOPHY, V27, P63, DOI 10.1007/s002490050111; Jensen LB, 2011, INT J PHARMACEUT, V416, P410, DOI 10.1016/j.ijpharm.2011.03.015; Jensen LB, 2010, BIOMACROMOLECULES, V11, P3571, DOI 10.1021/bm101033g; Karatasos K, 2012, MACROMOL BIOSCI, V12, P225, DOI 10.1002/mabi.201100276; Koutsilieri E, 2007, J NEURAL TRANSM-SUPP, P43; Kukowska-Latallo JF, 2000, HUM GENE THER, V11, P1385, DOI 10.1089/10430340050057468; KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897; Lee H, 2001, J CONTROL RELEASE, V76, P183, DOI 10.1016/S0168-3659(01)00426-6; Merkel OM, 2010, MOL PHARMACEUT, V7, P969, DOI 10.1021/mp100101s; NAYLOR AM, 1989, J AM CHEM SOC, V111, P2339, DOI 10.1021/ja00188a079; Neish CS, 2002, BRIT J PHARMACOL, V135, P1943, DOI 10.1038/sj.bjp.0704660; Ottaviani MF, 1996, J PHYS CHEM-US, V100, P13675, DOI 10.1021/jp960291r; Pavan GM, 2010, BIOMACROMOLECULES, V11, P721, DOI 10.1021/bm901298t; Perez AP, 2009, INT J PHARMACEUT, V380, P189, DOI 10.1016/j.ijpharm.2009.06.035; PUTMAN CAJ, 1994, APPL PHYS LETT, V64, P2454, DOI 10.1063/1.111597; Riddihough G, 2005, SCIENCE, V309, P1816; Shim MS, 2010, MICROSC RES TECHNIQ, V73, P845, DOI 10.1002/jemt.20856; Spagnou S, 2004, BIOCHEMISTRY-US, V43, P13348, DOI 10.1021/bi048950a; Wagner E, 2006, ADV POLYM SCI, V192, P135, DOI 10.1007/12_023; Yessine MA, 2004, ADV DRUG DELIVER REV, V56, P999, DOI 10.1016/j.addr.2003.10.039; Zeng FW, 1997, CHEM REV, V97, P1681, DOI 10.1021/cr9603892; Zhang J, 2007, MOL BIOTECHNOL, V37, P225, DOI 10.1007/s12033-007-9000-0	46	11	11	0	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2013	8	4							e61710	10.1371/journal.pone.0061710	http://dx.doi.org/10.1371/journal.pone.0061710			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IU	23637890	Green Submitted, Green Published, gold			2023-01-03	WOS:000317908700054
J	Paneth, N; Fine, P				Paneth, Nigel; Fine, Paul			The art of medicine The singular science of John Snow	LANCET			English	Editorial Material									[Paneth, Nigel] Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA; [Paneth, Nigel] Michigan State Univ, Coll Human Med, Dept Pediat & Human Dev, E Lansing, MI 48824 USA; [Fine, Paul] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England	Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Human Medicine; University of London; London School of Hygiene & Tropical Medicine	Paneth, N (corresponding author), Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.	paneth@epi.msu.edu						[Anonymous], 1855, LANCET, V1, P634; Snow J, 1853, ON CONTINUOUS MOLECU; Snow J, 1838, LANCET, V1, P264; Snow J, 1847, ON THE INHALATION OF; Snow J., 1849, MODE COMMUNICATION C; Vinten-Johansen P, 2003, CHOLERA CHLOROFORM A	6	5	5	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 13	2013	381	9874					1267	1268		10.1016/S0140-6736(13)60829-6	http://dx.doi.org/10.1016/S0140-6736(13)60829-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122XD	23589913				2023-01-03	WOS:000317351000016
J	Begum, R; Powner, MB; Hudson, N; Hogg, C; Jeffery, G				Begum, Rana; Powner, Michael B.; Hudson, Natalie; Hogg, Chris; Jeffery, Glen			Treatment with 670 nm Light Up Regulates Cytochrome C Oxidase Expression and Reduces Inflammation in an Age-Related Macular Degeneration Model	PLOS ONE			English	Article							COMPLEMENT FACTOR-H; EMITTING DIODE TREATMENT; NEAR-INFRARED LIGHT; AMYLOID-BETA; PHOTOBIOMODULATION; POLYMORPHISM; DYSFUNCTION; RADIATION; LESIONS; RETINA	Inflammation is an umbrella feature of ageing. It is present in the aged retina and many retinal diseases including age-related macular degeneration (AMD). In ageing and in AMD mitochondrial function declines. In normal ageing this can be manipulated by brief exposure to 670 nm light on the retina, which increases mitochondrial membrane potential and reduces inflammation. Here we ask if 670 nm exposure has the same ability in an aged mouse model of AMD, the complement factor H knockout (CFH-/-) where inflammation is a key feature. Further, we ask whether this occurs when 670 nm is delivered briefly in environmental lighting rather than directly focussed on the retina. Mice were exposed to 670 nm for 6 minutes twice a day for 14 days in the form of supplemented environmental light. Exposed animals had significant increase in cytochrome c oxidase (COX), which is a mitochondrial enzyme regulating oxidative phosphorylation. There was a significant reduction in complement component C3, an inflammatory marker in the outer retina. Vimetin and glial fibrillary acidic protein (GFAP) expression, which reflect retinal stress in Muller glia, were also significantly down regulated. There were also significant changes in outer retinal macrophage morphology. However, amyloid beta (A beta) load, which also increases with age in the outer retina and is pro-inflammatory, did not change. Hence, 670 nm is effective in reducing inflammation probably via COX activation in mice with a genotype similar to that in 50% of AMD patients even when brief exposures are delivered via environmental lighting. Further, inflammation can be reduced independent of A beta. The efficacy revealed here supports current early stage clinical trials of 670 nm in AMD patients.	[Begum, Rana; Powner, Michael B.; Hudson, Natalie; Hogg, Chris; Jeffery, Glen] UCL, Inst Ophthalmol, London, England; [Hogg, Chris] Moorfields Eye Hosp, London, England	University of London; University College London; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust	Jeffery, G (corresponding author), UCL, Inst Ophthalmol, London, England.	g.jeffery@ucl.ac.uk	Powner, Michael/CAG-7455-2022	Powner, Michael/0000-0003-4913-1004	Rosetrees Trust	Rosetrees Trust(Rosetrees Trust)	This study was funded by the Rosetrees Trust. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albarracin R, 2012, PHOTOCHEM PHOTOBIOL, V88, P1418, DOI 10.1111/j.1751-1097.2012.01130.x; Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664; Alonso-Fernandez Patricia, 2011, Curr Aging Sci, V4, P78; Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011; Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003; Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536; Catchpole IR, 2011, ARVO M 2011, V262, P1778; Chiang PK, 2008, CURR MOL MED, V8, P580, DOI 10.2174/156652408785747951; Chong NHV, 2005, AM J PATHOL, V166, P241, DOI 10.1016/S0002-9440(10)62248-1; Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104; Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012; Cunea A, 2007, VISUAL NEUROSCI, V24, P151, DOI 10.1017/S0952523807070204; CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Freund PR, 2011, DOC OPHTHALMOL, V122, P177, DOI 10.1007/s10633-011-9273-2; GRAYMORE CN, 1969, EXP EYE RES, V8, P375, DOI 10.1016/S0014-4835(69)80001-1; Hageman G.S., 2008, WEBVISION ORG RETINA; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026; Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7; Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Lim J, 2010, J PHOTOCH PHOTOBIO B, V99, P105, DOI 10.1016/j.jphotobiol.2010.03.002; Lim J, 2009, J BIOCHEM MOL TOXIC, V23, P1, DOI 10.1002/jbt.20257; Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7; Lutty G, 1999, MOL VIS, V5; Merry G., 2012, INVEST OPHTHALMOL VI, V53, P2049; Parihar MS, 2010, J ALZHEIMERS DIS, V22, P741, DOI 10.3233/JAD-2010-101020; PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3; Pastore D, 2000, FEBS LETT, V470, P88, DOI 10.1016/S0014-5793(00)01292-8; Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073; Puzzo D, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.020; SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002; von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Yeh S, 2008, J AUTOIMMUN, V31, P91, DOI 10.1016/j.jaut.2008.05.001	53	90	101	2	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57828	10.1371/journal.pone.0057828	http://dx.doi.org/10.1371/journal.pone.0057828			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469078	gold, Green Published, Green Accepted, Green Submitted			2023-01-03	WOS:000315524900174
J	Muller, P; Alber, DG; Turnbull, L; Schlothauer, RC; Carter, DA; Whitchurch, CB; Harry, EJ				Mueller, Patrick; Alber, Dagmar G.; Turnbull, Lynne; Schlothauer, Ralf C.; Carter, Dee A.; Whitchurch, Cynthia B.; Harry, Elizabeth J.			Synergism between Medihoney and Rifampicin against Methicillin-Resistant Staphylococcus aureus (MRSA)	PLOS ONE			English	Article							LEPTOSPERMUM-SCOPARIUM HONEY; PSEUDOMONAS-AERUGINOSA; MANUKA HONEY; NEW-ZEALAND; ANTIMICROBIAL ACTIVITY; ANTIBACTERIAL ACTIVITY; RNA-POLYMERASE; METHYLGLYOXAL; ANTIBIOTICS; WOUNDS	Skin and chronic wound infections caused by highly antibiotic resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) are an increasing and urgent health problem worldwide, particularly with sharp increases in obesity and diabetes. New Zealand manuka honey has potent broad-spectrum antimicrobial activity, has been shown to inhibit the growth of MRSA strains, and bacteria resistant to this honey have not been obtainable in the laboratory. Combinational treatment of chronic wounds with manuka honey and common antibiotics may offer a wide range of advantages including synergistic enhancement of the antibacterial activity, reduction of the effective dose of the antibiotic, and reduction of the risk of antibiotic resistance. The aim of this study was to investigate the effect of Medihoney in combination with the widely used antibiotic rifampicin on S. aureus. Using checkerboard microdilution assays, time-kill curve experiments and agar diffusion assays, we show a synergism between Medihoney and rifampicin against MRSA and clinical isolates of S. aureus. Furthermore, the Medihoney/rifampicin combination stopped the appearance of rifampicin-resistant S. aureus in vitro. Methylglyoxal (MGO), believed to be the major antibacterial compound in manuka honey, did not act synergistically with rifampicin and is therefore not the sole factor responsible for the synergistic effect of manuka honey with rifampicin. Our findings support the idea that a combination of honey and antibiotics may be an effective new antimicrobial therapy for chronic wound infections.	[Mueller, Patrick; Alber, Dagmar G.; Turnbull, Lynne; Whitchurch, Cynthia B.; Harry, Elizabeth J.] Univ Technol Sydney, Inst I3, Sydney, NSW 2007, Australia; [Schlothauer, Ralf C.] Comvita NZ Ltd, Te Puke, New Zealand; [Carter, Dee A.] Univ Sydney, Sch Mol Biosci, Sydney, NSW 2006, Australia	University of Technology Sydney; University of Sydney	Harry, EJ (corresponding author), Univ Technol Sydney, Inst I3, Sydney, NSW 2007, Australia.	Elizabeth.Harry@uts.edu.au	Harry, Liz/AAT-9396-2020; Harry, Elizabeth/G-8123-2017; Carter, Dee/C-1331-2010; Whitchurch, Cynthia/A-5954-2008; Turnbull, Lynne/A-2605-2012	Carter, Dee/0000-0002-4638-0059; Whitchurch, Cynthia/0000-0003-2296-3791; Harry, Elizabeth/0000-0003-0858-9473; Turnbull, Lynne/0000-0002-9255-9033	Australian Research Council [LP0990949]; Australian National Health and Medical Research Council Senior Research Fellowship [571905]; University of Technology Sydney Chancellors Postdoctoral Fellowship	Australian Research Council(Australian Research Council); Australian National Health and Medical Research Council Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); University of Technology Sydney Chancellors Postdoctoral Fellowship	Sources of funding that supported the work: 1. Australian Research Council (http://www.arc.gov.au/) in the form of an Australian Research Council Linkage Project (LP0990949) to EJH, CBW, LT, DAC and RCS. (http://www.comvita.co.nz/) 2. CBW is supported by an Australian National Health and Medical Research Council Senior Research Fellowship (571905). 3. LT was supported by a University of Technology Sydney Chancellors Postdoctoral Fellowship (http://www.uts.edu.au). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams CJ, 2008, CARBOHYD RES, V343, P651, DOI 10.1016/j.carres.2007.12.011; Adams CJ, 2009, CARBOHYD RES, V344, P1050, DOI 10.1016/j.carres.2009.03.020; ALLEN KL, 1991, J PHARM PHARMACOL, V43, P817, DOI 10.1111/j.2042-7158.1991.tb03186.x; Ankri S, 1999, MICROBES INFECT, V1, P125, DOI 10.1016/S1286-4579(99)80003-3; Aubry-Damon H, 1998, ANTIMICROB AGENTS CH, V42, P2590, DOI 10.1128/AAC.42.10.2590; BALS MG, 1969, ARZNEI-FORSCHUNG, V19, P1285; Blair SE, 2009, EUR J CLIN MICROBIOL, V28, P1199, DOI 10.1007/s10096-009-0763-z; Booth IR, 2003, BIOCHEM SOC T, V31, P1406; Braga LC, 2005, CAN J MICROBIOL, V51, P541, DOI [10.1139/w05-022, 10.1139/W05-022]; Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0; Cooper R, 2010, EUROPEAN J CLIN MICR, P1; Cooper RA, 2010, EUR J CLIN MICROBIOL, V29, P1237, DOI 10.1007/s10096-010-0992-1; Cooper RA, 2002, J APPL MICROBIOL, V93, P857, DOI 10.1046/j.1365-2672.2002.01761.x; Cosgrove SE, 2003, CLIN INFECT DIS, V36, P1433, DOI 10.1086/375081; Dowd SE, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-43; ECDC E, 2009, BACT CHALL TIM REACT; EFEM SEE, 1988, BRIT J SURG, V75, P679, DOI 10.1002/bjs.1800750718; Eliopoulos GM, 1996, ANTIBIOTICS LAB MED; ENG RHK, 1985, J ANTIMICROB CHEMOTH, V15, P201, DOI 10.1093/jac/15.2.201; Fazli M, 2009, J CLIN MICROBIOL, V47, P4084, DOI 10.1128/JCM.01395-09; Feklistov A, 2008, P NATL ACAD SCI USA, V105, P14820, DOI 10.1073/pnas.0802822105; GAL K, 1965, CAN MED ASSOC J, V93, P844; George NM, 2007, WOUNDS, V19, P231; Harbarth S, 2011, INT J ANTIMICROB AG, V37, P110, DOI 10.1016/j.ijantimicag.2010.10.022; Hemaiswarya S, 2008, PHYTOMEDICINE, V15, P639, DOI 10.1016/j.phymed.2008.06.008; Iyer S, 2004, J AM ACAD DERMATOL, V50, P854, DOI 10.1016/j.jaad.2003.12.043; Jabar MA, 2010, AFRICAN J BIOTECHNOL, P6; Jenkins RE, 2012, J ANTIMICROBIAL CHEM; Jenkins R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045600; Jenkins R, 2011, J ANTIMICROB CHEMOTH, V66, P2536, DOI 10.1093/jac/dkr340; Jenkins R, 2011, INT J ANTIMICROB AG, V37, P373, DOI 10.1016/j.ijantimicag.2010.11.036; JENSEN K, 1969, Q J MED, V38, P91; Kwakman PHS, 2012, IUBMB LIFE, V64, P48, DOI 10.1002/iub.578; Kwakman PHS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017709; Kwakman PHS, 2010, FASEB J, V24, P2576, DOI 10.1096/fj.09-150789; Lee JW, 2007, J MICROBIOL, V45, P350; Leibovici L, 2010, CLIN MICROBIOL INFEC, V16, P1736, DOI 10.1111/j.1469-0691.2010.03330.x; Lewis K, 2007, NATURE, V200, P6; Mavric E, 2008, MOL NUTR FOOD RES, V52, P483, DOI 10.1002/mnfr.200700282; Merckoll P, 2009, SCAND J INFECT DIS, V41, P341, DOI 10.1080/00365540902849383; Molan PC, 2008, EXPLANATION WHY MGO; Mukherjee S, 2011, INDIAN J EXP BIOL, V49, P547; Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301; Rahal JJ, 2006, CLIN INFECT DIS, V43, pS95, DOI 10.1086/504486; RIBNER B, 1976, CHEST, V70, P681, DOI 10.1378/chest.70.5.681; Saleem M, 2010, NAT PROD REP, V27, P238, DOI 10.1039/b916096e; Schierle CF, 2009, WOUND REPAIR REGEN, V17, P354, DOI 10.1111/j.1524-475X.2009.00489.x; Sen CK, 2009, WOUND REPAIR REGEN, V17, P763, DOI 10.1111/j.1524-475X.2009.00543.x; Sherlock O, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-47; Shiota S, 2004, MICROBIOL IMMUNOL, V48, P67, DOI 10.1111/j.1348-0421.2004.tb03489.x; Taormina PJ, 2001, INT J FOOD MICROBIOL, V69, P217, DOI 10.1016/S0168-1605(01)00505-0; Tiwari RP, 2005, INDIAN J MED RES, V122, P80; TRACZEWSKI MM, 1983, ANTIMICROB AGENTS CH, V23, P571, DOI 10.1128/AAC.23.4.571; Villar M, 2011, J ANTIMICROB CHEMOTH, V66, P997, DOI 10.1093/jac/dkr059; Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI 10.1016/j.phymed.2008.12.018; Wichelhaus TA, 1999, ANTIMICROB AGENTS CH, V43, P2813, DOI 10.1128/AAC.43.11.2813; WILLIX DJ, 1992, J APPL BACTERIOL, V73, P388, DOI 10.1111/j.1365-2672.1992.tb04993.x; Windsor S., 2012, J PHARMACOGN PHYTHER, V4, P6, DOI DOI 10.5897/JPP11.025; Zheng ZL, 2002, ANTIMICROB AGENTS CH, V46, P900, DOI 10.1128/AAC.46.3.900-903.2002	59	69	70	1	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57679	10.1371/journal.pone.0057679	http://dx.doi.org/10.1371/journal.pone.0057679			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469049	gold, Green Published, Green Submitted			2023-01-03	WOS:000315524900148
J	Conza, L; Pagani, SC; Gaia, V				Conza, Lisa; Pagani, Simona Casati; Gaia, Valeria			Presence of Legionella and Free-Living Amoebae in Composts and Bioaerosols from Composting Facilities	PLOS ONE			English	Article							LEGIONNAIRES-DISEASE; POTTING SOILS; PNEUMOPHILA; COCULTURE; AEROSOLS; WATER; SURVIVAL; SAMPLES	Several species of Legionella cause Legionnaires' disease (LD). Infection may occur through inhalation of Legionella or amoebal vesicles. The reservoirs of Legionella are water, soil, potting soil and compost. Some species of free-living amoebae (FLA) that are naturally present in water and soil were described as hosts for Legionella. This study aimed to understand whether or not the composting facilities could be sources of community-acquired Legionella infections after development of bioaerosols containing Legionella or FLA. We looked for the presence of Legionella (by co-culture) and FLA (by culture) in composts and bioaerosols collected at four composting facilities located in southern Switzerland. We investigated the association between the presence of Legionella and compost and air parameters and presence of FLA. Legionella spp. (including L. pneumophila) were detected in 69.3% (61/88) of the composts and FLA (mainly Acanthamoeba, Vermamoeba, Naegleria and Stenamoeba) in 92.0% (81/88). L. pneumophila and L. bozemanii were most frequently isolated. FLA as potential host for Legionella spp. were isolated from 40.9% (36/88) of the composts in all facilities. In Legionella-positive samples the temperature of compost was significantly lower (P = 0.012) than in Legionella-negative samples. Of 47 bioaerosol samples, 19.1% (9/47) were positive for FLA and 10.6% (5/47) for L. pneumophila. Composts (62.8%) were positive for Legionella and FLA contemporaneously, but both microorganisms were never detected simultaneously in bioaerosols. Compost can release bioaerosol containing FLA or Legionella and could represent a source of infection of community-acquired Legionella infections for workers and nearby residents.	[Conza, Lisa; Pagani, Simona Casati; Gaia, Valeria] Swiss Natl Reference Ctr Legionella, Cantonal Inst Microbiol, Bellinzona, Switzerland		Conza, L (corresponding author), Swiss Natl Reference Ctr Legionella, Cantonal Inst Microbiol, Bellinzona, Switzerland.	lisaconza@gmail.com			Ticino Pulmonary League; Lung Leagues of the Canton Ticino; Dr. Pierluigi Crivelli Foundation	Ticino Pulmonary League; Lung Leagues of the Canton Ticino; Dr. Pierluigi Crivelli Foundation	The work has been partially supported by the Ticino Pulmonary League. A special thanks to Lung Leagues of the Canton Ticino and to the Dr. Pierluigi Crivelli Foundation for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	BERENDT RF, 1980, J INFECT DIS, V141, P689, DOI 10.1093/infdis/141.5.689; Blatny JM, 2008, ENVIRON SCI TECHNOL, V42, P7360, DOI 10.1021/es800306m; Carvalho E, 2008, AEROBIOLOGIA, V24, P191, DOI 10.1007/s10453-008-9098-y; Casati S, 2010, CLIN MICROBIOL INFEC, V16, P945, DOI 10.1111/j.1469-0691.2009.03009.x; Casati S, 2009, CLIN MICROBIOL INFEC, V15, P571, DOI 10.1111/j.1469-0691.2009.02742.x; Conza L, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-49; Danon M, 2008, FEMS MICROBIOL ECOL, V65, P133, DOI 10.1111/j.1574-6941.2008.00506.x; Declerck P, 2007, WATER RES, V41, P3159, DOI 10.1016/j.watres.2007.04.011; den Boer JW, 2007, CLIN MICROBIOL INFEC, V13, P88, DOI 10.1111/j.1469-0691.2006.01562.x; DENNIS PJ, 1988, J APPL BACTERIOL, V65, P135, DOI 10.1111/j.1365-2672.1988.tb01501.x; DENNIS PJL, 1984, J HYG-CAMBRIDGE, V93, P349, DOI 10.1017/S0022172400064901; Descours G, 2012, J CLIN MICROBIOL, V50, P1725, DOI 10.1128/JCM.06531-11; Dey R, 2009, FEMS MICROBIOL LETT, V290, P10, DOI 10.1111/j.1574-6968.2008.01387.x; FLIERMANS CB, 1981, APPL ENVIRON MICROB, V41, P9, DOI 10.1128/AEM.41.1.9-16.1981; Fracchia L, 2006, J APPL MICROBIOL, V100, P973, DOI 10.1111/j.1365-2672.2006.02846.x; Gaia V, 2011, SYST APPL MICROBIOL, V34, P40, DOI 10.1016/j.syapm.2010.11.007; Greub G, 2004, CLIN MICROBIOL REV, V17, P413, DOI 10.1128/CMR.17.2.413-433.2004; Helbig JH, 2002, EUR J CLIN MICROBIOL, V21, P710, DOI 10.1007/s10096-002-0820-3; Helbig JH, 1997, J CLIN MICROBIOL, V35, P2841, DOI 10.1128/JCM.35.11.2841-2845.1997; Hryhorczuk D, 2001, ANN AGR ENV MED, V8, P177; Joseph CA, 2010, EURO SURVEILL; La Scola B, 2001, J CLIN MICROBIOL, V39, P365, DOI 10.1128/JCM.39.1.365-366.2001; Lin H, 2009, J APPL MICROBIOL, V106, P606, DOI 10.1111/j.1365-2672.2008.04031.x; Nguyen TMN, 2006, J INFECT DIS, V193, P102, DOI 10.1086/498575; Ratcliff RM, 1998, J CLIN MICROBIOL, V36, P1560, DOI 10.1128/JCM.36.6.1560-1567.1998; RODRIGUEZZARAGOZA S, 1994, CRIT REV MICROBIOL, V20, P225, DOI 10.3109/10408419409114556; ROWBOTHAM TJ, 1983, J CLIN PATHOL, V36, P978, DOI 10.1136/jcp.36.9.978; Sanchez-Monedero MA, 2005, J AIR WASTE MANAGE, V55, P612, DOI 10.1080/10473289.2005.10464652; Schuster FL, 2002, CLIN MICROBIOL REV, V15, P342, DOI 10.1128/CMR.15.3.342-354.2002; STEELE TW, 1990, APPL ENVIRON MICROB, V56, P2984, DOI 10.1128/AEM.56.10.2984-2988.1990; Storey MV, 2004, SCAND J INFECT DIS, V36, P656, DOI 10.1080/00365540410020785; Taha MPM, 2005, WASTE MANAGE, V25, P445, DOI 10.1016/j.wasman.2005.02.013; Thomas V, 2006, APPL ENVIRON MICROB, V72, P2428, DOI 10.1128/AEM.72.4.2428-2438.2006	33	37	38	1	60	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2013	8	7							e68244	10.1371/journal.pone.0068244	http://dx.doi.org/10.1371/journal.pone.0068244			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176XV	23844174	gold, Green Published, Green Submitted			2023-01-03	WOS:000321341000146
J	Kim, JJ; Cho, HW; Park, HR; Jung, U; Jo, SK; Yee, ST				Kim, Jong-Jin; Cho, Hyun Wook; Park, Hae-Ran; Jung, Uhee; Jo, Sung-Kee; Yee, Sung-Tae			Preventative Effect of an Herbal Preparation (HemoHIM) on Development of Airway Inflammation in Mice via Modulation of Th1/2 Cells Differentiation	PLOS ONE			English	Article							ENDOCRINE DISRUPTORS; TH2 POLARIZATION; MOUSE MODEL; T-CELLS; ASTHMA; HYPERRESPONSIVENESS; SUPPRESSION; INHIBITION; RESPONSES; EXTRACT	HemoHIM, an herbal preparation of three edible herbs (Angelica gigas Nakai, Cnidium officinale Makino, Paeonia japonica Miyabe) is known to increase the Th1 immune response as well as reduce the allergic response in human mast cells. Here, our goal was to determine whether or not HemoHIM could induce Th1 cell differentiation as well as inhibit the development of airway inflammation. To study Th1/Th2 cell differentiation, naive CD4(+) T cells isolated from C57BL/6 mouse spleens were cultured with or without HemoHIM. To examine airway inflammation, C57BL/6 mice were fed HemoHIM for 4 weeks before sensitization and provocation with ovalbumin (OVA). In an in vitro experiment, naive CD4(+) T cells displayed increased Th1 (IFN-gamma(+) cell) as well as decreased Th2 (IL-4(+) cell) differentiation in a HemoHIM concentration-dependent manner. Furthermore, in an airway inflammation mice model, eosinophil numbers in BALF, serum levels of OVA-specific IgE and IgG1, and cytokine (IL-4, IL-5, and IL-13) levels in BALF and the supernatant of splenocytes all decreased upon HemoHIM (100 mg/kg body weight) pretreatment (4 weeks). These results show that HemoHIM attenuated allergic airway inflammation in the mouse model through regulation of the Th1/Th2 balance.	[Kim, Jong-Jin; Cho, Hyun Wook; Yee, Sung-Tae] Sunchon Natl Univ, Dept Biol, Sunchon, South Korea; [Park, Hae-Ran; Jung, Uhee; Jo, Sung-Kee] Korea Atom Energy Res Inst KAERI, Radiat Res Div Biotechnol, Adv Radiat Technol Inst, Jeongeup, South Korea; [Yee, Sung-Tae] Sunchon Natl Univ, Dept Pharm, Sunchon, South Korea	Sunchon National University; Korea Atomic Energy Research Institute (KAERI); Sunchon National University	Yee, ST (corresponding author), Sunchon Natl Univ, Dept Biol, Sunchon, South Korea.	sungtae@sunchon.ac.kr		Kim, Jong-Jin/0000-0002-1810-5383	creative research project; Korea Atomic Energy Research Institute, Korea [KAERI 527910-12]	creative research project; Korea Atomic Energy Research Institute, Korea	This work was supported by a creative research project funded from Korea Atomic Energy Research Institute, Korea (KAERI 527910-12)(http://www.kaeri.re.kr/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; Denes A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.86; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; HAN Rui, 2009, Zhejiang Da Xue Xue Bao Yi Xue Ban, V38, P352; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Iwata M, 2004, IMMUNOL LETT, V94, P135, DOI 10.1016/j.imlet.2004.04.013; Jo SK, 2007, PHYTOTHER RES, V21, P625, DOI 10.1002/ptr.2068; Kato T, 2006, EUR J IMMUNOL, V36, P1199, DOI 10.1002/eji.200535140; Kato T, 2004, EUR J IMMUNOL, V34, P1312, DOI 10.1002/eji.200324667; Kim CK, 2010, RESP MED, V104, P1436, DOI 10.1016/j.rmed.2010.03.023; Kim JJ, 2009, J LIFE SCI, V12, P1808; Kim SH, 2009, J MED FOOD, V12, P1353, DOI 10.1089/jmf.2008.1322; Mahajan SG, 2011, EUR J PHARMACOL, V650, P458, DOI 10.1016/j.ejphar.2010.09.075; Meyts I, 2006, J IMMUNOL, V177, P6460, DOI 10.4049/jimmunol.177.9.6460; Miyaura H, 2002, J IMMUNOL, V168, P1087, DOI 10.4049/jimmunol.168.3.1087; Natarajan S, 2008, J IMMUNOL, V181, P8402, DOI 10.4049/jimmunol.181.12.8402; Nemzek JA, 2009, COMPARATIVE MED, V59, P321; Oh SW, 2011, J ETHNOPHARMACOL, V136, P414, DOI 10.1016/j.jep.2010.07.026; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Palmqvist C, 2007, BRIT J PHARMACOL, V151, P725, DOI 10.1038/sj.bjp.0707263; Park HR, 2008, PHYTOTHER RES, V22, P36, DOI 10.1002/ptr.2255; Park HR, 2012, RADIAT RES, V177, P676, DOI 10.1667/RR2768.1; Park HR, 2010, J MED FOOD, V13, P47, DOI 10.1089/jmf.2009.1049; Park HR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-85; Saito K, 2008, J IMMUNOL, V181, P6889, DOI 10.4049/jimmunol.181.10.6889; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; Tada-Oikawa S, 2008, BIOCHEM PHARMACOL, V75, P552, DOI 10.1016/j.bcp.2007.09.011; Torii M, 2010, EUR J IMMUNOL, V40, P787, DOI 10.1002/eji.200939724; Yang EJ, 2011, J ETHNOPHARMACOL, V136, P422, DOI 10.1016/j.jep.2010.05.066; Yang EJ, 2011, PHYTOTHER RES, V25, P59, DOI 10.1002/ptr.3220; Yu J, 2010, ALLERGY ASTHMA IMMUN, V2, P199, DOI 10.4168/aair.2010.2.3.199	31	11	13	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2013	8	7							e68552	10.1371/journal.pone.0068552	http://dx.doi.org/10.1371/journal.pone.0068552			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176XV	23844220	gold, Green Published, Green Submitted			2023-01-03	WOS:000321341000172
J	Lacombe, A; Li, RW; Klimis-Zacas, D; Kristo, AS; Tadepalli, S; Krauss, E; Young, R; Wu, VCH				Lacombe, Alison; Li, Robert W.; Klimis-Zacas, Dorothy; Kristo, Aleksandra S.; Tadepalli, Shravani; Krauss, Emily; Young, Ryan; Wu, Vivian C. H.			Lowbush Wild Blueberries Have the Potential to Modify Gut Microbiota and Xenobiotic Metabolism in the Rat Colon	PLOS ONE			English	Article							DIET VACCINIUM-ANGUSTIFOLIUM; POLYPHENOLS; ANTHOCYANINS; IMPROVEMENTS; COMPONENTS; PROBIOTICS; SEVERITY; BACTERIA; MODEL; FATE	The gastrointestinal tract is populated by an array of microbial species that play an important role in metabolic and immune functions. The composition of microorganisms is influenced by the components of the host's diet and can impact health. In the present study, dietary enrichment of lowbush wild blueberries (LWB) was examined to determine their effect on colon microbial composition and their potential in promoting gut health. The microbial composition and functional potential of the colon microbiota from Sprague Dawley rats fed control diets (AIN93) and LWB-enriched diets (AIN93+8% LWB powder substituting for dextrose) for 6 weeks were assessed using Illumina shotgun sequencing and bioinformatics tools. Our analysis revealed an alteration in the relative abundance of 3 phyla and 22 genera as representing approximately 14 and 8% of all phyla and genera identified, respectively. The LWB-enriched diet resulted in a significant reduction in the relative abundance of the genera Lactobacillus and Enterococcus. In addition, hierarchal analysis revealed a significant increase in the relative abundance of the phylum Actinobacteria, the order Actinomycetales, and several novel genera under the family Bifidobacteriaceae and Coriobacteriaceae, in the LWB group. Functional annotation of the shotgun sequences suggested that approximately 9% of the 4709 Kyoto Encyclopaedia of Gene and Genome (KEGG) hits identified were impacted by the LWB-diet. Open Reading Frames (ORFs) assigned to KEGG category xenobiotics biodegradation and metabolism were significantly greater in the LWB-enriched diet compared to the control and included the pathway for benzoate degradation [PATH:ko00362] and glycosaminoglycan degradation [PATH:ko00531]. Moreover, the number of ORFs assigned to the bacterial invasion of epithelial cells [PATH:ko05100] pathway was approximately 8 fold lower in the LWB group compared to controls. This study demonstrated that LWBs have the potential to promote gut health and can aid in the development of optimal diets.	[Lacombe, Alison; Klimis-Zacas, Dorothy; Kristo, Aleksandra S.; Tadepalli, Shravani; Krauss, Emily; Wu, Vivian C. H.] Univ Maine, Dept Food Sci & Human Nutr, Orono, ME USA; [Li, Robert W.] ARS, USDA, BARC, Bovine Funct Genom Lab, Beltsville, MD USA; [Young, Ryan] Univ Maine, Dept Mol & Biomed Sci, Orono, ME USA	University of Maine System; University of Maine Orono; United States Department of Agriculture (USDA); University of Maine System; University of Maine Orono	Wu, VCH (corresponding author), Univ Maine, Dept Food Sci & Human Nutr, Orono, ME USA.	vivian.wu@umit.maine.edu	Kristo, Aleksandra/AHC-3770-2022	Kristo, Aleksandra S./0000-0002-0733-4041; Wu, Vivian C.H./0000-0002-1525-1078	USDA ARS, and USDA National Needs Graduate Fellowship [2007-38420-17764]; UMaine Center for Excellence in Teaching and Assessment Active Student Learning Micro-Grants; Maine Agricultural and Forest Experiment Station at the University of Maine; Hatch from the USDA National Institute of Food and Agriculture [ME08562-10]	USDA ARS, and USDA National Needs Graduate Fellowship; UMaine Center for Excellence in Teaching and Assessment Active Student Learning Micro-Grants; Maine Agricultural and Forest Experiment Station at the University of Maine; Hatch from the USDA National Institute of Food and Agriculture	This research was supported by USDA ARS, and USDA National Needs Graduate Fellowship Competitive (award #:2007-38420-17764), UMaine Center for Excellence in Teaching and Assessment Active Student Learning Micro-Grants, and the Maine Agricultural and Forest Experiment Station at the University of Maine. This work is based upon research supported in part by Hatch (Grant number ME08562-10) from the USDA National Institute of Food and Agriculture. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson DI, 2011, FEMS MICROBIOL REV, V35, P901, DOI 10.1111/j.1574-6976.2011.00289.x; [Anonymous], J ANTIBIOT, V49, P560; Barnett AM, 2012, FOOD FUNCT, V3, P690, DOI 10.1039/c2fo30017f; Bo Liu TG, 2010, METAPHYLER TAXONOMIC; Cani PD, 2011, PHARMACOL THERAPEUT, V130, P202, DOI 10.1016/j.pharmthera.2011.01.012; Claus SP, 2011, MBIO, V2, DOI 10.1128/mBio.00271-10; Conterno L, 2011, GENES NUTR, V6, P241, DOI 10.1007/s12263-011-0230-1; Cox MP, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-485; Del Bo' C, 2012, NUTR METAB CARDIOVAS, V22, P127, DOI 10.1016/j.numecd.2010.05.004; Del Bo C, 2010, MUTAT RES-GEN TOX EN, V703, P158, DOI 10.1016/j.mrgentox.2010.08.013; Del Bo C, 2010, J AGR FOOD CHEM, V58, P2491, DOI 10.1021/jf903472x; Gerth K, 1996, J ANTIBIOT, V49, P560, DOI 10.7164/antibiotics.49.560; Gonzalez-Barrio R, 2011, DRUG METAB DISPOS, V39, P1680, DOI 10.1124/dmd.111.039651; Haiser HJT, 2012, PHARM RES, V11; Hakansson AB, 2012, PLOS ONE, V7, P14; Hakansson A, 2009, SCAND J GASTROENTERO, V44, P1213, DOI 10.1080/00365520903171268; Hardoim PR, 2011, FEMS MICROBIOL ECOL, V77, P154, DOI 10.1111/j.1574-6941.2011.01092.x; Harmsen HJM, 2000, APPL ENVIRON MICROB, V66, P4523, DOI 10.1128/AEM.66.10.4523-4527.2000; Hidalgo M, 2012, J AGR FOOD CHEM, V60, P3882, DOI 10.1021/jf3002153; Huang LP, 2011, J CHEM TECHNOL BIOT, V86, P481, DOI 10.1002/jctb.2551; Imhoff JF, 2010, PHOTOSYNTH RES, V104, P123, DOI 10.1007/s11120-009-9510-7; Jin JS, 2010, INT J SYST EVOL MICR, V60, P1721, DOI 10.1099/ijs.0.016774-0; Juskiewicz J, 2011, NUTRITION, V27, P351, DOI 10.1016/j.nut.2010.02.002; Kahle K, 2006, MOL NUTR FOOD RES, V50, P418, DOI 10.1002/mnfr.200500211; Kemperman RA, 2010, MICROBIOL-SGM, V156, P3224, DOI 10.1099/mic.0.042127-0; Keppler K, 2005, BIOORGAN MED CHEM, V13, P5195, DOI 10.1016/j.bmc.2005.05.003; Kiely PD, 2011, BIORESOURCE TECHNOL, V102, P361, DOI 10.1016/j.biortech.2010.05.017; Kristo AS, 2010, J AGR FOOD CHEM, V58, P11600, DOI 10.1021/jf101839u; Lamendella R, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-103; Langmead Ben, 2010, Curr Protoc Bioinformatics, VChapter 11, DOI 10.1002/0471250953.bi1107s32; Laparra JM, 2010, PHARMACOL RES, V61, P219, DOI 10.1016/j.phrs.2009.11.001; Le Roes-Hill M, 2011, ANTON LEEUW INT J G, V100, P589, DOI 10.1007/s10482-011-9614-x; le Roes-Hill M, 2011, APPL BIOCHEM BIOTECH, V164, P681, DOI 10.1007/s12010-011-9167-5; Leon-Tejera H, 2011, FOTTEA, V11, P235, DOI 10.5507/fot.2011.022; Li RW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024417; Martinez I, 2009, APPL ENVIRON MICROB, V75, P4175, DOI 10.1128/AEM.00380-09; Milbury PEK, 2010, J AGR FOOD CHEM, V58, P6; Molan AL, 2009, WORLD J MICROB BIOT, V25, P1243, DOI 10.1007/s11274-009-0011-9; Molan AL, 2010, WORLD J MICROB BIOT, V26, P1735, DOI 10.1007/s11274-010-0352-4; Monagas M, 2010, FOOD FUNCT, V1, P233, DOI 10.1039/c0fo00132e; Osman N, 2008, DIGEST DIS SCI, V53, P2464, DOI 10.1007/s10620-007-0174-x; Paturi G, 2012, NUTRITION, V28, P324, DOI 10.1016/j.nut.2011.07.018; Pezzoni M, 2011, J BASIC MICROB, V51, P325, DOI 10.1002/jobm.201000223; Poetsch A, 2011, PROTEOMICS, V11, P3244, DOI 10.1002/pmic.201000786; Possemiers S, 2011, FITOTERAPIA, V82, P53, DOI 10.1016/j.fitote.2010.07.012; Rastmanesh R, 2011, CHEM-BIOL INTERACT, V189, P1, DOI 10.1016/j.cbi.2010.10.002; Reeves PG, 1997, J NUTR, V127, pS838; Rho MN, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq747; Saad R, 2012, GUT PATHOG, V4, DOI 10.1186/1757-4749-4-16; Sarethy IP, 2011, J IND MICROBIOL BIOT, V38, P769, DOI 10.1007/s10295-011-0968-x; Scott KP, 2011, P NATL ACAD SCI USA, V108, P4672, DOI 10.1073/pnas.1000091107; Selma MV, 2009, J AGR FOOD CHEM, V57, P6485, DOI 10.1021/jf902107d; Serafini M, 2010, P NUTR SOC, V69, P273, DOI 10.1017/S002966511000162X; Silbaq FS, 2009, J APPL MICROBIOL, V106, P106, DOI 10.1111/j.1365-2672.2008.03981.x; Tokiwa Y, 2006, APPL MICROBIOL BIOT, V72, P244, DOI 10.1007/s00253-006-0488-1; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; van Dorsten FA, 2010, MOL NUTR FOOD RES, V54, P897, DOI 10.1002/mnfr.200900212; van Duynhoven J, 2011, P NATL ACAD SCI USA, V108, P4531, DOI 10.1073/pnas.1000098107; van Duynhoven J, 2009, MAGNETIC RESONANCE IN FOOD SCIENCE: CHALLENGES IN A CHANGING WORLD, P20; Vendrame S, 2013, J NUTR BIOC IN PRESS; Vendrame S, 2011, J AGR FOOD CHEM, V59, P12815, DOI 10.1021/jf2028686; Vieira-Silva S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000808; White MA, 2009, PLOS GENET, V5, P12; Wishon LM, 2010, MILCHWISSENSCHAFT, V65, P369	64	55	58	3	61	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e67497	10.1371/journal.pone.0067497	http://dx.doi.org/10.1371/journal.pone.0067497			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IH	23840722	Green Submitted, Green Published, gold			2023-01-03	WOS:000321148400092
J	Mulcahy, A; Harris, K; Finegold, K; Kellermann, A; Edelman, L; Sommers, BD				Mulcahy, Andrew; Harris, Katherine; Finegold, Kenneth; Kellermann, Arthur; Edelman, Laurel; Sommers, Benjamin D.			Insurance Coverage of Emergency Care for Young Adults under Health Reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; ACT; ECONOMICS; POLICIES; ACCESS	BACKGROUND The Affordable Care Act (ACA) established nationwide eligibility for young adults 19 to 25 years of age to retain coverage under their parents' private health plans. We conducted a study to determine how the implementation of this provision changed rates of insurance coverage for young adults seeking medical care for major emergencies. METHODS We evaluated more than 480,000 nondiscretionary visits made to emergency departments from 2009 through 2011, as recorded in a large, geographically diverse data set of hospital claims, to estimate how the ACA provision affected private insurance coverage of such visits by young adults (19 to 25 years of age). To adjust for underlying trends in insurance coverage, we compared changes in the target age group with changes among adults 26 to 31 years of age, who were unaffected by the provision (control group). RESULTS After the ACA provision took effect, private coverage of nondiscretionary visits to emergency departments by young adults increased by 3.1 percentage points (95% confidence interval [CI], 2.3 to 3.9; relative increase, 5.2%; P<0.001), as compared with similar visits in the control group. The percentage of visits by uninsured young adults also fell significantly (-1.7 percentage points; 95% CI, -2.8 to -0.7; relative decrease, 9.1%; P<0.001). The rates of nondiscretionary visits that were covered by Medicaid or other nonprivate insurers remained relatively steady throughout the study period. The coverage expansion led to an estimated 22,072 visits to emergency departments by newly insured young adults and $147 million in associated costs that were covered by private insurance plans during a 1-year period. CONCLUSIONS Enactment of the dependent-coverage provision was associated with a significant increase in the proportion of young adults who were protected from the financial consequences of a serious medical emergency.	[Mulcahy, Andrew; Harris, Katherine; Kellermann, Arthur] RAND, Arlington, VA USA; [Finegold, Kenneth; Sommers, Benjamin D.] Off Assistant Secretary Planning & Evaluat, Dept Hlth & Human Serv, Washington, DC USA; [Edelman, Laurel] IMS Hlth, Plymouth Meeting, PA USA; [Sommers, Benjamin D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	RAND Corporation; Harvard University; Harvard T.H. Chan School of Public Health	Mulcahy, A (corresponding author), 1200 S Hayes St, Arlington, VA 22202 USA.	amulcahy@rand.org			Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services [HHSP23320095649WC]	Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services	Funded by the Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services.; Supported by a contract with the Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services (HHSP23320095649WC).	[Anonymous], 2009, NAT EM DEP SAMPL; [Anonymous], 2009, ANN SURV DAT FISC YE; Antwi YA, 2012, EFFECTS FEDERAL POLI; Bureau of Labor Statistics, LAB FORC STAT CURR P; Callahan ST, 2005, PEDIATRICS, V116, P88, DOI 10.1542/peds.2004-1449; Cantor JC, 2012, HEALTH SERV RES, V47, P1773, DOI 10.1111/j.1475-6773.2012.01458.x; DeNavas-Walt C., 2012, INCOME POVERTY HLTH; DeNavas-Walt C., 2009, INCOME POVERTY HLTH; Hadley J, 2008, HEALTH AFFAIR, V27, pW399, DOI 10.1377/hlthaff.27.5.w399; Hsia RY, 2011, JAMA-J AM MED ASSOC, V305, P1978, DOI 10.1001/jama.2011.620; Institute of Medicine Committee on the Consequences of Uninsurance, 2002, HLTH INS IS FAM MATT; Institute of Medicine (US) Committee on the Consequences of Uninsurance, 2001, COV MATT INS HLTH CA; Levine PB, 2011, AM ECON J-ECON POLIC, V3, P129, DOI 10.1257/pol.3.1.129; MANNING WG, 1987, AM ECON REV, V77, P251; MEYER BD, 1995, J BUS ECON STAT, V13, P151, DOI 10.2307/1392369; Monheit AC, 2011, HEALTH SERV RES, V46, P251, DOI 10.1111/j.1475-6773.2010.01200.x; National Conference of State Legislatures, COV YOUNG AD THEIR P; Nicholson JL, 2009, RITE PASSAGE WHY YOU; PAULY MV, 1968, AM ECON REV, V58, P531; Sommers BD, 2011, 2 5 MILLION YOUNG AD; Sommers BD, 2012, NUMBER YOUNG ADULTS; Sommers BD, 2013, HEALTH AFFAIR, V32, P165, DOI 10.1377/hlthaff.2012.0552; Sommers BD, 2012, JAMA-J AM MED ASSOC, V307, P913, DOI 10.1001/jama.307.9.913; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112	24	67	67	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	2013	368	22					2105	2112		10.1056/NEJMsa1212779	http://dx.doi.org/10.1056/NEJMsa1212779			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	153AT	23718165	Green Published			2023-01-03	WOS:000319574200008
J	Loporto, M; Holmes, PS; Wright, DJ; McAllister, CJ				Loporto, Michela; Holmes, Paul S.; Wright, David J.; McAllister, Craig J.			Reflecting on Mirror Mechanisms: Motor Resonance Effects during Action Observation Only Present with Low-Intensity Transcranial Magnetic Stimulation	PLOS ONE			English	Article							VENTRAL PREMOTOR CORTEX; EXCITABILITY; FACILITATION; SYSTEM; BRAIN; MODULATION; IMITATION; MUSCLES; IMAGERY; PULSE	Transcranial magnetic stimulation (TMS) studies indicate that the observation of other people's actions influences the excitability of the observer's motor system. Motor evoked potential (MEP) amplitudes typically increase in muscles which would be active during the execution of the observed action. This 'motor resonance' effect is thought to result from activity in mirror neuron regions, which enhance the excitability of the primary motor cortex (M1) via cortico-cortical pathways. The importance of TMS intensity has not yet been recognised in this area of research. Low-intensity TMS predominately activates corticospinal neurons indirectly, whereas high-intensity TMS can directly activate corticospinal axons. This indicates that motor resonance effects should be more prominent when using low-intensity TMS. A related issue is that TMS is typically applied over a single optimal scalp position (OSP) to simultaneously elicit MEPs from several muscles. Whether this confounds results, due to differences in the manner that TMS activates spatially separate cortical representations, has not yet been explored. In the current study, MEP amplitudes, resulting from single-pulse TMS applied over M1, were recorded from the first dorsal interosseous (FDI) and abductor digiti minimi (ADM) muscles during the observation of simple finger abductions. We tested if the TMS intensity (110% vs. 130% resting motor threshold) or stimulating position (FDI-OSP vs. ADM-OSP) influenced the magnitude of the motor resonance effects. Results showed that the MEP facilitation recorded in the FDI muscle during the observation of index-finger abductions was only detected using low-intensity TMS. In contrast, changes in the OSP had a negligible effect on the presence of motor resonance effects in either the FDI or ADM muscles. These findings support the hypothesis that MN activity enhances M1 excitability via cortico-cortical pathways and highlight a methodological framework by which the neural underpinnings of action observation can be further explored.	[Loporto, Michela; Holmes, Paul S.] Manchester Metropolitan Univ, Inst Performance Res, Manchester M15 6BH, Lancs, England; [Wright, David J.] Univ Roehampton, Dept Life Sci, London, England; [McAllister, Craig J.] Aston Univ, Aston Brain Ctr, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England	Manchester Metropolitan University; Roehampton University; Aston University	Loporto, M (corresponding author), Manchester Metropolitan Univ, Inst Performance Res, Manchester M15 6BH, Lancs, England.	p.s.holmes@mmu.ac.uk		Holmes, Paul/0000-0003-0821-3580; Wright, David/0000-0001-9568-0237; McAllister, Craig/0000-0002-2972-039X	Government of Malta	Government of Malta	This work was partly funded by the Government of Malta. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Aglioti SM, 2008, NAT NEUROSCI, V11, P1109, DOI 10.1038/nn.2182; Alaerts K, 2009, CORTEX, V45, P1148, DOI 10.1016/j.cortex.2008.10.005; Alaerts K, 2009, NEUROPSYCHOLOGIA, V47, P415, DOI 10.1016/j.neuropsychologia.2008.09.012; Avenanti A, 2007, CURR BIOL, V17, P2129, DOI 10.1016/j.cub.2007.11.045; BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Caspers S, 2010, NEUROIMAGE, V50, P1148, DOI 10.1016/j.neuroimage.2009.12.112; Celnik P, 2008, STROKE, V39, P1814, DOI 10.1161/STROKEAHA.107.508184; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Clark S, 2004, NEUROPSYCHOLOGIA, V42, P105, DOI 10.1016/S0028-3932(03)00144-1; Davare M, 2008, J PHYSIOL-LONDON, V586, P2735, DOI 10.1113/jphysiol.2008.152603; DAY BL, 1989, J PHYSIOL-LONDON, V412, P449, DOI 10.1113/jphysiol.1989.sp017626; Di Lazzaro V, 2004, CLIN NEUROPHYSIOL, V115, P255, DOI 10.1016/j.clinph.2003.10.009; Di Lazzaro V, 2001, EXP BRAIN RES, V141, P121; Ertelt D, 2007, NEUROIMAGE, V36, pT164, DOI 10.1016/j.neuroimage.2007.03.043; Fadiga L, 2005, CURR OPIN NEUROBIOL, V15, P213, DOI 10.1016/j.conb.2005.03.013; FADIGA L, 1995, J NEUROPHYSIOL, V73, P2608, DOI 10.1152/jn.1995.73.6.2608; Gallese V, 2004, TRENDS COGN SCI, V8, P396, DOI 10.1016/j.tics.2004.07.002; Gangitano M, 2004, EUR J NEUROSCI, V20, P2193, DOI 10.1111/j.1460-9568.2004.03655.x; Grezes J, 2001, HUM BRAIN MAPP, V12, P1, DOI 10.1002/1097-0193(200101)12:1<1::AID-HBM10>3.0.CO;2-V; Holmes P.S., 2007, BRIT J OCCUP THER, V70, P454, DOI [10.1177/030802260707001007, DOI 10.1177/030802260707001007]; JEANNEROD M, 1994, BEHAV BRAIN SCI, V17, P187, DOI 10.1017/S0140525X00034026; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P250, DOI 10.1016/S1388-2457(00)00513-7; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Koch G, 2007, J NEUROSCI, V27, P6815, DOI 10.1523/JNEUROSCI.0598-07.2007; Koch G, 2010, NEUROPSYCHOLOGIA, V48, P3513, DOI 10.1016/j.neuropsychologia.2010.07.037; Labruna L, 2011, BRAIN STIMUL, V4, P152, DOI 10.1016/j.brs.2010.09.010; Loporto M, 2011, J MOTOR BEHAV, V43, P361, DOI 10.1080/00222895.2011.604655; Melgari JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003069; MILLS KR, 1992, ELECTROEN CLIN NEURO, V85, P17, DOI 10.1016/0168-5597(92)90096-T; Montagna M, 2005, EUR J NEUROSCI, V22, P1513, DOI 10.1111/j.1460-9568.2005.04336.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Rizzolatti G, 2001, NAT REV NEUROSCI, V2, P661, DOI 10.1038/35090060; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; Romani M, 2005, NEUROIMAGE, V26, P755, DOI 10.1016/j.neuroimage.2005.02.027; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Sanes JN, 2000, ANNU REV NEUROSCI, V23, P393, DOI 10.1146/annurev.neuro.23.1.393; Shimazu H, 2004, J NEUROSCI, V24, P1200, DOI 10.1523/JNEUROSCI.4731-03.2004; Urgesi C, 2006, EUR J NEUROSCI, V23, P2522, DOI 10.1111/j.1460-9568.2006.04772.x; Williams J, 2012, BEHAV BRAIN RES, V226, P369, DOI 10.1016/j.bbr.2011.09.014	39	35	35	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e64911	10.1371/journal.pone.0064911	http://dx.doi.org/10.1371/journal.pone.0064911			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155FM	23724104	Green Submitted, Green Published, gold, Green Accepted			2023-01-03	WOS:000319733000103
J	Lai, CH; Liu, XX; Tian, CL; Wu, FM				Lai, Chaohua; Liu, Xiaoxi; Tian, Changlin; Wu, Fangming			Integrin alpha 1 Has a Long Helix, Extending from the Transmembrane Region to the Cytoplasmic Tail in Detergent Micelles	PLOS ONE			English	Article							CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT; NMR; COMPLEX; DOMAIN; SUBUNIT; ACTIVATION; MECHANISM; BINDING	Integrin proteins are very important adhesion receptors that mediate cell-cell and cell-extracellular matrix interactions. They play essential roles in cell signaling and the regulation of cellular shape, motility, and the cell cycle. Here, the transmembrane and cytoplasmic (TMC) domains of integrin alpha 1 and beta 1 were over-expressed and purified in detergent micelles. The structure and backbone relaxations of alpha 1-TMC in LDAO micelles were determined and analyzed using solution NMR. A long helix, extending from the transmembrane region to the cytoplasmic tail, was observed in alpha 1-TMC. Structural comparisons of alpha 1-TMC with reported alpha IIb-TMC domains indicated different conformations in the transmembrane regions and cytoplasmic tails. An NMR titration experiment indicated weak interactions between alpha 1-TMC and beta 1-TMC through several alpha 1-TMC residues located at its N-terminal juxta-transmembrane region and C-terminal extended helix region.	[Lai, Chaohua; Liu, Xiaoxi; Tian, Changlin] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; [Lai, Chaohua; Liu, Xiaoxi; Tian, Changlin] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Tian, Changlin; Wu, Fangming] Chinese Acad Sci, High Field Magnet Lab, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS	Tian, CL (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China.	cltian@ustc.edu.cn; fmwu@hmfl.ac.cn	Tian, Changlin/P-1469-2014		Chinese National High-Tech Research Grant [2006AA02A321]; National Natural Science Foundation of China [30970577, 31100538]	Chinese National High-Tech Research Grant; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the Chinese National High-Tech Research Grant (2006AA02A321) and the National Natural Science Foundation of China (30970577) to CT, and the National Natural Science Foundation of China (31100538) to FW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abair TD, 2008, BLOOD, V112, P3242, DOI 10.1182/blood-2007-12-126433; Ahrens IG, 2006, EXP CELL RES, V312, P925, DOI 10.1016/j.yexcr.2005.11.036; Anthis NJ, 2011, TRENDS BIOCHEM SCI, V36, P191, DOI 10.1016/j.tibs.2010.11.002; Boehr DD, 2006, CHEM REV, V106, P3055, DOI 10.1021/cr050312q; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ekholm E, 2002, AM J PATHOL, V160, P1779, DOI 10.1016/S0002-9440(10)61124-8; Gardner H A, 1999, Curr Rheumatol Rep, V1, P28, DOI 10.1007/s11926-999-0021-5; Gottschalk KE, 2005, STRUCTURE, V13, P703, DOI 10.1016/j.str.2005.02.014; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Kalli AC, 2010, STRUCTURE, V18, P1280, DOI 10.1016/j.str.2010.07.012; Karpusas M, 2003, J MOL BIOL, V327, P1031, DOI 10.1016/S0022-2836(03)00203-1; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lau TL, 2008, J BIOL CHEM, V283, P16162, DOI 10.1074/jbc.M801748200; Lau TL, 2008, BIOCHEMISTRY-US, V47, P4008, DOI 10.1021/bi800107a; Lau TL, 2009, EMBO J, V28, P1351, DOI 10.1038/emboj.2009.63; Loster K, 2001, BIOCHEM J, V356, P233, DOI 10.1042/0264-6021:3560233; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Maltsev AS, 2012, BIOCHEMISTRY-US, V51, P631, DOI 10.1021/bi201435d; McBrien NA, 2006, INVEST OPHTH VIS SCI, V47, P4674, DOI 10.1167/iovs.05-1150; Metcalf DG, 2010, P NATL ACAD SCI USA, V107, P22481, DOI 10.1073/pnas.1015545107; Metcalf DG, 2009, J MOL BIOL, V392, P1087, DOI 10.1016/j.jmb.2009.06.032; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Rentala S, 2010, ASIAN J ANDROL, V12, P548, DOI 10.1038/aja.2010.20; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Shen Y, 2009, J BIOMOL NMR, V44, P213, DOI 10.1007/s10858-009-9333-z; Smerling C, 2007, EXP CELL RES, V313, P3153, DOI 10.1016/j.yexcr.2007.06.003; Suk JE, 2012, J AM CHEM SOC, V134, P9030, DOI 10.1021/ja304247f; Tulla M, 2001, J BIOL CHEM, V276, P48206, DOI 10.1074/jbc.M104058200; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Vossmeyer D, 2000, EXP CELL RES, V256, P321, DOI 10.1006/excr.2000.4831; Vossmeyer D, 2002, J BIOL CHEM, V277, P4636, DOI 10.1074/jbc.M105415200; Weigelt J, 1998, J AM CHEM SOC, V120, P10778, DOI 10.1021/ja982649y; Weljie AM, 2002, P NATL ACAD SCI USA, V99, P5878, DOI 10.1073/pnas.092515799; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yang J, 2009, P NATL ACAD SCI USA, V106, P17729, DOI 10.1073/pnas.0909589106; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200; Zhu J, 2009, MOL CELL, V34, P234, DOI 10.1016/j.molcel.2009.02.022	44	6	6	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62954	10.1371/journal.pone.0062954	http://dx.doi.org/10.1371/journal.pone.0062954			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23646163	gold, Green Published, Green Submitted			2023-01-03	WOS:000319077300117
J	Clond, MA; Lee, BS; Yu, JJ; Singer, MB; Amano, T; Lamb, AW; Drazin, D; Kateb, B; Ley, EJ; Yu, JS				Clond, Morgan A.; Lee, Bong-Seop; Yu, Jeffrey J.; Singer, Matthew B.; Amano, Takayuki; Lamb, Alexander W.; Drazin, Doniel; Kateb, Babak; Ley, Eric J.; Yu, John S.			Reactive Oxygen Species-Activated Nanoprodrug of Ibuprofen for Targeting Traumatic Brain Injury in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; VITAMIN-E; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION; PARKINSONS-DISEASE; UNITED-STATES; CARE-UNIT	Traumatic brain injury (TBI) is an enormous public health problem, with 1.7 million new cases of TBI recorded annually by the Centers for Disease Control. However, TBI has proven to be an extremely challenging condition to treat. Here, we apply a nanoprodrug strategy in a mouse model of TBI. The novel nanoprodrug contains a derivative of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen in an emulsion with the antioxidant a-tocopherol. The ibuprofen derivative, Ibu(2)TEG, contains a tetra ethylene glycol (TEG) spacer consisting of biodegradable ester bonds. The biodegradable ester bonds ensure that the prodrug molecules break down hydrolytically or enzymatically. The drug is labeled with the fluorescent reporter Cy5.5 using nonbiodegradable bonds to 1-octadecanethiol, allowing us to reliably track its accumulation in the brain after TBI. We delivered a moderate injury using a highly reproducible mouse model of closed-skull controlled cortical impact to the parietal region of the cortex, followed by an injection of the nanoprodrug at a dose of 0.2 mg per mouse. The blood brain barrier is known to exhibit increased permeability at the site of injury. We tested for accumulation of the fluorescent drug particles at the site of injury using confocal and bioluminescence imaging of whole brains and brain slices 36 hours after administration. We demonstrated that the drug does accumulate preferentially in the region of injured tissue, likely due to an enhanced permeability and retention (EPR) phenomenon. The use of a nanoprodrug approach to deliver therapeutics in TBI represents a promising potential therapeutic modality.	[Clond, Morgan A.; Singer, Matthew B.; Lamb, Alexander W.; Ley, Eric J.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Lee, Bong-Seop; Yu, Jeffrey J.; Amano, Takayuki; Drazin, Doniel; Kateb, Babak; Yu, John S.] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center	Yu, JS (corresponding author), Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA.	John.Yu@cshs.org		Yu, John/0000-0003-1230-8494; Clond, Morgan/0000-0002-3036-4193; Kateb, Babak/0000-0001-7546-7543	American Association for the Surgery of Trauma; Department of Health Services Division of Trauma Research	American Association for the Surgery of Trauma; Department of Health Services Division of Trauma Research	This study was sponsored by grants from the American Association for the Surgery of Trauma and the Department of Health Services Division of Trauma Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Afshari D, 2012, CLIN NEUROLOGY NEURO; [Anonymous], 1999, WISQARS YEARS POT LI; Bernardi A, 2012, INT J NANOMED, V7, P4927, DOI 10.2147/IJN.S35333; Bonina FP, 2001, EUR J PHARM SCI, V14, P123, DOI 10.1016/S0928-0987(01)00163-4; Botteri M, 2008, CRIT CARE MED, V36, P3089, DOI 10.1097/CCM.0b013e31818bd7df; BREITNER JCS, 1995, NEUROBIOL AGING, V16, P523, DOI 10.1016/0197-4580(95)00049-K; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; BURTON GW, 1982, LANCET, V2, P327; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chassidim Y, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-9; Chung ES, 2012, BRAIN RES, V1451, P110, DOI 10.1016/j.brainres.2012.02.058; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Cote S, 2012, ALZHEIMERS DEMENT, V8, P219, DOI 10.1016/j.jalz.2011.03.012; Dannhardt G, 2001, EUR J MED CHEM, V36, P109, DOI 10.1016/S0223-5234(01)01197-7; Faul M, 2010, TRAUMATIC BRAIN INJU, DOI DOI 10.15620/CDC.5571; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gilgun-Sherki Y, 2001, NEUROPHARMACOLOGY, V40, P959, DOI 10.1016/S0028-3908(01)00019-3; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; HALLIWELL B, 1989, ACTA NEUROL SCAND, V80, P23, DOI 10.1111/j.1600-0404.1989.tb01779.x; Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x; Hein AM, 2009, MOL NEUROBIOL, V40, P15, DOI 10.1007/s12035-009-8066-z; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Iadecola C, 2005, STROKE, V36, P182, DOI 10.1161/01.STR.0000153797.33611.d8; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Khaksari M, 2011, CAN J PHYSIOL PHARM, V89, P31, DOI [10.1139/Y10-103, 10.1139/y10-103]; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Langham J., 2003, COCHRANE DATABASE SY; Lee BS, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/980720; Lee BS, 2009, INT J PHARMACEUT, V372, P112, DOI 10.1016/j.ijpharm.2008.12.037; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lin Y, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/16/165101; LINDGREN S, 1966, RADIAT ENVIRON BIOPH, V3, P174, DOI DOI 10.1007/BF01191611; Liu ML, 2012, NEUROSCI LETT, V508, P31, DOI 10.1016/j.neulet.2011.12.010; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu WY, 1997, NEUROSURGERY, V41, P416, DOI 10.1097/00006123-199708000-00017; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Muehlschlegel S, 2009, NEUROCRIT CARE, V10, P103, DOI 10.1007/s12028-008-9133-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Niki E, 2004, ACCOUNTS CHEM RES, V37, P45, DOI 10.1021/ar030069m; Nogawa S, 1997, J NEUROSCI, V17, P2746; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pham LDD, 2012, GLIA, V60, P875, DOI 10.1002/glia.22320; Prabhakar U, 2013, CANCER RES, V73, P2412, DOI 10.1158/0008-5472.CAN-12-4561; Ravin R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039421; Rigotti A, 2007, MOL ASPECTS MED, V28, P423, DOI 10.1016/j.mam.2007.01.002; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sangiorgi S, 2013, J NEUROSURG, V118, P763, DOI 10.3171/2012.11.JNS12627; Sen AP, 2010, NEUROTHERAPEUTICS, V7, P91, DOI 10.1016/j.nurt.2009.10.014; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siskou IC, 2007, BIOORGAN MED CHEM, V15, P951, DOI 10.1016/j.bmc.2006.10.056; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; TAMMARA VK, 1993, PHARM RES-DORDR, V10, P1191, DOI 10.1023/A:1018976520391; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ, 2001, EPIDEMIOLOGY EC HEAD, P1193; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Viscomi MT, 2008, CEREBELLUM, V7, P401, DOI 10.1007/s12311-008-0042-z; Wallenquist U, 2012, RESTOR NEUROL NEUROS, V30, P9, DOI 10.3233/RNN-2011-0606; Warden SJ, 2010, PHYSICIAN SPORTSMED, V38, P132, DOI 10.3810/psm.2010.04.1770; Xu J, NATL VITAL STAT REPO, V58, P19; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	75	24	25	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2013	8	4							e61819	10.1371/journal.pone.0061819	http://dx.doi.org/10.1371/journal.pone.0061819			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136DE	23637912	Green Published, Green Submitted, gold			2023-01-03	WOS:000318340400053
J	Loggers, ET; Starks, H; Shannon-Dudley, M; Back, AL; Appelbaum, FR; Stewart, FM				Loggers, Elizabeth Trice; Starks, Helene; Shannon-Dudley, Moreen; Back, Anthony L.; Appelbaum, Frederick R.; Stewart, F. Marc			Implementing a Death with Dignity Program at a Comprehensive Cancer Center	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICIAN-ASSISTED SUICIDE; OREGON DEATH; ATTITUDES; EXPERIENCES; CARE; AID	BACKGROUND The majority of Death with Dignity participants in Washington State and Oregon have received a diagnosis of terminal cancer. As more states consider legislation regarding physician-assisted death, the experience of a comprehensive cancer center may be informative. METHODS We describe the implementation of a Death with Dignity program at Seattle Cancer Care Alliance, the site of care for the Fred Hutchinson-University of Washington Cancer Consortium, a comprehensive cancer center in Seattle that serves the Pacific Northwest. Institution-level data were compared with publicly available state-wide data from Oregon and Washington. RESULTS A total of 114 patients inquired about our Death with Dignity program between March 5, 2009, and December 31, 2011. Of these, 44 (38.6%) did not pursue the program, and 30 (26.3%) initiated the process but either elected not to continue or died before completion. Of the 40 participants who, after counseling and upon request, received a prescription for a lethal dose of secobarbital (35.1% of the 114 patients who inquired about the program), all died, 24 after medication ingestion (60% of those obtaining prescriptions). The participants at our center accounted for 15.7% of all participants in the Death with Dignity program in Washington (255 persons) and were typically white, male, and well educated. The most common reasons for participation were loss of autonomy (97.2%), inability to engage in enjoyable activities (88.9%), and loss of dignity (75.0%). Eleven participants lived for more than 6 months after prescription receipt. Qualitatively, patients and families were grateful to receive the lethal prescription, whether it was used or not. CONCLUSIONS Overall, our Death with Dignity program has been well accepted by patients and clinicians.	[Loggers, Elizabeth Trice; Appelbaum, Frederick R.; Stewart, F. Marc] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; [Loggers, Elizabeth Trice] Univ Washington, Grp Hlth Res Inst, Seattle, WA 98195 USA; [Loggers, Elizabeth Trice; Shannon-Dudley, Moreen; Back, Anthony L.; Appelbaum, Frederick R.; Stewart, F. Marc] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Cancer Care Alliance; University of Washington; University of Washington Seattle	Loggers, ET (corresponding author), 825 Eastlake Ave E, Seattle, WA 98109 USA.	eloggers@seattlecca.org		Loggers, Elizabeth/0000-0003-3432-0443	University of Washington Palliative Care Center of Excellence	University of Washington Palliative Care Center of Excellence	We thank Barbara Glidewell, M.B.S., C.E.C., former patient relations director, ombudsman, and assistant professor, Oregon Health and Science University (OHSU), and Linda Ganzini, M.D., M.P.H., professor of psychiatry and medicine, OHSU, for their consultation and expertise early in the formation of our Death with Dignity program; Danika Kubota for her administrative assistance; and the University of Washington Palliative Care Center of Excellence for its support.	Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Dobscha Steven K, 2004, J Palliat Med, V7, P451, DOI 10.1089/1096621041349374; Ganzini L, 2000, NEW ENGL J MED, V342, P1538; Ganzini L, 1996, AM J PSYCHIAT, V153, P1469; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Ganzini L, 1997, NEW ENGL J MED, V336, P1824, DOI 10.1056/NEJM199706193362511; Ganzini L, 2001, JAMA-J AM MED ASSOC, V285, P2363, DOI 10.1001/jama.285.18.2363; Ganzini L, 2008, J GEN INTERN MED, V23, P154, DOI 10.1007/s11606-007-0476-x; Ganzini L, 2009, J PAIN SYMPTOM MANAG, V38, P807, DOI 10.1016/j.jpainsymman.2009.04.026; Ganzini L, 2009, ARCH INTERN MED, V169, P489, DOI 10.1001/archinternmed.2008.579; Ganzini L, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1682; Hafner K., 2012, NY TIMES, pA1; Hawaii State Legislature, REL DEATH DIGN; Smith KA, 2011, J PALLIAT MED, V14, P445, DOI 10.1089/jpm.2010.0425; Starks H, 2005, J PAIN SYMPTOM MANAG, V30, P215, DOI 10.1016/j.jpainsymman.2005.03.012; State and County QuickFacts, 2012, CODATA DER POP EST A; State of Vermont, 2011, ACT REL PAT CHOIC CO; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822	20	78	80	0	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	2013	368	15					1417	1424		10.1056/NEJMsa1213398	http://dx.doi.org/10.1056/NEJMsa1213398			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122QT	23574120				2023-01-03	WOS:000317333600009
J	Chheng, K; Carter, MJ; Emary, K; Chanpheaktra, N; Moore, CE; Stoesser, N; Putchhat, H; Sona, S; Reaksmey, S; Kitsutani, P; Sar, B; van Doorn, HR; Uyen, NH; Tan, LV; Paris, D; Blacksell, SD; Amornchai, P; Wuthiekanun, V; Parry, CM; Day, NPJ; Kumar, V				Chheng, Kheng; Carter, Michael J.; Emary, Kate; Chanpheaktra, Ngoun; Moore, Catrin E.; Stoesser, Nicole; Putchhat, Hor; Sona, Soeng; Reaksmey, Sin; Kitsutani, Paul; Sar, Borann; van Doorn, H. Rogier; Nguyen Hanh Uyen; Le Van Tan; Paris, Daniel; Blacksell, Stuart D.; Amornchai, Premjit; Wuthiekanun, Vanaporn; Parry, Christopher M.; Day, Nicholas P. J.; Kumar, Varun			A Prospective Study of the Causes of Febrile Illness Requiring Hospitalization in Children in Cambodia	PLOS ONE			English	Article							REAL-TIME PCR; SOUTHERN VIETNAM; CLINICAL-SAMPLES; RAPID DETECTION; MURINE TYPHUS; SCRUB TYPHUS; HEALTH-CARE; SIEM REAP; INFECTIONS; DIAGNOSIS	Background: Febrile illnesses are pre-eminent contributors to morbidity and mortality among children in South-East Asia but the causes are poorly understood. We determined the causes of fever in children hospitalised in Siem Reap province, Cambodia. Methods and Findings: A one-year prospective study of febrile children admitted to Angkor Hospital for Children, Siem Reap. Demographic, clinical, laboratory and outcome data were comprehensively analysed. Between October 12th 2009 and October 12th 2010 there were 1225 episodes of febrile illness in 1180 children. Median (IQR) age was 2.0 (0.8-6.4) years, with 850 (69%) episodes in children,5 years. Common microbiological diagnoses were dengue virus (16.2%), scrub typhus (7.8%), and Japanese encephalitis virus (5.8%). 76 (6.3%) episodes had culture-proven bloodstream infection, including Salmonella enterica serovar Typhi (22 isolates, 1.8%), Streptococcus pneumoniae (13, 1.1%), Escherichia coli (8, 0.7%), Haemophilus influenzae (7, 0.6%), Staphylococcus aureus (6, 0.5%) and Burkholderia pseudomallei (6, 0.5%). There were 69 deaths (5.6%), including those due to clinically diagnosed pneumonia (19), dengue virus (5), and melioidosis (4). 10 of 69 (14.5%) deaths were associated with culture-proven bloodstream infection in logistic regression analyses (odds ratio for mortality 3.4, 95% CI 1.6-6.9). Antimicrobial resistance was prevalent, particularly in S. enterica Typhi, (where 90% of isolates were resistant to ciprofloxacin, and 86% were multi-drug resistant). Comorbid undernutrition was present in 44% of episodes and a major risk factor for acute mortality (OR 2.1, 95% CI 1.1-4.2), as were HIV infection and cardiac disease. Conclusion: We identified a microbiological cause of fever in almost 50% of episodes in this large study of community-acquired febrile illness in hospitalized children in Cambodia. The range of pathogens, antimicrobial susceptibility, and comorbidities associated with mortality described will be of use in the development of rational guidelines for infectious disease treatment and control in Cambodia and South-East Asia.	[Chheng, Kheng; Chanpheaktra, Ngoun; Moore, Catrin E.; Putchhat, Hor; Sona, Soeng; Reaksmey, Sin; Kumar, Varun] Angkor Hosp Children, Siem Reap, Cambodia; [Carter, Michael J.; Emary, Kate; Moore, Catrin E.; Stoesser, Nicole; Paris, Daniel; Blacksell, Stuart D.; Amornchai, Premjit; Wuthiekanun, Vanaporn; Parry, Christopher M.; Day, Nicholas P. J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; [Emary, Kate; Moore, Catrin E.; Stoesser, Nicole; van Doorn, H. Rogier; Paris, Daniel; Blacksell, Stuart D.; Parry, Christopher M.; Day, Nicholas P. J.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England; [Carter, Michael J.] UCL, Inst Child Hlth, London, England; [van Doorn, H. Rogier; Nguyen Hanh Uyen; Le Van Tan] Univ Oxford, Clin Res Unit, Hosp Trop Dis, Ho Chi Minh City, Vietnam; [Kitsutani, Paul; Sar, Borann] US Ctr Dis Control & Prevent, Cambodia Off, Influenza Program, Phnom Penh, Cambodia	Mahidol Oxford Tropical Medicine Research Unit (MORU); Mahidol University; University of Oxford; University of London; University College London; University of Oxford	Carter, MJ (corresponding author), Angkor Hosp Children, Siem Reap, Cambodia.	michael.james.carter@gmail.com; varun@angkorhospital.org	Moore, Catrin/K-1980-2017; Paris, Daniel/GLN-7566-2022; van Doorn, H. Rogier/H-3080-2019; Blacksell, Stuart/D-5530-2018; Stoesser, Nicole/H-3421-2019; Paris, Daniel/AFV-4762-2022	Moore, Catrin/0000-0002-8639-9846; van Doorn, H. Rogier/0000-0002-9807-1821; Blacksell, Stuart/0000-0001-6576-726X; Stoesser, Nicole/0000-0002-4508-7969; Le Van, Tan/0000-0002-1791-3901; CARTER, Michael/0000-0003-3403-4746; PARIS, Daniel/0000-0003-4743-5987; , Varun/0000-0003-4976-6229	Wellcome Trust of Great Britain; Li Ka Shing-University of Oxford Global Health Programme; EMPERIE (European Management Platform for Emerging and Re-emerging Infectious Disease Entities); Influenza Division, US Centers for Communicable Disease Control as part of ongoing public health surveillance for severe acute respiratory infection; UK National Institute of Health Research through the University of Oxford; University College London	Wellcome Trust of Great Britain(Wellcome Trust); Li Ka Shing-University of Oxford Global Health Programme; EMPERIE (European Management Platform for Emerging and Re-emerging Infectious Disease Entities); Influenza Division, US Centers for Communicable Disease Control as part of ongoing public health surveillance for severe acute respiratory infection; UK National Institute of Health Research through the University of Oxford; University College London(General Electric)	This study was supported by the Wellcome Trust of Great Britain, the Li Ka Shing-University of Oxford Global Health Programme, EMPERIE (European Management Platform for Emerging and Re-emerging Infectious Disease Entities). Respiratory virus assays were supported by the Influenza Division, US Centers for Communicable Disease Control as part of ongoing public health surveillance for severe acute respiratory infection (PK and BS). UK National Institute of Health Research provided grants for academic clinical fellowships to KE and MJC through the University of Oxford, and University College London, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2005, HDB INT MAN CHILDH I; Baron EJ, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1; Becker JU, 2009, LANCET INFECT DIS, V9, P577, DOI 10.1016/S1473-3099(09)70135-5; Benschop K, 2008, J CLIN VIROL, V41, P69, DOI 10.1016/j.jcv.2007.10.004; Bhutta ZA, 2008, LANCET, V372, P972, DOI 10.1016/S0140-6736(08)61407-5; Blacksell SD, 2008, DIAGN MICR INFEC DIS, V60, P43, DOI 10.1016/j.diagmicrobio.2007.07.011; Blacksell SD, 2007, CLIN INFECT DIS, V44, P391, DOI 10.1086/510585; Blacksell SD, 2010, AM J TROP MED HYG, V83, P365, DOI 10.4269/ajtmh.2010.09-0534; Cardosa MJ, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-9; Chheng K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006630; Chhour YM, 2002, EMERG INFECT DIS, V8, P485, DOI 10.3201/eid0805.010236; Clinical and Laboratory Standards Institute, 2012, M100S22 CLIN LAB STA; de Jong MD, 2000, J CLIN MICROBIOL, V38, P2568, DOI 10.1128/JCM.38.7.2568-2573.2000; Deen J, 2012, LANCET INFECT DIS, V12, P480, DOI 10.1016/S1473-3099(12)70028-2; Echevarria JE, 1998, J CLIN MICROBIOL, V36, P1388; Emary K, 2012, T ROY SOC TROP MED H, V106, P718, DOI 10.1016/j.trstmh.2012.08.007; Gueudin M, 2003, J VIROL METHODS, V109, P39, DOI 10.1016/S0166-0934(03)00042-9; Henry KM, 2007, MOL CELL PROBE, V21, P17, DOI 10.1016/j.mcp.2006.06.002; Jiang J, 2004, AM J TROP MED HYG, V70, P351, DOI 10.4269/ajtmh.2004.70.351; KARRON RA, 1994, J CLIN MICROBIOL, V32, P484, DOI 10.1128/JCM.32.2.484-488.1994; Kasper MR, 2012, AM J TROP MED HYG, V86, P246, DOI 10.4269/ajtmh.2012.11-0409; Kasper MR, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-320; Le VT, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000854; Leelarasamee Amorn, 2004, Journal of the Medical Association of Thailand, V87, P464; Liu L, 2012, LANCET, V379, P2151, DOI 10.1016/S0140-6736(12)60560-1; National Institute of Statistics, 2011, CAMB DEM HLTH SURV 2; Pagnarith Y, 2010, AM J TROP MED HYG, V82, P1106, DOI 10.4269/ajtmh.2010.10-0030; Peacock SJ, 2008, T ROY SOC TROP MED H, V102, P5, DOI 10.1016/j.trstmh.2007.06.004; Phetsouvanh R, 2006, AM J TROP MED HYG, V75, P978; Punjabi NH, 2012, AM J TROP MED HYG, V86, P46, DOI 10.4269/ajtmh.2012.10-0497; Thaipadunpanit J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016236; Tran VTN, 2012, T ROY SOC TROP MED H, V106, P26, DOI 10.1016/j.trstmh.2011.10.004; Khanh TH, 2012, EMERG INFECT DIS, V18, P2002, DOI 10.3201/eid1812.120929; van Doornum GJJ, 2003, J CLIN MICROBIOL, V41, P576, DOI 10.1128/JCM.41.2.576-580.2003; Vong S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000903; WHO Collaborating Centre for Influenza, 2009, I00705 CDC WHO COLL; Wijedoru LPM, 2012, J TROP PEDIATRICS, V58, P68, DOI 10.1093/tropej/fmr032; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C; Wuthiekanun V, 2007, J CLIN MICROBIOL, V45, P1363, DOI 10.1128/JCM.02430-06	39	70	70	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e60634	10.1371/journal.pone.0060634	http://dx.doi.org/10.1371/journal.pone.0060634			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23593267	gold, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000317909600030
J	Chiu, YC; Kocagoz, S; Larson, JC; Brey, EM				Chiu, Yu-Chieh; Kocagoez, Sevi; Larson, Jeffery C.; Brey, Eric M.			Evaluation of Physical and Mechanical Properties of Porous Poly (Ethylene Glycol)-co-(L-Lactic Acid) Hydrogels during Degradation	PLOS ONE			English	Article							B-PLA HYDROGEL; POLY(ETHYLENE GLYCOL) HYDROGELS; STATISTICAL KINETIC-MODEL; IN-VITRO DEGRADATION; BULK DEGRADATION; CROSS-LINKING; CELL; DELIVERY; REGENERATION; SCAFFOLDS	Porous hydrogels of poly(ethylene glycol) (PEG) have been shown to facilitate vascularized tissue formation. However, PEG hydrogels exhibit limited degradation under physiological conditions which hinders their ultimate applicability for tissue engineering therapies. Introduction of poly((L)-lactic acid) (PLLA) chains into the PEG backbone results in copolymers that exhibit degradation via hydrolysis that can be controlled, in part, by the copolymer conditions. In this study, porous, PEG-PLLA hydrogels were generated by solvent casting/particulate leaching and photopolymerization. The influence of polymer conditions on hydrogel architecture, degradation and mechanical properties was investigated. Autofluorescence exhibited by the hydrogels allowed for three-dimensional, non-destructive monitoring of hydrogel structure under fully swelled conditions. The initial pore size depended on particulate size but not polymer concentration, while degradation time was dependent on polymer concentration. Compressive modulus was a function of polymer concentration and decreased as the hydrogels degraded. Interestingly, pore size did not vary during degradation contrary to what has been observed in other polymer systems. These results provide a technique for generating porous, degradable PEG-PLLA hydrogels and insight into how the degradation, structure, and mechanical properties depend on synthesis conditions.	[Chiu, Yu-Chieh; Kocagoez, Sevi; Larson, Jeffery C.; Brey, Eric M.] IIT, Dept Biomed Engn, Chicago, IL 60616 USA; [Larson, Jeffery C.; Brey, Eric M.] Edward Hines Vet Adm Med Ctr, Res Serv, Hines, IL USA	Illinois Institute of Technology; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Brey, EM (corresponding author), IIT, Dept Biomed Engn, Chicago, IL 60616 USA.	brey@iit.edu			Veterans Administration; National Science Foundation [IIS 1125412, CBET 0854430]; Direct For Computer & Info Scie & Enginr [1125412] Funding Source: National Science Foundation	Veterans Administration(US Department of Veterans Affairs); National Science Foundation(National Science Foundation (NSF)); Direct For Computer & Info Scie & Enginr(National Science Foundation (NSF)NSF - Directorate for Computer & Information Science & Engineering (CISE))	The authors would like to acknowledge support from the Veterans Administration and the National Science Foundation (IIS 1125412 and CBET 0854430). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Betz MW, 2010, BIOMACROMOLECULES, V11, P1160, DOI 10.1021/bm100061z; Bryant SJ, 2004, ANN BIOMED ENG, V32, P407, DOI 10.1023/B:ABME.0000017535.00602.ca; Burdick JA, 2002, J CONTROL RELEASE, V83, P53, DOI 10.1016/S0168-3659(02)00181-5; Chiu YC, 2012, J FLUORESC; Chiu YC, 2011, BIOMATERIALS; Chiu YC, 2010, TISSUE ENG PART C-ME, V16, P905, DOI [10.1089/ten.tec.2009.0646, 10.1089/ten.TEC.2009.0646]; Chiu YC, 2009, CHEM MATER, V21, P1677, DOI 10.1021/cm803520j; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; Eskandari M, 2011, BIOTECHNOL BIOENG, V108, P435, DOI 10.1002/bit.22889; Evans GRD, 1999, BIOMATERIALS, V20, P1109, DOI 10.1016/S0142-9612(99)00010-1; Fisher JP, 2003, BIOMACROMOLECULES, V4, P1335, DOI 10.1021/bm0300296; Francis-Sedlak ME, 2010, MICROVASC RES, V80, P3, DOI 10.1016/j.mvr.2009.12.005; Francis-Sedlak ME, 2009, BIOMATERIALS, V30, P1851, DOI 10.1016/j.biomaterials.2008.12.014; Goraltchouk A, 2005, BIOMATERIALS, V26, P7555, DOI 10.1016/j.biomaterials.2005.05.026; Hattori K, 2001, MAT SCI ENG C-BIO S, V17, P27, DOI 10.1016/S0928-4931(01)00331-9; Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421; Jun HW, 2005, TISSUE ENG, V11, P1133, DOI 10.1089/ten.2005.11.1133; Levesque SG, 2005, BIOMATERIALS, V26, P7436, DOI 10.1016/j.biomaterials.2005.05.054; Lin CC, 2009, BIOMATERIALS, V30, P4907, DOI 10.1016/j.biomaterials.2009.05.083; Lovett M, 2010, TISSUE ENG PART C-ME, V16, P1565, DOI [10.1089/ten.tec.2010.0241, 10.1089/ten.TEC.2010.0241]; Metters AT, 2000, J PHYS CHEM B, V104, P7043, DOI 10.1021/jp000523t; Metters AT, 2000, POLYMER, V41, P3993, DOI 10.1016/S0032-3861(99)00629-1; Metters AT, 2001, J PHYS CHEM B, V105, P8069, DOI 10.1021/jp004083h; Moon JJ, 2010, BIOMATERIALS, V31, P3840, DOI 10.1016/j.biomaterials.2010.01.104; Nemir S, 2010, BIOTECHNOL BIOENG, V105, P636, DOI 10.1002/bit.22574; Nuttelman CR, 2008, PROG POLYM SCI, V33, P167, DOI 10.1016/j.progpolymsci.2007.09.006; Patel ZS, 2008, ACTA BIOMATER, V4, P1126, DOI 10.1016/j.actbio.2008.04.002; Saito T, 2004, ANN THORAC SURG, V77, P684, DOI 10.1016/S0003-4975(03)01341-9; Sokic S, 2012, TISSUE ENG PT A, V18, P2477, DOI [10.1089/ten.tea.2012.0173, 10.1089/ten.TEA.2012.0173]; Sokic S, 2012, ACTA BIOMATER, V8, P2213, DOI 10.1016/j.actbio.2012.03.017; VANDIJKWOLTHUIS WNE, 1995, MACROMOLECULES, V28, P6317, DOI 10.1021/ma00122a044; Vila A, 2004, J AEROSOL MED, V17, P174, DOI 10.1089/0894268041457183; Wachiralarpphaithoon C, 2007, BIOMATERIALS, V28, P984, DOI 10.1016/j.biomaterials.2006.10.024; Wu LB, 2004, BIOMATERIALS, V25, P5821, DOI 10.1016/j.biomaterials.2004.01.038; Yu HY, 2009, BIOMATERIALS, V30, P508, DOI 10.1016/j.biomaterials.2008.09.047; Zemel A, 2010, NAT PHYS, V6, P468, DOI 10.1038/NPHYS1613	36	48	49	2	69	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e60728	10.1371/journal.pone.0060728	http://dx.doi.org/10.1371/journal.pone.0060728			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23593296	Green Published, Green Submitted, gold			2023-01-03	WOS:000317909600042
J	Li, X; Yang, GY; Li, XX; Zhang, Y; Yang, JL; Chang, J; Sun, XX; Zhou, XY; Guo, Y; Xu, Y; Liu, JP; Bensoussan, A				Li, Xun; Yang, Guoyan; Li, Xinxue; Zhang, Yan; Yang, Jingli; Chang, Jiu; Sun, Xiaoxuan; Zhou, Xiaoyun; Guo, Yu; Xu, Yue; Liu, Jianping; Bensoussan, Alan			Traditional Chinese Medicine in Cancer Care: A Review of Controlled Clinical Studies Published in Chinese	PLOS ONE			English	Article								Background: Traditional Chinese medicine (TCM) has been widely applied for cancer care in China. There have been a large number of controlled clinical studies published in Chinese literature, yet no systematic searching and analysis has been done. This study summarizes the current evidence of controlled clinical studies of TCM for cancer. Methods: We searched all the controlled clinical studies of TCM therapies for all kinds of cancers published in Chinese in four main Chinese electronic databases from their inception to November 2011. We bibliometrically analyzed the included studies and assessed the reporting quality. Results: A total of 2964 reports (involving 253,434 cancer patients) including 2385 randomized controlled trials and 579 non-randomized controlled studies were included. The top seven cancer types treated were lung cancer, liver cancer, stomach cancer, breast cancer, esophagus cancer, colorectal cancer and nasopharyngeal cancer by both study numbers and case numbers. The majority of studies (72%) applied TCM therapy combined with conventional treatment, whilst fewer (28%) applied only TCM therapy in the experimental groups. Herbal medicine was the most frequently applied TCM therapy (2677 studies, 90.32%). The most frequently reported outcome was clinical symptom improvement (1667 studies, 56.24%) followed by biomarker indices (1270 studies, 42.85%), quality of life (1129 studies, 38.09%), chemo/radiotherapy induced side effects (1094 studies, 36.91%), tumor size (869 studies, 29.32%) and safety (547 studies, 18.45%). Completeness and adequacy of reporting appeared to improve with time. Conclusions: Data from controlled clinical studies of TCM therapies in cancer treatment is substantial, and different therapies are applied either as monotherapy or in combination with conventional medicine. Reporting of controlled clinical studies should be improved based on the CONSORT and TREND Statements in future. Further studies should address the most frequently used TCM therapy for common cancers and outcome measures should address survival, relapse/metastasis and quality of life.	[Li, Xun; Yang, Guoyan; Li, Xinxue; Liu, Jianping] Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China; [Li, Xun; Bensoussan, Alan] Univ Western Sydney, Ctr Complementary Med Res CompleMED, Sydney, NSW, Australia; [Zhang, Yan; Chang, Jiu; Sun, Xiaoxuan] Beijing Univ Chinese Med, Sch Preclin Med, Beijing, Peoples R China; [Yang, Jingli] Beijing Univ Chinese Med, Sch Management, Beijing, Peoples R China; [Zhou, Xiaoyun; Guo, Yu] Beijing Univ Chinese Med, Sch Acupuncture & Moxibust, Beijing, Peoples R China; [Xu, Yue] Beijing Univ Chinese Med, Sch Humanities, Beijing, Peoples R China	Beijing University of Chinese Medicine; Western Sydney University; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine; Beijing University of Chinese Medicine	Liu, JP (corresponding author), Beijing Univ Chinese Med, Ctr Evidence Based Chinese Med, Beijing, Peoples R China.	jianping_l@hotmail.com; a.bensoussan@uws.edu.au	Yang, Guoyan/AAG-7873-2021	Yang, Guoyan/0000-0002-8012-2379; Bensoussan, Alan/0000-0002-7433-667X; Liu, Jianping/0000-0002-0320-061X; Li, Xun/0000-0002-3513-5904	Program for Innovative Research Team of Beijing University of Chinese Medicine [2011-CXTD-09]; Ministry of Science and Technology of China [2011ZX09302-006]; State Administration of Traditional Chinese Medicine [101207007]	Program for Innovative Research Team of Beijing University of Chinese Medicine; Ministry of Science and Technology of China(Ministry of Science and Technology, China); State Administration of Traditional Chinese Medicine	This work was supported by Program for Innovative Research Team of Beijing University of Chinese Medicine (No.2011-CXTD-09), and grant number 2011ZX09302-006 from the Ministry of Science and Technology of China and 101207007 from the State Administration of Traditional Chinese Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, GLOBAL HEALTH RISKS: MORTALITY AND BURDEN OF DISEASE ATTRIBUTABLE TO SELECTED MAJOR RISKS, P1; [Anonymous], ICD 10 VERS 2010; Bao Y H, 1984, Zhong Xi Yi Jie He Za Zhi, V4, P16; Boon Heather S, 2007, BMC Womens Health, V7, P4, DOI 10.1186/1472-6874-7-4; Carmady B, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-22; Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027; Des Jarlais DC, 2004, AM J PUBLIC HEALTH, V94, P361, DOI 10.2105/AJPH.94.3.361; Ernst E, 2009, INT J SURG, V7, P499, DOI 10.1016/j.ijsu.2009.08.005; Guo Z, 2012, COCHRANE DATABASE SY; Huang S, 2011, THESIS BEIJING U CHI; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia LB, 2012, CHIN J INTEGR MED, V18, P325, DOI 10.1007/s11655-011-0950-5; Jiang M, 2012, PLANTA MED, V76, P2048; Li LN, 2003, SHANXI CANC ED, V11, P44; Li PW, 2003, MANAGEMENT CANC CHIN; Liu HT, 2009, ZHONG WAI YI XUE WEN, V8, P26; Liu JP, 2011, FORSCH KOMPLEMENTMED, V18, P257, DOI 10.1159/000333065; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Ni YH, 2012, COCHRANE DATABASE SY; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Tang X, 2008, COCHRANE DATABASE SY; Wang LF, 2010, SHANGHAI J TRADITION, V6, P41; Wang TX, 1985, CHINESE J CLIN ONCOL, V2, P144; Wei J, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004560.pub2; World Health Organization, 2012, CANC FACT SHEETS; Xie BH, 1985, CHINESE J INTEGRATED, V10, P586; Xu Zhen-ye, 2007, Zhongguo Zhong Xi Yi Jie He Za Zhi, V27, P874; Yang GY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/751046; Yoder Linda H, 2005, Medsurg Nurs, V14, P195; Zhang M, 2007, COCHRANE DATABASE SY; 吴涛, 2004, [中华流行病学杂志, Chinese Journal of Epidemiology], V25, P633	31	138	148	4	102	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2013	8	4							e60338	10.1371/journal.pone.0060338	http://dx.doi.org/10.1371/journal.pone.0060338			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143BA	23560092	gold, Green Published			2023-01-03	WOS:000318840100061
J	Vassilev, I; Rogers, A; Blickem, C; Brooks, H; Kapadia, D; Kennedy, A; Sanders, C; Kirk, S; Reeves, D				Vassilev, Ivaylo; Rogers, Anne; Blickem, Christian; Brooks, Helen; Kapadia, Dharmi; Kennedy, Anne; Sanders, Caroline; Kirk, Sue; Reeves, David			Social Networks, the 'Work' and Work Force of Chronic Illness Self-Management: A Survey Analysis of Personal Communities	PLOS ONE			English	Article							LONG-TERM CONDITIONS; BEHAVIOR-CHANGE; EXPERT PATIENTS; CARE; DYNAMICS; SUPPORT; ENGLAND; SPREAD; LIFE; TIES	Self-management support forms a central aspect of chronic Illness management nationally and globally. Evidence for the success of self-management support has mainly focussed on individually-centred outcomes of behavioural change. While it is recognised that social network members play an important role there is currently a gap in knowledge regarding who provides what type of support and under what circumstances. This is relevant for understanding the division of labour and the meeting of needs for those living with a long-term condition. We therefore took a network approach to explore self-management support conceptualising it as types of illness 'work' undertaken within peoples' social networks. 300 people from deprived areas and with chronic illnesses took part in a survey conducted in 2010 in the North West of England. A concentric circles diagram was used as a research tool with which participants identified 2,544 network members who contributed to illness management. The results provide an articulation of how social network members are substantially involved in illness management. Whilst partners and close family make the highest contributions there is evidence of inputs from a wide range of relationships. Network member characteristics (type of relationship, proximity, frequency of contact) impact on the amount of illness work undertaken in peoples' networks. In networks with 'no partner' other people tend to contribute more in the way of illness related work than in networks with a partner. This indicates a degree of substitutability between differently constituted networks, and that the level and type of input by different members of a network might change according to circumstances. A network perspective offers an opportunity to redress the balance of an exclusively individual focus on self-management because it addresses the broader set of contributions and resources available to people in need of chronic illness management and support.	[Vassilev, Ivaylo; Rogers, Anne; Blickem, Christian; Brooks, Helen; Kapadia, Dharmi; Sanders, Caroline; Kirk, Sue; Reeves, David] Univ Manchester, Ctr Primary Care, Inst Populat Hlth, Collaborat Leadership Appl Hlth Res CLAHRC, Manchester, Lancs, England; [Rogers, Anne; Kennedy, Anne] Univ Southampton, Fac Hlth Sci, Southampton, Hants, England; [Kirk, Sue] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester, Lancs, England	University of Manchester; University of Southampton; University of Manchester	Vassilev, I (corresponding author), Univ Manchester, Ctr Primary Care, Inst Populat Hlth, Collaborat Leadership Appl Hlth Res CLAHRC, Manchester, Lancs, England.	Ivaylo.vassilev@manchester.ac.uk	Reeves, David/H-6203-2014; Sanders, Caroline/G-8021-2014; Brooks, Helen/O-4307-2014; Brooks, Helen/N-3849-2018	Reeves, David/0000-0001-6377-6859; Sanders, Caroline/0000-0002-0539-928X; Brooks, Helen/0000-0002-2157-0200; Brooks, Helen/0000-0002-2157-0200; Kirk, Susan/0000-0002-1485-8804; Vassilev, Ivaylo/0000-0002-2206-8247	Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for Greater Manchester	Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for Greater Manchester	This research has been funded by the Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for Greater Manchester. CLAHRC Greater Manchester is a partnership between the Greater Manchester NHS Trusts and the University of Manchester and is part of the National Institute for Health Research. The authors are members of the Patient Theme of CLAHRC for Greater Manchester. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham C, 2008, HEALTH PSYCHOL, V27, P379, DOI 10.1037/0278-6133.27.3.379; Altschuler J, 2004, J WOMEN AGING, V16, P143, DOI 10.1300/J074v16n01_10; Bott E, 1957, FAM SOC NETWORK, V2nd; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939; Christakis NA., 2010, CONNECTED AMAZING PO; Christakis NA, 2008, NEW ENGL J MED, V358, P2249, DOI 10.1056/NEJMsa0706154; Christakis NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMsa066082; Conner M., 2005, PREDICTING HLTH BEHA; Corbin J., 1985, QUALITATIVE SOCIOLOG, V8, P224, DOI DOI 10.1007/BF00989485; Department of Health, 2005, SELF CAR REAL CHOIC; Department of Health, 2009, YOUR HLTH YOUR WAY G; Elder JP, 1999, AM J PREV MED, V17, P275, DOI 10.1016/S0749-3797(99)00094-X; Fiori KL, 2007, J GERONTOL B-PSYCHOL, V62, pP322, DOI 10.1093/geronb/62.6.P322; Flori KL, 2006, J GERONTOL B-PSYCHOL, V61, pP25, DOI 10.1093/geronb/61.1.P25; Fowler JH, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2338; Gallant MP, 2007, RES AGING, V29, P375, DOI 10.1177/0164027507303169; Gallant MP, 2003, HEALTH EDUC BEHAV, V30, P170, DOI 10.1177/1090198102251030; Hair J.F., 1995, MULTIVARIATE DATA AN, Vfourth; Hann M, 2008, QUAL LIFE RES, V17, P413, DOI 10.1007/s11136-008-9310-0; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Kendall E, 2007, DISABIL SOC, V22, P129, DOI 10.1080/09687590601141535; Kennedy A, 2007, J EPIDEMIOL COMMUN H, V61, P254, DOI 10.1136/jech.2006.053538; Litwin H, 1997, J Cross Cult Gerontol, V12, P45, DOI 10.1023/A:1006593025061; Litwin H, 2001, GERONTOLOGIST, V41, P516, DOI 10.1093/geront/41.4.516; McMunn A, 2009, AGEING SOC, V29, P765, DOI 10.1017/S0144686X08008350; Pahl R., 2004, CURR SOCIOL, V52, P199, DOI [DOI 10.1177/0011392104041808, 10.1177/0011392104041808]; Parsons T., 1991, SOCIAL SYSTEM, Vsecond; Perry BL, 2012, AM J SOCIOL, V118, P134, DOI 10.1086/666377; Perry BL, 2011, J HEALTH SOC BEHAV, V52, P460, DOI 10.1177/0022146511408913; PESCOSOLIDO BA, 1990, SOCIOL QUART, V31, P337, DOI 10.1111/j.1533-8525.1990.tb00332.x; Pescosolido BA, 2000, AM SOCIOL REV, V65, P52, DOI 10.2307/2657289; PESCOSOLIDO BA, 1992, AM J SOCIOL, V97, P1096, DOI 10.1086/229863; Pescosolido BA, 2006, J HEALTH SOC BEHAV, V47, P189, DOI 10.1177/002214650604700301; Phillipson C., 2001, FAMILY COMMUNITY LIF; Pilgrim J, 2012, CHRONIC ILLNESS; Rogers A, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-56; Rogers A, 2009, INT J HEALTH SERV, V39, P725, DOI 10.2190/HS.39.4.h; Scott J.P, 2000, SOCIAL NETWORK ANAL; Shaw M, 2004, BRIT J GEN PRACT, V54, P899; Smith KP, 2008, ANNU REV SOCIOL, V34, P405, DOI 10.1146/annurev.soc.34.040507.134601; Stoller EP, 2003, J AGING HEALTH, V15, P482, DOI 10.1177/0898264303253504; Taylor D, 2007, SOCIOL HEALTH ILL, V29, P27, DOI 10.1111/j.1467-9566.2007.00516.x; Thoits PA, 2011, J HEALTH SOC BEHAV, V52, P145, DOI 10.1177/0022146510395592; van der Meer M, 2003, COMP REPORT SOCIAL S; Vassilev I, 2011, CHRONIC ILLN, V7, P60, DOI 10.1177/1742395310383338; Webber MP, 2007, SOC SCI MED, V65, P481, DOI 10.1016/j.socscimed.2007.03.030; Wellman B, 1997, SOC NETWORKS, V19, P27, DOI 10.1016/S0378-8733(96)00289-4; WELLMAN B, 1990, AM J SOCIOL, V96, P558, DOI 10.1086/229572; Wellman B., 2000, COMPLEMENTARY ALTERN, P143; Wenger GC, 1997, AGING MENT HEALTH, V1, P311, DOI 10.1080/13607869757001; World Health Organisation, 2008, HLTH PROM GLOSS	51	110	111	0	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2013	8	4							e59723	10.1371/journal.pone.0059723	http://dx.doi.org/10.1371/journal.pone.0059723			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	127RY	23565162	Green Published, Green Accepted, gold			2023-01-03	WOS:000317717300031
J	Wynd, S; Westaway, M; Vohra, S; Kawchuk, G				Wynd, Shari; Westaway, Michael; Vohra, Sunita; Kawchuk, Greg			The Quality of Reports on Cervical Arterial Dissection following Cervical Spinal Manipulation	PLOS ONE			English	Article							ALTERNATIVE MEDICAL PROCEDURE; VERTEBRAL ARTERY; CHIROPRACTIC MANIPULATION; NECK MANIPULATION; CAROTID-ARTERY; RISK-FACTOR; SYSTEMATIC REVIEWS; STROKE; THERAPY; COMPLICATIONS	Background: Cervical artery dissection (CAD) and stroke are serious harms that are sometimes associated with cervical spinal manipulation therapy (cSMT). Because of the relative rarity of these adverse events, studying them prospectively is challenging. As a result, systematic review of reports describing these events offers an important opportunity to better understand the relation between adverse events and cSMT. Of note, the quality of the case report literature in this area has not yet been assessed. Purpose: 1) To systematically collect and synthesize available reports of CAD that have been associated with cSMT in the literature and 2) assess the quality of these reports. Methods: A systematic review of the literature was conducted using several databases. All clinical study designs involving CADs associated with cSMT were eligible for inclusion. Included studies were screened by two independent reviewers for the presence/absence of 11 factors considered to be important in understanding the relation between CAD and cSMT. Results: Overall, 43 articles reported 901 cases of CAD and 707 incidents of stroke reported to be associated with cSMT. The most common type of stroke reported was ischemic stroke (92%). Time-to-onset of symptoms was reported most frequently (95%). No single case included all 11 factors. Conclusions: This study has demonstrated that the literature infrequently reports useful data toward understanding the association between cSMT, CADs and stroke. Improving the quality, completeness, and consistency of reporting adverse events may improve our understanding of this important relation.	[Wynd, Shari] Texas Chiropract Coll, Pasadena, TX 77505 USA; [Westaway, Michael] Univ Alberta, Lifemark Hlth, Calgary, AB, Canada; [Vohra, Sunita] Univ Alberta, Dept Pediat, Fac Med & Dent, Edmonton, AB, Canada; [Vohra, Sunita] Alberta Innovates Hlth Solut, Complementary & Alternat Res & Educ Program, Pediat Complementary & Alternat Med Res & Educ Ne, Edmonton, AB, Canada; [Kawchuk, Greg] Univ Alberta, Dept Phys Therapy, Edmonton, AB, Canada	University of Alberta; University of Alberta; Alberta Innovates; University of Alberta	Wynd, S (corresponding author), Texas Chiropract Coll, Pasadena, TX 77505 USA.	swynd@txchiro.edu	Vohra, Sunita/F-5755-2016; Wynd, Shari E/E-8948-2017	Vohra, Sunita/0000-0002-6210-7933; Wynd, Shari E/0000-0002-8523-5137	Canada Research Chairs program; Alberta Innovates-Health Solutions	Canada Research Chairs program(Canada Research Chairs); Alberta Innovates-Health Solutions	Greg Kawchuk receives salary support from the Canada Research Chairs program. Sunita Vohra receives salary support from Alberta Innovates-Health Solutions. Training support for Shari Wynd was provided by the Alberta Canadian Institutes of Health Research (CIHR) Training Program in Bone and Joint Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bartels E, 2006, J NEUROIMAGING, V16, P24, DOI 10.1177/1051228405280646; Beaudry M, 2003, CAN J NEUROL SCI, V30, P320, DOI 10.1017/S0317167100003024; Bekavac N, 2006, EXPLORE-NY, V2, P150, DOI 10.1016/j.explore.2006.01.001; Beran RG, 2000, MED J AUSTRALIA, V173, P213, DOI 10.5694/j.1326-5377.2000.tb125606.x; Bergmann TF, 2011, CHIROPRACTIC TECHNIQ, V3rd; Bin Saeed A, 2000, CAN J NEUROL SCI, V27, P292, DOI 10.1017/S0317167100001025; Biondi D M, 2000, J Am Osteopath Assoc, V100, pS7; Cagnie B, 2006, SURG RADIOL ANAT, V28, P129, DOI 10.1007/s00276-005-0060-1; Caso V, 2005, FRONT NEUROL NEUROSC, V20, P44, DOI 10.1159/000088134; Cassidy JD, 2008, SPINE, V33, pS176, DOI 10.1097/BRS.0b013e3181644600; Cerimagic D, 2008, SOUTH MED J, V101, P568, DOI 10.1097/SMJ.0b013e31816c012b; Chen WL, 2006, EMERG MED J, V23, pE1, DOI 10.1136/emj.2004.015636; Choi S, 2010, J MANIP PHYSIOL THER, V34, P15; Cimini N, 2004, EUR NEUROL, V52, P207, DOI 10.1159/000082037; Colloca CJ, 2005, J MANIP PHYSIOL THER, V28, P414, DOI 10.1016/j.jmpt.2005.06.004; Czechowsky D, 2002, CEREBROVASC DIS, V13, P192, DOI 10.1159/000047775; Devereaux MW, 2000, J NEURO-OPHTHALMOL, V20, P236, DOI 10.1097/00041327-200020040-00004; Dittrich R, 2007, CEREBROVASC DIS, V23, P275, DOI 10.1159/000098327; Dorland, 2011, DORLANDS MED DICT; Dupeyron A., 2003, Annales de Readaptation et de Medecine Physique, V46, P33, DOI 10.1016/S0168-6054(02)00351-3; Dziewas R, 2003, J NEUROL, V250, P1179, DOI 10.1007/s00415-003-0174-5; Ernst E, 2010, INT J CLIN PRACT, V64, P1162, DOI 10.1111/j.1742-1241.2010.02352.x; Gouveia LO, 2009, SPINE, V34, pE405, DOI 10.1097/BRS.0b013e3181a16d63; Gross AR, 2004, SPINE, V29, P1541, DOI 10.1097/01.BRS.0000131218.35875.ED; Haldeman S, 2002, J NEUROL, V249, P1098, DOI 10.1007/s00415-002-0783-4; Haldeman S, 2002, SPINE, V27, P49, DOI 10.1097/00007632-200201010-00012; Haldeman S, 2001, CAN MED ASSOC J, V165, P905; Haldeman Scott, 2002, Spine J, V2, P334, DOI 10.1016/S1529-9430(02)00411-4; Haneline Michael T, 2009, Spine (Phila Pa 1976), V34, P2475, DOI 10.1097/BRS.0b013e3181b96cbe; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hurwitz EL, 2005, SPINE, V30, P1477, DOI 10.1097/01.brs.0000167821.39373.c1; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Jay Walter M, 2003, Semin Ophthalmol, V18, P205, DOI 10.1080/08820530390895217; Jeret JS, 2002, CEREBROVASC DIS, V13, P210, DOI 10.1159/000047778; KAWCHUK GN, 1993, J MANIP PHYSIOL THER, V16, P573; Kawchuk GN, 2008, J NEUROL, V255, P371, DOI 10.1007/s00415-008-0667-3; Kelly W, 2009, THERAPIE, V64, P289, DOI 10.2515/therapie/2009041; Khan AM, 2005, MT SINAI J MED, V72, P207; Leach RA, 2010, J MANIP PHYSIOL THER, V33, P62, DOI 10.1016/j.jmpt.2009.11.004; Leon-Sanchez A, 2007, SOUTH MED J, V100, P201, DOI 10.1097/SMJ.0b013e31802ed21f; Licht PB, 2002, J MANIP PHYSIOL THER, V25, P568, DOI 10.1067/mmt.2002.128367; Loke YK, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-32; Misra UK, 2001, SPINAL CORD, V39, P112, DOI 10.1038/sj.sc.3101105; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Nadgir RN, 2003, NEURORADIOLOGY, V45, P311, DOI 10.1007/s00234-003-0944-x; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Nazir FS, 2004, NEUROLOGY, V62, P1646, DOI 10.1212/01.WNL.0000123017.81529.32; Norris JW, 2001, CAN MED ASSOC J, V165, P887; Panagariya A, 2004, J Assoc Physicians India, V52, P556; Parwar BL, 2001, AM J OPHTHALMOL, V131, P523, DOI 10.1016/S0002-9394(00)00829-1; Pezzini A, 2002, J NEUROL, V249, P1401, DOI 10.1007/s00415-002-0851-9; Preul C, 2010, CLIN NEURORADIOL, V20, P255, DOI 10.1007/s00062-010-0021-x; Preutu G, 2009, INT J MUSCULOSKEL ME, V31, P149; Quintana JG, 2002, NEUROLOGY, V58, P1434, DOI 10.1212/WNL.58.9.1434; Reuter U, 2006, J NEUROL, V253, P724, DOI 10.1007/s00415-006-0099-x; Rothwell DM, 2001, STROKE, V32, P1054, DOI 10.1161/01.STR.32.5.1054; Sedat J, 2002, J MANIP PHYSIOL THER, V25, P588, DOI 10.1067/mmt.2002.128955; Sharmini J, 2010, NEUROL ASIA, V15, P167; Siegel D, 2001, AM J EMERG MED, V19, P171, DOI 10.1053/ajem.2001.21351; Silver B, 2006, CAN J NEUROL SCI, V33, P246, DOI 10.1017/S0317167100005084; Smith WS, 2003, NEUROLOGY, V60, P1424, DOI 10.1212/01.WNL.0000063305.61050.E6; Sorinola Olanrewaju, 2004, BMC Med Educ, V4, P4, DOI 10.1186/1472-6920-4-4; Stevinson G, 2001, J ROY SOC MED, V94, P107, DOI 10.1177/014107680109400302; Terret A, 2001, CURRENT CONCEPTS VER; Thomas LC, 2010, MAN THER; Tinel D., 2008, Annales de Readaptation et de Medecine Physique, V51, P403, DOI 10.1016/j.annrmp.2008.04.010; Touze E, 2003, NEUROLOGY, V61, P572, DOI 10.1212/01.WNL.0000078886.33560.A5; Trivedi A, 2007, ANN INDIAN ACAD NE S, P7; Vertinsky AT, 2008, AM J NEURORADIOL, V29, P1753, DOI 10.3174/ajnr.A1189; Weber M, 2004, J NEUROL, V251, P624, DOI 10.1007/s00415-004-0411-6; Yoshida S, 2000, NEUROL MED-CHIR, V40, P211, DOI 10.2176/nmc.40.211; Young Morgan, 2009, Spine (Phila Pa 1976), V34, P2476, DOI 10.1097/BRS.0b013e3181b96edd; Young YH, 2003, LARYNGOSCOPE, V113, P659, DOI 10.1097/00005537-200304000-00014	73	23	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2013	8	3							e59170	10.1371/journal.pone.0059170	http://dx.doi.org/10.1371/journal.pone.0059170			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SW	23527121	Green Published, Green Submitted, gold			2023-01-03	WOS:000317562600060
J	Gaudreau, K; Sanford, CJ; Cheverie, C; McClure, C				Gaudreau, Katherine; Sanford, Carolyn J.; Cheverie, Connie; McClure, Carol			The Effect of a Smoking Ban on Hospitalization Rates for Cardiovascular and Respiratory Conditions in Prince Edward Island, Canada	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; SECONDHAND SMOKE; 2ND-HAND SMOKE; PUBLIC PLACES; EXPOSURE; ASSOCIATION; RISK; LEGISLATION; WORKERS; HEALTH	Background: This is the first study to have examined the effect of smoking bans on hospitalizations in the Atlantic Canadian socio-economic, cultural and climatic context. On June 1, 2003 Prince Edward Island (PEI) enacted a province-wide smoking ban in public places and workplaces. Changes in hospital admission rates for cardiovascular (acute myocardial infarction, angina, and stroke) and respiratory (chronic obstructive pulmonary disease and asthma) conditions were examined before and after the smoking ban. Methods: Crude annual and monthly admission rates for the above conditions were calculated from April 1, 1995 to December 31, 2008 in all PEI acute care hospitals. Autoregressive Integrated Moving Average time series models were used to test for changes in mean and trend of monthly admission rates for study conditions, control conditions and a control province after the comprehensive smoking ban. Age-and sex-based analyses were completed. Results: The mean rate of acute myocardial infarctions was reduced by 5.92 cases per 100,000 person-months (P = 0.04) immediately after the smoking ban. The trend of monthly angina admissions in men was reduced by 20.44 cases per 100,000 person-months (P = 0.01) in the 67 months after the smoking ban. All other cardiovascular and respiratory admission changes were non-significant. Conclusions: A comprehensive smoking ban in PEI reduced the overall mean number of acute myocardial infarction admissions and the trend of angina hospital admissions.	[Gaudreau, Katherine; Sanford, Carolyn J.; Cheverie, Connie; McClure, Carol] Chief Publ Hlth Off, Dept Hlth & Wellness, Epidemiol Unit, Charlottetown, PE, Canada		McClure, C (corresponding author), Chief Publ Hlth Off, Dept Hlth & Wellness, Epidemiol Unit, Charlottetown, PE, Canada.	cmcclure@ihis.org			Canadian Chronic Disease Surveillance System (Public Health Agency of Canada)	Canadian Chronic Disease Surveillance System (Public Health Agency of Canada)	This project was funded by the Canadian Chronic Disease Surveillance System (Public Health Agency of Canada). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2009, REP GLOB TOB EP 2009; Barnoya J, 2005, CIRCULATION, V111, P2684, DOI 10.1161/CIRCULATIONAHA.104.492215; Barone-Adesi F, 2006, EUR HEART J, V27, P2468, DOI 10.1093/eurheartj/ehl201; Barr CD, 2012, AM J EPIDEMIOL, V176, P642, DOI 10.1093/aje/kws267; Bates MN, 2002, TOB CONTROL, V11, P125, DOI 10.1136/tc.11.2.125; Bell C, 2010, P EDWARD ISLAND HLTH; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Bonita R, 1999, TOB CONTROL, V8, P156, DOI 10.1136/tc.8.2.156; Box G.E.P., 1970, TIME SERIES ANAL FOR; Canadian Chronic Disease Surveillance System (CCDSS), CCDSS ALG ASTHM COPD; Canadian Institutes for Health Information (CIHI) Canadian Institute for Health Information (CIHI), 2011, DISCH ABSTR DAT DAD; Cesaroni G, 2008, CIRCULATION, V117, P1183, DOI 10.1161/CIRCULATIONAHA.107.729889; Desjardins R-M, 2005, SOCIOECONOMIC PROFIL; Dobre I., 2008, J APPL QUANTITATIVE, V3, P156; Dove MS, 2010, AM J PUBLIC HEALTH, V100, P2206, DOI 10.2105/AJPH.2009.189662; Eisner Mark D, 2009, Int J Chron Obstruct Pulmon Dis, V4, P169; Eisner MD, 2005, THORAX, V60, P814, DOI 10.1136/thx.2004.037283; Environmental Technology Advancement Directorate, 2004, NAT AIR POLL SURV NA; Fernandez E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004244; Gasparrini A, 2009, EUR J EPIDEMIOL, V24, P597, DOI 10.1007/s10654-009-9377-0; Glantz SA, 2008, PREV MED, V47, P452, DOI 10.1016/j.ypmed.2008.06.007; Government of Canada NRC, 2011, ATL MAR EC; Government of Canada SC, 2001, STAT CAN POP DWELL C; Government of Canada SC, 2011, STAT CAN 2006 CENS T; Government of Canada SC, 2011, STAT CAN 2006 COMM P; Griffiths D, 2011, STROKE RES TREAT, V2011, DOI 10.4061/2011/209370; Herman PM, 2011, AM J PUBLIC HEALTH, V101, P491, DOI 10.2105/AJPH.2009.179572; Iribarren C, 2004, NEUROEPIDEMIOLOGY, V23, P38, DOI 10.1159/000073973; Juster HR, 2007, AM J PUBLIC HEALTH, V97, P2035, DOI 10.2105/AJPH.2006.099994; Lemstra M, 2008, CAN J PUBLIC HEALTH, V99, P62, DOI 10.1007/BF03403743; Mackay D, 2010, NEW ENGL J MED, V363, P1139, DOI 10.1056/NEJMoa1002861; Marlow ML, 2012, APPL ECON LETT, V19, P1577, DOI 10.1080/13504851.2011.639730; McCord J, 2008, CIRCULATION, V117, P1897, DOI 10.1161/CIRCULATIONAHA.107.188950; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1249, DOI 10.1016/j.jacc.2009.07.022; Naiman A, 2010, CAN MED ASSOC J, V182, P761, DOI 10.1503/cmaj.091130; Panagiotakos DB, 2002, BMC PUBLIC HEALTH, V2, DOI 10.1186/1471-2458-2-9; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Pierce JP, 2008, LANCET ONCOL, V9, P614, DOI 10.1016/S1470-2045(08)70167-0; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Shetty KD, 2011, J POLICY ANAL MANAG, V30, P6, DOI 10.1002/pam.20548; Stata Corp LP, 2007, STAT REL 10 TIM SER; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; Valente P, 2007, TOB CONTROL, V16, P312, DOI 10.1136/tc.2006.019646; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x	44	28	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2013	8	3							e56102	10.1371/journal.pone.0056102	http://dx.doi.org/10.1371/journal.pone.0056102			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	140TZ	23520450	Green Published, Green Submitted, gold			2023-01-03	WOS:000318679900009
J	Theodoridou, A; Penton-Voak, IS; Rowe, AC				Theodoridou, Angeliki; Penton-Voak, Ian S.; Rowe, Angela C.			A Direct Examination of the Effect of Intranasal Administration of Oxytocin on Approach-Avoidance Motor Responses to Emotional Stimuli	PLOS ONE			English	Article							FACIAL EXPRESSIONS; AUTOMATIC EVALUATION; ARM FLEXION; FACES; HUMANS; AMYGDALA; RECOGNITION; BEHAVIOR; FEAR; NEUROPEPTIDES	Oxytocin has been shown to promote a host of social behaviors in humans but the exact mechanisms by which it exerts its effects are unspecified. One prominent theory suggests that oxytocin increases approach and decreases avoidance to social stimuli. Another dominant theory posits that oxytocin increases the salience of social stimuli. Herein, we report a direct test of these hypotheses. In a double-blind, placebo-controlled study we examined approach-avoidance motor responses to social and non-social emotional stimuli. One hundred and twenty participants self-administered either 24 IU oxytocin or placebo and moved a lever toward or away from pictures of faces depicting emotional expressions or from natural scenes appearing before them on a computer screen. Lever movements toward stimuli decreased and movements away increased stimuli size producing the illusion that stimuli moved away from or approached participants. Reaction time data were recorded. The task produced the effects that were anticipated on the basis of the approach-avoidance literature in relation to emotional stimuli, yet the anticipated speeded approach and slowed avoidance responses to emotional faces by the oxytocin group were not observed. Interestingly, the oxytocin treatment group was faster to approach and avoid faces depicting disgust relative to the placebo group, suggesting a salience of disgust for the former group. Results also showed that within the oxytocin group women's reaction times to all emotional faces were faster than those of men, suggesting sex specific effects of oxytocin. The present findings provide the first direct evidence that intranasal oxytocin administration does not enhance approach/avoidance to social stimuli and does not exert a stronger effect on social vs. non-social stimuli in the context of processing of emotional expressions and scenes. Instead, our data suggest that oxytocin administration increases the salience of certain social stimuli and point to a possible role for oxytocin in behavioral prophylaxis.	[Theodoridou, Angeliki; Penton-Voak, Ian S.; Rowe, Angela C.] Univ Bristol, Sch Expt Psychol, Bristol, Avon, England	University of Bristol	Theodoridou, A (corresponding author), Univ Bristol, Sch Expt Psychol, Bristol, Avon, England.	at4194@bristol.ac.uk		Penton-Voak, Ian/0000-0003-4232-0953	ESRC (Economic and Social Research Council) [PTA-031-2006-00552]; University of Bristol, United Kingdom	ESRC (Economic and Social Research Council); University of Bristol, United Kingdom	This work was financially supported by the ESRC (Economic and Social Research Council) (PTA-031-2006-00552) and the University of Bristol, United Kingdom. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adolphs R, 2008, CURR OPIN NEUROBIOL, V18, P166, DOI 10.1016/j.conb.2008.06.006; Alexopoulos T, 2007, J EXP SOC PSYCHOL, V43, P1010, DOI 10.1016/j.jesp.2006.10.017; Bartz JA, 2011, TRENDS COGN SCI, V15, P301, DOI 10.1016/j.tics.2011.05.002; Bech P, 1997, EUR PSYCHIAT, V12, P194, DOI 10.1016/S0924-9338(97)89104-3; Broad KD, 2006, PHILOS T R SOC B, V361, P2199, DOI 10.1098/rstb.2006.1940; CACIOPPO JT, 1993, J PERS SOC PSYCHOL, V65, P5; CACIOPPO JT, 1994, PSYCHOL BULL, V115, P401, DOI 10.1037/0033-2909.115.3.401; Chen M, 1999, PERS SOC PSYCHOL B, V25, P215, DOI 10.1177/0146167299025002007; Churchland PS, 2012, HORM BEHAV, V61, P392, DOI 10.1016/j.yhbeh.2011.12.003; De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108; De Dreu CKW, 2010, SCIENCE, V328, P1408, DOI 10.1126/science.1189047; Di Simplicio M, 2009, J PSYCHOPHARMACOL, V23, P241, DOI 10.1177/0269881108095705; Ditzen B, 2013, SOC COGN AFFECT NEUR, V8, P897, DOI 10.1093/scan/nss083; Ditzen B, 2009, BIOL PSYCHIAT, V65, P728, DOI 10.1016/j.biopsych.2008.10.011; Domes G, 2007, BIOL PSYCHIAT, V62, P1187, DOI 10.1016/j.biopsych.2007.03.025; Domes G, 2010, PSYCHONEUROENDOCRINO, V35, P83, DOI 10.1016/j.psyneuen.2009.06.016; Duckworth KL, 2002, PSYCHOL SCI, V13, P513, DOI 10.1111/1467-9280.00490; Evans S, 2010, NEUROPSYCHOPHARMACOL, V35, P2502, DOI 10.1038/npp.2010.110; Farah MJ, 2000, COGNITIVE NEUROPSYCH, V17, P117, DOI 10.1080/026432900380526; Feldman R, 2012, HORM BEHAV, V61, P380, DOI 10.1016/j.yhbeh.2012.01.008; Fischer-Shofty M, 2010, NEUROPSYCHOLOGIA, V48, P179, DOI 10.1016/j.neuropsychologia.2009.09.003; Fischer-Shofty M, 2013, SOC COGN AFFECT NEUR, V8, P313, DOI 10.1093/scan/nsr100; Galbally M, 2011, HARVARD REV PSYCHIAT, V19, P1, DOI 10.3109/10673229.2011.549771; Goeleven E, 2008, COGNITION EMOTION, V22, P1094, DOI 10.1080/02699930701626582; Guastella AJ, 2008, BIOL PSYCHIAT, V64, P256, DOI 10.1016/j.biopsych.2008.02.008; Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179; Kavaliers M, 2011, PSYCHOL SCI, V22, P1367, DOI 10.1177/0956797611420576; Kemp AH, 2011, CURR DIR PSYCHOL SCI, V20, P222, DOI 10.1177/0963721411417547; Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005; Kuehn BM, 2011, JAMA-J AM MED ASSOC, V305, P659, DOI 10.1001/jama.2011.117; Lang PJ, 1997, ATTENTION AND ORIENTING: SENSORY AND MOTIVATIONAL PROCESSES, P97; LANG PJ, 1990, PSYCHOL REV, V97, P377, DOI 10.1037/0033-295X.97.3.377; Leppanen JM, 2004, PSYCHOL RES-PSYCH FO, V69, P22, DOI 10.1007/s00426-003-0157-2; Leuine A, 2007, PEPTIDES, V28, P1162, DOI 10.1016/j.peptides.2007.04.016; Lewin K., 1935, DYNAMIC THEORY PERS; Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028; Lischke A, 2012, PSYCHONEUROENDOCRINO, V37, P475, DOI 10.1016/j.psyneuen.2011.07.015; Liu JCJ, 2012, HORM BEHAV, V62, P585, DOI 10.1016/j.yhbeh.2012.09.002; Lundqvist D., 1998, KAROLINSKA DIRECTED; Marsh AA, 2005, EMOTION, V5, P119, DOI 10.1037/1528-3542.5.1.119; Marsh AA, 2010, PSYCHOPHARMACOLOGY, V209, P225, DOI 10.1007/s00213-010-1780-4; Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044; Norman GJ, 2011, J PSYCHOPHARMACOL, V25, P1313, DOI 10.1177/0269881110367452; Osgood C.E., 1953, METHOD THEORY EXPT P; Petrovic P, 2008, J NEUROSCI, V28, P6607, DOI 10.1523/JNEUROSCI.4572-07.2008; Rimmele U, 2009, J NEUROSCI, V29, P38, DOI 10.1523/JNEUROSCI.4260-08.2009; Rotteveel M, 2004, EMOTION, V4, P156, DOI 10.1037/1528-3542.4.2.156; SCHNEIRLA TC, 1959, NEBR SYM MOTIV, V7, P1; Schulze L, 2011, PSYCHONEUROENDOCRINO, V36, P1378, DOI 10.1016/j.psyneuen.2011.03.011; Seidel EM, 2010, J EXP PSYCHOL HUMAN, V36, P500, DOI 10.1037/a0018169; Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009; Spielberger C.D., 1989, REDW CITY MIND GARD, Vsecond; Steyer R., 1997, MEHRDIMENSIONALE BEF; Taylor SE, 2006, CURR DIR PSYCHOL SCI, V15, P273, DOI 10.1111/j.1467-8721.2006.00451.x; Theodoridou A, 2009, HORM BEHAV, V56, P128, DOI 10.1016/j.yhbeh.2009.03.019; Tiddeman B, 2001, IEEE COMPUT GRAPH, V21, P42, DOI 10.1109/38.946630; Vuilleumier P, 2003, NAT NEUROSCI, V6, P624, DOI 10.1038/nn1057; Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327	58	38	41	1	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e58113	10.1371/journal.pone.0058113	http://dx.doi.org/10.1371/journal.pone.0058113			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469148	gold, Green Published, Green Submitted			2023-01-03	WOS:000315524900239
J	Wang, JN; Diao, S; Tang, YJ; Hou, AJ; Yuan, HB; Zheng, Y; Zhou, YH				Wang, Jie-Ning; Diao, Shu; Tang, Yuan-Jun; Hou, An-Ji; Yuan, Hai-Bo; Zheng, Yan; Zhou, Yu-Hao			Intracoronary versus Intravenous Administration of Abciximab in Patients with Acute Coronary Syndrome: A Meta-Analysis	PLOS ONE			English	Article							ELEVATION MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIALS; BOLUS ABCIXIMAB; INTERVENTION; REVASCULARIZATION; ANGIOPLASTY	Background: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (IC) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (IV) therapy. Methodology and Principal Findings: We systematically searched the Medline, Embase, and Cochrane Central Register of Controlled Trials databases and reference lists of articles and proceedings of major meetings for obtaining relevant literature. All eligible trials included ACS patients who received either IC administration of abciximab or IV therapy. The primary outcome was major cardiovascular events, and secondary outcomes included total mortality, reinfarction, and any possible adverse events. Of 660 identified studies, we included 9 trials reporting data on 3916 ACS patients. Overall, IC administration of abciximab resulted in 45% reduction in relative risk for major cardiovascular events (RR; 95% confidence interval [CI], 24-60%), 41% reduction in RR for reinfarction (95% CI, 7-63%), and 44% reduction in RR for congestive heart failure relative to IV therapy (95% CI, 8-66%); however, compared to IV therapy, IC administration of abciximab had no effect on total mortality (RR, 0.69; 95% CI, 0.45-1.07). No other significant differences were identified between the effect of IC abciximab administration and IV therapy. Conclusions/Significance: IC administration of abciximab can reduce the risk of major cardiovascular events, reinfarction, and congestive heart failure when compared with IV therapy.	[Wang, Jie-Ning; Diao, Shu] Shanghai Seventh Peoples Hosp, Shanghai, Peoples R China; [Tang, Yuan-Jun] Second Mil Med Univ, Dept Pharmaceut Anal, Sch Pharm, Shanghai, Peoples R China; [Hou, An-Ji] Shanghai Seventh Peoples Hosp, Dept Oncol, Shanghai, Peoples R China; [Yuan, Hai-Bo; Zheng, Yan] Shanghai Seventh Peoples Hosp, Dept Sci, Shanghai, Peoples R China; [Zhou, Yu-Hao] Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China	Naval Medical University	Zhou, YH (corresponding author), Shanghai Seventh Peoples Hosp, Dept Rehabil Inst, Shanghai, Peoples R China.	zhou_ly@126.com						Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; Bailey SR, 1997, CATHETER CARDIO DIAG, V42, P181, DOI 10.1002/(SICI)1097-0304(199710)42:2<181::AID-CCD18>3.0.CO;2-R; Bartorelli AL, 1999, CATHETER CARDIO INTE, V48, P211, DOI 10.1002/(SICI)1522-726X(199910)48:2<211::AID-CCD20>3.0.CO;2-V; Bellandi F, 2004, CATHETER CARDIO INTE, V62, P186, DOI 10.1002/ccd.20041; De Luca G, 2012, ATHEROSCLEROSIS, V222, P426, DOI 10.1016/j.atherosclerosis.2012.02.041; Deibele AJ, 2010, CIRCULATION, V121, P784, DOI 10.1161/CIRCULATIONAHA.109.882746; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Desch S, 2012, CLIN RES CARDIOL, V101, P117, DOI 10.1007/s00392-011-0372-6; Dominguez-Rodriguez A, 2009, ATHEROSCLEROSIS, V206, P523, DOI 10.1016/j.atherosclerosis.2009.03.011; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Friedland S, 2011, AM J CARDIOL, V108, P1244, DOI 10.1016/j.amjcard.2011.06.039; Gu YL, 2010, CIRCULATION, V122, P2709, DOI 10.1161/CIRCULATIONAHA.110.002741; Huynh T, 2009, CIRCULATION, V119, P3101, DOI 10.1161/CIRCULATIONAHA.108.793745; Iversen A, 2008, CURR CARDIOL REV, V4, P293, DOI 10.2174/157340308786349480; Iversen AZ, 2011, CARDIOLOGY, V120, P43, DOI 10.1159/000333117; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jefferson T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000975.pub2; Kakkar AK, 2004, CATHETER CARDIO INTE, V61, P31, DOI 10.1002/ccd.10730; Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.i4086, 10.1186/2046-4053-4-1, 10.1136/bmj.b2535]; Osuna JGG, 2006, REV ESP CARDIOL, V59, P567; Romagnoli E, 2005, INT J CARDIOL, V105, P250, DOI 10.1016/j.ijcard.2004.11.037; Romagnoli E, 2007, J THROMB THROMBOLYS, V23, P57, DOI 10.1007/s11239-006-9000-0; Schroder R, 2004, CIRCULATION, V110, pE506, DOI 10.1161/01.CIR.0000147778.05979.E6; Thiele H, 2008, CIRCULATION, V118, P49, DOI 10.1161/CIRCULATIONAHA.107.747642; Thiele H, 2012, LANCET, V379, P923, DOI 10.1016/S0140-6736(11)61872-2; Werf FV, 2003, EUR HEART J, V24, P28, DOI DOI 10.1016/S0195-668X(02)00618-8; Wohrle J, 2003, CIRCULATION, V107, P1840, DOI 10.1161/01.CIR.0000066852.98038.D1; Zhu MM, 2001, AM J CARDIOL, V88, P297, DOI 10.1016/S0002-9149(01)01645-9	28	4	4	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e58077	10.1371/journal.pone.0058077	http://dx.doi.org/10.1371/journal.pone.0058077			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469144	Green Published, gold, Green Submitted			2023-01-03	WOS:000315524900235
J	Ng, XW; Huang, YY; Chen, HH; Burnett, JC; Boey, FYC; Venkatraman, SS				Ng, Xu Wen; Huang, Yingying; Chen, Horng H.; Burnett, John C., Jr.; Boey, Freddy Y. C.; Venkatraman, Subbu S.			Cenderitide-Eluting Film for Potential Cardiac Patch Applications	PLOS ONE			English	Article							CHIMERIC NATRIURETIC PEPTIDE; MYOCARDIAL-INFARCTION; HEART-FAILURE; SUPPORT DEVICE; CD-NP; FIBROBLASTS; SYSTEM; CARDIOTROPHIN-1; DEGRADATION; NESIRITIDE	Cenderitide, also known as CD-NP, is a designer peptide developed by combining native mammalian c-type natriuretic peptide (CNP) and the C-terminus isolated from the dendroapis natriuretic peptide (DNP) of the venom from the green mamba. In early studies, intravenous and subcutaneous infusion of cenderitide was reported to reduce left ventricular (LV) mass and ameliorate cardiac remodelling. In this work, biodegradable polymeric films encapsulating CD-NP were developed and were investigated for their in vitro release and degradation characteristics. Subsequently, the bioactivity of released peptide and its effects on human cardiac fibroblast (HCF) were explored. We achieved sustained release from three films with low, intermediate and high release profiles for 30 days. Moreover, the bioactivity of released peptide was verified from the elevated production of cyclic guanosine monophospate (cGMP). The CD-NP released from films was able to inhibit the proliferation of hypertrophic HCF as well as suppress DNA synthesis in HCF. Furthermore, the sustained delivery from films showed comparable or superior suppressive actions on hypertrophic HCF compared to daily infusion of CD-NP. The results suggest that these films could be used to inhibit fibrosis and reduce cardiac remodelling via local delivery as cardiac patches.	[Ng, Xu Wen; Huang, Yingying; Boey, Freddy Y. C.; Venkatraman, Subbu S.] Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore; [Chen, Horng H.; Burnett, John C., Jr.] Mayo Clin, Div Cardiovasc Dis & Internal Med, Rochester, MN USA	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Mayo Clinic	Venkatraman, SS (corresponding author), Nanyang Technol Univ, Sch Mat Sci & Engn, Singapore 639798, Singapore.	assubbu@ntu.edu.sg	Venkatraman, Subramanian/A-2228-2011; Boey, Freddy Yin Chiang/G-2618-2017	Venkatraman, Subramanian/0000-0002-8693-1070; 	National Research Foundation - Competitive Research Programme [NRF-CRP 2-2007-01]	National Research Foundation - Competitive Research Programme	This work was supported by the following grant: The National Research Foundation - Competitive Research Programme, http://www.nrf.gov.sg/(NRF-CRP 2-2007-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abassi Z, 2004, PHARMACOL THERAPEUT, V102, P223, DOI 10.1016/j.pharmthera.2004.04.004; ALI SAM, 1993, BIOMATERIALS, V14, P648, DOI 10.1016/0142-9612(93)90063-8; Aronson D, 2004, AM HEART J, V148, DOI 10.1016/j.ahj.2004.05.027; Aronson D, 2012, PHARMACOL THERAPEUT, V135, P1, DOI 10.1016/j.pharmthera.2012.03.002; Asakura M, 2004, CIRC J, V68, P95, DOI 10.1253/circj.68.95; Barletta G, 1998, HYPERTENSION, V31, P802, DOI 10.1161/01.HYP.31.3.802; Baudino TA, 2006, AM J PHYSIOL-HEART C, V291, pH1015, DOI 10.1152/ajpheart.00023.2006; Bristow MR, 2002, CIRCULATION, V106, P1430, DOI 10.1161/01.CIR.0000034024.61382.42; Burnett JC, 2009, PCT Patent Application No PCT, Patent No. 046095; Chen HH, 2009, HEART, V95, P1315, DOI 10.1136/hrt.2008.153916; Chen HH, 2002, CIRCULATION, V105, P999, DOI 10.1161/hc0802.104282; Chen HH, 2002, J AM COLL CARDIOL, V40, P1186, DOI 10.1016/S0735-1097(02)02127-7; Chen HH, 2006, EUR HEART J SUPPL, V8, pE18, DOI 10.1093/eurheartj/sul026; Dickey DM, 2011, J MOL CELL CARDIOL, V51, P67, DOI 10.1016/j.yjmcc.2011.03.013; Freed DH, 2003, CARDIOVASC RES, V60, P365, DOI 10.1016/S0008-6363(03)00534-0; FURUYA M, 1992, BIOCHEM BIOPH RES CO, V183, P964, DOI 10.1016/S0006-291X(05)80284-0; Holmes JW, 2005, ANNU REV BIOMED ENG, V7, P223, DOI 10.1146/annurev.bioeng.7.060804.100453; HUNT PJ, 1994, J CLIN ENDOCR METAB, V78, P1428, DOI 10.1210/jc.78.6.1428; Kitakaze M, 2007, LANCET, V370, P2102; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Liao SY, 2010, J CARD FAIL, V16, P590, DOI 10.1016/j.cardfail.2010.02.007; Lisy O, 2008, J AM COLL CARDIOL, V52, P60, DOI 10.1016/j.jacc.2008.02.077; Liu KL, 2011, MOL PHARMACEUT, V8, P2173, DOI 10.1021/mp200513b; Manabe I, 2002, CIRC RES, V91, P1103, DOI 10.1161/01.RES.0000046452.67724.B8; Mann DL, 2007, ANN THORAC SURG, V84, P1226, DOI 10.1016/j.athoracsur.2007.03.095; Mann DL, 2012, J THORAC CARDIOV SUR, V143, P1036, DOI 10.1016/j.jtcvs.2011.06.014; Mattos C, 2001, CURR OPIN STRUC BIOL, V11, P761, DOI 10.1016/S0959-440X(01)00278-0; Mazzaferri EL, 2012, AM HEART J, V163, P812, DOI 10.1016/j.ahj.2012.02.013; Michaels AD, 2003, CIRCULATION, V107, P2697, DOI 10.1161/01.CIR.0000070547.88378.EA; Mitrovic V, 2006, EUR HEART J, V27, P2823, DOI 10.1093/eurheartj/ehl337; Miyagi Y, 2011, BIOMATERIALS, V32, P1280, DOI 10.1016/j.biomaterials.2010.10.007; Nikolic SD, 2009, J CARD FAIL, V15, P790, DOI 10.1016/j.cardfail.2009.05.014; Nishikimi T, 2006, CARDIOVASC RES, V69, P318, DOI 10.1016/j.cardiores.2005.10.001; Porter KE, 2009, PHARMACOL THERAPEUT, V123, P255, DOI 10.1016/j.pharmthera.2009.05.002; Rose RA, 2010, CURR OPIN INVEST DR, V11, P349; Schmitt M, 2004, ARTERIOSCL THROM VAS, V24, P911, DOI 10.1161/01.ATV.zhq0504.7914; Snider P, 2009, CIRC RES, V105, P934, DOI 10.1161/CIRCRESAHA.109.201400; Socki T, 2005, J AM COLL CARDIOL, V45, P608, DOI 10.1016/j.jacc.2004.10.067; Sutton MGS, 2000, CIRCULATION, V101, P2981, DOI 10.1161/01.CIR.101.25.2981; Tamargo J, 2011, NAT REV DRUG DISCOV, V10, P536, DOI 10.1038/nrd3431; Tonnessen T, 2005, EUR J HEART FAIL, V7, P704, DOI 10.1016/j.ejheart.2005.07.005; Tsai EJ, 2009, PHARMACOL THERAPEUT, V122, P216, DOI 10.1016/j.pharmthera.2009.02.009; van de Weert M, 2000, PHARM RES-DORDR, V17, P1159, DOI 10.1023/A:1026498209874; WOODWARD SC, 1985, J BIOMED MATER RES, V19, P437, DOI 10.1002/jbm.820190408	44	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2013	8	7							e68346	10.1371/journal.pone.0068346	http://dx.doi.org/10.1371/journal.pone.0068346			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204FO	23861890	Green Published, gold			2023-01-03	WOS:000323350700081
J	Hwang, YS; Chiang, PR; Hong, WH; Chiao, CC; Chu, IM; Hsiue, GH; Shen, CR				Hwang, Yih-Shiou; Chiang, Ping-Ray; Hong, Wei-Hsin; Chiao, Chuan-Chin; Chu, I-Ming; Hsiue, Ging-Ho; Shen, Chia-Rui			Study In Vivo Intraocular Biocompatibility of In Situ Gelation Hydrogels: Poly(2-Ethyl Oxazoline)-Block-Poly(epsilon-Caprolactone)-Block-Poly(2-Ethyl Oxazoline) Copolymer, Matrigel and Pluronic F127	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; DIBLOCK COPOLYMER; RELEASE; NEOVASCULARIZATION; VITRO; CYTOTOXICITY; RANIBIZUMAB; TRIBLOCK; BEHAVIOR	The long term in vivo biocompatibility is an essential feature for the design and development of sustained drug release carriers. In the recent intraocular drug delivery studies, hydrogels were suggested as sustained release carriers. The biocompatibility test for these hydrogels, however, was commonly performed only through in vitro cell culture examination, which is insufficient before the clinical applications. We compared three thermosensitive hydrogels that have been suggested as the carriers for drugs by their gel-solution phase-change properties. A new block terpolymer (PEOz-PCL-PEOz, ECE) and two commercial products (Matrigel (R) and Pluronic F127) were studied. The results demonstrated that the ocular media remained translucent for ECE and Pluronic F127 in the first 2 weeks, but cataract formation for Matrigel occurred in 2 weeks and for Pluronic F127 in 1 month, while turbid media was observed for both Matrigel and Pluronic F127 in 2 months. The electrophysiology examinations showed significant neuroretinal toxicity of Matrigel and Pluronic F127 but good biocompatibility of ECE. The neuroretinal toxicity of Matrigel and Pluronic F127 and superior biocompatibility of ECE hydrogel suggests ECE as more appropriate biomaterial for use in research and potentially in intraocular application.	[Hwang, Yih-Shiou] Chang Gung Mem Hosp, Dept Ophthalmol, Tao Yuan, Taiwan; [Hwang, Yih-Shiou] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Tao Yuan, Taiwan; [Chiang, Ping-Ray; Chu, I-Ming; Hsiue, Ging-Ho] Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu, Taiwan; [Hong, Wei-Hsin; Shen, Chia-Rui] Chang Gung Univ, Coll Med, Dept Med Biotechnol & Lab Sci, Tao Yuan, Taiwan; [Chiao, Chuan-Chin] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan; [Hsiue, Ging-Ho] Chung Yuan Christian Univ, Dept Chem Engn, R&D Ctr Membrane Technol, Chungli, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; National Tsing Hua University; Chang Gung University; National Tsing Hua University; Chung Yuan Christian University	Shen, CR (corresponding author), Chang Gung Univ, Coll Med, Dept Med Biotechnol & Lab Sci, Tao Yuan, Taiwan.	crshen@mail.cgu.edu.tw	Chiao, Chuan-Chin/L-7708-2019; Chu, I-Ming/AAL-1148-2021	Shen, Chia-Rui/0000-0002-8386-3965	National Science Council of the Republic of China, Taiwan [NSC 98-2622-E-033-011-CC1, NSC 99-2622-E-033-005-CC1, 101-2320-B-182-027-MY3]; Chang Gung Memorial Hospital funds [CMRPG 390311, CMRPG 380181, CMRPD180403, BMRP440]	National Science Council of the Republic of China, Taiwan(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital funds	This work was supported by the funding from the National Science Council of the Republic of China, Taiwan (NSC 98-2622-E-033-011-CC1, NSC 99-2622-E-033-005-CC1 and 101-2320-B-182-027-MY3), and the Chang Gung Memorial Hospital funds (CMRPG 390311, CMRPG 380181, CMRPD180403 and BMRP440). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andreoli CM, 2007, CURR OPIN OPHTHALMOL, V18, P502, DOI 10.1097/ICU.0b013e3282f0ca54; Bae SJ, 2006, MACROMOLECULES, V39, P4873, DOI 10.1021/ma060153s; Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019; Bian LM, 2011, BIOMATERIALS, V32, P6425, DOI 10.1016/j.biomaterials.2011.05.033; Choi BG, 2010, BIOMATERIALS, V31, P9266, DOI 10.1016/j.biomaterials.2010.08.067; DAVIDORF FH, 1990, RETINA-J RET VIT DIS, V10, P297, DOI 10.1097/00006982-199010000-00013; Deng JJ, 2011, SOFT MATTER, V7, P5944, DOI 10.1039/c1sm05259d; FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640; Gong J, 2008, EXP EYE RES, V86, P957, DOI 10.1016/j.exer.2008.03.014; Gu ZY, 2004, MACROMOLECULES, V37, P912, DOI 10.1021/ma0206218; Hsiue GH, 2006, INT J PHARM, V317, P69, DOI 10.1016/j.ijpharm.2006.03.002; Hyun H, 2007, BIOMACROMOLECULES, V8, P1093, DOI 10.1021/bm060991u; Kang Derwent J. J., 2008, T AM OPHTHAL SOC, V106, P206; Khattak SF, 2005, TISSUE ENG, V11, P974, DOI 10.1089/ten.2005.11.974; Kibbey Maura C., 1994, Journal of Tissue Culture Methods, V16, P227, DOI 10.1007/BF01540656; Kitahara S, 2010, MED MOL MORPHOL, V43, P26, DOI 10.1007/s00795-009-0481-8; Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004; Kloxin AM, 2010, NAT PROTOC, V5, P1867, DOI 10.1038/nprot.2010.139; Kweon H, 2003, BIOMATERIALS, V24, P801, DOI 10.1016/S0142-9612(02)00370-8; Kwon JW, 2005, J CATARACT REFR SURG, V31, P607, DOI 10.1016/j.jcrs.2004.05.051; Lee SC, 1999, MACROMOLECULES, V32, P1847, DOI 10.1021/ma981664k; Luxenhofer R, 2011, J CONTROL RELEASE, V153, P73, DOI 10.1016/j.jconrel.2011.04.010; Marashi SM, 2011, J ALLERGY CLIN IMMUN, V127, P1385, DOI 10.1016/j.jaci.2011.04.001; Matthew JE, 2002, BIOMATERIALS, V23, P4615, DOI 10.1016/S0142-9612(02)00208-9; Miller JW, 1997, DIABETES METAB REV, V13, P37, DOI 10.1002/(SICI)1099-0895(199703)13:1<37::AID-DMR174>3.0.CO;2-K; Misra GP, 2009, BIOMATERIALS, V30, P6541, DOI 10.1016/j.biomaterials.2009.08.025; Oh SH, 2008, BIOMATERIALS, V29, P1601, DOI 10.1016/j.biomaterials.2007.11.036; Paques M, 2007, INVEST OPHTH VIS SCI, V48, P2769, DOI 10.1167/iovs.06-1099; Peng K, 2010, SOFT MATTER, V6, P85, DOI 10.1039/b914166a; Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001; Qiu G, 2006, EXP EYE RES, V83, P141, DOI 10.1016/j.exer.2005.11.014; Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Schlaad H, 2010, MACROMOL RAPID COMM, V31, P511, DOI 10.1002/marc.200900683; Shen DF, 2006, OPHTHALMIC RES, V38, P71, DOI 10.1159/000090266; Shen WY, 2000, GRAEF ARCH CLIN EXP, V238, P273, DOI 10.1007/s004170050353; Shishido SM, 2003, BIOMATERIALS, V24, P3543, DOI 10.1016/S0142-9612(03)00153-4; Sonoda A, 2010, CARDIOVASC INTER RAD, V33, P135, DOI 10.1007/s00270-009-9741-1; Sun L, 2010, J POLYM SCI POL CHEM, V48, P4583, DOI 10.1002/pola.24255; Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151; Tan HP, 2009, BIOMATERIALS, V30, P6844, DOI 10.1016/j.biomaterials.2009.08.058; Turturro SB, 2011, BIOMATERIALS, V32, P3620, DOI 10.1016/j.biomaterials.2011.01.058; Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558; Wolinsky JB, 2007, MACROMOLECULES, V40, P7065, DOI 10.1021/ma071276v; Zhong X, 2011, J MATER SCI-MATER M, P1	45	23	28	2	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2013	8	7							e67495	10.1371/journal.pone.0067495	http://dx.doi.org/10.1371/journal.pone.0067495			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175ZH	23840873	Green Published, gold, Green Submitted			2023-01-03	WOS:000321271900012
J	Geary, SM; Lemke, CD; Lubaroff, DM; Salem, AK				Geary, Sean M.; Lemke, Caitlin D.; Lubaroff, David M.; Salem, Aliasger K.			The Combination of a Low-Dose Chemotherapeutic Agent, 5-Fluorouracil, and an Adenoviral Tumor Vaccine Has a Synergistic Benefit on Survival in a Tumor Model System	PLOS ONE			English	Article							T-CELL RESPONSES; SUPPRESSOR-CELLS; ANTITUMOR IMMUNITY; CANCER VACCINES; IMMUNOTHERAPY; CYCLOPHOSPHAMIDE; ANTIGEN; MICE; IMMUNIZATION; DOXORUBICIN	Standard cancer therapies, particularly those involving chemotherapy, are in need of modifications that both reduce short-term and long-term side effects as well as improve the overall survival of cancer patients. Here we show that combining low-dose chemotherapy with a therapeutic vaccination using an adenovirus encoding a model tumor-associated antigen, ovalbumin (Ad5-OVA), had a synergistic impact on survival in tumor-challenged mice. Mice that received the combinatorial treatment of Ad5-OVA plus low-dose 5-fluorouracil (5-FU) had a 95% survival rate compared to 7% and 30% survival rates for Ad5-OVA alone and 5-FU alone respectively. The presence of 5-FU enhanced the levels of OVA-specific CD8(+) T lymphocytes in the spleens and draining lymph nodes of Ad5-OVA-treated mice, a phenomenon that was dependent on the mice having been tumor-challenged. Thus 5-FU may have enhanced survival of Ad5-OVA-treated mice by enhancing the tumor-specific immune response combined with eliminating tumor bulk. We also investigated the possibility that the observed therapeutic benefit may have been derived from the capacity of 5-FU to deplete MDSC populations. The findings presented here promote the concept of combining adenoviral cancer vaccines with low-dose chemotherapy.	[Geary, Sean M.; Lemke, Caitlin D.; Salem, Aliasger K.] Univ Iowa, Coll Pharm, Div Pharmaceut, Iowa City, IA 52242 USA; [Lubaroff, David M.] Univ Iowa, Holden Comprehens Canc Ctr, Dept Urol, Iowa City, IA 52242 USA; [Lubaroff, David M.] Univ Iowa, Holden Comprehens Canc Ctr, Dept Microbiol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Salem, AK (corresponding author), Univ Iowa, Coll Pharm, Div Pharmaceut, Iowa City, IA 52242 USA.	aliasger-salem@uiowa.edu	Salem, Aliasger/J-3674-2012	Salem, Aliasger/0000-0002-1923-6633	American Cancer Society [RSG-09-015-01-CDD]; National Cancer Institute at the National Institutes of Health [1R21CA13345-01/1R21CA128414- 01A2/UI Mayo Clinic Lymphoma SPORE]; NATIONAL CANCER INSTITUTE [P30CA086862] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors gratefully acknowledge support from the American Cancer Society (RSG-09-015-01-CDD), and the National Cancer Institute at the National Institutes of Health (1R21CA13345-01/1R21CA128414- 01A2/UI Mayo Clinic Lymphoma SPORE). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amato RJ, 2010, EXPERT OPIN BIOL TH, V10, P281, DOI 10.1517/14712590903586213; American Cancer Society, 2012, CANC FACTS FIG 2012; Antonia SJ, 2006, CLIN CANCER RES, V12, P878, DOI 10.1158/1078-0432.CCR-05-2013; ARDALAN B, 1992, INT J RADIAT ONCOL, V22, P511, DOI 10.1016/0360-3016(92)90864-E; Backus HHJ, 2001, ANN ONCOL, V12, P209, DOI 10.1023/A:1008331525368; Bass KK, 1998, CANCER IMMUNOL IMMUN, V47, P1, DOI 10.1007/s002620050498; Cheng C, 2007, PLOS PATHOG, V3, P239, DOI 10.1371/journal.ppat.0030025; Elzey BD, 2001, INT J CANCER, V94, P842, DOI 10.1002/ijc.1556; Emens LA, 2009, J CLIN ONCOL, V27, P5911, DOI 10.1200/JCO.2009.23.3494; Fridlender ZG, 2010, MOL THER, V18, P1947, DOI 10.1038/mt.2010.159; Gallina G, 2006, J CLIN INVEST, V116, P2777, DOI 10.1172/JCI28828; Garnett CT, 2008, CLIN CANCER RES, V14, P3536, DOI 10.1158/1078-0432.CCR-07-4025; Geary SM, 2011, CANCER IMMUNOL IMMUN, V60, P1309, DOI 10.1007/s00262-011-1038-y; Hodge JW, 2012, SEMIN ONCOL, V39, P323, DOI 10.1053/j.seminoncol.2012.02.006; Karan D, 2007, INT J CANCER, V121, P1520, DOI 10.1002/ijc.22873; Kirkwood JM, 2008, J CLIN ONCOL, V26, P3445, DOI 10.1200/JCO.2007.14.6423; Ko HJ, 2007, CANCER RES, V67, P7477, DOI 10.1158/0008-5472.CAN-06-4639; Krishnamachari Y, 2011, PHARM RES-DORDR, V28, P215, DOI 10.1007/s11095-010-0241-4; Liniger M, 2007, EXPERT REV VACCINES, V6, P255, DOI 10.1586/14760584.6.2.255; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lu P, 2005, SEMIN NUCL MED, V35, P197, DOI 10.1053/j.semnuclmed.2005.02.005; Lutsiak MEC, 2005, BLOOD, V105, P2862, DOI 10.1182/blood-2004-06-2410; Machiels JPH, 2001, CANCER RES, V61, P3689; MacLean GD, 1996, J IMMUNOTHER, V19, P309, DOI 10.1097/00002371-199607000-00006; Matsuzaki J, 2003, CELL IMMUNOL, V224, P98, DOI 10.1016/j.cellimm.2003.08.009; Mauti LA, 2011, J CLIN INVEST, V121, P2794, DOI 10.1172/JCI41936; Miller G, 2002, CANCER RES, V62, P5260; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Morales JK, 2009, CANCER IMMUNOL IMMUN, V58, P941, DOI 10.1007/s00262-008-0609-z; Morse MA, 2008, BLOOD, V112, P610, DOI 10.1182/blood-2008-01-135319; Nowak AK, 2006, ADV DRUG DELIVER REV, V58, P975, DOI 10.1016/j.addr.2006.04.002; Ooboshi H, 1997, AM J PHYSIOL-HEART C, V273, pH265, DOI 10.1152/ajpheart.1997.273.1.H265; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Siemens DR, 2001, J IMMUNOL, V166, P731, DOI 10.4049/jimmunol.166.2.731; Sierro SR, 2011, EUR J IMMUNOL, V41, P2217, DOI 10.1002/eji.201041235; Srivastava MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040677; Tipton J. M., 2003, HDB CANC CHEMOTHERAP, P561; Tvinnereim AR, 2004, J IMMUNOL, V173, P1994, DOI 10.4049/jimmunol.173.3.1994; Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791	42	37	42	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e67904	10.1371/journal.pone.0067904	http://dx.doi.org/10.1371/journal.pone.0067904			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IH	23840786	Green Published, gold			2023-01-03	WOS:000321148400141
J	Noble, B				Noble, Bill			PERSONAL VIEW Legalising assisted dying puts vulnerable patients at risk and doctors must speak up	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DIE		Univ Sheffield, Acad Unit Support Care, Sheffield S11 9NE, S Yorkshire, England	University of Sheffield	Noble, B (corresponding author), Univ Sheffield, Acad Unit Support Care, Sheffield S11 9NE, S Yorkshire, England.	bill.noble@sheffield.ac.uk						Godlee F, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4075; Heath I, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3755; McPherson A, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2827; McPherson T, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4007; Tallis R, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4115	5	7	7	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2013	346								f4062	10.1136/bmj.f4062	http://dx.doi.org/10.1136/bmj.f4062			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175QL	23804182				2023-01-03	WOS:000321246200011
J	Appleby, J				Appleby, John			Are accident and emergency attendances increasing?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Kings Fund, London, England		Appleby, J (corresponding author), Kings Fund, London, England.	j.appleby@kingsfund.org.uk						Appleby J., 2013, SLIDESHOW PRESSURES; Department of Health, TOTAL TIME SPENT IN; NHS England, 2013, A E WAITING TIMES AN; NHS England, WEEKLY TIME SERIES A; NHS England, 2013, NHS SUPPORT PLAN LAU; Skidmore C., 2013, DAILY MAIL; Steventon A, 2011, J HEALTH SERV RES PO, V16, P90, DOI 10.1258/jhsrp.2010.010097	7	4	4	2	49	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ BRIT MED J	BMJ-British Medical Journal	JUN 7	2013	346								f3677	10.1136/bmj.f3677	http://dx.doi.org/10.1136/bmj.f3677			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	161YM	23747970				2023-01-03	WOS:000320230400007
J	Ding, ST; Wang, CL; Huang, YH; Shu, CC; Tseng, YT; Huang, CT; Hsu, NC; Lin, YF; Tsai, HB; Yang, MC; Ko, WJ				Ding, Shih-Tan; Wang, Chuan-Lan; Huang, Yu-Han; Shu, Chin-Chung; Tseng, Yu-Tzu; Huang, Chun-Ta; Hsu, Nin-Chieh; Lin, Yu-Feng; Tsai, Hung-Bin; Yang, Ming-Chin; Ko, Wen-Je			Demand and Predictors for Post-Discharge Medical Counseling in Home Care Patients: A Prospective Cohort Study	PLOS ONE			English	Article							HEALTH-CARE; INFORMATION-TRANSFER; HOSPITALIST SYSTEM; INTERNAL-MEDICINE; CONTINUITY; DISCHARGE; READMISSION; PREVALENCE; PHYSICIANS; PNEUMONIA	Rationale: Post-discharge care is challenging due to the high rate of adverse events after discharge. However, details regarding post-discharge care requirements remain unclear. Post-discharge medical counseling (PDMC) by telephone service was set-up to investigate its demand and predictors. Methods: This prospective study was conducted from April 2011 to March 2012 in a tertiary referral center in northern Taiwan. Patients discharged for home care were recruited and educated via telephone hotline counseling when needed. The patient's characteristics and call-in details were recorded, and predictors of PDMC use and worsening by red-flag sign were analyzed. Results: During the study period, 224 patients were enrolled. The PDMC was used 121 times by 65 patients in an average of 8.6 days after discharge. The red-flag sign was noted in 17 PDMC from 16 patients. Of the PDMC used, 50% (n = 60) were for symptom change and the rest were for post-discharge care problems and issues regarding other administrative services. Predictors of PDMC were underlying malignancy and lower Barthel index (BI). On the other hand, lower BI, higher adjusted Charlson co-morbidity index (CCI), and longer length of hospital stay were associated with PDMC and red-flag sign. Conclusions: Demand for PDMC may be as high as 29% in home care patients within 30 days after discharge. PDMC is needed more by patients with malignancy and lower BI. More focus should also be given to those with lower BI, higher CCI, and longer length of hospital stay, as they more frequently have red flag signs.	[Ding, Shih-Tan; Shu, Chin-Chung; Tseng, Yu-Tzu; Huang, Chun-Ta; Hsu, Nin-Chieh; Lin, Yu-Feng; Tsai, Hung-Bin; Ko, Wen-Je] Natl Taiwan Univ Hosp, Div Hosp Med, Dept Traumatol, Taipei, Taiwan; [Wang, Chuan-Lan; Huang, Yu-Han] Natl Taiwan Univ Hosp, Dept Nursing, Taipei, Taiwan; [Shu, Chin-Chung; Tseng, Yu-Tzu; Huang, Chun-Ta; Lin, Yu-Feng] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei 10764, Taiwan; [Hsu, Nin-Chieh; Yang, Ming-Chin] Natl Taiwan Univ, Inst Hlth Policy & Management, Coll Publ Hlth, Taipei 10764, Taiwan; [Ko, Wen-Je] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Shu, CC (corresponding author), Natl Taiwan Univ Hosp, Div Hosp Med, Dept Traumatol, Taipei, Taiwan.	ccshu139@ntu.edu.tw	Tsai, Hung-Bin/G-3761-2011	HSU, NIN-CHIEH/0000-0002-4997-1081; Tsai, Hung-Bin/0000-0002-0689-8339; YANG, MING-CHIN/0000-0001-7326-8671; SHU, CHIN-CHUNG/0000-0003-0311-5148; HUANG, CHUN-TA/0000-0002-5234-4986; LIN, YU-FENG/0000-0002-4350-7755	Bureau of National Health Insurance, Department of Health, Executive Yuan, Taiwan [DOH100-NH-1008]	Bureau of National Health Insurance, Department of Health, Executive Yuan, Taiwan	The authors thank the Bureau of National Health Insurance, Department of Health, Executive Yuan, Taiwan for funding support (DOH100-NH-1008). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aslanyan S, 2004, EUR J NEUROL, V11, P49, DOI 10.1046/j.1468-1331.2003.00749.x; Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581; Cabre M, 2010, AGE AGEING, V39, P39, DOI 10.1093/ageing/afp100; Chaudhry SI, 2007, CIRCULATION, V116, P1549, DOI 10.1161/CIRCULATIONAHA.107.690768; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Giannella M, 2012, CLIN MICROBIOL INFEC, V18, P786, DOI 10.1111/j.1469-0691.2011.03757.x; Hsien CCM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001799; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jerng JS, 2008, J FORMOS MED ASSOC, V107, P396, DOI 10.1016/S0929-6646(08)60105-9; Karapinar-Carkit F, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-39; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kuo Y, 2009, NEW ENGL J MED, V360, P1102, DOI 10.1056/NEJMsa0802381; Leong IYO, 2009, ANN ACAD MED SINGAP, V38, P113; Li JYZ, 2013, J EVAL CLIN PRACT, V19, P76, DOI 10.1111/j.1365-2753.2011.01772.x; Lindenauer PK, 2007, NEW ENGL J MED, V357, P2589, DOI 10.1056/NEJMsa067735; Ling Wang Y-ML, 2009, TAIWAN EC FORUM, V7, P36; Peterson MC, 2009, MAYO CLIN PROC, V84, P248, DOI 10.1016/S0025-6196(11)61142-7; Rennke S, 2012, AM J MED, V125, P28, DOI 10.1016/j.amjmed.2011.05.011; Sackley C, 2008, STROKE, V39, P3329, DOI 10.1161/STROKEAHA.108.518563; Sainsbury A, 2005, AGE AGEING, V34, P228, DOI 10.1093/ageing/afi063; Sharma G, 2009, JAMA-J AM MED ASSOC, V301, P1671, DOI 10.1001/jama.2009.517; Shu CC, 2012, INTERN MED J, V42, P677, DOI 10.1111/j.1445-5994.2011.02562.x; Shu CC, 2011, J HOSP MED, V6, P378, DOI [10.1002/Thm.896, 10.1002/jhm.896]; Shu CC, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-96; Stinson JN, 2006, PAIN, V125, P143, DOI 10.1016/j.pain.2006.05.006; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6; van Walraven C, 2010, J CLIN EPIDEMIOL, V63, P1000, DOI 10.1016/j.jclinepi.2010.01.023; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; Wang Han-Yi, 2007, Chang Gung Med J, V30, P437; Wen CP, 2008, ANN INTERN MED, V148, P258, DOI 10.7326/0003-4819-148-4-200802190-00004	30	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2013	8	5							e64274	10.1371/journal.pone.0064274	http://dx.doi.org/10.1371/journal.pone.0064274			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177SC	23737976	Green Published, Green Submitted, gold			2023-01-03	WOS:000321394700040
J	Tosh, W				Tosh, William			It can be tough for families when patients choose to die at home	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Russells Hall Hosp, Dept Anaesthesia, Dudley DY1 2HQ, W Midlands, England	Russells Hall Hospital	Tosh, W (corresponding author), Russells Hall Hosp, Dept Anaesthesia, Dudley DY1 2HQ, W Midlands, England.	w.tosh@doctors.org.uk							0	3	3	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2013	346								f3397	10.1136/bmj.f3397	http://dx.doi.org/10.1136/bmj.f3397			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	158DG	23719642				2023-01-03	WOS:000319948200010
J	Goodnough, LT; Levy, JH; Murphy, MF				Goodnough, Lawrence T.; Levy, Jerrold H.; Murphy, Michael F.			Concepts of blood transfusion in adults	LANCET			English	Article							FRESH-FROZEN PLASMA; CLINICAL-PRACTICE GUIDELINE; PROPHYLACTIC PLATELET TRANSFUSIONS; CARDIAC-SURGERY; CELL TRANSFUSION; CARDIOVASCULAR-ANESTHESIOLOGISTS; THORACIC-SURGEONS; HEMATOLOGICAL MALIGNANCIES; CONSENSUS CONFERENCE; PRACTICE PARAMETER	Recent progress has been made in the identification and implementation of best transfusion practices on the basis of evidence-based clinical trials, published clinical practice guidelines, and process improvements for blood use and clinical patient outcomes. However, substantial variability persists in transfusion outcomes for patients in some clinical settings-eg, patients undergoing cardiothoracic surgery. This variability could be the result of insufficient understanding of published guidelines; different recommendations of medical societies, including the specification of a haemoglobin concentration threshold to use as a transfusion trigger; the value of haemoglobin as a surrogate indicator for transfusion benefit, even though only changes in concentration and not absolute red cell mass of haemoglobin can be identified; and disagreement about the validity of the level 1 evidence for clinical practice guidelines. Nevertheless, institutional experience and national databases suggest that a restrictive blood transfusion approach is being increasingly implemented as best practice.	[Goodnough, Lawrence T.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Goodnough, Lawrence T.] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Levy, Jerrold H.] Duke Univ, Sch Med, Dept Anesthesiol, Durham, NC USA; [Murphy, Michael F.] Oxford Univ Hosp, NHS Blood & Transplant, Oxford, England; [Murphy, Michael F.] Univ Oxford, Oxford, England	Stanford University; Stanford University; Duke University; Oxford University Hospitals NHS Foundation Trust; University of Oxford	Goodnough, LT (corresponding author), Stanford Univ, Med Ctr, Transfus Serv, 300 Pasteur Dr, Stanford, CA 94305 USA.	ltgoodno@stanford.edu						Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Adams ES, 2011, PEDIATRICS, V127, pE1112, DOI 10.1542/peds.2010-3252; Adams RC., 1942, SURG GYNECOL OBSTET, V3, P603; Amer Soc Anesthesiologists Task Fo, 2006, ANESTHESIOLOGY, V105, P198; Australasian Society of Blood Transfusion, CLINICAL PRACTICE GU; Bennett-Guerrero E, 2010, JAMA-J AM MED ASSOC, V304, P1568, DOI 10.1001/jama.2010.1406; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P551; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; Bittencourt R, 2012, REV BRAS ANESTESIOL, V62, P402, DOI 10.1016/S0034-7094(12)70140-X; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; British Committee for Standards in Haematology (BCSH), GUIDELINE ON THE ADM; Cameron B, 2007, TRANSFUSION, V47, P206, DOI 10.1111/j.1537-2995.2007.01090.x; Carlier M, 2011, TRANSFUS CLIN BIOL, V18, P140, DOI 10.1016/j.tracli.2011.02.024; Carson JL, 2012, ANN INTERN MED, V157, P49, DOI 10.7326/0003-4819-157-1-201206190-00429; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; Carson JL, 2002, TRANSFUS MED REV, V16, P187, DOI 10.1053/tmrv.2002.33461; Carson JL, 2002, TRANSFUSION, V42, P812, DOI 10.1046/j.1537-2995.2002.00123.x; Carson JL, 2012, COCHRANE DB SYST REV, V18, P4, DOI DOI 10.1002/14651858.CD002042.PUB3; Chapman CE, 2009, TRANSFUSION, V49, P440, DOI 10.1111/j.1537-2995.2008.01948.x; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; CONTRERAS M, 1992, TRANSFUSION MED, V2, P57; Contreras M, 1998, TRANSFUSION, V38, P796, DOI 10.1046/j.1537-2995.1998.38898375520.x; COOPER ES, 1994, JAMA-J AM MED ASSOC, V271, P777, DOI 10.1001/jama.1994.03510340067036; Cotton BA, 2008, J TRAUMA, V64, P1177, DOI 10.1097/TA.0b013e31816c5c80; Cotton BA, 2009, J TRAUMA, V67, P1004, DOI 10.1097/TA.0b013e3181bcb2a8; Estcourt LJ, 2012, VOX SANG, V103, P284, DOI 10.1111/j.1423-0410.2012.01627.x; Estcourt L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004269.pub3; Estcourt LJ, 2011, BRIT J HAEMATOL, V154, P425, DOI 10.1111/j.1365-2141.2010.08483.x; Expert Working Group, 1997, CAN MED ASSOC J SUPP, V156, P1; Ferraris VA, 2007, ANN THORAC SURG, V83, P27, DOI 10.1016/j.athoracsur.2007.02.099; Ferraris VA, 2011, ANN THORAC SURG, V91, P944, DOI 10.1016/j.athoracsur.2010.11.078; FINCH CA, 1972, NEW ENGL J MED, V286, P407, DOI 10.1056/NEJM197202242860806; Frank SM, 2012, ANESTHESIOLOGY, V117, P99, DOI 10.1097/ALN.0b013e318255e550; Gammon HM, 2011, TRANSFUSION, V51, P2500, DOI 10.1111/j.1537-2995.2011.03406.x; Goodnough LT, 2013, CURR OPIN ANESTHESIO, V26, P208, DOI 10.1097/ACO.0b013e32835d6f8f; Goodnough Lawrence Tim, 2012, Ann Thorac Surg, V94, P709, DOI 10.1016/j.athoracsur.2012.04.016; Goodnough LT, 2012, ANESTHESIOLOGY, V116, P1367, DOI 10.1097/ALN.0b013e318254d1a3; Goodnough LT, 1999, NEW ENGL J MED, V340, P525, DOI 10.1056/NEJM199902183400706; Goodnough LT, 1996, ARCH PATHOL LAB MED, V120, P802; Goodnough LT, 2001, NEW ENGL J MED, V345, P1272, DOI 10.1056/NEJM200110253451711; Goodnough LT, 1999, NEW ENGL J MED, V340, P438, DOI 10.1056/NEJM199902113400606; GOODNOUGH LT, 1995, ANN THORAC SURG, V60, P473, DOI 10.1016/0003-4975(95)98960-3; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Haspel RL, 2012, TRANSFUSION, V52, P227, DOI 10.1111/j.1537-2995.2011.03191.x; Healthcare Cost and Utilization Project, HCUP FACTS AND FIGUR; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hessel EA, 2010, ANESTH ANALG, V111, P1555, DOI 10.1213/ANE.0b013e3181fbb386; Hogue CW, 1998, TRANSFUSION, V38, P924, DOI 10.1046/j.1537-2995.1998.381098440856.x; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Holland LL, 2006, AM J CLIN PATHOL, V126, P133, DOI 10.1309/NQXHUG7HND78LFFK; Hutton B, 2005, CAN J ANAESTH, V52, P581, DOI 10.1007/BF03015766; Inaba K, 2010, J AM COLL SURGEONS, V210, P957, DOI 10.1016/j.jamcollsurg.2010.01.031; Innes G, 1998, J Emerg Med, V16, P129; Jackman RP, 2012, TRANSFUSION, V52, P2533, DOI 10.1111/j.1537-2995.2012.03618.x; Joshi GP, 2005, ANESTH ANALG, V101, P601, DOI 10.1213/01.ANE.0000159171.26521.31; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Kelsey P, 2003, BRIT J HAEMATOL, V122, P10; Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group, 2012, KIDNEY INT SUPPL, V2, P279, DOI DOI 10.1038/kisup.2012.37; Levy JH, 2012, ANESTH ANALG, V114, P261, DOI 10.1213/ANE.0b013e31822e1853; Li GX, 2011, TRANSFUSION, V51, P338, DOI 10.1111/j.1537-2995.2010.02816.x; Likosky DS, 2010, ANESTH ANALG, V111, P316, DOI 10.1213/ANE.0b013e3181e329f1; Lin YL, 2012, TRANSFUSION, V52, P567, DOI 10.1111/j.1537-2995.2011.03330.x; Liumbruno G, 2009, BLOOD TRANSFUS-ITALY, V7, P132, DOI 10.2450/2009.0005-09; Madjdpour C, 2006, CRIT CARE MED, V34, pS102, DOI 10.1097/01.CCM.0000214317.26717.73; Moore FA, 2008, J TRAUMA, V64, P1010, DOI 10.1097/TA.0b013e31816a2417; Morton J, 2010, AM J MED QUAL, V25, P289, DOI 10.1177/1062860610366159; Mudumbai SC, 2011, TRANSFUSION, V51, P2148, DOI 10.1111/j.1537-2995.2011.03134.x; Murphy MF, 2011, VOX SANG, V100, P46, DOI 10.1111/j.1423-0410.2010.01366.x; Murphy MF, 2001, BRIT J HAEMATOL, V113, P24; MURPHY MF, 1992, TRANSFUSION MED, V2, P311, DOI 10.1111/j.1365-3148.1992.tb00175.x; Napolitano LM, 2009, J TRAUMA, V67, P1439, DOI 10.1097/TA.0b013e3181ba7074; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; National Blood Authority Australia,, PATIENT BLOOD MANAGE; O'Shaughnessy DF, 2004, BRIT J HAEMATOL, V126, P11, DOI 10.1111/j.1365-2141.2004.04972.x; Parrillo JE, 2001, CRIT CARE MED, V29, pS139, DOI 10.1097/00003246-200109001-00001; Pattakos G, 2012, ARCH INTERN MED, V172, P1154, DOI 10.1001/archinternmed.2012.2449; Rebulla P, 1997, NEW ENGL J MED, V337, P1870, DOI 10.1056/NEJM199712253372602; Roback JD, 2010, TRANSFUSION, V50, P1227, DOI 10.1111/j.1537-2995.2010.02632.x; Rodgers GM, 2012, J NATL COMPR CANC NE, V10, P628, DOI 10.6004/jnccn.2012.0064; Rogers MAM, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-37; Sack K., 2013, THE NEW YORK TIMES; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schiffer CA, 2001, J CLIN ONCOL, V19, P1519, DOI 10.1200/JCO.2001.19.5.1519; Segal JB, 2005, TRANSFUSION, V45, P1413, DOI 10.1111/j.1537-2995.2005.00546.x; Shander A, 2011, TRANSFUS MED REV, V25, P232, DOI 10.1016/j.tmrv.2011.02.001; Shander A, 2010, TRANSFUSION, V50, P753, DOI 10.1111/j.1537-2995.2009.02518.x; Shander AS, 2010, JAMA-J AM MED ASSOC, V304, P1610, DOI 10.1001/jama.2010.1483; Simon TL, 1998, ARCH PATHOL LAB MED, V122, P130; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; Snyder-Ramos SA, 2008, TRANSFUSION, V48, P1284, DOI 10.1111/j.1537-2995.2008.01666.x; SPENCE RK, 1992, AM SURGEON, V58, P92; Spinella PC, 2009, BLOOD REV, V23, P231, DOI 10.1016/j.blre.2009.07.003; Stanworth SJ, 2013, NEW ENGL J MED, V368, P1771, DOI 10.1056/NEJMoa1212772; Stanworth SJ, 2011, TRANSFUSION, V51, P62, DOI 10.1111/j.1537-2995.2010.02798.x; Stanworth SJ, 2004, BRIT J HAEMATOL, V126, P139, DOI 10.1111/j.1365-2141.2004.04973.x; Starr D., 1998, BLOOD AN EPIC HISTOR; Stehling LC, 1996, ANESTHESIOLOGY, V84, P732; Stover EP, 1998, ANESTHESIOLOGY, V88, P327, DOI 10.1097/00000542-199802000-00009; US Department of Health and Human Services, 2007, 2007 NATIONAL BLOOD; US Food and Drug Administration Center for Biologics Evaluation and Research, FATALITIES REPORTED; Vamvakas EC, 2013, TRANSFUSION, V53, P888, DOI 10.1111/j.1537-2995.2012.03825.x; VANWOERKENS ECSM, 1992, ANESTH ANALG, V75, P818; Villanueva C, 2013, NEW ENGL J MED, V368, P11, DOI 10.1056/NEJMoa1211801; Wandt H, 2012, LANCET, V380, P1309, DOI 10.1016/S0140-6736(12)60689-8; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393; Wu WC, 2001, NEW ENGL J MED, V345, P1230, DOI 10.1056/NEJMoa010615; Yang L, 2012, TRANSFUSION, V52, P1673, DOI 10.1111/j.1537-2995.2011.03515.x	109	169	170	2	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2013	381	9880					1845	1854		10.1016/S0140-6736(13)60650-9	http://dx.doi.org/10.1016/S0140-6736(13)60650-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151EO	23706801				2023-01-03	WOS:000319443700031
J	Spahn, DR; Goodnough, LT				Spahn, Donat R.; Goodnough, Lawrence T.			Alternatives to blood transfusion	LANCET			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; RANDOMIZED-CLINICAL-TRIAL; CORONARY-ARTERY-BYPASS; IRON-DEFICIENCY ANEMIA; PHASE-III TRIAL; DARBEPOETIN-ALPHA; STIMULATING AGENTS; EPOETIN-ALPHA; DOUBLE-BLIND; FACTOR-XIII	The use of alternatives to allogeneic blood continues to rest on the principles that blood transfusions have inherent risks, associated costs, and affect the blood inventory available for health-care delivery. Increasing evidence exists of a fall in the use of blood because of associated costs and adverse outcomes, and suggests that the challenge for the use of alternatives to blood components will similarly be driven by costs and patient outcomes. Additionally, the risk-benefit profiles of alternatives to blood transfusion such as autologous blood procurement, erythropoiesis-stimulating agents, and haemostatic agents are under investigation. Nevertheless, the inherent risks of blood, along with the continued rise in blood costs are likely to favour the continued development and use of alternatives to blood transfusion. We summarise the current roles of alternatives to blood in the management of medical and surgical anaemias.	[Spahn, Donat R.] Univ Zurich, Inst Anaesthesiol, CH-8091 Zurich, Switzerland; [Spahn, Donat R.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Goodnough, Lawrence T.] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; [Goodnough, Lawrence T.] Stanford Univ, Dept Med, Stanford, CA 94305 USA	University of Zurich; University of Zurich; University Zurich Hospital; Stanford University; Stanford University	Spahn, DR (corresponding author), Univ Zurich, Inst Anaesthesiol, CH-8091 Zurich, Switzerland.	donat.spahn@usz.ch			Swiss National Science Foundation (Bern, Switzerland); Swiss Society of Anaesthesiology and Reanimation (Bern, Switzerland); Swiss Foundation for Anesthesia Research (Zurich, Switzerland); Bundesprogramm Chancengleichheit (Bern, Switzerland); CSL Behring (Bern, Switzerland); Vifor SA (Villars-sur-Glane, Switzerland)	Swiss National Science Foundation (Bern, Switzerland)(Swiss National Science Foundation (SNSF)); Swiss Society of Anaesthesiology and Reanimation (Bern, Switzerland); Swiss Foundation for Anesthesia Research (Zurich, Switzerland); Bundesprogramm Chancengleichheit (Bern, Switzerland); CSL Behring (Bern, Switzerland); Vifor SA (Villars-sur-Glane, Switzerland)	DRS's academic department is receiving grant support from the Swiss National Science Foundation (Bern, Switzerland), the Swiss Society of Anaesthesiology and Reanimation (Bern, Switzerland), the Swiss Foundation for Anesthesia Research (Zurich, Switzerland), Bundesprogramm Chancengleichheit (Bern, Switzerland), CSL Behring (Bern, Switzerland), and Vifor SA (Villars-sur-Glane, Switzerland). In the past 5 years, DRS has received honoraria or travel support for consulting or lecturing from the following companies: AMGEN GmbH (Munich, Germany), Baxter AG (Volketswil, Switzerland), Baxter S. p. A. (Rome, Italy), CSL Behring GmbH (Hattersheim am Main, Germany and Bern, Switzerland), Ethicon Biosurgery (Sommerville, NJ, USA), Janssen-Cilag AG (Baar, Switzerland), Janssen-Cilag EMEA (Beerse, Belgium), Novo Nordisk A/S, (Bagsvard, Denmark), Octapharma AG (Lachen, Switzerland), Organon AG (Pfaffikon, Switzerland), Oxygen Biotherapeutics (Costa Mesa, CA, USA), Pentapharm GmbH (now tem Innovations GmbH; Munich, Germany), ratiopharm Arzneimittel Vertriebs-GmbH (Vienna, Austria), Roche Pharma (Switzerland) AG (Reinach, Switzerland), Vifor Pharma Deutschland GmbH (Munich, Germany), Vifor Pharma Osterreich GmbH (Vienna, Austria), Vifor (International) AG (St Gallen, Switzerland). LTG is a consultant for Amgen (Thousand Oaks, CA, USA), Luitpold (Shirley, NY, USA), Vifor (Glattbrugg, Switzerland), CSL Behring (King of Prussia, PA, USA), Hemocue (Cypress, CA, USA), and Octapharma (Hoboken, NJ, USA).	Afshari A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007871.pub2; BELL K, 1992, TRANSFUSION MED, V2, P295, DOI 10.1111/j.1365-3148.1992.tb00173.x; Bernard AC, 2009, J AM COLL SURGEONS, V208, P931, DOI 10.1016/j.jamcollsurg.2008.11.019; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Billote DB, 2002, J BONE JOINT SURG AM, V84A, P1299, DOI 10.2106/00004623-200208000-00003; Bohlius J, 2009, LANCET, V373, P1532, DOI 10.1016/S0140-6736(09)60502-X; Brecher ME, 2001, TRANSFUSION, V41, P1459, DOI 10.1046/j.1537-2995.2001.41121459.x; Bregman DB, 2013, AM J HEMATOL, V88, P97, DOI 10.1002/ajh.23354; Busch MP, 2003, JAMA-J AM MED ASSOC, V289, P959, DOI 10.1001/jama.289.8.959; Carless PA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001888.pub2; Carless PA, 2004, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001884.PUB2; Carson Jeffrey L, 2012, Cochrane Database Syst Rev, pCD002042, DOI 10.1002/14651858.CD002042.pub3; Cortet M, 2012, BRIT J ANAESTH, V108, P984, DOI 10.1093/bja/aes096; Crescenzi G, 2008, ANESTHESIOLOGY, V109, P1063, DOI 10.1097/ALN.0b013e31818db18b; D'Ambra MN, 1997, ANN THORAC SURG, V64, P1686, DOI 10.1016/S0003-4975(97)00839-4; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Fergusson DA, 2008, NEW ENGL J MED, V358, P2319, DOI 10.1056/NEJMoa0802395; Ferraris VA, 2011, ANN THORAC SURG, V91, P944, DOI 10.1016/j.athoracsur.2010.11.078; Franchini M, 2010, BLOOD TRANSFUS-ITALY, V8, P149, DOI [10.2450/2010-0149-09, 10.2450/2010.0149-09]; Frank SM, 2013, ANESTH ANALG, V116, P975, DOI 10.1213/ANE.0b013e31828843e6; Furie B, 2008, NEW ENGL J MED, V359, P938, DOI 10.1056/NEJMra0801082; Ganz T, 2011, BLOOD, V117, P4425, DOI 10.1182/blood-2011-01-258467; Gerlach R, 2002, STROKE, V33, P1618, DOI 10.1161/01.STR.0000017219.83330.FF; Godje O, 2006, THORAC CARDIOV SURG, V54, P26, DOI 10.1055/s-2005-872853; Gorlinger K, 2011, ANESTHESIOLOGY, V115, P1179, DOI 10.1097/ALN.0b013e31823497dd; Goodnough LT, 2011, BRIT J ANAESTH, V106, P13, DOI 10.1093/bja/aeq361; Goodnough LT, 2013, CURR OPIN ANESTHESIO, V26, P208, DOI 10.1097/ACO.0b013e32835d6f8f; Goodnough LT, 2013, ANESTH ANALG, V116, P15, DOI 10.1213/ANE.0b013e318273f4ae; Goodnough LT, 2012, TRANSFUSION, V52, P1584, DOI 10.1111/j.1537-2995.2011.03495.x; Goodnough LT, 2012, ANESTHESIOLOGY, V116, P1367, DOI 10.1097/ALN.0b013e318254d1a3; Goodnough LT, 2011, BLOOD, V117, P6091, DOI 10.1182/blood-2010-11-316075; Goodnough LT, 2010, BLOOD, V116, P4754, DOI 10.1182/blood-2010-05-286260; Goodnough LT, 2010, AM J HEMATOL, V85, P835, DOI 10.1002/ajh.21870; Goodnough LT, 1999, NEW ENGL J MED, V340, P525, DOI 10.1056/NEJM199902183400706; Goodnough LT, 2003, TRANSFUSION, V43, P668, DOI 10.1046/j.1537-2995.2003.00367.x; Goodnough LT, 1997, NEW ENGL J MED, V336, P933, DOI 10.1056/NEJM199703273361307; Goodnough LT., CRIT CARE M IN PRESS; Gruen RL, 2012, LANCET, V380, P1099, DOI 10.1016/S0140-6736(12)61224-0; Guralnik JM, 2004, BLOOD, V104, P2263, DOI 10.1182/blood-2004-05-1812; GUYATT GH, 1990, AM J MED, V88, P205, DOI 10.1016/0002-9343(90)90143-2; Guyatt GH, 2012, CHEST, V141, p7S, DOI 10.1378/chest.1412S3; Hadland BK, 2009, J CLIN ONCOL, V27, P4217, DOI 10.1200/JCO.2008.21.6945; Hanke AA, 2010, ANAESTHESIA, V65, P688, DOI 10.1111/j.1365-2044.2010.06367.x; Hedenus M, 2003, BRIT J HAEMATOL, V122, P394, DOI 10.1046/j.1365-2141.2003.04448.x; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Henry DA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub4; Henry DH, 2007, ONCOLOGIST, V12, P231, DOI 10.1634/theoncologist.12-2-231; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Hutton B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5798; Inbal A, 2012, BLOOD, V119, P5111, DOI 10.1182/blood-2011-10-386045; Innerhofer P, 2013, INJURY, V44, P209, DOI 10.1016/j.injury.2012.08.047; Isbister JP, 2011, TRANSFUS MED REV, V25, P89, DOI 10.1016/j.tmrv.2010.11.001; Karlsson M, 2009, THROMB HAEMOSTASIS, V102, P137, DOI 10.1160/TH08-09-0587; Ker K, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3054; Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group, 2012, KIDNEY INT SUPPL, V2, P279, DOI DOI 10.1038/kisup.2012.37; Korte WC, 2009, ANESTHESIOLOGY, V110, P239, DOI 10.1097/ALN.0b013e318194b21e; Kotze A, 2012, BRIT J ANAESTH, V108, P943, DOI 10.1093/bja/aes135; Kozek-Langenecker S, 2011, CRIT CARE, V15, DOI 10.1186/cc10583; Kozek-Langenecker S, 2011, CRIT CARE, V15, DOI 10.1186/cc10488; Levi M, 2010, NEW ENGL J MED, V363, P1791, DOI 10.1056/NEJMoa1006221; Levy JH, 2013, TRANSFUSION, V53, P1120, DOI 10.1111/j.1537-2995.2012.03865.x; Leyland-Jones B, 2005, J CLIN ONCOL, V23, P5960, DOI 10.1200/JCO.2005.06.150; Logan AC, 2011, ANN INTERN MED, V154, P516, DOI 10.7326/0003-4819-154-8-201104190-00002; Musallam KM, 2011, LANCET, V378, P1396, DOI 10.1016/S0140-6736(11)61381-0; Na HS, 2011, TRANSFUSION, V51, P118, DOI 10.1111/j.1537-2995.2010.02783.x; Nasso G, 2009, ANN THORAC SURG, V88, P1520, DOI 10.1016/j.athoracsur.2009.07.014; Nemeth Elizabeta, 2010, Adv Hematol, V2010, P750643, DOI 10.1155/2010/750643; Overgaard J, 2007, EJC SUPPL, V5, P7, DOI 10.1016/S1359-6349(07)70099-X; Peyssonnaux C, 2007, J CLIN INVEST, V117, P1926, DOI 10.1172/JCI31370; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Rahe-Meyer N, 2013, ANESTHESIOLOGY, V118, P40, DOI 10.1097/ALN.0b013e3182715d4d; Raje D, 2007, DIS COLON RECTUM, V50, P1211, DOI 10.1007/s10350-007-0249-y; Reiter RA, 2003, BLOOD, V102, P4594, DOI 10.1182/blood-2002-11-3566; Rizzo JD, 2010, J ONCOL PRACT, V6, P317, DOI 10.1200/JOP.2010.000132; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Rugeri L, 2007, J THROMB HAEMOST, V5, P289, DOI 10.1111/j.1538-7836.2007.02319.x; Schochl H, 2011, CRIT CARE, V15, DOI 10.1186/cc10078; Shander A, 2012, BRIT J ANAESTH, V109, P55, DOI 10.1093/bja/aes139; Shander A, 2010, TRANSFUSION, V50, P753, DOI 10.1111/j.1537-2995.2009.02518.x; Sinclair AM, 2010, BLOOD, V115, P4264, DOI 10.1182/blood-2009-10-248666; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Singla NK, 2011, J AM COLL SURGEONS, V213, P722, DOI 10.1016/j.jamcollsurg.2011.08.019; Smith RE, 2008, J CLIN ONCOL, V26, P1040, DOI 10.1200/JCO.2007.14.2885; Solomon SB, 2013, BLOOD, V121, P1663, DOI 10.1182/blood-2012-10-462945; Sowade O, 1997, BLOOD, V89, P411, DOI 10.1182/blood.V89.2.411; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Spotnitz WD, 2012, TRANSFUSION, V52, P2243, DOI 10.1111/j.1537-2995.2012.03707.x; Steinlechner B, 2011, ANN THORAC SURG, V91, P1420, DOI 10.1016/j.athoracsur.2011.01.052; Stowell CP, 2009, SPINE, V34, P2479, DOI 10.1097/BRS.0b013e3181bd163f; Swedberg K, 2013, NEW ENGL J MED, V368, P1210, DOI 10.1056/NEJMoa1214865; Swift S, 2010, BLOOD, V115, P4254, DOI 10.1182/blood-2009-10-248674; Tanno Toshihiko, 2010, Adv Hematol, V2010, P358283, DOI 10.1155/2010/358283; Thomas G, 2008, GYNECOL ONCOL, V108, P317, DOI 10.1016/j.ygyno.2007.10.011; Unger EF, 2010, NEW ENGL J MED, V362, P189, DOI 10.1056/NEJMp0912328; Untch M, 2011, ANN ONCOL, V22, P1988, DOI 10.1093/annonc/mdq709; Vamvakas EC, 2009, BLOOD, V113, P3406, DOI 10.1182/blood-2008-10-167643; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Virmani S, 2010, ANN CARD ANAESTH, V13, P34, DOI 10.4103/0971-9784.58832; Weber CF, 2012, ANESTHESIOLOGY, V117, P531, DOI 10.1097/ALN.0b013e318264c644; Weiss G, 2005, NEW ENGL J MED, V352, P1011, DOI 10.1056/NEJMra041809; Weltert L, 2013, TRANSFUSION, V53, P790, DOI 10.1111/j.1537-2995.2012.03836.x; Weltert L, 2010, J THORAC CARDIOV SUR, V139, P621, DOI 10.1016/j.jtcvs.2009.10.012; Wright JR, 2007, J CLIN ONCOL, V25, P1027, DOI 10.1200/JCO.2006.07.1514; Yank V, 2011, ANN INTERN MED, V154, P529, DOI 10.7326/0003-4819-154-8-201104190-00004; Yoo YC, 2011, ANESTHESIOLOGY, V115, P929, DOI 10.1097/ALN.0b013e318232004b	105	162	168	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2013	381	9880					1855	1865		10.1016/S0140-6736(13)60808-9	http://dx.doi.org/10.1016/S0140-6736(13)60808-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151EO	23706802	Green Published			2023-01-03	WOS:000319443700032
J	Moodley, D; Reddy, L; Mahungo, W; Masha, R				Moodley, Dhayendre; Reddy, Leanne; Mahungo, Wisani; Masha, Rebotile			Factors Associated with Coverage of Cotrimoxazole Prophylaxis in HIV-Exposed Children in South Africa	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RANDOMIZED CONTROLLED-TRIAL; PMTCT PROGRAM; DOUBLE-BLIND; TRANSMISSION; COHORT; PREVENTION; NEVIRAPINE; INFECTION; EFFICACY	Background: The World Health Organisation and the Joint United Nations Programme in 2006 reaffirmed the earlier recommendation of 2000 that all HIV-exposed infants in resource-poor countries should commence cotrimoxazole (CTX) prophylaxis at 6-weeks of life. CTX prophylaxis should be continued until the child is confirmed HIV-uninfected and there is no further exposure to breastmilk transmission. We determined CTX coverage and explored factors associated with CTX administration in HIV-exposed infants at a primary health clinic in South Africa. Methods: In a cross-sectional study of HIV-exposed infants 6-18 months of age attending a child immunisation clinic, data from the current visit and previous visits related to CTX prophylaxis, feeding practice and infant HIV testing were extracted from the child's immunisation record. Further information related to the administration of CTX prophylaxis was obtained from an interview with the child's mother. Results: One-third (33.0%) HIV-exposed infants had not initiated CTX at all and breastfed infants were more likely to have commenced CTX prophylaxis as compared to their non-breastfed counterparts (78.7% vs 63.4%) (p = 0.008). Availability of infant's HIV status was strongly associated with continuation or discontinuation of CTX after 6 months of age or after breastfeeding cessation. Maternal self-reports indicated that only 52.5% (95%CI 47.5-57.5) understood the reason for CTX prophylaxis, 126 (47%) did not dose during weekends; 55 (21%) dosed their infants 3 times a day and 70 (26%) dosed their infants twice daily. Conclusion: A third of HIV-exposed children attending a primary health care facility in this South African setting did not receive CTX prophylaxis. Not commencing CTX prophylaxis was strongly associated with infants not breastfeeding and unnecessary continued exposure to CTX in this paediatric population was due to limited availability of early infant diagnosis. Attendance at immunization clinics can be seen as missed opportunities for early infant diagnosis of HIV and related care.	[Moodley, Dhayendre; Reddy, Leanne; Mahungo, Wisani; Masha, Rebotile] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Obstet & Gynaecol, Womens Hlth & HIV Res Unit, Durban, South Africa	University of Kwazulu Natal	Moodley, D (corresponding author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, Dept Obstet & Gynaecol, Womens Hlth & HIV Res Unit, Durban, South Africa.	moodleyd1@ukzn.ac.za	Moodley, Dhayendre/U-6802-2019					[Anonymous], 2009, HIV INF FEED REV PRI; Bobat R, 1996, PEDIATR INFECT DIS J, V15, P604, DOI 10.1097/00006454-199607000-00009; Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4; Coovadia HM, 2012, LANCET, V379, P221, DOI 10.1016/S0140-6736(11)61653-X; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; Department of Health, 2010, NAT ANT SENT HIV SYP; Doherty T, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-406; Gill CJ, 2008, B WORLD HEALTH ORGAN, V86, P929, DOI 10.2471/BLT.07.049668; Goga A, 2011, ROM IT 6 INT AIDS SO; Graham SM, 2002, LANCET, V360, P1966, DOI 10.1016/S0140-6736(02)11921-0; Horwood C, 2010, TROP MED INT HEALTH, V15, P992, DOI 10.1111/j.1365-3156.2010.02576.x; le Roux DM, 2011, PEDIATR INFECT DIS J, V30, P904, DOI 10.1097/INF.0b013e318220a68b; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; National Department of Health, 2010, CLIN GUID PREV MOTH; National Department of Health, 2011, S AFR J CLIN NUTR, V24, P214; National Department of Health, 2008, POL GUID IMPL PMTCT; Taha TE, 2011, CLIN INFECT DIS, V53, P388, DOI 10.1093/cid/cir413; *UNAIDS UNICEF WHO, 2007, CHILDR AIDS STOCKT R; UNAIDS UNICEF WHO, 2010, 5 UNAIDS UNICEF WHO; WHO/UNAIDS/UNICEF, 2004, JOINT WHO UNAIDS UNI; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organisation Joint United Nations Programme on HIV/AIDS and United Nations Children Fund, 2010, UN ACC SCAL PRIOR HI, P88; World Health Organization, 2021, ANT DRUGS TREAT PREG	23	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2013	8	5							e63273	10.1371/journal.pone.0063273	http://dx.doi.org/10.1371/journal.pone.0063273			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	154EP	23667599	gold, Green Published, Green Submitted			2023-01-03	WOS:000319654700129
J	Pal, SK; Nelson, RA; Vogelzang, N				Pal, Sumanta K.; Nelson, Rebecca A.; Vogelzang, Nicholas			Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era	PLOS ONE			English	Article							INTERFERON-ALPHA; POPULATION	Background: Recent phase III studies of targeted agents for metastatic renal cell carcinoma (mRCC) have generated median survival estimates that far exceed those observed during the cytokine era. However, substantial population-based data does not exist to confirm this trend. We sought to determine whether survival has improved for patients with mRCC diagnosed in the era of targeted therapies, as compared to the era of immunotherapy. Methods: The Surveillance, Epidemiology, and End Results (SEER) Registry was used to identify patients aged 18 and older diagnosed stage IV RCC between 1992 and 2009. Patients had documented clear cell, papillary or chromophobe histology. The Kaplan Meier method and log-rank test were used to compare disease-specific survival (DSS) for patients diagnosed from 1992-2004 (i.e., the cytokine era) and 2005-2009 (i.e., the targeted therapy era). Univariate and multivariate analyses of relevant clinicopathologic characteristics were also performed. Results: Of 5,176 patients identified using the above characteristics, 2,392 patients were diagnosed from 1992-2004 and 2,784 from 2005-2009. Median DSS was improved in those patients diagnosed from 2005-2009 (16 months vs 13 months; P<0.0001). A similar temporal trend towards improving survival was noted in patients with clear cell (P = 0.0006), but not in patients with non-clear cell disease (P = 0.32). Notable findings on multivariate analysis include an association between shorter DSS and the following characteristics: (1) diagnosis from 1992-2004, (2) advanced age (80+), and (3) absence of cytoreductive nephrectomy. Conclusions: These data reflect progress in the management of mRCC, specifically in the era of targeted therapies. Notably, it was inferred that certain treatment strategies were employed during pre-specified time periods, representing a major caveat of the current analysis. Further studies related to the influence of age and race/ethnicity are warranted, as are studies exploring the role of cytoreductive nephrectomy and novel treatments for non-clear cell disease.	[Pal, Sumanta K.] City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA; [Nelson, Rebecca A.] City Hope Comprehens Canc Ctr, Dept Informat Sci, Div Biostat, Duarte, CA USA; [Vogelzang, Nicholas] Comprehens Canc Centers, US Oncol Res, Las Vegas, NV USA	City of Hope; City of Hope; US Oncology Network	Pal, SK (corresponding author), City Hope Comprehens Canc Ctr, Dept Med Oncol & Expt Therapeut, Duarte, CA USA.	spal@coh.org	Nelson, Rebecca/C-4438-2014		NIH [K12 2K12CA001727-16A1]; NATIONAL CANCER INSTITUTE [K12CA001727] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH K12 2K12CA001727-16A1 (S.K.P.). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, SEER MAN ON LIN 20 1, P34; [Anonymous], FDA APPR LETT SUN; [Anonymous], SEER MAN ON LIN; [Anonymous], 1973, RES DAT 1973 2 UNPUB; Edge S.B., 2010, AJCC CANC STAGING MA, V649; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849; Flanigan RC, 2001, NEW ENGL J MED, V345, P1655, DOI 10.1056/NEJMoa003013; Fyfe GA, 1996, J CLIN ONCOL, V14, P2410, DOI 10.1200/JCO.1996.14.8.2410; Harshman LC, 2012, LANCET ONCOL, V13, P927, DOI 10.1016/S1470-2045(12)70285-1; Harzstark AL, 2011, ASCO M ABSTR S15, V29, P4547; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Heng DYC, 2012, ASCO M, V30, P4536; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Manola J, 2011, CLIN CANCER RES, V17, P5443, DOI 10.1158/1078-0432.CCR-11-0553; Matsumoto K, 2007, INT J UROL, V14, P1000, DOI 10.1111/j.1442-2042.2007.01889.x; Motzer R, 2012, ANN ONCOL, V23; Motzer RJ, 2004, CLIN CANCER RES, V10, p6302S, DOI 10.1158/1078-0432.CCR-040031; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Patil S, 2012, J UROL; Plimack ER, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.4604; Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9; Shek D, 2012, CLIN GENITOURIN CANC, V10, P93, DOI 10.1016/j.clgc.2012.01.007; Stafford HS, 2008, J UROLOGY, V179, P1704, DOI 10.1016/j.juro.2008.01.027; Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Tripathi RT, 2006, UROLOGY, V68, P296, DOI 10.1016/j.urology.2006.02.036	29	54	55	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2013	8	5							e63341	10.1371/journal.pone.0063341	http://dx.doi.org/10.1371/journal.pone.0063341			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175AS	23658823	Green Submitted, Green Published, gold			2023-01-03	WOS:000321202100063
J	Yin, JJ; Sharma, S; Shumyak, SP; Wang, ZX; Zhou, ZW; Zhang, YD; Guo, PX; Li, CZ; Kanwar, JR; Yang, TX; Mohapatra, SS; Liu, WQ; Duan, W; Wang, JC; Li, Q; Zhang, XJ; Tan, J; Jia, L; Liang, J; Wei, MQ; Li, XT; Zhou, SF				Yin, Juan-Juan; Sharma, Sonali; Shumyak, Stepan P.; Wang, Zhi-Xin; Zhou, Zhi-Wei; Zhang, Yangde; Guo, Peixuan; Li, Chen-Zhong; Kanwar, Jagat R.; Yang, Tianxin; Mohapatra, Shyam S.; Liu, Wanqing; Duan, Wei; Wang, Jian-Cheng; Li, Qi; Zhang, Xueji; Tan, Jun; Jia, Lee; Liang, Jun; Wei, Ming Q.; Li, Xiaotian; Zhou, Shu-Feng			Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, beta-Cyclodextrin-Based Drug Complexes for Cancer Treatment	PLOS ONE			English	Article							HUMAN CYTOCHROME-P450 2D6; CHINESE HERBAL MEDICINE; MOLECULAR DOCKING; DELIVERY SYSTEMS; FOLATE; DOXORUBICIN; BINDING; LIGAND; CARDIOTOXICITY; ANTHRACYCLINES	Drug targeting is an active area of research and nano-scaled drug delivery systems hold tremendous potential for the treatment of neoplasms. In this study, a novel cyclodextrin (CD)-based nanoparticle drug delivery system has been assembled and characterized for the therapy of folate receptor-positive [FR(+)] cancer. Water-soluble folic acid (FA)conjugated CD carriers (FACDs) were successfully synthesized and their structures were confirmed by 1D/2D nuclear magnetic resonance (NMR), matrix-assisted laser desorption ionization time-of-flight mass spectrometer (MALDI-TOF-MS), high performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy (FTIR), and circular dichroism. Drug complexes of adamatane (Ada) and cytotoxic doxorubicin (Dox) with FACD were readily obtained by mixed solvent precipitation. The average size of FACD-Ada-Dox was 1.5-2.5 nm. The host-guest association constant K-a was 1,639 M-1 as determined by induced circular dichroism and the hydrophilicity of the FACDs was greatly enhanced compared to unmodified CD. Cellular uptake and FR binding competitive experiments demonstrated an efficient and preferentially targeted delivery of Dox into FR-positive tumor cells and a sustained drug release profile was seen in vitro. The delivery of Dox into FR(+) cancer cells via endocytosis was observed by confocal microscopy and drug uptake of the targeted nanoparticles was 8-fold greater than that of non-targeted drug complexes. Our docking results suggest that FA, FACD and FACD-Ada-Dox could bind human hedgehog interacting protein that contains a FR domain. Mouse cardiomyocytes as well as fibroblast treated with FACD-Ada-Dox had significantly lower levels of reactive oxygen species, with increased content of glutathione and glutathione peroxidase activity, indicating a reduced potential for Dox-induced cardiotoxicity. These results indicate that the targeted drug complex possesses high drug association and sustained drug release properties with good biocompatibility and physiological stability. The novel FA-conjugated beta-CD based drug complex might be promising as an anti-tumor treatment for FR(+) cancer.	[Yin, Juan-Juan; Sharma, Sonali; Shumyak, Stepan P.; Wang, Zhi-Xin; Zhou, Zhi-Wei; Liang, Jun; Zhou, Shu-Feng] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33620 USA; [Zhang, Yangde] Cent S Univ, Natl Hepatobiliary & Enter Surg Res Ctr, Changsha, Hunan, Peoples R China; [Guo, Peixuan] Univ Kentucky, Coll Pharm, Nanobiotechnol Ctr & Markey Canc Ctr, Lexington, KY USA; [Li, Chen-Zhong] Florida Int Univ, Nanobioengn & Bioelect Lab, Dept Biomed Engn, Miami, FL 33199 USA; [Kanwar, Jagat R.] Deakin Univ, Nanomed Lab Immunol & Mol Biomed Res LIMBR, Ctr Biotechnol & Interdisciplinary Biosci, Waurn Ponds, Vic, Australia; [Kanwar, Jagat R.] Deakin Univ, Inst Frontier Mat, Waurn Ponds, Vic, Australia; [Yang, Tianxin] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Yang, Tianxin] Salt Lake Vet Affairs Med Ctr, Salt Lake City, UT USA; [Mohapatra, Shyam S.] Univ S Florida, Nanomed Res Ctr, Tampa, FL USA; [Mohapatra, Shyam S.] Univ S Florida, Dept Internal Med, Div Translat Med, Morsani Coll Med, Tampa, FL 33612 USA; [Liu, Wanqing] Purdue Univ, Coll Pharm, Dept Med Chem & Mol Pharmacol, Indiana, PA USA; [Duan, Wei] Deakin Univ, Sch Med, Waurn Ponds, Vic, Australia; [Wang, Jian-Cheng; Jia, Lee] Peking Univ, State Key Lab Nat & Biomimet Drugs, Sch Pharmaceut Sci, Beijing 100871, Peoples R China; [Li, Qi] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Oncol, Shanghai, Peoples R China; [Zhang, Xueji] Univ Sci & Technol Beijing, Res Ctr Bioengineering & Sensing Technol, Beijing 100083, Peoples R China; [Tan, Jun] James A Haley Vet Adm Hosp, Tampa, FL USA; [Liang, Jun] Univ S Florida, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Morsani Coll Med, Tampa, FL USA; [Tan, Jun] Univ S Florida, Dept Psychiat & Behav Neurosci, Morsani Coll Med, Silver Child Dev Ctr,Rashid Lab Dev Neurobiol, Tampa, FL USA; [Liang, Jun] Fuzhou Univ, Coll Chem & Chem Engn, Canc Metastasis Alert & Prevent Ctr, Fuzhou 350002, Peoples R China; [Wei, Ming Q.] Griffith Univ, Griffith Hlth Inst, Div Mol & Gene Therapies, Sch Med Sci, Nathan, Qld 4111, Australia; [Li, Xiaotian] Fudan Univ, Obstet & Gynecol Hosp, Shanghai 200433, Peoples R China; [Li, Xiaotian] Fudan Univ, Inst Biomed, Shanghai, Peoples R China	State University System of Florida; University of South Florida; Central South University; University of Kentucky; State University System of Florida; Florida International University; Deakin University; Deakin University; Utah System of Higher Education; University of Utah; US Department of Veterans Affairs; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Purdue University System; Purdue University; Deakin University; Peking University; Shanghai University of Traditional Chinese Medicine; University of Science & Technology Beijing; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Fuzhou University; Griffith University; Menzies Health Institute Queensland; Fudan University; Fudan University	Zhou, SF (corresponding author), Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, Tampa, FL 33620 USA.	szhou@health.usf.edu	zhou, zhiwei/J-7878-2015; Guo, Peixuan/I-7184-2015; Li, Chenzhong/F-5087-2016; Duan, Wei/A-5181-2015; Guo, Peixuan/AAE-2573-2022; Mohapatra, Shyam/C-2500-2012; Zhou, Shu-Feng/E-3166-2013; Li, Xiaotian/ABI-3309-2020; wang, zhixin/GZH-2500-2022; zhang, xueji/B-1904-2010; zhang, xueji/ABE-6497-2020	zhou, zhiwei/0000-0002-8227-2573; Duan, Wei/0000-0001-5782-9184; Guo, Peixuan/0000-0001-5706-2833; Zhou, Shu-Feng/0000-0002-5542-6119; Li, Xiaotian/0000-0002-2051-4581; zhang, xueji/0000-0002-0035-3821; JIA, LEE/0000-0001-6839-5545; Liu, Wanqing/0000-0001-7727-6900	College of Pharmacy, University of South Florida, Tampa, Florida	College of Pharmacy, University of South Florida, Tampa, Florida	Dr JJY is supported by a postdoctoral scholarship from the College of Pharmacy, University of South Florida, 12901 Bruce B Downs Blvd., Tampa, Florida. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Bishop B, 2009, NAT STRUCT MOL BIOL, V16, P698, DOI 10.1038/nsmb.1607; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Chen G, 2011, CHEM SOC REV, V40, P2254, DOI 10.1039/c0cs00153h; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Crider KS, 2012, ADV NUTR, V3, P21, DOI 10.3945/an.111.000992; Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576; Dickey JS, 2012, CURR MOL MED, V12, P763; Eruslanov E, 2010, METHODS MOL BIOL, V594, P57, DOI 10.1007/978-1-60761-411-1_4; Fan J, 2012, SMALL; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gatenby RA, 2009, NATURE, V459, P508, DOI 10.1038/459508a; Granadero D, 2010, INT J MOL SCI, V11, P173, DOI 10.3390/ijms11010173; Hanusova V, 2011, DRUG METAB REV, V43, P540, DOI 10.3109/03602532.2011.609174; Hilgenbrink AR, 2005, J PHARM SCI-US, V94, P2135, DOI 10.1002/jps.20457; Hochdorffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m; Kizek R, 2012, PHARMACOL THERAPEUT, V133, P26, DOI 10.1016/j.pharmthera.2011.07.006; Kratz F, 2012, J CONTROL RELEASE, V164, P221, DOI 10.1016/j.jconrel.2012.05.045; Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063; Legigan T, 2012, J MED CHEM, V55, P4516, DOI 10.1021/jm300348r; Menna P, 2012, EXPERT OPIN DRUG SAF, V11, pS21, DOI 10.1517/14740338.2011.589834; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Mo SL, 2012, CURR PHARM BIOTECHNO, V13, P1640, DOI 10.2174/138920112800958779; Mo SL, 2012, COMB CHEM HIGH T SCR, V15, P36, DOI 10.2174/138620712798280826; Muro S, 2012, J CONTROL RELEASE, V164, P125, DOI 10.1016/j.jconrel.2012.05.052; Octavia Y, 2012, J MOL CELL CARDIOL, V52, P1213, DOI 10.1016/j.yjmcc.2012.03.006; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; PETTER RC, 1990, J AM CHEM SOC, V112, P3860, DOI 10.1021/ja00166a021; Roy PP, 2010, MOL SIMULAT, V36, P887, DOI 10.1080/08927022.2010.492834; Sabharanjak S, 2004, ADV DRUG DELIVER REV, V56, P1099, DOI 10.1016/j.addr.2004.01.010; Salas C, 2011, REV INVEST CLIN, V63, P53; Thun MJ, 2010, CARCINOGENESIS, V31, P100, DOI 10.1093/carcin/bgp263; Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; WEITMAN SD, 1992, CANCER RES, V52, P3396; Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306; Yague E, 2005, BRIT J CANCER, V93, P973, DOI 10.1038/sj.bjc.6602821; Zhao XB, 2008, EXPERT OPIN DRUG DEL, V5, P309, DOI 10.1517/17425247.5.3.309 	38	51	52	3	154	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2013	8	5							e62289	10.1371/journal.pone.0062289	http://dx.doi.org/10.1371/journal.pone.0062289			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175AF	23658721	Green Published, Green Submitted, gold			2023-01-03	WOS:000321200500022
J	Sutherland, T; Downing, J; Miller, S; Bishai, DM; Butrick, E; Fathalla, MMF; Mourad-Youssif, M; Ojengbede, O; Nsima, D; Kahn, JG				Sutherland, Tori; Downing, Janelle; Miller, Suellen; Bishai, David M.; Butrick, Elizabeth; Fathalla, Mohamed M. F.; Mourad-Youssif, Mohammed; Ojengbede, Oladosu; Nsima, David; Kahn, James G.			Use of the Non-Pneumatic Anti-Shock Garment (NASG) for Life-Threatening Obstetric Hemorrhage: A Cost-Effectiveness Analysis in Egypt and Nigeria	PLOS ONE			English	Article							INTERVENTIONS	Objective: To assess the cost-effectiveness of a non-pneumatic anti-shock garment (NASG) for obstetric hemorrhage in tertiary hospitals in Egypt and Nigeria. Methods: We combined published data from pre-intervention/NASG-intervention clinical trials with costs from study sites. For each country, we used observed proportions of initial shock level (mild: mean arterial pressure [MAP] >60 mmHg; severe: MAP <= 60 mmHg) to define a standard population of 1,000 women presenting in shock. We examined three intervention scenarios: no women in shock receive the NASG, only women in severe shock receive the NASG, and all women in shock receive the NASG. Clinical data included frequencies of adverse health outcomes (mortality, severe morbidity, severe anemia), and interventions to manage bleeding (uterotonics, blood transfusions, hysterectomies). Costs (in 2010 international dollars) included the NASG, training, and clinical interventions. We compared costs and disability-adjusted life years (DALYs) across the intervention scenarios. Results: For 1000 women presenting in shock, providing the NASG to those in severe shock results in decreased mortality and morbidity, which averts 357 DALYs in Egypt and 2,063 DALYs in Nigeria. Differences in use of interventions result in net savings of $9,489 in Egypt (primarily due to reduced transfusions) and net costs of $6,460 in Nigeria, with a cost per DALY averted of $3.13. Results of providing the NASG for women in mild shock has smaller and uncertain effects due to few clinical events in this data set. Conclusion: Using the NASG for women in severe shock resulted in markedly improved health outcomes (2-2.9 DALYs averted per woman, primarily due to reduced mortality), with net savings or extremely low cost per DALY averted. This suggests that in resource-limited settings, the NASG is a very cost-effective intervention for women in severe hypovolemic shock. The effects of the NASG for mild shock are less certain.	[Sutherland, Tori] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Downing, Janelle; Kahn, James G.] Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA; [Miller, Suellen; Butrick, Elizabeth] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, Bixby Ctr Global Reprod Hlth & Policy, San Francisco, CA USA; [Bishai, David M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA; [Fathalla, Mohamed M. F.] Assiut Univ, Fac Med, Womens Hlth Ctr, Dept Obstet & Gynecol, Assiut, Egypt; [Mourad-Youssif, Mohammed] El Galaa Matern Teaching Hosp, Dept Obstet & Gynecol, Cairo, Egypt; [Ojengbede, Oladosu] Univ Coll Hosp, Dept Obstet & Gynecol, Ibadan, Nigeria; [Nsima, David] Katsina Gen Hosp, Dept Obstet & Gynecol, Katsina, Nigeria	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Egyptian Knowledge Bank (EKB); Assiut University; Egyptian Knowledge Bank (EKB); General Organization of Teaching Hospitals & Institutes (GOTHI); University of Ibadan; University College Hospital, Ibadan	Downing, J (corresponding author), Univ Calif San Francisco, Philip R Lee Inst Hlth Policy Studies, San Francisco, CA 94143 USA.	janelle.downing@gmail.com	, David Bishai/GRO-4211-2022	Downing, Jae/0000-0002-2382-5537; Bishai, David/0000-0003-0714-9062				Acharya A., 2003, MAKING CHOICES HLTH; American College of Physicians (ACP), PRIM COST EFF AN; Atrash HK, 2006, MATERN CHILD HLTH J, V10, pS3, DOI 10.1007/s10995-006-0100-4; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Drummond M.F., 2015, METHODS EC EVALUATIO, V4; G?lmezoglu, 2009, WHO GUIDELINES MANAG; Galloway R, 2003, ANEMIA PREVENTIO 1 2; Goldie SJ, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000264; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Jamison DT, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1; Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9; Kidney E, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-2; Krahn MD, 1997, MED DECIS MAKING, V17, P142, DOI 10.1177/0272989X9701700204; Mantel GD, 1998, BRIT J OBSTET GYNAEC, V105, P985, DOI 10.1111/j.1471-0528.1998.tb10262.x; Miller S, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-64; Miller S, 2010, INT J GYNECOL OBSTET, V109, P20, DOI 10.1016/j.ijgo.2009.11.016; Miller S, 2009, INT J GYNECOL OBSTET, V107, P121, DOI 10.1016/j.ijgo.2009.06.005; Nyamtema AS, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-30; Ordi J, 2009, PLOS MED, V6, P174, DOI 10.1371/journal.pmed.1000036; Osobu-Asubiojo FBR, 2011, MERCHANTS BLOOD NEWS; PATH, 2011, AFF HIGH QUAL NONPN, P1; PPP, 2011, PPP CONV FACT GDP; Seligman B, 2006, EC ASSESSMENT INTERV; Sutherland T, 2010, INT J GYNECOL OBSTET, V108, P289, DOI 10.1016/j.ijgo.2009.11.007; UNICEF, GOAL 5 IMPR MAT HLTH, V5; United Nations, 2011, MILL DEV GOALS IND P; VANSLYKE DD, 1950, J BIOL CHEM, V183, P331; WHO, 2011, COMP NEW EM HLTH TEC	28	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62282	10.1371/journal.pone.0062282	http://dx.doi.org/10.1371/journal.pone.0062282			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23646124	Green Published, gold			2023-01-03	WOS:000319077300036
J	Young, GJ; Chou, CH; Alexander, J; Lee, SYD; Raver, E				Young, Gary J.; Chou, Chia-Hung; Alexander, Jeffrey; Lee, Shoou-Yih Daniel; Raver, Eli			Provision of Community Benefits by Tax-Exempt U.S. Hospitals	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONPROFIT HOSPITALS	BACKGROUND The Patient Protection and Affordable Care Act (ACA) requires tax-exempt hospitals to conduct assessments of community needs and address identified needs. Most tax-exempt hospitals will need to meet this requirement by the end of 2013. METHODS We conducted a national study of the level and pattern of community benefits that tax-exempt hospitals provide. The study comprised more than 1800 tax-exempt hospitals, approximately two thirds of all such institutions. We used reports that hospitals filed with the Internal Revenue Service for fiscal year 2009 that provide expenditures for seven types of community benefits. We combined these reports with other data to examine whether institutional, community, and market characteristics are associated with the provision of community benefits by hospitals. RESULTS Tax-exempt hospitals spent 7.5% of their operating expenses on community benefits during fiscal year 2009. More than 85% of these expenditures were devoted to charity care and other patient care services. Of the remaining community-benefit expenditures, approximately 5% were devoted to community health improvements that hospitals undertook directly. The rest went to education in health professions, research, and contributions to community groups. The level of benefits provided varied widely among the hospitals (hospitals in the top decile devoted approximately 20% of operating expenses to community benefits; hospitals in the bottom decile devoted approximately 1%). This variation was not accounted for by indicators of community need. CONCLUSIONS In 2009, tax-exempt hospitals varied markedly in the level of community benefits provided, with most of their benefit-related expenditures allocated to patient care services. Little was spent on community health improvement.	[Young, Gary J.; Chou, Chia-Hung; Raver, Eli] Northeastern Univ, Ctr Hlth Policy & Healthcare Res, Boston, MA 02115 USA; [Young, Gary J.; Chou, Chia-Hung; Raver, Eli] Northeastern Univ, Bouve Coll Hlth Sci, Boston, MA 02115 USA; [Young, Gary J.] Northeastern Univ, DAmore McKim Sch Business, Boston, MA 02115 USA; [Chou, Chia-Hung] Univ Chicago, Chicago, IL 60637 USA; [Alexander, Jeffrey; Lee, Shoou-Yih Daniel] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA	Northeastern University; Northeastern University; Northeastern University; University of Chicago; University of Michigan System; University of Michigan	Young, GJ (corresponding author), Northeastern Univ, 360 Huntington Ave,137 Richards Hall, Boston, MA 02115 USA.	ga.young@neu.edu						[Anonymous], 2009, COMM BEN REP US STAT; [Anonymous], 2007, HLTH CAR COMM BEN CO; [Anonymous], 1969, REV RUL 69 545; Bazzoli GJ, 2010, J HEALTH POLIT POLIC, V35, P999, DOI 10.1215/03616878-2010-036; Colombo John D., 2007, SAINT LOUIS U LAW J, V51; Congressional Budget Office, 2006, NONPR HOSP PROV COMM; Congressional Budget Office, 2006, NONPR HOSP VAR STAND; Folkemer D. C., 2011, HOSP COMMUNITY BENEF; Gray BH, 2009, HEALTH AFFAIR, V28, pW809, DOI 10.1377/hlthaff.28.5.w809; Health Forum, 2009, AHA GUID HLTH CAR FI; Hellinger FJ, 2009, J HEALTH POLIT POLIC, V34, P37, DOI 10.1215/03616878-2008-991; Japsen B., 2011, NY TIMES; Kane NM, 2007, ST LOUIS U L J, V51, P459; Rosenbaum S, 2011, PUBLIC HEALTH REP, V126, P283, DOI 10.1177/003335491112600220	14	123	123	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2013	368	16					1519	1527		10.1056/NEJMsa1210239	http://dx.doi.org/10.1056/NEJMsa1210239			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126HC	23594004				2023-01-03	WOS:000317603300009
J	He, F; Wu, XF; Xia, X; Peng, FF; Huang, FX; Yu, XQ				He, Feng; Wu, Xianfeng; Xia, Xi; Peng, Fenfen; Huang, Fengxian; Yu, Xueqing			Pneumonia and Mortality Risk in Continuous Ambulatory Peritoneal Dialysis Patients with Diabetic Nephropathy	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; HEMODIALYSIS-PATIENTS; RENAL-DISEASE; UNITED-STATES; SURVIVAL; OBESITY; ATHEROSCLEROSIS; HOSPITALIZATION; EPIDEMIOLOGY; INFLAMMATION	Background: Although clinical experience suggests that patients with diabetes mellitus are more susceptible to several types of infections, the overall scope of pneumonia in continuous ambulatory peritoneal dialysis (CAPD) patients with diabetic nephropathy (DN) has received little attention. Methods: This was a prospective observational cohort study in CAPD patients in which prognostic risks of pneumonia were evaluated in DN and non-DN patients by Cox regression analysis. Hazard ratios of pneumonia events, all-cause and pneumonia-related mortality were calculated by Kaplan-Meier curves and the Cox proportional hazards model for DN versus non-DN patients. Results: A total of 1148 patients (58.6% male, 48.34 +/- 15.78 years) had a median follow-up of 23.8 months and a maximum follow-up of 72.0 months. The pneumonia incidence rate of 62.3/1,000 patient-years in CAPD patients with DN was significantly higher than that of 28.5/1,000 patient-years in non-DN patients. On multivariate analysis, independent predictors of pneumonia occurrence in CAPD patients with DN were high body mass index (hazard ratio [HR], 1.15; 95% confidence interval [CI], 1.01-1.31; P = 0.037) and low serum albumin level (HR, 0.87; 95% CI, 0.78-0.98; P = 0.014). Older age (HR, 1.63; 95% CI, 1.35-1.96; P<0.001) was an independent risk factor for the presence of pneumonia in non-DN patients. CAPD patients with DN had higher pneumonia-related mortality (HR, 4.424; 95% CI, 1.871-10.461; P<0.001) and all-cause mortality (HR, 2.608; 95% CI, 1.890-3.599; P<0.001) hazards than their non-DN counterparts, even when extensive demographics, comorbidities, and lab adjustments were made. Conclusions: The pneumonia and all-cause mortality risks were strikingly higher in CAPD patients with DN than in non-DN counterparts, which may warrant further investigation and therapeutic care intensification.	[He, Feng; Wu, Xianfeng; Xia, Xi; Peng, Fenfen; Huang, Fengxian; Yu, Xueqing] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	He, F (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Nephrol, Guangzhou 510275, Guangdong, Peoples R China.	hfxyl@163.net; yuxq@mail.sysu.edu.cn		, xianfeng/0000-0001-7447-5189	National Key Basic Research Program of China [2011CB504005]; National Key Technology Research and Development Program of the Ministry of Science and Technology of China [2011BAI10B05]; National Natural Science Foundation of China [81170765]; Guangdong Natural Science Foundation [S2011020002359]	National Key Basic Research Program of China(National Basic Research Program of China); National Key Technology Research and Development Program of the Ministry of Science and Technology of China(National Key Technology R&D Program); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province)	This study was supported by the grants from the National Key Basic Research Program of China (grant number 2011CB504005), the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (grant number 2011BAI10B05), the National Natural Science Foundation of China (grant number 81170765), and the Guangdong Natural Science Foundation (grant number S2011020002359). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; [Anonymous], 1989, Stroke, V20, P1407; Beddhu S, 2003, J AM SOC NEPHROL, V14, P2366, DOI 10.1097/01.ASN.0000083905.72794.E6; Benfield T, 2007, DIABETOLOGIA, V50, P549, DOI 10.1007/s00125-006-0570-3; Bethesda, 2006, USRDS 2006 ANN DAT R; D'Agata EMC, 2000, AM J KIDNEY DIS, V35, P1083, DOI 10.1016/S0272-6386(00)70044-8; de Mutsert R, 2007, J AM SOC NEPHROL, V18, P967, DOI 10.1681/ASN.2006091050; Guo HF, 2008, NEPHROL DIAL TRANSPL, V23, P680, DOI 10.1093/ndt/gfm474; Hoogeveen EK, 2012, CLIN J AM SOC NEPHRO, V7, P280, DOI 10.2215/CJN.05700611; Kaparianos A, 2008, Chron Respir Dis, V5, P101, DOI 10.1177/1479972307086313; Kuriyama S, 2007, PERITON DIALYSIS INT, V27, pS190; Mcdonald SP, 2003, J AM SOC NEPHROL, V14, P2894, DOI 10.1097/01.ASN.0000091587.55159.5F; Miyamoto T, 2011, CURR OPIN NEPHROL HY, V20, P662, DOI 10.1097/MNH.0b013e32834ad504; Navab KD, 2011, CURR PHARM DESIGN, V17, P17; O'Meara ES, 2005, J AM GERIATR SOC, V53, P1108, DOI 10.1111/j.1532-5415.2005.53352.x; Piroddi M, 2007, AMINO ACIDS, V32, P573, DOI 10.1007/s00726-006-0433-8; Praga M, 2002, NEPHROL DIAL TRANSPL, V17, P1157, DOI 10.1093/ndt/17.7.1157; Remuzzi G, 2006, J AM SOC NEPHROL, V17, pS90, DOI 10.1681/ASN.2005121324; Sarnak MJ, 2001, CHEST, V120, P1883, DOI 10.1378/chest.120.6.1883; Shah BR, 2003, DIABETES CARE, V26, P510, DOI 10.2337/diacare.26.2.510; Slinin Y, 2006, KIDNEY INT, V70, P1135, DOI 10.1038/sj.ki.5001714; Stack AG, 2004, KIDNEY INT, V65, P2398, DOI 10.1111/j.1523-1755.2004.00654.x; Stenvinkel P, 1999, KIDNEY INT, V55, P1899, DOI 10.1046/j.1523-1755.1999.00422.x; Vardakas KZ, 2007, DIABETIC MED, V24, P1168, DOI 10.1111/j.1464-5491.2007.02234.x; Xie YS, 2008, AM J NEPHROL, V28, P1, DOI 10.1159/000108755; Yende S, 2007, J AM GERIATR SOC, V55, P518, DOI 10.1111/j.1532-5415.2007.01100.x	26	13	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e61497	10.1371/journal.pone.0061497	http://dx.doi.org/10.1371/journal.pone.0061497			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23585903	Green Submitted, Green Published, gold			2023-01-03	WOS:000317909600118
J	Kalish, BT; Le, HD; Gura, KM; Bistrian, BR; Puder, M				Kalish, Brian T.; Le, Hau D.; Gura, Kathleen M.; Bistrian, Bruce R.; Puder, Mark			A Metabolomic Analysis of Two Intravenous Lipid Emulsions in a Murine Model	PLOS ONE			English	Article							POLYUNSATURATED FATTY-ACIDS; TOTAL PARENTERAL-NUTRITION; ALPHA-LINOLENIC ACID; HEPATIC STEATOSIS; LIVER COMPLICATIONS; INFLAMMATION; ANTIOXIDANT; INJURY; OMEGA-3-FATTY-ACIDS; PATHOGENESIS	Background: Parenteral nutrition (PN), including intravenous lipid administration, is a life-saving therapy but can be complicated by cholestasis and liver disease. The administration of intravenous soy bean oil (SO) has been associated with the development of liver disease, while the administration of intravenous fish oil (FO) has been associated with the resolution of liver disease. The biochemical mechanism of this differential effect is unclear. This study compares SO and FO lipid emulsions in a murine model of hepatic steatosis, one of the first hits in PN-associated liver disease. Methods: We established a murine model of hepatic steatosis in which liver injury is induced by orally feeding mice a PN solution. C57BL/6J mice were randomized to receive PN alone (a high carbohydrate diet (HCD)), PN plus intravenous FO (Omegaven (R); Fresenius Kabi AG, Bad Homburg VDH, Germany), PN plus intravenous SO (Intralipid (R); Fresenius Kabi AG, Bad Homburg v.d.H., Germany, for Baxter Healthcare, Deerfield, IL), or a chow diet. After 19 days, liver tissue was harvested from all animals and subjected to metabolomic profiling. Results: The administration of an oral HCD without lipid induced profound hepatic steatosis. SO was associated with macro- and microvesicular hepatic steatosis, while FO largely prevented the development of steatosis. 321 detectable compounds were identified in the metabolomic analysis. HCD induced de novo fatty acid synthesis and oxidative stress. Both FO and SO relieved some of the metabolic shift towards de novo lipogenesis, but FO offered additional advantages in terms of lipid peroxidation and the generation of inflammatory precursors. Conclusions: Improved lipid metabolism combined with reduced oxidative stress may explain the protective effect offered by intravenous FO in vivo.	[Kalish, Brian T.; Le, Hau D.; Puder, Mark] Boston Childrens Hosp, Dept Surg, Boston, MA USA; [Kalish, Brian T.; Le, Hau D.; Puder, Mark] Boston Childrens Hosp, Vasc Biol Program, Boston, MA USA; [Gura, Kathleen M.] Boston Childrens Hosp, Dept Pharm, Boston, MA USA; [Bistrian, Bruce R.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Le, Hau D.] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center	Puder, M (corresponding author), Boston Childrens Hosp, Dept Surg, Boston, MA USA.	mark.puder@childrens.harvard.edu		Le, Hau/0000-0003-0514-3513	Howard Hughes Medical Institute Research Fellowship; Children's Hospital Surgical Foundation (Boston, Massachusetts)	Howard Hughes Medical Institute Research Fellowship; Children's Hospital Surgical Foundation (Boston, Massachusetts)	BTK was funded by a Howard Hughes Medical Institute Research Fellowship. HDL and MP were funded by the Children's Hospital Surgical Foundation (Boston, Massachusetts). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alwayn IPJ, 2005, PEDIATR RES, V57, P445, DOI 10.1203/01.PDR.0000153672.43030.75; Burdge GC, 2005, REPROD NUTR DEV, V45, P581, DOI 10.1051/rnd:2005047; Clayton PT, 1998, NUTRITION, V14, P158, DOI 10.1016/S0899-9007(97)00233-5; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Dentin R, 2005, J CLIN INVEST, V115, P2843, DOI 10.1172/JCI25256; El Kasmi KC, 2012, HEPATOLOGY, V55, P1518, DOI 10.1002/hep.25500; HALL RI, 1984, J CLIN INVEST, V74, P1658, DOI 10.1172/JCI111582; Hao W, 2010, J PEDIATR SURG, V45, P2412, DOI 10.1016/j.jpedsurg.2010.08.044; Hasanoglu A, 2005, PROSTAG LEUKOTR ESS, V73, P99, DOI 10.1016/j.plefa.2005.04.015; Hong L, 2007, JPEN-PARENTER ENTER, V31, P199, DOI 10.1177/0148607107031003199; Hong L, 2009, J PEDIATR SURG, V44, P1712, DOI 10.1016/j.jpedsurg.2009.04.002; Hussein N, 2005, J LIPID RES, V46, P269, DOI 10.1194/jlr.M400225-JLR200; IRITANI N, 1980, LIPIDS, V15, P371, DOI 10.1007/BF02533553; Javid PJ, 2005, J PEDIATR SURG, V40, P1446, DOI 10.1016/j.jpedsurg.2005.05.045; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Kajikawa S, 2009, PROSTAG LEUKOTR ESS, V80, P229, DOI 10.1016/j.plefa.2009.02.004; Kelly DA, 1998, NUTRITION, V14, P153, DOI 10.1016/S0899-9007(97)00232-3; Kosters A, 2010, SEMIN LIVER DIS, V30, P186, DOI 10.1055/s-0030-1253227; Lespine A, 2001, JPEN-PARENTER ENTER, V25, P52, DOI 10.1177/014860710102500252; Meisel JA, 2011, J PEDIATR SURG, V46, P666, DOI 10.1016/j.jpedsurg.2010.08.018; Miloudi K, 2012, CLIN NUTR, V31, P526, DOI 10.1016/j.clnu.2011.12.012; NASSAR BA, 1986, LIPIDS, V21, P652, DOI 10.1007/BF02537216; Pawlosky RJ, 2001, J LIPID RES, V42, P1257; Puder M, 2009, ANN SURG, V250, P395, DOI 10.1097/SLA.0b013e3181b36657; Sekiya M, 2003, HEPATOLOGY, V38, P1529, DOI 10.1016/j.hep.2003.09.028; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; Spite M, 2010, CIRC RES, V107, P1170, DOI 10.1161/CIRCRESAHA.110.223883; Squires RH, 2012, J PEDIATR-US, V161, P723, DOI 10.1016/j.jpeds.2012.03.062; Stoll B, 2010, J NUTR, V140, P2193, DOI 10.3945/jn.110.125799; WONG S, 1985, METABOLISM, V34, P900, DOI 10.1016/0026-0495(85)90135-0; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yeh SL, 1997, NUTRITION, V13, P32, DOI 10.1016/S0899-9007(97)90876-5	33	18	20	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2013	8	4							e59653	10.1371/journal.pone.0059653	http://dx.doi.org/10.1371/journal.pone.0059653			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127RY	23565157	Green Published, gold, Green Submitted			2023-01-03	WOS:000317717300026
J	Fu, AL; Zhang, MM; Gao, FY; Xu, XR; Chen, ZB				Fu, Ailing; Zhang, Miaomiao; Gao, Feiyan; Xu, Xingran; Chen, Zhangbao			A Novel Peptide Delivers Plasmids across Blood-Brain Barrier into Neuronal Cells as a Single-Component Transfer Vector	PLOS ONE			English	Article							EXPERIMENTAL PARKINSONS-DISEASE; CENTRAL-NERVOUS-SYSTEM; GENE-THERAPY; NEUROLOGICAL DISEASES; PENETRATING PEPTIDE; INTERFERING RNA; CELLULAR-UPTAKE; DNA; GLYCOPROTEIN; BDNF	There is no data up to now to show that peptide can deliver plasmid into brain as a single-component transfer vector. Here we show that a novel peptide, RDP (consisted of 39 amino acids), can be exploited as an efficient plasmid vector for brain-targeting delivery. The plasmids containing Lac Z reporter gene (pVAX-Lac Z) and BDNF gene (pVAX-BDNF) are complexed with RDP and intravenously injected into mice. The results of gel retardation assay show that RDP enables to bind DNA in a dose-dependent manner, and the X-Gal staining identity that Lac Z is specifically expressed in the brain. Also, the results of Western blot and immunofluorescence staining of BDNF indicate that pVAX-BDNF complexed with RDP can be delivered into brain, and show neuroprotective properties in experimental Parkinson's disease (PD) model. The results demonstrate that RDP enables to bind and deliver DNA into the brain, resulting in specific gene expression in the neuronal cells. This strategy provides a novel, simple and effective approach for non-viral gene therapy of brain diseases.	[Fu, Ailing; Zhang, Miaomiao; Gao, Feiyan; Xu, Xingran; Chen, Zhangbao] Southwest Univ, Sch Pharmaceut Sci, Chongqing, Peoples R China	Southwest University - China	Fu, AL (corresponding author), Southwest Univ, Sch Pharmaceut Sci, Chongqing, Peoples R China.	Fuailing1008@yahoo.com.cn			Natural Science Foundation of China [31072098, 81273416]; Natural Science Foundation of Chongqing [CSTC 2011BB5011]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing)	This work is supported by the grants from the Natural Science Foundation of China (31072098 and 81273416) and the Natural Science Foundation of Chongqing (CSTC 2011BB5011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adami RC, 1999, J PHARM SCI, V88, P739, DOI 10.1021/js990042p; Adami RC, 1998, J PHARM SCI, V87, P678, DOI 10.1021/js9800477; Allen C, 2013, GENE THER, V20, P444, DOI 10.1038/gt.2012.62; Banks WA, 1999, J NEUROVIROL, V5, P538, DOI 10.3109/13550289909021284; Bergen JM, 2008, PHARM RES-DORDR, V25, P983, DOI 10.1007/s11095-007-9439-5; de Silva S, 2011, CURR GENE THER, V11, P332; Du LT, 2011, HUM MOL GENET, V20, P3151, DOI 10.1093/hmg/ddr217; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; Fu AL, 2007, NEUROSCI LETT, V428, P77, DOI 10.1016/j.neulet.2007.09.040; Fu AL, 2010, BIOCHEM BIOPH RES CO, V397, P257, DOI 10.1016/j.bbrc.2010.05.095; Fu AL, 2010, NEUROPHARMACOLOGY, V58, P722, DOI 10.1016/j.neuropharm.2009.12.020; Fu AL, 2012, PHARM RES-DORDR, V29, P1562, DOI 10.1007/s11095-012-0667-y; Fu AL, 2010, BRAIN RES, V1352, P208, DOI 10.1016/j.brainres.2010.06.059; Fu AL, 2008, J PSYCHIATR RES, V43, P55, DOI 10.1016/j.jpsychires.2008.01.018; Fu AL, 2005, BIOCHEM BIOPH RES CO, V328, P901, DOI 10.1016/j.bbrc.2004.12.194; Hwang DW, 2011, BIOMATERIALS, V32, P4968, DOI 10.1016/j.biomaterials.2011.03.047; Klein RL, 1999, BRAIN RES, V847, P314, DOI 10.1016/S0006-8993(99)02116-2; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003; Masahira N, 2005, NEUROSCI LETT, V374, P17, DOI 10.1016/j.neulet.2004.10.023; Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Nagykery N, 2013, J NEUROSCI METH, V212, P106, DOI 10.1016/j.jneumeth.2012.09.021; Oehlke J, 1997, FEBS LETT, V415, P196, DOI 10.1016/S0014-5793(97)01123-X; Pardridge WM, 2007, J CONTROL RELEASE, V122, P345, DOI 10.1016/j.jconrel.2007.04.001; Plenat T, 2005, BIOPHYS J, V89, P4300, DOI 10.1529/biophysj.105.061697; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rodger J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031061; Rogers ML, 2012, J CONTROL RELEASE, V157, P183, DOI 10.1016/j.jconrel.2011.08.026; Rosenberg GA, 2012, J CEREBR BLOOD F MET, V32, P1139, DOI 10.1038/jcbfm.2011.197; Schlachetzki F, 2004, NEUROLOGY, V62, P1275, DOI 10.1212/01.WNL.0000120551.38463.D9; Shimamura M, 2011, CURR GENE THER, V11, P491, DOI 10.2174/156652311798192833; Singh Shalini, 2006, Indian Journal of Experimental Biology, V44, P699; Tang Qing, 2000, Virologica Sinica, V15, P22; Trabulo S, 2010, PHARMACEUTICALS, V3, P961, DOI 10.3390/ph3040961; TUFFEREAU C, 1989, VIROLOGY, V172, P206, DOI 10.1016/0042-6822(89)90122-0; Tuffereau C, 1998, J VIROL, V72, P1085, DOI 10.1128/JVI.72.2.1085-1091.1998; Xiang L, J DRUG TARGET, V19, P632; Zhang Y, 2009, PHARM RES-DORDR, V26, P1059, DOI 10.1007/s11095-008-9815-9	41	13	14	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 29	2013	8	3							e59642	10.1371/journal.pone.0059642	http://dx.doi.org/10.1371/journal.pone.0059642			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121SG	23555734	Green Published, Green Submitted, gold			2023-01-03	WOS:000317263900020
J	March, L				March, Lyn			Surgery and physical therapy did not differ for function in meniscal tears with knee osteoarthritis	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Sydney, Royal N Shore Hosp, Dept Rheumatol, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney	March, L (corresponding author), Univ Sydney, Royal N Shore Hosp, Dept Rheumatol, St Leonards, NSW 2065, Australia.							Hare KB, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-71; Sihvonen R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002510	2	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 16	2013	159	2							JC13	10.7326/0003-4819-159-2-201307160-02013	http://dx.doi.org/10.7326/0003-4819-159-2-201307160-02013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	187IX	23856699				2023-01-03	WOS:000322112000012
J	Steffens, DC				Steffens, David C.			Exercise for late-life depression? It depends	LANCET			English	Editorial Material							PHARMACOTHERAPY		Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA	University of Connecticut	Steffens, DC (corresponding author), Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA.	steffens@uchc.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH070027] Funding Source: NIH RePORTER; NIMH NIH HHS [K24 MH070027] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Barcelos-Ferreira R, 2013, J AFFECT DISORDERS, V150, P616, DOI 10.1016/j.jad.2013.02.024; Blumenthal JA, 1999, ARCH INTERN MED, V159, P2349, DOI 10.1001/archinte.159.19.2349; Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a; Bridle C, 2012, BRIT J PSYCHIAT, V201, P180, DOI 10.1192/bjp.bp.111.095174; Jarnum H, 2011, ACTA PSYCHIAT SCAND, V124, P435, DOI 10.1111/j.1600-0447.2011.01766.x; Lam LCW, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2012.03.008; Lavretsky H, 2011, AM J GERIAT PSYCHIAT, V19, P839, DOI 10.1097/JGP.0b013e31820ee9ef; Potter R, 2011, INT J GERIATR PSYCH, V26, P1000, DOI 10.1002/gps.2641; Roose SP, 2004, AM J PSYCHIAT, V161, P2050, DOI 10.1176/appi.ajp.161.11.2050; Rosenberg D, 2010, AM J GERIAT PSYCHIAT, V18, P221, DOI 10.1097/JGP.0b013e3181c534b5; Tsang HWH, 2006, INT J GERIATR PSYCH, V21, P890, DOI 10.1002/gps.1582; Underwood M, 2013, LANCET	12	3	4	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 6	2013	382	9886					4	5		10.1016/S0140-6736(13)60860-0	http://dx.doi.org/10.1016/S0140-6736(13)60860-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	177AD	23643109	Green Accepted			2023-01-03	WOS:000321347000005
J	Vincent, EE; Elder, DJE; Curwen, J; Kilgour, E; Hers, I; Tavare, JM				Vincent, Emma E.; Elder, Douglas J. E.; Curwen, Jon; Kilgour, Elaine; Hers, Ingeborg; Tavare, Jeremy M.			Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor	PLOS ONE			English	Article							HUMAN-BREAST-CANCER; IGF-I; MONOCLONAL-ANTIBODIES; CLINICAL DEVELOPMENT; BINDING PROTEIN-3; HYBRID RECEPTORS; PROSTATE-CANCER; PLASMA-LEVELS; EXPRESSION; LINES	Phase III trials of the anti-insulin-like growth factor-1 receptor (IGF1R) antibody figitumumab in non-small cell lung cancer (NSCLC) patients have been discontinued owing to lack of survival benefit. We investigated whether inhibition of the highly homologous insulin receptor (IR) in addition to the IGF1R would be more effective than inhibition of the IGF1R alone at preventing the proliferation of NSCLC cells. Signalling through IGF1R and IR in the NSCLC cell lines A549 and Hcc193 was stimulated by a combination of IGF1, IGF2 and insulin. It was inhibited by antibodies that block ligand binding, alpha IR3 (IGF1R) and IR47-9 (IR), and by the ATP-competitive small molecule tyrosine kinase inhibitors AZ12253801 and NVPAWD742 which inhibit both IGF1R and IR tyrosine kinases. The effect of inhibitors was determined by an anchorage-independent proliferation assay and by analysis of Akt phosphorylation. In Hcc193 cells the reduction in cell proliferation and Akt phosphorylation due to anti-IGF1R antibody was enhanced by antibody-mediated inhibition of the IR whereas in A549 cells, with a relatively low IR: IGF1R expression ratio, it was not. In each cell line proliferation and Akt phosphorylation were more effectively inhibited by AZ12253801 and NVPAWD742 than by combined alpha IR3 and IR47-9. When the IGF1R alone is inhibited, unencumbered signalling through the IR can contribute to continued NSCLC cell proliferation. We conclude that small molecule inhibitors targeting both the IR and IGF1R more effectively reduce NSCLC cell proliferation in a manner independent of the IR: IGF1R expression ratio, providing a therapeutic rationale for the treatment of this disease.	[Vincent, Emma E.; Elder, Douglas J. E.; Tavare, Jeremy M.] Univ Bristol, Sch Biochem, Bristol, Avon, England; [Curwen, Jon; Kilgour, Elaine] AstraZeneca, CIRA Discovery, Macclesfield, Cheshire, England; [Hers, Ingeborg] Univ Bristol, Sch Physiol & Pharmacol, Bristol, Avon, England	University of Bristol; AstraZeneca; University of Bristol	Tavare, JM (corresponding author), Univ Bristol, Sch Biochem, Med Sci Bldg, Bristol, Avon, England.	j.tavare@bristol.ac.uk	Hers, Ingeborg/ABG-3357-2020	Vincent, Emma/0000-0002-8917-7384; Hers, Ingeborg/0000-0002-6467-5715	Medical Research Council; AstraZeneca; British Heart Foundation [PG/10/100/28658, FS/12/3/29232] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); AstraZeneca(AstraZeneca); British Heart Foundation(British Heart Foundation)	The work described was funded by grants from the Medical Research Council and AstraZeneca to JMT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avnet S, 2009, CANCER RES, V69, P2443, DOI 10.1158/0008-5472.CAN-08-2645; Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226; Basu B, 2011, BRIT J CANCER, V104, P1, DOI 10.1038/sj.bjc.6606023; Brown J, 2008, EMBO J, V27, P265, DOI 10.1038/sj.emboj.7601938; Cappuzzo F, 2010, ANN ONCOL, V21, P562, DOI 10.1093/annonc/mdp357; Carboni JM, 2009, MOL CANCER THER, V8, P3341, DOI 10.1158/1535-7163.MCT-09-0499; Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960; Chang YS, 2002, CLIN CANCER RES, V8, P3669; Coldren CD, 2006, MOL CANCER RES, V4, P521, DOI 10.1158/1541-7786.MCR-06-0095; Dalby AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050253; David O, 2004, CLIN CANCER RES, V10, P6865, DOI 10.1158/1078-0432.CCR-04-0174; Dent P, 2005, BIOCHEM PHARMACOL, V70, P1685, DOI 10.1016/j.bcp.2005.08.020; Dong JY, 2010, MOL CANCER THER, V9, P2593, DOI 10.1158/1535-7163.MCT-09-1018; Dziadziuszko R, 2008, J THORAC ONCOL, V3, P815, DOI 10.1097/JTO.0b013e31818180f5; FAVONI RE, 1994, INT J CANCER, V56, P858, DOI 10.1002/ijc.2910560618; Feng Y, 2006, MOL CANCER THER, V5, P114, DOI 10.1158/1535-7163.MCT-05-0252; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Gong YX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007273; Goya M, 2004, CANCER RES, V64, P6252, DOI 10.1158/0008-5472.CAN-04-0919; Gridelli C, 2010, EXPERT OPIN INV DRUG, V19, P631, DOI 10.1517/13543781003767434; Gualberto A, 2011, BRIT J CANCER, V104, P68, DOI 10.1038/sj.bjc.6605972; Gualberto A, 2010, CLIN CANCER RES, V16, P4654, DOI 10.1158/1078-0432.CCR-10-0089; Gualberto A, 2009, CURR DRUG TARGETS, V10, P923, DOI 10.2174/138945009789577945; Hakam A, 1999, HUM PATHOL, V30, P1128, DOI 10.1016/S0046-8177(99)90027-8; Hellawell GO, 2002, CANCER RES, V62, P2942; Jassem J, 2010, J CLIN ONCOL S, V28; KAISER U, 1993, J CANCER RES CLIN, V119, P665, DOI 10.1007/BF01215985; KAREY KP, 1988, CANCER RES, V48, P4083; Karp DD, 2009, J CLIN ONCOL, V27, P2516, DOI 10.1200/JCO.2008.19.9331; Kornprat P, 2006, J CLIN PATHOL, V59, P202, DOI 10.1136/jcp.2005.028480; KULL FC, 1983, J BIOL CHEM, V258, P6561; Law JH, 2008, CANCER RES, V68, P10238, DOI 10.1158/0008-5472.CAN-08-2755; Ludovini V, 2009, ANN ONCOL, V20, P842, DOI 10.1093/annonc/mdn727; Massoner P, 2010, BRIT J CANCER, V103, P1479, DOI 10.1038/sj.bjc.6605932; Meng JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014124; MILAZZO G, 1992, CANCER RES, V52, P3924; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; Neal JW, 2010, CURR TREAT OPTION ON, V11, P36, DOI 10.1007/s11864-010-0120-6; OSBORNE CK, 1976, P NATL ACAD SCI USA, V73, P4536, DOI 10.1073/pnas.73.12.4536; Pal SK, 2010, EXPERT OPIN INV DRUG, V19, P1355, DOI 10.1517/13543784.2010.520701; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; PAPA V, 1993, CANCER RES, V53, P3736; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petridou E, 2003, ONCOLOGY-BASEL, V64, P341, DOI 10.1159/000070291; PILLEMER G, 1992, INT J CANCER, V50, P80, DOI 10.1002/ijc.2910500117; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Prince SN, 2007, MOL CANCER THER, V6, P607, DOI 10.1158/1535-7163.MCT-06-0509; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Rinaldi S, 2006, ENDOCR-RELAT CANCER, V13, P593, DOI 10.1677/erc.1.01150; Sachdev D, 2003, CANCER RES, V63, P627; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; Ulanet DB, 2010, P NATL ACAD SCI US; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Vincent EE, 2011, BR J CANC; Vincent EE, 2011, ANTICANCER RES, V31, P1577; Warshamana-Greene GS, 2004, MOL CANCER THER, V3, P527; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Yeh J, 2008, LUNG CANCER, V60, P166, DOI 10.1016/j.lungcan.2007.09.023; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zhang H, 2010, ONCOGENE, V29, P2517, DOI 10.1038/onc.2010.17; Zhao H, 2003, J UROLOGY, V169, P714, DOI 10.1016/S0022-5347(05)63999-7; Zhu CQ, 2007, P NATL ACAD SCI USA, V104, P11754, DOI 10.1073/pnas.0703040104	64	29	30	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2013	8	6							e66963	10.1371/journal.pone.0066963	http://dx.doi.org/10.1371/journal.pone.0066963			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JP	23826179	Green Published, gold, Green Submitted			2023-01-03	WOS:000321738400088
J	Gine-Garriga, M; Martin-Borras, C; Puig-Ribera, A; Martin-Cantera, C; Sola, M; Cuesta-Vargas, A				Gine-Garriga, Maria; Martin-Borras, Carme; Puig-Ribera, Anna; Martin-Cantera, Carlos; Sola, Merce; Cuesta-Vargas, Antonio		PPAF Grp	The Effect of a Physical Activity Program on the Total Number of Primary Care Visits in Inactive Patients: A 15-Month Randomized Controlled Trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; OLDER-ADULTS; HEALTH SURVEY; EXERCISE; WOMEN; INTERVENTIONS; RELIABILITY	Background: Effective promotion of exercise could result in substantial savings in healthcare cost expenses in terms of direct medical costs, such as the number of medical appointments. However, this is hampered by our limited knowledge of how to achieve sustained increases in physical activity. Objectives: To assess the effectiveness of a Primary Health Care (PHC) based physical activity program in reducing the total number of visits to the healthcare center among inactive patients, over a 15-month period. Research Design: Randomized controlled trial. Subjects: Three hundred and sixty-two (n = 362) inactive patients suffering from at least one chronic condition were included. One hundred and eighty-three patients (n = 183; mean (SD); 68.3 (8.8) years; 118 women) were randomly allocated to the physical activity program (IG). One hundred and seventy-nine patients (n = 179; 67.2 (9.1) years; 106 women) were allocated to the control group (CG). The IG went through a three-month standardized physical activity program led by physical activity specialists and linked to community resources. Measures: The total number of medical appointments to the PHC, during twelve months before and after the program, was registered. Self-reported health status (SF-12 version 2) was assessed at baseline (month 0), at the end of the intervention (month 3), and at 12 months follow-up after the end of the intervention (month 15). Results: The IG had a significantly reduced number of visits during the 12 months after the intervention: 14.8 (8.5). The CG remained about the same: 18.2 (11.1) (P = .002). Conclusions: Our findings indicate that a 3-month physical activity program linked to community resources is a short-duration, effective and sustainable intervention in inactive patients to decrease rates of PHC visits.	[Gine-Garriga, Maria; Martin-Borras, Carme] Univ Ramon Llull, FPCEE Blanquerna, Dept Phys Act & Sport Sci, Barcelona, Spain; [Gine-Garriga, Maria] Univ Ramon Llull, FPCEE Blanquerna, Dept Phys Therapy, Barcelona, Spain; [Puig-Ribera, Anna] Univ Vic, Dept Phys Act & Sport Sci, Vic, Spain; [Martin-Cantera, Carlos; Sola, Merce] Primary Healthcare Res Inst IDIAP Jordi Gol, Res Unit Barcelona, Barcelona, Spain; [Martin-Cantera, Carlos] Univ Autonoma Barcelona, Dept Med, E-08193 Barcelona, Spain; [Cuesta-Vargas, Antonio] Univ Malaga, Dept Phys Therapy, E-29071 Malaga, Spain	Universitat Ramon Llull; Universitat Ramon Llull; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); Autonomous University of Barcelona; Universidad de Malaga	Gine-Garriga, M (corresponding author), Univ Ramon Llull, FPCEE Blanquerna, Dept Phys Act & Sport Sci, Barcelona, Spain.	mariagg@blanquerna.url.edu	Giné-Garriga, Maria/AAF-9828-2019; Giné-Garriga, Maria/F-4089-2016; Martin Cantera, Carlos/D-2693-2011; del Val Garcia, Jose Luis/G-6195-2016	Giné-Garriga, Maria/0000-0003-4449-3524; Giné-Garriga, Maria/0000-0003-4449-3524; Martin Cantera, Carlos/0000-0003-0656-8126; del Val Garcia, Jose Luis/0000-0002-0391-9368; Cuesta-Vargas, Antonio I/0000-0002-8880-4315	Catalan Society of General Practice (CAMFIC)	Catalan Society of General Practice (CAMFIC)	This work was supported by a research award from the Catalan Society of General Practice (CAMFIC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; Anderson RT, 2005, ANN BEHAV MED, V30, P146, DOI 10.1207/s15324796abm3002_7; Bayliss Elizabeth A, 2003, Ann Fam Med, V1, P15, DOI 10.1370/afm.4; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Department of Health, 2010, 2009 ANN REP CHIEF M; Diari Oficial de la Generalitat de Catalunya, 2009, DIARI OFICIAL GEN CA; Enquesta de Salut de Catalunya, 2012, INF DELS PRINC RES; Fortin M, 2006, QUAL LIFE RES, V15, P83, DOI 10.1007/s11136-005-8661-z; Gine-Garriga M, 2008, ATEN PRIM, V40, P374, DOI 10.1157/13124135; Gine-Garriga M, 2010, J AGING PHYS ACTIV, V18, P401, DOI 10.1123/japa.18.4.401; Gine-Garriga M, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-31; Guyton AC, 2007, TRATADO FISIOLOGIA M; Hillsdon M, 2005, Cochrane Database Syst Rev, pCD003180; Hubbard RE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006174; Lawton BA, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2509; McCusker J, 2006, J GERONTOL A-BIOL, V61, P53, DOI 10.1093/gerona/61.1.53; Ministerio de Sanidad y Consumo, 2001, ENC NAC SAL; Murphy SL, 2002, J AM GERIATR SOC, V50, P516, DOI 10.1046/j.1532-5415.2002.50119.x; Nelson ME, 2007, MED SCI SPORT EXER, V39, P1435, DOI [10.1249/mss.0b013e3180616aa2, 10.1161/CIRCULATIONAHA.107.185650]; Orrow G, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1389; Palomo Luis, 2006, Gac Sanit, V20 Suppl 1, P182, DOI 10.1157/13086042; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID ADV CO; Prados-Torres A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032190; Ribera AP, 2006, HEALTH EDUC RES, V21, P538, DOI 10.1093/her/cyl008; Ribera AP, 2005, EUR J PUBLIC HEALTH, V15, P569, DOI 10.1093/eurpub/cki045; Robertson R., 2012, MENT HEALTH PHYS ACT, V5, P66, DOI [DOI 10.1016/J.MHPA.2012.03.002, 10.1016/j.mhpa.2012.03.002]; Rose Sally B, 2008, N Z Med J, V121, pU2897; Schuch FB, 2011, MENT HEALTH PHYS ACT, V4, p43e48; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Shumaker S. A., 1990, QUALITY LIFE ASSESSM, P95; SKELTON DA, 1995, J AM GERIATR SOC, V43, P1081, DOI 10.1111/j.1532-5415.1995.tb07004.x; Smith K, 2003, CAN J APPL PHYSIOL, V28, P462, DOI 10.1139/h03-034; Spirduso WW, 2001, MED SCI SPORT EXER, V33, pS598, DOI 10.1097/00005768-200106001-00028; Starfield Barbara, 2003, Ann Fam Med, V1, P8, DOI 10.1370/afm.1; van der Bij AK, 2002, AM J PREV MED, V22, P120, DOI 10.1016/S0749-3797(01)00413-5; Vedsted P, 2005, PUBLIC HEALTH, V119, P118, DOI 10.1016/j.puhe.2004.03.007; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Ware John E., 2002, SF 12V2TM SCORE VERS; WHO, 2010, WOR HEALT REP, P1; Williams NH, 2007, BRIT J GEN PRACT, V57, P979, DOI 10.3399/096016407782604866; Wilson T, 2005, BMJ-BRIT MED J, V330, P657, DOI 10.1136/bmj.330.7492.657; Wolfenstetter SB, 2012, ADV PREV MED, V2012, P601, DOI DOI 10.1155/2012/601631	44	6	6	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2013	8	6							e66392	10.1371/journal.pone.0066392	http://dx.doi.org/10.1371/journal.pone.0066392			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	170JP	23805219	Green Published, gold			2023-01-03	WOS:000320846500047
J	Clerget, E; Andres, M; Olivier, E				Clerget, Emeline; Andres, Michael; Olivier, Etienne			Deficit in Complex Sequence Processing after a Virtual Lesion of Left BA45	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; DORSAL PREMOTOR CORTEX; BROCAS AREA; HIERARCHICAL ORGANIZATION; PREFRONTAL CORTEX; COGNITIVE CONTROL; FRONTAL-CORTEX; LANGUAGE; BEHAVIOR; APHASIA	Although the contribution of Broca's area to motor cognition is generally accepted, its exact role remains controversial. A previous functional imaging study has suggested that Broca's area implements hierarchically organised motor behaviours and, in particular, that its anterior (Brodmann area 45, BA45) and posterior (BA44) parts process, respectively, higher and lower-level hierarchical elements. This function of Broca's area could generalize to other cognitive functions, including language. However, because of the correlative nature of functional imaging data, the causal relationship between Broca's region activation and its behavioural significance cannot be ascertained. To circumvent this limitation, we used on-line repetitive transcranial magnetic stimulation to disrupt neuronal processing in left BA45, left BA44 or left dorsal premotor cortex, three areas that have been shown to exhibit a phasic activation when participants performed hierarchically organised motor behaviours. The experiment was conducted in healthy volunteers performing the same two key-press sequences as those used in a previous imaging study, and which differed in terms of hierarchical organisation. The performance of the lower-order hierarchical task (Experiment #1) was unaffected by magnetic stimulation. In contrast, in the higher-order hierarchical task (Experiment #2, "superordinate" task), we found that a virtual lesion of the anterior part of Broca's area (left BA45) delayed the processing of the cue initiating the sequence in an effector-independent way. Interestingly, in this task, the initiation cue only informed the subjects about the rules to be applied to produce the appropriate response but did not allow them to anticipate the entire motor sequence. A second important finding was a RT decrease following left PMd virtual lesions in the superordinate task, a result compatible with the view that PMd plays a critical role in impulse control. The present study therefore demonstrates the role of left BA45 in planning the higher-order hierarchical levels of motor sequences.	[Clerget, Emeline; Olivier, Etienne] Catholic Univ Louvain, Neurophysiol Lab, Inst Neurosci, B-1200 Brussels, Belgium; [Andres, Michael] Univ Ghent, Fac Psychol, Dept Expt Psychol, B-9000 Ghent, Belgium	Universite Catholique Louvain; Ghent University	Olivier, E (corresponding author), Catholic Univ Louvain, Neurophysiol Lab, Inst Neurosci, B-1200 Brussels, Belgium.	etienne.olivier@uclouvain.be	Andres, Michael/I-2306-2019	Andres, Michael/0000-0002-7505-8157	Fonds pour la formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA); Fonds Speciaux de Recherche (FSR) of the Universite Catholique de Louvain; Fonds de la Recherche Scientifique Medicale (FRSM); Actions de Recherche Concertees (ARC) [07/12-007]	Fonds pour la formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA)(Fonds de la Recherche Scientifique - FNRS); Fonds Speciaux de Recherche (FSR) of the Universite Catholique de Louvain; Fonds de la Recherche Scientifique Medicale (FRSM)(Fonds de la Recherche Scientifique - FNRS); Actions de Recherche Concertees (ARC)	This work was supported by grants from the Fonds pour la formation a la Recherche dans l'Industrie et dans l'Agriculture (FRIA), from the Actions de Recherche Concertees (ARC, grant 07/12-007, Communaute Francaise de Belgique), from the Fonds Speciaux de Recherche (FSR) of the Universite Catholique de Louvain, from the Fonds de la Recherche Scientifique Medicale (FRSM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badre D, 2008, TRENDS COGN SCI, V12, P193, DOI 10.1016/j.tics.2008.02.004; Badre D, 2007, J COGNITIVE NEUROSCI, V19, P2082, DOI 10.1162/jocn.2007.19.12.2082; Badre D, 2010, NEURON, V66, P315, DOI 10.1016/j.neuron.2010.03.025; Badre D, 2009, NAT REV NEUROSCI, V10, P659, DOI 10.1038/nrn2667; Bahlmann J, 2008, NEUROIMAGE, V42, P525, DOI 10.1016/j.neuroimage.2008.04.249; Bahlmann J, 2009, BRAIN RES, V1298, P161, DOI 10.1016/j.brainres.2009.08.017; Botvinick MM, 2008, TRENDS COGN SCI, V12, P201, DOI 10.1016/j.tics.2008.02.009; Botvinick MM, 2007, PHILOS T R SOC B, V362, P1615, DOI 10.1098/rstb.2007.2056; Burns MS, 2010, TOP STROKE REHABIL, V17, P401, DOI 10.1310/tsr1706-401; Clerget E, 2013, BROCAS AREA IN PRESS; Clerget E, 2012, J COGNITIVE NEUROSCI, V24, P80, DOI 10.1162/jocn_a_00108; Clerget E, 2011, NEUROREPORT, V22, P965, DOI 10.1097/WNR.0b013e32834d87cd; Clerget E, 2009, NEUROREPORT, V20, P1496, DOI 10.1097/WNR.0b013e3283329be8; Davare M, 2006, J NEUROSCI, V26, P2260, DOI 10.1523/JNEUROSCI.3386-05.2006; Davare M, 2007, J NEUROSCI, V27, P3974, DOI 10.1523/JNEUROSCI.0426-07.2007; Dehaene S, 1997, P NATL ACAD SCI USA, V94, P13293, DOI 10.1073/pnas.94.24.13293; Dominey PF, 2003, BRAIN LANG, V86, P207, DOI 10.1016/S0093-934X(02)00529-1; Duque J, 2012, J NEUROSCI, V32, P806, DOI 10.1523/JNEUROSCI.4299-12.2012; Duque J, 2010, J COGNITIVE NEUROSCI, V22, P526, DOI 10.1162/jocn.2009.21213; Fadiga L, 2009, ANN NY ACAD SCI, V1169, P448, DOI 10.1111/j.1749-6632.2009.04582.x; Fazio P, 2009, BRAIN, V132, P1980, DOI 10.1093/brain/awp118; Fedorenko E, 2012, CURR BIOL, V22, P2059, DOI 10.1016/j.cub.2012.09.011; Fedorenko E, 2011, LANG LINGUIST COMPAS, V5, P78, DOI 10.1111/j.1749-818x.2010.00264.x; Friederici AD, 2006, CEREB CORTEX, V16, P1709, DOI 10.1093/cercor/bhj106; Friederici AD, 2011, BIOLINGUISTICS, V5, P87; Friedrich R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005599; GROSSMAN M, 1980, NEUROPSYCHOLOGIA, V18, P299, DOI 10.1016/0028-3932(80)90125-6; Hickok G, 1996, NEUROCASE, V2, P373, DOI 10.1080/13554799608402412; Hoen M, 2006, CORTEX, V42, P605, DOI 10.1016/S0010-9452(08)70398-8; Keel JC, 2001, CLIN NEUROPHYSIOL, V112, P720, DOI 10.1016/S1388-2457(00)00518-6; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; Koechlin E, 2007, TRENDS COGN SCI, V11, P229, DOI 10.1016/j.tics.2007.04.005; Koechlin E, 2006, NEURON, V50, P963, DOI 10.1016/j.neuron.2006.05.017; Maess B, 2001, NAT NEUROSCI, V4, P540, DOI 10.1038/87502; Musso M, 2003, NAT NEUROSCI, V6, P774, DOI 10.1038/nn1077; Noirhomme Q, 2004, IEEE T BIO-MED ENG, V51, P1994, DOI 10.1109/TBME.2004.834266; O'Shea J, 2007, EUR J NEUROSCI, V26, P2085, DOI 10.1111/j.1460-9568.2007.05795.x; O'Shea J, 2007, NEURON, V54, P479, DOI 10.1016/j.neuron.2007.04.021; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pallier C, 2011, P NATL ACAD SCI USA, V108, P2522, DOI 10.1073/pnas.1018711108; Pammi VSC, 2012, NEUROIMAGE, V59, P1180, DOI 10.1016/j.neuroimage.2011.08.006; Santi A, 2007, NEUROIMAGE, V37, P8, DOI 10.1016/j.neuroimage.2007.04.047; Schluter ND, 1998, BRAIN, V121, P785, DOI 10.1093/brain/121.5.785; Sparing R, 2008, HUM BRAIN MAPP, V29, P82, DOI 10.1002/hbm.20360; Terao Y, 1997, EXP BRAIN RES, V115, P541, DOI 10.1007/PL00005724; Tettamanti M, 2006, CORTEX, V42, P491, DOI 10.1016/S0010-9452(08)70384-8; Tyler LK, 2010, CEREB CORTEX, V20, P352, DOI 10.1093/cercor/bhp105; Verwey WB, 2001, ACTA PSYCHOL, V106, P69, DOI 10.1016/S0001-6918(00)00027-5; Ward NS, 2010, J NEUROSCI, V30, P9216, DOI 10.1523/JNEUROSCI.4499-09.2010; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wymbs NF, 2012, NEURON, V74, P936, DOI 10.1016/j.neuron.2012.03.038	51	19	20	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2013	8	6							e63722	10.1371/journal.pone.0063722	http://dx.doi.org/10.1371/journal.pone.0063722			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164VY	23762232	gold, Green Published			2023-01-03	WOS:000320440500004
J	Poff, AM; Ari, C; Seyfried, TN; D'Agostino, DP				Poff, Angela M.; Ari, Csilla; Seyfried, Thomas N.; D'Agostino, Dominic P.			The Ketogenic Diet and Hyperbaric Oxygen Therapy Prolong Survival in Mice with Systemic Metastatic Cancer	PLOS ONE			English	Article							LOW-CARBOHYDRATE DIETS; KETONE-BODIES; TUMOR-GROWTH; WEIGHT-LOSS; PROSTATE-CANCER; GENE-EXPRESSION; BRAIN-TUMOR; MOUSE MODEL; ENERGY RESTRICTION; VASCULAR DENSITY	Introduction: Abnormal cancer metabolism creates a glycolytic-dependency which can be exploited by lowering glucose availability to the tumor. The ketogenic diet (KD) is a low carbohydrate, high fat diet which decreases blood glucose and elevates blood ketones and has been shown to slow cancer progression in animals and humans. Abnormal tumor vasculature creates hypoxic pockets which promote cancer progression and further increase the glycolytic-dependency of cancers. Hyperbaric oxygen therapy (HBO2T) saturates tumors with oxygen, reversing the cancer promoting effects of tumor hypoxia. Since these non-toxic therapies exploit overlapping metabolic deficiencies of cancer, we tested their combined effects on cancer progression in a natural model of metastatic disease. Methods: We used the firefly luciferase-tagged VM-M3 mouse model of metastatic cancer to compare tumor progression and survival in mice fed standard or KD ad libitum with or without HBO2T (2.5 ATM absolute, 90 min, 3x/week). Tumor growth was monitored by in vivo bioluminescent imaging. Results: KD alone significantly decreased blood glucose, slowed tumor growth, and increased mean survival time by 56.7% in mice with systemic metastatic cancer. While HBO2T alone did not influence cancer progression, combining the KD with HBO2T elicited a significant decrease in blood glucose, tumor growth rate, and 77.9% increase in mean survival time compared to controls. Conclusions: KD and HBO2T produce significant anti-cancer effects when combined in a natural model of systemic metastatic cancer. Our evidence suggests that these therapies should be further investigated as potential non-toxic treatments or adjuvant therapies to standard care for patients with systemic metastatic disease.	[Poff, Angela M.; Ari, Csilla; D'Agostino, Dominic P.] Univ S Florida, Dept Mol Pharmacol & Physiol, Tampa, FL 33620 USA; [Seyfried, Thomas N.] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA	State University System of Florida; University of South Florida; Boston College	Poff, AM (corresponding author), Univ S Florida, Dept Mol Pharmacol & Physiol, Tampa, FL 33620 USA.	abennett@health.usf.edu	D'Agostino, Dominic/I-6194-2012; D'Agostino, Dominic/GPJ-9744-2022	Seyfried, Thomas/0000-0003-1491-3989	Office of Naval Research, ONR [N000140610105, N000140210643]	Office of Naval Research, ONR(Office of Naval Research)	This work was supported by the Office of Naval Research, ONR grant N000140610105 and ONR-DURIP equipment grant N000140210643 (http://www.onr.navy.mil/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelwahab MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036197; Al-Waili NS, 2005, MED SCI MONITOR, V11, pRA279; Astrup A, 2000, BRIT J NUTR, V83, pS25; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Bayley JP, 2012, CURR OPIN ONCOL, V24, P62, DOI 10.1097/CCO.0b013e32834deb9e; Bennett A, 2012, FASEB J; Bennett M, 2008, CANCER TREAT REV, V34, P577, DOI 10.1016/j.ctrv.2008.01.001; Bergamo A, 1999, J PHARMACOL EXP THER, V289, P559; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Cahill GF, 2006, ANNU REV NUTR, V26, P1, DOI 10.1146/annurev.nutr.26.061505.111258; Champ CE, 2012, INT J BREAST CANC, DOI DOI 10.1155/2012/506868; D'Agostino D, 2012, FASEB SAN DIEGO CA; D'agostino DP, 2009, NEUROSCIENCE, V159, P1011, DOI 10.1016/j.neuroscience.2009.01.062; D'Agostino DP, 2013, AM J PHYSL REGULATOR; Daruwalla J, 2006, WORLD J SURG, V30, P2112, DOI 10.1007/s00268-006-0190-6; Duranti L, 2012, TUMORI J, V98, P175, DOI 10.1700/1088.11927; Fine EJ, 2012, NUTRITION, V28, P1028, DOI 10.1016/j.nut.2012.05.001; Fomchenko EI, 2006, CLIN CANCER RES, V12, P5288, DOI 10.1158/1078-0432.CCR-06-0438; Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4; Gill AL, 2004, QJM, V97; Graeme M, 2004, CLIN ONCOLOGY, V16, P549; GRAY LH, 1953, BRIT J RADIOL, V26, P638, DOI 10.1259/0007-1285-26-312-638; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hoogsteen IJ, 2007, CLIN ONCOL-UK, V19, P385, DOI 10.1016/j.clon.2007.03.001; Hursting SD, 2010, CARCINOGENESIS, V31, P83, DOI 10.1093/carcin/bgp280; Hussain TA, 2012, NUTRITION, V28, P1016, DOI 10.1016/j.nut.2012.01.016; Huysentruyt LC, 2008, INT J CANCER, V123, P73, DOI 10.1002/ijc.23492; Huysentruyt LC, 2011, ASN NEURO, V3, P183, DOI 10.1042/AN20110011; Huysentruyt LC, 2010, INT J CANCER, V126, P65, DOI 10.1002/ijc.24649; Johnstone AM, 2008, AM J CLIN NUTR, V87, P44, DOI 10.1093/ajcn/87.1.44; Kashiwaya Y, 2013, NEUROBIOL AGING, V34, P1530, DOI 10.1016/j.neurobiolaging.2012.11.023; Katyal NG, 2000, CLIN PEDIATR, V39, P153, DOI 10.1177/000992280003900303; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; MAGEE BA, 1979, AUST J EXP BIOL MED, V57, P529, DOI 10.1038/icb.1979.54; Manninen AH, 2006, NUTR METAB, V3, DOI 10.1186/1743-7075-3-9; Marsh J, 2008, CLIN CANCER RES, V14, P7751, DOI 10.1158/1078-0432.CCR-08-0213; Marsh J, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-33; Martinez-Outschoorn UE, 2012, CELL CYCLE, V11, P3964, DOI 10.4161/cc.22137; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; Masko EM, 2010, CANCER PREV RES, V3, P1124, DOI 10.1158/1940-6207.CAPR-10-0071; Maurer GD, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-315; Mavropoulos JC, 2006, UROLOGY, V68, P15, DOI 10.1016/j.urology.2006.03.073; Mavropoulos JC, 2009, CANCER PREV RES, V2, P557, DOI 10.1158/1940-6207.CAPR-08-0188; McGuire WP, 1996, SEMIN ONCOL, V23, P40; Moen I, 2012, TARGET ONCOL, V7, P233, DOI 10.1007/s11523-012-0233-x; Moen I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006381; Mukherjee P, 1999, JNCI-J NATL CANCER I, V91, P512, DOI 10.1093/jnci/91.6.512; Mukherjee P, 2002, BRIT J CANCER, V86, P1615, DOI 10.1038/sj.bjc.6600298; Mukherjee P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-37; NEBELING LC, 1995, J AM DIET ASSOC, V95, P693, DOI 10.1016/S0002-8223(95)00189-1; NEBELING LC, 1995, J AM COLL NUTR, V14, P202; Otto C, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-122; Paoli A, 2012, J INT SOC SPORT NUTR, V9, DOI 10.1186/1550-2783-9-34; Petre PM, 2003, J THORAC CARDIOV SUR, V125, P85, DOI 10.1067/mtc.2003.90; Pilla R, 2012, 3 INT S DIET THER EP; ROSSIFANELLI F, 1991, CLIN NUTR, V10, P228, DOI 10.1016/0261-5614(91)90043-C; Salem AF, 2012, CELL CYCLE, V11, P2545, DOI 10.4161/cc.20920; Sawai M, 2004, ANTICANCER RES, V24, P2213; Scheck AC, 2012, EPILEPSY RES, V100, P327, DOI 10.1016/j.eplepsyres.2011.09.022; Schmidt M, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-54; Seyfried IN, 2012, CANC METABOLIC DIS O; Seyfried TN, 2010, LANCET ONCOL, V11, P811, DOI 10.1016/S1470-2045(10)70166-2; Seyfried TN, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-7; Seyfried TN, 2003, BRIT J CANCER, V89, P1375, DOI 10.1038/sj.bjc.6601269; Shelton LM, 2010, J NEURO-ONCOL, V99, P165, DOI 10.1007/s11060-010-0115-y; Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166; Skinner R, 2009, J PEDIATR SURG, V44, P212, DOI 10.1016/j.jpedsurg.2008.10.042; Stafford P, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-74; Stuhr LEB, 2004, CANCER LETT, V210, P35, DOI 10.1016/j.canlet.2004.02.012; Stuhr LEB, 2007, J NEURO-ONCOL, V85, P191, DOI 10.1007/s11060-007-9407-2; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Takiguchi N, 2001, CANCER CHEMOTH PHARM, V47, P11, DOI 10.1007/s002800000190; Thompson HJ, 2004, CANCER RES, V64, P5643, DOI 10.1158/0008-5472.CAN-04-0787; Thompson HJ, 2004, CANCER RES, V64, P1541, DOI 10.1158/0008-5472.CAN-03-3108; Thompson HJ, 2003, J MAMMARY GLAND BIOL, V8, P133, DOI 10.1023/A:1025743607445; TISDALE MJ, 1987, BRIT J CANCER, V56, P39, DOI 10.1038/bjc.1987.149; TISDALE MJ, 1983, BRIT J CANCER, V47, P293, DOI 10.1038/bjc.1983.38; TISDALE MJ, 1988, BRIT J CANCER, V58, P580, DOI 10.1038/bjc.1988.263; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Veech RL, 2001, IUBMB LIFE, V51, P241; Volek Js, 2004, Nutr Metab (Lond), V1, P13, DOI 10.1186/1743-7075-1-13; Volek JS, 2002, METABOLISM, V51, P864, DOI 10.1053/meta.2002.32037; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wheatley KE, 2008, NUTR CANCER, V60, P61, DOI 10.1080/01635580701510150; Wouters BG, 2004, DRUG RESIST UPDATE, V7, P25, DOI 10.1016/j.drup.2003.12.004; WU GY, 1988, BIOCHEM J, V255, P139, DOI 10.1042/bj2550139; Zhou WH, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-5; Zhu ZJ, 2005, MOL CARCINOGEN, V42, P170, DOI 10.1002/mc.20071; Zuccoli G, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-33	93	106	113	2	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2013	8	6							e65522	10.1371/journal.pone.0065522	http://dx.doi.org/10.1371/journal.pone.0065522			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166TB	23755243	gold, Green Published, Green Submitted			2023-01-03	WOS:000320579400061
J	Ruskin, DN; Svedova, J; Cote, JL; Sandau, U; Rho, JM; Kawamura, M; Boison, D; Masino, SA				Ruskin, David N.; Svedova, Julia; Cote, Jessica L.; Sandau, Ursula; Rho, Jong M.; Kawamura, Masahito, Jr.; Boison, Detlev; Masino, Susan A.			Ketogenic Diet Improves Core Symptoms of Autism in BTBR Mice	PLOS ONE			English	Article							FATTY LIVER-DISEASE; K-ATP CHANNELS; LOW-CARBOHYDRATE; SPECTRUM DISORDERS; ADULT RATS; EPILEPSY; ADENOSINE; METABOLISM; CHILDREN; BRAIN	Autism spectrum disorders share three core symptoms: impaired sociability, repetitive behaviors and communication deficits. Incidence is rising, and current treatments are inadequate. Seizures are a common comorbidity, and since the 1920's a high-fat, low-carbohydrate ketogenic diet has been used to treat epilepsy. Evidence suggests the ketogenic diet and analogous metabolic approaches may benefit diverse neurological disorders. Here we show that a ketogenic diet improves autistic behaviors in the BTBR mouse. Juvenile BTBR mice were fed standard or ketogenic diet for three weeks and tested for sociability, self-directed repetitive behavior, and communication. In separate experiments, spontaneous intrahippocampal EEGs and tests of seizure susceptibility (6 Hz corneal stimulation, flurothyl, SKF83822, pentylenetetrazole) were compared between BTBR and control (C57Bl/6) mice. Ketogenic diet-fed BTBR mice showed increased sociability in a three-chamber test, decreased self-directed repetitive behavior, and improved social communication of a food preference. Although seizures are a common comorbidity with autism, BTBR mice fed a standard diet exhibit neither spontaneous seizures nor abnormal EEG, and have increased seizure susceptibility in just one of four tests. Thus, behavioral improvements are dissociable from any antiseizure effect. Our results suggest that a ketogenic diet improves multiple autistic behaviors in the BTBR mouse model. Therefore, ketogenic diets or analogous metabolic strategies may offer novel opportunities to improve core behavioral symptoms of autism spectrum disorders.	[Ruskin, David N.; Svedova, Julia; Cote, Jessica L.; Masino, Susan A.] Trinity Coll, Neurosci Program, Hartford, CT 06106 USA; [Ruskin, David N.; Masino, Susan A.] Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; [Sandau, Ursula; Boison, Detlev] Legacy Res Inst, Robert Stone Dow Neurobiol Labs, Portland, OR USA; [Rho, Jong M.] Univ Calgary, Dept Pediat, Alberta Childrens Hosp, Fac Med, Calgary, AB T2N 1N4, Canada; [Rho, Jong M.] Univ Calgary, Dept Clin Neurosci, Alberta Childrens Hosp, Fac Med, Calgary, AB T2N 1N4, Canada; [Kawamura, Masahito, Jr.] Jikei Univ, Sch Med, Dept Pharmacol, Tokyo, Japan	Trinity College; Trinity College; Alberta Childrens Hospital; University of Calgary; Alberta Childrens Hospital; University of Calgary; Jikei University	Masino, SA (corresponding author), Trinity Coll, Neurosci Program, Hartford, CT 06106 USA.	susan.masino@trincoll.edu	Boison, Detlev/ABE-6302-2020	Boison, Detlev/0000-0002-7740-5781; Cote, Jessica/0000-0001-8967-2396	National Institutes of Health [R01 NS065957, R01 NS061844, R01 NS070267]; National Science Foundation [IOS-0843585]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS061844, R01NS070267, R01NS065957, R15NS066392] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by National Institutes of Health R01 NS065957, R01 NS061844 and R01 NS070267 (www.nih.gov), and National Science Foundation IOS-0843585 (www.nsf.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4; Baranano Kristin W, 2008, Curr Treat Options Neurol, V10, P410, DOI 10.1007/s11940-008-0043-8; Brinkworth GD, 2009, ARCH INTERN MED, V169, P1873, DOI 10.1001/archinternmed.2009.329; Burnstock G, 2011, PROG NEUROBIOL, V95, P229, DOI 10.1016/j.pneurobio.2011.08.006; Chadman KK, 2012, EXPERT OPIN DRUG DIS, V7, P407, DOI 10.1517/17460441.2012.678828; DIXON WJ, 1948, J AM STAT ASSOC, V43, P109, DOI 10.2307/2280071; Eapen V, 2011, AUTISM NEURODEVELOPM, P103; El-Ansary A, 2010, CLIN BIOCHEM, V43, P63, DOI 10.1016/j.clinbiochem.2009.09.008; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Evangeliou A, 2003, J CHILD NEUROL, V18, P113, DOI 10.1177/08830738030180020501; Forsythe CE, 2008, LIPIDS, V43, P65, DOI 10.1007/s11745-007-3132-7; Frye RE, 2011, PEDIATR RES, V69, p41R, DOI 10.1203/PDR.0b013e318212f16b; Gimenez-Cassina A, 2012, NEURON, V74, P719, DOI 10.1016/j.neuron.2012.03.032; Halyburton AK, 2007, AM J CLIN NUTR, V86, P580, DOI 10.1093/ajcn/86.3.580; Juge N, 2010, NEURON, V68, P99, DOI 10.1016/j.neuron.2010.09.002; Kawamura M, 2010, J NEUROSCI, V30, P3886, DOI 10.1523/JNEUROSCI.0055-10.2010; Kim DY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035476; Lund TM, 2009, J NEUROCHEM, V110, P80, DOI 10.1111/j.1471-4159.2009.06115.x; Ma WY, 2007, J NEUROSCI, V27, P3618, DOI 10.1523/JNEUROSCI.0132-07.2007; Masino SA, 2009, CURR NEUROPHARMACOL, V7, P257, DOI 10.2174/157015909789152164; Masino SA, 2012, NEUROSCIENCE; Masino SA, 2013, NEUROPHARMACOLOGY, V68, P116, DOI 10.1016/j.neuropharm.2012.08.013; Masino Susan A, 2010, Open Neurosci J, V4, P58; Masino SA, 2011, NEUROSCI LETT, V500, P1, DOI 10.1016/j.neulet.2011.06.007; Masino SA, 2011, J CLIN INVEST, V121, P2679, DOI 10.1172/JCI57813; McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x; Meidenbauer JJ, 2011, EPILEPSIA, V52, P347, DOI 10.1111/j.1528-1167.2010.02898.x; Milllward C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003498.pub3; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Park CR, 2001, BIOL PSYCHIAT, V50, P994, DOI 10.1016/S0006-3223(01)01255-0; Patel A, 2010, EPILEPSIA, V51, P1277, DOI 10.1111/j.1528-1167.2009.02488.x; Patterson PH, 2011, PEDIATR RES, V69, p34R, DOI 10.1203/PDR.0b013e318212b80f; Perez-Guisado J, 2011, J MED FOOD, V14, P677, DOI 10.1089/jmf.2011.0075; Pobbe RLH, 2011, BEHAV BRAIN RES, V216, P446, DOI 10.1016/j.bbr.2010.08.039; Ruskin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008349; Sansa G, 2011, EPILEPSIA, V52, P1071, DOI 10.1111/j.1528-1167.2011.03069.x; Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f; Sirven J, 1999, EPILEPSIA, V40, P1721, DOI 10.1111/j.1528-1157.1999.tb01589.x; Spence SJ, 2009, PEDIATR RES, V65, P599, DOI 10.1203/PDR.0b013e31819e7168; Stafstrom CE, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00059; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Tendler D, 2007, DIGEST DIS SCI, V52, P589, DOI 10.1007/s10620-006-9433-5; Tuchman R, 2002, LANCET NEUROL, V1, P352, DOI 10.1016/S1474-4422(02)00160-6; Vargas DL, 2005, ANN NEUROL, V57, P67, DOI 10.1002/ana.20315; Wilder R., 1921, MAY CLIN B, P308; Yudkoff M, 2007, ANNU REV NUTR, V27, P415, DOI 10.1146/annurev.nutr.27.061406.093722; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	47	100	106	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2013	8	6							e65021	10.1371/journal.pone.0065021	http://dx.doi.org/10.1371/journal.pone.0065021			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166TB	23755170	Green Published, gold			2023-01-03	WOS:000320579400036
J	Wang, HM; Liang, XB; Wang, X; Luo, DZ; Jia, J; Wang, XM				Wang, Haomin; Liang, Xibin; Wang, Xuan; Luo, Dingzhen; Jia, Jun; Wang, Xiaomin			Electro-Acupuncture Stimulation Improves Spontaneous Locomotor Hyperactivity in MPTP Intoxicated Mice	PLOS ONE			English	Article							RESTLESS LEGS SYNDROME; PARKINSONS-DISEASE; MOUSE MODEL; SUBSTANTIA-NIGRA; TRANSECTED RATS; MESSENGER-RNA; ACUPUNCTURE; NEURONS; DEGENERATION; SYMPTOMS	Bradykinesia is one of the major clinical symptoms of Parkinson's disease (PD) for which treatment is sought. In most mouse models of PD, decreased locomotor activity can be reflected in an open field behavioral test. Therefore the open field test provides a useful tool to study the clinic symptoms of PD patients. Our previous work demonstrated that 100 Hz electro-acupuncture (EA) stimulation at ZUSANLI and SANYINJIAO protected the dopaminergic nigrostriatal system of C57BL/6 mice from MPTP toxicity, indicating that acupuncture might be an effective therapy for PD sufferers. In the present study, we investigated the effects of 100 Hz EA stimulation on the spontaneous locomotor activity in MPTP injured mice. Here we found that, in MPTP treated mice, the total movements significantly decreased and the movement time, velocity and distance dramatically increased, although the dopaminergic nigrostriatal system was devastated, revealed by immunohistochemistry and HPLC-ECD. After 12 sessions of 100 Hz EA stimulation, the total movements elevated and the movement time, velocity and distance decreased, in MPTP mice. 100 Hz EA increased striatal dopamine content in MPTP mice by 35.9%, but decreased its striatal dopamine turnover. We assumed that the injury of other regions in the brain, such as the A11 group in diencephalon, might be involved in the hypermotility in MPTP mice. The effects of 100 Hz EA on spontaneous locomotor activity in MPTP mice might not relate with the striatal dopamine, but with its neuroprotective and regulatory effects on motor circuits in the brain. Our study suggests that EA might be a promising treatment for neurological disorders including PD.	[Wang, Haomin] Peking Univ, Neurosci Res Inst, Key Lab Neurosci, Minist Educ, Beijing 100871, Peoples R China; [Liang, Xibin] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Wang, Xuan; Luo, Dingzhen; Jia, Jun; Wang, Xiaomin] Capital Med Univ, Dept Physiol, Key Lab Neurodegenerat Disorders, Minist Educ, Beijing, Peoples R China	Peking University; Stanford University; Capital Medical University	Wang, XM (corresponding author), Capital Med Univ, Dept Physiol, Key Lab Neurodegenerat Disorders, Minist Educ, Beijing, Peoples R China.	xmwang@ccmu.edu.cn			National Basic Research Program of China [2011CB504100]; National Natural Science Foundation of China [30472245]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Basic Research Program of China (2011CB504100, http://www.973.gov.cn) and the National Natural Science Foundation of China ( 30472245, http://www.nsfc.gov.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barraud Q, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013306; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Chen L, 1998, J Tradit Chin Med, V18, P23; Connor JR, 2009, BRAIN, V132, P2403, DOI 10.1093/brain/awp125; Cristian A, 2005, MOVEMENT DISORD, V20, P1185, DOI 10.1002/mds.20503; Huang Y, 2010, INT J NEUROSCI, V120, P150, DOI 10.3109/00207450903316527; Huo LR, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/908439; Jeon S, 2008, PROTEOMICS, V8, P4822, DOI 10.1002/pmic.200700955; Jia J, 2010, BEHAV NEUROSCI, V124, P305, DOI 10.1037/a0018931; Jia J, 2009, BEHAV BRAIN RES, V205, P214, DOI 10.1016/j.bbr.2009.06.024; Kang JM, 2007, BRAIN RES, V1131, P211, DOI 10.1016/j.brainres.2006.10.089; Kim SN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027566; Lam YC, 2008, J ALTERN COMPLEM MED, V14, P662, DOI 10.1089/acm.2007.0011; Lee MS, 2008, MOVEMENT DISORD, V23, P1505, DOI 10.1002/mds.21993; Liang XB, 2003, NEUROREPORT, V14, P1177, DOI 10.1097/00001756-200306110-00015; Liang XB, 2002, MOL BRAIN RES, V108, P51, DOI 10.1016/S0169-328X(02)00513-2; Liu XY, 2004, EXP NEUROL, V189, P189, DOI 10.1016/j.expneurol.2004.05.028; Luo DZ, 2009, EUR J PHARMACOL, V617, P33, DOI 10.1016/j.ejphar.2009.06.015; Paulus W, 2007, MOVEMENT DISORD, V22, P1451, DOI 10.1002/mds.21533; Qu S, 2006, EXP BRAIN RES, V168, P152, DOI 10.1007/s00221-005-0075-1; Qu S, 2007, J NEUROPATH EXP NEUR, V66, P383, DOI 10.1097/nen.0b013e3180517b5f; Rabinstein AA, 2003, NEUROLOGIST, V9, P137, DOI 10.1097/00127893-200305000-00002; Ren Xiao-ming, 2008, J Tradit Chin Med, V28, P255; Rommelfanger KS, 2007, P NATL ACAD SCI USA, V104, P13804, DOI 10.1073/pnas.0702753104; Rousselet E, 2003, NEUROBIOL DIS, V14, P218, DOI 10.1016/S0969-9961(03)00108-6; Sedelis M, 2001, BEHAV BRAIN RES, V125, P109, DOI 10.1016/S0166-4328(01)00309-6; Shulman LM, 2002, MOVEMENT DISORD, V17, P799, DOI 10.1002/mds.10134; Wang HM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019790; Zhao F, 2010, J NEUROSCI METH, V192, P199, DOI 10.1016/j.jneumeth.2010.07.016; Zhuang X, 2000, J Tradit Chin Med, V20, P265	30	21	21	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 30	2013	8	5							e64403	10.1371/journal.pone.0064403	http://dx.doi.org/10.1371/journal.pone.0064403			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	177SC	23737982	Green Published, gold, Green Submitted			2023-01-03	WOS:000321394700047
J	Serenius, F; Kallen, K; Blennow, M; Ewald, U; Fellman, V; Holmstrom, G; Lindberg, E; Lundqvist, P; Marsal, K; Norman, M; Olhager, E; Stigson, L; Stjernqvist, K; Vollmer, B; Stromberg, B				Serenius, Fredrik; Kallen, Karin; Blennow, Mats; Ewald, Uwe; Fellman, Vineta; Holmstrom, Gerd; Lindberg, Eva; Lundqvist, Pia; Marsal, Karel; Norman, Mikael; Olhager, Elisabeth; Stigson, Lennart; Stjernqvist, Karin; Vollmer, Brigitte; Stromberg, Bo		EXPRESS Grp	Neurodevelopmental Outcome in Extremely Preterm Infants at 2.5 Years After Active Perinatal Care in Sweden	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT INFANTS; COGNITIVE-DEVELOPMENT; DEVELOPMENTAL DELAY; EXTREMELY PREMATURE; GENDER-DIFFERENCES; CHILDREN BORN; FOLLOW-UP; GROWTH; AGE; DISABILITY	Importance Active perinatal care increases survival of extremely preterm infants; however, improved survival might be associated with increased disability among survivors. Objective To determine neurodevelopmental outcome in extremely preterm children at 2.5 years (corrected age). Design, Setting, and Participants Population-based prospective cohort of consecutive extremely preterm infants born before 27 weeks of gestation in Sweden between 2004 and 2007. Of 707 live-born infants, 491 (69%) survived to 2.5 years. Survivors were assessed and compared with singleton control infants who were born at term and matched by sex, ethnicity, and municipality. Assessments ended in February 2010 and comparison estimates were adjusted for demographic differences. Main Outcomes and Measures Cognitive, language, and motor development was assessed with Bayley Scales of Infant and Toddler Development (3rd edition; Bayley-III), which are standardized to mean (SD) scores of 100 (15). Clinical examination and parental questionnaires were used for diagnosis of cerebral palsy and visual and hearing impairments. Assessments were made by week of gestational age. Results At a median age of 30.5 months (corrected), 456 of 491 (94%) extremely preterm children were evaluated (41 by chart review only). For controls, 701 had information on health status and 366 had Bayley-III assessments. Mean (SD) composite Bayley-III scores (cognition, 94 [12.3]; language, 98 [16.5]; motor, 94 [15.9]) were lower than the corresponding mean scores for controls (cognition, 104 [10.6]; P < .001; adjusted difference in mean scores, 9.2 [99% CI, 6.9-11.5]; language, 109 [12.3]; P < .001; adjusted difference in mean scores, 9.3 [99% Cl, 6.4-12.3]; and motor, 107 [13.7]; P < .001; adjusted difference in mean scores, 12.6 [99% Cl, 9.5-15.6]). Cognitive disability was moderate in 5% of the extremely preterm group vs 0.3% in controls (P < .001) and it was severe in 6.3% of the extremely preterm group vs 0.3% in controls (P < .001). Language disability was moderate in 9.4% of the extremely preterm group vs 2.5% in controls (P < .001) and severe in 6.6% of the extremely preterm group vs 0% in controls (P < .001). Other comparisons between the extremely preterm group vs controls were for cerebral palsy (7.0% vs 0.1%; P < .001), for blindness (0.9% vs 0%; P = .02), and for hearing impairment (moderate and severe, 0.9% vs 0%; P = .02, respectively). Overall, 42% (99% CI, 36%-48%) of extremely preterm children had no disability, 31% (99% CI, 25%-36%) had mild disability, 16% (99% CI, 12%-21%) had moderate disability, and 11% (99% CI, 7.2%-15%) had severe disability. Moderate or severe overall disability decreased with gestational age at birth (22 weeks, 60%; 23 weeks, 51%; 24 weeks, 34%; 25 weeks, 27%; and 26 weeks, 17%; P for trend < .001). Conclusions and Relevance Of children born extremely preterm and receiving active perinatal care, 73% had mild or no disability and neurodevelopmental outcome improved with each week of gestational age. These results are relevant for clinicians counseling families facing extremely preterm birth. JAMA. 2013;309(17):1810-1820	[Serenius, Fredrik; Ewald, Uwe; Stromberg, Bo] Uppsala Univ, Dept Womens & Childrens Hlth, Sect Pediat, S-75185 Uppsala, Sweden; [Holmstrom, Gerd] Uppsala Univ, Dept Neurosci Ophthalmol, S-75185 Uppsala, Sweden; [Serenius, Fredrik] Umea Univ, Dept Pediat, Inst Clin Sci, Umea, Sweden; [Kallen, Karin] Lund Univ, Ctr Reprod Epidemiol, Lund, Sweden; [Fellman, Vineta] Lund Univ, Dept Pediat, Clin Sci Lund, Lund, Sweden; [Lundqvist, Pia] Lund Univ, Dept Hlth Sci, Lund, Sweden; [Marsal, Karel] Lund Univ, Dept Obstet & Gynecol, Clin Sci Lund, Lund, Sweden; [Stjernqvist, Karin] Lund Univ, Dept Psychol, Lund, Sweden; [Blennow, Mats; Norman, Mikael] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden; [Vollmer, Brigitte] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden; [Lindberg, Eva] Univ Orebro, Dept Pediat, Orebro, Sweden; [Olhager, Elisabeth] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Stigson, Lennart] Gothenburg Univ, Dept Pediat, Inst Clin Sci, Sahlgrenska Acad, S-41124 Gothenburg, Sweden	Uppsala University; Uppsala University; Umea University; Lund University; Lund University; Lund University; Lund University; Lund University; Karolinska Institutet; Karolinska Institutet; Orebro University; Linkoping University; University of Gothenburg	Serenius, F (corresponding author), Uppsala Univ, Dept Womens & Childrens Hlth, Sect Pediat, S-75185 Uppsala, Sweden.	fredrik.serenius@kbh.uu.se	Blennow, Mats/AAX-6202-2021; vollmer, brigitte/AAB-3132-2020	vollmer, brigitte/0000-0003-4088-5336; Hellstrom-Westas, Lena/0000-0003-3498-6069; Norman, Mikael/0000-0003-4191-3781; Blennow, Mats/0000-0001-9517-0261; Hellstrom, Ann/0000-0002-9259-1244	Swedish Research Council [2006-3855, 2009-4250]; Uppsala-Orebro Regional Research Council [RFR-10324]; Research Council South East Region of Sweden; Swedish government; University of Umea; Vasterbotten County Council; Stockholm County Council; Karolinska Institute; "Lilla Barnets Fond" Children's fund; Evy and Gunnar Sandberg Foundation; Birgit and Hakan Ohlsson Foundation; EU	Swedish Research Council(Swedish Research CouncilEuropean Commission); Uppsala-Orebro Regional Research Council; Research Council South East Region of Sweden; Swedish government; University of Umea; Vasterbotten County Council; Stockholm County Council(Stockholm County Council); Karolinska Institute(Karolinska Institutet); "Lilla Barnets Fond" Children's fund; Evy and Gunnar Sandberg Foundation; Birgit and Hakan Ohlsson Foundation; EU(European Commission)	This study was supported by the Swedish Research Council grants 2006-3855 and 2009-4250, the Uppsala-Orebro Regional Research Council grant RFR-10324, a grant from the Research Council South East Region of Sweden, and grants to Researchers in the Public Health Care from the Swedish government. Financial support was also provided through a regional agreement between the University of Umea and Vasterbotten County Council and through a regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institute. The study also received support from The "Lilla Barnets Fond" Children's fund. Dr Kallen reported support from the Evy and Gunnar Sandberg and from the Birgit and Hakan Ohlsson Foundations and Dr Vollmer was supported by the Marie Curie Individual Intra-European Fellowship within the EU FP6 Framework Program.	Anderson PJ, 2010, ARCH PEDIAT ADOL MED, V164, P352, DOI 10.1001/archpediatrics.2010.20; Austeng D, 2010, ACTA PAEDIATR, V99, P978, DOI 10.1111/j.1651-2227.2010.01846.x; Bax M, 2005, DEV MED CHILD NEUROL, V47, P571, DOI 10.1017/S001216220500112X; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Bayley N, 2006, BAYLEY SCALES INFANT; Blennow M, 2009, JAMA-J AM MED ASSOC, V301, P2225, DOI 10.1001/jama.2009.771; Carlo WA, 2011, JAMA-J AM MED ASSOC, V306, P2348, DOI 10.1001/jama.2011.1752; Claas MJ, 2011, ARCH DIS CHILD-FETAL, V96, pF169, DOI 10.1136/adc.2009.174433; COCKBURN F, 1993, LANCET, V342, P193; De Groote I, 2007, OBSTET GYNECOL, V110, P855, DOI 10.1097/01.AOG.0000284447.43442.55; Delobel-Ayoub M, 2009, PEDIATRICS, V123, P1485, DOI 10.1542/peds.2008-1216; Doyle LW, 2010, J PEDIATR-US, V156, P49, DOI 10.1016/j.jpeds.2009.07.013; Ehrenkranz RA, 2006, PEDIATRICS, V117, P1253, DOI 10.1542/peds.2005-1368; Gargus RA, 2009, PEDIATRICS, V124, P112, DOI 10.1542/peds.2008-2742; Hack M, 2000, ARCH PEDIAT ADOL MED, V154, P725, DOI 10.1001/archpedi.154.7.725; Hack M, 2000, Semin Neonatol, V5, P89, DOI 10.1053/siny.1999.0001; Hindmarsh GJ, 2000, EARLY HUM DEV, V60, P115, DOI 10.1016/S0378-3782(00)00105-5; Hintz SR, 2006, ACTA PAEDIATR, V95, P1239, DOI 10.1080/08035250600599727; Hintz SR, 2011, PEDIATRICS, V127, P62, DOI 10.1542/peds.2010-1150; Markestad T, 2005, PEDIATRICS, V115, P1289, DOI 10.1542/peds.2004-1482; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; McCarton CM, 1997, JAMA-J AM MED ASSOC, V277, P126, DOI 10.1001/jama.277.2.126; Ment LR, 2003, JAMA-J AM MED ASSOC, V289, P705, DOI 10.1001/jama.289.6.705; Mercier CE, 2010, NEONATOLOGY, V97, P329, DOI 10.1159/000260136; Moore T, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e7961; Msall ME, 2010, J PEDIATR-US, V157, P863, DOI 10.1016/j.jpeds.2010.09.022; Rattihalli RR, 2011, ARCH DIS CHILD-FETAL, V96, pF329, DOI 10.1136/adc.2010.192559; Shepherd EG, 2012, J PERINATOL, V32, P33, DOI 10.1038/jp.2011.45; Spittle A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005495.pub3; Stjernqvist K, 1999, ACTA PAEDIATR, V88, P557, DOI 10.1080/08035259950169594; Stoll BJ, 2010, PEDIATRICS, V126, P443, DOI 10.1542/peds.2009-2959; Stoll BJ, 2004, JAMA-J AM MED ASSOC, V292, P2357, DOI 10.1001/jama.292.19.2357; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643; Tommiska V, 2003, ARCH DIS CHILD-FETAL, V88, P29; Tommiska V, 2007, PEDIATRICS, V119, P29, DOI 10.1542/peds.2006-1472; UNESCO Institute for Statistics, 2006, INT STAND CLASS ED I; Vohr BR, 2006, PEDIATRICS, V118, pE115, DOI 10.1542/peds.2005-2382; Vohr BR, 2012, J PEDIATR-US, V161, P222, DOI 10.1016/j.jpeds.2012.01.057; Vohr BR, 2005, PEDIATRICS, V116, P635, DOI 10.1542/peds.2004-2247; Walden RV, 2007, PEDIATRICS, V120, pE1512, DOI 10.1542/peds.2007-0354; WEISGLASKUPERUS N, 1993, PEDIATRICS, V92, P658; Weiss B, 1997, MENT RETARD DEV D R, V3, P246, DOI 10.1002/(SICI)1098-2779(1997)3:3<246::AID-MRDD5>3.0.CO;2-N; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	44	343	354	4	66	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2013	309	17					1810	1820		10.1001/jama.2013.3786	http://dx.doi.org/10.1001/jama.2013.3786			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134SU	23632725	Bronze			2023-01-03	WOS:000318235600029
J	Hu, EA; Toledo, E; Diez-Espino, J; Estruch, R; Corella, D; Salas-Salvado, J; Vinyoles, E; Gomez-Gracia, E; Aros, F; Fiol, M; Lapetra, J; Serra-Majem, L; Pinto, X; Portillo, MP; Lamuela-Raventos, RM; Ros, E; Sorli, JV; Martinez-Gonzalez, MA				Hu, Emily A.; Toledo, Estefania; Diez-Espino, Javier; Estruch, Ramon; Corella, Dolores; Salas-Salvado, Jordi; Vinyoles, Ernest; Gomez-Gracia, Enrique; Aros, Fernando; Fiol, Miquel; Lapetra, Jose; Serra-Majem, Lluis; Pinto, Xavier; Puy Portillo, Maria; Lamuela-Raventos, Rosa M.; Ros, Emilio; Sorli, Jose V.; Martinez-Gonzalez, Miguel A.			Lifestyles and Risk Factors Associated with Adherence to the Mediterranean Diet: A Baseline Assessment of the PREDIMED Trial	PLOS ONE			English	Article							PHYSICAL-ACTIVITY QUESTIONNAIRE; TYPE-2 DIABETES-MELLITUS; SEGUIMIENTO UNIVERSIDAD; WEIGHT CHANGE; PATTERNS; HEALTH; POPULATION; OBESITY; HABITS; PREVALENCE	Background: The traditional Mediterranean dietary pattern (MedDiet) is associated with longevity and low rates of cardiovascular disease (CVD). However, there is little information on who is more likely to follow this food pattern. Aim: To evaluate how different factors are associated with lower MedDiet adherence in older Spanish subjects. Methods: We included 7305 participants (men aged 55-80 y, women 60-80 y) at high-risk of CVD recruited into the PREDIMED trial (ISRCTN35739639). Socioeconomic, anthropometric, lifestyle characteristics and CVD risk factors were recorded. A validated 14-item questionnaire was used to evaluate MedDiet adherence at baseline. Multivariate models were used to estimate odds ratios (OR) and 95% confidence intervals for lower adherence to the MedDiet (<9 points out of 14) and ascertain factors independently associated with it. Results: Former smoking (OR = 0.87; 95% CI, 0.78-0.98), physical activity (OR for the 3rd vs. the 1st tertile: 0.69; 0.62-0.78), and higher educational level (OR for university vs. less than primary school: 0.54; 0.38-0.77) were associated with higher MedDiet adherence. Conversely, having a larger waist-to-height ratio (OR for 0.1 units, 1.35; 1.22-1.49), being diabetic (OR = 1.13; 1.03-1.24), being single (OR = 1.27; 1.01-1.61) or divorced or separated (OR = 1.44; 1.09-1.89), and current smoking (OR = 1.28; 1.11-1.47) were associated with lower adherence. Conclusions: Participants with little education, a larger waist-to-height ratio, or diabetes and those who were less physically active, single, divorced or separated, or smokers were less likely to adhere to the MedDiet, an ideal model for food choices. Stronger efforts of health promotion are needed in these groups to foster adoption of the MedDiet.	[Hu, Emily A.; Toledo, Estefania] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Toledo, Estefania; Diez-Espino, Javier; Martinez-Gonzalez, Miguel A.] Univ Navarra, Sch Med Clin, Dept Prevent Med & Publ Hlth, Navarra, Spain; [Toledo, Estefania; Diez-Espino, Javier; Gomez-Gracia, Enrique; Aros, Fernando; Fiol, Miquel; Lapetra, Jose; Serra-Majem, Lluis; Pinto, Xavier; Puy Portillo, Maria; Lamuela-Raventos, Rosa M.; Martinez-Gonzalez, Miguel A.] Spanish Govt, Inst Salud Carlos 3, RETIC RD06 0045, Madrid, Spain; [Toledo, Estefania; Estruch, Ramon; Corella, Dolores; Salas-Salvado, Jordi; Vinyoles, Ernest; Gomez-Gracia, Enrique; Aros, Fernando; Fiol, Miquel; Lapetra, Jose; Serra-Majem, Lluis; Pinto, Xavier; Puy Portillo, Maria; Lamuela-Raventos, Rosa M.; Ros, Emilio; Sorli, Jose V.; Martinez-Gonzalez, Miguel A.] Spanish Govt, Inst Salud Carlos 3, CIBER Fisiopatol Obesidad & Nutr CIBER Obn, Madrid, Spain; [Diez-Espino, Javier] Primary Hlth Care Ctr Tafalla Osasunbidea, Navarra, Spain; [Estruch, Ramon] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi Sunyer IDIBAPS, Dept Internal Med, Barcelona, Spain; [Corella, Dolores; Sorli, Jose V.] Univ Valencia, Dept Prevent Med, Valencia, Spain; [Salas-Salvado, Jordi] Univ Rovira & Virgili, Dept Human Nutr, IISPV, E-43201 Reus, Spain; [Vinyoles, Ernest] Univ Barcelona, La Mina Primary Care Ctr, E-08007 Barcelona, Spain; [Vinyoles, Ernest] IDIAP JordiGol, Barcelona, Spain; [Gomez-Gracia, Enrique] Univ Malaga, Dept Prevent Med, E-29071 Malaga, Spain; [Aros, Fernando] Univ Hosp Alava, Dept Cardiol, Vitoria, Spain; [Fiol, Miquel] Univ Balearic Isl, Inst Hlth Sci IUNICS, Palma De Mallorca, Spain; [Fiol, Miquel] Hosp Son Espases, Palma De Mallorca, Spain; [Lapetra, Jose] San Pablo Hlth Ctr, Primary Care Div Sevilla, Dept Family Med, Seville, Spain; [Serra-Majem, Lluis] Univ Las Palmas Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria, Spain; [Pinto, Xavier] Hosp Univ Bellvitge, Lipids & Vasc Risk Unit, Barcelona, Spain; [Puy Portillo, Maria] Univ Basque Cty UPV EHU, Sch Pharm, Dept Nutr & Food Sci, Vitoria, Spain; [Lamuela-Raventos, Rosa M.] Univ Barcelona, INSA, XaRTA, Dept Nutr & Food Sci,Sch Pharm, Barcelona, Spain; [Ros, Emilio] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi Sunyer IDIBAPS, Lipid Clin,Dept Endocrinol & Nutr, Barcelona, Spain	Harvard University; Harvard T.H. Chan School of Public Health; University of Navarra; CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Valencia; Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); University of Barcelona; Universidad de Malaga; Universitat de les Illes Balears; Hospital Universitari Son Espases; Universidad de Las Palmas de Gran Canaria; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Basque Country; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Toledo, E (corresponding author), Univ Navarra, Sch Med Clin, Dept Prevent Med & Publ Hlth, Navarra, Spain.	etoledo@unav.es	Serra-Majem, Lluis/I-6708-2019; Fiol, Miguel/F-6793-2016; Estruch, Ramon/AAZ-3723-2020; Toledo, Estefania/H-6211-2014; Portillo, Maria Puy/ABH-2374-2020; Martinez-Gonzalez, Miguel A./AAE-7669-2019; Sorlí, José V/L-8758-2014; Lapetra, Jose/F-2552-2015; Pintó, Xavier/AGI-4297-2022; Vinyoles, Ernest/GRX-4615-2022; Salas-Salvado, Jordi/C-7229-2017; IBIS, ATENCION PRIMARIA/I-3524-2016; Stefanadis, Christodoulos/ABH-2232-2020; Lamuela-Raventos, Rosa M/F-3986-2016	Serra-Majem, Lluis/0000-0002-9658-9061; Fiol, Miguel/0000-0002-5370-1391; Toledo, Estefania/0000-0002-6263-4434; Portillo, Maria Puy/0000-0003-0210-6549; Sorlí, José V/0000-0002-0130-2006; Pintó, Xavier/0000-0002-2216-2444; Salas-Salvado, Jordi/0000-0003-2700-7459; PORTILLO BAQUEDANO, MARIA PUY/0000-0003-2290-592X; Ros, Emilio/0000-0002-2573-1294; Stefanadis, Christodoulos/0000-0001-5974-6454; Lamuela-Raventos, Rosa M/0000-0002-1287-4560; Vinyoles, Ernest/0000-0002-8725-9431; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808	official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII) [RTIC G03/140, RTIC RD 06/0045]; official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII) through Centro de Investigacion Biomedica en Red de Fisiopatologia de la Obesidad y Nutricion [CIBERobn]); Centro Nacional de Investigaciones Cardiovasculares [CNIC 06/2007]; Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional [PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505]; Ministerio de Ciencia e Innovacion [AGL-2009- 13906-C02, AGL2010-22319-C03, SAF2009-12304]; Fundacion Mapfre; Consejeria de Salud de la Junta de Andalucia [PI0105/2007]; Public Health Division of the Department of Health of the Autonomous Government of Catalonia; Generalitat Valenciana [COMP06109, GVACOMP2010-181, CS2010- AP-111, CS2011-AP-042, BEST11-263, BEST/2011/261, GVACOMP2011-151, ACOMP/2011/145, ACOMP/2012/190]; Regional Government of Navarra [P27/2011]; Rio Hortega post-residency fellowship of ISCIII, Ministry of Economy and Competitiveness, Spanish Government; Fundacion Mutua Madrilena	official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII); official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII) through Centro de Investigacion Biomedica en Red de Fisiopatologia de la Obesidad y Nutricion [CIBERobn]); Centro Nacional de Investigaciones Cardiovasculares; Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional; Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion Mapfre; Consejeria de Salud de la Junta de Andalucia(Junta de Andalucia); Public Health Division of the Department of Health of the Autonomous Government of Catalonia; Generalitat Valenciana(Center for Forestry Research & Experimentation (CIEF)European Commission); Regional Government of Navarra; Rio Hortega post-residency fellowship of ISCIII, Ministry of Economy and Competitiveness, Spanish Government; Fundacion Mutua Madrilena(Instituto de Salud Carlos III)	Supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III (ISCIII), through grants provided to research networks specifically developed for the trial (RTIC G03/140, to Dr. Estruch; RTIC RD 06/0045, to Dr. Martinez-Gonzalez and through Centro de Investigacion Biomedica en Red de Fisiopatologia de la Obesidad y Nutricion [CIBERobn]), and by grants from Centro Nacional de Investigaciones Cardiovasculares (CNIC 06/2007), Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, and P11/02505), Ministerio de Ciencia e Innovacion (AGL-2009- 13906-C02, AGL2010-22319-C03 and SAF2009-12304), Fundacion Mapfre 2010, Consejeria de Salud de la Junta de Andalucia (PI0105/2007), Public Health Division of the Department of Health of the Autonomous Government of Catalonia, Generalitat Valenciana (ACOMP06109, GVACOMP2010-181, GVACOMP2011-151, CS2010- AP-111, CS2011-AP-042, BEST11-263, BEST/2011/261, GVACOMP2011-151, ACOMP/2011/145 and ACOMP/2012/190), and Regional Government of Navarra (P27/2011). Dr. Toledo is supported by a Rio Hortega post-residency fellowship of ISCIII, Ministry of Economy and Competitiveness, Spanish Government and by the Fundacion Mutua Madrilena. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Martinez-Gonzalez MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043134; Martinez-Gonzalez MA, 2012, INT J EPIDEMIOL, V41, P377, DOI 10.1093/ije/dyq250; Bach-Faig A, 2011, PUBLIC HEALTH NUTR, V14, P2274, DOI 10.1017/S1368980011002515; Boyle RG, 2000, PREV MED, V31, P177, DOI 10.1006/pmed.2000.0699; Buckland G, 2009, AM J EPIDEMIOL, V170, P1518, DOI 10.1093/aje/kwp282; Bullo M, 2011, PREV MED, V53, P155, DOI 10.1016/j.ypmed.2011.06.008; Costacou T, 2003, EUR J CLIN NUTR, V57, P1378, DOI 10.1038/sj.ejcn.1601699; Couto E, 2011, BRIT J CANCER, V104, P1493, DOI 10.1038/bjc.2011.106; Dallongeville J, 1998, J NUTR, V128, P1450; Diez-Espino J, 2011, ANN NUTR METAB, V58, P74, DOI 10.1159/000324718; ELOSUA R, 1994, AM J EPIDEMIOL, V139, P1197, DOI 10.1093/oxfordjournals.aje.a116966; Elosua R, 2000, MED SCI SPORT EXER, V32, P1431, DOI 10.1097/00005768-200008000-00011; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Esposito K, 2009, ANN INTERN MED, V151, P306, DOI 10.7326/0003-4819-151-5-200909010-00004; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Fernandez-Ballarth JD, 2010, BRIT J NUTR, V103, P1808, DOI 10.1017/S0007114509993837; Filippidis FT, 2011, PUBLIC HEALTH, V125, P436, DOI 10.1016/j.puhe.2011.03.009; Fung TT, 2004, ARCH INTERN MED, V164, P2235, DOI 10.1001/archinte.164.20.2235; González C.A., 2002, Gac Sanit, V16, P214; Guasch-Ferre M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043275; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Basterra-Gortari FJ, 2011, REV ESP CARDIOL, V64, P424, DOI [10.1016/j.rec.2010.06.015, 10.1016/j.recesp.2010.06.010]; Beunza JJ, 2010, AM J CLIN NUTR, V92, P1484, DOI 10.3945/ajcn.2010.29764; Jurado D, 2012, J ACAD NUTR DIET, V112, P887, DOI 10.1016/j.jand.2012.02.026; Katsarou A, 2010, PUBLIC HEALTH NUTR, V13, P1614, DOI 10.1017/S1368980010000479; Majem LS, 2001, MED CLIN-BARCELONA, V116, P129, DOI 10.1016/S0025-7753(01)71747-2; Martinez-Gonzalez MA, 2008, BMJ-BRIT MED J, V336, P1348, DOI 10.1136/bmj.39561.501007.BE; Martinez-Gonzalez MA, 2011, NUTR METAB CARDIOVAS, V21, P237, DOI 10.1016/j.numecd.2009.10.005; Mendez MA, 2006, J NUTR, V136, P2934, DOI 10.1093/jn/136.11.2934; Morabia A, 1999, EUR J CLIN NUTR, V53, P239, DOI 10.1038/sj.ejcn.1600710; MORABIA A, 1990, AM J CLIN NUTR, V52, P933, DOI 10.1093/ajcn/52.5.933; Mozaffarian D, 2009, ARCH INTERN MED, V169, P798, DOI 10.1001/archinternmed.2009.21; Panagiotakos DB, 2006, NUTRITION, V22, P449, DOI 10.1016/j.nut.2005.11.004; Panagiotakos DB, 2007, J AM COLL NUTR, V26, P32, DOI 10.1080/07315724.2007.10719583; Romaguera D, 2010, AM J CLIN NUTR, V92, P912, DOI 10.3945/ajcn.2010.29482; Salas-Salvado J, 2011, NUTR METAB CARDIOVAS, V21, pB32, DOI 10.1016/j.numecd.2011.03.009; Salas-Salvado J, 2011, DIABETES CARE, V34, P14, DOI 10.2337/dc10-1288; Sanchez-Benito JL, 2009, NUTR HOSP, V24, P77; Sanchez-Tainta A, 2008, EUR J CARDIOV PREV R, V15, P589, DOI 10.1097/HJR.0b013e328308ba61; Sanchez-Villegas A, 2003, EUR J CLIN NUTR, V57, P285, DOI 10.1038/sj.ejcn.1601528; Schroder H, 2011, J NUTR, V141, P1140, DOI 10.3945/jn.110.135566; Serra-Majem L, 2009, BRIT J NUTR, V101, pS21, DOI 10.1017/S0007114509990559; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337; Tur JA, 2004, BRIT J NUTR, V92, P341, DOI 10.1079/BJN20041209; van Dam RM, 2002, ANN INTERN MED, V136, P201, DOI 10.7326/0003-4819-136-3-200202050-00008; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; Zazpe I, 2010, EUR J NUTR, V49, P91, DOI 10.1007/s00394-009-0053-7	49	69	70	2	32	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2013	8	4							e60166	10.1371/journal.pone.0060166	http://dx.doi.org/10.1371/journal.pone.0060166			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	181JC	23637743	Green Published, gold, Green Submitted			2023-01-03	WOS:000321662800004
J	Luo, XF; Duan, S; Duan, QX; Pu, YC; Yang, YC; Ding, YY; Gao, MY; He, N				Luo, Xiaofeng; Duan, Song; Duan, Qixiang; Pu, Yongcheng; Yang, Yuecheng; Ding, Yingying; Gao, Meiyang; He, Na			Alcohol Use and Subsequent Sex among HIV-Infected Patients in an Ethnic Minority Area of Yunnan Province, China	PLOS ONE			English	Article							RISK BEHAVIORS; PREVALENCE; TRANSMISSION; PATTERNS; CONSUMPTION; ADHERENCE; DRINKING; HIV/AIDS; MEN; MSM	Objective: To examine alcohol use and subsequent HIV risky behaviors among a sample of predominately ethnic minority people living with HIV/AIDS (PLWHA) in a rural community in Yunnan Province, China. Method: A cross-sectional study with a face-to-face questionnaire interview was conducted among eligible participants. Results: In total, 455 (94.4%) out of 482 eligible HIV patients participated in the study. Of them, 82.6% were ethnic minorities; 15.4% were never married; 96.5% were sexually experienced; 55.4% had used drugs, 67% were receiving antiretroviral therapy (ART). Over 65% were ever drinkers; of whom 61.5% were current drinkers. Among current drinkers, 32.4% drank daily and 41.2% were hazardous drinkers. Chinese white wine was the preferred choice. Higher level of alcohol use among drinkers in the preceding month was positively associated with being males (OR = 2.76, 95% CI: 1.03-7.43), ethnic minorities (OR (Jingpo) = 2.21, 95% CI: 1.06-4.59; OR (other minorities) = 3.20, 95% CI: 1.34-7.62), higher education (OR1-6 = 1.98, 95% CI: 0.99-3.96; OR >= 7 = 2.35, 95% CI: 1.09-5.06) and being ART-naive (OR = 2.69, 95% CI: 1.67-4.32). About 39% of ever drinkers reported having engaged in sex after drinking since HIV diagnosis. Those who were younger than 46 years (OR16-25 = 7.77, 95% CI: 1.22-49.60, OR26-35 = 2.79, 95% CI: 1.06-7.35, OR36-45 = 2.96, 95% CI: 1.57-7.58), hazardous drinkers (OR = 1.99, 95% CI: 1.00-3.97) and drug users (OR = 3.01, 95% CI: 1.19-7.58) were more likely to have had sex after drinking. Approximately 56% of drug users had used drugs after drinking. Conclusions: High prevalence of alcohol use and subsequent risky behaviors including sexual engagement and drug use among HIV patients in rural Yunnan require tremendous and integrated efforts for prevention and control of alcohol and drug abuse and HIV spreading.	[Luo, Xiaofeng; Ding, Yingying; Gao, Meiyang; He, Na] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China; [Luo, Xiaofeng; Ding, Yingying; Gao, Meiyang; He, Na] Fudan Univ, Minist Educ, Key Lab Publ Hlth Safety, Shanghai 200433, Peoples R China; [Duan, Song; Yang, Yuecheng] Dehong Prefecture Ctr Dis Control & Prevent, Mangshi, Yunnan Province, Peoples R China; [Duan, Qixiang; Pu, Yongcheng] Longchuan Cty Ctr Dis Control & Prevent, Longchuan, Yunnan Province, Peoples R China	Fudan University; Fudan University	He, N (corresponding author), Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200433, Peoples R China.	nhe@shmu.edu.cn	ding, yy/HHS-9589-2022		National Natural Science Foundation of China [81072345, 81161120407]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (grant no. 81072345 and 81161120407 to N.H.). The funding agency played no role in the study design, data collection and analysis, interpretation of study results and writing of the manuscript.	Baum MK, 2010, AIDS RES HUM RETROV, V26, P511, DOI 10.1089/aid.2009.0211; Chander G, 2008, HIV MED, V9, P196, DOI 10.1111/j.1468-1293.2008.00545.x; Chander Geetanjali, 2011, Top Antivir Med, V19, P143; Chen GZ, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-58; China Ministry of Health UNAIDS WHO, 2012, 2011 UPD HIV AIDS EP; Cook RL, 2001, J GEN INTERN MED, V16, P83, DOI 10.1046/j.1525-1497.2001.00122.x; Crepaz N, 2002, AIDS, V16, P135, DOI 10.1097/00002030-200201250-00002; Davis KC, 2007, J STUD ALCOHOL DRUGS, V68, P843, DOI 10.15288/jsad.2007.68.843; Duan Song, 2008, Zhonghua Yufang Yixue Zazhi, V42, P866; Freiberg M, 2010, JAIDS-J ACQ IMM DEF, V53, P247, DOI 10.1097/QAI.0b013e3181c6c4b7; Galvan FH, 2002, J STUD ALCOHOL, V63, P179, DOI 10.15288/jsa.2002.63.179; Gwati B., 1995, Central African Journal of Medicine, V41, P179; Halkitis PN, 2003, AIDS CARE, V15, P367, DOI 10.1080/0954012031000105423; Hao W, 2005, ADDICTION, V100, P737, DOI 10.1111/j.1360-0443.2005.01036.x; Hao W, 2004, ALCOHOL ALCOHOLISM, V39, P43, DOI 10.1093/alcalc/agh018; He N, 2011, BIOSCI TRENDS, V5, P1, DOI 10.5582/bst.2011.v5.1.1; Hendershot CS, 2009, JAIDS-J ACQ IMM DEF, V52, P180, DOI 10.1097/QAI.0b013e3181b18b6e; Jia MH, 2010, JAIDS-J ACQ IMM DEF, V53, pS34, DOI 10.1097/QAI.0b013e3181c7d6ff; Kalichman SC, 2000, CLIN PSYCHOL-SCI PR, V7, P32, DOI 10.1093/clipsy/7.1.32; Kalichman SC, 2002, ANN BEHAV MED, V24, P229, DOI 10.1207/S15324796ABM2403_08; Kalichman SC, 2007, PREV SCI, V8, P141, DOI 10.1007/s11121-006-0061-2; Li Jianhua, 2010, SHANGHAI ARCH PSYCHI, V22, P440; Lin DH, 2005, DRUG ALCOHOL DEPEN, V79, P103, DOI 10.1016/j.drugalcdep.2005.01.003; Lu L., 2005, J CHINA AIDSSTD, V11, P172; Luo XF, 2012, BIOSCI TRENDS, V6, P288, DOI 10.5582/bst.2012.v6.6.288; Markos AR, 2005, INT J STD AIDS, V16, P123, DOI 10.1258/0956462053057639; Nehl EJ, 2012, AIDS CARE, V24, P324, DOI 10.1080/09540121.2011.608792; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Rubinsky AD, 2010, DRUG ALCOHOL DEPEN, V108, P29, DOI 10.1016/j.drugalcdep.2009.11.009; Samet JH, 2004, AIDS RES HUM RETROV, V20, P151, DOI 10.1089/088922204773004860; Shaffer D N, 2004, East Afr Med J, V81, P594; Shuper PA, 2009, AIDS BEHAV, V13, P1021, DOI 10.1007/s10461-009-9589-z; Stein M, 2005, ALCOHOL CLIN EXP RES, V29, P837, DOI 10.1097/01.ALC.0000164363.40533.E0; Wang B, 2010, SEX TRANSM DIS, V37, P629, DOI 10.1097/OLQ.0b013e3181e2118a; WHO, 2005, ALC US SEX RISK BEH; WHO UNAIDS Ministry of Health of the People's Republic of China, 2011, 2011 EST HIV AIDS EP; Wilsnack RW, 2009, ADDICTION, V104, P1487, DOI 10.1111/j.1360-0443.2009.02696.x; World Health Organization, 2011, GLOB STAT REP ALC HL; World Health Organization, 2011, GLOB SUMM HIV AIDS E; Yang XS, 2006, AIDS BEHAV, V10, P71, DOI 10.1007/s10461-005-9028-8	40	19	19	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e61660	10.1371/journal.pone.0061660	http://dx.doi.org/10.1371/journal.pone.0061660			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	131QH	23626712	Green Published, gold, Green Submitted			2023-01-03	WOS:000318008400076
J	Wu, CK; Wang, JH; Lee, CH; Wu, KL; Tai, WC; Lu, SN; Hu, TH; Chuah, SK				Wu, Cheng-Kun; Wang, Jing-Houng; Lee, Chen-Hsiang; Wu, Keng-Liang; Tai, Wei-Chen; Lu, Sheng-Nan; Hu, Tsung-Hui; Chuah, Seng-Kee			The Outcome of Prophylactic Intravenous Cefazolin and Ceftriaxone in Cirrhotic Patients at Different Clinical Stages of Disease after Endoscopic Interventions for Acute Variceal Hemorrhage	PLOS ONE			English	Article							PREVENTS BACTERIAL-INFECTION; ANTIBIOTIC-PROPHYLAXIS; NORFLOXACIN; THERAPY	Antibiotic prophylaxis with norfloxacin, intravenous ciprofloxacin, or ceftriaxone has been recommended for cirrhotic patients with gastrointestinal hemorrhage but little is known about intravenous cefazolin. This study aimed to compare the outcome of intravenous cefazolin and ceftriaxone as prophylactic antibiotics among cirrhotic patients at different clinical stages, and to identify the associated risk factors. The medical records of 713 patients with acute variceal bleeding who had received endoscopic procedures from were reviewed. Three hundred and eleven patients were entered for age-matched adjustment after strict exclusion criteria. After the adjustment, a total of 102 patients were enrolled and sorted into 2 groups according to the severity of cirrhosis: group A (Child's A patients, n = 51) and group B (Child's B and C patients, n = 51). The outcomes were prevention of infection, time of rebleeding, and death. Our subgroup analysis results failed to show a significant difference in infection prevention between patients who received prophylactic cefazolin and those who received ceftriaxone among Child's A patients (93.1% vs. 90.9%, p = 0.641); however, a trend of significance in favor of ceftriaxone prophylaxis (77.8% vs. 87.5%, p = 0.072) was seen among Child's B and C patients. More rebleeding cases were observed in patients who received cefazolin than in those who received ceftriaxone among Child's B and C patients (66.7% vs. 25.0%, p = 0.011) but not in Child's A patients (32% vs. 40.9%, p = 0.376). The risk factors associated with rebleeding were history of bleeding and use of prophylactic cefazolin among Child's B and C patients. In conclusion, this study suggests that prophylactic intravenous cefazolin may not be inferior to ceftriaxone in preventing infections and reducing rebleeding among Child's A cirrhotic patients after endoscopic interventions for acute variceal bleeding. Prophylactic intravenous ceftriaxone yields better outcome among Child's B and C patients.	[Wu, Cheng-Kun; Wang, Jing-Houng; Wu, Keng-Liang; Tai, Wei-Chen; Lu, Sheng-Nan; Hu, Tsung-Hui; Chuah, Seng-Kee] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan; [Wu, Cheng-Kun; Wang, Jing-Houng; Lee, Chen-Hsiang; Wu, Keng-Liang; Tai, Wei-Chen; Lu, Sheng-Nan; Hu, Tsung-Hui; Chuah, Seng-Kee] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Lee, Chen-Hsiang] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital	Chuah, SK (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Hepatogastroenterol, Kaohsiung, Taiwan.	chuahsk@seed.net.tw						Aldeyab MA, 2012, BRIT J CLIN PHARMACO, V74, P171, DOI 10.1111/j.1365-2125.2011.04161.x; [Anonymous], 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002907; Banerjee S, 2008, GASTROINTEST ENDOSC, V67, P791, DOI 10.1016/j.gie.2008.02.068; BERGERON MG, 1973, ANTIMICROB AGENTS CH, V4, P396, DOI 10.1128/AAC.4.4.396; Bernard B, 1999, HEPATOLOGY, V29, P1655, DOI 10.1002/hep.510290608; BLAISE M, 1994, HEPATOLOGY, V20, P34, DOI 10.1016/0270-9139(94)90131-7; CDC/NHSN Surveillance Definition of Healthcare-Associated Infection and Criteria for Specific Types of Infections in the Acute Care Setting, 2013, CDC WEBSITE, V17, P1; Chavez-Tapia NC, 2011, ALIMENT PHARM THER, V34, P509, DOI 10.1111/j.1365-2036.2011.04746.x; de Franchis R, 2010, J HEPATOL, V53, P762, DOI 10.1016/j.jhep.2010.06.004; DEFRANCHIS R, 1988, NEW ENGL J MED, V319, P983; Fernandez J, 2002, HEPATOLOGY, V35, P140, DOI 10.1053/jhep.2002.30082; Fernandez J, 2006, GASTROENTEROLOGY, V131, P1049, DOI 10.1053/j.gastro.2006.07.010; Garcia-Tsao G, 2007, HEPATOLOGY, V46, P922, DOI 10.1002/hep.21907; Hou MC, 2004, HEPATOLOGY, V39, P746, DOI 10.1002/hep.20126; Hsieh WJ, 1998, AM J GASTROENTEROL, V93, P962; Hung CH, 2003, J GASTROENTEROL, V38, P153, DOI 10.1007/s005350300025; Lee J, 2007, J ANTIMICROB CHEMOTH, V60, P629, DOI 10.1093/jac/dkm225; Lin Ying-Tsun, 2002, Zhonghua Yi Xue Za Zhi (Taipei), V65, P365; Pauwels A, 1996, HEPATOLOGY, V24, P802; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RIMOLA A, 1985, HEPATOLOGY, V5, P463, DOI 10.1002/hep.1840050320; SELBY WS, 1994, GASTROINTEST ENDOSC, V40, P680, DOI 10.1016/S0016-5107(94)70109-1; Soares-Weiser K, 2010, COCHRANE DB SYST REV; SORIANO G, 1992, GASTROENTEROLOGY, V103, P1267, DOI 10.1016/0016-5085(92)91514-5; WYKE RJ, 1987, GUT, V28, P623, DOI 10.1136/gut.28.5.623; Xu HW, 2011, SURG ENDOSC, V25, P2911, DOI 10.1007/s00464-011-1642-0	26	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2013	8	4							e61666	10.1371/journal.pone.0061666	http://dx.doi.org/10.1371/journal.pone.0061666			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JR	23630607	Green Published, gold, Green Submitted			2023-01-03	WOS:000317911500058
J	Tan, GKX; Ng, JKW; Tan, KW; Angeli, V; Moochhala, S; Ooi, EE; Alonso, S				Tan, Grace Kai Xin; Ng, Jowin Kai Wei; Tan, Kar Wai; Angeli, Veronique; Moochhala, Shabbir; Ooi, Eng Eong; Alonso, Sylvie			Hypertonic Saline Reduces Vascular Leakage in a Mouse Model of Severe Dengue	PLOS ONE			English	Article							SMALL-VOLUME RESUSCITATION; VIRUS; INFECTION; REPLICATION; ENDOTHELIUM; STRAIN; MICE	Dengue (DEN) is a mosquito-borne viral disease and represents a serious public health threat and an economical burden throughout the tropics. Dengue clinical manifestations range from mild acute febrile illness to severe DEN hemorrhagic fever/DEN shock syndrome (DHF/DSS). Currently, resuscitation with large volumes of isotonic fluid remains the gold standard of care for DEN patients who develop vascular leakage and shock. Here, we investigated the ability of small volume of hypertonic saline (HTS) suspensions to control vascular permeability in a mouse model of severe DEN associated with vascular leakage. Several HTS treatment regimens were considered and our results indicated that a single bolus of 7.5% NaCl at 4 mL per kg of body weight administered at the onset of detectable vascular leakage rapidly and significantly reduced vascular leak for several days after injection. This transient reduction of vascular leakage correlated with reduced intestine and liver damage with restoration of the hepatic functions, and resulted in delayed death of the infected animals. Mechanistically, we showed that HTS did not directly impact on the viral titers but resulted in lower immune cells counts and decreased systemic levels of soluble mediators involved in vascular permeability. In addition, we demonstrated that neutrophils do not play a critical role in DEN-associated vascular leakage and that the therapeutic effect of HTS is not mediated by its impact on the neutrophil counts. Together our data indicate that HTS treatment can transiently but rapidly reduce dengue-associated vascular leakage, and support the findings of a recent clinical trial which evaluated the efficacy of a hypertonic suspension to impact on vascular permeability in DSS children.	[Tan, Grace Kai Xin; Ng, Jowin Kai Wei; Tan, Kar Wai; Angeli, Veronique; Alonso, Sylvie] Natl Univ Singapore, Yong Loo Lin Sch Med, Inst Life Sci, Dept Microbiol,Immunol Programme, Singapore 117595, Singapore; [Moochhala, Shabbir; Ooi, Eng Eong] DSO Natl Labs, Singapore, Singapore; [Ooi, Eng Eong] Duke NUS Grad Med Sch, Progamme Emerging Infect Dis, Singapore, Singapore	National University of Singapore; National University of Singapore	Alonso, S (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Inst Life Sci, Dept Microbiol,Immunol Programme, Singapore 117595, Singapore.	micas@nus.edu.sg		Ooi, Eng Eong/0000-0002-0520-1544; MOOCHHALA, SHABBIR/0000-0003-4521-3192	National Medical Research Council under the TCR grant "STOP Dengue''	National Medical Research Council under the TCR grant "STOP Dengue''	This work was funded by the National Medical Research Council under the TCR grant "STOP Dengue''. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Basu A, 2008, FEMS IMMUNOL MED MIC, V53, P287, DOI 10.1111/j.1574-695X.2008.00420.x; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Ciesla DJ, 2000, J TRAUMA, V48, P388, DOI 10.1097/00005373-200003000-00004; COIMBRA R, 1995, SHOCK, V4, P45, DOI 10.1097/00024382-199507000-00007; Grant D, 2011, J VIROL, V85, P7775, DOI 10.1128/JVI.00665-11; Whitehorn J, 2011, CLIN MED, V11, P483, DOI 10.7861/clinmedicine.11-5-483; Junger WG, 1997, J TRAUMA, V42, P437, DOI 10.1097/00005373-199703000-00011; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; Kyle JL, 2008, ANNU REV MICROBIOL, V62, P71, DOI 10.1146/annurev.micro.62.081307.163005; Lee L, 2011, J SURG RES; McFarlane E, 2008, INFECT IMMUN, V76, P532, DOI 10.1128/IAI.01388-07; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; Pascual JL, 2003, J TRAUMA, V54, pS133, DOI 10.1097/01.TA.0000064526.33647.63; Pascual JL, 2002, ANN SURG, V236, P634, DOI 10.1097/00000658-200211000-00014; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Prestwood TR, 2012, J VIROL, V86, P12561, DOI 10.1128/JVI.06743-11; Rhee P, 2000, CRIT CARE MED, V28, P74, DOI 10.1097/00003246-200001000-00012; Rizoli SB, 1998, J IMMUNOL, V161, P6288; Schul W, 2007, J INFECT DIS, V195, P665, DOI 10.1086/511310; Somasetia DH, 2011, MKB BANDUNG MED J, V42, p23S; Srikiatkhachorn A, 2010, CURR TOP MICROBIOL, V338, P67, DOI 10.1007/978-3-642-02215-9_6; Srikiatkhachorn A, 2009, THROMB HAEMOSTASIS, V102, P1042, DOI 10.1160/TH09-03-0208; Tan GK, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000672; Tan GKX, 2011, ANN ACAD MED SINGAP, V40, P523; Tan PG, 2011, EMERG MED AUSTRALAS, V23, P665, DOI 10.1111/j.1742-6723.2011.01455.x; Trung DT, 2010, CURR TOP MICROBIOL, V338, P57, DOI 10.1007/978-3-642-02215-9_5; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754; World Health Organization (WHO), GUID DENG	31	3	4	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2013	8	4							e61621	10.1371/journal.pone.0061621	http://dx.doi.org/10.1371/journal.pone.0061621			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IU	23637867	Green Submitted, Green Published, gold			2023-01-03	WOS:000317908700048
J	Amendah, DD; Mukamah, G; Komba, A; Ndila, C; Williams, TN				Amendah, Djesika D.; Mukamah, George; Komba, Albert; Ndila, Carolyne; Williams, Thomas N.			Routine Paediatric Sickle Cell Disease (SCD) Outpatient Care in a Rural Kenyan Hospital: Utilization and Costs	PLOS ONE			English	Article							HEALTH-CARE; CHILDREN; EXPENDITURES; PROGRAM; COHORT; ADULTS	Background: More than 70% of children with sickle cell disease (SCD) are born in sub-Saharan Africa where the prevalence at birth of this disease reaches 2% or higher in some selected areas. There is a dearth of knowledge on comprehensive care received by children with SCD in sub-Saharan Africa and its associated cost. Such knowledge is important for setting prevention and treatment priorities at national and international levels. This study focuses on routine care for children with SCD in an outpatient clinic of the Kilifi District Hospital, located in a rural area on the coast of Kenya. Objective: To estimate the per-patient costs for routine SCD outpatient care at a rural Kenyan hospital. Methods: We collected routine administrative and primary cost data from the SCD outpatient clinic and supporting departments at Kilifi District Hospital, Kenya. Costs were estimated by evaluating inputs - equipment, medication, supplies, building use, utility, and personnel - to reflect the cost of offering this service within an existing healthcare facility. Annual economic costs were similarly calculated based on input costs, prorated lifetime of equipment and appropriate discount rate. Sensitivity analyses evaluated these costs under different pay scales and different discount rate. Results: We estimated that the annual economic cost per patient attending the SCD clinic was USD 138 in 2010 with a range of USD 94 to USD 229. Conclusion: This study supplies the first published estimate of the cost of routine outpatient care for children born with SCD in sub-Saharan Africa. Our study provides policy makers with an indication of the potential future costs of maintaining specialist outpatient clinics for children living with SCD in similar contexts.	[Amendah, Djesika D.] African Populat Hlth Res Ctr, Nairobi, Kenya; [Mukamah, George; Komba, Albert; Ndila, Carolyne; Williams, Thomas N.] Ctr Geog Med Res Coast, Kenya Med Res Inst KEMRI, Kilifi, Kenya; [Williams, Thomas N.] INDEPTH Network Demog Surveillance Sites, Accra, Ghana; [Williams, Thomas N.] Univ Oxford, Nuffield Dept Med, Oxford, England; [Williams, Thomas N.] Global Network Sickle Cell Dis, Toronto, ON, Canada	African Population & Health Research Centre; Kenya Medical Research Institute; INDEPTH Network; University of Oxford	Amendah, DD (corresponding author), African Populat Hlth Res Ctr, Nairobi, Kenya.	damendah@aphrc.org			Wellcome Trust [076934]	Wellcome Trust(Wellcome TrustEuropean Commission)	This work was funded by the Wellcome Trust through a fellowship awarded to TNW (grant 076934). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Africa Public Health Information Service, 2010, AFRICA HEALTH FINANC; Amendah DD, 2010, AM J PREV MED, V38, pS550, DOI 10.1016/j.amepre.2010.01.004; Auvert B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002679; Berruti AA, 2011, THE COST OF COMPREHE; Central Bank of Kenya, 2010, INDICATIVE EXCHANGE; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Gold MR, 1996, COST EFFECTIVENESS I; Kauf TL, 2009, AM J HEMATOL, V84, P323, DOI 10.1002/ajh.21408; Komba AN, 2009, CLIN INFECT DIS, V49, P216, DOI 10.1086/599834; Lanzkron S, 2008, ANN INTERN MED, V148, P939, DOI 10.7326/0003-4819-148-12-200806170-00221; Lee A, 1995, BRIT MED J, V311, P1600, DOI 10.1136/bmj.311.7020.1600; Marsh VM, 2010, BMC MED ETHICS, V11, DOI 10.1186/1472-6939-11-13; Marti-Carvajal AJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004344.pub3; Mosf, 2009, PLANNING MOSF; Mvundura M, 2009, PEDIATR BLOOD CANCER, V53, P642, DOI 10.1002/pbc.22069; Obiero W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053380; Odunvbun ME, 2008, PUBLIC HEALTH, V122, P1111, DOI 10.1016/j.puhe.2008.01.008; Ohene-Frempong K, 2010, BURDEN OF SICKLE CEL; Olnes M, 2009, AM J HEMATOL, V84, P530, DOI 10.1002/ajh.21446; Rahimy MC, 1999, AM J HEMATOL, V62, P1; RAHIMY MC, 2003, BLOOD, V102, P834, DOI DOI 10.1182/blood-2002-05-1453; Raphael JL, 2008, PEDIATR BLOOD CANCER, V51, P82, DOI 10.1002/pbc.21483; Rees DC, 2010, LANCET, V376, P2018, DOI 10.1016/S0140-6736(10)61029-X; Sadarangani M, 2009, BRIT J HAEMATOL, V146, P675, DOI 10.1111/j.1365-2141.2009.07771.x; Scott JAG, LANCET IN PRESS; Segbena AY, 1998, AM J HEMATOL, V59, P208, DOI 10.1002/(SICI)1096-8652(199811)59:3<208::AID-AJH5>3.0.CO;2-R; Streetly A, 2010, J CLIN PATHOL, V63, P626, DOI 10.1136/jcp.2010.077560; Weatherall DJ, 2011, BR J HAEMATOL; Williams RM, 2007, J NATL MED ASSOC, V99, P276; World Health Organization, 2006, EXECUTIVE BOARD RESO	30	8	8	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e61130	10.1371/journal.pone.0061130	http://dx.doi.org/10.1371/journal.pone.0061130			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23593408	Green Published, Green Submitted, gold			2023-01-03	WOS:000317909600084
J	Hamilton, EJ; Martin, N; Makepeace, A; Sillars, BA; Davis, WA; Davis, TME				Hamilton, Emma J.; Martin, Natalie; Makepeace, Ashley; Sillars, Brett A.; Davis, Wendy A.; Davis, Timothy M. E.			Incidence and Predictors of Hospitalization for Bacterial Infection in Community-Based Patients with Type 2 Diabetes: The Fremantle Diabetes Study0	PLOS ONE			English	Article							URINARY-TRACT-INFECTIONS; ACQUIRED PNEUMONIA; GLYCEMIC CONTROL; POSTMENOPAUSAL WOMEN; COMMON INFECTIONS; WESTERN-AUSTRALIA; PRIMARY-CARE; RISK; POPULATION; BACTEREMIA	Background: The few studies that have examined the relationship between diabetes and bacterial infections have utilized administrative databases and/or have had limited/incomplete data including recognized infection risk factors. The aim of this study was to determine the incidence and associates of bacterial infection severe enough to require hospitalization in well-characterized community-based patients with type 2 diabetes. Methods and Findings: We studied a cohort of 1,294 patients (mean +/- SD age 64.1 +/- 11.3 years) from the longitudinal observational Fremantle Diabetes Study Phase I (FDS1) and 5,156 age-, gender-and zip-code-matched non-diabetic controls. The main outcome measure was incident hospitalization for bacterial infection as principal diagnosis between 1993 and 2010. We also examined differences in statin use in 52 FDS1 pairs hospitalized with pneumonia (cases) or a contemporaneous non-infection-related cause (controls). During 12.0 +/- 5.4 years of follow-up, 251 (19.4%) patients were hospitalized on 368 occasions for infection (23.7/1,000 patient-years). This was more than double the rate in matched controls (incident rate ratio (IRR) (95% CI), 2.13 (1.88-2.42), P < 0.001). IRRs for pneumonia, cellulitis, and septicemia/bacteremia were 1.86 (1.55-2.21), 2.45 (1.92-3.12), and 2.08 (1.41-3.04), respectively (P < 0.001). Among the diabetic patients, older age, male sex, prior recent infection-related hospitalization, obesity, albuminuria, retinopathy and Aboriginal ethnicity were baseline variables independently associated with risk of first hospitalization with any infection (P <= 0.005). After adjustment for these variables, baseline statin treatment was not significant (hazard ratio (95% CI), 0.70 (0.39-1.25), P = 0.22). Statin use at hospitalization for pneumonia among the case-control pairs was similar (23.1% vs. 13.5%, P = 0.27). Conclusions: The risk of severe infection is increased among type 2 diabetic patients and is not reduced by statin therapy. There are a number of other easily-accessible sociodemographic and clinical variables that could be used to optimize infection-related education, prevention and management in type 2 diabetes.	[Hamilton, Emma J.; Makepeace, Ashley] Fremantle Hosp, Dept Endocrinol & Diabet, Fremantle, WA, Australia; [Martin, Natalie] Fremantle Hosp, Dept Geriatr Med, Fremantle, WA, Australia; [Makepeace, Ashley; Sillars, Brett A.; Davis, Wendy A.; Davis, Timothy M. E.] Univ Western Australia, Sch Med & Pharmacol, Fremantle Hosp, Fremantle, WA, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Davis, TME (corresponding author), Univ Western Australia, Sch Med & Pharmacol, Fremantle Hosp, Fremantle, WA, Australia.	tim.davis@uwa.edu.au	Davis, Timothy ME/M-5144-2014	Hamilton, Emma/0000-0003-1617-6353; Davis, Wendy/0000-0002-5709-8235; Davis, Timothy/0000-0003-0749-7411	Raine Foundation, University of Western Australia; National Health and Medical Research Council of Australia	Raine Foundation, University of Western Australia; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	The Fremantle Diabetes Study Phase I was supported by the Raine Foundation, University of Western Australia. TMED is supported by a National Health and Medical Research Council of Australia Practitioner Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004, 10.2337/dc12-s011]; Barcia AM, 2005, CLIN INFECT DIS, V41, pS498, DOI 10.1086/432005; Boyko EJ, 2002, DIABETES CARE, V25, P1778, DOI 10.2337/diacare.25.10.1778; Chua D, 2007, ANN PHARMACOTHER, V41, P647, DOI 10.1345/aph.1H550; Davis TM, 2013, INT J EPIDEMIOL; Davis TME, 2000, DIABETIC MED, V17, P667, DOI 10.1046/j.1464-5491.2000.00359.x; Davis TME, 2005, J DIABETES COMPLICAT, V19, P259, DOI 10.1016/j.jdiacomp.2005.03.003; Davis TME, 2004, DIABETOLOGIA, V47, P395, DOI 10.1007/s00125-004-1344-4; Davis WA, 2004, DIABETES CARE, V27, P752, DOI 10.2337/diacare.27.3.752; Falagas ME, 2008, J ANTIMICROB CHEMOTH, V61, P774, DOI 10.1093/jac/dkn019; FELDMAN EL, 1994, DIABETES CARE, V17, P1281, DOI 10.2337/diacare.17.11.1281; Fine MJ, 1996, JAMA-J AM MED ASSOC, V275, P134, DOI 10.1001/jama.275.2.134; Fry AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/jama.294.21.2712; Game F, 2010, NAT REV ENDOCRINOL, V6, P43, DOI 10.1038/nrendo.2009.243; Gorter KJ, 2010, FAM PRACT, V27, P379, DOI 10.1093/fampra/cmq026; Guvener M, 2002, ENDOCR J, V49, P531, DOI 10.1507/endocrj.49.531; Hirji I, 2012, J DIABETES COMPLICAT; Holman CDJ, 1999, AUST NZ J PUBL HEAL, V23, P453, DOI 10.1111/j.1467-842X.1999.tb01297.x; Hounsom L, 2011, POSTGRAD MED J, V87, P757, DOI 10.1136/pgmj.2010.116616; Jackson SL, 2005, DIABETES CARE, V28, P1730, DOI 10.2337/diacare.28.7.1730; Jacups SP, 2011, VACCINE, V29, P5386, DOI 10.1016/j.vaccine.2011.05.082; Jamsen E, 2012, J BONE JOINT SURG AM, V94, pe1011; JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977, DOI 10.1093/oxfordjournals.aje.a116770; Joshi N, 1999, NEW ENGL J MED, V341, P1906, DOI 10.1056/NEJM199912163412507; Karunajeewa H, 2005, DIABETOLOGIA, V48, P1288, DOI 10.1007/s00125-005-1794-3; Kish TD, 2010, AM J GERIATR PHARMAC, V8, P485, DOI 10.1016/S1543-5946(10)80002-9; Kornum JB, 2008, DIABETES CARE, V31, P1541, DOI 10.2337/dc08-0138; Laupland KB, 2011, INFECTION, V39, P405, DOI 10.1007/s15010-011-0149-x; Laupland KB, 2004, CRIT CARE MED, V32, P992, DOI 10.1097/01.CCM.0000119424.31648.1E; Leng GC, 1996, INT J EPIDEMIOL, V25, P1172, DOI 10.1093/ije/25.6.1172; Lepper PM, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3397; Magliano DJ, 2012, EUR J ENDOCRINOL, V167, P589, DOI 10.1530/EJE-12-0053; Mancuso P, 2012, PULM PHARM THER; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Mongardon N, 2012, CRIT CARE, V16, DOI 10.1186/cc11471; Muller LMAJ, 2005, CLIN INFECT DIS, V41, P281, DOI 10.1086/431587; Myint PK, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001030; PATEL MS, 1991, MED J AUSTRALIA, V155, P218, DOI 10.5694/j.1326-5377.1991.tb142224.x; Peleg AY, 2007, DIABETES-METAB RES, V23, P3, DOI 10.1002/dmrr.682; Shah BR, 2003, DIABETES CARE, V26, P510, DOI 10.2337/diacare.26.2.510; Stapleton A, 2002, AM J MED, V113, p80S; Thomsen RW, 2011, J INFECTION, V63, P8, DOI 10.1016/j.jinf.2011.05.013; Thomsen RW, 2004, DIABETES CARE, V27, P1143, DOI 10.2337/diacare.27.5.1143; Thomsen RW, 2012, OPEN INFECT DIS J S1, V6, P27, DOI DOI 10.2174/1874279301206010027; THORNTON GF, 1971, MED CLIN N AM, V55, P931, DOI 10.1016/S0025-7125(16)32487-7; Tleyjeh IM, 2009, ARCH INTERN MED, V169, P1658, DOI 10.1001/archinternmed.2009.286; van de Garde EMW, 2006, THORAX, V61, P957, DOI 10.1136/thx.2006.062885; van den Hoek HL, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7281; WALTERS DP, 1992, DIABETIC MED, V9, P354, DOI 10.1111/j.1464-5491.1992.tb01796.x; WHEAT LJ, 1980, DIABETES CARE, V3, P187, DOI 10.2337/diacare.3.1.187; Williams P, 1997, INT J EPIDEMIOL, V26, P797, DOI 10.1093/ije/26.4.797	51	41	44	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2013	8	3							e60502	10.1371/journal.pone.0060502	http://dx.doi.org/10.1371/journal.pone.0060502			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123NP	23536910	Green Published, gold, Green Submitted			2023-01-03	WOS:000317397200058
J	Urra, X; Arino, H; Llull, L; Amaro, S; Obach, V; Cervera, A; Chamorro, A				Urra, Xabier; Arino, Helena; Llull, Laura; Amaro, Sergio; Obach, Victor; Cervera, Alvaro; Chamorro, Angel			The Outcome of Patients with Mild Stroke Improves after Treatment with Systemic Thrombolysis	PLOS ONE			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; INTRAVENOUS THROMBOLYSIS; GUIDELINES; THERAPY; TRIAL; SCALE	Introduction: In up to one third of patients with mild stroke suitable to receive systemic thrombolysis the treatment is not administered because the treating physicians estimate a good spontaneous recovery. However, it is not settled whether the fate of these patients is equivalent to those who are thrombolysed. Methods: We analyzed 203 consecutive patients (134 men and 69 women, mean age 69614 years) without premorbid disability and a NIHSS score <= 5 at admission [median 3 (IQR 2-4)]. Intravenous thrombolysis was administered within 4.5 hours from stroke onset (n = 119), or it was withheld (n = 84) whenever the treating physician predicted a spontaneous recovery. The baseline risk factors, clinical course, infarction volume, bleeding complications, and functional outcome at 3 months were analyzed and declared to a Web-based registry which was accessible to the local Health Authorities. Results: Expectedly, not thrombolysed patients had the mildest strokes at admission [median 2 (IQR 1-3.75)]. At day 2 to 5, the infarct volume on DWI-MRI was similar in both groups. There were no symptomatic cerebral bleedings in the study. An ordinal regression model adjusted for baseline stroke severity showed that thrombolysis was associated with a greater proportion of patients who shifted down on the modified Rankin Scale score at 3 months (OR 2.66; 95% CI 1.49-4.74, p = 0.001). Conclusions: Intravenous thrombolysis seems to be safe in patients with mild stroke and may be associated with improved outcome compared with untreated patients. These results support the evaluation of the efficacy of intravenous thrombolysis in mild stroke patients in randomized clinical trials.	[Urra, Xabier; Arino, Helena; Llull, Laura; Amaro, Sergio; Obach, Victor; Cervera, Alvaro; Chamorro, Angel] Hosp Clin Barcelona, Funct Unit Cerebrovasc Dis, Barcelona, Spain; [Urra, Xabier; Amaro, Sergio; Cervera, Alvaro; Chamorro, Angel] Inst Invest Biomed August Pi i Sunyer, Barcelona, Spain; [Chamorro, Angel] Univ Barcelona, Sch Med, Dept Med, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona	Chamorro, A (corresponding author), Hosp Clin Barcelona, Funct Unit Cerebrovasc Dis, Barcelona, Spain.	achamorro@clinic.ub.es	Ariño, Helena/C-3248-2018; Urra, Xabier/B-7637-2019	Ariño, Helena/0000-0003-4036-1671; Urra, Xabier/0000-0002-4763-5252				Abilleira S, 2011, STROKE, V42, P2001, DOI 10.1161/STROKEAHA.110.605030; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; Barber PA, 2001, NEUROLOGY, V56, P1015, DOI 10.1212/WNL.56.8.1015; Bath PMW, 2012, STROKE, V43, P1171, DOI 10.1161/STROKEAHA.111.641456; Baumann CR, 2006, STROKE, V37, P1332, DOI 10.1161/01.STR.0000217272.38455.a2; Broderick JP, 2005, ANN EMERG MED, V46, P243, DOI 10.1016/j.annemergmed.2005.02.013; Dhamoon MS, 2009, STROKE, V40, P2805, DOI 10.1161/STROKEAHA.109.549576; Fonarow GC, 2012, J AM HEART ASSOC, V1, P42, DOI 10.1161/JAHA.111.000034; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Hassan AE, 2010, SOUTH MED J, V103, P398, DOI 10.1097/SMJ.0b013e3181d7814a; Kasner SE, 2006, LANCET NEUROL, V5, P603, DOI 10.1016/S1474-4422(06)70495-1; Khatri P, 2012, STROKE, V43, P560, DOI 10.1161/STROKEAHA.110.593897; Khatri P, 2011, STROKE, V42, pE66; Khatri P, 2010, STROKE, V41, P2581, DOI 10.1161/STROKEAHA.110.593632; Kohrmann M, 2009, CEREBROVASC DIS, V27, P160, DOI 10.1159/000185607; Leira EC, 2012, STROKE, V43, P782, DOI 10.1161/STROKEAHA.111.620674; Nedeltchev K, 2007, STROKE, V38, P2531, DOI 10.1161/STROKEAHA.107.482554; Rajajee V, 2006, NEUROLOGY, V67, P980, DOI 10.1212/01.wnl.0000237520.88777.71; Sandercock P, 2012, LANCET, V379, P2352, DOI 10.1016/S0140-6736(12)60768-5; Smith EE, 2005, STROKE, V36, P2497, DOI 10.1161/01.STR.0000185798.78817.f3; Smith EE, 2011, STROKE, V42, P3110, DOI 10.1161/STROKEAHA.111.613208; Strbian D, 2013, INT J STROKE, V8, P293, DOI 10.1111/j.1747-4949.2012.00808.x; Sun MC, 2011, ISRN NEUROL; Willey JZ, 2011, J STROKE CEREBROVASC, DOI [10.1016/j.jstrokecerebro-vasdis.2011.09.005, DOI 10.1016/J.JSTROKECEREBRO-VASDIS.2011.09.005]; Wityk RJ, 2001, ARCH NEUROL-CHICAGO, V58, P571, DOI 10.1001/archneur.58.4.571	27	30	34	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e59420	10.1371/journal.pone.0059420	http://dx.doi.org/10.1371/journal.pone.0059420			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SR	23527192	Green Published, gold, Green Submitted			2023-01-03	WOS:000317562100131
J	Raal, A; Volmer, D; Soukand, R; Hratkevits, S; Kalle, R				Raal, Ain; Volmer, Daisy; Soukand, Renata; Hratkevits, Sofia; Kalle, Raivo			Complementary Treatment of the Common Cold and Flu with Medicinal Plants - Results from Two Samples of Pharmacy Customers in Estonia	PLOS ONE			English	Article								The aim of the current survey was to investigate the complementary self-treatment of the common cold and flu with medicinal plants among pharmacy customers in Estonia. A multiple-choice questionnaire listing 10 plants and posing questions on the perceived characteristics of cold and flu, the effectiveness of plants, help-seeking behaviour, self-treatment and sources of information, was distributed to a sample of participants in two medium size pharmacies. The participants were pharmacy customers: 150 in Tallinn (mostly Russian speaking) and 150 in Kuressaare (mostly Estonian speaking). The mean number of plants used by participants was 4.1. Of the respondents, 69% self-treated the common cold and flu and 28% consulted with a general practitioner. In general, medicinal plants were considered effective in the treatment of the above-mentioned illnesses and 56% of the respondents had used exclusively medicinal plants or their combination with OTC medicines and other means of folk medicine for treatment. The use of medicinal plants increased with age and was more frequent among female than male respondents. Among Estonian-speaking customers lime flowers, blackcurrant and camomile were more frequently used, and among Russian speaking customers raspberry and lemon fruits. Regardless of some statistically significant differences in preferred species among different age, education, sex and nationality groups, the general attitude towards medicinal plants for self-treatment of the common cold and flu in Estonia was very favourable.	[Raal, Ain; Volmer, Daisy; Hratkevits, Sofia] Univ Tartu, Dept Pharm, EE-50090 Tartu, Estonia; [Soukand, Renata; Kalle, Raivo] Estonian Literary Museum, Tartu, Estonia	University of Tartu; Estonian Literary Museum	Soukand, R (corresponding author), Estonian Literary Museum, Tartu, Estonia.	renata@folklore.ee	Soukand, Renata/G-8243-2012; Raal, Ain/G-5755-2016; Sõukand, Renata/H-3243-2019	Soukand, Renata/0000-0002-0413-8723; Raal, Ain/0000-0001-8731-7366; Sõukand, Renata/0000-0002-0413-8723; Kalle, Raivo/0000-0002-2175-8617; Volmer, Daisy/0000-0001-6742-5044				[Anonymous], 2012, R LANG ENV STAT COMP; Barnes JA, 2004, MOL CELL BIOCHEM, V263, P3, DOI 10.1023/B:MCBI.0000041961.57973.e0; Eccles R, 2005, LANCET INFECT DIS, V5, P718, DOI 10.1016/S1473-3099(05)70270-X; Fintelmann V., 2000, HERBAL MED; Giovannini P, 2011, SOC SCI MED, V72, P928, DOI 10.1016/j.socscimed.2011.01.007; Hershenson MB, 2006, AM J RESP CRIT CARE, V174, P1284, DOI 10.1164/rccm.200609-1387ED; Kook O., 1962, EESTI NSV RAVIMTAIME; Kukk T, 1999, EESTITAIMESTIK VASCU; Mahlajuk VP, 1967, MED PLANTS ETHNOMEDI; Mathes Angelo, 2010, J Pharm Pract, V23, P117, DOI 10.1177/0897190009358711; Pohlebkin W, 2001, HIST MOST IMPORTANT; Pratter MR, 2006, CHEST, V129, p72S, DOI 10.1378/chest.129.1_suppl.72S; Soukand R, 2008, HIST DATABASE ESTONI; Soukand R, 2012, APPETITE, V59, P523, DOI 10.1016/j.appet.2012.06.017; Soukand Renata, 2012, Estonian Journal of Ecology, V61, P20, DOI 10.3176/eco.2012.1.04; Soukand R, 2011, J ETHNOPHARMACOL, V135, P251, DOI 10.1016/j.jep.2011.02.030; Soukand R, 2010, BIOSEMIOTICS-NETH, V3, P299, DOI 10.1007/s12304-010-9078-9; Tammeorg J., 1984, EESTI NSV RAVIMTAIME; Taubenberger JK, 2008, ANNU REV PATHOL-MECH, V3, P499, DOI 10.1146/annurev.pathmechdis.3.121806.154316; van Elden LJR, 2001, BRIT J GEN PRACT, V51, P630; Volmer D, 2007, MED LITH, V43, P70; Volmer D, 2011, PHYTOTHER RES, V25, P381, DOI 10.1002/ptr.3266	22	29	30	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2013	8	3							e58642	10.1371/journal.pone.0058642	http://dx.doi.org/10.1371/journal.pone.0058642			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	117EP	23484045	Green Published, gold			2023-01-03	WOS:000316936100132
J	Zheng, J; Rubin, EJ; Bifani, P; Mathys, V; Lim, V; Au, M; Jang, J; Nam, J; Dick, T; Walker, JR; Pethe, K; Camacho, LR				Zheng, Jun; Rubin, Eric J.; Bifani, Pablo; Mathys, Vanessa; Lim, Vivian; Au, Melvin; Jang, Jichan; Nam, Jiyoun; Dick, Thomas; Walker, John R.; Pethe, Kevin; Camacho, Luis R.			para-Aminosalicylic Acid Is a Prodrug Targeting Dihydrofolate Reductase in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROPTEROATE SYNTHASE; CRYSTAL-STRUCTURE; RIBOFLAVIN; EXPRESSION; RESISTANCE; EFFICIENT; REVEALS; WR99210; SCREEN; BCG	para-Aminosalicylic acid (PAS) is one of the antimycobacterial drugs currently used for multidrug-resistant tuberculosis. Although it has been in clinical use for over 60 years, its mechanism(s) of action remains elusive. Here we report that PAS is a prodrug targeting dihydrofolate reductase (DHFR) through an unusual and novel mechanism of action. We provide evidences that PAS is incorporated into the folate pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic activity. Interestingly, PAS is recognized by DHPS as efficiently as its natural substrate para-amino benzoic acid. Chemical inhibition of DHPS or mutation in DHFS prevents the formation of the antimetabolite, thereby conferring resistance to PAS. In addition, we identified a bifunctional enzyme (riboflavin biosynthesis protein (RibD)), a putative functional analog of DHFR in a knock-out strain. This finding is further supported by the identification of PAS-resistant clinical isolates encoding a RibD overexpression mutation displaying cross-resistance to genuine DHFR inhibitors. Our findings reveal that a metabolite of PAS inhibits DHFR in the folate pathway. RibD was shown to act as a functional analog of DHFR, and as for DHFS, both were shown to be associated in PAS resistance in laboratory strains and clinical isolates.	[Zheng, Jun; Bifani, Pablo; Lim, Vivian; Au, Melvin; Dick, Thomas; Camacho, Luis R.] Novartis Inst Trop Dis, Singapore 138670, Singapore; [Rubin, Eric J.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Mathys, Vanessa] Sci Inst Publ Hlth, Inst Pasteur, Lab Mol Pathol TB, B-1050 Brussels, Belgium; [Jang, Jichan; Nam, Jiyoun; Pethe, Kevin] Inst Pasteur Korea, Songnam 463400, South Korea; [Walker, John R.] Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Novartis; Harvard University; Harvard T.H. Chan School of Public Health; Institut Pasteur Korea; Novartis	Zheng, J (corresponding author), Vela Res Pte Ltd, Singapore 117406, Singapore.	zhjunyy@hotmail.com; camacholuis112@gmail.com	Pethe, Kevin/L-1199-2013; Zheng, Jun/AAN-4698-2020; Dick, Thomas/AAC-4824-2019; Pethe, Kevin/F-9495-2015; Dick, Thomas/AAB-4109-2019	Pethe, Kevin/0000-0003-0297-0150; Zheng, Jun/0000-0001-6329-4518; Dick, Thomas/0000-0002-9604-9452; Pethe, Kevin/0000-0003-0916-8873; Bifani, Pablo/0000-0001-9651-6439; Rubin, Eric/0000-0001-5120-962X	Korean Ministry of Education, Science and Technology	Korean Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	We acknowledge several scientists at Novartis: Bryan Yeung, Ravinder Kondreddi, and Ranga Rao for providing NITD344; Boon Heng Lee and Koh Sin for technical help with MIC assays and LC/MS analysis; Whitney Barnes for whole genome sequencing; Veronique Dartois for critical review of the manuscript; and Paul Smith for support and stimulating discussions. The Institute Pasteur-Korea receives support from the Korean Ministry of Education, Science and Technology.	Achari A, 1997, NAT STRUCT BIOL, V4, P490, DOI 10.1038/nsb0697-490; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; BROWN GM, 1982, ADV ENZYMOL RAMB, V53, P345; Chakraborty S, 2013, SCIENCE, V339, P88, DOI 10.1126/science.1228980; Chen SC, 2006, J BIOL CHEM, V281, P7605, DOI 10.1074/jbc.M510254200; Dye C, 2002, SCIENCE, V295, P2042, DOI 10.1126/science.1063814; Forgacs P, 2009, ANTIMICROB AGENTS CH, V53, P4789, DOI 10.1128/AAC.01658-08; Freuler F, 2008, PROTEIN EXPRES PURIF, V59, P232, DOI 10.1016/j.pep.2008.02.003; Gengenbacher M, 2008, FEMS MICROBIOL LETT, V287, P128, DOI 10.1111/j.1574-6968.2008.01302.x; Gerum AB, 2002, ANTIMICROB AGENTS CH, V46, P3362, DOI 10.1128/AAC.46.11.3362-3369.2002; Green J. C., 1996, ESCHERICHIA COLI SAL, P665; HekmatNejad M, 1997, EXP PARASITOL, V87, P222, DOI 10.1006/expr.1997.4228; Kurabachew M, 2008, J ANTIMICROB CHEMOTH, V62, P713, DOI 10.1093/jac/dkn269; LEHMANN J, 1946, LANCET, V250, P15; Li RB, 2000, J MOL BIOL, V295, P307, DOI 10.1006/jmbi.1999.3328; Mathieu M, 2005, J BIOL CHEM, V280, P18916, DOI 10.1074/jbc.M413799200; Mathys V, 2009, ANTIMICROB AGENTS CH, V53, P2100, DOI 10.1128/AAC.01197-08; Nopponpunth V, 1999, J BACTERIOL, V181, P6814, DOI 10.1128/JB.181.21.6814-6821.1999; Ong W, 2010, ANTIMICROB AGENTS CH, V54, P2748, DOI 10.1128/AAC.00029-10; Parish T, 2000, MICROBIOL-SGM, V146, P1969, DOI 10.1099/00221287-146-8-1969; Park SW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002264; Pethe K, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1060; RATLEDGE C, 1972, AM REV RESPIR DIS, V106, P774, DOI 10.1164/arrd.1972.106.5.774; Rengarajan J, 2004, MOL MICROBIOL, V53, P275, DOI 10.1111/j.1365-2958.2004.04120.x; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; Schmitt EK, 2011, ANGEW CHEM INT EDIT, V50, P5889, DOI 10.1002/anie.201101740; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; SHIOTA T, 1964, J BIOL CHEM, V239, P2259; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Wei JR, 2011, P NATL ACAD SCI USA, V108, P4176, DOI 10.1073/pnas.1018301108; WHO, 2011, WORLD REPORT ON DISABILITY, P1; YOUMANS GP, 1947, J BACTERIOL, V54, P409, DOI 10.1128/JB.54.4.409-416.1947; Young PG, 2008, ACTA CRYSTALLOGR D, V64, P745, DOI 10.1107/S0907444908012262	33	115	120	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2013	288	32					23447	23456		10.1074/jbc.M113.475798	http://dx.doi.org/10.1074/jbc.M113.475798			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302IN	23779105	Green Published, hybrid			2023-01-03	WOS:000330598200051
J	Annas, GJ; Crosby, SS; Glantz, LH				Annas, George J.; Crosby, Sondra S.; Glantz, Leonard H.			Guantanamo Bay: A Medical Ethics-free Zone?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUNGER STRIKES		[Annas, George J.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831; Crosby, Sondra/0000-0002-1672-5407; Glantz, Leonard/0000-0003-4591-2305				Annas GJ, 2006, NEW ENGL J MED, V355, P1377, DOI 10.1056/NEJMhle062316; Annas GJ., 2010, WORST CASE BIOETHICS; [Anonymous], 2013, REP CONST PROJ TASK; BEAM T, 2003, MILITARY MED ETHICS, V2; Crosby SS, 2007, JAMA-J AM MED ASSOC, V298, P563, DOI 10.1001/jama.298.5.563	5	22	23	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2013	369	2					101	103		10.1056/NEJMp1306065	http://dx.doi.org/10.1056/NEJMp1306065			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	180BH	23758205				2023-01-03	WOS:000321567300003
J	Bae, YJ; Hwang, YW; Yoon, SY; Kim, S; Lee, T; Lee, YS; Kwon, HS; Cho, YS; Shin, MJ; Moon, HB; Kim, TB				Bae, Yun-Jeong; Hwang, Ye Won; Yoon, Sun-young; Kim, Sujeong; Lee, Taehoon; Lee, Yoon Su; Kwon, Hyouk-Soo; Cho, You Sook; Shin, Myung Jin; Moon, Hee-Bom; Kim, Tae-Bum			The Effectiveness of Automatic Recommending System for Premedication in Reducing Recurrent Radiocontrast Media Hypersensitivity Reactions	PLOS ONE			English	Article							IODINATED CONTRAST-MEDIA; SURVEILLANCE; PREVENTION; MANAGEMENT; ALLERGY; KOREA	Background: Non-ionic radiocontrast media (RCM) is rarely associated with hypersensitivity reactions. Premedication of patients who reacted previously to RCM with systemic corticosteroids and/or antihistamines can help reduce recurrent hypersensitivity reactions. However, premedication is still not prescribed in many cases for various reasons. This study aimed to determine the effectiveness of our novel RCM hypersensitivity surveillance and automatic recommending system for premedication. Methods and Results: Hospitalized patients with a history of RCM hypersensitivity were identified in an electronic medical record system that included a mandatory reporting system for past adverse drug reactions. In 2009, a novel automatic prescription system was added that classified index RCM reactions by severity and dispensed appropriate corticosteroid and/or antihistamine pretreatment prior to new RCM exposures. The data from 12 months under the previous system and 12 months under the current system were compared. The two systems had similar overall premedication rates (91% and 95%) but the current system was associated with a significantly higher corticosteroid premedication rate (65% vs. 14%), which significantly reduced the breakthrough reaction rate (6.7% vs. 15.2%). The current system was also associated with increased corticosteroid and antihistamine premedication of patients with a mild index reaction (61% vs. 7%) and a reduction in their breakthrough reaction rate (6% vs. 15%). Conclusions: Premedication with corticosteroid and/or antihistamine, which was increased by our novel automatic prescription system, significantly reduced breakthrough reactions in patients with a history of RCM hypersensitivity.	[Bae, Yun-Jeong; Yoon, Sun-young; Kim, Sujeong; Lee, Taehoon; Lee, Yoon Su; Kwon, Hyouk-Soo; Cho, You Sook; Moon, Hee-Bom; Kim, Tae-Bum] Univ Ulsan, Coll Med, Div Allergy & Clin Immunol, Dept Internal Med,Asan Med Ctr, Seoul, South Korea; [Bae, Yun-Jeong] Asan Med Ctr, Dept Hlth Med, Hlth Screening & Promot Ctr, Seoul, South Korea; [Hwang, Ye Won; Kwon, Hyouk-Soo; Cho, You Sook; Kim, Tae-Bum] Asan Med Ctr, Pharmacovigilance Ctr, Seoul, South Korea; [Shin, Myung Jin] Univ Ulsan, Coll Med, Dept Radiol, Asan Med Ctr, Seoul, South Korea	University of Ulsan; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan	Kim, TB (corresponding author), Univ Ulsan, Coll Med, Div Allergy & Clin Immunol, Dept Internal Med,Asan Med Ctr, Seoul, South Korea.	allergy@medimail.co.kr	Lee, Taehoon/AHA-1437-2022	Lee, Taehoon/0000-0002-9224-0866; Cho, You Sook/0000-0001-8767-2667	National Project for Personalized Genomic Medicine, Ministry for Health & Welfare, Republic of Korea [A111218-PG01]	National Project for Personalized Genomic Medicine, Ministry for Health & Welfare, Republic of Korea	This study was supported by a grant from the National Project for Personalized Genomic Medicine, Ministry for Health & Welfare, Republic of Korea (A111218-PG01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brockow K, 2005, ALLERGY, V60, P150, DOI 10.1111/j.1398-9995.2005.00745.x; Caimmi S, 2010, CLIN EXP ALLERGY, V40, P805, DOI 10.1111/j.1365-2222.2010.03493.x; Christiansen C, 2005, TOXICOLOGY, V209, P185, DOI 10.1016/j.tox.2004.12.020; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Davenport MS, 2009, RADIOLOGY, V253, P372, DOI 10.1148/radiol.2532090465; Dormann H, 2000, DRUG SAFETY, V22, P161, DOI 10.2165/00002018-200022020-00007; Freed KS, 2001, AM J ROENTGENOL, V176, P1389, DOI 10.2214/ajr.176.6.1761389; GREENBERGER PA, 1991, J ALLERGY CLIN IMMUN, V87, P867, DOI 10.1016/0091-6749(91)90135-B; Idee JM, 2005, FUND CLIN PHARMACOL, V19, P263, DOI 10.1111/j.1472-8206.2005.00326.x; Kim SH, 2011, EUR J RADIOL, V80, P363, DOI 10.1016/j.ejrad.2010.06.014; Kopp AF, 2008, ACTA RADIOL, V49, P902, DOI 10.1080/02841850802282811; LASSER EC, 1987, NEW ENGL J MED, V317, P845, DOI 10.1056/NEJM198710013171401; Liccardi G, 2008, J INVEST ALLERG CLIN, V18, P1; Park CS, 2008, PHARMACOEPIDEM DR S, V17, P919, DOI 10.1002/pds.1612; Segal AJ, 2011, INVEST RADIOL, V46, P147, DOI 10.1097/RLI.0b013e3181f5409e; Thomsen HS, 2011, EUR J RADIOL, V80, P77, DOI 10.1016/j.ejrad.2010.12.104; Thong BYH, 2003, ANN ALLERG ASTHMA IM, V90, P342, DOI 10.1016/S1081-1206(10)61804-2; Tramer MR, 2006, BRIT MED J, V333, P675, DOI 10.1136/bmj.38905.634132.AE	18	24	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2013	8	6							e66014	10.1371/journal.pone.0066014	http://dx.doi.org/10.1371/journal.pone.0066014			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190ST	23840391	Green Published, Green Submitted, gold			2023-01-03	WOS:000322361200049
J	Yang, JS; Lin, CW; Hsin, CH; Hsieh, MJ; Chang, YC				Yang, Jia-Sin; Lin, Chiao-Wen; Hsin, Chung-Han; Hsieh, Ming-Ju; Chang, Yu-Chao			Selaginella tamariscina Attenuates Metastasis via Akt Pathways in Oral Cancer Cells	PLOS ONE			English	Article							NF-KAPPA-B; AMENTOFLAVONE INDUCES APOPTOSIS; MATRIX METALLOPROTEINASE-2; INHIBITS MIGRATION; CYCLE ARREST; TUMOR-CELL; IN-VITRO; INVASION; EXPRESSION; CARCINOMA	Background: Crude extracts of Selaginella tamariscina, an oriental medicinal herb, have been evidenced to treat several human diseases. This study investigated the mechanisms by which Selaginella tamariscina inhibits the invasiveness of human oral squamous-cell carcinoma (OSCC) HSC-3 cells. Methodology/Principal Findings: Herein, we demonstrate that Selaginella tamariscina attenuated HSC-3 cell migration and invasion in a dose-dependent manner. The anti-metastatic activities of Selaginella tamariscina occurred at least partially because of the down-regulation of matrix metalloproteinases (MMP)-2 and MMP-9 gelatinase activity and the down-regulation of protein expression. The expression and function of both MMP-2 and MMP-9 were regulated by Selaginella tamariscina at a transcriptional level, as shown by quantitative real-time PCR and reporter assays. Chromatin immunoprecipitation (ChIP) data further indicated that binding of the cAMP response element-binding (CREB) protein and activating protein-1 (AP-1) to the MMP-2 promoter diminished at the highest dosage level of Selaginella tamariscina. The DNA-binding activity of specificity protein 1 (SP-1) to the MMP-9 promoter was also suppressed at the same concentration. Selaginella tamariscina did not affect the mitogen-activated protein kinase signaling pathway, but did inhibit the effects of gelatinase by reducing the activation of serine-threonine kinase Akt. Conclusions: These results demonstrate that Selaginella tamariscina may be a potent adjuvant therapeutic agent in the prevention of oral cancer.	[Yang, Jia-Sin; Hsieh, Ming-Ju] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Lin, Chiao-Wen] Chung Shan Med Univ, Inst Oral Sci, Taichung, Taiwan; [Lin, Chiao-Wen; Chang, Yu-Chao] Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan; [Hsin, Chung-Han] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Hsin, Chung-Han] Chung Shan Med Univ Hosp, Dept Otolaryngol, Taichung, Taiwan; [Chang, Yu-Chao] Chung Shan Med Univ, Sch Dent, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University	Chang, YC (corresponding author), Chung Shan Med Univ Hosp, Dept Dent, Taichung, Taiwan.	cyc@csmu.edu.tw	Hsieh, Ming-Ju/GQB-3025-2022	Hsieh, Ming-Ju/0000-0001-9726-3234	National Science Council, Taiwan [NSC100-2632-B-040-001-MY3]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by a research grant from National Science Council, Taiwan (NSC100-2632-B-040-001-MY3). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Chakraborti S, 2003, MOL CELL BIOCHEM, V253, P269, DOI 10.1023/A:1026028303196; Chen PN, 2006, J DENT RES, V85, P220, DOI 10.1177/154405910608500303; Chiang YY, 2008, HISTOL HISTOPATHOL, V23, P1213, DOI 10.14670/HH-23.1213; Chien MH, 2012, FOOD CHEM TOXICOL, V50, P558, DOI 10.1016/j.fct.2011.12.016; Fullar A, 2012, EXP CELL RES, V318, P1517, DOI 10.1016/j.yexcr.2012.03.023; Hsieh YS, 2007, CARCINOGENESIS, V28, P977, DOI 10.1093/carcin/bgl221; Hwang IS, 2012, MYCOPATHOLOGIA, V173, P207, DOI 10.1007/s11046-011-9503-x; JUAREZ J, 1993, INT J CANCER, V55, P10, DOI 10.1002/ijc.2910550104; Jung HJ, 2007, BIOL PHARM BULL, V30, P1969, DOI 10.1248/bpb.30.1969; Jung HJ, 2006, ARCH PHARM RES, V29, P746, DOI 10.1007/BF02974074; Kim HS, 2004, ANTICANCER RES, V24, P747; Kuo HP, 2012, J AGR FOOD CHEM, V60, P9649, DOI 10.1021/jf302832n; Kuo YC, 1998, J LAB CLIN MED, V132, P76, DOI 10.1016/S0022-2143(98)90029-4; Lee IS, 1999, CANCER LETT, V144, P93, DOI 10.1016/S0304-3835(99)00202-5; Lee JS, 2009, BIOL PHARM BULL, V32, P1427, DOI 10.1248/bpb.32.1427; Lee J, 2009, J MICROBIOL BIOTECHN, V19, P204, DOI 10.4014/jmb.0810.566; Lee S, 2011, J MED FOOD, V14, P808, DOI 10.1089/jmf.2010.1428; Lu KW, 2011, HUM EXP TOXICOL, V30, P406, DOI 10.1177/0960327110372405; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Massano J, 2006, ORAL SURG ORAL MED O, V102, P67, DOI 10.1016/j.tripleo.2005.07.038; Miao N, 1996, Zhongguo Zhong Yao Za Zhi, V21, P493; Mirzoeva S, 2013, MOL CARCINOG; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Park SY, 2012, INT J ONCOL, V41, P933, DOI 10.3892/ijo.2012.1518; Pei JS, 2012, IN VIVO, V26, P963; Ribatti D, 2008, GENES NUTR, V3, P29, DOI 10.1007/s12263-008-0076-3; Satpathy M, 2009, J BIOL CHEM, V284, P15390, DOI 10.1074/jbc.M808331200; SOPATA I, 1979, BIOCHIM BIOPHYS ACTA, V571, P305, DOI 10.1016/0005-2744(79)90100-1; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sze KMF, 2011, HEPATOLOGY, V53, P1558, DOI 10.1002/hep.24232; Tang SW, 2011, CARCINOGENESIS, V32, P138, DOI 10.1093/carcin/bgq225; VARTIO T, 1981, J BIOL CHEM, V256, P3085; Wang KL, 2013, EXPERT OPIN THER TAR, V17, P337, DOI 10.1517/14728222.2013.756869; Weng CJ, 2008, CARCINOGENESIS, V29, P147, DOI 10.1093/carcin/bgm261; Yang JW, 2006, J ETHNOPHARMACOL, V105, P107, DOI 10.1016/j.jep.2005.10.001; Yang SF, 2007, J ETHNOPHARMACOL, V110, P483, DOI 10.1016/j.jep.2006.10.010; Yeh CB, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/595292; Yu YL, 2011, J BIOL CHEM, V286, P9657, DOI 10.1074/jbc.M110.185124; Yu YL, 2010, J AGR FOOD CHEM, V58, P1630, DOI 10.1021/jf903043r; Zheng XK, 2011, J ETHNOPHARMACOL, V137, P662, DOI 10.1016/j.jep.2011.06.018	41	11	12	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2013	8	6							e68035	10.1371/journal.pone.0068035	http://dx.doi.org/10.1371/journal.pone.0068035			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163UV	23799155	Green Published, Green Submitted, gold			2023-01-03	WOS:000320363300117
J	Al Batran, R; Al-Bayaty, F; Al-Obaidi, MMJ; Abdualkader, AM; Hadi, HA; Ali, HM; Abdulla, MA				Al Batran, Rami; Al-Bayaty, Fouad; Al-Obaidi, Mazen M. Jamil; Abdualkader, Abdualrahman Mohammed; Hadi, Hamid A.; Ali, Hapipah Mohd; Abdulla, Mahmood Ameen			In Vivo Antioxidant and Antiulcer Activity of Parkia speciosa Ethanolic Leaf Extract against Ethanol-Induced Gastric Ulcer in Rats	PLOS ONE			English	Article							CYTOPROTECTION; INHIBITION; MUCUS	Background: The current study was carried out to examine the gastroprotective effects of Parkia speciosa against ethanol-induced gastric mucosa injury in rats. Methodology/Principal Findings: Sprague Dawley rats were separated into 7 groups. Groups 1-2 were orally challenged with carboxymethylcellulose (CMC); group 3 received 20 mg/kg omeprazole and groups 4-7 received 50, 100, 200 and 400 mg/kg of ethanolic leaf extract, respectively. After 1 h, CMC or absolute ethanol was given orally to groups 2-7. The rats were sacrificed after 1 h. Then, the injuries to the gastric mucosa were estimated through assessment of the gastric wall mucus, the gross appearance of ulcer areas, histology, immunohistochemistry and enzymatic assays. Group 2 exhibited significant mucosal injuries, with reduced gastric wall mucus and severe damage to the gastric mucosa, whereas reductions in mucosal injury were observed for groups 4-7. Groups 3-7 demonstrated a reversal in the decrease in Periodic acid-Schiff (PAS) staining induced by ethanol. No symptoms of toxicity or death were observed during the acute toxicity tests. Conclusion: Treatment with the extract led to the upregulation of heat-shock protein 70 (HSP70) and the downregulation of the pro-apoptotic protein BAX. Significant increases in the levels of the antioxidant defense enzymes glutathione (GSH) and superoxide dismutase (SOD) in the gastric mucosal homogenate were observed, whereas that of a lipid peroxidation marker (MDA) was significantly decreased. Significance was defined as p<0.05 compared to the ulcer control group (Group 2).	[Al Batran, Rami; Al-Bayaty, Fouad; Al-Obaidi, Mazen M. Jamil] Univ Technol MARA UiTM, Ctr Studies Periodontol, Fac Dent, Shah Alam, Selangor, Malaysia; [Abdualkader, Abdualrahman Mohammed] Int Islam Univ Malaysia, Fac Pharm, Dept Pharmaceut Chem, Kuantan, Pahang, Malaysia; [Hadi, Hamid A.; Ali, Hapipah Mohd] Univ Malaya, Dept Chem, Fac Sci, Kuala Lumpur 59100, Malaysia; [Abdulla, Mahmood Ameen] Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia	Universiti Teknologi MARA; International Islamic University Malaysia; Universiti Malaya; Universiti Malaya	Abdulla, MA (corresponding author), Univ Malaya, Fac Med, Dept Biomed Sci, Kuala Lumpur, Malaysia.	ammeen@um.edu.my	Al-Obaidi, Mazen/GQR-0358-2022; Al Batran, Rami/D-2177-2015; Abdualkader, Abdualrahman M./A-8120-2012	Al-Obaidi, Mazen/0000-0001-5950-4498; Al Batran, Rami/0000-0001-5412-3346; Abdualkader, Abdualrahman M./0000-0001-8081-9988; AL BAYATY, FOUAD/0000-0002-3117-595X	University of Malaya [F000009-21001]	University of Malaya(Universiti Malaya)	The authors express gratitude to the University of Malaya for the financial support of UM/MOHE High Impact Research Grant (HIR Grant No. F000009-21001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelwahab SI, 2011, EVID-BASED COMPL ALT, V2011, DOI [10.1155/2011/156765, 10.1093/ecam/neq010]; Abdulla MA, 2010, AFR J PHARM PHARMACO, V4, P226; Bardi D. A. A., 2011, Scientific Research and Essays, V6, P3232; Behmer O.A., 1976, MANUAL TECNICAS HIST, V1st; BOLTON JP, 1978, AM J DIG DIS, V23, P359, DOI 10.1007/BF01072421; Chemicals D., 2005, OECD GUIDELINE TESTI; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Ching LS, 2001, J AGR FOOD CHEM, V49, P3101, DOI 10.1021/jf000891u; CLAMP JR, 1978, BRIT MED BULL, V34, P25, DOI 10.1093/oxfordjournals.bmb.a071455; DAVENPOR.HW, 1968, GASTROENTEROLOGY, V54, P175; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Dursun H, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-36; Gan CY, 2011, FOOD CHEM, V124, P1277, DOI 10.1016/j.foodchem.2010.07.074; Itatsu T, 2011, INTERNAL MED, V50, P713, DOI 10.2169/internalmedicine.50.4644; Jainu Mallika, 2006, Indian J Med Res, V123, P799; Johansen JS, 2005, CARDIOVASC DIABETOL, V4, DOI 10.1186/1475-2840-4-5; Konturek PC, 1999, J PHYSIOL PHARMACOL, V50, P211; Kushima W, 2005, J ETHNOPHARMACOL, V101, P61, DOI 10.1016/j.jep.2005.03.014; La Casa C, 2000, J ETHNOPHARMACOL, V71, P45, DOI 10.1016/S0378-8741(99)00174-9; Laine L, 2008, GASTROENTEROLOGY, V135, P41, DOI 10.1053/j.gastro.2008.05.030; Lanas A, 2009, AM J MED SCI, V338, P96, DOI 10.1097/MAJ.0b013e3181ad8cd3; LUKIE BE, 1972, BIOCHIM BIOPHYS ACTA, V273, P380, DOI 10.1016/0304-4165(72)90230-9; Mahmood AA, 2010, J MED PLANTS RES, V4, P685; Mahmood AA, 2011, J MED PLANTS RES, V5, P2562; Maity P, 2003, MOL CELL BIOCHEM, V253, P329, DOI 10.1023/A:1026040723669; MARHUENDA E, 1993, PHYTOTHER RES, V7, P13, DOI 10.1002/ptr.2650070105; MCMANUS JFA, 1948, STAIN TECHNOL, V23, P99, DOI 10.3109/10520294809106232; PIPER DW, 1970, GASTROENTEROLOGY, V59, P534; Repetto MG, 2002, BRAZ J MED BIOL RES, V35, P523, DOI 10.1590/S0100-879X2002000500003; Resources IoLA, 1996, GUIDE CARE USE LAB A; ROBERT A, 1984, GASTROENTEROLOGY, V86, P670; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SHAY H, 1945, GASTROENTEROLOGY, V5, P43; Soberg Taran, 2010, Tidsskr Nor Laegeforen, V130, P1135, DOI 10.4045/tidsskr.08.0693; SUN Y, 1988, CLIN CHEM, V34, P497; Thirunavukkarasu P., 2010, World Applied Sciences Journal, V9, P55; Tytell M, 2001, Expert Opin Ther Targets, V5, P267, DOI 10.1517/14728222.5.2.267; Wasman SQ, 2011, INDIAN J EXP BIOL, V49, P767; Wasman SQ, 2010, J MED PLANTS RES, V4, P2658; Yeomans ND, 2009, CURR MED RES OPIN, V25, P2785, DOI 10.1185/03007990903212682; Yuan L, 2010, CHINESE CHEM LETT, V21, P155, DOI 10.1016/j.cclet.2009.10.004	41	92	94	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e64751	10.1371/journal.pone.0064751	http://dx.doi.org/10.1371/journal.pone.0064751			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155FM	23724090	Green Published, gold, Green Submitted			2023-01-03	WOS:000319733000091
J	Cunningham, D; Hawkes, EA; Jack, A; Qian, WD; Smith, P; Mouncey, P; Pocock, C; Ardeshna, KM; Radford, JA; McMillan, A; Davies, J; Turner, D; Kruger, A; Johnson, P; Gambell, J; Linch, D				Cunningham, David; Hawkes, Eliza A.; Jack, Andrew; Qian, Wendi; Smith, Paul; Mouncey, Paul; Pocock, Christopher; Ardeshna, Kirit M.; Radford, John A.; McMillan, Andrew; Davies, John; Turner, Deborah; Kruger, Anton; Johnson, Peter; Gambell, Joanna; Linch, David			Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; 3-WEEKLY CHOP CHEMOTHERAPY; POOR-PROGNOSIS; ELDERLY-PATIENTS; STANDARD CHOP; AGGRESSIVE LYMPHOMAS; YOUNG-PATIENTS; ACVBP; TRANSPLANTATION; MULTICENTER	Background Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. We investigated whether this survival benefit from dose intensification persists in the presence of rituximab (R-CHOP) in all age groups. Methods Patients (aged >= 18 years) with previously untreated bulky stage IA to stage IV diffuse large B-cell lymphoma in 119 centres in the UK were randomly assigned centrally in a one-to-one ratio, using minimisation, to receive six cycles of R-CHOP every 14 days plus two cycles of rituximab (R-CHOP-14) or eight cycles of R-CHOP every 21 days (R-CHOP-21). R-CHOP-21 was intravenous cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) (maximum dose 2 mg), and rituximab 375 mg/m(2) on day 1, and oral prednisolone 40 mg/m(2) on days 1-5, administered every 21 days for a total of eight cycles. R-CHOP-14 was intravenous cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 2 mg, rituximab 375 mg/m(2) on day 1, and oral prednisolone 100 mg on days 1-5, administered every 14 days for six cycles, followed by two further infusions of rituximab 375 mg/m(2) on day 1 every 14 days. The trial was not masked. The primary outcome was overall survival (OS). This study is registered, number ISCRTN 16017947. Findings 1080 patients were assigned to R-CHOP-21 (n=540) and R-CHOP-14 (n=540). With a median follow-up of 46 months (IQR 35-57), 2-year OS was 82.7% (79.5-85.9) in the R-CHOP-14 group and 80.8% (77.5-84.2) in the R-CHOP-21 (standard) group (hazard ratio 0.90, 95% CI 0.70-1.15; p=0.3763). No significant improvement was noted in 2-year progression-free survival (R-CHOP-14 75.4%, 71.8-79.1, and R-CHOP-21 74.8%, 71.0-78.4; 0.94, 0.76-1.17; p=0.5907). High international prognostic index, poor-prognosis molecular characteristics, and cell of origin were not predictive for benefit from either schedule. Grade 3 or 4 neutropenia was higher in the R-CHOP-21 group (318 [60%] of 534 vs 167 [31%] of 534), with no prophylactic use of recombinant human granulocyte-colony stimulating factor mandated in this group, whereas grade 3 or 4 thrombo cytopenia was higher with R-CHOP-14 (50 [9%] vs 28 [5%]); other frequent grade 3 or 4 adverse events were febrile neutropenia (58 [11%] vs 28 [5%]) and infection (125 [23%] vs 96 [18%]). Frequencies of non-haematological adverse events were similar in the R-CHOP-21 and R-CHOP-14 groups. Interpretation R-CHOP-14 is not superior to R-CHOP-21 chemotherapy for previously untreated diffuse large B-cell lymphoma; therefore, R-CHOP-21 remains the standard first-line treatment in patients with this haematological malignancy. No molecular or clinical subgroup benefited from dose intensification in this study.	[Cunningham, David; Hawkes, Eliza A.] Royal Marsden NHS Fdn Trust, London, England; [Cunningham, David; Hawkes, Eliza A.] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England; [Jack, Andrew] St James Inst Oncol, Leeds, W Yorkshire, England; [Qian, Wendi] Cambridge Canc Trials Ctr, Cambridge Clin Trials Unit Canc Theme, Cambridge, England; [Qian, Wendi] MRC, Biostat Unit Hub Trials Methodol, Cambridge, England; [Smith, Paul; Mouncey, Paul; Gambell, Joanna] Canc Res UK, London, England; [Smith, Paul; Mouncey, Paul; Gambell, Joanna] UCL Canc Inst, UCL Canc Trials Ctr, London, England; [Pocock, Christopher] East Kent Hosp, Canterbury, Kent, England; [Ardeshna, Kirit M.] Mt Vernon Canc Ctr, Northwood, Middx, England; [Radford, John A.] Univ Manchester, Manchester, Lancs, England; [Radford, John A.] Christie NHS Fdn Trust, Manchester, Lancs, England; [McMillan, Andrew] City Hosp Nottingham, Nottingham, England; [Davies, John] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; [Turner, Deborah] Torbay Hosp, Torquay, England; [Kruger, Anton] Royal Cornwall Hosp, Truro, England; [Johnson, Peter] Canc Res UK Ctr, Southampton, Hants, England; [Ardeshna, Kirit M.; Linch, David] UCL, London WC1E 6BT, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Saint James's University Hospital; MRC Biostatistics Unit; Cancer Research UK; University of London; University College London; Mount Vernon Cancer Centre; University of Manchester; Christie NHS Foundation Trust; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Edinburgh; Royal Cornwall Hospital; Cancer Research UK; University of London; University College London	Cunningham, D (corresponding author), Royal Marsden Hosp, Dept Med, Downs Rd, Sutton SM2 5PT, Surrey, England.	david.cunningham@rmh.nhs.uk	Johnson, Peter/O-3529-2019; Radford, John A/N-1331-2015; , andrew.mcmillan@nhs.net/N-1627-2019; Hawkes, Eliza/G-2847-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Radford, John A/0000-0001-7898-2786; Hawkes, Eliza/0000-0002-0376-2559; Johnson, Peter/0000-0003-2306-4974; Mouncey, Paul/0000-0002-8510-8517; Cunningham, David/0000-0001-5158-1069	Chugai Pharmaceutical; Cancer Research UK; National Institute for Health Research Biomedical Research Centres at both University College London; Royal Marsden NHS Foundation Trust; Institute of Cancer Research; Roche; Amgen; Sanofi-Aventis; Novartis; Astra-Zeneca; Merck KGA; Celgene; Genentech; Millennium; Chugai Pharma	Chugai Pharmaceutical; Cancer Research UK(Cancer Research UK); National Institute for Health Research Biomedical Research Centres at both University College London; Royal Marsden NHS Foundation Trust(Royal Society of New ZealandMarsden Fund (NZ)); Institute of Cancer Research; Roche(Roche Holding); Amgen(Amgen); Sanofi-Aventis(Sanofi-Aventis); Novartis(Novartis); Astra-Zeneca(AstraZeneca); Merck KGA; Celgene(Bristol-Myers SquibbCelgene Corporation); Genentech(Roche HoldingGenentech); Millennium(Takeda Pharmaceutical Company Ltd); Chugai Pharma	Chugai Pharmaceutical, Cancer Research UK, National Institute for Health Research Biomedical Research Centres scheme at both University College London and the Royal Marsden NHS Foundation Trust, and Institute of Cancer Research.; DC received research grants from Roche, Amgen, Sanofi-Aventis, Novartis, Astra-Zeneca, Merck KGA, and Celgene; participated on compensated advisory boards for Amgen, Roche, Merck, and Sanofi-Aventis, and uncompensated advisory boards for Roche (honoraria), Merck, and Sanofi-Aventis; and provided uncompensated expert testimony for Amgen. EAH has received travel expenses from Roche. AJ has received research grants from Roche and Genentech. CP has participated on compensated advisory boards for Roche and Pfizer, and received travel expenses from Roche. KMA has received research funding and honoraria from Roche. JAR has received research grants from Millennium, and provided expert testimony for Millennium Pharmaceuticals, Bayer-Schering, Roche, Napp Pharmaceuticals, Novartis, and GlaxoSmithKline. AM has received a research grant from Roche, and consultancy fees, honoraria, and travel expenses from Roche. JD has received consultancy fees and travel expenses from Roche. DT has received travel expenses from Roche. PJ has participated on a compensated advisory board for and received travel expenses from Roche. DL has received research grants from Roche and Chugai Pharma; participated on compensated advisory boards for Roche, Chugai, Amgen, and Hospira; and received honoraria from Roche, Chugai, and Celgene. The other authors declare that they have no conflicts of interest.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Armitage JO, 1998, J CLIN ONCOL, V16, P2780, DOI 10.1200/JCO.1998.16.8.2780; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 2010, BLOOD, V116, P2040, DOI 10.1182/blood-2010-03-276246; Delarue R, 2012, J CLIN ONCOL, V30; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Glass B, 2010, ANN ONCOL, V21, P2255, DOI 10.1093/annonc/mdq235; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Jaffe E.S., 2001, PATHOLOGY GENETICS T, VVolume 3; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Le Gouill S, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8003; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Li SY, 2012, MODERN PATHOL, V25, P145, DOI 10.1038/modpathol.2011.147; Linch DC, 2010, BRIT J HAEMATOL, V149, P237, DOI 10.1111/j.1365-2141.2010.08081.x; Ohmachi K, 2011, ANN ONCOL, V22, P1382, DOI 10.1093/annonc/mdq619; Pfreundschuh M, 2004, BLOOD, V104, P626, DOI 10.1182/blood-2003-06-2094; Pfreundschuh M, 2004, BLOOD, V104, P634, DOI 10.1182/blood-2003-06-2095; Pfreundschuh M, 2008, LANCET ONCOL, V9, P105, DOI 10.1016/S1470-2045(08)70002-0; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Recher C, 2011, LANCET, V378, P1858, DOI 10.1016/S0140-6736(11)61040-4; Reyes F, 2005, NEW ENGL J MED, V352, P1197, DOI 10.1056/NEJMoa042040; Salles G, 2011, BLOOD, V117, P7070, DOI 10.1182/blood-2011-04-345256; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Stiff PJ, 2011, ASCO M S, V29, P8001; Tarella C, 2007, LEUKEMIA, V21, P1802, DOI 10.1038/sj.leu.2404781; Thieblemont C, 2011, J CLIN ONCOL, V29, P4079, DOI 10.1200/JCO.2011.35.4423; Tilly H, 2003, BLOOD, V102, P4284, DOI 10.1182/blood-2003-02-0542; Vitolo U, 2009, HAEMATOL-HEMATOL J, V94, P1250, DOI 10.3324/haematol.2009.007005; Vose JM, 2011, LANCET, V378, P1828, DOI 10.1016/S0140-6736(11)61269-5; Wilson WH, 2008, J CLIN ONCOL, V26, P2717, DOI 10.1200/JCO.2007.13.1391; Ziepert M, 2011, J CLIN ONCOL, V29, pE15, DOI 10.1200/JCO.2010.32.0127	35	346	361	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2013	381	9880					1817	1826		10.1016/S0140-6736(13)60313-X	http://dx.doi.org/10.1016/S0140-6736(13)60313-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151EO	23615461	Green Published			2023-01-03	WOS:000319443700027
J	Chen, HL; Zhang, ZP				Chen, Hailin; Zhang, Zuping			A Semi-Supervised Method for Drug-Target Interaction Prediction with Consistency in Networks	PLOS ONE			English	Article							DIVERSITY-ORIENTED SYNTHESIS; PHARMACOLOGY; INTEGRATION; MODEL	Computational prediction of interactions between drugs and their target proteins is of great importance for drug discovery and design. The difficulties of developing computational methods for the prediction of such potential interactions lie in the rarity of known drug-protein interactions and no experimentally verified negative drug-target interaction sample. Furthermore, target proteins need also to be predicted for some new drugs without any known target interaction information. In this paper, a semi-supervised learning method NetCBP is presented to address this problem by using labeled and unlabeled interaction information. Assuming coherent interactions between the drugs ranked by their relevance to a query drug, and the target proteins ranked by their relevance to the hidden target proteins of the query drug, we formulate a learning framework maximizing the rank coherence with respect to the known drug-target interactions. When applied to four classes of important drug-target interaction networks, our method improves previous methods in terms of cross-validation and some strongly predicted interactions are confirmed by the publicly accessible drug target databases, which indicates the usefulness of our method. Finally, a comprehensive prediction of drug-target interactions enables us to suggest many new potential drug-target interactions for further studies.	[Chen, Hailin; Zhang, Zuping] Cent S Univ, Sch Informat Sci & Engn, Changsha, Hunan, Peoples R China; [Chen, Hailin] Hunan Univ Humanities Sci & Technol, Dept Comp Sci & Technol, Loudi, Peoples R China	Central South University; Hunan University Of Humanities, Science & Technology	Zhang, ZP (corresponding author), Cent S Univ, Sch Informat Sci & Engn, Changsha, Hunan, Peoples R China.	zpzhang@mail.csu.edu.cn		Chen, Hailin/0000-0002-5119-4517	National Natural Science Foundation of China [60970095, 61003124, M1121008]; Research Fund for the Doctoral Program of Higher Education of China [20120162110077]; National High Technology Research and Development Program of China (863 Program) [2012AA011205]; Program for New Century Excellent Talents in University [NCET-12-0547]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Fund for the Doctoral Program of Higher Education of China(Research Fund for the Doctoral Program of Higher Education of China (RFDP)Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); National High Technology Research and Development Program of China (863 Program)(National High Technology Research and Development Program of China); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET))	This research was supported by the National Natural Science Foundation of China (Grants 60970095, 61003124 and M1121008), Research Fund for the Doctoral Program of Higher Education of China (Grant no. 20120162110077), the National High Technology Research and Development Program of China (863 Program, no. 2012AA011205), and the Program for New Century Excellent Talents in University (NCET-12-0547). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Bleakley K, 2009, BIOINFORMATICS, V25, P2397, DOI 10.1093/bioinformatics/btp433; Chen X, 2012, MOL BIOSYST, V8, P1970, DOI 10.1039/c2mb00002d; Cheng AC, 2007, NAT BIOTECHNOL, V25, P71, DOI 10.1038/nbt1273; Cheng FX, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002503; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777; Gonen M, 2012, BIOINFORMATICS, V28, P2304, DOI 10.1093/bioinformatics/bts360; Haggarty SJ, 2003, CHEM BIOL, V10, P383, DOI 10.1016/S1074-5521(03)00095-4; Hattori M, 2003, J AM CHEM SOC, V125, P11853, DOI 10.1021/ja036030u; Hecker N, 2012, NUCLEIC ACIDS RES, V40, pD1113, DOI 10.1093/nar/gkr912; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hwang TH, 2011, BIOINFORMATICS, V27, P2692, DOI 10.1093/bioinformatics/btr463; Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Knox C, 2011, NUCLEIC ACIDS RES, V39, pD1035, DOI 10.1093/nar/gkq1126; Kuruvilla FG, 2002, NATURE, V416, P653, DOI 10.1038/416653a; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Stettner M, 2007, MOL CANCER THER, V6, P2626, DOI 10.1158/1535-7163.MCT-07-0197; Tiihonen J, 2009, LANCET, V374, P620, DOI 10.1016/S0140-6736(09)60742-X; Xia Z, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S2-S6; Xie L, 2012, ANNU REV PHARMACOL, V52, P361, DOI 10.1146/annurev-pharmtox-010611-134630; Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162; Yamanishi Y, 2010, BIOINFORMATICS, V26, pi246, DOI 10.1093/bioinformatics/btq176; Zhu SF, 2005, BIOINFORMATICS, V21, P245, DOI 10.1093/bioinformatics/bti1141	27	95	96	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2013	8	5							e62975	10.1371/journal.pone.0062975	http://dx.doi.org/10.1371/journal.pone.0062975			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	154EP	23667553	gold, Green Published, Green Submitted			2023-01-03	WOS:000319654700091
J	Madsen, K; Reddy, RN; Price, SR; Williams, CR; Gooch, JL				Madsen, Kirsten; Reddy, Ramesh N.; Price, S. Russ; Williams, Clintoria R.; Gooch, Jennifer L.			Nutritional Intervention Restores Muscle but Not Kidney Phenotypes in Adult Calcineurin A alpha Null Mice	PLOS ONE			English	Article							BETA; RESTRICTION; ISOFORM; RAT	Mice lacking the alpha isoform of the catalytic subunit of calcineurin (CnA alpha) were first reported in 1996 and have been an important model to understand the role of calcineurin in the brain, immune system, bones, muscle, and kidney. Research using the mice has been limited, however, by failure to thrive and early lethality of most null pups. Work in our laboratory led to the rescue of CnA alpha-/- mice by supplemental feeding to compensate for a defect in salivary enzyme secretion. The data revealed that, without intervention, knockout mice suffer from severe caloric restriction. Since nutritional deprivation is known to significantly alter development, it is imperative that previous conclusions based on CnA alpha-/- mice are revisited to determine which aspects of the phenotype were attributable to caloric restriction versus a direct role for CnA alpha. In this study, we find that defects in renal development and function persist in adult CnA alpha-/- mice including a significant decrease in glomerular filtration rate and an increase in blood urea nitrogen levels. These data indicate that impaired renal development we previously reported was not due to caloric restriction but rather a specific role for CnA alpha in renal development and function. In contrast, we find that rather than being hypoglycemic, rescued mice are mildly hyperglycemic and insulin resistant. Examination of muscle fiber types shows that previously reported reductions in type I muscle fibers are no longer evident in rescued null mice. Rather, loss of CnA alpha likely alters insulin response due to a reduction in insulin receptor substrate-2 (IRS2) expression and signaling in muscle. This study illustrates the importance of re-examining the phenotypes of CnA alpha-/- mice and the advances that are now possible with the use of adult, rescued knockout animals.	[Williams, Clintoria R.; Gooch, Jennifer L.] Atlanta Vet Adm Med Ctr, Decatur, GA USA; [Madsen, Kirsten; Reddy, Ramesh N.; Price, S. Russ; Williams, Clintoria R.; Gooch, Jennifer L.] Emory Univ, Sch Med, Dept Med, Div Nephrol, Atlanta, GA USA; [Madsen, Kirsten] Univ Southern Denmark, Dept Cardiovasc & Renal Res, Odense, Denmark	Emory University; University of Southern Denmark	Gooch, JL (corresponding author), Atlanta Vet Adm Med Ctr, Decatur, GA USA.	jgooch@emory.edu			Department of Veterans Affairs; Presidential Early Career Award for Scientists and Engineers; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [DK50740, DK95610]; Danish Heart Foundation; Lundbeck Foundation; Hoerslev Foundation; Danish Medical Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK095610, T32DK007656, R01DK050740] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001456] Funding Source: NIH RePORTER; Novo Nordisk Fonden [NNF13OC0006215] Funding Source: researchfish	Department of Veterans Affairs(US Department of Veterans Affairs); Presidential Early Career Award for Scientists and Engineers(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Danish Heart Foundation; Lundbeck Foundation(Lundbeckfonden); Hoerslev Foundation; Danish Medical Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs); Novo Nordisk Fonden(Novo Nordisk Foundation)	Funding for this research was provided by the Department of Veterans Affairs, Presidential Early Career Award for Scientists and Engineers (JLG), and National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases DK50740 and DK95610 (SRP). In addition, the authors thank the Danish Heart Foundation, the Lundbeck Foundation, the Hoerslev Foundation and the Danish Medical Foundation for financial support (KM). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bailey JL, 2006, J AM SOC NEPHROL, V17, P1388, DOI 10.1681/ASN.2004100842; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P9398, DOI 10.1073/pnas.152665399; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; BUTTINI M, 1993, N-S ARCH PHARMACOL, V348, P679, DOI 10.1007/BF00167247; Gooch JL, 2007, TRANSPLANTATION, V83, P439, DOI 10.1097/01.tp.0000251423.78124.51; Gooch JL, 2006, J CELL SCI, V119, P2468, DOI 10.1242/jcs.02971; Gooch JL, 2004, AM J PATHOL, V165, P1755, DOI 10.1016/S0002-9440(10)63430-X; Gooch JL, 2006, AM J PHYSIOL-RENAL, V290, pF769, DOI 10.1152/ajprenal.00281.2005; Gooch JL, 2003, AM J PHYSIOL-RENAL, V284, pF144, DOI 10.1152/ajprenal.00158.2002; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Kelly FM, 2009, AM J PHYSIOL-RENAL, V296, pF512, DOI 10.1152/ajprenal.90629.2008; Kim M, 2010, EXP DERMATOL, V19, P501, DOI 10.1111/j.1600-0625.2009.00941.x; Komhoff M, 2000, KIDNEY INT, V57, P414; Norwood VF, 2000, KIDNEY INT, V58, P2291, DOI 10.1046/j.1523-1755.2000.00413.x; Parsons SA, 2004, J BIOL CHEM, V279, P26192, DOI 10.1074/jbc.M313800200; Parsons SA, 2003, MOL CELL BIOL, V23, P4331, DOI 10.1128/MCB.23.12.4331-4343.2003; Pena JA, 2009, J INVEST DERMATOL; Pena JA, 2010, J INVEST DERMATOL, V130, P135, DOI 10.1038/jid.2009.222; Puri S, 2004, J BIOL CHEM, V279, P55455, DOI 10.1074/jbc.M402905200; Reddy RN, 2011, AM J PATHOL, V178, P1605, DOI 10.1016/j.ajpath.2010.12.054; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Ryder JW, 2003, J BIOL CHEM, V278, P44298, DOI 10.1074/jbc.M304510200; Satoh S, 2008, NEUROPHARMACOLOGY, V55, P71, DOI 10.1016/j.neuropharm.2008.04.015; Schreuder MF, 2006, AM J PHYSIOL-RENAL, V291, pF1104, DOI 10.1152/ajprenal.00158.2006; Sun L, 2005, P NATL ACAD SCI USA, V102, P17130, DOI 10.1073/pnas.0508480102; Sun L, 2007, ANN NY ACAD SCI, V1116, P216, DOI 10.1196/annals.1402.050; Wlodek ME, 2008, KIDNEY INT, V74, P187, DOI 10.1038/ki.2008.153; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	30	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62503	10.1371/journal.pone.0062503	http://dx.doi.org/10.1371/journal.pone.0062503			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23638102	Green Published, gold, Green Submitted			2023-01-03	WOS:000319077300071
J	Ambroggio, EE; Sillibourne, J; Antonny, B; Manneville, JB; Goud, B				Ambroggio, Ernesto E.; Sillibourne, James; Antonny, Bruno; Manneville, Jean-Baptiste; Goud, Bruno			Arf1 and Membrane Curvature Cooperate to Recruit Arfaptin2 to Liposomes	PLOS ONE			English	Article							BIN/AMPHIPHYSIN/RVS BAR DOMAIN; ADP-RIBOSYLATION FACTORS; RAC1-INTERACTING PROTEIN; AMPHIPATHIC HELICES; MYRISTOYLATED ARF1; STRUCTURAL BASIS; ARL1; BINDING	Arfaptin2 contains a Bin/Amphiphysin/Rvs (BAR) domain and directly interacts with proteins of the Arf/Arl family in their active GTP-bound state. It has been proposed that BAR domains are able to sense membrane curvature and to induce membrane tubulation. We report here that active Arf1 is required for the recruitment of Arfaptin2 to artificial liposomes mimicking the Golgi apparatus lipid composition. The Arf1-dependent recruitment of Arfaptin2 increases with membrane curvature, while the recruitment of Arf1 itself is not sensitive to curvature. At high protein concentrations, the binding of Arfaptin2 induces membrane tubulation. Finally, membrane-bound Arfaptin2 is released from the liposome when ArfGAP1 catalyzes the hydrolysis of GTP to GDP in Arf1. These results show that both Arf1 activation and high membrane curvature are required for efficient recruitment of Arfaptin2 to membranes.	[Ambroggio, Ernesto E.] Univ Nacl Cordoba, Ctr Invest Quim Biol Cordoba CIQUIBIC, Lab Biofis Biomembranas, Dept Quim Biol,Fac Ciencias Quim,UNC CONICET, RA-5000 Cordoba, Argentina; [Sillibourne, James; Manneville, Jean-Baptiste; Goud, Bruno] Inst Curie, CNRS, UMR 144, Lab Mecanismes Mol Transport Intracellulaire, F-75231 Paris, France; [Antonny, Bruno] Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, Valbonne, France; [Antonny, Bruno] CNRS, F-06560 Valbonne, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS)	Ambroggio, EE (corresponding author), Univ Nacl Cordoba, Ctr Invest Quim Biol Cordoba CIQUIBIC, Lab Biofis Biomembranas, Dept Quim Biol,Fac Ciencias Quim,UNC CONICET, RA-5000 Cordoba, Argentina.	ambroggioernesto@yahoo.com; Jean-Baptiste.Manneville@curie.fr; Bruno.Goud@curie.fr	Antonny, Bruno/ABH-7434-2020; Manneville, Jean-Baptiste/L-5914-2019; Goud, Bruno/GWC-4807-2022	Antonny, Bruno/0000-0002-9166-8668; Manneville, Jean-Baptiste/0000-0002-8670-3940; Sillibourne, James/0000-0001-6755-3644	Centre National de la Recherche Scientifique (CNRS); Institut Curie; Agence Nationale de la Recherche [ANR-05-BLAN-0095]	Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut Curie; Agence Nationale de la Recherche(French National Research Agency (ANR))	This work was supported by the Centre National de la Recherche Scientifique (CNRS), the Institut Curie, and a grant from the Agence Nationale de la Recherche (ANR-05-BLAN-0095). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambroggio E, 2010, EMBO J, V29, P292, DOI 10.1038/emboj.2009.341; ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303, DOI 10.1039/dc9868100303; Bhatia VK, 2010, SEMIN CELL DEV BIOL, V21, P381, DOI 10.1016/j.semcdb.2009.12.004; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Blood PD, 2006, P NATL ACAD SCI USA, V103, P15068, DOI 10.1073/pnas.0603917103; Campelo F, 2010, FEBS LETT, V584, P1830, DOI 10.1016/j.febslet.2009.10.023; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; Gallop JL, 2005, BIOCHEM SOC SYMP, V72, P223, DOI 10.1042/bss0720223; Ha VL, 2005, METHOD ENZYMOL, V404, P164, DOI 10.1016/S0076-6879(05)04016-4; Hatzakis NS, 2009, NAT CHEM BIOL, V5, P835, DOI 10.1038/nchembio.213; Liu YZ, 2009, STRUCTURE, V17, P79, DOI 10.1016/j.str.2008.10.020; Lu L, 2001, J CELL SCI, V114, P4543; Man ZQ, 2011, J BIOL CHEM, V286, P11569, DOI 10.1074/jbc.M110.201442; Manneville JB, 2008, P NATL ACAD SCI USA, V105, P16946, DOI 10.1073/pnas.0807102105; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Nakamura K, 2012, J BIOL CHEM, V287, P25478, DOI 10.1074/jbc.M112.365783; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Peters PJ, 2002, NAT CELL BIOL, V4, P240, DOI 10.1038/ncb761; Rangone H, 2005, J BIOL CHEM, V280, P22021, DOI 10.1074/jbc.M407528200; Roux A, 2002, P NATL ACAD SCI USA, V99, P5394, DOI 10.1073/pnas.082107299; Shin OH, 2001, BIOCHEM BIOPH RES CO, V285, P1267, DOI 10.1006/bbrc.2001.5330; Stachowiak JC, 2012, NAT CELL BIOL; Tarricone C, 2001, NATURE, V411, P215, DOI 10.1038/35075620; Thoresen T, 2008, BIOCHEMISTRY-US, V47, P9514, DOI 10.1021/bi800747e; Van Valkenburgh H, 2001, J BIOL CHEM, V276, P22826, DOI 10.1074/jbc.M102359200; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x	27	10	11	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2013	8	4							e62963	10.1371/journal.pone.0062963	http://dx.doi.org/10.1371/journal.pone.0062963			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	181JC	23638170	gold, Green Submitted, Green Published			2023-01-03	WOS:000321662800069
J	Farroni, JS; Zwelling, L; Cortes, J; Kantarjian, H				Farroni, Jeffrey S.; Zwelling, Leonard; Cortes, Jorge; Kantarjian, Hagop			Saving Medicare through Patient-Centered Changes - The Case of Injectables	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Farroni, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, Dept Crit Care, Houston, TX 77030 USA; [Zwelling, Leonard] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Cortes, Jorge; Kantarjian, Hagop] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Farroni, JS (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Crit Care, Houston, TX 77030 USA.			Cortes, Jorge/0000-0002-8636-1071	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bach P, 2012, NY TIMES; Centers for Medicare & Medicaid Services, CMS PUB, V10-02; Goldberg SL, 2010, J CLIN ONCOL, V28, P2847, DOI 10.1200/JCO.2009.25.2395; Himmelstein DU, 2012, ARCH INTERN MED, V172, P1764, DOI 10.1001/2013.jamainternmed.272	4	6	6	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	2013	368	17					1572	1573		10.1056/NEJMp1213485	http://dx.doi.org/10.1056/NEJMp1213485			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130YK	23614583				2023-01-03	WOS:000317956300005
J	Loureiro, J; Sandoval, P; del Peso, G; Gonzalez-Mateo, G; Fernandez-Millara, V; Santamaria, B; Bajo, MA; Sanchez-Tomero, JA; Guerra-Azcona, G; Selgas, R; Lopez-Cabrera, M; Aguilera, AI				Loureiro, Jesus; Sandoval, Pilar; del Peso, Gloria; Gonzalez-Mateo, Guadalupe; Fernandez-Millara, Vanessa; Santamaria, Beatriz; Auxiliadora Bajo, Maria; Antonio Sanchez-Tomero, Jose; Guerra-Azcona, Gonzalo; Selgas, Rafael; Lopez-Cabrera, Manuel; Aguilera, Abelardo I.			Tamoxifen Ameliorates Peritoneal Membrane Damage by Blocking Mesothelial to Mesenchymal Transition in Peritoneal Dialysis	PLOS ONE			English	Article							SCLEROSING ENCAPSULATING PERITONITIS; IN-VITRO; MYOFIBROBLASTIC CONVERSION; CELLS; ESTROGEN; MECHANISMS; PROTECTS; FAILURE; INTACT; MICE	Mesothelial-to-mesenchymal transition (MMT) is an auto-regulated physiological process of tissue repair that in uncontrolled conditions such as peritoneal dialysis (PD) can lead to peritoneal fibrosis. The maximum expression of peritoneal fibrosis induced by PD fluids and other peritoneal processes is the encapsulating peritoneal sclerosis (EPS) for which no specific treatment exists. Tamoxifen, a synthetic estrogen, has successfully been used to treat retroperitoneal fibrosis and EPS associated with PD. Hence, we used in vitro and animal model approaches to evaluate the efficacy of Tamoxifen to inhibit the MMT as a trigger of peritoneal fibrosis. In vitro studies were carried out using omentum-derived mesothelial cells (MCs) and effluent-derived MCs. Tamoxifen blocked the MMT induced by transforming growth factor (TGF)-beta 1, as it preserved the expression of E-cadherin and reduced the expression of mesenchymal-associated molecules such as snail, fibronectin, collagen-I, alpha-smooth muscle actin, and matrix metalloproteinse-2. Tamoxifen-treatment preserved the fibrinolytic capacity of MCs treated with TGF-beta 1 and decreased their migration capacity. Tamoxifen did not reverse the MMT of non-epitheliod MCs from effluents, but it reduced the expression of some mesenchymal molecules. In mice PD model, we demonstrated that MMT progressed in parallel with peritoneal membrane thickness. In addition, we observed that Tamoxifen significantly reduced peritoneal thickness, angiogenesis, invasion of the compact zone by mesenchymal MCs and improved peritoneal function. Tamoxifen also reduced the effluent levels of vascular endothelial growth factor and leptin. These results demonstrate that Tamoxifen is a therapeutic option to treat peritoneal fibrosis, and that its protective effect is mediated via modulation of the MMT process.	[Loureiro, Jesus; Sandoval, Pilar; Lopez-Cabrera, Manuel] CSIC UAM, Ctr Biol Mol Severo Ochoa, Madrid, Spain; [del Peso, Gloria; Gonzalez-Mateo, Guadalupe; Fernandez-Millara, Vanessa; Auxiliadora Bajo, Maria; Selgas, Rafael] Hosp Univ La Paz, Inst Invest Sanitaria La Paz IdiPAZ, Serv Nefrol, Madrid, Spain; [Santamaria, Beatriz] Fdn Jimenez Diaz, Unidad Dialisis, E-28040 Madrid, Spain; [Santamaria, Beatriz] Fdn Jimenez Diaz, Lab Invest Renal & Vasc, E-28040 Madrid, Spain; [Antonio Sanchez-Tomero, Jose; Aguilera, Abelardo I.] Hosp Univ Princesa, Inst Invest Sanitaria Princesa IP, Unidad Biol Mol, Madrid, Spain; [Antonio Sanchez-Tomero, Jose; Aguilera, Abelardo I.] Hosp Univ Princesa, Inst Invest Sanitaria Princesa IP, Serv Nefrol, Madrid, Spain; [Guerra-Azcona, Gonzalo] Hosp Quiron San Camilo, Serv Cirugia, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Hospital Universitario La Paz	Aguilera, AI (corresponding author), Hosp Univ Princesa, Inst Invest Sanitaria Princesa IP, Unidad Biol Mol, Madrid, Spain.	abelardo.aguilera@salud.madrid.org	González-Mateo, Guadalupe T/G-2551-2016; Santamaria, Beatriz/B-3469-2015; Sandoval, Pilar/GVS-6463-2022; Cabrera, Manuel López/AAA-5463-2019; González-Mateo, Guadalupe Tirma/AAS-5509-2021; SANCHEZ TOMERO, JOSE ANTONIO/Q-9346-2017; Bajo, Maria A/ABF-6991-2020	González-Mateo, Guadalupe T/0000-0002-8144-904X; Santamaria, Beatriz/0000-0002-1990-2106; Sandoval, Pilar/0000-0002-5893-7037; González-Mateo, Guadalupe Tirma/0000-0002-8144-904X; Bajo, Maria A/0000-0001-7364-557X; Lopez Cabrera, Manuel/0000-0002-0976-9719; Loureiro, Jesus/0000-0003-4307-1303	"Ministerio de Economia y Competitividad" [SAF2010-21249]; "Comunidad Autonoma de Madrid" [S2010/BMD-2321]; "Fondo de Investigaciones Sanitarias" [PI 09/0776]; REDinREN, Fondos FEDER, EU [RETICS 06/0016]	"Ministerio de Economia y Competitividad"(Spanish Government); "Comunidad Autonoma de Madrid"(Comunidad de Madrid); "Fondo de Investigaciones Sanitarias"(Instituto de Salud Carlos III); REDinREN, Fondos FEDER, EU	This work was supported by grant SAF2010-21249 from the "Ministerio de Economia y Competitividad" to MLC and by grant S2010/BMD-2321 from "Comunidad Autonoma de Madrid" to MLC and RS. This work was also partially supported by grants PI 09/0776 from "Fondo de Investigaciones Sanitarias" to AA, and RETICS 06/0016 (REDinREN, Fondos FEDER, EU) to RS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilera Abelardo, 2005, Curr Opin Investig Drugs, V6, P262; Allaria PM, 1999, J NEPHROL, V12, P395; Aroeira LS, 2005, AM J KIDNEY DIS, V46, P938, DOI 10.1053/j.ajkd.2005.08.011; Aroeira LS, 2007, J AM SOC NEPHROL, V18, P2004, DOI 10.1681/ASN.2006111292; Balasubramaniam G, 2009, NEPHROL DIAL TRANSPL, V24, P3209, DOI 10.1093/ndt/gfp008; Blackwell KL, 2000, CLIN CANCER RES, V6, P4359; Cakmak A, 2005, AM J OBSTET GYNECOL, V193, P347, DOI 10.1016/j.ajog.2005.01.023; Christodoulakos GE, 2006, ANN NY ACAD SCI, V1092, P374, DOI 10.1196/annals.1365.034; CLARK CP, 1991, SURGERY, V109, P502; del Peso G, 2008, KIDNEY INT, V73, pS26, DOI 10.1038/sj.ki.5002598; del Peso Gloria, 2003, Adv Perit Dial, V19, P32; Delle H, 2012, J AM SOC NEPHROL, V23, P37, DOI 10.1681/ASN.2011010046; Devuyst O, 2010, J AM SOC NEPHROL, V21, P1077, DOI 10.1681/ASN.2009070694; Dhandapani KM, 2003, ENDOCRINE, V21, P59, DOI 10.1385/ENDO:21:1:59; Guo KY, 2007, ENDOCRINOLOGY, V148, P3987, DOI 10.1210/en.2007-0261; Hashimoto M, 1997, BIOCHEM BIOPH RES CO, V240, P464, DOI 10.1006/bbrc.1997.7681; Hausman GJ, 2004, J ANIM SCI, V82, P925; Hozumi Y, 2005, GYNECOL OBSTET INVES, V59, P70, DOI 10.1159/000082111; Huang JW, 2011, BLOOD PURIFICAT, V31, P252, DOI 10.1159/000322255; ISSANDOU M, 1990, CANCER RES, V50, P5845; Justo P, 2003, J AM SOC NEPHROL, V14, P3072, DOI 10.1097/01.ASN.0000099383.57934.0E; Kawanishi H, 2005, INT J ARTIF ORGANS, V28, P150, DOI 10.1177/039139880502800211; Korte MR, 2011, NEPHROL DIAL TRANSPL, V26, P691, DOI 10.1093/ndt/gfq362; Krediet RT, 2000, PERITON DIALYSIS INT, V20, pS19; Leung JCK, 2006, KIDNEY INT, V69, P2078, DOI 10.1038/sj.ki.5000409; Lopez-Cabrera M, 2006, PERITON DIALYSIS INT, V26, P26; Loureiro J, 2011, J AM SOC NEPHROL, V22, P1682, DOI 10.1681/ASN.2010111197; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Margetts PJ, 2003, PERITON DIALYSIS INT, V23, P530; Mele T, 2010, BREAST CANCER RES TR, V123, P795, DOI 10.1007/s10549-010-1063-0; Nomoto Y, 1996, AM J KIDNEY DIS, V28, P420, DOI 10.1016/S0272-6386(96)90501-6; Park WC, 2002, TRENDS MOL MED, V8, P82, DOI 10.1016/S1471-4914(02)02282-7; Reckless J, 1997, CIRCULATION, V95, P1542; Sandoval P, 2010, LAB INVEST, V90, P1517, DOI 10.1038/labinvest.2010.111; Selgas R, 2000, PERITON DIALYSIS INT, V20, P595; Shao ZM, 2000, CANCER LETT, V157, P133, DOI 10.1016/S0304-3835(00)00466-3; Sourla A, 1997, ENDOCRINOLOGY, V138, P5605, DOI 10.1210/en.138.12.5605; Strippoli R, 2008, DIS MODEL MECH, V1, P264, DOI 10.1242/dmm.001321; Tanos V, 2002, EUR J OBSTET GYN R B, V102, P188, DOI 10.1016/S0301-2115(01)00582-6; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809; Yang AH, 2003, KIDNEY INT, V63, P1530, DOI 10.1046/j.1523-1755.2003.00861.x; Yang AH, 2007, NEPHROL DIAL TRANSPL, V22, P756, DOI 10.1093/ndt/gfl715; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433	43	44	50	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e61165	10.1371/journal.pone.0061165	http://dx.doi.org/10.1371/journal.pone.0061165			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131QH	23637793	gold, Green Published, Green Submitted			2023-01-03	WOS:000318008400028
J	Choi, J; Kim, TH; Choi, TY; Lee, MS				Choi, Jiae; Kim, Tae-Hun; Choi, Tae-Young; Lee, Myeong Soo			Ginseng for Health Care: A Systematic Review of Randomized Controlled Trials in Korean Literature	PLOS ONE			English	Review							RED GINSENG; DOUBLE-BLIND; EFFICACY; SUPPLEMENTATION; STIFFNESS; DISEASE	Objective: This systematic review was performed to summarise randomised clinical trials (RCTs) assessing the efficacy and safety of ginseng in the Korean literature. Method: The study involved systematic searches conducted in eight Korean Medical databases. The methodological quality of all of the included studies was assessed using the Cochrane Risk of Bias tool. We included all RCTs on any type of ginseng compared to placebo, active treatment or no treatment in healthy individuals or patients regardless of conditions. Results: In total, 1415 potentially relevant studies were identified, and 30 randomised clinical trials were included. Nine RCTs assessed the effects of ginseng on exercise capacity, cognitive performance, somatic symptoms, quality of life, and sleeping in healthy persons. Six RCTs tested ginseng compared with placebo for erectile dysfunction, while another four studies evaluated the effects of ginseng against no treatment for gastric and colon cancer. Two RCTs compared the effect of red ginseng on diabetes mellitus with no treatment or placebo, and the other nine RCTs assessed the effects of ginseng compared with placebo or no treatment on various conditions. The methodological caveats of the included trials make their contribution to the current clinical evidence of ginseng somewhat limited. However, the 20 newly added trials (66.7% of the 30 trials) may provide useful information for future trials. Ginseng appears to be generally safe, and no serious adverse effects have been reported. Conclusions: The clinical effects of ginseng have been tested in a wide range of conditions in Korea. Although the quality of RCTs published in the Korean literature was generally poor, this review is useful for researchers to access studies that were originally published in languages that they would otherwise be unable to read and due to the paucity of evidence on this subject.	[Choi, Jiae; Choi, Tae-Young; Lee, Myeong Soo] Korea Inst Oriental Med, Div Med Res, Taejon, South Korea; [Kim, Tae-Hun] Mokhuri Neck & Back Hosp, Dept Spine Ctr, Seoul, South Korea	Korea Institute of Oriental Medicine (KIOM)	Lee, MS (corresponding author), Korea Inst Oriental Med, Div Med Res, Taejon, South Korea.	drmslee@gmail.com	Lee, Myeong Soo/C-8147-2013; Kim, Tae-Hun/G-8728-2014	Lee, Myeong Soo/0000-0001-6651-7641; Kim, Tae-Hun/0000-0002-8448-3219	KIOM [K13400, C12080]	KIOM	JC, TYC and MSL were supported by KIOM (K13400 and C12080). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An XD, 2011, RESP MED, V105, P165, DOI 10.1016/j.rmed.2010.11.007; 김덕기, 2007, [The Korean Journal of Medicine, 대한내과학회지], V72, P20; 권동현, 2011, [Journal of Korean Medicine for Obesity Research, 한방비만학회지], V11, P1; Buettner C, 2006, ANN PHARMACOTHER, V40, P83, DOI 10.1345/aph.1G216; Cherdrungsi P, 1995, J GINSENG RES, V19, P93; Cho GH., 2005, J GINSENG RES, V29, P27; Choi HK., 1999, J GINSENG RES, V23, P247; Choi HK., 2001, J GINSENG RES, V25, P112; Choi K.M., 1997, KOREAN J GINSENG SCI, V21, P153; Christensen LP, 2009, ADV FOOD NUTR RES, V55, P1, DOI 10.1016/S1043-4526(08)00401-4; Chung IM, 2010, J GINSENG RES, V34, P212, DOI 10.5142/jgr.2010.34.3.212; Ernst E, 2010, J GINSENG RES, V34, P259, DOI 10.5142/jgr.2010.34.4.259; 김홍식, 2006, The World Journal of Men's Health, V24, P84; Ham Won Sik, 2009, Investigative and Clinical Urology, V50, P159; Helms Steve, 2004, Altern Med Rev, V9, P259; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hong BS., 2001, THESIS U ULSAN ULSAN; Hur MH, 2010, J GINSENG RES, V34, P342, DOI 10.5142/jgr.2010.34.4.342; Hwang MK, 2006, THESIS KYUNG HEE U; Jang DJ, 2008, BRIT J CLIN PHARMACO, V66, P444, DOI 10.1111/j.1365-2125.2008.03236.x; Jeong D-W, 2006, J KOREAN ORIENT MED, V27, P38; Jia YL, 2012, COMPLEMENT THER MED, V20, P155, DOI 10.1016/j.ctim.2011.12.002; Jung, 1998, J GINSENG RES, V22, P32; Kim HO, 2011, THESIS PUSAN NATL U; 서성옥, 2004, Journal of Ginseng Research, V28, P104; Kim NR, 2010, J GINSENG RES, V34, P237, DOI 10.5142/jgr.2010.34.3.237; Kim S, 2011, CHIN J INTEGR MED, V17, P937, DOI 10.1007/s11655-011-0937-2; Kim SK, 2007, J GINSENG RES, V31, P93; Kim SW., 1999, KOREAN J ANDROL, V17, P23; Kulaputana Onanong, 2007, Journal of the Medical Association of Thailand, V90, P1172; Kwon DH, 2012, J GINSENG RES, V36, P176, DOI 10.5142/jgr.2012.36.2.176; Lee MS, 2009, J ALZHEIMERS DIS, V18, P339, DOI 10.3233/JAD-2009-1149; Lee NH, 2011, J ACUPUNCT MERIDIAN, V4, P85, DOI 10.1016/S2005-2901(11)60013-7; Lee NH, 2011, THESIS DAEJEON U; Lee S.A., 2010, SLEEP MED PSYCHOPHYS, V17, P85; Lee S. T., 2007, J GINSENG RES, V31, P51; Lee SJ, 2010, J GINSENG RES, V34, P122, DOI 10.5142/jgr.2010.34.2.122; Lee YH, 2009, THESIS EWHA WOMANS U; O. Kennedy D., 2007, Journal of Ginseng Research, V31, P34; Park BJ, 2012, KOREAN J FAM MED, V33, P190, DOI 10.4082/kjfm.2012.33.4.190; Park JW, 2010, J GINSENG RES, V34, P183, DOI 10.5142/jgr.2010.34.3.183; Rhee MY, 2011, J ALTERN COMPLEM MED, V17, P45, DOI 10.1089/acm.2010.0065; Seely D, 2008, J POPUL THER CLIN PH, V15, pE87; Seida JK, 2011, EVID-BASED COMPL ALT, V2001; Shergis JL, 2013, PHYTOTHER RES, V27, P949, DOI 10.1002/ptr.4832; Shin Kyeong Seob, 2007, Journal of Ginseng Research, V31, P109; Suh Sung Ock, 2007, Journal of Ginseng Research, V31, P54; Vogler BK, 1999, EUR J CLIN PHARMACOL, V55, P567, DOI 10.1007/s002280050674; Yeo HB, 2012, J GINSENG RES, V36, P190, DOI 10.5142/jgr.2012.36.2.190; 이선구, 2007, [Journal of Physiology & Pathology in Korean Medicine, 동의생리병리학회지], V21, P1185; Yoo HY, 1995, J KOREAN SURG SOC, V54, P854; Yoon SJ, 2008, J GINSENG RES, V32; 김재환, 2009, Journal of Ginseng Research, V33, P223; 강은호, 2009, Journal of Ginseng Research, V33, P219; 김동일, 2009, Journal of Ginseng Research, V33, P115; 서정철, 2004, [Journal of Physiology & Pathology in Korean Medicine, 동의생리병리학회지], V18, P606	56	68	71	2	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 1	2013	8	4							e59978	10.1371/journal.pone.0059978	http://dx.doi.org/10.1371/journal.pone.0059978			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	117CY	23560064	Green Published, Green Submitted, gold			2023-01-03	WOS:000316930900039
J	Olle, B				Olle, Bernat			Medicines from microbiota	NATURE BIOTECHNOLOGY			English	Article							INTESTINAL MICROBIOTA; GUT MICROBIOME; CLOSTRIDIUM		[Olle, Bernat] PureTech Ventures, Boston, MA 02116 USA; [Olle, Bernat] Vedanta Biosci, Boston, MA USA		Olle, B (corresponding author), PureTech Ventures, Boston, MA 02116 USA.	bolle@puretechventures.com						Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Blumberg R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004184; Britton RA, 2012, TRENDS MICROBIOL, V20, P313, DOI 10.1016/j.tim.2012.04.001; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Gough E, 2011, CLIN INFECT DIS, V53, P994, DOI 10.1093/cid/cir632; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Kachrimanidou M, 2011, CRIT REV MICROBIOL, V37, P178, DOI 10.3109/1040841X.2011.556598; Khoruts A, 2010, J CLIN GASTROENTEROL, V44, P354, DOI 10.1097/MCG.0b013e3181c87e02; Kuczynski J, 2012, NAT REV GENET, V13, P47, DOI 10.1038/nrg3129; Lawley TD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002995; Papa E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039242; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Tannock GW, 2010, MICROBIOL-SGM, V156, P3354, DOI 10.1099/mic.0.042010-0; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088; Yan F, 2007, GASTROENTEROLOGY, V132, P562, DOI 10.1053/j.gastro.2006.11.022; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053	20	103	123	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2013	31	4					309	315		10.1038/nbt.2548	http://dx.doi.org/10.1038/nbt.2548			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	120TI	23563425				2023-01-03	WOS:000317195500020
J	Wallace, WHB; Thompson, L; Anderson, RA				Wallace, W. H. B.; Thompson, L.; Anderson, R. A.		Guideline Dev Grp	GUIDELINES Long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Wallace, W. H. B.] Royal Hosp Sick Children, Dept Haematol & Oncol, Edinburgh EH9 1LF, Midlothian, Scotland; [Thompson, L.] Healthcare Improvement Scotland, Scottish Intercoll Guidelines Network, Edinburgh EH12 9EB, Midlothian, Scotland; [Anderson, R. A.] Univ Edinburgh, MRC Ctr Reprod Hlth, Queens Med Res Inst, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Wallace, WHB (corresponding author), Royal Hosp Sick Children, Dept Haematol & Oncol, Edinburgh EH9 1LF, Midlothian, Scotland.	hamish.wallace@nhs.net		wallace, william, hamish/0000-0001-8080-5674	MRC [G1002033, G1100357, G1002118] Funding Source: UKRI; Medical Research Council [G1100357, G1002118, G1002033] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], LONG TERM FOLL SURV; Cancer Research UK, CHILH CANC STAT; Children's Oncology Group, 2008, KEEP YOUR HEART HLTH; National Cancer Survivorship Initiative, RISK STRAT PATHW CAR; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Scottish Intercollegiate Guidelines Network, 2004, LONG TERM FOLL SURV; Zeltzer LK, 1997, J CLIN ONCOL, V15, P547, DOI 10.1200/JCO.1997.15.2.547	7	65	66	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 27	2013	346								f1190	10.1136/bmj.f1190	http://dx.doi.org/10.1136/bmj.f1190			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	117WT	23535255				2023-01-03	WOS:000316984500001
J	Xing, MZ; Haugen, BR; Schlumberger, M				Xing, Mingzhao; Haugen, Bryan R.; Schlumberger, Martin			Progress in molecular-based management of differentiated thyroid cancer	LANCET			English	Article							FINE-NEEDLE-ASPIRATION; 2ND PRIMARY MALIGNANCIES; BRAF V600E MUTATION; LONG-TERM SURVEILLANCE; LYMPH-NODE METASTASIS; PHASE-II TRIAL; RADIOACTIVE IODINE; BRAF(V600E) MUTATION; GENETIC ALTERATIONS; RADIOIODINE UPTAKE	Substantial developments have occurred in the past 5-10 years in clinical translational research of thyroid cancer. Diagnostic molecular markers, such as RET-PTC, RAS, and BRAF(V600E) mutations; galectin 3; and a new gene expression classifier, are outstanding examples that have improved diagnosis of thyroid nodules. BRAF mutation is a prognostic genetic marker that has improved risk stratification and hence tailored management of patients with thyroid cancer, including those with conventionally low risks. Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials; such treatments are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future. These novel molecular-based management strategies for thyroid nodules and thyroid cancer are the most exciting developments in this unprecedented era of molecular thyroid-cancer medicine.	[Xing, Mingzhao] Johns Hopkins Univ, Lab Cellular & Mol Thyroid Res, Div Endocrinol & Metab, Sch Med, Baltimore, MD 21287 USA; [Haugen, Bryan R.] Univ Colorado, Div Endocrinol Metab & Diabet, Sch Med, Aurora, CO USA; [Schlumberger, Martin] Inst Gustave Roussy, Dept Nucl Med & Endocrine Oncol, Ctr Reference Tumeurs Refractaires Thyroide, Villejuif, France; [Schlumberger, Martin] Univ Paris Sud, Villejuif, France	Johns Hopkins University; University of Colorado System; University of Colorado Anschutz Medical Campus; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Xing, MZ (corresponding author), Johns Hopkins Univ, Div Endocrinol & Metab, Sch Med, Baltimore, MD 21287 USA.	mxing1@jhmi.edu			Ardea Biosciences; Veracyte; Amgen; AstraZeneca; Bayer; Eisai; Exelixis; Genzyme; United States National Institutes of Health [R01CA134225, R01CA113507]; French National Cancer Institute; NATIONAL CANCER INSTITUTE [R01CA113507, R01CA134225] Funding Source: NIH RePORTER	Ardea Biosciences; Veracyte; Amgen(Amgen); AstraZeneca(AstraZeneca); Bayer(Bayer AG); Eisai(Eisai Co Ltd); Exelixis; Genzyme(Sanofi-AventisGenzyme Corporation); United States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); French National Cancer Institute(Institut National du Cancer (INCA) France); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	MX is coholder of a patent related to BRAF mutation and has received research support from Ardea Biosciences; BRH has received research support from Veracyte; and MS has received research funding from Amgen, AstraZeneca, Bayer, Eisai, Exelixis, and Genzyme.; The authors' effort for this manuscript is supported by the United States National Institutes of Health grants R01CA134225 and R01CA113507 to MX; Mary Rossick Kern and Jerome H Kern endowment for BRH; and a grant from the French National Cancer Institute to MS.	Abubaker J, 2008, J CLIN ENDOCR METAB, V93, P611, DOI 10.1210/jc.2007-1717; Agretti P, 2012, EUR J ENDOCRINOL, V167, P393, DOI 10.1530/EJE-12-0400; Ahmed M, 2011, EUR J ENDOCRINOL, V165, P315, DOI 10.1530/EJE-11-0129; Alexander EK, 2012, NEW ENGL J MED, V367, P705, DOI 10.1056/NEJMoa1203208; Alzahrani AS, 2013, ENDOCR-RELAT CANCER, V20, P13, DOI 10.1530/ERC-12-0309; Ball DW, 2012, ASCO ANN M JUN 1 5 C; Baloch ZW, 2008, DIAGN CYTOPATHOL, V36, P425, DOI 10.1002/dc.20830; Barollo S, 2010, EUR J ENDOCRINOL, V163, P659, DOI 10.1530/EJE-10-0290; Bartolazzi A, 2008, LANCET ONCOL, V9, P543, DOI 10.1016/S1470-2045(08)70132-3; Basolo F, 2010, J CLIN ENDOCR METAB, V95, P4197, DOI 10.1210/jc.2010-0337; Bass MB, 2010, J CLIN ENDOCR METAB, V95, P5018, DOI 10.1210/jc.2010-0947; Bayer HealthCare Pharmaceuticals Onyx Pharmaceuticals, 2013, PHAS 3 DECISION TRIA; Bible KC, 2010, LANCET ONCOL, V11, P962, DOI 10.1016/S1470-2045(10)70203-5; Brown AP, 2008, J CLIN ENDOCR METAB, V93, P504, DOI 10.1210/jc.2007-1154; Brown RL, 2011, J CANCER, V2, P193, DOI 10.7150/jca.2.193; Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0; Cabanillas ME, 2012, J CLIN ONCOL, V30; Cantara S, 2010, J CLIN ENDOCR METAB, V95, P1365, DOI 10.1210/jc.2009-2103; Carr LL, 2010, CLIN CANCER RES, V16, P5260, DOI 10.1158/1078-0432.CCR-10-0994; Chakravarty D, 2011, J CLIN INVEST, V121, P4700, DOI 10.1172/JCI46382; Chudova D, 2010, J CLIN ENDOCR METAB, V95, P5296, DOI 10.1210/jc.2010-1087; Cohen EEW, 2008, J CLIN ONCOL, V26, P4708, DOI 10.1200/JCO.2007.15.9566; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Crouzeix G, 2012, J CLIN ENDOCR METAB, V97, P3046, DOI 10.1210/jc.2012-1630; de la Chapelle A, 2011, J CLIN ENDOCR METAB, V96, P3326, DOI 10.1210/jc.2011-1004; Deandreis D, 2011, ENDOCR-RELAT CANCER, V18, P159, DOI 10.1677/ERC-10-0233; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; Durante C, 2006, J CLIN ENDOCR METAB, V91, P2892, DOI 10.1210/jc.2005-2838; Durante C, 2012, J CLIN ENDOCR METAB, V97, P2748, DOI 10.1210/jc.2012-1123; Elisei R, 2008, J CLIN ENDOCR METAB, V93, P3943, DOI 10.1210/jc.2008-0607; Elisei R, 2012, J CLIN ENDOCR METAB, V97, P4390, DOI 10.1210/jc.2012-1775; Fadda G, 2011, EUR J ENDOCRINOL, V165, P447, DOI 10.1530/EJE-11-0181; Fagin JA, 2004, J ENDOCRINOL, V183, P249, DOI 10.1677/joe.1.05895; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Fallahi B, 2011, CLIN NUCL MED, V36, P277, DOI 10.1097/RLU.0b013e31820a9fe3; Faroux MJ, 1997, PATHOL RES PRACT, V193, P705, DOI 10.1016/S0344-0338(97)80030-1; Ferraz C, 2011, J CLIN ENDOCR METAB, V96, P2016, DOI 10.1210/jc.2010-2567; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Franco C, 2009, APPL IMMUNOHISTO M M, V17, P211, DOI 10.1097/PAI.0b013e31818935a9; Fukahori M, 2012, THYROID, V22, P683, DOI 10.1089/thy.2011.0261; Garcia-Rostan G, 2003, J CLIN ONCOL, V21, P3226, DOI 10.1200/JCO.2003.10.130; Guerra A, 2011, ENDOCR J, V58, P31, DOI 10.1507/endocrj.K10E-260; Gupta-Abramson V, 2008, J CLIN ONCOL, V26, P4714, DOI 10.1200/JCO.2008.16.3279; Guth S, 2009, EUR J CLIN INVEST, V39, P699, DOI 10.1111/j.1365-2362.2009.02162.x; Hay ID, 2008, SURGERY, V144, P980, DOI 10.1016/j.surg.2008.08.035; Henderson YC, 2009, CLIN CANCER RES, V15, P485, DOI 10.1158/1078-0432.CCR-08-0933; Ho AL, 2013, NEW ENGL J MED, V368, P623, DOI 10.1056/NEJMoa1209288; Hoftijzer H, 2009, EUR J ENDOCRINOL, V161, P923, DOI 10.1530/EJE-09-0702; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Hou P, 2010, J CLIN ENDOCR METAB, V95, P820, DOI 10.1210/jc.2009-1888; Howell GM, 2013, ANN SURG ONCOL, V20, P47, DOI 10.1245/s10434-012-2611-0; Howlader N, 2011, SEER CANC STAT REV 1; Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jonklaas J, 2010, THYROID, V20, P1423, DOI 10.1089/thy.2010.0308; Joo JY, 2012, J CLIN ENDOCR METAB, V97, P3996, DOI 10.1210/jc.2012-2444; Kebebew E, 2007, ANN SURG, V246, P466, DOI 10.1097/SLA.0b013e318148563d; Keutgen XM, 2012, CLIN CANCER RES, V18, P2032, DOI 10.1158/1078-0432.CCR-11-2487; Kim TH, 2012, CANCER-AM CANCER SOC, V118, P1764, DOI 10.1002/cncr.26500; Kim TY, 2006, CLIN ENDOCRINOL, V65, P364, DOI 10.1111/j.1365-2265.2006.02605.x; Kloos RT, 2009, J CLIN ONCOL, V27, P1675, DOI 10.1200/JCO.2008.18.2717; Kouniavsky G, 2012, J SURG ONCOL, V105, P438, DOI 10.1002/jso.21935; Lang BHH, 2012, SURGERY, V151, P844, DOI 10.1016/j.surg.2011.12.019; Leboulleux S, 2012, LANCET ONCOL, V13, P897, DOI 10.1016/S1470-2045(12)70335-2; Leenhardt L, 2004, THYROID, V14, P1056, DOI 10.1089/thy.2004.14.1056; Li H, 2011, J CLIN ENDOCR METAB, V96, pE1719, DOI 10.1210/jc.2011-0459; Lin KL, 2010, ANN SURG ONCOL, V17, P3294, DOI 10.1245/s10434-010-1129-6; Liu DX, 2007, CLIN CANCER RES, V13, P1341, DOI 10.1158/1078-0432.CCR-06-1753; Liu DX, 2009, CANCER RES, V69, P7311, DOI 10.1158/0008-5472.CAN-09-1077; Liu RX, 2011, J CLIN ENDOCR METAB, V96, pE577, DOI 10.1210/jc.2010-2644; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Mallick U, 2012, NEW ENGL J MED, V366, P1674, DOI 10.1056/NEJMoa1109589; Massicotte M, 2012, 82 ANN M AM THYR ASS; MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; McLeod DSA, 2013, LANCET, V381, P1046, DOI 10.1016/S0140-6736(12)62205-3; Mian C, 2008, CLIN ENDOCRINOL, V68, P108, DOI 10.1111/j.1365-2265.2007.03008.x; Milas M, 2010, ANN SURG, V252, P643, DOI 10.1097/SLA.0b013e3181f5ba51; Miyauchi A, 2011, THYROID, V21, P707, DOI 10.1089/thy.2010.0355; Moses W, 2010, WORLD J SURG, V34, P2589, DOI 10.1007/s00268-010-0720-0; Murugan AK, 2011, CANCER RES, V71, P4403, DOI 10.1158/0008-5472.CAN-10-4041; Musuuza JS, 2012, J CLIN ONCOL, V30; Nikiforov YE, 2011, J CLIN ENDOCR METAB, V96, P3390, DOI 10.1210/jc.2011-1469; Nikiforov YE, 2009, J CLIN ENDOCR METAB, V94, P2092, DOI 10.1210/jc.2009-0247; Nikiforova MN, 2009, THYROID, V19, P1351, DOI 10.1089/thy.2009.0240; Noguchi S, 2008, WORLD J SURG, V32, P747, DOI 10.1007/s00268-007-9453-0; O'Neill CJ, 2010, SURGERY, V148, P1139, DOI 10.1016/j.surg.2010.09.005; Pelizzo MR, 2011, CLIN CHEM LAB MED, V49, P325, DOI 10.1515/CCLM.2011.031; Popadich A, 2011, SURGERY, V150, P1048, DOI 10.1016/j.surg.2011.09.003; Prescott JD, 2012, SURGERY, V152, P984, DOI 10.1016/j.surg.2012.08.039; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Riesco-Eizaguirre G, 2006, ENDOCR-RELAT CANCER, V13, P257, DOI 10.1677/erc.1.01119; Ringel MD, 2001, CANCER RES, V61, P6105; Robbins RJ, 2006, J CLIN ENDOCR METAB, V91, P498, DOI 10.1210/jc.2005-1534; Rossi M, 2012, J CLIN ENDOCR METAB, V97, P2354, DOI 10.1210/jc.2011-3494; Rubino C, 2003, BRIT J CANCER, V89, P1638, DOI 10.1038/sj.bjc.6601319; Sacks W, 2010, THYROID, V20, P1235, DOI 10.1089/thy.2009.0455; Saggiorato E, 2005, ENDOCR-RELAT CANCER, V12, P305, DOI 10.1677/erc.1.00944; Samija I, 2011, DIAGN MOL PATHOL, V20, P233, DOI 10.1097/PDM.0b013e31821a59f1; Sawka AM, 2008, ENDOCRIN METAB CLIN, V37, P457, DOI 10.1016/j.ecl.2008.02.007; Schlumberger M, 2011, ANN ENDOCRINOL-PARIS, V72, P149, DOI 10.1016/j.ando.2011.03.020; Schlumberger M, 2012, NEW ENGL J MED, V366, P1663, DOI 10.1056/NEJMoa1108586; Schvartz C, 2012, J CLIN ENDOCR METAB, V97, P1526, DOI 10.1210/jc.2011-2512; Shen RL, 2012, THYROID, V22, P9, DOI 10.1089/thy.2011.0081; Sherman SI, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.5503; Sherman SI, 2010, CLIN ONCOL-UK, V22, P464, DOI 10.1016/j.clon.2010.03.014; Sherman SI, 2008, NEW ENGL J MED, V359, P31, DOI 10.1056/NEJMoa075853; Smallridge RC, 2010, CLIN ONCOL-UK, V22, P486, DOI 10.1016/j.clon.2010.03.013; Spano JP, 2012, MED ONCOL, V29, P1421, DOI 10.1007/s12032-011-0070-2; Sprague BL, 2008, CANCER CAUSE CONTROL, V19, P585, DOI 10.1007/s10552-008-9122-0; Theoharis C, 2012, CURR OPIN ONCOL, V24, P35, DOI 10.1097/CCO.0b013e32834dcfca; Tsimberidou AM, 2009, J CLIN ENDOCR METAB, V94, P4423, DOI 10.1210/jc.2009-0743; Tufano RP, 2012, LARYNGOSCOPE, V122, P1634, DOI 10.1002/lary.23371; Umbricht CB, 2004, CLIN CANCER RES, V10, P5762, DOI 10.1158/1078-0432.CCR-03-0389; Volante M, 2009, J CLIN ENDOCR METAB, V94, P4735, DOI 10.1210/jc.2009-1233; Wang CCC, 2011, THYROID, V21, P243, DOI 10.1089/thy.2010.0243; Williams MD, 2009, ANN SURG ONCOL, V16, P3146, DOI 10.1245/s10434-009-0666-3; Xing M, JAMA IN PRESS; Xing MZ, 2007, ENDOCR REV, V28, P742, DOI 10.1210/er.2007-0007; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Xing MZ, 2010, MOL CELL ENDOCRINOL, V321, P86, DOI 10.1016/j.mce.2009.10.012; Xing MZ, 2009, J CLIN ONCOL, V27, P2977, DOI 10.1200/JCO.2008.20.1426; Xing MZ, 2005, J CLIN ENDOCR METAB, V90, P6373, DOI 10.1210/jc.2005-0987; Xing MZ, 2004, J CLIN ENDOCR METAB, V89, P2867, DOI 10.1210/jc.2003-032050; Yang J, 2007, CANCER CYTOPATHOL, V111, P306, DOI 10.1002/cncr.22955; Yip L, 2012, J CLIN ENDOCR METAB, V97, P1905, DOI 10.1210/jc.2011-3048; Yip L, 2009, SURGERY, V146, P1215, DOI 10.1016/j.surg.2009.09.011	128	380	408	9	104	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 23	2013	381	9871					1058	1069		10.1016/S0140-6736(13)60109-9	http://dx.doi.org/10.1016/S0140-6736(13)60109-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EU	23668556	Green Accepted			2023-01-03	WOS:000316936800035
J	Zhong, JH; Mo, XS; Xiang, BD; Yuan, WP; Jiang, JF; Xie, GS; Li, LQ				Zhong, Jian-Hong; Mo, Xin-Shao; Xiang, Bang-De; Yuan, Wei-Ping; Jiang, Jin-Fang; Xie, Gui-Sheng; Li, Le-Qun			Postoperative Use of the Chemopreventive Vitamin K2 Analog in Patients with Hepatocellular Carcinoma	PLOS ONE			English	Article							GAMMA-CARBOXY PROTHROMBIN; SURGICAL RESECTION; GROWTH-INHIBITION; RECURRENCE RATES; MENATETRENONE; METAANALYSIS; COMBINATION; SURVIVAL; ABLATION; DISEASE	Aim: To evaluate the chemopreventive efficacy of vitamin K2 (VK2) analog in patients with hepatocellular carcinoma (HCC) after curative hepatic resection or local ablation, since a recent randomized control trial (RCT) and systematic review have given contradictory results. Methods: MEDLINE, EMBASE and Cochrane library databases were systematically searched through the end of May 2012. Meta-analysis of RCTs and cohort studies was performed to estimate the effects of the VK2 analog on tumor recurrence rate and overall survival (OS). Risk ratios (RRs) and 95% confidence intervals (95% CIs) were calculated. Results: Six RCTs and one cohort study involving a total of 930 patients were included. VK2 analog therapy did not reduce the 1-year recurrence rate, with a pooled RR of 0.67 (95% CI 0.39-1.13, p = 0.13). However, VK2 analog therapy was associated with a significant reduction in the 2-and 3-year tumor recurrence rates, with respective pooled RRs of 0.65 (95% CI 0.51-0.83, p<0.001) and 0.70 (95% CI=0.58-0.85, p<0.001). The therapy was also associated with a significant improvement in 1-, 2-, and 3-year OS, with respective pooled RRs of 1.03 (95% CI 1.01-1.05, p = 0.02), 1.11 (95% CI 1.03-1.19, p = 0.005) and 1.14 (95% CI 1.02-1.28, p = 0.02). None of the studies reported adverse effects attributable to VK2 analog therapy. Conclusion: The VK2 analog may reduce recurrence rate after 1 year and improve OS in HCC patients as early as 1 year. However, these findings should be considered preliminary since the majority of patients came from an RCT with survival data out to only 1 year. More extensive studies with larger sample sizes and longer follow-up are needed.	[Zhong, Jian-Hong; Mo, Xin-Shao; Xiang, Bang-De; Yuan, Wei-Ping; Li, Le-Qun] Guangxi Med Univ, Tumor Hosp, Hepatobiliary Surg Dept, Nanning, Peoples R China; [Jiang, Jin-Fang] Guangxi Med Univ, Tumor Hosp, Dept Chemotherapy, Nanning, Peoples R China; [Xie, Gui-Sheng] Guangxi Med Univ, Affiliated Hosp 3, Dept Gen Surg, Nanning, Peoples R China	Guangxi Medical University; Guangxi Medical University; Guangxi Medical University	Li, LQ (corresponding author), Guangxi Med Univ, Tumor Hosp, Hepatobiliary Surg Dept, Nanning, Peoples R China.	xitongpingjia@163.com	Zhong, Jian-Hong/D-6641-2018; Li, Li/AEM-3636-2022; LI, LI QING/GRR-8855-2022; li, li/HII-4157-2022; LI, LI/GVS-5344-2022	Zhong, Jian-Hong/0000-0002-1494-6396; 	National Natural Science Foundation of China [81160262/H1602]; Guangxi Natural Science Foundation [2011GXNSFD018032]; Ministry of Health of Guangxi Province [Z2012345]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangxi Natural Science Foundation(National Natural Science Foundation of Guangxi Province); Ministry of Health of Guangxi Province	This work was supported by the grants from the National Natural Science Foundation of China (Project No: 81160262/H1602) and Guangxi Natural Science Foundation (Project No: 2011GXNSFD018032) to LQL, and the Self-raised Scientific Research Fund of the Ministry of Health of Guangxi Province (Project No: Z2012345) to JHZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Azuma K, 2009, ENDOCR J, V56, P843, DOI 10.1507/endocrj.K09E-108; Bertino G, 2010, DRUG NEWS PERSPECT, V23, P498, DOI 10.1358/dnp.2010.23.8.1444236; Chu KJ, 2010, ASIAN J SURG, V33, P120, DOI 10.1016/S1015-9584(10)60021-8; Habu D, 2004, JAMA-J AM MED ASSOC, V292, P358, DOI 10.1001/jama.292.3.358; Hosho K, 2008, YONAGO ACTA MED, V51, P95; Hotta N, 2007, HEPATO-GASTROENTEROL, V54, P2073; Ishizuka M, 2012, ANTICANCER RES, V32, P5415; Kakizaki S, 2007, J GASTROEN HEPATOL, V22, P518, DOI 10.1111/j.1440-1746.2007.04844.x; Kim HS, 2009, J CLIN GASTROENTEROL, V43, P482, DOI 10.1097/MCG.0b013e318182015a; Kubota K, 2011, EUR J CANCER, V47, pS470, DOI 10.1016/S0959-8049(11)71905-0; Lang HK, 2007, J AM COLL SURGEONS, V205, P27, DOI 10.1016/j.jamcollsurg.2007.03.002; Li L, 2010, MOL CELL BIOCHEM, V342, P125, DOI 10.1007/s11010-010-0476-8; Mizuta T, 2006, CANCER, V106, P867, DOI 10.1002/cncr.21667; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nakamura M, 2006, HEPATOL RES, V35, P289, DOI 10.1016/j.hepres.2006.04.014; Ozaki I, 2007, CLIN CANCER RES, V13, P2236, DOI 10.1158/1078-0432.CCR-06-2308; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Prabhoo Ram, 2010, J Indian Med Assoc, V108, P253; Sakaguchi T, 2010, SURG TODAY, V40, P638, DOI 10.1007/s00595-009-4109-3; Singal AK, 2010, ALIMENT PHARM THER, V32, P851, DOI 10.1111/j.1365-2036.2010.04414.x; Takahashi Shunsuke, 2008, Oncology, V75 Suppl 1, P91, DOI 10.1159/000173429; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; Yamamoto T, 2009, J GASTROENTEROL, V44, P228, DOI 10.1007/s00535-008-2304-4; Yoshida H, 2011, HEPATOLOGY, V54, P532, DOI 10.1002/hep.24430; Yoshiji H, 2009, J HEPATOL, V51, P315, DOI 10.1016/j.jhep.2009.04.011; Zerbini A, 2010, GASTROENTEROLOGY, V138, P1931, DOI 10.1053/j.gastro.2009.12.051; Zhong JH, 2010, HEPATOL RES, V40, P943, DOI 10.1111/j.1872-034X.2010.00710.x	27	24	29	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2013	8	3							e58082	10.1371/journal.pone.0058082	http://dx.doi.org/10.1371/journal.pone.0058082			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136BN	23505456	Green Published, Green Submitted, gold			2023-01-03	WOS:000318334500048
J	Yang, ZY; Yuan, JQ; Di, MY; Zheng, DY; Chen, JZ; Ding, H; Wu, XY; Huang, YF; Mao, C; Tang, JL				Yang, Zu-Yao; Yuan, Jin-Qiu; Di, Meng-Yang; Zheng, Da-Yong; Chen, Jin-Zhang; Ding, Hong; Wu, Xin-Yin; Huang, Ya-Fang; Mao, Chen; Tang, Jin-Ling			Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis	PLOS ONE			English	Article							PHASE-III TRIAL; GROWTH-FACTOR RECEPTOR; COLONY-STIMULATING FACTOR; CLINICAL-TRIALS; COMBINATION; ADENOCARCINOMA; CHEMOTHERAPY; DOCETAXEL; SURVIVAL; MULTICENTER	Background: This study aims to comprehensively summarize the currently available evidences on the efficacy and safety of gemcitabine plus erlotinib for treating advanced pancreatic cancer. Methodology/Principal Findings: PubMed, EMBASE, The Cochrane Library and abstracts of recent major conferences were systematically searched to identify relevant publications. Studies that were conducted in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib (with or without comparison with gemcitabine alone) and reporting objective response rate, disease control rate, progression-free survival, time-to-progression, overall survival, 1-year survival rate and/or adverse events were included. Data on objective response rate, disease control rate, 1-year survival rate and adverse events rate, respectively, were combined mainly by using Meta-Analyst software with a random-effects model. Data on progression-free survival, time-to-progression and overall survival were summarized descriptively. Sixteen studies containing 1,308 advanced pancreatic cancer patients treated with gemcitabine plus erlotinib were included. The reported median progression-free survival (or time-to-progression), median overall survival, 1-year survival rates, objective response rates and disease control rates were 2-9.6 months, 5-12.5 months, 20%-51%, 0%-28.6% and 25.0%-83.3%, respectively. The weighted 1-year survival rate, objective response rate and disease control rate based on studies reporting robust results were 27.9%, 9.1% and 57.0%, respectively. According to the studies with relevant data, the incidences of total and severe adverse events were 96.3% and 62.9%, respectively. The most frequently reported adverse events were leucopenia, rash, diarrhea, vomitting, neutropenia, thrombocytopenia, anaemia, stomatitis, drug-induced liver injury, fatigue and fever. Compared with gemcitabine alone, the progression-free survival and overall survival with gemcitabine plus erlotinib were significantly longer, but there were also more deaths and interstitial lung disease-like syndrome related to this treatment. Conclusions/Significance: Gemcitabine plus erlotinib represent a new option for the treatment of advanced pancreatic cancer, with mild but clinically meaningful additive efficacy compared with gemcitabine alone. Its safety profile is generally acceptable, although careful management is needed for some specific adverse events.	[Yang, Zu-Yao; Yuan, Jin-Qiu; Di, Meng-Yang; Wu, Xin-Yin; Huang, Ya-Fang; Mao, Chen; Tang, Jin-Ling] Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Div Epidemiol, Hong Kong, Hong Kong, Peoples R China; [Yang, Zu-Yao; Mao, Chen; Tang, Jin-Ling] Chinese Univ Hong Kong, Hong Kong Branch, Chinese Cochrane Ctr, Hong Kong, Hong Kong, Peoples R China; [Zheng, Da-Yong; Chen, Jin-Zhang] Southern Med Univ, Dept Oncol, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China; [Ding, Hong] Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, Guangzhou, Guangdong, Peoples R China; [Mao, Chen; Tang, Jin-Ling] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen Municipal Key Lab Hlth Risk Anal, Shenzhen, Guangdong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Southern Medical University - China; Southern Medical University - China; Chinese University of Hong Kong, Shenzhen	Mao, C (corresponding author), Chinese Univ Hong Kong, Jockey Club Sch Publ Hlth & Primary Care, Div Epidemiol, Hong Kong, Hong Kong, Peoples R China.	maochen@cuhk.edu.hk; jltang@cuhk.edu.hk	Mao, Chen/AAW-2742-2020; Mao, Chen/G-9805-2013; Yuan, Jinqiu/A-4867-2018; Tang, JL/G-1759-2013; Di, Mengyang/U-4847-2018	Mao, Chen/0000-0002-6537-6215; Mao, Chen/0000-0001-7471-1516; Di, Mengyang/0000-0001-6165-2617				Anderson KE, 2006, CANC EPIDEMIOLOGY PR; Androulakis N, 1999, J CLIN ONCOL, V17, P1779, DOI 10.1200/JCO.1999.17.6.1779; Aranda E, 2012, ANN ONCOL, V23, P1919, DOI 10.1093/annonc/mdr560; Ardavanis A, 2009, ANTICANCER RES, V29, P5211; Bengala C, 2009, PHASE 2 TRIAL ERLOTI; Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149; Boeck S, 2010, ANTI-CANCER DRUG, V21, P94, DOI 10.1097/CAD.0b013e32833123ed; Bond-Smith G, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2476; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cascinu S, 1999, ANN ONCOL, V10, P105, DOI 10.1023/A:1008205515591; Cheng Yue-Juan, 2010, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V32, P421, DOI 10.3881/j.issn.1000-503X.2010.04.013; Colucci G, 2002, CANCER, V94, P902, DOI 10.1002/cncr.10323.abs; Deeks JJ, COCHRANE HDB SYSTEMA; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dragovich T, 2007, CANCER CHEMOTH PHARM, V60, P295, DOI 10.1007/s00280-006-0389-0; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Feliu J, 2011, CANCER CHEMOTH PHARM, V67, P215, DOI 10.1007/s00280-010-1472-0; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Fjallskog MLH, 2003, CLIN CANCER RES, V9, P1469; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kim GP, 2011, RANDOMIZED PHASE 2 T; Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597; Lima CMR, 2004, J CLIN ONCOL, V22, P3776, DOI 10.1200/JCO.2004.12.082; Louvet C, 2005, J CLIN ONCOL, V23, P3509, DOI 10.1200/JCO.2005.06.023; Lowenfels AB, 2006, BEST PRACT RES CL GA, V20, P197, DOI 10.1016/j.bpg.2005.10.001; Lynch TJ, 2007, ONCOLOGIST, V12, P610, DOI 10.1634/theoncologist.12-5-610; Milella M, 2010, PHASE 2 STUDY ERLOTI; Miller VA, 2000, SEMIN ONCOL, V27, P3; Modiano M, 2012, APRICOT P RANDOMIZED; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Munoz Llarena A, 2011, GEMCITABINE G FIXED; Oettle H, 2005, ANN ONCOL, V16, P1639, DOI 10.1093/annonc/mdi309; Okusaka T, 2011, CANCER SCI, V102, P425, DOI 10.1111/j.1349-7006.2010.01810.x; Perez-Soler R, 2005, J CLIN ONCOL, V23, P5235, DOI 10.1200/JCO.2005.00.6916; Philip PA, 2012, PHASE 1 RANDOMIZED P; Scheithauer W, 2003, ANN ONCOL, V14, P97, DOI 10.1093/annonc/mdg029; Stathopoulos GP, 2008, ANTICANCER RES, V28, P1303; Stathopoulos GP, 2001, ANN ONCOL, V12, P101, DOI 10.1023/A:1008310106171; Stuebs P, 2010, 1 LINE THERAPY ADV P; Tobita K, 2003, INT J MOL MED, V11, P305; Ueda S, 2004, PANCREAS, V29, pE1, DOI 10.1097/00006676-200407000-00061; Van Cutsem E, 2009, J CLIN ONCOL, V27, P2231, DOI 10.1200/JCO.2008.20.0238; Xiong HQ, 2004, CANCER CHEMOTH PHARM, V54, pS69, DOI 10.1007/s00280-004-0890-2	45	32	34	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2013	8	3							e57528	10.1371/journal.pone.0057528	http://dx.doi.org/10.1371/journal.pone.0057528			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099RC	23472089	Green Published, Green Submitted, gold			2023-01-03	WOS:000315637900028
J	Lee, SY; Chen, YC; Tsai, IC; Yen, CJ; Chueh, SN; Chuang, HF; Wu, HY; Chiang, CK; Cheng, HT; Hung, KY; Huang, JW				Lee, Szu-Ying; Chen, Yin-Cheng; Tsai, I-Chieh; Yen, Chung-Jen; Chueh, Shu-Neng; Chuang, Hsueh-Fang; Wu, Hon-Yen; Chiang, Chih-Kang; Cheng, Hui-Teng; Hung, Kuan-Yu; Huang, Jenq-Wen			Glycosylated Hemoglobin and Albumin-Corrected Fructosamine Are Good Indicators for Glycemic Control in Peritoneal Dialysis Patients	PLOS ONE			English	Article							GLUCOSE MONITORING-SYSTEM; CHRONIC-RENAL-FAILURE; DIABETIC-PATIENTS; HEMODIALYSIS-PATIENTS; GLYCATED ALBUMIN; CARBAMYLATED HEMOGLOBIN; CELL SURVIVAL; A(1C) LEVELS; ICODEXTRIN; COHORT	Purpose: Diabetes mellitus (DM) is the most common cause of end-stage renal disease and is an important risk factor for morbidity and mortality after dialysis. However, glycemic control among such patients is difficult to assess. The present study examined glycemic control parameters and observed glucose variation after refilling different kinds of fresh dialysate in peritoneal dialysis (PD) patients. Methods: A total of 25 DM PD patients were recruited, and continuous glucose monitoring system (CGMS) was applied to measure interstitial fluid (ISF) glucose levels at 5-min intervals for 3 days. Patients filled out diet and PD fluid exchange diaries. The records measured with CGMS were analyzed and correlated with other glycemic control parameters such as fructosamine, albumin-corrected fructosamine (AlbF), glycosylated hemoglobin (HbA1c), and glycated albumin levels. Results: There were significant correlations between mean ISF glucose and fructosamine (r = 0.45, P<0.05), AlbF (r = 0.54, P<0.01), and HbA1c (r = 0.51, P<0.01). The ISF glucose levels in glucose-containing dialysate increased from approximately 7-8 mg/dL within 1 hour of exchange in contrast to icodextrin dialysate which kept ISF glucose levels unchanged. Conclusion: HbA1c and AlbF significantly correlated with the mean ISF glucose levels, indicating that they are reliable indices of glycemic control in DM PD patients. Icodextrin dialysate seems to have a favorable glycemic control effect when compared to the other glucose-containing dialysates.	[Lee, Szu-Ying] Natl Taiwan Univ Hosp, Dept Internal Med, Yun Lin Branch, Taipei, Yunlin County, Taiwan; [Chen, Yin-Cheng; Tsai, I-Chieh] Taipei Hosp, Dept Hlth, Dept Internal Med, Taipei, Taiwan; [Yen, Chung-Jen; Wu, Hon-Yen; Hung, Kuan-Yu; Huang, Jenq-Wen] Natl Taiwan Univ Hosp & Coll Med, Dept Internal Med, Taipei, Taiwan; [Chueh, Shu-Neng] Natl Taiwan Univ Hosp & Coll Med, Dept Nursing, Taipei, Taiwan; [Chuang, Hsueh-Fang] Natl Taiwan Univ Hosp, Dept Nursing, Bei Hu Branch, Taipei, Taiwan; [Wu, Hon-Yen] Far Eastern Mem Hosp, Dept Internal Med, New Taipei City, Taiwan; [Chiang, Chih-Kang] Natl Taiwan Univ Hosp & Coll Med, Dept Integrated Diagnost & Therapeut, Taipei, Taiwan; [Cheng, Hui-Teng] Natl Taiwan Univ Hosp, Dept Internal Med, Hsin Chu Branch, Hsinchu, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lee, SY (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Yun Lin Branch, Taipei, Yunlin County, Taiwan.	007378@ntuh.gov.tw	CHENG, HUI-TENG/AAD-9899-2020	CHENG, HUI-TENG/0000-0003-1544-7473; CHIANG, CHIH-KANG/0000-0001-9021-4616; HUANG, JENQ-WEN/0000-0001-8011-2317; HUNG, KUAN-YU/0000-0003-3472-5512; YEN, CHUNG-JEN/0000-0001-5372-3657	Department of Health, Taipei Hospital	Department of Health, Taipei Hospital	This work was supported by a grant from the Department of Health, Taipei Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2010, Diabetes Care, V33 Suppl 1, pS4, DOI 10.2337/dc10-S004; Babazono T, 2007, AM J NEPHROL, V27, P409, DOI 10.1159/000105123; BLUMENKRANTZ MJ, 1981, KIDNEY INT, V19, P593, DOI 10.1038/ki.1981.57; Bock HA, 2008, NEPHROL DIAL TRANSPL, V23, P301, DOI 10.1093/ndt/gfm579; CORONEL F, 1991, ADV PERIT D, V7, P253; Freedman BI, 2010, PERITON DIALYSIS INT, V30, P72, DOI 10.3747/pdi.2008.00243; Gillett Melissa J, 2009, Clin Biochem Rev, V30, P197; GOLDSTEIN DE, 1995, DIABETES CARE, V18, P896, DOI 10.2337/diacare.18.6.896; Gross T M, 2000, Diabetes Technol Ther, V2, P49, DOI 10.1089/152091500316737; Hung KY, 2000, ARTIF ORGANS, V24, P261, DOI 10.1046/j.1525-1594.2000.06478.x; Inaba M, 2007, J AM SOC NEPHROL, V18, P896, DOI 10.1681/ASN.2006070772; Joy MS, 2002, AM J KIDNEY DIS, V39, P297, DOI 10.1053/ajkd.2002.30549; Ly J, 2004, AM J KIDNEY DIS, V44, P715, DOI 10.1053/j.ajkd.2004.06.018; Marshall J, 2003, KIDNEY INT, V64, P1480, DOI 10.1046/j.1523-1755.2003.00209.x; McGahan Lynda, 2002, Issues Emerg Health Technol, P1; Mittman N, 2010, KIDNEY INT, V78, pS41, DOI 10.1038/ki.2010.193; Nakao T, 1998, INTERNAL MED, V37, P826, DOI 10.2169/internalmedicine.37.826; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; Paniagua R, 2009, PERITON DIALYSIS INT, V29, P422; PANZER S, 1982, BLOOD, V59, P1348; Peacock TP, 2008, KIDNEY INT, V73, P1062, DOI 10.1038/ki.2008.25; Reach G, 2008, DIABETES TECHNOL THE, V10, P69, DOI 10.1089/dia.2007.0261; Reach G, 2008, CURR DIABETES REV, V4, P175, DOI 10.2174/157339908785294488; Riveline JP, 2009, NEPHROL DIAL TRANSPL, V24, P2866, DOI 10.1093/ndt/gfp181; SMITH WGJ, 1989, NEPHROL DIAL TRANSPL, V4, P96; Sulowicz W, 2007, CLIN J AM SOC NEPHRO, V2, P637, DOI 10.2215/CJN.03631006; Tzamaloukas AH, 1996, ADV PERIT D, V12, P171; Weykamp CW, 1999, CLIN CHEM, V45, P438; Wong TY, 2008, LANCET, V371, P736, DOI 10.1016/S0140-6736(08)60343-8; Wu HY, 2008, AM J NEPHROL, V28, P765, DOI 10.1159/000128608; Wu HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030337; Wu HY, 2010, PERITON DIALYSIS INT, V30, P448, DOI 10.3747/pdi.2009.00063	32	21	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2013	8	3							e57762	10.1371/journal.pone.0057762	http://dx.doi.org/10.1371/journal.pone.0057762			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099PY	23469230	Green Submitted, Green Published, gold			2023-01-03	WOS:000315634900041
J	Ghosh, MC; Ray, AK				Ghosh, Manik C.; Ray, Arun K.			Membrane Phospholipid Augments Cytochrome P4501a Enzymatic Activity by Modulating Structural Conformation during Detoxification of Xenobiotics	PLOS ONE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; ENDOPLASMIC-RETICULUM STRESS; ANIONIC PHOSPHOLIPIDS; DRUG-METABOLISM; P450 REDUCTASE; HEPATIC DRUG; PROTEIN; CARBOFURAN; LIPIDS; LIVER	Cytochrome P450 is a superfamily of membrane-bound hemoprotein that gets involved with the degradation of xenobiotics and internal metabolites. Accumulated body of evidence indicates that phospholipids play a crucial role in determining the enzymatic activity of cytochrome P450 in the microenvironment by modulating its structure during detoxification; however, the structure-function relationship of cytochrome P4501A, a family of enzymes responsible for degrading lipophilic aromatic hydrocarbons, is still not well defined. Inducibility of cytochrome P4501A in cultured catfish hepatocytes in response to carbofuran, a widely used pesticide around the world, was studied earlier in our laboratory. In this present investigation, we observed that treating catfish with carbofuran augmented total phospholipid in the liver. We examined the role of phospholipid on the of cytochrome P4501A-marker enzyme which is known as ethoxyresorufin-O-deethylase (EROD) in the context of structure and function. We purified the carbofuran-induced cytochrome P4501A protein from catfish liver. Subsequently, we examined the enzymatic activity of purified P4501A protein in the presence of phospholipid, and studied how the structure of purified protein was influenced in the phospholipid environment. Membrane phospholipid appeared to accelerate the enzymatic activity of EROD by changing its structural conformation and thus controlling the detoxification of xenobiotics. Our study revealed the missing link of how the cytochrome P450 restores its enzymatic activity by changing its structural conformation in the phospholipid microenvironment.	[Ghosh, Manik C.] Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; [Ray, Arun K.] Bose Inst, Div Mol Med, Kolkata 700009, W Bengal, India	University of Tennessee System; University of Tennessee Health Science Center; Department of Science & Technology (India); Bose Institute	Ghosh, MC (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA.	ghosh.manik7@gmail.com			Department of Biotechnology of India	Department of Biotechnology of India	The Department of Biotechnology of India is acknowledged for funding of this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal PK, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-2; Agarwal PK, 2005, J AM CHEM SOC, V127, P15248, DOI 10.1021/ja055251s; Agarwal PK, 2012, PHYS LIFE REV; Ahn T, 2005, BIOCHEMISTRY-US, V44, P9188, DOI 10.1021/bi050051e; Ahn T, 2007, CURR PROTEIN PEPT SC, V8, P496, DOI 10.2174/138920307782411392; Backes WL, 2003, PHARMACOL THERAPEUT, V98, P221, DOI 10.1016/S0163-7258(03)00031-7; Begum G, 2001, ENVIRON MONIT ASSESS, V70, P233, DOI 10.1023/A:1010775224753; BIDLACK WR, 1984, J AM DIET ASSOC, V84, P892; BIDLACK WR, 1986, FASEB J, V45, P142; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAUSEY KM, 1990, MOL PHARMACOL, V38, P134; Cho EY, 2008, BIOCHEM BIOPH RES CO, V376, P584, DOI 10.1016/j.bbrc.2008.09.023; EDWARDS RJ, 1991, BIOCHEMISTRY-US, V30, P71, DOI 10.1021/bi00215a011; EDWARDS RJ, 1991, BIOCHEM J, V278, P749, DOI 10.1042/bj2780749; Elsherbiny ME, 2011, DRUG METAB REV, V43, P457, DOI 10.3109/03602532.2011.596204; Emoto Chie, 2009, Drug Metab Lett, V3, P207; Fernandez C, 2003, FEBS LETT, V555, P144, DOI 10.1016/S0014-5793(03)01155-4; Fleming CR, 2011, ECOTOXICOLOGY, V20, P1300, DOI 10.1007/s10646-011-0686-1; Flowers MT, 2008, PHYSIOL GENOMICS, V33, P361, DOI 10.1152/physiolgenomics.00139.2007; Fu PP, 2012, J ENVIRON SCI HEAL C, V30, P1, DOI 10.1080/10590501.2012.653887; Fu SN, 2011, NATURE, V473, P528, DOI 10.1038/nature09968; Ghosh MC, 2012, J CELL COMMUN SIGNAL, V6, P37, DOI 10.1007/s12079-011-0143-1; Ghosh MC, 2000, J BIOCHEM MOL TOXIC, V14, P204, DOI 10.1002/(SICI)1099-0461(2000)14:4<204::AID-JBT4>3.3.CO;2-#; Ghosh MC, 2001, ENVIRON RES, V86, P167, DOI 10.1006/enrs.2001.4249; GOKSOYR A, 1985, BIOCHIM BIOPHYS ACTA, V840, P409, DOI 10.1016/0304-4165(85)90222-3; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; GUPTA RC, 1994, J TOXICOL ENV HEALTH, V42, P451, DOI 10.1080/15287399409531895; GUPTA RC, 1994, J TOXICOL ENV HEALTH, V43, P383, DOI 10.1080/15287399409531931; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Huber WJ, 2007, BIOCHEMISTRY-US, V46, P12212, DOI 10.1021/bi701496z; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; INGELMANSUNDBERG M, 1981, BIOCHEMISTRY-US, V20, P4100, DOI 10.1021/bi00517a024; Jang HH, 2010, ARCH BIOCHEM BIOPHYS, V493, P143, DOI 10.1016/j.abb.2009.10.012; Kim KH, 2007, ARCH BIOCHEM BIOPHYS, V468, P226, DOI 10.1016/j.abb.2007.10.003; Kim KH, 2003, BIOCHEMISTRY-US, V42, P15377, DOI 10.1021/bi035280k; Kisselev P, 1998, J BIOL CHEM, V273, P1380, DOI 10.1074/jbc.273.3.1380; Kisselev P, 2002, EUR J BIOCHEM, V269, P1799, DOI 10.1046/j.1432-1033.2002.02848.x; Kleinschmidt JH, 2003, CELL MOL LIFE SCI, V60, P1547, DOI 10.1007/s00018-003-3170-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; Luthra A, 2011, ARCH BIOCHEM BIOPHYS, V507, P26, DOI 10.1016/j.abb.2010.12.008; NORRED W P, 1984, Drug-Nutrient Interactions, V3, P11; Nussio MR, 2010, CHEM PHYS LIPIDS, V163, P182, DOI 10.1016/j.chemphyslip.2009.11.003; Pagonis TA, 2008, CLIN TOXICOL, V46, P57, DOI 10.1080/15563650701590910; Ramanathan A, 2009, J PHYS CHEM B, V113, P16669, DOI 10.1021/jp9077213; Reed JR, 2010, METHODS MOL BIOL, V606, P11, DOI 10.1007/978-1-60761-447-0_2; Reed JR, 2006, DRUG METAB DISPOS, V34, P660, DOI 10.1124/dmd.105.006825; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; Sarasquete C, 2000, SCI TOTAL ENVIRON, V247, P313, DOI 10.1016/S0048-9697(99)00500-8; Sen A, 1998, J BIOCHEM MOL TOXIC, V12, P103, DOI 10.1002/(SICI)1099-0461(1998)12:2<103::AID-JBT5>3.0.CO;2-P; Shet MS, 1996, ARCH BIOCHEM BIOPHYS, V330, P199, DOI 10.1006/abbi.1996.0243; Snyder R, 2004, DRUG METAB REV, V36, P531, DOI 10.1081/DMR-200033445; STEGEMAN JJ, 1989, XENOBIOTICA, V19, P1093, DOI 10.3109/00498258909043164; SUZUKI K, 1993, BIOCHIM BIOPHYS ACTA, V1203, P215, DOI 10.1016/0167-4838(93)90086-7; van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330; Wang SC, 2007, BIOCHEMISTRY-US, V46, P14557, DOI 10.1021/bi701073d; Yun CH, 1997, J BIOL CHEM, V272, P19725, DOI 10.1074/jbc.272.32.19725	57	7	7	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57919	10.1371/journal.pone.0057919	http://dx.doi.org/10.1371/journal.pone.0057919			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23469105	Green Submitted, gold, Green Published			2023-01-03	WOS:000315524900200
J	Doll, J; Zeitler, E; Becker, R				Doll, Jacob; Zeitler, Emily; Becker, Richard			Generic Clopidogrel - Time to Substitute?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Doll, Jacob; Zeitler, Emily; Becker, Richard] Duke Univ, Med Ctr, Durham, NC USA	Duke University	Doll, J (corresponding author), Duke Univ, Med Ctr, Durham, NC USA.								0	8	8	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2013	310	2					145	146		10.1001/jama.2013.7155	http://dx.doi.org/10.1001/jama.2013.7155			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	179HU	23839745				2023-01-03	WOS:000321511500034
J	Schmidt, B; Whyte, RK; Asztalos, EV; Moddemann, D; Poets, C; Rabi, Y; Solimano, A; Roberts, RS				Schmidt, Barbara; Whyte, Robin K.; Asztalos, Elizabeth V.; Moddemann, Diane; Poets, Christian; Rabi, Yacov; Solimano, Alfonso; Roberts, Robin S.		Canadian Oxygen Trial COT Grp	Effects of Targeting Higher vs Lower Arterial Oxygen Saturations on Death or Disability in Extremely Preterm Infants A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-WEIGHT INFANTS; PULSE OXIMETRY; PREMATURE-INFANTS; RETINOPATHY; THERAPY; METAANALYSIS; UNCERTAINTY; GESTATION; CHILDREN	Importance The goal of oxygen therapy is to deliver sufficient oxygen to the tissues while minimizing oxygen toxicity and oxidative stress. It remains uncertain what values of arterial oxygen saturations achieve this balance in preterm infants. Objective To compare the effects of targeting lower or higher arterial oxygen saturations on the rate of death or disability in extremely preterm infants. Design, Setting, and Participants Randomized, double-blind trial in 25 hospitals in Canada, the United States, Argentina, Finland, Germany, and Israel in which 1201 infants with gestational ages of 23 weeks 0 days through 27 weeks 6 days were enrolled within 24 hours after birth between December 2006 and August 2010. Follow-up assessments began in October 2008 and ended in August 2012. Interventions Study participants were monitored until postmenstrual ages of 36 to 40 weeks with pulse oximeters that displayed saturations of either 3% above or below the true values. Caregivers adjusted the concentration of oxygen to achieve saturations between 88% and 92%, which produced 2 treatment groups with true target saturations of 85% to 89% (n=602) or 91% to 95% (n=599). Alarms were triggered when displayed saturations decreased to 86% or increased to 94%. Main Outcomes and Measures The primary outcome was a composite of death, gross motor disability, cognitive or language delay, severe hearing loss, or bilateral blindness at a corrected age of 18 months. Secondary outcomes included retinopathy of prematurity and brain injury. Results Of the 578 infants with adequate data for the primary outcome who were assigned to the lower target range, 298 (51.6%) died or survived with disability compared with 283 of the 569 infants (49.7%) assigned to the higher target range (odds ratio adjusted for center, 1.08; 95% CI, 0.85 to 1.37; P=.52). The rates of death were 16.6% for those in the 85% to 89% group and 15.3% for those in the 91% to 95% group (adjusted odds ratio, 1.11; 95% CI, 0.80 to 1.54; P=.54). Targeting lower saturations reduced the postmenstrual age at last use of oxygen therapy (adjusted mean difference, -0.8 weeks; 95% CI, -1.5 to -0.1; P=.03) but did not alter any other outcomes. Conclusion and Relevance In extremely preterm infants, targeting oxygen saturations of 85% to 89% compared with 91% to 95% had no significant effect on the rate of death or disability at 18 months. These results may help determine the optimal target oxygen saturation.	[Schmidt, Barbara] Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104 USA; [Schmidt, Barbara] Univ Penn, Philadelphia, PA 19104 USA; [Schmidt, Barbara; Roberts, Robin S.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Whyte, Robin K.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; [Asztalos, Elizabeth V.] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Moddemann, Diane] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Poets, Christian] Univ Tubingen, Dept Neonatol, Tubingen, Germany; [Rabi, Yacov] Univ Calgary, Dept Pediat, Calgary, AB T2N 1N4, Canada; [Solimano, Alfonso] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; McMaster University; Dalhousie University; University of Toronto; University of Manitoba; Eberhard Karls University of Tubingen; University of Calgary; University of British Columbia	Schmidt, B (corresponding author), Hosp Univ Penn, Div Neonatol, Ravdin 8,3400 Spruce St, Philadelphia, PA 19104 USA.	barbara.schmidt@uphs.upenn.edu	Shah, Prakesh S/I-8098-2013; Asztalos, Elizabeth/L-8834-2019; Kelly, Edmond/P-5857-2015	Asztalos, Elizabeth/0000-0002-9468-2860; Bairam, Aida/0000-0003-3475-6546; Bassler, Dirk/0000-0003-2358-4419	Canadian Institutes of Health Research [MCT-79217]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Funded exclusively by the Canadian Institutes of Health Research, grant MCT-79217.	Ahmed SJM, 2010, PEDIATRICS, V125, pE115, DOI 10.1542/peds.2008-1749; Anderson PJ, 2010, ARCH PEDIAT ADOL MED, V164, P352, DOI 10.1001/archpediatrics.2010.20; Armbruster J, 2010, J PERINATOL, V30, P531, DOI 10.1038/jp.2009.189; Askie LM, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-6; Askie LM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001077.pub2; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Bayley N, 2006, MANUAL BAYLEY SCALES; Brocklehurst P, 2011, BOOST 2 UK BENEFITS; Carlo WA, 2010, NEW ENGL J MED, V362, P1959, DOI 10.1056/NEJMoa0911781; Cole CH, 2003, PEDIATRICS, V112, P1415, DOI 10.1542/peds.112.6.1415; Deans Katherine J, 2004, Curr Opin Crit Care, V10, P579, DOI 10.1097/01.ccx.0000145097.36069.44; Greenspan JS, 2006, PEDIATRICS, V118, P1740, DOI 10.1542/peds.2006-1834; Hagadorn JI, 2006, PEDIATRICS, V118, P1574, DOI 10.1542/peds.2005-0413; Higgins RD, 2007, PEDIATRICS, V119, P790, DOI 10.1542/peds.2006-2200; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Johnston ED, 2011, ARCH DIS CHILD-FETAL, V96, pF429, DOI 10.1136/adc.2010.206011; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Lichtenstein SJ, 2006, PEDIATRICS, V117, P572, DOI 10.1542/peds.2005-2749; Msall ME, 2004, PEDIATRICS, V113, P790, DOI 10.1542/peds.113.4.790; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Rich W, 2012, PEDIATRICS, V129, P480, DOI 10.1542/peds.2011-2121; Saugstad OD, 2005, BIOL NEONATE, V88, P228, DOI 10.1159/000087586; Saugstad OD, 2011, NEONATOLOGY, V100, P1, DOI 10.1159/000322001; Silverman W. A., 1980, RETROLENTAL FIBROPLA; Silverman WA, 2004, PEDIATRICS, V113, P394, DOI 10.1542/peds.113.2.394; Stenson B, 2011, NEW ENGL J MED, V364, P1680, DOI 10.1056/NEJMc1101319; Tin W, 2001, ARCH DIS CHILD-FETAL, V84, pF106, DOI 10.1136/fn.84.2.F106; Tin W, 2002, PEDIATRICS, V110, P615, DOI 10.1542/peds.110.3.615; Vagedes J, 2013, ARCH DIS CHILD-FETAL, V98, pF265, DOI 10.1136/archdischild-2012-302543; Vaucher YE, 2012, NEW ENGL J MED, V367, P2495, DOI 10.1056/NEJMoa1208506; Weinberger B, 2002, TOXICOL APPL PHARM, V181, P60, DOI 10.1006/taap.2002.9387; WHYTE RK, 1992, BRIT MED J, V304, P343, DOI 10.1136/bmj.304.6823.343	32	251	260	0	46	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	2013	309	20					2111	2120		10.1001/jama.2013.5555	http://dx.doi.org/10.1001/jama.2013.5555			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148FU	23644995	Bronze			2023-01-03	WOS:000319229600027
J	Johnson, S				Johnson, Sonia			Can we reverse the rising tide of compulsory admissions?	LANCET			English	Editorial Material							HEALTH-CARE		UCL, Mental Hlth Sci Unit, London W1W 7EY, England	University of London; University College London	Johnson, S (corresponding author), UCL, Mental Hlth Sci Unit, London W1W 7EY, England.	s.johnson@ucl.ac.uk	Johnson, Sonia/ABF-1457-2020; Johnson, Sonia/A-5220-2008	Johnson, Sonia/0000-0002-2219-1384; Johnson, Sonia/0000-0002-2219-1384				Burns T, 2013, LANCET; Crawford V, 2003, DRUG-EDUC PREV POLIC, V10, pS1, DOI 10.1080/0968763031000072990; Henderson C, 2004, BRIT MED J, V329, P136, DOI 10.1136/bmj.38155.585046.63; Johnson S, 2005, BRIT MED J, V331, P599, DOI 10.1136/bmj.38519.678148.8F; Jones J, 2010, J PSYCHIATR MENT HLT, V17, P124, DOI 10.1111/j.1365-2850.2009.01482.x; Keown P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3736; Khurmi S, 2010, ADV PSYCHIAT TREAT, V16, P263; Kisely S. R., 2011, COCHRANE DB SYST REV, V2; Rowe R, 2006, EUR J PUBLIC HEALTH, V16, P4, DOI 10.1093/eurpub/ckl004; Rugkasa J, 2009, PSYCHIATRY, V8, P493, DOI DOI 10.1016/J.MPPSY.2009.09.009; Tew J, 2012, BRIT J SOC WORK, V42, P443, DOI 10.1093/bjsw/bcr076; The Schizophrenia Commission, 2012, THE ABANDONED ILLNES; Thornicroft G, 2013, LANCET; Wierdsma Andre I, 2009, Int J Integr Care, V9, pe90	14	14	14	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 11	2013	381	9878					1603	1604		10.1016/S0140-6736(13)60442-0	http://dx.doi.org/10.1016/S0140-6736(13)60442-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	146SX	23537604	Green Submitted			2023-01-03	WOS:000319112400006
J	Sleeman, KE; Collis, E				Sleeman, Katherine E.; Collis, Emily			Caring for a dying patient in hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARE		[Sleeman, Katherine E.] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London SE5 9PJ, England; [Collis, Emily] Cent London Community Healthcare Trust, St Charless Hosp, Pembridge Palliat Care Ctr, London W10 6DZ, England	University of London; King's College London	Sleeman, KE (corresponding author), Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London SE5 9PJ, England.	katherine.sleeman@kcl.ac.uk	Sleeman, Katherine/C-4941-2014	Sleeman, Katherine/0000-0002-9777-4373	National Institute for Health Research [CL-2010-17-009] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Association for Palliative Medicine, 2009, APM POS DOUBL EFF DE; Department of Health, 2012, 1 NAT VOICES SURV BE; Department of Health, 2008, END LIF CAR STRAT PR; General Medical Council, 2010, TREATM CAR END LIF G; Guy's and St Thomas' NHS Foundation Trust, AMBER CAR BUNDL; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Kamal AH, 2012, J PALLIAT MED, V15, P106, DOI 10.1089/jpm.2011.0110; Linklater GT, 2010, J ROY COLL PHYS EDIN, V40, P13, DOI 10.4997/JRCPE.2010.104; Liverpool Care Pathway for the Dying Patient (LCP), 2009, LIV CAR PATHW DYING; Mayor S, 2007, BRIT MED J, V334, P278, DOI 10.1136/bmj.39118.686100.DB; McCartney M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e7316; National Care of the Dying Audit-Hospitals (NCDAH), 2012, NAT CAR DYING AUD HO; National Institute for Health and Clinical Excellence, 2011, QUAL STAND END LIF C; NHS Scotland, 2008, LIV DYING WELL NAT A; NHS UK. National end of life care programme, 2012, NAT END LIF CAR PROG; Royal College of Physicians and British Society of Gastroenterology, 2010, OR FEED DIFF DIL GUI; Simon ST, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007354.pub2; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007	18	15	16	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	2013	346								f2174	10.1136/bmj.f2174	http://dx.doi.org/10.1136/bmj.f2174			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	131AT	23596214				2023-01-03	WOS:000317963400014
J	Smith, R; McCready, T; Yusuf, S				Smith, Richard; McCready, Tara; Yusuf, Salim			Combination Therapy to Prevent Cardiovascular Disease Slow Progress	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Smith, Richard] UnitedHlth Chron Dis Initiat, London, England; [McCready, Tara; Yusuf, Salim] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada; [McCready, Tara; Yusuf, Salim] Hamilton Hlth Sci, Hamilton, ON, Canada	McMaster University; Population Health Research Institute; McMaster University	Yusuf, S (corresponding author), McMaster Univ, Populat Hlth Res Inst, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca		Yusuf, Salim/0000-0003-4776-5601				American Heart Association, 2012, PEOPLE MORE LIKELY T; Chapman RH, 2005, ARCH INTERN MED, V165, P1147, DOI 10.1001/archinte.165.10.1147; Diaz R, 2012, EUROPEAN SOCIETY OF; Dudl RJ, 2009, AM J MANAG CARE, V15, pE88; Elley CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052145; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; The Global Summit on Combination Polypharmacy for Cardiovascular Disease, 2012, THE GLOBAL SUMMIT ON; Yusuf S, 2011, LANCET, V378, P1231, DOI 10.1016/S0140-6736(11)61215-4	8	15	15	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2013	309	15					1595	1596		10.1001/jama.2013.3180	http://dx.doi.org/10.1001/jama.2013.3180			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126FY	23529576				2023-01-03	WOS:000317599500021
J	Dunleavy, K; Pittaluga, S; Maeda, LS; Advani, R; Chen, CC; Hessler, J; Steinberg, SM; Grant, C; Wright, G; Varma, G; Staudt, LM; Jaffe, ES; Wilson, WH				Dunleavy, Kieron; Pittaluga, Stefania; Maeda, Lauren S.; Advani, Ranjana; Chen, Clara C.; Hessler, Julie; Steinberg, Seth M.; Grant, Cliona; Wright, George; Varma, Gaurav; Staudt, Louis M.; Jaffe, Elaine S.; Wilson, Wyndham H.			Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLASSICAL HODGKIN LYMPHOMA; GERMINAL-CENTER; CHEMOTHERAPY; DOXORUBICIN; AMPLIFICATION; RADIOTHERAPY; EXPRESSION; MANAGEMENT; SCLEROSIS; EFFICACY	BACKGROUND Primary mediastinal B-cell lymphoma is a distinct subtype of diffuse large-B-cell lymphoma that is closely related to nodular sclerosing Hodgkin's lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, but the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and obviates the need for radiotherapy. METHODS We conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal B-cell lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. RESULTS The patients had a median age of 30 years (range, 19 to 52) and a median tumor diameter of 11 cm; 59% were women. During a median of 5 years of follow-up, the event-free survival rate was 93%, and the overall survival rate was 97%. Among the 16 patients who were involved in the retrospective analysis at another center, over a median of 3 years of follow-up, the event-free survival rate was 100%, and no patients received radiotherapy. No late morbidity or cardiac toxic effects were found in any patients. After follow-up ranging from 10 months to 14 years, all but 2 of the 51 patients (4%) who received DA-EPOCH-R alone were in complete remission. The 2 remaining patients received radiotherapy and were disease-free at follow-up. CONCLUSIONS Therapy with DA-EPOCH-R obviated the need for radiotherapy in patients with primary mediastinal B-cell lymphoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00001337.)	[Dunleavy, Kieron; Pittaluga, Stefania; Hessler, Julie; Steinberg, Seth M.; Grant, Cliona; Staudt, Louis M.; Jaffe, Elaine S.; Wilson, Wyndham H.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Chen, Clara C.] NCI, Ctr Clin, NIH, Bethesda, MD 20892 USA; [Wright, George] NCI, Biometr Res Branch, Div Canc Treatment & Diag, NIH, Bethesda, MD 20892 USA; [Maeda, Lauren S.; Advani, Ranjana; Varma, Gaurav] Stanford Univ, Sch Med, Div Oncol, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University	Wilson, WH (corresponding author), NCI, Metab Branch, Bldg 10,Rm 4N-115,9000 Rockville Pike, Bethesda, MD 20892 USA.	wilsonw@mail.nih.gov	Wright, George W/M-1660-2017; Staudt, Louis/AAC-5324-2019; Carrasquillo, Jorge A/E-7120-2010; Jaffe, Elaine/G-8981-2014	Maeda, Lauren/0000-0001-9215-2965; Jaffe, Elaine/0000-0003-4632-0301; Varma, Gaurav/0000-0002-1903-9170; Advani, Ranjana/0000-0002-3219-2292	National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIDSC007202, ZIASC000550, ZIABC011070] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007952] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funded by the National Cancer Institute; Supported by the National Cancer Institute.	Bishop PC, 1999, J CLIN ONCOL, V17, P2479, DOI 10.1200/JCO.1999.17.8.2479; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Dunleavy K, 2005, BLOOD, V106, P623; Gerrard M, 2013, BLOOD, V121, P278, DOI 10.1182/blood-2012-04-422709; Gutierrez M, 2000, J CLIN ONCOL, V18, P3633, DOI 10.1200/JCO.2000.18.21.3633; Hodgson DC, 2011, HEMATOL-AM SOC HEMAT, P323, DOI 10.1182/asheducation-2011.1.323; Joos S, 2000, CANCER RES, V60, P549; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Juweid ME, 2007, J CLIN ONCOL, V25, P571, DOI 10.1200/JCO.2006.08.2305; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kirwan M, 2009, HUM MUTAT, V30, P1567, DOI 10.1002/humu.21115; LEGHA SS, 1982, ANN INTERN MED, V96, P133, DOI 10.7326/0003-4819-96-2-133; LONGO DL, 1991, J CLIN ONCOL, V9, P1409, DOI 10.1200/JCO.1991.9.8.1409; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Pileri SA, 2003, LEUKEMIA LYMPHOMA, V44, pS21, DOI 10.1080/10428190310001623810; Pileri SA, 2003, AM J PATHOL, V162, P243, DOI 10.1016/S0002-9440(10)63815-1; Rieger M, 2011, ANN ONCOL, V22, P664, DOI 10.1093/annonc/mdq418; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Savage KJ, 2006, ANN ONCOL, V17, P123, DOI 10.1093/annonc/mdj030; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Swerdlow S.H., 2008, WHO CLASSIFICATION T; van Besien K, 2001, J CLIN ONCOL, V19, P1855, DOI 10.1200/JCO.2001.19.6.1855; Vassilakopoulos TP, 2012, ONCOLOGIST, V17, P239, DOI 10.1634/theoncologist.2011-0275; WILSON WH, 1993, J CLIN ONCOL, V11, P1573, DOI 10.1200/JCO.1993.11.8.1573; Wilson WH, 2002, BLOOD, V99, P2685, DOI 10.1182/blood.V99.8.2685; Wilson WH, 2008, J CLIN ONCOL, V26, P2717, DOI 10.1200/JCO.2007.13.1391; Zinzani PL, 2001, HAEMATOLOGICA, V86, P187; Zinzani PL, 1999, BLOOD, V94, P3289, DOI 10.1182/blood.V94.10.3289.422k32_3289_3293	29	345	360	1	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 11	2013	368	15					1408	1416		10.1056/NEJMoa1214561	http://dx.doi.org/10.1056/NEJMoa1214561			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122QT	23574119	Green Accepted			2023-01-03	WOS:000317333600008
J	Christie, AF; Dent, C; McIntyre, P; Wilson, L; Studdert, DM				Christie, Andrew F.; Dent, Chris; McIntyre, Peter; Wilson, Lachlan; Studdert, David M.			Patents Associated with High-Cost Drugs in Australia	PLOS ONE			English	Article							INNOVATION	Australia, like most countries, faces high and rapidly-rising drug costs. There are longstanding concerns about pharmaceutical companies inappropriately extending their monopoly position by "evergreening" blockbuster drugs, through misuse of the patent system. There is, however, very little empirical information about this behaviour. We fill the gap by analysing all of the patents associated with 15 of the costliest drugs in Australia over the last 20 years. Specifically, we search the patent register to identify all the granted patents that cover the active pharmaceutical ingredient of the high-cost drugs. Then, we classify the patents by type, and identify their owners. We find a mean of 49 patents associated with each drug. Three-quarters of these patents are owned by companies other than the drug's originator. Surprisingly, the majority of all patents are owned by companies that do not have a record of developing top-selling drugs. Our findings show that a multitude of players seek monopoly control over innovations to blockbuster drugs. Consequently, attempts to control drug costs by mitigating misuse of the patent system are likely to miss the mark if they focus only on the patenting activities of originators.	[Christie, Andrew F.; Dent, Chris; Studdert, David M.] Univ Melbourne, Melbourne Law Sch, Melbourne, Vic, Australia; [McIntyre, Peter] RMIT Univ, Hlth Innovat Res Inst, Melbourne, Vic, Australia; [Wilson, Lachlan] Univ Melbourne, UoM Commercial Ltd, Melbourne, Vic, Australia; [Studdert, David M.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia	University of Melbourne; Royal Melbourne Institute of Technology (RMIT); University of Melbourne; University of Melbourne	Christie, AF (corresponding author), Univ Melbourne, Melbourne Law Sch, Melbourne, Vic, Australia.	a.christie@unimelb.edu.au	Studdert, David/AAF-3116-2021; Dent, Chris/R-1155-2019; Mcintyre, Peter/N-4109-2013	Studdert, David/0000-0003-0585-5537; Dent, Chris/0000-0002-1801-713X; Wilson, Lachlan/0000-0003-4534-2365; McIntyre, Peter/0000-0001-9506-5998	Australian Research Council [DP0987570]	Australian Research Council(Australian Research Council)	This research was funded by the Australian Research Council (http://www.arc.gov.au/), as Discovery Project DP0987570, Chief Investigators: AF Christie, DM Studdert, P McIntyre, C Dent. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aitken M, 2009, HEALTH AFFAIR, V28, pW151, DOI 10.1377/hlthaff.28.1.w151; Amin T, 2012, HEALTH AFFAIR, V31, P2286, DOI 10.1377/hlthaff.2012.0107; Australian Institute of Health and Welfare, 2011, HLTH WELFARE EXPENDI, V46; Bouchard R, 2010, NW J TECHNOLOGY INTE, V8, P174; Chalmers Robert, 2006, MELB UNIV LAW REV, V30, P29; Chesmond R, 2006, FLINDERS J L REF, V9, P51; Department of Health Housing and Community Services, 1992, AUSTR STAT MED; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Engelberg AB, 2009, NEW ENGL J MED, V361, P1917, DOI 10.1056/NEJMp0908496; European Commission Competition DG, 2009, PHARM SECT INQ FIN 1; European Patent Office, EXT INPADOC PAT FAM; European Patent Office, WORLDW PAT STAT DAT; Faunce T, 2007, AUST NZ HLTH POLICY, V4; Food and Drug Administration, OR BOOK APPR DRUG PR; Gladwell M, 2004, NEW YORKER; Glasgow Lara J., 2001, IDEA, V41, P227; Hemphill CS, 2012, J HEALTH ECON, V31, P327, DOI 10.1016/j.jhealeco.2012.01.004; Jackevicius CA, 2012, NEW ENGL J MED, V366, P201, DOI 10.1056/NEJMp1113112; Mergent Online, AB MERG ONL; O'Neil MJ, 2010, MERCK INDEX ENCY CHE; Ouellette Lisa Larrimore, 2010, MICH TELECOMM TECH L, V17, P300; Parker Scott, 2007, J COMMERCIAL BIOTECH, V13, P235, DOI DOI 10.1057/PALGRAVE.JCB.3050066; Westlaw, DERW WORLD PAT LEG L; WHO Collaborating Centre for Drug Statistics Methodology, ATC STRUCT PRINC; World Health Organization, INT NONPR NAM	25	9	9	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2013	8	4							e60812	10.1371/journal.pone.0060812	http://dx.doi.org/10.1371/journal.pone.0060812			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	146RZ	23577165	Green Published, gold			2023-01-03	WOS:000319109800103
J	Liao, Y; Wang, B; Huang, ZL; Shi, M; Yu, XJ; Zheng, LM; Li, SP; Li, L				Liao, Yuan; Wang, Bo; Huang, Zhi-Liang; Shi, Ming; Yu, Xing-Juan; Zheng, Limin; Li, Shengping; Li, Lian			Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study	PLOS ONE			English	Article							REGULATORY T-CELLS; ACTIVATED MONOCYTES; PERITUMORAL STROMA; CANCER; ENVIRONMENT; RECURRENCE; PHENOTYPE; SIGNATURE; CD4(+); BETA	Transarterial chemoembolization (TACE) has therapeutic effects in patients with unresectable hepatocellular carcinoma (HCC), but its impact on the cellular immune response during disease progression is largely unknown. Here we conducted a prospective study to evaluate the effect of TACE on immune status and to identify prognostic immune markers governing treatment success. In this study, 51 stage III HCC patients, 28 stage I HCC patients (TNM classification) and 20 healthy donors were enrolled. Flow cytometry and cytometric bead array were used to evaluate the circulating immune cell subsets, including CD4(+)T cells (Th1, Th17 and Treg cells), CD8(+)T cells, NK cells, and NKT cells, and plasma cytokines before TACE and 30 days after TACE. Interestingly, among those immune parameters, the frequency of circulating Th17 cells was higher in stage III HCC patients than in stage I HCC patients (P = 0.015) and healthy donors (P<0.001). Moreover, an increased frequency of circulating Th17 cells was observed 30 days after TACE (Th17(D30)) compared with the baseline level (P = 0.036). Kaplan-Meier analysis demonstrated that Th17(D30) was positively associated with overall survival (OS; P = 0.007) and time to progression (TTP; P = 0.009). Multivariate Cox analysis revealed that Th17(D30) was an independent prognostic factor for OS (HR = 0.317, P = 0.032) and TTP (HR = 0.304, P = 0.010). These results provide a potential prognostic marker for stage III HCC patients undergoing TACE and may be useful for identifying patients who can benefit from adjuvant immunotherapies.	[Liao, Yuan; Yu, Xing-Juan; Zheng, Limin; Li, Shengping] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China; [Wang, Bo; Zheng, Limin; Li, Lian] Sun Yat Sen Univ, State Key Lab Biocontrol, Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China; [Huang, Zhi-Liang; Shi, Ming; Li, Shengping] Sun Yat Sen Univ, Dept Hepatobiliary Oncol, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Li, SP (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China.	lishp@sysucc.org.cn; lilian-75@163.com	zheng, limin/HGB-2510-2022	Shi, Ming/0000-0002-4051-4474; Zheng, Limin/0000-0002-8281-1450	Ministry of Health of China [2012ZX10002-011]; National Natural Science Foundation of China [30901355, 91029737, 30872372]; Fundamental Research Funds for the Central Universities [11lgpy57]; Natural Science Foundation of Guangdong Province [S2011010001393]	Ministry of Health of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was supported by grants from the Ministry of Health of China (2012ZX10002-011), the National Natural Science Foundation of China (30901355, 91029737 and 30872372), the Fundamental Research Funds for the Central Universities (11lgpy57) and the Natural Science Foundation of Guangdong Province (S2011010001393). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Breous E, 2011, J HEPATOL, V54, P830, DOI 10.1016/j.jhep.2010.10.013; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Cariani E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032493; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fu JL, 2007, GASTROENTEROLOGY, V132, P2328, DOI 10.1053/j.gastro.2007.03.102; Fu YX, 2012, CELL MOL IMMUNOL, V9, P1, DOI 10.1038/cmi.2011.54; Hao Ming-Zhi, 2010, Chin J Cancer, V29, P172; Hoffmann K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-349; Huang ZL, 2011, J VASC INTERV RADIOL, V22, P702, DOI 10.1016/j.jvir.2010.12.041; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jung MC, 2002, LANCET INFECT DIS, V2, P43, DOI 10.1016/S1473-3099(01)00172-4; Kennedy R, 2008, IMMUNOL REV, V222, P129, DOI 10.1111/j.1600-065X.2008.00616.x; Koyama K, 2008, CLIN CANCER RES, V14, P6770, DOI 10.1158/1078-0432.CCR-08-1156; Kryczek I, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002949; Kryczek I, 2009, BLOOD, V114, P1141, DOI 10.1182/blood-2009-03-208249; Kuang DM, 2010, HEPATOLOGY, V51, P154, DOI 10.1002/hep.23291; Kuang DM, 2009, J EXP MED, V206, P1327, DOI 10.1084/jem.20082173; Lao XM, 2013, LIVER INT, V33, P595, DOI 10.1111/liv.12112; Lencioni R, 2010, ONCOLOGIST, V15, P42, DOI 10.1634/theoncologist.2010-S4-42; Luo J, 2011, ANN SURG ONCOL, V18, P413, DOI 10.1245/s10434-010-1321-8; Maniati E, 2010, ONCOGENE, V29, P5653, DOI 10.1038/onc.2010.367; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; Mizukoshi E, 2010, INT J CANCER, V126, P2164, DOI 10.1002/ijc.24882; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Muranski P, 2011, IMMUNITY, V35, P972, DOI 10.1016/j.immuni.2011.09.019; Pang XH, 2011, HEPATO-GASTROENTEROL, V58, P1687, DOI 10.5754/hge10799; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Park JW, 2012, J HEPATOL, V56, P1336, DOI 10.1016/j.jhep.2012.01.006; Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913; Shirabe K, 2010, INT J CLIN ONCOL, V15, P552, DOI 10.1007/s10147-010-0131-0; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Viaud S, 2011, CANCER RES, V71, P661, DOI 10.1158/0008-5472.CAN-10-1259; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Xu J, 2012, J HEPATOL, V57, P313, DOI 10.1016/j.jhep.2012.03.027; Yamashita F, 1997, ONCOLOGY, V54, P28; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zou WP, 2010, NAT REV IMMUNOL, V10, P248, DOI 10.1038/nri2742; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	41	41	46	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2013	8	4							e60444	10.1371/journal.pone.0060444	http://dx.doi.org/10.1371/journal.pone.0060444			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127RY	23565248	Green Published, Green Submitted, gold			2023-01-03	WOS:000317717300118
J	Detsky, AS; Berwick, DM				Detsky, Allan S.; Berwick, Donald M.			Teaching Physicians to Care Amid Chaos	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DUTY HOURS		[Detsky, Allan S.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada; [Berwick, Donald M.] Harvard Univ, Sch Med, Boston, MA USA; [Berwick, Donald M.] Inst Healthcare Improvement, Cambridge, MA USA	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Harvard University; Harvard Medical School; Institute for Healthcare Improvement	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, 600 Univ Ave,Ste 429, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca						Arora VM, 2012, JAMA-J AM MED ASSOC, V308, P2195, DOI 10.1001/jama.2012.14584; Cimino JJ, 2013, JAMA-J AM MED ASSOC, V309, P991, DOI 10.1001/jama.2013.890; Hirschtick RE, 2012, JAMA-J AM MED ASSOC, V308, P463, DOI 10.1001/jama.2012.8331; Horwitz LI, 2006, ARCH INTERN MED, V166, P1173, DOI 10.1001/archinte.166.11.1173; Lucas BP, 2012, JAMA-J AM MED ASSOC, V308, P2199, DOI 10.1001/jama.2012.36522; Rafelson WM, 2012, JAMA-J AM MED ASSOC, V308, P579, DOI 10.1001/jama.2012.8727; Rosenbaum L, 2012, NEW ENGL J MED, V367, P2044, DOI 10.1056/NEJMsr1210160; Toll E, 2012, JAMA-J AM MED ASSOC, V307, P2497, DOI 10.1001/jama.2012.4946	8	25	25	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 13	2013	309	10					987	988		10.1001/jama.2013.620	http://dx.doi.org/10.1001/jama.2013.620			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	103SH	23483169				2023-01-03	WOS:000315938700023
J	Jones, P; Peters, MJ; da Costa, NP; Kurth, T; Alberti, C; Kessous, K; Lode, N; Dauger, S				Jones, Peter; Peters, Mark J.; da Costa, Nathalia Pinto; Kurth, Tobias; Alberti, Corinne; Kessous, Katia; Lode, Noella; Dauger, Stephane			Atropine for Critical Care Intubation in a Cohort of 264 Children and Reduced Mortality Unrelated to Effects on Bradycardia	PLOS ONE			English	Article							CLINICAL-PRACTICE; COMPLICATIONS; INFANTS; PREMEDICATION; VARIABILITY; PARAMETERS; DEATH	Background: Atropine has is currently recommended to facilitate haemodynamic stability during critical care intubation. Our objective was to determine whether atropine use at induction influences ICU mortality. Methodology/Principal Findings: A 2-year prospective, observational study of all first non-planned intubations, September 2007-9 in PICU and Intensive Care Transport team of Hopital Robert Debre, Paris, 4 other PICUs and 5 NICUs in the Paris Region, France. Follow-up was from intubation to ICU discharge. A propensity score was used to adjust for patient specific characteristics influencing atropine prescription. 264/333 (79%) intubations were included. The unadjusted ICU mortality was 7.2% (9/124) for those who received atropine compared to 15.7% (22/140) for those who did not (OR 0.42, 95% CI 0.19-0.95, p = 0.04). One child died during intubation (1/264, 0.4%). Two age sub-groups of neonates (# 28 days) and older children (>28 days, <8 years) were examined. This difference in mortality arose from the higher mortality in children aged over one month when atropine was not used (propensity score adjusted OR 0.22, 95% CI 0.06-0.85, p = 0.028). No effect was seen in neonates (propensity score adjusted OR 1.3, 95% CI 0.31-5.1 p = 0.74). Using the propensity score, atropine maintained the mean heart rate 45.9 bpm above that observed when no atropine was used in neonates (95% CI 34.3-57.5, p, 0.001) and 43.5 bpm for older children (95% CI 25.5-61.5 bpm, p<0.001). Conclusions/Significance: Atropine use during induction was associated with a reduction in ICU mortality in children over one month. This effect is independent of atropine's capacity to attenuate bradycardia during intubation which occurred similarly in neonates and older children. This result needs to be confirmed in a study using randomised methodology.	[Jones, Peter; Peters, Mark J.] UCL, Inst Child Hlth, Crit Care Grp, Portex Unit, London, England; [Jones, Peter; da Costa, Nathalia Pinto; Kessous, Katia; Lode, Noella; Dauger, Stephane] Hop Robert Debre, AP HP, F-75019 Paris, France; [Kurth, Tobias] Inst Natl Sante & Rech Med, Bordeaux, France; [Kurth, Tobias] Univ Bordeaux, Bordeaux, France; [Kurth, Tobias] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02115 USA; [Alberti, Corinne] Hop Robert Debre, AP HP, Clin Epidemiol Unit, F-75019 Paris, France; [Alberti, Corinne] Hop Robert Debre, Inst Natl Sante & Rech Med CIE 5, F-75019 Paris, France; [Alberti, Corinne; Dauger, Stephane] Univ Paris Diderot, Paris, France	University of London; University College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Jones, P (corresponding author), UCL, Inst Child Hlth, Crit Care Grp, Portex Unit, London, England.	sejjprj@live.ucl.ac.uk	Dauger, Stéphane/AAX-9669-2021; Kurth, Tobias/A-9243-2012; Peters, Mark/AAD-7518-2019	Kurth, Tobias/0000-0001-7169-2620; Peters, Mark/0000-0003-3653-4808	Merck	Merck(Merck & Company)	The authors have the following interests. Tobias Kurth has received within the last 2 years investigator-initiated research funding from Merck. He is a consultant to World Health Information Science Consultants, LLC; he has received honoraria Merck for educational lectures and from MAP Pharmaceutical for contributing to a scientific advisory panel. The authors are grateful to Welch Allwyn for the generous donation of the ECG paper used by the ICT team. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Andriessen P, 2004, PEDIATR RES, V56, P939, DOI 10.1203/01.PDR.0000145257.75072.BB; [Anonymous], 2007, ANN REP PAED INT CAR, P115; Brady AR, 2006, PEDIATRICS, V117, pE733, DOI 10.1542/peds.2005-1853; Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6; Carroll CL, 2010, PEDIATR CRIT CARE ME, V11, P343, DOI 10.1097/PCC.0b013e3181c51426; Chow LTC, 2001, ANAT RECORD, V264, P169, DOI 10.1002/ar.1158; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Fastle RK, 2004, PEDIATR EMERG CARE, V20, P651, DOI 10.1097/01.pec.0000142947.35394.81; Gayat E, 2010, INTENS CARE MED, V36, P1993, DOI 10.1007/s00134-010-1991-5; Ghanta S, 2007, PEDIATRICS, V119, pE1248, DOI 10.1542/peds.2006-2708; Jaber S, 2006, CRIT CARE MED, V34, P2355, DOI 10.1097/01.CCM.0000233879.58720.87; Jones P, 2012, J INTENSIVE CARE SOC, V13, P2; Jones P, 2012, ARCH DIS CHILD, V97, P139, DOI 10.1136/adc.2010.210518; Kleinman ME, 2010, CIRCULATION, V122, P8466, DOI [10.1161/CIRCULATIONAHA.110.971093, 10.1542/peds.2010-2972A]; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; LEIGH MD, 1957, ANESTHESIOLOGY, V18, P698, DOI 10.1097/00000542-195709000-00004; Oei J, 2002, J PAEDIATR CHILD H, V38, P146, DOI 10.1046/j.1440-1754.2002.00726.x; PARNIS SJ, 1994, ANAESTH INTENS CARE, V22, P61, DOI 10.1177/0310057X9402200110; Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739; SAARNIVAARA L, 1985, ACTA ANAESTH SCAND, V29, P529, DOI 10.1111/j.1399-6576.1985.tb02248.x; Salata JJ, 2007, REFLEX CONTROL CIRCU, P67; SCHWARTZ DE, 1995, ANESTHESIOLOGY, V82, P367, DOI 10.1097/00000542-199502000-00007; Shaw CA, 2000, BRIT J ANAESTH, V84, P174, DOI 10.1093/oxfordjournals.bja.a013399; SHORTEN GD, 1995, CAN J ANAESTH, V42, P8, DOI 10.1007/BF03010563; Simon L, 2004, CRIT CARE MED, V32, P565, DOI 10.1097/01.CCM.0000108883.58081.E3; Taha S, 2005, CAN J ANAESTH, V52, P249, DOI 10.1007/BF03016058; Thomsen MB, 2005, BASIC RES CARDIOL, V100, P279, DOI 10.1007/s00395-005-0519-6; Tirel O, 2005, ANAESTHESIA, V60, P982, DOI 10.1111/j.1365-2044.2005.04298.x; Venkatesh V, 2009, EUROPEAN J PEDIAT, V170, P223; VIRTANEN R, 1982, ACTA ANAESTH SCAND, V26, P297, DOI 10.1111/j.1399-6576.1982.tb01770.x; WALSH CK, 1983, AM J CARDIOL, V51, P557, DOI 10.1016/S0002-9149(83)80096-4; Wyllie JP, 2008, ARCH DIS CHILDHOOD-E, V93, P44, DOI 10.1136/adc.2007.121160	32	27	27	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57478	10.1371/journal.pone.0057478	http://dx.doi.org/10.1371/journal.pone.0057478			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23468997	Green Published, Green Submitted, gold			2023-01-03	WOS:000315524900096
J	Levine, BL; June, CH				Levine, Bruce L.; June, Carl H.			PERSPECTIVE Assembly line immunotherapy	NATURE			English	Editorial Material									[Levine, Bruce L.; June, Carl H.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Levine, BL (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.							Baker M, 2011, NAT MED, V17, P519, DOI 10.1038/nm0511-519; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Levine BL, 1996, SCIENCE, V272, P1939, DOI 10.1126/science.272.5270.1939; Michalos G, 2010, CIRP J MANUF SCI TEC, V2, P81, DOI 10.1016/j.cirpj.2009.12.001; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849	5	33	33	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 27	2013	498	7455					S17	S17		10.1038/498S17a	http://dx.doi.org/10.1038/498S17a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	171LH	23803946	Bronze			2023-01-03	WOS:000320929400010
J	Lauche, R; Materdey, S; Cramer, H; Haller, H; Stange, R; Dobos, G; Rampp, T				Lauche, Romy; Materdey, Svitlana; Cramer, Holger; Haller, Heidemarie; Stange, Rainer; Dobos, Gustav; Rampp, Thomas			Effectiveness of Home-Based Cupping Massage Compared to Progressive Muscle Relaxation in Patients with Chronic Neck Pain-A Randomized Controlled Trial	PLOS ONE			English	Article							2000-2010 TASK-FORCE; CLINICAL-TRIALS; DISABILITY; WORKERS; QUESTIONNAIRE; PREVALENCE; DISORDERS; VALIDITY; BONE	Chronic neck pain is a major public health problem with very few evidence-based complementary treatment options. This study aimed to test the efficacy of 12 weeks of a partner-delivered home-based cupping massage, compared to the same period of progressive muscle relaxation in patients with chronic non-specific neck pain. Patients were randomly assigned to self-directed cupping massage or progressive muscle relaxation. They were trained and asked to undertake the assigned treatment twice weekly for 12 weeks. Primary outcome measure was the current neck pain intensity (0-100 mm visual analog scale; VAS) after 12 weeks. Secondary outcome measures included pain on motion, affective pain perception, functional disability, psychological distress, wellbeing, health-related quality of life, pressure pain thresholds and adverse events. Sixty one patients (54.1+/-12.7 years; 73.8% female) were randomized to cupping massage (n = 30) or progressive muscle relaxation (n = 31). After treatment, both groups showed significantly less pain compared to baseline however without significant group differences. Significant effects in favor of cupping massage were only found for wellbeing and pressure pain thresholds. In conclusion, cupping massage is no more effective than progressive muscle relaxation in reducing chronic non-specific neck pain. Both therapies can be easily used at home and can reduce pain to a minimal clinically relevant extent. Cupping massage may however be better than PMR in improving well-being and decreasing pressure pain sensitivity but more studies with larger samples and longer follow-up periods are needed to confirm these results.	[Lauche, Romy; Materdey, Svitlana; Cramer, Holger; Haller, Heidemarie; Dobos, Gustav; Rampp, Thomas] Univ Duisburg Essen, Fac Med, Kliniken Essen Mitte, Dept Internal & Integrat Med, Essen, Germany; [Stange, Rainer] Immanuel Hosp Berlin, Dept Internal & Complementary Med, Berlin, Germany	Kliniken Essen-Mitte; University of Duisburg Essen	Lauche, R (corresponding author), Univ Duisburg Essen, Fac Med, Kliniken Essen Mitte, Dept Internal & Integrat Med, Essen, Germany.	r.lauche@kliniken-essen-mitte.de	Lauche, Romy/AAQ-7175-2021; Haller, Heidemarie/AAX-5927-2021; Cramer, Holger/AAH-1794-2019	Lauche, Romy/0000-0002-4171-7935; Haller, Heidemarie/0000-0001-7973-4071; Cramer, Holger/0000-0002-3640-8046	Karl and Veronica Carstens Foundation, Essen, Germany [KVC 0/0430/2011]	Karl and Veronica Carstens Foundation, Essen, Germany	The researchers received a grant for this study from the Karl and Veronica Carstens Foundation, Essen, Germany (grant number: KVC 0/0430/2011, wwww.carstens-stiftung.de). They also received free arnica massage oils from the WELEDA AG, Schwabisch Gmund, Germany (www.weleda.de). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abele J., 2003, SCHROPFEN BEWAHRTE A; Ameen V, 2010, GASTROENTEROLOGY, V132, pA140; Bullinger M, 1998, SF 36 FRAGEBOGEN ZUM; Cao HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031793; Chirali I., 2007, TRADITIONAL CHINESE; Cote P, 1998, SPINE, V23, P1689, DOI 10.1097/00007632-199808010-00015; Cote P, 2008, SPINE, V33, pS60, DOI 10.1097/BRS.0b013e3181643ee4; Cramer H, 2012, EUR J INTEGR MED, V4, pE371, DOI 10.1016/j.eujim.2012.04.001; Cramer H, 2011, FORSCH KOMPLEMENTMED, V18, P327, DOI 10.1159/000335294; Deutsche Gesellschaft fur Allgemeinmedizin (DEGAM), 2009, LEITL 13 NACK; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Fejer R, 2006, EUR SPINE J, V15, P834, DOI 10.1007/s00586-004-0864-4; Fliege H, 2005, PSYCHOSOM MED, V67, P78, DOI 10.1097/01.psy.0000151491.80178.78; Geissner E, 1996, SCHMERZEMPFINDUNGSSK; Gustavsson C, 2006, J REHABIL MED, V38, P100, DOI 10.1080/16501970510044025; Hasenbring M, 1989, PATIENTENKONZEPTE KO, P25; Herrmann C., 1995, HOSP ANXIETY DEPRESS; Hurwitz EL, 2008, SPINE, V33, pS123, DOI 10.1097/BRS.0b013e3181644b1d; Irnich D, 2001, BMJ-BRIT MED J, V322, P1574, DOI 10.1136/bmj.322.7302.1574; Jacobson E., 1938, J ABNORM PSYCHOL; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Johnston V, 2008, PAIN, V137, P257, DOI 10.1016/j.pain.2007.08.037; Kim Jong-In, 2011, Evid Based Complement Alternat Med, V2011, P467014, DOI 10.1093/ecam/nep035; Kolip P, 1999, Z GESUNDHEITSPSYCHOL, V7, P77, DOI DOI 10.1026//0943-8149.7.2.77; Korb J, 2003, SCHMERZ, V17, pS47; La Touche R, 2010, J PAIN, V11, P256, DOI 10.1016/j.jpain.2009.07.003; Lauche R, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/429718; Lauche R, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-63; Madeleine P, 2003, INT ARCH OCC ENV HEA, V76, P39, DOI 10.1007/s00420-002-0375-8; Nagel B, 2002, SCHMERZ, V16, P263, DOI 10.1007/s00482-002-0162-1; Peloso P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000319.pub4; Schumann S, 2012, BMC COMPLEM ALTERN M, V12, P80; Techniker Krankenkasse, 2013, PROGR MUSCL REL; Tiplady B, 1998, AGE AGEING, V27, P63, DOI 10.1093/ageing/27.1.63; Treede RD, 2002, PAIN, V98, P235, DOI 10.1016/S0304-3959(02)00203-8; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Viljanen M, 2003, BRIT MED J, V327, P475, DOI 10.1136/bmj.327.7413.475; Weerapong P, 2005, SPORTS MED, V35, P235, DOI 10.2165/00007256-200535030-00004	38	49	51	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2013	8	6							e65378	10.1371/journal.pone.0065378	http://dx.doi.org/10.1371/journal.pone.0065378			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173QU	23762355	Green Published, gold, Green Submitted			2023-01-03	WOS:000321094800043
J	Grossman, D				Grossman, Daniel			Moving Oral Contraceptives Over the Counter as a Strategy to Reduce Unintended Pregnancy	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CONTRAINDICATIONS		Ibis Reprod Hlth, Oakland, CA 94612 USA		Grossman, D (corresponding author), Ibis Reprod Hlth, 1330 Broadway, Oakland, CA 94612 USA.	DGrossman@ibisreproductivehealth.org						Committee on Gynecologic Practice American College of Obstetricians and Gynecologists, 2012, Obstet Gynecol, V120, P1527, DOI 10.1097/01.AOG.0000423818.85283.bd; Finer LB, 2011, CONTRACEPTION, V84, P478, DOI 10.1016/j.contraception.2011.07.013; Grindlay K, 2012, CONTRACEPTION; Grossman D, 2012, CONTRACEPTION, V86, P293, DOI 10.1016/j.contraception.2012.05.033; Grossman D, 2008, OBSTET GYNECOL, V112, P572, DOI 10.1097/AOG.0b013e31818345f0; Hopkins K, 2012, CONTRACEPTION, V86, P376, DOI 10.1016/j.contraception.2012.03.003; Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1; Potter JE, 2011, OBSTET GYNECOL, V117, P551, DOI 10.1097/AOG.0b013e31820afc46; Shah MA, 2001, INT J GYNECOL OBSTET, V73, P243, DOI 10.1016/S0020-7292(01)00375-7; White K, 2012, CONTRACEPTION, V86, P199, DOI 10.1016/j.contraception.2012.01.008	10	5	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 4	2013	158	11					839	+		10.7326/0003-4819-158-11-201306040-00629	http://dx.doi.org/10.7326/0003-4819-158-11-201306040-00629			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	164AA	23529386				2023-01-03	WOS:000320379800007
J	Adler, JN; Colbert, JA				Adler, Jonathan N.; Colbert, James A.			Medicinal Use of Marijuana - Polling Results	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		[Anonymous], 2013, N ENGL J MED, V368, P866	1	54	55	1	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 30	2013	368	22					E30	E30		10.1056/NEJMclde1305159	http://dx.doi.org/10.1056/NEJMclde1305159			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	153AT	23718175				2023-01-03	WOS:000319574200015
J	Zhou, L; Situ, SJ; Huang, T; Hu, SX; Wang, XJ; Zhu, XP; Gao, LD; Li, Z; Feng, A; Jin, H; Wang, SY; Su, QR; Xu, Z; Feng, ZJ				Zhou, Lei; Situ, Sujian; Huang, Ting; Hu, Shixiong; Wang, Xianjun; Zhu, Xiaoping; Gao, Lidong; Li, Zhong; Feng, Ao; Jin, Hui; Wang, Shiyuan; Su, Qiru; Xu, Zhen; Feng, Zijian			Direct Medical Cost of Influenza-Related Hospitalizations among Severe Acute Respiratory Infections Cases in Three Provinces in China	PLOS ONE			English	Article							CHILDREN; IMPACT	Background: Influenza-related hospitalizations impose a considerable economic and social burden. This study aimed to better understand the economic burden of influenza-related hospitalizations among patients in China in different age and risk categories. Methods: Laboratory-confirmed influenza-related hospitalizations between December 2009 and June 2011 from three hospitals participating in the Chinese Severe Acute Respiratory Infections (SARI) sentinel surveillance system were included in this study. Hospital billing data were collected from each hospital's Hospital Information System (HIS) and divided into five cost categories. Demographic and clinical information was collected from medical records. Mean (range) and median (interquartile range [IQR]) costs were calculated and compared among children (<= 15 years), adults (16-64 years) and elderly (>= 65 years) groups. Factors influencing cost were analyzed. Results: A total of 106 laboratory-confirmed influenza-related hospitalizations were identified, 60% of which were children. The mean (range) direct medical cost was $1,797 ($80-$27,545) for all hospitalizations, and the median (IQR) direct medical cost was $231 ($164), $854 ($890), and $2,263 ($7,803) for children, adults, and elderly, respectively. Therapeutics and diagnostics were the two largest components of direct medical cost, comprising 57% and 23%, respectively. Cost of physician services was the lowest at less than 1%. Conclusion: Direct medical cost of influenza-related hospitalizations imposes a heavy burden on patients and their families in China. Further study is needed to provide more comprehensive evidence on the economic burden of influenza. Our study highlights the need to increase vaccination rate and develop targeted national preventive strategies.	[Zhou, Lei; Feng, Ao; Su, Qiru; Feng, Zijian] Chinese Ctr Dis Control & Prevent China CDC, Publ Hlth Emergency Ctr, Beijing, Peoples R China; [Situ, Sujian] US Ctr Dis Control & Prevent, Beijing, Peoples R China; [Huang, Ting; Zhu, Xiaoping] Sichuan Prov Ctr Dis Control & Prevent, Chengdu, Peoples R China; [Hu, Shixiong; Gao, Lidong] Hunan Prov Ctr Dis Control & Prevent, Changsha, Hunan, Peoples R China; [Wang, Xianjun; Li, Zhong] Shandong Prov Ctr Dis Control & Prevent, Jinan, Peoples R China; [Jin, Hui; Wang, Shiyuan] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing, Peoples R China; [Xu, Zhen] Chinese Ctr Dis Control & Prevent China CDC, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing, Peoples R China	Chinese Center for Disease Control & Prevention; Southeast University - China; Chinese Center for Disease Control & Prevention	Zhou, L (corresponding author), Chinese Ctr Dis Control & Prevent China CDC, Publ Hlth Emergency Ctr, Beijing, Peoples R China.	zhoulei@chinacdc.cn; xuzhen@chinacdc.cn	Jin, Hui/GXG-2296-2022; JIN, HUI/AAA-8732-2019		China-U.S. Collaborative Program on Emerging and Re-emerging Infectious Diseases	China-U.S. Collaborative Program on Emerging and Re-emerging Infectious Diseases	This study was supported by the China-U.S. Collaborative Program on Emerging and Re-emerging Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475; [Anonymous], FACT SHEET INFL SEAS; Census and statistics department Hong Kong SAR P.R. China, 2009, 2009 10 HOUS EXP SUR; Chinese Center for Disease Control and Prevention, 2011, SARI SURV PROT 2011; Chinese Center for Disease Control and Prevention, GUID SEAS INFL VACC; Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6; Feng LZ, 2012, B WORLD HEALTH ORGAN, V90, P279, DOI 10.2471/BLT.11.096958; Feng LZ, 2010, VACCINE, V28, P6778, DOI 10.1016/j.vaccine.2010.07.064; Financial management service, 2010, TREAS REP RAT EXCH D; Guo RN, 2011, PUBLIC HEALTH, V125, P389, DOI 10.1016/j.puhe.2011.03.004; Hall JL, 2005, J PEDIATR-US, V147, P807, DOI 10.1016/j.jpeds.2005.06.031; Hassan F, 2009, AM J PREV MED, V36, P292, DOI 10.1016/j.amepre.2008.11.016; Keren R, 2006, PEDIATRICS, V118, pE1321, DOI 10.1542/peds.2006-0598; Meltzer MI, 1999, EMERG INFECT DIS, V5, P659, DOI 10.3201/eid0505.990507; Ministry of Health of the People's Republic of China, GUID MIN HLTH 12 5 Y; Principi N, 2003, PEDIATR INFECT DIS J, V22, pS207, DOI 10.1097/01.inf.0000092188.48726.e4; World Bank, GDP PER CAP CURR US; World Health Organization Regional Office for Europe, 2011, WHO REG OFF EUR GUID; Zhang T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044391	19	22	35	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2013	8	5							e63788	10.1371/journal.pone.0063788	http://dx.doi.org/10.1371/journal.pone.0063788			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163UP	23717485	Green Published, Green Submitted, gold			2023-01-03	WOS:000320362700061
J	Pepponi, I; Stylianou, E; van Dolleweerd, C; Diogo, GR; Paul, MJ; Drake, PMW; Ma, JKC; Reljic, R				Pepponi, Ilaria; Stylianou, Elena; van Dolleweerd, Craig; Diogo, Gil Reynolds; Paul, Matthew J.; Drake, Pascal M. W.; Ma, Julian K. -C.; Reljic, Rajko			Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery	PLOS ONE			English	Article							T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS INFECTION; B SURFACE-ANTIGEN; MONOCLONAL-ANTIBODIES; CROSS-PRESENTATION; DENDRITIC CELLS; IMMUNOGLOBULIN-A; DORMANCY REGULON; IGG-ANTIBODIES; PROTEIN	Protein-based vaccine development faces the difficult challenge of finding robust yet non-toxic adjuvants suitable for humans. Here, using a molecular engineering approach, we have developed a molecular platform for generating self-adjuvanting immunogens that do not depend on exogenous adjuvants for induction of immune responses. These are based on the concept of Immune Complex Mimics (ICM), structures that are formed between an oligomeric antigen and a monoclonal antibody (mAb) to that antigen. In this way, the roles of antigens and antibodies within the structure of immune complexes are reversed, so that a single monoclonal antibody, rather than polyclonal sera or expensive mAb cocktails can be used. We tested this approach in the context of Mycobacterium tuberculosis (MTB) infection by linking the highly immunogenic and potentially protective Ag85B with the oligomeric Acr (alpha crystallin, HspX) antigen. When combined with an anti-Acr monoclonal antibody, the fusion protein formed ICM which bound to C1q component of the complement system and were readily taken up by antigen-presenting cells in vitro. ICM induced a strong Th1/Th2 mixed type antibody response, which was comparable to cholera toxin adjuvanted antigen, but only moderate levels of T cell proliferation and IFN-gamma secretion. Unfortunately, the systemic administration of ICM did not confer statistically significant protection against intranasal MTB challenge, although a small BCG-boosting effect was observed. We conclude that ICM are capable of inducing strong humoral responses to incorporated antigens and may be a suitable vaccination approach for pathogens other than MTB, where antibody-based immunity may play a more protective role.	[Pepponi, Ilaria; Stylianou, Elena; van Dolleweerd, Craig; Diogo, Gil Reynolds; Paul, Matthew J.; Drake, Pascal M. W.; Ma, Julian K. -C.; Reljic, Rajko] St Georges Univ London, Infect & Immun Res Ctr, London, England	St Georges University London	Reljic, R (corresponding author), St Georges Univ London, Infect & Immun Res Ctr, London, England.	rreljic@sgul.ac.uk	Pepponi, Ilaria/AAA-6083-2020	Pepponi, Ilaria/0000-0001-7610-738X; Drake, Pascal/0000-0002-6181-0600; Paul, Mathew/0000-0002-0852-8788; Ma, Julian/0000-0003-0767-0042; van Dolleweerd, Craig/0000-0002-1380-6930	Dunhill Medical Trust [R40/0207]	Dunhill Medical Trust(Dunhill Medical Trust)	The work was supported by Dunhill Medical Trust grant R40/0207 (www.dunhillmedical.org.uk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Motal U, 2006, J VIROL, V80, P6943, DOI 10.1128/JVI.00310-06; ANDERSEN P, 1995, J IMMUNOL, V154, P3359; Antoniou AN, 2002, EUR J IMMUNOL, V32, P530, DOI 10.1002/1521-4141(200202)32:2<530::AID-IMMU530>3.0.CO;2-X; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Berengian AR, 1999, J BIOL CHEM, V274, P6305, DOI 10.1074/jbc.274.10.6305; BOESEN H, 1995, INFECT IMMUN, V63, P1491, DOI 10.1128/IAI.63.4.1491-1497.1995; Caccamo N, 2004, EUR J IMMUNOL, V34, P2220, DOI 10.1002/eji.200425090; Cady CT, 2010, IMMUNOL LETT, V130, P57, DOI 10.1016/j.imlet.2009.12.001; CELIS E, 1984, SCIENCE, V224, P297, DOI 10.1126/science.6231724; CELIS E, 1984, P NATL ACAD SCI-BIOL, V81, P6846, DOI 10.1073/pnas.81.21.6846; Chang ZY, 1996, J BIOL CHEM, V271, P7218, DOI 10.1074/jbc.271.12.7218; Chargelegue D, 2005, INFECT IMMUN, V73, P5915, DOI 10.1128/IAI.73.9.5915-5922.2005; Cunningham AF, 1998, J BACTERIOL, V180, P801, DOI 10.1128/JB.180.4.801-808.1998; da Silva FP, 2007, NAT MED, V13, P1368, DOI 10.1038/nm1665; Demissie A, 2006, CLIN VACCINE IMMUNOL, V13, P179, DOI 10.1128/CVI.13.2.179-186.2006; den Haan JMM, 2002, J EXP MED, V196, P817, DOI 10.1084/jem.20020295; EISENBERG RJ, 1982, J VIROL, V41, P478, DOI 10.1128/JVI.41.2.478-488.1982; Falero-Diaz G, 2000, INT ARCH ALLERGY IMM, V122, P143, DOI 10.1159/000024370; Guyre PM, 1997, CANCER IMMUNOL IMMUN, V45, P146, DOI 10.1007/s002620050418; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; HEYMAN B, 1990, IMMUNOL TODAY, V11, P310, DOI 10.1016/0167-5699(90)90126-T; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; HOUSTON WE, 1977, J INFECT DIS, V135, P600, DOI 10.1093/infdis/135.4.600; JACKETT PS, 1988, J CLIN MICROBIOL, V26, P2313, DOI 10.1128/JCM.26.11.2313-2318.1988; Jacobsen M, 2007, J IMMUNOL, V179, P1331, DOI 10.4049/jimmunol.179.2.1331; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; Kennaway CK, 2005, J BIOL CHEM, V280, P33419, DOI 10.1074/jbc.M504263200; KLAUS GGB, 1978, IMMUNOLOGY, V34, P643; LAISSUE J, 1971, J IMMUNOL, V107, P822; Leyten EMS, 2006, MICROBES INFECT, V8, P2052, DOI 10.1016/j.micinf.2006.03.018; Li Q, 2011, SCAND J IMMUNOL, V73, P568, DOI 10.1111/j.1365-3083.2011.02531.x; MANCA F, 1988, J IMMUNOL, V140, P2893; MARUSICGALESIC S, 1992, IMMUNOLOGY, V75, P325; Matheoud D, 2010, BLOOD, V115, P4412, DOI 10.1182/blood-2009-11-255935; Moreno-Mendieta SA, 2010, FEMS IMMUNOL MED MIC, V58, P75, DOI 10.1111/j.1574-695X.2009.00629.x; Mustafa AS, 1998, SCAND J IMMUNOL, V48, P535; OSATO K, 1972, IMMUNOLOGY, V23, P545; Pal R, 2010, APMIS, V118, P729, DOI 10.1111/j.1600-0463.2010.02650.x; Phoolcharoen W, 2011, PLANT BIOTECHNOL J, V9, P807, DOI 10.1111/j.1467-7652.2011.00593.x; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Polyanskaya N, 2001, VIROLOGY, V279, P527, DOI 10.1006/viro.2000.0704; Raja A, 2002, CLIN DIAGN LAB IMMUN, V9, P308, DOI 10.1128/CDLI.9.2.308-312.2002; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; REID KBM, 1986, ESSAYS BIOCHEM, V22, P27; Reljic R, 2006, CLIN EXP IMMUNOL, V143, P467, DOI 10.1111/j.1365-2249.2006.03012.x; Reljic R, 2006, TUBERCULOSIS, V86, P179, DOI 10.1016/j.tube.2006.01.011; Roupie V, 2007, INFECT IMMUN, V75, P941, DOI 10.1128/IAI.01137-06; SCHALKE BCG, 1985, J IMMUNOL, V134, P3643; Schuurhuis DH, 2002, J IMMUNOL, V168, P2240, DOI 10.4049/jimmunol.168.5.2240; SIMITSEK PD, 1995, J EXP MED, V181, P1957, DOI 10.1084/jem.181.6.1957; TAYLOR RG, 1993, NUCLEIC ACIDS RES, V21, P1677, DOI 10.1093/nar/21.7.1677; TERRES G, 1972, J IMMUNOL, V108, P1473; Villinger F, 2003, J VIROL, V77, P10, DOI 10.1128/JVI.77.1.10-24.2003; Wen YM, 2009, EXPERT OPIN BIOL TH, V9, P285, DOI [10.1517/14712590802715749, 10.1517/14712590802715749 ]; WIERSMA EJ, 1989, SCAND J IMMUNOL, V29, P439, DOI 10.1111/j.1365-3083.1989.tb01143.x; Wilkinson RJ, 1998, SCAND J IMMUNOL, V48, P403; Williams A, 2004, IMMUNOLOGY, V111, P328, DOI 10.1111/j.1365-2567.2004.01809.x; Winau F, 2006, IMMUNITY, V24, P105, DOI 10.1016/j.immuni.2005.12.001; Yuan Y, 1998, P NATL ACAD SCI USA, V95, P9578, DOI 10.1073/pnas.95.16.9578; Yuan Y., 1996, J BACTERIOL, V178, P4484, DOI DOI 10.1128/JB.178.15.4484-4492.1996	60	16	16	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e60855	10.1371/journal.pone.0060855	http://dx.doi.org/10.1371/journal.pone.0060855			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131QH	23637771	Green Submitted, gold, Green Published, Green Accepted			2023-01-03	WOS:000318008400016
J	Kim, HG; Cho, JH; Yoo, SR; Lee, JS; Han, JM; Lee, NH; Ahn, YC; Son, CG				Kim, Hyeong-Geug; Cho, Jung-Hyo; Yoo, Sa-Ra; Lee, Jin-Seok; Han, Jong-Min; Lee, Nam-Hun; Ahn, Yo-Chan; Son, Chang-Gue			Antifatigue Effects of Panax ginseng CA Meyer: A Randomised, Double-Blind, Placebo-Controlled Trial	PLOS ONE			English	Article							CHRONIC-FATIGUE-SYNDROME; BLOOD-GLUCOSE LEVELS; OXIDATIVE STRESS; COGNITIVE PERFORMANCE; CLINICAL-TRIAL; RED GINSENG; ANTIOXIDANT; GLUTATHIONE; VOLUNTEERS; PEROXIDES	The present study investigated the antifatigue effects of Panax ginseng C. A. Meyer in 90 subjects (21 men and 69 women) with idiopathic chronic fatigue (ICF) in a randomised, double-blind, placebo-controlled and parallel designed trial. A bespoke 20% ethanol extract of P. ginseng (1 g or 2 g day(-1)) or a placebo was administered to each group for 4 weeks, and then fatigue severity was monitored using a self-rating numeric scale (NRS) and a visual analogue scale (VAS) as a primary endpoint. Serum levels of reactive oxygen species (ROS), malondialdehyde (MDA), total glutathione (GSH) contents and glutathione reductase (GSH-Rd) activity were determined. After 4-week, P. ginseng administration decreased the total NRS score, but they were not statistically significant compared with placebo (P > 0.05). Mental NRS score was significantly improved by P. ginseng administrations as 20.4 +/- 5.0 to 15.1 +/- 6.5 [95% CI 2.3 similar to 8.2] for 1 g and 20.7 +/- 6.3 to 13.8 +/- 6.2 [95% CI 20.1 similar to 4.2] for 2 g compared with placebo 20.9 +/- 4.5 to 18.8 +/- 2.9 [95% CI 4.1 similar to 9.9, P > 0.01]. Only 2 g P. ginseng significantly reduced the VAS score from 7.3 +/- 1.3 to 4.4 +/- 1.8 [95% CI 0.7 similar to 1.8] compared with the placebo 7.1 +/- 1.0 to 5.8 +/- 1.3 [95% CI 2.2 similar to 3.7, P > 0.01]. ROS and MDA levels were lowered by P. ginseng compared to placebo. P. ginseng 1 g increased GSH concentration and GSH-Rd activity. Our results provide the first evidence of the antifatigue effects of P. ginseng in patients with ICF, and we submit that these changes in antioxidant properties contribute in part to its mechanism.	[Kim, Hyeong-Geug; Cho, Jung-Hyo; Yoo, Sa-Ra; Lee, Jin-Seok; Han, Jong-Min; Lee, Nam-Hun; Son, Chang-Gue] Daejeon Univ, Daejeon Oriental Hosp, Liver & Immunol Res Ctr, Taejon, South Korea; [Ahn, Yo-Chan] Daejeon Univ, Dept Hlth Serv Management, Taejon, South Korea	Daejeon University; Daejeon University	Son, CG (corresponding author), Daejeon Univ, Daejeon Oriental Hosp, Liver & Immunol Res Ctr, Taejon, South Korea.	ckson@dju.ac.kr	son, chang gue/ABC-2215-2021		National Research Foundation [R01-2007-000-11248-0, 20110003150]; Republic of Korea's Ministry of Education, Science and Technology	National Research Foundation; Republic of Korea's Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This study was supported by a grant from the National Research Foundation (and R01-2007-000-11248-0 and 20110003150) from the Republic of Korea's Ministry of Education, Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bahrke MS, 2000, SPORTS MED, V29, P113, DOI 10.2165/00007256-200029020-00004; Barton DL, 2010, SUPPORT CARE CANCER, V18, P179, DOI 10.1007/s00520-009-0642-2; Bassi N, 2008, ISR MED ASSOC J, V10, P79; BEERS RF, 1952, J BIOL CHEM, V195, P133; Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5; Choi KT, 2008, ACTA PHARMACOL SIN, V29, P1109, DOI 10.1111/j.1745-7254.2008.00869.x; Coon JT, 2002, DRUG SAFETY, V25, P323, DOI 10.2165/00002018-200225050-00003; Craig T, 2002, AM FAM PHYSICIAN, V65, P1083; Dickson A, 2009, PSYCHOL MED, V39, P1567, DOI 10.1017/S0033291708004960; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Hartz AJ, 2004, PSYCHOL MED, V34, P51, DOI 10.1017/S0033291703008791; Hayashi I, 2007, MUTAT RES-GEN TOX EN, V631, P55, DOI 10.1016/j.mrgentox.2007.04.006; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Jason LA, 1999, ARCH INTERN MED, V159, P2129, DOI 10.1001/archinte.159.18.2129; Jia L, 2009, CURR MED CHEM, V16, P2475, DOI 10.2174/092986709788682146; Jo SA, 2007, INT J GERIATR PSYCH, V22, P218, DOI 10.1002/gps.1664; Jones James F, 2007, BMC Complement Altern Med, V7, P12, DOI 10.1186/1472-6882-7-12; KAMAL AAM, 1989, ENVIRON RES, V49, P173, DOI 10.1016/S0013-9351(89)80062-3; Kambayashi Y, 2009, J CLIN BIOCHEM NUTR, V44, P46, DOI 10.3164/jcbn.08-162; Kennedy DO, 2001, NUTR NEUROSCI, V4, P295, DOI 10.1080/1028415X.2001.11747370; Kim HG, 2011, FOOD CHEM TOXICOL, V49, P2229, DOI 10.1016/j.fct.2011.06.020; Kim SH, 2005, J SPORT MED PHYS FIT, V45, P178; Lee LS, 2008, J CLIN PHARMACOL, V48, P599, DOI 10.1177/0091270008314252; Lee NH, 2012, J ALTERN COMPLEM MED, V18, P1061, DOI 10.1089/acm.2011.0591; Lee NH, 2011, J ACUPUNCT MERIDIAN, V4, P85, DOI 10.1016/S2005-2901(11)60013-7; Lee ST, 2008, ALZ DIS ASSOC DIS, V22, P222, DOI 10.1097/WAD.0b013e31816c92e6; Littell R.C., 2006, SAS SYSTEM MIXED MOD, V2nd; Liu XL, 2011, FISH SHELLFISH IMMUN, V30, P495, DOI 10.1016/j.fsi.2010.11.018; Lu JM, 2009, CURR VASC PHARMACOL, V7, P293, DOI 10.2174/157016109788340767; Maes M, 2011, MED SCI MONITOR, V17, pSC11, DOI 10.12659/MSM.881699; Magder S, 2006, CRIT CARE, V10, DOI 10.1186/cc3992; Marshall PS, 1997, PSYCHOSOM MED, V59, P58, DOI 10.1097/00006842-199701000-00008; Morriss RK, 1998, J PSYCHOSOM RES, V45, P411, DOI 10.1016/S0022-3999(98)00022-1; OEI TPS, 1990, BRIT J CLIN PSYCHOL, V29, P429, DOI 10.1111/j.2044-8260.1990.tb00906.x; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Puri BK, 2009, PROSTAG LEUKOTR ESS, V81, P303, DOI 10.1016/j.plefa.2009.10.002; Raghavendra V, 2001, FREE RADICAL BIO MED, V30, P595, DOI 10.1016/S0891-5849(00)00447-0; Reay JL, 2005, J PSYCHOPHARMACOL, V19, P357, DOI 10.1177/0269881105053286; Reay JL, 2006, J PSYCHOPHARMACOL, V20, P771, DOI 10.1177/0269881106061516; Reay JL, 2010, HUM PSYCHOPHARM CLIN, V25, P462, DOI 10.1002/hup.1138; Richards RS, 2000, REDOX REP, V5, P35, DOI 10.1179/rer.2000.5.1.35; Roy-Byrne P, 2002, BRIT J PSYCHIAT, V180, P29, DOI 10.1192/bjp.180.1.29; Shim JY, 2010, TOXICOL APPL PHARM, V242, P318, DOI 10.1016/j.taap.2009.11.005; Shukla R, 2009, FOOD CHEM TOXICOL, V47, P769, DOI 10.1016/j.fct.2009.01.002; Son Chang-Gue, 2011, [Journal of Korean Medicine, 대한한의학회지], V32, P67; Suh SO, 2002, AM J CHINESE MED, V30, P483, DOI 10.1142/S0192415X02000661; Tang W, 2008, BIOL PHARM BULL, V31, P2024, DOI 10.1248/bpb.31.2024; Vuksan V, 2008, NUTR METAB CARDIOVAS, V18, P46, DOI 10.1016/j.numecd.2006.04.003; Wang J, 2010, J ETHNOPHARMACOL, V130, P421, DOI 10.1016/j.jep.2010.05.027; Wesnes KA, 2000, PSYCHOPHARMACOLOGY, V152, P353, DOI 10.1007/s002130000533; WORTHINGTON DJ, 1974, EUR J BIOCHEM, V48, P167, DOI 10.1111/j.1432-1033.1974.tb03754.x	52	64	69	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e61271	10.1371/journal.pone.0061271	http://dx.doi.org/10.1371/journal.pone.0061271			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IK	23613825	gold, Green Published			2023-01-03	WOS:000317907200044
J	Mourtada, R; Fonseca, SB; Wisnovsky, SP; Pereira, MP; Wang, XM; Hurren, R; Parfitt, J; Larsen, L; Smith, RAJ; Murphy, MP; Schimmer, AD; Kelley, SO				Mourtada, Rida; Fonseca, Sonali B.; Wisnovsky, Simon P.; Pereira, Mark P.; Wang, Xiaoming; Hurren, Rose; Parfitt, Jeremy; Larsen, Lesley; Smith, Robin A. J.; Murphy, Michael P.; Schimmer, Aaron D.; Kelley, Shana O.			Re-Directing an Alkylating Agent to Mitochondria Alters Drug Target and Cell Death Mechanism	PLOS ONE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; NITROGEN-MUSTARD; IN-VIVO; PENETRATING PEPTIDES; CHLORAMBUCIL; RESISTANCE; METABOLISM; APOPTOSIS; PHARMACOKINETICS; INDUCTION	We have successfully delivered a reactive alkylating agent, chlorambucil (Cbl), to the mitochondria of mammalian cells. Here, we characterize the mechanism of cell death for mitochondria-targeted chlorambucil (mt-Cbl) in vitro and assess its efficacy in a xenograft mouse model of leukemia. Using a rho degrees cell model, we show that mt-Cbl toxicity is not dependent on mitochondrial DNA damage. We also illustrate that re-targeting Cbl to mitochondria results in a shift in the cell death mechanism from apoptosis to necrosis, and that this behavior is a general feature of mitochondria-targeted Cbl. Despite the change in cell death mechanisms, we show that mt-Cbl is still effective in vivo and has an improved pharmacokinetic profile compared to the parent drug. These findings illustrate that mitochondrial rerouting changes the site of action of Cbl and also alters the cell death mechanism drastically without compromising in vivo efficacy. Thus, mitochondrial delivery allows the exploitation of Cbl as a promiscuous mitochondrial protein inhibitor with promising therapeutic potential.	[Mourtada, Rida; Fonseca, Sonali B.; Kelley, Shana O.] Univ Toronto, Fac Pharm, Dept Pharmaceut Sci, Toronto, ON, Canada; [Wisnovsky, Simon P.; Pereira, Mark P.; Kelley, Shana O.] Univ Toronto, Fac Med, Dept Biochem, Toronto, ON, Canada; [Wang, Xiaoming; Hurren, Rose; Schimmer, Aaron D.] Princess Margaret Hosp, Ontario Canc Inst, Campbell Family Canc Res Inst, Toronto, ON M4X 1K9, Canada; [Parfitt, Jeremy] Univ Western Ontario, Dept Pathol, London, ON, Canada; [Larsen, Lesley; Smith, Robin A. J.] Univ Otago, Dept Chem, Dunedin, New Zealand; [Murphy, Michael P.] MRC, Mitochondrial Biol Unit, Cambridge, England	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Western University (University of Western Ontario); University of Otago	Kelley, SO (corresponding author), Univ Toronto, Fac Pharm, Dept Pharmaceut Sci, Toronto, ON, Canada.	shana.kelley@utoronto.ca	Murphy, Michael P/C-2120-2009; Kelley, Shana/H-5856-2015; Kelley, Shana/ABA-7403-2021	Murphy, Michael P/0000-0003-1115-9618; Kelley, Shana/0000-0003-3360-5359; Schimmer, Aaron/0000-0003-4023-3899	Canadian Institute of Health; Terry Fox Foundation Strategic Training Initiative for Excellence in Radiation Research for the 21st Century (EIRR21) at CIHR; MRC [MC_U105663142] Funding Source: UKRI; Medical Research Council [MC_U105663142] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA157456] Funding Source: NIH RePORTER	Canadian Institute of Health(Canadian Institutes of Health Research (CIHR)); Terry Fox Foundation Strategic Training Initiative for Excellence in Radiation Research for the 21st Century (EIRR21) at CIHR(Canadian Institutes of Health Research (CIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to acknowledge the Canadian Institute of Health for the support of this work with an Operating Grant and a Proof of Principle I grant, and also acknowledge The Terry Fox Foundation Strategic Training Initiative for Excellence in Radiation Research for the 21st Century (EIRR21) at CIHR for their fellowship support of Rida Mourtada. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALBERTS DS, 1979, CANCER TREAT REV, V6, P9, DOI 10.1016/S0305-7372(79)80005-5; Amantana A, 2007, BIOCONJUGATE CHEM, V18, P1325, DOI 10.1021/bc070060v; ANSLOW WP, 1948, J PHARMACOL EXP THER, V93, P1; Begleiter A, 1996, LEUKEMIA LYMPHOMA, V23, P187, DOI 10.3109/10428199609054821; Bix G, 2006, J NATL CANCER I, V98, P1634, DOI 10.1093/jnci/djj441; BROOKES P, 1961, BIOCHEM J, V80, P496, DOI 10.1042/bj0800496; Carreon JR, 2007, BIOORG MED CHEM LETT, V17, P5182, DOI 10.1016/j.bmcl.2007.06.097; CHEN W, 1989, LEUKEMIA, V3, P264; Druzhyna NM, 2008, MECH AGEING DEV, V129, P383, DOI 10.1016/j.mad.2008.03.002; Fonseca SB, 2011, CHEM BIOL, V18, P445, DOI 10.1016/j.chembiol.2011.02.010; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Ganguly S, 2008, OLIGONUCLEOTIDES, V18, P277, DOI 10.1089/oli.2008.0140; GILMAN A, 1963, AM J SURG, V105, P574, DOI 10.1016/0002-9610(63)90232-0; Guidicelli G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005493; Horton KL, 2008, CHEM BIOL, V15, P375, DOI 10.1016/j.chembiol.2008.03.015; Hu X, 2008, CANCER LETT, V259, P127, DOI 10.1016/j.canlet.2007.11.007; King D, 1998, LEUKEMIA, V12, P1553, DOI 10.1038/sj.leu.2401153; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kiziltepe T, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.10; Krumbhaar EB, 1919, J MED RES, V40, P497; MASTA A, 1995, NUCLEIC ACIDS RES, V23, P3508, DOI 10.1093/nar/23.17.3508; MONTSERRAT E, 1993, BLOOD REV, V7, P164, DOI 10.1016/0268-960X(93)90003-M; Naito M, 2004, CANCER SCI, V95, P361, DOI 10.1111/j.1349-7006.2004.tb03216.x; Neidle S, 2005, NAT REV CANCER, V5, P285, DOI 10.1038/nrc1587; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Ross WCJ., 1962, BIOL ALKYLATING AGEN; Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722; Santos Janine H, 2006, Methods Mol Biol, V314, P183; Smith RA, 2011, ANTIOXID REDOX SIGNA; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Tann AW, 2011, J BIOL CHEM, V286, P31975, DOI 10.1074/jbc.M110.215715; Veerman G, 1996, CANCER CHEMOTH PHARM, V38, P335, DOI 10.1007/s002800050492; Yousif LF, 2009, CHEMBIOCHEM, V10, P2081, DOI 10.1002/cbic.200900017	34	31	32	2	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e60253	10.1371/journal.pone.0060253	http://dx.doi.org/10.1371/journal.pone.0060253			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23585833	Green Published, Green Submitted, gold			2023-01-03	WOS:000317909600016
J	Hassali, MA; Yahaya, AHM; Shafie, AA; Saleem, F; Chua, GN; Aljadhey, H				Hassali, Mohamed Azmi; Yahaya, Abdul Haniff Mohamad; Shafie, Asrul Akmal; Saleem, Fahad; Chua, Gin Nie; Aljadhey, Hisham			Patterns and Predictors of Non-Prescription Medicine Use among Malaysian Pharmacy Patrons: A National Cross Sectional Study	PLOS ONE			English	Article							DRUGS; RISK; OLD	Objective: The study aims to evaluate the predictors of non-prescription medicine purchasing patterns among pharmacy patrons in Malaysia. Methods: A cross-sectional nationwide study was undertaken in 2011 in sixty randomly selected community pharmacies across 14 Malaysian states. A pharmacy exit survey was conducted over a 6-month period across Malaysia. A one-stage random cluster sampling technique was employed as there was no national sampling framework available for conducting this survey. Face-to-face interviews using a validated and pre-tested questionnaire were conducted by trained data collectors. The non-prescription medicine purchasing pattern was explored and analysed descriptively. Chi-square/Fisher exact test was used to determine the association between study variables. Multinomial logistic regression analysis was used to determine the predictors of type of non-prescription medicine purchased. Results: A total of 2729 pharmacy patrons agreed to participate in 60 selected pharmacy outlets. A total of 3462 non-prescription medicine were purchased during the study period with an average of 1.3 medicines per participant. Most of the non-prescription medicine purchased was meant for alimentary tract and metabolism (31.8%), followed by respiratory system (19.4%) and musculoskeletal system (15.8%) usage. Factors found to be associated with the choice of non-prescription medicine purchased were age group [chi 2 = 170.75, (df = 57), p < 0.01], locality [chi 2 = 48.16, (df = 19), p<0.01], gender [chi 2 = 32.93, (df = 13), p = 0.002], ethnic group [chi 2 = 118.89, (df = 39), p<0.01] and type of occupation [chi 2 = 222.434, (df = 117), p<0.01]. Non-prescription medicine purchased defined about 20% of the variance in the combination of predictors such as locality, gender, age, ethnicity, type of occupation and household income. Conclusion: The predictors for selection of non-prescription medicine were locality (urban or rural), gender, age, ethnicity, type of occupation and household income per month. Future studies need to explore the safety and effectiveness of using these non-prescription medicines.	[Hassali, Mohamed Azmi; Yahaya, Abdul Haniff Mohamad; Shafie, Asrul Akmal; Saleem, Fahad; Chua, Gin Nie] Univ Sains Malaysia, Sch Pharmaceut Sci, Discipline Social & Adm Pharm, George Town, Malaysia; [Saleem, Fahad] Univ Balochistan, Dept Pharm, Quetta, Pakistan; [Aljadhey, Hisham] King Saud Univ, Coll Pharm, Riyadh, Saudi Arabia	Universiti Sains Malaysia; University of Balochistan; King Saud University	Saleem, F (corresponding author), Univ Sains Malaysia, Sch Pharmaceut Sci, Discipline Social & Adm Pharm, George Town, Malaysia.	fahaduob@gmail.com	Shafie, Asrul Akmal/F-7026-2010; Hassali, Azmi/D-3716-2014; Saleem, Fahad/D-8321-2014; Hassali, Mohamed Azmi/A-6895-2011	Shafie, Asrul Akmal/0000-0002-5629-9270; Hassali, Azmi/0000-0001-8269-885X; Saleem, Fahad/0000-0001-8100-8992; Hassali, Mohamed Azmi/0000-0001-9575-403X	Universiti Sains Malaysia through Universiti Research Grant	Universiti Sains Malaysia through Universiti Research Grant(Universiti Sains Malaysia)	The study was funded by the Universiti Sains Malaysia through Universiti Research Grant (COMPACT Study 1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1997, AM J HEALTH-SYST PH, V54, P2664; BENNETT S, 1991, World Health Statistics Quarterly, V44, P98; Benrimoj S, 1988, NONPRESCRIPTION MEDI; BOND C, 2001, PRIM CARE PHARM, V2, P5; Bradley C, 1996, BRIT MED J, V312, P835; Cabecas JM, 2006, ENTERPRISE WORK INNO, V2, P95; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; Covington TR, 2006, AM J PHARM EDUC, V70, DOI 10.5688/aj7006137; Dharmender S, 2010, STAR; Emmerton L, 2011, J PHARM MARK MANAGE, V15, P97; Euromonitor International, 2007, OTC HEALTHC MAL; Hassali MA, 2012, DRUG INF J, V46, P723, DOI 10.1177/0092861512457777; Malinauskiene V, 2002, OCCUP ENVIRON MED, V59, P745, DOI 10.1136/oem.59.11.745; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; Porteous T, 2005, FAM PRACT, V22, P78, DOI 10.1093/fampra/cmh719; QUAH S R, 1985, SMJ Singapore Medical Journal, V26, P123; Raosoft, 2011, SAMPL SIZ CALC; Tsai AC, 2006, AUSTRALAS J AGEING, V25, P191, DOI 10.1111/j.1741-6612.2006.00183.x; World Health Organization, 2003, INV MENT HLTH, P1	19	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2013	8	4							e59231	10.1371/journal.pone.0059231	http://dx.doi.org/10.1371/journal.pone.0059231			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143BA	23573195	Green Published, gold, Green Submitted			2023-01-03	WOS:000318840100014
J	Saito, M; Seo, Y; Yano, Y; Momose, K; Hirano, H; Yoshida, M; Azuma, T				Saito, Masaya; Seo, Yasushi; Yano, Yoshihiko; Momose, Kenji; Hirano, Hirotaka; Yoshida, Masaru; Azuma, Takeshi			Reduction in Non-Protein Respiratory Quotient Is Related to Overall Survival after Hepatocellular Carcinoma Treatment	PLOS ONE			English	Article							TRANSCATHETER OILY CHEMOEMBOLIZATION; RANDOMIZED CONTROLLED TRIAL; LATE EVENING SNACK; LIVER-CIRRHOSIS; TRANSARTERIAL CHEMOEMBOLIZATION; ARTERIAL CHEMOEMBOLIZATION; PROGNOSTIC-FACTORS; ENERGY-METABOLISM; CLIP SCORE; MANAGEMENT	Background: Transcatheter arterial chemoembolization (TACE) is an effective treatment for hepatocellular carcinoma (HCC) that can occasionally lead to the shortening of life expectancy. We aimed to make a new and more accurate prognostic model taking into account the course of disease after TACE. Methodology/Principal Findings: We performed a prospective cohort study involving 100 HCC patients who underwent TACE at Kobe University Hospital. Indirect calorimetry and blood biochemical examinations were performed before and 7 days after TACE. Time-dependent and time-fixed factors associated with 1-year mortality after TACE were assessed by multivariate analyses. A predictive model of 1-year mortality was established by the combination of odds ratios of these factors. Multivariate analyses showed that the ratio of non-protein respiratory quotient (npRQ) (7 days after/before TACE) and Cancer of Liver Italian Program (CLIP) score were independent factors of 1-year mortality after TACE (p = 0.014 and 0.013, respectively). Patient-specific 1-year mortality risk scores can be calculated by summarizing the individual risk scores and looking up the patient-specific risk on the graph. Conclusions: The short-term reduction of npRQ was a time-dependent prognostic factor associated with overall survival in HCC patients undergoing TACE. CLIP score was a time-fixed prognostic factor associated with overall survival. Using the prediction model, which consists of the combination of time-dependent (npRQ ratio) and time-fixed (CLIP score) prognostic factors, 1-year mortality risk after TACE would be better estimated by taking into account changes during the course of disease.	[Saito, Masaya; Seo, Yasushi; Yano, Yoshihiko; Momose, Kenji; Hirano, Hirotaka; Yoshida, Masaru; Azuma, Takeshi] Kobe Univ, Dept Internal Med, Grad Sch Med, Div Gastroenterol, Kobe, Hyogo 657, Japan; [Yano, Yoshihiko] Kobe Univ, Ctr Infect Dis, Grad Sch Med, Kobe, Hyogo 657, Japan; [Yoshida, Masaru] Kobe Univ, Dept Internal Med, Grad Sch Med, Div Metabol Res, Kobe, Hyogo 657, Japan	Kobe University; Kobe University; Kobe University	Azuma, T (corresponding author), Kobe Univ, Dept Internal Med, Grad Sch Med, Div Gastroenterol, Kobe, Hyogo 657, Japan.	azumat@med.kobe-u.ac.jp			Global COE Program, Global Center of Excellence for Education and Research on Signal Transduction Medicine in the Coming Generation from the Ministry of Education, Culture, Sports, Science, and Technology of Japan	Global COE Program, Global Center of Excellence for Education and Research on Signal Transduction Medicine in the Coming Generation from the Ministry of Education, Culture, Sports, Science, and Technology of Japan	This study was supported by Grant-in-Aid for Research Activity Start-up [MS], and was also supported by grants for the Global COE Program, Global Center of Excellence for Education and Research on Signal Transduction Medicine in the Coming Generation from the Ministry of Education, Culture, Sports, Science, and Technology of Japan [MY and TA]. MS had a role in study design, data collection, and analysis, and all authors including MS, MY and TA had a role in decision to publish and preparation of the manuscript.	[Anonymous], 1998, HEPATOLOGY, V28, P751; BISMUTH H, 1992, AM J SURG, V163, P387, DOI 10.1016/0002-9610(92)90039-T; BRONOWICKI JP, 1994, CANCER, V74, P16, DOI 10.1002/1097-0142(19940701)74:1<16::AID-CNCR2820740105>3.0.CO;2-V; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Cabibbo G, 2011, ALIMENT PHARM THER, V34, P196, DOI 10.1111/j.1365-2036.2011.04694.x; Camma C, 2009, LIVER INT, V29, P478, DOI 10.1111/j.1478-3231.2009.01994.x; Dhanasekaran R, 2010, HPB, V12, P174, DOI 10.1111/j.1477-2574.2009.00138.x; Harima Y, 2010, HEPATOL RES, V40, P574, DOI 10.1111/j.1872-034X.2010.00665.x; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Kawaoka T, 2010, HEPATOL RES, V40, P1082, DOI 10.1111/j.1872-034X.2010.00714.x; Kudo M, 2003, J GASTROENTEROL, V38, P207, DOI 10.1007/s005350300038; Kudo M, 2007, ONCOLOGY-BASEL, V72, P2, DOI 10.1159/000111702; LAUTZ HU, 1992, CLIN INVESTIGATOR, V70, P478, DOI 10.1007/BF00210228; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; MONDAZZI L, 1994, HEPATOLOGY, V19, P1115, DOI 10.1002/hep.1840190508; Nakaya Y, 2007, NUTRITION, V23, P113, DOI 10.1016/j.nut.2006.10.008; Nanashima A, 2004, EJSO-EUR J SURG ONC, V30, P765, DOI 10.1016/j.ejso.2004.05.003; OKUDA K, 1984, HEPATOLOGY, V4, pS3, DOI 10.1002/hep.1840040703; OWEN OE, 1983, J CLIN INVEST, V72, P1821, DOI 10.1172/JCI111142; Poon RTP, 2004, ALIMENT PHARM THERAP, V19, P779, DOI 10.1111/j.1365-2036.2004.01920.x; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; Saito M, 2012, ALIMENT PHARM THER, V35, P861, DOI 10.1111/j.1365-2036.2012.05021.x; Saito M, 2012, J GASTROENTEROL, V47, P704, DOI 10.1007/s00535-012-0535-x; STUART K, 1993, CANCER, V72, P3202, DOI 10.1002/1097-0142(19931201)72:11<3202::AID-CNCR2820721112>3.0.CO;2-4; Tajika M, 2002, NUTRITION, V18, P229, DOI 10.1016/S0899-9007(01)00754-7; Terakura Y, 2010, J NUTR SCI VITAMINOL, V56, P372, DOI 10.3177/jnsv.56.372; Tsuchiya M, 2005, HEPATOL RES, V31, P95, DOI 10.1016/j.hepres.2004.11.009; Ueno S, 2001, HEPATOLOGY, V34, P529, DOI 10.1053/jhep.2001.27219; Vauthey JN, 2002, J CLIN ONCOL, V20, P1527, DOI 10.1200/JCO.20.6.1527; VETTER D, 1991, HEPATOLOGY, V13, P427, DOI 10.1002/hep.1840130308; YAMADA R, 1990, CARDIOVASC INTER RAD, V13, P135, DOI 10.1007/BF02575464	34	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2013	8	3							e55441	10.1371/journal.pone.0055441	http://dx.doi.org/10.1371/journal.pone.0055441			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140TZ	23520445	gold, Green Published, Green Submitted			2023-01-03	WOS:000318679900004
J	Westreich, D; Maskew, M; Evans, D; Firnhaber, C; Majuba, P; Sanne, I				Westreich, Daniel; Maskew, Mhairi; Evans, Denise; Firnhaber, Cindy; Majuba, Pappie; Sanne, Ian			Incident Pregnancy and Time to Death or AIDS among HIV-Positive Women Receiving Antiretroviral Therapy	PLOS ONE			English	Article							MARGINAL STRUCTURAL MODELS; SINGLE-DOSE NEVIRAPINE; TO-CHILD TRANSMISSION; SOUTH-AFRICA; DISEASE PROGRESSION; PROSPECTIVE COHORT; GREATER ADHERENCE; NONPREGNANT WOMEN; FOLLOW-UP; SURVIVAL	Background: Little is known about the impact of pregnancy on response to highly active antiretroviral therapy (HAART) in sub-Saharan Africa. We examined the effect of incident pregnancy after HAART initiation on clinical response to HAART. Methods: We evaluated a prospective clinical cohort of adult women initiating HAART in Johannesburg, South Africa between 1 April 2004 and 31 March 2011, and followed up until an event, transfer, drop-out, or administrative end of follow-up on 30 September 2011. Women over age 45 and women who were pregnant at HAART initiation were excluded from the study. Main exposure was having experienced pregnancy after HAART initiation; main outcome was death and (separately) death or new AIDS event. We calculated adjusted hazard ratios (HRs) and 95% confidence limits (CL) using marginal structural Cox proportional hazards models. Results: The study included 7,534 women, and 20,813 person-years of follow-up; 918 women had at least one recognized pregnancy during follow-up. For death alone, the weighted (adjusted) HR was 0.84 (95% CL 0.44, 1.60). Sensitivity analyses confirmed main results, and results were similar for analysis of death or new AIDS event. Incident pregnancy was associated with a substantially reduced hazard of drop-out (HR = 0.62, 95% CL 0.51, 0.75). Conclusions: Recognized incident pregnancy after HAART initiation was not associated with increases in hazard of clinical events, but was associated with a decreased hazard of drop-out. High rates of pregnancy after initiation of HAART may point to a need to better integrate family planning services into clinical care for HIV-infected women.	[Westreich, Daniel] Duke Univ, Dept Obstet & Gynecol, Durham, NC 27708 USA; [Westreich, Daniel] Duke Univ, Duke Global Hlth Inst, Durham, NC USA; [Maskew, Mhairi; Evans, Denise] Univ Witwatersrand, Fac Hlth Sci, Dept Med, Hlth Econ & Epidemiol Res Off, Johannesburg, South Africa; [Maskew, Mhairi; Evans, Denise; Firnhaber, Cindy; Sanne, Ian] Univ Witwatersrand, Fac Hlth Sci, Dept Med, Clin HIV Res Unit, Johannesburg, South Africa; [Firnhaber, Cindy; Majuba, Pappie; Sanne, Ian] Right Care, Johannesburg, South Africa	Duke University; Duke University; University of Witwatersrand; University of Witwatersrand	Westreich, D (corresponding author), Duke Univ, Dept Obstet & Gynecol, Durham, NC 27708 USA.	daniel.westreich@duke.edu	Sanne, Ian/ABH-2231-2020	Westreich, Daniel/0000-0003-3069-1650; MASKEW, MHAIRI/0000-0003-4238-0200	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health & Human Development [R00-HD-06-3961]; National Institute of Allergy and Infectious Diseases through the Duke Center for AIDS Research [P30-AI-064518]; National and Gauteng Department of Health; United States President's Emergency Plan for AIDS Relief (PEPFAR); USAID to Right to Care and the Institution [674-A-00-08-00007-00]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R00HD063961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI064518] Funding Source: NIH RePORTER	National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health & Human Development; National Institute of Allergy and Infectious Diseases through the Duke Center for AIDS Research; National and Gauteng Department of Health; United States President's Emergency Plan for AIDS Relief (PEPFAR)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); USAID to Right to Care and the Institution(United States Agency for International Development (USAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health & Human Development [grant number R00-HD-06-3961 to D.W.]; National Institute of Allergy and Infectious Diseases through the Duke Center for AIDS Research [grant number P30-AI-064518]. The clinical activities of the Helen Joseph Hospital are supported by the National and Gauteng Department of Health and the United States President's Emergency Plan for AIDS Relief (PEPFAR) in a grant by USAID to Right to Care and the Institution (674-A-00-08-00007-00). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AWEEKA F, 2007, 14 C RETR OPP INF LO; Bardeguez AD, 2008, JAIDS-J ACQ IMM DEF, V48, P408, DOI 10.1097/QAI.0b013e31817bbe80; Black V, 2008, JAIDS-J ACQ IMM DEF, V49, P276, DOI 10.1097/QAI.0b013e318189a769; Chen PL, 2008, J INFECT DIS, V197, P1075, DOI 10.1086/529046; Chi BH, 2007, AIDS, V21, P957, DOI 10.1097/QAD.0b013e32810996b2; Coffie PA, 2008, CLIN INFECT DIS, V46, P611, DOI 10.1086/526780; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Eshleman SH, 2005, J INFECT DIS, V192, P30, DOI 10.1086/430764; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Floridia M, 2008, PHARMACOL RES, V58, P173, DOI 10.1016/j.phrs.2008.07.007; Fox MP, 2010, TROP MED INT HEALTH, V15, P405, DOI 10.1111/j.1365-3156.2010.02473.x; Fox MP, 2012, INT J EPIDE IN PRESS; Fox MP, 2012, INT J EPIDEMIOL; French R, 1998, BRIT J OBSTET GYNAEC, V105, P827, DOI 10.1111/j.1471-0528.1998.tb10226.x; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hernan MA, 2006, J EPIDEMIOL COMMUN H, V60, P578, DOI 10.1136/jech.2004.029496; Homsy J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004149; Jourdain G, 2004, NEW ENGL J MED, V351, P229, DOI 10.1056/NEJMoa041305; Kaplan R, 2008, AIDS, V22, P1679, DOI 10.1097/QAD.0b013e32830ebcee; Keiser O, 2008, AIDS, V22, P2323, DOI 10.1097/QAD.0b013e3283189bf1; Kingston MA, 2007, INT J STD AIDS, V18, P787, DOI 10.1258/095646207782212216; MacCarthy S, 2009, AIDS BEHAV; Matsui D., 2012, OBSTET GYNECOL INT, V2012, DOI DOI 10.1155/2012/796590]; Mirochnick M, 2004, CLIN PHARMACOKINET, V43, P1071, DOI 10.2165/00003088-200443150-00002; Myer L, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000229; Nachega JB, 2012, AIDS; Petersen ML, 2006, JAIDS-J ACQ IMM DEF, V43, pS96, DOI 10.1097/01.qai.0000248344.95135.8d; Pettifor AE, 2005, AIDS, V19, P1525, DOI 10.1097/01.aids.0000183129.16830.06; Prins M, 2005, AIDS, V19, P357, DOI 10.1097/01.aids.0000161765.75663.27; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Vaz MJR, 2007, INT J STD AIDS, V18, P28, DOI 10.1258/095646207779949808; Roustit M, 2008, BRIT J CLIN PHARMACO, V66, P179, DOI 10.1111/j.1365-2125.2008.03220.x; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sanne IM, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-38; South African National Department of Health, 2008, NAT HIV SYPH PREV SU; Tai JH, 2007, J INFECT DIS, V196, P1044, DOI 10.1086/520814; UNAIDS, 2009, AIDS EPIDEMIC UPDATE; *UNAIDS WHO, 2007, AIDS EP UPD 2007; Van der Paal L, 2007, TROP MED INT HEALTH, V12, P920, DOI [10.1111/j.1365-3156.2007.01873.x, 10.1111/j.1365-3156.2007.001873.x]; Westreich D, 2012, J ACQUIR IMMUNE DEFI; Westreich D, 2012, INFECT DIS IN PRESS; Westreich D, 2012, AIDS; Westreich D, 2008, J INFECT DIS, V197, P1074, DOI 10.1086/529045; Westreich D, 2007, J INFECT DIS, V195, P837, DOI 10.1086/511276; Westreich D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022778; Westreich D, 2010, AM J EPIDEMIOL, V171, P691, DOI 10.1093/aje/kwp418; Westreich D, 2009, AIDS, V23, P707, DOI 10.1097/QAD.0b013e328325d115; WHO, 2007, WHO CAS DEF IN PRESS; Zhang MJ, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-82; Zorrilla CD, 2003, CELL MOL BIOL, V49, P1187	52	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2013	8	3							e58117	10.1371/journal.pone.0058117	http://dx.doi.org/10.1371/journal.pone.0058117			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140TZ	23520489	Green Published, gold			2023-01-03	WOS:000318679900048
J	Comstock, CES; Augello, MA; Goodwin, JF; de Leeuw, R; Schiewer, MJ; Ostrander, WF; Burkhart, RA; McClendon, AK; McCue, PA; Trabulsi, EJ; Lallas, CD; Gomella, LG; Centenera, MM; Brody, JR; Butler, LM; Tilley, WD; Knudsen, KE				Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; de Leeuw, R.; Schiewer, M. J.; Ostrander, W. F., Jr.; Burkhart, R. A.; McClendon, A. K.; McCue, P. A.; Trabulsi, E. J.; Lallas, C. D.; Gomella, L. G.; Centenera, M. M.; Brody, J. R.; Butler, L. M.; Tilley, W. D.; Knudsen, K. E.			Targeting cell cycle and hormone receptor pathways in cancer	ONCOGENE			English	Article						PD-0332991; cyclin-dependent kinase; retinoblastoma protein; prostate cancer; tumor explants	DEPENDENT KINASE INHIBITOR; ANDROGEN RECEPTOR; CRYSTAL-STRUCTURE; PHASE-I; CDK4/6 INHIBITION; PD 0332991; PHARMACOLOGICAL INHIBITION; ANTITUMOR-ACTIVITY; DNA-REPAIR; FLAVOPIRIDOL	The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis is a critical modulator of cell cycle entry and is aberrant in many human cancers. New nodes of therapeutic intervention are needed that can delay or combat the onset of malignancies. The antitumor properties and mechanistic functions of PD-0332991 (PD; a potent and selective CDK4/6 inhibitor) were investigated using human prostate cancer (PCa) models and primary tumors. PD significantly impaired the capacity of PCa cells to proliferate by promoting a robust G(1)-arrest. Accordingly, key regulators of the G(1)-S cell cycle transition were modulated including G1 cyclins D, E and A. Subsequent investigation demonstrated the ability of PD to function in the presence of existing hormone-based regimens and to cooperate with ionizing radiation to further suppress cellular growth. Importantly, it was determined that PD is a critical mediator of PD action. The anti-proliferative impact of CDK4/6 inhibition was revealed through reduced proliferation and delayed growth using PCa cell xenografts. Finally, first-in-field effects of PD on proliferation were observed in primary human prostatectomy tumor tissue explants. This study shows that selective CDK4/6 inhibition, using PD either as a single-agent or in combination, hinders key proliferative pathways necessary for disease progression and that RB status is a critical prognostic determinant for therapeutic efficacy. Combined, these pre-clinical findings identify selective targeting of CDK4/6 as a bona fide therapeutic target in both early stage and advanced PCa and underscore the benefit of personalized medicine to enhance treatment response.	[Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; de Leeuw, R.; Schiewer, M. J.; Ostrander, W. F., Jr.; McClendon, A. K.; McCue, P. A.; Gomella, L. G.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Burkhart, R. A.; Brody, J. R.] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA; [McCue, P. A.] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Trabulsi, E. J.; Lallas, C. D.; Gomella, L. G.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA; [Centenera, M. M.; Butler, L. M.] Univ Adelaide, Dame Roma Mitchell Canc Res Lab, Sch Med, Hanson Inst, Adelaide, SA, Australia; [Tilley, W. D.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; Hanson Institute; University of Adelaide; Jefferson University	Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, 233 South 10th St,BLSB 1008A, Philadelphia, PA 19107 USA.	karen.knudsen@jefferson.edu	Butler, Lisa M/C-9843-2010; Butler, Lisa/AAP-9088-2020; Comstock, Clay/B-6122-2008	Butler, Lisa/0000-0003-2698-3220; Schiewer, Matthew/0000-0002-2325-4228; centenera, margaret/0000-0002-2206-0632; Knudsen, Karen/0000-0002-1301-890X; de Leeuw, Renee/0000-0002-5550-7613; Comstock, Clay/0000-0001-5867-1489; Tilley, Wayne/0000-0003-1893-2626	National Institutes of Health [CA099996, CA159945]; Department of Defense New Investigator Award [PC094507]; Department of Defense Predoctoral Fellowships [PC094596, PC094195]; National Health and Medical Research Council (NHMRC) of Australia [627185]; Cancer Council of South Australia Senior research Fellowship; Prostate Cancer Foundation of Australia; Enabling Grant from the NHMRC; NATIONAL CANCER INSTITUTE [R01CA159945, R01CA099996] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense New Investigator Award(United States Department of Defense); Department of Defense Predoctoral Fellowships(United States Department of Defense); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of South Australia Senior research Fellowship(Cancer Council South Australia); Prostate Cancer Foundation of Australia; Enabling Grant from the NHMRC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the KEK laboratory for ongoing scientific discussions and Dr Tanmayi Mankame for critical reading of the manuscript. We thank Dr Wen-Shuz Yeow (currently at TheGreenCell; Washington, DC) for assistance with the growth and maintenance of the CRPC cell lines. We especially thank Magdalena Potoczek for assistance regarding RB staining. This work was supported, in whole or in part, by: National Institutes of Health Grants: CA099996 and CA159945 (to KEK); Department of Defense New Investigator Award PC094507 (to CESC); and Department of Defense Predoctoral Fellowships: PC094596 (to MAA) and PC094195 (to MJS); National Health and Medical Research Council (NHMRC) of Australia (627185; to WDT and LMB), a Cancer Council of South Australia Senior research Fellowship (to LMB), and an infrastructure grant from the Prostate Cancer Foundation of Australia and an Enabling Grant from the NHMRC (to WDT).	Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Baughn LB, 2006, CANCER RES, V66, P7661, DOI 10.1158/0008-5472.CAN-06-1098; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Centenera MM, 2012, CLIN CANCER RES, V18, P3562, DOI 10.1158/1078-0432.CCR-12-0782; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Collins I, 2005, CURR OPIN PHARMACOL, V5, P366, DOI 10.1016/j.coph.2005.04.009; Comstock CES, 2011, J BIOL CHEM, V286, P8117, DOI 10.1074/jbc.M110.170720; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diaz-Padilla I, 2009, INVEST NEW DRUG, V27, P586, DOI 10.1007/s10637-009-9236-6; Dickson MA, 2009, CURR ONCOL, V16, P120; Drees M, 1997, CLIN CANCER RES, V3, P273; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Freemantle SJ, 2007, J CELL BIOCHEM, V102, P869, DOI 10.1002/jcb.21519; Fry DW, 2004, MOL CANCER THER, V3, P1427; Halvorsen OJ, 2000, CANCER, V88, P416, DOI 10.1002/(SICI)1097-0142(20000115)88:2<416::AID-CNCR24>3.3.CO;2-R; Heijink DM, 2011, ONCOGENE, V30, P2026, DOI 10.1038/onc.2010.578; Ismail A, 2011, CLIN CANCER RES, V17, P4513, DOI 10.1158/1078-0432.CCR-11-0244; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Johnson N, 2010, EXPERT OPIN THER TAR, V14, P1199, DOI 10.1517/14728222.2010.525221; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen KE, 2011, EXPERT REV ENDOCRINO, V6, P483, DOI 10.1586/EEM.11.33; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Korzynska A, 2008, BIOCYBERN BIOMED ENG, V28, P75; Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood-2011-10-388298; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Liu G, 2004, CLIN CANCER RES, V10, P924, DOI 10.1158/1078-0432.CCR-03-0050; Lolli G, 2004, STRUCTURE, V12, P2067, DOI 10.1016/j.str.2004.08.013; Lu H, 2006, J MED CHEM, V49, P3826, DOI 10.1021/jm0600388; Martin JM, 2011, DRUGS, V71, P1019, DOI 10.2165/11591500-000000000-00000; Marzec M, 2006, BLOOD, V108, P1744, DOI 10.1182/blood-2006-04-016634; Menu E, 2008, CANCER RES, V68, P5519, DOI 10.1158/0008-5472.CAN-07-6404; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Mostaghel EA, 2011, ENDOCRIN METAB CLIN, V40, P625, DOI 10.1016/j.ecl.2011.05.013; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Rivadeneira DB, 2010, GASTROENTEROLOGY, V138, P1920, DOI 10.1053/j.gastro.2010.01.007; Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002; Rodriguez-Otero P, 2011, BRIT J HAEMATOL, V155, P73, DOI 10.1111/j.1365-2141.2011.08812.x; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Schiewer MJ, 2012, MOL CELL ENDOCRINOL, V352, P34, DOI 10.1016/j.mce.2011.06.033; Schiewer MJ, 2012, ENDOCR-RELAT CANCER, V19, P1, DOI 10.1530/ERC-11-0072; Schwartz GK, 2011, BRIT J CANCER, V104, P1862, DOI 10.1038/bjc.2011.177; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Sutherland JJ, 2011, MOL CANCER THER, V10, P242, DOI 10.1158/1535-7163.MCT-10-0720; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Thomas JP, 2002, CANCER CHEMOTH PHARM, V50, P465, DOI 10.1007/s00280-002-0527-2; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Tzelepi V, 2012, CLIN CANCER RES, V18, P666, DOI 10.1158/1078-0432.CCR-11-1867; Udayakumar T, 2010, SEMIN RADIAT ONCOL, V20, P258, DOI 10.1016/j.semradonc.2010.05.007; Vaughn DJ, 2009, NEW ENGL J MED, V360, P423, DOI 10.1056/NEJMc0808558; Wang L, 2007, BLOOD, V110, P2075, DOI 10.1182/blood-2007-02-071266; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wesierska-Gadek J, 2011, J CELL PHYSIOL, V226, P341, DOI 10.1002/jcp.22426; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Zhang C, 2009, CLIN CANCER RES, V15, P238, DOI 10.1158/1078-0432.CCR-08-0897; Zhang CC, 2012, CLIN CANCER RES, V18, P1303, DOI 10.1158/1078-0432.CCR-11-1433	65	78	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5481	5491		10.1038/onc.2013.83	http://dx.doi.org/10.1038/onc.2013.83			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23708653	hybrid, Green Published			2023-01-03	WOS:000327780800005
J	Kerschbaum, J; Vychytil, A; Lhotta, K; Prischl, FC; Wiesholzer, M; Machhold-Fabrizii, V; Kopriva-Altfahrt, G; Schwarz, C; Balcke, P; Oberbauer, R; Kramar, R; Konig, P; Rudnicki, M				Kerschbaum, Julia; Vychytil, Andreas; Lhotta, Karl; Prischl, Friedrich C.; Wiesholzer, Martin; Machhold-Fabrizii, Veronika; Kopriva-Altfahrt, Gertrude; Schwarz, Christoph; Balcke, Peter; Oberbauer, Rainer; Kramar, Reinhard; Koenig, Paul; Rudnicki, Michael			Treatment with Oral Active Vitamin D Is Associated with Decreased Risk of Peritonitis and Improved Survival in Patients on Peritoneal Dialysis	PLOS ONE			English	Article							CALCIFICATION; FAILURE; D-3	Peritonitis is a major complication of peritoneal dialysis (PD) being associated with hospitalization, catheter loss, technique failure, and increased mortality. Data on incidence rates and risk factors for peritonitis episodes vary between centers. In seven Austrian PD units clinical and laboratory data on each peritonitis episode were collected from all patients (n = 726) who performed PD between January 2000 and December 2009. The peritonitis incidence rate was 0.32 episodes/patient-year. In a multivariate analysis the risk of peritonitis was decreased by 57% in patients treated with oral active vitamin D (HR 0.43; 95% CI 0.28-0.64). Renal disease classified as "other or unknown" (HR 1.65; 95% CI 1.08-2.53) and serum albumin,3500 mg/dl (HR 1.49; 95% CI 1.04-2.15) were also associated with an increased risk of peritonitis. Albumin levels,3500 mg/dl (HR 1.89; 95% CI 1.13-3.17), age (HR 1.06 per year; 95% CI 1.03-1.09), and cardiomyopathy (HR 3.01; 95% CI 1.62-5.59) were associated with increased mortality, whereas treatment with oral active vitamin D was associated with a significantly lower risk of death (HR 0.46; 95% CI 0.27-0.81). In this retrospective multi-center study we identified several factors being related to increased risk of peritonitis in PD patients. Treatment with oral active vitamin D was identified as being independently associated with decreased risk of peritonitis, and decreased all-cause mortality in PD patients.	[Kerschbaum, Julia; Koenig, Paul; Rudnicki, Michael] Med Univ Innsbruck, Dept Internal Med Nephrol & Hypertens 4, A-6020 Innsbruck, Austria; [Vychytil, Andreas; Oberbauer, Rainer] Med Univ Vienna, Dept Med 3, Div Nephrol, Vienna, Austria; [Lhotta, Karl] Acad Teaching Hosp Feldkirch, Dept Nephrol & Dialysis, Feldkirch, Austria; [Prischl, Friedrich C.] Klinikum Wels Grieskirchen, Dept Med 4, Clin Div Nephrol, Wels, Austria; [Wiesholzer, Martin; Balcke, Peter] Ao Krankenhaus St Polten, Dept Med 1, Div Nephrol & Dialysis, St Polten, Austria; [Machhold-Fabrizii, Veronika; Kopriva-Altfahrt, Gertrude] Wilhelminenspital Stadt Wien, Dept Med 6, Div Nephrol & Dialysis, Vienna, Austria; [Schwarz, Christoph; Oberbauer, Rainer] Krankenhaus Elisabethinen, Dept Nephrol, Linz, Austria; [Oberbauer, Rainer; Kramar, Reinhard] Austrian Dialysis & Transplant Registry, Linz, Austria	Medical University of Innsbruck; Medical University of Vienna; Wilhelminenspital; Ordensklinikum Linz Elisabethinen	Rudnicki, M (corresponding author), Med Univ Innsbruck, Dept Internal Med Nephrol & Hypertens 4, A-6020 Innsbruck, Austria.	michael.rudnicki@i-med.ac.at		Prischl, Friedrich/0000-0002-6187-9827	Fresenius Medical Care; Baxter Healthcare	Fresenius Medical Care; Baxter Healthcare	MR received an unrestricted research grant from Fresenius Medical Care and Baxter Healthcare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Fresenius Medical Care and Baxter Healthcare provided funding for this study. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.	Andrews PA, 1996, NEPHROL DIAL TRANSPL, V11, P1104; Biggar PH, 2011, PEDIATR NEPHROL, V26, P7, DOI 10.1007/s00467-010-1526-x; Chow KM, 2005, PERITON DIALYSIS INT, V25, P374; Chung SH, 2005, NEPHROL DIAL TRANSPL, V20, P1207, DOI 10.1093/ndt/gfh772; Churchill DN, 1996, J AM SOC NEPHROL, V7, P198; Cohen ML, 2001, KIDNEY INT, V59, P69, DOI 10.1046/j.1523-1755.2001.00467.x; Goldsmith DJA, 1997, NEPHRON, V77, P37, DOI 10.1159/000190244; Henley C, 2005, NEPHROL DIAL TRANSPL, V20, P1370, DOI 10.1093/ndt/gfh834; Kerschbaum J, 2011, WIEN KLIN WOCHENSCHR, V123, P204, DOI 10.1007/s00508-011-1551-1; Kopriva-Altfahrt G, 2009, PERITON DIALYSIS INT, V29, P330; Li PKT, 2010, PERITON DIALYSIS INT, V30, P393, DOI 10.3747/pdi.2010.00049; Lim WH, 2005, NEPHROLOGY, V10, P192, DOI 10.1111/j.1440-1797.2005.00374.x; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Lopez I, 2006, J AM SOC NEPHROL, V17, P795, DOI 10.1681/ASN.2005040342; Martineau AR, 2007, AM J RESP CRIT CARE, V176, P208, DOI 10.1164/rccm.200701-007OC; McDonald SR, 2004, PERITON DIALYSIS INT, V24, P340; Naves-Diaz M, 2008, KIDNEY INT, V74, P1070, DOI 10.1038/ki.2008.343; Rudnicki M, PERIT DIAL INT; Schaubel DE, 2001, PERITON DIALYSIS INT, V21, P365; Shoji T, 2004, NEPHROL DIAL TRANSPL, V19, P179, DOI 10.1093/ndt/gfg513; Sirivongs Dhavee, 2006, J Med Assoc Thai, V89 Suppl 2, pS138; Strippoli GFM, 2004, J AM SOC NEPHROL, V15, P2735, DOI 10.1097/01.ASN.0000141463.95561.79; Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573	23	23	26	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2013	8	7							e67836	10.1371/journal.pone.0067836	http://dx.doi.org/10.1371/journal.pone.0067836			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176XV	23844107	Green Submitted, Green Published, gold			2023-01-03	WOS:000321341000107
J	Wallerstedt, SM; Fastbom, J; Johnell, K; Sjoberg, C; Landahl, S; Sundstrom, A				Wallerstedt, Susanna M.; Fastbom, Johan; Johnell, Kristina; Sjoberg, Christina; Landahl, Sten; Sundstrom, Anders			Drug Treatment in Older People before and after the Transition to a Multi-Dose Drug Dispensing System-A Longitudinal Analysis	PLOS ONE			English	Article							MEDICATION ERRORS; ELDERLY-PATIENTS; NURSING-HOMES; HEALTH-CARE; QUALITY; PRESCRIPTION; DEMENTIA	Background: An association has been found between multi-dose drug dispensing (MDD) and use of many drugs. The aim of this study was to investigate the nature of this association, by performing a longitudinal analysis of the drug treatment before and after the transition to MDD. Methods: Inclusion critera in this register-based study were inhabitants in Region Vastra Gotaland, Sweden, who, at >= 65 years of age and between 1st July 2006 and 30th June 2010, filled their first MDD prescription. For each individual, prescribed drugs were estimated at three month intervals before and after (maximum 3 years, respectively) the first date of filling an MDD prescription (index date). Results: A total of 30,922 individuals matched the inclusion criteria (mean age: 83.2 years; 59.9% female). There was a temporal association between the transition to MDD and an increased number of drugs: 5.4 +/- 3.9 and 7.5 +/- 3.8 unique drugs three months before and after the index date, respectively, as well as worse outcomes on several indicators of prescribing quality. When either data before or after the index date were used, a multi-level regression analysis predicted the number of drugs at the index date at 5.76 (95% confidence limits: 5.71; 5.80) and 7.15 (7.10; 7.19), respectively, for an average female individual (83.2 years, 10.8 unique diagnoses, 2.4 healthcare contacts/three months). The predicted change in the number of drugs, from three months before the index date to the index date, was greater when data before this date was used as compared with data after this date: 0.12 (0.09; 0.14) versus 0.02 (-0.01; 0.05). Conclusions: After the patients entered the MDD system, they had an increased number of drugs, more often potentially harmful drug treatment, and fewer changes in drug treatment. These findings support a causal relationship between such a system and safety concerns as regards prescribing practices.	[Wallerstedt, Susanna M.] Sahlgrens Univ Hosp, Dept Clin Pharmacol, Gothenburg, Sweden; [Fastbom, Johan; Johnell, Kristina] Karolinska Inst, Aging Res Ctr, Stockholm, Sweden; [Fastbom, Johan; Johnell, Kristina] Stockholm Univ, S-10691 Stockholm, Sweden; [Sjoberg, Christina] Sahlgrenska Univ Hosp Molndal, Dept Geriatr, Molndal, Sweden; [Landahl, Sten] Sahlgrens Acad, Dept Geriatr, Molndal, Sweden; [Sundstrom, Anders] Karolinska Inst, Ctr Pharmacoepidemiol, Stockholm, Sweden	Sahlgrenska University Hospital; Karolinska Institutet; Stockholm University; Sahlgrenska University Hospital; Karolinska Institutet	Wallerstedt, SM (corresponding author), Sahlgrens Univ Hosp, Dept Clin Pharmacol, Gothenburg, Sweden.	susanna.wallerstedt@pharm.gu.se	Wallerstedt, Susanna/AAE-5607-2020	Wallerstedt, Susanna/0000-0001-7238-1680; Landahl, Sten/0000-0001-7251-9192	Swedish Medical Products Agency	Swedish Medical Products Agency	The study was funded by the Swedish Medical Products Agency. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alassaad A, 2013, J EVAL CLIN PRACT, V19, P185, DOI 10.1111/j.1365-2753.2011.01798.x; Bakken Toril, 2003, Tidsskr Nor Laegeforen, V123, P3595; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; Bergkvist A, 2009, EUR J CLIN PHARMACOL, V65, P1037, DOI 10.1007/s00228-009-0680-1; Bergman A, 2007, SCAND J PRIM HEALTH, V25, P9, DOI 10.1080/02813430600991980; Hoven JL, 2005, EUR J CLIN PHARMACOL, V60, P831, DOI 10.1007/s00228-004-0845-x; Johnell K, 2008, SCAND J PRIM HEALTH, V26, P86, DOI 10.1080/02813430802022196; Johnell K, 2007, ANN PHARMACOTHER, V41, P1243, DOI 10.1345/aph.1K154; Larsen Anna Bira, 2007, Res Social Adm Pharm, V3, P265, DOI 10.1016/j.sapharm.2006.10.002; McGraw C, 2000, Br J Community Nurs, V5, P326; MEANS BJ, 1975, AM J HOSP PHARM, V32, P186, DOI 10.1093/ajhp/32.2.186; Medical Products Agency, 2013, UTV DOSTJ, P10; Midlov P, 2005, PHARM WORLD SCI, V27, P116, DOI 10.1007/s11096-004-3705-y; Midlov P, 2012, INT J CLIN PHARM-NET, V34, P113, DOI 10.1007/s11096-011-9599-6; MURRAY MD, 1993, ANN PHARMACOTHER, V27, P616; Nordling S, 2009, VILKEN NYTTA HAR APO, P24, DOI The Swedish Institute for Health Economics; Olsson J, 2010, CLIN DRUG INVEST, V30, P289, DOI 10.2165/11534320-000000000-00000; Schneider LS, 2005, JAMA-J AM MED ASSOC, V294, P1934, DOI 10.1001/jama.294.15.1934; Sjoberg C, 2012, EUR J CLIN PHARMACOL, V68, P1095, DOI 10.1007/s00228-012-1230-9; Sjoberg C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026574; Sjoqvist F, 2012, INTERAKTION MELLAN L; Swedish Council on Technology Assessment in Health Care, 2009, CAN DRUG CONS ELD BE, p[12, 19]; Wekre LJ, 2012, SCAND J PUBLIC HEALT, V40, P523, DOI 10.1177/1403494812455468; Wekre LJ, 2011, SCAND J PRIM HEALTH, V29, P45, DOI 10.3109/02813432.2011.554002; Wekre LJ, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2009.038745	25	36	36	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2013	8	6							e67088	10.1371/journal.pone.0067088	http://dx.doi.org/10.1371/journal.pone.0067088			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	182JP	23826197	Green Published, gold, Green Submitted			2023-01-03	WOS:000321738400101
J	Dworzynski, K; Ritchie, G; Fenu, E; MacDermott, K; Playford, ED				Dworzynski, Katharina; Ritchie, Gill; Fenu, Elisabetta; MacDermott, Keith; Playford, E. Diane		Guideline Dev Grp	Rehabilitation after stroke: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Dworzynski, Katharina; Ritchie, Gill; Fenu, Elisabetta] Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England; [Playford, E. Diane] UCL Inst Neurol, London WC1N 1PJ, England	Royal College of Physicians; University of London; University College London	Dworzynski, K (corresponding author), Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England.	Katharina.Dworzynski@rcplondon.ac.uk		Playford, E Diane/0000-0001-7314-787X				Department of Health, 2007, 284536 DOH; GRADE Working Group, 2011, GRAD REC ASS DEV EV; National Institute for Health and Care Excellence, 2013, STROK REH LONG TERM; Townsend N, 2012, CORONARY HEART DIS S	4	45	48	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	2013	346								f3615	10.1136/bmj.f3615	http://dx.doi.org/10.1136/bmj.f3615			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	166WH	23760965				2023-01-03	WOS:000320589800003
J	Higgins, PC; Prigerson, HG				Higgins, Philip C.; Prigerson, Holly G.			Caregiver Evaluation of the Quality of End-Of-Life Care (CEQUEL) Scale: The Caregiver's Perception of Patient Care Near Death	PLOS ONE			English	Article							EXPLORATORY FACTOR-ANALYSIS; BEREAVED FAMILY-MEMBERS; INITIAL VALIDATION; TERMINAL ILLNESS; CANCER-PATIENTS; MENTAL-HEALTH; MEDICAL-CARE; COMMUNICATION; PROVIDERS; PERSPECTIVES	Purpose: End-of-life (EOL) measures are limited in capturing caregiver assessment of the quality of EOL care. Because none include caregiver perception of patient suffering or prolongation of death, we sought to develop and validate the Caregiver Evaluation of Quality of End-of-Life Care (CEQUEL) scale to include these dimensions of caregiver-perceived quality of EOL care. Patients and Methods: Data were derived from Coping with Cancer (CwC), a multisite, prospective, longitudinal study of advanced cancer patients and their caregivers (N = 275 dyads). Caregivers were assessed before and after patient deaths. CEQUEL's factor structure was examined; reliability was evaluated using Cronbach's alpha, and convergent validity by the strength of associations between CEQUEL scores and key EOL outcomes. Results: Factor analysis revealed four distinct factors: Prolongation of Death, Perceived Suffering, Shared Decision-Making, and Preparation for the Death. Each item loaded strongly on only a single factor. The 13-item CEQUEL and its subscales showed moderate to acceptable Cronbach's alpha (range: 0.52-0.78). 53% of caregivers reported patients suffering more than expected. Higher CEQUEL scores were positively associated with therapeutic alliance (rho =. 13; p <=.05) and hospice enrollment (z = -2.09; p <=.05), and negatively associated with bereaved caregiver regret (rho = -.36, p <=.001) and a diagnosis of Posttraumatic Stress Disorder (z = -2.06; p <=.05). Conclusion: CEQUEL is a brief, valid measure of quality of EOL care from the caregiver's perspective. It is the first scale to include perceived suffering and prolongation of death. If validated in future work, it may prove a useful quality indicator for the delivery of EOL care and a risk indicator for poor bereavement adjustment.	[Higgins, Philip C.] Boston Coll, Grad Sch Social Work, Chestnut Hill, MA 02167 USA; [Higgins, Philip C.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA; [Higgins, Philip C.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA; [Prigerson, Holly G.] Dana Farber Canc Inst, Dept Med Oncol, Div Populat Sci, Boston, MA 02115 USA; [Prigerson, Holly G.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Prigerson, Holly G.] Harvard Univ, Sch Med, Boston, MA USA	Boston College; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Prigerson, HG (corresponding author), Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02115 USA.	holly_prigerson@dfci.harvard.edu	Prigerson, Holly/GWV-3283-2022; Prigerson, Holly/L-3800-2019	Prigerson, Holly/0000-0002-7075-4268	American Cancer Society [DSW1009403SW]; National Institute of Mental Health [MH63892]; National Cancer Institute [CA106370, CA156732]; Center for Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute; NATIONAL CANCER INSTITUTE [U54CA156732, R01CA106370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063892] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This research was supported in part by the following grants to PCH: DSW1009403SW from the American Cancer Society; and to HGP: MH63892 from the National Institute of Mental Health and CA106370 and CA156732 from the National Cancer Institute; and the Center for Psychosocial Epidemiology and Outcomes Research, Dana-Farber Cancer Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addington-Hall J, 2001, J PAIN SYMPTOM MANAG, V22, P784, DOI 10.1016/S0885-3924(01)00330-X; Akiyama A, 2010, ARCH GERONTOL GERIAT, V50, P175, DOI 10.1016/j.archger.2009.03.006; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Barry LC, 2002, AM J GERIAT PSYCHIAT, V10, P447; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Byock IR, 1998, PALLIATIVE MED, V12, P231, DOI 10.1191/026921698670234618; CATTELL RB, 1966, MULTIVAR BEHAV RES, V1, P245, DOI 10.1207/s15327906mbr0102_10; Cherlin E, 2005, J PALLIAT MED, V8, P1176, DOI 10.1089/jpm.2005.8.1176; CORTINA JM, 1993, J APPL PSYCHOL, V78, P98, DOI 10.1037/0021-9010.78.1.98; Curtis JR, 2002, J PAIN SYMPTOM MANAG, V24, P17, DOI 10.1016/S0885-3924(02)00419-0; DeCoster J, 2005, SCALE CONSTRUCTION N; Emanuel L L, 2001, J Palliat Med, V4, P465, DOI 10.1089/109662101753381601; Emanuel L L, 2000, J Palliat Med, V3, P419, DOI 10.1089/jpm.2000.3.4.419; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; First M, 2016, STRUCTURED CLIN INTE; Fowler FJ, 1999, J PAIN SYMPTOM MANAG, V17, P114, DOI 10.1016/S0885-3924(98)00133-X; Fried TR, 2003, J AM GERIATR SOC, V51, P1398, DOI 10.1046/j.1532-5415.2003.51457.x; Ganzini L, 2009, J PAIN SYMPTOM MANAG, V38, P807, DOI 10.1016/j.jpainsymman.2009.04.026; Gries CJ, 2008, CHEST, V133, P704, DOI 10.1378/chest.07-1773; Hales S, 2010, PALLIATIVE MED, V24, P127, DOI 10.1177/0269216309351783; Hanson LC, 1997, J AM GERIATR SOC, V45, P1339, DOI 10.1111/j.1532-5415.1997.tb02933.x; Hayton JC, 2004, ORGAN RES METHODS, V7, P191, DOI 10.1177/1094428104263675; Hebert RS, 2008, J PALLIAT MED, V11, P476, DOI 10.1089/jpm.2007.0165; Heyland DK, 2006, CMAJ, V174; Hinton J, 1996, SOC SCI MED, V43, P1229, DOI 10.1016/0277-9536(95)00437-8; HOUTS P S, 1989, Journal of Psychosocial Oncology, V7, P113, DOI 10.1300/J077v07n03_08; Hudson PL, 2010, PALLIATIVE MED, V24, P656, DOI 10.1177/0269216310373167; Koop Priscilla M, 2003, Clin Nurs Res, V12, P127; Kris AE, 2006, AM J GERIAT PSYCHIAT, V14, P264, DOI 10.1097/01.JGP.0000194642.86116.ce; Latham AE, 2004, SUICIDE LIFE-THREAT, V34, P350, DOI 10.1521/suli.34.4.350.53737; Loggers ET, 2013, NEW ENGL J MED, V368, P1417, DOI 10.1056/NEJMsa1213398; Mack JW, 2009, CANCER-AM CANCER SOC, V115, P3302, DOI 10.1002/cncr.24360; McDonagh JR, 2004, CRIT CARE MED, V32, P1484, DOI 10.1097/01.CCM.0000127262.16690.65; Muthen B., 1997, ROBUST INFERENCE USI; Muthen LK, 2011, BINARY DATA FACTOR A; National Hospice and Palliative Care Organization, 2012, NHPCO FACTS FIG HOSP; Norton SA, 2003, AM J CRIT CARE, V12, P548, DOI 10.4037/ajcc2003.12.6.548; Ott CH, 2007, J NERV MENT DIS, V195, P332, DOI 10.1097/01.nmd.0000243890.93992.1e; Pargament KI, 2000, J CLIN PSYCHOL, V56, P519, DOI 10.1002/(SICI)1097-4679(200004)56:4<519::AID-JCLP6>3.3.CO;2-T; Pargament KI, 1998, J SCI STUD RELIG, V37, P710, DOI 10.2307/1388152; Patrick DL, 2001, J PAIN SYMPTOM MANAG, V22, P717, DOI 10.1016/S0885-3924(01)00333-5; Pearce MJ, 2006, J HEALTH PSYCHOL, V11, P743, DOI 10.1177/1359105306066629; Prigerson HG, 2003, AM J GERIAT PSYCHIAT, V11, P309, DOI 10.1176/appi.ajgp.11.3.309; Prigerson HG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000121; Russ AJ, 2005, CULT MED PSYCHIAT, V29, P103, DOI 10.1007/s11013-005-4625-6; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser Karen E, 2002, J Palliat Med, V5, P829, DOI 10.1089/10966210260499014; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P752, DOI 10.1016/S0885-3924(01)00331-1; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; Tilden Virginia P, 2002, Gerontologist, V42 Spec No 3, P71; Torges CM, 2008, PSYCHOL AGING, V23, P169, DOI 10.1037/0882-7974.23.1.169; Wendler D, 2011, ANN INTERN MED, V154, P336, DOI 10.7326/0003-4819-154-5-201103010-00008; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wright AA, 2010, J CLIN ONCOL, V28, P4457, DOI 10.1200/JCO.2009.26.3863; Wright AA, 2010, CANCER-AM CANCER SOC, V116, P4656, DOI 10.1002/cncr.25217; Yu CY, 2002, EVALUATING CUTOFF CR; Zhang BH, 2012, ARCH INTERN MED, V172, P1133, DOI 10.1001/archinternmed.2012.2364	62	29	30	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2013	8	6							e66066	10.1371/journal.pone.0066066	http://dx.doi.org/10.1371/journal.pone.0066066			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	173SK	23762467	Green Published, Green Submitted, gold			2023-01-03	WOS:000321099000125
J	Liao, WI; Sheu, WHH; Chang, WC; Hsu, CW; Chen, YL; Tsai, SH				Liao, Wen-I; Sheu, Wayne Huey-Herng; Chang, Wei-Chou; Hsu, Chin-Wang; Chen, Yu-Long; Tsai, Shih-Hung			An Elevated Gap between Admission and A(1C)-Derived Average Glucose Levels Is Associated with Adverse Outcomes in Diabetic Patients with Pyogenic Liver Abscess	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; GLYCEMIC CONTROL; KLEBSIELLA-PNEUMONIAE; STRESS-HYPERGLYCEMIA; HEAD-INJURY; A1C ASSAY; MELLITUS; SEPSIS; PROGNOSIS; INSULIN	Objectives: To assess whether chronic glycemic control and stress-induced hyperglycemia, determined by the gap between admission glucose levels and A(1C)-derived average glucose (ADAG) levels adversely affects outcomes in diabetic patients with pyogenic liver abscess (PLA). Methods: Clinical, laboratory, and multi-detector computed tomography (MDCT) findings of 329 PLA patients (2004-2010) were retrospectively reviewed. HbA(1C) levels were used to determine long-term glycemic control status, which were then converted to estimated average glucose values. For the gap between admission glucose levels and ADAG levels, we used receiver operating characteristic (ROC) curve to determine the optimal cut-off values predicting adverse outcomes. Univariate and multivariate logistic regressions were used to identify predictors of adverse outcomes. Results: Diabetic PLA patients with poorer glycemic control had significantly higher Klebsiella pneumoniae (KP) infection rates, lower albumin levels, and longer hospital stays than those with suboptimal and good glycemic control. The ROC curve showed that a glycemic gap of 72 mg/dL was the optimal cut-off value for predicting adverse outcomes and showed a 22.3% relative increase in adverse outcomes compared with a glycemic gap, 72 mg/dL. Multivariate analysis revealed that an elevated glycemic gap >= 72 mg/dL was important predictor of adverse outcomes. Conclusions: A glycemic gap >= 72 mg/dL, rather than admission hyperglycemia or chronic glycemic control, was significantly correlated with adverse outcomes in diabetic PLA patients. Poorer chronic glycemic control in diabetic PLA patients is associated with high incidence of KP infection, hypoalbuminemia and longer hospital stay.	[Liao, Wen-I; Chen, Yu-Long; Tsai, Shih-Hung] Natl Def Med Ctr, Triserv Gen Hosp, Dept Emergency Med, Taipei, Taiwan; [Sheu, Wayne Huey-Herng] Taichung Vet Gen Hosp, Dept Internal Med, Div Endocrinol & Metab, Taichung, Taiwan; [Chang, Wei-Chou] Natl Def Med Ctr, Triserv Gen Hosp, Dept Radiol, Taipei, Taiwan; [Hsu, Chin-Wang] Taipei Med Univ, Wan Fang Hosp, Dept Emergency & Crit Care Med, Taipei, Taiwan	National Defense Medical Center; Tri-Service General Hospital; Taichung Veterans General Hospital; National Defense Medical Center; Tri-Service General Hospital; Taipei Medical University; Taipei Municipal WanFang Hospital	Tsai, SH (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Dept Emergency Med, Taipei, Taiwan.	tsaishihung@yahoo.com.tw		Tsai, Shih-Hung/0000-0003-0215-3193	Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan [TSGH-C101-063, TSGH-C102-060]; National Science Council, Taipei, Taiwan [NSC 101-2314-B-016-037]	Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; National Science Council, Taipei, Taiwan(Ministry of Science and Technology, Taiwan)	The study was supported in part by research grants from the Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (TSGH-C101-063, and TSGH-C102-060) and the National Science Council, Taipei, Taiwan (NSC 101-2314-B-016-037). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alsaif HS, 2011, RADIOLOGY, V260, P129, DOI 10.1148/radiol.11101876; Annuzzi G, 2004, ARTERIOSCL THROM VAS, V24, P2397, DOI 10.1161/01.ATV.0000146267.71816.30; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Don BR, 2004, SEMIN DIALYSIS, V17, P432, DOI 10.1111/j.0894-0959.2004.17603.x; Egi M, 2008, CRIT CARE MED, V36, P2249, DOI 10.1097/CCM.0b013e318181039a; Egi M, 2011, CRIT CARE MED, V39, P105, DOI 10.1097/CCM.0b013e3181feb5ea; Fiaccadori E, 2001, KIDNEY INT, V59, P1510, DOI 10.1046/j.1523-1755.2001.0590041510.x; Foo NP, 2010, AM J GASTROENTEROL, V105, P328, DOI 10.1038/ajg.2009.586; Fung CP, 2002, GUT, V50, P420, DOI 10.1136/gut.50.3.420; GALLACHER SJ, 1995, DIABETIC MED, V12, P916, DOI 10.1111/j.1464-5491.1995.tb00396.x; Huang CW, 2008, EPILEPSY RES, V79, P71, DOI 10.1016/j.eplepsyres.2007.12.012; Kamouchi M, 2011, STROKE, V42, P2788, DOI 10.1161/STROKEAHA.111.617415; Kavanagh BP, 2010, NEW ENGL J MED, V363, P2540, DOI 10.1056/NEJMcp1001115; Kim SB, 2007, J COMPUT ASSIST TOMO, V31, P59, DOI 10.1097/01.rct.0000224629.48068.69; Kornum JB, 2008, DIABETES CARE, V31, P1541, DOI 10.2337/dc08-0138; Laine L, 2008, GASTROENTEROLOGY, V135, P41, DOI 10.1053/j.gastro.2008.05.030; Lamloum SM, 2009, MED PRIN PRACT, V18, P447, DOI 10.1159/000235893; Leonidou L, 2007, J INFECTION, V55, P340, DOI 10.1016/j.jinf.2007.05.177; Li ZM, 2010, MED PRIN PRACT, V19, P17, DOI 10.1159/000252829; Lin JC, 2006, J CLIN ENDOCR METAB, V91, P3084, DOI 10.1210/jc.2005-2749; Lind M, 2012, DIABETOLOGIA, V55, P2946, DOI 10.1007/s00125-012-2681-3; Marchant MH, 2009, J BONE JOINT SURG AM, V91A, P1621, DOI 10.2106/JBJS.H.00116; MARGULIES DR, 1994, AM SURGEON, V60, P387; Marik PE, 2004, INTENS CARE MED, V30, P748, DOI 10.1007/s00134-004-2167-y; McAlister FA, 2005, DIABETES CARE, V28, P810, DOI 10.2337/diacare.28.4.810; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Menchine MD, 2011, ACAD EMERG MED, V18, P326, DOI 10.1111/j.1553-2712.2011.01014.x; Nathan DM, 2008, DIABETES CARE, V31, P1473, DOI 10.2337/dc08-0545; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; OSWALD GA, 1986, BMJ-BRIT MED J, V293, P917, DOI 10.1136/bmj.293.6552.917; Rueda AM, 2010, J INFECTION, V60, P99, DOI 10.1016/j.jinf.2009.12.003; Saaddine JB, 2006, ANN INTERN MED, V144, P465, DOI 10.7326/0003-4819-144-7-200604040-00005; Sato H, 2010, J CLIN ENDOCR METAB, V95, P4338, DOI 10.1210/jc.2010-0135; Schuetz P, 2012, AM J MED, V125, P670, DOI 10.1016/j.amjmed.2012.03.001; Siu LK, 2012, LANCET INFECT DIS, V12, P881, DOI 10.1016/S1473-3099(12)70205-0; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Takahara M, 2010, DIABETES CARE, V33, P2538, DOI 10.2337/dc10-0939; Thomsen RW, 2007, CLIN INFECT DIS, V44, P1194, DOI 10.1086/513201; Tiruvoipati R, 2012, J CRIT CARE, V27, P153, DOI 10.1016/j.jcrc.2011.06.011; Wang JH, 1998, CLIN INFECT DIS, V26, P1434, DOI 10.1086/516369; YANG CC, 1993, AM J GASTROENTEROL, V88, P1911; Yang Ching-Cheng, 2004, Journal of Microbiology Immunology and Infection, V37, P176	43	32	36	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2013	8	5							e64476	10.1371/journal.pone.0064476	http://dx.doi.org/10.1371/journal.pone.0064476			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155FM	23724053	gold, Green Published, Green Submitted			2023-01-03	WOS:000319733000060
J	Cheifetz, AS				Cheifetz, Adam S.			Management of Active Crohn Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; PRACTICE GUIDELINES; RANDOMIZED-TRIAL; ACTIVITY INDEX; MAINTENANCE INFLIXIMAB; MONOCLONAL-ANTIBODY; HUMANIZED ANTIBODY; BIOLOGICAL THERAPY; AMERICAN-COLLEGE		[Cheifetz, Adam S.] Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA 02215 USA; [Cheifetz, Adam S.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Cheifetz, AS (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Div Gastroenterol, Rabb Rose 425,330 Brookline Ave, Boston, MA 02215 USA.	acheifet@bidmc.harvard.edu			Pfizer; National Institute of Diabetes and Digestive and Kidney Diseases [1R01DK092235-01A1]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK092235, U01DK062422] Funding Source: NIH RePORTER	Pfizer(Pfizer); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Cheifetz reports participation in advisory boards for UCB, Janssen (previously Centocor), Abbott, Warner-Chillcot (previously Procter & Gamble), Shire, Given Imaging, and Prometheus. He reports research support from Pfizer and the National Institute of Diabetes and Digestive and Kidney Diseases (grant 1R01DK092235-01A1).	Ananthakrishnan AN, 2013, INFLAMM BOWEL DIS, V19, P37, DOI [10.1097/MIB.0b013e3182902ad9, 10.1002/ibd.22951]; Baert F, 2010, GASTROENTEROLOGY, V138, P463, DOI 10.1053/j.gastro.2009.09.056; Beaugerie L, 2006, GASTROENTEROLOGY, V130, P650, DOI 10.1053/j.gastro.2005.12.019; Beaugerie L, 2009, LANCET, V374, P1617, DOI 10.1016/S0140-6736(09)61302-7; Benchimol EI, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006792.pub2; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Biancone L, 2008, J CROHNS COLITIS, V2, P63, DOI 10.1016/j.crohns.2007.12.001; Bodger K, 2009, ALIMENT PHARM THER, V30, P265, DOI 10.1111/j.1365-2036.2009.04033.x; Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Cheifetz AS, 2006, AM J GASTROENTEROL, V101, P2218, DOI 10.1111/j.1572-0241.2006.00761.x; Cho JH, 2011, GASTROENTEROLOGY, V140, P1704, DOI 10.1053/j.gastro.2011.02.046; Colombel JF, 2006, GUT, V55, P1561, DOI 10.1136/gut.2005.084301; Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492; Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2006.11.041; Cosnes J, 2005, GUT, V54, P237, DOI 10.1136/gut.2004.045294; Cosnes J, 2002, INFLAMM BOWEL DIS, V8, P244, DOI 10.1097/00054725-200207000-00002; Cullen G, 2011, ALIMENT PHARM THER, V34, P1318, DOI 10.1111/j.1365-2036.2011.04866.x; D'Haens G, 2008, LANCET, V371, P660, DOI 10.1016/S0140-6736(08)60304-9; Dignass A, 2010, J CROHNS COLITIS, V4, P28, DOI 10.1016/j.crohns.2009.12.002; Doherty GA, 2011, GASTROINTEST ENDOSC, V74, P167, DOI 10.1016/j.gie.2011.01.067; Farraye FA, 2010, GASTROENTEROLOGY, V138, P746, DOI [10.1053/j.gastro.2009.12.035, 10.1053/j.gastro.2009.12.037]; Faubion WA, 2001, GASTROENTEROLOGY, V121, P255, DOI 10.1053/gast.2001.26279; Feagan BG, 2005, NEW ENGL J MED, V352, P2499, DOI 10.1056/NEJMoa042982; Feagan BG, 2000, NEW ENGL J MED, V342, P1627, DOI 10.1056/NEJM200006013422202; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; Feagan BG, 2008, CLIN GASTROENTEROL H, V6, P1370, DOI 10.1016/j.cgh.2008.06.007; Feuerstein JD, 2013, ALIMENT PHARM THER, V37, P937, DOI 10.1111/apt.12290; Gibbons RJ, 2003, CIRCULATION, V107, P2979, DOI 10.1161/01.CIR.0000063682.20730.A5; GREENBERG GR, 1994, NEW ENGL J MED, V331, P836, DOI 10.1056/NEJM199409293311303; Hanauer SB, 2006, GASTROENTEROLOGY, V130, P323, DOI 10.1053/j.gastro.2005.11.030; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Hanauer SB, 2004, CLIN GASTROENTEROL H, V2, P379, DOI 10.1016/S1542-3565(04)00122-3; Heresbach D, 2005, GUT, V54, P215, DOI 10.1136/gut.2004.041715; Jess T, 2012, GASTROENTEROLOGY, V143, P375, DOI 10.1053/j.gastro.2012.04.016; Kornbluth A, 2004, AM J GASTROENTEROL, V99, P1371, DOI 10.1111/j.1572-0241.2004.40036.x; Korzenik JR, 2007, GUT, V56, P2, DOI 10.1136/gut.2006.095588; KURATA JH, 1992, GASTROENTEROLOGY, V102, P1940, DOI 10.1016/0016-5085(92)90317-R; Lahiff C, 2013, ALIMENT PHARM THER, V37, P786, DOI 10.1111/apt.12262; Lees CW, 2008, ALIMENT PHARM THER, V27, P220, DOI 10.1111/j.1365-2036.2007.03570.x; Lichtenstein GR, 2009, AM J GASTROENTEROL, V104, P465, DOI 10.1038/ajg.2008.168; Lichtenstein GR, 2006, CLIN GASTROENTEROL H, V4, P621, DOI 10.1016/j.cgh.2006.03.002; Lichtenstein GR, 2006, GASTROENTEROLOGY, V130, P940, DOI 10.1053/j.gastro.2006.01.048; Loftus EV, 1998, GASTROENTEROLOGY, V114, P1161, DOI 10.1016/S0016-5085(98)70421-4; Long MD, 2012, GASTROENTEROLOGY, V143, P390, DOI 10.1053/j.gastro.2012.05.004; Louis E, 2012, GASTROENTEROLOGY, V142, P63, DOI 10.1053/j.gastro.2011.09.034; MALCHOW H, 1984, GASTROENTEROLOGY, V86, P249; McLeod RS, 1997, GASTROENTEROLOGY, V113, P1823, DOI 10.1016/S0016-5085(97)70001-5; Moum B, 1997, SCAND J GASTROENTERO, V32, P1005, DOI 10.3109/00365529709011217; Mow WS, 2004, GASTROENTEROLOGY, V126, P414, DOI 10.1053/j.gastro.2003.11.015; MUNKHOLM P, 1995, SCAND J GASTROENTERO, V30, P699, DOI 10.3109/00365529509096316; Odes S, 2008, WORLD J GASTROENTERO, V14, P6641, DOI 10.3748/wjg.14.6641; Prefontaine E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000545.pub2; Prefontaine E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000067.pub2; Romberg-Camps MJL, 2009, AM J GASTROENTEROL, V104, P371, DOI 10.1038/ajg.2008.38; RUTGEERTS P, 1990, GASTROENTEROLOGY, V99, P956, DOI 10.1016/0016-5085(90)90613-6; Sandborn W., 2000, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000545; Sandborn WJ, 2007, GUT, V56, P1232, DOI 10.1136/gut.2006.106781; Sandborn WJ, 2008, GASTROENTEROLOGY, V135, P1130, DOI 10.1053/j.gastro.2008.07.014; Sandborn WJ, 2007, NEW ENGL J MED, V357, P228, DOI 10.1056/NEJMoa067594; Sandborn WJ, 2005, NEW ENGL J MED, V353, P1912, DOI 10.1056/NEJMoa043335; Sands BE, 2006, ALIMENT PHARM THERAP, V23, P1127, DOI 10.1111/j.1365-2036.2006.02878.x; Sands BE, 2005, INFLAMM BOWEL DIS, V11, P133, DOI 10.1097/00054725-200502000-00006; Schnitzler F, 2009, INFLAMM BOWEL DIS, V15, P1295, DOI 10.1002/ibd.20927; Seow CH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000296.pub3; Siegel CA, 2009, CLIN GASTROENTEROL H, V7, P874, DOI 10.1016/j.cgh.2009.01.004; Silverberg MS, 2005, CAN J GASTROENTEROL, V19, p5A, DOI 10.1155/2005/269076; SILVERSTEIN MD, 1989, AM J GASTROENTEROL, V84, P31; Singh B, 2004, BRIT J SURG, V91, P801, DOI 10.1002/bjs.4613; Stappenbeck TS, 2011, AUTOPHAGY, V7, P355, DOI [10.4161/auto.7.4.13074, 10.4161/auto.7.2.13074]; Thomsen OO, 1998, NEW ENGL J MED, V339, P370, DOI 10.1056/NEJM199808063390603; Toruner M, 2008, GASTROENTEROLOGY, V134, P929, DOI 10.1053/j.gastro.2008.01.012; Travis SPL, 2006, GUT, V55, DOI 10.1136/gut.2005.081950b; Treton X, 2009, CLIN GASTROENTEROL H, V7, P80, DOI 10.1016/j.cgh.2008.08.028; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; Van Assche G, 2011, AM J GASTROENTEROL, V106, P1594, DOI 10.1038/ajg.2011.211; Vasiliauskas EA, 2000, GUT, V47, P487, DOI 10.1136/gut.47.4.487; Vavricka SR, 2012, INFLAMM BOWEL DIS, V18, P496, DOI 10.1002/ibd.21719; Zimmermann EM, 2011, CURR OPIN GASTROEN, V27, P132, DOI 10.1097/MOG.0b013e3283438e5d	79	81	87	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	2013	309	20					2150	2158		10.1001/jama.2013.4466	http://dx.doi.org/10.1001/jama.2013.4466			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148FU	23695484	Green Accepted			2023-01-03	WOS:000319229600031
J	Kennedy, A; Bower, P; Reeves, D; Blakeman, T; Bowen, R; Chew-Graham, C; Eden, M; Fullwood, C; Gaffney, H; Gardner, C; Lee, V; Morris, R; Protheroe, J; Richardson, G; Sanders, C; Swallow, A; Thompson, D; Rogers, A				Kennedy, Anne; Bower, Peter; Reeves, David; Blakeman, Tom; Bowen, Robert; Chew-Graham, Carolyn; Eden, Martin; Fullwood, Catherine; Gaffney, Hannah; Gardner, Caroline; Lee, Victoria; Morris, Rebecca; Protheroe, Joanne; Richardson, Gerry; Sanders, Caroline; Swallow, Angela; Thompson, David; Rogers, Anne		Salford Natl Inst Hlth Res Gastroi	Implementation of self management support for long term conditions in routine primary care settings: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLYCEMIC CONTROL; PRACTICE NURSES; CHRONIC DISEASE; ULCERATIVE-COLITIS; COST-EFFECTIVENESS; HEALTH-CARE; FOLLOW-UP; PROGRAMS; INTERVENTION; PERFORMANCE	Objective To determine the effectiveness of an intervention to enhance self management support for patients with chronic conditions in UK primary care. Design Pragmatic, two arm, cluster randomised controlled trial. Setting General practices, serving a population in northwest England with high levels of deprivation. Participants 5599 patients with a diagnosis of diabetes (n=2546), chronic obstructive pulmonary disease (n=1634), and irritable bowel syndrome (n=1419) from 43 practices (19 intervention and 22 control practices). Intervention Practice level training in a whole systems approach to self management support. Practices were trained to use a range of resources: a tool to assess the support needs of patients, guidebooks on self management, and a web based directory of local self management resources. Training facilitators were employed by the health management organisation. Main outcome measures Primary outcomes were shared decision making, self efficacy, and generic health related quality of life measured at 12 months. Secondary outcomes were general health, social or role limitations, energy and vitality, psychological wellbeing, self care activity, and enablement. Results We randomised 44 practices and recruited 5599 patients, representing 43% of the eligible population on the practice lists. 4533 patients (81.0%) completed the six month follow-up and 4076 (72.8%) the 12 month follow-up. No statistically significant differences were found between patients attending trained practices and those attending control practices on any of the primary or secondary outcomes. All effect size estimates were well below the prespecified threshold of clinically important difference. Conclusions An intervention to enhance self management support in routine primary care did not add noticeable value to existing care for long term conditions. The active components required for effective self management support need to be better understood, both within primary care and in patients' everyday lives. Trial registration Current Controlled Trials ISRCTN90940049.	[Kennedy, Anne; Rogers, Anne] Univ Southampton, Fac Hlth Sci, Southampton SO17 1BJ, Hants, England; [Bower, Peter; Reeves, David; Blakeman, Tom; Bowen, Robert; Eden, Martin; Gaffney, Hannah; Gardner, Caroline; Lee, Victoria; Morris, Rebecca; Sanders, Caroline; Swallow, Angela] Univ Manchester, Manchester Acad Hlth Sci Ctr, Ctr Primary Care, Natl Inst Hlth Res,Sch Primary Care Res, Manchester, Lancs, England; [Chew-Graham, Carolyn; Protheroe, Joanne; Swallow, Angela] Keele Univ, Res Inst Primary Care & Hlth Sci, Keele, Staffs, England; [Fullwood, Catherine] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Biomed Res Ctr, Manchester, Lancs, England; [Richardson, Gerry] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [Richardson, Gerry] Univ York, NIHR Res Design Serv Yorkshire & Humber, York YO10 5DD, N Yorkshire, England; [Thompson, David] Univ Manchester, Salford Royal Hosp, Fac Med & Human Sci, Inst Inflammat & Repair, Salford, Lancs, England	University of Southampton; University of Manchester; Keele University; University of Manchester; University of York - UK; University of York - UK; Salford Royal NHS Foundation Trust; Salford Royal Hospital; University of Manchester	Kennedy, A (corresponding author), Univ Southampton, Fac Hlth Sci, Highfield Campus, Southampton SO17 1BJ, Hants, England.	a.kennedy@soton.ac.uk	Reeves, David/H-6203-2014; Bower, Peter/A-1508-2011; Sanders, Caroline/G-8021-2014; Fullwood, Catherine/AAM-7281-2020; Morris, Rebecca/A-1940-2019	Reeves, David/0000-0001-6377-6859; Bower, Peter/0000-0001-9558-3349; Sanders, Caroline/0000-0002-0539-928X; Fullwood, Catherine/0000-0003-4136-2027; Gardner, Caroline/0000-0003-0487-3979; Gaffney, Hannah/0000-0001-9561-2488; Lee, Victoria/0000-0001-9578-3260; Eden, Martin/0000-0002-1542-2527; Morris, Rebecca/0000-0003-1587-0802	National Primary Care Research and Development Centre; Department of Health; National Institute for Health Research [RP-PG-0407-10136]; National Institute for Health Research [CL-2009-06-004] Funding Source: researchfish	National Primary Care Research and Development Centre; Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	The trial was funded by the National Institute for Health Research and The National Primary Care Research and Development Centre (funded by the Department of Health). This paper presents independent research commissioned by the National Institute for Health Research under its programme grants for applied research funding scheme (RP-PG-0407-10136). The views expressed in this paper are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research, or the Department of Health.	Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Blakeman T, 2006, BRIT J GEN PRACT, V56, P407; Bodenheimar T, 2005, HELPING PATIENTS MAN; Bodenheimer T, 2008, NEW ENGL J MED, V359, P2086, DOI 10.1056/NEJMp0805631; Bodenheimer Thomas, 2003, Dis Manag, V6, P63, DOI 10.1089/109350703321908441; Bower P, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-7; Campbell SA, 2008, ANN FAM MED, V6, P228, DOI 10.1370/afm.844; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Communities and Local Government (CLG), 2013, IND DEPR 2007 DAT PR; Deakin T, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003417.pub2; Department of Health, 2010, EQ EXC LIB NHS; Doran T, 2006, NEW ENGL J MED, V355, P375, DOI 10.1056/NEJMsa055505; Effing T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002990.pub2; Egginton JS, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-72; Furler J, 2011, CHRONIC ILLN, V7, P3, DOI 10.1177/1742395310386978; Goodyear-Smith F, 2009, FAM PRACT, V26, P128, DOI 10.1093/fampra/cmp015; Groenwold RHH, 2012, AM J EPIDEMIOL, V175, P210, DOI 10.1093/aje/kwr302; Hornsten A, 2008, DIABETES RES CLIN PR, V81, P50, DOI 10.1016/j.diabres.2008.02.005; Jones R, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-5; Kennedy A, 2003, PATIENT EDUC COUNS, V50, P303, DOI 10.1016/S0738-3991(03)00054-5; Kennedy A, 2003, HEALTH SOC CARE COMM, V11, P64, DOI 10.1046/j.1365-2524.2003.00399.x; Kennedy A, 2007, BMJ-BRIT MED J, V335, P968, DOI 10.1136/bmj.39372.540903.94; Kennedy A, 2007, J EPIDEMIOL COMMUN H, V61, P254, DOI 10.1136/jech.2006.053538; Kennedy A, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-7; Kennedy AP, 2004, GUT, V53, P1639, DOI 10.1136/gut.2003.034256; Kind P, 1996, QUALITY LIFE PHARMAC; Lorig K., 1996, OUTCOME MEASURES HLT, VVol. 2019; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Macdonald W, 2008, J ADV NURS, V62, P191, DOI 10.1111/j.1365-2648.2007.04585.x; May C, 2009, SOCIOLOGY, V43, P535, DOI 10.1177/0038038509103208; McCall N, 2011, NEW ENGL J MED, V365, P1704, DOI 10.1056/NEJMsa1011785; McDonald AM, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-9; McDonald R, 2009, SOC SCI MED, V68, P1206, DOI 10.1016/j.socscimed.2009.01.039; McGregor W, 2008, BRIT J GEN PRACT, V58, P711, DOI 10.3399/bjgp08X342183; Motheral Brenda R, 2011, Am J Manag Care, V17, pe10; Murray E, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-63; Parchman ML, 2006, ANN FAM MED, V4, P40, DOI 10.1370/afm.422; Partners in Salford, 2013, OUR VIS HLTH CIT; Powell LH, 2010, JAMA-J AM MED ASSOC, V304, P1331, DOI 10.1001/jama.2010.1362; Protheroe J, 2012, J HLTH PSYCHOL; Protheroe J, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-206; Protheroe J, 2009, BRIT J GEN PRACT, V59, P721, DOI 10.3399/bjgp09X472584; Ritter PL, 2001, J CLIN EPIDEMIOL, V54, P136, DOI 10.1016/S0895-4356(00)00261-4; Robinson A, 2006, GUT, V55, P643, DOI 10.1136/gut.2004.062901; Robinson A, 2001, LANCET, V358, P976, DOI 10.1016/S0140-6736(01)06105-0; Ryan A, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-96; Salmon P, 2007, FAM PRACT, V24, P269, DOI 10.1093/fampra/cmm015; Shojania KG, 2006, JAMA-J AM MED ASSOC, V296, P427, DOI 10.1001/jama.296.4.427; Stange KC, 2010, J GEN INTERN MED, V25, P601, DOI 10.1007/s11606-010-1291-3; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Steventon A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3874; Torgerson DJ, 2001, BMJ-BRIT MED J, V322, P355, DOI 10.1136/bmj.322.7282.355; Trento M, 2010, DIABETES CARE, V33, P745, DOI 10.2337/dc09-2024; Vassilev I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059723; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; Williams AM, 2011, CHRONIC ILLN, V7, P20, DOI 10.1177/1742395310383339; Williams GC, 2005, PATIENT EDUC COUNS, V57, P39, DOI 10.1016/j.pec.2004.04.001; Williams GC, 2004, HEALTH PSYCHOL, V23, P58, DOI 10.1037/0278-6133.23.1.58; Woolhandler S, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5015; Zwar N, 2006, SYSTEMATIC REV CHRON	60	151	157	1	61	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 13	2013	346								f2882	10.1136/bmj.f2882	http://dx.doi.org/10.1136/bmj.f2882			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	148OC	23670660	Green Published, Green Accepted			2023-01-03	WOS:000319253600002
J	Zhong, J; Sakaki, M; Okada, H; Ahrens, ET				Zhong, Jia; Sakaki, Masashi; Okada, Hideho; Ahrens, Eric T.			In Vivo Intracellular Oxygen Dynamics in Murine Brain Glioma and Immunotherapeutic Response of Cytotoxic T Cells Observed by Fluorine-19 Magnetic Resonance Imaging	PLOS ONE			English	Article							TUMOR OXYGENATION; TENSION; HYPOXIA; VACCINATION; SPECTROSCOPY; RESISTANCE; REGRESSION; RELAXATION; SURVIVAL	Noninvasive biomarkers of anti-tumoral efficacy are of great importance to the development of therapeutic agents. Tumor oxygenation has been shown to be an important indicator of therapeutic response. We report the use of intracellular labeling of tumor cells with perfluorocarbon (PFC) molecules, combined with quantitative F-19 spin-lattice relaxation rate (R-1) measurements, to assay tumor cell oxygen dynamics in situ. In a murine central nervous system (CNS) GL261 glioma model, we visualized the impact of Pmel-1 cytotoxic T cell immunotherapy, delivered intravenously, on intracellular tumor oxygen levels. GL261 glioma cells were labeled ex vivo with PFC and inoculated into the mouse striatum. The R-1 of F-19 labeled cells was measured using localized single-voxel magnetic resonance spectroscopy, and the absolute intracellular partial pressure of oxygen (pO(2)) was ascertained. Three days after tumor implantation, mice were treated with 2x10(7) cytotoxic T cells intravenously. At day five, a transient spike in pO(2) was observed indicating an influx of T cells into the CNS and putative tumor cell apoptosis. Immunohistochemistry and quantitative flow cytometry analysis confirmed that the pO(2) was causally related to the T cells infiltration. Surprisingly, the pO(2) spike was detected even though few (similar to 4x10(4)) T cells actually ingress into the CNS and with minimal tumor shrinkage. These results indicate the high sensitivity of this approach and its utility as a non-invasive surrogate biomarker of anti-cancer immunotherapeutic response in preclinical models.	[Zhong, Jia; Ahrens, Eric T.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Zhong, Jia; Ahrens, Eric T.] Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; [Sakaki, Masashi; Okada, Hideho] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Brain Tumor Program,Canc Inst, Pittsburgh, PA 15261 USA	Carnegie Mellon University; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ahrens, ET (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.	eta@andrew.cmu.edu	Sakaki, Masashi/ABA-6069-2021	Sakaki, Masashi/0000-0002-4431-3493	National Institutes of Health; Dana Foundation	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dana Foundation	This work is supported in part by grants from the National Institutes of Health and the Dana Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahrens ET, 2005, NAT BIOTECHNOL, V23, P983, DOI 10.1038/nbt1121; Alberts Bruce, 2002, MOL BIOL CELL; Baldwin NJ, 1996, MAGN RESON IMAGING, V14, P541, DOI 10.1016/0730-725X(96)00049-5; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; DARDZINSKI BJ, 1994, MAGNET RESON MED, V32, P88, DOI 10.1002/mrm.1910320112; di Carlo E, 2007, CANCER IMMUNOL IMMUN, V56, P1323, DOI 10.1007/s00262-007-0326-z; Duong TQ, 2001, MAGN RESON MED, V45, P61, DOI 10.1002/1522-2594(200101)45:1<61::AID-MRM1010>3.0.CO;2-8; El Andaloussi A, 2006, J NEUROSURG, V105, P430, DOI 10.3171/jns.2006.105.3.430; Fujita M, 2009, CANCER RES, V69, P1587, DOI 10.1158/0008-5472.CAN-08-2915; GUO QZ, 1994, ARTIF CELL BLOOD SUB, V22, P1449, DOI 10.3109/10731199409138849; HEES PS, 1993, MAGNET RESON MED, V29, P303, DOI 10.1002/mrm.1910290305; HOLLADAY FP, 1992, NEUROSURGERY, V31, P528, DOI 10.1227/00006123-199209000-00015; Hou HA, 2003, ANESTH ANALG, V96, P1467, DOI 10.1213/01.ANE.0000055648.41152.63; Iwadate Y, 2003, INT J ONCOL, V23, P483; Kadayakkara DKK, 2010, MAGN RESON MED, V64, P1252, DOI 10.1002/mrm.22506; Kalinski P, 2010, SEMIN IMMUNOL, V22, P173, DOI 10.1016/j.smim.2010.03.002; Krohn KA, 2008, J NUCL MED, V49, p129S, DOI 10.2967/jnumed.107.045914; Laukemper-Ostendorf S, 2002, MAGN RESON MED, V47, P82, DOI 10.1002/mrm.10008; Lyng H, 1997, RADIOTHER ONCOL, V44, P163, DOI 10.1016/S0167-8140(97)01920-8; Maes W, 2009, NEURO-ONCOLOGY, V11, P529, DOI 10.1215/15228517-2009-004; MASON RP, 1993, MAGNET RESON MED, V29, P296, DOI 10.1002/mrm.1910290304; MASON RP, 1994, INT J RADIAT ONCOL, V29, P95, DOI 10.1016/0360-3016(94)90231-3; Matsumoto S, 2008, J CLIN INVEST, V118, P1965, DOI 10.1172/JCI34928; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Nishimura F, 2006, CANCER RES, V66, P4478, DOI 10.1158/0008-5472.CAN-05-3825; O I, 2002, ANTICANCER RES, V22, P613; Okada H, 2011, J CLIN ONCOL, V29, P330, DOI 10.1200/JCO.2010.30.7744; Okada H, 2009, CRIT REV IMMUNOL, V29, P1; Overwijk WW, 2003, J EXP MED, V198, P569, DOI 10.1084/jem.20030590; PARHAMI P, 1983, J PHYS CHEM-US, V87, P1928, DOI 10.1021/j100234a020; Perret R, 2008, TISSUE ANTIGENS, V72, P187, DOI 10.1111/j.1399-0039.2008.01088.x; Prins RM, 2003, CANCER RES, V63, P8487; Rosenberg SA, 2008, NAT REV CANCER, V8, P299, DOI 10.1038/nrc2355; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tatum JL, 2006, INT J RADIAT BIOL, V82, P699, DOI 10.1080/09553000601002324; TEICHER BA, 1995, HEMATOL ONCOL CLIN N, V9, P475; Van der Sanden BPJ, 1999, INT J RADIAT ONCOL, V44, P649, DOI 10.1016/S0360-3016(98)00555-0; Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xia MN, 2006, PHYS MED BIOL, V51, P45, DOI 10.1088/0031-9155/51/1/004; Yu JS, 2001, CANCER RES, V61, P842; Yu JX, 2005, CURR MED CHEM, V12, P819, DOI 10.2174/0929867053507342; Zhao DW, 2009, MAGN RESON MED, V62, P357, DOI 10.1002/mrm.22020; Zhao DW, 2004, METHOD ENZYMOL, V386, P378; Zhu XM, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-10	45	18	18	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2013	8	5							e59479	10.1371/journal.pone.0059479	http://dx.doi.org/10.1371/journal.pone.0059479			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145YI	23667419	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000319055600001
J	Roland, M; Paddison, C				Roland, Martin; Paddison, Charlotte			Better management of patients with multimorbidity	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							INVERSE CARE LAW; CLINICAL GUIDELINES; CONTINUITY; OUTCOMES; QUALITY; PAY; EPIDEMIOLOGY; PHYSICIANS; DISEASES; ENGLAND		[Roland, Martin; Paddison, Charlotte] Univ Cambridge, Cambridge Inst Publ Hlth, Cambridge CB2 0SR, England	University of Cambridge	Roland, M (corresponding author), Univ Cambridge, Cambridge Inst Publ Hlth, Cambridge CB2 0SR, England.	mr108@cam.ac.uk		Roland, Martin/0000-0002-8533-3060				Aboulghate A, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X653624; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Bayliss EA, 2007, ANN FAM MED, V5, P395, DOI 10.1370/afm.722; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Campbell SM, 2010, ANN FAM MED, V8, P499, DOI 10.1370/afm.1145; Doran T, 2008, NEW ENGL J MED, V359, P274, DOI 10.1056/NEJMsa0800310; Doran T, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2405; Fletcher KE, 2011, J HOSP MED, V6, P438, DOI 10.1002/jhm.916; Guthrie B, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e6341; Haggerty JL, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5915; Hill A, 2012, PROMOTING CONTINUITY; HJORTDAHL P, 1992, BRIT MED J, V304, P1287, DOI 10.1136/bmj.304.6837.1287; Hsiao CJ, 2008, AM J MED QUAL, V23, P302, DOI 10.1177/1062860608315643; Hughes LD, 2013, AGE AGEING, V42, P62, DOI 10.1093/ageing/afs100; Jamous H, 1970, PROFESSIONS PROFESSI, P115; Mercer SW, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4152; Reuben DB, 2012, NEW ENGL J MED, V366, P777, DOI 10.1056/NEJMp1113631; Ridd M, 2006, FAM PRACT, V23, P461, DOI 10.1093/fampra/cml010; Royal College of Physicians, 2005, DOCT SOC MED PROF CH; Rubin G, 2006, BRIT J GEN PRACT, V56, P743; Salisbury C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548929; Saultz JW, 2005, ANN FAM MED, V3, P159, DOI 10.1370/afm.285; Sharma G, 2009, JAMA-J AM MED ASSOC, V301, P1671, DOI 10.1001/jama.2009.517; Shippee ND, 2012, J CLIN EPIDEMIOL, V65, P1041, DOI 10.1016/j.jclinepi.2012.05.005; Smith SM, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5205; Stokes T, 2005, ANN FAM MED, V3, P353, DOI 10.1370/afm.351; Turner David, 2007, J Health Serv Res Policy, V12, P132, DOI 10.1258/135581907781543021; Watt G, 2002, LANCET, V360, P252, DOI 10.1016/S0140-6736(02)09466-7; Weyrauch K F, 1996, J Am Board Fam Pract, V9, P31	29	84	87	1	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 2	2013	346								f2510	10.1136/bmj.f2510	http://dx.doi.org/10.1136/bmj.f2510			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	139ET	23641032				2023-01-03	WOS:000318565300001
J	Wachman, EM; Hayes, MJ; Brown, MS; Paul, J; Harvey-Wilkes, K; Terrin, N; Huggins, GS; Aranda, JV; Davis, JM				Wachman, Elisha M.; Hayes, Marie J.; Brown, Mark S.; Paul, Jonathan; Harvey-Wilkes, Karen; Terrin, Norma; Huggins, Gordon S.; Aranda, Jacob V.; Davis, Jonathan M.			Association of OPRM1 and COMT Single-Nucleotide Polymorphisms With Hospital Length of Stay and Treatment of Neonatal Abstinence Syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GENETIC-VARIABILITY; A118G POLYMORPHISM; CLINICAL-EFFICACY; CANCER PAIN; METHADONE; MORPHINE; REQUIREMENTS; DEPENDENCE; BINDING	Importance Neonatal abstinence syndrome (NAS) caused by in utero opioid exposure is a growing problem; genetic factors influencing the incidence and severity have not been previously examined. Single-nucleotide polymorphisms (SNPs) in the mu-opioid receptor (OPRM1), multidrug resistance (ABCB1), and catechol-o-methyltransferase (COMT) genes are associated with risk for opioid addiction in adults. Objective To determine whether SNPs in the OPRM1, ABCB1, and COMT genes are associated with length of hospital stay and the need for treatment of NAS. Design, Setting, and Participants Prospective multicenter cohort study conducted at 5 tertiary care centers and community hospitals in Massachusetts and Maine between July 2011 and July 2012. DNA samples were genotyped for SNPs, and then NAS outcomes were correlated with genotype. Eighty-six of 140 eligible mother-infant dyads were enrolled. Infants were eligible if they were 36 weeks' gestational age or older and exposed to methadone or buprenorphine in utero. Main Outcomes and Measures Primary outcome measure was length of hospital stay, with between-group differences expressed as beta and calculated with linear regression models. Secondary outcome measures included need for any medical treatment for NAS and treatment with 2 or more medications. Results Infants with the OPRM1 118A > G AG/GG genotype had shortened length of stay (beta = -8.5 days; 95% CI, -14.9 to -2.1 days; P = .009) and were less likely to receive any treatment than AA infants (48% vs 72%; adjusted odds ratio, 0.76; 95% CI, 0.63-0.96; P = .006). The COMT 158A > G AG/GG genotype was associated with shortened length of stay (beta = -10.8 days; 95% CI, -18.2 to -3.4 days; P = .005) and less treatment with 2 or more medications (18% vs 56%; adjusted odds ratio, 0.68; 95% CI, 0.55-0.86; P = .001) than the AA genotype. Associations with the ABCB1 SNPs were not significant. Conclusions and Relevance Among infants with NAS, variants in the OPRM1 and COMT genes were associated with a shorter length of hospital stay and less need for treatment. These preliminary findings may provide insight into the mechanisms underlying NAS. JAMA. 2013;309(17):1821-1827	[Wachman, Elisha M.; Harvey-Wilkes, Karen; Davis, Jonathan M.] Tufts Med Ctr, Floating Hosp Children, Dept Pediat, Boston, MA 02111 USA; [Terrin, Norma] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA; [Huggins, Gordon S.] Tufts Med Ctr, Ctr Translat Genom, Mol Cardiol Res Inst, Boston, MA 02111 USA; [Terrin, Norma; Davis, Jonathan M.] Tufts Univ, Tufts Clin & Translat Sci Inst, Boston, MA 02111 USA; [Hayes, Marie J.] Univ Maine, Orono, ME USA; [Hayes, Marie J.] Univ Maine, Grad Sch Biomed Sci, Orono, ME USA; [Brown, Mark S.] Eastern Maine Med Ctr, Dept Pediat, Bangor, Gwynedd, Wales; [Paul, Jonathan] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA; [Aranda, Jacob V.] SUNY Downstate Brooklyn, Brooklyn, NY USA	Floating Hospital For Children; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts University; University of Maine System; University of Maine Orono; University of Maine System; University of Maine Orono; University of Texas System; University of Texas Medical Branch Galveston; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Davis, JM (corresponding author), Tufts Med Ctr, Floating Hosp Children, TMC 44, Div Newborn Med, 800 Washington St, Boston, MA 02111 USA.	jdavis@tuftsmedicalcenter.org			Winchester Hospital; Medical University of South Carolina; National Institutes of Health (NIH) [DA024806-01A2, R01DA032889-01A1]; Tufts Medical Center; National Research Service from the Eunice Kennedy Shriver National Institute of Child Health [T32HD055163]; National Center for Advancing Translational Sciences NIH through the Tufts Clinical and Translational Science Institute [UL1 TR000073]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD055163] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000073] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R21DA024806, R01DA032889] Funding Source: NIH RePORTER	Winchester Hospital; Medical University of South Carolina; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tufts Medical Center; National Research Service from the Eunice Kennedy Shriver National Institute of Child Health; National Center for Advancing Translational Sciences NIH through the Tufts Clinical and Translational Science Institute; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Davis reported receiving payment for lectures at Winchester Hospital and the Medical University of South Carolina. No other disclosures were reported.; This study was supported in part by National Institutes of Health (NIH) funding of data collection, single-nucleotide polymorphism genotyping, and data analyses (DA024806-01A2 to Dr Hayes and R01DA032889-01A1 to Dr Davis); the Tufts Medical Center's Natalie Zucker and Susan Saltonstall Grants to Dr Wachman, which supported laboratory analyses; National Research Service Award T32HD055163 from the Eunice Kennedy Shriver National Institute of Child Health to Dr Paul, which supported graduate education and training; and a National Center for Advancing Translational Sciences NIH grant UL1 TR000073 through the Tufts Clinical and Translational Science Institute to Drs Terrin and Davis.	[Anonymous], 2009, PAXGENE BLOOD DNA KI; [Anonymous], 2011, OR DNA COLL KIT PROT; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Coller JK, 2006, CLIN PHARMACOL THER, V80, P682, DOI 10.1016/j.clpt.2006.09.011; Finnegan LP., 1992, PRIMARY PEDIAT CARE, P1367; Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635; Hosak L, 2007, EUR PSYCHIAT, V22, P276, DOI 10.1016/j.eurpsy.2007.02.002; Jones HE, 2010, NEW ENGL J MED, V363, P2320, DOI 10.1056/NEJMoa1005359; Kendler KS, 2000, ARCH GEN PSYCHIAT, V57, P261, DOI 10.1001/archpsyc.57.3.261; Klepstad P, 2005, ACTA ANAESTH SCAND, V49, P902, DOI 10.1111/j.1399-6576.2005.00772.x; Levran O, 2008, HUM MOL GENET, V17, P2219, DOI 10.1093/hmg/ddn122; Lotsch J, 2004, CLIN PHARMACOKINET, V43, P983; Mague SD, 2010, DRUG ALCOHOL DEPEN, V108, P172, DOI 10.1016/j.drugalcdep.2009.12.016; Mague SD, 2009, P NATL ACAD SCI USA, V106, P10847, DOI 10.1073/pnas.0901800106; Patrick SW, 2012, JAMA-J AM MED ASSOC, V307, P1934, DOI 10.1001/jama.2012.3951; Pritham UA, 2012, JOGNN-J OBST GYN NEO, V41, P180, DOI 10.1111/j.1552-6909.2011.01330.x; Rakvag TT, 2005, PAIN, V116, P73, DOI 10.1016/j.pain.2005.03.032; Ray R, 2011, P NATL ACAD SCI USA, V108, P9268, DOI 10.1073/pnas.1018699108; Reyes-Gibby CC, 2007, PAIN, V130, P25, DOI 10.1016/j.pain.2006.10.023; Seligman NS, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.06.088; US Department of Health and Human Services Substance Abuse and Mental Health Administration, 2009, RES 2009 NAT SURV DR; Zhang W, 2011, MINERVA ANESTESIOL, V77, P33; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	23	134	135	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2013	309	17					1821	1827		10.1001/jama.2013.3411	http://dx.doi.org/10.1001/jama.2013.3411			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134SU	23632726	Green Accepted, Bronze			2023-01-03	WOS:000318235600030
J	Kurlbaum, M; Mulek, M; Hogger, P				Kurlbaum, Max; Muelek, Melanie; Hoegger, Petra			Facilitated Uptake of a Bioactive Metabolite of Maritime Pine Bark Extract (Pycnogenol) into Human Erythrocytes	PLOS ONE			English	Article							RED-BLOOD-CELLS; GLUCOSE-TRANSPORTER; MASS-SPECTROMETRY; ANTIOXIDANT ACTIVITY; URINARY METABOLITES; GLUTATHIONE; QUERCETIN; POLYPHENOLS; BINDING; PHARMACOKINETICS	Many plant secondary metabolites exhibit some degree of biological activity in humans. It is a common observation that individual plant-derived compounds in vivo are present in the nanomolar concentration range at which they usually fail to display measurable activity in vitro. While it is debatable that compounds detected in plasma are not the key effectors of bioactivity, an alternative hypothesis may take into consideration that measurable concentrations also reside in compartments other than plasma. We analysed the binding of constituents and the metabolite delta-(3,4-dihydroxy-phenyl)-gamma-valerolactone (M1), that had been previously detected in plasma samples of human consumers of pine bark extract Pycnogenol, to human erythrocytes. We found that caffeic acid, taxifolin, and ferulic acid passively bind to red blood cells, but only the bioactive metabolite M1 revealed pronounced accumulation. The partitioning of M1 into erythrocytes was significantly diminished at higher concentrations of M1 and in the presence of glucose, suggesting a facilitated transport of M1 via GLUT-1 transporter. This concept was further supported by structural similarities between the natural substrate alpha-D-glucose and the S-isomer of M1. After cellular uptake, M1 underwent further metabolism by conjugation with glutathione. We present strong indication for a transporter-mediated accumulation of a flavonoid metabolite in human erythrocytes and subsequent formation of a novel glutathione adduct. The physiologic role of the adduct remains to be elucidated.	[Kurlbaum, Max; Muelek, Melanie; Hoegger, Petra] Univ Wurzburg, Inst Pharm & Lebensmittelchem, D-97070 Wurzburg, Germany	University of Wurzburg	Hogger, P (corresponding author), Univ Wurzburg, Inst Pharm & Lebensmittelchem, D-97070 Wurzburg, Germany.	hogger@pzlc.uni-wuerzburg.de	Kurlbaum, Max/ABV-8275-2022		German Research Foundation (DFG); University of Wurzburg in the funding programme Open Access Publishing	German Research Foundation (DFG)(German Research Foundation (DFG)); University of Wurzburg in the funding programme Open Access Publishing	This publication was funded by the German Research Foundation (DFG) and the University of Wurzburg in the funding programme Open Access Publishing. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso GL, 2007, J BIOL PHYS, V33, P485, DOI 10.1007/s10867-008-9104-1; Awad HM, 2003, CHEM RES TOXICOL, V16, P822, DOI 10.1021/tx020079g; AWASTHI YC, 1983, BRIT J HAEMATOL, V55, P419, DOI 10.1111/j.1365-2141.1983.tb02156.x; BAILLIE TA, 1993, BIOL MASS SPECTROM, V22, P319, DOI 10.1002/bms.1200220602; Biasutto L, 2010, MOLECULES, V15, P6570, DOI 10.3390/molecules15096570; Boots AW, 2005, BIOCHEM BIOPH RES CO, V338, P923, DOI 10.1016/j.bbrc.2005.10.031; Castro-Perez J, 2005, RAPID COMMUN MASS SP, V19, P798, DOI 10.1002/rcm.1855; Cunningham P, 2006, J BIOL CHEM, V281, P5797, DOI 10.1074/jbc.M509422200; DAS NP, 1971, BIOCHEM PHARMACOL, V20, P3435, DOI 10.1016/0006-2952(71)90449-7; Duweler KG, 2000, PHARMAZIE, V55, P364; Fan HT, 2001, BRIT J PHARMACOL, V133, P1096, DOI 10.1038/sj.bjp.0704159; GALBRAITH DA, 1980, BIOCHEM J, V191, P63, DOI 10.1042/bj1910063; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Grimm T, 2004, FREE RADICAL BIO MED, V36, P811, DOI 10.1016/j.freeradbiomed.2003.12.017; Grimm Tanja, 2006, BMC Clin Pharmacol, V6, P4, DOI 10.1186/1472-6904-6-4; Grimm Tanja, 2006, J Inflamm (Lond), V3, P1, DOI 10.1186/1476-9255-3-1; Hapner CD, 2010, CHEM-BIOL INTERACT, V186, P275, DOI 10.1016/j.cbi.2010.05.010; Highley MS, 1996, PHARM RES-DORDR, V13, P186, DOI 10.1023/A:1016074627293; Hinderling PH, 1997, PHARMACOL REV, V49, P279; JACOBS H, 2011, FREE RADIC BIOL MED, DOI DOI 10.1016/J.FREERADBI0MED.2011.09.013; Kalsi KK, 2008, PFLUG ARCH EUR J PHY, V456, P991, DOI 10.1007/s00424-008-0459-8; Koren E, 2010, EXP BIOL MED, V235, P689, DOI 10.1258/ebm.2010.009370; Kurlbaum M, 2011, J PHARMACEUT BIOMED, V54, P127, DOI 10.1016/j.jpba.2010.07.038; LAGERQUIST HC, 2003, J BIOCHEM BIOPH METH, V55, P127; Leitch JM, 2009, AM J PHYSIOL-CELL PH, V296, pC151, DOI 10.1152/ajpcell.00359.2008; Li C, 2000, CHEM RES TOXICOL, V13, P177, DOI 10.1021/tx9901837; Li CA, 2001, CHEM RES TOXICOL, V14, P702, DOI 10.1021/tx0002536; Maimoona A, 2011, J ETHNOPHARMACOL, V133, P261, DOI 10.1016/j.jep.2010.10.041; *MAR PIN EXTR, 2011, US PHARM, P1196; MARCUS CJ, 1978, ARCH BIOCHEM BIOPHYS, V188, P287, DOI 10.1016/S0003-9861(78)80011-3; Martial S, 1996, AM J PHYSIOL-RENAL, V271, pF1264, DOI 10.1152/ajprenal.1996.271.6.F1264; Martin HJ, 2003, CHEM-BIOL INTERACT, V146, P225, DOI 10.1016/j.cbi.2003.06.001; Montel-Hagen A, 2008, CELL, V132, P1039, DOI 10.1016/j.cell.2008.01.042; Montel-Hagen A, 2009, CURR OPIN HEMATOL, V16, P165, DOI 10.1097/MOH.0b013e328329905c; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Packer L, 1999, FREE RADICAL BIO MED, V27, P704, DOI 10.1016/S0891-5849(99)00090-8; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; Perez A, 2011, BIOCHEMISTRY-US, V50, P8834, DOI 10.1021/bi200748b; Raja MM, 2003, J BIOL CHEM, V278, P49154, DOI 10.1074/jbc.M306881200; RAPPOLD M, 2010, THESIS U WURZBURG WU, P11; Rohdewald P, 2002, INT J CLIN PHARM TH, V40, P158; SALAUZE D, 1994, COMP HAEMATOL INT, V4, P34, DOI 10.1007/BF00368264; Sana TR, 2008, J CHROMATOGR B, V871, P314, DOI 10.1016/j.jchromb.2008.04.030; Schrijvers D, 2003, CLIN PHARMACOKINET, V42, P779, DOI 10.2165/00003088-200342090-00001; Sugano K, 2010, NAT REV DRUG DISCOV, V9, P597, DOI 10.1038/nrd3187; Thorens B, 1996, AM J PHYSIOL-GASTR L, V270, pG541, DOI 10.1152/ajpgi.1996.270.4.G541; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Uhlenhut K, 2012, FREE RADICAL BIO MED, V53, P305, DOI 10.1016/j.freeradbiomed.2012.04.013; van Bladeren PJ, 2000, CHEM-BIOL INTERACT, V129, P61, DOI 10.1016/S0009-2797(00)00214-3; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yu SX, 2005, RAPID COMMUN MASS SP, V19, P250, DOI 10.1002/rcm.1777; Zhang JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P173, DOI 10.1006/abbi.1999.1489; Zhang JZ, 2001, AM J PHYSIOL-CELL PH, V280, pC1277, DOI 10.1152/ajpcell.2001.280.5.C1277	55	23	23	0	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e63197	10.1371/journal.pone.0063197	http://dx.doi.org/10.1371/journal.pone.0063197			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23646194	Green Published, Green Submitted, gold			2023-01-03	WOS:000319077300151
J	Smelt, MJ; de Haan, BJ; Bron, PA; van Swam, I; Meijerink, M; Wells, JM; Kleerebezem, M; Faas, MM; de Vos, P				Smelt, Maaike J.; de Haan, Bart J.; Bron, Peter A.; van Swam, Iris; Meijerink, Marjolein; Wells, Jerry M.; Kleerebezem, Michiel; Faas, Marijke M.; de Vos, Paul			The Impact of Lactobacillus plantarum WCFS1 Teichoic Acid D-Alanylation on the Generation of Effector and Regulatory T-cells in Healthy Mice	PLOS ONE			English	Article							INFLAMMATORY-BOWEL-DISEASE; LIPOTEICHOIC ACID; DOUBLE-BLIND; DENDRITIC CELLS; MAINTAINING REMISSION; ACIDOPHILUS DEFICIENT; ULCERATIVE-COLITIS; PROBIOTIC THERAPY; RESPONSES; GG	To date it remains unclear how probiotics affect the immune system. Bacterial envelope components may play an essential role, as these are the first to establish bacterial-host cell interactions. Teichoic acids (TAs), and especially lipoteichoic acids, are the most pro-inflammatory components of the gram-positive bacterial envelope. This effect is dependent on D-alanyl substitution of the TA backbone and interactions with TLR2 on host cells. Although the pro-inflammatory properties of TAs have been established in vitro, it remains unclear how TAs affect immunomodulation in vivo. In this study, we investigated the role of TA D-alanylation on L. plantarum-induced intestinal and systemic immunomodulation in vivo. For this, we compared the effect of L. plantarum WCFS1 and its TA D-Alanylation negative derivative (dltX-D) on the distribution of dendritic cell and T cell populations and responses in healthy mice. We demonstrated that the majority of the L. plantarum-induced in vivo immunomodulatory effects were dependent on D-alanylation (D-Ala), as some L. plantarum WCFS1-induced immune changes were not observed in the dltX-D-treated group and some were only observed after treatment with dltX-D. Strikingly, not only pro-inflammatory immune responses were abolished in the absence of D-Ala substitution, but also anti-inflammatory responses, such as the L. plantarum-induced generation of regulatory T cells in the spleen. With this study we provide insight in host-microbe interactions, by demonstrating the involvement of D-alanylation of TAs on the bacterial membrane in intestinal and systemic immunomodulation in healthy mice.	[Smelt, Maaike J.; Bron, Peter A.; van Swam, Iris; Meijerink, Marjolein; Wells, Jerry M.; Kleerebezem, Michiel; de Vos, Paul] Top Inst Food & Nutr, Wageningen, Netherlands; [Smelt, Maaike J.; de Haan, Bart J.; Faas, Marijke M.; de Vos, Paul] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands; [Smelt, Maaike J.; de Haan, Bart J.; Faas, Marijke M.; de Vos, Paul] Univ Groningen, Dept Pathol & Med Biol, Groningen, Netherlands; [Bron, Peter A.; van Swam, Iris; Kleerebezem, Michiel] NIZO Food Res, Ede, Netherlands; [Meijerink, Marjolein; Wells, Jerry M.; Kleerebezem, Michiel] Wageningen Univ, Dept Host Microbe Interact Grp, NL-6700 AP Wageningen, Netherlands; [Bron, Peter A.] Kluyver Ctr Fermentat & Genom, Delft, Netherlands	Top Institute Food & Nutrition; University of Groningen; University of Groningen; NIZO Food Research; Wageningen University & Research	de Vos, P (corresponding author), Top Inst Food & Nutr, Wageningen, Netherlands.	p.de.vos@umcg.nl	Kleerebezem, Michiel/AAT-2078-2021; de Vos, Paul/A-3170-2013; Meijerink, Marjolein/B-9258-2014	Meijerink, Marjolein/0000-0003-3994-9785; de vos, paul/0000-0001-9618-2408; Kleerebezem, Michiel/0000-0001-8552-2235	Top Institute Food and Nutrition, Wageningen, The Netherlands	Top Institute Food and Nutrition, Wageningen, The Netherlands(Netherlands Government)	This work was supported by a project from the Top Institute Food and Nutrition, Wageningen, The Netherlands. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aumeunier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011484; Boge T, 2009, VACCINE, V27, P5677, DOI 10.1016/j.vaccine.2009.06.094; Bron PA, 2012, MICROB CELL FACT, V11, DOI 10.1186/1475-2859-11-123; Bron PA, 2012, NAT REV MICROBIOL, V10, P66, DOI 10.1038/nrmicro2690; Calcinaro F, 2005, DIABETOLOGIA, V48, P1565, DOI 10.1007/s00125-005-1831-2; CAMPBELL LK, 1978, INFECT IMMUN, V22, P842, DOI 10.1128/IAI.22.3.842-851.1978; Chen Q, 2009, J IMMUNOL, V183, P4458, DOI 10.4049/jimmunol.0901465; Claes IJJ, 2010, CLIN EXP IMMUNOL, V162, P306, DOI 10.1111/j.1365-2249.2010.04228.x; Davidson LE, 2011, EUR J CLIN NUTR, V65, P501, DOI 10.1038/ejcn.2010.289; Dennehy KM, 2009, EUR J IMMUNOL, V39, P1379, DOI 10.1002/eji.200838543; Denning TL, 2011, J IMMUNOL, V187, P733, DOI 10.4049/jimmunol.1002701; Foligne B, 2006, DIGEST DIS SCI, V51, P390, DOI 10.1007/s10620-006-3143-x; Foligne B, 2007, GASTROENTEROLOGY, V133, P862, DOI 10.1053/j.gastro.2007.06.018; Foligne B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000313; Foligne B, 2007, WORLD J GASTROENTERO, V13, P236, DOI 10.3748/wjg.v13.i2.236; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gionchetti P, 2003, GASTROENTEROLOGY, V124, P1202, DOI 10.1016/S0016-5085(03)00171-9; Gosselink MP, 2004, DIS COLON RECTUM, V47, P876, DOI 10.1007/s10350-004-0525-z; Grangette C, 2005, P NATL ACAD SCI USA, V102, P10321, DOI 10.1073/pnas.0504084102; Guandalini S, 2002, DIGEST LIVER DIS, V34, pS63, DOI 10.1016/S1590-8658(02)80167-0; Guandalini S, 2010, J PEDIATR GASTR NUTR, V51, P24, DOI 10.1097/MPG.0b013e3181ca4d95; Hansson GC, 2010, GUT MICROBES, V1, P51, DOI 10.4161/gmic.1.1.10470; Hatakka K, 2001, BMJ-BRIT MED J, V322, P1327, DOI 10.1136/bmj.322.7298.1327; Hirose Y, 2010, MICROBIOL IMMUNOL, V54, P143, DOI 10.1111/j.1348-0421.2009.00189.x; Hojsak I, 2010, PEDIATRICS, V125, pE1171, DOI 10.1542/peds.2009-2568; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Jacobo P, 2011, REPRODUCTION, V141, P249, DOI 10.1530/REP-10-0362; Johansson MEV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012238; Johansson MEV, 2008, P NATL ACAD SCI USA, V105, P15064, DOI 10.1073/pnas.0803124105; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kang SS, 2011, MOL IMMUNOL, V48, P2170, DOI 10.1016/j.molimm.2011.07.009; Khazaie K, 2012, P NATL ACAD SCI USA, V109, P10462, DOI 10.1073/pnas.1207230109; Kleerebezem M, 2003, P NATL ACAD SCI USA, V100, P1990, DOI 10.1073/pnas.0337704100; Kleerebezem M, 2010, FEMS MICROBIOL REV, V34, P199, DOI [10.1111/j.1574-6976.2010.00208.x, 10.1111/j.1574-6976.2009.00208.x]; KNOX KW, 1972, INFECT IMMUN, V6, P43, DOI 10.1128/IAI.6.1.43-49.1972; Kruis W, 2004, GUT, V53, P1617, DOI 10.1136/gut.2003.037747; Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107; Lebeer S, 2008, MICROBIOL MOL BIOL R, V72, P728, DOI 10.1128/MMBR.00017-08; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Maddur MS, 2012, AM J PATHOL, V181, P8, DOI 10.1016/j.ajpath.2012.03.044; Manicassamy S, 2009, NAT MED, V15, P401, DOI 10.1038/nm.1925; Marco ML, 2007, APPL ENVIRON MICROB, V73, P124, DOI 10.1128/AEM.01475-06; Marco ML, 2006, CURR OPIN BIOTECH, V17, P204, DOI 10.1016/j.copbio.2006.02.005; Matsumoto S, 2005, CLIN EXP IMMUNOL, V140, P417, DOI 10.1111/j.1365-2249.2005.02790.x; Meijer K, 2010, CURR OPIN CLIN NUTR, V13, P715, DOI 10.1097/MCO.0b013e32833eebe5; Meijerink M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010632; Miettinen M, 1998, INFECT IMMUN, V66, P6058, DOI 10.1128/IAI.66.12.6058-6062.1998; Mimura T, 2004, GUT, V53, P108, DOI 10.1136/gut.53.1.108; Mohamadzadeh M, 2011, P NATL ACAD SCI USA, V108, P4623, DOI 10.1073/pnas.1005066107; Morath S, 2005, J ENDOTOXIN RES, V11, P348, DOI 10.1179/096805105X67328; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Niers LEM, 2005, CLIN EXP ALLERGY, V35, P1481, DOI 10.1111/j.1365-2222.2005.02375.x; O'Flaherty S, 2010, GUT MICROBES, V1, P293, DOI 10.4161/gmic.1.5.12924; O'Hara AM, 2006, IMMUNOLOGY, V118, P202, DOI 10.1111/j.1365-2567.2006.02358.x; Paineau D, 2008, FEMS IMMUNOL MED MIC, V53, P107, DOI 10.1111/j.1574-695X.2008.00413.x; Palumbo E, 2006, J BACTERIOL, V188, P3709, DOI 10.1128/JB.188.10.3709-3715.2006; Remus DM, 2011, EUR J PHARMACOL, V668, pS33, DOI 10.1016/j.ejphar.2011.07.012; Rockel C, 2011, IMMUNOBIOLOGY, V216, P316, DOI 10.1016/j.imbio.2010.08.001; Ryu YH, 2009, INT IMMUNOPHARMACOL, V9, P127, DOI 10.1016/j.intimp.2008.10.014; Saber R, 2011, IMMUNOTHERAPY-UK, V3, P337, DOI 10.2217/IMT.10.119; Smelt MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047244; So JS, 2008, MOL IMMUNOL, V45, P2690, DOI 10.1016/j.molimm.2007.12.010; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Tsilingiri K, 2012, GUT, V61, P1007, DOI 10.1136/gutjnl-2011-300971; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Tursi A, 2004, MED SCI MONITOR, V10, pPI126; van Baarlen P, 2009, P NATL ACAD SCI USA, V106, P2371, DOI 10.1073/pnas.0809919106; van der Waaij LA, 2005, INFLAMM BOWEL DIS, V11, P865, DOI 10.1097/01.mib.0000179212.80778.d3; van Hemert S, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-293; Vaughan EE, 2002, ANTON LEEUW INT J G, V82, P341, DOI 10.1023/A:1020672724450; Wells JM, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-S1-S17; Xia GQ, 2010, INT J MED MICROBIOL, V300, P148, DOI 10.1016/j.ijmm.2009.10.001; Yamazaki S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018833; Zadeh M, 2012, J INFLAMM-LOND, V9, DOI 10.1186/1476-9255-9-7; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	75	37	39	4	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e63099	10.1371/journal.pone.0063099	http://dx.doi.org/10.1371/journal.pone.0063099			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23646181	Green Published, Green Submitted, gold			2023-01-03	WOS:000319077300136
J	Wang, SQ; Li, XJ; Zhou, SB; Sun, DX; Wang, H; Cheng, PF; Ma, XR; Liu, L; Liu, JX; Wang, FF; Liang, YF; Wu, JM				Wang, Shu-Qiu; Li, Xiao-Jie; Zhou, Shaobo; Sun, Di-Xiang; Wang, Hui; Cheng, Peng-Fei; Ma, Xiao-Ru; Liu, Lei; Liu, Jun-Xing; Wang, Fang-Fang; Liang, Yan-Feng; Wu, Jia-Mei			Intervention Effects of Ganoderma Lucidum Spores on Epileptiform Discharge Hippocampal Neurons and Expression of Neurotrophin-4 and N-Cadherin	PLOS ONE			English	Article							IN-VIVO; BDNF; NT-4; RECEPTORS; NGF; REORGANIZATION; EPILEPSY; CORTEX; DEATH	Epilepsy can cause cerebral transient dysfunctions. Ganoderma lucidum spores (GLS), a traditional Chinese medicinal herb, has shown some antiepileptic effects in our previous studies. This was the first study of the effects of GLS on cultured primary hippocampal neurons, treated with Mg2+ free medium. This in vitro model of epileptiform discharge hippocampal neurons allowed us to investigate the anti-epileptic effects and mechanism of GLS activity. Primary hippocampal neurons from <1 day old rats were cultured and their morphologies observed under fluorescence microscope. Neurons were confirmed by immunofluorescent staining of neuron specific enolase (NSE). Sterile method for GLS generation was investigated and serial dilutions of GLS were used to test the maximum non-toxic concentration of GLS on hippocampal neurons. The optimized concentration of GLS of 0.122 mg/ml was identified and used for subsequent analysis. Using the in vitro model, hippocampal neurons were divided into 4 groups for subsequent treatment i) control, ii) model (incubated with Mg2+ free medium for 3 hours), iii) GLS group I (incubated with Mg2+ free medium containing GLS for 3 hours and replaced with normal medium and incubated for 6 hours) and iv) GLS group II (neurons incubated with Mg2+ free medium for 3 hours then replaced with a normal medium containing GLS for 6 hours). Neurotrophin-4 and N-Cadherin protein expression were detected using Western blot. The results showed that the number of normal hippocampal neurons increased and the morphologies of hippocampal neurons were well preserved after GLS treatment. Furthermore, the expression of neurotrophin-4 was significantly increased while the expression of N-Cadherin was decreased in the GLS treated group compared with the model group. This data indicates that GLS may protect hippocampal neurons by promoting neurotrophin-4 expression and inhibiting N-Cadherin expression.	[Wang, Shu-Qiu; Zhou, Shaobo; Sun, Di-Xiang; Wang, Hui; Cheng, Peng-Fei; Ma, Xiao-Ru; Liu, Lei; Liu, Jun-Xing; Wang, Fang-Fang; Liang, Yan-Feng; Wu, Jia-Mei] Jiamusi Univ, Sch Basic Med Sci, Dept Pathophysiol, Jiamusi, Heilongjiang Pr, Peoples R China; [Li, Xiao-Jie] Jiamusi Univ, Sch Rehabil Med Sci, Jiamusi, Heilongjiang Pr, Peoples R China; [Wang, Shu-Qiu; Li, Xiao-Jie] Jiamusi Univ, Children Neural Rehabil Lab, Jiamusi, Heilongjiang Pr, Peoples R China; [Zhou, Shaobo] Univ Bedfordshire, Inst Biomed & Environm Sci & Technol, Dept Life Sci, Luton, Beds, England	Jiamusi University; Jiamusi University; Jiamusi University; University of Bedfordshire	Wang, SQ (corresponding author), Jiamusi Univ, Sch Basic Med Sci, Dept Pathophysiol, Jiamusi, Heilongjiang Pr, Peoples R China.		Zhou, Shaobo/I-1536-2019	Zhou, Shaobo/0000-0001-5214-2973	National Natural Science Foundation, Beijing, P.R. China [81241112]; Innovation Scientific Research Foundation for Postgraduates in Heilongjiang Province [YJSC2011-375HLJ]	National Natural Science Foundation, Beijing, P.R. China(National Natural Science Foundation of China (NSFC)); Innovation Scientific Research Foundation for Postgraduates in Heilongjiang Province	This work was supported by the National Natural Science Foundation, Beijing, P.R. China(No. 81241112) and Innovation Scientific Research Foundation for Postgraduates in Heilongjiang Province (No. YJSC2011-375HLJ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, LANCET, V380, P1121, DOI 10.1016/S0140-6736(12)61646-8; ARDELT AA, 1994, BRAIN RES, V647, P340, DOI 10.1016/0006-8993(94)91333-1; BANDOPADHYAY R, 1991, NEUROPEPTIDES, V18, P159, DOI 10.1016/0143-4179(91)90108-U; Buckmaster PS, 1999, J NEUROPHYSIOL, V81, P712, DOI 10.1152/jn.1999.81.2.712; Cavazos JE, 2004, NEUROSCIENCE, V126, P677, DOI 10.1016/j.neuroscience.2004.04.014; Chen MW, 2006, FOREIGN MED SCI, V33, P401; Chen YH, 2000, J KUNMING MED COLL, V21, P8; CHENG B, 1994, BRAIN RES, V650, P331, DOI 10.1016/0006-8993(94)91801-5; Dudek FE, 2007, PROG BRAIN RES, V163, P755, DOI 10.1016/S0079-6123(07)63041-6; Engelhardt M, 2007, EUR J NEUROSCI, V25, P529, DOI 10.1111/j.1460-9568.2006.05301.x; Fujita M, 2001, NEUROSCI LETT, V297, P13, DOI 10.1016/S0304-3940(00)01635-9; GOBBI G, 1992, LANCET, V340, P439; HYMAN C, 1994, J NEUROSCI, V14, P335; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; Leite JP, 2005, EPILEPSIA, V46, P134, DOI 10.1111/j.1528-1167.2005.01021.x; [李晶 LI Jing], 2009, [中国病理生理杂志, Chinese Journal of Pathophysiology], V25, P386; Lin Zhi-bin, 2006, Beijing Da Xue Xue Bao Yi Xue Ban, V38, P541; Liu J, 2007, FOOD CHEM, V100, P1691, DOI 10.1016/j.foodchem.2006.01.003; Liu Y, 2009, BRAIN RES, V1278, P27, DOI 10.1016/j.brainres.2009.04.043; Lobner D, 2002, BRAIN RES, V954, P42, DOI 10.1016/S0006-8993(02)03337-1; Mikati MA, 2003, EPILEPSIA, V44, P282, DOI 10.1046/j.1528-1157.2003.22502.x; O'Mahony R, 2005, J MICROBIOL METH, V61, P105, DOI 10.1016/j.mimet.2004.11.020; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Sakuma K, 2001, BRAIN RES, V907, P1, DOI 10.1016/S0006-8993(01)02288-0; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Sliva D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047873; SOMBATI S, 1995, J NEUROPHYSIOL, V73, P1706, DOI 10.1152/jn.1995.73.4.1706; Somjen GG, 2000, BRAIN RES, V885, P102, DOI 10.1016/S0006-8993(00)02948-6; Su T, 2011, BRAIN RES, V1385, P68, DOI 10.1016/j.brainres.2011.01.115; Treubert-Zimmermann U, 2002, J NEUROSCI, V22, P7617; VONBARTHELD CS, 1995, J NEUROSCI, V15, P2225, DOI 10.1523/JNEUROSCI.15-03-02225.1995; Wang H, 2005, CHIN J CLIN REHABIT, V9, P71; Wang Q, 2003, MED ENG PHYS, V25, P887, DOI 10.1016/S1350-4533(03)00114-0; Wang WQ, 2005, HEILONGJIANG MED PHA, P48; Wasterlain CG, 2002, PROG BRAIN RES, V135, P335; Yun TK, 1999, ANN NY ACAD SCI, V889, P157, DOI 10.1111/j.1749-6632.1999.tb08734.x; Zhang HT, 2007, J HISTOCHEM CYTOCHEM, V55, P1, DOI 10.1369/jhc.6A6952.2006; [赵爽 ZHAO Shuang], 2007, [中国病理生理杂志, Chinese Journal of Pathophysiology], V23, P1153	39	14	18	2	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 24	2013	8	4							e61687	10.1371/journal.pone.0061687	http://dx.doi.org/10.1371/journal.pone.0061687			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136DE	23637882	gold, Green Submitted, Green Published			2023-01-03	WOS:000318340400039
J	Nguyen, NP; Ceizyk, M; Vos, P; Betz, M; Chi, A; Almeida, F; Davis, R; Slane, B; Gelumbauskas, S; Smith-Raymond, L; Abraham, D; Stevie, M; Jang, SY; Vinh-Hung, V				Nguyen, Nam P.; Ceizyk, Misty; Vos, Paul; Betz, Michael; Chi, Alexander; Almeida, Fabio; Davis, Rick; Slane, Benjamin; Gelumbauskas, Steven; Smith-Raymond, Lexie; Abraham, Dave; Stevie, Michelle; Jang, Siyoung; Vinh-Hung, Vincent			Feasibility of Tomotherapy-Based Image-Guided Radiotherapy for Locally Advanced Oropharyngeal Cancer	PLOS ONE			English	Article							INTENSITY-MODULATED RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA; NECK-CANCER; HELICAL TOMOTHERAPY; CONCURRENT CHEMORADIOTHERAPY; NASOPHARYNGEAL CARCINOMA; RADIATION-THERAPY; HEAD; CHEMORADIATION; AMIFOSTINE	Purpose: The study aims to assess the feasibility of tomotherapy-based image-guided (IGRT) radiotherapy for locally advanced oropharyngeal cancer. A retrospective review of 33 patients undergoing concurrent chemoradiation for locally advanced oropharyngeal cancers was conducted. Radiotherapy planning, treatment toxicity and loco-regional control were assessed. Results: At a median follow-up of 32 months (6-47 months), no patient developed loco-regional recurrence. Two patients (6%) developed distant metastases. Grade 3-4 acute toxicity was respectively 72% and 25% for mucositis and gastrointestinal toxicity. Two patients (6%) had long-term dependence on tube feedings. Dose-volume histogram demonstrated excellent target volume coverage and low radiation dose to the organs at risk for complications. Conclusions and clinical relevance: IGRT provides excellent loco-regional control but acute toxicity remains significant and needs to be addressed in future prospective trials. The feasibility of Tomotherapy to decrease radiation dose to the normal tissues merits further investigations.	[Nguyen, Nam P.; Ceizyk, Misty; Davis, Rick; Slane, Benjamin; Gelumbauskas, Steven; Smith-Raymond, Lexie; Abraham, Dave; Stevie, Michelle; Jang, Siyoung] Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA; [Vos, Paul] E Carolina Univ, Dept Biostat, Greenville, NC USA; [Betz, Michael] Hirslanden Radiat Oncol Inst, Lausanne, Switzerland; [Chi, Alexander] W Virginia Univ, Dept Radiat Oncol, Morgantown, WV 26506 USA; [Almeida, Fabio] Southwest PET CT Inst, Tucson, AZ USA; [Vinh-Hung, Vincent] Univ Hosp Geneva, Dept Radiat Oncol, Geneva, Switzerland	University of Arizona; University of North Carolina; East Carolina University; West Virginia University; University of Geneva	Nguyen, NP (corresponding author), Univ Arizona, Dept Radiat Oncol, Tucson, AZ 85721 USA.	NamPhong.Nguyen@yahoo.com	Vinh-Hung, Vincent/A-5762-2008	Vinh-Hung, Vincent/0000-0002-6403-6120				Buntzel J, 2007, ANTICANCER RES, V27, P1953; Buntzel J, 1998, ANN ONCOL, V9, P505, DOI 10.1023/A:1008282412670; Cannon DM, 2008, INT J RADIAT ONCOL, V70, P660, DOI 10.1016/j.ijrobp.2007.09.018; Chen AM, 2010, TECHNOL CANCER RES T, V9, P291, DOI 10.1177/153303461000900308; Daly ME, 2010, INT J RADIAT ONCOL, V76, P1339, DOI 10.1016/j.ijrobp.2009.04.006; de Arruda FF, 2006, INT J RADIAT ONCOL, V64, P363, DOI 10.1016/j.ijrobp.2005.03.006; Feng FY, 2010, J CLIN ONCOL, V28, P2732, DOI 10.1200/JCO.2009.24.6199; Jacob V, 2010, STRAHLENTHER ONKOL, V186, P502, DOI 10.1007/s00066-010-2124-3; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kuntz AL, 1999, LARYNGOSCOPE, V109, P1334, DOI 10.1097/00005537-199908000-00030; LAUCIELLO FR, 1980, J PROSTHET DENT, V43, P204, DOI 10.1016/0022-3913(80)90188-2; Lee TF, 2008, RADIOTHER ONCOL, V89, P89, DOI 10.1016/j.radonc.2008.05.010; Malone JP, 2009, ARCH OTOLARYNGOL, V135, P1119, DOI 10.1001/archoto.2009.152; Murthy V, 2010, J CANCER RES THER, V6, P194, DOI 10.4103/0973-1482.65245; Nguyen NP, 2010, QJM-INT J MED, V103, P229, DOI 10.1093/qjmed/hcp176; Nguyen NP, 2009, BRIT J RADIOL, V82, P675, DOI 10.1259/bjr/72852974; Nguyen NP, 2007, AM J OTOLARYNG, V28, P3, DOI 10.1016/j.amjoto.2006.03.007; Nguyen NP, 2011, ORAL ONCOL, V47, P414, DOI 10.1016/j.oraloncology.2011.03.011; Nguyen NP, 2010, ORAL ONCOL, V46, P283, DOI 10.1016/j.oraloncology.2010.01.010; Ong SC, 2008, J NUCL MED, V49, P532, DOI 10.2967/jnumed.107.044792; Parsons JT, 2002, CANCER-AM CANCER SOC, V94, P2967, DOI 10.1002/cncr.10567; Pauloski BR, 2004, HEAD NECK-J SCI SPEC, V26, P625, DOI 10.1002/hed.20013; Salaun PY, 2007, HEAD NECK-J SCI SPEC, V29, P1125; Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998; Soo KC, 2005, BRIT J CANCER, V93, P279, DOI 10.1038/sj.bjc.6602696; Ulrich S, 2009, MED PHYS, V36, P4702, DOI 10.1118/1.3223633; Yao M, 2005, INT J RADIAT ONCOL, V63, P991, DOI 10.1016/j.ijrobp.2005.03.066	27	5	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2013	8	3							e60268	10.1371/journal.pone.0060268	http://dx.doi.org/10.1371/journal.pone.0060268			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121RP	23555938	Green Published, Green Submitted, gold			2023-01-03	WOS:000317262200103
J	Bennett, CL; Djulbegovic, B; Norris, LB; Armitage, JO				Bennett, Charles L.; Djulbegovic, Benjamin; Norris, LeAnn B.; Armitage, James O.			Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; NON-HODGKIN-LYMPHOMA; CELL LUNG-CANCER; BREAST-CANCER; MYELODYSPLASTIC SYNDROME; CLINICAL-TRIALS; GROWTH-FACTORS; SOLID TUMORS; DOSE-DENSE	A 55-year-old, previously healthy woman received a diagnosis of diffuse large-B-cell lymphoma after the evaluation of an enlarged left axillary lymph node obtained on biopsy. She had been asymptomatic except for the presence of enlarged axillary lymph nodes, which she had found while bathing. She was referred to an oncologist, who performed a staging evaluation. A complete blood count and test results for liver and renal function and serum lactate dehydrogenase were normal. Positron-emission tomography and computed tomography (PET-CT) identified enlarged lymph nodes with abnormal uptake in the left axilla, mediastinum, and retroperitoneum. Results on bone marrow biopsy were normal. The patient's oncologist recommends treatment with six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab (CHOP-R) at 21-day intervals. Is the administration of prophylactic granulocyte colony-stimulating factor (G-CSF) with the first cycle of chemotherapy indicated?	[Bennett, Charles L.; Norris, LeAnn B.] Univ S Carolina, South Carolina Coll Pharm, South Carolina Ctr Econ Excellence Medicat Safety, Columbia, SC 29208 USA; [Bennett, Charles L.; Norris, LeAnn B.] Univ S Carolina, South Carolina Coll Pharm, Southern Network Adverse React SONAR, Columbia, SC 29208 USA; [Bennett, Charles L.; Norris, LeAnn B.] Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Bennett, Charles L.; Norris, LeAnn B.] William Jennings Bryan Dorn Vet Affairs Med Ctr, Columbia, SC USA; [Djulbegovic, Benjamin] Univ S Florida, Morsani Coll Med, Ctr Evidence Based Med & Hlth Outcome Res, Clin & Translat Sci Inst,Dept Med, Tampa, FL USA; [Djulbegovic, Benjamin] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol, Tampa, FL USA; [Djulbegovic, Benjamin] H Lee Moffitt Canc Ctr & Res Inst, Dept Hlth Outcomes & Behav, Tampa, FL USA; [Armitage, James O.] Univ Nebraska, Omaha Sch Med, Omaha, NE 68182 USA	Medical University of South Carolina; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; University of Nebraska System	Bennett, CL (corresponding author), South Carolina Coll Pharm, 715 Sumter St, Columbia, SC 29208 USA.	bennettc@sccp.sc.edu	Djulbegovic, Benjamin/I-3661-2012; Norris, LeAnn B./H-8313-2019	Djulbegovic, Benjamin/0000-0003-0671-1447; Norris, LeAnn B./0000-0001-7656-1259	NCI [1R01CA 102713-01, 1R01CA165609-01A1, 1R01HL71650-01]; National Heart, Lung, and Blood Institute [1R01HL71650-01]; South Carolina Centers of Economic Excellence; Center for Medication Safety initiative; Doris Levkoff Meddin Medication Safety Education Program, South Carolina College of Pharmacy, the University of South Carolina; NATIONAL CANCER INSTITUTE [R01CA102713, R01CA165609] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071650] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); South Carolina Centers of Economic Excellence; Center for Medication Safety initiative; Doris Levkoff Meddin Medication Safety Education Program, South Carolina College of Pharmacy, the University of South Carolina; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported in part by grants from the NCI (1R01CA 102713-01, 1R01CA165609-01A1, and 1R01HL71650-01, to Dr. Bennett; and 1R01CA165609-01A1, to Dr. Norris), grants from the National Heart, Lung, and Blood Institute (1R01HL71650-01, to Dr. Djulbegovic), the South Carolina Centers of Economic Excellence, the Center for Medication Safety initiative, and the Doris Levkoff Meddin Medication Safety Education Program, South Carolina College of Pharmacy, the University of South Carolina.	Aapro MS, 2011, EUR J CANCER, V47, P8, DOI 10.1016/j.ejca.2010.10.013; [Anonymous], 2011, NEUL PEGF; [Anonymous], 2012, NEUP FILGR; Bacher U, 2007, BRIT J HAEMATOL, V137, P78, DOI 10.1111/j.1365-2141.2007.06529.x; BENNETT CL, 1995, J CLIN ONCOL, V13, P2457, DOI 10.1200/JCO.1995.13.9.2457; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; Bohlius J., 2008, COCHRANE DB SYST REV, V4; Bucaneve G, 2005, NEW ENGL J MED, V353, P977, DOI 10.1056/NEJMoa044097; Burris HA, 2010, J ONCOL PRACT, V6, P133, DOI 10.1200/JOP.091094; Caggiano V, 2005, CANCER-AM CANCER SOC, V103, P1916, DOI 10.1002/cncr.20983; Citron ML, 2003, J CLIN ONCOL, V21, P1431, DOI 10.1200/JCO.2003.09.081; Clark OAC, 2005, J CLIN ONCOL, V23, P4198, DOI 10.1200/JCO.2005.05.645; Confer DL, 2007, BRIT J HAEMATOL, V137, P77, DOI 10.1111/j.1365-2141.2007.06524.x; Cooper KL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-404; Crawford J, 2002, DRUGS, V62, P89, DOI 10.2165/00003495-200262001-00007; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; Cullen M, 2005, NEW ENGL J MED, V353, P988, DOI 10.1056/NEJMoa050078; Donadieu J, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-26; Engert A, 2009, ONKOLOGIE, V32, P599, DOI 10.1159/000232580; Gafter-Gvili A, 2005, ANN INTERN MED, V142, P979, DOI 10.7326/0003-4819-142-12_Part_1-200506210-00008; Gafter-Gvili A, 2006, ANN INTERN MED, V144, P704, DOI 10.7326/0003-4819-144-9-200605020-00027; GULATI SC, 1992, ANN INTERN MED, V116, P177, DOI 10.7326/0003-4819-116-3-177; Hadji P, 2012, INT J CLIN PHARM TH, V50, P281, DOI 10.5414/CP201633; Hershman D, 2007, JNCI-J NATL CANCER I, V99, P196, DOI 10.1093/jnci/djk028; Holig K, 2009, BLOOD, V114, P3757, DOI 10.1182/blood-2009-04-218651; Jelkmann W, 2010, AM J HEMATOL, V85, P771, DOI 10.1002/ajh.21805; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; Kuderer NM, 2006, CANCER-AM CANCER SOC, V106, P2258, DOI 10.1002/cncr.21847; Lokich JJ, 2006, AM J CLIN ONCOL-CANC, V29, P361, DOI 10.1097/01.coc.0000217816.16236.22; Lyman GH, 2012, CRIT REV ONCOL HEMAT, V81, P296, DOI 10.1016/j.critrevonc.2011.04.010; Lyman GH, 2010, J CLIN ONCOL, V28, P2914, DOI 10.1200/JCO.2009.25.8723; National Comprehensive Cancer Network, MYEL GROWTH FACT V10; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; Potosky AL, 2011, JNCI-J NATL CANCER I, V103, P979, DOI 10.1093/jnci/djr152; Ramsey SD, 2010, AM J MANAG CARE, V16, P678; Relling MV, 2003, BLOOD, V101, P3862, DOI 10.1182/blood-2002-08-2405; Ringden O, 2004, J CLIN ONCOL, V22, P416, DOI 10.1200/JCO.2004.06.102; Schnipper LE, 2012, J CLIN ONCOL, V30, P1715, DOI 10.1200/JCO.2012.42.8375; Smith RE, 2003, J CLIN ONCOL, V21, P1195, DOI 10.1200/JCO.2003.03.114; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Sung L, 2007, ANN INTERN MED, V147, P400, DOI 10.7326/0003-4819-147-6-200709180-00010; Veerappan R, 2007, BONE MARROW TRANSPL, V40, P361, DOI 10.1038/sj.bmt.1705736; Vogel CL, 2005, J CLIN ONCOL, V23, P1178, DOI 10.1200/JCO.2005.09.102; Waters GE, J ONCOL PRA IN PRESS; Zwick C, 2011, ANN ONCOL, V22, P1872, DOI 10.1093/annonc/mdq674	45	114	123	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 21	2013	368	12					1131	1139		10.1056/NEJMct1210890	http://dx.doi.org/10.1056/NEJMct1210890			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	108TH	23514290	Green Accepted			2023-01-03	WOS:000316318600006
J	Galan-Jimenez, MD; Mishael, YG; Nir, S; Morillo, E; Undabeytia, T				del Carmen Galan-Jimenez, Maria; Mishael, Yael-Golda; Nir, Shlomo; Morillo, Esmeralda; Undabeytia, Tomas			Factors Affecting the Design of Slow Release Formulations of Herbicides Based on Clay-Surfactant Systems. A Methodological Approach	PLOS ONE			English	Article							MONOVALENT ORGANIC CATIONS; SOLID-WATER INTERFACE; NONIONIC SURFACTANTS; ADSORPTION; MONTMORILLONITE; SEPIOLITE; SORPTION; METRIBUZIN; SOIL; NORFLURAZON	A search for clay-surfactant based formulations with high percentage of the active ingredient, which can yield slow release of active molecules is described. The active ingredients were the herbicides metribuzin (MZ), mesotrione (MS) and flurtamone (FL), whose solubilities were examined in the presence of four commercial surfactants; (i) neutral: two berols (B048, B266) and an alkylpolyglucoside (AG6202); (ii) cationic: an ethoxylated amine (ET/15). Significant percent of active ingredient (a. i.) in the clay/surfactant/herbicide formulations could be achieved only when most of the surfactant was added as micelles. MZ and FL were well solubilized by berols, whereas MS by ET/15. Sorption of surfactants on the clay mineral sepiolite occurred mostly by sorption of micelles, and the loadings exceeded the CEC. Higher loadings were determined for B266 and ET/15. The sorption of surfactants was modeled by using the Langmuir-Scatchard equation which permitted the determination of binding coefficients that could be used for further predictions of the sorbed amounts of surfactants under a wide range of clay/surfactant ratios. A possibility was tested of designing clay-surfactant based formulations of certain herbicides by assuming the same ratio between herbicides and surfactants in the formulations as for herbicides incorporated in micelles in solution. Calculations indicated that satisfactory FL formulations could not be synthesized. The experimental fractions of herbicides in the formulations were in agreement with the predicted ones for MS and MZ. The validity of this approach was confirmed in in vitro release tests that showed a slowing down of the release of a. i. from the designed formulations relative to the technical products. Soil dissipation studies with MS formulations also showed improved bioactivity of the clay-surfactant formulation relative to the commercial one. This methodological approach can be extended to other clay-surfactant systems for encapsulation and slow release of target molecules of interest.	[del Carmen Galan-Jimenez, Maria; Morillo, Esmeralda; Undabeytia, Tomas] Inst Nat Resources & Agrobiol, Spanish Res Council, Agrochem & Soil Conservat Dept, Seville, Spain; [Mishael, Yael-Golda; Nir, Shlomo] Hebrew Univ Jerusalem, Seagram Ctr Soil & Water Sci, Robert H Smith Fac Agr Food & Environm, IL-76100 Rehovot, Israel	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); Hebrew University of Jerusalem	Undabeytia, T (corresponding author), Inst Nat Resources & Agrobiol, Spanish Res Council, Agrochem & Soil Conservat Dept, Seville, Spain.	undabeyt@irnase.csic.es	Mishael, Yael/AAB-1826-2020; Morillo, Esmeralda/E-2180-2017	Morillo, Esmeralda/0000-0002-4485-2315	Spanish Ministry of Economy and Competitiveness [CTM2009-07425, PRI-PIBAR-1393]; Junta de Andalucia [P09-RNM4581]; European Social Fund	Spanish Ministry of Economy and Competitiveness(Spanish Government); Junta de Andalucia(Junta de Andalucia); European Social Fund(European Social Fund (ESF))	This research was supported by the projects CTM2009-07425 and PRI-PIBAR-1393 from the Spanish Ministry of Economy and Competitiveness, and Junta de Andalucia Project P09-RNM4581. These projects received funding by the European Social Fund. M.C. Galan-Jimenez acknowledges a research contract from Junta de Andalucia in the frame of the project P09-RNM4581. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akcay G, 2005, J COLLOID INTERF SCI, V281, P27, DOI 10.1016/j.jcis.2004.08.080; Backhaus WK, 2001, J COLLOID INTERF SCI, V242, P6, DOI 10.1006/jcis.2001.7781; Bojemueller E, 2001, APPL CLAY SCI, V18, P277, DOI 10.1016/S0169-1317(01)00027-8; CASES JM, 1992, LANGMUIR, V8, P1251, DOI 10.1021/la00041a005; Daniel PE, 2002, ENVIRON TOXICOL CHEM, V21, P2567, DOI 10.1897/1551-5028(2002)021&lt;2567:AAMSIS&gt;2.0.CO;2; Deng YJ, 2006, COLLOID POLYM SCI, V284, P347, DOI 10.1007/s00396-005-1388-0; Denoyel R, 1991, COLLOID INTERFACE SC, V43, P555; El-Nahhal Y, 2001, J AGR FOOD CHEM, V49, P5364, DOI 10.1021/jf010561p; Feng SS, 2009, BIOMATERIALS, V30, P3297, DOI 10.1016/j.biomaterials.2009.02.045; Harvey CC, 2006, DEV CLAY SCI, V1, P501, DOI 10.1016/S1572-4352(05)01016-0; Henriksen T, 2004, J ENVIRON QUAL, V33, P619, DOI 10.2134/jeq2004.0619; Hou YB, 2010, LANGMUIR, V26, P28, DOI 10.1021/la903672r; Levis SR, 2003, INT J PHARM, V253, P145, DOI 10.1016/S0378-5173(02)00702-0; LEVITZ P, 1991, LANGMUIR, V7, P1595, DOI 10.1021/la00056a010; Li ZH, 2003, CLAY CLAY MINER, V51, P445, DOI 10.1346/CCMN.2003.0510411; Maqueda C, 2008, J AGR FOOD CHEM, V56, P11941, DOI 10.1021/jf802364t; Maqueda C, 2009, APPL CLAY SCI, V46, P289, DOI 10.1016/j.clay.2009.08.019; Mishael YG, 2003, J AGR FOOD CHEM, V51, P2253, DOI 10.1021/jf0261497; Mishael YG, 2002, J AGR FOOD CHEM, V50, P2856, DOI 10.1021/jf011496m; Nennemann A, 2001, APPL CLAY SCI, V18, P285, DOI 10.1016/S0169-1317(01)00025-4; Nir S, 2000, ENVIRON SCI TECHNOL, V34, P1269, DOI 10.1021/es9903781; Paria S, 2004, ADV COLLOID INTERFAC, V110, P75, DOI 10.1016/j.cis.2004.03.001; Park JK, 2008, INT J PHARM, V359, P198, DOI 10.1016/j.ijpharm.2008.04.012; Radian A, 2008, ENVIRON SCI TECHNOL, V42, P1511, DOI 10.1021/es7023753; Rehab A, 2002, J POLYM SCI POL CHEM, V40, P2513, DOI 10.1002/pola.10326; Ruiz-Hitzky E, 2001, J MATER CHEM, V11, P86, DOI 10.1039/b003197f; RUIZHITZKY E, 1976, CLAY CLAY MINER, V24, P25, DOI 10.1346/CCMN.1976.0240102; Rytwo G, 1998, CLAY CLAY MINER, V46, P340, DOI 10.1346/CCMN.1998.0460313; Sabah E, 2002, WATER RES, V36, P3957, DOI 10.1016/S0043-1354(02)00110-0; Sanchez-Verdejo T, 2008, ENVIRON SCI TECHNOL, V42, P5779, DOI 10.1021/es800743p; Shen YH, 2000, CHEMOSPHERE, V41, P711, DOI 10.1016/S0045-6535(99)00436-1; Sonon LS, 2005, CLAY CLAY MINER, V53, P45, DOI 10.1346/CCMN.2005.0530106; Toerne K, 2001, LANGMUIR, V17, P6119, DOI 10.1021/la010559s; Undabeytia T, 2000, J AGR FOOD CHEM, V48, P4767, DOI 10.1021/jf9907945; Undabeytia T, 2000, J AGR FOOD CHEM, V48, P4774, DOI 10.1021/jf9912405; Undabeytia T, 2004, LANGMUIR, V20, P6605, DOI 10.1021/la0494472; Undabeytia T, 2003, ENVIRON SCI TECHNOL, V37, P4475, DOI 10.1021/es0343508; Undabeytia T, 2008, WATER RES, V42, P1211, DOI 10.1016/j.watres.2007.09.004; Viseras C, 2010, APPL CLAY SCI, V48, P291, DOI 10.1016/j.clay.2010.01.007	39	8	8	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e59060	10.1371/journal.pone.0059060	http://dx.doi.org/10.1371/journal.pone.0059060			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SR	23527087	gold, Green Published, Green Submitted			2023-01-03	WOS:000317562100071
J	Turturro, MV; Christenson, MC; Larson, JC; Young, DA; Brey, EM; Papavasiliou, G				Turturro, Michael V.; Christenson, Megan C.; Larson, Jeffery C.; Young, Daniel A.; Brey, Eric M.; Papavasiliou, Georgia			MMP-Sensitive PEG Diacrylate Hydrogels with Spatial Variations in Matrix Properties Stimulate Directional Vascular Sprout Formation	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DIRECTED CELL-MIGRATION; COVALENTLY IMMOBILIZED GRADIENTS; VEGF; MUSCLE; SCAFFOLDS; ANGIOGENESIS; ORGANIZATION; DEGRADATION; FIBRONECTIN	The spatial presentation of immobilized extracellular matrix (ECM) cues and matrix mechanical properties play an important role in directed and guided cell behavior and neovascularization. The goal of this work was to explore whether gradients of elastic modulus, immobilized matrix metalloproteinase (MMP)-sensitivity, and YRGDS cell adhesion ligands are capable of directing 3D vascular sprout formation in tissue engineered scaffolds. PEGDA hydrogels were engineered with mechanical and biofunctional gradients using perfusion-based frontal photopolymerization (PBFP). Bulk photopolymerized hydrogels with uniform mechanical properties, degradation, and immobilized biofunctionality served as controls. Gradient hydrogels exhibited an 80.4% decrease in elastic modulus and a 56.2% decrease in immobilized YRGDS. PBFP hydrogels also demonstrated gradients in hydrogel degradation with degradation times ranging from 10-12 hours in the more crosslinked regions to 4-6 hours in less crosslinked regions. An in vitro model of neovascularization, composed of co-culture aggregates of endothelial and smooth muscle cells, was used to evaluate the effect of these gradients on vascular sprout formation. Aggregate invasion in gradient hydrogels occurred bi-directionally with sprout alignment observed in the direction parallel to the gradient while control hydrogels with homogeneous properties resulted in uniform invasion. In PBFP gradient hydrogels, aggregate sprout length was found to be twice as long in the direction parallel to the gradient as compared to the perpendicular direction after three weeks in culture. This directionality was found to be more prominent in gradient regions of increased stiffness, crosslinked MMP-sensitive peptide presentation, and immobilized YRGDS concentration.	[Turturro, Michael V.; Christenson, Megan C.; Larson, Jeffery C.; Young, Daniel A.; Brey, Eric M.; Papavasiliou, Georgia] IIT, Dept Biomed Engn, Chicago, IL 60616 USA; [Brey, Eric M.] Edward Hines Jr VA Hosp, Res Serv, Hines, IL USA	Illinois Institute of Technology; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital	Papavasiliou, G (corresponding author), IIT, Dept Biomed Engn, Chicago, IL 60616 USA.	papavasiliou@iit.edu	Young, Daniel/F-9652-2017; Papavailiou, Georgia/D-2645-2014	Young, Daniel/0000-0003-1214-9577; Papavailiou, Georgia/0000-0002-6730-7360	Searle Funds at the Chicago Community Trust; National Institutes of Health [R21HL094916]; Veterans Administration; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL094916] Funding Source: NIH RePORTER	Searle Funds at the Chicago Community Trust; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Administration(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We would like to thank the CBC-UIC Research Resources Center Proteomics and Informatics Services Facility, which was established by a grant from The Searle Funds at the Chicago Community Trust to the Chicago Biomedical Consortium, for their help with performing mass spectroscopy on our synthesized peptides. The authors would also like to acknowledge the laboratory of Professor David Venerus in the department of Chemical and Biological Engineering at the Illinois Institute of Technology for providing access for mechanical testing of our samples. Finally the authors thank Dr. Howard Greisler (Edward Hines Jr. VA Hospital, Hines, Illinois) for his stimulating discussions and input during the early phases of this work.; This work was supported by National Institutes of Health (Grant No. R21HL094916) and the Veterans Administration. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barkefors I, 2008, J BIOL CHEM, V283, P13905, DOI 10.1074/jbc.M704917200; Borselli C, 2007, J BIOMED MATER RES A, V80A, P297, DOI 10.1002/jbm.a.30896; Borselli C, 2010, J BIOMED MATER RES A, V92A, P94, DOI 10.1002/jbm.a.32332; Bott K, 2010, BIOMATERIALS, V31, P8454, DOI 10.1016/j.biomaterials.2010.07.046; Brey EA, 2004, ANN BIOMED ENG, V32, P1100, DOI 10.1114/B:ABME.0000036646.17362.c4; Bryant SJ, 2004, ANN BIOMED ENG, V32, P407, DOI 10.1023/B:ABME.0000017535.00602.ca; Burdick JA, 2004, LANGMUIR, V20, P5153, DOI 10.1021/la049298n; Cai KY, 2009, COLLOID SURFACE B, V72, P230, DOI 10.1016/j.colsurfb.2009.04.008; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cavalcanti-Adam EA, 2006, EUR J CELL BIOL, V85, P219, DOI 10.1016/j.ejcb.2005.09.011; Chen RR, 2007, FASEB J, V21, P3896, DOI 10.1096/fj.06-7873com; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; DeKosky BJ, 2010, TISSUE ENG PART C-ME, V16, P1533, DOI 10.1089/ten.tec.2009.0761; DeLong SA, 2005, J CONTROL RELEASE, V109, P139, DOI 10.1016/j.jconrel.2005.09.020; DeLong SA, 2005, BIOMATERIALS, V26, P3227, DOI 10.1016/j.biomaterials.2004.09.021; Francis-Sedlak ME, 2010, MICROVASC RES, V80, P3, DOI 10.1016/j.mvr.2009.12.005; Geiger B, 2009, NAT REV MOL CELL BIO, V10, P21, DOI 10.1038/nrm2593; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Guarnieri D, 2010, ACTA BIOMATER, V6, P2532, DOI 10.1016/j.actbio.2009.12.050; Guarnieri D, 2008, MACROMOL SYMP, V266, P36, DOI 10.1002/masy.200850607; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Korff T, 2001, FASEB J, V15, P447, DOI 10.1096/fj.00-0139com; Kraehenbuehl TP, 2009, BIOMATERIALS, V30, P4318, DOI 10.1016/j.biomaterials.2009.04.057; Leslie-Barbick JE, 2009, J BIOMAT SCI-POLYM E, V20, P1763, DOI 10.1163/156856208X386381; Liu LY, 2007, LANGMUIR, V23, P11168, DOI 10.1021/la701435x; Mac Gabhann F, 2007, J APPL PHYSIOL, V102, P722, DOI 10.1152/japplphysiol.00800.2006; Mann BK, 2001, BIOMATERIALS, V22, P3045, DOI 10.1016/S0142-9612(01)00051-5; Moon JJ, 2010, BIOMATERIALS, V31, P3840, DOI 10.1016/j.biomaterials.2010.01.104; Nemir S, 2010, BIOTECHNOL BIOENG, V105, P636, DOI 10.1002/bit.22574; Odedra D, 2011, ACTA BIOMATER, V7, P3027, DOI 10.1016/j.actbio.2011.05.002; Papavasiliou G, 2010, J INVEST MED, V58, P838, DOI 10.231/JIM.0b013e3181f18e38; Patterson J, 2011, BIOMATERIALS, V32, P1301, DOI 10.1016/j.biomaterials.2010.10.016; Patterson J, 2010, BIOMATERIALS, V31, P7836, DOI 10.1016/j.biomaterials.2010.06.061; Porter AM, 2011, BIOMACROMOLECULES, V12, P242, DOI 10.1021/bm101220b; Seliktar D, 2004, J BIOMED MATER RES A, V68A, P704, DOI 10.1002/jbm.a.20091; Singh M, 2008, TISSUE ENG PART B-RE, V14, P341, DOI 10.1089/ten.teb.2008.0304; Smith JT, 2006, EXP CELL RES, V312, P2424, DOI 10.1016/j.yexcr.2006.04.005; Smith JT, 2009, COMB CHEM HIGH T SCR, V12, P598, DOI 10.2174/138620709788681871; Thery M, 2006, P NATL ACAD SCI USA, V103, P19771, DOI 10.1073/pnas.0609267103; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Turturro MV, 2012, J BIOMAT SCI-POLYM E, V23, P917, DOI 10.1163/092050611X566450; Wallace CS, 2007, AM J PHYSIOL-HEART C, V293, pH1978, DOI 10.1152/ajpheart.00618.2007; Wang Z, 2012, J MATER SCI-MATER M, V14, P14; West JL, 1999, MACROMOLECULES, V32, P241, DOI 10.1021/ma981296k; Xia N, 2008, FASEB J, V22, P1649, DOI 10.1096/fj.07-090571; Zisch AH, 2003, FASEB J, V17, P2260, DOI 10.1096/fj.02-1041fje	46	55	60	1	84	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2013	8	3							e58897	10.1371/journal.pone.0058897	http://dx.doi.org/10.1371/journal.pone.0058897			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107WV	23554954	Green Published, Green Submitted, gold			2023-01-03	WOS:000316252500055
J	Ghanbarian, E; Motamedi, F				Ghanbarian, Elham; Motamedi, Fereshteh			Ventral Tegmental Area Inactivation Suppresses the Expression of CA1 Long Term Potentiation in Anesthetized Rat	PLOS ONE			English	Article							SYNAPTIC PLASTICITY; NUCLEUS-ACCUMBENS; HIPPOCAMPAL CA1; REVERSIBLE INACTIVATION; DOPAMINE-RECEPTOR; MEMORY FORMATION; EPISODIC MEMORY; LOCUS-COERULEUS; LTP INDUCTION; REGION	The hippocampus receives dopaminergic projections from the ventral tegmental area (VTA). Modulatory effect of dopamine on hippocampal long term potentiation (LTP) has been studied before, but there are conflicting results and some limitations in previous reports. Most of these studies show a significant effect of dopamine on the late phase of LTP in CA1 area of the hippocampus, while few reports show an effect on the early phase. Moreover, they generally manipulated dopamine receptors in the hippocampus and there are few studies investigating influence of the VTA neural activity on hippocampal LTP in the intact brain. Besides, VTA neurons contain other neurotransmitters such as glutamate and GABA that may modify the net effect of dopamine. In this study we examined the effect of VTA reversible inactivation on the induction and maintenance of early LTP in the CA1 area of anesthetized rats, and also on different phases of learning of a passive avoidance (PA) task. We found that inactivation of the VTA by lidocaine had no effect on CA1 LTP induction and paired-pulse facilitation, but its inactivation immediately after tetanic stimulation transiently suppressed the expression of LTP. Blockade of the VTA 20 min after tetanic stimulation had no effect on the magnitude of LTP. Moreover, VTA inactivation immediately after training impaired memory in the passive avoidance task, while its blockade before or 20 min after training produced no memory deficit. It can be concluded that VTA activity has no effect on CA1 LTP induction and acquisition of PA task, but involves in the expression of LTP and PA memory consolidation.	[Ghanbarian, Elham; Motamedi, Fereshteh] Inst Res Fundamental Sci IPM, SCS, Tehran, Iran; [Ghanbarian, Elham; Motamedi, Fereshteh] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Fac Med, Tehran, Iran; [Ghanbarian, Elham; Motamedi, Fereshteh] Shahid Beheshti Univ Med Sci, Dept Physiol, Fac Med, Tehran, Iran	Shahid Beheshti University Medical Sciences; Shahid Beheshti University Medical Sciences	Motamedi, F (corresponding author), Inst Res Fundamental Sci IPM, SCS, Tehran, Iran.	motamedi@ams.ac.ir		Motamedi, Fereshteh/0000-0003-4030-8627	Institute for Research in Fundamental Sciences (IPM), Tehran, Iran	Institute for Research in Fundamental Sciences (IPM), Tehran, Iran	This work was supported in part by a grant from Institute for Research in Fundamental Sciences (IPM), Tehran, Iran. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Adcock RA, 2006, NEURON, V50, P507, DOI 10.1016/j.neuron.2006.03.036; Bernabeu R, 1997, P NATL ACAD SCI USA, V94, P7041, DOI 10.1073/pnas.94.13.7041; Bethus I, 2010, J NEUROSCI, V30, P1610, DOI 10.1523/JNEUROSCI.2721-09.2010; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOEIJINGA PH, 1993, NEUROSCIENCE, V53, P1049, DOI 10.1016/0306-4522(93)90488-2; Buschler A, 2012, HIPPOCAMPUS, V22, P2238, DOI 10.1002/hipo.22041; CASTELLANO C, 1991, BEHAV NEURAL BIOL, V56, P283, DOI 10.1016/0163-1047(91)90439-W; Chowdhury R, 2012, J NEUROSCI, V32, P14193, DOI 10.1523/JNEUROSCI.1278-12.2012; CORRADETTI R, 1992, NEUROSCIENCE, V46, P511, DOI 10.1016/0306-4522(92)90140-W; Costa C, 2012, BRAIN, V135, P1884, DOI 10.1093/brain/aws101; da Silva WCN, 2012, NEUROBIOL LEARN MEM, V97, P271, DOI 10.1016/j.nlm.2012.01.005; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.neuro.15.1.353; Davoodi FG, 2011, BEHAV BRAIN RES, V221, P1, DOI 10.1016/j.bbr.2011.02.020; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Fields HL, 2007, ANNU REV NEUROSCI, V30, P289, DOI 10.1146/annurev.neuro.30.051606.094341; FREY U, 1990, BRAIN RES, V522, P69, DOI 10.1016/0006-8993(90)91578-5; GASBARRI A, 1994, BRAIN RES BULL, V33, P445, DOI 10.1016/0361-9230(94)90288-7; Granado N, 2008, CEREB CORTEX, V18, P1, DOI 10.1093/cercor/bhm026; Gurden H, 1999, NEUROSCIENCE, V94, P1019, DOI 10.1016/S0306-4522(99)00395-4; Hamilton TJ, 2010, P NATL ACAD SCI USA, V107, P18185, DOI 10.1073/pnas.1011558107; Hansen N, 2012, CEREB CORTE IN PRESS; Hefco V, 2003, EUR J PHARMACOL, V475, P55, DOI 10.1016/S0014-2999(03)02115-0; HUANG Q, 1992, P NATL ACAD SCI USA, V89, P11988, DOI 10.1073/pnas.89.24.11988; HUANG YY, 1995, P NATL ACAD SCI USA, V92, P2446, DOI 10.1073/pnas.92.7.2446; Kahn I, 2013, HIPPOCAMPUS, V23, P187, DOI 10.1002/hipo.22077; Katsuki H, 1997, J NEUROPHYSIOL, V77, P3013, DOI 10.1152/jn.1997.77.6.3013; Lapish CC, 2006, ALCOHOL CLIN EXP RES, V30, P1451, DOI 10.1111/j.1530-0277.2006.00176.x; Lashgari R, 2008, NEUROBIOL LEARN MEM, V90, P309, DOI 10.1016/j.nlm.2008.05.012; Lemon N, 2006, J NEUROSCI, V26, P7723, DOI 10.1523/JNEUROSCI.1454-06.2006; Lemon N, 2009, CEREB CORTEX, V19, P2827, DOI 10.1093/cercor/bhp065; Levita L, 2002, BEHAV BRAIN RES, V137, P115, DOI 10.1016/S0166-4328(02)00287-5; Li SM, 2003, NAT NEUROSCI, V6, P526, DOI 10.1038/nn1049; Lisman JE, 2005, NEURON, V46, P703, DOI 10.1016/j.neuron.2005.05.002; Lisman J, 2011, TRENDS NEUROSCI, V34, P536, DOI 10.1016/j.tins.2011.07.006; Lorenzini CA, 1996, BRAIN RES, V730, P32, DOI 10.1016/0006-8993(96)00427-1; Malpeli JG, 1999, J NEUROSCI METH, V86, P119, DOI 10.1016/S0165-0270(98)00161-7; MALPELI JG, 1979, J NEUROSCI METH, V1, P143, DOI 10.1016/0165-0270(79)90011-6; Martig AK, 2011, HIPPOCAMPUS, V21, P172, DOI 10.1002/hipo.20734; Navakkode S, 2007, NEUROPHARMACOLOGY, V52, P1547, DOI 10.1016/j.neuropharm.2007.02.010; O'Carroll CM, 2004, NEUROPHARMACOLOGY, V47, P324, DOI 10.1016/j.neuropharm.2004.04.005; O'Carroll CM, 2006, LEARN MEMORY, V13, P760, DOI 10.1101/lm.321006; OADES RD, 1987, BRAIN RES REV, V12, P117, DOI 10.1016/0165-0173(87)90011-7; Oleson EB, 2012, J NEUROSCI, V32, P14804, DOI 10.1523/JNEUROSCI.3087-12.2012; Ortiz O, 2010, J NEUROSCI, V30, P12288, DOI 10.1523/JNEUROSCI.2655-10.2010; Otmakhova NA, 1996, J NEUROSCI, V16, P7478; Paxinos G., 2005, RAT BRAIN STEREOTAXI; Rossato JI, 2009, SCIENCE, V325, P1017, DOI 10.1126/science.1172545; Scheiderer CL, 2004, J NEUROPHYSIOL, V91, P1071, DOI 10.1152/jn.00420.2003; Shakesby AC, 2002, J NEUROSCI, V22, P3638; Sombers LA, 2009, J NEUROSCI, V29, P1735, DOI 10.1523/JNEUROSCI.5562-08.2009; SPENCER PM, 1990, J PHYSIOL-LONDON, V423, P77, DOI 10.1113/jphysiol.1990.sp018012; STAUBLI U, 1995, J NEUROSCI, V15, P2445, DOI 10.1523/JNEUROSCI.15-03-02445.1995; Stuber GD, 2010, J NEUROSCI, V30, P8229, DOI 10.1523/JNEUROSCI.1754-10.2010; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; Tang JR, 2009, NEURON, V63, P673, DOI 10.1016/j.neuron.2009.07.025; Tecuapetla F, 2010, J NEUROSCI, V30, P7105, DOI 10.1523/JNEUROSCI.0265-10.2010; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Tritsch NX, 2012, NATURE, V490, P262, DOI 10.1038/nature11466; Wang RY, 1998, BRAIN RES, V779, P309, DOI 10.1016/S0006-8993(97)01174-8; Wisman LAB, 2008, J NEUROSCI, V28, P7797, DOI 10.1523/JNEUROSCI.1885-08.2008; Wittmann BC, 2005, NEURON, V45, P459, DOI 10.1016/j.neuron.2005.01.010; Yamaguchi T, 2011, J NEUROSCI, V31, P8476, DOI 10.1523/JNEUROSCI.1598-11.2011; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.ne.12.030189.000305	63	25	26	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2013	8	3							e58844	10.1371/journal.pone.0058844	http://dx.doi.org/10.1371/journal.pone.0058844			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107WI	23536829	gold, Green Submitted, Green Published			2023-01-03	WOS:000316251100094
J	Dey, SK; Chisti, MJ; Das, SK; Shaha, CK; Ferdous, F; Farzana, FD; Ahmed, S; Malek, MA; Faruque, ASG; Ahmed, T; Salam, MA				Dey, Sanjoy Kumer; Chisti, Mohammod Jobayer; Das, Sumon Kumar; Shaha, Chandan Kumar; Ferdous, Farzana; Farzana, Fahmida Dil; Ahmed, Shahnawaz; Malek, Mohammad Abdul; Faruque, Abu Syed Golam; Ahmed, Tahmeed; Salam, Mohammed Abdus			Characteristics of Diarrheal Illnesses in Non-Breast Fed Infants Attending a Large Urban Diarrheal Disease Hospital in Bangladesh	PLOS ONE			English	Article							BREAST-FED INFANTS; SECRETORY IMMUNOGLOBULIN-A; ROTAVIRUS DIARRHEA; HUMAN-MILK; CAMPYLOBACTER DIARRHEA; DEVELOPING-COUNTRIES; ESCHERICHIA-COLI; IGA ANTIBODIES; PROTECTION; CHILDREN	Background: Lack of breast feeding is associated with higher morbidity and case-fatality from both bacterial and viral etiologic diarrheas. However, there is very limited data on the characteristics of non-breastfed infants attending hospital with diarrheal illnesses caused by common bacterial and viral pathogens. Our objective was to assess the impact of lack of breast feeding on diarrheal illnesses in infants living in urban Bangladesh. Methods: We extracted data of infants (0-11 months) for analyses from the data archive of Diarrheal Disease Surveillance System (DDSS) of the Dhaka Hospital of icddr,b for the period 2008-2011. Results: The prevalence of breastfeeding in infants attending the hospital with diarrhea reduced from 31% in 2008 to 17% in 2011, with corresponding increase in the prevalence of non-breastfed (chi square for trend <0.001). Among breastfed infants, the incidence of rotavirus infections was higher (43%) among the 0-5 months age group than infants aged 9-11 months (18%). On the other hand, among non-breastfed infants, the incidence of rotavirus infections was much higher (82%) among 9-11 months old infants compared to those in 0-5 months age group (57%) (chi square for trend <0.001). Very similar trends were also observed in the incidence of cholera and ETEC diarrheas among different age groups of breastfed and non-breastfed infants (chi square for trend 0.020 and 0.001 respectively). However, for shigellosis, the statistical difference remained unchanged among both the groups (chi square for trend 0.240). Conclusion and Significance: We observed protective role of breastfeeding in infantile diarrhea caused by the major viral and common bacterial agents. These findings underscore the importance of promotion and expansion of breastfeeding campaigns in Bangladesh and elsewhere.	[Dey, Sanjoy Kumer; Shaha, Chandan Kumar] Bangabandhu Sheikh Mujib Med Univ, Dept Neonatol, Dhaka, Bangladesh; [Chisti, Mohammod Jobayer; Das, Sumon Kumar; Ferdous, Farzana; Farzana, Fahmida Dil; Ahmed, Shahnawaz; Malek, Mohammad Abdul; Faruque, Abu Syed Golam; Ahmed, Tahmeed] Int Ctr Diarrhoeal Dis Res, Ctr Nutr & Food Secur, Bangladesh Icddr B, Dhaka 1000, Bangladesh; [Salam, Mohammed Abdus] Icddr B, RAS, Dhaka, Bangladesh	Bangabandhu Sheikh Mujib Medical University (BSMMU); International Centre for Diarrhoeal Disease Research (ICDDR); International Centre for Diarrhoeal Disease Research (ICDDR)	Faruque, ASG (corresponding author), Int Ctr Diarrhoeal Dis Res, Ctr Nutr & Food Secur, Bangladesh Icddr B, GPO Box 128, Dhaka 1000, Bangladesh.	gfaruque@icddrb.org	Dey, Sanjoy Kumer/AAN-6937-2020; Das, Sumon Kumar/T-6384-2019; Chisti, Mohammod J/A-7216-2018; Das, Sumon Kumar/AAD-1551-2019	Ahmed, Shahnawaz/0000-0001-8339-4137; FERDOUS, FARZANA/0000-0002-6373-3581	icddr,b; Government of the People's Republic of Bangladesh through its IHP under HNPSP	icddr,b; Government of the People's Republic of Bangladesh through its IHP under HNPSP	Diarrhoeal Disease Surveillance System at the Dhaka Hospital of icddr,b was funded by icddr,b and the Government of the People's Republic of Bangladesh through its IHP under HNPSP. icddr,b acknowledges with gratitude the commitment of the Government of the People's Republic of Bangladesh to its research efforts. icddr,b also gratefully acknowledges the following donors which provide unrestricted support to the Centre's research efforts: Australian Agency for International Development (AusAID), Government of the People's Republic of Bangladesh, Canadian International Development Agency (CIDA), Embassy of the Kingdom of the Netherlands (EKN), Swedish International Development Cooperation Agency (Sida), Swiss Agency for Development and Cooperation (SDC), and Department for International Development, UK (DFID). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Bresee JS, 1999, VACCINE, V17, P2207, DOI 10.1016/S0264-410X(98)00376-4; Chisti MJ, 2011, ACTA PAEDIATR, V100, pE275, DOI 10.1111/j.1651-2227.2011.02368.x; CLEMENS J, 1993, PEDIATRICS, V92, P680; CRUZ JR, 1988, ACTA PAEDIATR SCAND, V77, P658, DOI 10.1111/j.1651-2227.1988.tb10726.x; Faruque ASG, 2004, SCAND J INFECT DIS, V36, P204, DOI 10.1080/00365540410019219; GLASS RI, 1986, ACTA PAEDIATR SCAND, V75, P713, DOI 10.1111/j.1651-2227.1986.tb10279.x; GLASS RI, 1983, NEW ENGL J MED, V308, P1389, DOI 10.1056/NEJM198306093082304; GLASS RI, 1989, ACTA PAEDIATR SCAND, P131; Glass RI, 2003, CONTROL FOOD FLUID I, P17; Hanson Lars A., 1994, Acta Paediatrica Japonica, V36, P557; HAYANI KC, 1991, J CLIN MICROBIOL, V29, P2599, DOI 10.1128/JCM.29.11.2599-2603.1991; HAYANI KC, 1992, J PEDIATR-US, V121, P852, DOI 10.1016/S0022-3476(05)80327-0; Liu L, 2012, LANCET; MACAULAY D, 1961, ARCH DIS CHILD, V36, P543, DOI 10.1136/adc.36.189.543; Morrow AL, 2005, J NUTR, V135, P1304, DOI 10.1093/jn/135.5.1304; Morrow AL, 2004, J PEDIATR-US, V145, P297, DOI 10.1016/j.jpeds.2004.04.054; Morrow Ardythe L, 2004, Semin Pediatr Infect Dis, V15, P221, DOI 10.1053/j.spid.2004.07.002; Naficy AB, 1999, AM J EPIDEMIOL, V150, P770, DOI 10.1093/oxfordjournals.aje.a010080; Podewils Laura Jean, 2004, Semin Pediatr Infect Dis, V15, P155, DOI 10.1053/j.spid.2004.05.008; Qadri F, 2005, EMERG INFECT DIS, V11, P1104, DOI 10.3201/eid1107.041266; Rahman M, 2003, J CLIN MICROBIOL, V41, P2088, DOI 10.1128/JCM.41.5.2088-2095.2003; Rice AL, 2000, B WORLD HEALTH ORGAN, V78, P1207; RUIZPALACIOS GM, 1990, J PEDIATR-US, V116, P707, DOI 10.1016/S0022-3476(05)82652-6; Strina A, 2012, T ROY SOC TROP MED H, V106, P445, DOI 10.1016/j.trstmh.2012.02.001; TORRES O, 1993, ACTA PAEDIATR, V82, P835, DOI 10.1111/j.1651-2227.1993.tb17622.x; World Health Organization, 1987, MAN LAB INV AC ENT I	28	6	7	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2013	8	3							e58228	10.1371/journal.pone.0058228	http://dx.doi.org/10.1371/journal.pone.0058228			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140TZ	23520496	Green Published, gold, Green Submitted			2023-01-03	WOS:000318679900055
J	Volta, V; Ranzato, E; Martinotti, S; Gallo, S; Russo, MV; Mutti, L; Biffo, S; Burlando, B				Volta, Viviana; Ranzato, Elia; Martinotti, Simona; Gallo, Simone; Russo, Maria Veronica; Mutti, Luciano; Biffo, Stefano; Burlando, Bruno			Preclinical Demonstration of Synergistic Active Nutrients/Drug (AND) Combination as a Potential Treatment for Malignant Pleural Mesothelioma	PLOS ONE			English	Article							GAMMA-CATENIN; CANCER CELLS; GREEN TEA; VITAMIN-E; IN-VIVO; ASCORBATE; GEMCITABINE; EPIGALLOCATECHIN-3-GALLATE; INHIBITION; MANAGEMENT	Malignant pleural mesothelioma (MPM) is a poor prognosis disease lacking adequate therapy. We have previously shown that ascorbic acid administration is toxic to MPM cells. Here we evaluated a new combined therapy consisting of ascorbate/epigallocatechin-3-gallate/gemcitabine mixture (called AND, for Active Nutrients/Drug). In vitro effects of AND therapy on various MPM cell lines revealed a synergistic cytotoxic mechanism. In vivo experiments on a xenograft mouse model for MPM, obtained by REN cells injection in immunocompromised mice, showed that AND strongly reduced the size of primary tumor as well as the number and size of metastases, and prevented abdominal hemorrhage. Kaplan Meier curves and the log-rank test indicated a marked increase in the survival of AND-treated animals. Histochemical analysis of dissected tumors showed that AND induced a shift from cell proliferation to apoptosis in cancer cells. Lysates of tumors from AND-treated mice, analyzed with an antibody array, revealed decreased TIMP-1 and -2 expressions and no effects on angiogenesis regulating factors. Multiplex analysis for signaling protein phosphorylation exhibited inactivation of cell proliferation pathways. The complex of data showed that the AND treatment is synergistic in vitro on MPM cells, and blocks in vivo tumor progression and metastasization in REN-based xenografts. Hence, the AND combination is proposed as a new treatment for MPM.	[Volta, Viviana; Gallo, Simone; Russo, Maria Veronica; Biffo, Stefano] Ist Sci San Raffaele, Mol Histol & Cell Growth Lab, I-20132 Milan, Italy; [Ranzato, Elia; Martinotti, Simona; Biffo, Stefano; Burlando, Bruno] Univ Piemonte Orientale, Dipartimento Sci & Innovaz Tecnol, Alessandria, Italy; [Mutti, Luciano] Vercelli Natl Hlth Trust, Dept Gen Med, Vercelli, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Eastern Piedmont Amedeo Avogadro	Burlando, B (corresponding author), Univ Piemonte Orientale, Dipartimento Sci & Innovaz Tecnol, Alessandria, Italy.	burlando@unipmn.it	Martinotti, Simona/ABF-3600-2020; Mutti, Luciano/A-3545-2011	Burlando, Bruno/0000-0001-7545-0311; Martinotti, Simona/0000-0003-2891-1810; biffo, stefano/0000-0002-3780-1050; Volta, Viviana/0000-0001-9999-3732; Mutti, Luciano/0000-0002-1578-2637	Fondazione Buzzi Unicem (Casale Monferrato, Italy); Associazione Italiana per la Ricerca sul Cancro (AIRC); University of Piemonte Orientale; Italian Ministry of University and Research (MIUR)	Fondazione Buzzi Unicem (Casale Monferrato, Italy); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); University of Piemonte Orientale; Italian Ministry of University and Research (MIUR)(Ministry of Education, Universities and Research (MIUR))	This work was supported by Fondazione Buzzi Unicem (Casale Monferrato, Italy, www.fondazionebuzziunicem.org) and Associazione Italiana per la Ricerca sul Cancro (AIRC, www.airc.it). ER is recipient of a Research Fellowship from the University of Piemonte Orientale. SM is recipient of a PhD scholarship from the Italian Ministry of University and Research (MIUR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amoh Y, 2006, ANTICANCER RES, V26, P3237; Azam S, 2004, TOXICOL IN VITRO, V18, P555, DOI 10.1016/j.tiv.2003.12.012; Belli C, 2009, EXPERT OPIN EMERG DR, V14, P423, DOI 10.1517/14728210903074563; Bertino P, 2008, CLIN CANCER RES, V14, P541, DOI 10.1158/1078-0432.CCR-07-1388; Bocci G, 2005, BRIT J CANCER, V93, P319, DOI 10.1038/sj.bjc.6602720; CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538; Carbone M, 2007, NAT REV CANCER, V7, P147, DOI 10.1038/nrc2068; Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chuu CP, 2009, CANCER LETT, V275, P86, DOI 10.1016/j.canlet.2008.10.001; Constantinou C, 2008, INT J CANCER, V123, P739, DOI 10.1002/ijc.23689; Cooper R, 2005, J ALTERN COMPLEM MED, V11, P521, DOI 10.1089/acm.2005.11.521; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Dorrell MI, 2007, P NATL ACAD SCI USA, V104, P967, DOI 10.1073/pnas.0607542104; Ellis P, 2006, J THORAC ONCOL, V1, P591, DOI 10.1097/01243894-200607000-00017; Ermakova SP, 2006, CANCER RES, V66, P9260, DOI 10.1158/0008-5472.CAN-06-1586; Espey MG, 2011, FREE RADICAL BIO MED, V50, P1610, DOI 10.1016/j.freeradbiomed.2011.03.007; Feng MQ, 2011, J CANCER, V2, P123, DOI 10.7150/jca.2.123; Frizelle SP, 2000, CANCER GENE THER, V7, P1421, DOI 10.1038/sj.cgt.7700241; Grad JM, 2001, DRUG RESIST UPDATE, V4, P85, DOI 10.1054/drup.2001.0192; Harris JE, 2011, J SURG RES, V171, pE75, DOI 10.1016/j.jss.2011.06.058; Isbrucker RA, 2006, FOOD CHEM TOXICOL, V44, P626, DOI 10.1016/j.fct.2005.07.005; Kindler HL, 2002, SEMIN ONCOL, V29, P70, DOI 10.1053/sonc.2002.30232; Kroczynska B, 2006, P NATL ACAD SCI USA, V103, P14128, DOI 10.1073/pnas.0604544103; Lang M, 2009, LIVER INT, V29, P670, DOI 10.1111/j.1478-3231.2009.01984.x; Li GX, 2010, CARCINOGENESIS, V31, P902, DOI 10.1093/carcin/bgq039; Luo T, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2473; Maeda O, 2004, ONCOGENE, V23, P964, DOI 10.1038/sj.onc.1207254; Martinotti S, 2011, TOXICOL IN VITRO, V25, P1568, DOI 10.1016/j.tiv.2011.05.023; Mereles D, 2011, INT J MOL SCI, V12, P5592, DOI 10.3390/ijms12095592; Montanaro F, 2009, INT J CANCER, V124, P201, DOI 10.1002/ijc.23874; Nagy B, 2002, ANTICANCER RES, V22, P135; Orecchia S, 2004, LUNG CANCER, V45, pS37, DOI 10.1016/j.lungcan.2004.04.027; Orengo AM, 1999, EUR RESPIR J, V13, P527, DOI 10.1183/09031936.99.13352799; Padayatty SJ, 2000, J AM COLL NUTR, V19, P423, DOI 10.1080/07315724.2000.10718941; PEPE MS, 1989, BIOMETRICS, V45, P497, DOI 10.2307/2531492; Ranzato E, 2012, J CELL MOL MED, V16, P2667, DOI 10.1111/j.1582-4934.2012.01584.x; Ranzato E, 2011, AM J RESP CELL MOL, V44, P108, DOI 10.1165/rcmb.2009-0340OC; Reagan-Shaw S, 2008, PROSTATE, V68, P1624, DOI 10.1002/pros.20824; Riordan Hugh D, 2005, P R Health Sci J, V24, P269; Scherpereel A, 2010, EUR RESPIR J, V35, P479, DOI [10.1183/09031936.00063109, 10.3779/j.issn.1009-3419.2010.10.14]; SMYTHE WR, 1994, CANCER RES, V54, P2055; Sugarbaker DJ, 1998, CHEST, V113, p61S, DOI 10.1378/chest.113.1_Supplement.61S; van Meerbeeck JP, 2005, J CLIN ONCOL, V23, P6881, DOI 10.1200/JCO.20005.14.589; Verrax J, 2009, FREE RADICAL BIO MED, V47, P32, DOI 10.1016/j.freeradbiomed.2009.02.016; Wang Lin-Run, 2005, J Zhejiang Univ Sci B, V6, P446, DOI 10.1631/jzus.2005.B0446; West SD, 2006, CLIN CHEST MED, V27, P335, DOI 10.1016/j.ccm.2006.01.004; Yang CS, 2009, NAT REV CANCER, V9, P429, DOI 10.1038/nrc2641; Zauderer MG, 2011, CURR TREAT OPTION ON, V12, P163, DOI 10.1007/s11864-011-0146-4	49	17	17	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 6	2013	8	3							e58051	10.1371/journal.pone.0058051	http://dx.doi.org/10.1371/journal.pone.0058051			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	117EP	23526965	Green Submitted, Green Published, gold			2023-01-03	WOS:000316936100070
J	Lo-Coco, F; Avvisati, G; Vignetti, M; Thiede, C; Orlando, SM; Iacobelli, S; Ferrara, F; Fazi, P; Cicconi, L; Di Bona, E; Specchia, G; Sica, S; Divona, M; Levis, A; Fiedler, W; Cerqui, E; Breccia, M; Fioritoni, G; Salih, HR; Cazzola, M; Melillo, L; Carella, AM; Brandts, CH; Morra, E; von Lilienfeld-Toal, M; Hertenstein, B; Wattad, M; Lubbert, M; Hanel, M; Schmitz, N; Link, H; Kropp, MG; Rambaldi, A; La Nasa, G; Luppi, M; Ciceri, F; Finizio, O; Venditti, A; Fabbiano, F; Dohner, K; Sauer, M; Ganser, A; Amadori, S; Mandelli, F; Dohner, H; Ehninger, G; Schlenk, RF; Platzbecker, U				Lo-Coco, F.; Avvisati, G.; Vignetti, M.; Thiede, C.; Orlando, S. M.; Iacobelli, S.; Ferrara, F.; Fazi, P.; Cicconi, L.; Di Bona, E.; Specchia, G.; Sica, S.; Divona, M.; Levis, A.; Fiedler, W.; Cerqui, E.; Breccia, M.; Fioritoni, G.; Salih, H. R.; Cazzola, M.; Melillo, L.; Carella, A. M.; Brandts, C. H.; Morra, E.; von Lilienfeld-Toal, M.; Hertenstein, B.; Wattad, M.; Luebbert, M.; Haenel, M.; Schmitz, N.; Link, H.; Kropp, M. G.; Rambaldi, A.; La Nasa, G.; Luppi, M.; Ciceri, F.; Finizio, O.; Venditti, A.; Fabbiano, F.; Doehner, K.; Sauer, M.; Ganser, A.; Amadori, S.; Mandelli, F.; Doehner, H.; Ehninger, G.; Schlenk, R. F.; Platzbecker, U.		Grp Italiano Malattie Ematologiche; German-Austrian Acute Myeloid; Study Alliance Leukemia	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; MINIMAL-RESIDUAL-DISEASE; FUSION GENE TRANSCRIPTS; FRONT-LINE THERAPY; CONSOLIDATION THERAPY; CHEMOTHERAPY; ANTHRACYCLINE; RELAPSE; TRIAL; RISK	BACKGROUND All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, <= 10x10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P = 0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P = 0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P = 0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL.	[Lo-Coco, F.; Cicconi, L.; Venditti, A.; Amadori, S.] Univ Roma Tor Vergata, Dipartimento Biomed Prevenzione, Rome, Italy; [Iacobelli, S.] Univ Roma Tor Vergata, Ctr Biostat Bioinformat, Rome, Italy; [Lo-Coco, F.] Santa Lucia Fdn, Rome, Italy; [Avvisati, G.] Univ Campus Biomed, Dipartimento Ematol, Rome, Italy; [Vignetti, M.; Fazi, P.; Mandelli, F.] GIMEMA Data Ctr, Orlando, FL USA; [Mandelli, F.] Hlth Outcomes Res Unit, Rome, Italy; [Cazzola, M.] Dipartimento Ematol & Trapianto Cellule Staminali, Naples, Italy; [Di Bona, E.] Osped S Bortolo, Unita Operat Ematol, Dipartimento Terapie Cellulari Ematol, Vicenza, Italy; [Specchia, G.] Univ Bari, Dipartimento Ematol, Bari, Italy; [Sica, S.] Univ Cattolica Sacro Cuore, Ist Ematol, Rome, Italy; [Divona, M.] Policlinico Univ Tor Vergata, Rome, Italy; [Cerqui, E.] Spedali Civil Brescia, Dipartimento Ematol, I-25125 Brescia, Italy; [Breccia, M.] Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari Ematol, Rome, Italy; [Fioritoni, G.] Osped Civile, Dipartimento Ematol, Pescara, Italy; [Cazzola, M.] Univ Pavia, Dipartimento Ematol Oncol, IRCCS, I-27100 Pavia, Italy; [Melillo, L.] Osped Casa Sollievo Sofferenza, Div Ematol Trapianto Cellule Staminali, San Giovanni Rotondo, Italy; [Carella, A. M.] AOU San Martino IST, IRCCS, UOC Ematologia 1, Genoa, Italy; [Morra, E.] Ospedale Niguarda Ca Granda, Dipartimento Ematol, Milan, Italy; [Kropp, M. G.] Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy; [Rambaldi, A.] USC Ematol Azienda Ospedaliera Papa Giovanni XXII, Bergamo, Italy; [La Nasa, G.] Univ Cagliari, Osped R Binaghi, Ctr Trapianti Midollo Osseo, Dipartimento Sci Med, Cagliari, Italy; [Luppi, M.] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, Modena, Italy; [Ciceri, F.] Ist Sci San Raffaele, Dipartimento Ematol Trapianto Midollo, Milan, Italy; [Finizio, O.] Osped Cardarelli, Div Ematol TERE, Naples, Italy; [Fabbiano, F.] Ospedali Riuniti Villa Sofia Cervello, Div Ematol Unita Trapianti Midollo Osseo, Palermo, Italy; [Sauer, M.; Ehninger, G.; Platzbecker, U.] Universitatsklin Carl Gustav Carus, Dresden, Germany; [Fiedler, W.] Univ Med Ctr Hamburg Eppendorf, Hubertus Wald Univ Canc Ctr, Dept Hematol & Oncol, Hamburg, Germany; [Salih, H. R.] Univ Tubingen, Abteilug Hamatol Onkol Rheumatol Immunol & Pulmol, Tubingen, Germany; [Brandts, C. H.] Goethe Univ Frankfurt, Dept Med Hematol Oncol, D-60054 Frankfurt, Germany; [von Lilienfeld-Toal, M.] Univ Hosp Bonn, Dept Internal Med 3, Bonn, Germany; [Hertenstein, B.] Klinikum Bremen Mitte, Med Klin 1, Bremen, Germany; [Wattad, M.] Kliniken Essen Sud, Essen, Germany; [Luebbert, M.] Univ Hosp Freiburg, Dept Internal Med 1, Freiburg, Germany; [Haenel, M.] Klinikum Chemnitz, Chemnitz, Germany; [Schmitz, N.] Asklepios Klin St Georg Hamburg, Abt Hamatol Onkol & Stammzelltransplantat, Hamburg, Germany; [Link, H.] Kaiserslautern, Westpfalzklinikum, Dept Med 1, Kaiserslautern, Germany; [Doehner, K.; Doehner, H.; Schlenk, R. F.] Univ Ulm, D-89069 Ulm, Germany; [Ganser, A.] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Santa Lucia; University Campus Bio-Medico - Rome Italy; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; Universita degli Studi di Bari Aldo Moro; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Hospital Spedali Civili Brescia; Sapienza University Rome; University of Pavia; IRCCS Casa Sollievo Della Sofferenza; University of Genoa; IRCCS AOU San Martino IST; Ospedale Niguarda Ca' Granda; ASST Papa Giovanni XXIII; University of Cagliari; Universita di Modena e Reggio Emilia; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Antonio Cardarelli Hospital; Technische Universitat Dresden; University of Hamburg; University Medical Center Hamburg-Eppendorf; Eberhard Karls University of Tubingen; Goethe University Frankfurt; University of Bonn; Klinikum Bremen-Mitte; University of Freiburg; Chemnitz Clinic; Asklepios Klinik St. Georg; Ulm University; Hannover Medical School	Lo-Coco, F (corresponding author), Univ Roma Tor Vergata, Dipartimento Biomed Prevenzione, Rome, Italy.		Rambaldi, Alessandro/M-6172-2019; Döhner, Hartmut/C-8933-2016; Rambaldi, Alessandro/P-2603-2018; Breccia, Massimo/G-6026-2018; Vignetti, Marco/HHS-9990-2022; Luppi, Mario/J-3668-2016; Link, Hartmut/AAP-8537-2020; sica, simona/AAC-3679-2020; Haenel, Mathias Hänel/AAF-2220-2021; Cazzola, Mario/AAQ-8854-2021; Venditti, Adriano/E-4139-2015; Thiede, Christian/AAS-7595-2020; Schlenk, Richard/AAG-3218-2019; Specchia, Giorgina/K-3084-2016	Rambaldi, Alessandro/0000-0002-3739-7502; Döhner, Hartmut/0000-0003-2116-5536; Rambaldi, Alessandro/0000-0002-3739-7502; Breccia, Massimo/0000-0003-1163-6162; Luppi, Mario/0000-0002-0373-1154; Cazzola, Mario/0000-0001-6984-8817; Venditti, Adriano/0000-0002-0245-0553; Thiede, Christian/0000-0003-1241-2048; Melillo, Lorella/0000-0003-0455-2251; fazi, paola/0000-0002-4211-9240; La Nasa, Giorgio/0000-0002-8247-583X; Vignetti, Marco/0000-0003-1278-604X; Salih, Helmut/0000-0002-6719-1847; Specchia, Giorgina/0000-0002-2479-9529; LO COCO, FRANCESCO/0000-0002-9499-8005; Fiedler, Walter/0000-0003-0275-8803; Avvisati, Giuseppe/0000-0002-5027-5868; sica, simona/0000-0003-2426-3465; Amadori, Sergio/0000-0002-2356-8681; Brandts, Christian H./0000-0003-1732-2535	Associazione Italiana contro le Leucemie; Associazione Italiana per la Ricerca sul Cancro [IG 5916]; German Ministry of Education and Research [01KG0903]	Associazione Italiana contro le Leucemie; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); German Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	Supported by grants from Associazione Italiana contro le Leucemie and Associazione Italiana per la Ricerca sul Cancro (IG 5916, to Dr. Lo-Coco) and the German Ministry of Education and Research (01KG0903, to Dr. Platzbecker).	Ades L, 2008, BLOOD, V111, P1078, DOI 10.1182/blood-2007-07-099978; Ades L, 2010, BLOOD, V115, P1690, DOI 10.1182/blood-2009-07-233387; Asou N, 2007, BLOOD, V110, P59, DOI 10.1182/blood-2006-08-043992; Avvisati G, 2011, BLOOD, V117, P4716, DOI 10.1182/blood-2010-08-302950; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Breccia M, 2012, EXPERT OPIN PHARMACO, V13, P1031, DOI 10.1517/14656566.2012.677436; Burnett AK, 2013, LEUKEMIA, V27, P843, DOI 10.1038/leu.2012.360; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; de The H, 2010, NAT REV CANCER, V10, P775, DOI 10.1038/nrc2943; Diverio D, 1998, BLOOD, V92, P784; Estey E, 2006, BLOOD, V107, P3469, DOI 10.1182/blood-2005-10-4006; Falini B, 1997, BLOOD, V90, P4046, DOI 10.1182/blood.V90.10.4046; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Ghavamzadeh A, 2011, J CLIN ONCOL, V29, P2753, DOI 10.1200/JCO.2010.32.2107; Grimwade D, 2000, BLOOD, V96, P1297; Grimwade D, 2010, CANCER TREAT RES, V145, P219, DOI 10.1007/978-0-387-69259-3_13; Grimwade D, 2009, J CLIN ONCOL, V27, P3650, DOI 10.1200/JCO.2008.20.1533; Hu J, 2009, P NATL ACAD SCI USA, V106, P3342, DOI 10.1073/pnas.0813280106; Iland HJ, 2012, BLOOD, V120, P1570, DOI 10.1182/blood-2012-02-410746; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lengfelder E, 2009, LEUKEMIA, V23, P2248, DOI 10.1038/leu.2009.183; Lo-Coco F, 2010, BLOOD, V116, P3171, DOI 10.1182/blood-2010-03-276196; Mathews V, 2006, BLOOD, V107, P2627, DOI 10.1182/blood-2005-08-3532; Montesinos P, 2009, BLOOD, V113, P775, DOI 10.1182/blood-2008-07-168617; Powell BL, 2010, BLOOD, V116, P3751, DOI 10.1182/blood-2010-02-269621; Ravandi F, 2009, J CLIN ONCOL, V27, P504, DOI 10.1200/JCO.2008.18.6130; SAGIE A, 1992, AM J CARDIOL, V70, P797, DOI 10.1016/0002-9149(92)90562-D; Sanz MA, 2000, BLOOD, V96, P1247; Sanz MA, 2010, BLOOD, V115, P5137, DOI 10.1182/blood-2010-01-266007; Sanz MA, 2009, BLOOD, V113, P1875, DOI 10.1182/blood-2008-04-150250; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852; Tallman MS, 2002, BLOOD, V100, P4298, DOI 10.1182/blood-2002-02-0632; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Tsimberidou AM, 2006, LEUKEMIA LYMPHOMA, V47, P1062, DOI 10.1080/10428190500463932; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; ZHANG P, 1996, CHIN J HEMATOL, V17, P58; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	40	940	982	7	120	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2013	369	2					111	121		10.1056/NEJMoa1300874	http://dx.doi.org/10.1056/NEJMoa1300874			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180BH	23841729	Bronze, Green Submitted			2023-01-03	WOS:000321567300007
J	Colbert, JA; Adler, JN				Colbert, James A.; Adler, Jonathan N.			Family Presence during Cardiopulmonary Resuscitation - Polling Results	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Henderson DP, 2005, PEDIATR EMERG CARE, V21, P787, DOI 10.1097/01.pec.0000188877.41095.5a; Jabre P, 2013, NEW ENGL J MED, V368, P1008, DOI 10.1056/NEJMoa1203366	3	19	20	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 27	2013	368	26					E38	+		10.1056/NEJMclde1307088	http://dx.doi.org/10.1056/NEJMclde1307088			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	171KQ	23802541				2023-01-03	WOS:000320926900002
J	Goldberger, JJ; Buxton, AE				Goldberger, Jeffrey J.; Buxton, Alfred E.			Personalized Medicine vs Guideline-Based Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; ACUTE MYOCARDIAL-INFARCTION; RISK STRATIFICATION		[Goldberger, Jeffrey J.] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA; [Goldberger, Jeffrey J.] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA; [Buxton, Alfred E.] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Boston, MA 02215 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Harvard University; Beth Israel Deaconess Medical Center	Goldberger, JJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 251 E Huron St,Feinberg 8-503, Chicago, IL 60611 USA.	j-goldberger@northwestern.edu	Goldberger, Jeffrey J/AAB-3684-2020					[Anonymous], PRIOR PERS MED; Epstein AE, 2008, CIRCULATION, V117, pE350, DOI 10.1161/CIRCUALTIONAHA.108.189742; Goldberger JJ, 2011, CIRCULATION, V123, P2423, DOI 10.1161/CIRCULATIONAHA.110.959734; Goldberger JJ, 2009, J AM COLL CARDIOL, V54, P2001, DOI 10.1016/j.jacc.2009.08.018; Goldenberg I, 2008, J AM COLL CARDIOL, V51, P288, DOI 10.1016/j.jacc.2007.08.058; Hohnloser SH, 2004, NEW ENGL J MED, V351, P2481, DOI 10.1056/NEJMoa041489; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Steinbeck G, 2009, NEW ENGL J MED, V361, P1427, DOI 10.1056/NEJMoa0901889; VanderWeele TJ, 2011, ANN INTERN MED, V154, P680, DOI 10.7326/0003-4819-154-10-201105170-00008; Wilber DJ, 2004, CIRCULATION, V109, P1082, DOI 10.1161/01.CIR.0000121328.12536.07	10	67	70	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2013	309	24					2559	2560		10.1001/jama.2013.6629	http://dx.doi.org/10.1001/jama.2013.6629			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	170KD	23712449				2023-01-03	WOS:000320848100024
J	Teto, G; Kanmogne, GD; Torimiro, JN; Alemnji, G; Nguemaim, FN; Takou, D; Nanfack, A; Tazoacha, A				Teto, Georges; Kanmogne, Georgette D.; Torimiro, Judith N.; Alemnji, George; Nguemaim, Flore N.; Takou, Desire; Nanfack, Aubin; Tazoacha, Asonganyi			Lipid Peroxidation and Total Cholesterol in HAART-Naive Patients Infected with Circulating Recombinant Forms of Human Immunodeficiency Virus Type-1 in Cameroon	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; FREE-RADICALS; HIV DISEASE; PLASMA	Background: HIV infection has commonly been found to affect lipid profile and antioxidant defense. Objectives: To determine the effects of Human Immunodeficiency Virus (HIV) infection and viral subtype on patient's cholesterol and oxidative stress markers, and determine whether in the absence of Highly Active Antiretroviral Therapy (HAART), these biochemical parameters could be useful in patient's management and monitoring disease progression in Cameroon. For this purpose, we measured total cholesterol (TC), LDL cholesterol (LDLC), HDL cholesterol (HDLC), total antioxidant ability (TAA), lipid peroxidation indices (LPI), and malondialdehyde (MDA) in HIV negative persons and HIV positive HAART-naive patients infected with HIV-1 group M subtypes. Methods: We measured serum TC, LDLC, HDLC, plasma MDA, and TAA concentrations, and calculated LPI indices in 151 HIV-positive HAART-naive patients and 134 seronegative controls. We also performed gene sequence analysis on samples from 30 patients to determine the effect of viral genotypes on these biochemical parameters. We also determined the correlation between CD4 cell count and the above biochemical parameters. Results: We obtained the following controls/patients values for TC (1.96+/-0.54/1.12+/-0.48 g/l), LDLC (0.67+/-0.46/0.43+/-0.36 g/l), HDLC (105.51+/-28.10/46.54+/-23.36 mg/dl) TAA (0.63+/-0.17/0.16+/-0.16 mM), MDA (0.20+/-0.07/0.41+/-0.10 mM) and LPI (0.34+/-0.14/26.02+/-74.40). In each case, the difference between the controls and patients was statistically significant (p<0.05). There was a positive and statistically significant Pearson correlation between CD4 cell count and HDLC (r = +0.272; p<0.01), TAA (r = +0.199; p<0.05) and a negative and statistically significant Pearson correlation between CD4 cell count and LPI (r = 20.166; p<0.05). Pearson correlation between CD4 cell count and TC, CD4cell count and LDLC was positive but not statistically significant while it was negative but not statistically significant with MDA. The different subtypes obtained after sequencing were CRF02_AG (43.3%), CRF01_AE (20%), A1 (23.3%), H (6.7%), and G (6.7%). None of the HIV-1 subtypes significantly influenced the levels of the biochemical parameters, but by grouping them as pure subtypes and circulating recombinant forms (CRFs), the CRF significantly influenced TC levels. TC was significantly lower in patients infected with CRF (0.87+/-0.27 g/l) compared to patients infected with pure HIV-1 subtypes (1.32+/-0.68 g/l) (p<0.017). MDA levels were also significantly higher in patients infected with HIV-1CRF01_AE (0.50+/-0.10 mM), compared to ;patients infected with CRF02_AG (0.38+/-0.08 mM) (p<0.018). Conclusion: These results show that HIV infection in Cameroon is associated with significant decrease in TAA, LDLC, HDLC and TC, and increased MDA concentration and LPI indices which seem to be linked to the severity of HIV infection as assessed by CD4 cell count. The data suggests increased oxidative stress and lipid peroxidation in HIV-infected patients in Cameroon, and an influence of CRFs on TC and MDA levels.	[Teto, Georges; Alemnji, George; Nguemaim, Flore N.; Tazoacha, Asonganyi] Univ Yaounde I, Lab Immunol Biochem & Biotechnol, Yaounde, Cameroon; [Torimiro, Judith N.; Takou, Desire; Nanfack, Aubin] CIRCB Chantal Biya Int Res Ctr, Yaounde, Cameroon; [Teto, Georges; Torimiro, Judith N.; Alemnji, George; Nguemaim, Flore N.; Tazoacha, Asonganyi] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon; [Kanmogne, Georgette D.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA	University of Yaounde I; University of Yaounde I; University of Nebraska System; University of Nebraska Medical Center	Teto, G (corresponding author), Univ Yaounde I, Lab Immunol Biochem & Biotechnol, Yaounde, Cameroon.	ggteto@yahoo.fr			United States National Institute of Health [R01 MH094160]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH094160] Funding Source: NIH RePORTER	United States National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	CIRCB for the facilities put at our disposal for this project. Dr. Georgette Kanmogne is partially supported by the United States National Institute of Health grant R01 MH094160. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adje C, 2001, J ACQ IMMUN DEF SYND, V26, P501, DOI 10.1097/00126334-200104150-00018; Agwale SM, 2001, J CLIN MICROBIOL, V39, P2110, DOI 10.1128/JCM.39.6.2110-2114.2001; Ariel C, 1997, CARDIOLOGIE PATHOLOG; Belec L, 1993, MEDECINE, P9; Belec L, 2007, TRANSMISSION SEXUELL, P301; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Chaix M, 2007, LETT INFECT, V22, P56; Djinhi J, 2008, BIOL CLIN, P11; Ducobu J, 2000, Rev Med Brux, V21, P11; Fawzi WW, 2004, NEW ENGL J MED, V351, P23, DOI 10.1056/NEJMoa040541; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FULBERT JC, 1992, PATHOL BIOL, V40, P66; HALLIWELL B, 1991, ARCH INTERN MED, V151, P29, DOI 10.1001/archinte.151.1.29; HAMSTEN A, 1990, BAILLIERE CLIN ENDOC, V4, P895, DOI 10.1016/S0950-351X(05)80084-9; Heyndrickx L, 2000, AIDS, V14, P1862, DOI 10.1097/00002030-200008180-00028; Heyndrickx L, 2002, HETERODUPLEX MOBILIT; I-Favier Hinninger, 2011, LIPIDES DERIVES COUR; Jerri L, 1997, AM J CLIN PATHOL, V109, P268; Julian Falutz, 2010, J ACQUIR IMMUNE DEFI; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kohn HI, 1944, J PHARMACOL EXP THER, V82, P292; L'Henaff M, 2006, J SIDA; Lefevre G, 1998, ANN BIOL CLIN-PARIS, V56, P305; Levy JA, 2007, AM SOC MICROBIOLOGY, V3, P87; Lopez O, 1996, CLIN CHIM ACTA, V247, P181, DOI 10.1016/0009-8981(95)06249-1; Marston B, 2004, NEW ENGL J MED, V351, P78, DOI 10.1056/NEJMe048134; Montagnier L, 2003, APPORTS RECHERCHE LU; National AIDS Control Committee/National Statistique Institute, 2006, PREL REP CAM DEM HLT; Ndembi N, 2004, JAIDS-J ACQ IMM DEF, V37, P1641, DOI 10.1097/00126334-200412150-00019; Ndongmo CB, 2006, AIDS RES HUM RETROV, V22, P812, DOI 10.1089/aid.2006.22.812; Nguemaim N. F., 2012, Journal of Medical Sciences (Pakistan), V12, P131, DOI 10.3923/jms.2012.131.140; Nguemaim N, 2010, HIV MED, V11, P353, DOI 10.1111/j.1468-1293.2009.00784.x; Plantier JC, 2009, NAT MED, P1; Rabaud C, 1997, ANN BIOL CLIN-PARIS, V55, P565; Raisonnier A, 1988, ANN U SC SANTE, V5, P755; Rasheed Suraiya, 2008, OPEN ACCESS, V3, P1; Robertson DL, 2000, SCIENCE, V288, P55, DOI 10.1126/science.288.5463.55d; Safrin S, 1999, AIDS, V13, P2493, DOI 10.1097/00002030-199912240-00002; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Suresh DR, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-61; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UNAIDS, 2011, JOURN MOND SID 2011; UNAIDS, 2010, RAPP ONUSIDA EP MOND; Zabell Martin, 2011, NORMAL CHOLESTEROL L	45	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2013	8	6							e65126	10.1371/journal.pone.0065126	http://dx.doi.org/10.1371/journal.pone.0065126			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173QU	23762297	gold, Green Published, Green Submitted			2023-01-03	WOS:000321094800020
J	Cheson, BD				Cheson, Bruce D.			Therapy for diffuse large B-cell lymphoma: getting personal	LANCET			English	Editorial Material							CHEMOTHERAPY PLUS RITUXIMAB; STANDARD REGIMEN CHOP; ELDERLY-PATIENTS; TRIAL		Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	Georgetown University	Cheson, BD (corresponding author), Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.	bdc4@georgetown.edu						Advani RH, 2013, J CLIN ONCOL, V31, P88, DOI 10.1200/JCO.2012.42.7906; Benito JM, 2012, BLOOD, V120; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Cunningham D, 2013, LANCET; Davids MS, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.304.304; Delarue R, 2013, LANCET ONCOL; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Flinn WI HM, 2012, BLOOD, V120, P3663; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Hernandez-Ilizaliturri FJ, 2011, CANCER-AM CANCER SOC, V117, P5058, DOI 10.1002/cncr.26135; JONES SE, 1979, CANCER, V43, P417, DOI 10.1002/1097-0142(197902)43:2<417::AID-CNCR2820430203>3.0.CO;2-I; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Pfreundschuh M, 2004, BLOOD, V104, P634, DOI 10.1182/blood-2003-06-2095; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Recher C, 2011, LANCET, V378, P1858, DOI 10.1016/S0140-6736(11)61040-4; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Ruan J, 2011, J CLIN ONCOL, V29, P690, DOI 10.1200/JCO.2010.31.1142; Sharman J, 2011, ASH ANN M, V118, P1787; Wilson WH, 2012, HAEMATOL-HEMATOL J, V97, P758, DOI 10.3324/haematol.2011.056531	20	6	6	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 25	2013	381	9880					1793	1794		10.1016/S0140-6736(13)60849-1	http://dx.doi.org/10.1016/S0140-6736(13)60849-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	151EO	23615460				2023-01-03	WOS:000319443700005
J	Ehrhardt, C; Dudek, SE; Holzberg, M; Urban, S; Hrincius, ER; Haasbach, E; Seyer, R; Lapuse, J; Planz, O; Ludwig, S				Ehrhardt, Christina; Dudek, Sabine Eva; Holzberg, Magdalena; Urban, Sabine; Hrincius, Eike Roman; Haasbach, Emanuel; Seyer, Roman; Lapuse, Julia; Planz, Oliver; Ludwig, Stephan			A Plant Extract of Ribes nigrum folium Possesses Anti-Influenza Virus Activity In Vitro and In Vivo by Preventing Virus Entry to Host Cells	PLOS ONE			English	Article							INFLUENZA-A VIRUS; ACTIVATED RECEPTOR-2; BLACK-CURRANTS; H5N1 VIRUS; PROTEIN; PROANTHOCYANIDINS; RESISTANCE; HEALTH; LEAVES; MICE	Infections with influenza A viruses (IAV) are still amongst the major causes of highly contagious severe respiratory diseases not only bearing a devastating effect to human health, but also significantly impact the economy. Besides vaccination that represents the best option to protect from IAV infections, only two classes of anti-influenza drugs, inhibitors of the M2 ion channel and the neuraminidase, often causing resistant IAV variants have been approved. That is why the need for effective and amply available antivirals against IAV is of high priority. Here we introduce LADANIA067 from the leaves of the wild black currant (Ribes nigrum folium) as a potent compound against IAV infections in vitro and in vivo. LADANIA067 treatment resulted in a reduction of progeny virus titers in cell cultures infected with prototype avian and human influenza virus strains of different subtypes. At the effective dose of 100 mu g/ml the extract did not exhibit apparent harming effects on cell viability, metabolism or proliferation. Further, viruses showed no tendency to develop resistance to LADANIA067 when compared to amantadine that resulted in the generation of resistant variants after only a few passages. On a molecular basis the protective effect of LADANIA067 appears to be mainly due to interference with virus internalisation. In the mouse infection model LADANIA067 treatment reduces progeny virus titers in the lung upon intranasal application. In conclusion, an extract from the leaves of the wild black currant might be a promising source for the development of new antiviral compounds to fight IAV infections.	[Ehrhardt, Christina; Dudek, Sabine Eva; Holzberg, Magdalena; Urban, Sabine; Hrincius, Eike Roman; Seyer, Roman; Ludwig, Stephan] Univ Munster, Inst Mol Virol, Ctr Mol Biol Inflammat ZMBE, D-48149 Munster, Germany; [Haasbach, Emanuel; Planz, Oliver] Univ Tubingen, Dept Immunol, Interfac Inst Cell Biol, Tubingen, Germany; [Lapuse, Julia] Dr Pandalis NatUrprod GmbH, Glandorf, Germany	University of Munster; Eberhard Karls University of Tubingen	Ludwig, S (corresponding author), Univ Munster, Inst Mol Virol, Ctr Mol Biol Inflammat ZMBE, D-48149 Munster, Germany.	ludwigs@uni-muenster.de		Ludwig, Stephan/0000-0003-4490-3052	Deutsche Forschungsgemeinschaft [EH 235/1-2]; DFG Graduate School [GRK 1409]; University of Muenster Medical School; German ministry of education and research (BMBF)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); DFG Graduate School(German Research Foundation (DFG)); University of Muenster Medical School; German ministry of education and research (BMBF)(Federal Ministry of Education & Research (BMBF))	This work was supported by grants of the Deutsche Forschungsgemeinschaft (EH 235/1-2), the DFG Graduate School GRK 1409 and the fund "Innovative Medical Research" (IMF) of the University of Muenster Medical School. It is part of the activities of the German FluResearchNet, a nationwide research network on zoonotic influenza, funded by the German ministry of education and research (BMBF). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Bearman Gonzalo M L, 2010, Recent Pat Antiinfect Drug Discov, V5, P152; Boltz DA, 2010, J GEN VIROL, V91, P949, DOI 10.1099/vir.0.017459-0; Daglia M, 2012, CURR OPIN BIOTECH, V23, P174, DOI 10.1016/j.copbio.2011.08.007; Ehrhardt C, 2004, FEBS LETT, V567, P230, DOI 10.1016/j.febslet.2004.04.069; Ehrhardt C, 2007, ANTIVIR RES, V76, P38, DOI 10.1016/j.antiviral.2007.05.002; Eierhoff T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001099; Eierhoff T, 2009, BIOL CHEM, V390, P509, DOI 10.1515/BC.2009.053; Feld M, 2008, J IMMUNOL, V180, P6903, DOI 10.4049/jimmunol.180.10.6903; Garbacki Nancy, 2004, BMC Pharmacology, V4, P25, DOI 10.1186/1471-2210-4-25; Gopalan A, 2012, FOOD FUNCT, V3, P795, DOI 10.1039/c2fo30058c; Hurt AC, 2012, LANCET INFECT DIS, V12, P240, DOI 10.1016/S1473-3099(11)70318-8; Ikuta K, 2012, MICROBIOL IMMUNOL, V56, P805, DOI 10.1111/j.1348-0421.2012.00510.x; Kalus U, 2009, ANTIVIR RES, V84, P267, DOI 10.1016/j.antiviral.2009.10.001; Karoline D, 2007, ANTIVIR RES, V76, P1, DOI 10.1016/j.antiviral.2007.04.001; Khoufache K, 2013, J CLIN INVEST, V123, P206, DOI 10.1172/JCI61667; Khoufache K, 2009, J IMMUNOL, V182, P7795, DOI 10.4049/jimmunol.0803743; Le QM, 2005, NATURE, V437, P1108, DOI 10.1038/4371108a; Nicholls JM, 2008, TRENDS MICROBIOL, V16, P149, DOI 10.1016/j.tim.2008.01.008; Puthavathana P, 2005, J GEN VIROL, V86, P423, DOI 10.1099/vir.0.80368-0; Seyer R, 2012, J INFECT DIS, V205, P262, DOI 10.1093/infdis/jir716; Tabart J, 2006, J AGR FOOD CHEM, V54, P6271, DOI 10.1021/jf061112y; Tabart J, 2011, J AGR FOOD CHEM, V59, P4763, DOI 10.1021/jf104445c; TITS M, 1992, J PHARMACEUT BIOMED, V10, P1097, DOI 10.1016/0731-7085(91)80128-V; Tosh C, 2011, VIRUS GENES, V42, P10, DOI 10.1007/s11262-010-0534-z; van der Vries E, 2011, CURR OPIN INFECT DIS, V24, P599, DOI 10.1097/QCO.0b013e32834cfb43; Wright PF, 2007, FIELDS VIROLOGY, V2, P1691	28	21	21	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2013	8	5							e63657	10.1371/journal.pone.0063657	http://dx.doi.org/10.1371/journal.pone.0063657			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151BM	23717460	Green Published, gold, Green Submitted			2023-01-03	WOS:000319435600026
J	Hu, Y; McIntosh, GH; Le Leu, RK; Nyskohus, LS; Woodman, RJ; Young, GP				Hu, Ying; McIntosh, Graeme H.; Le Leu, Richard K.; Nyskohus, Laura S.; Woodman, Richard J.; Young, Graeme P.			Combination of Selenium and Green Tea Improves the Efficacy of Chemoprevention in a Rat Colorectal Cancer Model by Modulating Genetic and Epigenetic Biomarkers	PLOS ONE			English	Article							INDUCED COLON TUMORS; HISTONE DEACETYLASE; NATURAL COMPOUNDS; BETA-CATENIN; IN-VIVO; AZOXYMETHANE; PREVENTION; CARCINOGENESIS; CELLS; MICE	Dietary supplementation of selenium and green tea holds promise in cancer prevention. In this study, we evaluated the efficacies of selenium and green tea administered individually and in combination against colorectal cancer in an azoxymethane (AOM)-induced rat colonic carcinogenesis model and determined the underlying mechanisms of the protection. Four-week old Sprague-Dawley male rats were fed with diets containing 0.5% green tea extract, 1ppm selenium as selenium-enriched milk protein, or combination of 1ppm selenium and 0.5% green tea extract. Animals received 2 AOM (15 mg/kg) treatments to induce colonic oncogenesis. Rats were killed 8 or 30 wk later after the last AOM to examine the effect of dietary intervention on aberrant crypt foci (ACF) formation or tumor development. On sacrifice, colons were examined for ACF and tumors, the mRNA levels of SFRP5 and Cyclin D1, and the proteins levels of beta-catenin, COX-2, Ki-67, DNMT1 and acetyl histone H3. The combination of selenium and green tea resulted in a significant additive inhibition of large ACF formation, this effect was greater than either selenium or green tea alone, P<0.01; the combination also had a significant additive inhibition effect on all tumor endpoints, the effect of the combination diet on tumor incidence, multiplicity and size was greater than selenium or green tea alone, P<0.01. Rats fed the combination diet showed marked reduction of DNMT1 expression and induction of histone H3 acetylation, which were accompanied by restoration of SFRP5 mRNA in normal-appearing colonic crypts. The combination diet also significantly reduced beta-catenin nuclear translocation, Cyclin D1 expression and cell proliferation. These data show, for the first time, that combination of selenium and green tea is more effective in suppressing colorectal oncogenesis than either agent alone. The preventive effect is associated with regulation of genetic and epigenetic biomarkers implicated in colonic carcinogenesis.	[Hu, Ying; McIntosh, Graeme H.; Le Leu, Richard K.; Nyskohus, Laura S.; Young, Graeme P.] Flinders Univ South Australia, Flinders Ctr Innovat Canc, Adelaide, SA, Australia; [Woodman, Richard J.] Flinders Univ South Australia, Flinders Prevent Promot & Primary Hlth Care, Adelaide, SA, Australia	Flinders University South Australia; Flinders University South Australia	Hu, Y (corresponding author), Flinders Univ South Australia, Flinders Ctr Innovat Canc, Adelaide, SA, Australia.	ying.hu@flinders.edu.au	Le Leu, Richard K/H-4555-2013	Le Leu, Richard K/0000-0003-4704-4943; Woodman, Richard/0000-0002-4094-1222; Young, Graeme/0000-0001-9458-8383	National Health and Medical Research Council; Cancer Council of South Australia [1007501, 525925]	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of South Australia(Cancer Council South Australia)	Financial support was provided by National Health and Medical Research Council grant and Cancer Council of South Australia (project number 1007501 and 525925). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adhami VM, 2007, CLIN CANCER RES, V13, P1611, DOI 10.1158/1078-0432.CCR-06-2269; Amin ARMR, 2010, J BIOL CHEM, V285, P34557, DOI 10.1074/jbc.M110.141135; Amin ARMR, 2009, J CLIN ONCOL, V27, P2712, DOI 10.1200/JCO.2008.20.6235; Arasaradnam RP, 2008, EPIGENETICS-US, V3, P193, DOI 10.4161/epi.3.4.6508; Burdge GC, 2010, GENOME MED, V2, DOI 10.1186/gm201; Chung FL, 2003, J NUTR, V133, p3268S, DOI 10.1093/jn/133.10.3268S; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Clevers H, 2004, CANCER CELL, V5, P5, DOI 10.1016/S1535-6108(03)00339-8; Dashwood RH, 2007, SEMIN CANCER BIOL, V17, P363, DOI 10.1016/j.semcancer.2007.04.001; Davis CD, 2007, EXP BIOL MED, V232, P176; de Sousa EMF, 2011, CLIN CANCER RES, V17, P647, DOI 10.1158/1078-0432.CCR-10-1204; Dennert G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005195.pub2; Eisinger AL, 2006, J BIOL CHEM, V281, P20474, DOI 10.1074/jbc.M602859200; Fang MZ, 2003, CANCER RES, V63, P7563; Gerner EW, 2009, CLIN CANCER RES, V15, P758, DOI 10.1158/1078-0432.CCR-08-2235; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Group CW, 1999, CANCER RES, V59, P4743; Half E, 2009, EXPERT OPIN PHARMACO, V10, P211, DOI [10.1517/14656560802560153 , 10.1517/14656560802560153]; Hamdy SM, 2011, TOXICOL IND HLTH; Hao XP, 2007, NUTR CANCER, V59, P62, DOI 10.1080/01635580701365050; Hu Y, 2005, INT J CANCER, V115, P561, DOI 10.1002/ijc.20876; Hu Y, 2011, BR J NUTR, P1; Hu Y, 2008, CANCER RES, V68, P4936, DOI 10.1158/0008-5472.CAN-07-6042; Inoue M, 2009, GUT, V58, P1323, DOI 10.1136/gut.2008.166710; Lee JI, 2009, CANCER PREV RES, V2, P683, DOI 10.1158/1940-6207.CAPR-09-0047; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; McIntosh GH, 2006, NUTR CANCER, V54, P209, DOI 10.1207/s15327914nc5402_7; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Novotny L, 2010, NEOPLASMA, V57, P383, DOI 10.4149/neo_2010_05_383; Ohishi T, 2002, CANCER LETT, V177, P49, DOI 10.1016/S0304-3835(01)00767-4; Polakis P, 2000, GENE DEV, V14, P1837; Rao CV, 2009, CANCER RES, V69, P8175, DOI 10.1158/0008-5472.CAN-09-1377; Reddy Bandaru S, 2007, Subcell Biochem, V42, P213; Reddy BS, 2004, ENVIRON MOL MUTAGEN, V44, P26, DOI 10.1002/em.20026; Simon P, 2003, BIOINFORMATICS, V19, P1439, DOI 10.1093/bioinformatics/btg157; Sporn MB, 2008, CANCER PREV RES, V1, P9, DOI 10.1158/1940-6207.CAPR-08-0049; Suh N, 2007, CLIN CANCER RES, V13, P350, DOI 10.1158/1078-0432.CCR-06-1528; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319; Telang N, 2007, ONCOL REP, V17, P909; Thakur VS, 2010, CANCER LETT, V296, P225, DOI 10.1016/j.canlet.2010.04.012; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Tulp M, 2006, DRUG DISCOV TODAY, V11, P1115, DOI 10.1016/j.drudis.2006.10.010; Volate SR, 2009, MOL CARCINOGEN, V48, P920, DOI 10.1002/mc.20542; Wali RK, 2002, CANCER EPIDEM BIOMAR, V11, P1316; Wang LS, 2013, NUTR CANCER, V65, P118, DOI 10.1080/01635581.2013.741759; Wang LS, 2011, CLIN CANCER RES, V17, P598, DOI 10.1158/1078-0432.CCR-10-1260; Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X; Xiao H, 2008, CARCINOGENESIS, V29, P113, DOI 10.1093/carcin/bgm204; Xu G, 2010, FOOD CHEM TOXICOL, V48, P390, DOI 10.1016/j.fct.2009.10.027; Xu J, 2008, J AGR FOOD CHEM, V56, P3869, DOI 10.1021/jf073063a; Xu J, 2007, J AGR FOOD CHEM, V55, P5349, DOI 10.1021/jf070568s; Yang CS, 1997, NATURE, V389, P134, DOI 10.1038/38154; Yang H, 2011, CARCINOGENESIS, V32, P381, DOI 10.1093/carcin/bgq279; Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371; Zhang YK, 2011, EXP BIOL MED, V236, P714, DOI 10.1258/ebm.2011.010347; Zhou JR, 2007, AM J CLIN NUTR, V86, p882S, DOI 10.1093/ajcn/86.3.882S	58	35	35	1	46	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2013	8	5							e64362	10.1371/journal.pone.0064362	http://dx.doi.org/10.1371/journal.pone.0064362			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	151BM	23717604	Green Published, gold, Green Submitted			2023-01-03	WOS:000319435600061
J	Fairfield, K				Fairfield, Kathleen			Review: Replacing dietary saturated fatty acids with n-6 polyunsaturated fatty acids does not reduce mortality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Maine Med Ctr, Portland, ME 04102 USA	Maine Medical Center	Fairfield, K (corresponding author), Maine Med Ctr, Portland, ME 04102 USA.			Zamora, Daisy/0000-0003-2114-5156				Harris WS, 2009, CIRCULATION, V119, P902, DOI 10.1161/CIRCULATIONAHA.108.191627; Stryjecki C, 2011, EUR J CLIN NUTR, V65, P285, DOI 10.1038/ejcn.2010.277	2	0	0	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 21	2013	158	10							JC6	10.7326/0003-4819-158-10-201305210-02006	http://dx.doi.org/10.7326/0003-4819-158-10-201305210-02006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	154HY	23689785				2023-01-03	WOS:000319666200005
J	McIntyre, H				McIntyre, Hugh			Admission to hospital could be considered a disease	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							30-DAY READMISSIONS		Conquest Hosp, Hastings TN37 7RD, E Sussex, England		McIntyre, H (corresponding author), Conquest Hosp, Hastings TN37 7RD, E Sussex, England.	hugh.mcintyre@esht.nhs.uk						[Anonymous], MEDLINE PLUS MEDICAL; Billings J, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001667; Centers for Medicare and Medicaid Services, 2013, READMISSIONS REDUCTI; Clarke A, 2012, J EPIDEMIOL COMMUN H, V66, pA45, DOI 10.1136/jech-2012-201753.117; Department of Health, 2011, PAYMENT BY RESULTS P; Krumholz HM, 2013, NEW ENGL J MED, V368, P100, DOI 10.1056/NEJMp1212324; McHugh MD, 2013, MED CARE, V51, P52, DOI [10.1097/MLR.0b013e3182763284, 10.1097/01.NNA.0000435146.46961.d1]	7	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 20	2013	346								f3242	10.1136/bmj.f3242	http://dx.doi.org/10.1136/bmj.f3242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	153AA	23690462				2023-01-03	WOS:000319572300004
J	Wu, CK; Huang, YT; Lin, HH; Yang, CY; Lien, YC; Lee, JK; Huang, JW; Hung, KY				Wu, Cho-Kai; Huang, Yin-Tsen; Lin, Heng-Hsu; Yang, Chung-Yi; Lien, Yu-Chung; Lee, Jen-Kuang; Huang, Jenq-Wen; Hung, Kuan-Yu			Dissecting the Mechanisms of Left Ventricular Diastolic Dysfunction and Inflammation in Peritoneal Dialysis Patients	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; SYSTEM GENE POLYMORPHISMS; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; HEART-FAILURE; EJECTION FRACTION; CYTOKINES; THERAPY; MICE; ECHOCARDIOGRAPHY	Objective: Patients with symptoms of heart failure and preserved left ventricular (LV) systolic function are commonly encountered in clinical practice especially in peritoneal dialysis (PD) patients. We hypothesized that adiposity might influence LV diastolic function through systemic inflammation in this specific group. Methods: We designed a cross-sectional study in 173 prevalent PD patients. LV diastolic dysfunction was diagnosed by echocardiography. PD patient without LV diastolic dysfunction served as the control group. Serum inflammatory biomarkers were examined including tissue necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6). The location and amount of adipose tissue were assessed by computerized tomography (CT) at the level of the fourth lumbar vertebra. Results: Subjects with LV diastolic dysfunction had higher levels of the pro-inflammation cytokines and more visceral and peritoneal fat (all P<0.001) than control subjects. A significant correlation was found between visceral adipose tissue and pro-inflammatory cytokines (r = 0.70; P<0.001). Multivariable regression analysis found that the relationship between visceral adipose tissue and LV diastolic dysfunction became insignificant when either TNF-alpha or IL-6 were introduced into the model, although TNF-alpha and IL-6 were both significantly associated with LV diastolic dysfunction even after adjusting for visceral fat (OR = 1.51; 95% CI = 1.09-2.02; P = 0.033 and OR = 1.62; 95% CI = 1.09-1.82; P = 0.031, respectively). Conclusions: Larger amounts of adipose tissue were associated with higher serum pro-inflammatory levels in PD patients, which might be related to the development of LV diastolic dysfunction. Modulating inflammatory reactions in PD patients can be a useful therapeutic approach for managing LV diastolic dysfunction.	[Wu, Cho-Kai] Natl Taiwan Univ, Div Cardiol, Dept Internal Med, Coll Med & Hosp, Taipei 10764, Taiwan; [Wu, Cho-Kai] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan; [Huang, Yin-Tsen] Far Eastern Mem Hosp, Dept Family Med, New Taipei City, Taiwan; [Huang, Yin-Tsen] Far Eastern Mem Hosp, Hlth Management Ctr, New Taipei City, Taiwan; [Lin, Heng-Hsu] Far Eastern Mem Hosp, Dept Internal Med, Div Cardiol, New Taipei City, Taiwan; [Yang, Chung-Yi] Natl Taiwan Univ, Coll Med & Hosp, Dept Med Imaging, Taipei 10764, Taiwan; [Lien, Yu-Chung; Huang, Jenq-Wen; Hung, Kuan-Yu] Natl Taiwan Univ, Div Nephrol, Dept Internal Med, Coll Med & Hosp, Taipei 10764, Taiwan; [Lee, Jen-Kuang] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Lee, Jen-Kuang] Far Eastern Mem Hosp, Dept Clin Pathol, New Taipei City, Taiwan; [Lee, Jen-Kuang] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University; Far Eastern Memorial Hospital; Far Eastern Memorial Hospital; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Far Eastern Memorial Hospital; National Taiwan University	Lee, JK (corresponding author), Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.	b85401104@gmail.com; 007378@ntuh.gov.tw	; Stefanadis, Christodoulos/ABH-2232-2020	HUANG, JENQ-WEN/0000-0001-8011-2317; Stefanadis, Christodoulos/0000-0001-5974-6454; HUNG, KUAN-YU/0000-0003-3472-5512; WU, CHO-KAI/0000-0002-3867-150X	Far Eastern Memorial Hospital [FEMH-2012-C-046, FEMH-2012-C-048, FEMH-2012-C-051, FEMH-2012-C-007]	Far Eastern Memorial Hospital	The authors have financial supports from the research grants of Far Eastern Memorial Hospital number: FEMH-2012-C-046, FEMH-2012-C-048, FEMH-2012-C-051, FEMH-2012-C-007. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arici M, 2001, KIDNEY INT, V59, P407, DOI 10.1046/j.1523-1755.2001.059002407.x; Bajraktari G, 2009, CROAT MED J, V50, P543, DOI 10.3325/cmj.2009.50.543; Bryant D, 1998, CIRCULATION, V97, P1375, DOI 10.1161/01.CIR.97.14.1375; de Mattos AM, 2013, INFLAMMAINFLAMM 0116; Deswal A, 2001, CIRCULATION, V103, P2055; Ernanuela M, 2007, BIOMED PHARMACOTHER, V61, P360, DOI 10.1016/j.biopha.2007.03.002; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; Gaasch WH, 2004, ANNU REV MED, V55, P373, DOI 10.1146/annurev.med.55.091902.104417; Gniuli D, 2010, INT J OBESITY, V34, P1726, DOI 10.1038/ijo.2010.99; Hillebrand JJG, 2010, OBESITY, V18, P848, DOI 10.1038/oby.2009.341; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Ikonomidis I, 2010, SHOCK, V33, P141, DOI 10.1097/SHK.0b013e3181ad31f8; Kapadia SR, 2000, J AM COLL CARDIOL, V36, P208, DOI 10.1016/S0735-1097(00)00721-X; Lee JK, 2012, NUTR METAB CARDIOVAS, V22, P974, DOI 10.1016/j.numecd.2011.01.001; Lester SJ, 2008, J AM COLL CARDIOL, V51, P679, DOI 10.1016/j.jacc.2007.09.061; London GM, 2003, SEMIN DIALYSIS, V16, P85, DOI 10.1046/j.1525-139X.2003.16023.x; Nagueh SF, 2001, CIRCULATION, V103, P1844; Nagueh SF, 2009, EUR J ECHOCARDIOGR, V10, P165, DOI 10.1093/ejechocard/jep007; Oberg BP, 2004, KIDNEY INT, V65, P1009, DOI 10.1111/j.1523-1755.2004.00465.x; OGSTON D, 1964, LANCET, V2, P1205; Panagiotakos DB, 2005, ATHEROSCLEROSIS, V183, P308, DOI 10.1016/j.atherosclerosis.2005.03.010; Paraskevas KI, 2008, INT UROL NEPHROL, V40, P165, DOI 10.1007/s11255-007-9307-6; Prabhu SD, 2004, CIRC RES, V95, P1140, DOI 10.1161/01.RES.0000150734.79804.92; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Saiki A, 2005, INT J OBESITY, V29, P1115, DOI 10.1038/sj.ijo.0803009; SOLERTE SB, 1989, INT J OBESITY, V13, P203; Stenvinkel P, 2006, NEPHROLOGY, V11, P36, DOI 10.1111/j.1440-1797.2006.00541.x; Wu CK, 2008, EUR J CLIN INVEST, V38, P789, DOI 10.1111/j.1365-2362.2008.02017.x; Wu CK, 2012, OBESITY, V20, P730, DOI 10.1038/oby.2011.30; Wu CK, 2011, CRIT CARE MED, V39, P984, DOI 10.1097/CCM.0b013e31820a91b9; Wu CK, 2009, ATHEROSCLEROSIS, V205, P497, DOI 10.1016/j.atherosclerosis.2008.12.033; Wu CK, 2009, J HYPERTENS, V27, P502, DOI 10.1097/HJH.0b013e32831fda3a	33	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2013	8	5							e62722	10.1371/journal.pone.0062722	http://dx.doi.org/10.1371/journal.pone.0062722			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145RZ	23675418	Green Published, gold, Green Submitted			2023-01-03	WOS:000319036100007
J	Molina-Lopez, RA; Casal, J; Darwich, L				Molina-Lopez, Rafael A.; Casal, Jordi; Darwich, Laila			Final Disposition and Quality Auditing of the Rehabilitation Process in Wild Raptors Admitted to a Wildlife Rehabilitation Centre in Catalonia, Spain, during a Twelve Year Period (1995-2007)	PLOS ONE			English	Article							MORTALITY; MORBIDITY; VIRGINIA; PREVALENCE; CALIFORNIA; REPTILES	Background: Variability in reporting and classification methods in previous published data of the final dispositions in the rehabilitation of wild raptors makes use of this data limited in trying to audit the quality of the rehabilitation process. Crude as well as stratified disposition rates are needed if quality auditing of the rehabilitation process is to be adequately performed. Methodology: Final dispositions of 6221 hospitalized wild raptors admitted at a wildlife rehabilitation centre (WRC) of Catalonia during 1995-2007 were analyzed. These dispositions were calculated as the euthanasia (Er), unassisted mortality (Mr), release (Rr) and captivity rates (Cr)., time to death (Td) for dead and euthanized raptors, and length of stay for released (Tr) raptors was estimated. Stratified analyses by main causes of admission and clinical signs were performed. Results: The disposition for the total population were: Er = 30.6%, Mr = 19.1%, Rr = 47.2%, and Cr = 3%. By main causes of admission, Er was higher in the trauma category (34.2%), whereas Mr was found similar between trauma (37.4%) and nontrauma categories (34.8%). The highest Rr was observed for the orphaned group (77.9%). Furthermore, Cr was low in all the categories (, 4%). By clinical signs, the highest Er was found in animals suffering musculoskeletal (37.9%) or skin (32.3%) lesions; Mr was high in infectious/parasitic diseases (66.7%) and in case of neurological symptoms (64.5%). The euthanized birds had a median Td = 1 day (P-10 = 0-P-90 = 59) for both trauma and non-trauma categories, and Td = 36 days for the orphaned young group (P-10= 0; P-90 = 596). The median Td in the unassisted dead birds was 2 days for all the categories (P-10 = 0-P-90 = 31). Finally, the median Tr in the centre was variable among categories. Conclusions/Significance: Reporting of final dispositions in wildlife rehabilitation should include the crude and stratified rates (Er, Mr, Rr, and Cr), by causes and clinical presentation, as well as Td and Tr, to allow meaningful auditing of the rehabilitation process quality.	[Molina-Lopez, Rafael A.] Catalan Wildlife Serv Forestal Catalana, Ctr Fauna Salvatge Torreferrussa, Barcelona, Spain; [Molina-Lopez, Rafael A.; Casal, Jordi; Darwich, Laila] Univ Autonoma Barcelona, Fac Vet, Dept Sanit & Anat Anim, E-08193 Barcelona, Spain; [Casal, Jordi; Darwich, Laila] UAB IRTA, Ctr Recerca Sanit Anim CReSA, Barcelona, Spain	Autonomous University of Barcelona; IRTA	Molina-Lopez, RA (corresponding author), Catalan Wildlife Serv Forestal Catalana, Ctr Fauna Salvatge Torreferrussa, Barcelona, Spain.	rafael.molina@gencat.cat	Casal, Jordi/F-3020-2016; Darwich, Laila/F-5330-2016	Casal, Jordi/0000-0002-6909-9366; Darwich, Laila/0000-0001-9027-9452; Molina Lopez, Rafael/0000-0002-9043-2346	Catalan Wildlife-Service and Forestal Catalana	Catalan Wildlife-Service and Forestal Catalana	The study has been supported by the Catalan Wildlife-Service and Forestal Catalana. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arent L, 2001, RECONDITIONING RAPTO, P32; Black PA, 2011, J AVIAN MED SURG, V25, P192, DOI 10.1647/2010-024.1; Braun JP, 2010, ANASTH INTENSIVMED, V51, pS809, DOI 10.3205/000111; Brown JD, 2002, J WILDLIFE DIS, V38, P699, DOI 10.7589/0090-3558-38.4.699; Cabezon O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029549; COOPER J E, 1987, Journal of Raptor Research, V21, P21; Cooper JE, 2006, IN PRACTICE, V28, P2, DOI 10.1136/inpract.28.1.2; Deem SL, 1998, J ZOO WILDLIFE MED, V29, P160; Duke G.E., 1981, Raptor Research, V15, P97; FIX AS, 1990, J WILDLIFE DIS, V26, P18, DOI 10.7589/0090-3558-26.1.18; Garcia RE, 2001, REV MED CHILE, V129, P825; Harris S, 2005, PRACTICAL WILDLIFE CARE, 2ND EDITION, P159; Hartup BK, 1996, J WILDLIFE DIS, V32, P109, DOI 10.7589/0090-3558-32.1.109; Jiménez Paneque Rosa E, 2004, Rev Cubana Salud Pública, V30, P0; Kelly TR, 2003, J WILDLIFE DIS, V39, P467, DOI 10.7589/0090-3558-39.2.467; Kirkwood James K., 2003, P1; Kotter T, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-21; Komnenou AT, 2005, J ZOO WILDLIFE MED, V36, P222, DOI 10.1638/04-061.1; Kramer JL, 1997, J RAPTOR RES, V31, P327; Lawrence J, 1997, THESIS U TENNESSEE; Martinez Climent Jose Antonio, 2001, Biota (Race), V2, P163; Miller EA., 2012, MINIMUM STANDARDS WI, P116; Millsap Brian A., 2007, P437; Molina-Lopez RA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024603; Morishita TY, 1998, J AVIAN MED SURG, V12, P78; OECD, 2011, AV LENGTH STAY HOSP; Punch P, 2001, AUST VET J, V79, P747, DOI 10.1111/j.1751-0813.2001.tb10890.x; Redig Patrick T., 2007, P411; REDIG PT, 1995, T N AM WILDL NAT RES, P162; Ress S, 2004, J RAPTOR RES, V38, P77; Richards J, 2005, J ZOO WILDLIFE MED, V36, P485, DOI 10.1638/04-075.1; Rodriguez B, 2010, J RAPTOR RES, V44, P30, DOI 10.3356/JRR-09-40.1; Simo MR, 2010, CIR ESPAN, V88, P81, DOI 10.1016/j.ciresp.2010.03.021; Samour JH, 2003, J AVIAN MED SURG, V17, P136, DOI 10.1647/2001-047; Sleeman JM, 2003, J AVIAN MED SURG, V17, P33, DOI 10.1647/1082-6742(2003)017[0033:CWMANP]2.0.CO;2; Sleeman Jonathan M., 2008, P97; Smith WA, 2002, J ZOO WILDLIFE MED, V33, P228, DOI 10.1638/1042-7260(2002)033[0228:SICWSP]2.0.CO;2; Alvarez JS, 2007, AN MED INTERN, V24, P517; Weiner BJ, 2006, HEALTH SERV RES, V41, P307, DOI 10.1111/j.1475-6773.2005.00483.x; Woodford MH, 2000, QUARANTINE HLTH SCRE, P87; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2, P125	41	23	23	2	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e60242	10.1371/journal.pone.0060242	http://dx.doi.org/10.1371/journal.pone.0060242			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IK	23613722	Green Published, Green Submitted, gold			2023-01-03	WOS:000317907200005
J	Lee, P				Lee, Pyng			Primary spontaneous pneumothorax: to pleurodese or not?	LANCET			English	Editorial Material							COMPUTED-TOMOGRAPHY; TALC PLEURODESIS; THORACOSCOPY; MANAGEMENT; RECURRENCE; SURGERY		[Lee, Pyng] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore; [Lee, Pyng] Natl Univ Singapore Hosp, Div Resp & Crit Care Med, Singapore 119228, Singapore	National University of Singapore; National University of Singapore	Lee, P (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore.	pynglee@hotmail.com						Barker A, 2007, LANCET, V370, P329, DOI 10.1016/S0140-6736(07)61163-5; Baumann MH, 2001, CHEST, V119, P590, DOI 10.1378/chest.119.2.590; Baumann MH, 1997, CHEST, V112, P789, DOI 10.1378/chest.112.3.789; BENSE L, 1993, CHEST, V103, P433, DOI 10.1378/chest.103.2.433; BOUTIN C, 1995, CLIN CHEST MED, V16, P497; Chen J-S, 2013, LANCET; Horio H, 1998, SURG ENDOSC-ULTRAS, V12, P1155, DOI 10.1007/s004649900805; Huang TW, 2007, CHEST, V132, P1146, DOI 10.1378/chest.06-2772; KENNEDY L, 1994, CHEST, V106, P1215, DOI 10.1378/chest.106.4.1215; LESUR O, 1990, CHEST, V98, P341, DOI 10.1378/chest.98.2.341; Loubani M, 2000, RESP MED, V94, P888, DOI 10.1053/rmed.2000.0862; MacDuff A, 2010, THORAX, V65, P18, DOI 10.1136/thx.2010.136986; Melton LJ, 1987, AM REV RESPIR DIS, V29, P1379; Noppen M, 2006, AM J RESP CRIT CARE, V174, P26, DOI 10.1164/rccm.200602-259OC; Noppen M, 2002, AM J RESP CRIT CARE, V165, P1240, DOI 10.1164/rccm.200111-078OC; Sadikot RT, 1997, THORAX, V52, P805, DOI 10.1136/thx.52.9.805; SENAC JP, 1985, ANN RADIOL, V28, P586; Tschopp JM, 1997, THORAX, V52, P329, DOI 10.1136/thx.52.4.329; VANDERSCHUEREN RGJRA, 1990, LUNG, V168, P1122, DOI 10.1007/BF02718252; WARNER BW, 1991, AM J SURG, V162, P39, DOI 10.1016/0002-9610(91)90199-N	20	7	10	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2013	381	9874					1252	1254		10.1016/S0140-6736(13)60285-8	http://dx.doi.org/10.1016/S0140-6736(13)60285-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122XD	23489755				2023-01-03	WOS:000317351000006
J	McCartney, M				McCartney, Margaret			How do we know whether medical apps work?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Adams S., 2013, DAILY TELEGRAPH; [Anonymous], COMM US PULS OX SPOR; Food and Drug Administration, 2011, GUID IND FO IN PRESS; Iacobucci G, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1501; Instant Heart Rate by Azumio, INST HEART RAT; MHRA, FREQ ASK QUEST OTH D; NHS Choices, HLTH APPS LIB; Sharpe R, 2012, LACKING REGULATION M; Thomas DB, 2002, JNCI-J NATL CANCER I, V94, P1445, DOI 10.1093/jnci/94.19.1445; Wolf JA, 2013, JAMA DERMATOL, V149, P422, DOI 10.1001/jamadermatol.2013.2382	10	34	35	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 20	2013	346								f1811	10.1136/bmj.f1811	http://dx.doi.org/10.1136/bmj.f1811			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	113MG	23516158				2023-01-03	WOS:000316671500012
J	Ding, LC; Song, T; Yi, CR; Huang, Y; Yu, W; Ling, L; Dai, YT; Wei, ZQ				Ding, Liucheng; Song, Tao; Yi, Chaoran; Huang, Yi; Yu, Wen; Ling, Lin; Dai, Yutian; Wei, Zhongqing			Transcutaneous Electrical Nerve Stimulation (TENS) Improves the Diabetic Cytopathy (DCP) via Up-Regulation of CGRP and cAMP	PLOS ONE			English	Article							PRIMARY SENSORY NEURONS; BLADDER DYSFUNCTION; SACRAL NEUROMODULATION; VOIDING DYSFUNCTION; PEPTIDE; RATS; EXPRESSION; DETRUSOR	The objective of this study was to investigate the effects and mechanism of Transcutaneous Electrical Nerve Stimulation (TENS) on the diabetic cytopathy (DCP) in the diabetic bladder. A total of 45 rats were randomly divided into diabetes mellitus (DM)/TENS group (n = 15), DM group (n = 15) and control group (n = 15). The rats in the DM/TENS and TENS groups were electronically stimulated (stimulating parameters: intensity-31 V, frequency-31 Hz, and duration of stimulation of 15 min) for three weeks. Bladder histology, urodynamics and contractile responses to field stimulation and carbachol were determined. The expression of calcitonin gene-related peptide (CGRP) was analyzed by RT-PCR and Western blotting. The results showed that contractile responses of the DM rats were ameliorated after 3 weeks of TENS. Furthermore, TENS significantly increased bladder wet weight, volume threshold for micturition and reduced PVR, V% and cAMP content of the bladder. The mRNA and protein levels of CGRP in dorsal root ganglion (DRG) in the DM/TENS group were higher than those in the DM group. TENS also significantly up-regulated the cAMP content in the bladder body and base compared with diabetic rats. We conclude that TENS can significantly improve the urine contractility and ameliorate the feeling of bladder fullness in DM rats possibly via up-regulation of cAMP and CGRP in DRG.	[Ding, Liucheng; Huang, Yi; Wei, Zhongqing] Nanjing Med Univ, Affiliated Hosp 2, Dept Urol, Nanjing, Jiangsu, Peoples R China; [Yi, Chaoran; Yu, Wen; Ling, Lin; Dai, Yutian] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Urol, Nanjing 210008, Jiangsu, Peoples R China; [Song, Tao] Chinese PLA 454 Hosp, Dept Urol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing University	Wei, ZQ (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Dept Urol, Nanjing, Jiangsu, Peoples R China.	weizq1@163.com		Huang, Yi/0000-0002-1245-6764	Natural Science Foundation of Jiangsu [SBK201123829]	Natural Science Foundation of Jiangsu(Natural Science Foundation of Jiangsu Province)	This work was supported in part by grants from the Natural Science Foundation of Jiangsu (SBK201123829). No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boudreau-Lariviere C, 1999, FEBS LETT, V444, P22, DOI 10.1016/S0014-5793(99)00015-0; CAMILLERI M, 1984, AM J PHYSIOL, V247, pG703, DOI 10.1152/ajpgi.1984.247.6.G703; Daneshgari F, 2006, J UROLOGY, V176, P380, DOI 10.1016/S0022-5347(06)00582-9; FALL M, 1980, J UROLOGY, V123, P192, DOI 10.1016/S0022-5347(17)55850-4; Feifer A, 2008, NEUROUROL URODYNAM, V27, P475, DOI 10.1002/nau.20569; Gladh G, 2003, NEUROUROL URODYNAM, V22, P233, DOI 10.1002/nau.10078; Horvath EE, 2010, NEUROUROL URODYNAM, V29, P401, DOI 10.1002/nau.20766; Jezernik S, 2002, NEUROL RES, V24, P413, DOI 10.1179/016164102101200294; Kessler TM, 2008, NAT CLIN PRACT UROL, V5, P657, DOI 10.1038/ncpuro1251; Leiria LOS, 2011, BRIT J PHARMACOL, V163, P1276, DOI 10.1111/j.1476-5381.2011.01311.x; Li XQ, 2004, J NEUROPATH EXP NEUR, V63, P1092, DOI 10.1093/jnen/63.10.1092; Lin ZY, 2004, DIABETES CARE, V27, P1071, DOI 10.2337/diacare.27.5.1071; LUHESHI GN, 1990, BRIT J PHARMACOL, V101, P411, DOI 10.1111/j.1476-5381.1990.tb12723.x; Martens FMJ, 2011, SPINAL CORD, V49, P566, DOI 10.1038/sc.2010.134; Martens FMJ, 2011, J UROLOGY, V186, P798, DOI 10.1016/j.juro.2011.02.2696; MCCARTHY PW, 1990, NEUROSCIENCE, V34, P623, DOI 10.1016/0306-4522(90)90169-5; Mumtaz FH, 1999, UROL RES, V27, P470, DOI 10.1007/s002400050137; Ruiz G, 2005, BRAIN RES, V1042, P44, DOI 10.1016/j.brainres.2005.02.009; Sasaki K, 2003, UROL CLIN N AM, V30, P1, DOI 10.1016/S0094-0143(02)00116-7; Tian XY, 2006, BRAIN RES, V1088, P101, DOI 10.1016/j.brainres.2006.03.014; van Balken MR, 2004, J UROLOGY, V172, P846, DOI 10.1097/01.ju.0000134418.21959.98; van Kerrebroeck PEV, 2007, J UROLOGY, V178, P2029, DOI 10.1016/j.juro.2007.07.032; Van Rey FS, 2008, UROL INT, V81, P373, DOI 10.1159/000167831; Wang XM, 2010, J DIABETES COMPLICAT, V24, P121, DOI 10.1016/j.jdiacomp.2009.06.002; Yi CR, 2006, ACTA PHARMACOL SIN, V27, P1037, DOI 10.1111/j.1745-7254.2006.00333.x; Yokozuka M, 2004, CLIN REHABIL, V18, P899, DOI 10.1191/0269215504cr803oa; Zhang Sui-Yang, 2001, Shengli Xuebao, V53, P219	27	27	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e57477	10.1371/journal.pone.0057477	http://dx.doi.org/10.1371/journal.pone.0057477			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	23468996	Green Submitted, Green Published, gold			2023-01-03	WOS:000315524900095
J	Spence, D				Spence, Des			Reefer madness: doctors need more drugs training	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk						Frank, DRUGS A Z; Home Office, 2012, TABL DRUG MIS DECL F	2	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	2013	346								f4105	10.1136/bmj.f4105	http://dx.doi.org/10.1136/bmj.f4105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	179AA	23814068				2023-01-03	WOS:000321487300005
J	Hasegawa, Y; Tachibana, Y; Sakagami, J; Zhang, M; Urade, M; Ono, T				Hasegawa, Yoko; Tachibana, Yoshihisa; Sakagami, Joe; Zhang, Min; Urade, Masahiro; Ono, Takahiro			Flavor-Enhanced Modulation of Cerebral Blood Flow during Gum Chewing	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; NEAR-INFRARED SPECTROSCOPY; ORBITOFRONTAL CORTEX; BRAIN ACTIVATION; TASTE; STIMULATION; HUMANS; MONKEY; AREAS; PET	Background: Flavor perception, the integration of taste and odor, is a critical factor in eating behavior. It remains unclear how such sensory signals influence the human brain systems that execute the eating behavior. Methods: We tested cerebral blood flow (CBF) in the frontal lobes bilaterally while subjects chewed three types of gum with different combinations of taste and odor: no taste/no odor gum (C-gum), sweet taste/no odor gum (T-gum), and sweet taste/lemon odor gum (TO-gum). Simultaneous recordings of transcranial Doppler ultrasound (TCD) and near infrared spectrometer (NIRS) were used to measure CBF during gum chewing in 25 healthy volunteers. Bilateral masseter muscle activity was also monitored. Results: We found that subjects could discriminate the type of gum without prior information. Subjects rated the TO-gum as the most flavorful gum and the C-gum as the least flavorful. Analysis of masseter muscle activity indicated that masticatory motor output during gum chewing was not affected by taste and odor. The TCD/NIRS measurements revealed significantly higher hemodynamic signals when subjects chewed the TO-gum compared to when they chewed the C-gum and T-gum. Conclusions: These data suggest that taste and odor can influence brain activation during chewing in sensory, cognitive, and motivational processes rather than in motor control.	[Hasegawa, Yoko; Urade, Masahiro] Hyogo Coll Med, Dept Dent & Oral Surg, Nishinomiya, Hyogo 6638501, Japan; [Hasegawa, Yoko; Sakagami, Joe; Ono, Takahiro] Osaka Univ, Div Oromaxillofacial Regenerat, Course Integrated Oral Sci, Grad Sch Dent, Suita, Osaka, Japan; [Tachibana, Yoshihisa] Natl Inst Physiol Sci, Div Syst Neurophysiol, Okazaki, Aichi 444, Japan; [Zhang, Min] Fourth Mil Med Univ, Dept Gen Dent & Emergency, Sch Stomatol, Xian 710032, Peoples R China	Hyogo College of Medicine; Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Air Force Military Medical University	Hasegawa, Y (corresponding author), Hyogo Coll Med, Dept Dent & Oral Surg, Nishinomiya, Hyogo 6638501, Japan.	cem17150@hyo-med.ac.jp; ono@dent.osaka-u.ac.jp	Morosolli, Aline/P-1984-2014	Hasegawa, Yoko/0000-0001-9112-5981	KAKENHI from the Ministry of Education, Science and Culture of Japan [21791887, 23792263]; Global COE Program in "In Silico Medicine'' of Osaka University	KAKENHI from the Ministry of Education, Science and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Global COE Program in "In Silico Medicine'' of Osaka University	This study was supported by KAKENHI from the Ministry of Education, Science and Culture of Japan (grant numbers 21791887 and 23792263) and the Global COE Program in "In Silico Medicine'' of Osaka University. The authors declare no conflict of interest with any financial organization regarding the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Aaslid R., 1992, TRANSCRANIAL DOPPLER; BATES JF, 1993, J COMP NEUROL, V336, P211, DOI 10.1002/cne.903360205; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Cerf-Ducastel B, 2003, BRAIN RES, V986, P39, DOI 10.1016/S0006-8993(03)03168-8; Cruz A, 2000, NATURE, V403, P889, DOI 10.1038/35002581; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Gilbertson TA, 2000, CURR OPIN NEUROBIOL, V10, P519, DOI 10.1016/S0959-4388(00)00118-5; Hasegawa Y, 2007, J DENT RES, V86, P64, DOI 10.1177/154405910708600110; Hasegawa Y, 2009, CLIN ORAL INVEST; Hock C, 1997, BRAIN RES, V755, P293, DOI 10.1016/S0006-8993(97)00122-4; Kelly RM, 2003, J NEUROSCI, V23, P8432; Kobayashi M, 2002, EUR J NEUROSCI, V16, P975, DOI 10.1046/j.1460-9568.2002.02151.x; Kringelbach ML, 2003, CEREB CORTEX, V13, P1064, DOI 10.1093/cercor/13.10.1064; Momose T, 1997, ARCH ORAL BIOL, V42, P57, DOI 10.1016/S0003-9969(96)00081-7; Obrig H, 2003, J CEREBR BLOOD F MET, V23, P1, DOI 10.1097/01.WCB.0000043472.45775.29; Ono T, 2007, J NEUROL, V254, P1427, DOI 10.1007/s00415-007-0570-3; Onozuka M, 2002, J DENT RES, V81, P743, DOI 10.1177/154405910208101104; Onozuka M, 2003, J DENT RES, V82, P657, DOI 10.1177/154405910308200817; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Salmon G, 1973, ATLAS ARTERIES HUMAN; Shepherd GM, 2006, NATURE, V444, P316, DOI 10.1038/nature05405; Suzuki M, 2004, NEUROIMAGE, V23, P1020, DOI 10.1016/j.neuroimage.2004.07.002; Takada T, 2004, NEUROSCI LETT, V360, P137, DOI 10.1016/j.neulet.2004.02.052; Villringer K, 1997, ADV EXP MED BIOL, V413, P149; WYATT JS, 1990, J APPL PHYSIOL, V68, P1086; Yamamoto T, 2006, ARCH HISTOL CYTOL, V69, P243, DOI 10.1679/aohc.69.243	29	21	21	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2013	8	6							e66313	10.1371/journal.pone.0066313	http://dx.doi.org/10.1371/journal.pone.0066313			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190ST	23840440	Green Submitted, Green Published, gold			2023-01-03	WOS:000322361200068
J	Glasziou, P				Glasziou, Paul			Mediterranean diets reduced cardiovascular events more than a low-fat diet in high-risk persons	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							METAANALYSIS		Bond Univ, Gold Coast, Qld, Australia	Bond University	Glasziou, P (corresponding author), Bond Univ, Gold Coast, Qld, Australia.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X				de Lorgeril M, 1994, LANCET, V343, P1454; Nordmann AJ, 2011, AM J MED, V124, P841, DOI 10.1016/j.amjmed.2011.04.024; Rizos EC, 2012, JAMA-J AM MED ASSOC, V308, P1024, DOI 10.1001/2012.jama.11374	3	0	0	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 18	2013	158	12							JC3	10.7326/0003-4819-158-12-201306180-02003	http://dx.doi.org/10.7326/0003-4819-158-12-201306180-02003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	167PW	23778927				2023-01-03	WOS:000320645000002
J	Cen, JR; Shi, MS; Yang, YF; Fu, YX; Zhou, HL; Wang, MQ; Su, ZY; Wei, Q				Cen, Juren; Shi, Mingshu; Yang, Yanfang; Fu, Yanxia; Zhou, Hailing; Wang, Mengqi; Su, Zhenyi; Wei, Qun			Isogarcinol Is a New Immunosuppressant	PLOS ONE			English	Article							CYCLOSPORINE-A; BENZOPHENONE DERIVATIVES; ORGAN-TRANSPLANTATION; MEDICINAL PROPERTIES; CARDIAC GROWTH; CALCINEURIN; INHIBITION; KAEMPFEROL; MECHANISM; FRUIT	Calcineurin (CN), a unique protein phosphatase, plays an important role in immune regulation. In this study we used CN as a target enzyme to investigate the immunosuppressive properties of a series of natural compounds from Garcinia mangostana L., and discovered an active compound, isogarcinol. Enzymatic assays showed that isogarcinol inhibited CN in a dose-dependent manner. At concentrations resulting in relatively low cytotoxicity isogarcinol significantly inhibited proliferation of murine spleen T-lymphocytes induced by concanavalin A (ConA) and the mixed lymphocyte reaction (MLR). In addition, it performed much better in acute toxicity tests and via oral administration in mice than cyclosporin A (CsA), with few adverse reactions and low toxicity in experimental animals. Oral administration of isogarcinol in mice resulted in a dose-dependent decrease in delayed type hypersensitivity (DTH) and prolonged graft survival in allogeneic skin transplantation. These findings suggest that isogarcinol could serve as a new oral immunomodulatory drug for preventing transplant rejection, and for long-term medication in autoimmune diseases.	[Cen, Juren; Shi, Mingshu; Fu, Yanxia; Zhou, Hailing; Wang, Mengqi; Su, Zhenyi; Wei, Qun] Beijing Normal Univ, Gene Engn & Biotechnol Beijing Key Lab, Dept Biochem & Mol Biol, Beijing 100875, Peoples R China; [Yang, Yanfang] Hubei Univ Chinese Med, Prov & Minist Established Key Lab Resource & Comp, Wuhan, Peoples R China	Beijing Normal University; Hubei University of Chinese Medicine	Wei, Q (corresponding author), Beijing Normal Univ, Gene Engn & Biotechnol Beijing Key Lab, Dept Biochem & Mol Biol, Beijing 100875, Peoples R China.	weiq@bnu.edu.cn	Su, Zhenyi/AHC-5959-2022		National Natural Science Foundation of China; National Important Novel Medicine Research Project; International Cooperation Project; Fundamental Research Funds for the Central Universities	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Important Novel Medicine Research Project; International Cooperation Project; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	The work was supported by grants from the National Natural Science Foundation of China, the National Important Novel Medicine Research Project, the International Cooperation Project and the Fundamental Research Funds for the Central Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baksh S, 2000, SEMIN IMMUNOL, V12, P405, DOI 10.1006/smim.2000.0221; BENNETT WM, 1986, ANNU REV MED, V37, P215; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; Cardenas ME, 1998, TRENDS BIOTECHNOL, V16, P427, DOI 10.1016/S0167-7799(98)01239-6; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; Cuesta-Rubio O, 2005, STUD NAT PROD CHEM, V32, P671; Cui JH, 2010, PHARMACOL BIOCHEM BE, V95, P166, DOI 10.1016/j.pbb.2009.12.021; Feng YH, 2002, ACTA PHARMACOL SIN, V23, P893; Gonsette RE, 2004, J NEUROL SCI, V223, P87, DOI 10.1016/j.jns.2004.04.025; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hong JC, 2000, SEMIN NEPHROL, V20, P108; Iinuma M, 1996, BIOL PHARM BULL, V19, P311, DOI 10.1248/bpb.19.311; Issa F, 2010, EXPERT REV CLIN IMMU, V6, P155, DOI 10.1586/ECI.09.64; Ito C, 2003, J NAT PROD, V66, P206, DOI 10.1021/np020372g; Jorgensen KA, 2003, SCAND J IMMUNOL, V57, P93, DOI 10.1046/j.1365-3083.2003.01221.x; Kobayashi K, 2001, MICROSC RES TECHNIQ, V53, P241, DOI 10.1002/jemt.1090; Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251; Lei H, 2011, FOOD CHEM, V127, P1169, DOI 10.1016/j.foodchem.2011.01.119; Lei H, 2009, BBA-PROTEINS PROTEOM, V1794, P1269, DOI 10.1016/j.bbapap.2009.04.014; Li JY, 2010, PHARM BIOL, V48, P1177, DOI 10.3109/13880200903573169; Li X, 2012, INT IMMUNOPHARMACOLO; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mantelingu K, 2007, CHEM BIOL, V14, P645, DOI 10.1016/j.chembiol.2007.04.011; Marti G, 2010, MOLECULES, V15, P7106, DOI 10.3390/molecules15107106; Matsumoto K, 2003, BIOL PHARM BULL, V26, P569, DOI 10.1248/bpb.26.569; Moussay E, 2010, RES DETERMINATION GE; Pedraza-Chaverri J, 2008, FOOD CHEM TOXICOL, V46, P3227, DOI 10.1016/j.fct.2008.07.024; Peng LQ, 2011, IUBMB LIFE, V63, P14, DOI 10.1002/iub.408; Rathee P, 2012, PHARM INNOVATION J, V1, P90; Roy J, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2100re9; Rukachaisirikul V, 2005, CHEM PHARM BULL, V53, P342, DOI 10.1248/cpb.53.342; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016/j.intimp.2005.06.008; Shen J, 2006, STUDIES CHEM CONSTIT; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; STALLARD N, 1995, HUM EXP TOXICOL, V14, P315, DOI 10.1177/096032719501400401; THOMSON AW, 1984, AGENTS ACTIONS, V15, P307, DOI 10.1007/BF01972366; Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200; Wang HL, 2007, IUBMB LIFE, V59, P388, DOI 10.1080/15216540701370721; Wang H, 2008, IUBMB LIFE, V60, P549, DOI 10.1002/iub.94; Wang H, 2010, J BIOCHEM, V147, P185, DOI 10.1093/jb/mvp163; Yu LM, 2007, FOOD CHEM, V104, P176, DOI 10.1016/j.foodchem.2006.11.018; Zhou R, 2005, INT IMMUNOPHARMACOL, V5, P1895, DOI 10.1016/j.intimp.2005.06.009	44	96	102	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2013	8	6							e66503	10.1371/journal.pone.0066503	http://dx.doi.org/10.1371/journal.pone.0066503			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	172XB	23785505	gold, Green Published, Green Submitted			2023-01-03	WOS:000321038800016
J	Xu, J; Zhao, XQ; Wang, YL; Wang, CX; Liu, LP; Sun, BY; Wang, AX; Wang, YJ				Xu, Jie; Zhao, Xingquan; Wang, Yilong; Wang, Chunxue; Liu, Liping; Sun, Baoying; Wang, Anxin; Wang, Yongjun			Impact of a Better Persistence with Antihypertensive Agents on Ischemic Stroke Outcomes for Secondary Prevention	PLOS ONE			English	Article							MEDICATION ADHERENCE; THERAPY; EVENTS	Background: The efficacy of antihypertensive (AH) treatment after stroke has been investigated in several randomized clinical trials. However, non-adherence to AH medication is common for stroke patients in "real world" setting. The purpose of this study was to assess the impact of persistence with AH agents on ischemic stroke (IS) outcomes. Methods and Results: Using the China National Stroke Registry, we analyzed data from 8409 IS patients with hypertension. Persistence with AH therapy (high persistence >= 75%, low persistence <75%) was measured by patient self-report at 3, 6, and 12 months after stroke. Multivariate logistic regression model was used to assess the relationship between persistence and IS outcomes (stroke recurrence, combined vascular events and death) at 12 months. Of the 8409 patients in this study, 40.0% were female and the mean age at study entry was 66.7 years. 31.6% of patients had high persistence with AH drugs, and 68.4% had low persistence during 1 year after stroke onset. High persistence with AH drugs significantly decreased the risk of stroke recurrence (odds ratio, 0.78; 95% CI, 0.68 to 0.89), combined vascular events (0.71; 0.63-0.81) and death (0.44; 0.36-0.53) compared with low persistence. Conclusions: Our study reinforces the benefits of AH medications in routine clinical practice and highlights the importance of persistence with AH therapy among IS patients known to be hypertensive within the first year of an event.	[Xu, Jie; Zhao, Xingquan; Wang, Yilong; Wang, Chunxue; Liu, Liping; Wang, Anxin; Wang, Yongjun] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China; [Sun, Baoying] Shandong Univ, Jinan Cent Hosp, Jinan 250100, Shandong, Peoples R China	Capital Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Wang, YJ (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.	yongjunwang1962@gmail.com	liu, li/HGC-0900-2022		Ministry of Sciences and Technology; Ministry of Health of the People's Republic of China [2006BA101A11, 2009CB521905, 200902004]; National Science Foundation [81071115]	Ministry of Sciences and Technology; Ministry of Health of the People's Republic of China; National Science Foundation(National Science Foundation (NSF))	The China National Stroke Registry was funded by the Ministry of Sciences and Technology and the Ministry of Health of the People's Republic of China (grants 2006BA101A11, 2009CB521905 and 200902004) and the National Science Foundation (grant 81071115). The current analysis of the CNSR data was supported by Beijing Novartis Pharma Co., Ltd. In compliance with the Uniform Requirements for Manuscripts, established by the International Committee of Medical Journal Editors, Novartis did not impose any impediment, directly or indirectly, on the publication of the study's results. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1989, STROKE, V20, P1407; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Bushnell CD, 2011, NEUROLOGY, V77, P1182, DOI 10.1212/WNL.0b013e31822f0423; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Colivicchi F, 2007, STROKE, V38, P2652, DOI 10.1161/STROKEAHA.107.487017; Gehi AK, 2007, ARCH INTERN MED, V167, P1798, DOI 10.1001/archinte.167.16.1798; Gerstein HC, 2000, LANCET, V355, P253; Graves JW, 2012, J HYPERTENS, V30, P1233, DOI 10.1097/HJH.0b013e328353968d; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; Ho PM, 2009, CIRCULATION, V119, P3028, DOI 10.1161/CIRCULATIONAHA.108.768986; Kettani FZ, 2009, STROKE, V40, P213, DOI 10.1161/STROKEAHA.108.522193; LIU LS, 1995, CHINESE MED J-PEKING, V108, P710; Muntner P, 2011, J CLIN HYPERTENS, V13, P479, DOI 10.1111/j.1751-7176.2011.00464.x; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Ovbiagele B, 2010, CEREBROVASC DIS, V29, P146, DOI 10.1159/000262311; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Rashid P, 2003, STROKE, V34, P2741, DOI 10.1161/01.STR.0000092488.40085.15; Schrader J, 2005, STROKE, V36, P1218, DOI 10.1161/01.STR.0000166048.35740.a9; Walsh JC, 2002, AIDS, V16, P269, DOI 10.1097/00002030-200201250-00017; Wang YJ, 2011, INT J STROKE, V6, P355, DOI 10.1111/j.1747-4949.2011.00584.x; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593	22	13	14	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2013	8	6							e65233	10.1371/journal.pone.0065233	http://dx.doi.org/10.1371/journal.pone.0065233			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169CU	23776454	Green Submitted, gold, Green Published			2023-01-03	WOS:000320755400017
J	Doig, GS; Simpson, F; Sweetman, EA; Finfer, SR; Cooper, DJ; Heighes, PT; Davies, AR; O'Leary, M; Solano, T; Peake, S				Doig, Gordon S.; Simpson, Fiona; Sweetman, Elizabeth A.; Finfer, Simon R.; Cooper, D. Jamie; Heighes, Philippa T.; Davies, Andrew R.; O'Leary, Michael; Solano, Tom; Peake, Sandra		Early PN Investigators ANZICS Clin	Early Parenteral Nutrition in Critically Ill Patients With Short-term Relative Contraindications to Early Enteral Nutrition A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS; GUIDELINES; MORTALITY; THERAPY; QUALITY; HUMANS; ADULTS; DISUSE	Importance Systematic reviews suggest adult patients in intensive care units (ICUs) with relative contraindications to early enteral nutrition (EN) may benefit from parenteral nutrition (PN) provided within 24 hours of ICU admission. Objective To determine whether providing early PN to critically ill adults with relative contraindications to early EN alters outcomes. Design, Setting, and Participants Multicenter, randomized, single-blind clinical trial conducted between October 2006 and June 2011 in ICUs of 31 community and tertiary hospitals in Australia and New Zealand. Participants were critically ill adults with relative contraindications to early EN who were expected to remain in the ICU longer than 2 days. Interventions Random allocation to pragmatic standard care or early PN. Main Outcomes and Measures Day-60 mortality; quality of life, infections, and body composition. Results A total of 1372 patients were randomized (686 to standard care, 686 to early PN). Of 682 patients receiving standard care, 199 patients (29.2%) initially commenced EN, 186 patients (27.3%) initially commenced PN, and 278 patients (40.8%) remained unfed. Time to EN or PN in patients receiving standard care was 2.8 days (95% CI, 2.3 to 3.4). Patients receiving early PN commenced PN a mean of 44 minutes after enrollment (95% CI, 36 to 55). Day-60 mortality did not differ significantly (22.8% for standard care vs 21.5% for early PN; risk difference, -1.26%; 95% CI, -6.6 to 4.1; P=.60). Early PN patients rated day-60 quality of life (RAND-36 General Health Status) statistically, but not clinically meaningfully, higher (45.5 for standard care vs 49.8 for early PN; mean difference, 4.3; 95% CI, 0.95 to 7.58; P=.01). Early PN patients required fewer days of invasive ventilation (7.73 vs 7.26 days per 10 patient x ICU days, risk difference, -0.47; 95% CI, -0.82 to -0.11; P=.01) and, based on Subjective Global Assessment, experienced less muscle wasting (0.43 vs 0.27 score increase per week; mean difference, -0.16; 95% CI, -0.28 to -0.038; P=.01) and fat loss (0.44 vs 0.31 score increase per week; mean difference, -0.13; 95% CI, -0.25 to -0.01; P=.04). Conclusions and Relevance The provision of early PN to critically ill adults with relative contraindications to early EN, compared with standard care, did not result in a difference in day-60 mortality. The early PN strategy resulted in significantly fewer days of invasive ventilation but not significantly shorter ICU or hospital stays.	[Doig, Gordon S.; Simpson, Fiona; Sweetman, Elizabeth A.; Heighes, Philippa T.] Univ Sydney, Northern Clin Sch, Intens Care Res Unit, Sydney, NSW 2006, Australia; [Finfer, Simon R.] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2006, Australia; [Cooper, D. Jamie; Davies, Andrew R.] Alfred Hosp, Melbourne, Vic, Australia; [O'Leary, Michael] Royal Prince Alfred Hosp, Sydney, NSW, Australia; [Solano, Tom] Westmead Hosp, Sydney, NSW, Australia; [Peake, Sandra] Queen Elizabeth Hosp, Adelaide, SA, Australia	University of Sydney; George Institute for Global Health; University of Sydney; Florey Institute of Neuroscience & Mental Health; University of Sydney; University of Sydney	Doig, GS (corresponding author), Royal N Shore Hosp, Intens Care Unit, Pacific Hwy, St Leonards, NSW 2065, Australia.	gdoig@med.usyd.edu.au	O'Leary, Michael/S-8980-2019; Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051; Hammond, Naomi/0000-0002-6559-7747; /0000-0002-4157-5148; Finfer, Simon/0000-0002-2785-5864; SHEHABI, Yahya/0000-0003-4707-7462; Knowles, Serena/0000-0002-5028-3825; Doig, Gordon/0000-0003-2141-7000; Rye, Peter/0000-0002-9085-2092; Simpson, Fiona/0000-0002-4598-2488; Micallef, Sharon/0000-0002-8496-2324	Fresenius Kabi Deutschland; Baxter Healthcare; Nestle Nutrition; Pfizer; Astra; Fresenius Kabi Australia; Esai; Eli Lilly; Australian National Health and Medical Research Council (NHMRC)	Fresenius Kabi Deutschland; Baxter Healthcare; Nestle Nutrition(Nestle SA); Pfizer(Pfizer); Astra; Fresenius Kabi Australia; Esai; Eli Lilly(Eli Lilly); Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Doig reported receiving academic research grants from Fresenius Kabi Deutschland and Baxter Healthcare; consulting fees from Nestle Nutrition, Fresenius Kabi Deutschland, and Baxter Healthcare; speakers' honoraria from Nestle Nutrition, Baxter Healthcare, and Fresenius Kabi Deutschland; and travel support from Fresenius Kabi Deutschland, Baxter Healthcare, and Nestle Nutrition. Ms Simpson reported receiving academic research grants from Fresenius Kabi Deutschland and Baxter Healthcare, speakers' honoraria from Fresenius Kabi, and travel support from Fresenius Kabi Deutschland and Baxter Healthcare. Dr Solano reported receiving consulting fees from Pfizer and Astra and conference attendance support from Pfizer. Dr Finfer reported receiving academic research grants from Fresenius Kabi Deutschland and Fresenius Kabi Australia and consultancy fees from Esai and Eli Lilly. Ms Heighes reported receiving academic research grants and travel support from Fresenius Kabi Deutschland and Baxter Healthcare. Dr O'Leary reported receiving speakers' honoraria from Baxter Healthcare. Ms Sweetman reported receiving academic research grants from Fresenius Kabi Deutschland and Baxter Healthcare. No other disclosures were reported.; This work was supported by a peer-reviewed academic grant from the Australian National Health and Medical Research Council (NH&MRC) and unrestricted academic grants from Fresenius Kabi Deutschland and Baxter Healthcare. Fresenius Kabi Australia supplied the study parenteral nutrition.	[Anonymous], EARL PN TRIAL HARR B; Bassler D, 2010, JAMA-J AM MED ASSOC, V303, P1180, DOI 10.1001/jama.2010.310; Bender R, 2010, CONTEMP CLIN TRIALS, V31, P498, DOI 10.1016/j.cct.2010.07.005; Bernard GR, 1995, AM J RESP CRIT CARE, V151, pA323; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Casaer MP, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-21; Cohen J, 2004, CRIT CARE MED, V32, P1510, DOI [10.1097/01.CCM.0000129973.13104.2D, 10.1097/01.CCM.0000145917.89975.F5]; DETSKY AS, 1987, JPEN-PARENTER ENTER, V11, P8, DOI 10.1177/014860718701100108; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Doig GS, STAT ANAL PLAN MULTI; DUDRICK SJ, 1968, SURGERY, V64, P134; Dudrick SJ, 2003, JPEN-PARENTER ENTER, V27, P291, DOI 10.1177/0148607103027004291; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; Heyland DK, 2008, JPEN-PARENTER ENTER, V32, P486, DOI 10.1177/0148607108320659; Hussain SNA, 2010, AM J RESP CRIT CARE, V182, P1377, DOI 10.1164/rccm.201002-0234OC; Jaber S, 2011, CRIT CARE, V15, DOI 10.1186/cc10023; Kelsey JL, 1986, METHODS OBSERVATIONA, P254; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Marik PE, 2011, CRIT CARE MED, V39, P1536, DOI 10.1097/CCM.0b013e318218542c; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; Meijer Alfred J., 2008, V445, P89, DOI 10.1007/978-1-59745-157-4_5; Monk DN, 1996, ANN SURG, V223, P395, DOI 10.1097/00000658-199604000-00008; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PINGLETON S K, 1987, Journal of the American Medical Association, V257, P3094, DOI 10.1001/jama.257.22.3094; Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Simpson F, ANTHROPOMETRIC PROCE; Simpson F, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-17; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; van Nieuwenhoven CA, 2001, JAMA-J AM MED ASSOC, V286, P335, DOI 10.1001/jama.286.3.335; Walters SJ, 2009, PHARM STAT, V8, P163, DOI 10.1002/pst.334; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zubrod C.G., 1960, J CHRON DIS, V11, P7	38	329	359	3	58	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 22	2013	309	20					2130	2138		10.1001/jama.2013.5124	http://dx.doi.org/10.1001/jama.2013.5124			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	148FU	23689848	Bronze			2023-01-03	WOS:000319229600029
J	Roegholt, E; van Vonderen, JJ; Walther, FJ; Roehr, CC; te Pas, AB				Roegholt, Evelien; van Vonderen, Jeroen J.; Walther, Frans J.; Roehr, Charles C.; te Pas, Arjan B.			Do We Deliver the Pressures We Intend to When Using a T-Piece Resuscitator?	PLOS ONE			English	Article							2010 INTERNATIONAL CONSENSUS; CARDIOVASCULAR CARE SCIENCE; NEONATAL RESUSCITATION; CARDIOPULMONARY-RESUSCITATION; TREATMENT RECOMMENDATIONS; FACE MASKS; VENTILATION; INFANTS; PEEP	Background: A T-piece resuscitator (TPR) uses a built-in manometer to set the inflation pressures, but we are not informed what pressures are actually delivered distally. Aim of this study was to measure the proximal and distal pressures under different gas conditions when using a TPR. Methodology/Findings: A test lung was ventilated using a TPR (PIP 25 cmH(2)O, PEEP 5 cmH(2)O) with a gas flow rate of 8 L/min. A) Pressure delivered by six different TPRs was tested. To test variability 20 participants were asked to set PEEP and PIP pressures to 25/5 cmH(2)O. B) PIP and PEEP were measured proximal and distal of the TPR when using standard tubing or heated tubing with or without a humidifier. In experiment A mean (SD) proximal PIP and PEEP of the TPRs were respectively 20.3 (0.3) cmH(2)O (19.9-20.6 cmH(2)O) and 4.9 (0.1) cmH(2)O. When 20 participants set pressures; PIP 26.7 (0.5) cmH(2)O and PEEP 5.9 (0.44) cmH(2)O were measured. Experiment B showed that the decrease of PIP between proximal and distal pressures was not clinically significant. However there was a significant decrease of PEEP using the standard tubing (5.1 (0.1) cmH(2)O proximally versus 4.8 (0.2) cmH(2)O distally; p < 0.001) compared to, when using a humidifier with associated tubing and the humidifier turned on, 5.1 (0.1) proximally versus 3.9 (0.2) cmH2O distally; (p < 0.001). Conclusion/Significance: The accuracy of the built-in manometer of a TPR is acceptable. Most pressures set proximally are comparable to the actual pressures delivered distally. However, when using tubing associated with the humidifier PEEP decreases distally by 1.1-1.2 cmH(2)O and users should anticipate on this.	[Roegholt, Evelien; van Vonderen, Jeroen J.; Walther, Frans J.; te Pas, Arjan B.] Leiden Univ, Med Ctr, Dept Pediat, Div Neonatol, Leiden, Netherlands; [Roehr, Charles C.] Charite Univ Med Ctr, Dept Neonatol, Berlin, Germany	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	van Vonderen, JJ (corresponding author), Leiden Univ, Med Ctr, Dept Pediat, Div Neonatol, Leiden, Netherlands.	j.j.van_vonderen@lumc.nl	van Vonderen, Jeroen J./L-4067-2019; pas, arjan te/AAA-9019-2020	van Vonderen, Jeroen J./0000-0002-1258-5224; pas, arjan te/0000-0001-7831-8797; Roehr, Charles Christoph/0000-0001-7965-4637; Walther, Frans/0000-0003-1931-159X	Veni-grant; Innovational Research Incentives Scheme Veni-Vidi-Vici [91612027]; Willem-Alexander Children's Foundation scholarship	Veni-grant; Innovational Research Incentives Scheme Veni-Vidi-Vici; Willem-Alexander Children's Foundation scholarship	A.B. te Pas is recipient of a Veni-grant, The Netherlands Organisation for Health Research and Development (ZonMw), part of the Innovational Research Incentives Scheme Veni-Vidi-Vici, project number 91612027. J.J. van Vonderen is recipient of Willem-Alexander Children's Foundation scholarship. www.willemalexanderkinderfonds.nl. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Dawson JA, 2011, J PAEDIATR CHILD H, V47, P698, DOI 10.1111/j.1440-1754.2011.02036.x; Fox R.W., 2004, INTRO FLUID MECH; Fuchs H, 2012, NEOREVIEWS, V13, P353; Hawkes CP, 2011, ACTA PAEDIATR, V100, P360, DOI 10.1111/j.1651-2227.2010.02086.x; Kelm M, 2009, KLIN PADIATR, V221, P415, DOI 10.1055/s-0029-1233493; O'Donnell CPF, 2005, ARCH DIS CHILD-FETAL, V90, pF392, DOI 10.1136/adc.2004.064691; O'Donnell CPF, 2004, ACTA PAEDIATR, V93, P583, DOI 10.1111/j.1651-2227.2004.tb02981.x; PALME C, 1985, LANCET, V1, P207; Perlman JM, 2010, PEDIATRICS, V126, pE1319, DOI 10.1542/peds.2010-2972B; Perlman JM, 2010, CIRCULATION, V122, P8516, DOI 10.1161/CIRCULATIONAHA.110.971127; Schmolzer GM, 2012, J PEDIATR-US, V160, P377, DOI 10.1016/j.jpeds.2011.09.017; Schmolzer GM, 2008, J PEDIATR-US, V153, P741, DOI 10.1016/j.jpeds.2008.08.016; Te Pas AB, 2008, J PEDIATR-US, V152, P607, DOI 10.1016/j.jpeds.2007.10.041	13	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2013	8	5							e64706	10.1371/journal.pone.0064706	http://dx.doi.org/10.1371/journal.pone.0064706			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163UP	23717652	Green Published, Green Submitted, gold			2023-01-03	WOS:000320362700168
J	Konieczna, P; Ferstl, R; Ziegler, M; Frei, R; Nehrbass, D; Lauener, RP; Akdis, CA; O'Mahony, L				Konieczna, Patrycja; Ferstl, Ruth; Ziegler, Mario; Frei, Remo; Nehrbass, Dirk; Lauener, Roger P.; Akdis, Cezmi A.; O'Mahony, Liam			Immunomodulation by Bifidobacterium infantis 35624 in the Murine Lamina Propria Requires Retinoic Acid-Dependent and Independent Mechanisms	PLOS ONE			English	Article							CD103(+) DENDRITIC CELLS; IRRITABLE-BOWEL-SYNDROME; REGULATORY T-CELLS; IMMUNE-RESPONSES; TGF-BETA; INFLAMMATION; MICROBIOTA; MICE; MACROPHAGES; EFFICACY	Appropriate dendritic cell processing of the microbiota promotes intestinal homeostasis and protects against aberrant inflammatory responses. Mucosal CD103(+) dendritic cells are able to produce retinoic acid from retinal, however their role in vivo and how they are influenced by specific microbial species has been poorly described. Bifidobacterium infantis 35624 (B. infantis) feeding to mice resulted in increased numbers of CD103+ retinaldehyde dehydrogenase (RALDH)(+) dendritic cells within the lamina propria (LP). Foxp3(+) lymphocytes were also increased in the LP, while T(H)1 and T(H)17 subsets were decreased. 3,7-dimethyl-2,6-octadienal (citral) treatment of mice blocked the increase in CD103(+)RALDH(+) dendritic cells and the decrease in T(H)1 and T(H)17 lymphocytes, but not the increase in Foxp3(+) lymphocytes. B. infantis reduced the severity of DSS-induced colitis, associated with decreased T(H)1 and T(H)17 cells within the LP. Citral treatment confirmed that these effects were RALDH mediated. RALDH(+) dendritic cells decreased within the LP of control inflamed animals, while RALDH(+) dendritic cells numbers were maintained in the LP of B. infantis-fed mice. Thus, CD103(+)RALDH(+) LP dendritic cells are important cellular targets for microbiota-associated effects on mucosal immunoregulation.	[Konieczna, Patrycja; Ferstl, Ruth; Ziegler, Mario; Frei, Remo; Akdis, Cezmi A.; O'Mahony, Liam] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Frei, Remo; Lauener, Roger P.; Akdis, Cezmi A.] Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland; [Nehrbass, Dirk] AO Res Inst Davos ARI, Davos, Switzerland; [Lauener, Roger P.] Hochgebirgsklin Davos Wolfgang, Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; University of Zurich	O'Mahony, L (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland.	liam.omahony@siaf.uzh.ch	Ferstl, Ruth/ABB-9679-2021; Lauener, Roger P/O-8612-2016; Frei, Remo/AAI-9180-2020; O'Mahony, Liam/AAG-5838-2019; Akdis, Cezmi/AAV-4844-2020	Lauener, Roger P/0000-0002-8412-606X; O'Mahony, Liam/0000-0003-4705-3583; Akdis, Cezmi/0000-0001-8020-019X	Swiss National Foundation [32030-132899, 310030-127356]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); European Union (EU) Marie Curie; Novartis; Stallergenes	Swiss National Foundation(Swiss National Science Foundation (SNSF)); Christine Kuhne Center for Allergy Research and Education (CK-CARE); European Union (EU) Marie Curie; Novartis(Novartis); Stallergenes	The authors are supported by Swiss National Foundation grants (project numbers 32030-132899 and 310030-127356), Christine Kuhne Center for Allergy Research and Education (CK-CARE) and European Union (EU) Marie Curie grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have the following conflicts. Liam O'Mahony is a consultant to Alimentary Health Ltd. Cezmi A. Akdis has received research support from Novartis and Stallergenes and consulted for Actellion, Aventis and Allergopharma. Patrycja Konieczna, Mario Ziegler, Dirk Nehrbass, Remo Frei, Ruth Ferstl and Roger P. Lauener have no conflict of interest. The authors do not have any additional financial or non-financial disclosures, which have not already been described online. This does not alter their adherence to all the PLOS ONE policies on sharing data and materials.	Barnes MJ, 2009, IMMUNITY, V31, P401, DOI 10.1016/j.immuni.2009.08.011; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Denning TL, 2011, J IMMUNOL, V187, P733, DOI 10.4049/jimmunol.1002701; Feng T, 2011, MUCOSAL IMMUNOL, V4, P15, DOI 10.1038/mi.2010.60; Frei R, 2012, ALLERGY, V67, P451, DOI 10.1111/j.1398-9995.2011.02783.x; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jaensson E, 2008, J EXP MED, V205, P2139, DOI 10.1084/jem.20080414; Jeon SG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002714; Kinnebrew MA, 2012, IMMUNITY, V36, P276, DOI 10.1016/j.immuni.2011.12.011; Konieczna P, 2012, GUT MICROBES, V3, P261, DOI 10.4161/gmic.20358; Konieczna P, 2012, GUT, V61, P354, DOI 10.1136/gutjnl-2011-300936; Laffont S, 2010, EUR J IMMUNOL, V40, P1877, DOI 10.1002/eji.200939957; Leavy O, 2012, NAT REV IMMUNOL, V12, P319, DOI 10.1038/nri3213; Lee YK, 2010, SCIENCE, V330, P1768, DOI 10.1126/science.1195568; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Manicassamy S, 2009, NAT MED, V15, P401, DOI 10.1038/nm.1925; Manicassamya S, 2009, SEMIN IMMUNOL, V21, P22, DOI 10.1016/j.smim.2008.07.007; McCarthy J, 2003, GUT, V52, P975, DOI 10.1136/gut.52.7.975; Miller JC, 2012, NAT IMMUNOL, V13, P888, DOI 10.1038/ni.2370; Murphy CT, 2010, J LEUKOCYTE BIOL, V88, P1271, DOI 10.1189/jlb.0909627; Niess JH, 2010, J IMMUNOL, V184, P2026, DOI 10.4049/jimmunol.0901936; O'Mahony C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000112; O'Mahony L, 2005, GASTROENTEROLOGY, V128, P541, DOI 10.1053/j.gastro.2004.11.050; Rivollier A, 2012, J EXP MED, V209, P139, DOI 10.1084/jem.20101387; Shanahan F, 2010, AM J GASTROENTEROL, V105, P275, DOI 10.1038/ajg.2009.729; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Takahashi H, 2012, NAT IMMUNOL, V13, P587, DOI 10.1038/ni.2286; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; Uematsu S, 2008, NAT IMMUNOL, V9, P769, DOI 10.1038/ni.1622; van der Kleij H, 2008, AM J PHYSIOL-REG I, V295, pD1131, DOI 10.1152/ajpregu.90434.2008; Wermers JD, 2011, GASTROENTEROLOGY, V140, P1526, DOI 10.1053/j.gastro.2011.01.044; Whorwell PJ, 2006, AM J GASTROENTEROL, V101, P1581, DOI 10.1111/j.1572-0241.2006.00734.x; Wingender G, 2012, GASTROENTEROLOGY, V143, P418, DOI 10.1053/j.gastro.2012.04.017	33	64	66	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2013	8	5							e62617	10.1371/journal.pone.0062617	http://dx.doi.org/10.1371/journal.pone.0062617			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	149OK	23704880	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000319330200009
J	Yang, CS; Yuk, JM; Kim, JJ; Hwang, JH; Lee, CH; Kim, JM; Oh, GT; Choi, HS; Jo, EK				Yang, Chul-Su; Yuk, Jae-Min; Kim, Jwa-Jin; Hwang, Jung Hwan; Lee, Chul-Ho; Kim, Jin-Man; Oh, Goo Taeg; Choi, Hueng-Sik; Jo, Eun-Kyeong			Small Heterodimer Partner-Targeting Therapy Inhibits Systemic Inflammatory Responses through Mitochondrial Uncoupling Protein 2	PLOS ONE			English	Article							NUCLEAR RECEPTOR SHP; GENE-EXPRESSION; NITRIC-OXIDE; FENOFIBRATE; KINASE; ALPHA; AMPK; METABOLISM; ACTIVATION; MECHANISMS	The orphan nuclear receptor, small heterodimer partner (SHP), appears to play a negative regulatory role in innate immune signaling. Emerging evidence warrants further study on the therapeutic targeting of SHP to suppress excessive and deleterious inflammation. Here we show that fenofibrate, which targets SHP, is required for inhibiting systemic inflammation via mitochondrial uncoupling protein 2 (UCP2). In vivo administration of fenofibrate ameliorated systemic inflammatory responses and increased survival upon experimental sepsis through SHP. An abundance of SHP was observed in mice fed fenofibrate and in cultured macrophages through LKB1-dependent activation of the AMP-activated protein kinase pathway. Fenofibrate significantly blocked endotoxin-triggered inflammatory signaling responses via SHP, but not via peroxisome proliferator-activated receptor (PPAR)-alpha. In addition to the known mechanism by which SHP modulates innate signaling, we identify a new role of fenofibrate-induced SHP on UCP2 induction, which is required for the suppression of inflammatory responses through modulation of mitochondrial ROS production. These data strongly suggest that the SHP-inducing drug fenofibrate paves the way for novel therapies for systemic inflammation by targeting SHP.	[Yang, Chul-Su; Yuk, Jae-Min; Kim, Jwa-Jin; Jo, Eun-Kyeong] Chungnam Natl Univ, Sch Med, Dept Microbiol, Taejon, South Korea; [Kim, Jin-Man] Chungnam Natl Univ, Sch Med, Dept Pathol, Taejon, South Korea; [Yang, Chul-Su; Yuk, Jae-Min; Kim, Jwa-Jin; Kim, Jin-Man; Jo, Eun-Kyeong] Chungnam Natl Univ, Sch Med, Infect Signaling Network Res Ctr, Taejon, South Korea; [Hwang, Jung Hwan; Lee, Chul-Ho] Korea Res Inst Biosci & Biotechnol, Lab Anim Ctr, Taejon, South Korea; [Oh, Goo Taeg] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul, South Korea; [Choi, Hueng-Sik] Chonnam Natl Univ, Sch Biol Sci & Technol, Hormone Res Ctr, Natl Creat Res Initiat Ctr Nucl Receptor Signals, Kwangju, South Korea	Chungnam National University; Chungnam National University; Chungnam National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Ewha Womans University; Chonnam National University	Jo, EK (corresponding author), Chungnam Natl Univ, Sch Med, Dept Microbiol, Taejon, South Korea.	hayoungj@cnu.ac.kr	Yang, Chul-Su/J-3833-2013; Oh, Goo Taeg/AAQ-9995-2021	Yuk, Jae-Min/0000-0002-0630-9194; Eun-Kyeong, Jo/0000-0001-7191-0587; KIM, JIN MAN/0000-0003-0905-9730	Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [A100588]; National Research Foundation of Korea (NRF) grant; Korea government (MEST) [2007-0054932]; National Creative Research Initiatives Grant from the Korean Ministry of Education, Science and Technology; Korea Research Institute of Bioscience and Biotechnology Research Initiative Program	Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea; National Research Foundation of Korea (NRF) grant(National Research Foundation of Korea); Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); National Creative Research Initiatives Grant from the Korean Ministry of Education, Science and Technology; Korea Research Institute of Bioscience and Biotechnology Research Initiative Program	This work was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A100588), by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2007-0054932), by National Creative Research Initiatives Grant from the Korean Ministry of Education, Science and Technology, and by the Korea Research Institute of Bioscience and Biotechnology Research Initiative Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Asquith M, 2010, J EXP MED, V207, P1573, DOI 10.1084/jem.20101330; Bai AP, 2010, BIOCHEM PHARMACOL, V80, P1708, DOI 10.1016/j.bcp.2010.08.009; Bai Y, 2005, J BIOL CHEM, V280, P19062, DOI 10.1074/jbc.M500566200; Bavner A, 2005, TRENDS ENDOCRIN MET, V16, P478, DOI 10.1016/j.tem.2005.10.005; Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049; Burris TP, 2012, CHEM BIOL, V19, P51, DOI 10.1016/j.chembiol.2011.12.011; Carling D, 2008, INT J OBESITY, V32, pS55, DOI 10.1038/ijo.2008.124; CARLSON CA, 1973, J BIOL CHEM, V248, P378; Chanda D, 2008, AM J PHYSIOL-ENDOC M, V295, pE368, DOI 10.1152/ajpendo.00800.2007; Chanda D, 2008, ENDOCR J, V55, P253, DOI 10.1507/endocrj.K07E-103; Chanda D, 2009, J BIOL CHEM, V284, P28510, DOI 10.1074/jbc.M109.022244; Chanda D, 2009, HEPATOLOGY, V50, P880, DOI 10.1002/hep.23049; Chen WL, 2012, BIOCHEM PHARMACOL, V84, P522, DOI 10.1016/j.bcp.2012.05.022; Diano S, 2012, TRENDS MOL MED, V18, P52, DOI 10.1016/j.molmed.2011.08.003; Emre Y, 2007, P NATL ACAD SCI USA, V104, P19085, DOI 10.1073/pnas.0709557104; Fic E, 2010, ELECTROPHORESIS, V31, P3573, DOI 10.1002/elps.201000197; Garruti G, 2012, J LIPIDS, V2012, DOI 10.1155/2012/304292; Glass CK, 2010, NAT REV IMMUNOL, V10, P365, DOI 10.1038/nri2748; Goto M, 2010, MOD RHEUMATOL, V20, P238, DOI 10.1007/s10165-009-0261-2; Gouni-Berthold I., 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P513, DOI 10.2174/156800605774962022; Hiukka A, 2010, NAT REV ENDOCRINOL, V6, P454, DOI 10.1038/nrendo.2010.89; Kato Y, 2010, HORM METAB RES, V42, P632, DOI 10.1055/s-0030-1255033; Keating GM, 2007, DRUGS, V67, P121, DOI 10.2165/00003495-200767010-00013; Kim YD, 2008, DIABETES, V57, P306, DOI 10.2337/db07-0381; Kladna A, 2006, BIOPOLYMERS, V82, P99, DOI 10.1002/bip.20402; Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007; Lalloyer F, 2011, ARTERIOSCL THROM VAS, V31, P1573, DOI 10.1161/ATVBAHA.110.220525; Lee YS, 2007, INT REV CYTOL, V261, P117, DOI 10.1016/S0074-7696(07)61003-1; Leloup C, 2011, ANTIOXID REDOX SIGN, V14, P519, DOI 10.1089/ars.2010.3424; Li YTY, 2007, ARTERIOSCL THROM VAS, V27, P2606, DOI 10.1161/ATVBAHA.107.152694; Mailloux RJ, 2011, FREE RADICAL BIO MED, V51, P1106, DOI 10.1016/j.freeradbiomed.2011.06.022; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mansouri RM, 2008, ENDOCRINOLOGY, V149, P3215, DOI 10.1210/en.2007-1339; Marshall JC, 2001, CRIT CARE MED, V29, pS99, DOI 10.1097/00003246-200107001-00032; McKeage K, 2011, DRUGS, V71, P1917, DOI 10.2165/11208090-000000000-00000; Myerburg MM, 2010, AM J RESP CELL MOL, V42, P676, DOI 10.1165/2009-0147OC; Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367; Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980; Nath N, 2005, J IMMUNOL, V175, P566, DOI 10.4049/jimmunol.175.1.566; Pardee K, 2011, SUBCELL BIOCHEM, V52, P123, DOI 10.1007/978-90-481-9069-0_6; Pascual G, 2006, TRENDS ENDOCRIN MET, V17, P321, DOI 10.1016/j.tem.2006.08.005; Patel NSA, 2009, J PHARMACOL EXP THER, V328, P635, DOI 10.1124/jpet.108.146191; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0; Sehgal N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035427; Straus DS, 2007, TRENDS IMMUNOL, V28, P551, DOI 10.1016/j.it.2007.09.003; Tomizawa A, 2011, METABOLISM, V60, P513, DOI 10.1016/j.metabol.2010.04.020; Tsoyi K, 2011, BRIT J PHARMACOL, V162, P1498, DOI 10.1111/j.1476-5381.2010.01126.x; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wong TY, 2012, AM J OPHTHALMOL, V154, P6, DOI 10.1016/j.ajo.2012.03.013; Yang CS, 2007, J EXP MED, V204, P583, DOI 10.1084/jem.20061849; Yang ZG, 2010, J BIOL CHEM, V285, P19051, DOI 10.1074/jbc.M110.123620; Yuk JM, 2011, NAT IMMUNOL, V12, P742, DOI 10.1038/ni.2064; Zhang YX, 2011, BBA-MOL BASIS DIS, V1812, P893, DOI 10.1016/j.bbadis.2010.10.006; Zhang YX, 2010, MOL CELL BIOL, V30, P1341, DOI 10.1128/MCB.01076-09; Zhao X, 2008, AM J PHYSIOL-LUNG C, V295, pL497, DOI 10.1152/ajplung.90210.2008; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663	58	21	23	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2013	8	5							e63435	10.1371/journal.pone.0063435	http://dx.doi.org/10.1371/journal.pone.0063435			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	149OK	23704907	gold, Green Submitted, Green Published			2023-01-03	WOS:000319330200037
J	Gillespie, U; Alassaad, A; Hammarlund-Udenaes, M; Morlin, C; Henrohn, D; Bertilsson, M; Melhus, H				Gillespie, Ulrika; Alassaad, Anna; Hammarlund-Udenaes, Margareta; Morlin, Claes; Henrohn, Dan; Bertilsson, Maria; Melhus, Hakan			Effects of Pharmacists' Interventions on Appropriateness of Prescribing and Evaluation of the Instruments' (MAI, STOPP and STARTs') Ability to Predict Hospitalization-Analyses from a Randomized Controlled Trial	PLOS ONE			English	Article							INAPPROPRIATE MEDICATION USE; ADVERSE DRUG EVENTS; OLDER PERSONS PRESCRIPTIONS; ELDERLY-PATIENTS; SCREENING TOOL; ALERT DOCTORS; EXPLICIT CRITERIA; QUALITY; RISK; INPATIENTS	Background: Appropriateness of prescribing can be assessed by various measures and screening instruments. The aims of this study were to investigate the effects of pharmacists' interventions on appropriateness of prescribing in elderly patients, and to explore the relationship between these results and hospital care utilization during a 12-month follow-up period. Methods: The study population from a previous randomized controlled study, in which the effects of a comprehensive pharmacist intervention on re-hospitalization was investigated, was used. The criteria from the instruments MAI, STOPP and START were applied retrospectively to the 368 study patients (intervention group (I) n = 182, control group (C) n = 186). The assessments were done on admission and at discharge to detect differences over time and between the groups. Hospital care consumption was recorded and the association between scores for appropriateness, and hospitalization was analysed. Results: The number of Potentially Inappropriate Medicines (PIMs) per patient as identified by STOPP was reduced for I but not for C (1.42 to 0.93 vs. 1.46 to 1.66 respectively, p<0.01). The number of Potential Prescription Omissions (PPOs) per patient as identified by START was reduced for I but not for C (0.36 to 0.09 vs. 0.42 to 0.45 respectively, p<0.001). The summated score for MAI was reduced for I but not for C (8.5 to 5.0 and 8.7 to 10.0 respectively, p<0.001). There was a positive association between scores for MAI and STOPP and drug-related readmissions (RR 8-9% and 30-34% respectively). No association was detected between the scores of the tools and total re-visits to hospital. Conclusion: The interventions significantly improved the appropriateness of prescribing for patients in the intervention group as evaluated by the instruments MAI, STOPP and START. High scores in MAI and STOPP were associated with a higher number of drug-related readmissions.	[Gillespie, Ulrika; Hammarlund-Udenaes, Margareta] Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden; [Gillespie, Ulrika; Alassaad, Anna; Hammarlund-Udenaes, Margareta; Henrohn, Dan; Melhus, Hakan] Univ Uppsala Hosp, Uppsala, Sweden; [Alassaad, Anna; Henrohn, Dan; Melhus, Hakan] Uppsala Univ, Dept Med Sci, Uppsala, Sweden; [Morlin, Claes] Univ Uppsala Hosp, Dept Med, Uppsala, Sweden; [Henrohn, Dan] Med Prod Agcy, Uppsala, Sweden; [Bertilsson, Maria] Uppsala Clin Res Ctr, Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University; Uppsala University Hospital; Medical Products Agency; Uppsala University	Gillespie, U (corresponding author), Uppsala Univ, Dept Pharmaceut Biosci, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden.	Ulrika.gillespie@akademiska.se			Swedish Academy for Pharmaceutical Sciences; University Hospital of Uppsala, Uppsala University; Hospital Pharmacy (Apoteket AB)	Swedish Academy for Pharmaceutical Sciences; University Hospital of Uppsala, Uppsala University; Hospital Pharmacy (Apoteket AB)	The study was funded by the non-profit organization Swedish Academy for Pharmaceutical Sciences (one PHD student via annual scholarships). The University Hospital of Uppsala, Uppsala University and The Hospital Pharmacy (Apoteket AB) all co-funded the study by letting all involved physicians and pharmacists in the study participate in meetings and other tasks surrounding the study during work hours. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnett K, 2011, BMJ QUAL SAF, V20, P275, DOI 10.1136/bmjqs.2009.039818; Barry PJ, 2007, AGE AGEING, V36, P632, DOI 10.1093/ageing/afm118; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Bonnet-Zamponi D, 2013, J AM GERIATR SOC, V61, P113, DOI 10.1111/jgs.12037; Burnett KM, 2009, AM J HEALTH-SYST PH, V66, P854, DOI 10.2146/ajhp080176; Crotty Maria, 2004, Am J Geriatr Pharmacother, V2, P257, DOI 10.1016/j.amjopharm.2005.01.001; Dalleur O, 2012, DRUG AGING, V29, P829, DOI 10.1007/s40266-012-0016-1; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gallagher PF, 2011, CLIN PHARMACOL THER, V89, P845, DOI 10.1038/clpt.2011.44; Gallagher P, 2008, AGE AGEING, V37, P673, DOI 10.1093/ageing/afn197; Gallagher P, 2009, AGE AGEING, V38, P603, DOI 10.1093/ageing/afp058; Gallagher PF, 2008, AGE AGEING, V37, P96, DOI 10.1093/ageing/afm116; Gillespie U, 2009, ARCH INTERN MED, V169, P894, DOI 10.1001/archinternmed.2009.71; Gurwitz JH, 2002, ARCH INTERN MED, V162, P1670, DOI 10.1001/archinte.162.15.1670; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; Hamilton H, 2011, ARCH INTERN MED, V171, P1013, DOI 10.1001/archinternmed.2011.215; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Hellstrom LM, 2011, EUR J CLIN PHARMACOL, V67, P741, DOI 10.1007/s00228-010-0982-3; KOCH GG, 1982, BIOMETRICS, V38, P563, DOI 10.2307/2530041; Lau DT, 2005, ARCH INTERN MED, V165, P68, DOI 10.1001/archinte.165.1.68; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Luo RY, 2012, J EVAL CLIN PRACT, V18, P1196, DOI 10.1111/j.1365-2753.2011.01758.x; Mainz J, 2003, INT J QUAL HEALTH C, V15, pI5, DOI 10.1093/intqhc/mzg084; Patterson SM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008165.pub2; Pozzi C, 2010, PHARMACOEPIDEM DR S, V19, P954, DOI 10.1002/pds.1997; Pronovost PJ, 2004, LANCET, V363, P1061, DOI 10.1016/S0140-6736(04)15843-1; Rubin HR, 2001, INT J QUAL HEALTH C, V13, P489, DOI 10.1093/intqhc/13.6.489; Ruggiero C, 2010, DRUG AGING, V27, P747, DOI 10.2165/11538240-000000000-00000; SAMSA GP, 1994, J CLIN EPIDEMIOL, V47, P891, DOI 10.1016/0895-4356(94)90192-9; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Scullin C, 2007, J EVAL CLIN PRACT, V13, P781, DOI 10.1111/j.1365-2753.2006.00753.x; Simonson W, 2005, DRUG AGING, V22, P559, DOI 10.2165/00002512-200522070-00002; Spinewine A, 2007, J AM GERIATR SOC, V55, P658, DOI 10.1111/j.1532-5415.2007.01132.x; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Spinewine A, 2012, DRUG AGING, V29, P495, DOI 10.2165/11631720-000000000-00000; Steinman MA, 2007, MED CARE, V45, P95, DOI 10.1097/01.mlr.0000241111.11991.62; Stokes ME, 2000, CATEGORICAL DATA ANA	42	84	86	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2013	8	5							e62401	10.1371/journal.pone.0062401	http://dx.doi.org/10.1371/journal.pone.0062401			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	146RJ	23690938	Green Submitted, gold, Green Published			2023-01-03	WOS:000319107900008
J	Kosaka, J; Morimatsu, H; Takahashi, T; Shimizu, H; Kawanishi, S; Omori, E; Endo, Y; Tamaki, N; Morita, M; Morita, K				Kosaka, Junko; Morimatsu, Hiroshi; Takahashi, Toru; Shimizu, Hiroko; Kawanishi, Susumu; Omori, Emiko; Endo, Yasumasa; Tamaki, Naofumi; Morita, Manabu; Morita, Kiyoshi			Effects of Biliverdin Administration on Acute Lung Injury Induced by Hemorrhagic Shock and Resuscitation in Rats	PLOS ONE			English	Article							MULTIPLE ORGAN FAILURE; RESPIRATORY-DISTRESS-SYNDROME; DECREASED PROGRESSION; REPERFUSION INJURY; HEME OXYGENASE-1; OXIDATIVE DAMAGE; PROTECTS; MODEL; INFLAMMATION; DYSFUNCTION	Hemorrhagic shock and resuscitation induces pulmonary inflammation that leads to acute lung injury. Biliverdin, a metabolite of heme catabolism, has been shown to have potent cytoprotective, anti-inflammatory, and anti-oxidant effects. This study aimed to examine the effects of intravenous biliverdin administration on lung injury induced by hemorrhagic shock and resuscitation in rats. Biliverdin or vehicle was administered to the rats 1 h before sham or hemorrhagic shock-inducing surgery. The sham-operated rats underwent all surgical procedures except bleeding. To induce hemorrhagic shock, rats were bled to achieve a mean arterial pressure of 30 mmHg that was maintained for 60 min, followed by resuscitation with shed blood. Histopathological changes in the lungs were evaluated by histopathological scoring analysis. Inflammatory gene expression was determined by Northern blot analysis, and oxidative DNA damage was assessed by measuring 8-hydroxy-2' deoxyguanosine levels in the lungs. Hemorrhagic shock and resuscitation resulted in prominent histopathological damage, including congestion, edema, cellular infiltration, and hemorrhage. Biliverdin administration prior to hemorrhagic shock and resuscitation significantly ameliorated these lung injuries as judged by histopathological improvement. After hemorrhagic shock and resuscitation, inflammatory gene expression of tumor necrosis factor-alpha and inducible nitric oxide synthase were increased by 18- and 8-fold, respectively. Inflammatory gene expression significantly decreased when biliverdin was administered prior to hemorrhagic shock and resuscitation. Moreover, after hemorrhagic shock and resuscitation, lung 8-hydroxy-2' deoxyguanosine levels in mitochondrial DNA expressed in the pulmonary interstitium increased by 1.5-fold. Biliverdin administration prior to hemorrhagic shock and resuscitation decreased mitochondrial 8-hydroxy-2' deoxyguanosine levels to almost the same level as that in the control animals. We also confirmed that biliverdin administration after hemorrhagic shock and resuscitation had protective effects on lung injury. Our findings suggest that biliverdin has a protective role, at least in part, against hemorrhagic shock and resuscitation-induced lung injury through anti-inflammatory and anti-oxidant mechanisms.	[Kosaka, Junko; Morimatsu, Hiroshi; Takahashi, Toru; Shimizu, Hiroko; Kawanishi, Susumu; Omori, Emiko; Morita, Kiyoshi] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Anesthesiol & Resuscitol, Okayama, Japan; [Takahashi, Toru] Okayama Prefectural Univ, Fac Hlth & Welf Sci, Okayama, Japan; [Endo, Yasumasa; Morita, Manabu] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Prevent Dent, Okayama, Japan; [Tamaki, Naofumi] Univ Tokushima, Grad Sch, Dept Prevent Dent, Inst Hlth Biosci, Tokushima 770, Japan	Okayama University; Okayama Prefectural University; Okayama University; Tokushima University	Morimatsu, H (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Anesthesiol & Resuscitol, Okayama, Japan.	morima-h@md.okayama-u.ac.jp	Morimatsu, Hiroshi/B-2236-2011	Morimatsu, Hiroshi/0000-0002-6744-0508	Grants-in-Aid for Scientific Research [24592735] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Anaya-Prado R, 2002, J SURG RES, V105, P248, DOI 10.1006/jsre.2002.6385; Baek JH, 2012, J CLIN INVEST, V122, P1444, DOI 10.1172/JCI59770; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Ciesla DJ, 2006, SURGERY, V140, P640, DOI 10.1016/j.surg.2006.06.015; Ciesla DJ, 2005, SURGERY, V138, P749, DOI 10.1016/j.surg.2005.07.020; Deguchi K, 2008, BRAIN RES, V1188, P1, DOI 10.1016/j.brainres.2007.07.104; Dennery PA, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00115; Dewar D, 2009, INJURY, V40, P912, DOI 10.1016/j.injury.2009.05.024; Fondevila C, 2004, HEPATOLOGY, V40, P1333, DOI 10.1002/hep.20480; Franklin GA, 2006, SURGERY, V140, P647; Jansen T, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00030; Jiang HC, 2007, SURGERY, V141, P32, DOI 10.1016/j.surg.2006.03.024; Kanagawa F, 2010, J TRAUMA, V69, P185, DOI 10.1097/TA.0b013e3181bbd516; Kasai H, 2002, FREE RADICAL BIO MED, V33, P450, DOI 10.1016/S0891-5849(02)00818-3; Maeshima K, 2005, BIOCHEM PHARMACOL, V69, P1667, DOI 10.1016/j.bcp.2005.03.007; Malangoni MA, 2005, SURGERY, V138, P757; Murakami K, 2002, SHOCK, V18, P236, DOI 10.1097/00024382-200209000-00006; Nakao A, 2004, GASTROENTEROLOGY, V127, P595, DOI 10.1053/j.gastro.2004.05.059; Nicholson SE, 2011, J TRAUMA, V70, P466, DOI 10.1097/TA.0b013e3182032584; Rushing GD, 2008, ANN SURG, V247, P929, DOI 10.1097/SLA.0b013e31816757f7; Sarady-Andrews JK, 2005, AM J PHYSIOL-LUNG C, V289, pL1131, DOI 10.1152/ajplung.00458.2004; STEPHENS KE, 1988, AM REV RESPIR DIS, V137, P1364, DOI 10.1164/ajrccm/137.6.1364; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Tomofuji T, 2006, FEBS LETT, V580, P3601, DOI 10.1016/j.febslet.2006.05.041; Tomofuji T, 2011, BIOMED RES-TOKYO, V32, P343, DOI 10.2220/biomedres.32.343; Uehara K, 2005, CRIT CARE MED, V33, P381, DOI 10.1097/01.CCM.0000153407.14237.7F; Umeda K, 2009, SHOCK, V31, P40, DOI 10.1097/SHK.0b013e318177823a; Yamashita K, 2004, FASEB J, V18, P765, DOI 10.1096/fj.03-0839fje; Zegdi R, 2003, SHOCK, V20, P569, DOI 10.1097/01.shk.0000094765.36694.92	30	34	37	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2013	8	5							e63606	10.1371/journal.pone.0063606	http://dx.doi.org/10.1371/journal.pone.0063606			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	154EP	23667646	Green Published, Green Submitted, gold			2023-01-03	WOS:000319654700167
J	Yan, JH; Gu, WJ; Sun, J; Zhang, WX; Li, BW; Pan, L				Yan, Jun-Hong; Gu, Wan-Jie; Sun, Jian; Zhang, Wen-Xiao; Li, Bao-Wei; Pan, Lei			Efficacy of Tai Chi on Pain, Stiffness and Function in Patients with Osteoarthritis: A Meta-Analysis	PLOS ONE			English	Article							QUALITY-OF-LIFE; KNEE OSTEOARTHRITIS; OLDER-ADULTS; EXERCISE; BALANCE; WOMEN	Background: Whether Tai Chi benefits patients with osteoarthritis remains controversial. We performed a meta-analysis to assess the effectiveness of Tai Chi exercise for pain, stiffness, and physical function in patients with osteoarthritis. Methods: A computerized search of PubMed and Embase (up to Sept 2012) was performed to identify relevant studies. The outcome measures were pain, stiffness, and physical function. Two investigators identified eligible studies and extracted data independently. The quality of the included studies was assessed by the Jadad score. Standard mean differences (SMDs) and 95% confidence intervals (CIs) were calculated and pooled using a random effects model. The change in outcomes from baseline was compared to the minimum clinically important difference. Results: A total of seven randomized controlled trials involving 348 patients with osteoarthritis met the inclusion criteria. The mean Jadad score was 3.6. The pooled SMD was -0.45 (95% CI -0.70--0.20, P = 0.0005) for pain, -0.31 (95% CI -0.60--0.02, P = 0.04) for stiffness, and -0.61 (95% CI -0.85--0.37, P<0.00001) for physical function. A change of 32.2-36.4% in the outcomes was greater than the minimum clinically important difference. Conclusions: Twelve-week Tai Chi is beneficial for improving arthritic symptoms and physical function in patients with osteoarthritis and should be included in rehabilitation programs. However, the evidence may be limited by potential biases; thus, larger scale randomized controlled trials are needed to confirm the current findings and investigate the long-term effects of Tai Chi.	[Yan, Jun-Hong; Sun, Jian; Zhang, Wen-Xiao; Li, Bao-Wei] Binzhou Med Coll, Dept Clin Med Technol, Affiliated Hosp, Binzhou, Peoples R China; [Gu, Wan-Jie] Guangxi Med Univ, Affiliated Hosp 1, Dept Anaesthesiol, Nanning, Guangxi, Peoples R China; [Pan, Lei] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China	Binzhou Medical University; Guangxi Medical University; Guangzhou Medical University	Pan, L (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.	zypl781102@163.com	Gu, Wan-Jie/AAN-5417-2020	Gu, Wan-Jie/0000-0003-4923-8282				Adler PA, 2007, THESIS CASE W RESERV; Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; Arden N, 2006, BEST PRACT RES CL RH, V20, P3, DOI 10.1016/j.berh.2005.09.007; 송라윤, 2009, [The Journal of Muscle and Joint Health, 근관절건강학회지], V16, P46; BARR S, 1994, J RHEUMATOL, V21, P2106; Bennell KL, 2011, J SCI MED SPORT, V14, P4, DOI 10.1016/j.jsams.2010.08.002; Brismee JM, 2007, CLIN REHABIL, V21, P99, DOI 10.1177/0269215506070505; Chyu MC, 2011, ARTHRITIS, DOI 10.1155/2011/364319; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Faber MJ, 2006, ARCH PHYS MED REHAB, V87, P885, DOI 10.1016/j.apmr.2006.04.005; Fransen M, 2007, ARTHRIT RHEUM-ARTHR, V57, P407, DOI 10.1002/art.22621; Gatts Strawberry, 2008, Curr Aging Sci, V1, P68; Gecht MR, 1996, ARTHRIT CARE RES, V9, P82, DOI 10.1002/1529-0131(199604)9:2<82::AID-ANR1790090203>3.0.CO;2-T; Guan HW, 2011, AM J CHINESE MED, V39, P251, DOI 10.1142/S0192415X11008798; Hartman CA, 2000, J AM GERIATR SOC, V48, P1553, DOI 10.1111/j.1532-5415.2000.tb03863.x; Hawker GA, 2011, OSTEOARTHR CARTILAGE, V19, P366, DOI 10.1016/j.joca.2011.01.021; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hmamouchi Ihsane, 2012, BMC Res Notes, V5, P58, DOI 10.1186/1756-0500-5-58; Hochberg MC, 2010, SEMIN ARTHRITIS RHEU, V39, P321, DOI 10.1016/j.semarthrit.2010.02.001; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kang JW, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2010-000035; Katz JD, 2009, ANN NY ACAD SCI, V1154, P3, DOI 10.1111/j.1749-6632.2009.04380.x; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Lee Hea-Young, 2006, Taehan Kanho Hakhoe Chi, V36, P571; Lee HJ, 2009, CLIN REHABIL, V23, P504, DOI 10.1177/0269215508101746; Lee MS, 2008, CLIN RHEUMATOL, V27, P211, DOI 10.1007/s10067-007-0700-4; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Manninen P, 2001, RHEUMATOLOGY, V40, P432, DOI 10.1093/rheumatology/40.4.432; Munro JF, 2004, J EPIDEMIOL COMMUN H, V58, P1004, DOI 10.1136/jech.2003.014225; Ni GX, 2010, JCR-J CLIN RHEUMATOL, V16, P64, DOI 10.1097/RHU.0b013e3181cf344f; Pan L, 2013, EUR J HEART FAIL, V15, P316, DOI 10.1093/eurjhf/hfs170; Ramachandran AK, 2007, GAIT POSTURE, V26, P248, DOI 10.1016/j.gaitpost.2006.09.005; Richmond J, 2010, J BONE JOINT SURG AM, V92A, P990, DOI 10.2106/JBJS.I.00982; Sayre EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010470; Song R, 2003, J RHEUMATOL, V30, P2039; Song Rhayun, 2007, Taehan Kanho Hakhoe Chi, V37, P249; Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832; Yocum DE, 2000, RHEUM DIS CLIN N AM, V26, P145, DOI 10.1016/S0889-857X(05)70128-9; ZHUO DH, 1982, AM J CHINESE MED, V10, P32, DOI 10.1142/S0192415X82000063	39	46	48	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2013	8	4							e61672	10.1371/journal.pone.0061672	http://dx.doi.org/10.1371/journal.pone.0061672			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JA	23620778	Green Published, gold, Green Submitted			2023-01-03	WOS:000317909500058
J	Bell, D; Lambourne, A; Percival, F; Laverty, AA; Ward, DK				Bell, Derek; Lambourne, Adrian; Percival, Frances; Laverty, Anthony A.; Ward, David K.			Consultant Input in Acute Medical Admissions and Patient Outcomes in Hospitals in England: A Multivariate Analysis	PLOS ONE			English	Article							QUALITY-OF-CARE; MORTALITY; WEEKENDS; VOLUME; IMPACT	Recent recommendations for physicians in the UK outline key aspects of care that should improve patient outcomes and experience in acute hospital care. Included in these recommendations are Consultant patterns of work to improve timeliness of clinical review and improve continuity of care. This study used a contemporaneous validated survey compared with clinical outcomes derived from Hospital Episode Statistics, between April 2009 and March 2010 from 91 acute hospital sites in England to evaluate systems of consultant cover for acute medical admissions. Clinical outcomes studied included adjusted case fatality rates (aCFR), including the ratio of weekend to weekday mortality, length of stay and readmission rates. Hospitals that had an admitting Consultant presence within the Acute Medicine Unit (AMU, or equivalent) for a minimum of 4 hours per day (65% of study group) had a lower aCFR compared with hospitals that had Consultant presence for less than 4 hours per day (p<0.01) and also had a lower 28 day re-admission rate (p<0.01). An 'all inclusive' pattern of Consultant working, incorporating all the guideline recommendations and which included the minimum Consultant presence of 4 hours per day (29%) was associated with reduced excess weekend mortality (p<0.05). Hospitals with >40 acute medical admissions per day had a lower aCFR compared to hospitals with fewer than 40 admissions per day (p<0.03) and had a lower 7 day re-admission rate (p<0.02). This study is the first large study to explore the potential relationships between systems of providing acute medical care and clinical outcomes. The results show an association between well-designed systems of Consultant working practices, which promote increased patient contact, and improved patient outcomes in the acute hospital setting.	[Bell, Derek] Univ London Imperial Coll Sci Technol & Med, London, England; [Lambourne, Adrian; Percival, Frances] pH Associates Ltd, Marlow, Bucks, England; [Laverty, Anthony A.] Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Publ Hlth, London, England; [Ward, David K.] Queen Elizabeth Hosp, South London Healthcare NHS Trust, Woolwich, England	Imperial College London; Imperial College London	Bell, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, London, England.	d.bell@imperial.ac.uk		Bell, Derek/0000-0002-9944-1097; Laverty, Anthony/0000-0003-1318-8439	independent consultancy pH associates	independent consultancy pH associates	This study was supported by an independent consultancy pH associates, the employer of A Lambourne and F Percival. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.	*AC MED TASKF, 2007, AC MED CAR RIGHT PER; Aylin P, 2010, QUAL SAF HEALTH CARE, V19, P213, DOI 10.1136/qshc.2008.028639; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cram P, 2004, AM J MED, V117, P151, DOI 10.1016/j.amjmed.2004.02.035; Dr Foster Intelligence, 2011, INS YOUR HOSP FOST H, P19; Joynt KE, 2011, ANN INTERN MED, V154, P94, DOI 10.7326/0003-4819-154-2-201101180-00008; McQuillan P, 1998, BMJ-BRIT MED J, V316, P1853; Moore S, 2006, CLIN MED, V6, P286, DOI 10.7861/clinmedicine.6-3-286; National Confidential Enquiry into Patient Outcome and Death, 2007, EMERGENCY ADMISSIONS; National Confidential Enquiry into Patient Outcome and Death (NCEPOD), 2005, AC PROBL REP NAT CON; NHS Staff - 2001-2011, 2001, MED DENT DET VIEW NH; NHS-London, 2011, AD EM SERV AC MED EM; Office for National Statistics, 2014, SUP OUTP AR; Payne RA, 2012, HLTH STAT Q      SPR; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Ross JS, 2010, NEW ENGL J MED, V362, P1110, DOI 10.1056/NEJMsa0907130; Royal College of Physicians (London), 2010, EV CONS INP AC MED A; Schmulewitz L, 2005, CLIN MED, V5, P621, DOI 10.7861/clinmedicine.5-6-621; Scott I, 2009, INT J QUAL HEALTH C, V21, P397, DOI 10.1093/intqhc/mzp045; Seward E, 2003, CLIN MED, V3, P425, DOI 10.7861/clinmedicine.3-5-425	21	53	53	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e61476	10.1371/journal.pone.0061476	http://dx.doi.org/10.1371/journal.pone.0061476			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IK	23613858	Green Published, Green Submitted, gold			2023-01-03	WOS:000317907200058
J	de Roode, JC; Lefevre, T; Hunter, MD				de Roode, Jacobus C.; Lefevre, Thierry; Hunter, Mark D.			Self-Medication in Animals	SCIENCE			English	Editorial Material							TOXINS; RESIN		[de Roode, Jacobus C.] Emory Univ, Dept Biol, Atlanta, GA 30322 USA; [Lefevre, Thierry] Inst Rech Dev, Malad Infect & Vecteurs Ecol Genet Evolut Control, F-34394 Montpellier, France; [Hunter, Mark D.] Univ Michigan, Dept Ecol & Evolutionary Biol, Ann Arbor, MI 48109 USA	Emory University; Institut de Recherche pour le Developpement (IRD); University of Michigan System; University of Michigan	de Roode, JC (corresponding author), Emory Univ, Dept Biol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	jderood@emory.edu	Lefèvre, Thierry/E-2157-2011	Lefèvre, Thierry/0000-0002-9736-6142; Hunter, Mark/0000-0003-3761-8237				Castella G, 2008, ANIM BEHAV, V75, P1591, DOI 10.1016/j.anbehav.2007.10.014; de Roode JC, 2011, J EVOLUTION BIOL, V24, P712, DOI 10.1111/j.1420-9101.2010.02213.x; FOSTER MA, 1992, J ANIM ECOL, V61, P509, DOI 10.2307/5606; Greischar MA, 2007, ECOL LETT, V10, P418, DOI 10.1111/j.1461-0248.2007.01028.x; Huffman MA, 2003, P NUTR SOC, V62, P371, DOI 10.1079/PNS2003257; Janzen D.H., 1978, P73; Kacsoh BZ, 2013, SCIENCE, V339, P947, DOI 10.1126/science.1229625; Lefevre T, 2010, ECOL LETT, V13, P1485, DOI 10.1111/j.1461-0248.2010.01537.x; Lozano GA, 1998, ADV STUD BEHAV, V27, P291; Milan NF, 2012, CURR BIOL, V22, P488, DOI 10.1016/j.cub.2012.01.045; Raberg L, 2007, SCIENCE, V318, P812, DOI 10.1126/science.1148526; Raubenheimer D, 2009, INTEGR COMP BIOL, V49, P329, DOI 10.1093/icb/icp050; Simone-Finstrom M, 2010, APIDOLOGIE, V41, P295, DOI 10.1051/apido/2010016; Singer MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004796; Suarez-Rodriguez M, 2013, BIOL LETTERS, V9, DOI 10.1098/rsbl.2012.0931	15	152	154	5	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2013	340	6129					150	151		10.1126/science.1235824	http://dx.doi.org/10.1126/science.1235824			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122TQ	23580516				2023-01-03	WOS:000317341400040
J	Yoshida, C; Tsuji, AB; Sudo, H; Sugyo, A; Kikuchi, T; Koizumi, M; Arano, Y; Saga, T				Yoshida, Chisato; Tsuji, Atsushi B.; Sudo, Hitomi; Sugyo, Aya; Kikuchi, Tatsuya; Koizumi, Mitsuru; Arano, Yasushi; Saga, Tsuneo			Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer	PLOS ONE			English	Article							MESYLATE LACKS ACTIVITY; IMATINIB MESYLATE; PHASE-II; GROWTH; PROTEIN; INHIBITION; EXPRESSION; MUTATIONS; SURVIVAL; SCLC	Small cell lung cancer (SCLC) is an aggressive tumor and prognosis remains poor. Therefore, the development of more effective therapy is needed. We previously reported that high levels of an anti-c-kit antibody (12A8) accumulated in SCLC xenografts. In the present study, we evaluated the efficacy of two antibodies (12A8 and 67A2) for radioimmunotherapy (RIT) of an SCLC mouse model by labeling with the Y-90 isotope. Methods: In-111- or I-125-labeled antibodies were evaluated in vitro by cell binding, competitive inhibition and cellular internalization assays in c-kit-expressing SY cells and in vivo by biodistribution in SY-bearing mice. Therapeutic efficacy of Y-90-labeled antibodies was evaluated in SY-bearing mice upto day 28 and histological analysis was conducted at day 7. Results: [In-111]12A8 and [In-111]67A2 specifically bound to SY cells with high affinity (8.0 and 1.9 nM, respectively). 67A2 was internalized similar to 12A8. High levels of [In-111]12A8 and [In-111]67A2 accumulated in tumors, but not in major organs. [In-111]67A2 uptake by the tumor was 1.7 times higher than for [In-111]12A8. [Y-90]12A8, but not [Y-90]67A2, suppressed tumor growth in a dose-dependent manner. Tumors treated with 3.7 MBq of [Y-90]12A8, and 1.85 and 3.7 MBq of [Y-90]67A2 (absorbed doses were 21.0, 18.0 and 35.9 Gy, respectively) almost completely disappeared approximately 2 weeks after injection, and regrowth was not observed except for in one mouse treated with 1.85 MBq [Y-90]67A2. The area of necrosis and fibrosis increased depending on the RIT effect. Apoptotic cell numbers increased with increased doses of [Y-90]12A8, whereas no dose-dependent increase was observed following [Y-90]67A2 treatment. Body weight was temporarily reduced but all mice tolerated the RIT experiments well. Conclusion: Treatment with [Y-90]12A8 and [Y-90]67A2 achieved a complete therapeutic response when SY tumors received an absorbed dose greater than 18 Gy and thus are promising RIT agents for metastatic SCLC cells at distant sites.	[Yoshida, Chisato; Tsuji, Atsushi B.; Sudo, Hitomi; Sugyo, Aya; Koizumi, Mitsuru; Saga, Tsuneo] Natl Inst Radiol Sci, Mol Imaging Ctr, Diagnost Imaging Program, Chiba 260, Japan; [Yoshida, Chisato; Arano, Yasushi] Chiba Univ, Grad Sch Pharmaceut Sci, Dept Mol Imaging & Radiotherapy, Chiba, Japan; [Kikuchi, Tatsuya] Natl Inst Radiol Sci, Mol Imaging Ctr, Mol Probe Program, Chiba 260, Japan	National Institutes for Quantum Science & Technology; Chiba University; National Institutes for Quantum Science & Technology	Tsuji, AB (corresponding author), Natl Inst Radiol Sci, Mol Imaging Ctr, Diagnost Imaging Program, Chiba 260, Japan.	a_tsuji@nirs.go.jp	TSUJI, Atsushi B/I-9922-2019	TSUJI, Atsushi B/0000-0003-2726-288X; Kikuchi, Tatsuya/0000-0003-2966-3126	National Institute of Radiological Sciences	National Institute of Radiological Sciences	This study was funded by National Institute of Radiological Sciences to TS. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altundag O, 2005, CANCER, V104, P2033, DOI 10.1002/cncr.21407; Blackhall FH, 2007, CURR OPIN ONCOL, V19, P103, DOI 10.1097/CCO.0b013e328011bec3; Burger H, 2003, EUR J CANCER, V39, P793, DOI 10.1016/S0959-8049(03)00026-1; Cheson BD, 2003, BLOOD, V101, P391, DOI 10.1182/blood-2002-06-1793; Chute JP, 1997, MAYO CLIN PROC, V72, P901; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Eckerman EF, 2010, MIRD RADIONUCLIDE DA; El Maalouf Ghassan, 2007, Lung Cancer, V57 Suppl 2, pS30, DOI 10.1016/S0169-5002(07)70425-7; Elias AD, 1997, CHEST, V112, pS251, DOI 10.1378/chest.112.4_Supplement.251S; Fischer B, 2007, CANCER TREAT REV, V33, P391, DOI 10.1016/j.ctrv.2007.01.006; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HIBI K, 1991, ONCOGENE, V6, P2291; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Johnson BE, 2003, CLIN CANCER RES, V9, P5880; Kassis AI, 2008, SEMIN NUCL MED, V38, P358, DOI 10.1053/j.semnuclmed.2008.05.002; Kitamura Y, 2004, CELL MOL LIFE SCI, V61, P2924, DOI 10.1007/s00018-004-4273-y; Krug LM, 2005, CANCER, V103, P2128, DOI 10.1002/cncr.21000; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lebitasy MP, 2001, BRIT J CANCER, V85, P808, DOI 10.1054/bjoc.2001.1955; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; Lloyd Katherine P, 2002, Clin Lung Cancer, V3, P213, DOI 10.3816/CLC.2002.n.005; Loke KS, 2012, WORLD J NUCL MED, V10, P122; PACKER AI, 1995, MOL REPROD DEV, V42, P303, DOI 10.1002/mrd.1080420307; Pouget JP, 2011, NAT REV CLIN ONCOL, V8, P720, DOI 10.1038/nrclinonc.2011.160; Regan JL, 2012, ONCOGENE, V31, P869, DOI 10.1038/onc.2011.289; Ronnstrand L, 2004, CELL MOL LIFE SCI, V61, P2535, DOI 10.1007/s00018-004-4189-6; SAGA T, 1991, CANCER RES, V51, P990; Saga T, 1997, JPN J CANCER RES, V88, P1171, DOI 10.1111/j.1349-7006.1997.tb00346.x; SEIFTER EJ, 1988, SEMIN ONCOL, V15, P278; SEKIDO Y, 1991, CANCER RES, V51, P2416; Sharkey RM, 2011, IMMUNOTHERAPY-UK, V3, P349, DOI 10.2217/IMT.10.114; Sihto H, 2005, J CLIN ONCOL, V23, P49, DOI 10.1200/JCO.2005.02.093; Slotman B, 2007, NEW ENGL J MED, V357, P664, DOI 10.1056/NEJMoa071780; Sogawa C, 2010, NUCL MED BIOL, V37, P179, DOI 10.1016/j.nucmedbio.2009.10.008; Sudo H, 2012, CANCER SCI, V103, P203, DOI 10.1111/j.1349-7006.2011.02126.x; Tolvanen T, 2010, EUR J NUCL MED MOL I, V37, P874, DOI 10.1007/s00259-009-1346-z; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Yoshida C, 2011, NUCL MED BIOL, V38, P331, DOI 10.1016/j.nucmedbio.2010.10.005; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055	39	26	28	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2013	8	3							e59248	10.1371/journal.pone.0059248	http://dx.doi.org/10.1371/journal.pone.0059248			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	109YM	23516616	Green Published, gold, Green Submitted			2023-01-03	WOS:000316407400101
J	Gysels, M; Evans, N; Menaca, A; Higginson, IJ; Harding, R; Pool, R				Gysels, Marjolein; Evans, Natalie; Menaca, Arantza; Higginson, Irene J.; Harding, Richard; Pool, Robert		Project PRISMA	Diversity in Defining End of Life Care: An Obstacle or the Way Forward?	PLOS ONE			English	Article							PALLIATIVE-CARE; DEFINITIONS; PERSPECTIVE; ADVANCE	Aim: The terms used to describe care at the end of life (EoL), and its definitions, have evolved over time and reflect the changes in meaning the concept has undergone as the field develops. We explore the remit of EoL care as defined by experts in EoL care, from across Europe and beyond, to understand its current usage and meanings. Method: A qualitative survey attached to a call for expertise on cultural issues in EoL care was sent to experts in the field identified through the literature, European EoL care associations, and conferences targeted at EoL care professionals. Respondents were asked to identify further contacts for snowball recruitment. The responses were analysed using content and discourse analysis. Results: Responses were received from 167 individuals (33% response rate), mainly from academics (39%) and clinical practitioners working in an academic context (23%) from 19 countries in Europe and beyond. 29% of respondents said explicitly that there was no agreed definition of EoL care in practice and only 14% offered a standard definition (WHO, or local institution). 2% said that the concept of EoL care was not used in their country, and 5% said that there was opposition to the concept for religious or cultural reasons. Two approaches were identified to arrive at an understanding of EoL care: exclusively by drawing boundaries through setting time frames, and inclusively by approaching its scope in an integrative way. This led to reflections about terminology and whether defining EoL care is desirable. Conclusion: The global expansion of EoL care contributes to the variety of interpretations of what it means. This complicates the endeavour of defining the field. However, when diversity is taken seriously it can open up new perspectives to underpin the ethical framework of EoL care.	[Gysels, Marjolein; Pool, Robert] Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands; [Gysels, Marjolein; Higginson, Irene J.; Harding, Richard] Kings Coll London, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England; [Gysels, Marjolein; Menaca, Arantza; Pool, Robert] Univ Barcelona, Barcelona Ctr Int Hlth Res, Barcelona, Spain; [Evans, Natalie] Vrije Univ Amsterdam, Dept Publ & Occupat Hlth, Emgo Inst Hlth & Care Res, Expertise Ctr Palliat Care,Med Ctr, Amsterdam, Netherlands	University of Amsterdam; University of London; King's College London; ISGlobal; CRESIB; University of Barcelona; Vrije Universiteit Amsterdam	Gysels, M (corresponding author), Univ Amsterdam, Ctr Social Sci & Global Hlth, Amsterdam, Netherlands.	mhgysels@gmail.com	Evans, Natalie/M-1631-2013; Daveson, Barbara A/G-3122-2012; Murtagh, Fliss/C-3216-2009; Higginson, Irene Julie/C-7309-2012	Evans, Natalie/0000-0001-7124-9282; Deliens, Luc/0000-0002-8158-2422; Haugen, Dagny Faksvag/0000-0002-8592-4995; Koffman, Jonathan/0000-0001-8513-5681; Harding, Richard/0000-0001-9653-8689; Murtagh, Fliss/0000-0003-1289-3726; Higginson, Irene Julie/0000-0002-3687-1313; Daveson, Barbara/0000-0001-8039-8749	European Commission FP7 [Health-F2-2008-201655]	European Commission FP7(European CommissionEuropean Commission Joint Research Centre)	Funding provided by European Commission FP7(contract number: Health-F2-2008-201655). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrew EVW, 2013, PALLIATIVE MED, V27, P131, DOI 10.1177/0269216311429619; Bernheim JL, 2008, BRIT MED J, V336, P864, DOI 10.1136/bmj.39497.397257.AD; Boldt AM, 2006, J PALLIAT MED, V9, P1128, DOI 10.1089/jpm.2006.9.1128; Borry P, 2005, BIOETHICS, V19, P49, DOI 10.1111/j.1467-8519.2005.00424.x; Chapple A, 2006, INT J NURS STUD, V43, P1011, DOI 10.1016/j.ijnurstu.2005.11.007; Cherny NI, 2009, CANCER-AM CANCER SOC, V115, P1808, DOI 10.1002/cncr.24212; Clark D, 2000, PALLIATIVE MED, V14, P479, DOI 10.1191/026921600701536408; CLARK D, 1999, REFLECTIONS PALLIATI; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Department of Health, 2008, END LIF CAR STRAT AD; Evans N, 2012, J PALLIAT MED, V15, P812, DOI 10.1089/jpm.2011.0526; Evans N, 2012, PATIENT EDUC COUNS, V87, P277, DOI 10.1016/j.pec.2011.10.004; Evans N, 2012, J PAIN SYMPTOM MANAG, V43, P261, DOI 10.1016/j.jpainsymman.2011.04.012; Evans N, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-141; Fadul N, 2009, CANCER-AM CANCER SOC, V115, P2013, DOI 10.1002/cncr.24206; Gott M, 2012, PALLIATIVE MED, V26, P232, DOI 10.1177/0269216311408993; Griffiths J., 1998, EUTHANASIA LAW NETHE; Gysels M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034188; HAMILTON J, 1995, CAN MED ASSOC J, V153, P334; Harding R, 2010, EUR J CANCER, V46, P1493, DOI 10.1016/j.ejca.2010.01.035; Hermsen MA, 2001, PALLIATIVE MED, V15, P425, DOI 10.1191/026921601680419483; Hui D, 2012, J PAIN SYMPTOM MANAG, V43, P582, DOI 10.1016/j.jpainsymman.2011.04.016; Kleinman A, 2009, LANCET, V373, P292, DOI 10.1016/S0140-6736(09)60087-8; Larkin PJ, 2008, NURS ETHICS, V15, P234, DOI 10.1177/0969733007086021; Lorenz K, 2004, END OF LIFE CARE OUT; Lynn J, 2003, LIVING WELL END LIFE; Menaca A, 2011, CRITICAL REV ONCOLOG, DOI [10.1177/0269216311429619, DOI 10.1177/0269216311429619]; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Pastrana T, 2008, PALLIATIVE MED, V22, P222, DOI 10.1177/0269216308089803; Putnam RD, 1998, HOUS POLICY DEBATE, V9, pV; Saunders, 1964, NEED I CARE PATIENT, P1; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; Shipman C, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1720; St John of God Health Care, 2019, OUR VIS; The A-M, 2010, VERLOSSERS NAAST GOD; Walshe C, 2011, DIET AND NUTRITION IN PALLIATIVE CARE, P17; World Health Organisation, WHO DEF PALL CAR	37	22	22	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 3	2013	8	7							e68002	10.1371/journal.pone.0068002	http://dx.doi.org/10.1371/journal.pone.0068002			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	182HT	23844145	Green Published, Green Submitted, gold			2023-01-03	WOS:000321733000124
J	Milburn, JA; Ford, I; Mutch, NJ; Fluck, N; Brittenden, J				Milburn, James A.; Ford, Isobel; Mutch, Nicola J.; Fluck, Nicholas; Brittenden, Julie			Thrombin-Anti-Thrombin Levels and Patency of Arterio-Venous Fistula in Patients Undergoing Haemodialysis Compared to Healthy Volunteers: A Prospective Analysis	PLOS ONE			English	Article							C-REACTIVE PROTEIN; PLASMINOGEN-ACTIVATOR; VASCULAR ACCESS; RISK-FACTORS; COAGULATION-FACTORS; PLATELET-FUNCTION; TISSUE FACTOR; PLASMA; ATHEROSCLEROSIS; ANTICOAGULATION	Background: Patients on haemodialysis (HD) are at an increased risk of sustaining thrombotic events especially to their vascular access which is essential for maintenance of HD. Objectives: To assess whether 1) markers of coagulation, fibrinolysis or endothelial activation are increased in patients on HD compared to controls and 2) if measurement of any of these factors could help to identify patients at increased risk of arteriovenous (AVF) access occlusion. Patients/Methods: Venous blood samples were taken from 70 patients immediately before a session of HD and from 78 resting healthy volunteers. Thrombin-antithrombin (TAT), D-dimer, von Willebrand factor (vWF), plasminogen activator inhibitor-1 antigen (PAI-1) and soluble p-selectin were measured by ELISA. C-reactive protein (hsCRP) was measured by an immunonephelometric kinetic assay. Determination of the patency of the AVF was based upon international standards and was prospectively followed up for a minimum of four years or until the AVF was non-functioning. Results: A total of 70 patients were studied with a median follow-up of 740 days (range 72-1788 days). TAT, D-dimer, vWF, p-selectin and hsCRP were elevated in patients on HD compared with controls. At one year follow-up, primary patency was 66% (46 patients). In multivariate analysis TAT was inversely associated with primary assisted patency (r=-0.250, p=0.044) and secondary patency (r=-0.267, p=0.031). Conclusions: The novel finding of this study is that in patients on haemodialysis, TAT levels were increased and inversely correlated with primary assisted patency and secondary patency. Further evaluation is required into the possible role of TAT as a biomarker of AVF occlusion.	[Milburn, James A.] Aberdeen Royal Infirm, Dept Vasc Surg, Aberdeen, Scotland; [Ford, Isobel; Mutch, Nicola J.; Brittenden, Julie] Univ Aberdeen, Div Appl Med, Aberdeen, Scotland; [Fluck, Nicholas] Aberdeen Royal Infirm, Aberdeen, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen	Milburn, JA (corresponding author), Aberdeen Royal Infirm, Dept Vasc Surg, Aberdeen, Scotland.	j.milburn@nhs.net		Mutch, Nicola/0000-0002-7452-0813	Grampian Renal Research Fund; British Heart Foundation [FS/11/02/28579]; British Heart Foundation [FS/11/2/28579] Funding Source: researchfish	Grampian Renal Research Fund; British Heart Foundation(British Heart Foundation); British Heart Foundation(British Heart Foundation)	This project was funded by the Grampian Renal Research Fund. N.J.M. was supported by the British Heart Foundation (FS/11/02/28579). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Saady NM, 1999, HEART, V81, P134, DOI 10.1136/hrt.81.2.134; Bartels PCM, 2000, SCAND J CLIN LAB INV, V60, P283, DOI 10.1080/003655100750046440; Bisoendial RJ, 2010, EUR HEART J, V31, P2087, DOI 10.1093/eurheartj/ehq238; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; Borawski J, 2001, NEPHROL DIAL TRANSPL, V16, P1442, DOI 10.1093/ndt/16.7.1442; Casonato A, 2001, CLIN APPL THROMB-HEM, V7, P81, DOI 10.1177/107602960100700201; Casserly LF, 2003, SEMIN DIALYSIS, V16, P245, DOI 10.1046/j.1525-139X.2003.16048.x; Chou CY, 2006, BLOOD PURIFICAT, V24, P342, DOI 10.1159/000092558; Covic A, 2003, J NEPHROL, V16, P476; D'Elia JA, 2005, INT J CARDIOL, V101, P19, DOI 10.1016/j.ijcard.2004.03.007; Da Silva A, 2008, COCHRANE DB SYST REV, V4; Darlington A, 2011, THROMB HAEMOSTASIS, V106, P67, DOI 10.1160/TH10-12-0785; DeMarchi S, 1996, J AM SOC NEPHROL, V7, P1169; Erdem Y, 1996, NEPHROL DIAL TRANSPL, V11, P1299; Feldman HI, 1996, J AM SOC NEPHROL, V7, P523; GREAVES M, 1987, DIABETOLOGIA, V30, P160, DOI 10.1007/BF00274221; Gyongyosi M, 2004, AM HEART J, V147, P158, DOI 10.1016/j.ahj.2003.07.015; Hakim R, 1998, KIDNEY INT, V54, P1029, DOI 10.1046/j.1523-1755.1998.00122.x; Haznedaroglu IC, 1996, BLOOD PURIFICAT, V14, P227, DOI 10.1159/000170265; Huijbregts HJT, 2008, CLIN J AM SOC NEPHRO, V3, P714, DOI 10.2215/CJN.02950707; Hutchinson WL, 2000, CLIN CHEM, V46, P934; Inoue A, 2000, CLIN APPL THROMB-HEM, V6, P100, DOI 10.1177/107602960000600210; Kadir RA, 1999, THROMB HAEMOSTASIS, V82, P1456; Kirmizis D, 2006, MED SCI MONITOR, V12, pCR55; Malyszko J, 1996, THROMB RES, V83, P351, DOI 10.1016/0049-3848(96)00145-4; Milburn JA, 2012, INT J LAB HEMATOL, V34, P52, DOI 10.1111/j.1751-553X.2011.01356.x; Milburn JA, 2011, INT J ARTIF ORGANS, V34, P280, DOI 10.5301/IJAO.2011.6469; Muller I, 2002, PATHOPHYSIOL HAEMO T, V32, P16, DOI 10.1159/000057284; Oda H, 2000, Adv Perit Dial, V16, P152; Paffen E, 2006, CARDIOVASC RES, V71, P30, DOI 10.1016/j.cardiores.2006.03.004; Pawlak K, 2007, THROMB RES, V119, P475, DOI 10.1016/j.thromres.2006.03.011; Rao AK, 2006, THROMB HAEMOSTASIS, V96, P738, DOI 10.1160/TH06-08-0451; Sadosty AT, 2001, J EMERG MED, V21, P423, DOI 10.1016/S0736-4679(01)00408-5; Sagedal S, 2001, NEPHROL DIAL TRANSPL, V16, P987, DOI 10.1093/ndt/16.5.987; Salobir B, 2008, THER APHER DIAL, V12, P133, DOI 10.1111/j.1744-9987.2008.00558.x; Segarra A, 2001, J AM SOC NEPHROL, V12, P1255, DOI 10.1681/ASN.V1261255; Sidawy AN, 2002, J VASC SURG, V35, P603, DOI 10.1067/mva.2002.122025; Sioulis A, 2009, HIPPOKRATIA, V13, P237; Stolic RV, 2008, INT UROL NEPHROL, V40, P503, DOI 10.1007/s11255-007-9321-8; Trimarchi H, 2008, J VASC ACCESS, V9, P142, DOI 10.1177/112972980800900212	40	14	18	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2013	8	7							e67799	10.1371/journal.pone.0067799	http://dx.doi.org/10.1371/journal.pone.0067799			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176XV	23844096	Green Published, gold, Green Submitted			2023-01-03	WOS:000321341000099
J	Stanworth, SJ; Estcourt, LJ; Powter, G; Kahan, BC; Dyer, C; Choo, L; Bakrania, L; Llewelyn, C; Littlewood, T; Soutar, R; Norfolk, D; Copplestone, A; Smith, N; Kerr, P; Jones, G; Raj, K; Westerman, DA; Szer, J; Jackson, N; Bardy, PG; Plews, D; Lyons, S; Bielby, L; Wood, EM; Murphy, MF				Stanworth, Simon J.; Estcourt, Lise J.; Powter, Gillian; Kahan, Brennan C.; Dyer, Claire; Choo, Louise; Bakrania, Lekha; Llewelyn, Charlotte; Littlewood, Timothy; Soutar, Richard; Norfolk, Derek; Copplestone, Adrian; Smith, Neil; Kerr, Paul; Jones, Gail; Raj, Kavita; Westerman, David A.; Szer, Jeffrey; Jackson, Nicholas; Bardy, Peter G.; Plews, Dianne; Lyons, Simon; Bielby, Linley; Wood, Erica M.; Murphy, Michael F.		TOPPS Investigators	A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANCIES; TRIAL	BACKGROUND The effectiveness of platelet transfusions to prevent bleeding in patients with hematologic cancers remains unclear. This trial assessed whether a policy of not giving prophylactic platelet transfusions was as effective and safe as a policy of providing prophylaxis. METHODS We conducted this randomized, open-label, noninferiority trial at 14 centers in the United Kingdom and Australia. Patients were randomly assigned to receive, or not to receive, prophylactic platelet transfusions when morning platelet counts were less than 10x10(9) per liter. Eligible patients were persons 16 years of age or older who were receiving chemotherapy or undergoing stem-cell transplantation and who had or were expected to have thrombocytopenia. The primary end point was bleeding of World Health Organization (WHO) grade 2, 3, or 4 up to 30 days after randomization. RESULTS A total of 600 patients (301 in the no-prophylaxis group and 299 in the prophylaxis group) underwent randomization between 2006 and 2011. Bleeding of WHO grade 2, 3, or 4 occurred in 151 of 300 patients (50%) in the no-prophylaxis group, as compared with 128 of 298 (43%) in the prophylaxis group (adjusted difference in proportions, 8.4 percentage points; 90% confidence interval, 1.7 to 15.2; P = 0.06 for noninferiority). Patients in the no-prophylaxis group had more days with bleeding and a shorter time to the first bleeding episode than did patients in the prophylaxis group. Platelet use was markedly reduced in the no-prophylaxis group. A prespecified subgroup analysis identified similar rates of bleeding in the two study groups among patients undergoing autologous stem-cell transplantation. CONCLUSIONS The results of our study support the need for the continued use of prophylaxis with platelet transfusion and show the benefit of such prophylaxis for reducing bleeding, as compared with no prophylaxis. A significant number of patients had bleeding despite prophylaxis. (Funded by the National Health Service Blood and Transplant Research and Development Committee and the Australian Red Cross Blood Service; TOPPS Controlled-Trials. com number, ISRCTN08758735.)	[Stanworth, Simon J.; Estcourt, Lise J.; Powter, Gillian; Dyer, Claire; Murphy, Michael F.] John Radcliffe Hosp, NHS Blood & Transplant, Oxford Univ Hosp NHS Trust, Oxford OX3 9BQ, England; [Stanworth, Simon J.; Estcourt, Lise J.; Murphy, Michael F.] Univ Oxford, Nuffield Dept Med, Oxford, England; [Littlewood, Timothy] Churchill Hosp, Oxford Univ Hosp NHS Trust, Oxford OX3 7LJ, England; [Kahan, Brennan C.; Choo, Louise] MRC, Clin Trials Unit, London, England; [Raj, Kavita] Guys & St Thomas Hosp, London SE1 9RT, England; [Powter, Gillian; Dyer, Claire; Bakrania, Lekha; Llewelyn, Charlotte] MRC, Clin Studies Unit, NHS Blood & Transplant, Cambridge, England; [Soutar, Richard] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Norfolk, Derek] Leeds Teaching Hosp, Leeds, W Yorkshire, England; [Copplestone, Adrian] Plymouth Derriford Hosp, Plymouth, Devon, England; [Smith, Neil] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; [Kerr, Paul] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; [Jones, Gail] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England; [Jackson, Nicholas] Univ Hosp, Coventry, W Midlands, England; [Plews, Dianne] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [Lyons, Simon] Sunderland City Hosp, Sunderland, England; [Westerman, David A.; Wood, Erica M.] Peter MacCallum Canc Ctr, East Melbourne, Vic, Australia; [Szer, Jeffrey; Wood, Erica M.] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Bielby, Linley; Wood, Erica M.] Australian Red Cross Blood Serv, Melbourne, Vic, Australia; [Bardy, Peter G.] Royal Adelaide Hosp, Adelaide, SA 5000, Australia	Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; Medical Research Council Clinical Trials Unit; Guy's & St Thomas' NHS Foundation Trust; Beatson Oncology Centre; University of Leeds; Derriford Hospital; Heart of England NHS Foundation Trust; University of Birmingham; University of Exeter; Newcastle Freeman Hospital; Newcastle University - UK; University of Warwick; James Cook University Hospital; Peter Maccallum Cancer Center; Royal Melbourne Hospital; Australian Red Cross Blood Service; Royal Adelaide Hospital	Stanworth, SJ (corresponding author), John Radcliffe Hosp, NHS Blood & Transplant, Level 2, Oxford OX3 9BQ, England.		Estcourt, Lise/B-6995-2013; Jackson, Nicholas/A-4609-2016; Wood, Erica M/I-1956-2014	Estcourt, Lise/0000-0003-4309-9162; Wood, Erica M/0000-0001-7527-2340; Raj, Kavita/0000-0002-8258-354X; Casbard, Angela/0000-0001-6241-3052; Choo, Louise/0000-0003-4040-1522; Szer, Jeff/0000-0001-6783-2301	National Health Service Blood and Transplant Research and Development Committee; Australian Red Cross Blood Service [ISRCTN08758735]; National Health Service Blood and Transplant Research and Development Committee [PG04-05]; Chugai Pharmaceutical; Celgene; MRC [MC_U122870183] Funding Source: UKRI; Cancer Research UK [15954] Funding Source: researchfish; Medical Research Council [MC_U122870183] Funding Source: researchfish	National Health Service Blood and Transplant Research and Development Committee; Australian Red Cross Blood Service; National Health Service Blood and Transplant Research and Development Committee; Chugai Pharmaceutical; Celgene(Bristol-Myers SquibbCelgene Corporation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Funded by the National Health Service Blood and Transplant Research and Development Committee and the Australian Red Cross Blood Service; TOPPS Controlled-Trials.com number, ISRCTN08758735.; Supported by grants from the National Health Service Blood and Transplant Research and Development Committee (PG04-05) and the Australian Red Cross Blood Service.; Dr. Soutar reports serving on an advisory board for Celgene and receiving lecture fees from Chugai Pharmaceutical. Dr. Raj reports receiving lecture fees from Celgene and travel support from Therakos, a Johnson & Johnson company. Dr. Plews reports receiving travel support from Roche. No other potential conflict of interest relevant to this article was reported.	Altman DG, 2005, BRIT MED J, V330, P843, DOI 10.1136/bmj.330.7495.843; Estcourt LJ, 2012, VOX SANG, V103, P284, DOI 10.1111/j.1423-0410.2012.01627.x; Estcourt L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004269.pub3; Estcourt LJ, 2013, TRANSFUSION; Heddle NM, 2011, TRANSFUSION, V51, P430, DOI 10.1111/j.1537-2995.2010.02982.x; Heddle NM, 2009, BLOOD, V113, P1564, DOI 10.1182/blood-2008-09-178236; HIGBY DJ, 1974, TRANSFUSION, V14, P440, DOI 10.1111/j.1537-2995.1974.tb04558.x; Jones B, 1996, BRIT MED J, V313, P550; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Kahan BC, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5840; Kahan BC, 2012, STAT MED, V31, P328, DOI 10.1002/sim.4431; Kelsey P, 2003, BRIT J HAEMATOL, V122, P10; MURPHY S, 1982, AM J HEMATOL, V12, P347, DOI 10.1002/ajh.2830120406; Rebulla P, 1997, NEW ENGL J MED, V337, P1870, DOI 10.1056/NEJM199712253372602; Schiffer CA, 2001, J CLIN ONCOL, V19, P1519, DOI 10.1200/JCO.2001.19.5.1519; Slichter SJ, 2010, NEW ENGL J MED, V362, P600, DOI 10.1056/NEJMoa0904084; Slichter Sherrill J, 2007, Hematology Am Soc Hematol Educ Program, P172, DOI 10.1182/asheducation-2007.1.172; SOLOMON J, 1978, LANCET, V1, P267; Stanworth SJ, 2010, TRANSFUS MED REV, V24, P163, DOI 10.1016/j.tmrv.2009.11.002; Stanworth SJ, 2006, VOX SANG, V91, P63, DOI 10.1111/j.1423-0410.2006.00785.x; Wandt H, 2012, LANCET, V380, P1309, DOI 10.1016/S0140-6736(12)60689-8; WHO, 1979, WHO HDB REP RES CANC; Wiens BL, 2007, CLIN TRIALS, V4, P286, DOI 10.1177/1740774507079443	23	278	284	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	2013	368	19					1771	1780		10.1056/NEJMoa1212772	http://dx.doi.org/10.1056/NEJMoa1212772			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	138WA	23656642	Bronze			2023-01-03	WOS:000318540000005
J	Bhasin, MK; Dusek, JA; Chang, BH; Joseph, MG; Denninger, JW; Fricchione, GL; Benson, H; Libermann, TA				Bhasin, Manoj K.; Dusek, Jeffery A.; Chang, Bei-Hung; Joseph, Marie G.; Denninger, John W.; Fricchione, Gregory L.; Benson, Herbert; Libermann, Towia A.			Relaxation Response Induces Temporal Transcriptome Changes in Energy Metabolism, Insulin Secretion and Inflammatory Pathways	PLOS ONE			English	Article							PROTEIN REFERENCE DATABASE; SET ENRICHMENT ANALYSIS; NF-KAPPA-B; NITRIC-OXIDE; OXIDATIVE-STRESS; PSYCHOLOGICAL STRESS; RISK-FACTORS; GENOME-WIDE; EXPRESSION; MEDITATION	The relaxation response (RR) is the counterpart of the stress response. Millennia-old practices evoking the RR include meditation, yoga and repetitive prayer. Although RR elicitation is an effective therapeutic intervention that counteracts the adverse clinical effects of stress in disorders including hypertension, anxiety, insomnia and aging, the underlying molecular mechanisms that explain these clinical benefits remain undetermined. To assess rapid time-dependent (temporal) genomic changes during one session of RR practice among healthy practitioners with years of RR practice and also in novices before and after 8 weeks of RR training, we measured the transcriptome in peripheral blood prior to, immediately after, and 15 minutes after listening to an RR-eliciting or a health education CD. Both short-term and long-term practitioners evoked significant temporal gene expression changes with greater significance in the latter as compared to novices. RR practice enhanced expression of genes associated with energy metabolism, mitochondrial function, insulin secretion and telomere maintenance, and reduced expression of genes linked to inflammatory response and stress-related pathways. Interactive network analyses of RR-affected pathways identified mitochondrial ATP synthase and insulin (INS) as top upregulated critical molecules (focus hubs) and NF-kappa B pathway genes as top downregulated focus hubs. Our results for the first time indicate that RR elicitation, particularly after long-term practice, may evoke its downstream health benefits by improving mitochondrial energy production and utilization and thus promoting mitochondrial resiliency through upregulation of ATPase and insulin function. Mitochondrial resiliency might also be promoted by RR-induced downregulation of NF-kappa B-associated upstream and downstream targets that mitigates stress.	[Bhasin, Manoj K.; Denninger, John W.; Fricchione, Gregory L.; Benson, Herbert; Libermann, Towia A.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA; [Denninger, John W.; Fricchione, Gregory L.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA; [Benson, Herbert] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA; [Bhasin, Manoj K.; Libermann, Towia A.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Interdisciplinary Med & Biotechnol, Boston, MA 02215 USA; [Bhasin, Manoj K.; Joseph, Marie G.; Libermann, Towia A.] Beth Israel Deaconess Med Ctr, BIDMC Genom & Prote Ctr, Boston, MA 02215 USA; [Dusek, Jeffery A.] Abbott NW Hosp, Inst Hlth & Healing, Minneapolis, MN 55407 USA; [Chang, Bei-Hung] VA Boston Healthcare Syst, Boston, MA USA; [Chang, Bei-Hung] Boston Univ, Dept Hlth Policy & Management, Sch Publ Hlth, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University	Libermann, TA (corresponding author), Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA.	tliberma@bidmc.harvard.edu		Bhasin, Manoj/0000-0001-5172-420X; Chang, Bei-Hung/0000-0001-9632-9713; Dusek, Jeffery/0000-0001-9581-0564; Libermann, Towia/0000-0002-4006-8179	Centers for Disease Control and Prevention (CDC) [H75/CCH123424, R01 DP000339]; National Center for Complementary and Alternative Medicine (NCCAM) [RO1 AT006464-01]; NCRR, National Institutes of Health (The Harvard-Thorndike GCRC) [M01 RR01032]; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [R01DP000339] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT006464] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR, National Institutes of Health (The Harvard-Thorndike GCRC); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The study was funded by grants H75/CCH123424 and R01 DP000339 from the Centers for Disease Control and Prevention (CDC) (HB), RO1 AT006464-01 from the National Center for Complementary and Alternative Medicine (NCCAM) (HB) and grant M01 RR01032 from the NCRR, National Institutes of Health (The Harvard-Thorndike GCRC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham NG, 2007, ANN NY ACAD SCI, V1113, P256, DOI 10.1196/annals.1391.015; Adaikalakoteswari A, 2007, ATHEROSCLEROSIS, V195, P83, DOI 10.1016/j.atherosclerosis.2006.12.003; ALEXANDER CN, 1989, J PERS SOC PSYCHOL, V57, P950, DOI 10.1037/0022-3514.57.6.950; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI 10.1164/rccm.200406-710ST; Antoni MH, 2012, BIOL PSYCHIAT, V71, P366, DOI 10.1016/j.biopsych.2011.10.007; ARCHER S, 1993, FASEB J, V7, P349, DOI 10.1096/fasebj.7.2.8440411; Astin JA, 2002, ARTHRIT RHEUM-ARTHR, V47, P291, DOI 10.1002/art.10416; BENSON H, 1978, PSYCHOTHER PSYCHOSOM, V30, P229, DOI 10.1159/000287304; BENSON H, 1974, PSYCHIATRY, V37, P37, DOI 10.1080/00332747.1974.11023785; Benson H., 1975, RELAXATION RESPONSE; Benson H., 2011, RELAXATION REVOLUTIO; Bierhaus A, 2004, PEDIATR NEPHROL, V19, P1189, DOI 10.1007/s00467-004-1603-0; Black D.S., 2012, PSYCHONEUROENDOCRINO; Chang BH, 2011, PSYCHOSOMATICS, V52, P550, DOI 10.1016/j.psym.2011.05.001; Cohen S, 2007, JAMA-J AM MED ASSOC, V298, P1685, DOI 10.1001/jama.298.14.1685; Dusek JA, 2006, MED SCI MONITOR, V12, pCR1; Dusek JA, 2008, J ALTERN COMPLEM MED, V14, P129, DOI 10.1089/acm.2007.0623; Dusek Jeffery A, 2009, Minn Med, V92, P47; Dusek JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002576; Epel E, 2009, ANN NY ACAD SCI, V1172, P34, DOI 10.1111/j.1749-6632.2009.04414.x; Epel ES, 2006, PSYCHONEUROENDOCRINO, V31, P277, DOI 10.1016/j.psyneuen.2005.08.011; Fisher RA, 1922, J R STAT SOC, V85, P87, DOI 10.2307/2340521; FREEMAN BA, 1995, AM J PHYSIOL-LUNG C, V268, pL697, DOI 10.1152/ajplung.1995.268.5.L697; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; Galluzzi L, 2012, CIRC RES, V111, P1198, DOI 10.1161/CIRCRESAHA.112.268946; Galvin Jennifer A, 2006, Complement Ther Clin Pract, V12, P186, DOI 10.1016/j.ctcp.2006.02.004; Hasegawa Y, 2012, CIRCULATION, V125, P1122, DOI 10.1161/CIRCULATIONAHA.111.054346; Hegde SV, 2011, DIABETES CARE, V34, P2208, DOI 10.2337/dc10-2430; HOFFMAN DW, 1980, J NEUROCHEM, V34, P1785, DOI 10.1111/j.1471-4159.1980.tb11279.x; Hofmann MA, 1999, DIABETOLOGIA, V42, P222, DOI 10.1007/s001250051142; Huang DW, 2007, NUCLEIC ACIDS RES, V35, pW169, DOI 10.1093/nar/gkm415; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JACOBS GD, 1993, BEHAV MODIF, V17, P498, DOI 10.1177/01454455930174005; Jacobs GD, 1996, AM J MED, V100, P212, DOI 10.1016/S0002-9343(97)89461-2; Jacobs TL, 2011, PSYCHONEUROENDOCRINO, V36, P664, DOI 10.1016/j.psyneuen.2010.09.010; Jayapandian M, 2007, NUCLEIC ACIDS RES, V35, pD566, DOI 10.1093/nar/gkl859; Lazar SW, 2000, NEUROREPORT, V11, P1581, DOI 10.1097/00001756-200005150-00041; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V201, P883, DOI 10.1006/bbrc.1994.1784; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin CY, 2008, NUCLEIC ACIDS RES, V36, pW438, DOI 10.1093/nar/gkn257; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Mitchell Brett M, 2002, Biol Res Nurs, V4, P16, DOI 10.1177/1099800402004001003; MORIN CM, 1992, SLEEP, V15, P302, DOI 10.1093/sleep/15.4.302; Morita K, 2005, NEUROSCI LETT, V381, P57, DOI 10.1016/j.neulet.2005.01.081; Mostafavi S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-s1-s4; Nagabhushan M, 2001, BRAIN BEHAV IMMUN, V15, P78, DOI 10.1006/brbi.2000.0589; Nakao M, 2001, PSYCHOTHER PSYCHOSOM, V70, P50, DOI 10.1159/000056225; Peng CK, 2004, INT J CARDIOL, V95, P19, DOI 10.1016/j.ijcard.2003.02.006; Perron NR, 2013, J BIOENERG BIOMEMBR, V45, P101, DOI 10.1007/s10863-012-9477-5; Prasad TSK, 2009, METHODS MOL BIOL, V577, P67, DOI 10.1007/978-1-60761-232-2_6; Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787; Saleh MC, 2008, DIABETES-METAB RES, V24, P392, DOI 10.1002/dmrr.819; Segman RH, 2010, MOL PSYCHIATR, V15, P93, DOI 10.1038/mp.2009.65; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stefano GB, 2001, INT J MOL MED, V7, P119; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Tamashiro KLK, 2011, ANN NY ACAD SCI, V1231, P46, DOI 10.1111/j.1749-6632.2011.06134.x; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; WALLACE RK, 1971, AM J PHYSIOL, V221, P795, DOI 10.1152/ajplegacy.1971.221.3.795; Wiederkehr A, 2006, ENDOCRINOLOGY, V147, P2643, DOI 10.1210/en.2006-0057; Wilson CL, 2005, BIOINFORMATICS, V21, P3683, DOI 10.1093/bioinformatics/bti605; Xenarios I, 2001, NUCLEIC ACIDS RES, V29, P239, DOI 10.1093/nar/29.1.239; Zangar RC, 2004, TOXICOL APPL PHARM, V199, P316, DOI 10.1016/j.taap.2004.01.018; Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697	69	137	137	1	58	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 1	2013	8	5							e62817	10.1371/journal.pone.0062817	http://dx.doi.org/10.1371/journal.pone.0062817			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	147KY	23650531	gold, Green Published, Green Submitted			2023-01-03	WOS:000319167000076
J	Eurich, DT; Simpson, S; Senthilselvan, A; Asche, CV; Sandhu-Minhas, JK; McAlister, FA				Eurich, D. T.; Simpson, S.; Senthilselvan, A.; Asche, C. V.; Sandhu-Minhas, J. K.; McAlister, F. A.			Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DIPEPTIDYL PEPTIDASE-4 INHIBITORS; INCRETIN-BASED THERAPIES; CARDIOVASCULAR OUTCOMES; ACUTE-PANCREATITIS; GLYCEMIC CONTROL; MORTALITY; METFORMIN; RISK; SULFONYLUREA; EXENATIDE	Objective To determine if the use of sitagliptin in newly treated patients with type 2 diabetes is associated with any changes in clinical outcomes. Design Retrospective population based cohort study. Setting Large national commercially insured US claims and integrated laboratory database. Participants Inception cohort of new users of oral antidiabetic drugs between 2004 and 2009 followed until death, termination of medical insurance, or December 31 2010. Main outcome measure Composite endpoint of all cause hospital admission and all cause mortality, assessed with time varying Cox proportional hazards regression after adjustment for demographics, clinical and laboratory data, pharmacy claims data, healthcare use, and time varying propensity scores. Results The cohort included 72 738 new users of oral antidiabetic drugs (8032 (11%) used sitagliptin; 7293 (91%) were taking it in combination with other agents) followed for a total of 182 409 patient years. The mean age was 52 (SD 9) years, 54% (39 573) were men, 11% (8111) had ischemic heart disease, and 9% (6378) had diabetes related complications at the time their first antidiabetic drug was prescribed. 14 215 (20%) patients met the combined endpoint. Sitagliptin users showed similar rates of all cause hospital admission or mortality to patients not using sitagliptin (adjusted hazard ratio 0.98, 95% confidence interval 0.91 to 1.06), including patients with a history of ischemic heart disease (adjusted hazard ratio 1.10, 0.94 to 1.28) and those with estimated glomerular filtration rate below 60 mL/min (1.11, 0.88 to 1.41). Conclusions Sitagliptin use was not associated with an excess risk of all cause hospital admission or death compared with other glucose lowering agents among newly treated patients with type 2 diabetes. Most patients prescribed sitagliptin in this cohort were concordant with clinical practice guidelines, in that it was used as add-on treatment.	[Eurich, D. T.; Senthilselvan, A.] Univ Alberta, Sch Publ Hlth, Dept Publ Hlth Sci, Edmonton, AB T6G 2G3, Canada; [Eurich, D. T.; Simpson, S.; Sandhu-Minhas, J. K.] Univ Alberta, Alliance Canadian Hlth Outcomes Res Diabet, Edmonton, AB T6G 2E1, Canada; [Simpson, S.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2B7, Canada; [Asche, C. V.] Univ Illinois, Coll Med Peoria, Ctr Hlth Outcomes, Peoria, IL 61656 USA; [Asche, C. V.] Univ Illinois, Coll Pharm, Dept Pharm Adm, Chicago, IL 60612 USA; [McAlister, F. A.] Univ Alberta, Fac Med & Dent, Dept Med, Edmonton, AB T6G 2B7, Canada; [McAlister, F. A.] Univ Alberta, Edmonton, AB T6G 2B7, Canada	University of Alberta; University of Alberta; University of Alberta; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Alberta; University of Alberta	Eurich, DT (corresponding author), Univ Alberta, Li Ka Shing Ctr Hlth Res Innovat 2 040, Edmonton, AB T6G 2E1, Canada.	deurich@ualberta.ca	; McAlister, Finlay/C-4151-2013	Simpson, Scot/0000-0002-9880-2129; McAlister, Finlay/0000-0001-7435-3341	Canadian Diabetes Association [OG-2-09-2691-DE]; Canadian Institutes of Health Research (CIHR) [MOP-126093]; Alberta Innovates Health Solution (AIHS); CIHR	Canadian Diabetes Association; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Alberta Innovates Health Solution (AIHS); CIHR(Canadian Institutes of Health Research (CIHR))	This work was funded by operating grants from the Canadian Diabetes Association (OG-2-09-2691-DE) and the Canadian Institutes of Health Research (CIHR) (MOP-126093). DTE receives salary support from Alberta Innovates Health Solution (AIHS) and the CIHR. FAM is a senior health scholar with AIHS. The study sponsors played no role in study design or conduct; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the paper for publication.	[Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004, 10.2337/dc12-s011]; Austin PC, 2011, MED CARE, V49, P940, DOI 10.1097/MLR.0b013e318229360e; Borah BJ, 2009, CLIN THER, V31, P623, DOI 10.1016/j.clinthera.2009.03.005; Bowker SL, 2010, DIABETOLOGIA, V53, P1631, DOI 10.1007/s00125-010-1750-8; Burgmaier M, 2013, DIABETIC MED, V30, P289, DOI 10.1111/j.1464-5491.2012.03746.x; Canadian Diabetes Association Expert Panel Committee, 2008, CAN J DIABETES, V32, pS168; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; Dore DD, 2009, CURR MED RES OPIN, V25, P1019, DOI [10.1185/03007990902820519, 10.1185/03007990902820519 ]; Drucker DJ, 2010, DIABETES CARE, V33, P428, DOI 10.2337/dc09-1499; Duh MS, 2009, AM J MANAG CARE, V15, P681; Eurich DT, 2005, DIABETES CARE, V28, P2345, DOI 10.2337/diacare.28.10.2345; Evans JMM, 2006, DIABETOLOGIA, V49, P930, DOI 10.1007/s00125-006-0176-9; Frederich R, 2010, POSTGRAD MED, V122, P16, DOI 10.3810/pgm.2010.05.2138; Garg R, 2010, DIABETES CARE, V33, P2349, DOI 10.2337/dc10-0482; Huberman M, 1999, AM J EPIDEMIOL, V150, P1340; Inzucchi SE, 2008, CIRCULATION, V117, P574, DOI 10.1161/CIRCULATIONAHA.107.735795; Johns Hopkins University, 2012, J HOPK ACG SYST; Johnson JA, 2005, DIABETIC MED, V22, P497, DOI 10.1111/j.1464-5491.2005.01448.x; Johnson JA, 2002, DIABETES CARE, V25, P2244, DOI 10.2337/diacare.25.12.2244; Lipscombe LL, 2007, JAMA-J AM MED ASSOC, V298, P2634, DOI 10.1001/jama.298.22.2634; McAlister FA, 2008, EUR J HEART FAIL, V10, P703, DOI 10.1016/j.ejheart.2008.05.013; Monami M, 2011, CURR MED RES OPIN, V27, P57, DOI 10.1185/03007995.2011.602964; National Institute for Health and Clinical Excellence, 2011, QUAL STAT 4 GLYC CON; Okerson T, 2012, CARDIOVASC THER, V30, pe146, DOI 10.1111/j.1755-5922.2010.00256.x; Patil HR, 2012, AM J CARDIOL, V110, P826, DOI 10.1016/j.amjcard.2012.04.061; Pendergrass M, 2012, DIABETES OBES METAB, V14, P596, DOI 10.1111/j.1463-1326.2012.01567.x; Penson DF, 2001, J CLIN EPIDEMIOL, V54, P350, DOI 10.1016/S0895-4356(00)00312-7; Peters A, 2010, AM J MED, V123, pS28, DOI 10.1016/j.amjmed.2009.12.007; Ranganath LR, 2008, J CLIN PATHOL, V61, P401, DOI 10.1136/jcp.2006.043232; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; Riedel AA, 2007, PHARMACOTHERAPY, V27, P1102, DOI 10.1592/phco.27.8.1102; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; Segal JB, 2007, CLIN THER, V29, P1784, DOI 10.1016/j.clinthera.2007.08.021; Simpson SH, 2006, CAN MED ASSOC J, V174, P169, DOI 10.1503/cmaj.050748; Willemen MJ, 2011, DIABETES CARE, V34, P369, DOI 10.2337/dc10-1771; Winkelmayer WC, 2008, ARCH INTERN MED, V168, P2368, DOI 10.1001/archinte.168.21.2368	36	59	62	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	2013	346								f2267	10.1136/bmj.f2267	http://dx.doi.org/10.1136/bmj.f2267			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134PN	23618722	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000318225000001
J	Maxwell, E				Maxwell, Elaine			Francis inquiry: compulsory work as healthcare assistants won't make better nurses	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Hlth Fdn, London WC2E 9RA, England		Maxwell, E (corresponding author), Hlth Fdn, London WC2E 9RA, England.	Elaine.Maxwell@health.org.uk						Aiken LH, 2008, J NURS ADMIN, V38, P223, DOI 10.1097/01.NNA.0000312773.42352.d7; Buchan J, 2012, OVERSTRETCHED UNDER; Jarman B, 1999, BMJ-BRIT MED J, V318, P1515, DOI 10.1136/bmj.318.7197.1515; Nursing and Midwifery Council, STAT AN REG 1 APR 20; Royal College of Nursing, 2012, QUAL COMP FUT NURS E	5	2	2	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 25	2013	346								f2480	10.1136/bmj.f2480	http://dx.doi.org/10.1136/bmj.f2480			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	134PN	23620583				2023-01-03	WOS:000318225000003
J	Eappen, S; Lane, BH; Rosenberg, B; Lipsitz, SA; Sadoff, D; Matheson, D; Berry, WR; Lester, M; Gawande, AA				Eappen, Sunil; Lane, Bennett H.; Rosenberg, Barry; Lipsitz, Stuart A.; Sadoff, David; Matheson, Dave; Berry, William R.; Lester, Mark; Gawande, Atul A.			Relationship Between Occurrence of Surgical Complications and Hospital Finances	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LENGTH-OF-STAY; POSTOPERATIVE COMPLICATIONS; SAFETY CHECKLIST; ADVERSE EVENTS; RISK-FACTORS; QUALITY; SURGERY; COSTS; PROGRAM; PERFORMANCE	Importance The effect of surgical complications on hospital finances is unclear. Objective To determine the relationship between major surgical complications and per-encounter hospital costs and revenues by payer type. Design, Setting, and Participants Retrospective analysis of administrative data for all inpatient surgical discharges during 2010 from a nonprofit 12-hospital system in the southern United States. Discharges were categorized by principal procedure and occurrence of 1 or more postsurgical complications, using International Classification of Diseases, Ninth Revision, diagnosis and procedure codes. Nine common surgical procedures and 10 major complications across 4 payer types were analyzed. Hospital costs and revenue at discharge were obtained from hospital accounting systems and classified by payer type. Main Outcomes and Measures Hospital costs, revenues, and contribution margin (defined as revenue minus variable expenses) were compared for patients with and without surgical complications according to payer type. Results Of 34 256 surgical discharges, 1820 patients (5.3%; 95% CI, 4.4%-6.4%) experienced 1 or more postsurgical complications. Compared with absence of complications, complications were associated with a $39 017 (95% CI, $20 069-$50 394; P<.001) higher contribution margin per patient with private insurance ($55 953 vs $16 936) and a $1749 (95% CI, $976-$3287; P<.001) higher contribution margin per patient with Medicare ($3629 vs $1880). For this hospital system in which private insurers covered 40% of patients (13 544), Medicare covered 45% (15 406), Medicaid covered 4% (1336), and self-payment covered 6% (2202), occurrence of complications was associated with an $8084 (95% CI, $4903-$9740; P<.001) higher contribution margin per patient ($15 726 vs $7642) and with a $7435 lower per-patient total margin (95% CI, $5103-$10 507; P<.001) ($1013 vs -$6422). Conclusions and Relevance In this hospital system, the occurrence of postsurgical complications was associated with a higher per-encounter hospital contribution margin for patients covered by Medicare and private insurance but a lower one for patients covered by Medicaid and who self-paid. Depending on payer mix, many hospitals have the potential for adverse near-term financial consequences for decreasing postsurgical complications. JAMA. 2013;309(15):1599-1606 www.jama.com	[Eappen, Sunil] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02115 USA; [Lane, Bennett H.; Rosenberg, Barry; Sadoff, David; Matheson, Dave] Boston Consulting Grp Inc, Boston, MA USA; [Lipsitz, Stuart A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Surg & Publ Hlth, Boston, MA 02115 USA; [Berry, William R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Lester, Mark] Texas Hlth Resources, Arlington, TX USA; [Gawande, Atul A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Gawande, Atul A.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; Boston Consulting Group (BCG); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Gawande, AA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge Bldg,Room 400, Boston, MA 02115 USA.	agawande@hsph.harvard.edu		Lane, Bennett/0000-0001-9860-2285; Gawande, Atul/0000-0002-1824-9176	Boston Consulting Group; Texas Health Resources	Boston Consulting Group; Texas Health Resources	This research was supported by funding from the Boston Consulting Group and Texas Health Resources.	Agency for Healthcare Research and Quality, 2008, HEALTHC COST UT PROJ; Andrews RM., 2011, NATL HOSP BILL MOST; Bazzoli GJ, 2003, HEALTH AFFAIR, V22, P40, DOI 10.1377/hlthaff.22.6.40; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Center for Medicare and Medicaid Services, 2010, NAT HLTH CAR EXP DAT; Centers for Medicare & Medicaid Services (CMS), HHS MED PROGR CHANG, P33; Centers for Medicare & Medicaid Services (CMS), 2008, HHS MED PROGR CHANG; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Conley DM, 2011, J AM COLL SURGEONS, V212, P873, DOI 10.1016/j.jamcollsurg.2011.01.052; Davenport DL, 2005, ANN SURG, V242, P463, DOI 10.1097/01.sla.0000183348.15117.ab; de Lissovoy G, 2009, AM J INFECT CONTROL, V37, P387, DOI 10.1016/j.ajic.2008.12.010; de Vries EN, 2010, NEW ENGL J MED, V363, P1928, DOI 10.1056/NEJMsa0911535; Delia D, 2008, HEALTH AFFAIR, V27, P1688, DOI 10.1377/hlthaff.27.6.1688; DiCiccio TJ, 1996, STAT SCI, V11, P189; Dimick JB, 2006, J AM COLL SURGEONS, V202, P933, DOI 10.1016/j.jamcollsurg.2006.02.015; Dimick JB, 2004, J AM COLL SURGEONS, V199, P531, DOI 10.1016/j.jamcollsurg.2004.05.276; Dimick JB, 2003, J AM COLL SURGEONS, V196, P671, DOI 10.1016/S1072-7515(03)00122-4; Englesbe MJ, 2007, ANN SURG, V246, P456, DOI 10.1097/SLA.0b013e31814855f2; Farley DO, 2002, MED CARE RES REV, V59, P319, DOI 10.1177/1077558702059003005; Gawande AA, 1999, SURGERY, V126, P66, DOI 10.1067/msy.1999.98664; Goodman DC, 2009, HYP IM SIGN PROC EV, P1; Gordon HS, 2005, MED CARE, V43, P159, DOI 10.1097/00005650-200502000-00009; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Horton NJ, 1999, STAT MED, V18, P213, DOI 10.1002/(SICI)1097-0258(19990130)18:2<213::AID-SIM999>3.0.CO;2-E; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Kable AK, 2002, INT J QUAL HEALTH C, V14, P269, DOI 10.1093/intqhc/14.4.269; Khan NA, 2006, J GEN INTERN MED, V21, P177, DOI 10.1111/j.1525-1497.2006.00319.x; Khuri SF, 1998, ANN SURG, V228, P491, DOI 10.1097/00000658-199810000-00006; Korn EL., 1999, ANAL HLTH SURVEYS; Krupka DC, 2012, HEALTH AFFAIR, V31, P2571, DOI 10.1377/hlthaff.2011.0605; Librero J, 2004, INT J QUAL HEALTH C, V16, P51, DOI 10.1093/intqhc/mzh008; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Medicare program, 2007, FED REGISTER, V72, P47379; Neily J, 2010, JAMA-J AM MED ASSOC, V304, P1693, DOI 10.1001/jama.2010.1506; Penel N, 2008, INT J ORAL MAX SURG, V37, P135, DOI 10.1016/j.ijom.2007.08.002; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Rajakaruna C, 2005, J THORAC CARDIOV SUR, V130, P1270, DOI 10.1016/j.jtcvs.2005.06.050; Rosenberg BL, 2005, SURGERY, V137, P285, DOI 10.1016/j.surg.2004.09.007; Rosenthal MB, 2007, NEW ENGL J MED, V357, P1573, DOI 10.1056/NEJMp078184; Schauffler HH, 2001, ANNU REV PUBL HEALTH, V22, P69, DOI 10.1146/annurev.publhealth.22.1.69; Sisko AM, 2010, HEALTH AFFAIR, V29, P1933, DOI 10.1377/hlthaff.2010.0788; The DRG Handbook, 2006, DRG HDB; Thompson DA, 2006, ANN SURG, V243, P547, DOI 10.1097/01.sla.0000207097.38963.3b; Wachter RM, 2009, NEW ENGL J MED, V361, P1401, DOI 10.1056/NEJMsb0903885; Wright SB, 2003, INFECT CONT HOSP EP, V24, P946, DOI 10.1086/502164	46	144	145	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2013	309	15					1599	1606		10.1001/jama.2013.2773	http://dx.doi.org/10.1001/jama.2013.2773			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	126FY	23592104	Green Published			2023-01-03	WOS:000317599500023
J	Rechel, B; Grundy, E; Robine, JM; Cylus, J; Mackenbach, JP; Knai, C; McKee, M				Rechel, Bernd; Grundy, Emily; Robine, Jean-Marie; Cylus, Jonathan; Mackenbach, Johan P.; Knai, Cecile; McKee, Martin			Ageing in the European Union	LANCET			English	Article							LIFE-COURSE APPROACH; HEALTH-CARE; OLDER-PEOPLE; LAST YEAR; ELDERLY POPULATION; HEART-DISEASE; EXPECTANCY; COSTS; TRENDS; AGE	The ageing of European populations presents health, long-term care, and welfare systems with new challenges. Although reports of ageing as a fundamental threat to the welfare state seem exaggerated, societies have to embrace various policy options to improve the robustness of health, long-term care, and welfare systems in Europe and to help people to stay healthy and active in old age. These policy options include prevention and health promotion, better selfcare, increased coordination of care, improved management of hospital admissions and discharges, improved systems of long-term care, and new work and pension arrangements. Ageing of the health workforce is another challenge, and policies will need to be pursued that meet the particular needs of older workers (ie, those aged 50 years or older) while recruiting young practitioners.	[Rechel, Bernd; Cylus, Jonathan; McKee, Martin] Univ London London Sch Hyg & Trop Med, European Observ Hlth Syst & Policies, London WC1H 9SH, England; [Rechel, Bernd; Knai, Cecile; McKee, Martin] Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1H 9SH, England; [Grundy, Emily] Univ Cambridge, Cambridge, England; [Robine, Jean-Marie] French Natl Inst Hlth & Med Res INSERM, Paris, France; [Cylus, Jonathan] Univ London London Sch Econ & Polit Sci, European Observ Hlth Syst & Policies, London WC2A 2AE, England; [Mackenbach, Johan P.] Univ Med Ctr Rotterdam, Erasmus MC, Rotterdam, Netherlands	European Observatory on Health Systems & Policies; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); European Observatory on Health Systems & Policies; University of London; London School Economics & Political Science; Erasmus University Rotterdam; Erasmus MC	Rechel, B (corresponding author), Univ London London Sch Hyg & Trop Med, 15-17 Tavistock Pl, London WC1H 9SH, England.	bernd.rechel@lshtm.ac.uk	McKee, Marc D/E-2187-2011; Grundy, Emily/AAC-3260-2019; Robine, Jean-Marie/F-5439-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Grundy, Emily/0000-0002-9633-1116; Robine, Jean-Marie/0000-0002-4111-6195; Mckee, Martin/0000-0002-0121-9683; Knai, Cecile/0000-0001-6663-7379; Cylus, Jonathan/0000-0001-8269-1578; Rechel, Bernd/0000-0001-8020-3956	European Observatory on Health Systems and Policies	European Observatory on Health Systems and Policies	This work has been supported by the European Observatory on Health Systems and Policies.	Angevaren M, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005381.pub3, 10.1002/14651858.CD005381.pub2]; [Anonymous], 2007, TRENDS SEVERE DISABI; [Anonymous], 2006, SECURING GOOD CARE O; Attias-Donfut C., 2003, MYTH GENERATIONAL CO, P22; Beard JR, 2010, PUBLIC HEALTH REV, V32, P427, DOI 10.1007/BF03391610; Bech M, 2011, EUR J HEALTH ECON, V12, P469, DOI 10.1007/s10198-010-0260-4; Borsch-Supan A, 2005, HLTH AGEING RETIREME, P133; Breyer F, 2006, HEALTH POLICY, V75, P178, DOI 10.1016/j.healthpol.2005.03.011; Bronnum-Hansen H, 2005, EUR J PUBLIC HEALTH, V15, P20, DOI 10.1093/eurpub/cki106; Byberg L, 2009, BMJ-BRIT MED J, V338, P688; Calfo S, 2009, LAST YEAR LIFE STUDY; Casey B., 2003, POLICIES AGEING SOC; Chen KM, 2009, INT J NURS STUD, V46, P154, DOI 10.1016/j.ijnurstu.2008.09.005; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Coyte PC, 2008, CAN SITTINGS USED PR; Dale B, 2012, SCAND J CARING SCI, V26, P113, DOI 10.1111/j.1471-6712.2011.00917.x; Daviglus ML, 2005, ARCH INTERN MED, V165, P1028, DOI 10.1001/archinte.165.9.1028; Dormont B., 2009, DEPENSES SANTE AUGME; Doyle Y., 2009, BMJ-BRIT MED J, V339, P892; Doyle YG, 2012, EUR J PUBLIC HEALTH, V22, P71, DOI 10.1093/eurpub/ckq132; Dubois C-A, 2006, HUMAN RESOURCES HLTH, P15; European Commission, 2008, LONG TERM CAR EUR UN; European Commission, 2013, EUR DAT; European Commission, 2008, GREEN PAP EUR WORKF; European Commission, 2006, COMM COMM DEM FUT EU; European Commission, 2009, 2009 AG REP EC BUDG; Eurostat, 2011, ACT AG SOL GEN STAT; Fahy N, 2011, BMJ-BRIT MED J, V342, P3815; Figueras J., 2008, HLTH SYSTEMS HLTH WE; Forster A., 2009, COCHRANE DB SYST REV, V1; Fratiglioni L, 2000, LANCET, V355, P1315, DOI 10.1016/S0140-6736(00)02113-9; Freedman VA, 2006, GERONTOLOGIST, V46, P124, DOI 10.1093/geront/46.1.124; Fries JF, 2005, AM J PREV MED, V29, P164, DOI 10.1016/j.amepre.2005.07.004; FRIES JF, 1983, MILBANK FUND Q, V61, P397, DOI 10.2307/3349864; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FUCHS VR, 1984, MILBANK FUND Q, V62, P143; Gandjour A, 2005, J HEALTH ECON, V24, P715, DOI 10.1016/j.jhealeco.2004.11.009; Gandjour A., 2008, HEALTH ECON, V18, P355; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Glei DA, 2010, INT DIFFERENCES MORT, P17; Glymour M, 2012, BMJ-BRIT MED J, V345, P10; GRUENBERG EM, 1977, MILBANK FUND Q, V55, P3, DOI 10.2307/3349592; Hakkinen U, 2008, HEALTH ECON POLICY L, V3, P165, DOI 10.1017/S174413310800443X; Hartman M, 2008, HEALTH AFFAIR, V27, pW1, DOI 10.1377/hlthaff.27.1.w1; Hillman K, 1999, MED J AUSTRALIA, V170, P325, DOI 10.5694/j.1326-5377.1999.tb127789.x; Holt-Lunstad J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000316; Hubbard RE, 2004, AGE AGEING, V33, P479, DOI 10.1093/ageing/afh164; Jagger C, 2011, GERONTOLOGIST, V51, P250; Jagger C, 2008, LANCET, V372, P2124, DOI 10.1016/S0140-6736(08)61594-9; Jagger C, 2011, INT HANDB POPUL, V2, P551, DOI 10.1007/978-90-481-9996-9_26; Kardamanidis K, 2007, MED J AUSTRALIA, V187, P383, DOI 10.5694/j.1326-5377.2007.tb01306.x; Kendrick S, 2006, EUR J POPUL, V22, P281, DOI 10.1007/s10680-006-9002-9; King AC, 2010, PUBLIC HEALTH REV, V32, P401, DOI 10.1007/BF03391609; Kohler H-P, 2003, ENCY POPULATION, P405; KRAMER M, 1980, ACTA PSYCHIAT SCAND, V62, P382, DOI 10.1111/j.1600-0447.1980.tb07714.x; Kuh D, 2012, PUBLIC HEALTH, V126, P193, DOI 10.1016/j.puhe.2012.01.025; Kuh D, 2007, J GERONTOL A-BIOL, V62, P717, DOI 10.1093/gerona/62.7.717; Laatikainen T, 2005, AM J EPIDEMIOL, V162, P764, DOI 10.1093/aje/kwi274; Lievre A, 2007, J NUTR HEALTH AGING, V11, P508; Mackenbach JP, 2011, EUR J EPIDEMIOL, V26, P903, DOI 10.1007/s10654-011-9633-y; Majer IM, 2011, OBESITY, V19, P1451, DOI 10.1038/oby.2011.46; Mangin D, 2007, BMJ-BRIT MED J, V335, P285, DOI 10.1136/bmj.39241.630741.BE1; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MANTON KG, 1982, MILBANK FUND Q, V60, P183, DOI 10.2307/3349767; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Matthews RJ, 2006, SOC SCI MED, V62, P2489, DOI 10.1016/j.socscimed.2005.11.019; McGrail K, 2000, AGE AGEING, V29, P249, DOI 10.1093/ageing/29.3.249; Mistry M, 2011, BRIT J CANCER, V105, P1795, DOI 10.1038/bjc.2011.430; MOON L, 2003, STROKE CARE OECD COU; Mura T, 2010, EUR J NEUROL, V17, P252, DOI 10.1111/j.1468-1331.2009.02783.x; Nolte E, 2008, CARING PEOPLE CHRONI; Nusselder WJ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-487; Oliveira Martins J, 2006, PROJECTING OECD HLTH; Oliveira Martins J, 2005, IMPACTS AGEING DEMAN; Olshansky S.J., 1991, J AGING HEALTH, V3, P194, DOI DOI 10.1177/089826439100300205; Organisation for Economic Co-operation and Development, 2008, LOOM CRIS HLT WORKF; Organisation for Economic Co-operation and Development, 2011, PENS GLANC; Organisation for Economic Co-operation and Development, 2010, LAB FORC STAT OECD M; Oxley H., 2009, POLICIES HLTH AGEING; Parker M, 2005, J GERONTOL A-BIOL, V60, P933; Parker MG, 2007, GERONTOLOGIST, V47, P150, DOI 10.1093/geront/47.2.150; Polder JJ, 2006, SOC SCI MED, V63, P1720, DOI 10.1016/j.socscimed.2006.04.018; PRESTON SH, 1989, DEMOGRAPHY, V26, P691, DOI 10.2307/2061266; Rathmann W, 2005, GESUNDHEITSWESEN, V67, pS110, DOI 10.1055/s-2005-858227; Rechel B., 2009, INVESTING HOSP FUTUR; Rechel B., 2010, CAN HLTH SYSTEMS RES; Rechel B, 2013, LANCET; Ritsatakis A., 2008, DEMYSTIFYING MYTHS A; Robine JM, 2009, QUAL AGEING OLDER AD, V10, P5, DOI 10.1108/14717794200900012; ROBINE JM, 1992, B WORLD HEALTH ORGAN, V70, P791; Saltman RB, 1997, EUROPEAN HLTH CARE R; Schelleman H, 2004, J HUM HYPERTENS, V18, P317, DOI 10.1038/sj.jhh.1001672; Seeman TE, 2000, AM J HEALTH PROMOT, V14, P362, DOI 10.4278/0890-1171-14.6.362; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Sihvonen AP, 1998, SOC SCI MED, V47, P303, DOI 10.1016/S0277-9536(98)00020-3; Steinberg BA, 2008, AM HEART J, V156, P719, DOI 10.1016/j.ahj.2008.05.020; Stevens JA, 2008, J SAFETY RES, V39, P345, DOI 10.1016/j.jsr.2008.05.002; Suhrcke M, 2006, BRIT MED J, V333, P1017, DOI 10.1136/bmj.38951.614144.68; The Economist, 2009, HEALTHC STRAT AG SOC; Trippel M, 2011, TRULY IMPOSSIBLE EQU; UN, REPL MIGR IS SOL DEC; van Baal PH, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-51; van Baal PHM, 2008, PLOS MED, V5, P242, DOI 10.1371/journal.pmed.0050029; van Gool CH, 2011, INT J EPIDEMIOL, V40, P1056, DOI 10.1093/ije/dyr009; Vass M, 2007, Z GERONTOL GERIATR, V40, P209, DOI 10.1007/s00391-007-0470-2; Vickerstaff S., 2011, WORK HLTH WELLBEING; Werblow A, 2007, HEALTH ECON, V16, P1109, DOI 10.1002/hec.1213; Winblad K, 2001, J CLIN EPIDEMIOL, V54, P1019; Wiskow C., 2010, CREATE ATTRACTIVE SU	109	373	376	13	183	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2013	381	9874					1312	1322		10.1016/S0140-6736(12)62087-X	http://dx.doi.org/10.1016/S0140-6736(12)62087-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	122XD	23541057				2023-01-03	WOS:000317351000034
J	Matthews, GV; Ali, RJ; Avihingsanon, A; Amin, J; Hammond, R; Bowden, S; Lewin, SR; Sasadeusz, J; Littlejohn, M; Locarnini, SL; Ruxrungtham, K; Dore, GJ				Matthews, Gail V.; Ali, Rachel J.; Avihingsanon, Anchalee; Amin, Janaki; Hammond, Rachel; Bowden, Scott; Lewin, Sharon R.; Sasadeusz, Joe; Littlejohn, Margaret; Locarnini, Stephen L.; Ruxrungtham, Kiat; Dore, Gregory J.			Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; E-ANTIGEN SEROCONVERSION; SURFACE-ANTIGEN; PEGINTERFERON ALPHA-2A; VIROLOGICAL RESPONSE; ADEFOVIR DIPIVOXIL; NATURAL-HISTORY; THERAPY; LAMIVUDINE; COMBINATION	Objective: Anti-HBe seroconversion and HBsAg loss are important therapeutic endpoints in patients with hepatitis B virus (HBV) infection. Quantitative measures of hepatitis B surface antigen (qHBsAg) and e antigen (qHBeAg) have been identified as potentially useful indicators of therapeutic response in HBV monoinfection. The aim of this study was to examine serological change including quantitative biomarkers in HIV-HBV coinfected patients initiating HBV active antiretroviral therapy (ART). Methods: HIV-HBV coinfected individuals from Thailand were followed for up to 168 weeks post ART. Rates and associations of qualitative serological change were determined. Longitudinal changes in qHBsAg and qHBeAg were measured and their utility as predictors of response examined. Results: Forty seven patients were included of whom 27 (57%) were HBeAg positive at baseline. Median CD4 count was 48 cells/mm(3). Over a median follow-up of 108 weeks 48% (13/27) lost HBeAg, 12/27 (44%) achieved anti-HBe seroconversion and 13% (6/47) HBsAg loss. Anti-HBe seroconversion was associated with higher baseline ALT (p = 0.034), lower qHBsAg (p = 0.015), lower qHBeAg (p = 0.031) and greater HBV DNA decline to week 24 (p = 0.045). Sensitivity and specificity for qHBsAg and qHBeAg decline of >0.5 log at week 12 and >1.0 log at week 24 were high for both anti-HBe seroconversion and HBsAg loss. Conclusions: Rates of serological change in these HIV-HBV coinfected individuals with advanced immunodeficiency initiating HBV-active ART were high. Baseline and on treatment factors were identified that were associated with a greater likelihood of subsequent anti-HBe seroconversion, including both quantitative HBsAg and HBeAg, suggesting these biomarkers may have utility in this clinical setting.	[Matthews, Gail V.; Ali, Rachel J.; Amin, Janaki; Dore, Gregory J.] Univ New S Wales, Kirby Inst, Sydney, NSW, Australia; [Avihingsanon, Anchalee; Ruxrungtham, Kiat] Chulongkorn Univ, Dept Med, Thai Red Cross AIDS Res Ctr, HIV NAT, Bangkok, Thailand; [Hammond, Rachel; Bowden, Scott; Littlejohn, Margaret; Locarnini, Stephen L.] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia; [Lewin, Sharon R.] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Lewin, Sharon R.] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia; [Lewin, Sharon R.] Burnet Inst, Ctr Virol, Melbourne, Vic, Australia; [Sasadeusz, Joe] Royal Melbourne Hosp, Melbourne, Vic, Australia	University of New South Wales Sydney; Kirby Institute; Chulalongkorn University; Thai Red Cross Society; Victorian Infectious Diseases Reference Laboratory; Monash University; Florey Institute of Neuroscience & Mental Health; Burnet Institute; Royal Melbourne Hospital	Matthews, GV (corresponding author), Univ New S Wales, Kirby Inst, Sydney, NSW, Australia.	gmatthews@kirby.unsw.edu.au	Lewin, Sharon/Z-3297-2019; matthews, gail/AFL-8501-2022; matthews, gail/AAG-8626-2022; Dore, Gregory John/ABD-5665-2021	Dore, Gregory John/0000-0002-4741-2622; Littlejohn, Margaret/0000-0002-8206-2664; Matthews, Gail/0000-0002-1048-6396; Amin, Janaki/0000-0003-2161-9366; Ruxrungtham, Kiat/0000-0001-7348-2352; Lewin, Sharon Ruth/0000-0002-0330-8241	Gilead sciences; Gilead; MSD; Merck; BMS; Roche; Melbourne Health; Receipt of Intellectual Property Rights/Patent Holder; National Research University Project of CHE [HR1161A]; Ministry of Education; GlaxoSmithKline; Janssen	Gilead sciences(Gilead Sciences); Gilead(Gilead Sciences); MSD; Merck(Merck & Company); BMS(Bristol-Myers Squibb); Roche(Roche Holding); Melbourne Health; Receipt of Intellectual Property Rights/Patent Holder; National Research University Project of CHE; Ministry of Education; GlaxoSmithKline(GlaxoSmithKline); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc)	Gilead sciences provided unrestricted grant support to complete quantitative testing for this study. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have read the journals policy and declare the following conflicts. Matthews GV: Grant funding: Gilead, MSD, Speakers bureau: Gilead, Roche, MSD, BMS, Janssen, Travel support: Janssen, MSD. Ali RJ: None. Avihingsanon A: None. Lewin SR: Grant funding: Gilead and Merck; Paid consultant and speaker: Gilead, Viiv Healthcare; Advisory Board: Gilead and Merck. Sasadeusz J: Gilead: research funding, meeting sponsorship, Merck: research funding, meeting sponsorship, BMS: research funding, Roche: research funding, paid speaker, advisory board. Hammond R: None. Bowden S: Speaker with honorarium for Gilead, Bristol-Myers Squibb, Roche and Merck. Littlejohn M: None. Locarnini S: Royalties - "Melbourne Health; Receipt of Intellectual Property Rights/Patent Holder -" Melbourne Health; Consulting Fees (eg. Advisory Boards) - Evivar Pty Ltd, Gilead, Bristol-Myers Squibb; Fees for Non-CME Services Received Directly from a Commercial Interest or their Agent -Bristol-Myers Squibb, Merck Sharpe and Dohme Pty Ltd. Ruxrungtham K has been awarded Senior Researcher Scholar, Thai Research Fund; The National Research University Project of CHE (HR1161A), Ministry of Education; and the Professional Research Team Strengthening Fund, from the National Science and Technology Development Agency (NSTDA), BIOTEC, Ministry of Science and Technology; Thailand. He has also served as a consultant for Merck, and Tibotec. He has been a speaker with honorarium for Bristol-Myers Squibb, Merck, Roche, Jensen-Cilag, GlaxoSmithKline, and GPO. Dore GJ: Board membership: Roche, Merck, Janssen, Gilead, BMS; Honoraria: Roche, Merck, Janssen, Gilead, BMS; Research grants: Roche, Merck, Janssen, Gilead, BMS; Scholarship: Roche, Merck, Janssen. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Ayihingsanon A, 2010, ANTIVIR THER, V15, P917, DOI 10.3851/IMP1645; BODSWORTH NJ, 1991, J INFECT DIS, V163, P1138, DOI 10.1093/infdis/163.5.1138; Brunetto MR, 2009, HEPATOLOGY, V49, P1141, DOI 10.1002/hep.22760; Cai W, 2010, J CLIN VIROL, V48, P22, DOI 10.1016/j.jcv.2010.02.014; Chang TT, 2006, NEW ENGL J MED, V354, P1001, DOI 10.1056/NEJMoa051285; Chen CH, 2004, EUR J GASTROEN HEPAT, V16, P1213, DOI 10.1097/00042737-200411000-00021; de Vries-Sluijs TEMS, 2010, GASTROENTEROLOGY, V139, P1934, DOI 10.1053/j.gastro.2010.08.045; Gane E, 2010, 61 ANN M AM ASS STUD; Heathcote EJ, 2011, GASTROENTEROLOGY, V140, P132, DOI 10.1053/j.gastro.2010.10.011; JANSSEN HLA, 1994, ANTIVIR RES, V23, P251, DOI 10.1016/0166-3542(94)90022-1; Jung YK, 2010, J CLIN GASTROENTEROL, V44, P653, DOI 10.1097/MCG.0b013e3181d52946; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lau GKK, 2005, NEW ENGL J MED, V352, P2682, DOI 10.1056/NEJMoa043470; Lee JM, 2011, HEPATOLOGY, V53, P1486, DOI 10.1002/hep.24221; Leung NWY, 2001, HEPATOLOGY, V33, P1527, DOI 10.1053/jhep.2001.25084; Liaw YF, 2003, J GASTROEN HEPATOL, V18, P246, DOI 10.1046/j.1440-1746.2003.02976.x; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; Matthews GV, 2008, HEPATOLOGY, V48, P1062, DOI 10.1002/hep.22462; Maylin S, 2012, AIDS, V26, P939, DOI 10.1097/QAD.0b013e328352224d; Miailhes P, 2007, CLIN INFECT DIS, V45, P624, DOI 10.1086/520752; Moucari R, 2009, HEPATOLOGY, V49, P1151, DOI 10.1002/hep.22744; Piratvisuth T, 2011, HEPATOL INT; Reijnders JGP, 2011, J HEPATOL, V54, P449, DOI 10.1016/j.jhep.2010.07.046; Thibault V, 2011, ANTIVIR THER, V16, P199, DOI 10.3851/IMP1723; Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1; Thompson AJV, 2010, HEPATOLOGY, V51, P1933, DOI 10.1002/hep.23571; Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018; Yuen MF, 2003, GUT, V52, P416, DOI 10.1136/gut.52.3.416	28	37	38	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2013	8	4							e61297	10.1371/journal.pone.0061297	http://dx.doi.org/10.1371/journal.pone.0061297			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JB	23593455	Green Published, Green Submitted, gold			2023-01-03	WOS:000317909600102
J	Yu, YL; Chou, RH; Liang, JH; Chang, WJ; Su, KJ; Tseng, YJ; Huang, WC; Wang, SC; Hung, MC				Yu, Yung-Luen; Chou, Ruey-Hwang; Liang, Jia-Hong; Chang, Wei-Jung; Su, Kuo-Jung; Tseng, Yen-Ju; Huang, Wei-Chien; Wang, Shao-Chun; Hung, Mien-Chie			Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides	PLOS ONE			English	Article							NUCLEAR ANTIGEN PCNA; INVASIVE DUCTAL CARCINOMA; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PROGNOSTIC-FACTOR; EXPRESSION; TRANSLOCATION; ANGIOGENESIS; REPLICATION; COMBINATION	Tyrosine 211 (Y211) phosphorylation of proliferation cell nuclear antigen (PCNA) coincides with pronounced cancer cell proliferation and correlates with poor survival of breast cancer patients. In epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant cells, both nuclear EGFR (nEGFR) expression and PCNA Y211 phosphorylation are increased. Moreover, the resistance to EGFR TKI is a major clinical problem in treating EGFR-overexpressing triple-negative breast cancer (TNBC). Thus, effective treatment to combat resistance is urgently needed. Here, we show that treatment of cell-penetrating PCNA peptide (CPPP) inhibits growth and induces apoptosis of human TNBC cells. The Y211F CPPP specifically targets EGFR and competes directly for PCNA tyrosine Y211 phosphorylation and prevents nEGFR from binding PCNA in vivo; it also suppresses tumor growth by sensitizing EGFR TKI resistant cells, which have enhanced nEGFR function and abrogated classical EGFR membrane signaling. Furthermore, we identify an active motif of CPPP, RFLNFF (RF6 CPPP), which is necessary and sufficient to inhibit TKI-resistant TNBC cell growth of orthotopic implanted tumor in mice. Finally, the activity of its synthetic retro-inverted derivative, D-RF6 CPPP, on an equimolar basis, is more potent than RF6 CPPP. Our study reveals a drug candidate with translational potential for the future development of safe and effective therapeutic for EGFR TKI resistance in TNBC.	[Yu, Yung-Luen; Chou, Ruey-Hwang; Liang, Jia-Hong; Chang, Wei-Jung; Su, Kuo-Jung; Tseng, Yen-Ju; Huang, Wei-Chien; Hung, Mien-Chie] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Yu, Yung-Luen; Chou, Ruey-Hwang; Liang, Jia-Hong; Chang, Wei-Jung; Su, Kuo-Jung; Tseng, Yen-Ju; Huang, Wei-Chien; Hung, Mien-Chie] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Yu, Yung-Luen; Chou, Ruey-Hwang] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Su, Kuo-Jung] China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung, Taiwan; [Wang, Shao-Chun] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH USA; [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; China Medical University Taiwan; University System of Ohio; University of Cincinnati; University of Texas System; UTMD Anderson Cancer Center	Yu, YL (corresponding author), China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan.	ylyu@mail.cmu.edu.tw; mhung@mdanderson.org	Chou, Ruey-Hwang/K-8541-2013; Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019; Huang, Wei-Chien/H-3126-2019; Huang, Wei-Chien/D-1740-2012	Chou, Ruey-Hwang/0000-0002-2297-2180; Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682; Huang, Wei-Chien/0000-0001-6467-8716; Huang, Wei-Chien/0000-0001-6467-8716	National Institutes of Health [RO1 CA109311, PO1 CA099031, DMR-101-115, NSC99-2320-B-039-030-MY3, NSC99-2632-B-039-001-MY3, NSC101-2321-B-039, NSC101-2311-B-039-001, NSC101-2320-B-039-048, NSC102-2911-I-002-303, NHRI-EX102-10245BI, DOH102-TD-B-111-004, DOH102-TD-C-111-005, CMU100-N2-09]; NATIONAL CANCER INSTITUTE [P01CA099031, R01CA109311] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the following grants: National Institutes of Health (RO1 CA109311 and PO1 CA099031), DMR-101-115, NSC99-2320-B-039-030-MY3, NSC99-2632-B-039-001-MY3, NSC101-2321-B-039, NSC101-2311-B-039-001, NSC101-2320-B-039-048, NSC102-2911-I-002-303, NHRI-EX102-10245BI, DOH102-TD-B-111-004, DOH102-TD-C-111-005, CMU100-N2-09. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AALTOMAA S, 1993, ANTICANCER RES, V13, P533; Baselga J, 2005, J CLIN ONCOL, V23, P5323, DOI 10.1200/JCO.2005.08.326; Bitler BG, 2009, CLIN CANCER RES, V15, P100, DOI 10.1158/1078-0432.CCR-08-1745; Bukholm IRK, 2003, J CLIN PATHOL, V56, P368, DOI 10.1136/jcp.56.5.368; Cardo-Vila M, 2010, P NATL ACAD SCI USA, V107, P5118, DOI 10.1073/pnas.0915146107; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017844, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0024144]; Chu JS, 1998, CANCER LETT, V131, P145, DOI 10.1016/S0304-3835(98)00118-9; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Grossi F, 2003, EUR J CANCER, V39, P1242, DOI 10.1016/S0959-8049(03)00232-6; Heimann R, 1997, CANCER J, V3, P224; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Huo LF, 2010, P NATL ACAD SCI USA, V107, P16125, DOI 10.1073/pnas.1000743107; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kato, 1999, Breast Cancer, V6, P370, DOI 10.1007/BF02966456; Kato T, 2003, BRIT J CANCER, V88, P1900, DOI 10.1038/sj.bjc.6600921; Korsching E, 2008, J CLIN PATHOL, V61, P553, DOI 10.1136/jcp.2008.055475; Lee JS, 2001, ANAL QUANT CYTOL, V23, P161; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Liu XJ, 2008, NAT MED, V14, P1325, DOI 10.1038/nm.1883; Lo HW, 2005, CANCER RES, V65, P338; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Pero SC, 2007, BRIT J CANCER, V96, P1520, DOI 10.1038/sj.bjc.6603732; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036; Tachibana KEK, 2005, J PATHOL, V205, P123, DOI 10.1002/path.1708; Taghibiglou C, 2009, NAT MED, V15, P1399, DOI 10.1038/nm.2064; TAHAN SR, 1993, CANCER, V71, P3552, DOI 10.1002/1097-0142(19930601)71:11<3552::AID-CNCR2820711115>3.0.CO;2-N; Tan AR, 2004, J CLIN ONCOL, V22, P3080, DOI 10.1200/JCO.2004.08.189; Tsurimoto T, 1998, BBA-GENE STRUCT EXPR, V1443, P23, DOI 10.1016/S0167-4781(98)00204-8; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Xia WY, 2009, MOL CARCINOGEN, V48, P610, DOI 10.1002/mc.20504; Yu YL, 2012, J BIOL CHEM; Zhao HJ, 2011, MOL CANCER THER, V10, P29, DOI 10.1158/1535-7163.MCT-10-0778	41	52	57	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2013	8	4							e61362	10.1371/journal.pone.0061362	http://dx.doi.org/10.1371/journal.pone.0061362			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130FG	23593472	Green Published, Green Submitted, gold			2023-01-03	WOS:000317898000128
J	Chen, K; Kobayashi, S; Xu, XM; Viollet, B; Liang, QR				Chen, Kai; Kobayashi, Satoru; Xu, Xianmin; Viollet, Benoit; Liang, Qiangrong			AMP Activated Protein Kinase Is Indispensable for Myocardial Adaptation to Caloric Restriction in Mice	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; CARDIAC-HYPERTROPHY; NEGATIVE REGULATORS; DIASTOLIC FUNCTION; SIGNALING PATHWAY; RHESUS-MONKEYS; AUTOPHAGY; HEART; DYSFUNCTION; SURVIVAL	Caloric restriction (CR) is a robust dietary intervention known to enhance cardiovascular health. AMP activated protein kinase (AMPK) has been suggested to mediate the cardioprotective effects of CR. However, this hypothesis remains to be tested by using definitive loss-of-function animal models. In the present study, we subjected AMPK alpha 2 knockout (KO) mice and their wild type (WT) littermates to a CR regimen that reduces caloric intake by 20%-40% for 4 weeks. CR decreased body weight, heart weight and serum levels of insulin in both WT and KO mice to the same degree, indicating the effectiveness of the CR protocol. CR activated cardiac AMPK signaling in WT mice, but not in AMPK alpha 2 KO mice. Correspondingly, AMPK alpha 2 KO mice had markedly reduced cardiac function during CR as determined by echocardiography and hemodynamic measurements. The compromised cardiac function was associated with increased markers of oxidative stress, endoplasmic reticulum stress and myocyte apoptosis. Mechanistically, CR down-regulated the expression of ATP5g2, a subunit of mitochondrial ATP synthase, and reduced ATP content in AMPK alpha 2 KO hearts, but not in WT hearts. In addition, CR accelerated cardiac autophagic flux in WT mice, but failed to do so in AMPK alpha 2 KO mice. These results demonstrated that without AMPK, CR triggers adverse effects that can lead to cardiac dysfunction, suggesting that AMPK signaling pathway is indispensible for energy homeostasis and myocardial adaptation to CR, a dietary intervention that normally produces beneficial cardiac effects.	[Chen, Kai; Kobayashi, Satoru; Xu, Xianmin; Liang, Qiangrong] Univ S Dakota, Cardiovasc Hlth Res Ctr, Sanford Res, Sioux Falls, SD USA; [Viollet, Benoit] Inst Cochin Genet Mol, INSERM, U1016, F-75014 Paris, France; [Viollet, Benoit] CNRS, UMR8104, Paris, France; [Viollet, Benoit] Univ Paris 05, Paris, France	Sanford Health; University of South Dakota; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Liang, QR (corresponding author), New York Inst Technol, Dept Biomed Sci, Coll Osteopath Med, Old Westbury, NY 11568 USA.	Qiangrong.Liang@sanfordhealth.org	Viollet, Benoit/O-6927-2017; Viollet, Benoit/N-2397-2019	Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224	American Diabetes Association [1-09-CD-09]; National Center for Research Resources [5P20RR017662-10]; National Institute of General Medical Sciences from the National Institutes of Health [8 P20 GM103455-10]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103455] Funding Source: NIH RePORTER	American Diabetes Association(American Diabetes Association); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of General Medical Sciences from the National Institutes of Health(General Electric); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by a Career Development Grant (1-09-CD-09) from the American Diabetes Association and by grants from the National Center for Research Resources (5P20RR017662-10) and the National Institute of General Medical Sciences (8 P20 GM103455-10) from the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006; Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894; Beauloye C, 2011, CARDIOVASC RES; Bergamini E, 2007, ANN NY ACAD SCI, V1114, P69, DOI 10.1196/annals.1396.020; Canto C, 2011, PHYSIOLOGY, V26, P214, DOI 10.1152/physiol.00010.2011; Chen JH, 2011, CIRCULATION, V123, P584, DOI 10.1161/CIRCULATIONAHA.110.971853; Chen K, 2011, J BIOL CHEM, V286, P21993, DOI 10.1074/jbc.M111.225805; Cheng H, 2011, J MOL CELL CARDIOL, V51, P607, DOI 10.1016/j.yjmcc.2010.11.020; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Cruzen C, 2009, CLIN GERIATR MED, V25, P733, DOI 10.1016/j.cger.2009.07.001; Dhahbi JM, 2006, J GERONTOL A-BIOL, V61, P218, DOI 10.1093/gerona/61.3.218; Dolinsky VW, 2010, HYPERTENSION, V56, P412, DOI 10.1161/HYPERTENSIONAHA.110.154732; Edwards AG, 2010, MECH AGEING DEV, V131, P739, DOI 10.1016/j.mad.2010.09.007; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Gottlieb RA, 2010, BIOCHIM BIOPHYS ACTA, V1813, P1295; Gottlieb RA, 2010, AM J PHYSIOL-CELL PH, V299, pC203, DOI 10.1152/ajpcell.00097.2010; Greer EL, 2009, ANN NY ACAD SCI, V1170, P688, DOI 10.1111/j.1749-6632.2009.04019.x; Hardt SE, 2004, CARDIOVASC RES, V63, P500, DOI 10.1016/j.cardiores.2004.03.015; Hepple RT, 2009, EXERC SPORT SCI REV, V37, P23, DOI 10.1097/JES.0b013e3181877dc5; Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Jia KL, 2007, AUTOPHAGY, V3, P597, DOI 10.4161/auto.4989; Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]; Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249; Katare RG, 2009, J MOL CELL CARDIOL, V46, P405, DOI 10.1016/j.yjmcc.2008.10.027; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kim M, 2011, J MOL CELL CARDIOL; Kobayashi S, 2007, J BIOL CHEM, V282, P21945, DOI 10.1074/jbc.M703048200; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lane Mark A, 2007, Methods Mol Biol, V371, P143; Lu J, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-012-0326-9; Madeo F, 2010, NAT CELL BIOL, V12, P842, DOI 10.1038/ncb0910-842; Martin Bronwen, 2007, IBS J Sci, V2, P35; Maslov MY, 2007, AM J PHYSIOL-HEART C, V292, pH387, DOI 10.1152/ajpheart.00737.2006; Masoro EJ, 2009, BIOCH BIOPHYS ACTA; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Mattison JA, 2012, NATURE, V489, P318, DOI 10.1038/nature11432; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; McCarty MF, 2004, MED HYPOTHESES, V63, P334, DOI 10.1016/j.mehy.2004.01.043; Meyer TE, 2006, J AM COLL CARDIOL, V47, P398, DOI 10.1016/j.jacc.2005.08.069; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mizushima N, 2007, AUTOPHAGY, V3; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004; Muthukumar A, 2003, J CLIN IMMUNOL, V23, P23, DOI 10.1023/A:1021996130672; Nagata D, 2010, HYPERTENS RES, V33, P22, DOI 10.1038/hr.2009.187; Nakai A, 2007, NAT MED, V13, P619, DOI 10.1038/nm1574; Narbonne P, 2009, NATURE, V457, P210, DOI 10.1038/nature07536; Osborne TB, 1917, SCIENCE, V45, P294, DOI 10.1126/science.45.1160.294; Pamplona R, 2002, MECH AGEING DEV, V123, P1437, DOI 10.1016/S0047-6374(02)00076-3; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Raeini-Sarjaz M, 2001, AM J CLIN NUTR, V73, P262; Rattan SIS, 2004, MECH AGEING DEV, V125, P285, DOI 10.1016/j.mad.2004.01.006; Riordan MM, 2008, AM J PHYSIOL-HEART C, V294, pH1174, DOI 10.1152/ajpheart.01236.2007; Russell RR, 2004, J CLIN INVEST, V114, P495, DOI 10.1172/JCI200419297; Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005; Schumacher B, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000161; Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295; Shinmura K, 2007, CIRCULATION, V116, P2809, DOI 10.1161/CIRCULATIONAHA.107.725697; Shinmura K, 2008, AM J PHYSIOL-HEART C, V295, pH2348, DOI 10.1152/ajpheart.00602.2008; Shioji K, 2002, CIRCULATION, V106, P1403, DOI 10.1161/01.CIR.0000027817.55925.B4; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Spindler SR, 2009, AGEING RES REV; Spindler SR, 2010, AGEING RES REV, V9, P324, DOI 10.1016/j.arr.2009.10.003; Tang YD, 2005, CIRCULATION, V112, P3122, DOI 10.1161/CIRCULATIONAHA.105.572883; Terai K, 2005, MOL CELL BIOL, V25, P9554, DOI 10.1128/MCB.25.21.9554-9575.2005; Viljanen APM, 2009, AM J CARDIOL, V103, P1721, DOI 10.1016/j.amjcard.2009.02.025; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Viollet B, 2009, FRONT BIOSCI-LANDMRK, V14, P19, DOI 10.2741/3229; Wan R, 2009, J NUTR BIOCH; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618; Williams TD, 2002, AM J PHYSIOL-REG I, V282, pR1459, DOI 10.1152/ajpregu.00612.2001; Wohlgemuth SE, 2007, REJUV RES, V10, P281, DOI 10.1089/rej.2006.0535; Wu SJ, 2009, CARDIOVASC RES, V84, P119, DOI 10.1093/cvr/cvp180; Yang YF, 2011, CIRC RES, V108, P305, DOI 10.1161/CIRCRESAHA.110.228437; Zhang P, 2008, HYPERTENSION, V52, P918, DOI 10.1161/HYPERTENSIONAHA.108.114702	82	22	23	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e59682	10.1371/journal.pone.0059682	http://dx.doi.org/10.1371/journal.pone.0059682			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SR	23527250	gold, Green Published, Green Submitted			2023-01-03	WOS:000317562100158
J	Pauliah, SS; Shankaran, S; Wade, A; Cady, EB; Thayyil, S				Pauliah, Shreela S.; Shankaran, Seetha; Wade, Angie; Cady, Ernest B.; Thayyil, Sudhin			Therapeutic Hypothermia for Neonatal Encephalopathy in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; RANDOMIZED-CONTROLLED-TRIAL; LOW-RESOURCE SETTINGS; PERINATAL ASPHYXIA; NEWBORN-INFANTS; MILD HYPOTHERMIA; TERM; OUTCOMES; OPINION; DEATHS	Although selective or whole body cooling combined with optimal intensive care improves outcomes following neonatal encephalopathy in high-income countries, the safety and efficacy of cooling in low-and middle-income countries is not known. Objective: We performed a systematic review and meta-analysis of all published randomised or quasi-randomised controlled trials of cooling therapy for neonatal encephalopathy in low-and middle-income countries. Results: Seven trials, comprising a total of 567 infants were included in the meta-analysis. Most study infants had mild (15%) or moderate encephalopathy (48%) and did not receive invasive ventilation (88%). Cooling devices included water-circulating cooling caps, frozen gel packs, ice, water bottles, and phase-changing material. No statistically significant reduction in neonatal mortality was seen with cooling (risk ratio: 0.74, 95% confidence intervals: 0.44 to 1.25). Data on other neonatal morbidities and long-term neurological outcomes were insufficient. Conclusion: Cooling therapy was not associated with a statistically significant reduction in neonatal mortality in low-and middle-income countries although the confidence intervals were wide and not incompatible with results seen in high-income countries. The apparent lack of treatment effect may be due to the heterogeneity and poor quality of the included studies, inefficiency of the low technology cooling devices, lack of optimal neonatal intensive care, sedation and ventilatory support, overuse of oxygen, or may be due to the intrinsic difference in the population, for example higher rates of perinatal infection, obstructed labor, intrauterine growth retardation and maternal malnutrition. Evaluation of the safety and efficacy of cooling in adequately powered randomised controlled trials is required before cooling is offered in routine clinical practice in low-and middle-income countries.	[Pauliah, Shreela S.; Thayyil, Sudhin] UCL, Inst Womens Hlth, London, England; [Shankaran, Seetha] Wayne State Univ, Childrens Hosp Michigan, Sch Med, Detroit, MI USA; [Shankaran, Seetha] Hutzel Womens Hosp, Detroit, MI USA; [Wade, Angie] UCL, Inst Child Hlth, London, England; [Cady, Ernest B.] Univ Coll Hosp NHS Fdn Trust, London, England	University of London; University College London; Children's Hospital of Michigan; Wayne State University; University of London; University College London; University of London; University College London	Thayyil, S (corresponding author), UCL, Inst Womens Hlth, London, England.	s.thayyil@ucl.ac.uk		Thayyil, Sudhin/0000-0001-8795-5165	Department of Health [NIHR/CS/010/022] Funding Source: Medline; National Institute for Health Research [NIHR/CS/010/022] Funding Source: researchfish	Department of Health; National Institute for Health Research(National Institute for Health Research (NIHR))		Akisu M, 2003, PROSTAG LEUKOTR ESS, V69, P45, DOI 10.1016/S0952-3278(03)00055-3; Bharadwaj SK, 2012, J TROP PEDIATRICS, V58, P382, DOI 10.1093/tropej/fms005; Bhat MA, 2006, ARCH DIS CHILD-FETAL, V91, pF464, DOI 10.1136/fnn.2006.097915; Blackmon L, 2004, PEDIATRICS, V114, P1341, DOI 10.1542/peds.2004-1697; Dalen ML, 2012, PEDIATR RES, V71, P247, DOI 10.1038/pr.2011.43; Edwards AD, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c363; Higgins RD, 2011, J PEDIATR-US, V159, P851, DOI 10.1016/j.jpeds.2011.08.004; Horn AR, 2006, SAMJ S AFR MED J, V96, P976; Horn AR, 2010, J TROP PEDIATRICS, V56, P172, DOI 10.1093/tropej/fmp089; Horn A, 2009, PEDIATRICS, V123, pE1090, DOI 10.1542/peds.2007-3766; Horn AR, 2012, J TROP PEDIATRICS, V58, P236, DOI 10.1093/tropej/fmr069; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Joolay Y, 2012, J PERINAT MED, V40, P447, DOI 10.1515/jpm-2011-0292; Kapetanakis A, 2009, ACTA PAEDIATR, V98, P631, DOI 10.1111/j.1651-2227.2008.01159.x; Kumar V, 2009, J PERINATOL, V29, P401, DOI 10.1038/jp.2008.233; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS123, DOI 10.1016/j.ijgo.2009.07.021; Li Tongchuan, 2009, Hosp Pract (1995), V37, P147, DOI 10.3810/hp.2009.12.269; Lin ZL, 2006, J PERINATOL, V26, P180, DOI 10.1038/sj.jp.7211412; Mullany LC, 2010, SEMIN PERINATOL, V34, P426, DOI 10.1053/j.semperi.2010.09.007; Rajhans A, 2012, WHOLE BODY HYPOTHERM; Regier DA, 2010, VALUE HEALTH, V13, P695, DOI 10.1111/j.1524-4733.2010.00731.x; Robertson NJ, 2008, LANCET, V372, P801, DOI 10.1016/S0140-6736(08)61329-X; Robertson NJ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-138; Robertson NJ, 2010, SEMIN FETAL NEONAT M, V15, P276, DOI 10.1016/j.siny.2010.03.006; See K C, 2012, Med J Malaysia, V67, P265; Shankaran S, 2012, NEW ENGL J MED, V366, P2085, DOI 10.1056/NEJMoa1112066; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Tann C, 2010, PED AC SOC ANN M VAN; Thayyil S, 2013, HYPOTHERMIA ENCEPHAL; Thayyil S, 2010, ARCH DIS CH IN PRESS; Thomas N, 2011, INDIAN PEDIATR, V48, P445, DOI 10.1007/s13312-011-0076-z; Thompson CM, 1997, ACTA PAEDIATR, V86, P757, DOI 10.1111/j.1651-2227.1997.tb08581.x; Thoresen M, 2001, PEDIATR RES, V50, P405, DOI 10.1203/00006450-200109000-00017; Wilkinson DJ, 2011, ARCH DIS CHILD-FETAL, V96, pF75, DOI 10.1136/adc.2010.184689; World Bank, 2011, WE CLASS COUNTR; Zhou WH, 2010, J PEDIATR-US, V157, P367, DOI 10.1016/j.jpeds.2010.03.030	37	116	117	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e58834	10.1371/journal.pone.0058834	http://dx.doi.org/10.1371/journal.pone.0058834			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SR	23527034	Green Published, gold			2023-01-03	WOS:000317562100049
J	Weintraub, K				Weintraub, Karen			The new gold standard	NATURE			English	Editorial Material							PHOTOTHERMAL THERAPY; DELIVERY; SIRNA											Gad SC, 2012, INT J TOXICOL, V31, P584, DOI 10.1177/1091581812465969; Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a; Huang XH, 2008, LASER MED SCI, V23, P217, DOI 10.1007/s10103-007-0470-x; Huschka R, 2012, ACS NANO, V6, P7681, DOI 10.1021/nn301135w; Jun YW, 2009, P NATL ACAD SCI USA, V106, P17735, DOI 10.1073/pnas.0907367106; Moyano DF, 2012, J AM CHEM SOC, V134, P3965, DOI 10.1021/ja2108905; Zhang K, 2012, J AM CHEM SOC, V134, P16488, DOI 10.1021/ja306854d; Zheng D, 2012, P NATL ACAD SCI USA, V109, P11975, DOI 10.1073/pnas.1118425109	8	62	100	3	137	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 14	2013	495	7440					S14	S16		10.1038/495S14a	http://dx.doi.org/10.1038/495S14a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113FP	23486097	Bronze			2023-01-03	WOS:000316652300032
J	Yang, ZX; Han, ZB; Ji, YR; Wang, YW; Liang, L; Chi, Y; Yang, SG; Li, LN; Luo, WF; Li, JP; Chen, DD; Du, WJ; Cao, XC; Zhuo, GS; Wang, T; Han, ZC				Yang, Zhou Xin; Han, Zhi-Bo; Ji, Yue Ru; Wang, You Wei; Liang, Lu; Chi, Ying; Yang, Shao Guang; Li, Li Na; Luo, Wei Feng; Li, Jian Ping; Chen, Dan Dan; Du, Wen Jing; Cao, Xiao Cang; Zhuo, Guang Sheng; Wang, Tao; Han, Zhong Chao			CD106 Identifies a Subpopulation of Mesenchymal Stem Cells with Unique Immunomodulatory Properties	PLOS ONE			English	Article							HUMAN BONE-MARROW; STROMAL CELLS; UMBILICAL-CORD; HUMAN PLACENTA; IFN-GAMMA; ADHESION MOLECULE-1; ADIPOSE-TISSUE; TNF-ALPHA; EXPRESSION; TOLERANCE	Mesenchymal stem cells (MSCs) reside in almost all of the body tissues, where they undergo self-renewal and multi-lineage differentiation. MSCs derived from different tissues share many similarities but also show some differences in term of biological properties. We aim to search for significant differences among various sources of MSCs and to explore their implications in physiopathology and clinical translation. We compared the phenotype and biological properties among different MSCs isolated from human term placental chorionic villi (CV), umbilical cord (UC), adult bone marrow (BM) and adipose (AD). We found that CD106 (VCAM-1) was expressed highest on the CV-MSCs, moderately on BM-MSCs, lightly on UC-MSCs and absent on AD-MSCs. CV-MSCs also showed unique immune-associated gene expression and immunomodulation. We thus separated CD106(+) cells and CD106(-) cells from CV-MSCs and compared their biological activities. Both two subpopulations were capable of osteogenic and adipogenic differentiation while CD106(+) CV-MSCs were more effective to modulate T helper subsets but possessed decreased colony formation capacity. In addition, CD106(+) CV-MSCs expressed more cytokines than CD106(-) CV-MSCs. These data demonstrate that CD106 identifies a subpopulation of CV-MSCs with unique immunoregulatory activity and reveal a previously unrecognized mechanism underlying immunomodulation of MSCs.	[Yang, Zhou Xin; Han, Zhi-Bo; Ji, Yue Ru; Wang, You Wei; Chi, Ying; Yang, Shao Guang; Li, Jian Ping; Chen, Dan Dan; Du, Wen Jing; Han, Zhong Chao] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China; [Yang, Zhou Xin; Han, Zhi-Bo; Ji, Yue Ru; Wang, You Wei; Chi, Ying; Yang, Shao Guang; Li, Jian Ping; Chen, Dan Dan; Du, Wen Jing; Han, Zhong Chao] Chinese Acad Med Sci, Hosp Blood Dis, Tianjin, Peoples R China; [Yang, Zhou Xin; Han, Zhi-Bo; Ji, Yue Ru; Wang, You Wei; Chi, Ying; Yang, Shao Guang; Li, Jian Ping; Chen, Dan Dan; Du, Wen Jing; Han, Zhong Chao] Peking Union Med Coll, Tianjin, Peoples R China; [Wang, You Wei; Liang, Lu; Han, Zhong Chao] Natl Engn Res Ctr Cell Prod, Tianjin, Peoples R China; [Han, Zhi-Bo; Liang, Lu; Zhuo, Guang Sheng; Wang, Tao] Beijing Inst Hlth & Stem Cells, Beijing, Peoples R China; [Li, Li Na; Luo, Wei Feng] Jinan Univ, Sch Med, Guangzhou, Guangdong, Peoples R China; [Cao, Xiao Cang] Tianjin Med Univ, Tianjin Med Univ Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Jinan University; Tianjin Medical University	Han, ZC (corresponding author), Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China.	hanzhongchao@hotmail.com	Wang, Youwei/M-4544-2019; Chen, Dan/GRY-2691-2022; Han, Zhong Chao/D-7157-2016; Li, Jianping/Q-1618-2019; Li, Jianping/U-6806-2017; Du, Weiting/C-9971-2014	Chen, Dan/0000-0002-1570-9034; Han, Zhong Chao/0000-0002-2687-7682; cao, xiaocang/0000-0001-8376-3481	863 project [2011AA020118]; 973 program of China from the Ministry Science & Technology of China [2011 CB964800, 2011CB964802]	863 project(National High Technology Research and Development Program of China); 973 program of China from the Ministry Science & Technology of China	This study was supported by the 863 project (Grant no. 2011AA020118) and the 973 program of China 2011 CB964800 (Grant no. 2011CB964802) from the Ministry Science & Technology of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Bernardo ME, 2007, CONNECT TISSUE RES, V48, P132, DOI 10.1080/03008200701228464; Bieback K, 2008, BIO-MED MATER ENG, V18, pS71; Braun D, 2005, BLOOD, V106, P2375, DOI 10.1182/blood-2005-03-0979; Cesario A, 2011, CURR MED CHEM, V18, P2263, DOI 0929-8673/11 $58.00+.00; Chen K, 2010, CLIN IMMUNOL, V135, P448, DOI 10.1016/j.clim.2010.01.015; D'Addio F, 2011, J IMMUNOL, V187, P4530, DOI 10.4049/jimmunol.1002031; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; English K, 2007, IMMUNOL LETT, V110, P91, DOI 10.1016/j.imlet.2007.04.001; Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22-5-649; Gieseke F, 2010, BLOOD, V116, P3770, DOI 10.1182/blood-2010-02-270777; Guleria I, 2005, J EXP MED, V202, P231, DOI 10.1084/jem.20050019; GURTNER GC, 1995, GENE DEV, V9, P1, DOI 10.1101/gad.9.1.1; Hsieh JY, 2010, STEM CELLS DEV, V19, P1895, DOI 10.1089/scd.2009.0485; Hwang JH, 2009, J KOREAN MED SCI, V24, P547, DOI 10.3346/jkms.2009.24.4.547; Jansen BJH, 2010, STEM CELLS DEV, V19, P481, DOI 10.1089/scd.2009.0288; Kokovay E, 2012, CELL STEM CELL, V11, P220, DOI 10.1016/j.stem.2012.06.016; Kolf CM, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2116; Krampera M, 2006, STEM CELLS, V24, P386, DOI 10.1634/stemcells.2005-0008; KWEE L, 1995, DEVELOPMENT, V121, P489; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Li G, 2009, PROTEOMICS, V9, P20, DOI 10.1002/pmic.200701195; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu M, 2010, PLATELETS, V21, P199, DOI 10.3109/09537101003602483; Lu LL, 2006, HAEMATOLOGICA, V91, P1017; MATTSSON R, 1991, J REPROD IMMUNOL, V19, P115, DOI 10.1016/0165-0378(91)90012-F; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080; Nemeth K, 2010, P NATL ACAD SCI USA, V107, P5652, DOI 10.1073/pnas.0910720107; Paulesu L, 2008, EVOL DEV, V10, P778, DOI 10.1111/j.1525-142X.2008.00292.x; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Polchert D, 2008, EUR J IMMUNOL, V38, P1745, DOI 10.1002/eji.200738129; Prasanna SJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0014189, 10.1371/journal.pone.0009016]; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2010, J IMMUNOL, V184, P2321, DOI 10.4049/jimmunol.0902023; Robin C, 2009, CELL STEM CELL, V5, P385, DOI 10.1016/j.stem.2009.08.020; Selmani Z, 2009, TRANSPLANTATION, V87, pS62, DOI 10.1097/TP.0b013e3181a2a4b3; SIMMONS PJ, 1992, BLOOD, V80, P388; Simon C, 1998, FERTIL STERIL, V70, P896, DOI 10.1016/S0015-0282(98)00275-1; Terness P, 2007, AM J REPROD IMMUNOL, V58, P238, DOI 10.1111/j.1600-0897.2007.00510.x; TERRANOVA PF, 1995, P SOC EXP BIOL MED, V209, P325; Trowsdale J, 2006, NAT IMMUNOL, V7, P241, DOI 10.1038/ni1317; Vacchio MS, 2005, J IMMUNOL, V174, P4657, DOI 10.4049/jimmunol.174.8.4657; Wang D, 2010, EXP CELL RES, V316, P2414, DOI 10.1016/j.yexcr.2010.04.018; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	49	100	109	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2013	8	3							e59354	10.1371/journal.pone.0059354	http://dx.doi.org/10.1371/journal.pone.0059354			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	107WV	23555021	Green Published, gold, Green Submitted			2023-01-03	WOS:000316252500083
J	Evans, N; Pasman, HR; Alonso, TV; van den Block, L; Miccinesi, G; Van Casteren, V; Donker, G; Bertolissi, S; Zurriaga, O; Deliens, L; Onwuteaka-Philipsen, B				Evans, Natalie; Pasman, H. Roeline; Vega Alonso, Tomas; van den Block, Lieve; Miccinesi, Guido; Van Casteren, Viviane; Donker, Ge; Bertolissi, Stefano; Zurriaga, Oscar; Deliens, Luc; Onwuteaka-Philipsen, Bregje		EUROIMPACT	End-of-Life Decisions: A Cross-National Study of Treatment Preference Discussions and Surrogate Decision-Maker Appointments	PLOS ONE			English	Article							TERMINALLY-ILL PATIENTS; PALLIATIVE CARE; ADVANCE DIRECTIVES; CANCER-PATIENTS; HEALTH-CARE; PROFESSIONALS; FEASIBILITY; NETHERLANDS; DISCLOSURE; PHYSICIANS	Background: Making treatment decisions in anticipation of possible future incapacity is an important part of patient participation in end-of-life decision-making. This study estimates and compares the prevalence of GP-patient end-of-life treatment discussions and patients' appointment of surrogate decision-makers in Italy, Spain, Belgium and the Netherlands and examines associated factors. Methods: A cross-sectional, retrospective survey was conducted with representative GP networks in four countries. GPs recorded the health and care characteristics in the last three months of life of 4,396 patients who died non-suddenly. Prevalences were estimated and logistic regressions were used to examine between country differences and country-specific associated patient and care factors. Results: GP-patient discussion of treatment preferences occurred for 10%, 7%, 25% and 47% of Italian, Spanish, Belgian and of Dutch patients respectively. Furthermore, 6%, 5%, 16% and 29% of Italian, Spanish, Belgian and Dutch patients had a surrogate decision-maker. Despite some country-specific differences, previous GP-patient discussion of primary diagnosis, more frequent GP contact, GP provision of palliative care, the importance of palliative care as a treatment aim and place of death were positively associated with preference discussions or surrogate appointments. A diagnosis of dementia was negatively associated with preference discussions and surrogate appointments. Conclusions: The study revealed a higher prevalence of treatment preference discussions and surrogate appointments in the two northern compared to the two southern European countries. Factors associated with preference discussions and surrogate appointments suggest that delaying diagnosis discussions impedes anticipatory planning, whereas early preference discussions, particularly for dementia patients, and the provision of palliative care encourage participation.	[Evans, Natalie; Pasman, H. Roeline; Deliens, Luc; Onwuteaka-Philipsen, Bregje] Vrije Univ Amsterdam Med Ctr, EMGO Inst, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Vega Alonso, Tomas] Minist Hlth, Publ Hlth Directorate, Direcc Gen Salud Publ, Valladolid, Spain; [Vega Alonso, Tomas] Minist Hlth, Publ Hlth Directorate, Direcc Gen Salud Publ, Castille, Spain; [Vega Alonso, Tomas] Minist Hlth, Publ Hlth Directorate, Direcc Gen Salud Publ, Leon, Spain; [van den Block, Lieve; Deliens, Luc] Vrije Universiteit Brussel, End Of Life Care Res Grp, Brussels, Belgium; [Miccinesi, Guido] ISPO, Canc Prevent & Res Inst, Clin & Descript Epidemiol Unit, Florence, Italy; [Van Casteren, Viviane] Inst Sci Sante Publ, WIV ISP Wetenschappelijk Inst Volksgezondheid, Brussels, Belgium; [Donker, Ge] Netherlands Inst Hlth Serv Res, Utrecht, Netherlands; [Bertolissi, Stefano] SIMG, Italian Soc Gen Practice, Florence, France; [Zurriaga, Oscar] Valencian Reg Hlth Adm, Publ Hlth & Res Gen Directorate, Valencia, Spain; [Zurriaga, Oscar] CSISP, Higher Publ Hlth Res Ctr, Valencia, Spain; [Zurriaga, Oscar] Spanish Consortium Res Epidemiol & Publ Hlth, Madrid, Spain	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Netherlands Institute for Health Services Research	Evans, N (corresponding author), Vrije Univ Amsterdam Med Ctr, EMGO Inst, Dept Publ & Occupat Hlth, Amsterdam, Netherlands.	n.evans@vumc.nl	Van den Block, Lieve/D-1247-2011; Caraceni, Augusto/C-1012-2017; Evans, Natalie/M-1631-2013; Zurriaga, Oscar/J-3046-2019; Donker, Gé/AAX-8564-2021; miccinesi, guido/AAB-5476-2022; Zurriaga, Oscar/F-9877-2010	Van den Block, Lieve/0000-0002-7770-348X; Caraceni, Augusto/0000-0002-0375-6204; Evans, Natalie/0000-0001-7124-9282; Zurriaga, Oscar/0000-0001-7279-432X; miccinesi, guido/0000-0002-7452-9594; Zurriaga, Oscar/0000-0001-7279-432X; Harding, Richard/0000-0001-9653-8689; Deliens, Luc/0000-0002-8158-2422; Donker, Ge/0000-0001-6314-9249; Brearley, Sarah Grace/0000-0003-4764-3276	Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project (SBO) [SBO IWT 050158]; Vrije Universiteit Brussel, Ghent University; Antwerp University; Scientific Institute for Public Health, Belgium; VU University Medical Centre Amsterdam, the Netherlands; Italian Ministry of Health; European Union [264697]	Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project (SBO); Vrije Universiteit Brussel, Ghent University; Antwerp University; Scientific Institute for Public Health, Belgium; VU University Medical Centre Amsterdam, the Netherlands(Netherlands Government); Italian Ministry of Health(Ministry of Health, Italy); European Union(European Commission)	Funding for the study came from the Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project (SBO) (contract SBO IWT 050158) (2006-2010), as part of the 'Monitoring Quality of End-of-Life Care (MELC) Study', a collaboration between the Vrije Universiteit Brussel, Ghent University, Antwerp University, the Scientific Institute for Public Health, Belgium, and VU University Medical Centre Amsterdam, the Netherlands. Funding also came from the Italian Ministry of Health through the 'Evaluation, testing and implementation of supportive care, care interventions, integrated programs and improving the quality of care for cancer patients' program 'Integrated Oncology Project n degrees 6, years 2008-2011' led by Massimo Costantini (IRCCS AOU San Martino-IST, Genoa), from the annual budgets of the Autonomous Community of Castilla y Leon and Comunitat Valenciana and from EUROIMPACT: European Intersectorial and Multidisciplinary Palliative Care Research Training, funded by the European Union Seventh Framework Programme (FP7/2007-2013, under grant agreement nu [264697]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abarshi E, 2011, J PALLIAT MED, V14, P323, DOI 10.1089/jpm.2010.0312; Albert SM, 1999, J NEUROL SCI, V169, P108, DOI 10.1016/S0022-510X(99)00227-0; Andorno R, 2009, EUR J HEALTH LAW, V16, P207, DOI 10.1163/157180909X453053; Boerma W., 2003, PROFILES GEN PRACTIC; Borreani C, 2012, J PAIN SYMPTOM MANAG, V43, P739, DOI 10.1016/j.jpainsymman.2011.05.011; Boustani M, 2003, ANN INTERN MED, V138, P927, DOI 10.7326/0003-4819-138-11-200306030-00015; Bravo G, 2003, ALZ DIS ASSOC DIS, V17, P215, DOI 10.1097/00002093-200310000-00004; Cartwright C, 2007, PALLIATIVE MED, V21, P295, DOI 10.1177/0269216307079063; Claessen SJJ, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X625184; Conroy S, 2009, CLIN MED, V9, P76, DOI 10.7861/clinmedicine.9-1-76; Costantini A, 2009, J CANCER EDUC, V24, P180, DOI 10.1080/08858190902876262; Costantini M, 2006, ANN ONCOL, V17, P853, DOI 10.1093/annonc/mdl028; Desmedt M, 2002, SUPPORT CARE CANCER, V10, P343, DOI 10.1007/s00520-002-0345-4; Eizenga WH, 2006, HUISARTS WETENSCHAP, V49, P308; ESTAPE J, 1992, ANN ONCOL, V3, P451, DOI 10.1093/oxfordjournals.annonc.a058233; Formiga F, 2004, QJM-INT J MED, V97, P803, DOI 10.1093/qjmed/hch135; Gysels M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034188; Havens GAD, 2000, RES NURS HEALTH, V23, P319, DOI 10.1002/1098-240X(200008)23:4<319::AID-NUR8>3.0.CO;2-6; Hoving C, 2010, PATIENT EDUC COUNS, V78, P275, DOI 10.1016/j.pec.2010.01.015; IIS, 2009, AT CUID PAL ORG COM; Janssens RJPA, 2001, PALLIATIVE MED, V15, P481, DOI 10.1191/026921601682553969; Lofmark R, 2006, J PALLIATIVE CARE, V22, P105, DOI 10.1177/082585970602200207; Martin-Matthews A, 2011, CAN J AGING, V30, P339, DOI 10.1017/S0714980811000201; Meeussen K, 2011, J PAIN SYMPTOM MANAG, V42, P565, DOI 10.1016/j.jpainsymman.2011.01.011; Menaca A, 2012, CRIT REV ONCOL HEMAT, V82, P387, DOI 10.1016/j.critrevonc.2011.06.002; Miccinesi G, 2005, SOC SCI MED, V60, P1961, DOI 10.1016/j.socscimed.2004.08.061; Morrison RS, 2004, ARCH INTERN MED, V164, P2421, DOI 10.1001/archinte.164.22.2421; Ott B B, 1999, Am J Crit Care, V8, P514; Parker SM, 2007, J PAIN SYMPTOM MANAG, V34, P81, DOI 10.1016/j.jpainsymman.2006.09.035; Pelayo M, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-37; Pool R, 2000, NEGOTIATING GOOD DEA; Proot IM, 2004, PALLIATIVE MED, V18, P53, DOI 10.1191/0268216304pm818oa; Robinson C, 2012, CAN FAM PHYSICIAN, V58, pE229; Sbanotto A, 1998, SUPPORT CARE CANCER, V6, P426, DOI 10.1007/s005200050189; Simon-Lorda P, 2008, BIOETHICS, V22, P346, DOI 10.1111/j.1467-8519.2008.00644.x; Sizoo EM, 2012, EUR J CANCER, V48, P226, DOI 10.1016/j.ejca.2011.11.010; Toscani F, 2006, AM J BIOETHICS, V6, pW6, DOI 10.1080/15265160500394994; van Alphen JE, 2010, BRIT J GEN PRACT, V60, P263, DOI 10.3399/bjgp10X483931; Van den Block L, 2012, NATIONWIDE MONITORIN; Van den Block L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-69; Van den Block L, 2007, JAMA-J AM MED ASSOC, V298, P1638, DOI 10.1001/jama.298.14.1638; Van den Block Lieve, 2007, BMC Palliat Care, V6, P6; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; Vega Alonso A, 2006, GAC SANIT S3, V20, P52; Voltz R, 1998, J PAIN SYMPTOM MANAG, V16, P153, DOI 10.1016/S0885-3924(98)00067-0	45	48	48	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2013	8	3							e57965	10.1371/journal.pone.0057965	http://dx.doi.org/10.1371/journal.pone.0057965			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	099RC	23472122	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000315637900065
J	Schoene, D; Lord, SR; Delbaere, K; Severino, C; Davies, TA; Smith, ST				Schoene, Daniel; Lord, Stephen R.; Delbaere, Kim; Severino, Connie; Davies, Thomas A.; Smith, Stuart T.			A Randomized Controlled Pilot Study of Home-Based Step Training in Older People Using Videogame Technology	PLOS ONE			English	Article							FALLS PREVENTION INTERVENTIONS; POSTURAL SWAY; REACTION-TIME; FUNCTIONAL MOBILITY; BALANCE CONFIDENCE; PREDICTING FALLS; TAI CHI; WII FIT; EXERCISE; ADULTS	Background: Stepping impairments are associated with physical and cognitive decline in older adults and increased fall risk. Exercise interventions can reduce fall risk, but adherence is often low. A new exergame involving step training may provide an enjoyable exercise alternative for preventing falls in older people. Purpose: To assess the feasibility and safety of unsupervised, home-based step pad training and determine the effectiveness of this intervention on stepping performance and associated fall risk in older people. Design: Single-blinded two-arm randomized controlled trial comparing step pad training with control (no-intervention). Setting/Participants: Thirty-seven older adults residing in independent-living units of a retirement village in Sydney, Australia. Intervention: Intervention group (IG) participants were provided with a computerized step pad system connected to their TVs and played a step game as often as they liked (with a recommended dose of 2-3 sessions per week for 15-20 minutes each) for eight weeks. In addition, IG participants were asked to complete a choice stepping reaction time (CSRT) task once each week. Main Outcome Measures: CSRT, the Physiological Profile Assessment (PPA), neuropsychological and functional mobility measures were assessed at baseline and eight week follow-up. Results: Thirty-two participants completed the study (86.5%). IG participants played a median 2.75 sessions/week and no adverse events were reported. Compared to the control group, the IG significantly improved their CSRT (F-31,F-1 = 18.203, p < .001), PPA composite scores (F-31,F-1 = 12.706, p = 0.001), as well as the postural sway (F-31,F-1 = 4.226, p = 0.049) and contrast sensitivity (F-31,F-1 = 4.415, p = 0.044) PPA sub-component scores. In addition, the IG improved significantly in their dual-task ability as assessed by a timed up and go test/verbal fluency task (F-31,F-1 = 4.226, p = 0.049). Conclusions: Step pad training can be safely undertaken at home to improve physical and cognitive parameters of fall risk in older people without major cognitive and physical impairments.	[Schoene, Daniel; Lord, Stephen R.; Delbaere, Kim; Severino, Connie; Davies, Thomas A.; Smith, Stuart T.] Neurosci Res Australia, Falls & Balance Res Grp, Sydney, NSW, Australia; [Schoene, Daniel; Lord, Stephen R.; Delbaere, Kim] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia	Neuroscience Research Australia; University of New South Wales Sydney	Smith, ST (corresponding author), Neurosci Res Australia, Falls & Balance Res Grp, Sydney, NSW, Australia.	s.smith@neura.edu.au	Smith, Stuart T/B-8144-2011; Lord, Stephen R/C-9612-2011; Delbaere, Kim/D-6370-2011; Schoene, Daniel/H-8861-2019	Smith, Stuart T/0000-0002-4735-6026; Delbaere, Kim/0000-0002-5655-0234; Schoene, Daniel/0000-0003-0717-5746; Lord, Stephen R/0000-0002-7111-8802	National Health and Medical Research Council (NHMRC) [568724]	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia)	This study was financially supported by a National Health and Medical Research Council (NHMRC) project grant (grant number 568724) (http://www.nhmrc.gov.au). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angevaren M, 2008, COCHRANE DATABASE SY; Annesi JJ, 1997, PERCEPT MOTOR SKILL, V85, P835, DOI 10.2466/pms.1997.85.3.835; Anstey KJ, 2009, NEUROPSYCHOLOGY, V23, P500, DOI 10.1037/a0015389; Ashworth NL, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004017.pub2; Baranowski T, 2008, AM J PREV MED, V34, P74, DOI 10.1016/j.amepre.2007.09.027; Brumels KA, 2008, CLIN KINES, V62, P26; CSUKA M, 1985, AM J MED, V78, P77, DOI 10.1016/0002-9343(85)90465-6; Cyarto EV, 2008, GERONTOLOGY, V54, P272, DOI 10.1159/000155653; de Bruin ED, 2010, Z GERONTOL GERIATR, V43, P229, DOI 10.1007/s00391-010-0124-7; DEBRUIN ED, 2011, J NOV PHYSIOTHER, V1, P104, DOI DOI 10.4172/2165-7025.1000104; Delbaere K, 2011, J GERONTOL A-BIOL, V66, P674, DOI 10.1093/gerona/glr019; FERNIE GR, 1982, AGE AGEING, V11, P11, DOI 10.1093/ageing/11.1.11; Gillespie Lesley D, 2012, Cochrane Database Syst Rev, pCD007146, DOI 10.1002/14651858.CD007146.pub3; Graves LEF, 2010, J PHYS ACT HEALTH, V7, P393, DOI 10.1123/jpah.7.3.393; Guderian B, 2010, J SPORT MED PHYS FIT, V50, P436; Hale LA, 2012, ARCH PHYS MED REHAB, V93, P27, DOI 10.1016/j.apmr.2011.08.004; Hsu CL, 2012, OSTEOPOROS INT; Lajoie Y, 2004, ARCH GERONTOL GERIAT, V38, P11, DOI 10.1016/S0167-4943(03)00082-7; Lezak MD, 2004, NEUROPSYCHOLOGICAL A; Li RJ, 2009, NAT NEUROSCI, V12, P549, DOI 10.1038/nn.2296; Liu-Ambrose T, 2009, BRIT J SPORT MED, V43, P25, DOI 10.1136/bjsm.2008.055616; Liu-Ambrose T, 2008, J AM GERIATR SOC, V56, P1821, DOI [10.1111/j.1532-5415.2008.01931.x, 10.1111/j.1532-5415.2008.01984.x]; Loram ID, 2005, J PHYSIOL-LONDON, V564, P295, DOI 10.1113/jphysiol.2004.076307; LORD SR, 1994, J AM GERIATR SOC, V42, P1110, DOI 10.1111/j.1532-5415.1994.tb06218.x; Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237; Lord SR, 2001, J GERONTOL A-BIOL, V56, pM627, DOI 10.1093/gerona/56.10.M627; Maddison R, 2007, PEDIATR EXERC SCI, V19, P334, DOI 10.1123/pes.19.3.334; Maki BE, 2006, AGE AGEING, V35, P12, DOI 10.1093/ageing/afl078; Mansfield A, 2010, PHYS THER, V90, P476, DOI 10.2522/ptj.20090070; Masud T, 2001, AGE AGEING, V30, P3, DOI 10.1093/ageing/30.suppl_4.3; Melzer I, 2010, AGING CLIN EXP RES, V22, P360, DOI 10.1007/BF03324940; Nyman SR, 2012, AGE AGEING, V41, P16, DOI 10.1093/ageing/afr103; Nyman SR, 2011, AGE AGEING, V40, P430, DOI 10.1093/ageing/afr016; Pfeifer M, 2001, EXP CLIN ENDOCR DIAB, V109, P87, DOI 10.1055/s-2001-14831; Pijnappels M, 2010, AGE AGEING, V39, P99, DOI 10.1093/ageing/afp200; Plante TG, 2003, COMPUT HUM BEHAV, V19, P495, DOI 10.1016/S0747-5632(02)00074-2; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Raudenbush B, 2009, PERCEPT MOTOR SKILL, V108, P439, DOI 10.2466/PMS.108.2.439-448; Rhodes RE, 2009, PSYCHOL HEALTH MED, V14, P631, DOI 10.1080/13548500903281088; Rogers MW, 2003, J GERONTOL A-BIOL, V58, P46; Schoene D, 2012, J AGING PHYS ACTIV, V20, pS186; Schoene D, 2011, ARCH PHYS MED REHAB, V92, P947, DOI 10.1016/j.apmr.2011.01.012; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Shigematsu R, 2008, J GERONTOL A-BIOL, V63, P76, DOI 10.1093/gerona/63.1.76; Taylor D, 2012, J AM GERIATR SOC, V60, P841, DOI 10.1111/j.1532-5415.2012.03928.x; Tiedemann A, 2008, AGE AGEING, V37, P430, DOI 10.1093/ageing/afn100; Tseng SC, 2009, J GERONTOL A-BIOL, V64, P807, DOI 10.1093/gerona/glp027; WAGNER EH, 1994, AM J PUBLIC HEALTH, V84, P1800, DOI 10.2105/AJPH.84.11.1800; Wolf SL, 1996, J AM GERIATR SOC, V44, P489, DOI 10.1111/j.1532-5415.1996.tb01432.x	49	145	147	7	88	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2013	8	3							e57734	10.1371/journal.pone.0057734	http://dx.doi.org/10.1371/journal.pone.0057734			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	099RC	23472104	Green Published, gold			2023-01-03	WOS:000315637900043
J	Collis, E; Al-Qurainy, R				Collis, Emily; Al-Qurainy, R.			Care of the dying patient in the community	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SPOTLIGHT PALLIATIVE CARE; PEOPLE DIE; LIFE CARE; DEATH; HOME; PLACE; CANCER; END; INTERVENTION; PREFERENCES		[Collis, Emily; Al-Qurainy, R.] Cent London Community Healthcare Trust, Pembridge Palliat Care Ctr, St Charles Ctr Hlth & Wellbeing, London W10 6DZ, England		Collis, E (corresponding author), Cent London Community Healthcare Trust, Pembridge Palliat Care Ctr, St Charles Ctr Hlth & Wellbeing, London W10 6DZ, England.	emily.collis@clch.nhs.uk	Hill-Cawthorne, Grant A/B-8039-2009; Westby, Maggie/O-8794-2014	Hill-Cawthorne, Grant A/0000-0002-3828-5473; Westby, Maggie/0000-0003-4273-3942				Abel J, 2013, BMJ SUPPORT PALLIAT, V3, P168, DOI 10.1136/bmjspcare-2012-000327; Arthur A, 2011, BEREAVEMENT CARE SER; Bomba P, 2012, BMJ SUPPORT PALLIAT, V2, P184; Boyd K, 2010, BR J GEN PRACT, V60, pe449; Boyd K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4863; Brumley Richard D, 2003, J Palliat Med, V6, P715, DOI 10.1089/109662103322515220; Calanzani N., 2013, CURRENT FUTURE NEEDS; Candy B, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007544.pub2; Dale J, 2009, QUAL SAF HEALTH CARE, V18, P174, DOI 10.1136/qshc.2007.024836; Department of Health, 2013, HLTH SOC CAR ACT 201; Department of Health, 2012, 1 NAT VOICES SURV BE; Department of Health, 2008, END LIF CAR STRAT PR; Gao W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001410; General Medical Council, 2010, TREATM CAR END LIF G; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; GOMES B, 2013, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD007760.PUB2; Gomes B, 2012, BMJ SUPPORT PALLIAT, V2, P6; Gomes B., 2011, LOCAL PREFERENCES PL; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Gomez-Batiste X, 2012, BMJ SUPPORT PALLIAT; Gott M, 2004, PALLIATIVE MED, V18, P460, DOI 10.1191/0269216304pm889oa; Grande GE, 2004, J PALLIATIVE CARE, V20, P69, DOI 10.1177/082585970402000202; Grant L, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4859; Grbich Carol, 2005, Palliat Support Care, V3, P5; Gruneir A, 2007, MED CARE RES REV, V64, P351, DOI 10.1177/1077558707301810; Harding R, 2013, PSYCHOONCOLOGY, DOI 10.1002/pon.3283; Harrison N, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X641465; Hasselaar J, 2012, BMJ-BRIT MED J, V2, P4; Houttekier D, 2010, J AM GERIATR SOC, V58, P751, DOI 10.1111/j.1532-5415.2010.02771.x; Hughes PM, 2010, PALLIATIVE MED, V24, P68, DOI 10.1177/0269216309346591; Hughes-Hallett T, 2011, FUNDING RIGHT CARE S; Jones J, 1999, BMJ-BRIT MED J, V319, P1547, DOI 10.1136/bmj.319.7224.1547; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Lyons P., 2011, BMJ SUPPORT PALLIAT, V1, P81, DOI [DOI 10.1136/BMJSPCARE-2011-000053.54, 10.1136/bmjspcare-2011-000053.54]; Millington-Sanders C, 2013, EPACCS NATL CONTEXT; Mitchell GK, 2002, PALLIATIVE MED, V16, P457, DOI 10.1191/0269216302pm573oa; National Audit Office, 2008, END LIFE CARE; National Center forHealth Statistics, 2011, HLTH US 2010 SPEC FE; National Institute for Clinical Excellence, 2004, IMPR SUPP PALL CAR A; Petkova H., 2012, UNDERSTANDING PLACE; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Royal College of General Practitioners, 2013, RCGP COMM GUID END L; Royal College of Physicians and British Society of Gastroenterology, 2010, OR FEED DIFF DIL GUI; Shepperd S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009231; Shepperd S, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007491; Sleeman KE, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2174; Thomas K, 2007, PALLIATIVE MED, V21, P49, DOI 10.1177/0269216306072501; Thoonsen B, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X654597; Tibaldi V, 2004, ARCH GERONTOL GERIAT, P431; Travis SS, 2002, GERONTOLOGIST, V42, P342, DOI 10.1093/geront/42.3.342	52	13	13	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2013	347								f4085	10.1136/bmj.f4085	http://dx.doi.org/10.1136/bmj.f4085			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	180CZ	23823993				2023-01-03	WOS:000321571800001
J	Banugaria, SG; Prater, SN; Patel, TT; DeArmey, SM; Milleson, C; Sheets, KB; Bali, DS; Rehder, CW; Raiman, JAJ; Wang, RA; Labarthe, F; Charrow, J; Harmatz, P; Chakraborty, P; Rosenberg, AS; Kishnani, PS				Banugaria, Suhrad G.; Prater, Sean N.; Patel, Trusha T.; DeArmey, Stephanie M.; Milleson, Christie; Sheets, Kathryn B.; Bali, Deeksha S.; Rehder, Catherine W.; Raiman, Julian A. J.; Wang, Raymond A.; Labarthe, Francois; Charrow, Joel; Harmatz, Paul; Chakraborty, Pranesh; Rosenberg, Amy S.; Kishnani, Priya S.			Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT	PLOS ONE			English	Article							ENZYME REPLACEMENT THERAPY; ACID ALPHA-GLUCOSIDASE; ALGLUCOSIDASE ALPHA; CLINICAL-OUTCOMES; ANTIBODIES	Objective: Although enzyme replacement therapy (ERT) is a highly effective therapy, CRIM-negative (CN) infantile Pompe disease (IPD) patients typically mount a strong immune response which abrogates the efficacy of ERT, resulting in clinical decline and death. This study was designed to demonstrate that immune tolerance induction (ITI) prevents or diminishes the development of antibody titers, resulting in a better clinical outcome compared to CN IPD patients treated with ERT monotherapy. Methods: We evaluated the safety, efficacy and feasibility of a clinical algorithm designed to accurately identify CN IPD patients and minimize delays between CRIM status determination and initiation of an ITI regimen (combination of rituximab, methotrexate and IVIG) concurrent with ERT. Clinical and laboratory data including measures of efficacy analysis for response to ERT were analyzed and compared to CN IPD patients treated with ERT monotherapy. Results: Seven CN IPD patients were identified and started on the ITI regimen concurrent with ERT. Median time from diagnosis of CN status to commencement of ERT and ITI was 0.5 months (range: 0.1-1.6 months). At baseline, all patients had significant cardiomyopathy and all but one required respiratory support. The ITI regimen was safely tolerated in all seven cases. Four patients never seroconverted and remained antibody-free. One patient died from respiratory failure. Two patients required another course of the ITI regimen. In addition to their clinical improvement, the antibody titers observed in these patients were much lower than those seen in ERT monotherapy treated CN patients. Conclusions: The ITI regimen appears safe and efficacious and holds promise in altering the natural history of CN IPD by increasing ERT efficacy. An algorithm such as this substantiates the benefits of accelerated diagnosis and management of CN IPD patients, thus, further supporting the importance of early identification and treatment initiation with newborn screening for IPD.	[Banugaria, Suhrad G.; Prater, Sean N.; Patel, Trusha T.; DeArmey, Stephanie M.; Milleson, Christie; Sheets, Kathryn B.; Bali, Deeksha S.; Kishnani, Priya S.] Duke Univ, Med Ctr, Dept Pediat, Div Med Genet, Durham, NC 27710 USA; [Rehder, Catherine W.] Duke Univ Hlth Syst, Clin Mol Diagnost Labs, Durham, NC USA; [Raiman, Julian A. J.] Univ Toronto, Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada; [Wang, Raymond A.] Childrens Hosp Orange Cty, Orange, CA 92668 USA; [Labarthe, Francois] Univ Hosp, Hop Clocheville, Tours, France; [Charrow, Joel] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA; [Harmatz, Paul] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA; [Chakraborty, Pranesh] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Rosenberg, Amy S.] US FDA, Div Therapeut Prot, Off Biotechnol Prod, Ctr Drug Evaluat & Res, Bethesda, MD 20014 USA	Duke University; Duke University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Childrens Hospital of Orange County; CHU Tours; Northwestern University; Feinberg School of Medicine; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland; University of Ottawa; US Food & Drug Administration (FDA)	Kishnani, PS (corresponding author), Duke Univ, Med Ctr, Dept Pediat, Div Med Genet, Durham, NC 27710 USA.	priya.kishnani@duke.edu	Wang, Raymond Yu Jeang/H-8870-2019; Harmatz, Paul/AAY-5866-2020; Wang, Raymond Yu Jeang/CAJ-3535-2022	Wang, Raymond Yu Jeang/0000-0001-6494-7613; Harmatz, Paul/0000-0001-5603-2085; 	Lysosomal Disease Network, a part of National Institutes of Health Rare Diseases Clinical Research Network (RDCRN); NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS) [U54NS065768]; National Institute of Neurological Disorders and Stroke (NINDS) [U54NS065768]; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [U54NS065768]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS065768] Funding Source: NIH RePORTER	Lysosomal Disease Network, a part of National Institutes of Health Rare Diseases Clinical Research Network (RDCRN); NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was funded in part by the Lysosomal Disease Network, a part of National Institutes of Health Rare Diseases Clinical Research Network (RDCRN). The Lysosomal Disease Network (U54NS065768) is a part of the National Institutes of Health (NIH) Rare Diseases Clinical Research Network (RDCRN), supported through collaboration between the NIH Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Science (NCATS), the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank the patients and their families who participated in this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott MA, 2011, MOL GENET METAB, V104, P583, DOI 10.1016/j.ymgme.2011.08.003; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Bali DS, 2012, AM J MED GENET C, V160C, P40, DOI 10.1002/ajmg.c.31319; Banugaria SG, 2012, GENET MED; Banugaria SG, 2012, EXPERT REV CLIN IMMU, V8, P497, DOI 10.1586/ECI.12.40; Banugaria SG, 2012, MOL GENET METAB, V105, P677, DOI 10.1016/j.ymgme.2012.01.019; Banugaria SG, 2011, GENET MED, V13, P729, DOI 10.1097/GIM.0b013e3182174703; Chien YH, 2009, PEDIATRICS, V124, pE1116, DOI 10.1542/peds.2008-3667; HALL PD, 1993, PHARMACOTHERAPY, V13, P564; HERS HG, 1963, BIOCHEM J, V86, P11, DOI 10.1042/bj0860011; Hirschhorn R, 2009, GLYCOGEN STORAGE DIS; Hunley TE, 2004, PEDIATRICS, V114, pE532, DOI 10.1542/peds.2003-0988-L; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Khallaf HA, 2013, JIMD REPORTS CASE RE, P133; Kishnani PS, 2007, NEUROLOGY, V68, P99, DOI 10.1212/01.wnl.0000251268.41188.04; Kishnani PS, 2010, MOL GENET METAB, V99, P26, DOI 10.1016/j.ymgme.2009.08.003; Kishnani PS, 2009, PEDIATR RES, V66, P329, DOI 10.1203/PDR.0b013e3181b24e94; Kishnani PS, 2006, J PEDIATR-US, V149, P89, DOI 10.1016/j.jpeds.2006.02.035; Mendelsohn NJ, 2009, NEW ENGL J MED, V360, P194, DOI 10.1056/NEJMc0806809; Messinger YH, 2012, GENET MED, V14, P135, DOI 10.1038/gim.2011.4; Moyer VA, 2008, HASTINGS CENT REP, V38, P32, DOI 10.1353/hcr.0.0011; Nicolino M, 2009, GENET MED, V11, P210, DOI 10.1097/GIM.0b013e31819d0996; Prater SN, 2012, GENET MED, V14, P800, DOI 10.1038/gim.2012.44; Rezvani AR, 2011, BEST PRACT RES CL HA, V24, P203, DOI 10.1016/j.beha.2011.02.009; Rigter T, 2012, MOL GENET METAB, V107, P448, DOI 10.1016/j.ymgme.2012.09.017; Rohrbach M, 2010, J INHERIT METAB DIS, V33, P751, DOI 10.1007/s10545-010-9209-0	26	82	85	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2013	8	6							e67052	10.1371/journal.pone.0067052	http://dx.doi.org/10.1371/journal.pone.0067052			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175IB	23825616	Green Submitted, Green Published, gold			2023-01-03	WOS:000321223000068
J	Rathleff, MS; Thorborg, K; Bandholm, T				Rathleff, Michael Skovdal; Thorborg, Kristian; Bandholm, Thomas			Concentric and Eccentric Time-Under-Tension during Strengthening Exercises: Validity and Reliability of Stretch-Sensor Recordings from an Elastic Exercise-Band	PLOS ONE			English	Article							SUBACROMIAL IMPINGEMENT SYNDROME; RANDOMIZED CONTROLLED-TRIAL; KNEE OSTEOARTHRITIS; CONTRACTION TYPES; MUSCLE STRENGTH; HOME EXERCISE; PROGRAM; TENDON; MANAGEMENT; ACHILLES	Background: Total, single repetition and contraction-phase specific (concentric and eccentric) time-under-tension (TUT) are important exercise-descriptors, as they are linked to the physiological and clinical response in exercise and rehabilitation. Objective: To investigate the validity and reliability of total, single repetition, and contraction-phase specific TUT during shoulder abduction exercises, based on data from a stretch-sensor attached to an elastic exercise band. Methods: A concurrent validity and interrater reliability study with two raters was conducted. Twelve participants performed five sets of 10 repetitions of shoulder abduction exercises with an elastic exercise band. Exercises were video-recorded to assess concurrent validity between TUT from stretch-sensor data and from video recordings (gold standard). Agreement between methods was calculated using Limits of Agreement (LoA), and the association was assessed by Pearson correlation coefficients. Interrater reliability was calculated using intraclass correlation coefficients (ICC 2.1). Results: Total, single repetition, and contraction-phase specific TUT-determined from video and stretch-sensor data-were highly correlated (r>0.99). Agreement between methods was high, as LoA ranged from 0.0 to 3.1 seconds for total TUT (2.6% of mean TUT), from -0.26 to 0.56 seconds for single repetition TUT (6.9%), and from -0.29 to 0.56 seconds for contraction-phase specific TUT (13.2-21.1%). Interrater reliability for total, single repetition and contraction-phase specific TUT was high (ICC>0.99). Interrater agreement was high, as LoA ranged from -2.11 to 2.56 seconds for total TUT (4.7%), from -0.46 to 0.50 seconds for single repetition TUT (9.7%) and from -0.41 to 0.44 seconds for contraction-phase specific TUT (5.2-14.5%). Conclusion: Data from a stretch-sensor attached to an elastic exercise band is a valid measure of total and single repetition time-under-tension, and the procedure is highly reliable. This method will enable clinicians and researchers to objectively quantify if home-based exercises are performed as prescribed, with respect to time-under-tension.	[Rathleff, Michael Skovdal] Aalborg Univ Hosp, Orthopaed Surg Res Unit, Aalborg, Denmark; [Thorborg, Kristian] Univ Copenhagen Hosp, Arthroscop Ctr Amager, DK-2100 Copenhagen, Denmark; [Thorborg, Kristian; Bandholm, Thomas] Copenhagen Univ Hosp, Dept Orthoped Surg, Hvidovre, Denmark; [Thorborg, Kristian; Bandholm, Thomas] Copenhagen Univ Hosp, Dept Phys Therapy Phys Med & Rehabil Res Copenhag, Hvidovre, Denmark; [Bandholm, Thomas] Univ Copenhagen Hosp, Clin Res Ctr, DK-2100 Copenhagen, Denmark	Aalborg University; Aalborg University Hospital; University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen	Rathleff, MS (corresponding author), Aalborg Univ Hosp, Orthopaed Surg Res Unit, Aalborg, Denmark.	michaelrathleff@gmail.com	Bandholm, Thomas/AAZ-8632-2020	Bandholm, Thomas/0000-0001-6884-1971; Rathleff, Michael Skovdal/0000-0003-1173-0335	Bevica Foundation	Bevica Foundation	The Bevica Foundation paid supplied funding for the hardware used in the current study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez RG, 2006, FOOT ANKLE INT, V27, P2, DOI 10.1177/107110070602700102; Andersen LL, 2011, PAIN, V152, P440, DOI 10.1016/j.pain.2010.11.016; Beers Amanda, 2008, Physiother Can, V60, P180, DOI 10.3138/physio.60.2.180; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brown S, 2010, TLS-TIMES LIT SUPPL, P24; Buitrago S, 2012, EUR J APPL PHYSIOL, V112, P2739, DOI 10.1007/s00421-011-2249-9; Burd NA, 2012, J PHYSIOL-LONDON, V590, P351, DOI 10.1113/jphysiol.2011.221200; Comstock BA, 2011, J STRENGTH COND RES, V25, P2293, DOI 10.1519/JSC.0b013e318200b78c; Dunstan DW, 2005, DIABETES CARE, V28, P3, DOI 10.2337/diacare.28.1.3; ELIASZIW M, 1994, PHYS THER, V74, P777, DOI 10.1093/ptj/74.8.777; Heinemeier KM, 2007, J PHYSIOL-LONDON, V582, P1303, DOI 10.1113/jphysiol.2007.127639; Heinemeier KM, 2007, J APPL PHYSIOL, V102, P573, DOI 10.1152/japplphysiol.00866.2006; Holmgren T, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e787; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; Kappel SL, 2012, SENSORS; Kaux JF, 2013, J ORTHOP RES, V31, P119, DOI 10.1002/jor.22202; Kottner J, 2011, INT J NURS STUD, V48, P661, DOI 10.1016/j.ijnurstu.2011.01.016; Kuhn JE, 2009, J SHOULDER ELB SURG, V18, P138, DOI 10.1016/j.jse.2008.06.004; Mafi N, 2001, KNEE SURG SPORT TR A, V9, P42, DOI 10.1007/s001670000148; Malliaras P, 2013, SPORTS MED, V43, P267, DOI 10.1007/s40279-013-0019-z; McCarthy CJ, 2004, RHEUMATOLOGY, V43, P880, DOI 10.1093/rheumatology/keh188; McLean SM, 2010, MANUAL THER, V15, P514, DOI 10.1016/j.math.2010.05.012; Mohamad NI, 2011, STRENGTH COND J, V33, P81, DOI 10.1519/SSC.0b013e3181fe7164; Or CKL, 2011, J AM MED INFORM ASSN, V18, P51, DOI 10.1136/jamia.2010.007336; Rathleff MS, 2013, BRIT J SPORT MED; Ravaud P, 2004, ANN RHEUM DIS, V63, P703, DOI 10.1136/ard.2003.009803; Roig M, 2009, BRIT J SPORT MED, V43, P556, DOI 10.1136/bjsm.2008.051417; Schoenfeld BJ, 2010, J STRENGTH COND RES, V24, P2857, DOI 10.1519/JSC.0b013e3181e840f3; Thomas KS, 2005, ARTHRIT RHEUM-ARTHR, V53, P388, DOI 10.1002/art.21173; Thomas KS, 2002, BMJ-BRIT MED J, V325, P752, DOI 10.1136/bmj.325.7367.752; Toigo M, 2006, EUR J APPL PHYSIOL, V97, P643, DOI 10.1007/s00421-006-0238-1; Tran QT, 2006, EUR J APPL PHYSIOL, V98, P402, DOI 10.1007/s00421-006-0297-3; Walther M, 2004, J SHOULDER ELB SURG, V13, P417, DOI 10.1016/j.jse.2004.02.002; Yu J, 2013, AM J PHYS MED REHAB, V92, P68, DOI 10.1097/PHM.0b013e31826eda63	34	13	13	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2013	8	6							e68172	10.1371/journal.pone.0068172	http://dx.doi.org/10.1371/journal.pone.0068172			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175IB	23825696	Green Published, Green Submitted, gold			2023-01-03	WOS:000321223000130
J	Gong, P; Zhang, MY; Zhao, H; Tang, ZR; Hua, R; Mei, X; Cui, J; Li, CS				Gong, Ping; Zhang, Ming-Yue; Zhao, Hong; Tang, Zi-Ren; Hua, Rong; Mei, Xue; Cui, Juan; Li, Chun-Sheng			Effect of Mild Hypothermia on the Coagulation-Fibrinolysis System and Physiological Anticoagulants after Cardiopulmonary Resuscitation in a Porcine Model	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; THERAPEUTIC HYPOTHERMIA; COAGULOPATHY; INFLAMMATION; COMPRESSIONS; ACTIVATION; MECHANISMS; HEART; CARE	The aim of this study was to evaluate the effect of mild hypothermia on the coagulation-fibrinolysis system and physiological anticoagulants after cardiopulmonary resuscitation (CPR). A total of 20 male Wuzhishan miniature pigs underwent 8 min of untreated ventricular fibrillation and CPR. Of these, 16 were successfully resuscitated and were randomized into the mild hypothermia group (MH, n = 8) or the control normothermia group (CN, n = 8). Mild hypothermia (33 degrees C) was induced intravascularly, and this temperature was maintained for 12 h before pigs were actively rewarmed. The CN group received normothermic post-cardiac arrest (CA) care for 72 h. Four animals were in the sham operation group (SO). Blood samples were taken at baseline, and 0.5, 6, 12, 24, and 72 h after ROSC. Whole-body mild hypothermia impaired blood coagulation during cooling, but attenuated blood coagulation impairment at 72 h after ROSC. Mild hypothermia also increased serum levels of physiological anticoagulants, such as PRO C and AT-III during cooling and after rewarming, decreased EPCR and TFPI levels during cooling but not after rewarming, and inhibited fibrinolysis and platelet activation during cooling and after rewarming. Finally, mild hypothermia did not affect coagulation-fibrinolysis, physiological anticoagulants, or platelet activation during rewarming. Thus, our findings indicate that mild hypothermia exerted an anticoagulant effect during cooling, which may have inhibitory effects on microthrombus formation. Furthermore, mild hypothermia inhibited fibrinolysis and platelet activation during cooling and attenuated blood coagulation impairment after rewarming. Slow rewarming had no obvious adverse effects on blood coagulation.	[Gong, Ping] Dalian Med Univ, Hosp Affiliated 1, Dept Emergency, Dalian, Liaoning, Peoples R China; [Zhang, Ming-Yue; Zhao, Hong; Tang, Zi-Ren; Hua, Rong; Mei, Xue; Cui, Juan; Li, Chun-Sheng] Capital Med Univ, Dept Emergency, Beijing Chaoyang Hosp, Beijing, Peoples R China	Dalian Medical University; Capital Medical University	Li, CS (corresponding author), Capital Med Univ, Dept Emergency, Beijing Chaoyang Hosp, Beijing, Peoples R China.	lcscyyy@163.com	Gong, Ping/AAV-1936-2021	Gong, Ping/0000-0001-9910-7948	National Natural Science Foundation of China [30972863]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 30972863, http://159.226.244.22/portal/proj_search.asp). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adrie C, 2005, J AM COLL CARDIOL, V46, P21, DOI 10.1016/j.jacc.2005.03.046; Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Adrie Christophe, 2004, Curr Opin Crit Care, V10, P208, DOI 10.1097/01.ccx.0000126090.06275.fe; Andre P, 2004, BRIT J HAEMATOL, V126, P298, DOI 10.1111/j.1365-2141.2004.05032.x; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bottiger B W, 2001, Curr Opin Crit Care, V7, P176; BOTTIGER BW, 1995, CIRCULATION, V92, P2572, DOI 10.1161/01.CIR.92.9.2572; Bottiger BW, 2002, CRIT CARE MED, V30, P2473, DOI 10.1097/01.CCM.0000034689.78033.E2; Esmon CT, 2003, J ENDOTOXIN RES, V9, P192, DOI 10.1179/096805103125001603; Esmon CT, 2004, MATURITAS, V47, P305, DOI 10.1016/j.maturitas.2003.10.015; Fischer M, 1996, INTENS CARE MED, V22, P1214; Gando S, 1997, THROMB HAEMOSTASIS, V77, P278; Gong P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035313; Green David, 2006, Hemodial Int, V10 Suppl 2, pS2, DOI 10.1111/j.1542-4758.2006.00119.x; Hekimian G, 2004, SHOCK, V22, P116, DOI 10.1097/01.shk.0000132489.79498.c7; Hu CL, 2011, AM J EMERG MED, V29, P1103, DOI 10.1016/j.ajem.2010.07.016; Hua R, 2012, AM J EMERG MED, V30, P1420, DOI 10.1016/j.ajem.2011.10.022; Ji XF, 2012, RESUSCITATION, V83, P640, DOI 10.1016/j.resuscitation.2011.11.014; Ji XF, 2011, SHOCK, V35, P530, DOI 10.1097/SHK.0b013e31820e2058; Ji XF, 2010, RESUSCITATION, V81, P1031, DOI 10.1016/j.resuscitation.2010.04.023; Kazanskaya GM, 1999, MICROVASC RES, V58, P250, DOI 10.1006/mvre.1999.2181; Levi M, 2003, CARDIOVASC RES, V60, P26, DOI 10.1016/S0008-6363(02)00857-X; Meybohm P, 2010, CRIT CARE, V14, DOI 10.1186/cc8879; Meybohm P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007588; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nolan JP, 2007, ANAESTHESIA, V62, P1207, DOI 10.1111/j.1365-2044.2007.05232.x; Nozza S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037032; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; Schochl H, 2013, RESUSCITATION, V84, P454, DOI 10.1016/j.resuscitation.2012.08.318; Staikou C, 2011, J SURG RES, V167, P125, DOI 10.1016/j.jss.2009.07.037; Su ZY, 2011, AM J EMERG MED, V29, P913, DOI 10.1016/j.ajem.2010.04.001; Tang ZR, 2013, AM J EMERG MED, V31, P86, DOI 10.1016/j.ajem.2012.06.008; VALERI CR, 1995, CRIT CARE MED, V23, P698, DOI 10.1097/00003246-199504000-00019; VALERI CR, 1987, ANN SURG, V205, P175, DOI 10.1097/00000658-198702000-00012; van der Spuy WJ, 2012, REV NEUROSCIENCE, V23, P269, DOI 10.1515/revneuro-2012-0028; Wang S, 2010, CRIT CARE MED, V38, P2024, DOI 10.1097/CCM.0b013e3181eed90a; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Wu JY, 2009, AM J EMERG MED, V27, P823, DOI 10.1016/j.ajem.2008.07.001; Zhao H, 2012, RESUSCITATION, V83, P913, DOI 10.1016/j.resuscitation.2012.01.001	40	17	22	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 20	2013	8	6							e67476	10.1371/journal.pone.0067476	http://dx.doi.org/10.1371/journal.pone.0067476			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190LY	23818980	Green Submitted, Green Published, gold			2023-01-03	WOS:000322342800137
J	Dong, MH; Zhao, L; Yuan, K; Zeng, F; Sun, JB; Liu, JX; Yu, DH; von Deneen, KM; Liang, FR; Qin, W; Tian, J				Dong, Minghao; Zhao, Ling; Yuan, Kai; Zeng, Fang; Sun, Jinbo; Liu, Jixin; Yu, Dahua; von Deneen, Karen M.; Liang, Fanrong; Qin, Wei; Tian, Jie			Length of Acupuncture Training and Structural Plastic Brain Changes in Professional Acupuncturists	PLOS ONE			English	Article							TACTILE SPATIAL-RESOLUTION; HUMAN CEREBELLUM; PREFRONTAL CORTEX; MR-IMAGES; MECHANISMS; PAIN; DISCRIMINATION; REGISTRATION; RELIABILITY; CINGULATE	Background: The research on brain plasticity has fascinated researchers for decades. Use/training serves as an instrumental factor to influence brain neuroplasticity. Parallel to acquisition of behavioral expertise, extensive use/training is concomitant with substantial changes of cortical structure. Acupuncturists, serving as a model par excellence to study tactile-motor and emotional regulation plasticity, receive intensive training in national medical schools following standardized training protocol. Moreover, their behavioral expertise is corroborated during long-term clinical practice. Although our previous study reported functional plastic brain changes in the acupuncturists, whether or not structural plastic changes occurred in acupuncturists is yet elusive. Methodology/Principal Findings: Cohorts of acupuncturists (N = 22) and non-acupuncturists (N = 22) were recruited. Behavioral tests were delivered to assess the acupuncturists' behavioral expertise. The results confirmed acupuncturists' tactile-motor skills and emotion regulation proficiency compared to non-acupuncturists. Using the voxel-based morphometry technique, we revealed larger grey matter volumes in acupuncturists in the hand representation of the contralateral primary somatosensory cortex (SI), the right lobule V/VI and the bilateral ventral anterior cingulate cortex/ventral medial prefrontal cortex. Grey matter volumes of the SI and Lobule V/VI positively correlated with the duration of acupuncture practice. Conclusions: To our best knowledge, this study provides first evidence for the anatomical alterations in acupuncturists, which would possibly be the neural correlates underlying acupuncturists' exceptional skills. On one hand, we suggest our findings may have ramifications for tactile-motor rehabilitation. On the other hand, our results in emotion regulation domain may serve as a target for our future studies, from which we can understand how modulations of aversive emotions elicited by empathic pain develop in the context of expertise. Future longitudinal study is necessary to establish the presence and direction of a causal link between practice/use and brain anatomy.	[Dong, Minghao; Yuan, Kai; Sun, Jinbo; Liu, Jixin; Yu, Dahua; von Deneen, Karen M.; Qin, Wei; Tian, Jie] Xidian Univ, Sch Life Sci & Technol, Xian, Shaanxi, Peoples R China; [Zhao, Ling; Zeng, Fang; Liang, Fanrong] Chengdu Univ Tradit Chinese Med, Teaching Hosp 3, Chengdu, Sichuan, Peoples R China; [Yu, Dahua] Inner Mongolia Univ Sci & Technol, Sch Informat Engn, Informat Proc Lab, Baotou, Inner Mongolia, Peoples R China; [Tian, Jie] Chinese Acad Sci, Inst Automat, Beijing, Peoples R China	Xidian University; Chengdu University of Traditional Chinese Medicine; Inner Mongolia University of Science & Technology; Chinese Academy of Sciences; Institute of Automation, CAS	Qin, W (corresponding author), Xidian Univ, Sch Life Sci & Technol, Xian, Shaanxi, Peoples R China.	wqin@xidian.edu.cn; tian@ieee.org	Dong, Minghao/A-6425-2014; Yu, Dahua/N-7242-2013; 秦, 伟/J-9770-2016; Yuan, Kai/M-9403-2013; JinBo, Sun/GLT-2082-2022; tian, jie/M-6336-2013; Tian, Jie/H-1190-2011; Life, PAM/M-9552-2013; Yuan, Kai/I-4150-2016	Dong, Minghao/0000-0002-0190-6985; Yu, Dahua/0000-0001-7850-7512; 秦, 伟/0000-0003-4583-0406; Tian, Jie/0000-0003-0498-0432; Yuan, Kai/0000-0002-3098-1124; Liang, Fanrong/0000-0003-2210-2027	Project for the National Key Basic Research and Development Program (973) [2011CB707702, 2012CB518501]; National Natural Science Foundation of China [30930112, 30970774, 81000640, 81000641, 81101036, 81030027, 81101108, 31150110171, 30901900, 81271644, 31200837]; Fundamental Research Funds for the Central Universities	Project for the National Key Basic Research and Development Program (973)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This paper is supported by the Project for the National Key Basic Research and Development Program (973) under Grant Nos. 2011CB707702, 2012CB518501, the National Natural Science Foundation of China under Grant Nos. 30930112, 30970774, 81000640, 81000641, 81101036, 81030027, 81101108, 31150110171, 30901900, 81271644, 31200837, the Fundamental Research Funds for the Central Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert J, 2011, HUM BRAIN MAPP; Andersson J.L.R, 2007, TR07JA2 FMRIB; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ballmaier M, 2004, AM J PSYCHIAT, V161, P99, DOI 10.1176/appi.ajp.161.1.99; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; Cheng XN, 2010, CHINESE ACUPUNCTURE; Cheng YW, 2007, CURR BIOL, V17, P1708, DOI 10.1016/j.cub.2007.09.020; Cicchetti DV, 2001, J CLIN EXP NEUROPSYC, V23, P695, DOI 10.1076/jcen.23.5.695.1249; Davis M. H., 1994, EMPATHY SOCIAL PSYCH; Diedrichsen J, 2010, CURR OPIN NEUROL, V23, P382, DOI 10.1097/WCO.0b013e32833be837; Diedrichsen J, 2009, NEUROIMAGE, V46, P39, DOI 10.1016/j.neuroimage.2009.01.045; Diedrichsen J, 2006, NEUROIMAGE, V33, P127, DOI 10.1016/j.neuroimage.2006.05.056; Doherty RW, 1997, J NONVERBAL BEHAV, V21, P131, DOI 10.1023/A:1024956003661; Draganski B, 2008, BEHAV BRAIN RES, V192, P137, DOI 10.1016/j.bbr.2008.02.015; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; Fields RD, 2011, NEUROSCIENTIST, V17, P185, DOI 10.1177/1073858410383696; Franklin DW, 2011, NEURON, V72, P425, DOI 10.1016/j.neuron.2011.10.006; Goldreich D, 2003, J NEUROSCI, V23, P3439; Good C, 2002, VOXEL BASED MORPHOME; Grodd W, 2001, HUM BRAIN MAPP, V13, P55, DOI 10.1002/hbm.1025; Hanggi J, 2010, HUM BRAIN MAPP, V31, P1196, DOI 10.1002/hbm.20928; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Herdener M, 2010, J NEUROSCI, V30, P1377, DOI 10.1523/JNEUROSCI.4513-09.2010; Jancke L, 2009, RESTOR NEUROL NEUROS, V27, P521, DOI 10.3233/RNN-2009-0519; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; JOHNSON KO, 1992, ANNU REV NEUROSCI, V15, P227, DOI 10.1146/annurev.ne.15.030192.001303; JOHNSON KO, 1981, J NEUROPHYSIOL, V46, P1177, DOI 10.1152/jn.1981.46.6.1177; Koeneke S, 2004, NEUROREPORT, V15, P1279, DOI 10.1097/01.wnr.0000127463.10147.e7; Lamm C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001292; Larsell O, 1972, COMP ANATOMY HISTOLO; Lissek S, 2009, CURR BIOL, V19, P837, DOI 10.1016/j.cub.2009.03.065; Luders E, 2009, NEUROIMAGE, V45, P672, DOI 10.1016/j.neuroimage.2008.12.061; Manto MU, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00001; May A, 2011, TRENDS COGN SCI; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.1.30; Munte TF, 2002, NAT REV NEUROSCI, V3, P473, DOI 10.1038/nrn843; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park IS, 2009, CEREBELLUM, V8, P334, DOI 10.1007/s12311-009-0100-1; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; Quirk GJ, 2006, CURR OPIN NEUROBIOL, V16, P723, DOI 10.1016/j.conb.2006.07.004; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Sathian K, 1996, NEUROLOGY, V46, P1464, DOI 10.1212/WNL.46.5.1464; Schmahmann J.D., 2000, MRI ATLAS HUMAN CERE; Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stoodley CJ, 2009, NEUROIMAGE, V44, P489, DOI 10.1016/j.neuroimage.2008.08.039; Tegenthoff M, 2005, PLOS BIOL, V3, P2031, DOI 10.1371/journal.pbio.0030362; Van Boven RW, 2000, NEUROLOGY, V54, P2230; Van Boven RW, 2005, P NATL ACAD SCI USA, V102, P12601, DOI 10.1073/pnas.0505907102; VANBOVEN RW, 1994, BRAIN, V117, P149, DOI 10.1093/brain/117.1.149; Vogt BA, 2005, NAT REV NEUROSCI, V6, P533, DOI 10.1038/nrn1704; Wolpert DM, 2011, NAT REV NEUROSCI; Wong M, 2011, J NEUROSCI, V31, P7028, DOI 10.1523/JNEUROSCI.6461-10.2011; Yang J. C., 1983, PAIN MEASUREMENT ASS; Zhang MM, 2005, HUM BRAIN MAPP, V25, P370, DOI 10.1002/hbm.20107; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	61	8	8	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2013	8	6							e66591	10.1371/journal.pone.0066591	http://dx.doi.org/10.1371/journal.pone.0066591			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190ST	23840505	gold, Green Submitted, Green Published			2023-01-03	WOS:000322361200094
J	Lu, RM; Chen, MS; Chang, DK; Chiu, CY; Lin, WC; Yan, SL; Wang, YP; Kuo, YS; Yeh, CY; Lo, A; Wu, HC				Lu, Ruei-Min; Chen, Min-Shan; Chang, De-Kuan; Chiu, Chien-Yu; Lin, Wei-Chuan; Yan, Shin-Long; Wang, Yi-Ping; Kuo, Yuan-Sung; Yeh, Chen-Yun; Lo, Albert; Wu, Han-Chung			Targeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging	PLOS ONE			English	Article							SINGLE-CHAIN FV; MACROMOLECULAR THERAPEUTICS; EFFICACY; PENETRATION; LIPOSOMES; IMMUNOLIPOSOMES; NANOTECHNOLOGY; MECHANISM; CARCINOMA; AFFINITY	Targeted delivery of drugs to tumors represents a significant advance in cancer diagnosis and therapy. Therefore, development of novel tumor-specific ligands or pharmaceutical nanocarriers is highly desirable. In this study, we utilized phage display to identify a new targeting peptide, SP90, which specifically binds to breast cancer cells, and recognizes tumor tissues from breast cancer patients. We used confocal and electron microscopy to reveal that conjugation of SP90 with liposomes enables efficient delivery of drugs into cancer cells through endocytosis. Furthermore, in vivo fluorescent imaging demonstrated that SP90-conjugated quantum dots possess tumor-targeting properties. In tumor xenograft and orthotopic models, SP90-conjugated liposomal doxorubicin was found to improve the therapeutic index of the chemotherapeutic drug by selectively increasing its accumulation in tumors. We conclude that the targeting peptide SP90 has significant potential in improving the clinical benefits of chemotherapy in the treatment and the diagnosis of breast cancer.	[Lu, Ruei-Min; Chen, Min-Shan; Chang, De-Kuan; Chiu, Chien-Yu; Lin, Wei-Chuan; Yan, Shin-Long; Wang, Yi-Ping; Yeh, Chen-Yun; Lo, Albert; Wu, Han-Chung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan; [Chen, Min-Shan; Wu, Han-Chung] Natl Taiwan Univ, Coll Med, Grad Inst Oral Biol, Taipei, Taiwan; [Kuo, Yuan-Sung] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Surg, Taipei 10764, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University; National Taiwan University Hospital	Wu, HC (corresponding author), Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.	hcw0928@gate.sinica.edu.tw	Wu, Han-Chung/B-1209-2011; Lu, Ruei-Min/ABF-4388-2021	Wu, Han-Chung/0000-0002-5185-1169; Lu, Ruei-Min/0000-0003-3792-5499; Wang, Yi-Ping/0000-0001-9574-2194	Academia Sinica; National Science Council, Taiwan [NSC-100-2325-B-001-011, NSC-100-2321-B-001-038]	Academia Sinica(Academia Sinica - Taiwan); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	Funding provided by Academia Sinica and National Science Council (NSC-100-2325-B-001-011 and NSC-100-2321-B-001-038), Taiwan (HCW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams GP, 2001, CANCER RES, V61, P4750; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]; Barenholz Y, 2012, J CONTROL RELEASE, V160, P117, DOI 10.1016/j.jconrel.2012.03.020; Bosslet K, 1998, CANCER RES, V58, P1195; Cai WB, 2008, NAT PROTOC, V3, P89, DOI 10.1038/nprot.2007.478; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chang DK, 2009, J BIOL CHEM, V284, P12905, DOI 10.1074/jbc.M900280200; Chang DK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004171; Cheng WW, 2010, EXPERT OPIN DRUG DEL, V7, P461, DOI 10.1517/17425240903579963; Cho HJ, 2012, BIOMATERIALS, V33, P1190, DOI 10.1016/j.biomaterials.2011.10.064; Cobleigh MA, 2011, SEMIN ONCOL, V38, pS11, DOI 10.1053/j.seminoncol.2011.04.005; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m; Hambley TW, 2009, CANCER RES, V69, P1259, DOI 10.1158/0008-5472.CAN-08-3786; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; IBER FL, 1958, J CLIN INVEST, V37, P1442, DOI 10.1172/JCI103735; Kohschutter J, 2008, EXPERT OPIN DRUG DEL, V5, P653, DOI [10.1517/17425240802145320, 10.1517/17425247.5.6.653 ]; Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010; Lee CMY, 2007, NAT PROTOC, V2, P3001, DOI 10.1038/nprot.2007.448; Lee TY, 2007, CANCER RES, V67, P10958, DOI 10.1158/0008-5472.CAN-07-2233; Lee TY, 2004, CANCER RES, V64, P8002, DOI 10.1158/0008-5472.CAN-04-1948; Lo A, 2008, MOL CANCER THER, V7, P579, DOI 10.1158/1535-7163.MCT-07-2359; Lu RM, 2011, BIOMATERIALS, V32, P3265, DOI 10.1016/j.biomaterials.2010.12.061; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Nellis DF, 2005, BIOTECHNOL PROGR, V21, P205, DOI 10.1021/bp049840y; O'Brien MER, 2004, ANN ONCOL, V15, P440, DOI 10.1093/annonc/mdh097; O'Shaughnessy JA, 2012, ONCOLOGIST, V17, P476, DOI 10.1634/theoncologist.2011-0281; Park JH, 2009, SMALL, V5, P694, DOI 10.1002/smll.200801789; Park JW, 2002, CLIN CANCER RES, V8, P1172; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rudnick SI, 2011, CANCER RES, V71, P2250, DOI 10.1158/0008-5472.CAN-10-2277; Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4; Shadidi M, 2002, FASEB J, V16, P256, DOI 10.1096/fj.02-0280fje; Shi JJ, 2010, NANO LETT, V10, P3223, DOI 10.1021/nl102184c; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Slingerland M, 2012, DRUG DISCOV TODAY, V17, P160, DOI 10.1016/j.drudis.2011.09.015; Svensen N, 2012, TRENDS PHARMACOL SCI, V33, P186, DOI 10.1016/j.tips.2012.02.002; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Torchilin V, 2008, EXPERT OPIN DRUG DEL, V5, P1003, DOI 10.1517/17425247.5.9.1003 ; Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006-1211; Wang T, 2010, NANOMEDICINE-UK, V5, P563, DOI 10.2217/NNM.10.30; Wu D.-K.C. Han-Chung, 2006, J CANC MOL, V2, P57; Wu HC, 2010, J ONCOL, V2010, DOI 10.1155/2010/723798	47	55	59	0	63	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2013	8	6							e66128	10.1371/journal.pone.0066128	http://dx.doi.org/10.1371/journal.pone.0066128			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	169CU	23776619	Green Published, Green Submitted, gold			2023-01-03	WOS:000320755400112
J	Walsh, AA; Szklarz, GD; Scott, EE				Walsh, Agnes A.; Szklarz, Grazyna D.; Scott, Emily E.			Human Cytochrome P450 1A1 Structure and Utility in Understanding Drug and Xenobiotic Metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; P450 1A1; HUMAN LUNG; CATALYTIC-ACTIVITIES; SUBSTRATE-BINDING; ACTIVATION; EXPRESSION; OXIDATION; CYP1A1; 1B1	Cytochrome P450 (CYP) 1A1 is an extrahepatic monooxygenase involved in the metabolism of endogenous substrates and drugs, as well as the activation of certain toxins and environmental pollutants. CYP1A1 is particularly well known for its ability to biotransform polycyclic aromatic hydrocarbons, such as benzo[a] pyrene in tobacco smoke, into carcinogens. CYP1A1 possesses functional similarities and differences with human CYP1A2 and CYP1B1 enzymes, but the structural basis for this has been unclear. We determined a 2.6 angstrom structure of human CYP1A1 with the inhibitor alpha-naphthoflavone. alpha-Naphthoflavone binds within an enclosed active site, with the planar benzochromen-4-one core packed flat against the I helix that composes one wall of the active site, and the 2-phenyl substituent oriented toward the catalytic heme iron. Comparisons with previously determined structures of the related cytochrome P450 1A2 and 1B1 enzymes reveal distinct features among the active sites that may underlie the functional variability of these enzymes. Finally, docking studies probed the ability of CYP1A structures to assist in understanding their known in vitro interactions with several typical substrates and inhibitors.	[Walsh, Agnes A.; Scott, Emily E.] Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA; [Szklarz, Grazyna D.] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA	University of Kansas; West Virginia University	Scott, EE (corresponding author), Univ Kansas, Dept Med Chem, 1251 Wescoe Hall Dr, Lawrence, KS 66045 USA.	eescott@ku.edu			National Institutes of Health [R01 GM076343, GM103393, RR001209, RR017708, GM103420]; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209, P20RR017708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103420, R01GM076343, P41GM103393] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants R01 GM076343 (to E.E.S.), RR001209 (to the Stanford Synchrotron Radiation Lightsource), GM103393 and RR001209 (to the SSRL Structural Molecular Biology Program), and RR017708 and GM103420 (to the Protein Structure Laboratory at the University of Kansas).	Androutsopoulos VP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-187; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Arnold C, 2010, PHARMACOL REP, V62, P536, DOI 10.1016/S1734-1140(10)70311-X; BAUER E, 1995, CHEM RES TOXICOL, V8, P136, DOI 10.1021/tx00043a018; Chi AC, 2009, ORAL ONCOL, V45, P980, DOI 10.1016/j.oraloncology.2009.05.562; Chun YJ, 1999, BIOCHEM BIOPH RES CO, V262, P20, DOI 10.1006/bbrc.1999.1152; Chun YJ, 2001, DRUG METAB DISPOS, V29, P389; De Kerkhof EGV, 2008, DRUG METAB DISPOS, V36, P604, DOI 10.1124/dmd.107.018820; Delano W.L, 2002, DELANO SCI; DeVore NM, 2009, DRUG METAB DISPOS, V37, P1319, DOI 10.1124/dmd.109.026765; Doostdar H, 2000, TOXICOLOGY, V144, P31, DOI 10.1016/S0300-483X(99)00215-2; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Ericksen SS, 2005, J BIOMOL STRUCT DYN, V23, P243, DOI 10.1080/07391102.2005.10507063; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hakkola J, 1996, BIOCHEM PHARMACOL, V52, P379, DOI 10.1016/0006-2952(96)00216-X; Hammons GJ, 1997, CARCINOGENESIS, V18, P851, DOI 10.1093/carcin/18.4.851; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; Hayes CL, 1996, P NATL ACAD SCI USA, V93, P9776, DOI 10.1073/pnas.93.18.9776; Honma W, 2005, ARCH BIOCHEM BIOPHYS, V435, P157, DOI 10.1016/j.abb.2004.12.014; Huang QB, 2012, DRUG METAB DISPOS, V40, P2324, DOI 10.1124/dmd.112.047308; Huang QB, 2010, DRUG METAB DISPOS, V38, P1039, DOI 10.1124/dmd.109.030767; Iba MM, 2010, TOXICOLOGY, V273, P35, DOI 10.1016/j.tox.2010.04.012; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010; Kim JH, 2004, TOXICOL APPL PHARM, V199, P210, DOI 10.1016/j.taap.2003.11.015; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Lautraite S, 2002, MUTAGENESIS, V17, P45, DOI 10.1093/mutage/17.1.45; Lee AJ, 2003, ENDOCRINOLOGY, V144, P3382, DOI 10.1210/en.2003-0192; Leong CO, 2003, BRIT J CANCER, V88, P470, DOI 10.1038/sj.bjc.6600719; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Liu JG, 2004, ARCH BIOCHEM BIOPHYS, V424, P33, DOI 10.1016/j.abb.2003.12.040; Liu JG, 2003, DRUG METAB DISPOS, V31, P412, DOI 10.1124/dmd.31.4.412; Ma XC, 2005, DRUG METAB DISPOS, V33, P489, DOI 10.1124/dmd.104.002410; Mast N, 2008, P NATL ACAD SCI USA, V105, P9546, DOI 10.1073/pnas.0803717105; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Nishimura M, 2003, YAKUGAKU ZASSHI, V123, P369; PAULSEN MD, 1992, J COMPUT AID MOL DES, V6, P449, DOI 10.1007/BF00130396; PAULSEN MD, 1991, PROTEINS, V11, P184, DOI 10.1002/prot.340110304; Piver B, 2004, BIOCHEM PHARMACOL, V68, P773, DOI 10.1016/j.bcp.2004.05.008; Porubsky PR, 2010, J BIOL CHEM, V285, P22282, DOI 10.1074/jbc.M110.109017; Reid JM, 1999, CLIN CANCER RES, V5, P2192; Rendic S, 2002, DRUG METAB REV, V34, P83, DOI 10.1081/DMR-120001392; Rendic S, 2012, CHEM RES TOXICOL, V25, P1316, DOI 10.1021/tx300132k; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; Sansen S, 2007, J BIOL CHEM, V282, P14348, DOI 10.1074/jbc.M611692200; Schwarz D, 2004, BIOCHEM PHARMACOL, V67, P1445, DOI 10.1016/j.bcp.2003.12.023; Shah MB, 2012, BIOCHEMISTRY-US, V51, P7225, DOI 10.1021/bi300894z; Shimada T, 2004, CANCER SCI, V95, P1, DOI 10.1111/j.1349-7006.2004.tb03162.x; SHIMADA T, 1992, MOL PHARMACOL, V41, P856; Shimada T, 1998, ARCH BIOCHEM BIOPHYS, V357, P111, DOI 10.1006/abbi.1998.0808; Shimada T, 1997, DRUG METAB DISPOS, V25, P617; Shimada T, 1996, CANCER RES, V56, P2979; Shimada T, 2006, DRUG METAB PHARMACOK, V21, P257, DOI 10.2133/dmpk.21.257; Shimada T, 2010, CHEM RES TOXICOL, V23, P1921, DOI 10.1021/tx100286d; Suter M, 2010, METABOLISM, V59, P1481, DOI 10.1016/j.metabol.2010.01.013; Szklarz GD, 2002, J BIOMOL STRUCT DYN, V20, P155, DOI 10.1080/07391102.2002.10506831; Tu Y, 2008, DRUG METAB DISPOS, V36, P2371, DOI 10.1124/dmd.108.022640; Turesky RJ, 1998, CHEM RES TOXICOL, V11, P925, DOI 10.1021/tx980022n; Wang A, 2012, J BIOL CHEM, V287, P10834, DOI 10.1074/jbc.M111.307918; Wang A, 2011, J BIOL CHEM, V286, P5736, DOI 10.1074/jbc.M110.204420; Willey JC, 1997, AM J RESP CELL MOL, V17, P114, DOI 10.1165/ajrcmb.17.1.2783; Wogan GN, 2004, SEMIN CANCER BIOL, V14, P473, DOI 10.1016/j.semcancer.2004.06.010; Yengi LG, 2003, ANAL BIOCHEM, V316, P103, DOI 10.1016/S0003-2697(03)00042-3; Zhao YG, 2007, BIOCHEMISTRY-US, V46, P11559, DOI 10.1021/bi7011614; Zhou SF, 2009, AAPS J, V11, P481, DOI 10.1208/s12248-009-9127-y	66	187	193	6	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2013	288	18					12932	12943		10.1074/jbc.M113.452953	http://dx.doi.org/10.1074/jbc.M113.452953			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	139AZ	23508959	Green Published, hybrid			2023-01-03	WOS:000318555100047
J	Barker, RW; Brindley, DA; Schuh, A				Barker, Richard W.; Brindley, David A.; Schuh, Anna			Establish good genomic. practice to guide medicine forward	NATURE MEDICINE			English	Editorial Material									[Barker, Richard W.; Brindley, David A.] Univ Oxford, Oxford UCL Ctr Adv Sustainable Med Innovat, Oxford, England; [Brindley, David A.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Brindley, David A.] Harvard Stem Cell Inst, Cambridge, MA USA; [Schuh, Anna] Oxford Biomed Res Ctr, Haematomol Diagnost Ctr, Oxford, England	University of Oxford; University of Oxford; Harvard University; University of Oxford	Barker, RW (corresponding author), Univ Oxford, Oxford UCL Ctr Adv Sustainable Med Innovat, Oxford, England.		Schuh, Anna/D-8954-2014	Anna, schuh/0000-0002-3938-8490					0	8	8	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2013	19	5					530	530		10.1038/nm0513-530	http://dx.doi.org/10.1038/nm0513-530			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	139LA	23652098	Bronze			2023-01-03	WOS:000318583000018
J	Zhao, DL; Sun, XF; Yao, L; Lin, HL; Li, JJ; Zhao, JY; Zhang, ZM; Lun, LD; Zhang, JR; Li, MX; Huang, Q; Yang, Y; Jiang, SM; Wang, Y; Zhu, HY; Chen, XM				Zhao, Delong; Sun, Xuefeng; Yao, Li; Lin, Hongli; Li, Jijun; Zhao, Jiuyang; Zhang, Zhimin; Lun, Lide; Zhang, Jianrong; Li, Mingxu; Huang, Qi; Yang, Yang; Jiang, Shimin; Wang, Yong; Zhu, Hanyu; Chen, Xiangmei			The Clinical Significance and Risk Factors of Anti-Platelet Factor 4/heparin Antibody on Maintenance Hemodialysis Patients: A Two-Year Prospective Follow-up	PLOS ONE			English	Article							HEPARIN-INDUCED THROMBOCYTOPENIA; UREMIC PATIENTS; THROMBOSIS; DIALYSIS; SPECIFICITY; PREVALENCE; FREQUENCY; DIAGNOSIS; IGG	Background: Heparin-induced thrombocytopenia is an immune response mediated by anti-PF4/heparin antibody, which is clinically characterized by thrombocytopenia and thromboembolic events. In this study, a prospective and multi-center clinical investigation (1) determined the positive rate of anti-PF4/heparin antibody in maintenance hemodialysis patients in China, (2) identified the related risk factors, and (3) further explored the effect of the anti-PF4/heparin antibody on bleeding, thromboembolic events, and risk of death in the patients. Methods: The serum anti-PF4/heparin antibody was measured in 661 patients from nine hemodialysis centers, detected by IgG-specific ELISA and followed by confirmation with excess heparin. Risk factors of these patients were analyzed. Based on a two-year follow-up, the association between the anti-PF4/heparin antibody and bleeding, thromboembolic events, and risk of death in the patients was investigated. Results: (1) The positivity rate of the anti-PF4/heparin antibody in maintenance hemodialysis patients was 5.6%. With diabetes as an independent risk factor, the positivity rate of the anti-PF4/heparin antibody decreased in the patients undergoing weekly dialyses >= 3 times. (2) The positivity rate of the anti-PF4/heparin antibody was not related to the occurrence of clinical thromboembolic events and was not a risk factor for death within two years in maintenance hemodialysis patients. (3) Negativity for the anti-PF4/heparin antibody combined with a reduction of the platelet count or combined with the administration of antiplatelet drugs yielded a significant increase in bleeding events. However, the composite determination of the anti-PF4/heparin antibody and thrombocytopenia, as well as the administration of antiplatelet drugs, was not predictive for the risk of thromboembolic events in the maintenance hemodialysis patients. Conclusions: A single detection of the anti-PF4/heparin antibody did not predict the occurrence of clinical bleeding, thromboembolic events, or risk of death in the maintenance hemodialysis patients.	[Zhao, Delong; Sun, Xuefeng; Huang, Qi; Yang, Yang; Jiang, Shimin; Wang, Yong; Zhu, Hanyu; Chen, Xiangmei] Chinese Peoples Liberat Army Gen Hosp, Dept Nephrol, State Key Lab Kidney Dis 2011DAV00088, Beijing, Peoples R China; [Yao, Li] Chinese Med Univ, Affiliated Hosp 1, Dept Nephrol, Shenyang, Peoples R China; [Lin, Hongli] Dalian Med Coll, Affiliated Hosp 1, Dept Nephrol, Dalian, Peoples R China; [Li, Jijun] Gen Hosp PLA, Affiliated Hosp 1, Dept Nephrol, Beijing, Peoples R China; [Zhao, Jiuyang] Dalian Med Coll, Affiliated Hosp 2, Dept Nephrol, Dalian, Peoples R China; [Zhang, Zhimin] Gen Hosp Gen Headquarters, Dept Nephrol, Beijing, Peoples R China; [Lun, Lide] Gen Hosp AF, Dept Nephrol, Beijing, Peoples R China; [Zhang, Jianrong] Gen Hosp Force Police Army, Dept Nephrol, Beijing, Peoples R China; [Li, Mingxu] Gen Hosp Navy, Dept Nephrol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; China Medical University; Dalian Medical University; Chinese People's Liberation Army General Hospital; Dalian Medical University; Sixth Medical Center of Chinese PLA General Hospital	Sun, XF (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Nephrol, State Key Lab Kidney Dis 2011DAV00088, Beijing, Peoples R China.	xfssun@126.com; xmchen301@126.com			Major State Basic Research Development Program of China [2013CB530800]; National Natural Science Foundation of China [81270819]; National Key Technology RD Program [2011BAI10B00]	Major State Basic Research Development Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Technology RD Program(National Key Technology R&D Program)	This work was supported by the grants from the Major State Basic Research Development Program of China (2013CB530800), http://www.973.gov.cn/AreaMana.aspx; National Natural Science Foundation of China (81270819), http://isis.nsfc.gov.cn; National Key Technology R&D Program (2011BAI10B00), http://kjzc.jhgl.org. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arepally GM, 2006, NEW ENGL J MED, V355, P809, DOI 10.1056/NEJMcp052967; Asmis LM, 2008, THROMB HAEMOSTASIS, V100, P498, DOI 10.1160/TH08-03-0144; Aster RH, 1999, SEMIN HEMATOL, V36, P2; Aster RH., 2010, BLOOD, P116; Ban-Hoefen M, 2009, THROMB RES, V124, P189, DOI 10.1016/j.thromres.2009.01.006; Benjamin J, 2009, CLIN NEPHROL, V71, P263; Bream-Rouwenhorst HR, 2008, J INTERV CARDIOL, V21, P350, DOI 10.1111/j.1540-8183.2008.00363.x; Canaud B, 2011, CLIN J AM SOC NEPHRO, V6, P1651, DOI 10.2215/CJN.03530410; Chauveau P, 2005, AM J KIDNEY DIS, V45, P565, DOI 10.1053/j.ajkd.2004.11.014; Davenport A, 2009, AM J KIDNEY DIS, V54, P361, DOI 10.1053/j.ajkd.2009.03.012; de la Vega LP, 2005, MAYO CLIN PROC, V80, P995, DOI 10.4065/80.8.995; Diaz J, 2010, CLIN APPL THROMB-HEM, V16, P121, DOI 10.1177/1076029609350621; Greinacher A, 2007, J THROMB HAEMOST, V5, P1666, DOI 10.1111/j.1538-7836.2007.02617.x; GREINACHER A, 2004, HEPARIN INDUCED THRO, P335; Gruel Y, 1991, Ann Vasc Surg, V5, P552, DOI 10.1007/BF02015283; Haase M, 2005, NEPHROL DIAL TRANSPL, V20, P444, DOI 10.1093/ndt/gfh544; Hirsh J, 2004, ARCH INTERN MED, V164, P361, DOI 10.1001/archinte.164.4.361; Hutchison CA, 2007, NEPHROL DIAL TRANSPL, V22, P1680, DOI 10.1093/ndt/gfm055; Inaba M, 2012, NEPHRON CLIN PRACT, V120, pC91, DOI 10.1159/000335979; KAPPA JR, 1989, J VASC SURG, V9, P574, DOI 10.1067/mva.1989.vs0090574; Kato S, 2011, BRIT J HAEMATOL, V154, P373, DOI 10.1111/j.1365-2141.2011.08746.x; Kelton JG, 2005, CHEST, V127, p9S, DOI 10.1378/chest.127.2_suppl.9S; LIGTHART GJ, 1984, MECH AGEING DEV, V28, P47, DOI 10.1016/0047-6374(84)90152-0; Martel N, 2005, BLOOD, V106, P2710, DOI 10.1182/blood-2005-04-1546; Matsuo T, 2008, CLIN APPL THROMB-HEM, V14, P459, DOI 10.1177/1076029607309184; Matsuo T, 2006, PATHOPHYSIOL HAEMO T, V35, P445, DOI 10.1159/000102052; McFarland J, 2012, AM J HEMATOL, V87, P776, DOI 10.1002/ajh.23248; Nakamoto Hidetomo, 2005, Hemodial Int, V9 Suppl 1, pS2, DOI 10.1111/j.1542-4758.2005.01163.x; O'Shea SI, 2003, J VASC SURG, V38, P541, DOI 10.1016/S0741-5214(03)00321-5; O'Shea SI, 2002, AM J HEMATOL, V69, P72, DOI 10.1002/ajh.10032; Palomo I, 2005, J CLIN LAB ANAL, V19, P189, DOI 10.1002/jcla.20076; Poncz M, 2005, SEMIN THORAC CARDIOV, V17, P73, DOI 10.1053/j.semtcvs.2004.12.007; Pouplard C, 2010, THROMB HAEMOSTASIS, V103, P145, DOI 10.1160/TH09-04-0253; Shen JI, 2012, AM J KIDNEY DIS, V60, P473, DOI 10.1053/j.ajkd.2012.03.017; Tsai YF, 2012, CLIN EXP NEPHROL, V16, P300, DOI 10.1007/s10157-011-0555-5; Warkentin TE, 2008, J THROMB HAEMOST, V6, P1304, DOI 10.1111/j.1538-7836.2008.03025.x; Warkentin TE, 2010, J THROMB HAEMOST, V8, P216, DOI 10.1111/j.1538-7836.2009.03645.x; Warkentin TE, 2005, J LAB CLIN MED, V146, P341, DOI 10.1016/j.lab.2005.08.003; Warkentin TE, 2004, SEMIN THROMB HEMOST, V30, P273, DOI 10.1055/s-2004-831039; Warkentin TE, 2008, CHEST, V133, p340S, DOI 10.1378/chest.08-0677; Warkentin TE, 2006, TRANSFUS MED REV, V20, P259, DOI 10.1016/j.tmrv.2006.05.001; Whitlatch NL, 2010, BLOOD, V116, P1761, DOI 10.1182/blood-2010-01-262659; Yu A, 2002, CLIN CHEM LAB MED, V40, P21, DOI 10.1515/CCLM.2002.005	43	10	11	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62239	10.1371/journal.pone.0062239	http://dx.doi.org/10.1371/journal.pone.0062239			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23646121	Green Published, gold, Green Submitted			2023-01-03	WOS:000319077300032
J	Starowicz, K; Makuch, W; Korostynski, M; Malek, N; Slezak, M; Zychowska, M; Petrosino, S; De Petrocellis, L; Cristino, L; Przewlocka, B; Di Marzo, V				Starowicz, Katarzyna; Makuch, Wioletta; Korostynski, Michal; Malek, Natalia; Slezak, Michal; Zychowska, Magdalena; Petrosino, Stefania; De Petrocellis, Luciano; Cristino, Luigia; Przewlocka, Barbara; Di Marzo, Vincenzo			Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism	PLOS ONE			English	Article							FATTY-ACID AMIDE; VANILLOID RECEPTORS; CANNABINOID RECEPTOR; ENDOCANNABINOID LEVELS; SENSORY NEURONS; TRP CHANNELS; PAIN; 2-ARACHIDONOYLGLYCEROL; PHARMACOLOGY; CB1	Neuropathic pain elevates spinal anandamide (AEA) levels in a way further increased when URB597, an inhibitor of AEA hydrolysis by fatty acid amide hydrolase (FAAH), is injected intrathecally. Spinal AEA reduces neuropathic pain by acting at both cannabinoid CB1 receptors and transient receptor potential vanilloid-1 (TRPV1) channels. Yet, intrathecal URB597 is only partially effective at counteracting neuropathic pain. We investigated the effect of high doses of intrathecal URB597 on allodynia and hyperalgesia in rats with chronic constriction injury (CCI) of the sciatic nerve. Among those tested, the 200 mu g/rat dose of URB597 was the only one that elevated the levels of the FAAH non-endocannabinoid and anti-inflammatory substrates, oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), and of the endocannabinoid FAAH substrate, 2-arachidonoylglycerol, and fully inhibited thermal and tactile nociception, although in a manner blocked almost uniquely by TRPV1 antagonism. Surprisingly, this dose of URB597 decreased spinal AEA levels. RT-qPCR and western blot analyses demonstrated altered spinal expression of lipoxygenases (LOX), and baicalein, an inhibitor of 12/15-LOX, significantly reduced URB597 analgesic effects, suggesting the occurrence of alternative pathways of AEA metabolism. Using immunofluorescence techniques, FAAH, 15-LOX and TRPV1 were found to co-localize in dorsal spinal horn neurons of CCI rats. Finally, 15-hydroxy-AEA, a 15-LOX derivative of AEA, potently and efficaciously activated the rat recombinant TRPV1 channel. We suggest that intrathecally injected URB597 at full analgesic efficacy unmasks a secondary route of AEA metabolism via 15-LOX with possible formation of 15-hydroxy-AEA, which, together with OEA and PEA, may contribute at producing TRPV1-mediated analgesia in CCI rats.	[Starowicz, Katarzyna; Makuch, Wioletta; Malek, Natalia; Zychowska, Magdalena; Przewlocka, Barbara] Polish Acad Sci, Inst Pharmacol, Dept Pain Pharmacol, Krakow, Poland; [Korostynski, Michal; Slezak, Michal] Polish Acad Sci, Inst Pharmacol, Dept Mol Neuropharmacol, Krakow, Poland; [Petrosino, Stefania; Di Marzo, Vincenzo] CNR, Ist Chim Biomol, Endocannabinoid Res Grp, I-80125 Naples, Italy; [De Petrocellis, Luciano; Cristino, Luigia] CNR, Ist Cibernet, Endocannabinoid Res Grp, I-80125 Naples, Italy	Polish Academy of Sciences; Polish Academy of Sciences; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR)	Przewlocka, B (corresponding author), Polish Acad Sci, Inst Pharmacol, Dept Pain Pharmacol, Krakow, Poland.	przebar@if-pan.krakow.pl; vdimarzo@icmib.na.cnr.it	Di Marzo, Vincenzo/AAD-7742-2019; Cristino, Luigia/AAE-3934-2020; Korostynski, Michal/AAS-2626-2021; Malek, Natalia/AAF-2857-2019; Starowicz, Katarzyna/AAB-8595-2022	Di Marzo, Vincenzo/0000-0002-1490-3070; Cristino, Luigia/0000-0002-0182-4699; Korostynski, Michal/0000-0002-4273-7401; Malek, Natalia/0000-0003-3602-5122; Starowicz, Katarzyna/0000-0003-0091-0066; PRZEWLOCKA, BARBARA/0000-0002-6672-1906; Slezak, Michal/0000-0003-2224-3989; Makuch, Wioletta/0000-0002-1579-3643	Dept.'s of Pain Pharmacology statutory funds from Ministry of Science and Higher Education, Warsaw, Poland; Ministry of Science and Higher Education, Warsaw, Poland [N N401 015235]; National Institutes of Health [DA009789]; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA009789] Funding Source: NIH RePORTER	Dept.'s of Pain Pharmacology statutory funds from Ministry of Science and Higher Education, Warsaw, Poland(Ministry of Science and Higher Education, Poland); Ministry of Science and Higher Education, Warsaw, Poland(Ministry of Science and Higher Education, Poland); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by Dept.'s of Pain Pharmacology statutory funds and by a grant (N N401 015235), both of which were from Ministry of Science and Higher Education, Warsaw, Poland. Dr. V. Di Marzo is grateful to the National Institutes of Health for partly funding this study (grant nr. DA009789). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alawi K, 2010, PHARMACOL THERAPEUT, V125, P181, DOI 10.1016/j.pharmthera.2009.10.005; Amadio D, 2010, BIOCHIMIE, V92, P378, DOI 10.1016/j.biochi.2010.01.001; Ambrosino P, 2013, BRIT J PHARMACOL, V168, P1430, DOI 10.1111/bph.12029; BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; Brownjohn PW, 2012, NEUROSCIENCE, V203, P180, DOI 10.1016/j.neuroscience.2011.12.028; Chung MK, 2011, ADV EXP MED BIOL, V704, P615, DOI 10.1007/978-94-007-0265-3_33; Cortright DN, 2009, CURR PHARM DESIGN, V15, P1736, DOI 10.2174/138161209788186308; Costa B, 2008, PAIN, V139, P541, DOI 10.1016/j.pain.2008.06.003; Craib SJ, 2001, BRIT J PHARMACOL, V134, P30, DOI 10.1038/sj.bjp.0704223; de Lago E, 2005, BIOCHEM PHARMACOL, V70, P446, DOI 10.1016/j.bcp.2005.05.011; De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200; Di Marzo V, 2008, REV PHYSIOL BIOCH P, V160, P1, DOI 10.1007/112_0505; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Di Marzo V, 2008, TRENDS PHARMACOL SCI, V29, P229, DOI 10.1016/j.tips.2008.03.001; Di Marzo V, 2012, PHILOS T R SOC B, V367, P3216, DOI 10.1098/rstb.2011.0382; Dinh TP, 2002, CHEM PHYS LIPIDS, V121, P149, DOI 10.1016/S0009-3084(02)00150-0; Edgemond WS, 1998, MOL PHARMACOL, V54, P180, DOI 10.1124/mol.54.1.180; Forsell PKA, 2012, LIPIDS, V47, P781, DOI 10.1007/s11745-012-3684-z; Gatta L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031111; Gonsiorek W, 2000, MOL PHARMACOL, V57, P1045; Goparaju SK, 1998, FEBS LETT, V422, P69, DOI 10.1016/S0014-5793(97)01603-7; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Kinsey SG, 2009, J PHARMACOL EXP THER, V330, P902, DOI 10.1124/jpet.109.155465; Kinsey SG, 2010, J PAIN, V11, P1420, DOI 10.1016/j.jpain.2010.04.001; Kozak KR, 2002, J BIOL CHEM, V277, P23278, DOI 10.1074/jbc.M201084200; Lang WS, 1999, J MED CHEM, V42, P896, DOI 10.1021/jm980461j; Mabalirajan U, 2012, P NATL ACAD SCI USA, V109, pE1, DOI 10.1073/pnas.1118477109; Maione S, 2006, J PHARMACOL EXP THER, V316, P969, DOI 10.1124/jpet.105.093286; Matias I, 2004, J PHARMACOL EXP THER, V309, P745, DOI 10.1124/jpet.103.061705; Movahed P, 2005, J BIOL CHEM, V280, P38496, DOI 10.1074/jbc.M507429200; Petrosino S, 2007, NEUROPHARMACOLOGY, V52, P415, DOI 10.1016/j.neuropharm.2006.08.011; Re G, 2007, VET J, V173, P21, DOI 10.1016/j.tvjl.2005.10.003; Rice ASC, 2002, PROSTAG LEUKOTR ESS, V66, P243, DOI 10.1054/plef.2001.0362; Ross RA, 2003, BRIT J PHARMACOL, V140, P790, DOI 10.1038/sj.bjp.0705467; Ross RA, 2001, BRIT J PHARMACOL, V132, P631, DOI 10.1038/sj.bjp.0703850; Starowicz K, 2012, NEUROPHARMACOLOGY, V62, P1746, DOI 10.1016/j.neuropharm.2011.11.021; Starowicz K, 2008, CURR PHARM DESIGN, V14, P42; Starowicz K, 2007, J NEUROSCI, V27, P13739, DOI 10.1523/JNEUROSCI.3258-07.2007; Starowicz K, 2007, PHARMACOL THERAPEUT, V114, P13, DOI 10.1016/j.pharmthera.2007.01.005; Suardiaz M, 2007, PAIN, V133, P99, DOI 10.1016/j.pain.2007.03.008; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; Talwar R, 2011, CNS NEUROL DISORD-DR, V10, P536, DOI 10.2174/187152711796235005; Tarzia G, 2003, J MED CHEM, V46, P2352, DOI 10.1021/jm021119g; Umar A, 2012, J NATL CANCER I, V104, P645, DOI 10.1093/jnci/djs192; Veldhuis WB, 2003, J NEUROSCI, V23, P4127; Wahl P, 2001, MOL PHARMACOL, V59, P9, DOI 10.1124/mol.59.1.9; Wang XB, 2005, J PHYSIOL-LONDON, V564, P541, DOI 10.1113/jphysiol.2004.081844; Woodward DF, 2008, PHARMACOL THERAPEUT, V120, P71, DOI 10.1016/j.pharmthera.2008.08.001; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	52	66	66	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 3	2013	8	4							e60040	10.1371/journal.pone.0060040	http://dx.doi.org/10.1371/journal.pone.0060040			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	143BA	23573230	Green Published, Green Submitted, gold			2023-01-03	WOS:000318840100044
J	Chapman, ALN				Chapman, Ann L. N.			Outpatient parenteral antimicrobial therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							INFECTIOUS-DISEASE CONSULTATION; ANTIBIOTIC-THERAPY; JOINT INFECTIONS; MANAGEMENT; ENDOCARDITIS; EXPERIENCE; DIAGNOSIS; OPAT; UK; GUIDELINES		Sheffield Teaching Hosp NHS Foundat Trust, Dept Infect & Trop Med, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England	University of Sheffield	Chapman, ALN (corresponding author), Sheffield Teaching Hosp NHS Foundat Trust, Dept Infect & Trop Med, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England.	ann.chapman@sth.nhs.uk						Amodeo MR, 2009, J INFECTION, V59, P387, DOI 10.1016/j.jinf.2009.09.009; Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564; Barr DA, 2012, EUR J CLIN MICROBIOL, V31, P2611, DOI 10.1007/s10096-012-1604-z; Barr DA, 2012, INT J ANTIMICROB AG, V39, P407, DOI 10.1016/j.ijantimicag.2012.01.016; Bazaz R, 2010, J ANTIMICROB CHEMOTH, V65, P1510, DOI 10.1093/jac/dkq152; Chapman ALN, 2012, J ANTIMICROB CHEMOTH, V67, P1053, DOI 10.1093/jac/dks003; Chapman ALN, 2009, J ANTIMICROB CHEMOTH, V64, P1316, DOI 10.1093/jac/dkp343; Chary A, 2006, CLIN INFECT DIS, V43, P1290, DOI 10.1086/508456; Corwin P, 2005, BRIT MED J, V330, P129, DOI 10.1136/bmj.38309.447975.EB; CREST, 2005, GUID MAN CELL AD; Department of Health, 2011, ANT STEW START SMART; Duncan CJA, 2012, INT J CLIN PHARM-NET, V34, P410, DOI 10.1007/s11096-012-9637-z; Esposito S, 2007, J CHEMOTHERAPY, V19, P417, DOI 10.1179/joc.2007.19.4.417; Gilchrist M, 2008, J ANTIMICROB CHEMOTH, V62, P177, DOI 10.1093/jac/dkn152; Gould FK, 2012, J ANTIMICROB CHEMOTH, V67, P269, DOI 10.1093/jac/dkr450; Habib G, 2009, EUR HEART J, V30, P2369, DOI 10.1093/eurheartj/ehp285; Heintz BH, 2011, ANN PHARMACOTHER, V45, P1329, DOI 10.1345/aph.1Q240; Howden BP, 2002, MED J AUSTRALIA, V176, P440, DOI 10.5694/j.1326-5377.2002.tb04450.x; Ingram PR, 2008, RESPIROLOGY, V13, P893, DOI 10.1111/j.1440-1843.2008.01370.x; Lipsky BA, 2012, CLIN INFECT DIS, V54, P1679, DOI [10.1093/cid/cis460, 10.1093/cid/cis346]; Mackintosh CL, 2011, J ANTIMICROB CHEMOTH, V66, P408, DOI 10.1093/jac/dkq445; Marwick C, 2011, J ANTIMICROB CHEMOTH, V66, P387, DOI 10.1093/jac/dkq362; Matthews PC, 2008, J ANTIMICROB CHEMOTH, V61, P226; Montalto M, 1998, MED J AUSTRALIA, V168, P277, DOI 10.5694/j.1326-5377.1998.tb140161.x; Nathwani D, 2000, CLIN MICROBIOL INFEC, V6, P464, DOI 10.1046/j.1469-0691.2000.00113.x; Partridge DG, 2012, POSTGRAD MED J, V88, P377, DOI 10.1136/postgradmedj-2011-130355; Phoenix G, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e4955; Royal College of Nursing, 2010, STAND INF THER; RUCKER RW, 1974, PEDIATRICS, V54, P358; Seaton RA, 2005, J ANTIMICROB CHEMOTH, V55, P764, DOI 10.1093/jac/dki092; Sharma R, 2005, AM J MED SCI, V330, P60, DOI 10.1097/00000441-200508000-00002; Shrestha NK, 2012, J HOSP MED, V7, P365, DOI 10.1002/jhm.1902; Teuffel O, 2011, ANN ONCOL, V22, P2358, DOI 10.1093/annonc/mdq745; Tice AD, 1999, CLIN INFECT DIS, V29, P1394, DOI 10.1086/313503; Tice AD, 2004, CLIN INFECT DIS, V38, P1651, DOI 10.1086/420939	35	26	26	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 26	2013	346								f1585	10.1136/bmj.f1585	http://dx.doi.org/10.1136/bmj.f1585			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117WO	23532865				2023-01-03	WOS:000316984000008
J	Weber, NS; Fisher, JA; Cowan, DN; Postolache, TT; Larsen, RA; Niebuhr, DW				Weber, Natalya S.; Fisher, Jared A.; Cowan, David N.; Postolache, Teodor T.; Larsen, Rakel A.; Niebuhr, David W.			Descriptive Epidemiology and Underlying Psychiatric Disorders among Hospitalizations with Self-Directed Violence	PLOS ONE			English	Article							ATTEMPTED-SUICIDE; UNITED-STATES; HARM; LETHALITY; INJURY; ADULTS; INTENT; RATES; RISK	Background: Suicide claims over one million lives worldwide each year. In the United States, 1 per 10,000 persons dies from suicide every year, and these rates have remained relatively constant over the last 20 years. There are nearly 25 suicide attempts for each suicide, and previous self-directed violence is a strong predictor of death from suicide. While many studies have focused on suicides, the epidemiology of non-fatal self-directed violence is not well-defined. Objective: We used a nationally representative survey to examine demographics and underlying psychiatric disorders in United States (US) hospitalizations with non-fatal self-directed violence (SDV). Method: International Classification of Disease, 9th Revision (ICD-9) discharge diagnosis data from the National Hospital Discharge Survey (NHDS) were examined from 1997 to 2006 using frequency measures and adjusted logistic regression. Results: The rate of discharges with SDV remained relatively stable over the study time period with 4.5 to 5.7 hospitalizations per 10,000 persons per year. Excess SDV was documented for females, adolescents, whites, and those from the Midwest or West. While females had a higher likelihood of self-poisoning, both genders had comparable proportions of hospitalizations with SDV resulting in injury. Over 86% of the records listing SDV also included psychiatric disorders, with the most frequent being affective (57.8%) and substance abuse (37.1%) disorders. The association between psychiatric disorders and self-injury was strongest for personality disorders for both males (OR = 2.1; 95% CI = 1.3-3.4) and females (OR = 3.8; 95% CI = 2.7-5.3). Conclusion: The NHDS provides new insights into the demographics and psychiatric morbidity of those hospitalized with SDV. Classification of SDV as self-injury or self-poisoning provides an additional parameter useful to epidemiologic studies.	[Weber, Natalya S.; Fisher, Jared A.; Cowan, David N.; Larsen, Rakel A.; Niebuhr, David W.] Walter Reed Army Inst Res, Prevent Med Program, Silver Spring, MD USA; [Fisher, Jared A.; Cowan, David N.; Larsen, Rakel A.] Allied Technol Grp Inc, Rockville, MD USA; [Postolache, Teodor T.] Univ Maryland, Sch Med, Dept Psychiat, Mood & Anxiety Program, Baltimore, MD 21201 USA; [Niebuhr, David W.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); University System of Maryland; University of Maryland Baltimore; Uniformed Services University of the Health Sciences - USA	Weber, NS (corresponding author), Walter Reed Army Inst Res, Prevent Med Program, Silver Spring, MD USA.	Natalya.Weber@us.army.mil		Postolache, Teodor/0000-0001-6056-4244	Stanley Medical Research Institute, Bethesda, MD, (CRADA) [DAMD17-04-0041]; Department of the Army; Walter Reed Army Institute of Research (WRAIR)	Stanley Medical Research Institute, Bethesda, MD, (CRADA); Department of the Army; Walter Reed Army Institute of Research (WRAIR)	The effort is funded by the Stanley Medical Research Institute, Bethesda, MD, (CRADA# DAMD17-04-0041, http://www.stanleyresearch.org/dnn/ResearchGrants/Overview/tabid/156/Default.aspx) and the Department of the Army. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; ATG has had a service support contract with the Walter Reed Army Institute of Research (WRAIR) for over 15 years. ATG personnel include epidemiologists and statisticians who support and collaborate with the WRAIR researchers. ATG staff are all at the master's or doctoral level of training, and they assist in the design, analysis, interpretation and presentation of studies, and in writing and publishing of manuscripts for peer-reviewed journals. There is no financial or other conflict of interest between ATG staff and any of the research with which they participate. ATG and its staff members are contractors with no vested interests in the results, conclusions, and recommendations resulting from any research and have no interests related to employment, consultancy, patents, products in development or marketed products, or any other aspect of this research. Even though Natalya S. Weber, M. D., M. P. H., is a PLOS One Editorial board member, this does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	[Anonymous], 2012, NAT HOSP DISCH SURV; [Anonymous], 2000, DIAGN STAT MAN MENT, P385; Bailey RK, 2011, J NATL MED ASSOC, V103, P614, DOI 10.1016/S0027-9684(15)30388-6; Bergen H, 2012, J AFFECT DISORDERS, V136, P526, DOI 10.1016/j.jad.2011.10.036; Bertolote Jose Manoel, 2004, Crisis, V25, P147, DOI 10.1027/0227-5910.25.4.147; Bolton JM, 2010, AM J PUBLIC HEALTH, V100, P2473, DOI 10.2105/AJPH.2010.192252; Caine ED, 2001, INT CLIN PSYCHOPHARM, V16, pS25, DOI 10.1097/00004850-200103002-00005; Center for Disease Control & Prevention (CDC), 2012, WEB BAS INJ STAT QUE; Cooper J, 2005, AM J PSYCHIAT, V162, P297, DOI 10.1176/appi.ajp.162.2.297; Crosby A.E., 2011, SELF DIRECTED VIOLEN; Crosby Alex E., 2011, Morbidity and Mortality Weekly Report, V60, P1; De Leo D, 2001, INT J GERIATR PSYCH, V16, P300, DOI 10.1002/gps.337.abs; Dennison C, 2000, Vital Health Stat 1, P1; Dombrovski AY, 2008, AM J GERIAT PSYCHIAT, V16, P905, DOI 10.1097/JGP.0b013e3181860034; Doshi A, 2005, ANN EMERG MED, V46, P369, DOI 10.1016/j.annemergmed.2005.04.018; Fliege H, 2009, J PSYCHOSOM RES, V66, P477, DOI 10.1016/j.jpsychores.2008.10.013; Gabbard G O, 2000, J Psychother Pract Res, V9, P1; Goodman M, 2000, Curr Psychiatry Rep, V2, P56, DOI 10.1007/s11920-000-0043-1; Harriss L, 2005, BRIT J PSYCHIAT, V186, P60, DOI 10.1192/bjp.186.1.60; Haw C, 2003, SUICIDE LIFE-THREAT, V33, P353, DOI 10.1521/suli.33.4.353.25232; Houston K, 2001, J AFFECT DISORDERS, V63, P159, DOI 10.1016/S0165-0327(00)00175-0; Inskip HM, 1998, BRIT J PSYCHIAT, V172, P35, DOI 10.1192/bjp.172.1.35; Kausch O, 2003, J CLIN PSYCHIAT, V64, P1031, DOI 10.4088/JCP.v64n0908; Lubin G, 2010, SUICIDE LIFE-THREAT, V40, P421, DOI 10.1521/suli.2010.40.5.421; Lundin A, 2011, ACTA PSYCHIAT SCAND, V124, P454, DOI 10.1111/j.1600-0447.2011.01752.x; Mann JJ, 2002, ANN INTERN MED, V136, P302, DOI 10.7326/0003-4819-136-4-200202190-00010; MEEHAN PJ, 1992, AM J PSYCHIAT, V149, P41; Miller M, 2002, EPIDEMIOLOGY, V13, P517, DOI 10.1097/00001648-200209000-00006; Moscicki EK, 2001, CLIN NEUROSCI RES, V1, P310, DOI 10.1016/S1566-2772(01)00032-9; Moscicki Eve K., 1994, Annals of Epidemiology, V4, P152; National Center for Health Statistics, 1999, HOSP PAY INT CLASS D; NIMEUS A., 2002, ARCH SUICIDE RES, V6, P211, DOI DOI 10.1080/13811110214142; Novick DM, 2010, BIPOLAR DISORD, V12, P1, DOI 10.1111/j.1399-5618.2009.00786.x; Patrick AR, 2010, PHARMACOEPIDEM DR S, V19, P1263, DOI 10.1002/pds.2037; Rhodes Anne E, 2002, Chronic Dis Can, V23, P139; RICH CL, 1988, ARCH GEN PSYCHIAT, V45, P589, DOI 10.1001/archpsyc.1988.01800300087012; RUNESON B, 1989, ACTA PSYCHIAT SCAND, V79, P490, DOI 10.1111/j.1600-0447.1989.tb10292.x; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; U.S. Department of Health and HumanServices (HHS), 2012, 2012 NAT STRAT SUIC; Wilkinson P, 2011, EUR CHILD ADOLES PSY, V20, P103, DOI 10.1007/s00787-010-0156-y; Zanni Guido R, 2010, Consult Pharm, V25, P93, DOI 10.4140/TCP.n.2010.93	41	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2013	8	3							e59818	10.1371/journal.pone.0059818	http://dx.doi.org/10.1371/journal.pone.0059818			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	123VE	23555791	Green Submitted, gold, Green Published			2023-01-03	WOS:000317418500094
J	Kyula, JN; Khan, AA; Mansfield, D; Karapanagiotou, EM; McLaughlin, M; Roulstone, V; Zaidi, S; Pencavel, T; Touchefeu, Y; Seth, R; Chen, NG; Yu, YA; Zhang, Q; Melcher, AA; Vile, RG; Pandha, HS; Ajaz, M; Szalay, AA; Harrington, KJ				Kyula, J. N.; Khan, A. A.; Mansfield, D.; Karapanagiotou, E. M.; McLaughlin, M.; Roulstone, V.; Zaidi, S.; Pencavel, T.; Touchefeu, Y.; Seth, R.; Chen, N. G.; Yu, Y. A.; Zhang, Q.; Melcher, A. A.; Vile, R. G.; Pandha, H. S.; Ajaz, M.; Szalay, A. A.; Harrington, K. J.			Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-alpha signaling	ONCOGENE			English	Article						oncolytic vaccinia; GLV-1h68; JNK; TNF-alpha; RT; apoptosis	NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; CELL LUNG; NUDE-MICE; VIRUS; CANCER; ACTIVATION; THERAPY; BRAF; COMBINATION	Melanoma is an aggressive skin cancer that carries an extremely poor prognosis when local invasion, nodal spread or systemic metastasis has occurred. Recent advances in melanoma biology have revealed that RAS-RAF-MEK-ERK signaling has a pivotal role in governing disease progression and treatment resistance. Proof-of-concept clinical studies have shown that direct BRAF inhibition yields impressive responses in advanced disease but these are short-lived as treatment resistance rapidly emerges. Therefore, there is a pressing need to develop new targeted strategies for BRAF mutant melanoma. As such, oncolytic viruses represent a promising cancer-specific approach with significant activity in melanoma. This study investigated interactions between genetically-modified vaccinia virus (GLV-1h68) and radiotherapy in melanoma cell lines with BRAF mutant, Ras mutant or wild-type genotype. Preclinical studies revealed that GLV-1h68 combined with radiotherapy significantly increased cytotoxicity and apoptosis relative to either single agent in (V600D)BRAF/(V600E)BRAF mutant melanoma in vitro and in vivo. The mechanism of enhanced cytotoxicity with GLV-1h68/radiation (RT) was independent of viral replication and due to attenuation of JNK, p38 and ERK MAPK phosphorylation specifically in BRAF mutant cells. Further studies showed that JNK pathway inhibition sensitized BRAF mutant cells to GLV-1h68-mediated cell death, mimicking the effect of RT. GLV-1h68 infection activated MAPK signaling in (V600D)BRAF/(V600E)BRAF mutant cell lines and this was associated with TNF-alpha secretion which, in turn, provided a prosurvival signal. Combination GLV-1h68/RT (or GLV-1h68/JNK inhibition) caused abrogation of TNF-alpha secretion. These data provide a strong rationale for combining GLV-1h68 with irradiation in (V600D/E)BRAF mutant tumors.	[Kyula, J. N.; Khan, A. A.; Mansfield, D.; Karapanagiotou, E. M.; McLaughlin, M.; Roulstone, V.; Zaidi, S.; Pencavel, T.; Touchefeu, Y.; Seth, R.; Harrington, K. J.] Inst Canc Res, Div Canc Biol, Targeted Therapy Team, London SW3 6JB, England; [Chen, N. G.; Yu, Y. A.; Zhang, Q.; Szalay, A. A.] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA; [Melcher, A. A.; Vile, R. G.] Leeds Inst Mol Med, Leeds, W Yorkshire, England; [Vile, R. G.] Mayo Clin, Mol Med Program, Rochester, MN USA; [Pandha, H. S.; Ajaz, M.] Univ Surrey, Postgrad Med Sch, Guildford GU2 5XH, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Leeds; Mayo Clinic; University of Surrey	Kyula, JN (corresponding author), Inst Canc Res, Div Canc Biol, Targeted Therapy Team, 237 Fulham Rd, London SW3 6JB, England.	Joan.Kyula@icr.ac.uk	Touchefeu, Yann/M-2969-2015; Khan, Aadil/AAB-6853-2021; Touchefeu, Yann/AGH-7655-2022	Touchefeu, Yann/0000-0001-8421-3182; Khan, Aadil/0000-0003-1284-6049; Harrington, Kevin/0000-0002-6014-348X; Melcher, Alan/0000-0002-2042-3380; McLaughlin, Martin/0000-0002-9739-7133	Myfanwy Townsend Melanoma Research Fund; Cotswold Trust; Cancer Research UK [13244] Funding Source: researchfish; Rosetrees Trust [M236-CD1] Funding Source: researchfish	Myfanwy Townsend Melanoma Research Fund; Cotswold Trust; Cancer Research UK(Cancer Research UK); Rosetrees Trust(Rosetrees Trust)	We would like to thank Dr Khin Thway and Dr Michelle Wilkinson for their assistance with data acquisition and analysis. This work was supported in part by research grants from the Myfanwy Townsend Melanoma Research Fund and the Cotswold Trust.	Amaravadi RK, 2009, CLIN CANCER RES, V15, P7711, DOI 10.1158/1078-0432.CCR-09-2074; Andrade AA, 2004, BIOCHEM J, V381, P437, DOI 10.1042/BJ20031375; Ascierto ML, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-451; Beyaert R, 2002, INT REV CYTOL, V214, P225; BLISS CI, 1956, BACTERIOL REV, V20, P243, DOI 10.1128/MMBR.20.4.243-258.1956; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Comins C, 2010, CLIN CANCER RES, V16, P5564, DOI 10.1158/1078-0432.CCR-10-1233; de Magalhaes JC, 2001, J BIOL CHEM, V276, P38353, DOI 10.1074/jbc.M100183200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Gentschev I, 2009, CANCER GENE THER, V16, P320, DOI 10.1038/cgt.2008.87; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880; GRECO WR, 1995, PHARMACOL REV, V47, P331; Gutermann A, 2006, HUM GENE THER, V17, P1241, DOI 10.1089/hum.2006.17.1241; Harrington KJ, 2010, CLIN CANCER RES, V16, P3067, DOI 10.1158/1078-0432.CCR-10-0054; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Heinemann L, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-221; Kelly KJ, 2008, HUM GENE THER, V19, P774, DOI 10.1089/hum.2008.036; Khan N, 2011, INT J RADIAT ONCOL, V80, P645, DOI 10.1016/j.ijrobp.2010.12.071; King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554; Lin SF, 2008, J CLIN ENDOCR METAB, V93, P4403, DOI 10.1210/jc.2008-0316; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; Mansfield D, 2013, ORAL ONCOL, V49, P108, DOI 10.1016/j.oraloncology.2012.07.019; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Pandha HS, 2009, CLIN CANCER RES, V15, P6158, DOI 10.1158/1078-0432.CCR-09-0796; Pawlik TM, 2002, CANCER-AM CANCER SOC, V95, P1171, DOI 10.1002/cncr.10776; Post DE, 2004, CLIN CANCER RES, V10, P8603, DOI 10.1158/1078-0432.CCR-04-1432; Raki M, 2005, GENE THER, V12, P1198, DOI 10.1038/sj.gt.3302517; Soares JAP, 2009, J VIROL, V83, P6883, DOI 10.1128/JVI.00245-09; Tawbi HA, 2007, SEMIN ONCOL, V34, P532, DOI 10.1053/j.seminoncol.2007.09.008; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Twigger K, 2008, CLIN CANCER RES, V14, P912, DOI 10.1158/1078-0432.CCR-07-1400; Tyminski E, 2005, CANCER RES, V65, P6850, DOI 10.1158/0008-5472.CAN-05-0154; Wang G, 2006, P NATL ACAD SCI USA, V103, P4640, DOI 10.1073/pnas.0509341103; Wullaert A, 2006, BIOCHEM PHARMACOL, V72, P1090, DOI 10.1016/j.bcp.2006.07.003; Yu YA, 2009, MOL CANCER THER, V8, P141, DOI 10.1158/1535-7163.MCT-08-0533; Yu ZJ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-45; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146	42	30	31	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1700	1712		10.1038/onc.2013.112	http://dx.doi.org/10.1038/onc.2013.112			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23624923	Green Accepted, Bronze			2023-01-03	WOS:000334344700010
J	McDermott, MM; Liu, K; Guralnik, JM; Criqui, MH; Spring, B; Tian, L; Domanchuk, K; Ferrucci, L; Lloyd-Jones, D; Kibbe, M; Tao, HM; Zhao, LH; Liao, YH; Rejeski, WJ				McDermott, Mary M.; Liu, Kiang; Guralnik, Jack M.; Criqui, Michael H.; Spring, Bonnie; Tian, Lu; Domanchuk, Kathryn; Ferrucci, Luigi; Lloyd-Jones, Donald; Kibbe, Melina; Tao, Huimin; Zhao, Lihui; Liao, Yihua; Rejeski, W. Jack			Home-Based Walking Exercise Intervention in Peripheral Artery Disease A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FUNCTIONAL PERFORMANCE PREDICTS; LOWER-EXTREMITY FUNCTION; ANKLE BRACHIAL INDEX; PHYSICAL-ACTIVITY; TREADMILL WALKING; MOBILITY LOSS; DAILY-LIFE; LEG; ASSOCIATION; MORTALITY	IMPORTANCE Clinical practice guidelines state there is insufficient evidence to support advising patients with peripheral artery disease (PAD) to participate in a home-based walking exercise program. OBJECTIVE To determine whether a home-based walking exercise program that uses a group-mediated cognitive behavioral intervention, incorporating both group support and self-regulatory skills, can improve functional performance compared with a health education control group in patients with PAD with and without intermittent claudication. DESIGN, SETTING, AND PATIENTS Randomized controlled clinical trial of 194 patients with PAD, including 72.2% without classic symptoms of intermittent claudication, performed in Chicago, Illinois between July 22, 2008, and December 14, 2012. INTERVENTIONS Participants were randomized to 1 of 2 parallel groups: a home-based group-mediated cognitive behavioral walking intervention or an attention control condition. MAIN OUTCOMES AND MEASURES The primary outcomewas 6-month change in 6-minute walk performance. Secondary outcomes included 6-month change in treadmill walking, physical activity, the Walking Impairment Questionnaire (WIQ), and Physical and Mental Health Composite Scores from the 12-item Short-Form Health Survey. RESULTS Participants randomized to the intervention group significantly increased their 6-minute walk distance ([reported in meters] 357.4 to 399.8 vs 353.3 to 342.2 for those in the control group; mean difference, 53.5 [95% CI, 33.2 to 73.8]; P<.001), maximal treadmill walking time (intervention, 7.91 to 9.44 minutes vs control, 7.56 to 8.09; mean difference, 1.01 minutes [95% CI, 0.07 to 1.95]; P=.04), accelerometer-measured physical activity over 7 days (intervention, 778.0 to 866.1 vs control, 671.6 to 645.0; mean difference, 114.7 activity units [95% CI, 12.82 to 216.5]; P=.03), WIQ distance score (intervention, 35.3 to 47.4 vs control, 33.3 to 34.4; mean difference, 11.1 [95% CI, 3.9 to 18.1]; P=.003), and WIQ speed score (intervention, 36.1 to 47.7 vs control, 35.3-36.6; mean difference, 10.4 [95% CI, 3.4 to 17.4]; P=.004). CONCLUSION AND RELEVANCE A home-based walking exercise program significantly improved walking endurance, physical activity, and patient-perceived walking endurance and speed in PAD participants with and without classic claudication symptoms. These findings have implications for the large number of patients with PAD who are unable or unwilling to participate in supervised exercise programs.	[McDermott, Mary M.; Liu, Kiang; Domanchuk, Kathryn] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [McDermott, Mary M.; Liu, Kiang; Spring, Bonnie; Lloyd-Jones, Donald; Tao, Huimin; Zhao, Lihui; Liao, Yihua] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Guralnik, Jack M.] Univ Maryland, Dept Epidemiol, Baltimore, MD 21201 USA; [Criqui, Michael H.] Univ Calif San Diego, San Diego, CA 92103 USA; [Tian, Lu] Stanford Univ, Dept Hlth Res & Policy, Stanford, CA 94305 USA; [Ferrucci, Luigi] NIA, Div Intramural Res, Baltimore, MD 21224 USA; [Kibbe, Melina] Northwestern Univ, Dept Surg, Chicago, IL 60611 USA; [Rejeski, W. Jack] Wake Forest Univ, Dept Hlth & Exercise Sci, Winston Salem, NC 27109 USA; [Rejeski, W. Jack] Wake Forest Univ, Dept Geriatr Med, Winston Salem, NC 27109 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego; Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Northwestern University; Wake Forest University; Wake Forest University	McDermott, MM (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, 750 N Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.	mdm608@northwestern.edu		Lloyd-Jones, Donald/0000-0003-0847-6110; Spring, Bonnie/0000-0003-0692-9868; tian, lu/0000-0002-5893-0169	National Heart, Lung, and Blood Institute [R01-HL088589, R01-HL107510]; Intramural Research Program, National Institutes on Aging (NIA), National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL107510, R01HL088589] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural Research Program, National Institutes on Aging (NIA), National Institutes of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by R01-HL088589 and R01-HL107510 from the National Heart, Lung, and Blood Institute. Supported in part by the Intramural Research Program, National Institutes on Aging (NIA), National Institutes of Health. No other funding was used to carry out the study or complete the manuscript.	Amirhamzeh MMR, 1997, EUR J VASC ENDOVASC, V13, P301, DOI 10.1016/S1078-5884(97)80102-5; Bandura A, 1998, PSYCHOL HEALTH, V13, P623, DOI 10.1080/08870449808407422; Baumeister R.F., 1994, LOSING CONTROL WHY P, DOI 10.5860/choice.32-6508; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cartwright D. E., 1953, GROUP DYNAMICS RES T; Collins TC, 2011, DIABETES CARE, V34, P2174, DOI 10.2337/dc10-2399; Criqui M H, 1996, Vasc Med, V1, P65; Fakhry F, 2012, J VASC SURG, V56, P1132, DOI 10.1016/j.jvs.2012.04.046; Gardner AW, 2011, CIRCULATION, V123, P491, DOI 10.1161/CIRCULATIONAHA.110.963066; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; Garg PK, 2009, CIRCULATION, V119, P251, DOI 10.1161/CIRCULATIONAHA.108.791491; GREIG C, 1993, J AM GERIATR SOC, V41, P15, DOI 10.1111/j.1532-5415.1993.tb05941.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Heun R, 1998, INT J GERIATR PSYCH, V13, P368, DOI 10.1002/(SICI)1099-1166(199806)13:6<368::AID-GPS775>3.3.CO;2-0; Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526; Hirsch AT, 2001, VASC MED, V6, P87, DOI 10.1191/135886301701568756; McDermott MM, 2008, J VASC SURG, V48, P1231, DOI 10.1016/j.jvs.2008.06.050; McDermott MM, 2008, J AM COLL CARDIOL, V51, P1482, DOI 10.1016/j.jacc.2007.12.034; McDermott MM, 2007, J AM COLL CARDIOL, V50, P974, DOI 10.1016/j.jacc.2007.05.030; McDermott MM, 2012, CONTEMP CLIN TRIALS, V33, P1311, DOI 10.1016/j.cct.2012.08.001; McDermott MM, 2011, J AM COLL CARDIOL, V57, P962, DOI 10.1016/j.jacc.2010.09.053; McDermott MM, 2009, JAMA-J AM MED ASSOC, V301, P165, DOI 10.1001/jama.2008.962; McDermott MM, 2002, J GEN INTERN MED, V17, P895, DOI 10.1046/j.1525-1497.2002.20307.x; McDermott MM, 2002, ANN INTERN MED, V136, P873, DOI 10.7326/0003-4819-136-12-200206180-00008; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 2001, J AM GERIATR SOC, V49, P747, DOI 10.1046/j.1532-5415.2001.49151.x; McDermott MM, 2004, JAMA-J AM MED ASSOC, V292, P453, DOI 10.1001/jama.292.4.453; Menard JR, 2004, J VASC SURG, V39, P1186, DOI 10.1016/j.jvs.2004.01.034; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Regensteiner JG, 1997, ANGIOLOGY, V48, P291, DOI 10.1177/000331979704800402; Regensteiner JG, 1990, J VASC MED BIOL, V2, P142; Regensteiner Judith G., 2004, Current Drug Targets - Cardiovascular & Haematological Disorders, V4, P233, DOI 10.2174/1568006043336195; Richardson M T, 1995, J Cardiopulm Rehabil, V15, P107, DOI 10.1097/00008483-199503000-00003; Rooke TW, 2011, CIRCULATION, V124, P2020, DOI 10.1161/CIR.0b013e31822e80c3; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Savage P, 2001, J Cardiopulm Rehabil, V21, P152, DOI 10.1097/00008483-200105000-00006; Shadman R, 2004, J AM COLL CARDIOL, V44, P618, DOI 10.1016/j.jacc.2004.04.044; Stevens JW, 2012, BRIT J SURG, V99, P1630, DOI 10.1002/bjs.8895; SWERTS PMJ, 1990, PHYS THER, V70, P439, DOI 10.1093/ptj/70.7.439; TASC Working Group, 2000, EUR J VASC ENDOVASC, V19, pS1; Tian L, 2012, BIOSTATISTICS, V13, P256, DOI 10.1093/biostatistics/kxr050; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Watson L, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000990.pub2	44	183	186	4	56	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 3	2013	310	1					57	65		10.1001/jama.2013.7231	http://dx.doi.org/10.1001/jama.2013.7231			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	175SK	23821089	Green Accepted, Bronze			2023-01-03	WOS:000321253000023
J	Hull, SC; Colloca, L; Avins, A; Gordon, NP; Somkin, CP; Kaptchuk, TJ; Miller, FG				Hull, Sara Chandros; Colloca, Luana; Avins, Andrew; Gordon, Nancy P.; Somkin, Carol P.; Kaptchuk, Ted J.; Miller, Franklin G.			Patients' attitudes about the use of placebo treatments: telephone survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE SURVEY; CLINICAL-PRACTICE; INTERVENTIONS; PHYSICIANS; ETHICS	Objective To examine the attitudes of US patients about the use of placebo treatments in medical care. Design One time telephone surveys. Setting Northern California. Participants 853 members of Kaiser Permanente Northern California, aged 18-75, who had been seen by a primary care provider for a chronic health problem at least once in the prior six months. Results The response rate was 53.4% (853/1598) of all members who were eligible to participate, and 73.2% (853/1165) of all who could be reached by telephone. Most respondents (50-84%) judged it acceptable for doctors to recommend placebo treatments under conditions that varied according to doctors' level of certainty about the benefits and safety of the treatment, the purpose of the treatment, and the transparency with which the treatment was described to patients. Only 21.9% of respondents judged that it was never acceptable for doctors to recommend placebo treatments. Respondents valued honesty by physicians regarding the use of placebos and believed that non-transparent use could undermine the relationship between patients and physicians. Conclusions Most patients in this survey seemed favorable to the idea of placebo treatments and valued honesty and transparency in this context, suggesting that physicians should consider engaging with patients to discuss their values and attitudes about the appropriateness of using treatments aimed at promoting placebo responses in the context of clinical decision making.	[Hull, Sara Chandros] NHGRI, Off Clin Director, NIH, Bethesda, MD 20892 USA; [Hull, Sara Chandros; Colloca, Luana; Miller, Franklin G.] NIH, Dept Bioeth, Ctr Clin, Bethesda, MD 20892 USA; [Colloca, Luana; Miller, Franklin G.] NIMH, NIH, Bethesda, MD 20892 USA; [Colloca, Luana] NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; [Avins, Andrew; Gordon, Nancy P.; Somkin, Carol P.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA; [Kaptchuk, Ted J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Program Placebo Studies, Boston, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; Kaiser Permanente; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Hull, SC (corresponding author), NHGRI, Off Clin Director, NIH, Bethesda, MD 20892 USA.	shull@mail.nih.gov	Colloca, Luana/S-1389-2018	Colloca, Luana/0000-0002-6503-4709	National Center for Complementary and Alternative Medicine; Clinical Center; National Human Genome Research Institute, National Institutes of Health; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [ZIAAT000019] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIDHG200347, P20HG007243] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Clinical Center; National Human Genome Research Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This research was supported by the National Center for Complementary and Alternative Medicine, the Clinical Center, and the intramural research program of the National Human Genome Research Institute, National Institutes of Health. The opinions expressed are those of the authors and do not necessarily reflect the policies or views of the National Institutes of Health or the Department of Health and Human Services. The study funders played no role in the study design; collection, analysis, and interpretation of data; writing of the report; or the decision to submit the article for publication. Researchers were independent of influence from study funders.	American Medical Association, 2007, AM MED ASS COD MED E; Berthelot JM, 2001, JOINT BONE SPINE, V68, P65, DOI 10.1016/S1297-319X(00)00225-6; Bishop FL, 2012, SOC SCI MED, V8, P1138; Boozang Kathleen M, 2002, Fla Law Rev, V54, P687; BRODY H, 1982, ANN INTERN MED, V97, P112, DOI 10.7326/0003-4819-97-1-112; Brody H, 2012, J GEN INTERN MED, V27, P739, DOI 10.1007/s11606-011-1977-1; Chen GF, 2009, NEW ZEAL MED J, V122, P35; Colloca L, 2011, PHILOS T R SOC B, V366, P1922, DOI 10.1098/rstb.2010.0399; Fassler M, 2011, BRIT J GEN PRACT, V61, P101, DOI 10.3399/bjgp11X556209; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Gordon NP, 2012, SIMILARITY ADULT KAI; Hrobjartsson A, 2003, EVAL HEALTH PROF, V26, P153, DOI 10.1177/0163278703026002002; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Kermen R, 2010, FAM MED, V42, P636; Kolber AJ., 2007, YALE LAW POLICY REV, V26; Louhiala P, 2012, J MED ETHICS, V38, P403, DOI 10.1136/medethics-2011-100420; LYNOE N, 1993, SOC SCI MED, V36, P767, DOI 10.1016/0277-9536(93)90037-5; Miller FG, 2009, AM J BIOETHICS, V9, P39, DOI 10.1080/15265160903316263; Nitzan U, 2004, BMJ-BRIT MED J, V329, P944, DOI 10.1136/bmj.38236.646678.55; ONEILL O, 1984, J MED ETHICS, V10, P173, DOI 10.1136/jme.10.4.173; Tilburt JC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1938	22	63	63	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	2013	347								f3757	10.1136/bmj.f3757	http://dx.doi.org/10.1136/bmj.f3757			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	180CL	23819963	Green Published, hybrid			2023-01-03	WOS:000321570400002
J	Tura, A; Sbrignadello, S; Mambelli, E; Ravazzani, P; Santoro, A; Pacini, G				Tura, Andrea; Sbrignadello, Stefano; Mambelli, Emanuele; Ravazzani, Paolo; Santoro, Antonio; Pacini, Giovanni			Sodium Concentration Measurement during Hemodialysis through Ion-Exchange Resin and Conductivity Measure Approach: In Vitro Experiments	PLOS ONE			English	Article							SELECTIVE ELECTRODES; POTASSIUM; PLASMA; DIALYSIS	Sodium measurement during hemodialysis treatment is important to preserve the patient from clinical events related to hypo- or hyper-natremia Usually, sodium measurement is performed through laboratory equipment which is typically expensive, and requires manual intervention. We propose a new method, based on conductivity measurement after treatment of dialysate solution through ion-exchange resin. To test this method, we performed in vitro experiments. We prepared 40 ml sodium chloride (NaCl) samples at 280, 140, 70, 35, 17.5, 8.75, 4.375 mEq/l, and some "mixed samples", i.e., with added potassium chloride (KCl) at different concentrations (4.375-17.5 mEq/l), to simulate the confounding factors in a conductivity-based sodium measurement. We measured the conductivity of all samples. Afterwards, each sample was treated for 1 min with 1 g of Dowex G-26 resin, and conductivity was measured again. On average, the difference in the conductivity between mixed samples and corresponding pure NaCl samples (at the same NaCl concentration) was 20.9%. After treatment with the exchange resin, it was 14.7%, i.e., 42% lower. Similar experiments were performed with calcium chloride and magnesium chloride as confounding factors, with similar results. We also performed some experiments on actual dialysate solution during hemodialysis sessions in 15 patients, and found that the correlation between conductivity measures and sodium concentration improved after resin treatment (R=0.839 before treatment, R=0.924 after treatment, P<0.0001). We conclude that ion-exchange resin treatment coupled with conductivity measures may improve the measurement of sodium compared to conductivity measures alone, and may become a possible simple approach for continuous and automatic sodium measurement during hemodialysis.	[Tura, Andrea; Sbrignadello, Stefano; Ravazzani, Paolo; Pacini, Giovanni] CNR, Inst Biomed Engn, Padua, Italy; [Mambelli, Emanuele; Santoro, Antonio] St Orsola Marcello Malpighi Hosp, Nephrol Dialysis & Hypertens Unit, Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Azienda Ospedaliero-Universitaria di Bologna	Tura, A (corresponding author), CNR, Inst Biomed Engn, Padua, Italy.	tura@isib.cnr.it	Ravazzani, Paolo/B-9139-2015	Ravazzani, Paolo/0000-0003-0282-3329; Sbrignadello, Stefano/0000-0002-3795-2887				Awan SA, 2005, IEEE T INSTRUM MEAS, V54, P516, DOI 10.1109/TIM.2005.843582; Burnett RW, 2000, CLIN CHEM LAB MED, V38, P1065, DOI 10.1515/CCLM.2000.159; Caduff A, 2011, DIABETOLOGIA, V54, P2678, DOI 10.1007/s00125-011-2210-9; Charra Bernard, 2007, Hemodial Int, V11, P21, DOI 10.1111/j.1542-4758.2007.00148.x; Goureau Y, 1990, ASAIO Trans, V36, pM444; Gourzi M., 2003, Journal of Medical Engineering & Technology, V27, P276, DOI 10.1080/0309190031000098845; Gourzi M., 2005, Journal of Medical Engineering & Technology, V29, P22, DOI 10.1080/03091900410001720247; Guyton AC, 1999, J AM SOC NEPHROL, V10, P2248; Hecking M, 2011, AM J NEPHROL, V33, P39, DOI 10.1159/000322572; Kim Gheun-Ho, 2009, Electrolyte Blood Press, V7, P31, DOI 10.5049/EBP.2009.7.2.31; Kitiyakara C, 2003, J AM SOC NEPHROL, V14, P2775, DOI 10.1097/01.ASN.0000092145.90389.65; LADENSON JH, 1977, J LAB CLIN MED, V90, P654; Locatelli F, 1995, INT J ARTIF ORGANS, V18, P716, DOI 10.1177/039139889501801106; MAAS AHJ, 1985, CLIN CHEM, V31, P482; Musso CG, 2009, INT UROL NEPHROL, V41, P357, DOI 10.1007/s11255-009-9548-7; PETITCLERC T, 1992, BLOOD PURIFICAT, V10, P309, DOI 10.1159/000170062; PETITCLERC T, 1993, INT J ARTIF ORGANS, V16, P585, DOI 10.1177/039139889301600804; PETITCLERC T, 1995, NEPHROL DIAL TRANSPL, V10, P212; Santos SFF, 2008, CLIN J AM SOC NEPHRO, V3, P522, DOI 10.2215/CJN.03360807; Sbrignadello S, 2013, J SPECTROSC, V2013, DOI 10.1155/2013/571372; Titze J, 2002, AM J PHYSIOL-RENAL, V283, pF134, DOI 10.1152/ajprenal.00323.2001; Tura A, 2007, BIOPHYS CHEM, V129, P235, DOI 10.1016/j.bpc.2007.06.001; Tura A, 2010, SENSORS-BASEL, V10, P5346, DOI 10.3390/s100605346; WORTH HGJ, 1985, ANN CLIN BIOCHEM, V22, P343, DOI 10.1177/000456328502200402	24	14	14	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2013	8	7							e69227	10.1371/journal.pone.0069227	http://dx.doi.org/10.1371/journal.pone.0069227			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176XV	23844253	Green Submitted, Green Published, gold			2023-01-03	WOS:000321341000186
J	Joynt, KE; Gawande, AA; Orav, EJ; Jha, AK				Joynt, Karen E.; Gawande, Atul A.; Orav, E. John; Jha, Ashish K.			Contribution of Preventable Acute Care Spending to Total Spending for High-Cost Medicare Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY-DEPARTMENT VISITS; SENSITIVE CONDITIONS; HEALTH-CARE; HOSPITALIZATIONS; BENEFICIARIES; PROGRAMS	Importance A small proportion of patients account for the majority of US health care spending, and understanding patterns of spending among this cohort is critical to reducing health care costs. The degree to which preventable acute care services account for spending among these patients is largely unknown. Objective To quantify preventable acute care services among high-cost Medicare patients. Design, Setting, and Participants We summed standardized costs for each inpatient and outpatient service contained in standard 5% Medicare files from 2009 and 2010 across the year for each patient in our sample, and defined those in the top decile of spending in 2010 as high-cost patients and those in the top decile in both 2009 and 2010 as persistently high-cost patients. We used standard algorithms to identify potentially preventable emergency department (ED) visits and acute care inpatient hospitalizations. A total of 1 114 469 Medicare fee-for-service beneficiaries aged 65 years or older were included. Main Outcomes and Measures Proportion of acute care hospital and ED costs deemed preventable among high-cost patients. Results The 10% of Medicare patients in the high-cost group were older, more often male, more often black, and had more comorbid illnesses than non-high-cost patients. In 2010, 32.9% (95% CI, 32.9%-32.9%) of total ED costs were incurred by high-cost patients. Based on validated algorithms, 41.0% (95% CI, 40.9%-41.0%) of these costs among high-cost patients were potentially preventable compared with 42.6% (95% CI, 42.6%-42.6%) among non-high-cost patients. High-cost patients accounted for 79.0% (95% CI, 79.0%-79.0%) of inpatient costs, 9.6% (95% CI, 9.6%-9.6%) of which were due to preventable hospitalizations; 16.8% (95% CI, 16.8%-16.8%) of costs within the non-high-cost group were due to preventable hospitalizations. Comparable proportions of ED spending (43.3%; 95% CI, 43.3%-43.3%) and inpatient spending (13.5%; 95% CI, 13.5%-13.5%) were preventable among persistently high-cost patients. Regions with high primary care physician supply had higher preventable spending for high-cost patients. Conclusions and Relevance Among a sample of patients in the top decile of Medicare spending in 2010, only a small percentage of costs appeared to be related to preventable ED visits and hospitalizations. The ability to lower costs for these patients through better outpatient care may be limited.	[Joynt, Karen E.; Gawande, Atul A.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Orav, E. John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Orav, E. John; Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; [Gawande, Atul A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Gawande, Atul A.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; [Joynt, Karen E.; Jha, Ashish K.] VA Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Joynt, KE (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	kjoynt@partners.org		Gawande, Atul/0000-0002-1824-9176	Rx Foundation; West Wireless Foundation	Rx Foundation; West Wireless Foundation	This study was funded by the Rx Foundation and the West Wireless Foundation.	Agency for Healthcare Research and Quality, 2011, PREV QUAL IND OV; Baicker K, 2004, HEALTH AFFAIR, V23, pW4184, DOI 10.1377/hlthaff.W4.184; Ballard DW, 2010, MED CARE, V48, P58, DOI 10.1097/MLR.0b013e3181bd49ad; Basu J, 2002, MED CARE, V40, P1260, DOI 10.1097/00005650-200212000-00013; Bhattacharya J, 2010, RES FINDINGS EC AGIN, P387; Billings J, 1996, HEALTH AFFAIR, V15, P239, DOI 10.1377/hlthaff.15.3.239; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Braunstein JB, 2003, J AM COLL CARDIOL, V42, P1226, DOI 10.1016/S0735-1097(03)00947-1; Brown RS, 2012, HEALTH AFFAIR, V31, P1156, DOI 10.1377/hlthaff.2012.0393; Cebul RD, 2008, J ECON PERSPECT, V22, P93, DOI 10.1257/jep.22.4.93; Congressional Budget Office, 2012, LESS MED DEM PROJ DI; Congressional Budget Office,, 2005, HIGH COST MED BEN; Dartmouth Institute for Health Policy and Clinical Practice, 2012, DARTM ATL HLTH CAR; Garber AM, 1998, NBER FR HLTH POL RES, V1, P153; Miller DC, 2011, HEALTH AFFAIR, V30, P2107, DOI 10.1377/hlthaff.2011.0783; Niefeld MR, 2003, DIABETES CARE, V26, P1344, DOI 10.2337/diacare.26.5.1344; NYU Wagner, 2000, NYU ED ALG BACKGR; Oster A, 2003, MED CARE, V41, P198, DOI 10.1097/00005650-200302000-00002; Riley GF, 2007, HEALTH AFFAIR, V26, P808, DOI 10.1377/hlthaff.26.3.808; Smulowitz PB, 2011, ANN EMERG MED, V58, P225, DOI 10.1016/j.annemergmed.2011.02.020; Wharam JF, 2007, JAMA-J AM MED ASSOC, V297, P1093, DOI 10.1001/jama.297.10.1093	21	153	153	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 26	2013	309	24					2572	2578		10.1001/jama.2013.7103	http://dx.doi.org/10.1001/jama.2013.7103			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	170KD	23797716	Green Published, Bronze			2023-01-03	WOS:000320848100027
J	Tsai, CC; Lin, CR; Tsai, HY; Chen, CJ; Li, WT; Yu, HM; Ke, YY; Hsieh, WY; Chang, CY; Wu, CY; Chen, ST; Wong, CH				Tsai, Chia-Che; Lin, Chih-Ru; Tsai, Hsien-Yu; Chen, Chia-Jung; Li, Wen-Tai; Yu, Hui-Ming; Ke, Yi-Yu; Hsieh, Wei-Ying; Chang, Cheng-Yen; Wu, Chung-Yi; Chen, Shui-Tein; Wong, Chi-Huey			The Immunologically Active Oligosaccharides Isolated from Wheatgrass Modulate Monocytes via Toll-like Receptor-2 Signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCAN; IMMUNE-SYSTEM; POLYSACCHARIDES; INNATE; INTERLEUKIN-12; MACROPHAGES; GANODERMA; DECTIN-1; DIETARY; TLR2	Wheatgrass is one of the most widely used health foods, but its functional components and mechanisms remain unexplored. Herein, wheatgrass-derived oligosaccharides (WG-PS3) were isolated and found to induce CD69 and Th1 cytokine expression in human peripheral blood mononuclear cells. In particular, WG-PS3 directly activated the purified monocytes by inducing the expression of CD69, CD80, CD86, IL-12, and TNF-alpha but affected NK and T cells only in the presence of monocytes. After further purification and structural analysis, maltoheptaose was identified from WG-PS3 as an immunomodulator. Maltoheptaose activated monocytes via Toll-like receptor 2 (TLR-2) signaling, as discovered by pretreatment of blocking antibodies against Toll-like receptors (TLRs) and also determined by click chemistry. This study is the first to reveal the immunostimulatory component of wheatgrass with well defined molecular structures and mechanisms.	[Tsai, Chia-Che; Lin, Chih-Ru; Tsai, Hsien-Yu; Chen, Chia-Jung; Li, Wen-Tai; Hsieh, Wei-Ying; Chang, Cheng-Yen; Chen, Shui-Tein; Wong, Chi-Huey] Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; [Yu, Hui-Ming; Ke, Yi-Yu; Wu, Chung-Yi; Chen, Shui-Tein; Wong, Chi-Huey] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lin, Chih-Ru; Chen, Shui-Tein; Wong, Chi-Huey] Natl Taiwan Univ, Coll Life Sci, Inst Biochem Sci, Taipei 106, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University	Chen, ST (corresponding author), Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan.	bcchen@gate.sinica.edu.tw	Wu, Chung-Yi/K-8334-2018	Tsai, Hsien-Yu/0000-0003-2842-1133	National Science Council, Development Program of Industrialization for Agricultural Biotechnology Grant [098S0030049-AI]	National Science Council, Development Program of Industrialization for Agricultural Biotechnology Grant	This work was supported by the National Science Council, Development Program of Industrialization for Agricultural Biotechnology Grant 098S0030049-AI.	Abdelsadik A, 2011, HUM IMMUNOL, V72, P1188, DOI 10.1016/j.humimm.2011.08.015; Ahmad A, 2012, CRIT REV FOOD SCI, V52, P201, DOI 10.1080/10408398.2010.499806; Alitheen NB, 2011, PAK J PHARM SCI, V24, P243; Arpaia N, 2011, CURR OPIN VIROL, V1, P447, DOI 10.1016/j.coviro.2011.10.006; Ben-Arye E, 2002, SCAND J GASTROENTERO, V37, P444, DOI 10.1080/003655202317316088; Bland EJ, 2004, CARBOHYD RES, V339, P1673, DOI 10.1016/j.carres.2004.05.009; Chang R, 2002, J ALTERN COMPLEM MED, V8, P559, DOI 10.1089/107555302320825066; Crozat K, 2009, IMMUNOL REV, V227, P129, DOI 10.1111/j.1600-065X.2008.00736.x; Das A, 2012, INT J FOOD SCI NUTR, V63, P718, DOI 10.3109/09637486.2011.644769; Figueiredo RT, 2012, CARBOHYD RES, V356, P260, DOI 10.1016/j.carres.2012.02.028; Kankkunen P, 2010, J IMMUNOL, V184, P6335, DOI 10.4049/jimmunol.0903019; Keystone EC, 2010, J RHEUMATOL, V37, P27, DOI 10.3899/jrheum.091463; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; Lee SM, 1998, LEUKEMIA LYMPHOMA, V29, P427, DOI 10.3109/10428199809050903; Liu JJ, 2009, RECENT PAT ANTI-CANC, V4, P101, DOI 10.2174/157489209788452858; Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532; Murphy EA, 2010, CURR OPIN CLIN NUTR, V13, P656, DOI 10.1097/MCO.0b013e32833f1afb; Parihar A, 2010, J INNATE IMMUN, V2, P204, DOI 10.1159/000296507; Pietrocola G, 2011, INT J ARTIF ORGANS, V34, P799, DOI 10.5301/ijao.5000030; Ramberg JE, 2010, NUTR J, V9, DOI 10.1186/1475-2891-9-54; Rosso M, 2011, CRIT REV IMMUNOL, V31, P379, DOI 10.1615/CritRevImmunol.v31.i5.20; Russell R, 2006, PHYTOCHEMISTRY, V67, P1985, DOI 10.1016/j.phytochem.2006.07.004; Shahinian S, 2000, MOL MICROBIOL, V35, P477, DOI 10.1046/j.1365-2958.2000.01713.x; Shao BM, 2004, BIOCHEM BIOPH RES CO, V323, P133, DOI 10.1016/j.bbrc.2004.08.069; SHERMER M, 2008, SCI AM, V299, P42; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; Sletmoen M, 2008, BIOPOLYMERS, V89, P310, DOI 10.1002/bip.20920; Trinchieri G, 1996, J LEUKOCYTE BIOL, V59, P505, DOI 10.1002/jlb.59.4.505; Tsai CC, 2008, COMB CHEM HIGH T SCR, V11, P834, DOI 10.2174/138620708786734307; Volman JJ, 2010, NUTR RES, V30, P40, DOI 10.1016/j.nutres.2009.10.023; Wu ML, 2010, BIOTECHNOL PROGR, V26, P1391, DOI 10.1002/btpr.429; Yoshikai Yasunobu, 2006, Nihon Rinsho, V64, P1223; Zheng Z, 1998, Chin J Biotechnol, V14, P93	33	30	32	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2013	288	24					17689	17697		10.1074/jbc.M112.448381	http://dx.doi.org/10.1074/jbc.M112.448381			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164AH	23629653	hybrid, Green Published			2023-01-03	WOS:000320380600059
J	Alonso, J; Vilagut, G; Adroher, ND; Chatterji, S; He, YL; Andrade, LH; Bromet, E; Bruffaerts, R; Fayyad, J; Florescu, S; de Girolamo, G; Gureje, O; Haro, JM; Hinkov, H; Hu, CY; Iwata, N; Lee, S; Levinson, D; Lepine, JP; Matschinger, H; Medina-Mora, ME; O'Neill, S; Hormel, J; Posada-Villa, JA; Taib, NI; Xavier, M; Kessler, RC				Alonso, Jordi; Vilagut, Gemma; Adroher, Nuria D.; Chatterji, Somnath; He, Yanling; Andrade, Laura Helena; Bromet, Evelyn; Bruffaerts, Ronny; Fayyad, John; Florescu, Silvia; de Girolamo, Giovanni; Gureje, Oye; Maria Haro, Josep; Hinkov, Hristo; Hu, Chiyi; Iwata, Noboru; Lee, Sing; Levinson, Daphna; Lepine, Jean Pierre; Matschinger, Herbert; Elena Medina-Mora, Maria; O'Neill, Siobhan; Hormel, J.; Posada-Villa, Jose A.; Taib, Nezar Ismet; Xavier, Miguel; Kessler, Ronald C.			Disability Mediates the Impact of Common Conditions on Perceived Health	PLOS ONE			English	Article							SELF-RATED HEALTH; QUALITY-OF-LIFE; CHRONIC MEDICAL CONDITIONS; MENTAL-HEALTH; OLDER-PEOPLE; CHRONIC DISEASES; REPORTED HEALTH; WORLD; MODEL; REHABILITATION	Background: We examined the extent to which disability mediates the observed associations of common mental and physical conditions with perceived health. Methods and Findings: WHO World Mental Health (WMH) Surveys carried out in 22 countries worldwide (n = 51,344 respondents, 72.0% response rate). We assessed nine common mental conditions with the WHO Composite International Diagnostic Interview (CIDI), and ten chronic physical with a checklist. A visual analog scale (VAS) score (0, worst to 100, best) measured perceived health in the previous 30 days. Disability was assessed using a modified WHO Disability Assessment Schedule (WHODAS), including: cognition, mobility, self-care, getting along, role functioning (life activities), family burden, stigma, and discrimination. Path analysis was used to estimate total effects of conditions on perceived health VAS and their separate direct and indirect (through the WHODAS dimensions) effects. Twelve-month prevalence was 14.4% for any mental and 51.4% for any physical condition. 31.7% of respondents reported difficulties in role functioning, 11.4% in mobility, 8.3% in stigma, 8.1% in family burden and 6.9% in cognition. Other difficulties were much less common. Mean VAS score was 81.0 (SD = 0.1). Decrements in VAS scores were highest for neurological conditions (9.8), depression (8.2) and bipolar disorder (8.1). Across conditions, 36.8% (IQR: 31.2-51.5%) of the total decrement in perceived health associated with the condition were mediated by WHODAS disabilities (significant for 17 of 19 conditions). Role functioning was the dominant mediator for both mental and physical conditions. Stigma and family burden were also important mediators for mental conditions, and mobility for physical conditions. Conclusions: More than a third of the decrement in perceived health associated with common conditions is mediated by disability. Although the decrement is similar for physical and mental conditions, the pattern of mediation is different. Research is needed on the benefits for perceived health of targeted interventions aimed at particular disability dimensions.	[Alonso, Jordi; Vilagut, Gemma; Adroher, Nuria D.] IMIM Inst Hosp Mar Invest Med, Barcelona, Spain; [Alonso, Jordi] Pompeu Fabra Univ, Barcelona, Spain; [Alonso, Jordi; Adroher, Nuria D.] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Chatterji, Somnath] WHO, CH-1211 Geneva, Switzerland; [He, Yanling] Shangai Mental Hlth Ctr, Shanghai, Peoples R China; [Andrade, Laura Helena] Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo, Brazil; [Bromet, Evelyn] SUNY Stony Brook, Stony Brook, NY 11794 USA; [Bruffaerts, Ronny] Katholieke Univ Leuven, Univ Psychiat Ctr, Louvain, Belgium; [Fayyad, John] Inst Dev Res Advocacy & Appl Care, Beirut, Lebanon; [Fayyad, John] St George Hosp Univ Med Ctr, Beirut, Lebanon; [Florescu, Silvia] Natl Sch Publ Hlth Management & Profess Dev, Bucharest, Romania; [de Girolamo, Giovanni] IRCCS Ctr S Giovanni Dio Fatebenefratelli, Brescia, Italy; [Gureje, Oye] Univ Coll Hosp, Ibadan, Nigeria; [Maria Haro, Josep] Parc Sanitari St Joan de Deu, Barcelona, Spain; [Maria Haro, Josep] CIBERSAM, Barcelona, Spain; [Hinkov, Hristo] Natl Ctr Publ Hlth Protect, Sofia, Bulgaria; [Hu, Chiyi] Shenzhen Inst Mental Hlth, Shenzhen, Guangdong, Peoples R China; [Hu, Chiyi] Shenzhen Kangning Hosp, Shenzhen, Guangdong, Peoples R China; [Iwata, Noboru] Hiroshima Int Univ, Higashihiroshima, Japan; [Lee, Sing] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China; [Levinson, Daphna] Minist Hlth, Jerusalem, Israel; [Lepine, Jean Pierre] Hop St Louis Lariboisiere Fernand Widal, Paris, France; [Matschinger, Herbert] Univ Leipzig, D-04109 Leipzig, Germany; [Elena Medina-Mora, Maria] Inst Nacl Psiquiatria Ramon de la Fuente, Mexico City, DF, Mexico; [O'Neill, Siobhan] Univ Ulster, Coleraine BT52 1SA, Londonderry, North Ireland; [Hormel, J.] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands; [Posada-Villa, Jose A.] Pontificia Univ Javeriana, Bogota, Colombia; [Xavier, Miguel] Univ Nova Lisboa, P-1200 Lisbon, Portugal; [Kessler, Ronald C.] Harvard Univ, Sch Med, Boston, MA USA	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; World Health Organization; Universidade de Sao Paulo; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; KU Leuven; IRCCS Fatebenefratelli; University of Ibadan; University College Hospital, Ibadan; CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Medical University Sofia; Chinese University of Hong Kong; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Leipzig University; Instituto Nacional de Psiquiatria Ramon de la Fuente Muniz; Ulster University; University of Groningen; Pontificia Universidad Javeriana; Universidade Nova de Lisboa; Harvard University; Harvard Medical School	Alonso, J (corresponding author), IMIM Inst Hosp Mar Invest Med, Barcelona, Spain.	jalonso@imim.es	Adewuya, Abiodun/N-4997-2017; Haro, Josep Maria/D-1423-2011; Ormel, Johan/C-6094-2013; de Girolamo, Giovanni/K-3062-2016; Medina-Mora, María Elena I/T-5937-2018; Posada-Villa, Jose/AAA-2355-2019; CHATTERJI, Somnath/ABE-6832-2020; BRUFFAERTS, RONNY/AAA-2364-2021; Gureje, Oye/J-1183-2014; Lee, Sing/O-2136-2015; Florescu, Silvia/AAX-7951-2020; Alonso, Jordi/A-5514-2010; Andrade, Laura Helena S. G./F-3023-2010; Vilagut, Gemma/N-8718-2014	Adewuya, Abiodun/0000-0002-7611-6953; Haro, Josep Maria/0000-0002-3984-277X; de Girolamo, Giovanni/0000-0002-1611-8324; Medina-Mora, María Elena I/0000-0001-9300-0752; Posada-Villa, Jose/0000-0001-5840-3118; BRUFFAERTS, RONNY/0000-0002-0330-3694; Gureje, Oye/0000-0003-0094-5947; Alonso, Jordi/0000-0001-8627-9636; Andrade, Laura Helena S. G./0000-0002-2362-3521; Vilagut, Gemma/0000-0002-3714-226X; O'Neill, Siobhan/0000-0002-8786-2118; Adroher, Nuria D/0000-0003-2668-1820; Xavier, Miguel/0000-0003-2698-1284; Matschinger, Herbert/0000-0001-7146-6770	National Institute of Mental Health (NIMH) [R01 MH070884, U01-MH60220]; John D. and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]; Fogarty International Center [FIRCA R03-TW006481]; Pan American Health Organization; Eli Lilly and Company; Ortho-McNeil Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb; State of Sao Paulo Research Foundation Thematic Project [03/00204-3]; Ministry of Health; National Center for Public Health Protection; Shenzhen Bureau of Health; Shenzhen Bureau of Science, Technology, and Information; Ministry of Social Protection; European Commission [QLG5-1999-01042, SANCO 2004123, EAHC 20081308]; Piedmont Region (Italy); Fondo de Investigacion Sanitaria; Instituto de Salud Carlos III, Spain [FIS 00/0028]; Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Departament de Salut; Generalitat de Catalunya, Spain; Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]; Government of India; World Health Organization (WHO). Implementation of the Iraq Mental Health Survey (IMHS); United Nations Development Group Iraq Trust Fund; Israel National Institute for Health Policy and Health Services Research; National Insurance Institute of Israel; Japan Ministry of Health, Labour and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; Lebanese Ministry of Public Health; WHO (Lebanon); National Institute of Health/Fogarty International Center [R03 TW006481-01]; Janssen Cilag; Eli Lilly; Astra Zeneca; Hikma Pharm; Novartis; National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]; National Council on Science and Technology [CONACyT-G30544-H]; WHO (Geneva); WHO (Nigeria); Federal Ministry of Health, Abuja, Nigeria; Health & Social Care Research & Development Division of the Public Health Agency; Champalimaud Foundation; Gulbenkian Foundation; Foundation for Science and Technology; US National Institute of Mental Health [RO1-MH61905]; Robert Wood Johnson Foundation (RWJF) [044708]; FOGARTY INTERNATIONAL CENTER [R03TW006481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R13MH066849, U01MH060220, R01MH061905, R01MH069864, R01MH070884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016558] Funding Source: NIH RePORTER	National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); John D. and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Pan American Health Organization; Eli Lilly and Company(Eli Lilly); Ortho-McNeil Pharmaceutical, Inc.; GlaxoSmithKline(GlaxoSmithKline); Bristol-Myers Squibb(Bristol-Myers Squibb); State of Sao Paulo Research Foundation Thematic Project; Ministry of Health; National Center for Public Health Protection; Shenzhen Bureau of Health; Shenzhen Bureau of Science, Technology, and Information; Ministry of Social Protection; European Commission(European CommissionEuropean Commission Joint Research Centre); Piedmont Region (Italy)(Regione PiemonteInstituto de Salud Carlos III); Fondo de Investigacion Sanitaria(Instituto de Salud Carlos III); Instituto de Salud Carlos III, Spain(Instituto de Salud Carlos III); Ministerio de Ciencia y Tecnologia, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Departament de Salut; Generalitat de Catalunya, Spain(Generalitat de Catalunya); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Government of India; World Health Organization (WHO). Implementation of the Iraq Mental Health Survey (IMHS); United Nations Development Group Iraq Trust Fund; Israel National Institute for Health Policy and Health Services Research; National Insurance Institute of Israel; Japan Ministry of Health, Labour and Welfare(Ministry of Health, Labour and Welfare, Japan); Lebanese Ministry of Public Health; WHO (Lebanon)(World Health Organization); National Institute of Health/Fogarty International Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Janssen Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Eli Lilly(Eli Lilly); Astra Zeneca(AstraZeneca); Hikma Pharm; Novartis(Novartis); National Institute of Psychiatry Ramon de la Fuente; National Council on Science and Technology; WHO (Geneva)(World Health Organization); WHO (Nigeria)(World Health Organization); Federal Ministry of Health, Abuja, Nigeria; Health & Social Care Research & Development Division of the Public Health Agency; Champalimaud Foundation; Gulbenkian Foundation; Foundation for Science and Technology; US National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Robert Wood Johnson Foundation (RWJF)(Robert Wood Johnson Foundation (RWJF)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The World Health Organization World Mental Health (WMH) Survey Initiative is supported by the National Institute of Mental Health (NIMH; R01 MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical, Inc., GlaxoSmithKline, and Bristol-Myers Squibb. Each WMH country obtained funding for its own survey. The Sao Paulo Megacity Mental Health Survey is supported by the State of Sao Paulo Research Foundation Thematic Project Grant 03/00204-3. The Bulgarian Epidemiological Study of common mental disorders EPIBUL is supported by the Ministry of Health and the National Center for Public Health Protection. The Chinese World Mental Health Survey Initiative is supported by the Pfizer Foundation. The Shenzhen Mental Health Survey is supported by the Shenzhen Bureau of Health and the Shenzhen Bureau of Science, Technology, and Information. The Colombian National Study of Mental Health is supported by the Ministry of Social Protection. The ESEMeD project is funded by the European Commission (Contracts QLG5-1999-01042; SANCO 2004123, and EAHC 20081308), the Piedmont Region (Italy), Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III, Spain (FIS 00/0028), Ministerio de Ciencia y Tecnologia, Spain (SAF 2000-158-CE), Departament de Salut, Generalitat de Catalunya, Spain, Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local agencies and by an unrestricted educational grant from GlaxoSmithKline. The Epidemiological Study on Mental Disorders in India was funded jointly by the Government of India and the World Health Organization (WHO). Implementation of the Iraq Mental Health Survey (IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP with direct support from the Iraqi IMHS team with funding from both the Japanese and European Funds through United Nations Development Group Iraq Trust Fund. The Israel National Health Survey is funded by the Ministry of Health with support from the Israel National Institute for Health Policy and Health Services Research and the National Insurance Institute of Israel. The World Mental Health Japan Survey is supported by the Grant for Research on Psychiatric and Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013) from the Japan Ministry of Health, Labour and Welfare. The Lebanese National Mental Health Survey is supported by the Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health/Fogarty International Center (R03 TW006481-01), anonymous private donations to IDRAAC, Lebanon, and unrestricted grants from Janssen Cilag, Eli Lilly, GlaxoSmithKline, Astra Zeneca, Hikma Pharm and Novartis. The Mexican National Comorbidity Survey is supported by The National Institute of Psychiatry Ramon de la Fuente (INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544-H), with supplemental support from the PanAmerican Health Organization (PAHO). The Nigerian Survey of Mental Health and Wellbeing is supported by the WHO (Geneva), the WHO (Nigeria), and the Federal Ministry of Health, Abuja, Nigeria. The Northern Ireland Study of Mental Health was funded by the Health & Social Care Research & Development Division of the Public Health Agency.; The Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for Science and Technology and Ministry of Health. The Romania WMH study projects "Policies in Mental Health Area" and "National Study regarding Mental Health and Services Use" were carried out by National School of Public Health & Health Services Management (former National Institute for Research & Development in Health, present National School of Public Health Management & Professional Development, Bucharest), with technical support of Metro Media Transilvania, the National Institute of Statistics - National Centre for Training in Statistics, SC. Cheyenne Services SRL, Statistics Netherlands and were funded by Ministry of Public Health (former Ministry of Health) with supplemental support of Eli Lilly Romania SRL. The Ukraine Comorbid Mental Disorders during Periods of Social Disruption study is funded by the US National Institute of Mental Health (RO1-MH61905). The US National Comorbidity Survey Replication is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental support from the National Institute of Drug Abuse, the Substance Abuse and Mental Health Services Administration, the Robert Wood Johnson Foundation (RWJF; Grant 044708), and the John W. Alden Trust. All the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alonso J, 2004, QUAL LIFE RES, V13, P283, DOI 10.1023/B:QURE.0000018472.46236.05; Alonso J, 2011, PSYCHOL MED, V41, P873, DOI 10.1017/S0033291710001212; Alonso J, 2000, Gac Sanit, V14, P163; [Anonymous], 2008, WHO WORLD MENTAL HLT; Ashburner JM, 2011, AM J EPIDEMIOL, V173, P882, DOI 10.1093/aje/kwq445; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Baumeister H, 2010, J CLIN EPIDEMIOL, V63, P558, DOI 10.1016/j.jclinepi.2009.08.009; Blain H, 2010, J NUTR HEALTH AGING, V14, P595, DOI 10.1007/s12603-010-0111-0; Boot CRL, 2011, J OCCUP REHABIL, V21, P211, DOI 10.1007/s10926-010-9273-1; Buist-Bouwman MA, 2008, ACTA PSYCHIAT SCAND, V118, P451, DOI 10.1111/j.1600-0447.2008.01285.x; Carlson B, 2012, J CARDIOVAS IN PRESS; Coggon D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039820; Damian Javier, 2008, BMC Geriatr, V8, P5, DOI 10.1186/1471-2318-8-5; DeSalvo KB, 2005, HEALTH SERV RES, V40, P1234, DOI 10.1111/j.1475-6773.2005.00404.x; Fowler F.J., 1990, STANDARDIZED SURVEY, VVolume 18; Garin O, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-51; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Haro JM, 2006, INT J METH PSYCH RES, V15, P167, DOI 10.1002/mpr.196; Heistaro S, 1996, PREV MED, V25, P625, DOI 10.1006/pmed.1996.0098; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Imrie R, 1997, DISABIL REHABIL, V19, P263, DOI 10.3109/09638289709166537; Jamoom EW, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-10; Kriegsman DMW, 1996, J CLIN EPIDEMIOL, V49, P1407, DOI 10.1016/S0895-4356(96)00274-0; Lee HY, 2008, INT J NURS STUD, V45, P1042, DOI 10.1016/j.ijnurstu.2007.05.007; Lee Y, 2003, ARCH GERONTOL GERIAT, V37, P63, DOI 10.1016/S0167-4943(03)00021-9; LEFLEY HP, 1990, HOSP COMMUNITY PSYCH, V41, P277; Leinonen R, 2001, SOC SCI MED, V52, P1329, DOI 10.1016/S0277-9536(00)00249-5; Machacova K, 2011, J SPINAL CORD MED, V34, P265, DOI 10.1179/107902610X12883422813660; Madan I, 2008, INT J EPIDEMIOL, V37, P1181, DOI 10.1093/ije/dyn085; Mavaddat N, 2011, J EPIDEMIOL COMMUN H, V65, P800, DOI 10.1136/jech.2009.090845; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; Ormel J, 1997, PSYCHOL MED, V27, P1065, DOI 10.1017/S0033291797005321; Ormel J, 1998, J AM GERIATR SOC, V46, P39, DOI 10.1111/j.1532-5415.1998.tb01011.x; Ormel J, 2008, BRIT J PSYCHIAT, V192, P368, DOI 10.1192/bjp.bp.107.039107; Pearl J, 2012, PREV SCI, V13, P426, DOI 10.1007/s11121-011-0270-1; Pennell B. E., 2008, The WHO world mental health surveys: global perspectives on the epidemiology of mental disorders, P33; Perruccio AV, 2007, J EPIDEMIOL COMMUN H, V61, P1056, DOI 10.1136/jech.2006.047308; Rohrer JE, 2007, J EVAL CLIN PRACT, V13, P150, DOI 10.1111/j.1365-2753.2006.00692.x; Saarni SI, 2006, QUAL LIFE RES, V15, P1403, DOI 10.1007/s11136-006-0020-1; Salomon JA, 2004, BMJ-BRIT MED J, V328, P258, DOI 10.1136/bmj.37963.691632.44; Schootman M, 2012, ANN EPIDEMIOL, V22, P79, DOI 10.1016/j.annepidem.2011.10.011; Schultz Susan E, 2003, Health Rep, V14, P41; Sen A, 2002, BRIT MED J, V324, P860, DOI 10.1136/bmj.324.7342.860; Sokka T, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2951; Steiner WA, 2002, PHYS THER, V82, P1098, DOI 10.1093/ptj/82.11.1098; Ustun B., 2010, MEASURING HLTH DISAB; Valderas JM, 2008, QUAL LIFE RES, V17, P1125, DOI 10.1007/s11136-008-9396-4; van Dijk A, 2008, PAIN RES MANAG, V13, P407, DOI 10.1155/2008/419073; Von Korff M, 2008, J CLIN EPIDEMIOL, V61, P1132, DOI 10.1016/j.jclinepi.2007.12.009; Wang PP, 2006, DISABIL REHABIL, V28, P135, DOI 10.1080/09638280500167761; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; WITTCHEN HU, 1994, J PSYCHIAT RES, V28, P57, DOI 10.1016/0022-3956(94)90036-1	52	25	26	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 6	2013	8	6							e65858	10.1371/journal.pone.0065858	http://dx.doi.org/10.1371/journal.pone.0065858			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	173SK	23762442	Green Submitted, Green Published, gold			2023-01-03	WOS:000321099000112
J	Ashby, M				Ashby, Michael			Caring for dying patients is not about prolonging life at all costs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARE		[Ashby, Michael] Univ Tasmania, Royal Hobart Hosp, Southern Tasmania Area Hlth Serv, Hobart, Tas 7001, Australia; [Ashby, Michael] Univ Tasmania, Fac Hlth Sci, Hobart, Tas 7001, Australia	Royal Hobart Hospital; University of Tasmania; University of Tasmania	Ashby, M (corresponding author), Univ Tasmania, Royal Hobart Hosp, Southern Tasmania Area Hlth Serv, Hobart, Tas 7001, Australia.	michael.ashby@dhhs.tas.gov.au						[Anonymous], 1996, HASTINGS CTR REPOR S, V26, pS1; Ashby MA, 2013, MED J AUSTRALIA, V198, P188, DOI 10.5694/mja12.10498; Ashby MA, 2011, J BIOETHIC INQ, V8, P151, DOI 10.1007/s11673-011-9291-5; Breen E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1837; Economist Intelligence Unit, 2010, QUAL DEATH RANK END; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; Hanson MJ, 1999, GOALS MED FORGOTTEN; Hastings Center, J LYNN CALLS REF END; Kellehear A, 1999, HLTH PROMOTING PALLI	9	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	2013	346								f3027	10.1136/bmj.f3027	http://dx.doi.org/10.1136/bmj.f3027			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	158CZ	23714191				2023-01-03	WOS:000319947500004
J	Jabaudon, M; Perbet, S; Pereira, B; Soummer, A; Roszyk, L; Guerin, R; Futier, E; Lu, Q; Bazin, JE; Sapin, V; Rouby, JJ; Constantin, JM				Jabaudon, Matthieu; Perbet, Sebastien; Pereira, Bruno; Soummer, Alexis; Roszyk, Laurence; Guerin, Renaud; Futier, Emmanuel; Lu, Qin; Bazin, Jean-Etienne; Sapin, Vincent; Rouby, Jean-Jacques; Constantin, Jean-Michel			Plasma Levels of sRAGE, Loss of Aeration and Weaning Failure in ICU Patients: A Prospective Observational Multicenter Study	PLOS ONE			English	Article							GLYCATION END-PRODUCTS; RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; SOLUBLE RECEPTOR; MECHANICAL VENTILATION; REGIONAL-DISTRIBUTION; ULTRASOUND ASSESSMENT; DYSFUNCTION; OUTCOMES; MARKER	Rationale: Postextubation distress after a successful spontaneous breathing trial (SBT) is associated with increased morbidity and mortality. Lung ultrasound determination of changes in lung aeration predicts weaning failure. It remains unknown whether this derecruitment is related to alveolar epithelial dysfunction or not. Objective: To verify whether lung alveolar type I epithelial cell injury marker sRAGE (soluble form of the receptor for advanced glycation end-products) is predictive of postextubation distress and weaning failure or not, and to verify whether plasma sRAGE levels can be related to lung derecruitment during the process of weaning from mechanical ventilation or not. Interventions, Measurements: 88 patients from 2 intensive care units were included in this observational prospective study. Plasma sRAGE levels were measured in duplicate by ELISA before, at the end of a 60-minute SBT, and 4 hours after extubation. To quantify lung aeration, a lung ultrasound score was calculated. Main Results: 34% of extubated patients experienced postextubation distress. Patients with or without postextubation distress had comparable sRAGE levels before SBT, after SBT, and 4 hours after extubation. In patients with postextubation distress, sRAGE levels were not predictive of the need for mechanical ventilation. sRAGE levels were not associated with lung aeration as assessed by echography. Patients who succeeded SBT (86%) and those who failed (14%) had no differences in sRAGE levels, before (median 1111 vs 1021 pg/mL, p = 0,87) and at the end of SBT (1165 vs 1038 pg/mL, p = 0.74). Conclusions: Plasma levels of sRAGE do not predict postextubation distress or SBT failure/success in patients weaning from mechanical ventilation. Lung aeration loss during a successful weaning trial predicts postextubation distress, but may not be evaluable by plasma levels of sRAGE, a marker of alveolar type I epithelial cell injury.	[Jabaudon, Matthieu; Perbet, Sebastien; Guerin, Renaud; Futier, Emmanuel; Bazin, Jean-Etienne; Constantin, Jean-Michel] Univ Auvergne Clermont Ferrand 1, CHU Clermont Ferrand, Estaing Hosp, Intens Care Unit,Dept Anesthesiol & Crit Care Med, Clermont Ferrand, France; [Jabaudon, Matthieu; Perbet, Sebastien; Futier, Emmanuel; Sapin, Vincent; Constantin, Jean-Michel] Univ Auvergne Clermont Ferrand 1, Sch Med, EA R2D2 7281, Clermont Ferrand, France; [Pereira, Bruno] CHU Clermont Ferrand, Dept Clin Res & Innovat DRCI, Clermont Ferrand, France; [Soummer, Alexis; Lu, Qin; Rouby, Jean-Jacques] Univ Paris 06, La Pitie Salpetriere Hosp, AP HP,Dept Anesthesiol & Crit Care Med, Intens Care Unit Pierre Viars, Paris, France; [Roszyk, Laurence; Sapin, Vincent] Univ Auvergne Clermont Ferrand 1, CHU Clermont Ferrand, Estaing Univ Hosp, Dept Med Biochem & Mol Biol, Clermont Ferrand, France	CHU Clermont Ferrand; Universite de Franche-Comte; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Clermont Ferrand	Jabaudon, M (corresponding author), Univ Auvergne Clermont Ferrand 1, CHU Clermont Ferrand, Estaing Hosp, Intens Care Unit,Dept Anesthesiol & Crit Care Med, Clermont Ferrand, France.	mjabaudon@chu-clermontferrand.fr	Jabaudon, Matthieu/GLQ-8455-2022	Jabaudon, Matthieu/0000-0002-8121-1680; Pereira, Bruno/0000-0003-3778-7161; Rouby, Jean-Jacques/0000-0001-9092-4642				Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Bouhemad B, 2011, AM J RESP CRIT CARE, V183, P341, DOI 10.1164/rccm.201003-0369OC; Calfee CS, 2008, THORAX, V63, P1083, DOI 10.1136/thx.2008.095588; Challier M, 2005, CLIN CHEM, V51, P1749, DOI 10.1373/clinchem.2005.051961; Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009; Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0; Determann RM, 2008, AM J PHYSIOL-LUNG C, V294, pL344, DOI 10.1152/ajplung.00268.2007; Emanuele E, 2005, ARCH NEUROL-CHICAGO, V62, P1734, DOI 10.1001/archneur.62.11.1734; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Falcone C, 2005, ARTERIOSCL THROM VAS, V25, P1032, DOI 10.1161/01.ATV.0000160342.20342.00; Geroldi D, 2005, J HYPERTENS, V23, P1725, DOI 10.1097/01.hjh.0000177535.45785.64; Guo WA, 2012, INTENS CARE MED, V38, P1588, DOI 10.1007/s00134-012-2624-y; Jabaudon M, 2011, CRIT CARE MED, V39, P480, DOI 10.1097/CCM.0b013e318206b3ca; Kalousova M, 2006, AM J KIDNEY DIS, V47, P406, DOI 10.1053/j.ajkd.2005.12.028; Lichtenstein DA, 2004, INTENS CARE MED, V30, P276, DOI 10.1007/s00134-003-2075-6; Mauri T, 2010, TOHOKU J EXP MED, V222, P105, DOI 10.1620/tjem.222.105; Mukherjee TK, 2008, RESP PHYSIOL NEUROBI, V162, P210, DOI 10.1016/j.resp.2008.07.001; Penuelas O, 2011, AM J RESP CRIT CARE, V184, P430, DOI 10.1164/rccm.201011-1887OC; Pullerits R, 2005, ARTHRITIS RES THER, V7, pR817, DOI 10.1186/ar1749; Puybasset L, 2000, INTENS CARE MED, V26, P857, DOI 10.1007/s001340051274; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rouby JJ, 2000, INTENS CARE MED, V26, P1046, DOI 10.1007/s001340051317; Shirasawa M, 2004, GENES CELLS, V9, P165, DOI 10.1111/j.1356-9597.2004.00712.x; Soummer A, 2012, CRIT CARE MED, V40, P2064, DOI 10.1097/CCM.0b013e31824e68ae; Tobin MJ, 2006, INTENS CARE MED, V32, P2002, DOI 10.1007/s00134-006-0439-4; Uchida T, 2006, AM J RESP CRIT CARE, V173, P1008, DOI 10.1164/rccm.200509-1477OC; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; Vassilakopoulos T, 2008, INTENS CARE MED, V34, P7, DOI 10.1007/s00134-007-0866-x	29	7	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2013	8	5							e64083	10.1371/journal.pone.0064083	http://dx.doi.org/10.1371/journal.pone.0064083			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155HH	23724022	Green Published, gold, Green Submitted			2023-01-03	WOS:000319738100018
J	Lin, AY; Almeida, JPM; Bear, A; Liu, N; Luo, L; Foster, AE; Drezek, RA				Lin, Adam Yuh; Almeida, Joao Paulo Mattos; Bear, Adham; Liu, Nathan; Luo, Laureen; Foster, Aaron Edward; Drezek, Rebekah Anna			Gold Nanoparticle Delivery of Modified CpG Stimulates Macrophages and Inhibits Tumor Growth for Enhanced Immunotherapy	PLOS ONE			English	Article							ANTITUMOR-ACTIVITY; CELLULAR UPTAKE; TLR9 AGONISTS; LYMPH-NODE; DNA; OLIGONUCLEOTIDES; CELLS; BIODISTRIBUTION; INJECTION; ADJUVANT	Gold nanoparticle accumulation in immune cells has commonly been viewed as a side effect for cancer therapeutic delivery; however, this phenomenon can be utilized for developing gold nanoparticle mediated immunotherapy. Here, we conjugated a modified CpG oligodeoxynucleotide immune stimulant to gold nanoparticles using a simple and scalable self-assembled monolayer scheme that enhanced the functionality of CpG in vitro and in vivo. Nanoparticles can attenuate systemic side effects by enhancing CpG delivery passively to innate effector cells. The use of a triethylene glycol (TEG) spacer on top of the traditional poly-thymidine spacer increased CpG macrophage stimulatory effects without sacrificing DNA content on the nanoparticle, which directly correlates to particle uptake. In addition, the immune effects of modified CpG-AuNPs were altered by the core particle size, with smaller 15 nm AuNPs generating maximum immune response. These TEG modified CpG-AuNP complexes induced macrophage and dendritic cell tumor infiltration, significantly inhibited tumor growth, and promoted survival in mice when compared to treatments with free CpG.	[Lin, Adam Yuh; Almeida, Joao Paulo Mattos; Liu, Nathan; Luo, Laureen; Drezek, Rebekah Anna] Rice Univ, Dept Bioengn, Houston, TX 77251 USA; [Bear, Adham; Foster, Aaron Edward] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA	Rice University; Baylor College of Medicine	Drezek, RA (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77251 USA.	drezek@rice.edu	; Liu, Nathan/A-6484-2016	Lin, Adam/0000-0001-9359-882X; Liu, Nathan/0000-0002-4129-7846	Cancer Prevention and Research Institute of Texas [5RP100189]; National Institutes of Health [R01CA172836]; Keck Center of the Gulf Coast Consortia Nanobiology Interdisciplinary Graduate Training Program, National Institute of Biomedical Imaging and Bioengineering (NIBIB) [T32EB009379]; National Science Foundation; Howard Hughes Medical Institute Med into Grad fellowship; Medical Scientist Training Program at Baylor College of Medicine; Edward Josephine Hudson Scholarship,; Ruth L. Kirschstein National Research Service Awards [F30]; NATIONAL CANCER INSTITUTE [R01CA172836, F30CA165686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [T32EB009379] Funding Source: NIH RePORTER	Cancer Prevention and Research Institute of Texas; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Keck Center of the Gulf Coast Consortia Nanobiology Interdisciplinary Graduate Training Program, National Institute of Biomedical Imaging and Bioengineering (NIBIB); National Science Foundation(National Science Foundation (NSF)); Howard Hughes Medical Institute Med into Grad fellowship; Medical Scientist Training Program at Baylor College of Medicine; Edward Josephine Hudson Scholarship,; Ruth L. Kirschstein National Research Service Awards(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This project was funded by the Cancer Prevention and Research Institute of Texas 5RP100189 and National Institutes of Health R01CA172836. In addition, this research was funded by a training fellowship from the Keck Center of the Gulf Coast Consortia Nanobiology Interdisciplinary Graduate Training Program, National Institute of Biomedical Imaging and Bioengineering (NIBIB) T32EB009379. J. Almeida would also like to acknowledge support from the National Science Foundation Graduate Research Fellowship and the Howard Hughes Medical Institute Med into Grad fellowship. A. Lin would like to acknowledge support from the Medical Scientist Training Program at Baylor College of Medicine, the Edward Josephine Hudson Scholarship, and the Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral MD/PhD Fellows (F30). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida JPM, 2011, NANOMEDICINE-UK, V6, P815, DOI [10.2217/nnm.11.79, 10.2217/NNM.11.79]; Arnida Janat-Amsbury MM, EUROPEAN J IN PRESS; Askew D, 2000, J IMMUNOL, V165, P6889, DOI 10.4049/jimmunol.165.12.6889; Behboudi S, 2000, IMMUNOLOGY, V99, P361, DOI 10.1046/j.1365-2567.2000.00979.x; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/ERV.10.174, 10.1586/erv.10.174]; Bourquin C, 2008, J IMMUNOL, V181, P2990, DOI 10.4049/jimmunol.181.5.2990; Buhtoiarov IN, 2007, IMMUNOLOGY, V120, P412, DOI 10.1111/j.1365-2567.2006.02517.x; Chen HC, 2011, BIOMATERIALS, V32, P1731, DOI 10.1016/j.biomaterials.2010.10.059; Chithrani BD, 2006, NANO LETT, V6, P662, DOI 10.1021/nl052396o; Cubillos-Ruiz JR, 2009, J CLIN INVEST, V119, P2231, DOI 10.1172/JCI37716; de Jong S, 2007, CANCER IMMUNOL IMMUN, V56, P1251, DOI 10.1007/s00262-006-0276-x; Demers LM, 2000, ANAL CHEM, V72, P5535, DOI 10.1021/ac0006627; Franca A, 2011, NANOMEDICINE LOND; Gao HJ, 2005, P NATL ACAD SCI USA, V102, P9469, DOI 10.1073/pnas.0503879102; Giljohann DA, 2007, NANO LETT, V7, P3818, DOI 10.1021/nl072471q; Heckelsmiller K, 2002, J IMMUNOL, V169, P3892, DOI 10.4049/jimmunol.169.7.3892; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Huang XH, 2007, NANOMEDICINE-UK, V2, P681, DOI 10.2217/17435889.2.5.681; Hurst SJ, 2006, ANAL CHEM, V78, P8313, DOI 10.1021/ac0613582; Jewell CM, 2011, P NATL ACAD SCI USA, V108, P15745, DOI 10.1073/pnas.1105200108; Khlebtsov N, 2011, CHEM SOC REV; Krieg AM, 2008, ONCOGENE, V27, P161, DOI 10.1038/sj.onc.1210911; Kwong B, 2011, BIOMATERIALS, V32, P5134, DOI 10.1016/j.biomaterials.2011.03.067; Lee IH, 2012, ANGEW CHEM INT EDIT, V51, P8800, DOI 10.1002/anie.201203193; Lou YY, 2011, J IMMUNOTHER, V34, P279, DOI 10.1097/CJI.0b013e31820d2a05; Love JC, 2005, CHEM REV, V105, P1103, DOI 10.1021/cr0300789; Mao X, 2009, CHEM COMMUN, P3065, DOI 10.1039/b822582f; Massich MD, 2010, ACS NANO, V4, P5641, DOI 10.1021/nn102228s; Murad YM, 2009, BIODRUGS, V23, P361, DOI 10.2165/11316930-000000000-00000; Nardini E, 2005, J CELL PHYSIOL, V204, P889, DOI 10.1002/jcp.20360; Nierkens S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008368; Qiao GM, 2011, CHEM COMMUN, V47, P7458, DOI 10.1039/c1cc11490e; Rosi NL, 2006, SCIENCE, V312, P1027, DOI 10.1126/science.1125559; Schuller VJ, 2011, ACS NANO, V5, P9696, DOI 10.1021/nn203161y; Shirota Y, 2012, J IMMUNOL, V188, P1592, DOI 10.4049/jimmunol.1101304; Song XT, 2008, NAT MED, V14, P258, DOI 10.1038/nm1721; Taton T Andrew, 2002, Curr Protoc Nucleic Acid Chem, VChapter 12, DOI 10.1002/0471142700.nc1202s09; Wei M, 2012, ANGEW CHEM INT EDIT, V51, P1202, DOI 10.1002/anie.201105187; Weiner GJ, 2000, J LEUKOCYTE BIOL, V68, P455; Wilson KD, 2007, INT IMMUNOPHARMACOL, V7, P1064, DOI 10.1016/j.intimp.2007.04.002; Yao L, 2007, J CHEM PHYS, V127, DOI 10.1063/1.2786984; Zoglmeier C, 2011, CLIN CANCER RES, V17, P1765, DOI 10.1158/1078-0432.CCR-10-2672	42	170	178	0	105	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2013	8	5							e63550	10.1371/journal.pone.0063550	http://dx.doi.org/10.1371/journal.pone.0063550			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145XK	23691064	Green Published, gold			2023-01-03	WOS:000319052700046
J	Collis, E; Sleeman, KE				Collis, Emily; Sleeman, Katherine E.			Do patients need to know they are terminally ill? Yes	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CANCER		[Collis, Emily] Cent London Community Healthcare Trust, St Charles Hosp, Pembridge Palliat Care Ctr, London W10 6DZ, England; [Sleeman, Katherine E.] Kings Coll London, Cicely Saunders Inst, London WC2R 2LS, England	Imperial College London; University of London; King's College London	Collis, E (corresponding author), Cent London Community Healthcare Trust, St Charles Hosp, Pembridge Palliat Care Ctr, London W10 6DZ, England.	emily.collis@clch.nhs.uk	Sleeman, Katherine/C-4941-2014	Sleeman, Katherine/0000-0002-9777-4373	National Institute for Health Research [CL-2010-17-009] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Bennett M, 1996, POSTGRAD MED J, V72, P25, DOI 10.1136/pgmj.72.843.25; CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; DAVIES E, 1973, P ROY SOC MED, V66, P533; Department for Work and Pensions, BEN INC DIS MAT BER; General Medical Council, 2010, TREATM CAR END LIF G; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; GOSTIN LO, 1995, JAMA-J AM MED ASSOC, V274, P844; Rousseau P, 2000, WESTERN J MED, V173, P117, DOI 10.1136/ewjm.173.2.117; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410	9	3	3	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 24	2013	346								f2589	10.1136/bmj.f2589	http://dx.doi.org/10.1136/bmj.f2589			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	134PM	23615596				2023-01-03	WOS:000318224900018
J	Bell, KJ; Fulcher, ML; Rowlands, DS; Kerse, N				Bell, Kevin J.; Fulcher, Mark L.; Rowlands, David S.; Kerse, Ngaire			Impact of autologous blood injections in treatment of mid-portion Achilles tendinopathy: double blind randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLATELET-RICH PLASMA; ELBOW TENDINOPATHY; CLINICAL-TRIAL; COL5A1 GENE; VISA-A; EPICONDYLITIS; MANAGEMENT; THERAPY; QUESTIONNAIRE; CELLS	Objective To assess the effectiveness of two peritendinous autologous blood injections in addition to a standardised eccentric calf strengthening programme in improving pain and function in patients with mid-portion Achilles tendinopathy. Design Single centre, participant and single assessor blinded, parallel group, randomised, controlled trial. Setting Single sports medicine clinic in New Zealand. Participants 53 adults (mean age 49, 53% men) with symptoms of unilateral mid-portion Achilles tendinopathy for at least three months. Participants were excluded if they had a history of previous Achilles tendon rupture or surgery or had undergone previous adjuvant treatments such as injectable therapies, glyceryl trinitrate patches, or extracorporeal shockwave therapy. Interventions All participants underwent two unguided peritendinous injections one month apart with a standardised protocol. The treatment group had 3 mL of their own whole blood injected while the control group had no substance injected (needling only). Participants in both groups carried out a standardised and monitored 12 week eccentric calf training programme. Follow-up was at one, two, three and six months. Main outcome measures The primary outcome measure was the change in symptoms and function from baseline to six months with the Victorian Institute of Sport Assessment-Achilles (VISA-A) score. Secondary outcomes were the participant's perceived rehabilitation and their ability to return to sport. Results 26 participants were randomly assigned to the treatment group and 27 to the control group. In total, 50 (94%) completed the six month study, with 25 in each group. Clear and clinically worthwhile improvements in the VISA-A score were evident at six months in both the treatment (change in score 18.7, 95% confidence interval 12.3 to 25.1) and control (19.9, 13.6 to 26.2) groups. The overall effect of treatment was not significant (P=0.689) and the 95% confidence intervals at all points precluded clinically meaningful benefit or harm. There was no significant difference between groups in secondary outcomes or in the levels of compliance with the eccentric calf strengthening programme. No adverse events were reported. Conclusion The administration of two unguided peritendinous autologous blood injections one month apart, in addition to a standardised eccentric training programme, provides no additional benefit in the treatment of mid-portion Achilles tendinopathy.	[Bell, Kevin J.] Sydney Sports Med Ctr, Sydney, NSW 2127, Australia; [Fulcher, Mark L.; Kerse, Ngaire] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Dept Gen Practice & Primary Hlth Care, Auckland 1, New Zealand; [Rowlands, David S.] Massey Univ, Sch Sport & Exercise, Wellington, New Zealand	University of Auckland; Massey University	Bell, KJ (corresponding author), Sydney Sports Med Ctr, POB 3275, Rhodes, NSW 2138, Australia.	kevtherev77@hotmail.com	Kerse, Ngaire/AFF-8119-2022					Abbassian A, 2009, BRIT J HOSP MED, V70, P519, DOI 10.12968/hmed.2009.70.9.43869; Alfredson H, 2003, CLIN SPORT MED, V22, P727, DOI 10.1016/S0278-5919(03)00010-3; Alfredson H, 1998, AM J SPORT MED, V26, P360, DOI 10.1177/03635465980260030301; Alfredson Hakan, 2005, Foot Ankle Clin, V10, P321, DOI 10.1016/j.fcl.2005.01.002; ASTROM M, 1995, CLIN ORTHOP RELAT R, P151; Bisset L, 2006, BMJ-BRIT MED J, V333, P939, DOI 10.1136/bmj.38961.584653.AE; Brown R, 2006, BRIT J SPORT MED, V40, P275, DOI 10.1136/bjsm.2005.021931; Connell DA, 2006, SKELETAL RADIOL, V35, P371, DOI 10.1007/s00256-006-0081-9; Creaney L, 2011, BRIT J SPORT MED, V45, P966, DOI 10.1136/bjsm.2010.082503; de Jonge S, 2011, AM J SPORT MED, V39, P1623, DOI 10.1177/0363546511404877; de Vos RJ, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.032532; de Vos RJ, 2010, JAMA-J AM MED ASSOC, V303, P144, DOI 10.1001/jama.2009.1986; Edwards SG, 2003, J HAND SURG-AM, V28A, P272, DOI 10.1053/jhsu.2003.50041; Fredberg U, 2004, SCAND J RHEUMATOL, V33, P94, DOI 10.1080/03009740310004126; Gaweda K, 2010, INT J SPORTS MED, V31, P577, DOI 10.1055/s-0030-1255028; Iversen JV, 2012, INT J SPORTS PHYS TH, V7, P76; IWASAKI M, 1995, J BONE JOINT SURG AM, V77A, P543, DOI 10.2106/00004623-199504000-00007; James SLJ, 2007, BRIT J SPORT MED, V41, P518, DOI 10.1136/bjsm.2006.034686; Kajikawa Y, 2008, J CELL PHYSIOL, V215, P837, DOI 10.1002/jcp.21368; Kazemi M, 2010, AM J PHYS MED REHAB, V89, P660, DOI 10.1097/PHM.0b013e3181ddcb31; Kingma JJ, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.030916; Lake JE, 2009, FOOT ANKLE CLIN, V14, P663, DOI 10.1016/j.fcl.2009.07.003; LEADBETTER WB, 1995, CLIN SPORT MED, V14, P353; Longo UG, 2009, SPORTS MED ARTHROSC, V17, P112, DOI 10.1097/JSA.0b013e3181a3d625; Magnussen RA, 2009, CLIN J SPORT MED, V19, P54, DOI 10.1097/JSM.0b013e31818ef090; Mishra A, 2006, AM J SPORT MED, V34, P1774, DOI 10.1177/0363546506288850; Mokone GG, 2006, SCAND J MED SCI SPOR, V16, P19, DOI 10.1111/j.1600-0838.2005.00439.x; Ohta T, 2008, J BIOL CHEM, V283, P9377, DOI 10.1074/jbc.M709377200; Orchard J, 2008, CLIN ORTHOP RELAT R, V466, P1625, DOI 10.1007/s11999-008-0254-z; Ozturan Kutay E, 2010, Orthopedics, V33, P84, DOI 10.3928/01477447-20100104-09; Pearson J, 2012, J SPORT REHABIL, V21, P218, DOI 10.1123/jsr.21.3.218; Raleigh SM, 2009, BRIT J SPORT MED, V43, P514, DOI 10.1136/bjsm.2008.053892; Rasmussen S, 2008, ACTA ORTHOP, V79, P249, DOI 10.1080/17453670710015058; Robinson JM, 2001, BRIT J SPORT MED, V35, P335, DOI 10.1136/bjsm.35.5.335; Rolf C, 1997, FOOT ANKLE INT, V18, P565, DOI 10.1177/107110079701800906; Rompe JD, 2007, AM J SPORT MED, V35, P374, DOI 10.1177/0363546506295940; Rompe JD, 2008, DISABIL REHABIL, V30, P1666, DOI 10.1080/09638280701785825; September AV, 2009, BRIT J SPORT MED, V43, P357, DOI 10.1136/bjsm.2008.048793; Snedecor G.W., 1983, AMES IOWA STATE U PR, V6th; Suresh SPS, 2006, BRIT J SPORT MED, V40, P935, DOI 10.1136/bjsm.2006.029983; Thanasas C, 2011, AM J SPORT MED, V39, P2130, DOI 10.1177/0363546511417113; Wolf JM, 2011, J HAND SURG-AM, V36A, P1269, DOI 10.1016/j.jhsa.2011.05.014; Yelland MJ, 2011, BRIT J SPORT MED, V45, P421, DOI 10.1136/bjsm.2009.057968; Zafar MS, 2009, SPORTS MED ARTHROSC, V17, P190, DOI 10.1097/JSA.0b013e3181b37eb7; Zeisig E, 2008, BRIT J SPORT MED, V42, P267, DOI 10.1136/bjsm.2007.042762	45	43	44	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 18	2013	346								f2310	10.1136/bmj.f2310	http://dx.doi.org/10.1136/bmj.f2310			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131AZ	23599320	Green Published, hybrid			2023-01-03	WOS:000317964200006
J	Thorpe, SD; Nagel, T; Carroll, SF; Kelly, DJ				Thorpe, Stephen D.; Nagel, Thomas; Carroll, Simon F.; Kelly, Daniel J.			Modulating Gradients in Regulatory Signals within Mesenchymal Stem Cell Seeded Hydrogels: A Novel Strategy to Engineer Zonal Articular Cartilage	PLOS ONE			English	Article							CYCLIC HYDROSTATIC-PRESSURE; DYNAMIC COMPRESSION; FUNCTIONAL-PROPERTIES; CHONDROGENIC PHENOTYPE; MECHANICAL STIMULATION; TISSUE DIFFERENTIATION; LOADING IMPROVES; PROGENITOR CELLS; GENE-EXPRESSION; MATRIX	Engineering organs and tissues with the spatial composition and organisation of their native equivalents remains a major challenge. One approach to engineer such spatial complexity is to recapitulate the gradients in regulatory signals that during development and maturation are believed to drive spatial changes in stem cell differentiation. Mesenchymal stem cell (MSC) differentiation is known to be influenced by both soluble factors and mechanical cues present in the local microenvironment. The objective of this study was to engineer a cartilaginous tissue with a native zonal composition by modulating both the oxygen tension and mechanical environment thorough the depth of MSC seeded hydrogels. To this end, constructs were radially confined to half their thickness and subjected to dynamic compression (DC). Confinement reduced oxygen levels in the bottom of the construct and with the application of DC, increased strains across the top of the construct. These spatial changes correlated with increased glycosaminoglycan accumulation in the bottom of constructs, increased collagen accumulation in the top of constructs, and a suppression of hypertrophy and calcification throughout the construct. Matrix accumulation increased for higher hydrogel cell seeding densities; with DC further enhancing both glycosaminoglycan accumulation and construct stiffness. The combination of spatial confinement and DC was also found to increase proteoglycan-4 (lubricin) deposition toward the top surface of these tissues. In conclusion, by modulating the environment through the depth of developing constructs, it is possible to suppress MSC endochondral progression and to engineer tissues with zonal gradients mimicking certain aspects of articular cartilage.	[Thorpe, Stephen D.; Nagel, Thomas; Carroll, Simon F.; Kelly, Daniel J.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Trinity Ctr Bioengn, Dublin, Ireland; [Thorpe, Stephen D.; Nagel, Thomas; Carroll, Simon F.; Kelly, Daniel J.] Trinity Coll Dublin, Sch Engn, Dept Mech & Mfg Engn, Dublin, Ireland	Trinity College Dublin; Trinity College Dublin	Kelly, DJ (corresponding author), Trinity Coll Dublin, Trinity Biomed Sci Inst, Trinity Ctr Bioengn, Dublin, Ireland.	kellyd9@tcd.ie	Nagel, Thomas/T-8805-2019; Thorpe, Stephen/C-1656-2018; Nagel, Thomas/E-9966-2017	Nagel, Thomas/0000-0001-8459-4616; Thorpe, Stephen/0000-0002-4707-7756; Nagel, Thomas/0000-0001-8459-4616; Kelly, Daniel/0000-0003-4091-0992	Science Foundation Ireland [08/Y15/B1336]; European Research Council [258463]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); European Research Council(European Research Council (ERC)European Commission)	Funding was provided by Science Foundation Ireland (President of Ireland Young Researcher Award: 08/Y15/B1336) and the European Research Council (StemRepair Project number 258463). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AKIZUKI S, 1986, J ORTHOPAED RES, V4, P379, DOI 10.1002/jor.1100040401; Albro MB, 2011, J BIOMECH, V44, P1654, DOI 10.1016/j.jbiomech.2011.03.026; Albro MB, 2008, J BIOMECH, V41, P3152, DOI 10.1016/j.jbiomech.2008.08.023; Angele P, 2004, BIORHEOLOGY, V41, P335; Angele P, 2003, J ORTHOPAED RES, V21, P451, DOI 10.1016/S0736-0266(02)00230-9; Baker BM, 2011, TISSUE ENG PT A, V17, P1445, DOI [10.1089/ten.TEA.2010.0535, 10.1089/ten.tea.2010.0535]; Baumgartner L, 2010, J BIOMED MATER RES A, V93A, P930, DOI 10.1002/jbm.a.32577; Bian LM, 2012, TISSUE ENG PT A, V18, P715, DOI [10.1089/ten.tea.2011.0455, 10.1089/ten.TEA.2011.0455]; BROCKLEHURST R, 1984, J BONE JOINT SURG AM, V66A, P95, DOI 10.2106/00004623-198466010-00013; Buckley CT, 2010, OSTEOARTHR CARTILAGE, V18, P1345, DOI 10.1016/j.joca.2010.07.004; Buckley CT, 2012, TISSUE ENG PT A, V18, P382, DOI [10.1089/ten.tea.2011.0145, 10.1089/ten.TEA.2011.0145]; Buckley CT, 2009, TISSUE ENG PT A, V15, P3213, DOI [10.1089/ten.tea.2008.0531, 10.1089/ten.TEA.2008.0531]; Buckley CT, 2009, J MECH BEHAV BIOMED, V2, P512, DOI 10.1016/j.jmbbm.2008.12.007; Campbell JJ, 2006, BIORHEOLOGY, V43, P455; Candrian C, 2008, ARTHRITIS RHEUM-US, V58, P197, DOI 10.1002/art.23155; CARTER DR, 1988, J ORTHOP RES, V6, P736, DOI 10.1002/jor.1100060517; Connelly JT, 2010, TISSUE ENG PT A, V16, P1913, DOI [10.1089/ten.tea.2009.0561, 10.1089/ten.TEA.2009.0561]; Demarteau O, 2003, BIOCHEM BIOPH RES CO, V310, P580, DOI 10.1016/j.bbrc.2003.09.099; Farrell MJ, 2012, EUR CELLS MATER, V23, P425, DOI 10.22203/eCM.v023a33; Gannon AR, 2012, OSTEOARTHR CARTILAGE, V20, P1417, DOI 10.1016/j.joca.2012.08.005; Goerke UJ, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4001312; Gu WY, 2003, J BIOMECH, V36, P593, DOI 10.1016/S0021-9290(02)00437-2; Hall BK, 2005, BONES CARTILAGE DEV, Vxxviii; Haugh MG, 2011, TISSUE ENG PT A, V17, P3085, DOI 10.1089/ten.tea.2011.0198; Huang AH, 2010, EUR CELLS MATER, V19, P72, DOI 10.22203/eCM.v019a08; Huang AH, 2010, J BIOMECH, V43, P128, DOI 10.1016/j.jbiomech.2009.09.018; Huang CYC, 2004, STEM CELLS, V22, P313, DOI 10.1634/stemcells.22-3-313; Hwang NS, 2007, FEBS LETT, V581, P4172, DOI 10.1016/j.febslet.2007.07.049; Ignat'eva NY, 2007, J ANAL CHEM+, V62, P51, DOI 10.1134/S106193480701011X; Kafienah W, 2003, METH MOL B, V238, P217; Kanichai M, 2008, J CELL PHYSIOL, V216, P708, DOI 10.1002/jcp.21446; Kelly DJ, 2010, BIRTH DEFECTS RES C, V90, P75, DOI 10.1002/bdrc.20173; Khan WS, 2010, KNEE, V17, P369, DOI 10.1016/j.knee.2009.12.003; Kim TK, 2003, OSTEOARTHR CARTILAGE, V11, P653, DOI 10.1016/S1063-4584(03)00120-1; KIM YJ, 1988, ANAL BIOCHEM, V174, P168, DOI 10.1016/0003-2697(88)90532-5; Kisiday JD, 2009, TISSUE ENG PT A, V15, P2817, DOI [10.1089/ten.tea.2008.0357, 10.1089/ten.TEA.2008.0357]; Klein TJ, 2003, OSTEOARTHR CARTILAGE, V11, P595, DOI 10.1016/S1063-4584(03)00090-6; Krinner A, 2009, CELL PROLIFERAT, V42, P471, DOI 10.1111/j.1365-2184.2009.00621.x; Kupcsik L, 2010, TISSUE ENG PT A, V16, P1845, DOI [10.1089/ten.tea.2009.0531, 10.1089/ten.TEA.2009.0531]; Laasanen MS, 2003, BIORHEOLOGY, V40, P133; Lecocq M, 2008, EQUINE VET J, V40, P442, DOI 10.2746/042516408X297453; Lee CSD, 2007, BIOMATERIALS, V28, P2987, DOI 10.1016/j.biomaterials.2007.02.035; Li JT, 2011, CELL TISSUE RES, V345, P357, DOI [10.1007/s00441-011-1212-8, 10.1007/s00441-011-1220-8]; Lion A, 1997, ACTA MECH, V123, P1, DOI 10.1007/BF01178397; Liu YR, 2012, TISSUE ENG PT A, V18, P1531, DOI [10.1089/ten.tea.2011.0575, 10.1089/ten.TEA.2011.0575]; Mauck RL, 2007, BIOMECH MODEL MECHAN, V6, P113, DOI 10.1007/s10237-006-0042-1; Mauck RL, 2003, J BIOMECH ENG-T ASME, V125, P602, DOI 10.1115/1.1611512; Meyer EG, 2011, J MECH BEHAV BIOMED, V4, P1257, DOI 10.1016/j.jmbbm.2011.04.012; Meyer EG, 2010, J BIOMECH, V43, P2516, DOI 10.1016/j.jbiomech.2010.05.020; Miyanishi K, 2006, TISSUE ENG, V12, P1419, DOI 10.1089/ten.2006.12.1419; Mow V, 2002, ANNU REV BIOMED ENG, V4, P175, DOI 10.1146/annurev.bioeng.4.110701.120309; Mow V.C., 2001, BASIC BIOMECHANICS M, P60; Nagel T, 2012, TISSUE EN A IN PRESS; Ng KW, 2006, BIORHEOLOGY, V43, P497; Ng KW, 2009, TISSUE ENG PT A, V15, P2315, DOI 10.1089/ten.tea.2008.0391; Ng KW, 2005, J ORTHOP RES, V23, P134, DOI 10.1016/j.orthres.2004.05.015; Nguyen LH, 2011, BIOMATERIALS, V32, P6946, DOI 10.1016/j.biomaterials.2011.06.014; Nguyen LH, 2011, BIOMATERIALS, V32, P1327, DOI 10.1016/j.biomaterials.2010.10.009; Pattappa G, 2013, TISSUE ENG PART C-ME, V19, DOI [10.1089/ten.tec.2011.0734, 10.1089/ten.TEC.2011.0734]; Pattappa G, 2011, J CELL PHYSIOL, V226, P2562, DOI 10.1002/jcp.22605; PAUWELS F, 1960, Z Anat Entwicklungsgesch, V121, P478, DOI 10.1007/BF00523401; Pelttari K, 2009, SWISS MED WKLY, V139, P602, DOI smw-12742; Prendergast PJ, 1997, J BIOMECH, V30, P539, DOI 10.1016/S0021-9290(96)00140-6; Schinagl RM, 1997, J ORTHOPAED RES, V15, P499, DOI 10.1002/jor.1100150404; Sengers BG, 2005, J BIOMECH ENG-T ASME, V127, P758, DOI 10.1115/1.1993664; Sharma B, 2007, TISSUE ENG, V13, P405, DOI 10.1089/ten.2006.0068; Sheehy EJ, 2013, ACTA BIOMATER, V9, P5484, DOI 10.1016/j.actbio.2012.11.008; Sheehy EJ, 2012, BIOCHEM BIOPH RES CO, V417, P305, DOI 10.1016/j.bbrc.2011.11.105; Sheehy EJ, 2011, J TISSUE ENG REGEN M, V5, P747, DOI 10.1002/term.385; Steward AJ, 2012, ACTA BIOMATER, V8, P2153, DOI 10.1016/j.actbio.2012.03.016; Storn R, 1997, J GLOBAL OPTIM, V11, P341, DOI 10.1023/A:1008202821328; Thorpe SD, 2008, BIOCHEM BIOPH RES CO, V377, P458, DOI 10.1016/j.bbrc.2008.09.154; Thorpe SD, 2012, J BIOMECH, V45, P2483, DOI 10.1016/j.jbiomech.2012.07.024; Thorpe SD, 2010, ANN BIOMED ENG, V38, P2896, DOI 10.1007/s10439-010-0059-6; Vinardell T, 2012, EUR CELLS MATER, V23, P121, DOI 10.22203/eCM.v023a09; Vinatier C, 2009, CURR STEM CELL RES T, V4, P318, DOI 10.2174/157488809789649205; Woodfield TBF, 2005, TISSUE ENG, V11, P1297, DOI 10.1089/ten.2005.11.1297; Zhou SD, 2004, ARTHRITIS RHEUM-US, V50, P3915, DOI 10.1002/art.20675	78	56	58	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2013	8	4							e60764	10.1371/journal.pone.0060764	http://dx.doi.org/10.1371/journal.pone.0060764			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130DR	23613745	Green Published, gold			2023-01-03	WOS:000317893400021
J	Goncalves, MJF; Ferreira, AA				Ferreira Goncalves, Maria Jacirema; Ferreira, Alaidistania A.			Factors Associated with Length of Hospital Stay among HIV Positive and HIV Negative Patients with Tuberculosis in Brazil	PLOS ONE			English	Article							SOCIAL-FACTORS; SMOKING	Objective: Identify and analyze the factors associated to length of hospital stay among HIV positive and HIV negative patients with tuberculosis in Manaus city, state of Amazonas, Brazil, in 2010. Methods: Epidemiological study with primary data obtained from monitoring of hospitalized patients with tuberculosis in Manaus. Data were collected by interviewing patients and analyzing medical records, according to the following study variables age, sex, co-morbidities, education, race, income, lifestyle, history of previous treatment or hospitalization due to tuberculosis, treatment regimen, adverse reactions, smear test, clinical form, type of discharge, and length of hospital stay. The associated factors were identified through chi-square or t-Student test at a 5% significance level. Results: Income from 1 to 3 minimum wages (P = 0.028), pulmonary tuberculosis form (P = 0.011), negative smear test or no information in this regard (P = 0.014), initial 6-month treatment scheme (P = 0.029), and adverse drug reactions (P = 0.021) were associated to prolonged hospital stay in HIV positive patients. Conclusion: We found out that although there were no significant differences in the length of hospital stay in HIV positive patients, all factors significantly associated to prolonged hospital stay occurred in this group of patients. This finding corroborates other studies indicating the severity of tuberculosis in HIV patients, which may also contribute to lengthen their hospital stay.	[Ferreira Goncalves, Maria Jacirema; Ferreira, Alaidistania A.] Fed Univ Para, Amazonas Fed Univ, Postgrad Program Hlth Soc & Endem Dis Amazon, Leonidas & Maria Deane Inst,Fiocruz Fdn, Manaus, Amazonas, Brazil; [Ferreira Goncalves, Maria Jacirema; Ferreira, Alaidistania A.] Amazonas Fed Univ, Manaus Nursing Sch, Manaus, Amazonas, Brazil; [Ferreira Goncalves, Maria Jacirema] Fiocruz Fdn, Leonidas & Maria Deane Inst, Manaus, Amazonas, Brazil	Fundacao Oswaldo Cruz; Universidade Federal do Para; Fundacao Oswaldo Cruz	Goncalves, MJF (corresponding author), Fed Univ Para, Amazonas Fed Univ, Postgrad Program Hlth Soc & Endem Dis Amazon, Leonidas & Maria Deane Inst,Fiocruz Fdn, Manaus, Amazonas, Brazil.	jaciremagoncalves@gmail.com	Goncalves, Maria Jacirema/B-7018-2009; Goncalves, Maria Jacirema/Q-7455-2019	Goncalves, Maria Jacirema/0000-0002-8460-8501; Goncalves, Maria Jacirema/0000-0002-8460-8501; Ferreira, Alaidistania Aparecida Ferreira/0000-0001-8553-7269	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) from Brazil [014/2008, 481423/2008-7]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) from Brazil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This research was financed by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) from Brazil - Universal Announcement 014/2008 - Process no. 481423/2008-7. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apetse K, 2011, Bull Soc Pathol Exot, V104, P352, DOI 10.1007/s13149-011-0139-3; Atun RA, 2005, INT J TUBERC LUNG D, V9, P1140; Brazilian Institute of Geography and Statistics, 2010, DEM CENS; Brazilian Institute of Geography and Statistics, 2008, RAC ETHN FEAT POP ST; Brazilian Institute of Geography and Statistics, 2008, TABL 2 24 PROP PEOPL; Brazilian Ministry of Health, INF SYST NOT DIS SIN; Brazilian Ministry of Health, 2011, MAN REC TUB CONTR BR; Brazilian Ministry of Health, 2008, NAT POL MEN HLTH PRI; Campomizzi JB, 2009, THESIS MINAS GERAIS; Courtwright A, 2010, PUBLIC HEALTH REP, V125, P34, DOI 10.1177/00333549101250S407; Craig GM, 2007, J ADV NURS, V58, P418, DOI 10.1111/j.1365-2648.2007.04257.x; Cramm JM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-72; de Oliveira HMDG, 2009, J BRAS PNEUMOL, V35, P780, DOI 10.1590/S1806-37132009000800010; de Meneses-Gaya IC, 2009, J BRAS PNEUMOL, V35, P73, DOI 10.1590/S1806-37132009000100011; Ewing JA, 1984, CAGE CUT ANNOYED GUI; Fortes Deguenonvo L, 2011, Bull Soc Pathol Exot, V104, P366, DOI 10.1007/s13149-011-0178-9; Kra O, 2012, B SOC PATHOL EXOT, P1; Lins Tatiana Bacelar Acioli, 2012, Infez Med, V20, P108; Munro SA, 2007, PLOS MED, V4, P1230, DOI 10.1371/journal.pmed.0040238; Sissolak D, 2010, INT J INFECT DIS, V14, pE423, DOI 10.1016/j.ijid.2009.06.030; Suhadev M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019485; Wang JM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-292; Wen CP, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-156; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1	24	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2013	8	4							e60487	10.1371/journal.pone.0060487	http://dx.doi.org/10.1371/journal.pone.0060487			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123JP	23593227	Green Published, gold, Green Submitted			2023-01-03	WOS:000317385300018
J	Bryant, RA; Hung, L				Bryant, Richard A.; Hung, Lynette			Oxytocin Enhances Social Persuasion during Hypnosis	PLOS ONE			English	Article							RESPONSES; BEHAVIOR	It has long been argued that hypnosis cannot promote behaviors that people will not otherwise engage in. Oxytocin can enhance trust in others, and may promote the extent to which a hypnotized person complies with the suggestion of a hypnotist. This double-blind placebo study administered oxytocin or placebo to high hypnotizable participants (N = 28), who were then administered hypnotic suggestions for socially unorthodox behaviors, including swearing during the experiment, singing out loud, and dancing in response to a posthypnotic cue. Participants who received oxytocin were significantly more likely to swear and dance than those who received the placebo. This finding may be interpreted in terms of oxytocin increasing social compliance in response as a function of (a) increased trust in the hypnotist, (b) reduced social anxiety, or (c) enhanced sensitivity to cues to respond to experimental expectations. These results point to the potential role of oxytocin in social persuasion.	[Bryant, Richard A.; Hung, Lynette] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia	University of New South Wales Sydney	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X	Australian Research Council	Australian Research Council(Australian Research Council)	This project was supported by an Australian Research Council Discovery Grant. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bartz J, 2011, SOC COGN AFFECT NEUR, V6, P556, DOI 10.1093/scan/nsq085; Bartz JA, 2006, HORM BEHAV, V50, P518, DOI 10.1016/j.yhbeh.2006.06.018; Bartz JA, 2010, P NATL ACAD SCI USA, V107, P21371, DOI 10.1073/pnas.1012669107; Bogousslavsky J, 2009, EUR NEUROL, V62, P193, DOI 10.1159/000228252; Breuer Josef., 1955, STANDARD EDITION COM; BRYANT RA, 1989, J ABNORM PSYCHOL, V98, P71, DOI 10.1037/0021-843X.98.1.71; Bryant RA, 2012, PSYCHONEUROENDOCRINO, V37, P162, DOI 10.1016/j.psyneuen.2011.05.010; Burbach JPH, 2006, KNOBIL AND NEILL'S PHYSIOLOGY OF REPRODUCTION, VOLS 1 AND 2, 3RD EDITON, P3055; De Dreu CKW, 2011, P NATL ACAD SCI USA, V108, P1262, DOI 10.1073/pnas.1015316108; Declerck CH, 2010, HORM BEHAV, V57, P368, DOI 10.1016/j.yhbeh.2010.01.006; DEGROOT HP, 1988, J PERS SOC PSYCHOL, V54, P1049, DOI 10.1037/0022-3514.54.6.1049; Domes G, 2007, BIOL PSYCHIAT, V61, P731, DOI 10.1016/j.biopsych.2006.07.015; GFELLER JD, 1987, J PERS SOC PSYCHOL, V52, P586, DOI 10.1037/0022-3514.52.3.586; Guastella AJ, 2008, BIOL PSYCHIAT, V63, P3, DOI 10.1016/j.biopsych.2007.06.026; Heinrichs M, 2003, BIOL PSYCHIAT, V54, P1389, DOI 10.1016/S0006-3223(03)00465-7; INSEL TR, 1992, ANN NY ACAD SCI, V652, P122, DOI 10.1111/j.1749-6632.1992.tb34350.x; Janet P, 1907, MAJOR SYMPTOMS HYSTE, DOI 10.1037/10008-000; Kirsch P, 2005, J NEUROSCI, V25, P11489, DOI 10.1523/JNEUROSCI.3984-05.2005; Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701; Lim MM, 2006, HORM BEHAV, V50, P506, DOI 10.1016/j.yhbeh.2006.06.028; Lynn S., 2012, OXFORD HDB HYPNOSIS, P111, DOI DOI 10.1093/OXFORDHB/9780198570097.013.0005; Mikolajczak M, 2010, PSYCHOL SCI, V21, P1072, DOI 10.1177/0956797610377343; Neumann ID, 2002, PROG BRAIN RES, V139, P147; ORNE MT, 1972, INT J CLIN EXP HYP, V20, P101, DOI 10.1080/00207147208409281; ORNE MT, 1965, J PERS SOC PSYCHOL, V1, P189, DOI 10.1037/h0021933; PICCIONE C, 1989, J PERS SOC PSYCHOL, V56, P289, DOI 10.1037/0022-3514.56.2.289; Ring RH, 2006, PSYCHOPHARMACOLOGY, V185, P218, DOI 10.1007/s00213-005-0293-z; Scheele D, 2012, J NEUROSCI, V32, P16074, DOI 10.1523/JNEUROSCI.2755-12.2012; Shamay-Tsoory SG, 2009, BIOL PSYCHIAT, V66, P864, DOI 10.1016/j.biopsych.2009.06.009; Sheehan P.W., 1982, HYPNOSIS EXPERIENCE; SHEEHAN PW, 1980, J ABNORM PSYCHOL, V89, P263, DOI 10.1037/0021-843X.89.2.263; Shor RE, 1962, HARVARD GROUP SCALE; SJOBERG BM, 1965, PSYCHOPHARMACOLOGIA, V8, P251, DOI 10.1007/BF00407857; SPANOS NP, 1986, BEHAV BRAIN SCI, V9, P449, DOI 10.1017/S0140525X00046537; Striepens N, 2012, P NATL ACAD SCI USA, V109, P18144, DOI 10.1073/pnas.1208852109; UVNASMOBERG K, 1994, PHARMACOL BIOCHEM BE, V49, P101, DOI 10.1016/0091-3057(94)90462-6; Weitzenhoffer A. M., 1962, STANFORD HYPNOTIC SU; Woody EZ, 2005, PSYCHOL ASSESSMENT, V17, P200, DOI 10.1037/1040-3590.17.2.200; Young LJ, 2004, NAT NEUROSCI, V7, P1048, DOI 10.1038/nn1327; Young PC, 1952, EXPT HYPNOSIS, P376	40	7	7	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2013	8	4							e60711	10.1371/journal.pone.0060711	http://dx.doi.org/10.1371/journal.pone.0060711			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	146RZ	23577153	Green Published, gold			2023-01-03	WOS:000319109800095
J	Saman, DM; Kavanagh, KT; Johnson, B; Lutfiyya, MN				Saman, Daniel M.; Kavanagh, Kevin T.; Johnson, Brian; Lutfiyya, M. Nawal			Can Inpatient Hospital Experiences Predict Central Line-Associated Bloodstream Infections?	PLOS ONE			English	Article							QUALITY	Background: Factors that increase the risk of central line-associated bloodstream infections (CLABSIs) are not fully understood. Recently, Hospital Compare began compiling data from hospital-required reporting to the CDC's National Healthcare Safety Network on CLABSIs in intensive care units (ICUs), at over 4,000 Medicare-certified hospitals in the United States, and made this data accessible on a central website. Also available on the same website are results from the Hospital Consumer Assessment of Healthcare Providers and Systems survey of patients' hospital experiences. Utilizing both databases, our objective was to determine whether patients' hospital experiences were significantly associated with increased risk for reported ICU CLABSI. Methods and Findings: We conducted a zero-inflated Poisson regression analysis at the hospital level on CLABSI-observed cases by ICUs in acute care hospitals (n = 1987) in the United States between January 1, 2011, and December 31, 2011. During this period there were a total of 10,866 CLABSI cases and 9,543,765 central line days. In our final model, the percent of patients who reported that they "sometimes" or "never" received help as soon as they wanted was significantly associated with an increased risk for CLABSIs. Conclusions: Using national datasets, we found that inpatients' hospital experiences were significantly associated with an increased risk of ICU reported CLABSIs. This study suggests that hospitals with lower staff responsiveness, perhaps because of an understaffing of nurse and supportive personnel, are at an increased risk for CLABSIs. This study bolsters the evidence that patient surveys may be a useful surrogate to predicting the incidence of hospital acquired conditions, including CLABSIs. Moreover, our study found that poor staff responsiveness may be indicative of greater hospital problems and generally poorly performing hospitals; and that this finding may be a symptom of hospitals with a multitude of problems, including patient safety problems, and not a direct cause.	[Saman, Daniel M.; Johnson, Brian; Lutfiyya, M. Nawal] Essentia Inst Rural Hlth, Duluth, MN USA; [Saman, Daniel M.; Kavanagh, Kevin T.] Hlth Watch USA, Somerset, KY USA		Saman, DM (corresponding author), Essentia Inst Rural Hlth, Duluth, MN USA.	dsaman@eirh.org		Kavanagh, Kevin/0000-0002-4588-6509; Saman, Daniel/0000-0002-8372-4615				Agency for Healthcare Research and Quality, 2012, HEALTHC ASS INF; Aiken LH, 2011, MED CARE, V49, P1047, DOI 10.1097/MLR.0b013e3182330b6e; Allison, 2001, LOGISTIC REGRESSION; [Anonymous], 2012, CONSUMER REPORTS; Barrera L, 2011, AM J INFECT CONTROL, V39, P633, DOI 10.1016/j.ajic.2010.11.004; Berenholtz SM, 2004, CRIT CARE MED, V32, P2014, DOI 10.1097/01.CCM.0000142399.70913.2F; Birnbaum D, 2011, INFECT CONT HOSP EP, V32, P276, DOI 10.1086/658331; Center for Disease Control and Prevention, 2011, NAT STAT HEALTHC ASS; Centers for Disease Control and Prevention, 2011, HEALTHC FAC REP VIA; Centers for Disease Control and Prevention, 2012, NAT STAT HEALTHC INF; Centers for Disease Control and Prevention, 2012, CENTR LIN ASS BLOODS; Centers for Medicare & Medicaid Services, 2011, DAT MED GOV SURV PAT; Centers for Medicare & Medicaid Services, 2012, HOSP COMP DAT MED GO; Cimiotti JP, 2012, AM J INFECT CONTROL, V40, P486, DOI 10.1016/j.ajic.2012.02.029; Dixon-Woods M, 2011, MILBANK Q, V89, P167, DOI 10.1111/j.1468-0009.2011.00625.x; Edwards JR, 2009, AM J INFECT CONTROL, V37, P783, DOI 10.1016/j.ajic.2009.10.001; Gawande A., 2009, COST CONUNDRUM NEW Y; Glance LG, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-247; Greaves F, 2012, ARCH INTERN MED, V172, P435, DOI 10.1001/archinternmed.2011.1675; Guerin K, 2010, AM J INFECT CONTROL, V38, P430, DOI 10.1016/j.ajic.2010.03.007; HCAHPS, 2012, CAHPS HOSP SURV QUAL; Institute for Digital Research and Education idre UCLA, 2012, SAS DAT AN EXP ZER I; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Kane R. L., 2007, AHRQ PUBLICATION, V07-E005; Kavanagh KT, 2012, J NURS SCHOLARSHIP, V44, P385, DOI 10.1111/j.1547-5069.2012.01469.x; Kutney-Lee A, 2009, HEALTH AFFAIR, V28, pW669, DOI 10.1377/hlthaff.28.4.w669; PRONOVOST P, 2008, AM J INFECT CONTROL, V36; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Saman DM, 2013, J PATIENT S IN PRESS; Santa J, 2012, CONSUMER REPORTS ACC; SAS Institute Inc, 2011, SAS 9 3; Scott RD, 2009, DIRECT MED COSTS HEA; Srinivasan A., 2011, Morbidity and Mortality Weekly Report, V60, P243; Witherington EMA, 2008, QUAL SAF HEALTH CARE, V17, P71, DOI 10.1136/qshc.2006.020842	34	21	21	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2013	8	4							e61097	10.1371/journal.pone.0061097	http://dx.doi.org/10.1371/journal.pone.0061097			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146RZ	23577195	Green Published, Green Submitted, gold			2023-01-03	WOS:000319109800122
J	Luty, J				Luty, Jason			Promoting abstinence for drug users is about saving money not science	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							METHADONE-MAINTENANCE; OPIOID DEPENDENCE		Ipswich Subst Misuse Serv, Ipswich IP1 2NZ, England		Luty, J (corresponding author), Ipswich Subst Misuse Serv, Ipswich IP1 2NZ, England.	jason.luty@yahoo.co.uk						AMATO L, 2003, COCHRANE DB SYST REV, P3409; Amato L, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005031.pub4; [Anonymous], 2009, BBC NEWS; Easton M., 2008, BBC NEWS; GOSSOP M, 2001, NATL TREATMENT OUTCO; HM Government, 2017, DRUG STRAT 2010 RED; Judd LL, 1998, JAMA-J AM MED ASSOC, V280, P1936; National Treatment Agency for Substance Misuse, 2012, MED REC REOR DRUG DE; Nosyk B, 2012, ADDICTION, V107, P1621, DOI 10.1111/j.1360-0443.2012.03870.x; Sees KL, 2000, JAMA-J AM MED ASSOC, V283, P1303, DOI 10.1001/jama.283.10.1303; Simpson DD, 1997, DRUG ALCOHOL DEPEN, V47, P227; Ward J, 1999, LANCET, V353, P221, DOI 10.1016/S0140-6736(98)05356-2	12	4	4	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 22	2013	346								f1481	10.1136/bmj.f1481	http://dx.doi.org/10.1136/bmj.f1481			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	113MQ	23525865				2023-01-03	WOS:000316672500010
J	Wang, SH; An, TT; Duan, JC; Zhang, LJ; Wu, MN; Zhou, QH; Chen, JF; Zhuo, ML; Yang, L; Wang, YY; Bai, H; Wang, J				Wang, Shuhang; An, Tongtong; Duan, Jianchun; Zhang, Lijian; Wu, Meina; Zhou, Qinghua; Chen, Jinfeng; Zhuo, Minglei; Yang, Lu; Wang, Yuyan; Bai, Hua; Wang, Jie			Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer	PLOS ONE			English	Article							FACTOR RECEPTOR MUTATIONS; MET AMPLIFICATION; GEFITINIB; SENSITIVITY; RESISTANCE; ERLOTINIB; TUMORS	Introduction: Genetic aberrancies within epidermal growth factor receptor (EGFR) pathway are associated with therapeutic outcomes of EGFR-tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). However, the impact of chemotherapy on EGFR-related genes alterations has not been defined in NSCLC. Our study aims to investigate the impact of neoadjuvant chemotherapy (Neoadj-Chemo) on EGFR activating mutations and associated EGFR-TKIs resistance-related genes. Patients and Methods: Matched tumor samples were obtained retrospectively from 66 NSCLC patients (stages IIb-IIIb) corresponding to pre-and post-Neoadj-Chemo. EGFR mutations were detected by denaturing high performance liquid chromatography (DHPLC) and confirmed by Amplification Refractory Mutation System technology (ARMS), KRAS mutations, T790M mutation and c-MET amplification were identified using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP), ARMS, and real-time PCR, respectively. Results: Before Neoadj-Chemo, EGFR mutations were identified in 33.3% (22/66) of NSCLC patients. Only 18.2% (12/66) of patients carried EGFR mutations after Neoadj-Chemo (p = 0.013). The median peak value of EGFR 19 exon mutations decreased non-significantly after Neoadj-Chemo. KRAS mutation rate decreased from 4.6% (3/66) to 3.0% (2/66) with Neoadj-Chemo. Although the overall percentage of patients exhibiting c-MET amplifications (6.1% [4/66]) did not change with Neoadj-Chemo, two patients transitioned from negative to positive c-MET amplification, and two patients reversed these changes post-Neoadj-Chemo. T790M mutations were absent from all samples. Conclusion: Neoadjuvant chemotherapy tends to decrease the mutation frequency of EGFR mutation and downstream genes, which suggests that real-time samples analysis for genetic aberrancies within EGFR pathways have important value to delineate specific patient populations and facilitate individualized treatment.	[Wang, Shuhang; An, Tongtong; Duan, Jianchun; Wu, Meina; Zhuo, Minglei; Yang, Lu; Wang, Yuyan; Bai, Hua; Wang, Jie] Peking Univ, Sch Oncol, Dept Thorac Med Oncol,Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China; [Zhang, Lijian; Chen, Jinfeng] Peking Univ, Sch Oncol, Dept Thorac Surg,Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China; [Zhou, Qinghua] Tianjin Med Univ Gen Hosp, Dept Thorac Surg, Tianjin, Peoples R China	Peking University; Peking University; Tianjin Medical University	Bai, H (corresponding author), Peking Univ, Sch Oncol, Dept Thorac Med Oncol,Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China.	baihuahb@sina.com; wangjie_cc@yahoo.com	Duan, Jianchun/AAM-5765-2020	zhuo, minglei/0000-0003-2489-7791	National Natural Sciences Foundation Distinguished Young Scholars [81025012]; National Natural Sciences Foundation General Program [81172235]; Capital Development Foundation [2007-1023]; Beijing Health Systems Academic Leader [2011-2-22]; Science and Technology Project of Beijing [Z090507017709015]; National Natural Sciences Foundation China Youth Science Foundation [81101726]	National Natural Sciences Foundation Distinguished Young Scholars; National Natural Sciences Foundation General Program; Capital Development Foundation; Beijing Health Systems Academic Leader; Science and Technology Project of Beijing; National Natural Sciences Foundation China Youth Science Foundation	Supported by grants from National Natural Sciences Foundation Distinguished Young Scholars (81025012), National Natural Sciences Foundation General Program (81172235), the Capital Development Foundation (2007-1023), Beijing Health Systems Academic Leader (2011-2-22) and Science and Technology Project of Beijing (Z090507017709015), National Natural Sciences Foundation China Youth Science Foundation (81101726). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai H, 2012, J CLIN ONCOL, V30, P3077, DOI 10.1200/JCO.2011.39.3744; Bai H, 2009, J CLIN ONCOL, V27, P2653, DOI 10.1200/JCO.2008.17.3930; Beau-Faller M, 2008, J THORAC ONCOL, V3, P331, DOI 10.1097/JTO.0b013e318168d9d4; Chin TM, 2008, CLIN CANCER RES, V14, P6867, DOI 10.1158/1078-0432.CCR-08-0093; Dong Qiang-gang, 2006, Zhonghua Zhongliu Zazhi, V28, P686; Duan Jian-chun, 2012, Zhonghua Jie He He Hu Xi Za Zhi, V35, P323; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714; Lee JS, 2009, J THORAC ONCOL, V4, pS283; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mu XL, 2005, CLIN CANCER RES, V11, P4289, DOI 10.1158/1078-0432.CCR-04-2506; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Park S, 2009, J THORAC ONCOL, V4, P809, DOI 10.1097/JTO.0b013e3181a94af4; Rosell R, 2011, CLIN CANCER RES, V17, P1160, DOI 10.1158/1078-0432.CCR-10-2158; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Schmid K, 2009, CLIN CANCER RES, V15, P4554, DOI 10.1158/1078-0432.CCR-09-0089; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Taniguchi K, 2008, CANCER SCI, V99, P929, DOI 10.1111/j.1349-7006.2008.00782.x; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Wang SH, 2010, CLIN CANCER RES, V16, P1324, DOI 10.1158/1078-0432.CCR-09-2672; Yatabe Y, 2008, CANCER RES, V68, P2106, DOI 10.1158/0008-5472.CAN-07-5211; Yatabe Y, 2011, J CLIN ONCOL, V29, P2972, DOI 10.1200/JCO.2010.33.3906; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Zhou Q, 2011, J CLIN ONCOL, V29, P3316, DOI 10.1200/JCO.2010.33.3757	34	7	7	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2013	8	3							e51021	10.1371/journal.pone.0051021	http://dx.doi.org/10.1371/journal.pone.0051021			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	140TZ	23520442	gold, Green Submitted, Green Published			2023-01-03	WOS:000318679900001
J	Ferner, R				Ferner, Robin			Divination	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Birmingham City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England		Ferner, R (corresponding author), Birmingham City Hosp, West Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	R.E.Ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Australian Government Therapeutic Goods Administration, 2013, LAB PACK PRACT SUMM; Flynn EA, 2006, TROUBLING AMINE; Garrett D, TALL MAN LETT; Kondrak G, 2006, ARTIF INTELL MED, V36, P29, DOI 10.1016/j.artmed.2005.07.005; MACINTYRE IM, 1972, LANCET, V1, P1094; Nelson RL, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003431.pub3; Smith VM, 2012, BRIT J DERMATOL, V167, P1048, DOI 10.1111/j.1365-2133.2012.11185.x; Timur, LEVENSHTEIN DISTANCE; US Food and Drug Administration, FDA DRUG SAF COMM ME; US Food and Drug Administration, MED ERR NAM DIFF PRO	10	0	0	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	2013	346								f1536	10.1136/bmj.f1536	http://dx.doi.org/10.1136/bmj.f1536			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104MT	23471365				2023-01-03	WOS:000315998500004
J	Gross, ML				Gross, Michael L.			Force-Feeding, Autonomy, and the Public Interest	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Haifa, Sch Polit Sci, IL-31999 Haifa, Israel	University of Haifa	Gross, ML (corresponding author), Univ Haifa, Sch Polit Sci, IL-31999 Haifa, Israel.							[Anonymous], 2005, FORC FEED HUNG STRIK; Glick SM, 1997, NEW ENGL J MED, V336, P954; Howe EG, 2009, INTERROGATIONS FORCE, P75; Visser SL., 2003, TXB MILITARY MED MIL, P251; World Medical Association, 2006, WMA DECL MALT HUNG S	5	14	14	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2013	369	2					103	105		10.1056/NEJMp1306325	http://dx.doi.org/10.1056/NEJMp1306325			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	180BH	23758204				2023-01-03	WOS:000321567300004
J	Loupakis, F; Cremolini, C; Yang, DY; Salvatore, L; Zhang, W; Wakatsuki, T; Bohanes, P; Schirripa, M; Benhaim, L; Lonardi, S; Antoniotti, C; Aprile, G; Graziano, F; Ruzzo, A; Lucchesi, S; Ronzoni, M; De Vita, F; Tonini, G; Falcone, A; Lenz, HJ				Loupakis, Fotios; Cremolini, Chiara; Yang, Dongyun; Salvatore, Lisa; Zhang, Wu; Wakatsuki, Takeru; Bohanes, Pierre; Schirripa, Marta; Benhaim, Leonor; Lonardi, Sara; Antoniotti, Carlotta; Aprile, Giuseppe; Graziano, Francesco; Ruzzo, Annamaria; Lucchesi, Sara; Ronzoni, Monica; De Vita, Ferdinando; Tonini, Giuseppe; Falcone, Alfredo; Lenz, Heinz-Josef			Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab	PLOS ONE			English	Article							CLINICAL-TRIAL DESIGNS; CHINESE POPULATION; GENETIC-VARIATIONS; PHASE-3 TRIAL; POLYMORPHISMS; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; BIOMARKERS; RESISTANCE	Purpose: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mCRC patients receiving bev-containing regimens has been investigated in retrospective experiences with contrasting results. We previously reported the association of VEGFA rs833061 C/T variants with PFS in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. The primary objective of this work was to prospectively validate that retrospective finding. A confirmatory analysis of other SNPs of VEGF/VEGFR pathway genes was included. Experimental design: To detect a HR for PFS of 1.7 for VEGFA rs833061 T/T compared to C-variants in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab, setting two-sided alpha = 0.05 and beta = 0.20, 199 events were required. VEGFA rs699946 A/G, rs699947 A/C, VEGFR1 rs9582036 A/C and rs7993418 A/G, VEGFR2 rs11133360 C/T, rs12505758 C/T and rs2305948 C/T and EPAS1 rs4145836 A/G were also tested. Germ-line DNA was extracted from peripheral blood. SNPs were analyzed by PCR and sequencing. Results: Four-hundred-twenty-four pts were included. At the univariate analysis, no differences according to VEGFA rs833061 C/T variants were observed in PFS (p = 0.38) or OS (p = 0.95). Among analyzed SNPs, only VEGFR2 rs12505758 C-variants, compared to T/T, were associated to shorter PFS (HR: 1.36 [1.05-1.75], p = 0.015, dominant genetic model) and OS, with a trend toward significance (HR: 1.34 [0.95-1.88], p = 0.088). In the multivariate model, this association retained significance (HR: 1.405 [1.082-1.825], p = 0.012) in PFS, that was lost by applying multiple testing correction (p = 0.14). Conclusion: This prospective experience failed to validate the hypothesized predictive impact of VEGFA rs833061 variants. Retrospective findings on different candidate SNPs were not confirmed. Only VEGFR2 rs12505758 variants, whose prognostic and not predictive impact was previously reported, correlated with PFS. Given the complexity of angiogenesis, it is rather unlike that a single germ-line SNP might be a good predictor of benefit from bevacizumab.	[Loupakis, Fotios; Yang, Dongyun; Zhang, Wu; Wakatsuki, Takeru; Bohanes, Pierre; Benhaim, Leonor; Lenz, Heinz-Josef] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Loupakis, Fotios; Cremolini, Chiara; Salvatore, Lisa; Schirripa, Marta; Antoniotti, Carlotta; Falcone, Alfredo] Azienda Osped Univ Pisana, Ist Toscano Tumori, Pisa, Italy; [Lonardi, Sara] Oncol Inst Veneto, Unit Med Oncol 1, Padua, Italy; [Aprile, Giuseppe] Azienda Osped Univ Udine, Udine, Italy; [Graziano, Francesco] Azienda Osped Osped San Salvatore, Med Oncol Unit, Pesaro, Italy; [Ruzzo, Annamaria] Univ Urbino, Sect Biochem & Mol Biol G Fornaini, Dept Biomol Sci, I-61029 Urbino, Italy; [Lucchesi, Sara] Ist Toscano Tumori, Med Oncol Unit, Azienda Pontedera USL5, Pisa, Italy; [Ronzoni, Monica] Ist Sci San Raffaele, Unit Oncol, Milan, Italy; [De Vita, Ferdinando] Univ Naples 2, Med Oncol Unit, Naples, Italy; [Tonini, Giuseppe] Univ Campus Biomed, Med Oncol Unit, Rome, Italy	University of Southern California; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Pisa; Azienda Ospedaliero Universitaria Pisana; IRCCS Istituto Oncologico Veneto (IOV); University of Udine; University Hospital of Udine; University of Urbino; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Universita della Campania Vanvitelli; University Campus Bio-Medico - Rome Italy	Loupakis, F (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.	fotiosloupakis@gmail.com	Schirripa, Marta/F-3688-2017; Lonardi, Sara/F-4228-2014; Salvatore, Lisa/L-7746-2019; Falcone, Alfredo/G-5217-2013; Cremolini, Chiara/AAC-1889-2019; Yang, Dongyun/M-2579-2019; Loupakis, Fotios/I-7243-2012; Ruzzo, Annamaria/Q-2155-2016	Schirripa, Marta/0000-0001-8316-4411; Lonardi, Sara/0000-0002-7593-8138; Yang, Dongyun/0000-0003-0736-4977; Loupakis, Fotios/0000-0001-9651-0395; Ruzzo, Annamaria/0000-0003-2815-1890; Ronzoni, Monica/0000-0002-2845-275X; Salvatore, Lisa/0000-0003-3864-0719; Tonini, Giuseppe/0000-0003-4442-8677; Falcone, Alfredo/0000-0001-5840-2529; CREMOLINI, CHIARA/0000-0002-0520-4841				Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1; Bocci G, 2011, PHARMACOGENOMICS, V12, P1077, DOI [10.2217/PGS.11.75, 10.2217/pgs.11.75]; Bottsford-Miller JN, 2012, J CLIN ONCOL, V30, P4026, DOI 10.1200/JCO.2012.41.9242; Buyse M, 2010, NAT REV CLIN ONCOL, V7, P309, DOI 10.1038/nrclinonc.2010.43; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Gerger A, 2011, CLIN CANCER RES, V17, P5783, DOI 10.1158/1078-0432.CCR-11-1115; Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305; Grothey A, 2008, J CLIN ONCOL, V26, P183, DOI 10.1200/JCO.2007.13.8099; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63; Lambrechts D, 2011, EUR J CANCER, V47, pS173, DOI 10.1016/S0959-8049(11)70907-8; Lambrechts D, 2012, LANCET ONCOL, V13, P724, DOI 10.1016/S1470-2045(12)70231-0; Liu L, 2011, CARCINOGENESIS, V32, P336, DOI 10.1093/carcin/bgq264; Loupakis F, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-247; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Mandrekar SJ, 2009, J CLIN ONCOL, V27, P4027, DOI 10.1200/JCO.2009.22.3701; Pander J, 2011, ANN ONCOL, V22, P1147, DOI 10.1093/annonc/mdq572; Sargent DJ, 2005, J CLIN ONCOL, V23, P2020, DOI 10.1200/JCO.2005.01.112; Schneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612; Schultheis AM, 2008, CLIN CANCER RES, V14, P7554, DOI 10.1158/1078-0432.CCR-08-0351; Tejpar S, 2012, ONCOLOGIST, V17, P1039, DOI 10.1634/theoncologist.2012-0068; Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201; Zhong R, 2013, CARCINOGENESIS, V34, P936, DOI 10.1093/carcin/bgs395	24	53	56	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2013	8	7							e66774	10.1371/journal.pone.0066774	http://dx.doi.org/10.1371/journal.pone.0066774			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204FO	23861747	Green Published, Green Submitted, gold			2023-01-03	WOS:000323350700007
J	Schabussova, I; Ul-Haq, O; Hoflehner, E; Akgun, J; Wagner, A; Loupal, G; Joachim, A; Ruttkowski, B; Maizels, RM; Wiedermann, U				Schabussova, Irma; Ul-Haq, Onisa; Hoflehner, Elisabeth; Akguen, Johnnie; Wagner, Angelika; Loupal, Gerhard; Joachim, Anja; Ruttkowski, Baerbel; Maizels, Rick M.; Wiedermann, Ursula			Oesophagostomum dentatum Extract Modulates T Cell-Dependent Immune Responses to Bystander Antigens and Prevents the Development of Allergy in Mice	PLOS ONE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PLACEBO-CONTROLLED TRIAL; TRICHURIS-SUIS THERAPY; SKIN-TEST REACTIVITY; HELMINTH INFECTION; HUMORAL RESPONSES; HUMAN ONCHOCERCIASIS; AIRWAY INFLAMMATION; TETANUS VACCINATION; HOOKWORM INFECTION	One third of the human population is currently infected by one or more species of parasitic helminths. Certain helminths establish long-term chronic infections resulting in a modulation of the host's immune system with attenuated responsiveness to "bystander" antigens such as allergens or vaccines. In this study we investigated whether parasite-derived products suppress the development of allergic inflammation in a mouse model. We show that extract derived from adult male Oesophagostomum dentatum (eMOD) induced Th2 and regulatory responses in BALB/c mice. Stimulation of bone marrow-derived dendritic cells induced production of regulatory cytokines IL-10 and TGF-beta. In a mouse model of birch pollen allergy, co-administration of eMOD with sensitizing allergen Bet v 1 markedly reduced the production of allergen-specific antibodies in serum as well as IgE-dependent basophil degranulation. Furthermore, eMOD prevented the development of airway inflammation, as demonstrated by attenuation of bronchoalveolar lavages eosinophil influx, peribronchial inflammatory infiltrate, and mucus secretion in lungs and IL-4 and IL-5 levels in lung cell cultures. Reduced secretion of Th2-related cytokines by birch pollen-re-stimulated splenocytes and mesenteric lymph node cells was observed in eMOD-treated/sensitized and challenged mice in comparison to sensitized and challenged controls. The suppressive effects of eMOD were heat-stable. Immunization with model antigens in the presence of eMOD reduced production of antibodies to thymus-dependent but not to thymus-independent antigen, suggesting that suppression of the immune responses by eMOD was mediated by interference with antigen presenting cell or T helper cell function but did not directly suppress B cell function. In conclusion, we have shown that eMOD possesses immunomodulatory properties and that heat-stable factors in eMOD are responsible for the dramatic suppression of allergic responses in a mouse model of type I allergy. The identification and characterization of parasite-derived immune-modulating molecules might have potential for designing novel prophylactic/therapeutic strategies for immune-mediated diseases.	[Schabussova, Irma; Ul-Haq, Onisa; Hoflehner, Elisabeth; Akguen, Johnnie; Wagner, Angelika; Wiedermann, Ursula] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Loupal, Gerhard] Univ Vet Med, Inst Pathol & Forens Vet Med, Dept Pathobiol, Vienna, Austria; [Joachim, Anja; Ruttkowski, Baerbel] Univ Vet Med, Inst Parasitol, Vienna, Austria; [Maizels, Rick M.] Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh, Midlothian, Scotland	Medical University of Vienna; University of Veterinary Medicine Vienna; University of Veterinary Medicine Vienna; University of Edinburgh	Schabussova, I (corresponding author), Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.	irma.schabussova@meduniwien.ac.at		Schabussova, Irma/0000-0002-2109-2640; Joachim, Anja/0000-0003-3082-6885; Wiedermann, Ursula/0000-0002-1302-3223; Wagner, Angelika/0000-0002-5447-9534	Austrian Science Fund [F46]	Austrian Science Fund(Austrian Science Fund (FWF))	This work was financially supported by SFB grant "Towards prevention and therapy of allergy", F46 from Austrian Science Fund. The Austrian Science Fund had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcantara-Neves NM, 2012, J ALLERGY CLIN IMMUN, V129, P359, DOI 10.1016/j.jaci.2011.09.015; Bager P, 2012, J ALLERGY CLIN IMMUN, V125, pe121; Baumgart M, 2006, J IMMUNOL, V176, P5374, DOI 10.4049/jimmunol.176.9.5374; Boitelle A, 2005, INT J PARASITOL, V35, P765, DOI 10.1016/j.ijpara.2005.02.013; Bourke CD, 2012, CLIN EXP ALLERGY, V42, P1582, DOI 10.1111/j.1365-2222.2012.04063.x; Cardoso LS, 2010, CLIN EXP IMMUNOL, V160, P266, DOI 10.1111/j.1365-2249.2009.04084.x; Cooper PJ, 1999, INFECT IMMUN, V67, P5951, DOI 10.1128/IAI.67.11.5951-5957.1999; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Donnelly S, 2006, CHEM IMMUNOL ALLERGY, V90, P45, DOI 10.1159/000088880; Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x; Elias D, 2008, VACCINE, V26, P3897, DOI 10.1016/j.vaccine.2008.04.083; Endara P, 2010, CLIN EXP ALLERGY, V40, P1669, DOI 10.1111/j.1365-2222.2010.03559.x; Esen M, 2012, VACCINE; Feary J, 2009, CLIN EXP ALLERGY, V39, P1060, DOI 10.1111/j.1365-2222.2009.03187.x; Feary JR, 2010, CLIN EXP ALLERGY, V40, P299, DOI 10.1111/j.1365-2222.2009.03433.x; Fleming JO, 2011, MULT SCLER J, V17, P743, DOI 10.1177/1352458511398054; Flohr C, 2010, CLIN EXP ALLERGY, V40, P131, DOI 10.1111/j.1365-2222.2009.03346.x; Flohr C, 2009, CLIN EXP ALLERGY, V39, P20, DOI 10.1111/j.1365-2222.2008.03134.x; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; Gasser RB, 2007, BIOTECHNOL ADV, V25, P281, DOI 10.1016/j.biotechadv.2007.01.008; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Grainger JR, 2010, J EXP MED, V207, P2331, DOI 10.1084/jem.20101074; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hartgers FC, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000227; Hartmann W, 2012, EXP PARASITOL; Hartmann W, 2011, J IMMUNOL, V187, P4088, DOI 10.4049/jimmunol.1004136; Hufnagl K, 2003, CLIN EXP IMMUNOL, V133, P170, DOI 10.1046/j.1365-2249.2003.02210.x; Ilic N, 2011, PARASITE IMMUNOL, V33, P572, DOI 10.1111/j.1365-3024.2011.01322.x; Joachim A, 2001, PARASITOL INT, V50, P41, DOI 10.1016/S1383-5769(00)00070-2; Joachim A, 1999, PARASITOLOGY, V119, P491, DOI 10.1017/S0031182099004965; Johnston MJG, 2010, INFECT IMMUN, V78, P1364, DOI 10.1128/IAI.01349-08; KILIAN HD, 1989, TROP MED PARASITOL, V40, P445; Kuijk LM, 2012, MOL IMMUNOL, V51, P210, DOI 10.1016/j.molimm.2012.03.020; Lack G, 1996, J IMMUNOL, V157, P1432; Lee KH, 2008, VET PARASITOL, V156, P216, DOI 10.1016/j.vetpar.2008.06.016; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Maizels RM, 2012, CURR OPIN IMMUNOL, V24, P459, DOI 10.1016/j.coi.2012.06.003; McSorley HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024092; McSorley HJ, 2012, EUR J IMMUNOL; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; Noland GS, 2010, VACCINE, V28, P2917, DOI 10.1016/j.vaccine.2010.02.055; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Randolph DA, 1999, J IMMUNOL, V162, P2375; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; ROUGEMONT A, 1977, LANCET, V1, P309; Schabussova I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040271; Schabussova I, 2011, VACCINE, V29, P1981, DOI 10.1016/j.vaccine.2010.12.101; Schabussova I, 2008, CURR OPIN ALLERGY CL, V8, P557, DOI 10.1097/ACI.0b013e328317b88b; Schnoeller C, 2008, J IMMUNOL, V180, P4265, DOI 10.4049/jimmunol.180.6.4265; Slotved HC, 1996, VET PARASITOL, V63, P237, DOI 10.1016/0304-4017(95)00916-7; Smits HH, 2010, CURR ALLERGY ASTHM R, V10, P3, DOI 10.1007/s11882-009-0085-3; Stewart GR, 1999, CLIN EXP IMMUNOL, V117, P517; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Summers RW, 2003, AM J GASTROENTEROL, V98, P2034, DOI [10.1016/S0002-9270(03)00623-3, 10.1111/j.1572-0241.2003.07660.x]; Taylor MD, 2012, TRENDS IMMUNOL, V33, P181, DOI 10.1016/j.it.2012.01.001; Taylor MD, 2009, EUR J IMMUNOL, V39, P192, DOI 10.1002/eji.200838727; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van Riet E, 2007, J INFECT DIS, V196, P1671, DOI 10.1086/522010; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Yan S, 2012, J BIOL CHEM, V287, P28276, DOI 10.1074/jbc.M112.353128; Zheng XP, 2008, J NEUROIMMUNOL, V194, P107, DOI 10.1016/j.jneuroim.2007.12.001	64	21	22	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2013	8	7							e67544	10.1371/journal.pone.0067544	http://dx.doi.org/10.1371/journal.pone.0067544			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	176XV	23844022	Green Submitted, Green Published, gold			2023-01-03	WOS:000321341000052
J	Cen, JR; Shi, MS; Yang, YF; Fu, YX; Zhou, HL; Wang, MQ; Su, ZY; Wei, Q				Cen, Juren; Shi, Mingshu; Yang, Yanfang; Fu, Yanxia; Zhou, Hailing; Wang, Mengqi; Su, Zhenyi; Wei, Qun			Isogarcinol Is a New Immunosuppressant	PLOS ONE			English	Article							CYCLOSPORINE-A; BENZOPHENONE DERIVATIVES; GARCINIA-MANGOSTANA; LYMPHOCYTE-ACTIVATION; ORGAN-TRANSPLANTATION; MEDICINAL PROPERTIES; CARDIAC GROWTH; CALCINEURIN; FK506; INHIBITION	Calcineurin (CN), a unique protein phosphatase, plays an important role in immune regulation. In this study we used CN as a target enzyme to investigate the immunosuppressive properties of a series of natural compounds from Garcinia mangostana L., and discovered an active compound, isogarcinol. Enzymatic assays showed that isogarcinol inhibited CN in a dose-dependent manner. At concentrations resulting in relatively low cytotoxicity isogarcinol significantly inhibited proliferation of murine spleen T-lymphocytes induced by concanavalin A (ConA) and the mixed lymphocyte reaction (MLR). In addition, it performed much better in acute toxicity tests and via oral administration in mice than cyclosporin A (CsA), with few adverse reactions and low toxicity in experimental animals. Oral administration of isogarcinol in mice resulted in a dose-dependent decrease in delayed type hypersensitivity (DTH) and prolonged graft survival in allogeneic skin transplantation. These findings suggest that isogarcinol could serve as a new oral immunomodulatory drug for preventing transplant rejection, and for long-term medication in autoimmune diseases.	[Cen, Juren; Shi, Mingshu; Fu, Yanxia; Zhou, Hailing; Wang, Mengqi; Su, Zhenyi; Wei, Qun] Beijing Normal Univ, Dept Biochem & Mol Biol, Gene Engn & Biotechnol Beijing Key Lab, Beijing 100875, Peoples R China; [Yang, Yanfang] Hubei Univ Chinese Med, Prov & Minist Established Key Lab Resource & Comp, Wuhan, Peoples R China	Beijing Normal University; Hubei University of Chinese Medicine	Wei, Q (corresponding author), Beijing Normal Univ, Dept Biochem & Mol Biol, Gene Engn & Biotechnol Beijing Key Lab, Beijing 100875, Peoples R China.	weiq@bnu.edu.cn	Su, Zhenyi/AHC-5959-2022		National Natural Science Foundation of China; National Important Novel Medicine Research Project; International Cooperation Project; Fundamental Research Funds for the Central Universities	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Important Novel Medicine Research Project; International Cooperation Project; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	The work was supported by grants from the National Natural Science Foundation of China, the National Important Novel Medicine Research Project, the International Cooperation Project and the Fundamental Research Funds for the Central Universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baksh S, 2000, SEMIN IMMUNOL, V12, P405, DOI 10.1006/smim.2000.0221; BENNETT WM, 1986, ANNU REV MED, V37, P215; BIERER BE, 1993, CURR OPIN IMMUNOL, V5, P763, DOI 10.1016/0952-7915(93)90135-F; Cardenas ME, 1998, TRENDS BIOTECHNOL, V16, P427, DOI 10.1016/S0167-7799(98)01239-6; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; Cuesta-Rubio O, 2005, STUD NAT PROD CHEM, V32, P671; Cui JH, 2010, PHARMACOL BIOCHEM BE, V95, P166, DOI 10.1016/j.pbb.2009.12.021; Feng YH, 2002, ACTA PHARMACOL SIN, V23, P893; Gonsette RE, 2004, J NEUROL SCI, V223, P87, DOI 10.1016/j.jns.2004.04.025; Ho S, 1996, CLIN IMMUNOL IMMUNOP, V80, pS40, DOI 10.1006/clin.1996.0140; Hong JC, 2000, SEMIN NEPHROL, V20, P108; Iinuma M, 1996, BIOL PHARM BULL, V19, P311, DOI 10.1248/bpb.19.311; Issa F, 2010, EXPERT REV CLIN IMMU, V6, P155, DOI 10.1586/ECI.09.64; Ito C, 2003, J NAT PROD, V66, P206, DOI 10.1021/np020372g; Jorgensen KA, 2003, SCAND J IMMUNOL, V57, P93, DOI 10.1046/j.1365-3083.2003.01221.x; Kobayashi K, 2001, MICROSC RES TECHNIQ, V53, P241, DOI 10.1002/jemt.1090; Lechler RI, 2005, NAT MED, V11, P605, DOI 10.1038/nm1251; Lei H, 2011, FOOD CHEM, V127, P1169, DOI 10.1016/j.foodchem.2011.01.119; Lei H, 2009, BBA-PROTEINS PROTEOM, V1794, P1269, DOI 10.1016/j.bbapap.2009.04.014; Li JY, 2010, PHARM BIOL, V48, P1177, DOI 10.3109/13880200903573169; Li X, 2012, INT IMMUNOPHARMACOLO; Liang QR, 2003, EMBO J, V22, P5079, DOI 10.1093/emboj/cdg474; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mantelingu K, 2007, CHEM BIOL, V14, P645, DOI 10.1016/j.chembiol.2007.04.011; Marti G, 2010, MOLECULES, V15, P7106, DOI 10.3390/molecules15107106; Matsumoto K, 2003, BIOL PHARM BULL, V26, P569, DOI 10.1248/bpb.26.569; Moussay E, 2010, RES DETERMINATION GE; Pedraza-Chaverri J, 2008, FOOD CHEM TOXICOL, V46, P3227, DOI 10.1016/j.fct.2008.07.024; Peng LQ, 2011, IUBMB LIFE, V63, P14, DOI 10.1002/iub.408; Rathee P, 2012, PHARM INNOVATION J, V1, P90; Roy J, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2100re9; Rukachaisirikul V, 2005, CHEM PHARM BULL, V53, P342, DOI 10.1248/cpb.53.342; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Salem ML, 2005, INT IMMUNOPHARMACOL, V5, P1749, DOI 10.1016/j.intimp.2005.06.008; Shen J, 2006, STUDIES CHEM CONSTIT; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; STALLARD N, 1995, HUM EXP TOXICOL, V14, P315, DOI 10.1177/096032719501400401; Thomson A, 1984, INFLAMM RES, V15, P306; Vega RB, 2003, J BIOL CHEM, V278, P36981, DOI 10.1074/jbc.R300023200; Wang HL, 2007, IUBMB LIFE, V59, P388, DOI 10.1080/15216540701370721; Wang H, 2008, IUBMB LIFE, V60, P549, DOI 10.1002/iub.94; Wang H, 2010, J BIOCHEM, V147, P185, DOI 10.1093/jb/mvp163; Yu LM, 2007, FOOD CHEM, V104, P176, DOI 10.1016/j.foodchem.2006.11.018; Zhou R, 2005, INT IMMUNOPHARMACOL, V5, P1895, DOI 10.1016/j.intimp.2005.06.009	44	96	102	1	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2013	8	6							e66503	10.1371/journal.pone.0066503	http://dx.doi.org/10.1371/journal.pone.0066503			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	172XB	23785505	gold, Green Submitted, Green Published			2023-01-03	WOS:000321038800024
J	Campanella, F; Fabbro, F; Urgesi, C				Campanella, Fabio; Fabbro, Franco; Urgesi, Cosimo			Cognitive and Anatomical Underpinnings of the Conceptual Knowledge for Common Objects and Familiar People: A Repetitive Transcranial Magnetic Stimulation Study	PLOS ONE			English	Article							FUSIFORM FACE AREA; SEMANTIC DEMENTIA; FAMOUS FACES; PROPER-NAMES; RECOGNITION; APHASIA; ORGANIZATION; ACCESS; REPRESENTATION; MEMORY	Several studies have addressed the issue of how knowledge of common objects is organized in the brain, whereas the cognitive and anatomical underpinnings of familiar people knowledge have been less explored. Here we applied repetitive transcranial magnetic stimulation (rTMS) over the left and right temporal poles before asking healthy individuals to perform a speeded word-to-picture matching task using familiar people and common objects as stimuli. We manipulated two widely used semantic variables, namely the semantic distance and the familiarity of stimuli, to assess whether the semantic organization of familiar people knowledge is similar to that of common objects. For both objects and faces we reliably found semantic distance and familiarity effects, with less accurate and slower responses for stimulus pairs that were more closely related and less familiar. However, the effects of semantic variables differed across categories, with semantic distance effects larger for objects and familiarity effects larger for faces, suggesting that objects and faces might share a partially comparable organization of their semantic representations. The application of rTMS to the left temporal pole modulated, for both categories, semantic distance, but not familiarity effects, revealing that accessing object and face concepts might rely on overlapping processes within left anterior temporal regions. Crucially, rTMS of the left temporal pole affected only the recognition of pairs of stimuli that could be discriminated at specific levels of categorization (e.g., two kitchen tools or two famous persons), with no effect for discriminations at either superordinate or individual levels. Conversely, rTMS of the right temporal pole induced an overall slowing of reaction times that positively correlated with the visual similarity of the stimuli, suggesting a more perceptual rather than semantic role of the right anterior temporal regions. Results are discussed in the light of current models of face and object semantic representations in the brain.	[Campanella, Fabio] Azienda Osped Univ Santa Maria Misericord, Neurosurg Unit, Udine, Italy; [Campanella, Fabio; Fabbro, Franco; Urgesi, Cosimo] Univ Udine, Dept Human Sci, I-33100 Udine, Italy; [Fabbro, Franco; Urgesi, Cosimo] Ist Ricovero & Cura Carattere Sci E Medea, San Vito Al Tagliamento, Pordenone, Italy	Hospital Santa Maria della Misericordia; University of Udine; IRCCS Eugenio Medea	Campanella, F (corresponding author), Azienda Osped Univ Santa Maria Misericord, Neurosurg Unit, Udine, Italy.	fabio.campanella@uniud.it	Urgesi, Cosimo/K-4688-2016	Urgesi, Cosimo/0000-0003-0572-1328; FABBRO, Franco/0000-0003-3476-6867	Fondazione Cassa di Risparmio di Udine e Pordenone (CRUP); Scientific Institute (IRCCS) 'E. Medea' (Ricerca Corrente, Italian Ministry of Health); Consorzio Universitario Italia Argentina (CUIA)	Fondazione Cassa di Risparmio di Udine e Pordenone (CRUP); Scientific Institute (IRCCS) 'E. Medea' (Ricerca Corrente, Italian Ministry of Health); Consorzio Universitario Italia Argentina (CUIA)	This work was supported by grants from Fondazione Cassa di Risparmio di Udine e Pordenone (CRUP) (http://www.fondazionecrup.it/)to FF, and from Scientific Institute (IRCCS) 'E. Medea' (Ricerca Corrente 2011, Italian Ministry of Health) and Consorzio Universitario Italia Argentina (CUIA) (http://www.cuia.net/) to CU. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bertinetto PM, CORPUS LESSICO FREQU; Brambati SM, 2006, J COGNITIVE NEUROSCI, V18, P1644, DOI 10.1162/jocn.2006.18.10.1644; BRIGGS G G, 1975, Cortex, V11, P230; Campanella F, 2010, NEUROPSYCHOLOGIA, V48, P1583, DOI 10.1016/j.neuropsychologia.2010.02.002; Campanella F, 2009, BRAIN, V132, P87, DOI 10.1093/brain/awn302; Capitani E, 2003, COGN NEUROPSYCHOL, V20, P213, DOI 10.1080/02643290244000266; Crutch SJ, 2005, COGN NEUROPSYCHOL, V22, P851, DOI 10.1080/02643290442000374; Crutch SJ, 2005, BRAIN, V128, P615, DOI 10.1093/brain/awh349; Crutch SJ, 2004, NEUROPSYCHOLOGIA, V42, P584, DOI 10.1016/j.neuropsychologia.2003.10.009; Crutch SJ, 2003, BRAIN, V126, P1821, DOI 10.1093/brain/awg187; Damasio H, 1996, NATURE, V380, P499, DOI 10.1038/380499a0; Douville K, 2005, NEUROPSYCHOLOGIA, V43, P693, DOI 10.1016/j.neuropsychologia.2004.09.005; EVANS JJ, 1995, BRAIN, V118, P1, DOI 10.1093/brain/118.1.1; FORDE E, 1995, MEMORY, V3, P265, DOI 10.1080/09658219508253154; Gainotti G, 2000, CORTEX, V36, P539, DOI 10.1016/S0010-9452(08)70537-9; Gainotti G, 2007, NEUROPSYCHOLOGIA, V45, P1591, DOI 10.1016/j.neuropsychologia.2006.12.013; Gainotti G, 2012, CORTEX, V48, P521, DOI 10.1016/j.cortex.2011.06.019; Gauthier I, 2003, COGN NEUROPSYCHOL, V20, P507, DOI 10.1080/02643290244000275; Gauthier I, 2000, NAT NEUROSCI, V3, P191, DOI 10.1038/72140; Gauthier I, 2000, J COGNITIVE NEUROSCI, V12, P495, DOI 10.1162/089892900562165; Gauthier I, 1997, CURR BIOL, V7, P645, DOI 10.1016/S0960-9822(06)00291-0; Gorno-Tempini ML, 2001, BRAIN, V124, P2087, DOI 10.1093/brain/124.10.2087; Gross CG, 2002, NEUROSCIENTIST, V8, P512, DOI 10.1177/107385802237175; HINTON GE, 1991, PSYCHOL REV, V98, P74, DOI 10.1037/0033-295X.98.1.74; Hodges JR, 1998, NEUROPSYCHOLOGIA, V36, P803, DOI 10.1016/S0028-3932(97)00126-7; HODGES JR, 1992, BRAIN, V115, P1783, DOI 10.1093/brain/115.6.1783; Jefferies E, 2007, NEUROPSYCHOLOGIA, V45, P1065, DOI 10.1016/j.neuropsychologia.2006.09.009; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KERR NH, 1982, MEM COGNITION, V10, P603, DOI 10.3758/BF03202443; Kitchener EG, 1999, COGNITIVE NEUROPSYCH, V16, P589, DOI 10.1080/026432999380744; Leveroni CL, 2000, J NEUROSCI, V20, P878, DOI 10.1523/JNEUROSCI.20-02-00878.2000; Lubrano V, 2014, HUM BRAIN MAPP, V35, P429, DOI 10.1002/hbm.22189; MCNEIL JE, 1994, NEUROPSYCHOLOGIA, V32, P193, DOI 10.1016/0028-3932(94)90005-1; Miceli G, 2000, COGN NEUROPSYCHOL, V17, P489, DOI 10.1080/02643290050110629; Mion M, 2010, BRAIN, V133, P3256, DOI 10.1093/brain/awq272; Nakamura K, 2000, BRAIN, V123, P1903, DOI 10.1093/brain/123.9.1903; NOBLE CE, 1954, J EXP PSYCHOL, V47, P13, DOI 10.1037/h0060025; Papagno C, 2001, NEUROPSYCHOLOGIA, V39, P678, DOI 10.1016/S0028-3932(01)00007-0; Papagno C, 2011, BRAIN, V134, P405, DOI 10.1093/brain/awq283; Pascual-Leone A, 1999, PHILOS T R SOC B, V354, P1229, DOI 10.1098/rstb.1999.0476; Patterson K, 2007, NAT REV NEUROSCI, V8, P976, DOI 10.1038/nrn2277; PLAUT DC, 1993, COGNITIVE NEUROPSYCH, V10, P377, DOI 10.1080/02643299308253469; Pobric G, 2007, P NATL ACAD SCI USA, V104, P20137, DOI 10.1073/pnas.0707383104; Quiroga RQ, 2008, TRENDS COGN SCI, V12, P87, DOI 10.1016/j.tics.2007.12.003; Quiroga RQ, 2005, NATURE, V435, P1102, DOI 10.1038/nature03687; Ralph MAL, 2009, CEREB CORTEX, V19, P832, DOI 10.1093/cercor/bhn131; Rogers TT, 2006, COGN AFFECT BEHAV NE, V6, P201, DOI 10.3758/CABN.6.3.201; Rogers TT, 2004, PSYCHOL REV, V111, P205, DOI 10.1037/0033-295X.111.1.205; Seidenberg M, 2002, NEUROPSYCHOLOGIA, V40, P446, DOI 10.1016/S0028-3932(01)00096-3; SEMENZA C, 1989, NATURE, V342, P678, DOI 10.1038/342678a0; SEMENZA C, 1988, COGNITIVE NEUROPSYCH, V5, P711, DOI 10.1080/02643298808253279; SMITH RC, 1971, J EXP PSYCHOL, V88, P279, DOI 10.1037/h0031002; Snowden J.S., 1989, BEHAV NEUROL, V2, P167, DOI DOI 10.1155/1989/124043; Snowden JS, 2004, BRAIN, V127, P860, DOI 10.1093/brain/awh099; Tempini MLG, 1998, BRAIN, V121, P2103, DOI 10.1093/brain/121.11.2103; Thompson SA, 2004, NEUROPSYCHOLOGIA, V42, P359, DOI 10.1016/j.neuropsychologia.2003.08.004; Tyler LK, 2004, J COGNITIVE NEUROSCI, V16, P351, DOI 10.1162/089892904322926692; TYRRELL PJ, 1990, J NEUROL NEUROSUR PS, V53, P1046, DOI 10.1136/jnnp.53.12.1046; WARRINGTON EK, 1979, BRAIN, V102, P43, DOI 10.1093/brain/102.1.43; Warrington EK, 2004, COGN NEUROPSYCHOL, V21, P299, DOI 10.1080/02643290342000546; WARRINGTON EK, 1975, Q J EXP PSYCHOL, V27, P635, DOI 10.1080/14640747508400525; Warrington EK, 1996, BRAIN, V119, P611, DOI 10.1093/brain/119.2.611; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8	63	7	7	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2013	8	5							e64596	10.1371/journal.pone.0064596	http://dx.doi.org/10.1371/journal.pone.0064596			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	149OK	23704999	Green Published, Green Submitted, gold			2023-01-03	WOS:000319330200153
J	Salido, EM; Dorfman, D; Bordone, M; Chianelli, M; Fleitas, MFG; Rosenstein, RE				Salido, Ezequiel M.; Dorfman, Damian; Bordone, Melina; Chianelli, Monica; Gonzalez Fleitas, Maria Florencia; Rosenstein, Ruth E.			Global and Ocular Hypothermic Preconditioning Protect the Rat Retina from Ischemic Damage	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; GANGLION-CELLS; GLUTAMINE-SYNTHETASE; CIRCULATORY ARREST; LOCAL HYPOTHERMIA; NMDA RECEPTORS; NEURONS; MECHANISMS; INDUCTION; TOLERANCE	Retinal ischemia could provoke blindness. At present, there is no effective treatment against retinal ischemic damage. Strong evidence supports that glutamate is implicated in retinal ischemic damage. We investigated whether a brief period of global or ocular hypothermia applied 24 h before ischemia (i.e. hypothermic preconditioning, HPC) protects the retina from ischemia/reperfusion damage, and the involvement of glutamate in the retinal protection induced by HPC. For this purpose, ischemia was induced by increasing intraocular pressure to 120 mm Hg for 40 min. One day before ischemia, animals were submitted to global or ocular hypothermia (33 degrees C and 32 degrees C for 20 min, respectively) and fourteen days after ischemia, animals were subjected to electroretinography and histological analysis. Global or ocular HPC afforded significant functional (electroretinographic) protection in eyes exposed to ischemia/reperfusion injury. A marked alteration of the retinal structure and a decrease in retinal ganglion cell number were observed in ischemic retinas, whereas global or ocular HPC significantly preserved retinal structure and ganglion cell count. Three days after ischemia, a significant decrease in retinal glutamate uptake and glutamine synthetase activity was observed, whereas ocular HPC prevented the effect of ischemia on these parameters. The intravitreal injection of supraphysiological levels of glutamate induced alterations in retinal function and histology which were significantly prevented by ocular HPC. These results support that global or ocular HPC significantly protected retinal function and histology from ischemia/reperfusion injury, probably through a glutamate-dependent mechanism.	[Salido, Ezequiel M.; Dorfman, Damian; Bordone, Melina; Chianelli, Monica; Gonzalez Fleitas, Maria Florencia; Rosenstein, Ruth E.] Univ Buenos Aires, Dept Human Biochem, CEFyBO,CONICET, Lab Retinal Neurochem & Expt Ophthalmol,Sch Med, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires	Rosenstein, RE (corresponding author), Univ Buenos Aires, Dept Human Biochem, CEFyBO,CONICET, Lab Retinal Neurochem & Expt Ophthalmol,Sch Med, Buenos Aires, DF, Argentina.	ruthr@fmed.uba.ar	Salido, Ezequiel Martin/AAF-7166-2021	Salido, Ezequiel Martin/0000-0003-3741-3389; Gonzalez Fleitas, Maria Florencia/0000-0001-5795-8365; Bordone, Melina/0000-0003-4912-228X	Agencia Nacional de Promocion Cientifica y Tecnologica; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina	Agencia Nacional de Promocion Cientifica y Tecnologica(ANPCyT); University of Buenos Aires(University of Buenos Aires); Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET))	This research was supported by grants from the Agencia Nacional de Promocion Cientifica y Tecnologica; The University of Buenos Aires; and Consejo Nacional de Investigaciones Cientificas y Tecnicas, Argentina. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adachi K, 1998, EUR J PHARMACOL, V350, P53, DOI 10.1016/S0014-2999(98)00317-3; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Bhagatte Y, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.84; Biermann J, 2010, INVEST OPHTH VIS SCI, V51, P3784, DOI 10.1167/iovs.09-4894; Birnbaum Y, 1997, CIRCULATION, V96, P1641, DOI 10.1161/01.CIR.96.5.1641; BUCHAN A, 1992, NEUROL CLIN, V10, P49, DOI 10.1016/S0733-8619(18)30233-0; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Cambria RP, 1997, J VASC SURG, V25, P234, DOI 10.1016/S0741-5214(97)70365-3; Cazevieille C, 1997, BRAIN RES, V755, P91, DOI 10.1016/S0006-8993(97)00090-5; Corbett D, 2000, EXP NEUROL, V163, P200, DOI 10.1006/exnr.2000.7369; Dave KR, 2006, NEUROSCI LETT, V404, P170, DOI 10.1016/j.neulet.2006.05.037; DEROUICHE A, 1995, J NEUROSCI RES, V42, P131, DOI 10.1002/jnr.490420115; FABEROWSKI N, 1989, INVEST OPHTH VIS SCI, V30, P2309; Faridar Alireza, 2011, Front Neurol, V2, P80, DOI 10.3389/fneur.2011.00080; Fernandez DC, 2009, J NEUROCHEM, V111, P488, DOI 10.1111/j.1471-4159.2009.06334.x; Franco PJ, 2008, INVEST OPHTH VIS SCI, V49, P4604, DOI 10.1167/iovs.08-2054; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; IKEDA H, 1992, EXP EYE RES, V55, P435, DOI 10.1016/0014-4835(92)90116-A; IVERSEN L L, 1991, Eye (London), V5, P194; Izumi Y, 2003, VISUAL NEUROSCI, V20, P97, DOI 10.1017/S0952523803202017; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KATO H, 1992, NEUROSCI LETT, V139, P118, DOI 10.1016/0304-3940(92)90871-4; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kwong JMK, 2003, BRAIN RES, V970, P119, DOI 10.1016/S0006-8993(03)02298-4; Leben J, 1997, ANN NY ACAD SCI, V813, P807, DOI 10.1111/j.1749-6632.1997.tb51785.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Moore EM, 2011, INJURY, V42, P843, DOI 10.1016/j.injury.2011.03.027; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NAKATA N, 1993, NEUROREPORT, V4, P695, DOI 10.1097/00001756-199306000-00023; NAYAK MS, 1995, CURR EYE RES, V14, P81, DOI 10.3109/02713689508999918; NEAL MJ, 1994, J NEUROCHEM, V62, P1025; Ning XH, 1998, AM J PHYSIOL-HEART C, V274, pH786, DOI 10.1152/ajpheart.1998.274.3.H786; Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237; Nishio S, 2000, J NEUROSURG, V93, P845, DOI 10.3171/jns.2000.93.5.0845; Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001; Poitry S, 2000, J NEUROSCI, V20, P1809; Quina LA, 2005, J NEUROSCI, V25, P11595, DOI 10.1523/JNEUROSCI.2837-05.2005; Quinones-Hinojosa A, 2003, NEUROSURGERY, V52, P1178, DOI 10.1227/01.NEU.0000057836.64972.A0; RIEPE RE, 1977, NATURE, V268, P654, DOI 10.1038/268654a0; Roth S, 2004, BRAIN RES BULL, V62, P461, DOI 10.1016/j.brainresbull.2003.07.006; Roth S, 1998, INVEST OPHTH VIS SCI, V39, P777; Sakamoto K, 2004, BRAIN RES, V1015, P154, DOI 10.1016/j.brainres.2004.04.074; SARTHY PV, 1978, J CELL BIOL, V78, P675, DOI 10.1083/jcb.78.3.675; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SOLOMON RA, 1991, NEUROSURGERY, V29, P732, DOI 10.1227/00006123-199111000-00015; Sumioka K, 2000, INVEST OPHTH VIS SCI, V41, P29; Tamai K, 1997, EXP EYE RES, V65, P733, DOI 10.1006/exer.1997.0386; THARION J, 1982, J THORAC CARDIOV SUR, V84, P66; Thoreson WB, 1999, PROG RETIN EYE RES, V18, P765, DOI 10.1016/S1350-9462(98)00031-7; Wang RB, 2010, J NEUROTRAUM, V27, P763, DOI 10.1089/neu.2009.1005; Wang XD, 2002, NEUROL RES, V24, P730, DOI 10.1179/016164102101200663; Yunoki M, 2002, J NEUROSURG, V97, P650, DOI 10.3171/jns.2002.97.3.0650	54	22	22	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e61656	10.1371/journal.pone.0061656	http://dx.doi.org/10.1371/journal.pone.0061656			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	131QH	23626711	Green Published, Green Submitted, gold			2023-01-03	WOS:000318008400075
J	Amengual, JL; Rojo, N; Heras, MVD; Marco-Pallares, J; Grau-Sanchez, J; Schneider, S; Vaquero, L; Juncadella, M; Montero, J; Mohammadi, B; Rubio, F; Rueda, N; Duarte, E; Grau, C; Altenmuller, E; Munte, TF; Rodriguez-Fornells, A				Amengual, Julia L.; Rojo, Nuria; de Las Heras, Misericordia Veciana; Marco-Pallares, Josep; Grau-Sanchez, Jennifer; Schneider, Sabine; Vaquero, Lucia; Juncadella, Montserrat; Montero, Jordi; Mohammadi, Bahram; Rubio, Francisco; Rueda, Nohora; Duarte, Esther; Grau, Carles; Altenmueller, Eckart; Muente, Thomas F.; Rodriguez-Fornells, Antoni			Sensorimotor Plasticity after Music-Supported Therapy in Chronic Stroke Patients Revealed by Transcranial Magnetic Stimulation	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; HUMAN MOTOR CORTEX; LONG-TERM CHANGES; BRAIN PLASTICITY; SUBCORTICAL STROKE; FOLLOW-UP; REORGANIZATION; RECOVERY; EXCITABILITY; OUTPUT	Background: Several recently developed therapies targeting motor disabilities in stroke sufferers have shown to be more effective than standard neurorehabilitation approaches. In this context, several basic studies demonstrated that music training produces rapid neuroplastic changes in motor-related brain areas. Music-supported therapy has been recently developed as a new motor rehabilitation intervention. Methods and Results: In order to explore the plasticity effects of music-supported therapy, this therapeutic intervention was applied to twenty chronic stroke patients. Before and after the music-supported therapy, transcranial magnetic stimulation was applied for the assessment of excitability changes in the motor cortex and a 3D movement analyzer was used for the assessment of motor performance parameters such as velocity, acceleration and smoothness in a set of diadochokinetic movement tasks. Our results suggest that the music-supported therapy produces changes in cortical plasticity leading the improvement of the subjects' motor performance. Conclusion: Our findings represent the first evidence of the neurophysiological changes induced by this therapy in chronic stroke patients, and their link with the amelioration of motor performance. Further studies are needed to confirm our observations.	[Amengual, Julia L.; Rojo, Nuria; Marco-Pallares, Josep; Grau-Sanchez, Jennifer; Vaquero, Lucia; Rodriguez-Fornells, Antoni] Bellvitge Biomed Res Inst, Cognit & Brain Plast Grp, Barcelona, Spain; [Amengual, Julia L.; Grau, Carles] Univ Barcelona, Dept Psychiat & Clin Psychobiol, Neurodynam Lab, Barcelona, Spain; [Amengual, Julia L.; Rojo, Nuria; Marco-Pallares, Josep; Grau-Sanchez, Jennifer; Vaquero, Lucia; Rodriguez-Fornells, Antoni] Univ Barcelona, Dept Basic Psychol, Barcelona, Spain; [de Las Heras, Misericordia Veciana; Juncadella, Montserrat; Montero, Jordi; Rubio, Francisco] Univ Barcelona, Hosp Univ Bellvitge, Neurol Sect, Bellvitge Biomed Res Inst, Barcelona, Spain; [Schneider, Sabine; Altenmueller, Eckart] Univ Mus & Drama Hannover, Inst Mus Physiol & Musicians Med, Hannover, Germany; [Mohammadi, Bahram] Int Neurosci Inst Hannover, Hannover, Germany; [Rueda, Nohora; Duarte, Esther] Hosp Mar & Esperanca, Dept Phys Med & Rehabil, Barcelona, Spain; [Muente, Thomas F.] Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany; [Rodriguez-Fornells, Antoni] Catalan Inst Res & Adv Studies, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; University of Lubeck; ICREA	Amengual, JL (corresponding author), Bellvitge Biomed Res Inst, Cognit & Brain Plast Grp, Barcelona, Spain.	julian.amengual@gmail.com	LUO, JINGJING/AAZ-6697-2021; Rodriguez-Fornells, Antoni/L-5878-2014; Marco-Pallares, Josep/C-1256-2008; Marco-Pallares, Josep/GNH-1787-2022; Vaquero, Lucia/AAS-9867-2020; Münte, Thomas/C-2077-2014; Duarte, Esther/L-9771-2017; Altenmuller, Eckart/AAB-9948-2021	LUO, JINGJING/0000-0002-3222-1276; Rodriguez-Fornells, Antoni/0000-0002-3249-6931; Marco-Pallares, Josep/0000-0001-9175-1480; Marco-Pallares, Josep/0000-0001-9175-1480; Vaquero, Lucia/0000-0003-0361-0771; Duarte, Esther/0000-0002-4058-1802; Amengual, Julian/0000-0002-8613-6325; Grau-Sanchez, Jennifer/0000-0002-8123-1745; Veciana de las Heras, Misericordia/0000-0002-1878-8663	la Fundacio La Marato TV3 (Neuroscience program); Catalan Government [2009 SGR 93]; DZNE (German Center for Neurodegenerative Diseases); Spanish government [SEJ2006-13998, PSI2011-29219]; ICREA Funding Source: Custom	la Fundacio La Marato TV3 (Neuroscience program); Catalan Government; DZNE (German Center for Neurodegenerative Diseases); Spanish government(Spanish GovernmentEuropean Commission); ICREA(ICREA)	This project has been supported by la Fundacio La Marato TV3 (Neuroscience program, 2007-2010), Catalan Government (2009 SGR 93) and the DZNE (German Center for Neurodegenerative Diseases). JLA has been supported by a grant from the Spanish government (SEJ2006-13998). ARF has also been supported by a grant from the Spanish government (MICINN, PSI2011-29219). The funders have no role in study design, data collection and analysis, decision to publish or preparation to manuscript.	Altenmuller E, 2009, ANN NY ACAD SCI, V1169, P395, DOI 10.1111/j.1749-6632.2009.04580.x; BRION JP, 1989, STROKE, V20, P1079, DOI 10.1161/01.STR.20.8.1079; Butefisch CM, 2006, J PHYSIOL-PARIS, V99, P437, DOI 10.1016/j.jphysparis.2006.03.001; Byrnes ML, 1999, CLIN NEUROPHYSIOL, V110, P487, DOI 10.1016/S1388-2457(98)00044-3; Byrnes ML, 2001, BRAIN RES, V889, P278, DOI 10.1016/S0006-8993(00)03089-4; CARROLL D, 1965, J CHRON DIS, V18, P479, DOI 10.1016/0021-9681(65)90030-5; Chen JL, 2009, ANN NY ACAD SCI, V1169, P15, DOI 10.1111/j.1749-6632.2009.04556.x; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Cicinelli P, 1997, ELECTROMYOGR MOTOR C, V105, P438, DOI 10.1016/S0924-980X(97)00052-0; Delvendahl I, 2012, BRAIN STIMUL, V5, P586, DOI 10.1016/j.brs.2011.11.005; FUHR P, 1991, ELECTROEN CLIN NEURO, V81, P257, DOI 10.1016/0168-5597(91)90011-L; Herholz SC, 2012, NEURON, V76, P486, DOI 10.1016/j.neuron.2012.10.011; Hermsdorfer J, 2002, NEUROPSYCHOLOGIA, V40, P2100, DOI 10.1016/S0028-3932(02)00048-9; Imfeld A, 2009, NEUROIMAGE, V46, P600, DOI 10.1016/j.neuroimage.2009.02.025; Koelsch S, 2010, TRENDS COGN SCI, V14, P131, DOI 10.1016/j.tics.2010.01.002; Koski L, 2004, NEUROREHAB NEURAL RE, V18, P230, DOI 10.1177/1545968304269210; Koski L, 2007, NEUROSCI RES, V58, P19, DOI 10.1016/j.neures.2007.01.007; Kraft E, 2007, CLIN NEUROPHYSIOL, V118, pe62; Lappe C, 2008, J NEUROSCI, V28, P9632, DOI 10.1523/JNEUROSCI.2254-08.2008; Liepert J, 2005, STROKE, V36, P2648, DOI 10.1161/01.STR.0000189629.10603.02; Liepert J, 2001, J NEUROL, V248, P315, DOI 10.1007/s004150170207; Liepert J, 2006, COGN BEHAV NEUROL, V19, P41, DOI 10.1097/00146965-200603000-00005; Munte TF, 2002, NAT REV NEUROSCI, V3, P473, DOI 10.1038/nrn843; Nelles G, 2001, NEUROIMAGE, V13, P1146, DOI 10.1006/nimg.2001.0757; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Page SJ, 2011, CLIN REHABIL, V25, P627, DOI 10.1177/0269215510395793; Pantev C, 2011, NEUROSCI BIOBEHAV R, V35, P2140, DOI 10.1016/j.neubiorev.2011.06.010; Pascual-Leone A, 1995, ELECTROENCEPHALOGRAP, V97, P25; Platz T, 2005, J NEUROL, V252, P1363, DOI 10.1007/s00415-005-0868-y; Rojo N, 2011, BRAIN INJURY, V25, P787, DOI 10.3109/02699052.2011.576305; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 2003, LANCET NEUROL, V2, P493, DOI 10.1016/S1474-4422(03)00485-X; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Schneider S, 2007, J NEUROL, V254, P1339, DOI 10.1007/s00415-006-0523-2; Schneider S, 2010, MUSIC PERCEPT, V27, P271, DOI 10.1525/MP.2010.27.4.271; Talelli P, 2006, CLIN NEUROPHYSIOL, V117, P1641, DOI 10.1016/j.clinph.2006.01.016; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Traversa R, 2000, CLIN NEUROPHYSIOL, V111, P1695, DOI 10.1016/S1388-2457(00)00373-4; van der Putten JJMF, 1999, J NEUROL NEUROSUR PS, V66, P480, DOI 10.1136/jnnp.66.4.480; Wan CY, 2010, NEUROSCIENTIST, V16, P566, DOI 10.1177/1073858410377805; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; Zatorre RJ, 2007, NAT REV NEUROSCI, V15, P528; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006	44	57	59	0	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e61883	10.1371/journal.pone.0061883	http://dx.doi.org/10.1371/journal.pone.0061883			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IK	23613966	Green Published, Green Submitted, gold			2023-01-03	WOS:000317907200099
J	Wang, YB; Hu, Y; Li, Z; Wang, P; Xue, YX; Yao, YL; Yu, B; Liu, YH				Wang, Ying-Bin; Hu, Yi; Li, Zhen; Wang, Ping; Xue, Yi-Xue; Yao, Yi-Long; Yu, Bo; Liu, Yun-Hui			Artemether Combined with shRNA Interference of Vascular Cell Adhesion Molecule-1 Significantly Inhibited the Malignant Biological Behavior of Human Glioma Cells	PLOS ONE			English	Article							GROWTH IN-VITRO; MATRIX METALLOPROTEINASE-2; ARTEMISININ DERIVATIVES; EXTRACELLULAR-MATRIX; EXPRESSION; VIVO; ANGIOGENESIS; VCAM-1; CARCINOMA; INVASION	Artemether is the derivative extracted from Chinese traditional herb and originally used for malaria. Artemether also has potential therapeutic effects against tumors. Vascular cell adhesion molecule-1 (VCAM-1) is an important cell surface adhesion molecule associated with malignancy of gliomas. In this work, we investigated the role and mechanism of artemether combined with shRNA interference of VCAM-1 (shRNA-VCAM-1) on the migration, invasion and apoptosis of glioma cells. U87 human glioma cells were treated with artemether at various concentrations and shRNA interfering technology was employed to silence the expression of VCAM-1. Cell viability, migration, invasiveness and apoptosis were assessed with MTT, wound healing, Transwell and Annexin V-FITC/PI staining. The expression of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and phosphorylated Akt (p-Akt) was checked by Western blot assay. Results showed that artemether and shRNA-VCAM-1 not only significantly inhibited the migration, invasiveness and expression of MMP-2/9 and p-Akt, but also promoted the apoptosis of U87 cells. Combined treatment of both displayed the maximum inhibitory effects on the malignant biological behavior of glioma cells. Our work revealed the potential therapeutic effects of artemether and antiVCAM-1 in the treatments of gliomas.	[Wang, Ying-Bin; Hu, Yi; Li, Zhen; Yao, Yi-Long; Yu, Bo; Liu, Yun-Hui] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang, Liaoning Provin, Peoples R China; [Wang, Ping; Xue, Yi-Xue] China Med Univ, Coll Basic Med, Dept Neurobiol, Shenyang, Liaoning Provin, Peoples R China; [Wang, Ping; Xue, Yi-Xue] China Med Univ, Inst Pathol & Pathophysiol, Shenyang, Liaoning Provin, Peoples R China	China Medical University; China Medical University; China Medical University	Liu, YH (corresponding author), China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang, Liaoning Provin, Peoples R China.	liuyunhuicmu@yahoo.com.cn			Natural Science Foundation of China [81171131, 81172197, 81272564, 30973079, 81072056]; special fund for Scientific Research of Doctor-degree Subjects in Colleges and Universities [20092104110015, 20102104110009]; Natural Science Foundation of Liaoning Province in China [201102300]; Liaoning Science and Technology Plan Projects [2011225020]; College Science and Technology Research Project of Education Department in Liaoning Province [L2010585]; Shenyang Science and Technology Plan Projects [F11-264-1-15, F12-277-1-05]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); special fund for Scientific Research of Doctor-degree Subjects in Colleges and Universities; Natural Science Foundation of Liaoning Province in China(Natural Science Foundation of Liaoning Province); Liaoning Science and Technology Plan Projects; College Science and Technology Research Project of Education Department in Liaoning Province; Shenyang Science and Technology Plan Projects	This work was supported by grants from the Natural Science Foundation of China (no. 81171131, no. 81172197, no. 81272564, no. 30973079 and no. 81072056) (www.nsfc.gov.cn), the special fund for Scientific Research of Doctor-degree Subjects in Colleges and Universities, (no. 20092104110015, 20102104110009) (www.cutech.edu.cn), the Natural Science Foundation of Liaoning Province in China (no. 201102300) (www.lninfo.gov.cn), Liaoning Science and Technology Plan Projects (no. 2011225020) (www.lninfo.gov.cn), College Science and Technology Research Project of Education Department in Liaoning Province (no. L2010585) (www.lnein.gov.cn), and Shenyang Science and Technology Plan Projects (no. F11-264-1-15 and F12-277-1-05) (http: //www.systplan.gov.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcantara DDA, 2013, J APPL TOXICOL, V33, P151, DOI 10.1002/jat.1734; Bai J, 2012, J CANCER RES CLIN, V138, P991, DOI 10.1007/s00432-012-1172-8; Chen HH, 2003, PHARMACOL RES, V48, P231, DOI 10.1016/S1043-6618(03)00107-5; Deem TL, 2004, BLOOD, V104, P2385, DOI 10.1182/blood-2004-02-0665; Ding YB, 2003, WORLD J GASTROENTERO, V9, P1409, DOI 10.3748/wjg.v9.i7.1409; Efferth T, 2002, BIOCHEM PHARMACOL, V64, P617, DOI 10.1016/S0006-2952(02)01221-2; Farsam V, 2011, INT IMMUNOPHARMACOL, V11, P1802, DOI 10.1016/j.intimp.2011.07.008; FISHWICK J, 1995, CHEM-BIOL INTERACT, V96, P263, DOI 10.1016/0009-2797(94)03597-2; Florio T, 2012, DRUG DISCOV TODAY, V17, P1103, DOI 10.1016/j.drudis.2012.06.001; Forsyth PA, 1999, BRIT J CANCER, V79, P1828, DOI 10.1038/sj.bjc.6690291; Gautam A, 2009, CURR DRUG METAB, V10, P289, DOI 10.2174/138920009787846323; Geisberger G, 2013, CARBOHYD POLYM, V91, P58, DOI 10.1016/j.carbpol.2012.08.009; Hai J, 2008, NEUROL RES, V30, P99, DOI 10.1179/016164107X228697; Hartmann W, 2006, CLIN CANCER RES, V12, P3019, DOI 10.1158/1078-0432.CCR-05-2187; Horn L, 2009, J CLIN ONCOL, V27, P6006, DOI 10.1200/JCO.2009.23.7545; Hou JM, 2008, CLIN CANCER RES, V14, P5519, DOI 10.1158/1078-0432.CCR-08-0197; Hu Y, 2012, J MOL NEUROSCI, V48, P127, DOI 10.1007/s12031-012-9784-7; Kamugisha E, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-58; Klemke M, 2007, J CELL PHYSIOL, V212, P368, DOI 10.1002/jcp.21029; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Kokwaro G O, 1998, Afr J Health Sci, V5, P8; Kubiatowski T, 2001, J NEUROSURG, V95, P480, DOI 10.3171/jns.2001.95.3.0480; Lai SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038103; Levine DA, 2005, CLIN CANCER RES, V11, P2875, DOI 10.1158/1078-0432.CCR-04-2142; Li Y, 1998, Med Trop (Mars), V58, P9; Lima FRS, 2012, BBA-REV CANCER, V1826, P338, DOI 10.1016/j.bbcan.2012.05.004; Lodge NJ, 2013, NEUROPHARMACOLOGY, V67, P284, DOI 10.1016/j.neuropharm.2012.10.025; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; Manning L, 2011, ANTIMICROB AGENTS CH, V55, P5027, DOI 10.1128/AAC.00375-11; Maurer CA, 1998, INT J CANCER, V79, P76, DOI 10.1002/(SICI)1097-0215(19980220)79:1<76::AID-IJC15>3.0.CO;2-F; Nakase I, 2008, INT J PHARM, V354, P28, DOI 10.1016/j.ijpharm.2007.09.003; Nyakern M, 2006, LEUKEMIA, V20, P230, DOI 10.1038/sj.leu.2404057; Okell LC, 2008, PLOS MED, V5, P1617, DOI 10.1371/journal.pmed.0050226; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Pu PY, 2006, TECHNOL CANCER RES T, V5, P271, DOI 10.1177/153303460600500308; Pu PY, 2006, J NEURO-ONCOL, V76, P1, DOI 10.1007/s11060-005-3029-3; Pu PY, 2004, TUMOR BIOL, V25, P172, DOI 10.1159/000081099; Qi ST, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038842; Roos N, 2007, J PHARMACOL EXP THER, V321, P583, DOI 10.1124/jpet.106.117051; Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf; Sariahmetoglu M, 2007, FASEB J, V21, P2486, DOI 10.1096/fj.06-7938com; Shabaik YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054346; Shao JF, 2011, ACTA BIOCH BIOPH SIN, V43, P267, DOI 10.1093/abbs/gmr011; Shiozaki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038049; Siebzehnrubl FA, 2011, GLIA, V59, P1135, DOI 10.1002/glia.21143; Singh NP, 2006, INTEGR CANCER THER, V5, P391, DOI 10.1177/1534735406295311; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Uegaki K, 2005, ONCOL REP, V14, P389; Wang DY, 2005, BRAIN PATHOL, V15, P318; Wang MD, 2005, J NEURO-ONCOL, V72, P1, DOI 10.1007/s11060-004-1392-0; Wu ZP, 2009, INTEGR CANCER THER, V8, P88, DOI 10.1177/1534735408330714; Xie LH, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-112; Zhan Q, 2011, BRAZ J MED BIOL RES, V44, P489, DOI 10.1590/S0100-879X2011007500052; Zhang CZ, 2012, BIOCHEM PHARMACOL, V83, P1278, DOI 10.1016/j.bcp.2012.02.002; Zhao JX, 2007, EUR J NEUROL, V14, P510, DOI 10.1111/j.1468-1331.2006.01705.x	55	21	24	2	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2013	8	4							e60834	10.1371/journal.pone.0060834	http://dx.doi.org/10.1371/journal.pone.0060834			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123JA	23593320	Green Published, gold, Green Submitted			2023-01-03	WOS:000317383200020
J	Darby, SC; Ewertz, M; McGale, P; Bennet, AM; Blom-Goldman, U; Bronnum, D; Correa, C; Cutter, D; Gagliardi, G; Gigante, B; Jensen, MB; Nisbet, A; Peto, R; Rahimi, K; Taylor, C; Hall, P				Darby, Sarah C.; Ewertz, Marianne; McGale, Paul; Bennet, Anna M.; Blom-Goldman, Ulla; Bronnum, Dorthe; Correa, Candace; Cutter, David; Gagliardi, Giovanna; Gigante, Bruna; Jensen, Maj-Britt; Nisbet, Andrew; Peto, Richard; Rahimi, Kazem; Taylor, Carolyn; Hall, Per			Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CAUSE-SPECIFIC MORTALITY; CARDIOVASCULAR-DISEASES; MYOCARDIAL-INFARCTION; SURVIVORS; COHORT	BACKGROUND Radiotherapy for breast cancer often involves some incidental exposure of the heart to ionizing radiation. The effect of this exposure on the subsequent risk of ischemic heart disease is uncertain. METHODS We conducted a population-based case-control study of major coronary events (i.e., myocardial infarction, coronary revascularization, or death from ischemic heart disease) in 2168 women who underwent radiotherapy for breast cancer between 1958 and 2001 in Sweden and Denmark; the study included 963 women with major coronary events and 1205 controls. Individual patient information was obtained from hospital records. For each woman, the mean radiation doses to the whole heart and to the left anterior descending coronary artery were estimated from her radiotherapy chart. RESULTS The overall average of the mean doses to the whole heart was 4.9 Gy (range, 0.03 to 27.72). Rates of major coronary events increased linearly with the mean dose to the heart by 7.4% per gray (95% confidence interval, 2.9 to 14.5; P<0.001), with no apparent threshold. The increase started within the first 5 years after radiotherapy and continued into the third decade after radiotherapy. The proportional increase in the rate of major coronary events per gray was similar in women with and women without cardiac risk factors at the time of radiotherapy. CONCLUSIONS Exposure of the heart to ionizing radiation during radiotherapy for breast cancer increases the subsequent rate of ischemic heart disease. The increase is proportional to the mean dose to the heart, begins within a few years after exposure, and continues for at least 20 years. Women with preexisting cardiac risk factors have greater absolute increases in risk from radiotherapy than other women. (Funded by Cancer Research UK and others.)	[Darby, Sarah C.; McGale, Paul; Cutter, David; Peto, Richard; Taylor, Carolyn] Univ Oxford, Clin Trial Serv Unit, Oxford, England; [Rahimi, Kazem] Univ Oxford, George Ctr Healthcare Innovat, Oxford, England; [Nisbet, Andrew] Royal Surrey Cty Hosp, Dept Med Phys, Guildford, Surrey, England; [Nisbet, Andrew] Univ Surrey, Guildford GU2 5XH, Surrey, England; [Ewertz, Marianne] Univ Southern Denmark, Inst Clin Res, Odense Univ Hosp, Dept Oncol, Odense, Denmark; [Bronnum, Dorthe] Aalborg Hosp, Dept Oncol, Aalborg, Denmark; [Jensen, Maj-Britt] Rigshosp, Danish Breast Canc Cooperat Grp, DK-2100 Copenhagen, Denmark; [Bennet, Anna M.; Hall, Per] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Gigante, Bruna] Karolinska Inst, Inst Environm Med, Div Cardiovasc Epidemiol, S-10401 Stockholm, Sweden; [Gigante, Bruna] Karolinska Inst, Dept Clin Sci, Danderyd Hosp, Div Cardiovasc Med, Stockholm, Sweden; [Blom-Goldman, Ulla] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden; [Gagliardi, Giovanna] Karolinska Univ Hosp, Dept Med Phys, Stockholm, Sweden; [Taylor, Carolyn] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA	University of Oxford; University of Oxford; Royal Surrey County Hospital; University of Surrey; University of Southern Denmark; Odense University Hospital; Aalborg University; Aalborg University Hospital; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen; Karolinska Institutet; Karolinska Institutet; Danderyds Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Darby, SC (corresponding author), Clin Trial Serv Unit, Richard Doll Bldg,Old Rd Campus, Oxford OX3 7LF, England.	sarah.darby@ctsu.ox.ac.uk	Nisbet, Andrew/AAK-9799-2021; Cutter, David/AAU-6599-2021; Rahimi, Kazem/AAA-4250-2022; Gigante, Bruna/I-9252-2012; Nisbet, Andrew/A-9651-2013; Rahimi, Kazem/Q-1279-2015	Nisbet, Andrew/0000-0002-0652-808X; Cutter, David/0000-0001-7307-7488; Nisbet, Andrew/0000-0002-0652-808X; Rahimi, Kazem/0000-0002-4807-4610; Bennet-Bark, Anna/0000-0003-2704-2625; Ewertz, Marianne/0000-0002-5965-969X; Bronnum, Dorthe Scavenius/0000-0002-2723-9148; Gigante, Bruna/0000-0003-4508-7990	Cancer Research UK; British Heart Foundation; U.K. Medical Research Council; European Commission [FI6R-012796]; U.K. Department of Health [RRX 108]; British Heart Foundation Centre for Research Excellence [CRE RE/08/004]; Oxford National Institute for Health Research Biomedical Research Centre; Medical Research Council [MC_U137686858] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); British Heart Foundation(British Heart Foundation); U.K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Commission(European CommissionEuropean Commission Joint Research Centre); U.K. Department of Health; British Heart Foundation Centre for Research Excellence; Oxford National Institute for Health Research Biomedical Research Centre(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by funding to the Oxford University Clinical Trial Service Unit from Cancer Research UK, the British Heart Foundation, and the U.K. Medical Research Council and by grants from the European Commission (FI6R-012796), the U.K. Department of Health (RRX 108), the British Heart Foundation Centre for Research Excellence (CRE RE/08/004, to Dr. Cutter), and the Oxford National Institute for Health Research Biomedical Research Centre (to Dr. Rahimi).	Abe O, 2005, LANCET, V366, P2087; Aleman BMP, 2003, J CLIN ONCOL, V21, P3431, DOI 10.1200/JCO.2003.07.131; American Cancer Society, 2012, BREAST CANC FACTS FI; Ares C, 2010, INT J RADIAT ONCOL, V76, P685, DOI 10.1016/j.ijrobp.2009.02.062; Azizova TV, 2010, RADIAT RES, V174, P155, DOI 10.1667/RR1789.1; Aznar MC, 2011, BRIT J RADIOL, V84, P743, DOI 10.1259/bjr/12497075; Barlow L, 2009, ACTA ONCOL, V48, P27, DOI 10.1080/02841860802247664; Berry JD, 2012, NEW ENGL J MED, V366, P321, DOI 10.1056/NEJMoa1012848; Borger JH, 2007, INT J RADIAT ONCOL, V69, P1131, DOI 10.1016/j.ijrobp.2007.04.042; Bouillon K, 2011, J AM COLL CARDIOL, V57, P445, DOI 10.1016/j.jacc.2010.08.638; Carr ZA, 2005, INT J RADIAT ONCOL, V61, P842, DOI 10.1016/j.ijrobp.2004.07.708; Cutter D, 2013, CANC HEART, P88; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; Darby SC, 2005, LANCET ONCOL, V6, P557, DOI 10.1016/S1470-2045(05)70251-5; Early Breast Canc Trialists Collab, 2011, LANCET, V378, P1707, DOI 10.1016/S0140-6736(11)61629-2; Ferlay J, 2010, IARC CANCERBASE; Gagliardi G, 2010, INT J RADIAT ONCOL, V76, pS77, DOI 10.1016/j.ijrobp.2009.04.093; Gulyban A, 2008, STRAHLENTHER ONKOL, V184, P262, DOI 10.1007/s00066-008-1770-1; HANCOCK SL, 1993, JAMA-J AM MED ASSOC, V270, P1949, DOI 10.1001/jama.270.16.1949; Hooning MJ, 2007, JNCI-J NATL CANCER I, V99, P365, DOI 10.1093/jnci/djk064; Jagsi R, 2010, INT J RADIAT ONCOL, V78, P1594, DOI 10.1016/j.ijrobp.2010.04.072; Jones B, 2001, CLIN ONCOL-UK, V13, P71, DOI 10.1007/s001740170083; Kleinbaum DG, 1988, APPL REGRESSION ANAL; Lohr F, 2009, INT J RADIAT ONCOL, V74, P73, DOI 10.1016/j.ijrobp.2008.07.018; McGale P, 2008, INT J EPIDEMIOL, V37, P518, DOI 10.1093/ije/dyn067; McGale P, 2011, RADIOTHER ONCOL, V100, P167, DOI 10.1016/j.radonc.2011.06.016; Moller S, 2008, ACTA ONCOL, V47, P506, DOI 10.1080/02841860802059259; Plummer M, 2004, STAT MED, V23, P93, DOI 10.1002/sim.1485; PRESTON D. L., 1993, EPICURE USERS GUIDE; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; Schubert LK, 2011, RADIOTHER ONCOL, V100, P241, DOI 10.1016/j.radonc.2011.01.004; Schultz-Hector S, 2007, INT J RADIAT ONCOL, V67, P10, DOI 10.1016/j.ijrobp.2006.08.071; Shimizu Y, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5349; Smolina K, 2012, BRIT MED J, V344, DOI 10.1136/bmj.d8059; StataCorp, 2011, BEVOLKING; Swerdlow AJ, 2007, J NATL CANCER I, V99, P206, DOI 10.1093/jnci/djk029; Taylor CW, 2008, INT J RADIAT ONCOL, V72, P501, DOI 10.1016/j.ijrobp.2007.12.058; Taylor CW, 2007, INT J RADIAT ONCOL, V69, P1484, DOI 10.1016/j.ijrobp.2007.05.034; Taylor CW, 2011, RADIOTHER ONCOL, V100, P176, DOI 10.1016/j.radonc.2011.01.020; Taylor CW, 2009, RADIOTHER ONCOL, V90, P127, DOI 10.1016/j.radonc.2008.09.029; Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050	41	2229	2315	4	190	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 14	2013	368	11					987	998		10.1056/NEJMoa1209825	http://dx.doi.org/10.1056/NEJMoa1209825			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	104HF	23484825	Bronze, Green Published			2023-01-03	WOS:000315982100005
J	Wolchok, JD; Kluger, H; Callahan, MK; Postow, MA; Rizvi, NA; Lesokhin, AM; Segal, NH; Ariyan, CE; Gordon, RA; Reed, K; Burke, MM; Caldwell, A; Kronenberg, SA; Agunwamba, BU; Zhang, XL; Lowy, I; Inzunza, HD; Feely, W; Horak, CE; Hong, Q; Korman, AJ; Wigginton, JM; Gupta, A; Sznol, M				Wolchok, Jedd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Rizvi, Naiyer A.; Lesokhin, Alexander M.; Segal, Neil H.; Ariyan, Charlotte E.; Gordon, Ruth-Ann; Reed, Kathleen; Burke, Matthew M.; Caldwell, Anne; Kronenberg, Stephanie A.; Agunwamba, Blessing U.; Zhang, Xiaoling; Lowy, Israel; Inzunza, Hector David; Feely, William; Horak, Christine E.; Hong, Quan; Korman, Alan J.; Wigginton, Jon M.; Gupta, Ashok; Sznol, Mario			Nivolumab plus Ipilimumab in Advanced Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODY; SAFETY; THERAPY; CTLA-4; PD-1	BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis of their distinct immunologic mechanisms of action and supportive preclinical data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma. METHODS We administered intravenous doses of nivolumab and ipilimumab in patients every 3 weeks for 4 doses, followed by nivolumab alone every 3 weeks for 4 doses (concurrent regimen). The combined treatment was subsequently administered every 12 weeks for up to 8 doses. In a sequenced regimen, patients previously treated with ipilimumab received nivolumab every 2 weeks for up to 48 doses. RESULTS A total of 53 patients received concurrent therapy with nivolumab and ipilimumab, and 33 received sequenced treatment. The objective-response rate (according to modified World Health Organization criteria) for all patients in the concurrent-regimen group was 40%. Evidence of clinical activity (conventional, unconfirmed, or immune-related response or stable disease for >= 24 weeks) was observed in 65% of patients. At the maximum doses that were associated with an acceptable level of adverse events (nivolumab at a dose of 1 mg per kilogram of body weight and ipilimumab at a dose of 3 mg per kilogram), 53% of patients had an objective response, all with tumor reduction of 80% or more. Grade 3 or 4 adverse events related to therapy occurred in 53% of patients in the concurrent-regimen group but were qualitatively similar to previous experience with monotherapy and were generally reversible. Among patients in the sequenced-regimen group, 18% had grade 3 or 4 adverse events related to therapy and the objective-response rate was 20%. CONCLUSIONS Concurrent therapy with nivolumab and ipilimumab had a manageable safety profile and provided clinical activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients.	[Wolchok, Jedd D.; Callahan, Margaret K.; Postow, Michael A.; Rizvi, Naiyer A.; Lesokhin, Alexander M.; Segal, Neil H.; Ariyan, Charlotte E.; Gordon, Ruth-Ann; Kronenberg, Stephanie A.; Agunwamba, Blessing U.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, New York, NY 10065 USA; [Kluger, Harriet; Reed, Kathleen; Burke, Matthew M.; Caldwell, Anne; Sznol, Mario] Yale Univ, Sch Med, New Haven, CT USA; [Kluger, Harriet; Reed, Kathleen; Burke, Matthew M.; Caldwell, Anne; Sznol, Mario] Yale New Haven Med Ctr, Smilow Canc Ctr, New Haven, CT 06504 USA; [Zhang, Xiaoling] Dako North Amer, Carpinteria, CA USA; [Korman, Alan J.] Bristol Myers Squibb, Redwood City, CA USA; [Lowy, Israel; Inzunza, Hector David; Feely, William; Horak, Christine E.; Hong, Quan; Wigginton, Jon M.; Gupta, Ashok] Bristol Myers Squibb Co, Princeton, NJ USA	Memorial Sloan Kettering Cancer Center; Yale University; Yale University; Bristol-Myers Squibb; Bristol-Myers Squibb	Wolchok, JD (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.	wolchokj@mskcc.org		Sznol, Mario/0000-0002-4359-8749; Ariyan, Charlotte/0000-0003-0818-3895	Bristol-Myers Squibb; Ono Pharmaceutical; Ziopharm Oncology; Polynoma; Merck; GlaxoSmithKline; MedImmune; Genesis Biopharma; Nektar; Anaeropharma Science; BeiGene; Genzyme; Johnson Johnson; Prometheus Medical; Institute for Medical Education and Research; TRM Oncology; DAVA Oncology; Center for Biomedical Continuing Education; NATIONAL CANCER INSTITUTE [K24CA172123, P30CA008748] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); Ono Pharmaceutical; Ziopharm Oncology; Polynoma; Merck(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); MedImmune(AstraZenecaMedimmune); Genesis Biopharma; Nektar; Anaeropharma Science; BeiGene; Genzyme(Sanofi-AventisGenzyme Corporation); Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); Prometheus Medical; Institute for Medical Education and Research; TRM Oncology; DAVA Oncology; Center for Biomedical Continuing Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Bristol-Myers Squibb and Ono Pharmaceutical.; Dr. Wolchok reports receiving consulting fees from Bristol-Myers Squibb, Ziopharm Oncology, Polynoma, and Merck and grant support from Bristol-Myers Squibb, GlaxoSmithKline, and MedImmune on behalf of his institution. Dr. Postow reports receiving grant support from Bristol-Myers Squibb on behalf of his institution and serving as an unpaid consultant for and receiving reimbursement for travel expenses from Bristol-Myers Squibb. Dr. Lesokhin reports receiving consulting fees from Bristol-Myers Squibb and grant support from Bristol-Myers Squibb on behalf of his institution. Dr. Segal reports receiving grant support from Bristol-Myers Squibb on behalf of his institution. Dr. Ariyan reports receiving consulting fees from Bristol-Myers Squibb. Ms. Gordon reports receiving consulting fees from Bristol-Myers Squibb. Mr. Burke reports receiving lecture fees from Bristol-Myers Squibb. Dr. Lowy reports being a former employee of and holding stock in Bristol-Myers Squibb. U. S. patents on human monoclonal antibodies against Bacillus anthracis protective antigen and antibodies against Clostridium difficile toxins and a surrogate therapeutic end point for anti-CLTA-4-based immunotherapy of disease have been issued; Dr. Lowy is listed as an inventor on the patents, which are owned by Bristol-Myers Squibb. Dr. Inzunza reports being an employee of Bristol-Myers Squibb. Mr. Feely and Drs. Horak, Hong, Wigginton, and Gupta report being employees of and holding stock or stock options in Bristol-Myers Squibb. Dr. Korman reports being an employee of, holding stock or stock options in, and receiving reimbursement for travel expenses from Bristol-Myers Squibb. Dr. Sznol reports receiving consulting fees from Bristol-Myers Squibb, Genesis Biopharma, Nektar, Anaeropharma Science, Genzyme, BeiGene, Johnson & Johnson, and Prometheus Medical and lecture fees from the Institute for Medical Education and Research, TRM Oncology, DAVA Oncology, and the Center for Biomedical Continuing Education. No other potential conflict of interest relevant to this article was reported.	Berman DM, 2009, J CLIN ONCOL S, V27, p15s; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; *CTEP COMM TERM, 2006, CANC THER EV PROGR C; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; DELYON J, 2013, ANN ONCOL; Fong L, 2008, J CLIN ONCOL, V26, P5275, DOI 10.1200/JCO.2008.17.8954; GORDON MS, 2013, ANN M AM ASS CANC RE; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Ku GY, 2010, CANCER-AM CANCER SOC, V116, P1767, DOI 10.1002/cncr.24951; Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625; ODAYSJ, 2007, CANCER, V110, P2614; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Postow MA, 2012, J CLIN ONCOL S, V30; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Robert C, 2009, ONCOLOGIST, V14, P848, DOI 10.1634/theoncologist.2009-0028; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; SELBY M, 2013, J CLIN ONCOL S, V31; SZNOL M, 2013, J CLIN ONCOL S, P31; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; WOLCHOK JD, 2013, ANN ONCOL; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; 2012, YERV	27	3066	3281	7	361	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 11	2013	369	2					122	133		10.1056/NEJMoa1302369	http://dx.doi.org/10.1056/NEJMoa1302369			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	180BH	23724867	Bronze, Green Accepted			2023-01-03	WOS:000321567300008
J	Tian, W; Ding, WP; Kim, S; Zheng, LZ; Zhang, L; Li, XP; Gu, JC; Zhang, L; Pan, MG; Chen, SY				Tian, Wei; Ding, Wenping; Kim, Sungkyoung; Zheng, Leizhen; Zhang, Li; Li, Xiaoping; Gu, Jianchun; Zhang, Lian; Pan, Minggui; Chen, Siyu			Efficacy and Safety Profile of Combining Vandetanib with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Meta-Analysis	PLOS ONE			English	Article							1ST-LINE TREATMENT; PLUS DOCETAXEL; TUMOR-GROWTH; PHASE-II; INHIBITOR; ERLOTINIB; ZD6474	Objective: To evaluate the efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), ASCO Abstracts, ESMO Abstracts, Wanfang Database, CNKI were searched. Eligible studies were the randomized clinical trials (RCTs) that compared the efficacy and safety profile of adding vandetanib to chemotherapy with single chemotherapy in patients with advanced NSCLC. The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicities. All meta-analysis were performed using Review Manager 5.1. The fixed-effect model weighted by the Mantel-Haenszel method was used. When considerable heterogeneity was found (p<0.1, or I-2>50%), further analysis (subgroup analysis, sensitivity analysis or random-effect model) was performed to identify potential cause. Results: Results reported from 5 RCTs involving 2284 patients were included in the analysis. Compared to chemotherapy alone, the addition of vandetanib resulted in a significant longer PFS (HR 0.79 [0.72-0.87], p<0.00001) and a higher ORR (RR 1.75 [1.43-2.15], p<0.00001), but failed to show advantage on OS (HR 0.96 [0.87-1.06], p = 0.44). Conclusion: Vandetanib has activity in NSCLC. Identification of predictive biomarkers is warranted in future trials to select a subset of patients with advanced NSCLC who may benefit from vandetanib.	[Tian, Wei; Ding, Wenping; Kim, Sungkyoung; Zheng, Leizhen; Zhang, Li; Li, Xiaoping; Gu, Jianchun; Zhang, Lian; Chen, Siyu] Shanghai Jiao Tong Univ, Dept Oncol, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China; [Pan, Minggui] Kaiser Permanente Med Ctr, Dept Med Oncol & Hematol, Santa Clara, CA USA	Shanghai Jiao Tong University; Kaiser Permanente	Chen, SY (corresponding author), Shanghai Jiao Tong Univ, Dept Oncol, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China.	siyu.chen@shsmu.edu.cn	Pan, Minggui/AAB-7371-2020; CHEN, SI/GZL-4800-2022		National Natural Science Foundation of China [81274142, 30300139]; Key Project of Shanghai Municipal Education Commission [07zz43]; Natural Science Foundation of Science and Technology Commission of Shanghai Municipality [11ZR1423400]; Jiayan Foundation; Kaiser Foundation Community Benefit Research Grant	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of Shanghai Municipal Education Commission(Science & Technology Commission of Shanghai Municipality (STCSM)); Natural Science Foundation of Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Jiayan Foundation; Kaiser Foundation Community Benefit Research Grant	This work was supported in part by the National Natural Science Foundation of China (81274142, 30300139), the Key Project of Shanghai Municipal Education Commission (07zz43), the Natural Science Foundation of Science and Technology Commission of Shanghai Municipality (11ZR1423400). M.P. was partly supported by the Jiayan Foundation and the Kaiser Foundation Community Benefit Research Grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carlomagno F, 2002, CANCER RES, V62, P7284; Ciardiello F, 2006, ANN ONCOL, V17, pVII109, DOI 10.1093/annonc/mdl962; Lima ABC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022681; de Boer RH, 2011, J CLIN ONCOL, V29, P1067, DOI 10.1200/JCO.2010.29.5717; Fischer C, 2006, NAT MED, V12, P732, DOI 10.1038/nm0706-732; Gridelli C, 2012, J CLIN ONCOL S, V30; Guan JL, 2013, ANN SURG ONCOL, V20, P1381, DOI 10.1245/s10434-012-2754-z; Hanrahan EO, 2009, CLIN CANCER RES, V15, P3600, DOI 10.1158/1078-0432.CCR-08-2568; Herbst RS, 2010, LANCET ONCOL, V11, P619, DOI 10.1016/S1470-2045(10)70132-7; Heymach JV, 2007, J CLIN ONCOL, V25, P4270, DOI 10.1200/JCO.2006.10.5122; Heymach JV, 2008, J CLIN ONCOL, V26, P5407, DOI 10.1200/JCO.2008.17.3138; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mao C, 2010, LUNG CANCER, V69, P272, DOI 10.1016/j.lungcan.2009.11.020; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Rosen AC, 2012, J CLIN ENDOCR METAB, V97, P1125, DOI 10.1210/jc.2011-2677; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Wedge SR, 2002, CANCER RES, V62, P4645; Xiao YY, 2013, CLIN ONCOL-UK, V25, pE7, DOI 10.1016/j.clon.2012.09.005; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X	26	9	10	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 4	2013	8	7							e67929	10.1371/journal.pone.0067929	http://dx.doi.org/10.1371/journal.pone.0067929			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204FO	23861835	Green Published, Green Submitted, gold			2023-01-03	WOS:000323350700063
J	Wilbur, K; Hazi, H; El-Bedawi, A				Wilbur, Kerry; Hazi, Huda; El-Bedawi, Aya			Drug-Related Hospital Visits and Admissions Associated with Laboratory or Physiologic Abnormalities-A Systematic-Review	PLOS ONE			English	Review							OLDER-PEOPLE; PREVALENCE; CARE; EVENTS; UNIT; PREVENTABILITY; MEDICATIONS; FREQUENCY; SAFETY	Countless studies have demonstrated that many emergency-room visits and hospital admissions are drug-related and that a significant proportion of these drug-related visits (DRVs) are preventable. It has not been previously studied which DRVs could be prevented through enhanced monitoring of therapy. The objective of the study was to determine the incidence of DRVs attributed to laboratory or physiologic abnormalities. Three authors independently performed comprehensive searches in relevant health care databases using pre-determined search terms. Articles discussing DRV associated with poisoning, substance abuse, or studied among existing in-patient populations were excluded. Study country, year, sample, design, duration, DRV identification method, proportion of DRVs associated with laboratory or physiologic abnormalities and associated medications were extracted. The three authors independently assessed selected relevant articles according to the Strengthening the reporting of observational studies in epidemiology (STROBE) as applicable according to the studies' methodology. The initial literature search yielded a total of 1,524 articles of which 30 articles meeting inclusion criteria and reporting sufficient laboratory or physiologic data were included in the overall analysis. Half employed prospective methodologies, which included both chart review and patient interview; however, the overwhelming majority of identified studies assessed only adverse drug reactions (ADRs) as a drug-related cause for DRV. The mean (range) prevalence of DRVs found in all studies was 15.4% (0.44%-66.7%) of which an association with laboratory or physiologic abnormalities could be attributed to a mean (range) of 29.4% (4.3%-78.1%) of cases. Most laboratory-associated DRVs could be linked to immunosuppressant, antineoplastic, anticoagulant and diabetes therapy, while physiologic-associated DRVs were attributed to cardiovascular therapies and NSAIDs. Significant proportions of laboratory and physiologic abnormalities contribute to DRVs and are consistently linked to specific drugs. These therapies are potential targets for enhanced medication monitoring initiatives to proactively avert potential DRVs.	[Wilbur, Kerry; Hazi, Huda; El-Bedawi, Aya] Qatar Univ, Coll Pharm, Doha, Qatar	Qatar University	Wilbur, K (corresponding author), Qatar Univ, Coll Pharm, Doha, Qatar.	kwilbur@qu.edu.qa		Wilbur, Kerry/0000-0002-5936-4429	Qatar University	Qatar University(Qatar National Research Fund (QNRF))	The research was funded by a Qatar University student grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajdukovic Maja, 2007, Pharm Pract (Granada), V5, P162; Alexopoulou A, 2008, EUR J INTERN MED, V19, P505, DOI 10.1016/j.ejim.2007.06.030; Atiqi R, 2010, INT J CLIN PHARM TH, V48, P517; Barry Arden R, 2012, Can Pharm J (Ott), V145, P174, DOI 10.3821/145.4.cpj174; Bhardwaja B, 2011, PHARMACOTHERAPY, V31, P346, DOI 10.1592/phco.31.4.346; Bolesta S, 2011, AM J PHARM EDUC, V75, DOI 10.5688/ajpe75229; Brvar Miran, 2009, BMC Clin Pharmacol, V9, P8, DOI 10.1186/1472-6904-9-8; Chan M, 2001, INTERN MED J, V31, P199, DOI 10.1046/j.1445-5994.2001.00044.x; Easton KL, 2004, BRIT J CLIN PHARMACO, V57, P611, DOI 10.1111/j.1365-2125.2003.02052.x; Foisy M M, 2000, Can J Infect Dis, V11, P193; Fokter N, 2010, WIEN KLIN WOCHENSCHR, V122, P81, DOI 10.1007/s00508-009-1251-2; Franceschi M, 2008, DRUG SAFETY, V31, P545, DOI 10.2165/00002018-200831060-00009; Gallagher RM, 2011, J CLIN PHARM THER, V36, P194, DOI 10.1111/j.1365-2710.2010.01194.x; Goldman RE, 2010, J EVAL CLIN PRACT, V16, P1136, DOI 10.1111/j.1365-2753.2009.01282.x; Green CF, 2000, J CLIN PHARM THER, V25, P355, DOI 10.1046/j.1365-2710.2000.00298.x; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; Hartholt KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013977; Hellstrom LM, 2011, EUR J CLIN PHARMACOL, V67, P741, DOI 10.1007/s00228-010-0982-3; HEPLER CD, 1990, AM J HOSP PHARM, V47, P533, DOI 10.1093/ajhp/47.3.533; Herwaarden MFWV, 2012, DRUG SAFETY, V35, P245, DOI 10.2165/11596000-000000000-00000; Hofer-Dueckelmann C, 2011, INT J CLIN PHARM TH, V49, P577, DOI 10.5414/CP201514; Hohl CM, 2001, ANN EMERG MED, V38, P666, DOI 10.1067/mem.2001.119456; Hohl CM, 2010, ANN EMERG MED, V55, P493, DOI 10.1016/j.annemergmed.2009.10.008; Hopf Y, 2008, PHARM WORLD SCI, V30, P854, DOI 10.1007/s11096-008-9240-5; Howard RL, 2003, QUAL SAF HEALTH CARE, V12, P280, DOI 10.1136/qhc.12.4.280; Howard RL, 2006, BR J CLIN PHARM, V6, P136; James K, 2000, Crit Care Resusc, V2, P108; Jones TA, 2003, PHARMACOTHERAPY, V23, P855, DOI 10.1592/phco.23.7.855.32729; Juntti-Patinen L, 2006, BASIC CLIN PHARMACOL, V98, P212, DOI 10.1111/j.1742-7843.2006.pto_264.x; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; Leendertse AJ, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-4; Leendertse AJ, 2010, DRUG SAFETY, V33, P233, DOI 10.2165/11319030-000000000-00000; Marcum ZA, 2012, J AM GERIATR SOC, V60, P34, DOI 10.1111/j.1532-5415.2011.03772.x; McDonnell PJ, 2002, ANN PHARMACOTHER, V36, P1331, DOI 10.1345/aph.1A333; Miranda V, 2011, J PAIN SYMPTOM MANAG, V42, P342, DOI 10.1016/j.jpainsymman.2010.11.014; Mjorndal T, 2002, PHARMACOEPIDEM DR S, V11, P65, DOI 10.1002/pds.667; Morrato EH, 2008, J CLIN PSYCHIAT, V69, P316, DOI 10.4088/JCP.v69n0219; Noize P, 2011, PHARMACOEPIDEM DR S, V20, P747, DOI 10.1002/pds.2128; Patel Hitesh, 2007, BMC Clin Pharmacol, V7, P9, DOI 10.1186/1472-6904-7-9; Raebel MA, 2005, ARCH INTERN MED, V165, P2395, DOI 10.1001/archinte.165.20.2395; Rivkin A, 2007, AM J HEALTH-SYST PH, V64, P1840, DOI 10.2146/ajhp060641; Rodenburg EM, 2011, BRIT J CLIN PHARMACO, V71, P95, DOI 10.1111/j.1365-2125.2010.03811.x; Rogers S, 2009, DRUG AGING, V26, P951, DOI 10.2165/11316750-000000000-00000; Samoy LJ, 2006, PHARMACOTHERAPY, V26, P1578, DOI 10.1592/phco.26.11.1578; Schumock G T, 1992, Hosp Pharm, V27, P538; Shojania KG, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001096.pub2; Singh H, 2011, J PHARMACOL PHARMACO, V2, P17, DOI 10.4103/0976-500X.77095; Smith DH, 2009, AM J MANAG CARE, V15, P281; Smyth RMD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0024061; Somers A, 2010, J NUTR HEALTH AGING, V14, P477, DOI 10.1007/s12603-009-0237-0; Steinman MA, 2011, J AM GERIATR SOC, V59, P1513, DOI 10.1111/j.1532-5415.2011.03500.x; Tija J, 2011, ANN PHARMACOTHER, V45, P1077; Tjia J, 2010, AM J MANAG CARE, V16, P489; van Mil JWF, 2004, ANN PHARMACOTHER, V38, P859, DOI 10.1345/aph.1D182; Varallo FR, 2011, J PHARM PHARM SCI, V14, P283, DOI 10.18433/J3P01J; von Euler M, 2006, PHARMACOEPIDEM DR S, V15, P179, DOI 10.1002/pds.1154; Wasserfallen J -B., 2001, Eur J Intern Med, V12, P442, DOI 10.1016/S0953-6205(01)00159-5; Wawruch M, 2009, ARCH GERONTOL GERIAT, V48, P186, DOI 10.1016/j.archger.2008.01.004; World Health Organization, 1970, DRUG INTELL CLIN PHA, V4, P101; Zed PJ, 2008, CAN MED ASSOC J, V178, P1563, DOI 10.1503/cmaj.071594	63	9	9	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2013	8	6							e66803	10.1371/journal.pone.0066803	http://dx.doi.org/10.1371/journal.pone.0066803			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IX	23826139	Green Submitted, Green Published, gold			2023-01-03	WOS:000321150000011
J	Crescenti, A; Sola, R; Valls, RM; Caimari, A; del Bas, JM; Anguera, A; Angles, N; Arola, L				Crescenti, Anna; Sola, Rosa; Valls, Rosa M.; Caimari, Antoni; del Bas, Josep M.; Anguera, Anna; Angles, Neus; Arola, Lluis			Cocoa Consumption Alters the Global DNA Methylation of Peripheral Leukocytes in Humans with Cardiovascular Disease Risk Factors: A Randomized Controlled Trial	PLOS ONE			English	Article							DIETARY POLYPHENOLS; HYPERMETHYLATION; GENISTEIN; POLYMORPHISM; GENES; HYPOMETHYLATION; INHIBITION; EXPRESSION; VARIANTS; IMPACT	DNA methylation regulates gene expression and can be modified by different bioactive compounds in foods, such as polyphenols. Cocoa is a rich source of polyphenols, but its role in DNA methylation is still unknown. The objective was to assess the effect of cocoa consumption on DNA methylation and to determine whether the enzymes involved in the DNA methylation process participate in the mechanisms by which cocoa exerts these effects in humans. The global DNA methylation levels in the peripheral blood were evaluated in 214 volunteers who were pre-hypertensive, stage-1 hypertensive or hypercholesterolemic. The volunteers were divided into two groups: 110 subjects who consumed cocoa (6 g/d) for two weeks and 104 control subjects. In addition, the peripheral blood mononuclear cells (PBMCs) from six subjects were treated with a cocoa extract to analyze the mRNA levels of the DNA methyltransferases (DNMTs), methylenetetrahydrofolate reductase (MTHFR), and methionine synthase reductase (MTRR) genes. Cocoa consumption significantly reduced the DNA methylation levels (2.991 +/- 0.366 vs. 3.909 +/- 0.380, p<0.001). Additionally, we found an association between the cocoa effects on DNA methylation and three polymorphisms located in the MTHFR, MTRR, and DNMT3B genes. Furthermore, in PBMCs, the cocoa extract significantly lowered the mRNA levels of the DNMTs, MTHFR, and MTRR. Our study demonstrates for the first time that the consumption of cocoa decreases the global DNA methylation of peripheral leukocytes in humans with cardiovascular risk factors. In vitro experiments with PBMCs suggest that cocoa may exert this effect partially via the down-regulation of DNMTs, MTHFR and MTRR, which are key genes involved in this epigenetic process.	[Crescenti, Anna; Caimari, Antoni; del Bas, Josep M.; Arola, Lluis] TECNIO, CTNS, Reus, Spain; [Sola, Rosa; Valls, Rosa M.] Univ Rovira & Virgili, IISPV, Hosp Univ St Joan Reus, Unitat Recerca Lipids & Arteriosclerosi,CIBERDEM, E-43201 Reus, Spain; [Anguera, Anna] Rottapharm Madaus SL, Barcelona, Spain; [Angles, Neus] La Morella Nuts SAU, Tarragona, Spain; [Arola, Lluis] Univ Rovira & Virgili, Nutrigen Res Grp, Dept Bioquim & Biotecnol, E-43007 Tarragona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERDEM; Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); Universitat Rovira i Virgili	Crescenti, A (corresponding author), TECNIO, CTNS, Reus, Spain.	anna.crescenti@ctns.cat	Crescenti, Anna/AAA-7557-2019; Valls, Rosa M/AAB-1163-2019; del Bas, Josep M/K-2327-2014; del Bas, Josep Maria/K-9310-2019; SOLÀ, Rosa/N-5919-2014; Arola, Lluís/C-6074-2011	Valls, Rosa M/0000-0002-3351-0942; del Bas, Josep M/0000-0002-0700-2004; del Bas, Josep Maria/0000-0002-0700-2004; Arola, Lluís/0000-0003-2767-1974; SOLA, Rosa/0000-0002-8359-235X; Crescenti, Anna/0000-0001-8581-0616; Caimari, Antoni/0000-0001-6144-0294	ACC1O [TECCT11-1-0012]; Ministerio de Economia y Competitividad [AGL2008-00387]	ACC1O; Ministerio de Economia y Competitividad(Spanish Government)	This work was supported by ACC1O (TECCT11-1-0012) and the Ministerio de Economia y Competitividad (AGL2008-00387). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Buitrago-Lopez A, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4488; Chen UL, 2009, BIOCHEM BIOPH RES CO, V378, P57, DOI 10.1016/j.bbrc.2008.10.173; Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S; de Vogel S, 2009, CANCER EPIDEM BIOMAR, V18, P3086, DOI 10.1158/1055-9965.EPI-09-0289; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Dong M, 2006, CHEM RES TOXICOL, V19, P50, DOI 10.1021/tx050252j; Duthie SJ, 2011, P NUTR SOC, V70, P47, DOI 10.1017/S0029665110003952; Fang JY, 2003, J GASTROENTEROL, V38, P821, DOI 10.1007/s00535-003-1207-7; Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S; Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406; Fini L, 2007, J NUTR, V137, P2622, DOI 10.1093/jn/137.12.2622; Friso S, 2005, CANCER EPIDEM BIOMAR, V14, P938, DOI 10.1158/1055-9965.EPI-04-0601; Guerrero-Bosagna Carlos M., 2008, BMC Physiology, V8, P17, DOI 10.1186/1472-6793-8-17; Hammoud Saher Sue, 2013, Methods Mol Biol, V927, P451; Kato K, 2008, BRIT J CANCER, V99, P647, DOI 10.1038/sj.bjc.6604521; Kim M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009692; Kinney SRM, 2009, CANCER PREV RES, V2, P1065, DOI 10.1158/1940-6207.CAPR-09-0010; Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206; Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367; Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966; Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036; Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016/j.bmcl.2008.12.041; Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662; Olteanu H, 2002, BIOCHEMISTRY-US, V41, P13378, DOI 10.1021/bi020536s; Pandey M, 2010, INT J CANCER, V126, P2520, DOI 10.1002/ijc.24988; Pearce MS, 2012, INT J EPIDEMIOL, V41, P210, DOI 10.1093/ije/dys020; Perez-Jimenez J, 2010, EUR J CLIN NUTR, V64, pS112, DOI 10.1038/ejcn.2010.221; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Ramsahoye BH, 2002, METHODS, V27, P156, DOI 10.1016/S1046-2023(02)00069-5; Ried K, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-39; Rimbach G, 2009, INT J MOL SCI, V10, P4290, DOI 10.3390/ijms10104290; Sola R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031103; Sola R, 2010, ATHEROSCLEROSIS, V211, P630, DOI 10.1016/j.atherosclerosis.2010.03.010; Stenvinkel P, 2007, J INTERN MED, V261, P488, DOI 10.1111/j.1365-2796.2007.01777.x; Wang LS, 2011, CLIN CANCER RES, V17, P598, DOI 10.1158/1078-0432.CCR-10-1260; Weisberg IS, 2001, ATHEROSCLEROSIS, V156, P409, DOI 10.1016/S0021-9150(00)00671-7; Zhao JY, 2012, DIABETES, V61, P542, DOI 10.2337/db11-1048	39	41	42	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2013	8	6							e65744	10.1371/journal.pone.0065744	http://dx.doi.org/10.1371/journal.pone.0065744			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	178DN	23840361	Green Submitted, gold, Green Published			2023-01-03	WOS:000321424400012
J	Rhodes, J; Dejsirilert, S; Maloney, SA; Jorakate, P; Kaewpan, A; Salika, P; Akarachotpong, T; Prapasiri, P; Naorat, S; Areerat, P; Ruayajin, A; Sawanpanyalert, P; Akarasewi, P; Peruski, LF; Baggett, HC				Rhodes, Julia; Dejsirilert, Surang; Maloney, Susan A.; Jorakate, Possawat; Kaewpan, Anek; Salika, Prasert; Akarachotpong, Thantapat; Prapasiri, Prabda; Naorat, Sathapana; Areerat, Peera; Ruayajin, Asadang; Sawanpanyalert, Pathom; Akarasewi, Pasakorn; Peruski, Leonard F., Jr.; Baggett, Henry C.			Pneumococcal Bacteremia Requiring Hospitalization in Rural Thailand: An Update on Incidence, Clinical Characteristics, Serotype Distribution, and Antimicrobial Susceptibility, 2005-2010	PLOS ONE			English	Article							STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; DISEASE; RESISTANCE; INFLUENZA; CHILDREN; BURDEN; IMPACT; ASIA	Background: Streptococcus pneumoniae is an important cause of morbidity and mortality in Southeast Asia, but regional data is limited. Updated burden estimates are critical as pneumococcal conjugate vaccine (PCV) is highly effective, but not yet included in the Expanded Program on Immunization of Thailand or neighboring countries. Methods: We implemented automated blood culture systems in two rural Thailand provinces as part of population-based surveillance for bacteremia. Blood cultures were collected from hospitalized patients as clinically indicated. Results: From May 2005- March 2010, 196 cases of pneumococcal bacteremia were confirmed in hospitalized patients. Of these, 57% had clinical pneumonia, 20% required mechanical ventilation, and 23% (n = 46) died. Antibiotic use before blood culture was confirmed in 25% of those with blood culture. Annual incidence of hospitalized pneumococcal bacteremia was 3.6 per 100,000 person-years; rates were higher among children aged <5 years at 11.7 and adults >= 65 years at 14.2, and highest among infants <1 year at 33.8. The median monthly case count was higher during December-March compared to the rest of the year 6.0 vs. 1.0 (p<0.001). The most common serotypes were 23F (16%) and 14 (14%); 61% (74% in patients <5 years) were serotypes in the 10-valent PCV (PCV 10) and 82% (92% in <5 years) in PCV 13. All isolates were sensitive to penicillin, but non-susceptibility was high for co-trimoxazole (57%), erythromycin (30%), and clindamycin (20%). Conclusions: We demonstrated a high pneumococcal bacteremia burden, yet underestimated incidence because we captured only hospitalized cases, and because pre-culture antibiotics were frequently used. Our findings together with prior research indicate that PCV would likely have high serotype coverage in Thailand. These findings will complement ongoing cost effectiveness analyses and support vaccine policy evaluation in Thailand and the region.	[Rhodes, Julia; Maloney, Susan A.; Jorakate, Possawat; Kaewpan, Anek; Salika, Prasert; Akarachotpong, Thantapat; Prapasiri, Prabda; Naorat, Sathapana; Peruski, Leonard F., Jr.; Baggett, Henry C.] Thailand Minist Publ Hlth, US Ctr Dis Control & Prevent Collaborat, Global Dis Detect Reg Ctr, Int Emerging Infect Program, Nonthaburi, Thailand; [Dejsirilert, Surang; Sawanpanyalert, Pathom] Minist Publ Hlth, Natl Inst Hlth, Nonthaburi, Thailand; [Ruayajin, Asadang] Sa Kaeo Prov Hlth Off, Sa Kaeo, Thailand; [Areerat, Peera] Nakhon Phanom Prov Hlth Off, Nakhon Phanom, Thailand; [Akarasewi, Pasakorn] Minist Publ Hlth, Bur Epidemiol, Nonthaburi, Thailand	Ministry of Public Health - Thailand; Ministry of Public Health - Thailand; Ministry of Public Health - Thailand	Rhodes, J (corresponding author), Thailand Minist Publ Hlth, US Ctr Dis Control & Prevent Collaborat, Global Dis Detect Reg Ctr, Int Emerging Infect Program, Nonthaburi, Thailand.	juliar@th.cdc.gov			Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP); GAVI Alliance	Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP); GAVI Alliance	Partial support was provided by the Pneumococcal vaccines Accelerated Development and Introduction Plan (PneumoADIP), which was funded by the GAVI Alliance and based at the Johns Hopkins Bloomberg School of Public Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	[Anonymous], 2007, Wkly Epidemiol Rec, V82, P93; [Anonymous], POP PROJ THAIL 2000; Baggett HC, 2012, EUR J CLIN MICROBIOL, V31, P753, DOI 10.1007/s10096-011-1370-3; Baggett HC, 2010, INT S PNEUM PNEUM DI; Baggett HC, 2009, CLIN INFECT DIS, V48, pS65, DOI 10.1086/596484; Bravo LC, 2009, VACCINE, V27, P7282, DOI 10.1016/j.vaccine.2009.04.046; *CLSI, 2008, PERF STAND ANT SUS S; Dejsirilert S, 2010, 7 INT S PNEUM PNEUM; Dejsirilert Surang, 2009, J Med Assoc Thai, V92 Suppl 4, pS19; Department of Provincial Administration, POP IND AG; Dowell SF, 2003, EMERG INFECT DIS, V9, P573, DOI 10.3201/eid0905.020556; GAVI World Bank, 2012, CREAT MARK SAV LIV F; Hennessy TW, 2005, VACCINE, V23, P5464, DOI 10.1016/j.vaccine.2005.08.100; Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642; Mindy J., 2003, MANUAL LAB IDENTIFIC; Netsawang Supichaya, 2010, Journal of the Medical Association of Thailand, V93, pS6; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Olsen SJ, 2010, EPIDEMIOL INFECT, V138, P1811, DOI 10.1017/S0950268810000646; Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006; Rhodes J, 2010, AM J TROP MED HYG, V83, P301, DOI 10.4269/ajtmh.2010.09-0584; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Simmerman JM, 2008, INFLUENZA OTHER RESP, V2, P81, DOI 10.1111/j.1750-2659.2008.00045.x; Simmerman JM, 2009, PLOS ONE, V4, pA107, DOI 10.1371/journal.pone.0007776; Sirinavin Sayomporn, 2003, International Journal of Infectious Diseases, V7, P183, DOI 10.1016/S1201-9712(03)90050-6; Siripongpreeda Natawan, 2010, Journal of the Medical Association of Thailand, V93, pS1; Song JH, 2004, ANTIMICROB AGENTS CH, V48, P2101, DOI 10.1128/AAC.48.6.2101-2107.2004; Srifeungfung S, 2010, VACCINE, V28, P3440, DOI 10.1016/j.vaccine.2010.02.071; Srifuengfung Somporn, 2010, Journal of the Medical Association of Thailand, V93, pS27; Suwanpakdee Detchvijitr, 2010, Journal of the Medical Association of Thailand, V93, pS40; Walter ND, 2010, CLIN INFECT DIS, V50, P175, DOI 10.1086/649208; Walter ND, 2009, NEW ENGL J MED, V361, P2584, DOI 10.1056/NEJMc0904844; Wongsawat Jurai, 2010, Journal of the Medical Association of Thailand, V93, pS53	32	21	21	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2013	8	6							e66038	10.1371/journal.pone.0066038	http://dx.doi.org/10.1371/journal.pone.0066038			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	178DN	23840395	Green Published, gold			2023-01-03	WOS:000321424400017
J	Ogbomo, H; Zemp, FJ; Lun, XQ; Zhang, JQ; Stack, D; Rahman, MM; Mcfadden, G; Mody, CH; Forsyth, PA				Ogbomo, Henry; Zemp, Franz J.; Lun, Xueqing; Zhang, Jiqing; Stack, Danuta; Rahman, Masmudur M.; Mcfadden, Grant; Mody, Christopher H.; Forsyth, Peter A.			Myxoma Virus Infection Promotes NK Lysis of Malignant Gliomas In Vitro and In Vivo	PLOS ONE			English	Article							TGF-BETA; MHC-I; CELLS; EXPRESSION; GLIOBLASTOMA; VIROTHERAPY; THERAPY; SURFACE; NKG2D; RESISTANCE	Myxoma virus (MYXV) is a well-established oncolytic agent against different types of tumors. MYXV is also known for its immunomodulatory properties in down-regulating major histocompatibility complex (MHC) I surface expression (via the M153R gene product, a viral E3-ubiquitin ligase) and suppressing T cell killing of infected target cells. MHC I down-regulation, however, favors NK cell activation. Brain tumors including gliomas are characterized by high MHC I expression with impaired NK activity. We thus hypothesized that MYXV infection of glioma cells will promote NK cell-mediated recognition and killing of gliomas. We infected human gliomas with MYXV and evaluated their susceptibility to NK cell-mediated cytotoxicity. MYXV enhanced NK cell-mediated killing of glioma cells (U87 cells, MYXV vs. Mock: 51.73% vs. 28.63%, P =.0001, t test; U251 cells, MYXV vs. Mock: 40.4% vs. 20.03%, P.0007, t test). Using MYXV M153R targeted knockout (designated vMyx-M153KO) to infect gliomas, we demonstrate that M153R was responsible for reduced expression of MHC I on gliomas and enhanced NK cell-mediated antiglioma activity (U87 cells, MYXV vs. vMyx-M153KO: 51.73% vs. 25.17%, P =.0002, t test; U251 cells, MYXV vs. vMyx-M153KO: 40.4% vs. 19.27, P =.0013, t test). Consequently, NK cell-mediated lysis of established human glioma tumors in CB-17 SCID mice was accelerated with improved mouse survival (log-rank P =.0072). These results demonstrate the potential for combining MYXV with NK cells to effectively kill malignant gliomas.	[Ogbomo, Henry; Zemp, Franz J.; Lun, Xueqing; Zhang, Jiqing; Forsyth, Peter A.] Univ Calgary, Dept Oncol, Calgary, AB, Canada; [Ogbomo, Henry; Zemp, Franz J.; Lun, Xueqing; Zhang, Jiqing; Forsyth, Peter A.] Univ Calgary, Dept Biochem, Calgary, AB, Canada; [Ogbomo, Henry; Zemp, Franz J.; Lun, Xueqing; Zhang, Jiqing; Forsyth, Peter A.] Univ Calgary, Dept Mol Biol, Calgary, AB, Canada; [Ogbomo, Henry; Stack, Danuta; Mody, Christopher H.] Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB, Canada; [Ogbomo, Henry; Stack, Danuta; Mody, Christopher H.] Univ Calgary, Dept Internal Med, Calgary, AB, Canada; [Rahman, Masmudur M.; Mcfadden, Grant] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL USA; [Forsyth, Peter A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Neurooncol, Tampa, FL USA; [Forsyth, Peter A.] Univ S Florida, Tampa, FL USA	University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; State University System of Florida; University of Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Forsyth, PA (corresponding author), Univ Calgary, Dept Oncol, Calgary, AB, Canada.	Peter.Forsyth@moffitt.org		Mody, Christopher H./0000-0001-7264-3679; McFadden, Grant/0000-0002-2556-3526	National Cancer Institute of Canada; Canadian Cancer Society Research Institute; National Cancer Institutes of Canada-Terry Fox Research Institute; Alberta Cancer Foundation; Alberta Innovates and Health Solutions postdoctoral fellowships; Canadian Institute for Health Research; Jessie Bowden Lloyd Professorship in Immunology; Alberta Innovates and Health Solutions; Killam Memorial Trust; Canadian Institute for Health Research Vanier Award; National Institutes of Health [AI080607, CA138541]; NATIONAL CANCER INSTITUTE [R01CA138541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080607] Funding Source: NIH RePORTER	National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); National Cancer Institutes of Canada-Terry Fox Research Institute; Alberta Cancer Foundation; Alberta Innovates and Health Solutions postdoctoral fellowships; Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Jessie Bowden Lloyd Professorship in Immunology; Alberta Innovates and Health Solutions; Killam Memorial Trust; Canadian Institute for Health Research Vanier Award(Canadian Institutes of Health Research (CIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Cancer Institute of Canada; Canadian Cancer Society Research Institute; National Cancer Institutes of Canada-Terry Fox Research Institute; Families of Clark H. Smith and Kathleen Lorette (PAF), Alberta Cancer Foundation and Alberta Innovates and Health Solutions postdoctoral fellowships (HO), Canadian Institute for Health Research grants and Jessie Bowden Lloyd Professorship in Immunology (CHM), Alberta Innovates and Health Solutions, Killam Memorial Trust, and Canadian Institute for Health Research Vanier Award (FJZ), National Institutes of Health R01 grants (AI080607 and CA138541; GM's lab). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alvarez-Breckenridge CA, 2012, NAT MED, V18, P1827, DOI 10.1038/nm.3013; Alvarez-Breckenridge CA, 2012, ADV VIROL, V2012, DOI 10.1155/2012/702839; Avril T, 2010, J NEUROIMMUNOL, V225, P22, DOI 10.1016/j.jneuroim.2010.04.003; BARBA D, 1989, J NEUROSURG, V70, P175, DOI 10.3171/jns.1989.70.2.0175; Bhat R, 2011, INT J CANCER, V128, P908, DOI 10.1002/ijc.25415; BOSHKOV LK, 1992, J IMMUNOL, V148, P881; Castriconi R, 2009, J IMMUNOL, V182, P3530, DOI 10.4049/jimmunol.0802845; Collin N, 2005, VIROLOGY, V343, P171, DOI 10.1016/j.virol.2005.07.032; Crane CA, 2010, NEURO-ONCOLOGY, V12, P7, DOI 10.1093/neuonc/nop009; Diaz RM, 2007, CANCER RES, V67, P2840, DOI 10.1158/0008-5472.CAN-06-3974; Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205; Friese MA, 2003, CANCER RES, V63, P8996; Glynn SA, 2004, BRIT J CANCER, V91, P1800, DOI 10.1038/sj.bjc.6602221; Guerin JL, 2002, J VIROL, V76, P2912, DOI 10.1128/JVI.76.6.2912-2923.2002; Holmes TD, 2011, J IMMUNOL, V186, P1538, DOI 10.4049/jimmunol.1000951; Ishikawa E, 2004, ANTICANCER RES, V24, P1861; JACKSON EW, 1966, NATURE, V211, P313, DOI 10.1038/211313a0; Johnston JB, 2003, J VIROL, V77, P5877, DOI 10.1128/JVI.77.10.5877-5888.2003; JOLY E, 1991, SCIENCE, V253, P1283, DOI 10.1126/science.1891717; Liang YH, 2004, INT J CANCER, V111, P484, DOI 10.1002/ijc.20230; Liu J, 2010, MICROBES INFECT, V12, P1144, DOI 10.1016/j.micinf.2010.08.012; Lun XQ, 2005, CANCER RES, V65, P9982, DOI 10.1158/0008-5472.CAN-05-1201; Lun XQ, 2010, CANCER RES, V70, P598, DOI 10.1158/0008-5472.CAN-09-1510; Mansouri M, 2003, J VIROL, V77, P1427, DOI 10.1128/JVI.77.2.1427-1440.2003; Ogbomo H, 2006, BIOCHEM BIOPH RES CO, V339, P375, DOI 10.1016/j.bbrc.2005.11.025; Ogbomo H, 2011, TRENDS MOL MED, V17, P433, DOI 10.1016/j.molmed.2011.03.004; Ogbomo H, 2010, MED MICROBIOL IMMUN, V199, P93, DOI 10.1007/s00430-009-0139-0; Ogbomo H, 2008, NEOPLASIA, V10, P1402, DOI 10.1593/neo.08972; Parney IF, 2000, NEUROSURGERY, V46, P1169, DOI 10.1097/00006123-200005000-00030; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Preusser M, 2006, WIEN MED WOCHENSCHR, V156, P332, DOI 10.1007/s10354-006-0304-7; Sloan KE, 2005, CANCER RES, V65, P10930, DOI 10.1158/0008-5472.CAN-05-1890; Smallwood Sherin E, 2010, Curr Protoc Microbiol, VChapter 14, DOI 10.1002/9780471729259.mc14a01s17; Stanford MM, 2007, VET RES, V38, P299, DOI 10.1051/vetres:2006054; Stanford MM, 2007, J VIROL, V81, P1251, DOI 10.1128/JVI.01408-06; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Szentirmai O, 2006, NEUROSURGERY, V58, P365, DOI 10.1227/01.NEU.0000195114.24819.4F; Vauleon E, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/689171; Wu AH, 2007, J NEURO-ONCOL, V83, P121, DOI 10.1007/s11060-006-9265-3; Yang WQ, 2003, CANCER RES, V63, P3162	40	38	40	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2013	8	6							e66825	10.1371/journal.pone.0066825	http://dx.doi.org/10.1371/journal.pone.0066825			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	164VY	23762498	Green Submitted, gold, Green Published			2023-01-03	WOS:000320440500071
J	Guerin, C; Reignier, J; Richard, JC; Beuret, P; Gacouin, A; Boulain, T; Mercier, E; Badet, M; Mercat, A; Baudin, O; Clavel, M; Chatellier, D; Jaber, S; Rosselli, S; Mancebo, J; Sirodot, M; Hilbert, G; Bengler, C; Richecoeur, J; Gainnier, M; Bayle, F; Bourdin, G; Leray, V; Girard, R; Baboi, L; Ayzac, L				Guerin, Claude; Reignier, Jean; Richard, Jean-Christophe; Beuret, Pascal; Gacouin, Arnaud; Boulain, Thierry; Mercier, Emmanuelle; Badet, Michel; Mercat, Alain; Baudin, Olivier; Clavel, Marc; Chatellier, Delphine; Jaber, Samir; Rosselli, Sylvene; Mancebo, Jordi; Sirodot, Michel; Hilbert, Gilles; Bengler, Christian; Richecoeur, Jack; Gainnier, Marc; Bayle, Frederique; Bourdin, Gael; Leray, Veronique; Girard, Raphaele; Baboi, Loredana; Ayzac, Louis		PROSEVA Study Grp	Prone Positioning in Severe Acute Respiratory Distress Syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LUNG INJURY; RANDOMIZED CONTROLLED-TRIAL; VENTILATION; FAILURE; METAANALYSIS; RECRUITMENT; MULTICENTER; DEFINITION; PHYSIOLOGY; SURVIVAL	Background Previous trials involving patients with the acute respiratory distress syndrome (ARDS) have failed to show a beneficial effect of prone positioning during mechanical ventilatory support on outcomes. We evaluated the effect of early application of prone positioning on outcomes in patients with severe ARDS. Methods In this multicenter, prospective, randomized, controlled trial, we randomly assigned 466 patients with severe ARDS to undergo prone-positioning sessions of at least 16 hours or to be left in the supine position. Severe ARDS was defined as a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (Fio(2)) of less than 150 mm Hg, with an Fio(2) of at least 0.6, a positive end-expiratory pressure of at least 5 cm of water, and a tidal volume close to 6 ml per kilogram of predicted body weight. The primary outcome was the proportion of patients who died from any cause within 28 days after inclusion. Results A total of 237 patients were assigned to the prone group, and 229 patients were assigned to the supine group. The 28-day mortality was 16.0% in the prone group and 32.8% in the supine group (P<0.001). The hazard ratio for death with prone positioning was 0.39 (95% confidence interval [CI], 0.25 to 0.63). Unadjusted 90-day mortality was 23.6% in the prone group versus 41.0% in the supine group (P<0.001), with a hazard ratio of 0.44 (95% CI, 0.29 to 0.67). The incidence of complications did not differ significantly between the groups, except for the incidence of cardiac arrests, which was higher in the supine group. Conclusions In patients with severe ARDS, early application of prolonged prone-positioning sessions significantly decreased 28-day and 90-day mortality.	[Guerin, Claude; Richard, Jean-Christophe; Bayle, Frederique; Bourdin, Gael; Leray, Veronique; Baboi, Loredana] Hop Croix Rousse, Serv Reanimat Med, F-69004 Lyon, France; [Guerin, Claude; Richard, Jean-Christophe; Bayle, Frederique; Leray, Veronique; Baboi, Loredana] Univ Lyon, Lyon, France; [Guerin, Claude; Richard, Jean-Christophe; Bayle, Frederique; Bourdin, Gael; Leray, Veronique; Baboi, Loredana] Creatis INSERM 1044, Lyon, France; [Reignier, Jean] CRICS Grp, La Roche Sur Yon, France; [Gacouin, Arnaud] Hop Pontchaillou, Rennes, France; [Boulain, Thierry] Hop Orleans, CRICS Grp, Orleans, France; [Mercier, Emmanuelle] Hop Bretonneau, Tours, France; [Mercier, Emmanuelle] Univ Tours, Tours, France; [Badet, Michel] Hop Chambery, Chambery, France; [Mercat, Alain] Univ Angers, CHU Angers, Univ Nantes Angers Le Mans, Angers, France; [Baudin, Olivier] Hop Angouleme, CRICS Grp, Angouleme, France; [Clavel, Marc] Hop Limoges, Reanimat Polyvalente Ctr, Invest Clin 0801, Limoges, France; [Clavel, Marc] Hosp Civils Lyon, CRICS Grp, Lyon, France; [Chatellier, Delphine] Hop Poitiers, Poitiers, France; [Chatellier, Delphine] CRICS Grp, Poitiers, France; [Chatellier, Delphine] Univ Poitiers, Poitiers, France; [Jaber, Samir] Hop St Eloi, INSERM, U1046, Montpellier, France; [Jaber, Samir] Univ Montpellier, F-34059 Montpellier, France; [Rosselli, Sylvene] Hop St Joseph & St Luc, Lyon, France; [Sirodot, Michel] Hop Annecy, Annecy, France; [Hilbert, Gilles] Hop Pellegrin, F-33076 Bordeaux, France; [Hilbert, Gilles] Univ Bordeaux, Bordeaux, France; [Bengler, Christian] Hop Nimes, Nimes, France; [Bengler, Christian] Univ Nimes Montpellier, Nimes, France; [Richecoeur, Jack] Hop Cergy Pontoise, Cergy Pontoise, France; [Gainnier, Marc] Hop La Timone, Marseille, France; [Gainnier, Marc] Univ Aix Marseille 2, Marseille, France; [Girard, Raphaele] Hosp Civils Lyon, Grp Hosp Lyon Sud, Serv Hyg Hosp, Pierre Benite, France; [Baboi, Loredana] Hop Henri Gabrielle, Ctr Coordinat & Lutte Contre Infect Nosocomiales, St Genis Laval, France; [Mancebo, Jordi] Hosp Santa Creu & Sant Pau, Serv Med Intens, Barcelona, Spain	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Rennes; Centre Hospitalier Regional d'Orleans; CHU Tours; Universite de Tours; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Limoges; CHU Lyon; CHU Poitiers; Universite de Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Centre Hospitalier Annecy Genevois; CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Universite de Montpellier; CHU de Nimes; Centre Hospitalier Rene Dubos, Pontoise; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Aix-Marseille Universite; CHU Lyon; CHU Lyon; Hospital of Santa Creu i Sant Pau	Guerin, C (corresponding author), Hop Croix Rousse, Serv Reanimat Med, 103 Grande Rue Croix Rousse, F-69004 Lyon, France.	claude.guerin@chu-lyon.fr	Boulain, Thierry/M-3309-2019; guerin, claude/H-5692-2014; Chiche, Jean-Daniel/P-5220-2017; Mercat, Alain/AFU-4426-2022; RICHARD, Jean-Christophe/A-4097-2009	Boulain, Thierry/0000-0003-4664-3661; guerin, claude/0000-0003-4700-6672; Chiche, Jean-Daniel/0000-0002-6433-6254; RICHARD, Jean-Christophe/0000-0003-1503-3035; GAINNIER, Marc/0000-0002-5353-9275; Johnston, Andrew McDonald/0000-0002-0220-0589; wallet, florent/0000-0003-3174-6246; BISBAL, MAGALI/0000-0001-6571-0861; Aguirre-Bermeo, Hernan/0000-0001-7205-7020	French Ministry of Health	French Ministry of Health	Funded by the Programme Hospitalier de Recherche Clinique National 2006 and 2010 of the French Ministry of Health; PROSEVA ClinicalTrials.gov number, NCT00527813.)	Abroug F, 2008, INTENS CARE MED, V34, P1002, DOI 10.1007/s00134-008-1062-3; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Broccard A, 2000, CRIT CARE MED, V28, P295, DOI 10.1097/00003246-200002000-00001; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Charron C, 2011, INTENS CARE MED, V37, P785, DOI 10.1007/s00134-011-2180-x; Ferguson ND, 2013, NEW ENGL J MED, V368, P795, DOI 10.1056/NEJMoa1215554; Galiatsou E, 2006, AM J RESP CRIT CARE, V174, P187, DOI 10.1164/rccm.200506-899OC; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gattinoni L, 2010, MINERVA ANESTESIOL, V76, P448; Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Mancebo J, 2006, AM J RESP CRIT CARE, V173, P1233, DOI 10.1164/rccm.200503-353OC; MCCABE WR, 1983, AM J MED, V75, P7, DOI 10.1016/0002-9343(83)90067-0; Mentzelopoulos SD, 2005, EUR RESPIR J, V25, P534, DOI 10.1183/09031936.05.00105804; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; MUTOH T, 1992, AM REV RESPIR DIS, V146, P300, DOI 10.1164/ajrccm/146.2.300; Papazian L, 2005, CRIT CARE MED, V33, P2162, DOI 10.1097/01.CCM.0000181298.05474.2B; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Sud S, 2010, INTENS CARE MED, V36, P585, DOI 10.1007/s00134-009-1748-1; Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614; Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	26	1994	2136	7	144	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 6	2013	368	23					2159	2168		10.1056/NEJMoa1214103	http://dx.doi.org/10.1056/NEJMoa1214103			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	158DN	23688302				2023-01-03	WOS:000319948900004
J	Izuma, K; Adolphs, R				Izuma, Keise; Adolphs, Ralph			Social Manipulation of Preference in the Human Brain	NEURON			English	Article							ANTERIOR CINGULATE CORTEX; MEDIAL FRONTAL-CORTEX; MULTISOURCE INTERFERENCE TASK; ERROR-RELATED NEGATIVITY; COGNITIVE-DISSONANCE; DECISION-MAKING; ATTITUDE-CHANGE; NEURAL SYSTEM; REWARD; FMRI	Our preferences are influenced by what other people like, but depend critically on how we feel about those people, a classical psychological effect called "cognitive balance." Here, we manipulated preferences for goods by telling participants the preferences of strongly liked or disliked groups of other people. Participants' preferences converged to those of the liked group, but diverged from the disliked group. Activation of dorsomedial prefrontal cortex (dmPFC) tracked the discrepancy between one's own preference and its social ideal and was associated with subsequent preference change (toward the liked and away from the disliked group), even several months later. A follow-up study found overlapping activation in this same region of dmPFC with negative monetary outcomes, but no overlap with nearby activations induced by response conflict. A single social encounter can thus result in long-lasting preference change, a mechanism that recruits dmPFC and that may reflect the aversive nature of cognitive imbalance.	[Izuma, Keise; Adolphs, Ralph] CALTECH, Div Humanities & Social Sci, Pasadena, CA 91125 USA	California Institute of Technology	Izuma, K (corresponding author), CALTECH, Div Humanities & Social Sci, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	izuma@caltech.edu			Japan Society for the Promotion of Science Fellows; National Science Foundation; National Institute of Mental Health; Gordon and Betty Moore Foundation; Tamagawa University Global Centers of Excellence grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH094258] Funding Source: NIH RePORTER; Direct For Biological Sciences [0922982] Funding Source: National Science Foundation	Japan Society for the Promotion of Science Fellows(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Science Foundation(National Science Foundation (NSF)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); Tamagawa University Global Centers of Excellence grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Direct For Biological Sciences(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	We thank John P. O'Doherty and Dan Kennedy for helpful comments on the manuscript, and the staff of the Caltech Brain Imaging Center for their assistance in conducting the fMRI. This work was funded by the Japan Society for the Promotion of Science Fellows (K.I.), as well as the National Science Foundation, a Conte Center grant from the National Institute of Mental Health, the Gordon and Betty Moore Foundation, and the Tamagawa University Global Centers of Excellence grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (R.A.).	Abelson R.P., 1968, THEORIES COGNITIVE C; Berns GS, 2010, NEUROIMAGE, V49, P2687, DOI 10.1016/j.neuroimage.2009.10.070; Botvinick MM, 2007, COGN AFFECT BEHAV NE, V7, P356, DOI 10.3758/CABN.7.4.356; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Bush G, 2003, MOL PSYCHIATR, V8, P60, DOI 10.1038/sj.mp.4001217; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Bush G, 2006, NAT PROTOC, V1, P308, DOI 10.1038/nprot.2006.48; Campbell-Meiklejohn DK, 2012, NEUROPSYCHOPHARMACOL, V37, P1517, DOI 10.1038/npp.2011.337; Campbell-Meiklejohn DK, 2012, CURR BIOL, V22, pR123, DOI 10.1016/j.cub.2012.01.012; Campbell-Meiklejohn DK, 2010, CURR BIOL, V20, P1165, DOI 10.1016/j.cub.2010.04.055; Cialdini RB, 2004, ANNU REV PSYCHOL, V55, P591, DOI 10.1146/annurev.psych.55.090902.142015; Eisenberger NI, 2004, TRENDS COGN SCI, V8, P294, DOI 10.1016/j.tics.2004.05.010; Esterman M, 2010, NEUROIMAGE, V50, P572, DOI 10.1016/j.neuroimage.2009.10.092; Etkin A, 2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Festinger L., 1957, COGNITIVE DISSONANCE; Friston KJ, 2005, NEUROIMAGE, V25, P661, DOI 10.1016/j.neuroimage.2005.01.013; Gawronski B, 2012, SOC COGNITION, V30, P652, DOI 10.1521/soco.2012.30.6.652; Greenwald AG, 2002, PSYCHOL REV, V109, P3, DOI 10.1037/0033-295X.109.1.3; Harmon-Jones E, 2004, BIOL PSYCHOL, V67, P51, DOI 10.1016/j.biopsycho.2004.03.003; Hayden BY, 2011, J NEUROSCI, V31, P4178, DOI 10.1523/JNEUROSCI.4652-10.2011; Heider F., 1958, PSYCHOL INTERPERSONA, DOI [DOI 10.1037/10628-004, DOI 10.1037/14200-000]; Heider F, 1946, J PSYCHOL, V21, P107, DOI 10.1080/00223980.1946.9917275; Henson R, 2006, TRENDS COGN SCI, V10, P64, DOI 10.1016/j.tics.2005.12.005; Hikosaka O, 2010, TRENDS COGN SCI, V14, P154, DOI 10.1016/j.tics.2010.01.006; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; INSKO CA, 1984, ADV EXP SOC PSYCHOL, V18, P89, DOI 10.1016/S0065-2601(08)60143-4; Izuma K, 2010, P NATL ACAD SCI USA, V107, P22014, DOI 10.1073/pnas.1011879108; Jocham G, 2009, J NEUROSCI, V29, P7489, DOI 10.1523/JNEUROSCI.0349-09.2009; Klucharev V, 2011, J NEUROSCI, V31, P11934, DOI 10.1523/JNEUROSCI.1869-11.2011; Klucharev V, 2009, NEURON, V61, P140, DOI 10.1016/j.neuron.2008.11.027; Knutson B, 2000, NEUROIMAGE, V12, P20, DOI 10.1006/nimg.2000.0593; Kruglanski ArieW., 2012, COGNITIVE CONSISTENC; Miltner WHR, 1997, J COGNITIVE NEUROSCI, V9, P788, DOI 10.1162/jocn.1997.9.6.788; Nichols T, 2005, NEUROIMAGE, V25, P653, DOI 10.1016/j.neuroimage.2004.12.005; O'Doherty J, 2003, J NEUROSCI, V23, P7931; Ochsner KN, 2008, CURR DIR PSYCHOL SCI, V17, P153, DOI 10.1111/j.1467-8721.2008.00566.x; Ochsner KN, 2004, J COGNITIVE NEUROSCI, V16, P1746, DOI 10.1162/0898929042947829; OSGOOD CE, 1955, PSYCHOL REV, V62, P42, DOI 10.1037/h0048153; Poldrack RA, 2011, NEURON, V72, P692, DOI 10.1016/j.neuron.2011.11.001; Proulx T, 2012, TRENDS COGN SCI, V16, P285, DOI 10.1016/j.tics.2012.04.002; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Rushworth MFS, 2004, TRENDS COGN SCI, V8, P410, DOI 10.1016/j.tics.2004.07.009; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994; Sharot T, 2011, NAT NEUROSCI, V14, P1475, DOI 10.1038/nn.2949; Shima K, 1998, SCIENCE, V282, P1335, DOI 10.1126/science.282.5392.1335; Somerville LH, 2006, NAT NEUROSCI, V9, P1007, DOI 10.1038/nn1728; Ullsperger M, 2004, TRENDS COGN SCI, V8, P445, DOI 10.1016/j.tics.2004.08.013; Ullsperger M, 2003, J NEUROSCI, V23, P4308, DOI 10.1523/jneurosci.23-10-04308.2003; van Veen V, 2009, NAT NEUROSCI, V12, P1469, DOI 10.1038/nn.2413; Walther E., 2012, COGNITIVE CONSISTENC, P351; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI 10.1037/0033-295x.111.4.931; Zajonc R.B., 1968, HDB SOCIAL PSYCHOL, P320; Zaki J, 2011, PSYCHOL SCI, V22, P894, DOI 10.1177/0956797611411057	56	121	123	0	55	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0896-6273			NEURON	Neuron	MAY 8	2013	78	3					563	573		10.1016/j.neuron.2013.03.023	http://dx.doi.org/10.1016/j.neuron.2013.03.023			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	144SW	23664619	Green Accepted, Bronze			2023-01-03	WOS:000318961700017
J	Das, H; Wang, ZH; Niazi, MKK; Aggarwal, R; Lu, JW; Kanji, S; Das, M; Joseph, M; Gurcan, M; Cristini, V				Das, Hiranmoy; Wang, Zhihui; Niazi, M. Khalid Khan; Aggarwal, Reeva; Lu, Jingwei; Kanji, Suman; Das, Manjusri; Joseph, Matthew; Gurcan, Metin; Cristini, Vittorio			Impact of Diffusion Barriers to Small Cytotoxic Molecules on the Efficacy of Immunotherapy in Breast Cancer	PLOS ONE			English	Article							GAMMA-DELTA-EXPRESSION; T-CELLS; IFN-GAMMA; LYMPHOCYTES; RECEPTOR; DEATH; MICROENVIRONMENT; RECOGNITION; ACTIVATION; EVOLUTION	Molecular-focused cancer therapies, e. g., molecularly targeted therapy and immunotherapy, so far demonstrate only limited efficacy in cancer patients. We hypothesize that underestimating the role of biophysical factors that impact the delivery of drugs or cytotoxic cells to the target sites (for associated preferential cytotoxicity or cell signaling modulation) may be responsible for the poor clinical outcome. Therefore, instead of focusing exclusively on the investigation of molecular mechanisms in cancer cells, convection-diffusion of cytotoxic molecules and migration of cancer-killing cells within tumor tissue should be taken into account to improve therapeutic effectiveness. To test this hypothesis, we have developed a mathematical model of the interstitial diffusion and uptake of small cytotoxic molecules secreted by T-cells, which is capable of predicting breast cancer growth inhibition as measured both in vitro and in vivo. Our analysis shows that diffusion barriers of cytotoxic molecules conspire with gamma delta T-cell scarcity in tissue to limit the inhibitory effects of gamma delta T-cells on cancer cells. This may increase the necessary ratios of gamma delta T-cells to cancer cells within tissue to unrealistic values for having an intended therapeutic effect, and decrease the effectiveness of the immunotherapeutic treatment.	[Das, Hiranmoy; Aggarwal, Reeva; Lu, Jingwei; Kanji, Suman; Das, Manjusri; Joseph, Matthew] Ohio State Univ, Dept Med, Wexner Med Ctr, Columbus, OH 43210 USA; [Wang, Zhihui; Cristini, Vittorio] Univ New Mexico, Dept Pathol, Albuquerque, NM 87131 USA; [Niazi, M. Khalid Khan; Gurcan, Metin] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; [Cristini, Vittorio] Univ New Mexico, Dept Chem Engn, Albuquerque, NM 87131 USA; [Cristini, Vittorio] Univ New Mexico, Ctr Biomed Engn, Albuquerque, NM 87131 USA	University System of Ohio; Ohio State University; University of New Mexico; University System of Ohio; Ohio State University; University of New Mexico; University of New Mexico	Das, H (corresponding author), Ohio State Univ, Dept Med, Wexner Med Ctr, Columbus, OH 43210 USA.	hiranmoy.das@osumc.edu; metin.gurcan@osumc.edu; vcristini@salud.unm.edu	Wang, Zhihui/B-2464-2009; Gurcan, Metin/F-4536-2012; Cristini, Vittorio/N-3540-2013; Das, Hiranmoy/R-7452-2019	Wang, Zhihui/0000-0001-6262-700X; Gurcan, Metin/0000-0002-2421-8229; Cristini, Vittorio/0000-0002-7909-4278; Das, Hiranmoy/0000-0002-3343-0096	National Cancer Institute [CTO PSOC - 1U54CA143837, TCCN - 1U54CA151668, USC PSOC - 1U54CA143907, ICBP - 1U54CA149196]; National Institutes of Health [K01 AR054114, SBIR R44 HL092706-01]; Ohio State University; NCI [R01CA134451]; NATIONAL CANCER INSTITUTE [U54CA149196, U54CA143907, R01CA134451, U54CA143837, U54CA151668] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL092706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR054114] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ohio State University(Ohio State University); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	VC and ZW were supported by National Cancer Institute grants: CTO PSOC - 1U54CA143837, TCCN - 1U54CA151668, USC PSOC - 1U54CA143907, and ICBP - 1U54CA149196. VC also acknowledges the Surface Family Professorship. HD was supported by National Institutes of Health grants, K01 AR054114 (NIAMS), SBIR R44 HL092706-01 (NHLBI), and The Ohio State University start-up fund. MG was supported by R01CA134451 from the NCI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALAM SM, 1992, IMMUNOL LETT, V31, P279, DOI 10.1016/0165-2478(92)90127-A; Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042; Arya SK, 2012, LAB CHIP, V12, P2362, DOI 10.1039/c2lc21174b; Bagri A, 2010, CLIN CANCER RES, V16, P3887, DOI 10.1158/1078-0432.CCR-09-3100; BANK I, 1993, CLIN IMMUNOL IMMUNOP, V67, P17, DOI 10.1006/clin.1993.1040; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; Brown CE, 2007, J IMMUNOL, V179, P3332, DOI 10.4049/jimmunol.179.5.3332; Bukowski JF, 1999, IMMUNITY, V11, P57, DOI 10.1016/S1074-7613(00)80081-3; Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; Das H, 2004, J IMMUNOL, V172, P6578, DOI 10.4049/jimmunol.172.11.6578; Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Elden L, 2008, SIAM REV, V50, P154; FERRARINI M, 1995, J IMMUNOL, V154, P3704; Frieboes HB, 2006, CANCER RES, V66, P1597, DOI 10.1158/0008-5472.CAN-05-3166; Frieboes HB, 2009, CANCER RES, V69, P4484, DOI 10.1158/0008-5472.CAN-08-3740; Gurcan Metin N, 2009, IEEE Rev Biomed Eng, V2, P147, DOI 10.1109/RBME.2009.2034865; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Jackson TL, 2003, J THEOR BIOL, V220, P201, DOI 10.1006/jtbi.2003.3156; Jain R, 1999, IEEE MULTIMEDIA, V6, P1, DOI 10.1109/MMUL.1999.809225; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kabelitz D, 2004, INT J CANCER, V112, P727, DOI 10.1002/ijc.20445; KAPUR JN, 1985, COMPUT VISION GRAPH, V29, P273, DOI 10.1016/0734-189X(85)90125-2; Lee HO, 2011, CANCER RES, V71, P6327, DOI 10.1158/0008-5472.CAN-11-0304; Lu JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023348; Macklin P, 2009, J MATH BIOL, V58, P765, DOI 10.1007/s00285-008-0216-9; MELDER RJ, 1988, CANCER RES, V48, P3461; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002; Owen MR, 2009, J MATH BIOL, V58, P689, DOI 10.1007/s00285-008-0213-z; Raspollini MR, 2005, ANN ONCOL, V16, P590, DOI 10.1093/annonc/mdi112; ROBERTSON AR, 1990, COLOR RES APPL, V15, P167, DOI 10.1002/col.5080150308; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; Shin S, 2005, SCIENCE, V308, P252, DOI 10.1126/science.1106480; Sinek JP, 2009, J MATH BIOL, V58, P485, DOI 10.1007/s00285-008-0214-y; Wang LS, 2001, J IMMUNOL, V167, P6195, DOI 10.4049/jimmunol.167.11.6195; Wang LS, 2001, J CLIN INVEST, V108, P1349, DOI 10.1172/JCI13584; Wang Z, 2010, MATH MED BIOL; Wang Z, 2011, FRONTIERS C IN PRESS; Wang ZH, 2009, BIOINFORMATICS, V25, P2389, DOI 10.1093/bioinformatics/btp416; WATANABE N, 1995, CLIN EXP IMMUNOL, V102, P167	45	28	28	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2013	8	4							e61398	10.1371/journal.pone.0061398	http://dx.doi.org/10.1371/journal.pone.0061398			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JA	23620747	Green Published, gold, Green Submitted			2023-01-03	WOS:000317909500027
J	Pathania, S; Randhawa, V; Bagler, G				Pathania, Shivalika; Randhawa, Vinay; Bagler, Ganesh			Prospecting for Novel Plant-Derived Molecules of Rauvolfia serpentina as Inhibitors of Aldose Reductase, a Potent Drug Target for Diabetes and Its Complications	PLOS ONE			English	Article							RAUWOLFIA-SERPENTINA; DOCKING; DYNAMICS; DISCOVERY; DATABASE; OPTIMIZATION; SIMULATIONS; EPALRESTAT; NEUROPATHY; DESIGN	Aldose Reductase (AR) is implicated in the development of secondary complications of diabetes, providing an interesting target for therapeutic intervention. Extracts of Rauvolfia serpentina, a medicinal plant endemic to the Himalayan mountain range, have been known to be effective in alleviating diabetes and its complications. In this study, we aim to prospect for novel plant-derived inhibitors from R. serpentina and to understand structural basis of their interactions. An extensive library of R. serpentina molecules was compiled and computationally screened for inhibitory action against AR. The stability of complexes, with docked leads, was verified using molecular dynamics simulations. Two structurally distinct plant-derived leads were identified as inhibitors: indobine and indobinine. Further, using these two leads as templates, 16 more leads were identified through ligand-based screening of their structural analogs, from a small molecules database. Thus, we obtained plant-derived indole alkaloids, and their structural analogs, as potential AR inhibitors from a manually curated dataset of R. serpentina molecules. Indole alkaloids reported herein, as a novel structural class unreported hitherto, may provide better insights for designing potential AR inhibitors with improved efficacy and fewer side effects.	[Pathania, Shivalika; Randhawa, Vinay; Bagler, Ganesh] CSIR, Inst Himalayan Bioresource Technol, Div Biotechnol, Palampur, Himachal Prades, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Himalayan Bioresource Technology (IHBT)	Bagler, G (corresponding author), CSIR, Inst Himalayan Bioresource Technol, Div Biotechnol, Palampur, Himachal Prades, India.	bagler@ihbt.res.in	; Bagler, Ganesh/A-1102-2009	Randhawa, Vinay/0000-0002-5070-6218; Bagler, Ganesh/0000-0003-1924-6070				Akileshwari C, 2012, EXP DIABETES RES, DOI 10.1155/2012/147965; Alexiou P, 2009, CURR MED CHEM, V16, P734, DOI 10.2174/092986709787458362; Alonso H, 2006, MED RES REV, V26, P531, DOI 10.1002/med.20067; [Anonymous], 2012, DATABASE ANTIDIABETI; Azmi MB, 2012, J FOOD DRUG ANAL, V20, P484, DOI 10.6227/jfda.2012200208; Barnes EC, 2012, ORG BIOMOL CHEM, V10, P4015, DOI 10.1039/c2ob00029f; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI 10.1007/978-94-015-7658-1_21; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Buckingham J., 2011, DICT NATURAL PRODUCT; Cereto-Massague A, 2012, BIOINFORMATICS, V28, P1661, DOI 10.1093/bioinformatics/bts249; Cole JC, 2005, PROTEINS, V60, P325, DOI 10.1002/prot.20497; Cordell G. A., 1998, ALKALOIDS; Costantino L, 2002, BIOORGAN MED CHEM, V10, P3923, DOI 10.1016/S0968-0896(02)00318-8; Costantino L, 1999, AID MED2 3 0 CO, P2; Dey A, 2011, J MED PLANTS RES, V5, P144; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Foppiano M, 1997, LANCET, V349, P399, DOI 10.1016/S0140-6736(97)80018-9; Giannoukakis Nick, 2003, Curr Opin Investig Drugs, V4, P1233; GOOD A. C., 1996, REV COMPUTATIONAL CH, P67, DOI [DOI 10.1002/9780470125847.CH2, 10.1002/9780470125847]; Haider SI, 1986, EXTENDED STUDIES ALK; Hess B, 1997, AID JCC4 3 0 CO, P2; Hotta N, 1996, J DIABETES COMPLICAT, V10, P168, DOI 10.1016/1056-8727(96)00113-4; Howard EI, 2004, PROTEINS, V55, P792, DOI 10.1002/prot.20015; Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356; Hung HY, 2012, NAT PROD REP, V29, P580, DOI 10.1039/c2np00074a; INDIA HERBS, 2002, CARD SYST SUPP; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; KADOR PF, 1985, J MED CHEM, V28, P841, DOI 10.1021/jm00145a001; KINOSHITA JH, 1990, EXP EYE RES, V50, P567, DOI 10.1016/0014-4835(90)90096-D; Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549; Kraemer O, 2004, PROTEINS, V55, P814, DOI 10.1002/prot.20057; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Lengauer T, 2004, DRUG DISCOV TODAY, V9, P27, DOI 10.1016/S1359-6446(04)02939-3; Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6; Logendra S, 2006, PHYTOCHEMISTRY, V67, P1539, DOI 10.1016/j.phytochem.2006.05.015; Manske R.H.F., 1965, ALKALOIDS CHEM PHYSL; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24; Naeem S, 2012, BIOORGAN MED CHEM, V20, P1251, DOI 10.1016/j.bmc.2011.12.033; Nikolova N, 2004, QSAR COMB SCI, V22, P1006, DOI 10.1002/qsar.200330831; O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33; Oates PJ, 2008, CURR DRUG TARGETS, V9, P14, DOI 10.2174/138945008783431781; Pant KK, 2008, SCI WORLD, V6, P58, DOI DOI 10.3126/SW.V6I6.2635; Puppala M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031399; Qiu LX, 2012, EXP DIABETES RES, DOI 10.1155/2012/789730; Qureshi SA, 2009, INT J PHARMACOL, V5, P323, DOI 10.3923/ijp.2009.323.326; Ramunno A, 2012, EUR J MED CHEM, V51, P216, DOI 10.1016/j.ejmech.2012.02.045; Randhawa V, 2012, OMICS, V16, P513, DOI 10.1089/omi.2011.0160; Rastelli G, 2002, BIOORGAN MED CHEM, V10, P1437, DOI 10.1016/S0968-0896(01)00410-2; Rodrigo R, 1965, ALKALOIDS CHEM PHYSL; Rosen J, 2009, J MED CHEM, V52, P1953, DOI 10.1021/jm801514w; Sakkiah S, 2012, J MOL MODEL, V18, P3267, DOI 10.1007/s00894-011-1247-5; Saraswat M, 2008, ASIA PAC J CLIN NUTR, V17, P558; Schemmel KE, 2010, J DIABETES COMPLICAT, V24, P354, DOI 10.1016/j.jdiacomp.2009.07.005; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Srivastava SK, 2011, CHEM-BIOL INTERACT, V191, P330, DOI 10.1016/j.cbi.2011.02.023; Srivastava SK, 2005, ENDOCR REV, V26, P380, DOI 10.1210/er.2004-0028; STEELE JW, 1993, DRUG AGING, V3, P532, DOI 10.2165/00002512-199303060-00007; Tang WH, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00087; Triballeau N, 2005, J MED CHEM, V48, P2534, DOI 10.1021/jm049092j; Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334; van Dieren S, 2010, EUR J CARDIOV PREV R, V17, pS3, DOI 10.1097/01.hjr.0000368191.86614.5a; Villacanas O, 2002, J BIOMOL STRUCT DYN, V20, P347, DOI 10.1080/07391102.2002.10506853; Wang ZG, 2009, J MOL GRAPH MODEL, V28, P162, DOI 10.1016/j.jmgm.2009.06.003; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Xie HZ, 2009, BIOORG MED CHEM LETT, V19, P1944, DOI 10.1016/j.bmcl.2009.02.049; Yabe-Nishimura C, 1998, PHARMACOL REV, V50, P21; Yap BK, 2012, J MOL MODEL, V18, P3639, DOI 10.1007/s00894-012-1368-5; Zaidi SSA, 1986, STUDIES ALKALOIDAL C	73	34	35	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 17	2013	8	4							e61327	10.1371/journal.pone.0061327	http://dx.doi.org/10.1371/journal.pone.0061327			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130IK	23613832	Green Published, gold, Green Submitted			2023-01-03	WOS:000317907200047
J	Famm, K; Litt, B; Tracey, KJ; Boyden, ES; Slaoui, M				Famm, Kristoffer; Litt, Brian; Tracey, Kevin J.; Boyden, Edward S.; Slaoui, Moncef			A jump-start for electroceuticals	NATURE			English	Editorial Material									[Famm, Kristoffer] GlaxoSmithKline, Bioelect Res & Dev, Brentford TW8 9GS, England	GlaxoSmithKline	Famm, K (corresponding author), GlaxoSmithKline, Bioelect Res & Dev, Brentford TW8 9GS, England.	kristoffer.h.famm@gsk.com		Tracey, Kevin J/0000-0003-1884-6314	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048598, U24NS063930] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057226] Funding Source: Medline; NINDS NIH HHS [R01 NS048598, U24 NS063930] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alivisatos AP, 2013, ACS NANO, V7, P1850, DOI 10.1021/nn4012847; Andersson U, 2012, J EXP MED, V209, P1057, DOI 10.1084/jem.20120571; Aponte Y, 2011, NAT NEUROSCI, V14, P351, DOI 10.1038/nn.2739; Chow BY, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3003101; Huber D, 2008, NATURE, V451, P61, DOI 10.1038/nature06445; Kandel E.R., 2012, PRINCIPLES NEURAL SC, VFifth; Kodandaramaiah SB, 2012, NAT METHODS, V9, P585, DOI [10.1038/NMETH.1993, 10.1038/nmeth.1993]; KOOPMAN FA, 2012, ARTHRITIS RHEUM S, V64; Rapoport BI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042492; Wang ZL, 2012, ANGEW CHEM INT EDIT, V51, P11700, DOI 10.1002/anie.201201656	10	340	351	3	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	2013	496	7444					159	161		10.1038/496159a	http://dx.doi.org/10.1038/496159a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	122VM	23579662	Green Accepted, Green Submitted			2023-01-03	WOS:000317346300017
J	Wang, W; Gu, F; Wei, C; Tang, YG; Zheng, X; Ren, MQ; Qin, YD				Wang, Wei; Gu, Fang; Wei, Cai; Tang, Yigui; Zheng, Xin; Ren, Mingqiang; Qin, Yide			PGPIPN, a Therapeutic Hexapeptide, Suppressed Human Ovarian Cancer Growth by Targeting BCL2	PLOS ONE			English	Article							MILK PROTEIN; BETA-CASEIN; BINDING-SITES; PEPTIDES; APOPTOSIS; CELLS; LACTOFERRIN; INHIBITION	Bioactive peptides, either derived from nature resources or synthesized by rational design, have been demonstrated potential for therapeutic agents against numerous human diseases, including cancer. However, the mechanism of therapeutic peptides against cancer has not been well elucidated. Here we show that PGPIPN, a hexapeptide derived from bovine beta-casein, inhibited the proliferation of human ovarian cancer cells line SKOV3 as well as the primary ovarian cancer cells in vitro. Consistently, PGPIPIN also decreased tumor growth rate in xenograft ovarian cancer model mice in a dose-dependent manner. Further study demonstrated that the anti-tumor effect of PGPIPN is partially through promoting cell apoptosis by inhibiting BCL2 pathway. Thus, our study suggests that PGPIPN is a potential therapeutic agent for the treatment of ovarian cancer or other types of cancer.	[Wang, Wei; Gu, Fang; Wei, Cai; Tang, Yigui; Zheng, Xin; Ren, Mingqiang; Qin, Yide] Anhui Med Univ, Dept Biochem & Mol Biol, Hefei, Anhui, Peoples R China; [Ren, Mingqiang] Georgia Hlth Sci Univ, Ctr Canc, Augusta, GA USA	Anhui Medical University; University System of Georgia; Augusta University	Qin, YD (corresponding author), Anhui Med Univ, Dept Biochem & Mol Biol, Hefei, Anhui, Peoples R China.	yideqin@hotmail.com			National Natural Science Foundation of China [30872992]; Province Natural Science Foundation of Anhui [03043802]; National Natural Science Foundation of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Province Natural Science Foundation of Anhui; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (30872992) and the Province Natural Science Foundation of Anhui (03043802). The 300000 RMB was granted for this research by the National Natural Science Foundation of China, the URL of which is http://www.nsfc.gov.cn. The Province Natural Science Foundation of Anhui funded 100000 RMB for the study. The funders had role in study design, experiments, data collection and analysis, preparation of the manuscript.	Almansour NM, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-65; Bishop EF, 2007, MODERN PATHOL, V20, P1036, DOI 10.1038/modpathol.3800933; Brix S, 2005, J DAIRY RES, V72, P217, DOI 10.1017/S0022029905000877; Cheok CF, 2012, DISCOV MED, V14, P263; Chronopoulou R, 2006, BRIT J NUTR, V96, P553, DOI 10.1079/BJN20061834; Dong Hua-sheng, 2007, Chinese Pharmacological Bulletin, V23, P73; Fiedorowicz E, 2011, PEPTIDES, V32, P707, DOI 10.1016/j.peptides.2010.12.003; Gill HS, 2000, BRIT J NUTR, V84, pS111; Gu Fang, 2006, Acta Nutrimenta Sinica, V28, P326; Istivan TS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024809; JAZIRI M, 1992, BIOCHIM BIOPHYS ACTA, V1160, P251, DOI 10.1016/0167-4838(92)90085-R; Jiang B, 1999, BASIS CLIN CELL APOP; Kannan A, 2011, J SCI FOOD AGR, V91, P1920, DOI 10.1002/jsfa.4464; Kanwar JR, 2009, CURR PROTEIN PEPT SC, V10, P308, DOI 10.2174/138920309788922234; Kitazawa H, 2007, INT IMMUNOPHARMACOL, V7, P1150, DOI 10.1016/j.intimp.2007.04.008; Kreider RB, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-99; Li DP, 2011, ANTICANCER RES, V31, P529; Li JT, 2013, FOOD CHEM TOXICOL, V51, P297, DOI 10.1016/j.fct.2012.09.038; Li SP, 2005, ACTA U MED ANHUI, V40, P499; Mader JS, 2006, AM J PATHOL, V169, P1753, DOI 10.2353/ajpath.2006.051229; Martinez-Maqueda D, 2012, J AGR FOOD CHEM, V60, P8600, DOI 10.1021/jf301279k; Meisel H, 2003, CURR PHARM DESIGN, V9, P1289, DOI 10.2174/1381612033454847; MIGLIORESAMOUR D, 1989, J DAIRY RES, V56, P357, DOI 10.1017/S0022029900028806; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Urista CM, 2011, FOOD SCI TECHNOL INT, V17, P293, DOI 10.1177/1082013211398801; Nagpal R, 2011, FOOD FUNCT, V2, P18, DOI 10.1039/c0fo00016g; Raucher D, 2009, EXPERT OPIN DRUG DEL, V6, P1049, DOI 10.1517/17425240903158909; Riedl S, 2011, CHEM PHYS LIPIDS, V164, P766, DOI 10.1016/j.chemphyslip.2011.09.004; Saito T, 2008, ADV EXP MED BIOL, V606, P295, DOI 10.1007/978-0-387-74087-4_12; Sambrook J, 2001, MOL CLONING LAB MANU, p[387, 611]; Spadaro M, 2008, FASEB J, V22, P2747, DOI 10.1096/fj.07-098038; Spadaro M, 2007, CANCER RES, V67, P6425, DOI 10.1158/0008-5472.CAN-06-4080; Su LY, 2010, ONCOL REP, V23, P3, DOI 10.3892/or_00000599; Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808; Xiao CW, 2001, J SCI FOOD AGR, V81, P300, DOI 10.1002/1097-0010(200102)81:3&lt;300::AID-JSFA807&gt;3.0.CO;2-D; Xiao Yan, 2007, Ai Zheng, V26, P386; Xue QS, 2003, PRINCIPLE TECHNOLOGY, P343; Yan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024705; Zheng DH, 2012, TRENDS MOL MED, V18, P304, DOI 10.1016/j.molmed.2012.03.006	39	17	18	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2013	8	4							e60701	10.1371/journal.pone.0060701	http://dx.doi.org/10.1371/journal.pone.0060701			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130FG	23593287	Green Published, gold, Green Submitted			2023-01-03	WOS:000317898000053
J	Tomosada, Y; Villena, J; Murata, K; Chiba, E; Shimazu, T; Aso, H; Iwabuchi, N; Xiao, J; Saito, T; Kitazawa, H				Tomosada, Yohsuke; Villena, Julio; Murata, Kozue; Chiba, Eriko; Shimazu, Tomoyuki; Aso, Hisashi; Iwabuchi, Noriyuki; Xiao, Jin-zhong; Saito, Tadao; Kitazawa, Haruki			Immunoregulatory Effect of Bifidobacteria Strains in Porcine Intestinal Epithelial Cells through Modulation of Ubiquitin-Editing Enzyme A20 Expression	PLOS ONE			English	Article							NF-KAPPA-B; NEGATIVE REGULATORS; IMMUNE-RESPONSE; GUT; INFLAMMATION; TOLL-LIKE-RECEPTOR-2; HOMEOSTASIS; ACTIVATION; INHIBITOR; SYSTEM	Background: We previously showed that evaluation of anti-inflammatory activities of lactic acid bacteria in porcine intestinal epithelial (PIE) cells is useful for selecting potentially immunobiotic strains. Objective: The aims of the present study were: i) to select potentially immunomodulatory bifidobacteria that beneficially modulate the Toll-like receptor (TLR)-4-triggered inflammatory response in PIE cells and; ii) to gain insight into the molecular mechanisms involved in the anti-inflammatory effect of immunobiotics by evaluating the role of TLR2 and TLR negative regulators in the modulation of proinflammatory cytokine production and activation of mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-kappa B) pathways in PIE cells. Results: Bifidobacteria longum BB536 and B. breve M-16V strains significantly downregulated levels of interleukin (IL)-8, monocyte chemotactic protein (MCP)-1 and IL-6 in PIE cells challenged with heat-killed enterotoxigenic Escherichia coli. Moreover, BB536 and M-16V strains attenuated the proinflammatory response by modulating the NF-kappa B and MAPK pathways. In addition, our findings provide evidence for a key role for the ubiquitin-editing enzyme A20 in the anti-inflammatory effect of immunobiotic bifidobacteria in PIE cells. Conclusions: We show new data regarding the mechanism involved in the anti-inflammatory effect of immunobiotics. Several strains with immunoregulatory capabilities used a common mechanism to induce tolerance in PIE cells. Immunoregulatory strains interacted with TLR2, upregulated the expression of A20 in PIE cells, and beneficially modulated the subsequent TLR4 activation by reducing the activation of MAPK and NF-kappa B pathways and the production of proinflammatory cytokines. We also show that the combination of TLR2 activation and A20 induction can be used as biomarkers to screen and select potential immunoregulatory bifidobacteria strains.	[Tomosada, Yohsuke; Villena, Julio; Murata, Kozue; Chiba, Eriko; Saito, Tadao; Kitazawa, Haruki] Tohoku Univ, Grad Sch Agr Sci, Food & Feed Immunol Grp, Sendai, Miyagi 980, Japan; [Villena, Julio] Reference Ctr Lactobacilli CERELA CONICET, Lab Clin & Expt Biochem, San Miguel De Tucuman, Argentina; [Shimazu, Tomoyuki] Tohoku Univ, Grad Sch Agr Sci, Lab Anim Breeding & Genet, Sendai, Miyagi 980, Japan; [Aso, Hisashi] Tohoku Univ, Grad Sch Agr Sci, Cell Biol Lab, Sendai, Miyagi 980, Japan; [Iwabuchi, Noriyuki; Xiao, Jin-zhong] Morinaga Milk Ind Co Ltd, Inst Food Sci & Technol, Zama, Kanagawa, Japan	Tohoku University; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Tohoku University; Tohoku University; Morinaga Milk Industry Company, Ltd	Kitazawa, H (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Food & Feed Immunol Grp, Sendai, Miyagi 980, Japan.	haruki@bios.tohoku.ac.jp	Iwabuchi, Noriyuki/H-9139-2019; Xiao, Jinzhong/HIR-9791-2022	Kitazawa, Haruki/0000-0003-4586-5553	Japan Society for the Promotion of Science (JSPS) [21380164, 24380146, 23658216]; Kieikai Research Foundation; Japan Racing Association; JSPS [21-09335]; Morinaga Milk Industry Co., Ltd.	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Kieikai Research Foundation(Kieikai Research Foundation); Japan Racing Association(Japan Racing Association); JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Morinaga Milk Industry Co., Ltd.	This study was supported by a Grant-in-Aid for Scientific Research (B)(2) (No. 21380164, 24380146) and Challenging Exploratory Research (No. 23658216) from the Japan Society for the Promotion of Science (JSPS), the Kieikai Research Foundation, and Japan Racing Association to Dr. H. Kitazawa. Dr. Julio Villena was supported by JSPS (Postdoctoral Fellowship for Foreign Researchers, Program No. 21-09335) and Morinaga Milk Industry Co., Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Bron PA, 2012, NAT REV MICROBIOL, V10, P66, DOI 10.1038/nrmicro2690; Cerf-Bensussan N, 2010, NAT REV IMMUNOL, V10, P735, DOI 10.1038/nri2850; Dong HL, 2012, BRIT J NUTR, V108, P459, DOI 10.1017/S0007114511005824; Fujie H, 2011, FEMS IMMUNOL MED MIC, V63, P129, DOI 10.1111/j.1574-695X.2011.00837.x; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Hitotsumatsu O, 2008, IMMUNITY, V28, P381, DOI 10.1016/j.immuni.2008.02.002; Hoarau C, 2006, J ALLERGY CLIN IMMUN, V117, P696, DOI 10.1016/j.jaci.2005.10.043; Hosoya S, 2012, J MICROBIOL IN PRESS; Hosoya S, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-111; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Lebeer S, 2010, NAT REV MICROBIOL, V8, P171, DOI 10.1038/nrmicro2297; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lin SC, 2008, J MOL BIOL, V376, P526, DOI 10.1016/j.jmb.2007.11.092; Lopez P, 2010, INT J FOOD MICROBIOL, V138, P157, DOI 10.1016/j.ijfoodmicro.2009.12.023; Moue M, 2008, BBA-GEN SUBJECTS, V1780, P134, DOI 10.1016/j.bbagen.2007.11.006; Otte JM, 2004, AM J PHYSIOL-GASTR L, V286, pG613, DOI 10.1152/ajpgi.00341.2003; Shibolet O, 2007, AM J PHYSIOL-GASTR L, V292, pG1469, DOI 10.1152/ajpgi.00531.2006; Shimazu T, 2012, INFECT IMMUN, V80, P276, DOI 10.1128/IAI.05729-11; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; Turer EE, 2008, J EXP MED, V205, P451, DOI 10.1084/jem.20071108; Vereecke L, 2010, J EXP MED, V207, P1513, DOI 10.1084/jem.20092474; Villena J, 2012, PROBIOTICS IN PRESS; Villena J, 2012, CLIN VACCINE IMMUNOL, V19, P1038, DOI 10.1128/CVI.00199-12; Wang J, 2009, J IMMUNOL, V183, P1384, DOI 10.4049/jimmunol.0803987; Wang YY, 2004, FEBS LETT, V576, P86, DOI 10.1016/j.febslet.2004.08.071; Wells JM, 2011, P NATL ACAD SCI USA, V108, P4607, DOI 10.1073/pnas.1000092107; Werner SL, 2008, GENE DEV, V22, P2093, DOI 10.1101/gad.1680708; Westendorf AM, 2010, INT J MED MICROBIOL, V300, P11, DOI 10.1016/j.ijmm.2009.08.009; Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012; You J, 2012, FEMS IMMUNO IN PRESS; Zeuthen LH, 2008, IMMUNOLOGY, V124, P489, DOI 10.1111/j.1365-2567.2007.02800.x	33	76	100	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2013	8	3							e59259	10.1371/journal.pone.0059259	http://dx.doi.org/10.1371/journal.pone.0059259			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123VE	23555642	gold, Green Published, Green Submitted			2023-01-03	WOS:000317418500028
J	Hemphill, CS; Sampat, B				Hemphill, C. Scott; Sampat, Bhaven			Drug Patents at the Supreme Court	SCIENCE			English	Editorial Material									[Sampat, Bhaven] Columbia Univ, Columbia Law Sch, New York, NY 10032 USA; Columbia Univ, New York, NY 10032 USA	Columbia University; Columbia University	Sampat, B (corresponding author), Columbia Univ, Columbia Law Sch, New York, NY 10032 USA.	bns3@columbia.edu						Correa C.M., 2007, GUIDELINES EXAMINATI; Dickey Bret, 2010, Ann Health Law, V19, P367; European Commission, 2009, PHARM SECT INQ FIN R; FTC, 2013, AGR FIL FTC MED PRES; Gal A., 2013, WATERTIGHT COMPOSITI; Hemphill CS, 2012, J HEALTH ECON, V31, P327, DOI 10.1016/j.jhealeco.2012.01.004; Hemphill CS, 2011, J EMPIR LEGAL STUD, V8, P613, DOI 10.1111/j.1740-1461.2011.01235.x; Hemphill CS, 2009, COLUMBIA LAW REV, V109, P629; IMS Health, 2012, EC AN GEN DRUG US US; Kanter J., 2013, NY TIMES, pB1; Nikhil S., 2007, PREDICTING PARA; PRIEST GL, 1984, J LEGAL STUD, V13, P1, DOI 10.1086/467732; RBC Capital Markets, 2010, PHARM AN LIT SUCC RA	13	24	24	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 22	2013	339	6126					1386	1387		10.1126/science.1235857	http://dx.doi.org/10.1126/science.1235857			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	114KU	23520096				2023-01-03	WOS:000316740700025
J	Liu, TY; Sanders, JL; Tsui, FC; Espino, JU; Dato, VM; Suyama, J				Liu, Timothy Y.; Sanders, Jason L.; Tsui, Fu-Chiang; Espino, Jeremy U.; Dato, Virginia M.; Suyama, Joe			Association of Over-The-Counter Pharmaceutical Sales with Influenza-Like-Illnesses to Patient Volume in an Urgent Care Setting	PLOS ONE			English	Article							SYNDROMIC SURVEILLANCE; EMERGENCY; OUTBREAKS; VISITS	We studied the association between OTC pharmaceutical sales and volume of patients with influenza-like-illnesses (ILI) at an urgent care center over one year. OTC pharmaceutical sales explain 36% of the variance in the patient volume, and each standard deviation increase is associated with 4.7 more patient visits to the urgent care center (p<0.0001). Cross-correlation function analysis demonstrated that OTC pharmaceutical sales are significantly associated with patient volume during non-flu season (p<0.0001), but only the sales of cough and cold (p<0.0001) and thermometer (p<0.0001) categories were significant during flu season with a lag of two and one days, respectively. Our study is the first study to demonstrate and measure the relationship between OTC pharmaceutical sales and urgent care center patient volume, and presents strong evidence that OTC sales predict urgent care center patient volume year round.	[Liu, Timothy Y.; Sanders, Jason L.; Tsui, Fu-Chiang; Espino, Jeremy U.; Dato, Virginia M.; Suyama, Joe] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Tsui, Fu-Chiang; Espino, Jeremy U.] Real Time Outbreak & Dis Surveillance Lab, Pittsburgh, PA USA; [Suyama, Joe] Univ Pittsburgh, Med Ctr Urgent Care Shadyside, Pittsburgh, PA USA; [Dato, Virginia M.] Penn Dept Hlth, Harrisburg, PA 17108 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Suyama, J (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.	suyamaj@upmc.edu						Batal H, 2001, ACAD EMERG MED, V8, P48, DOI 10.1111/j.1553-2712.2001.tb00550.x; *CDC, 1998, PREV EM INF DIS STRA, P12380; Das Debjani, 2005, MMWR Suppl, V54, P41; Edge VL, 2004, CAN J PUBLIC HEALTH, V95, P446, DOI 10.1007/BF03403991; Espino JU, 2001, J AM MED INFORM ASSN, P164; Ginsberg J, 2009, NATURE, V457, P1012, DOI 10.1038/nature07634; Heffernan R, 2004, EMERG INFECT DIS, V10, P858, DOI 10.3201/eid1005.030646; Henning Kelly J, 2004, MMWR Suppl, V53, P5; Hogan WR, 2003, J AM MED INFORM ASSN, V10, P555, DOI 10.1197/jamia.M1377; Holleman DR, 1996, J GEN INTERN MED, V11, P237, DOI 10.1007/BF02642481; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; Lindsley WG, 2010, CLIN INFECT DIS, V50, P693, DOI 10.1086/650457; Magruder SF, 2003, J HOPKINS APL TECH D, V24, P349; Mandl KD, 2004, J AM MED INFORM ASSN, V11, P141, DOI 10.1197/jamia.M1356; McIsaac WJ, 1998, J FAM PRACTICE, V47, P366; Metzger Kristina B, 2004, MMWR Suppl, V53, P106; Miller B, 2004, EMERG INFECT DIS, V10, P1806, DOI 10.3201/eid1010.030789; Naphade M, 2004, SCI ENG BIOL INFORM, V2, P143; Salisbury C, 2003, BRIT J GEN PRACT, V53, P53; Schappert Susan M, 2011, Vital Health Stat 13, P1; Suyama J, 2003, ACAD EMERG MED, V10, P753, DOI 10.1111/j.1553-2712.2003.tb00070.x; Urgent Care Association of America, 2009, URG CAR IND INF KIT; Wagner Michael M, 2004, MMWR Suppl, V53, P40; Wagner MM, 2003, J AM MED INFORM ASSN, V10, P409, DOI 10.1197/jamia.M1357; Wagner MM, 2004, HDB BIOSURVEILLANCE; Wargon M, 2009, EMERG MED J, V26, P395, DOI 10.1136/emj.2008.062380; Zeng XM, 2001, J AM MED INFORM ASSN, P781	27	6	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2013	8	3							e59273	10.1371/journal.pone.0059273	http://dx.doi.org/10.1371/journal.pone.0059273			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	111UM	23555647	gold, Green Published, Green Accepted			2023-01-03	WOS:000316546400030
J	Lunardi, A; Ala, U; Epping, MT; Salmena, L; Clohessy, JG; Webster, KA; Wang, GC; Mazzucchelli, R; Bianconi, M; Stack, EC; Lis, R; Patnaik, A; Cantley, LC; Bubley, G; Cordon-Cardo, C; Gerald, WL; Montironi, R; Signoretti, S; Loda, M; Nardella, C; Pandolfi, PP				Lunardi, Andrea; Ala, Ugo; Epping, Mirjam T.; Salmena, Leonardo; Clohessy, John G.; Webster, Kaitlyn A.; Wang, Guocan; Mazzucchelli, Roberta; Bianconi, Maristella; Stack, Edward C.; Lis, Rosina; Patnaik, Akash; Cantley, Lewis C.; Bubley, Glenn; Cordon-Cardo, Carlos; Gerald, William L.; Montironi, Rodolfo; Signoretti, Sabina; Loda, Massimo; Nardella, Caterina; Pandolfi, Pier Paolo			A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer	NATURE GENETICS			English	Article							GENE-EXPRESSION ANALYSIS; PANCREATIC-CANCER; APOPTOSIS; PROGRESSION; XAF1; TARGET; CELLS; P53; DUTASTERIDE; SIGNATURES	Here we report an integrated analysis that leverages data from treatment of genetic mouse models of prostate cancer along with clinical data from patients to elucidate new mechanisms of castration resistance. We show that castration counteracts tumor progression in a Pten loss-driven mouse model of prostate cancer through the induction of apoptosis and proliferation block. Conversely, this response is bypassed with deletion of either Trp53 or Zbtb7a together with Pten, leading to the development of castration-resistant prostate cancer (CRPC). Mechanistically, the integrated acquisition of data from mouse models and patients identifies the expression patterns of XAF1, XIAP and SRD5A1 as a predictive and actionable signature for CRPC. Notably, we show that combined inhibition of XIAP, SRD5A1 and AR pathways overcomes castration resistance. Thus, our co-clinical approach facilitates the stratification of patients and the development of tailored and innovative therapeutic treatments.	[Lunardi, Andrea; Ala, Ugo; Epping, Mirjam T.; Salmena, Leonardo; Clohessy, John G.; Webster, Kaitlyn A.; Wang, Guocan; Nardella, Caterina; Pandolfi, Pier Paolo] Harvard Univ, Beth Israel Deaconess Med Ctr, Beth Israel Deaconess Canc Ctr, Canc Genet Program,Dept Med & Pathol,Med Sch, Boston, MA 02215 USA; [Ala, Ugo] Univ Turin, Ctr Mol Biotechnol, Dept Genet Biol & Biochem, Turin, Italy; [Salmena, Leonardo; Clohessy, John G.; Wang, Guocan; Nardella, Caterina; Pandolfi, Pier Paolo] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Canc Biol & Genet Program, New York, NY 10021 USA; [Salmena, Leonardo; Clohessy, John G.; Wang, Guocan; Gerald, William L.; Nardella, Caterina; Pandolfi, Pier Paolo] Mem Sloan Kettering Canc Ctr, Dept Pathol, Human Oncol & Pathogenesis Program, New York, NY 10021 USA; [Wang, Guocan] Cornell Univ, Weill Grad Sch Med Sci, Biochem Cell & Mol Biol Program, New York, NY 10021 USA; [Mazzucchelli, Roberta; Montironi, Rodolfo] Polytech Univ Marche Reg Ancona, United Hosp, Inst Pathol Anat & Histopathol, Ancona, Italy; [Bianconi, Maristella] Polytech Univ Marche Reg Ancona, United Hosp, Postgrad Sch Med Oncol, Clin Oncol, Ancona, Italy; [Stack, Edward C.; Lis, Rosina; Loda, Massimo] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Boston, MA 02115 USA; [Stack, Edward C.; Lis, Rosina; Signoretti, Sabina; Loda, Massimo] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Stack, Edward C.; Signoretti, Sabina] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Patnaik, Akash; Bubley, Glenn] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA; [Cantley, Lewis C.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA; [Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; [Cordon-Cardo, Carlos] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA; [Loda, Massimo] Broad Inst Harvard & MIT, Cambridge, MA USA; [Nardella, Caterina] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Preclin Murine Pharmacogenet Facil, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Turin; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Marche Polytechnic University; Marche Polytechnic University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Icahn School of Medicine at Mount Sinai; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Pandolfi, PP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Beth Israel Deaconess Canc Ctr, Canc Genet Program,Dept Med & Pathol,Med Sch, Boston, MA 02215 USA.	ppandolf@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014; Ala, Ugo/K-2029-2016	Cantley, Lewis C/0000-0002-1298-7653; Ala, Ugo/0000-0001-5408-6397; Webster, Kaitlyn/0000-0001-9902-0500; Clohessy, John/0000-0001-5186-9775; Pandolfi, Pier Paolo/0000-0002-5352-5295; Bianconi, Maristella/0000-0003-3475-2529; Salmena, Leonardo/0000-0003-4023-658X; Patnaik, Akash/0000-0001-5306-0208	National Cancer Institute Cancer Center Support grant (US National Institutes of Health (NIH)) [5 P30 CA06516]; Italian Association for Cancer Research (AIRC) [IG-9408]; Istituto Toscano Tumori (ITT, Italy); Mouse Models of Human Cancer Consortium/National Cancer Institute [RC2 CA147940-01]; A. David Mazzone Research Awards Program, Project Development Award; NATIONAL CANCER INSTITUTE [P30CA006516, RC2CA147940, U01CA141457] Funding Source: NIH RePORTER	National Cancer Institute Cancer Center Support grant (US National Institutes of Health (NIH)); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Istituto Toscano Tumori (ITT, Italy); Mouse Models of Human Cancer Consortium/National Cancer Institute; A. David Mazzone Research Awards Program, Project Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank current members of the Pandolfi laboratory for critical discussion and T. Garvey for insightful editing. We are grateful to the Preclinical Murine Pharmacogenetics Facility at Beth Israel Deaconess Medical Center and the Dana-Farber/Harvard Cancer Center for expert support in all aspects related to the work in mice. The Dana-Farber/Harvard Cancer Center is supported in part by a National Cancer Institute Cancer Center Support grant (US National Institutes of Health (NIH) 5 P30 CA06516). We also thank C. Abate-Shen (Columbia University) for kindly providing the antibody to Probasin and the Small-Animal Imaging Facility at Beth Israel Deaconess Medical Center for the MRI work. Additionally, we are grateful to G. Fedele and X. Wu from the Loda laboratory and the Center for Molecular Oncologic Pathology at Dana-Farber/Brigham and Women's for their technical support in the generation, staining and analysis of the TMA. U. A. has been supported by a fellowship from the Italian Association for Cancer Research (AIRC) under grant IG-9408. A. L. has been supported in part by a fellowship from the Istituto Toscano Tumori (ITT, Italy). This work has been supported through the Mouse Models of Human Cancer Consortium/National Cancer Institute grant (RC2 CA147940-01) and the A. David Mazzone Research Awards Program, Project Development Award to P.P.P.	Abou-Kheir WG, 2010, STEM CELLS, V28, P2129, DOI 10.1002/stem.538; Baretton GB, 1999, BRIT J CANCER, V80, P546, DOI 10.1038/sj.bjc.6690390; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Chang KH, 2011, P NATL ACAD SCI USA, V108, P13728, DOI 10.1073/pnas.1107898108; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Dai Y, 2011, AM J CANCER RES, V1, P128; Dai Y, 2009, MOL CANCER THER, V8, P2762, DOI 10.1158/1535-7163.MCT-09-0509; Danquah M, 2012, PHARM RES-DORDR, V29, P2079, DOI 10.1007/s11095-012-0737-1; Dubrez-Daloz L, 2008, CELL CYCLE, V7, P1036, DOI 10.4161/cc.7.8.5783; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Huang J, 2010, CANCER SCI, V101, P559, DOI 10.1111/j.1349-7006.2009.01396.x; Jiang C, 2012, WORLD J GASTROENTERO, V18, P2956, DOI 10.3748/wjg.v18.i23.2956; Kent EC, 2003, UROLOGY, V62, P134, DOI 10.1016/j.urology.2003.09.005; Kent Elizabeth C, 2003, Rev Urol, V5 Suppl 3, pS28; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; LaTulippe E, 2002, CANCER RES, V62, P4499; Lee SU, 2012, IMMUNOL REV, V247, P107, DOI 10.1111/j.1600-065X.2012.01116.x; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Luo JH, 2002, MOL CARCINOGEN, V33, P25, DOI 10.1002/mc.10018; Maeda T, 2009, DEV CELL, V17, P527, DOI 10.1016/j.devcel.2009.09.005; Markert EK, 2011, P NATL ACAD SCI USA, V108, P21276, DOI 10.1073/pnas.1117029108; Molina A, 2011, J UROLOGY, V185, P787, DOI 10.1016/j.juro.2010.10.042; Nardella C, 2011, CANCER DISCOV, V1, P108, DOI 10.1158/2159-8290.CD-11-0061; Nastiuk Kent L, 2007, BMC Urol, V7, P12, DOI 10.1186/1471-2490-7-12; Nikolovska-Coleska Z, 2004, J MED CHEM, V47, P2430, DOI 10.1021/jm030420+; Pourmand Gholamreza, 2007, Urol J, V4, P95; Qiao L, 2009, INT J COLORECTAL DIS, V24, P245, DOI 10.1007/s00384-008-0566-1; Sartor O, 2009, CLIN GENITOURIN CANC, V7, pE90, DOI 10.3816/CGC.2009.n.030; Sartor O, 2009, CAN J UROL, V16, P4806; Schlomm T, 2008, MODERN PATHOL, V21, P1371, DOI 10.1038/modpathol.2008.104; Stephenson AJ, 2005, CANCER-AM CANCER SOC, V104, P290, DOI 10.1002/cncr.21157; Taplin ME, 2009, CLIN CANCER RES, V15, P7099, DOI 10.1158/1078-0432.CCR-09-1722; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tepper CG, 2005, PROSTATE, V65, P375, DOI 10.1002/pros.20308; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Tu SP, 2009, INT J CANCER, V125, P688, DOI 10.1002/ijc.24282; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wang GC, 2013, NAT GENET, V45, P739, DOI 10.1038/ng.2654; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Yamaoka M, 2010, CLIN CANCER RES, V16, P4319, DOI 10.1158/1078-0432.CCR-10-0255; Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008-5472.CAN-08-4385; Zou B, 2012, MOL CARCINOGEN, V51, P422, DOI 10.1002/mc.20807	49	117	123	5	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2013	45	7					747	+		10.1038/ng.2650	http://dx.doi.org/10.1038/ng.2650			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	172LQ	23727860	Green Submitted, Green Accepted			2023-01-03	WOS:000321005200009
J	Kwon, JH; Lee, N; Park, JY; Yu, YS; Kim, JP; Shin, JH; Kim, DS; Joh, JW; Kim, DS; Choi, KY; Kang, KJ; Kim, G; Moon, YH; Wang, HJ				Kwon, Jung-Hee; Lee, Namgyu; Park, Jin Young; Yu, Yun Suk; Kim, Jin Pyo; Shin, Ji Hye; Kim, Dong-Sik; Joh, Jae Won; Kim, Dae Shick; Choi, Kwan Yong; Kang, Koo-Jeong; Kim, Gundo; Moon, Young Ho; Wang, Hee Jung			Actionable Gene Expression-Based Patient Stratification for Molecular Targeted Therapy in Hepatocellular Carcinoma	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; SORAFENIB; BIOMARKERS; RESISTANCE; MUTATIONS; PROGNOSIS; RAPAMYCIN; SURVIVAL; CANCER; MODEL	Background: The effectiveness of molecular targeted agents is modest in hepatocellular carcinoma (HCC). Efficacy of molecular targeted therapies has been better in cancer patients with high expression of actionable molecules defined as cognate target molecules. However, patient stratification based on the actionable molecules dictating the effectiveness of targeted drugs has remained understudied in HCC. Experimental Design & Results: Paired tumor and non-tumoral tissues derived from a total of 130 HCC patients were studied. Real-time RT-PCR was used to analyze the mRNA expression of actionable molecules in the tissues. mRNA levels of EGFR, VEGFR2, PDGFR beta, FGFR1, and mTOR were up-regulated in tumors compared to non-tumors in 35.4, 42.3, 61.5, 24.6, and 50.0% of patients, respectively. Up-regulation of EGFR was observed at early stage and tended to gradually decrease toward late stages (BCLC stage A: 41.9%; B: 30.8%; C: 17.6%). Frequency of VEGFR2 expression in tumors at stage C was lower than that in the other stages (BCLC stage A: 45.9%; B: 41.0%; C: 29.4%). PDGFR beta and mTOR were observed to be up-regulated in more than 50% of tumors in all the stages whereas FGFR1 was up-regulated in only about 20% of HCC irrespective of stages. A cluster analysis of actionable gene expression revealed that HCC can be categorized into different subtypes that predict the effectiveness of molecular targeted agents and combination therapies in clinical trials. Analysis of in vitro sensitivity to sorafenib demonstrated that HCC cells with up-regulation of PDGFR beta and c-Raf mRNA are more susceptible to sorafenib treatment in a dose and time-dependent manner than cells with low expression of the genes. Conclusions: mRNA expression analysis of actionable molecules could provide the rationale for new companion diagnostics-based therapeutic strategies in the treatment of HCC.	[Kwon, Jung-Hee; Park, Jin Young; Yu, Yun Suk; Kim, Jin Pyo; Moon, Young Ho] Cbs Biosci Inc, Taejon, South Korea; [Lee, Namgyu; Shin, Ji Hye; Choi, Kwan Yong] Pohang Univ Sci & Technol, Dept Life Sci, Pohang, South Korea; [Kim, Dong-Sik] Korea Univ, Div HBP Surg & Liver Transplantat, Dept Surg, Seoul, South Korea; [Joh, Jae Won] Sungkyunkwan Univ, Dept Surg, Samsung Med Ctr, Sch Med, Seoul, South Korea; [Kim, Dae Shick] Sungkyunkwan Univ, Dept Pathol, Samsung Med Ctr, Sch Med, Seoul, South Korea; [Kang, Koo-Jeong] Keimyung Univ, Sch Med, Dept Surg, Taegu, South Korea; [Kim, Gundo] Pukyong Natl Univ, Dept Microbiol, Pusan, South Korea; [Wang, Hee Jung] Ajou Univ, Dept Surg, Sch Med, Suwon 441749, South Korea	Pohang University of Science & Technology (POSTECH); Korea University; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Keimyung University; Pukyong National University; Ajou University	Moon, YH (corresponding author), Cbs Biosci Inc, Taejon, South Korea.	yhmoon62@cbsbio.com; wanghj@ajou.ac.kr	Kang, Koo Jeong/Z-4448-2019	Joh, Jae-Won/0000-0003-1732-6210; Lee, Namgyu/0000-0002-2980-2758; Kim, Dong-Sik/0000-0002-0608-1580	CbsBioscience intramural research funds [CBS-11-13]; National R & D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea; Next-Generation BioGreen 21 Program [PJ009503]; Rural Development Administration	CbsBioscience intramural research funds; National R & D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); Next-Generation BioGreen 21 Program(Rural Development Administration (RDA), Republic of Korea); Rural Development Administration(Rural Development Administration (RDA), Republic of Korea)	This work was supported by the CbsBioscience intramural research funds CBS-11-13, and a grant from the National R & D Program for Cancer Control, Ministry of Health & Welfare, Republic of Korea. NL, JHS, and KYC were supported by a grant from the Next-Generation BioGreen 21 Program (No. PJ009503), Rural Development Administration. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Blivet-Van Eggelpoel MJ, 2012, J HEPATOL, V57, P108, DOI 10.1016/j.jhep.2012.02.019; Buckley AF, 2008, AM J CLIN PATHOL, V129, P245, DOI 10.1309/WF10QAAED3PP93BH; Chen L, 2011, INT J BIOL MARKER, V26, P108, DOI 10.5301/JBM.2011.8322; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; Ezzoukhry Z, 2012, INT J CANCER, V131, P2961, DOI 10.1002/ijc.27604; Forner A, 2010, SEMIN LIVER DIS, V30, P61, DOI 10.1055/s-0030-1247133; Gedaly R, 2010, ANTICANCER RES, V30, P4951; Huynh H, 2010, BIOCHEM PHARMACOL, V80, P550, DOI 10.1016/j.bcp.2010.03.034; Huynh H, 2009, J CELL MOL MED, V13, P2673, DOI 10.1111/j.1582-4934.2009.00692.x; Jia JB, 2009, J CANCER RES CLIN, V135, P847, DOI 10.1007/s00432-008-0521-0; Kim SM, 2012, HEPATOLOGY, V55, P1443, DOI 10.1002/hep.24813; Kwon JH, 2010, CLIN CANCER RES, V16, P5511, DOI 10.1158/1078-0432.CCR-10-0825; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Llovet JM, 2012, CLIN CANCER RES, V18, P2290, DOI 10.1158/1078-0432.CCR-11-2175; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Morelli MP, 2009, MOL CANCER THER, V8, P2546, DOI 10.1158/1535-7163.MCT-09-0380; Nault JC, 2011, SEMIN LIVER DIS, V31, P173, DOI 10.1055/s-0031-1276646; Newell P, 2009, J HEPATOL, V51, P725, DOI 10.1016/j.jhep.2009.03.028; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Patel SH, 2011, ANN SURG ONCOL, V18, P3384, DOI 10.1245/s10434-011-1775-3; Poste G, 2012, CLIN CANCER RES, V18, P1515, DOI 10.1158/1078-0432.CCR-11-2206; Sieghart W, 2012, J HEPATOL, V57, P592, DOI 10.1016/j.jhep.2012.04.034; Smith NR, 2010, CLIN CANCER RES, V16, P3548, DOI 10.1158/1078-0432.CCR-09-2797; Su MC, 2005, CANCER LETT, V224, P117, DOI 10.1016/j.canlet.2004.10.010; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vidwans SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018257; Villanueva A, 2012, CLIN CANCER RES, V18, P1824, DOI 10.1158/1078-0432.CCR-12-0151; Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006; Villanueva A, 2010, ANNU REV MED, V61, P317, DOI 10.1146/annurev.med.080608.100623; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wang Z, 2008, CLIN CANCER RES, V14, P5124, DOI 10.1158/1078-0432.CCR-07-4774; West L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031906; Williams PM, 2012, CLIN CANCER RES, V18, P1531, DOI 10.1158/1078-0432.CCR-11-2203; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Zhou LD, 2010, MED ONCOL, V27, P255, DOI 10.1007/s12032-009-9201-4; Zhu AX, 2012, SEMIN ONCOL, V39, P493, DOI 10.1053/j.seminoncol.2012.05.014; Ziegler A, 2012, HUM GENET, V131, P1627, DOI 10.1007/s00439-012-1188-9	40	13	15	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 13	2013	8	6							e64260	10.1371/journal.pone.0064260	http://dx.doi.org/10.1371/journal.pone.0064260			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	172XB	23785399	Green Submitted, gold, Green Published			2023-01-03	WOS:000321038800118
J	Tannieres, M; Beury-Cirou, A; Vigouroux, A; Mondy, S; Pellissier, F; Dessaux, Y; Faure, D				Tannieres, Melanie; Beury-Cirou, Amelie; Vigouroux, Armelle; Mondy, Samuel; Pellissier, Franck; Dessaux, Yves; Faure, Denis			A Metagenomic Study Highlights Phylogenetic Proximity of Quorum-Quenching and Xenobiotic-Degrading Amidases of the AS-Family	PLOS ONE			English	Article							N-ACYLHOMOSERINE LACTONASE; HOMOSERINE LACTONE; SP STRAIN; SENSING SIGNALS; BACTERIA; GENE; IDENTIFICATION; DISCOVERY; HYDROLASE; MECHANISM	Quorum-sensing (QS) signals of the N-acylhomoserine lactone (NAHL) class are cleaved by quorum-quenching enzymes, collectively named NAHLases. Here, functional metagenomics allowed the discovery of a novel bacterial NAHLase in a rhizosphere that was treated with gamma-caprolactone. As revealed by rrs-DGGE and rrs-pyrosequencing, this treatment increased the percentage of the NAHL-degrading bacteria and strongly biased the structure of the bacterial community, among which Azospirillum dominated. Among the 29 760 fosmids of the metagenomic library, a single one was detected that expressed the qsdB gene conferring NAHL-degradation upon E. coli and decreased QS-regulated virulence in Pectobacterium. Phylogenetic analysis of the 34 orfs of the fosmid suggested that it would belong to an unknown Proteobacterium - probably a gamma-proteobacterium. qPCR quantification of the NAHLase-encoding genes attM, qsdA, and qsdB revealed their higher abundance in the gamma-caprolactone-treated rhizosphere as compared to an untreated control. The purified QsdB enzyme exhibited amidase activity. QsdB is the first amidase signature (AS) family member exhibiting NAHLase-activity. Point mutations in the AS-family catalytic triad K-S-S abolished the NAHLase activity of QsdB. This study extends the diversity of NAHLases and highlights a common phylogenic origin of AS-family enzymes involved in the degradation of natural compounds, such as NAHLs, and xenobiotics, such as nylon and linuron.	[Tannieres, Melanie; Beury-Cirou, Amelie; Mondy, Samuel; Dessaux, Yves; Faure, Denis] Ctr Natl Rech Sci, UPR2355, Inst Sci Vegetal, Gif Sur Yvette, France; [Beury-Cirou, Amelie] CNPPT, Achicourt, France; [Vigouroux, Armelle] Ctr Natl Rech Sci, UPR3082, LEBS, Gif Sur Yvette, France; [Pellissier, Franck] Ctr Natl Rech Sci, UPR2301, Inst Chim Subst Nat, Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC)	Faure, D (corresponding author), Ctr Natl Rech Sci, UPR2355, Inst Sci Vegetal, Gif Sur Yvette, France.	faure@isv.cnrs-gif.fr	Mondy, Samuel/AAG-8805-2019	Mondy, Samuel/0000-0002-9203-6398; TANNIERES, Melanie/0000-0003-2335-3776	Reseau de Recherche sur le Developpement Soutenable (R2DS, Region Ile-de-France); Comite Nord Plants de Pommes de Terre (CNPPT, France); Centre de la Recherche Scientifique (CNRS); program Ecosphere Continentale et Cotiere (EC2CO, CNRS); French programs Ingenierie Ecologique (CNRS); Projets innovants (Fondation pour la Recherche sur la Biodiversite, FRB); PESTICIDES (Ministere de l'ecologie, du developpement durable, des transports et du logement)	Reseau de Recherche sur le Developpement Soutenable (R2DS, Region Ile-de-France); Comite Nord Plants de Pommes de Terre (CNPPT, France); Centre de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); program Ecosphere Continentale et Cotiere (EC2CO, CNRS); French programs Ingenierie Ecologique (CNRS); Projets innovants (Fondation pour la Recherche sur la Biodiversite, FRB); PESTICIDES (Ministere de l'ecologie, du developpement durable, des transports et du logement)	MT was supported by a PhD grant from Reseau de Recherche sur le Developpement Soutenable (R2DS, Region Ile-de-France), AB-C by a post-doctoral fellowship from Comite Nord Plants de Pommes de Terre (CNPPT, France). YD and DF were funded by Centre de la Recherche Scientifique (CNRS) and program Ecosphere Continentale et Cotiere (EC2CO, CNRS); DF received financial support from the French programs Ingenierie Ecologique (CNRS), Projets innovants (Fondation pour la Recherche sur la Biodiversite, FRB), and PESTICIDES (Ministere de l'ecologie, du developpement durable, des transports et du logement). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbey C, 2012, J PROTEOME RES, V11, P206, DOI 10.1021/pr200936q; Bers K, 2011, APPL ENVIRON MICROB, V77, P8754, DOI 10.1128/AEM.06162-11; Bijtenhoorn P, 2011, J BIOTECHNOL, V155, P86, DOI 10.1016/j.jbiotec.2010.12.016; Bijtenhoorn P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026278; Boyer M, 2009, FEMS MICROBIOL ECOL, V70, P1, DOI 10.1111/j.1574-6941.2009.00745.x; Carlier A, 2003, APPL ENVIRON MICROB, V69, P4989, DOI 10.1128/AEM.69.8.4989-4993.2003; Cha C, 1998, MOL PLANT MICROBE IN, V11, P1119, DOI 10.1094/MPMI.1998.11.11.1119; Cirou A, 2007, ENVIRON MICROBIOL, V9, P1511, DOI 10.1111/j.1462-2920.2007.01270.x; Cirou A, 2012, APPL ENVIRON MICROB, V78, P481, DOI 10.1128/AEM.06159-11; Cirou A, 2011, RES MICROBIOL, V162, P945, DOI 10.1016/j.resmic.2011.01.010; d'Angelo-Picard C, 2004, FEMS MICROBIOL ECOL, V51, P19, DOI 10.1016/j.femsec.2004.07.008; Dong YH, 2004, APPL ENVIRON MICROB, V70, P954, DOI 10.1128/AEM.70.2.954-960.2004; Dong YH, 2000, P NATL ACAD SCI USA, V97, P3526, DOI 10.1073/pnas.060023897; Dong YH, 2001, NATURE, V411, P813, DOI 10.1038/35081101; Faure D, 2011, METAGENOMICS: CURRENT INNOVATIONS AND FUTURE TRENDS, P253; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Fukuta Y, 2010, ENZYME MICROB TECH, V46, P237, DOI 10.1016/j.enzmictec.2009.09.010; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Gabor EM, 2004, ENVIRON MICROBIOL, V6, P948, DOI 10.1111/j.1462-2920.2004.00643.x; Guan CH, 2007, APPL ENVIRON MICROB, V73, P3669, DOI 10.1128/AEM.02617-06; Hao YA, 2010, ENVIRON MICROBIOL, V12, P105, DOI 10.1111/j.1462-2920.2009.02049.x; Haudecoeur E, 2009, P NATL ACAD SCI USA, V106, P14587, DOI 10.1073/pnas.0808005106; Haudecoeur E, 2009, MOL PLANT MICROBE IN, V22, P529, DOI 10.1094/MPMI-22-5-0529; Huang JJ, 2006, APPL ENVIRON MICROB, V72, P1190, DOI 10.1128/AEM.72.2.1190-1197.2006; Huang JJ, 2003, APPL ENVIRON MICROB, V69, P5941, DOI 10.1128/AEM.69.10.5941-5949.2003; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; KANAGAWA K, 1989, J BACTERIOL, V171, P3181, DOI 10.1128/jb.171.6.3181-3186.1989; Kaufmann GF, 2005, P NATL ACAD SCI USA, V102, P309, DOI 10.1073/pnas.0408639102; Kennedy J, 2011, J APPL MICROBIOL, V111, P787, DOI 10.1111/j.1365-2672.2011.05106.x; Labahn J, 2002, J MOL BIOL, V322, P1053, DOI 10.1016/S0022-2836(02)00886-0; Leveau JHJ, 2008, FEMS MICROBIOL ECOL, V65, P238, DOI 10.1111/j.1574-6941.2008.00436.x; Lin YH, 2003, MOL MICROBIOL, V47, P849, DOI 10.1046/j.1365-2958.2003.03351.x; McClean KH, 1997, MICROBIOL-UK, V143, P3703, DOI 10.1099/00221287-143-12-3703; Mei GY, 2010, APPL ENVIRON MICROB, V76, P4933, DOI 10.1128/AEM.00477-10; Monier JM, 2011, CURR OPIN MICROBIOL, V14, P229, DOI 10.1016/j.mib.2011.04.010; Negoro S, 2012, J BIOL CHEM, V287, P5079, DOI 10.1074/jbc.M111.321992; OKADA H, 1983, NATURE, V306, P203, DOI 10.1038/306203a0; Park SY, 2005, APPL ENVIRON MICROB, V71, P2632, DOI 10.1128/AEM.71.5.2632-2641.2005; Park SY, 2003, MICROBIOL-SGM, V149, P1541, DOI 10.1099/mic.0.26269-0; Piel J, 2011, ANNU REV MICROBIOL, V65, P431, DOI 10.1146/annurev-micro-090110-102805; Riaz K, 2008, ENVIRON MICROBIOL, V10, P560, DOI 10.1111/j.1462-2920.2007.01475.x; Romero M, 2008, FEMS MICROBIOL LETT, V280, P73, DOI 10.1111/j.1574-6968.2007.01046.x; Schipper C, 2009, APPL ENVIRON MICROB, V75, P224, DOI 10.1128/AEM.01389-08; Smadja B, 2004, MOL PLANT MICROBE IN, V17, P1269, DOI 10.1094/MPMI.2004.17.11.1269; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Taupp M, 2011, CURR OPIN BIOTECH, V22, P465, DOI 10.1016/j.copbio.2011.02.010; TSUCHIYA K, 1989, J BACTERIOL, V171, P3187, DOI 10.1128/jb.171.6.3187-3191.1989; Uroz S, 2003, MICROBIOL-SGM, V149, P1981, DOI 10.1099/mic.0.26375-0; Uroz S, 2008, APPL ENVIRON MICROB, V74, P1357, DOI 10.1128/AEM.02014-07; Uroz S, 2009, CHEMBIOCHEM, V10, P205, DOI 10.1002/cbic.200800521; Valina ALB, 2004, BIOCHEMISTRY-US, V43, P15657, DOI 10.1021/bi049025r; Wang WZ, 2010, APPL ENVIRON MICROB, V76, P2524, DOI 10.1128/AEM.02738-09; Wisniewski-Dye F, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002430; Zhang HB, 2002, P NATL ACAD SCI USA, V99, P4638, DOI 10.1073/pnas.022056699; Zhang LH, 2003, TRENDS PLANT SCI, V8, P238, DOI 10.1016/S1360-1385(03)00063-3	55	20	22	0	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2013	8	6							e65473	10.1371/journal.pone.0065473	http://dx.doi.org/10.1371/journal.pone.0065473			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173QU	23762380	Green Published, Green Submitted, gold			2023-01-03	WOS:000321094800054
J	Yue, GF; Wei, J; Qian, XP; Yu, LX; Zou, ZY; Guan, WX; Wang, H; Shen, J; Liu, BR				Yue, Guofeng; Wei, Jia; Qian, Xiaoping; Yu, Lixia; Zou, Zhengyun; Guan, Wenxian; Wang, Hao; Shen, Jie; Liu, Baorui			Synergistic Anticancer Effects of Polyphyllin I and Evodiamine on Freshly-Removed Human Gastric Tumors	PLOS ONE			English	Article							THYMIDYLATE SYNTHASE GENE; MESSENGER-RNA EXPRESSION; DRUG RESPONSE ASSAY; PROTEIN EXPRESSION; GROWTH-INHIBITION; CANCER PATIENTS; MITOTIC ARREST; LUNG-CANCER; APOPTOSIS; CELLS	Objective: The present study was designed to examine the anticancer effect of Traditional Chinese Medicine of polyphyllin I (PPI) and evodiamine (EVO) on freshly-removed gastric tumor tissues. Methods: Sixty freshly-removed gastric tumor tissues were collected. Their sensitivity to PPI, EVO, platinum (Pt), 5-FU, irinotecan (CPT-11) were determined by histoculture drug response assay (HDRA). Those samples were also formalin-fixed and paraffin-embedded, which were used to examine the mRNA expression levels of aprataxin(APTX), excision repair cross-complementing 1(ERCC1), thymidylate synthase(TS) and topoisomerase I(TOPO1) by quantitative RT-PCR. The association of the gene expression levels and in vitro sensitivity were analyzed. Results: PPI, EVO, Pt, 5-FU and CPT-11 had anticancer effects on the freshly-removed gastric tumor tissues with average inhibition rates of 20.64%+/-14.25% for PPI, 21.14%+/-13.43% for EVO, 50.57%+/-22.37% for Pt, 53.54%+/-22.03% for 5-FU, and 39.33%+/-24.79% for CPT-11, respectively. Combination of PPI and Pt, EVO and Pt, EVO and 5-FU had higher inhibition rates than any single drug of them (P<0.001, P = 0.028, P = 0.017, respectively). The mRNA expression levels of ERCC1 were correlated with Pt sensitivity (rho = -0.645, P<0.001); the mRNA expression levels of TS were correlated with 5-FU sensitivity (rho = -0.803, P<0.001). There were also weak but significant correlations between APTX mRNA expression levels and CPT-11 sensitivity (rho = -0.376, P = 0.017) or EVO sensitivity (rho = -0.322, P = 0.036). ERCC1 mRNA expression levels was markedly suppressed by the presentation of PPI (P = 0.001) and slightly suppressed by the presentation of EVO (P = 0.04); whereas, TS mRNA expression levels was markedly decreased by the presentation of EVO (P = 0.017) and slightly decreased by the presentation of PPI (P = 0.047). Conclusion: PPI and EVO both could inhibit the activity of freshly-removed gastric tumor, and they could enhance the anticancer effect of Pt and 5-FU by reducing the mRNA expression levels of ERCC1 and TS.	[Yue, Guofeng; Wei, Jia; Qian, Xiaoping; Yu, Lixia; Zou, Zhengyun; Shen, Jie; Liu, Baorui] Nanjing Univ Chinese Med, Drum Tower Clin Med Coll, Ctr Comprehens Canc, Nanjing, Jiangsu, Peoples R China; [Wei, Jia; Qian, Xiaoping; Yu, Lixia; Zou, Zhengyun; Shen, Jie; Liu, Baorui] Nanjing Univ, Clin Canc Inst, Sch Med, Drum Tower Hosp,Comprehens Canc Ctr, Nanjing 210008, Jiangsu, Peoples R China; [Guan, Wenxian; Wang, Hao] Nanjing Univ, Sch Med, Drum Tower Hosp, Dept Surg, Nanjing 210008, Jiangsu, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University; Nanjing University	Shen, J (corresponding author), Nanjing Univ Chinese Med, Drum Tower Clin Med Coll, Ctr Comprehens Canc, Nanjing, Jiangsu, Peoples R China.	shenjie2008nju@163.com; baoruiliu@nju.edu.cn	Wei, Jia/AAE-9973-2020		National Natural Science Foundation of China [81172094]; Top Six Talents Project of Jiangsu Province [2011ws005]; Medical Science and Technology Development Projects of Nanjing [ZKX10011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Top Six Talents Project of Jiangsu Province; Medical Science and Technology Development Projects of Nanjing	Supported by grants from the National Natural Science Foundation of China (Grant No. 81172094), Top Six Talents Project of Jiangsu Province (Grant No. 2011ws005), and Medical Science and Technology Development Projects of Nanjing (Grant No. ZKX10011). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams M, 2007, PLANTA MED, V73, P1554, DOI 10.1055/s-2007-993743; Ariyoshi Y, 2003, ORAL ONCOL, V39, P701, DOI 10.1016/S1368-8375(03)00082-4; Bathe OF, 1999, CANCER J SCI AM, V5, P34; Cascinu S, 1999, CLIN CANCER RES, V5, P1996; Cecere F, 2006, NEW ENGL J MED, V355, P2590; Chan ALF, 2009, MOLECULES, V14, P1342, DOI 10.3390/molecules14041342; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Dopeso H, 2010, CLIN CANCER RES, V16, P2375, DOI 10.1158/1078-0432.CCR-09-3275; Fujita Y, 2009, ONCOL REP, V21, P499, DOI 10.3892/or_00000250; FURUKAWA T, 1995, CLIN CANCER RES, V1, P305; Hasegawa Y, 2007, ORAL ONCOL, V43, P749, DOI 10.1016/j.oraloncology.2006.09.003; Huang DM, 2005, J UROLOGY, V173, P256, DOI 10.1097/01.ju.0000141587.72429.e3; Huang YC, 2004, LIFE SCI, V75, P35, DOI 10.1016/j.lfs.2003.11.025; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; JOHNSTON PG, 1995, CANCER RES, V55, P1407; Kong MJ, 2010, ACTA BIOCH BIOPH SIN, V42, P827, DOI 10.1093/abbs/gmq091; Lee MS, 2005, CANCER BIOL THER, V4, P1248, DOI 10.4161/cbt.4.11.2136; Lenz HJ, 1996, J CLIN ONCOL, V14, P176, DOI 10.1200/JCO.1996.14.1.176; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Margeli M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009499; MILLER BE, 1984, J CELL PHYSIOL, P105; Ong RCY, 2008, CANCER LETT, V261, P158, DOI 10.1016/j.canlet.2007.11.005; Pan XB, 2012, PHYTOMEDICINE, V19, P618, DOI 10.1016/j.phymed.2012.02.003; Rosell R, 2004, CLIN CANCER RES, V10, p4215S, DOI 10.1158/1078-0432.CCR-040006; Shen J, 2012, INT J CANCER, V131, pE938, DOI 10.1002/ijc.27530; Sun J, 2007, PHYTOTHER RES, V21, P1102, DOI 10.1002/ptr.2196; Tanino H, 2001, ANTICANCER RES, V21, P4083; Wagner AD, 2006, J CLIN ONCOL, V24, P2903, DOI 10.1200/JCO.2005.05.0245; Wei J, 2008, BRIT J CANCER, V98, P1398, DOI 10.1038/sj.bjc.6604317; Wei J, 2011, J NATL CANCER I, V103, P1552, DOI 10.1093/jnci/djr326; Zhang Y, 2004, J ASIAN NAT PROD RES, V6, P19, DOI 10.1080/1028602031000119772; Zhang Y, 2003, BIOL PHARM BULL, V26, P1543, DOI 10.1248/bpb.26.1543	33	40	46	2	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2013	8	6							e65164	10.1371/journal.pone.0065164	http://dx.doi.org/10.1371/journal.pone.0065164			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	173QU	23762305	Green Published, Green Submitted, gold			2023-01-03	WOS:000321094800021
J	Wu, ZY; Liu, SQ; Huang, DJ				Wu, Ziyun; Liu, Shao Quan; Huang, Dejian			Dietary Restriction Depends on Nutrient Composition to Extend Chronological Lifespan in Budding Yeast Saccharomyces cerevisiae	PLOS ONE			English	Article							CALORIC RESTRICTION; STATIONARY-PHASE; NONQUIESCENT CELLS; SCH9; LONGEVITY; DROSOPHILA; GROWTH; QUIESCENT; PATHWAYS; SIRTUINS	The traditional view on dietary restriction has been challenged with regard to extending lifespan of the fruit fly Drosophila melanogaster. This is because studies have shown that changing the balance of dietary components without reduction of dietary intake can increase lifespan, suggesting that nutrient composition other than dietary restriction play a pivotal role in regulation of longevity. However, this opinion has not been reflected in yeast aging studies. Inspired by this new finding, response surface methodology was applied to evaluate the relationships between nutrients (glucose, amino acids and yeast nitrogen base) and lifespan as well as biomass production in four Saccharomyces cerevisiae strains (wild-type BY4742, sch9 Delta, tor1 Delta, and sir2 Delta mutants) using a high throughput screening assay. Our results indicate that lifespan extension by a typical dietary restriction regime was dependent on the nutrients in media and that nutrient composition was a key determinant for yeast longevity. Four different yeast strains were cultured in various media, which showed similar response surface trends in biomass production and viability at day two but greatly different trends in lifespan. The pH of aging media was dependent on glucose concentration and had no apparent correlation with lifespan under conditions where amino acids and YNB were varied widely, and simply buffering the pH of media could extend lifespan significantly. Furthermore, the results showed that strain sch9 Delta was more responsive in nutrient-sensing than the other three strains, suggesting that Sch9 (serine-threonine kinase pathway) was a major nutrient-sensing factor that regulates cell growth, cell size, metabolism, stress resistance and longevity. Overall, our findings support the notion that nutrient composition might be a more effective way than simple dietary restriction to optimize lifespan and biomass production from yeast to other organisms.	[Wu, Ziyun; Liu, Shao Quan; Huang, Dejian] Natl Univ Singapore, Dept Chem, Food Sci & Technol Programme, Singapore 117548, Singapore	National University of Singapore	Huang, DJ (corresponding author), Natl Univ Singapore, Dept Chem, Food Sci & Technol Programme, Singapore 117548, Singapore.	chmhdj@nus.edu.sg	Liu, shao quan/D-3172-2016; Huang, Dejian/A-7439-2010; Wu, Ziyun/C-1592-2009	Liu, shao quan/0000-0003-0868-2731; Wu, Ziyun/0000-0001-8239-1890; Huang, Dejian/0000-0002-2305-3960	National University of Singapore Virtual Institute for the Study of Aging (VISA) [R143-000-437-290]	National University of Singapore Virtual Institute for the Study of Aging (VISA)	The authors are grateful for the financial support of National University of Singapore Virtual Institute for the Study of Aging (VISA) (grant number: R143-000-437-290). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen C, 2006, J CELL BIOL, V174, P89, DOI 10.1083/jcb.200604072; Alvers AL, 2009, AGING CELL, V8, P353, DOI 10.1111/j.1474-9726.2009.00469.x; Aragon AD, 2008, MOL BIOL CELL, V19, P1271, DOI 10.1091/mbc.E07-07-0666; Bas D, 2007, J FOOD ENG, V78, P836, DOI 10.1016/j.jfoodeng.2005.11.024; Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188; Burtner CR, 2009, CELL CYCLE, V8, P1256, DOI 10.4161/cc.8.8.8287; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Elshorbagy AK, 2010, NUTRITION, V26, P1201, DOI 10.1016/j.nut.2009.09.017; Fabrizio P, 2004, J CELL BIOL, V166, P1055, DOI 10.1083/jcb.200404002; Fabrizio P, 2003, AGING CELL, V2, P73, DOI 10.1046/j.1474-9728.2003.00033.x; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fabrizio P, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001024; Fanson BG, 2009, AGING CELL, V8, P514, DOI 10.1111/j.1474-9726.2009.00497.x; Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539; Goldberg AA, 2009, EXP GERONTOL, V44, P555, DOI 10.1016/j.exger.2009.06.001; Grandison RC, 2009, NATURE, V462, P1061, DOI 10.1038/nature08619; Greer EL, 2009, AGING CELL, V8, P113, DOI 10.1111/j.1474-9726.2009.00459.x; Guarente L, 2011, NEW ENGL J MED, V364, P2235, DOI 10.1056/NEJMra1100831; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Huber A, 2011, EMBO J, V30, P3052, DOI 10.1038/emboj.2011.221; Huber A, 2009, GENE DEV, V23, P1929, DOI 10.1101/gad.532109; Ja WW, 2009, P NATL ACAD SCI USA, V106, P18633, DOI 10.1073/pnas.0908016106; Jiang JC, 2000, FASEB J, V14, P2135; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kaeberlein M, 2007, PLOS GENET, V3, P655, DOI 10.1371/journal.pgen.0030084; Kaeberlein M, 2006, SCIENCE, V312, DOI 10.1126/science.1124608; Kaeberlein M, 2010, NATURE, V464, P513, DOI 10.1038/nature08981; Koc A, 2004, P NATL ACAD SCI USA, V101, P7999, DOI 10.1073/pnas.0307929101; Lamming DW, 2006, SCIENCE, P312; Lee KP, 2008, P NATL ACAD SCI USA, V105, P2498, DOI 10.1073/pnas.0710787105; Lombard DB, 2011, NATURE, V477, P410, DOI 10.1038/477410a; Longo VD, 2012, CELL METAB, V16, P18, DOI 10.1016/j.cmet.2012.06.002; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; Malloy VL, 2006, AGING CELL, V5, P305, DOI 10.1111/j.1474-9726.2006.00220.x; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Meydani M, 2001, ANN NY ACAD SCI, V928, P226; Mieulet V, 2009, AMINO ACIDS, V37, P67; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Minois N, 2009, AGING CELL, V8, P36, DOI 10.1111/j.1474-9726.2008.00446.x; Murakami C, 2012, CELL CYCLE, V11, P3087, DOI 10.4161/cc.21465; Murakami CJ, 2008, J GERONTOL A-BIOL, V63, P113, DOI 10.1093/gerona/63.2.113; Murakami CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024530; Piper MDW, 2011, CELL METAB, V14, P154, DOI 10.1016/j.cmet.2011.06.013; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Skorupa DA, 2008, AGING CELL, V7, P478, DOI 10.1111/j.1474-9726.2008.00400.x; Smith DL, 2007, AGING CELL, V6, P649, DOI 10.1111/j.1474-9726.2007.00326.x; Thomas KC, 2002, APPL ENVIRON MICROB, V68, P1616, DOI 10.1128/AEM.68.4.1616-1623.2002; Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020; Wu ZY, 2011, EXP GERONTOL, V46, P915, DOI 10.1016/j.exger.2011.08.002; Zimmerman JA, 2003, EXP GERONTOL, V38, P47, DOI 10.1016/S0531-5565(02)00149-3	51	38	39	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2013	8	5							e64448	10.1371/journal.pone.0064448	http://dx.doi.org/10.1371/journal.pone.0064448			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146RJ	23691220	Green Published, gold, Green Submitted			2023-01-03	WOS:000319107900099
J	Fallis, BA; Dhalla, IA; Klemensberg, J; Bell, CM				Fallis, Brooks A.; Dhalla, Irfan A.; Klemensberg, Jason; Bell, Chaim M.			Primary Medication Non-Adherence after Discharge from a General Internal Medicine Service	PLOS ONE			English	Article							ADHERENCE; THERAPY; HOSPITALIZATION; DISCONTINUATION; MORTALITY; IMPACT; CARE	Background: Medication non-adherence frequently leads to suboptimal patient outcomes. Primary non-adherence, which occurs when a patient does not fill an initial prescription, is particularly important at the time of hospital discharge because new medications are often being prescribed to treat an illness rather than for prevention. Methods: We studied older adults consecutively discharged from a general internal medicine service at a large urban teaching hospital to determine the prevalence of primary non-adherence and identify characteristics associated with primary non-adherence. We reviewed electronic prescriptions, electronic discharge summaries and pharmacy dispensing data from April to August 2010 for drugs listed on the public formulary. Primary non-adherence was defined as failure to fill one or more new prescriptions after hospital discharge. In addition to descriptive analyses, we developed a logistical regression model to identify patient characteristics associated with primary non-adherence. Results: There were 493 patients eligible for inclusion in our study, 232 of whom were prescribed new medications. In total, 66 (28%) exhibited primary non-adherence at 7 days after discharge and 55 (24%) at 30 days after discharge. Examples of medications to which patients were non-adherent included antibiotics, drugs for the management of coronary artery disease (e. g. beta-blockers, statins), heart failure (e. g. beta-blockers, angiotensin converting enzyme inhibitors, furosemide), stroke (e. g. statins, clopidogrel), diabetes (e. g. insulin), and chronic obstructive pulmonary disease (e. g. long-acting bronchodilators, prednisone). Discharge to a nursing home was associated with an increased risk of primary non-adherence (OR 2.25, 95% CI 1.01-4.95). Conclusions: Primary non-adherence after medications are newly prescribed during a hospitalization is common, and was more likely to occur in patients discharged to a nursing home.	[Fallis, Brooks A.; Dhalla, Irfan A.; Bell, Chaim M.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Dhalla, Irfan A.; Bell, Chaim M.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Dhalla, Irfan A.] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; [Dhalla, Irfan A.; Klemensberg, Jason] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Dhalla, Irfan A.; Bell, Chaim M.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Bell, Chaim M.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Bell, CM (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.	cbell@mtsinai.on.ca	Bell, Chaim/C-4611-2015	Bell, Chaim/0000-0002-3778-9469	Canadian Institutes of Health Research; Canadian Patient Safety Institute Chair in Patient Safety and Continuity of Care	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Patient Safety Institute Chair in Patient Safety and Continuity of Care	Dr. Bell is supported by a Canadian Institutes of Health Research and Canadian Patient Safety Institute Chair in Patient Safety and Continuity of Care. The funding agencies had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. The corresponding author had full access to all of the data and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors report no conflicts of interest.	Baudendistel TE, 2011, J HOSP MED, V6, P487, DOI 10.1002/jhm.998; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; Bell CM, 2011, JAMA-J AM MED ASSOC, V306, P840, DOI 10.1001/jama.2011.1206; Boockvar KS, 2007, J AM GERIATR SOC, V55, P1078, DOI 10.1111/j.1532-5415.2007.01235.x; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Fischer MA, 2011, AM J MED, V124, DOI 10.1016/j.amjmed.2011.05.028; Fischer MA, 2010, J GEN INTERN MED, V25, P284, DOI 10.1007/s11606-010-1253-9; Ho PM, 2006, ARCH INTERN MED, V166, P1836, DOI 10.1001/archinte.166.17.1836; Ho PM, 2006, ARCH INTERN MED, V166, P1842, DOI 10.1001/archinte.166.17.1842; Jackevicius CA, 2002, JAMA-J AM MED ASSOC, V288, P462, DOI 10.1001/jama.288.4.462; Jackevicius CA, 2008, CIRCULATION, V117, P1028, DOI 10.1161/CIRCULATIONAHA.107.706820; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Maslove DM, 2009, J GEN INTERN MED, V24, P995, DOI 10.1007/s11606-009-1053-2; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Raebel MA, 2011, ANN PHARMACOTHER, V45, P1053, DOI 10.1345/aph.1Q146; Sokol MC, 2005, MED CARE, V43, P521, DOI 10.1097/01.mlr.0000163641.86870.af	17	66	67	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 2	2013	8	5							e61735	10.1371/journal.pone.0061735	http://dx.doi.org/10.1371/journal.pone.0061735			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	175AF	23658698	Green Published, Green Submitted, gold			2023-01-03	WOS:000321200500011
J	Gostin, LO; Buckley, GJ; Kelley, PW				Gostin, Lawrence O.; Buckley, Gillian J.; Kelley, Patrick W.			Stemming the Global Trade in Falsified and Substandard Medicines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUGS		[Gostin, Lawrence O.] Georgetown Univ, Ctr Law, Washington, DC 20001 USA; [Buckley, Gillian J.; Kelley, Patrick W.] Natl Acad Sci, Inst Med, Board Global Hlth, Washington, DC 20418 USA	Georgetown University; National Academies of Sciences, Engineering & Medicine	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				Arie S, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e951; Bate R, 2013, INT J TUBERC LUNG D, V17, P308, DOI 10.5588/ijtld.12.0355; Centers for Disease Control and Prevention, MULTISTATE FUNGAL ME; Institute of Medicine of the National Academies, 2013, COUNTERING THE PROBL; Nayyar GML, 2012, LANCET INFECT DIS, V12, P488, DOI 10.1016/S1473-3099(12)70064-6; United Nations Office on Drugs and Crime, 2009, TRANSNATIONAL TRAFFI; World Health Organization, 2012, BUILDING GLOBAL CAPA	7	23	23	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2013	309	16					1693	1694		10.1001/jama.2013.3048	http://dx.doi.org/10.1001/jama.2013.3048			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130IG	23579391	Green Published			2023-01-03	WOS:000317906700024
J	Cai, XY; Li, Y				Cai, Xueya; Li, Yue			Are AMI Patients with Comorbid Mental Illness More Likely to be Admitted to Hospitals with Lower Quality of AMI Care?	PLOS ONE			English	Article							CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; MEDICAL-CARE; HEALTH-CARE; ADMINISTRATIVE DATA; MORTALITY-RATES; UNITED-STATES; DISORDERS; PERFORMANCE; DEPRESSION	Objective: Older patients with comorbid mental illness are shown to receive less appropriate care for their medical conditions. This study analyzed Medicare patients hospitalized for acute myocardial infarction (AMI) and determined whether those with comorbid mental illness were more likely to present to hospitals with lower quality of AMI care. Methods: Retrospective analyses of Medicare claims in 2008. Hospital quality was measured using the five "Hospital Compare'' process indicators (aspirin at admission/discharge, beta-blocker at admission/discharge, and angiotension-converting enzyme inhibitor or angiotension receptor blocker for left ventricular dysfunction). Multinomial logit model determined the association of mental illness with admission to low-quality hospitals (rank of the composite process score <10th percentile) or high-quality hospitals (rank>90th percentile), compared to admissions to other hospitals with medium quality. Multivariate analyses further determined the effects of hospital type and mental diagnosis on outcomes. Results: Among all AMI admissions to 2,845 hospitals, 41,044 out of 287,881 patients were diagnosed with mental illness. Mental illness predicted a higher likelihood of admission to low-quality hospitals (unadjusted rate 2.9% vs. 2.0%; adjusted odds ratio [OR]1.25, 95% confidence interval [CI] 1.17-1.34, p<0.01), and an equal likelihood to high-quality hospitals (unadjusted rate 9.8% vs. 10.3%; adjusted OR 0.97, 95% CI 0.93-1.01, p = 0.11). Both lower hospital quality and mental diagnosis predicted higher rates of 30-day readmission, 30-day mortality, and 1-year mortality. Conclusions: Among Medicare myocardial infarction patients, comorbid mental illness was associated with an increased risk for admission to lower-quality hospitals. Both lower hospital quality and mental illness predicted worse post-AMI outcomes.	[Cai, Xueya; Li, Yue] Univ Rochester, Sch Med & Dent, Dept Biostat & Computat Biol, Rochester, NY 14627 USA; [Cai, Xueya; Li, Yue] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY USA	University of Rochester; University of Rochester	Cai, XY (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biostat & Computat Biol, Rochester, NY 14627 USA.	xueya_cai@urmc.rochester.edu			National Institute on Aging (NIA) [R01AG033202]; NATIONAL INSTITUTE ON AGING [R01AG033202] Funding Source: NIH RePORTER	National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by the National Institute on Aging (NIA) under grant R01AG033202. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert CM, 2005, CIRCULATION, V111, P480, DOI 10.1161/01.CIR.0000153813.64165.5D; [Anonymous], 2005, RURAL HLTH RES CTR R; Barefoot JC, 1996, CIRCULATION, V93, P1976, DOI 10.1161/01.CIR.93.11.1976; BLUSTEIN J, 1995, AM J PUBLIC HEALTH, V85, P345, DOI 10.2105/AJPH.85.3.345; Bunde J, 2006, PSYCHOSOM MED, V68, P51, DOI 10.1097/01.psy.0000195724.58085.f0; Desai MM, 2002, J NERV MENT DIS, V190, P51, DOI 10.1097/00005053-200201000-00014; Druss BG, 2007, J CLIN PSYCHIAT, V68, P40, DOI 10.4088/JCP.0407e09; Druss BG, 2000, JAMA-J AM MED ASSOC, V283, P506, DOI 10.1001/jama.283.4.506; Druss BG, 2001, ARCH GEN PSYCHIAT, V58, P565, DOI 10.1001/archpsyc.58.6.565; Druss BG, 1998, AM J PSYCHIAT, V155, P1775, DOI 10.1176/ajp.155.12.1775; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Gehi A, 2005, ARCH INTERN MED, V165, P2508, DOI 10.1001/archinte.165.21.2508; Hippisley-Cox J, 2007, HEART, V93, P1256, DOI 10.1136/hrt.2006.110171; Horvitz-Lennon M, 2006, HEALTH AFFAIR, V25, P659, DOI 10.1377/hlthaff.25.3.659; Jha AK, 2007, HEALTH AFFAIR, V26, P1104, DOI 10.1377/hlthaff.26.4.1104; Jha AK, 2010, ANN INTERN MED, V153, P299, DOI 10.7326/0003-4819-153-5-201009070-00004; KAWACHI I, 1994, CIRCULATION, V90, P2225, DOI 10.1161/01.CIR.90.5.2225; Kisely S, 2009, BRIT J PSYCHIAT, V195, P545, DOI 10.1192/bjp.bp.109.067082; Kovner C, 2002, HEALTH SERV RES, V37, P611; Landrum MB, 2000, HLTH SERVICES OUTCOM, V1, P23, DOI [10.1023/A:1010093701870, DOI 10.1023/A:1010093701870]; Li Y, 2007, MED CARE, V45, P587, DOI 10.1097/MLR.0b013e31803d3b54; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; McCulloch C.E., 2001, GEN LINEAR MIXED MOD; Newcomer JW, 2007, JAMA-J AM MED ASSOC, V298, P1794, DOI 10.1001/jama.298.15.1794; Phibbs CS, 1995, MED CARE RES REV, V52, P532, DOI 10.1177/107755879505200406; Popescu I, 2010, ARCH INTERN MED, V170, P1209, DOI 10.1001/archinternmed.2010.227; Popescu I, 2009, CIRC-CARDIOVASC QUAL, V2, P221, DOI 10.1161/CIRCOUTCOMES.108.813790; Rieckmann N, 2006, AM HEART J, V152, P922, DOI 10.1016/j.ahj.2006.05.014; Shaller D, 2003, HEALTH AFFAIR, V22, P95, DOI 10.1377/hlthaff.22.2.95; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694; Werner RM, 2010, HEALTH AFFAIR, V29, P1319, DOI 10.1377/hlthaff.2008.0770; Williams SC, 2006, CIRCULATION, V114, P558, DOI 10.1161/CIRCULATIONAHA.105.600973	33	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2013	8	4							e60258	10.1371/journal.pone.0060258	http://dx.doi.org/10.1371/journal.pone.0060258			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	127RY	23565212	Green Submitted, Green Published, gold			2023-01-03	WOS:000317717300081
J	Distefano, G; Ferrari, RJ; Weiss, C; Deasy, BM; Boninger, ML; Fitzgerald, GK; Huard, J; Ambrosio, F				Distefano, Giovanna; Ferrari, Ricardo Jose; Weiss, Christopher; Deasy, Bridget M.; Boninger, Michael L.; Fitzgerald, G. Kelley; Huard, Johnny; Ambrosio, Fabrisia			Neuromuscular Electrical Stimulation as a Method to Maximize the Beneficial Effects of Muscle Stem Cells Transplanted into Dystrophic Skeletal Muscle	PLOS ONE			English	Article							MDX MICE; MYOBLAST TRANSPLANTATION; REPAIR; ADULT; REGENERATION; EXPRESSION; IMPROVES	Cellular therapy is a potential approach to improve the regenerative capacity of damaged or diseased skeletal muscle. However, its clinical use has often been limited by impaired donor cell survival, proliferation and differentiation following transplantation. Additionally, functional improvements after transplantation are all-too-often negligible. Because the host microenvironment plays an important role in the fate of transplanted cells, methods to modulate the microenvironment and guide donor cell behavior are warranted. The purpose of this study was to investigate whether the use of neuromuscular electrical stimulation (NMES) for 1 or 4 weeks following muscle-derived stem cell (MDSC) transplantation into dystrophic skeletal muscle can modulate the fate of donor cells and enhance their contribution to muscle regeneration and functional improvements. Animals submitted to 4 weeks of NMES after transplantation demonstrated a 2-fold increase in the number of dystrophin+ myofibers as compared to control transplanted muscles. These findings were concomitant with an increased vascularity in the MDSC+NMES group when compared to non-stimulated counterparts. Additionally, animals subjected to NMES (with or without MDSC transplantation) presented an increased maximal specific tetanic force when compared to controls. Although cell transplantation and/or the use of NMES resulted in no changes in fatigue resistance, the combination of both MDSC transplantation and NMES resulted in a faster recovery from fatigue, when compared to non-injected and non-stimulated counterparts. We conclude that NMES is a viable method to improve MDSC engraftment, enhance dystrophic muscle strength, and, in combination with MDSC transplantation, improve recovery from fatigue. These findings suggest that NMES may be a clinically-relevant adjunct approach for cell transplantation into skeletal muscle.	[Distefano, Giovanna; Ferrari, Ricardo Jose; Weiss, Christopher; Boninger, Michael L.; Ambrosio, Fabrisia] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; [Distefano, Giovanna; Ferrari, Ricardo Jose; Fitzgerald, G. Kelley; Ambrosio, Fabrisia] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA USA; [Huard, Johnny; Ambrosio, Fabrisia] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA; [Huard, Johnny; Ambrosio, Fabrisia] Univ Pittsburgh, Dept Microbiol & Mol Genet, Pittsburgh, PA USA; [Deasy, Bridget M.; Boninger, Michael L.; Huard, Johnny; Ambrosio, Fabrisia] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ambrosio, F (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA.	ambrosiof@upmc.edu	Distefano, Giovanna/AAB-9914-2022	Distefano, Giovanna/0000-0003-1208-5008; Fitzgerald, G Kelley/0000-0001-6293-3103; Boninger, Michael/0000-0001-6966-919X; Weiss, Christopher/0000-0003-4704-9533	Foundation for Physical Therapy; NIH K12 for Physical and Occupational Therapists-Comprehensive Opportunities in Rehabilitation Research Training [K12 HD055931]; Competitive Medical Research Fund of the University of Pittsburgh; Department of Physical Medicine & Rehabilitation at the University of Pittsburgh; Cook MyoSite Incorporated; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD055931] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K01AG039477, P30AG024827] Funding Source: NIH RePORTER	Foundation for Physical Therapy; NIH K12 for Physical and Occupational Therapists-Comprehensive Opportunities in Rehabilitation Research Training; Competitive Medical Research Fund of the University of Pittsburgh(University of Pittsburgh); Department of Physical Medicine & Rehabilitation at the University of Pittsburgh; Cook MyoSite Incorporated; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding Source: - Foundation for Physical Therapy (http://foundation4pt.org/) - NIH K12 for Physical and Occupational Therapists-Comprehensive Opportunities in Rehabilitation Research Training (K12 HD055931, FA) (http://www.corrt.pitt.edu/) - Competitive Medical Research Fund of the University of Pittsburgh (http://www.oorhs.pitt.edu/funding/cmrf.aspx) Department of Physical Medicine & Rehabilitation at the University of Pittsburgh (http://www.rehabmedicine.pitt.edu/) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have read the journal's policy and have the following conflicts: One of the co-authors, Johnny Huard, has a potential financial conflict of interest because he has received remuneration as a consultant with Cook MyoSite Incorporated during the performance period of this project. None of the other authors has a financial or other relationship that might lead to conflict of interest concerning the publication of this manuscript. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Ambrosio F, 2010, TISSUE ENG PT A, V16, P839, DOI [10.1089/ten.tea.2009.0113, 10.1089/ten.TEA.2009.0113]; Ambrosio F, 2012, JOVE-J VIS EXP, DOI 10.3791/3914; Ambrosio F, 2009, ARCH PHYS MED REHAB, V90, P66, DOI 10.1016/j.apmr.2008.06.035; Annex BH, 1998, AM J PHYSIOL-HEART C, V274, pH860, DOI 10.1152/ajpheart.1998.274.3.H860; Auda-Boucher G, 2007, EXP CELL RES, V313, P997, DOI 10.1016/j.yexcr.2006.12.021; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; Bouchentouf M, 2006, NEUROMUSCULAR DISORD, V16, P518, DOI 10.1016/j.nmd.2006.06.003; Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; Brutsaert Tom D, 2002, BMC Physiol, V2, P8, DOI 10.1186/1472-6793-2-8; de Juan-Pardo EM, 2006, INT J NANOMED, V1, P203, DOI 10.2147/nano.2006.1.2.203; Gargioli C, 2008, NAT MED, V14, P973, DOI 10.1038/nm.1852; Gharaibeh B, 2008, NAT PROTOC, V3, P1501, DOI 10.1038/nprot.2008.142; Goudemant JF, 1998, NEUROMUSCULAR DISORD, V8, P371, DOI 10.1016/S0960-8966(98)00049-2; Gregory CM, 2005, PHYS THER, V85, P358, DOI 10.1093/ptj/85.4.358; HANG J, 1995, AM J PHYSIOL-HEART C, V269, pH1827, DOI 10.1152/ajpheart.1995.269.5.H1827; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; Li Y, 2002, AM J PATHOL, V161, P895, DOI 10.1016/S0002-9440(10)64250-2; Mueller GM, 2002, HUM GENE THER, V13, P1081, DOI 10.1089/104303402753812485; Oshima H, 2005, MOL THER, V12, P1130, DOI 10.1016/j.ymthe.2005.07.686; Payne TR, 2007, J AM COLL CARDIOL, V50, P1677, DOI 10.1016/j.jacc.2007.04.100; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; Rudnicki MA, 2008, COLD SH Q B, V73, P323, DOI 10.1101/sqb.2008.73.064; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404	25	28	28	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e54922	10.1371/journal.pone.0054922	http://dx.doi.org/10.1371/journal.pone.0054922			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SR	23526927	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000317562100003
J	Jokubaitis, VG; Spelman, T; Lechner-Scott, J; Barnett, M; Shaw, C; Vucic, S; Liew, D; Butzkueven, H; Slee, M				Jokubaitis, Vilija G.; Spelman, Tim; Lechner-Scott, Jeannette; Barnett, Michael; Shaw, Cameron; Vucic, Steve; Liew, Danny; Butzkueven, Helmut; Slee, Mark		Australian MSBase Study Grp	The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform	PLOS ONE			English	Article							INTERFERON BETA-1A; ADHERENCE; THERAPY; NATALIZUMAB; TRIAL	Objective: To prospectively characterise treatment persistence and predictors of treatment discontinuation in an Australian relapsing-remitting multiple sclerosis (RRMS) population. Methods: Tertiary MS treatment centres participating in the MSBase registry prospectively assessed treatment utilisation, persistence, predictors of treatment discontinuation and switch rates. Multivariable survival analyses were used to compare treatment persistence between drugs and to identify predictors of treatment discontinuation. Results: 1113 RRMS patients were studied. Patients persisted on their first disease-modifying therapy (DMT) for a median of 2.5 years. Treatment persistence on GA was shorter than on all IFN beta products (p<0.03). Younger age at treatment initiation and higher EDSS were predictive of DMT discontinuation. Patients persisted on subsequent DMTs, for 2.3 years. Patients receiving natalizumab (NAT) as a subsequent DMT persisted longer on treatment than those on IFN beta or GA (p<0.000). The primary reason for treatment discontinuation for any drug class was poor tolerability. Annualised switch or cessation rates were 9.5-12.5% for individual IFN beta products, 11.6% for GA and 4.4% for NAT. Conclusion: This multicentre MS cohort study is the first to directly compare treatment persistence on IFN beta and GA to NAT. We report that treatment persistence in our Australian RRMS population is short, although patients receiving IFN beta as a first DMT persisted longer on treatment than those on GA. Additionally, patients receiving NAT as a subsequent DMT were more likely to persist on treatment than those switched to IFN beta or GA. EDSS and age at DMT initiation were predictive of DMT discontinuation. Treatment intolerance was the principal reason for treatment cessation.	[Jokubaitis, Vilija G.; Liew, Danny; Butzkueven, Helmut] Univ Melbourne, Dept Med, Melbourne Brain Ctr RMH, Parkville, Vic 3052, Australia; [Jokubaitis, Vilija G.; Spelman, Tim; Butzkueven, Helmut] Royal Melbourne Hosp, Dept Neurol, Parkville, Vic 3050, Australia; [Lechner-Scott, Jeannette] John Hunter Hosp, Dept Neurol, Newcastle, NSW, Australia; [Lechner-Scott, Jeannette] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW 2300, Australia; [Barnett, Michael] Brain Mind Res Inst, Sydney, NSW, Australia; [Shaw, Cameron] Geelong Hosp, Dept Neurosci, Geelong, Vic, Australia; [Vucic, Steve] Westmead Hosp, Dept Neurol, Westmead, NSW 2145, Australia; [Butzkueven, Helmut] Monash Univ, Dept Neurol, Box Hill Hosp, Box Hill, Vic, Australia; [Slee, Mark] Flinders Univ & Med Ctr, Adelaide, SA, Australia	University of Melbourne; Royal Melbourne Hospital; John Hunter Hospital; Hunter Medical Research Institute; University of Newcastle; University of Sydney; Geelong Hospital; University of Sydney; Box Hill Hospital; Monash University; Flinders University South Australia	Jokubaitis, VG (corresponding author), Univ Melbourne, Dept Med, Melbourne Brain Ctr RMH, Parkville, Vic 3052, Australia.	vilija.jokubaitis@unimelb.edu.au	Jokubaitis, Vilija G./AAD-5949-2019; Slee, Mark/J-4731-2015	Jokubaitis, Vilija G./0000-0002-3942-4340; Slee, Mark/0000-0003-4323-2453; Butzkueven, Helmut/0000-0003-3940-8727; Liew, Danny/0000-0002-0131-623X; Vucic, Steve/0000-0002-8323-873X; Lechner-Scott, Jeannette/0000-0002-3850-447X; Kilpatrick, Trevor/0000-0003-3999-085X	MSBase Foundation; Merck Serono; Biogen Idec; Novartis Pharma; Genzyme; CSL; Novartis Australia; Bayer Schering; Sanofi; Teva	MSBase Foundation; Merck Serono(Merck & Company); Biogen Idec(Biogen); Novartis Pharma; Genzyme(Sanofi-AventisGenzyme Corporation); CSL; Novartis Australia(Novartis); Bayer Schering(Bayer AG); Sanofi; Teva(Teva Pharmaceutical Industries)	This study was sponsored by the MSBase Foundation, a not-for-profit organisation. The MSBase Foundation receives financial support from Merck Serono, Biogen Idec, Novartis Pharma, Genzyme and CSL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Dr Jokubaitis reports no disclosures. Dr Spelman has received a travel grant from Novartis Australia. Dr Lechner-Scott's institution receives non-directed funding as well as honoraria for presentations and membership on advisory boards from CSL, Genzyme, Biogen Idec, Bayer Health Care, Merck Serono and Novartis Australia. Dr Barnett has received research support and/or honoraria from Bayer Schering, Biogen Idec, Merck Serono, Novartis Pharma, Sanofi and Teva. Dr Shaw reports no disclosures. Dr Vucic serves on the scientific advisory board from Novartis Pharma, Merck Serono Australia and Bayer Schering Australia. Dr Vucic serves as a medical consultant for Merck Serono Australia. Dr Liew has received honoraria from Novartis and Sanofi. Dr Butzkueven has served on scientific advisory boards for Biogen Idec, Novartis and Sanofi and has received conference travel support from Novartis, Biogen Idec and Sanofi. He serves on steering committees for trials conducted by Merck Serono, Biogen Idec and Novartis. Dr Butzkueven has received research support from Merck Serono, Novartis and Biogen Idec in his capacity as honorary chair of the MSBase Foundation. He is on the editorial board of Multiple Sclerosis International. Dr Slee reports participating in advisory boards for Sanofi, Merck Serono, Biogen Idec, Novartis Pharma and Bayer Schering. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.	Butzkueven H, 2006, MULT SCLER, V12, P769, DOI 10.1177/1352458506070775; Comi G, 2009, LANCET, V374, P1503, DOI 10.1016/S0140-6736(09)61259-9; Dor A, 2010, ADV HEALTH ECON HEAL, V22, P175, DOI 10.1108/S0731-2199(2010)0000022011; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Kappos L, 2006, NEUROLOGY, V67, P944, DOI 10.1212/01.wnl.0000237994.95410.ce; Kappos L, 2009, LANCET NEUROL, V8, P987, DOI 10.1016/S1474-4422(09)70237-6; Kleinman Nathan L, 2010, J Med Econ, V13, P633, DOI 10.3111/13696998.2010.527588; Meyniel C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038661; Mikol DD, 2008, LANCET NEUROL, V7, P903, DOI 10.1016/S1474-4422(08)70200-X; Miller AE, 2012, CURR OPIN NEUROL, V25, pS4, DOI 10.1097/01.wco.0000413319.87092.19; Mohr DC, 1997, ARCH NEUROL-CHICAGO, V54, P531, DOI 10.1001/archneur.1997.00550170015009; Mohr DC, 1999, MULT SCLER, V5, P192, DOI 10.1191/135245899678846069; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Portaccio E, 2008, EUR NEUROL, V59, P131, DOI 10.1159/000111875; Reynolds Matthew W, 2010, J Med Econ, V13, P90, DOI 10.3111/13696990903579501; Reynolds MW, 2010, CURR MED RES OPIN, V26, P663, DOI 10.1185/03007990903554257; Rio L, 2005, MULT SCLER, V11, P306, DOI 10.1191/1352458505ms1173oa; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Sabate E, 2003, ADHERENCE LONG TERM; Tremlett HL, 2003, NEUROLOGY, V61, P551, DOI 10.1212/01.WNL.0000078885.05053.7D; Wong J, 2011, CAN J NEUROL SCI, V38, P429, DOI 10.1017/S0317167100011823; World Health Organization, 2008, ATL MULT SCLER RES W; Zhang J, 2011, CURR RHEUMATOL REP, V13, P273, DOI 10.1007/s11926-011-0168-8	23	35	35	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e59694	10.1371/journal.pone.0059694	http://dx.doi.org/10.1371/journal.pone.0059694			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SR	23527252	gold, Green Published, Green Submitted			2023-01-03	WOS:000317562100159
J	Seabrook, GR				Seabrook, Gary R.			Does Rigorous Quality Process Reporting Guarantee Superior-Quality Health Care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SURGICAL-SITE INFECTIONS; RISK	IMPORTANCE Timing of prophylactic antibiotic administration for surgical procedures is a nationally mandated and publicly reported quality metric sponsored by the Centers for Medicare and Medicaid Services Surgical Care Improvement Project. Numerous studies have failed to demonstrate that adherence to the Surgical Care Improvement Project prophylactic antibiotic timely administration measure is associated with decreased surgical site infection (SSI). OBJECTIVE To determine whether prophylactic antibiotic timing is associated with SSI occurrence. DESIGN Retrospective cohort study using national Veterans Affairs patient-level data on prophylactic antibiotic timing for orthopedic, colorectal, vascular, and gynecologic procedures from 2005 through 2009. SETTING National Veterans Affairs Surgical Care Improvement Project data from 112 Veterans Affairs hospitals and matched Veterans Affairs Surgical Quality Improvement Program data. PATIENTS Patients undergoing hip or knee arthroplasty, colorectal surgical procedures, arterial vascular surgical procedures, and hysterectomy. INTERVENTION Timing of prophylactic antibiotic administration with respect to surgical incision time. MAIN OUTCOMES AND MEASURES Data for prophylactic antibiotic agent, prophylactic antibiotic timing with respect to surgical incision, and patient and procedure risk variables were assessed for their relationship with the occurrence of a composite superficial or deep incisional SSI within 30 days after the procedure. Nonlinear generalized additive models were used to examine the association between antibiotic timing and SSI. RESULTS Of the 32 459 operations, prophylactic antibiotics were administered at a median of 28 minutes (interquartile range, 17-39minutes) prior to surgical incision, and 1497 cases (4.6%) developed an SSI. Compared with procedures with antibiotic administration within 60 minutes prior to incision, higher SSI rates were observed for timing more than 60 minutes prior to incision (unadjusted odds ratio [OR] = 1.34; 95% CI, 1.08-1.66) but not after incision (unadjusted OR = 1.26; 95% CI, 0.92-1.72). In unadjusted generalized additive models, we observed a significant nonlinear relationship between prophylactic antibiotic timing and SSI when considering timing as a continuous variable (P = .01). In generalized additive models adjusted for patient, procedure, and antibiotic variables, no significant association between prophylactic antibiotic timing and SSI was observed. Vancomycin hydrochloride was associated with higher SSI occurrence for orthopedic procedures (adjusted OR = 1.75; 95% CI, 1.16-2.65). Cefazolin sodium and quinolone in combination with an anaerobic agent were associated with fewer SSI events (cefazolin: adjusted OR = 0.49; 95% CI, 0.34-0.71; quinolone: adjusted OR = 0.55; 95% CI, 0.35-0.87) for colorectal procedures. CONCLUSIONS AND RELEVANCE The SSI risk varies by patient and procedure factors as well as antibiotic properties but is not significantly associated with prophylactic antibiotic timing. While adherence to the timely prophylactic antibiotic measure is not bad care, there is little evidence to suggest that it is better care.	Med Coll Wisconsin, Div Vasc Surg, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Seabrook, GR (corresponding author), Med Coll Wisconsin, Div Vasc Surg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	gseabroo@mcw.edu						[Anonymous], FED REG; Centers for Medicare & Medicaid Services, 2011, FED REGISTER, V76, P74538; Darouiche RO, 2010, NEW ENGL J MED, V362, P18, DOI 10.1056/NEJMoa0810988; Edmiston CE, 2008, J AM COLL SURGEONS, V207, P233, DOI 10.1016/j.jamcollsurg.2007.12.054; Edmiston CE, 2013, SURGERY, V154, P89, DOI 10.1016/j.surg.2013.03.008; Edmiston CE, 2011, SURG INFECT, V12, P169, DOI 10.1089/sur.2011.036; Hawn MT, 2011, ANN SURG, V254, P494, DOI 10.1097/SLA.0b013e31822c6929; Hawn MT, JAMA SURG, DOI 10.100/jamasurg.2013.134; Lyu H, 2013, JAMA SURG, V148, P362, DOI 10.1001/2013.jamasurg.270; Nicholas LH, 2010, ARCH SURG-CHICAGO, V145, P999, DOI 10.1001/archsurg.2010.191	10	2	2	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 17	2013	310	3					316	317		10.1001/jama.2013.7131	http://dx.doi.org/10.1001/jama.2013.7131			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	183RU	23860990				2023-01-03	WOS:000321835700019
J	Harvey, HB; Cohen, IG				Harvey, H. Benjamin; Cohen, I. Glenn			The Looming Threat of Liability for Accountable Care Organizations and What to Do About It	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Harvey, H. Benjamin] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Cohen, I. Glenn] Harvard Univ, Sch Law, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University	Cohen, IG (corresponding author), Harvard Univ, Sch Law, 1525 Massachusetts Ave,Griswold Hall,Room 503, Cambridge, MA 02138 USA.	igcohen@law.harvard.edu						[Anonymous], 2012, NEW RISK MAN FRONT A; Blue Cross Blue Shield of Massachusetts, 2012, MASS PAYM REF MOD RE; Emanuel EJ, 2012, JAMA-J AM MED ASSOC, V307, P2263, DOI 10.1001/jama.2012.4313; Hellinger FJ, 2005, AM J PUBLIC HEALTH, V95, P217, DOI 10.2105/AJPH.2004.037895; Orszag P, 2010, NY TIMES; Smith Christopher, 2011, Ann Health Law, V20, P165; Weisman R, 2012, BOSTON GLOBE	7	7	7	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 10	2013	310	2					141	142		10.1001/jama.2013.7339	http://dx.doi.org/10.1001/jama.2013.7339			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	179HU	23775236				2023-01-03	WOS:000321511500008
J	Hung, PH; Tsai, HB; Lin, CH; Hung, KY				Hung, Peir-Haur; Tsai, Hung-Bin; Lin, Chien-Hung; Hung, Kuan-Yu			Abdominal Obesity Is Associated with Peripheral Artery Disease in Hemodialysis Patients	PLOS ONE			English	Article							C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE INDEX; METABOLIC SYNDROME; CARDIOVASCULAR MORTALITY; INFLAMMATORY MARKERS; ADIPOSE-TISSUE; RISK-FACTORS; INSULIN-RESISTANCE	Background: Peripheral arterial disease (PAD) is a leading cause of morbidity in hemodialysis (HD) patients. Recent evidence suggests that abdominal obesity (AO) may play a role in PAD. However, the association between AO and PAD has not been thoroughly studied in HD patients. Methods: The present cross-sectional study aimed to examine the relationship between AO and PAD in a cohort of 204 chronic HD patients. The ankle brachial index (ABI) was used as an estimate of the presence of PAD. Plasma adiponectin levels, interleukin-6 (IL-6) levels, high sensitivity C-reactive protein (hs-CRP) levels, asymmetric dimethylarginine (ADMA) levels, and lipid profiles were measured. Logistic regression was used to estimate the association between the presence of PAD and AO as well as other potential risk factors. Results: The metabolic risk factors and all individual traits, including elevated ln-transformed hs-CRP, were found to be significant (P<0.05) more frequently in HD patients with AO than that in control subjects. Patients with AO had a higher prevalence of PAD than the control individuals, with a mean ABI of 0.96 +/- 0.23 and 1.08 +/- 0.16 (P<0.0001) and PAD prevalence of 26.9% and 10.8% (P=0.003), respectively. By multivariate analysis, AO (odds ratio [OR], 4.532; 95% CI, 1.765-11.639; P=0.002), elevated serum ln-transformed ADMA (OR, 5.535; 95% CI, 1.323-23.155; P=0.019), and ln-transformed IL-6 (OR, 1.567; 95% CI, 1.033-2.378; P=0.035) were independent predictors of the presence of PAD. Conclusions: HD patients with AO exhibited a cluster of metabolic risk factors and lower ABI. AO, elevated serum lntransformed ADMA, and ln-transformed IL-6 were independent predictors of the presence of PAD.	[Hung, Peir-Haur] Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Internal Med, Chiayi, Taiwan; [Hung, Peir-Haur] Chia Nan Univ Pharm & Sci, Dept Appl Life Sci & Hlth, Tainan, Taiwan; [Tsai, Hung-Bin] Natl Taiwan Univ Hosp, Dept Tramatol, Taipei, Taiwan; [Lin, Chien-Hung] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; [Lin, Chien-Hung] Taipei City Hosp, Zhongxing Branch, Dept Pediat, Taipei, Taiwan; [Hung, Kuan-Yu] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan	Chia Nan University of Pharmacy & Science; National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University; Taipei City Hospital; National Taiwan University; National Taiwan University Hospital	Hung, KY (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan.	kyhung@ntu.edu.tw	Tsai, Hung-Bin/G-3761-2011	HUNG, KUAN-YU/0000-0003-3472-5512; Tsai, Hung-Bin/0000-0002-0689-8339	National Science Council [NSC 97-2314-B-002-053-MY3]; Mrs. Hsiu-Chin Lee Kidney Foundation	National Science Council(Ministry of Science and Technology, Taiwan); Mrs. Hsiu-Chin Lee Kidney Foundation	This study was supported by grants from the National Science Council (NSC 97-2314-B-002-053-MY3) and Mrs. Hsiu-Chin Lee Kidney Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abeywardena MY, 2009, CURR PHARM DESIGN, V15, P1809, DOI 10.2174/138161209788186290; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Boger RH, 2000, J AM COLL CARDIOL, V36, P2287, DOI 10.1016/S0735-1097(00)01013-5; Boger RH, 1997, CIRCULATION, V95, P2068, DOI 10.1161/01.CIR.95.8.2068; Burton JO, 2012, NEPHROL DIAL TRANSPL, V27, P1860, DOI 10.1093/ndt/gfr574; Carbayo JA, 2007, NUTR METAB CARDIOVAS, V17, P41, DOI 10.1016/j.numecd.2005.08.009; Carr DB, 2004, DIABETES, V53, P2087, DOI 10.2337/diabetes.53.8.2087; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cooke JP, 2010, J AM COLL CARDIOL, V55, P2017, DOI 10.1016/j.jacc.2009.08.090; Cooke JP, 2004, CIRCULATION, V109, P1813, DOI 10.1161/01.CIR.0000126823.07732.D5; DAUGIRDAS JT, 2001, HDB DIALYSIS, P15; de Vinuesa SG, 2006, J AM SOC NEPHROL, V17, pS206, DOI 10.1681/ASN.2006080916; Elsayed EF, 2008, AM J KIDNEY DIS, V52, P29, DOI 10.1053/j.ajkd.2008.02.363; FISHBANE S, 1995, AM J KIDNEY DIS, V25, P34, DOI 10.1016/0272-6386(95)90622-3; Furuki K, 2007, ATHEROSCLEROSIS, V191, P206, DOI 10.1016/j.atherosclerosis.2006.03.022; Golledge J, 2007, J VASC SURG, V45, P40, DOI 10.1016/j.jvs.2006.09.006; Gorter PM, 2004, ATHEROSCLEROSIS, V173, P363, DOI 10.1016/j.atherosclerosis.2003.12.033; Haddy N, 2003, ATHEROSCLEROSIS, V170, P277, DOI 10.1016/S0021-9150(03)00287-9; Hozawa A, 2004, HYPERTENS RES, V27, P955, DOI 10.1291/hypres.27.955; Joviliano EE, 2011, ANN VASC SURG, V25, P846, DOI 10.1016/j.avsg.2011.02.026; Jurek A, 2008, CLIN BIOCHEM, V41, P1015, DOI 10.1016/j.clinbiochem.2008.04.019; Kals J, 2006, AM J HYPERTENS, V19, P902, DOI 10.1016/j.amjhyper.2006.02.003; Klouche M, 2000, CIRCULATION, V101, P1799, DOI 10.1161/01.CIR.101.15.1799; Komulainen P, 2007, AGE AGEING, V36, P443, DOI 10.1093/ageing/afm051; Libra M, 2006, J CLIN PATHOL, V59, P211, DOI 10.1136/jcp.2004.025452; McDermott MM, 2005, AM HEART J, V150, P276, DOI 10.1016/j.ahj.2004.09.032; Nylaende M, 2006, VASC MED, V11, P21, DOI 10.1191/1358863x06vm662oa; O'Hare A, 2001, J AM SOC NEPHROL, V12, P2838, DOI 10.1681/ASN.V12122838; Olijhoek JK, 2004, EUR HEART J, V25, P342, DOI 10.1016/j.ehj.2003.12.007; Ono K, 2003, J AM SOC NEPHROL, V14, P1591, DOI 10.1097/01.ASN.0000065547.98258.3D; Planas A, 2001, INT J OBESITY, V25, P1068, DOI 10.1038/sj.ijo.0801638; Postorino M, 2009, J AM COLL CARDIOL, V53, P1265, DOI 10.1016/j.jacc.2008.12.040; POULIOT MC, 1994, AM J CARDIOL, V73, P460, DOI 10.1016/0002-9149(94)90676-9; Saetre T, 2011, ANGIOLOGY, V62, P301, DOI 10.1177/0003319710385338; Selvin E, 2004, CIRCULATION, V110, P738, DOI 10.1161/01.CIR.0000137913.26087.F0; Sjostrom L, 1998, ACTA MED SCAND, V723, P169; Suda O, 2004, ARTERIOSCL THROM VAS, V24, P1682, DOI 10.1161/01.ATV.0000136656.26019.6e; Sundstrom J, 2006, BMJ-BRIT MED J, V332, P878, DOI 10.1136/bmj.38766.624097.1F; Tarkun I, 2005, EUR J ENDOCRINOL, V153, P115, DOI 10.1530/eje.1.01948; Toikka JO, 1999, ARTERIOSCL THROM VAS, V19, P436, DOI 10.1161/01.ATV.19.2.436; Tzoulaki I, 2005, CIRCULATION, V112, P976, DOI 10.1161/CIRCULATIONAHA.104.513085; Vaziri ND, 2009, KIDNEY INT, V76, P437, DOI 10.1038/ki.2009.177; VOGT MT, 1993, AM J EPIDEMIOL, V137, P559, DOI 10.1093/oxfordjournals.aje.a116709; Wisse BE, 2004, J AM SOC NEPHROL, V15, P2792, DOI 10.1097/01.ASN.0000141966.69934.21; Witasp A, 2011, J INTERN MED, V269, P410, DOI 10.1111/j.1365-2796.2010.02293.x; Yang SY, 2007, BLOOD PURIFICAT, V25, P252, DOI 10.1159/000101698; Yu HI, 2004, DIABETIC MED, V21, P336, DOI 10.1111/j.1464-5491.2004.01144.x; Zeymer U, 2009, CLIN RES CARDIOL, V98, P249, DOI 10.1007/s00392-009-0754-1; Zoccali C, 2004, NEPHROL DIAL TRANSPL, V19, P67, DOI 10.1093/ndt/gfh1059	49	8	8	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2013	8	6							e67555	10.1371/journal.pone.0067555	http://dx.doi.org/10.1371/journal.pone.0067555			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	174IH	23840739	Green Published, Green Submitted, gold			2023-01-03	WOS:000321148400106
J	Hermann, PC; Trabulo, SM; Sainz, B; Balic, A; Garcia, E; Hahn, SA; Vandana, M; Sahoo, SK; Tunici, P; Bakker, A; Hidalgo, M; Heeschen, C				Hermann, Patrick C.; Trabulo, Sara M.; Sainz, Bruno, Jr.; Balic, Anamaria; Garcia, Elena; Hahn, Stephan A.; Vandana, Mallaredy; Sahoo, Sanjeeb K.; Tunici, Patrizia; Bakker, Annette; Hidalgo, Manuel; Heeschen, Christopher			Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts	PLOS ONE			English	Article							SELF-RENEWAL; GEMCITABINE	Purpose: In spite of intense research efforts, pancreatic ductal adenocarcinoma remains one of the most deadly malignancies in the world. We and others have previously identified a subpopulation of pancreatic cancer stem cells within the tumor as a critical therapeutic target and additionally shown that the tumor stroma represents not only a restrictive barrier for successful drug delivery, but also serves as a paracrine niche for cancer stem cells. Therefore, we embarked on a large-scale investigation on the effects of combining chemotherapy, hedgehog pathway inhibition, and mTOR inhibition in a preclinical mouse model of pancreatic cancer. Experimental Design: Prospective and randomized testing in a set of almost 200 subcutaneous and orthotopic implanted whole-tissue primary human tumor xenografts. Results: The combined targeting of highly chemoresistant cancer stem cells as well as their more differentiated progenies, together with abrogation of the tumor microenvironment by targeting the stroma and enhancing tissue penetration of the chemotherapeutic agent translated into significantly prolonged survival in preclinical models of human pancreatic cancer. Most pronounced therapeutic effects were observed in gemcitabine-resistant patient-derived tumors. Intriguingly, the proposed triple therapy approach could be further enhanced by using a PEGylated formulation of gemcitabine, which significantly increased its bioavailability and tissue penetration, resulting in a further improved overall outcome. Conclusions: This multimodal therapeutic strategy should be further explored in the clinical setting as its success may eventually improve the poor prognosis of patients with pancreatic ductal adenocarcinoma.	[Hermann, Patrick C.; Trabulo, Sara M.; Sainz, Bruno, Jr.; Balic, Anamaria; Heeschen, Christopher] Spanish Natl Canc Res Ctr CNIO, Clin Res Programme, Stem Cells & Canc Grp, Madrid, Spain; [Garcia, Elena; Hidalgo, Manuel] Spanish Natl Canc Res Ctr CNIO, Clin Res Programme, Gastrointestinal Canc Clin Res Unit, Madrid, Spain; [Hahn, Stephan A.] Ruhr Univ Bochum, Dept Mol GI Oncol, Bochum, Germany; [Vandana, Mallaredy; Sahoo, Sanjeeb K.] Inst Life Sci, Nanomed Lab, Bhubaneswar, Orissa, India; [Tunici, Patrizia] Siena Biotech SpA, Dept Oncol, Siena, Italy; [Bakker, Annette] Childrens Tumor Fdn, New York, NY USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Ruhr University Bochum; Department of Biotechnology (DBT) India; Institute of Life Sciences India (ILS); Siena Biotech	Heeschen, C (corresponding author), Spanish Natl Canc Res Ctr CNIO, Clin Res Programme, Stem Cells & Canc Grp, Madrid, Spain.	cheeschen@cnio.es	Guba, Markus/M-4309-2019; Hahn, Stephan/E-3880-2010; Hermann, Patrick/Y-6254-2019; Anding, Bruno Sainz/ABH-5365-2020; Hahn, Stephan A./AAV-6062-2021; HIDALGO, MANUEL/I-4995-2015; Sanjeeb, Sahoo/ABF-3419-2020	Hahn, Stephan/0000-0003-0855-9741; Hermann, Patrick/0000-0003-0418-0478; Anding, Bruno Sainz/0000-0003-4829-7651; Hahn, Stephan A./0000-0003-0855-9741; HIDALGO, MANUEL/0000-0002-3765-3318; Balic, Anamaria/0000-0001-6796-1197; Heeschen, Christopher/0000-0002-1158-8554; bakker, annette/0000-0001-8420-7831	Siena Biotech, an ERC [Pa-CSC 233460]; Subdireccion General de Evaluacion y Fomento de la Investigacion, Fondo de Investigacion Sanitaria; Ministerio de Ciencia e Innovacion, Spain [PS09/02129]; Programa Nacional de Internacionalizacion de la I+D, Subprogramma: FCCI 2009 (Modalidad ACI-PLAN E Celulas Madre Proyectos [PLE2009-0105]; Modalidad ACI-Colobra India	Siena Biotech, an ERC; Subdireccion General de Evaluacion y Fomento de la Investigacion, Fondo de Investigacion Sanitaria; Ministerio de Ciencia e Innovacion, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Programa Nacional de Internacionalizacion de la I+D, Subprogramma: FCCI 2009 (Modalidad ACI-PLAN E Celulas Madre Proyectos; Modalidad ACI-Colobra India	The present work was supported by unrestricted research grant from Siena Biotech, an ERC Advanced Investigator Grant (Pa-CSC 233460), the Subdireccion General de Evaluacion y Fomento de la Investigacion, Fondo de Investigacion Sanitaria (PS09/02129, Ministerio de Ciencia e Innovacion, Spain) and the Programa Nacional de Internacionalizacion de la I+D, Subprogramma: FCCI 2009 (Modalidad ACI-PLAN E Celulas Madre Proyectos PLE2009-0105 and Modalidad ACI-Colobra India, both Ministerio de Ciencia e Innovacion). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asuthkar S, 2012, EXPERT OPIN INV DRUG, V21, P143, DOI 10.1517/13543784.2012.651124; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Cosco D, 2009, CANCER CHEMOTH PHARM, V64, P1009, DOI 10.1007/s00280-009-0957-1; Ferruzzi P, 2012, INT J CANCER, V131, pE33, DOI 10.1002/ijc.27349; Gallmeier E, 2011, STEM CELLS, V29, P418, DOI 10.1002/stem.595; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hermann PC, 2010, SEMIN CANCER BIOL, V20, P77, DOI 10.1016/j.semcancer.2010.03.004; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jimeno A, 2009, MOL CANCER THER, V8, P310, DOI 10.1158/1535-7163.MCT-08-0924; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009; Lonardo E, 2012, CELL CYCLE, V11, P1282, DOI 10.4161/cc.19679; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Lonardo E, 2010, MOL ONCOL, V4, P431, DOI 10.1016/j.molonc.2010.06.002; Matano E, 2000, BRIT J CANCER, V82, P1772, DOI 10.1054/bjoc.1999.1139; Mueller MT, 2009, GASTROENTEROLOGY, V137, P1102, DOI 10.1053/j.gastro.2009.05.053; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Philip PA, 2009, J CLIN ONCOL, V27, P5660, DOI 10.1200/JCO.2009.21.9022; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rothenberg ML, 1996, ANN ONCOL, V7, P347; Vandana M, 2010, BIOMATERIALS, V31, P9340, DOI 10.1016/j.biomaterials.2010.08.010; Von Hoff DD, 2011, J CLIN ONCOLOGY; Von Hoff DD, 2011, CELL STEM CELL; Wang Y, 2007, KIDNEY INT; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028	28	28	28	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2013	8	6							e66371	10.1371/journal.pone.0066371	http://dx.doi.org/10.1371/journal.pone.0066371			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	166SA	23825539	Green Submitted, Green Published, gold			2023-01-03	WOS:000320576400094
J	Liu, L; Wang, ZW; Jiang, SQ; Shao, BF; Liu, JB; Zhang, SQ; Zhou, YL; Zhou, Y; Zhang, YX				Liu, Lei; Wang, Zhiwei; Jiang, Songqi; Shao, Bingfeng; Liu, Jibing; Zhang, Suqing; Zhou, Yilong; Zhou, Yuan; Zhang, Yixin			Perioperative Allogenenic Blood Transfusion Is Associated with Worse Clinical Outcomes for Hepatocellular Carcinoma: A Meta-Analysis	PLOS ONE			English	Article							MALIGNANT HEPATOBILIARY DISEASES; 1222 CONSECUTIVE PATIENTS; HEPATIC RESECTION; CURATIVE RESECTION; SYSTEMATIC REVIEWS; FAS LIGAND; INTRAHEPATIC RECURRENCE; PROSPECTIVE DATABASE; PROGNOSTIC-FACTORS; CELL TRANSFUSION	Background and Objective: The impact of perioperative allogenenic blood transfusion (ABT) on clinical outcomes for hepatocellular carcinoma (HCC) is conflicting and unclear. The aim of this meta-analysis is to evaluate the association between ABT and HCC clinical outcomes. Outcomes evaluated were all-cause death, tumor recurrence and postoperative complications. Methods: Relevant articles were identified through MEDLINE search (up to November 2012). Meta-analyses were performed by using the fixed or random effect models. Study heterogeneity was assessed by Q-test and I-2 test. Publication bias was evaluated by funnel plots, Egger's and Begg's test. Results: A total of 5635 cases from 22 studies finally met our inclusion criteria. Meta-analysis indicated HCC patients with ABT had an increased risk of all-cause death at 3 and 5 years after surgery (respectively: OR = 1.92, 95% CI, 1.61-2.29, P<0.001; OR = 1.60, 95% CI, 1.47-1.73, P<0.001) compared with those without ABT. The risk of tumor recurrence was significantly higher for ABT cases at 1, 3 and 5 years (respectively: OR = 1.70, 95% CI, 1.38-2.10, P<0.001; OR = 1.22, 95% CI, 1.08-1.38, P<0.001; OR = 1.16, 95% CI, 1.08-1.24, P<0.001). The HCC cases with ABT significantly increased postoperative complications occurrence compared with non-ABT cases (OR = 1.78,95% CI, 1.34-2.37, P<0.001). Conclusions: The findings from the current meta-analysis demonstrated that ABT was associated with adverse clinical outcomes for HCC patients undergoing surgery, including increased death, recurrence and complications. Therefore, ABT should not be performed if possible.	[Liu, Lei; Jiang, Songqi; Shao, Bingfeng; Liu, Jibing; Zhang, Suqing; Zhou, Yilong; Zhou, Yuan; Zhang, Yixin] Affiliated Tumor Hosp Nantong Univ, Dept Surg, Nantong, Jiangsu, Peoples R China; [Wang, Zhiwei] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Surg, Shanghai 200030, Peoples R China	Nantong University; Shanghai Jiao Tong University	Zhang, YX (corresponding author), Affiliated Tumor Hosp Nantong Univ, Dept Surg, Nantong, Jiangsu, Peoples R China.	Doczhangyx@126.com			Natural Science Foundation Jiangsu Ministry of Health [H200957]	Natural Science Foundation Jiangsu Ministry of Health	This study was supported by a grant from The Natural Science Foundation Jiangsu Ministry of Health (grant no.: H200957). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Wahab M, 2010, LANGENBECK ARCH SURG, V395, P625, DOI 10.1007/s00423-010-0643-0; Acheson AG, 2012, ANN SURG, V256, P235, DOI 10.1097/SLA.0b013e31825b35d5; Akobeng AK, 2005, ARCH DIS CHILD, V90, P845, DOI 10.1136/adc.2004.058230; Asahara T, 1999, WORLD J SURG, V23, P676, DOI 10.1007/PL00012367; Blajchman MA, 1998, VOX SANG, V74, P315, DOI 10.1111/j.1423-0410.1998.tb05437.x; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; Cescon M, 2009, ANN SURG, V249, P995, DOI 10.1097/SLA.0b013e3181a63c74; Choi GH, 2009, J GASTROEN HEPATOL, V24, P391, DOI 10.1111/j.1440-1746.2008.05637.x; Domen RE, 2003, ARCH PATHOL LAB MED, V127, P316; Ercolani G, 2003, ANN SURG, V237, P536, DOI 10.1097/00000658-200304000-00016; Gang Chen, 2007, Journal of Zhejiang University-Science B, V8, P560, DOI 10.1631/jzus.2007.B0560; Ghio M, 1999, BLOOD, V93, P1770, DOI 10.1182/blood.V93.5.1770.405a14_1770_1777; Hanazaki K, 2005, HEPATO-GASTROENTEROL, V52, P524; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Ho WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029179; Huang J, 2009, J GASTROINTEST SURG, V13, P1627, DOI 10.1007/s11605-009-0933-4; Itasaka H, 1995, HEPATO-GASTROENTEROL, V42, P465; Kaibori M, 2008, ANTICANCER RES, V28, P1749; Kitagawa K, 2001, ANTICANCER RES, V21, P3663; Kuroda S, 2012, WORLD J SURG, V36, P651, DOI 10.1007/s00268-012-1425-3; Kwon AH, 2001, CANCER-AM CANCER SOC, V91, P771; Laurent C, 2005, J AM COLL SURGEONS, V201, P656, DOI 10.1016/j.jamcollsurg.2005.05.027; Leucht S, 2009, ACTA PSYCHIAT SCAND, V119, P443, DOI 10.1111/j.1600-0447.2009.01388.x; Mak A, 2010, INT J RHEUM DIS, V13, P101, DOI 10.1111/j.1756-185X.2010.01471.x; Makino Y, 2000, AM J GASTROENTEROL, V95, P1294; Marcucci C, 2004, BRIT MED BULL, V70, P15, DOI 10.1093/bmb/ldh023; Mathurin P, 2003, ALIMENT PHARM THER, V17, P1247, DOI 10.1046/j.1365-2036.2003.01580.x; MATSUMATA T, 1993, CANCER, V72, P1866, DOI 10.1002/1097-0142(19930915)72:6<1866::AID-CNCR2820720613>3.0.CO;2-F; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Nanashima A, 2011, ANTICANCER RES, V31, P4545; NIELSEN HJ, 1995, BRIT J SURG, V82, P582, DOI 10.1002/bjs.1800820505; Okamura Y, 2011, J SURG ONCOL, V104, P814, DOI 10.1002/jso.21977; Peng BG, 2009, AM J SURG, V198, P313, DOI 10.1016/j.amjsurg.2008.09.026; Poon RT, 2004, ANN SURG, V240, P698, DOI 10.1097/01.sla.0000141195.66155.0c; Puppo F, 2000, INT IMMUNOL, V12, P195, DOI 10.1093/intimm/12.2.195; Puppo F, 2001, TRANSFUSION, V41, P416, DOI 10.1046/j.1537-2995.2001.41030416.x; Sasaki Y, 2002, CANCER-AM CANCER SOC, V94, P1777, DOI 10.1002/cncr.10402; Sasaki Y, 2006, ANN SURG, V244, P771, DOI 10.1097/01.sla.0000225126.56483.b3; Sauerland S, 2005, WORLD J SURG, V29, P582, DOI 10.1007/s00268-005-7917-7; Sugita S, 2008, EJSO-EUR J SURG ONC, V34, P339, DOI 10.1016/j.ejso.2007.02.010; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; Vamvakas EC, 2007, BLOOD REV, V21, P327, DOI 10.1016/j.blre.2007.07.003; Venook AP, 2010, ONCOLOGIST, V15, P5, DOI 10.1634/theoncologist.2010-S4-05; Wall WJ, 2000, LIVER TRANSPLANT, V6, pS16, DOI 10.1053/jlts.2000.19010; Wang CC, 2009, ANN SURG ONCOL, V16, P1832, DOI 10.1245/s10434-009-0448-y; Wei AC, 2003, BRIT J SURG, V90, P33, DOI 10.1002/bjs.4018; Yamamoto J, 1996, BRIT J SURG, V83, P1219; Yang T, 2011, WORLD J SURG, V35, P2073, DOI 10.1007/s00268-011-1161-0; Yao HS, 2008, WORLD J SURG, V32, P2038, DOI 10.1007/s00268-008-9675-9; Ydy LRA, 2007, WORLD J SURG, V31, P2044, DOI 10.1007/s00268-007-9159-3	50	89	99	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2013	8	5							e64261	10.1371/journal.pone.0064261	http://dx.doi.org/10.1371/journal.pone.0064261			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	156DC	23741309	Green Submitted, Green Published, gold			2023-01-03	WOS:000319799900021
J	Schanen, BC; Das, S; Reilly, CM; Warren, WL; Self, WT; Seal, S; Drake, DR				Schanen, Brian C.; Das, Soumen; Reilly, Christopher M.; Warren, William L.; Self, William T.; Seal, Sudipta; Drake, Donald R., III			Immunomodulation and T Helper TH1/TH2 Response Polarization by CeO2 and TiO2 Nanoparticles	PLOS ONE			English	Article							CERIUM OXIDE NANOPARTICLES; DENDRITIC CELL MATURATION; ANTIGEN-PRESENTING CELLS; REACTIVE OXYGEN; IN-VITRO; TITANIUM-DIOXIDE; CYTOKINE RELEASE; SURFACE; ACTIVATION; MODEL	Immunomodulation by nanoparticles, especially as related to the biochemical properties of these unique materials, has scarcely been explored. In an in vitro model of human immunity, we demonstrate two catalytic nanoparticles, TiO2 (oxidant) and CeO2 (antioxidant), have nearly opposite effects on human dendritic cells and T helper (T-H) cells. For example, whereas TiO2 nanoparticles potentiated DC maturation that led towards T(H)1-biased responses, treatment with antioxidant CeO2 nanoparticles induced APCs to secrete the anti-inflammatory cytokine, IL-10, and induce a T(H)2-dominated T cell profile. In subsequent studies, we demonstrate these results are likely explained by the disparate capacities of the nanoparticles to modulate ROS, since TiO2, but not CeO2 NPs, induced inflammatory responses through an ROS/inflammasome/IL-1 beta pathway. This novel capacity of metallic NPs to regulate innate and adaptive immunity in profoundly different directions via their ability to modulate dendritic cell function has strong implications for human health since unintentional exposure to these materials is common in modern societies.	[Schanen, Brian C.; Warren, William L.; Drake, Donald R., III] Sanofi Pasteur, Orlando, FL USA; [Schanen, Brian C.; Warren, William L.; Self, William T.] UCF Coll Med, Dept Mol Biol & Microbiol, Burnett Sch Biomed Sci, Orlando, FL USA; [Das, Soumen; Seal, Sudipta] Nanosci & Technol Ctr NSTC, Dept Mech Mat & Aerosp Engn MMAE, AMPAC, Orlando, FL USA; [Reilly, Christopher M.] Virginia Tech, Virginia Maryland Reg Coll Vet Med, Virginia Coll Osteopath Med Res, Blacksburg, VA USA	Sanofi-Aventis; State University System of Florida; University of Central Florida; Virginia Polytechnic Institute & State University	Drake, DR (corresponding author), Sanofi Pasteur, VaxDesign Campus, Orlando, FL USA.	Donald.Drake@sanofipasteur.com	Self, William/Q-4113-2019; Self, William/A-6704-2008; Seal, Sudipta/A-7698-2012	Self, William/0000-0001-9874-0194	NSF [CBET-0711239]	NSF(National Science Foundation (NSF))	This work was funded by NSF Grant CBET-0711239 (http://www.nsf.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allouni ZE, 2012, TOXICOL IN VITRO, V26, P469, DOI 10.1016/j.tiv.2012.01.019; Asati A, 2010, ACS NANO, V4, P5321, DOI 10.1021/nn100816s; Bar-Ilan O, NANOTOXICOLOGY, V0, P1; Boonstra A, 2006, J IMMUNOL, V177, P7551, DOI 10.4049/jimmunol.177.11.7551; Boscolo P, 2010, J BIOL REG HOMEOS AG, V24, P207; Bruchhausen S, 2003, J INVEST DERMATOL, V121, P1039, DOI 10.1046/j.1523-1747.2003.12510.x; Byers AM, 2009, BIOLOGICALS, V37, P148, DOI 10.1016/j.biologicals.2009.02.018; Cai X, 2012, BIOMATERIALS, V33, P8771, DOI 10.1016/j.biomaterials.2012.08.030; Chauveau C, 2005, BLOOD, V106, P1694, DOI 10.1182/blood-2005-02-0494; Churg A, 1998, AM J PHYSIOL-LUNG C, V274, pL81, DOI 10.1152/ajplung.1998.274.1.L81; Colon J, 2010, NANOMED-NANOTECHNOL, V6, P698, DOI 10.1016/j.nano.2010.01.010; Deng ZJ, 2011, NAT NANOTECHNOL, V6, P39, DOI 10.1038/NNANO.2010.250; Dhir V, 2011, J IMMUNOTOXICOL; Dhir V, 2012, J IMMUNOTOXICOL, V9, P34, DOI 10.3109/1547691X.2011.613419; Donaldson K, 1996, TOXICOL LETT, V88, P293, DOI 10.1016/0378-4274(96)03752-6; Dowding JM, 2012, CHEM COMMUN, V48, P4896, DOI 10.1039/c2cc30485f; Drake DR, 2012, DISRUPTIVE SCI TECHN, V1, P28; Duffin R, 2007, INHAL TOXICOL, V19, P849, DOI 10.1080/08958370701479323; Fan AM, 2010, J NANOSCI NANOTECHNO, V10, P8646, DOI 10.1166/jnn.2010.2493; Fialkow L, 2007, FREE RADICAL BIO MED, V42, P153, DOI 10.1016/j.freeradbiomed.2006.09.030; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Gaiser BK, 2012, ENVIRON TOXICOL CHEM, V31, P144, DOI 10.1002/etc.703; Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292; Goncalves DM, 2010, TOXICOL IN VITRO, V24, P1002, DOI 10.1016/j.tiv.2009.12.007; Hanley C, 2009, NANOSCALE RES LETT, V4, P1409, DOI 10.1007/s11671-009-9413-8; Higbee RG, 2009, ATLA-ALTERN LAB ANIM, V37, P19, DOI 10.1177/026119290903701S05; Hirst SM, 2009, SMALL, V5, P2848, DOI 10.1002/smll.200901048; Karakoti AS, 2009, J AM CHEM SOC, V131, P14144, DOI 10.1021/ja9051087; Kotake Y, 2003, SHOCK, V19, P252, DOI 10.1097/00024382-200303000-00009; Lamkanfi M, 2009, J BIOL CHEM, V284, P20574, DOI 10.1074/jbc.M109.023689; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Liu Y, 2009, BIOMATERIALS, V30, P3934, DOI 10.1016/j.biomaterials.2009.04.001; Lutsiak MEC, 2006, J PHARM PHARMACOL, V58, P739, DOI 10.1211/jpp.58.6.0004; Ma YF, 2010, IMMUNOLOGY, V130, P374, DOI 10.1111/j.1365-2567.2009.03237.x; Mayer A, 2009, TOXICOLOGY, V258, P139, DOI 10.1016/j.tox.2009.01.015; MNneil SE, 2005, J LEUKOCYTE BIOL, V78, P585, DOI 10.1189/jlb.0205074; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Moser JM, 2010, J IMMUNOL METHODS, V353, P8, DOI 10.1016/j.jim.2009.11.006; Patil S, 2007, BIOMATERIALS, V28, P4600, DOI 10.1016/j.biomaterials.2007.07.029; Paulsen M, 2011, CELL DEATH DIFFER, V18, P619, DOI 10.1038/cdd.2010.134; Rutault K, 1999, FREE RADICAL BIO MED, V26, P232, DOI 10.1016/S0891-5849(98)00194-4; Schanen BC, 2008, J IMMUNOL METHODS, V335, P53, DOI 10.1016/j.jim.2008.02.021; Schanen BC, 2011, VACCINE, V29, P3299, DOI 10.1016/j.vaccine.2011.02.019; Schanen BC, 2009, ACS NANO, V3, P2523, DOI 10.1021/nn900403h; Schroecksnadel Katharina, 2007, Drug Metab Lett, V1, P166; Shin SH, 2007, INT IMMUNOPHARMACOL, V7, P1813, DOI 10.1016/j.intimp.2007.08.025; Song HF, 2010, VACCINE, V28, P5524, DOI 10.1016/j.vaccine.2010.06.044; Stringer B, 1996, AM J RESP CELL MOL, V14, P155, DOI 10.1165/ajrcmb.14.2.8630265; Sun Q, 2012, J BIOMED MAT RES A; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Thevenot P, 2008, CURR TOP MED CHEM, V8, P270; Thevenot P, 2008, NANOMED-NANOTECHNOL, V4, P226, DOI 10.1016/j.nano.2008.04.001; Tse HM, 2004, FREE RADICAL BIO MED, V36, P233, DOI 10.1016/j.freeradbiomed.2003.10.029; Warheit David B, 2009, Inhal Toxicol, V21 Suppl 1, P61, DOI 10.1080/08958370902942640; Wason MS, 2012, NANOMEDICINE; Wittman V, 2010, IDRUGS, V13, P248; Xu MH, 1998, SUPRAMOL SCI, V5, P449, DOI 10.1016/S0968-5677(98)00048-0; Yang D, 2010, ACS NANO, V4, P1178, DOI 10.1021/nn901478z; Yang HY, 2004, J APPL POLYM SCI, V92, P3201, DOI 10.1002/app.20327; Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107; Zhang AP, 2004, WORLD J GASTROENTERO, V10, P3191; Zhu ZJ, 2008, J AM CHEM SOC, V130, P14139, DOI 10.1021/ja805392f	63	62	66	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 8	2013	8	5							e62816	10.1371/journal.pone.0062816	http://dx.doi.org/10.1371/journal.pone.0062816			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	145YI	23667525	Green Published, gold, Green Submitted			2023-01-03	WOS:000319055600046
J	Pilakka-Kanthikeel, S; Atluri, VSR; Sagar, V; Saxena, SK; Nair, M				Pilakka-Kanthikeel, Sudheesh; Atluri, Venkata Subba Rao; Sagar, Vidya; Saxena, Shailendra K.; Nair, Madhavan			Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study	PLOS ONE			English	Article							ELEMENT-BINDING PROTEIN; HIV-ASSOCIATED DEMENTIA; CENTRAL-NERVOUS-SYSTEM; LONG-TERM-MEMORY; FACTOR PREVENTS; SUBSTANTIA-NIGRA; EXPOSURE ALTERS; RAT HIPPOCAMPUS; SPINE DENSITY; CELL-DEATH	Parenteral use of drugs; such as opiates exert immunomodulatory effects and serve as a cofactor in the progression of HIV-1 infection, thereby potentiating HIV related neurotoxicity ultimately leading to progression of NeuroAIDS. Morphine exposure is known to induce apoptosis, down regulate cAMP response element-binding (CREB) expression and decrease in dendritic branching and spine density in cultured cells. Use of neuroprotective agent; brain derived neurotropic factor (BDNF), which protects neurons against these effects, could be of therapeutic benefit in the treatment of opiate addiction. Previous studies have shown that BDNF was not transported through the blood brain barrier (BBB) in-vivo.; and hence it is not effective in-vivo. Therefore development of a drug delivery system that can cross BBB may have significant therapeutic advantage. In the present study, we hypothesized that magnetically guided nanocarrier may provide a viable approach for targeting BDNF across the BBB. We developed a magnetic nanoparticle (MNP) based carrier bound to BDNF and evaluated its efficacy and ability to transmigrate across the BBB using an in-vitro BBB model. The end point determinations of BDNF that crossed BBB were apoptosis, CREB expression and dendritic spine density measurement. We found that transmigrated BDNF was effective in suppressing the morphine induced apoptosis, inducing CREB expression and restoring the spine density. Our results suggest that the developed nanocarrier will provide a potential therapeutic approach to treat opiate addiction, protect neurotoxicity and synaptic density degeneration.	[Pilakka-Kanthikeel, Sudheesh; Atluri, Venkata Subba Rao; Sagar, Vidya; Nair, Madhavan] Florida Int Univ, Herbert Wertheim Coll Med, Inst NeuroImmune Pharmacol, Dept Immunol, Miami, FL 33199 USA; [Saxena, Shailendra K.] CSIR Ctr Cellular & Mol Biol, Hyderabad, Andhra Pradesh, India	State University System of Florida; Florida International University; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Nair, M (corresponding author), Florida Int Univ, Herbert Wertheim Coll Med, Inst NeuroImmune Pharmacol, Dept Immunol, Miami, FL 33199 USA.	nairm@fiu.edu	Saxena, Shailendra K/ABK-6489-2022; Saxena, Shailendra K/X-4252-2019; Atluri, Venkata/G-3277-2014	Saxena, Shailendra K/0000-0003-2856-4185; Saxena, Shailendra K/0000-0003-2856-4185; Atluri, Venkata/0000-0002-8070-6745	National Institute of Drug abuse [1R01-DA027049]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA027049] Funding Source: NIH RePORTER	National Institute of Drug abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by grant from National Institute of Drug abuse (1R01-DA027049). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134; Alexiou C, 2006, EUR BIOPHYS J BIOPHY, V35, P446, DOI 10.1007/s00249-006-0042-1; Alonso M, 2005, LEARN MEMORY, V12, P504, DOI 10.1101/lm.27305; ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347; AYRE SG, 1989, MED HYPOTHESES, V29, P283, DOI 10.1016/0306-9877(89)90113-8; Bachis A, 2003, J NEUROSCI, V23, P5715; Bernabeu R, 1997, P NATL ACAD SCI USA, V94, P7041, DOI 10.1073/pnas.94.13.7041; BETZ AL, 1980, BRAIN RES, V192, P17, DOI 10.1016/0006-8993(80)91004-5; BETZ AL, 1986, ANNU REV PHYSIOL, V48, P241; BETZ AL, 1978, SCIENCE, V202, P225, DOI 10.1126/science.211586; Blitts B, 2003, NEUROSCIENCE, V118, P271, DOI 10.1016/S0306-4522(02)00970-3; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Boyum A, 1968, SCAND J CLIN LAB INV, P77; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Cammarota M, 2000, MOL BRAIN RES, V76, P36, DOI 10.1016/S0169-328X(99)00329-0; Chapleau CA, 2008, J NEUROSCI METH, V169, P182, DOI 10.1016/j.jneumeth.2007.12.006; Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050; Frankfurt M, 2011, SYNAPSE, V65, P955, DOI 10.1002/syn.20918; FREIER DO, 1993, J PHARMACOL EXP THER, V265, P81; FUCHS BA, 1993, J PHARMACOL EXP THER, V266, P417; Gandhi N, 2010, J NEUROVIROL, V16, P294, DOI 10.3109/13550284.2010.499891; Garden GA, 2002, J NEUROSCI, V22, P4015, DOI 10.1523/JNEUROSCI.22-10-04015.2002; Goswami R, 1998, J NEUROCHEM, V70, P1376; Guo CJ, 2002, J INVEST MED, V50, P435, DOI 10.1136/jim-50-06-03; Han B, 2009, ADDICTION, V104, P88, DOI 10.1111/j.1360-0443.2008.02411.x; Han BH, 2000, NEUROBIOL DIS, V7, P38; HURWITZ AA, 1994, ADV NEUROIMMUNOL, V4, P249, DOI 10.1016/S0960-5428(06)80263-9; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1; Itoh K, 2000, ACTA NEUROPATHOL, V99, P376, DOI 10.1007/s004010051139; James HJ, 1999, NEUROPATH APPL NEURO, V25, P380, DOI 10.1046/j.1365-2990.1999.00195.x; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kwon M, 2011, J NEUROSCI, V31, P9735, DOI 10.1523/JNEUROSCI.6785-10.2011; Kwon SG, 2007, J AM CHEM SOC, V129, P12571, DOI 10.1021/ja074633q; Li YF, 2007, NEUROSCI LETT, V418, P227, DOI 10.1016/j.neulet.2007.03.023; Lubbe AS, 1996, CANCER RES, V56, P4694; Mahajan SD, 2005, CLIN IMMUNOL, V115, P323, DOI 10.1016/j.clim.2005.02.004; Mamounas LA, 1995, J NEUROSCI, V15, P7929; Mandel RJ, 1999, EXP NEUROL, V155, P59, DOI 10.1006/exnr.1998.6961; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Mocchetti I, 2007, ANN NY ACAD SCI, V1122, P144, DOI 10.1196/annals.1403.010; Nair MPN, 1997, CLIN DIAGN LAB IMMUN, V4, P127, DOI 10.1128/CDLI.4.2.127-132.1997; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nosheny RL, 2007, EUR J NEUROSCI, V25, P2275, DOI 10.1111/j.1460-9568.2007.05506.x; Pardridge WM, 2007, DRUG DISCOV TODAY, V12, P54, DOI 10.1016/j.drudis.2006.10.013; Pardridge WM, 1998, PHARMACEUT RES, V15, P576, DOI 10.1023/A:1011981927620; Persidsky Y, 1997, J IMMUNOL, V158, P3499; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Purohit V, 2011, MOL NEUROBIOL, V44, P102, DOI 10.1007/s12035-011-8195-z; Robinson TE, 1999, EUR J NEUROSCI, V11, P1598, DOI 10.1046/j.1460-9568.1999.00576.x; Roy S, 1996, NEUROCHEM RES, V21, P1375, DOI 10.1007/BF02532379; Saiyed ZM, 2007, J BIOTECHNOL, V131, P240, DOI 10.1016/j.jbiotec.2007.06.017; Saiyed ZM, 2007, ANAL BIOCHEM, V363, P288, DOI 10.1016/j.ab.2007.01.008; Saiyed ZM, 2010, INT J NANOMED, V5, P157; Saiyed ZM, 2009, J NEUROVIROL, V15, P343, DOI 10.1080/13550280903062813; Sarti F, 2007, EUR J NEUROSCI, V26, P749, DOI 10.1111/j.1460-9568.2007.05689.x; Silva GA, 2007, SURG NEUROL, V67, P113, DOI 10.1016/j.surneu.2006.08.033; Singhal PC, 1998, J IMMUNOL, V160, P1886; Singhal PG, 1999, J LEUKOCYTE BIOL, V66, P650, DOI 10.1002/jlb.66.4.650; Smith DL, 2009, P NATL ACAD SCI USA, V106, P16877, DOI 10.1073/pnas.0908706106; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; Strathdee Steffanie A, 2010, Curr HIV/AIDS Rep, V7, P99, DOI 10.1007/s11904-010-0043-7; Suri Sarabjeet Singh, 2007, J Occup Med Toxicol, V2, P16, DOI 10.1186/1745-6673-2-16; Taubenfeld SM, 1999, NAT NEUROSCI, V2, P309, DOI 10.1038/7217; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Thorne RG, 2001, CLIN PHARMACOKINET, V40, P907, DOI 10.2165/00003088-200140120-00003; Viola HE, 2000, J NEUROSCI, V20; Wallace DR, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/65741; Wang GJ, 2004, BRAIN, V127, P2452, DOI 10.1093/brain/awh269; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Xia Y, 2010, NEUROPHARMACOLOGY, V58, P330, DOI 10.1016/j.neuropharm.2009.10.009; Yin DL, 1999, NATURE, V397, P218, DOI 10.1038/16612	72	68	71	1	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62241	10.1371/journal.pone.0062241	http://dx.doi.org/10.1371/journal.pone.0062241			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23653680	gold, Green Published			2023-01-03	WOS:000319077300033
J	Ayuso-Mateos, JL; Miret, M; Caballero, FF; Olaya, B; Haro, JM; Kowal, P; Chatterji, S				Luis Ayuso-Mateos, Jose; Miret, Marta; Felix Caballero, Francisco; Olaya, Beatriz; Maria Haro, Josep; Kowal, Paul; Chatterji, Somnath			Multi-Country Evaluation of Affective Experience: Validation of an Abbreviated Version of the Day Reconstruction Method in Seven Countries	PLOS ONE			English	Article							CONFIRMATORY FACTOR-ANALYSIS; POSITIVE AFFECT; LIFE	Background: The Day Reconstruction Method (DRM) was developed to assess affective states as measures of experienced well-being. The present study aimed to validate an abbreviated version of the DRM in a representative sample of the population in seven countries (China, Ghana, India, Mexico, Russia, South Africa, and Spain), and to examine whether there are country differences in affect and in the relationships among the activities based on the similarity of the affect associated with each of them. Methods: Interviews were conducted with 47,222 non-institutionalized adults from seven countries, using an abbreviated version of the DRM. A cluster analysis was carried out to classify activities on the basis of the similarity of the associated affect. In each country, the factorial structure of the affect adjectives was tested through Confirmatory Factor Analysis. Internal consistency and construct validity were also assessed. Moreover, the differences in affect across countries and the diurnal cycles of affect were evaluated. Results: The DRM showed adequate psychometric properties regarding reliability and construct validity in all countries. Respondents from Ghana and South Africa reported more positive net affect whereas Indian respondents reported less positive net affect. Most of the countries showed a similar diurnal variation of affect, which tended to improve throughout the day. Conclusions: The results show that this abbreviated version of the DRM is a useful tool for multi-country evaluation of experienced well-being.	[Luis Ayuso-Mateos, Jose; Miret, Marta; Felix Caballero, Francisco; Maria Haro, Josep] CIBERSAM, Inst Salud Carlos III, Ctr Invest Biomed Red Salud Mental, Madrid, Spain; [Luis Ayuso-Mateos, Jose; Miret, Marta; Felix Caballero, Francisco] Hosp Univ La Princesa, Inst Invest Sanitaria Princesa IP, Dept Psychiat, Madrid, Spain; [Luis Ayuso-Mateos, Jose; Miret, Marta; Felix Caballero, Francisco] Univ Autonoma Madrid, Dept Psychiat, Madrid, Spain; [Olaya, Beatriz; Maria Haro, Josep] Univ Barcelona, Barcelona, Spain; [Kowal, Paul; Chatterji, Somnath] WHO, Dept Hlth Stat & Informat Syst, CH-1211 Geneva, Switzerland; [Kowal, Paul] Univ Newcastle, Res Ctr Gender Hlth & Ageing, Newcastle, NSW 2300, Australia	CIBER - Centro de Investigacion Biomedica en Red; CIBERSAM; Instituto de Salud Carlos III; Autonomous University of Madrid; University of Barcelona; World Health Organization; University of Newcastle	Chatterji, S (corresponding author), WHO, Dept Hlth Stat & Informat Syst, CH-1211 Geneva, Switzerland.	chatterjis@who.int	Haro, Josep Maria/D-1423-2011; Olaya, Beatriz/AAB-1952-2020; Miret, Marta/C-6103-2019; CHATTERJI, Somnath/ABE-6832-2020	Haro, Josep Maria/0000-0002-3984-277X; Olaya, Beatriz/0000-0003-2046-3929; Miret, Marta/0000-0003-3252-854X; Kowal, Paul/0000-0002-6314-8753; Ayuso-Mateos, Jose Luis/0000-0002-7544-826X	United States National Institute on Aging's Division of Behavioral and Social Research [OGHA 04034785, YA1323-08-CN-0020, Y1-AG-1005-01, R01-AG034479]; World Health Organization's Department of Health Statistics and Information Systems; European Community [223071]; Instituto de Salud Carlos III-FIS [PS09/00295, PS09/01845]; Spanish Ministry of Science and Innovation ACI-Promociona [ACI2009-1010]; Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red de Salud Mental, CIBERSAM; NATIONAL INSTITUTE ON AGING [R01AG034479] Funding Source: NIH RePORTER	United States National Institute on Aging's Division of Behavioral and Social Research; World Health Organization's Department of Health Statistics and Information Systems; European Community(European Commission); Instituto de Salud Carlos III-FIS(Instituto de Salud Carlos IIIEuropean Commission); Spanish Ministry of Science and Innovation ACI-Promociona(Spanish Government); Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red de Salud Mental, CIBERSAM(Instituto de Salud Carlos III); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This paper uses data from WHO SAGE and from COURAGE in Europe. WHO's Study on Global Ageing and Adult Health is supported by the United States National Institute on Aging's Division of Behavioral and Social Research through Interagency Agreements (OGHA 04034785; YA1323-08-CN-0020; Y1-AG-1005-01) and through a research grant (R01-AG034479) and the World Health Organization's Department of Health Statistics and Information Systems. The research leading to these results has also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement number 223071 (COURAGE in Europe), from the Instituto de Salud Carlos III-FIS research grants number PS09/00295 and PS09/01845, and from the Spanish Ministry of Science and Innovation ACI-Promociona (ACI2009-1010). The study was supported by the Instituto de Salud Carlos III, Centro de Investigacion Biomedica en Red de Salud Mental, CIBERSAM. The authors would like to acknowledge the principal investigators at the SAGE sites: P. Arokiasamy (India), R. Biritwum (Ghana), Wu Fan (China), R. Lopez Riadura (Mexico), T. Maximova (Russian Federation) and N. Phaswanamafuya (South Africa). The views expressed in this paper are those of the author(s) and do not necessarily represent the views or policies of the World Health Organization. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.107.2.238; Bhattacharyya MR, 2008, PSYCHOSOM MED, V70, P1020, DOI 10.1097/PSY.0b013e318189afcc; Burnham K.P., 2011, MODEL SELECTION MULT, VNew ed; Bylsma LM, 2011, J ABNORM PSYCHOL, V120, P155, DOI 10.1037/a0021662; Cohen J., 2013, STAT POWER ANAL BEHA; Diener E, 2010, J PERS SOC PSYCHOL, V99, P52, DOI 10.1037/a0018066; Dockray S, 2010, SOC INDIC RES, V99, P269, DOI 10.1007/s11205-010-9578-7; Flora DB, 2004, PSYCHOL METHODS, V9, P466, DOI 10.1037/1082-989X.9.4.466; Goss CH, 2009, J CYST FIBROS, V8, P245, DOI 10.1016/j.jcf.2009.04.003; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Kahneman D, 2006, J ECON PERSPECT, V20, P3, DOI 10.1257/089533006776526030; Kahneman D, 2004, SCIENCE, V306, P1776, DOI 10.1126/science.1103572; Kahneman D, 2010, P NATL ACAD SCI USA, V107, P16489, DOI 10.1073/pnas.1011492107; Kopperud K. H., 2008, J POSIT PSYCHOL, V3, P174, DOI DOI 10.1080/17439760801999420; Kowal P, 2012, INT J EPIDEMIOL, V41, P1639, DOI 10.1093/ije/dys210; Krueger AB, 2008, J PUBLIC ECON, V92, P1833, DOI 10.1016/j.jpubeco.2007.12.015; Krueger AB, 2008, LANCET, V371, P1519, DOI 10.1016/S0140-6736(08)60656-X; Lucas RE, 1996, J PERS SOC PSYCHOL, V71, P616, DOI 10.1037/0022-3514.71.3.616; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Miret M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043887; Miron-Shatz T, 2009, EMOTION, V9, P206, DOI 10.1037/a0015295; Muthen L. K., 2010, MPLUS USERS GUIDE, V6th; Oishi Shigehiro., 2010, INT DIFFERENCES WELL, P34, DOI DOI 10.1093/ACPROF:OSO/9780199732739.003.0003; R Core Team, 2021, R LANG ENV STAT COMP; Raykov T., 2011, INTRO PSYCHOMETRIC T; REISE SP, 1993, PSYCHOL BULL, V114, P552, DOI 10.1037/0033-2909.114.3.552; Schreiber JB, 2006, J EDUC RES, V99, P323, DOI 10.3200/JOER.99.6.323-338; Schumacker R., 2004, BEGINNERS GUIDE STRU; SOKAL ROBERT R., 1962, TAXON, V11, P33, DOI 10.2307/1217208; Srivastava S, 2008, J RES PERS, V42, P1613, DOI 10.1016/j.jrp.2008.05.002; StataCorp, 2010, STAT STAT SOFTW REL; Steiger JH, 2007, PERS INDIV DIFFER, V42, P893, DOI 10.1016/j.paid.2006.09.017; Suzuki R, 2006, BIOINFORMATICS, V22, P1540, DOI 10.1093/bioinformatics/btl117; Yu C.Y., 2002, EVALUATING CUTOFF CR	35	27	28	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2013	8	4							e61534	10.1371/journal.pone.0061534	http://dx.doi.org/10.1371/journal.pone.0061534			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	131QH	23626697	Green Published, Green Submitted, gold			2023-01-03	WOS:000318008400061
J	Heyland, D; Muscedere, J; Wischmeyer, PE; Cook, D; Jones, G; Albert, M; Elke, G; Berger, MM; Day, AG				Heyland, Daren; Muscedere, John; Wischmeyer, Paul E.; Cook, Deborah; Jones, Gwynne; Albert, Martin; Elke, Gunnar; Berger, Mette M.; Day, Andrew G.		Canadian Critical Care Trials Grp	A Randomized Trial of Glutamine and Antioxidants in Critically Ill Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OXIDATIVE STRESS; SELENIUM; SUPPLEMENTATION	BACKGROUND Critically ill patients have considerable oxidative stress. Glutamine and antioxidant supplementation may offer therapeutic benefit, although current data are conflicting. METHODS In this blinded 2-by-2 factorial trial, we randomly assigned 1223 critically ill adults in 40 intensive care units (ICUs) in Canada, the United States, and Europe who had multiorgan failure and were receiving mechanical ventilation to receive supplements of glutamine, antioxidants, both, or placebo. Supplements were started within 24 hours after admission to the ICU and were provided both intravenously and enterally. The primary outcome was 28-day mortality. Because of the interim-analysis plan, a P value of less than 0.044 at the final analysis was considered to indicate statistical significance. RESULTS There was a trend toward increased mortality at 28 days among patients who received glutamine as compared with those who did not receive glutamine (32.4% vs. 27.2%; adjusted odds ratio, 1.28; 95% confidence interval [CI], 1.00 to 1.64; P = 0.05). In-hospital mortality and mortality at 6 months were significantly higher among those who received glutamine than among those who did not. Glutamine had no effect on rates of organ failure or infectious complications. Antioxidants had no effect on 28-day mortality (30.8%, vs. 28.8% with no antioxidants; adjusted odds ratio, 1.09; 95% CI, 0.86 to 1.40; P = 0.48) or any other secondary end point. There were no differences among the groups with respect to serious adverse events (P = 0.83). CONCLUSIONS Early provision of glutamine or antioxidants did not improve clinical outcomes, and glutamine was associated with an increase in mortality among critically ill patients with multiorgan failure. (Funded by the Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT00133978.)	[Heyland, Daren; Muscedere, John; Day, Andrew G.] Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada; [Cook, Deborah] St Josephs Healthcare, Hamilton, ON, Canada; [Jones, Gwynne] Ottawa Hosp, Ottawa, ON, Canada; [Albert, Martin] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada; [Wischmeyer, Paul E.] Univ Colorado, Sch Med, Aurora, CO USA; [Elke, Gunnar] Univ Med Ctr Schleswig Holstein, Kiel, Germany; [Berger, Mette M.] CHU Vaudois, Lausanne, Switzerland	Queens University - Canada; University of Ottawa; Ottawa Hospital Research Institute; Universite de Montreal; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Kiel; Schleswig Holstein University Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Heyland, D (corresponding author), Kingston Gen Hosp, Angada 4, Kingston, ON K7L 2V7, Canada.	dkh2@queensu.ca	Elke, Gunnar/S-8579-2016; BERGER, Mette/AAF-1284-2020; Muscedere, John/AAH-9291-2021	Elke, Gunnar/0000-0002-4948-1605; BERGER, Mette/0000-0001-5427-1648; 	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by the Canadian Institutes of Health Research.	Andrews PJD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1542; Angstwurm MWA, 2007, CRIT CARE MED, V35, P118, DOI 10.1097/01.CCM.0000251124.83436.0E; Brealey David, 2002, Lancet (North American Edition), V360, P219, DOI 10.1016/S0140-6736(02)09459-X; ClinicalTrials.gov, TRIAL GLUT ANT SUPPL; de Vega JMA, 2002, CRIT CARE MED, V30, P1782, DOI 10.1097/00003246-200208000-00018; GOODE HF, 1995, CRIT CARE MED, V23, P646, DOI 10.1097/00003246-199504000-00011; Goodyear-Bruch C, 2002, AM J CRIT CARE, V11, P543, DOI 10.4037/ajcc2002.11.6.543; Hardy G, 2012, NUTR CLIN PRACT, V27, P21, DOI 10.1177/0884533611434116; Heyland DK, 2007, JPEN-PARENTER ENTER, V31, P109, DOI 10.1177/0148607107031002109; Heyland DK, 2006, P NUTR SOC, V65, P250, DOI 10.1079/PNS2006505; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Johnson CC, 2010, P NUTR SOC, V69, P119, DOI 10.1017/S0029665109991807; Manzanares W, 2012, CRIT CARE, V16, DOI 10.1186/cc11316; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; Motoyama T, 2003, CRIT CARE MED, V31, P1048, DOI 10.1097/01.CCM.0000055371.27268.36; Novak F, 2002, CRIT CARE MED, V30, P2022, DOI 10.1097/00003246-200209000-00011; Oudemans-van Straaten HM, 2001, INTENS CARE MED, V27, P84, DOI 10.1007/s001340000703; Rayman MP, 2012, LANCET, V379, P1256, DOI 10.1016/S0140-6736(11)61452-9; Wang Z, 2009, SHOCK, V32, P140, DOI 10.1097/SHK.0b013e318193c35d; Wernerman J, 2011, ACTA ANAESTH SCAND, V55, P812, DOI 10.1111/j.1399-6576.2011.02453.x	20	524	570	1	58	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2013	368	16					1489	1497		10.1056/NEJMoa1212722	http://dx.doi.org/10.1056/NEJMoa1212722			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126HC	23594003	Bronze, Green Published			2023-01-03	WOS:000317603300006
J	Xiang, H; Mertz, KJ; Arena, VC; Brink, LL; Xu, XH; Bi, YY; Talbott, EO				Xiang, Hao; Mertz, Kristen J.; Arena, Vincent C.; Brink, Luann L.; Xu, Xiaohui; Bi, Yongyi; Talbott, Evelyn O.			Estimation of Short-Term Effects of Air Pollution on Stroke Hospital Admissions in Wuhan, China	PLOS ONE			English	Article							CASE-CROSSOVER ANALYSIS; CARDIOVASCULAR-DISEASES; PARTICULATE MATTER; TIME-SERIES; AMBIENT AIR; CEREBROVASCULAR DISEASES; MEDICARE BENEFICIARIES; MYOCARDIAL-INFARCTION; REFERENT SELECTION; MEASUREMENT-ERROR	Background and Objective: High concentrations of air pollutants have been linked to increased incidence of stroke in North America and Europe but not yet assessed in mainland China. The aim of this study is to evaluate the association between stroke hospitalization and short-term elevation of air pollutants in Wuhan, China. Methods: Daily mean NO2, SO2 and PM10 levels, temperature and humidity were obtained from 2006 through 2008. Data on stroke hospitalizations (ICD 10: I60-I69) at four hospitals in Wuhan were obtained for the same period. A time-stratified case-crossover design was performed by season (April-September and October-March) to assess effects of pollutants on stroke hospital admissions. Results: Pollution levels were higher in October-March with averages of 136.1 mu g/m(3) for PM10, 63.6 mu g/m(3) for NO2 and 71.0 mu g/m(3) for SO2 than in April-September when averages were 102.0 mu g/m(3), 41.7 mu g/m(3) and 41.7 mu g/m(3), respectively (p<.001). During the cold season, every 10 mu g/m(3) increase in NO2 was associated with a 2.9% (95% C.I. 1.2%-4.6%) increase in stroke admissions on the same day. Every 10 mu g/m(3) increase in PM10 daily concentration was significantly associated with an approximate 1% (95% C.I. 0.1%-1.4%) increase in stroke hospitalization. A two-pollutant model indicated that NO2 was associated with stroke admissions when controlling for PM10. During the warm season, no significant associations were noted for any of the pollutants. Conclusions: Exposure to NO2 is significantly associated with stroke hospitalizations during the cold season in Wuhan, China when pollution levels are 50% greater than in the warm season. Larger and multi-center studies in Chinese cities are warranted to validate our findings.	[Xiang, Hao] Wuhan Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430072, Hubei, Peoples R China; [Xiang, Hao; Bi, Yongyi] Wuhan Univ, Wuhan Univ Global Hlth Inst, Wuhan 430072, Hubei, Peoples R China; [Mertz, Kristen J.; Brink, Luann L.; Talbott, Evelyn O.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA; [Arena, Vincent C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Xu, Xiaohui] Univ Florida, Coll Med, Coll Publ Hlth & Hlth Profess, Dept Epidemiol, Gainesville, FL USA; [Bi, Yongyi] Wuhan Univ, Sch Publ Hlth, Dept Labor & Environm Hyg, Wuhan 430072, Peoples R China	Wuhan University; Wuhan University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of Florida; Wuhan University	Talbott, EO (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.	eot1@pitt.edu	Xu, Xiaohui/H-5397-2019	Xu, Xiaohui/0000-0001-7269-4089; Arena, Vincent/0000-0002-1634-7207; Talbott, Evelyn/0000-0002-5198-7939				Abraham JH, 2005, ENVIRON HEALTH PERSP, V113, P1516, DOI 10.1289/ehp.7632; Ali R, 2008, ECOHEALTH, V5, P159, DOI 10.1007/s10393-008-0172-2; Arena VC, 2006, J OCCUP ENVIRON MED, V48, P38, DOI 10.1097/01.jom.0000183096.20678.f1; Ballester F, 2001, J EPIDEMIOL COMMUN H, V55, P57, DOI 10.1136/jech.55.1.57; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130, DOI 10.1080/00039899909602248; Carracedo-Martinez E, 2010, ENVIRON HEALTH PERSP, V118, P1173, DOI 10.1289/ehp.0901485; Chan CC, 2006, EUR HEART J, V27, P1238, DOI 10.1093/eurheartj/ehi835; D'Ippoliti D, 2003, EPIDEMIOLOGY, V14, P528, DOI 10.1097/01.ede.0000082046.22919.72; Fang SC, 2010, INT J ENV RES PUB HE, V7, P1773, DOI 10.3390/ijerph7041773; Hong YC, 2002, STROKE, V33, P2165, DOI 10.1161/01.STR.0000026865.52610.5B; Janes H, 2005, EPIDEMIOLOGY, V16, P717, DOI 10.1097/01.ede.0000181315.18836.9d; Kan HD, 2003, J OCCUP HEALTH, V45, P321, DOI 10.1539/joh.45.321; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658, DOI 10.1136/bmj.314.7095.1658; Le Tertre A, 2002, J EPIDEMIOL COMMUN H, V56, P773, DOI 10.1136/jech.56.10.773; Levy D, 2001, EPIDEMIOLOGY, V12, P186, DOI 10.1097/00001648-200103000-00010; Linn WS, 2000, ENVIRON HEALTH PERSP, V108, P427, DOI 10.2307/3454383; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Moolgavkar SH, 2000, J AIR WASTE MANAGE, V50, P1199, DOI 10.1080/10473289.2000.10464162; Nemmar A, 2003, CIRCULATION, V107, P1202, DOI 10.1161/01.CIR.0000053568.13058.67; Peters A, 2001, CIRCULATION, V103, P2810; Poloniecki JD, 1997, OCCUP ENVIRON MED, V54, P535, DOI 10.1136/oem.54.8.535; Ponka A, 1996, AM J PUBLIC HEALTH, V86, P1273, DOI 10.2105/AJPH.86.9.1273; Qian ZM, 2007, ENVIRON RES, V105, P380, DOI 10.1016/j.envres.2007.05.007; Rich DQ, 2005, AM J EPIDEMIOL, V161, P1123, DOI 10.1093/aje/kwi143; Schwartz J, 2001, ENVIRON HEALTH PERSP, V109, P405, DOI 10.2307/3434788; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Sunyer J, 2003, EUR HEART J, V24, P752, DOI 10.1016/S0195-668X(02)00808-4; Tong SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037500; Tsai SS, 2003, STROKE, V34, P2612, DOI 10.1161/01.STR.0000095564.33543.64; van Eeden SF, 2002, J TOXICOL ENV HEAL A, V65, P1597, DOI 10.1080/00984100290071685; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; Wellenius GA, 2005, AM J EPIDEMIOL, V161, P1030, DOI 10.1093/aje/kwi135; Wichmann J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022904; Wong TW, 1999, OCCUP ENVIRON MED, V56, P679, DOI 10.1136/oem.56.10.679; Wordley J, 1997, OCCUP ENVIRON MED, V54, P108, DOI 10.1136/oem.54.2.108; Yang CY, 2004, J TOXICOL ENV HEAL A, V67, P483, DOI 10.1080/15287390490276502; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382; Zeka A, 2004, ENVIRON HEALTH PERSP, V112, P1686, DOI 10.1289/ehp.7286	38	50	53	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2013	8	4							e61168	10.1371/journal.pone.0061168	http://dx.doi.org/10.1371/journal.pone.0061168			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123JP	23593421	gold, Green Published, Green Accepted			2023-01-03	WOS:000317385300055
J	Wu, L; Li, X; Zhu, HG; Xu, P; Gao, X				Wu, Lin; Li, Xiang; Zhu, Hongguang; Xu, Ping; Gao, Xin			A Prescribed Chinese Herbal Medicine Improves Glucose Profile and Ameliorates Oxidative Stress in Goto-Kakisaki Rats Fed with High Fat Diet	PLOS ONE			English	Article							BETA-CELLS; ENDOTHELIAL FUNCTION; METABOLIC SYNDROME; INSULIN-SECRETION; DIABETIC-RATS; ANTIOXIDANT; OBESITY; DYSFUNCTION; TETRAMETHYLPYRAZINE; INFLAMMATION	Oxidative stress (OS) plays a role in hyperglycemia induced islet beta cell dysfunction, however, studies on classic anti-oxidants didn't show positive results in treating diabetes. We previously demonstrated that the prescribed Chinese herbal medicine preparation "Qing Huo Yi Hao'' (QHYH) improved endothelial function in type 2 diabetic patients. QHYH protected endothelial cells from high glucose-induced damages by scavenging superoxide anion and reducing production of reactive oxygen species. Its active component protected C2C12 myotubes against palmitate-induced oxidative damage and mitochondrial dysfunction. In the present study, we investigated whether QHYH protected islet beta cell function exacerbated by high fat diet (HFD) in hyperglycemic GK rats. 4-week-old male rats were randomly divided into high HFD feeding group (n = 20) and chow diet feeding group (n = 10). Each gram of HFD contained 4.8 kcal of energy, 52% of which from fat. Rats on HFD were further divided into 2 groups given either QHYH (3 ml/Kg/d) or saline through gastric tube. After intervention, serum glucose concentrations were monitored; IPGTTs were performed without anesthesia on 5 fasting rats randomly chosen from each group on week 4 and 16. Serum malondialdehyde (MDA) concentrations and activities of serum antioxidant enzymes were measured on week 4 and 16. Islet beta cell mass and OS marker staining was done by immunohistochemistry on week 16. QHYH prevented the exacerbation of hyperglycemia in HFD feeding GK rats for 12 weeks. On week 16, it improved the exacerbated glucose tolerance and prevented the further loss of islet beta cell mass induced by HFD. QHYH markedly decreased serum MDA concentration, increased serum catalase (CAT) and SOD activities on week 4. However, no differences of serum glucose concentration or OS were observed on week 16. We concluded that QHYH decreased hyperglycemia exacerbated by HFD in GK rats by improving beta cell function partly via its antioxidant effect.	[Li, Xiang; Gao, Xin] Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, Shanghai 200433, Peoples R China; [Wu, Lin] Fudan Univ, Zhongshan Hosp, Dept Geriatr, Shanghai 200433, Peoples R China; [Zhu, Hongguang] Fudan Univ, Dept Pathol, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Xu, Ping] Chinese Acad Sci, Shanghai Lab Anim Ctr, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Chinese Academy of Sciences	Gao, X (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Endocrinol & Metab, Shanghai 200433, Peoples R China.	gao.xin@zs-hospital.sh.cn			National Basic Research Program of China [2012CB524906, 2011CB504004]; National Natural Science Foundation of China [30871196]; Specialized Research Fund for the Doctoral Program of Higher Education [20060246076]	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Specialized Research Fund for the Doctoral Program of Higher Education(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	This work was supported by: 1. Grants from the National Basic Research Program of China (2012CB524906 and 2011CB504004 to XG) (www.973.gov.cn); 2. The National Natural Science Foundation of China (No 30871196 to XG) (www.nsfc.gov.cn); 3. Specialized Research Fund for the Doctoral Program of Higher Education (20060246076 to XG) (www.cutech.edu.cn). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin KA, 2009, DIABETOL METAB SYNDR, V1, DOI 10.1186/1758-5996-1-17; Bjelakovic G, 2008, ALIMENT PHARM THER, V28, P689, DOI 10.1111/j.1365-2036.2008.03785.x; Blixt M, 2010, J ENDOCRINOL, V206, P47, DOI 10.1677/JOE-10-0074; Briaud I, 2002, DIABETES, V51, P662, DOI 10.2337/diabetes.51.3.662; Cerf ME, 2007, PANCREAS, V34, P347, DOI 10.1097/MPA.0b013e31802ee9ae; Ceriello A, 2007, DIABETES CARE, V30, P649, DOI 10.2337/dc06-2048; Ceriello A, 2009, DIABETES CARE, V32, pS232, DOI 10.2337/dc09-S316; Cinti S, 2005, PROSTAG LEUKOTR ESS, V73, P9, DOI 10.1016/j.plefa.2005.04.010; de Oliveira AM, 2011, DIABETES RES CLIN PR, V92, P253, DOI 10.1016/j.diabres.2011.02.010; Defronzo R.A., 2011, J CLIN ENDOCRINOL ME; Drews G, 2010, PFLUG ARCH EUR J PHY, V460, P703, DOI 10.1007/s00424-010-0862-9; Speretta GFF, 2012, CLINICS, V67, P1469, DOI 10.6061/clinics/2012(12)19; Gao X, 2011, LIFE SCI, V88, P803, DOI 10.1016/j.lfs.2011.02.025; Hutton MJH, 2010, ISLETS, V2, P104, DOI 10.4161/isl.2.2.11209; Kahn SE, 2006, NEW ENGL J MED, V355, P2427, DOI 10.1056/NEJMoa066224; Kang YX, 2009, LIFE SCI, V84, P428, DOI 10.1016/j.lfs.2009.01.003; Keaney JF, 2003, ARTERIOSCL THROM VAS, V23, P434, DOI 10.1161/01.ATV.0000058402.34138.11; Koeck T, 2009, ARCH BIOCHEM BIOPHYS, V484, P221, DOI 10.1016/j.abb.2009.01.021; Lacraz G, 2010, AM J PHYSIOL-ENDOC M, V298, pE17, DOI 10.1152/ajpendo.90871.2008; Lacraz G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006500; Li XL, 2009, INT J BIOCHEM CELL B, V41, P1526, DOI 10.1016/j.biocel.2009.01.002; Louro T, 2011, J PHYSL BIOCH; Lu TH, 2011, TOXICOL LETT, V201, P15, DOI 10.1016/j.toxlet.2010.11.019; Markovits N, 2009, ISR MED ASSOC J, V11, P598; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; Plaisance V, 2011, DIABETOLOGIA; Portha B, 2009, MOL CELL ENDOCRINOL, V297, P73, DOI 10.1016/j.mce.2008.06.013; Robertson P, 2005, MEDICOGRAPHIA, V27, P320; Robertson RP, 2007, CELL BIOCHEM BIOPHYS, V48, P139, DOI 10.1007/s12013-007-0026-5; Rudge MVC, 2007, BRAZ J MED BIOL RES, V40, P1095, DOI 10.1590/S0100-879X2006005000132; Sena CM, 2008, BRIT J PHARMACOL, V153, P894, DOI 10.1038/sj.bjp.0707474; Sena CM, 2009, PHYSIOL RES, V58, P203, DOI 10.33549/physiolres.931480; Shang WB, 2002, PANCREAS, V25, P393, DOI 10.1097/00006676-200211000-00012; Sjoholm A, 2010, PHARMACEUTICALS-BASE, V3, P764, DOI 10.3390/ph3030764; Tabur S, 2010, EUR J ENDOCRINOL, V162, P535, DOI 10.1530/EJE-09-0732; Takase H, 2012, EUR J CLIN INVEST, V42, P1287, DOI 10.1111/eci.12000; Tamai M, 2006, DIABETES RES CLIN PR, V71, P140, DOI 10.1016/j.diabres.2005.05.006; Xu Q, 2012, ACTA PHARMACOL SIN, V33, P496, DOI 10.1038/aps.2011.191; [余丹箐 Yu Danqing], 2004, [上海医学, Shanghai medical journal], V27, P466	39	2	2	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2013	8	4							e60262	10.1371/journal.pone.0060262	http://dx.doi.org/10.1371/journal.pone.0060262			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127RY	23565214	Green Published, Green Submitted, gold			2023-01-03	WOS:000317717300083
J	Francis, SC; Baisley, K; Lees, SS; Andrew, B; Zalwango, F; Seeley, J; Vandepitte, J; Ao, TT; van de Wijgert, J; Watson-Jones, D; Kapiga, S; Grosskurth, H; Hayes, RJ				Francis, Suzanna C.; Baisley, Kathy; Lees, Shelley S.; Andrew, Bahati; Zalwango, Flavia; Seeley, Janet; Vandepitte, Judith; Ao, Trong T.; van de Wijgert, Janneke; Watson-Jones, Deborah; Kapiga, Saidi; Grosskurth, Heiner; Hayes, Richard J.			Vaginal Practices among Women at High Risk of HIV Infection in Uganda and Tanzania: Recorded Behaviour from a Daily Pictorial Diary	PLOS ONE			English	Article							INTRAVAGINAL PRACTICES; SEXUAL PRACTICES; MICROBICIDES; ACQUISITION; PREFERENCES	Background: Intravaginal practices (IVP) are highly prevalent in sub-Saharan African and have been implicated as risk factors for HIV acquisition. However, types of IVP vary between populations, and detailed information on IVP among women at risk for HIV in different populations is needed. We investigated IVP among women who practice transactional sex in two populations: semi-urban, facility workers in Tanzania who engage in opportunistic sex work; and urban, self-identified sex workers and bar workers in Uganda. The aim of the study was to describe and compare IVP using a daily pictorial diary. Methodology/Principal Findings: Two hundred women were recruited from a HIV prevention intervention feasibility study in Kampala, Uganda and in North-West Tanzania. Women were given diaries to record IVP daily for six weeks. Baseline data showed that Ugandan participants had more lifetime partners and transactional sex than Tanzanian participants. Results from the diary showed that 96% of Tanzanian participants and 100% of Ugandan participants reported intravaginal cleansing during the six week study period. The most common types of cleansing were with water only or water and soap. In both countries, intravaginal insertion (e.g. with herbs) was less common than cleansing, but insertion was practiced by more participants in Uganda (46%) than in Tanzania (10%). In Uganda, participants also reported more frequent sex, and more insertion related to sex. In both populations, cleansing was more often reported on days with reported sex and during menstruation, and in Uganda, when participants experienced vaginal discomfort. Participants were more likely to cleanse after sex if they reported no condom use. Conclusions: While intravaginal cleansing was commonly practiced in both cohorts, there was higher frequency of cleansing and insertion in Uganda. Differences in IVP were likely to reflect differences in sexual behaviour between populations, and may warrant different approaches to interventions targeting IVP. Vaginal practices among women at high risk in Uganda and Tanzania: recorded behaviour from a daily pictorial diary.	[Francis, Suzanna C.; Baisley, Kathy; Lees, Shelley S.; Seeley, Janet; Ao, Trong T.; Kapiga, Saidi; Grosskurth, Heiner; Hayes, Richard J.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England; [Francis, Suzanna C.; Lees, Shelley S.; Andrew, Bahati; Ao, Trong T.; Watson-Jones, Deborah; Kapiga, Saidi] Natl Inst Med Res, Mwanza Ctr, Mwanza Intervent Trials Unit, Mwanza, Tanzania; [Zalwango, Flavia; Seeley, Janet; Vandepitte, Judith; Grosskurth, Heiner] Uganda Virus Res Inst, MRC UVRI Uganda Res Unit AIDS, Entebbe, Uganda; [Seeley, Janet] Univ E Anglia, Sch Int Dev, Norwich NR4 7TJ, Norfolk, England; [van de Wijgert, Janneke] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England; [Watson-Jones, Deborah] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England	University of London; London School of Hygiene & Tropical Medicine; National Institute of Medical Research; Uganda Virus Research Institute; University of East Anglia; University of Liverpool; University of London; London School of Hygiene & Tropical Medicine	Francis, SC (corresponding author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1, England.	suzanna.francis@lshtm.ac.uk		Kapiga, Saidi/0000-0003-1753-4060; van de Wijgert, Janneke H.H.M./0000-0003-2728-4560; Seeley, Janet/0000-0002-0583-5272; Hayes, Richard/0000-0002-1729-9892; Grosskurth, Heiner/0000-0001-9960-7280; Francis, Suzanna Carter/0000-0002-3724-4813	United Kingdom Medical Research Council; European and Developing Countries Clinical Trials Partnership; MRC [G0901756, G0701039, G0700837, G1002369, MC_U950097154] Funding Source: UKRI; Medical Research Council [G1002369, G0901756, G0701039, MC_U950097154, G0700837] Funding Source: researchfish	United Kingdom Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European and Developing Countries Clinical Trials Partnership; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Financial support for the Intravaginal Practices Project was provided by the United Kingdom Medical Research Council, and the European and Developing Countries Clinical Trials Partnership. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allen CF, 2007, SEX TRANSM INFECT, V83, P490, DOI 10.1136/sti.2007.024810; Braunstein S, 2005, J WOMENS HEALTH, V14, P424, DOI 10.1089/jwh.2005.14.424; Brown JE, 2000, SEX TRANSM DIS, V27, P183, DOI 10.1097/00007435-200004000-00001; BROWN JE, 1993, SOC SCI MED, V37, P989, DOI 10.1016/0277-9536(93)90433-5; BROWN RC, 1993, SEX TRANSM DIS, V20, P96, DOI 10.1097/00007435-199303000-00007; Desmond N, 2005, SOC SCI MED, V60, P1739, DOI 10.1016/j.socscimed.2004.08.027; Ferguson AG, 2006, CULT HEALTH SEX, V8, P175, DOI 10.1080/13691050600665006; Francis SC, 2010, 2010 AIDS C VIENN AU; Francis SC, 2012, SEX TRANSM DIS, V39, P614, DOI 10.1097/OLQ.0b013e3182515fe4; Gafos M, 2010, CULT HEALTH SEX, V12, P929, DOI 10.1080/13691058.2010.507876; Hilber AM, 2007, SEX TRANSM INFECT, V83, P505, DOI 10.1136/sti.2007.028597; Hilber AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009119; Hilber AM, 2010, SOC SCI MED, V70, P392, DOI 10.1016/j.socscimed.2009.10.023; Kapiga SH, 2002, J ACQ IMMUN DEF SYND, V29, P409, DOI 10.1097/00126334-200204010-00013; Kapiga SH, 2013, PLSO ONE UNPUB; Lees S, 2010, SEX TRANSM DIS, V37, P497, DOI 10.1097/OLQ.0b013e3181d4722d; Low N, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000416; Ramjee G, 1999, SEX TRANSM DIS, V26, P374, DOI 10.1097/00007435-199908000-00002; van de Wijgert JHHM, 2000, J INFECT DIS, V181, P587, DOI 10.1086/315227; van de Wijgert JHHM, 2000, J ACQ IMMUN DEF SYND, V24, P62; Vandepitte J, 2010, SEXUALLY TRANSMITTED, V38, P316; Watson-Jones D, 2007, JAIDS-J ACQ IMM DEF, V46, P631, DOI 10.1097/QAI.0b013e31815b2d9c	22	21	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2013	8	3							e59085	10.1371/journal.pone.0059085	http://dx.doi.org/10.1371/journal.pone.0059085			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	123VE	23555618	Green Accepted, Green Published, gold, Green Submitted			2023-01-03	WOS:000317418500020
J	Wilson, N; Nghiem, N; Foster, RH				Wilson, Nick; Nghiem, Nhung; Foster, Rachel H.			The Feasibility of Achieving Low-Sodium Intake in Diets That Are Also Nutritious, Low-Cost, and Have Familiar Meal Components	PLOS ONE			English	Article							SALT INTAKE; MEDITERRANEAN DIET; CARDIOVASCULAR-DISEASE; COLORECTAL-CANCER; METAANALYSIS; HEALTH; REDUCTION; PATTERNS; RISK; CONSUMPTION	Objective: Given the importance of high sodium diets as a risk factor for disease burden (ranked 11th in importance in the Global Burden of Disease Study 2010), we aimed to determine the feasibility of low-sodium diets that were also low-cost, nutritious and (for some scenarios) included familiar meals. Methods: The mathematical technique of "linear programming" was used to model eight optimized daily diets (some with uncertainty), including some diets that contained "familiar meals" for New Zealanders or were Mediterranean-, Asian- and Pacific-style diets. Data inputs included nutrients in foods, food prices and food wastage. Findings: Using nutrient recommendations for men and a cost constraint of <NZ$9/d (US$6.84), the sodium intake levels in the eight optimized daily diets were all well below the 2300 mg/d (5.8 g salt/d) recommended maximum. The only diet to not consistently fall below the recommended "target" upper limit of 1600 mg/d included an evening meal with sausages (median = 1640 mg/d, 95% simulation interval: 1551-1735 mg/d). Many additional nutritional aspects of these optimized low-sodium diets suggest that they would reduce cardiovascular disease risk in other ways (e.g., improved polyunsaturated to saturated fat ratio) and also reduce risk of cancer and other chronic diseases (e.g., via higher intakes of vegetables, fruits and dietary fiber). Even healthier diets (e.g., with higher intakes of fruit) occurred when the cost constraint was relaxed to $NZ15/d (US$11.40). Similar results were obtained when the modeling considered diets for women. Conclusions: These results provide some reassurance for the feasibility of substantially reducing population sodium intake given currently available low-cost foods and while maintaining some level of familiar meals. Policy makers could consider ways to promote such optimized diets and foods, including regulations on maximum salt levels in processed foods, and taxes on alternative foods that are high in salt, sugar and saturated fat.	[Wilson, Nick; Nghiem, Nhung; Foster, Rachel H.] Univ Otago, Dept Publ Hlth, Wellington, New Zealand	University of Otago	Wilson, N (corresponding author), Univ Otago, Dept Publ Hlth, Wellington, New Zealand.	nick.wilson@otago.ac.nz		Nghiem, Nhung/0000-0003-0078-4549	Health Research Council of New Zealand [10/248]	Health Research Council of New Zealand(Health Research Council of New Zealand)	This project was part of the BODE3 Program, which receives funding support from the Health Research Council of New Zealand (Project number 10/248). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, 2009 NZ TOT DIET STU; Appel LJ, 2012, ANN EPIDEMIOL, V22, P417, DOI 10.1016/j.annepidem.2012.04.003; Arcand J, 2012, AM J HYPERTENS, V25, P19, DOI 10.1038/ajh.2011.187; Aune D, 2012, BREAST CANCER RES TR, V134, P479, DOI 10.1007/s10549-012-2118-1; Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0; Briend A, 2003, J PEDIATR GASTR NUTR, V36, P12, DOI 10.1097/00005176-200301000-00006; Carter P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4229; Faber J, 2012, BEHAV CLIMATE CHANGE; Fahimi S, 2012, AM J HYPERTENS, V25, P17, DOI 10.1038/ajh.2011.183; Graudal NA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004022.pub3; Hawkes C, 2009, NUTR REV, V67, P333, DOI 10.1111/j.1753-4887.2009.00206.x; He FJ, 2012, ANN MED, V44, pS127, DOI 10.3109/07853890.2012.660495; He FJ, 2003, HYPERTENSION, V42, P1093, DOI 10.1161/01.HYP.0000102864.05174.E8; Holt E, 2011, LANCET, V378, P755, DOI 10.1016/S0140-6736(11)61359-7; Human Nutrition University of Otago, FOOD COST SURV; Institute of Medicine (US) Committee on Strategies to Reduce Sodium Intake, 2010, STRAT RED COD INT US; Kastorini CM, 2011, J AM COLL CARDIOL, V57, P1299, DOI 10.1016/j.jacc.2010.09.073; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Magalhaes B, 2012, EUR J CANCER PREV, V21, P15, DOI 10.1097/CEJ.0b013e3283472241; Maillot M, 2012, AM J PREV MED, V42, P174, DOI 10.1016/j.amepre.2011.10.009; Maillot M, 2010, PUBLIC HEALTH NUTR, V13, P1178, DOI 10.1017/S1368980009993028; McLean R, 2011, JOINT ANN SCI M AUST; Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38; Mozaffarian D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000252; NHMRC, 2006, NUTR REF VAL AUSTR N; O'Donnell MJ, 2011, JAMA-J AM MED ASSOC, V306, P2229, DOI 10.1001/jama.2011.1729; Pan A, 2012, ARCH INTERN MED, V172, P555, DOI 10.1001/archinternmed.2011.2287; Scarborough P, 2012, EUR J CLIN NUTR, V66, P710, DOI 10.1038/ejcn.2012.34; Sherzai A, 2012, NUTR REV, V70, P423, DOI 10.1111/j.1753-4887.2012.00490.x; Sofi F, 2010, AM J CLIN NUTR, V92, P1189, DOI 10.3945/ajcn.2010.29673; Statistics New Zealand, 2011, FOOD PRIC IND 2011; Strazzullo P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4567; Taylor RS, 2011, AM J HYPERTENS, V24, P843, DOI 10.1038/ajh.2011.115; Thomson BM, 2009, BRIT J NUTR, V102, P757, DOI 10.1017/S000711450928901X; Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337; University of Otago, 2011, FOC NUTR KEY FIND 20; Villanueva T, 2011, CAN MED ASSOC J, V183, pE1229, DOI 10.1503/cmaj.109-4031; WHO, 2012, GUID SOD INT AD CHIL; Wilson Nick, 2007, N Z Med J, V120, pU2665; World Cancer Research Fund & American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P; WRAP, 2009, HOUSEHOLD FOOD DRINK; Yusof AS, 2012, ASIAN PAC J CANCER P, V13, P4713, DOI 10.7314/APJCP.2012.13.9.4713	43	5	5	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2013	8	3							e58539	10.1371/journal.pone.0058539	http://dx.doi.org/10.1371/journal.pone.0058539			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	136BN	23505532	Green Submitted, Green Published, gold			2023-01-03	WOS:000318334500099
J	He, P; Li, PT; Hua, Q; Liu, Y; Staufenbiel, M; Li, RN; Shen, Y				He, Ping; Li, Pengtao; Hua, Qian; Liu, Yuan; Staufenbiel, Matthias; Li, Rena; Shen, Yong			Chronic Administration of Anti-Stroke Herbal Medicine TongLuoJiuNao Reduces Amyloidogenic Processing of Amyloid Precursor Protein in a Mouse Model of Alzheimer's Disease	PLOS ONE			English	Article							GAMMA-SECRETASE INHIBITOR; NF-KAPPA-B; BETA-SECRETASE; GINSENOSIDE RG1; HEME OXYGENASE-1; TRANSGENIC MICE; MEMORY DEFICITS; RECEPTOR PLAYS; EXPRESSION; CLEAVAGE	Composed of Ginsenoside Rg1 and Geniposide, the herbal medicine TongLuoJiuNao (TLJN) injection liquid has anti-inflammatory properties and can improve learning and memory in mice. Recently, TLJN has been used to treat the patients with cerebral ischemic stroke and vascular dementia, which significantly increase the risk of developing Alzheimer's disease (AD) in the early human beings. Although beneficial effects of TLJN have been reported in the vascular-associated brain disorders, the roles of TLJN in AD brains are still not clear. In this study, we chronically administered TLJN in amyloid precursor protein (APP) Swedish mutant transgenic mice (APP23) from 6 months old of age, which is at the onset of A beta plaques, to 12 months old. We found that TLJN significantly decreased A beta production and deposition in the brain of APP23 mice. Furthermore, we observed that TLJN down-regulated the levels and activity of beta-secretase 1 (BACE1) protein as well as the expression levels of gamma-secretase complex components: PS1, nicastrin and anterior pharynx-defective 1 (APH1) but not presenilin enhancer 2 (PEN2). The results suggest an inhibitory effect of TLJN on amyloidogenic APP processing by down-regulating the cleavage enzymes BACE1 and gamma-secretase.	[He, Ping; Shen, Yong] Roskamp Inst, Ctr Adv Therapeut Strategies Brain Disorders, Sarasota, FL USA; [Li, Pengtao; Hua, Qian; Liu, Yuan] Beijing Univ Chinese Med, Dept Pathol, Sch Preclin Med, Beijing, Peoples R China; [Staufenbiel, Matthias] Novartis Pharm Ltd, Nervous Syst Res, Basel, Switzerland; [Li, Rena] Roskamp Inst, Ctr Hormone Adv Sci & Educ, Sarasota, FL USA	Beijing University of Chinese Medicine; Novartis	Shen, Y (corresponding author), Roskamp Inst, Ctr Adv Therapeut Strategies Brain Disorders, Sarasota, FL USA.	yshen@rfdn.org			Alzheimer Association [IIRG-09-61521, IIRG-07-59510]; AHAF [G2006-118, A2008-642]; State Key Development Program for Basic Research of China [2012CB518602]; Production of New Medicine Program of Ministry of Science and Technology of China [2008ZX09101-027]; National Natural Science Foundation of China [81072901];  [NIH/NIA025888];  [NIH/NIAR01AG032441]; NATIONAL INSTITUTE ON AGING [R01AG032441] Funding Source: NIH RePORTER	Alzheimer Association(Alzheimer's AssociationBrightFocus Foundation); AHAF; State Key Development Program for Basic Research of China(State Key Development Program for Basic Research of China); Production of New Medicine Program of Ministry of Science and Technology of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); ; ; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work is supported by grants from NIH/NIA025888 (YS), NIH/NIAR01AG032441 (RL), Alzheimer Association: IIRG-09-61521 (YS) and IIRG-07-59510 (RL); AHAF: G2006-118 (RL) and A2008-642 (PH), The State Key Development Program for Basic Research of China: 2012CB518602 (PTL), Production of New Medicine Program of Ministry of Science and Technology of China: 2008ZX09101-027 (PTL) and National Natural Science Foundation of China: 81072901 (QH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bao HY, 2005, ARCH PHARM RES, V28, P335, DOI 10.1007/BF02977802; Bertram L, 2008, NAT REV NEUROSCI, V9, P768, DOI 10.1038/nrn2494; Best JD, 2005, J PHARMACOL EXP THER, V313, P902, DOI 10.1124/jpet.104.081174; Chang Y, 2008, EUR J PHARMACOL, V578, P28, DOI 10.1016/j.ejphar.2007.09.023; Chen F, 2006, FASEB J, V20, P1269, DOI 10.1096/fj.05-5530fje; Chen LM, 2012, EUR J PHARMACOL, V675, P15, DOI 10.1016/j.ejphar.2011.11.039; Choi K, 2007, NEUROSCI LETT, V421, P37, DOI 10.1016/j.neulet.2007.05.017; Choo MK, 2008, ONCOL REP, V19, P595; Cole SL, 2008, J BIOL CHEM, V283, P29621, DOI 10.1074/jbc.R800015200; Duarte AI, 2005, FREE RADICAL BIO MED, V39, P876, DOI 10.1016/j.freeradbiomed.2005.05.002; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Gandy S, 2005, J CLIN INVEST, V115, P1121, DOI 10.1172/JCI200525100; Gu Z, 2007, CHANGCHUN MED SCH CH; Guo LX, 2012, ACTA PHARMACOL SIN, V33, P237, DOI 10.1038/aps.2011.146; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He P, 2013, PLOS ONE; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; He P, 2012, FASEB J, V26, P334, DOI 10.1096/fj.11-192716; He P, 2009, J NEUROSCI, V29, P6545, DOI 10.1523/JNEUROSCI.0421-09.2009; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hua Q, 2008, BIOL PHARM BULL, V31, P633, DOI 10.1248/bpb.31.633; Hua QA, 2010, J ETHNOPHARMACOL, V129, P306, DOI 10.1016/j.jep.2010.03.024; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Jazwa A, 2010, CURR DRUG TARGETS, V11, P1517, DOI 10.2174/1389450111009011517; Ji HF, 2008, ACTA PHARMACOL SIN, V29, P143, DOI 10.1111/j.1745-7254.2008.00752.x; Joo SS, 2008, BIOL PHARM BULL, V31, P1392, DOI 10.1248/bpb.31.1392; Kim BH, 2009, PLANTA MED, V75, P321, DOI 10.1055/s-0028-1112218; Kim YJ, 2008, BIOL PHARM BULL, V31, P826, DOI 10.1248/bpb.31.826; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; Kuo YM, 2001, MOL MED, V7, P609, DOI 10.1007/BF03401867; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SY, 2009, BIOSCI BIOTECH BIOCH, V73, P811, DOI 10.1271/bbb.80637; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Li XJ, 2012, J ETHNOPHARMACOL, V141, P927, DOI 10.1016/j.jep.2012.03.042; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Liu JH, 2009, ACTA PHARMACOL SIN, V30, P159, DOI 10.1038/aps.2008.25; Liu Ying, 2006, Zhongguo Zhong Xi Yi Jie He Za Zhi, V26, P956; Liu Y, 2011, J ETHNOPHARMACOL, V137, P1035, DOI 10.1016/j.jep.2011.07.031; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Searfoss GH, 2003, J BIOL CHEM, V278, P46107, DOI 10.1074/jbc.M307757200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Selkoe DJ, 2011, NAT MED, V17, P1060, DOI 10.1038/nm.2460; Selkoe DJ, 2003, NEUROCHEM RES, V28, P1705, DOI 10.1023/A:1026065122854; Shi C, 2012, BBA-GEN SUBJECTS, V1820, P453, DOI 10.1016/j.bbagen.2011.12.005; Shi YQ, 2010, J ALZHEIMERS DIS, V19, P977, DOI 10.3233/JAD-2010-1296; Siemers ER, 2006, NEUROLOGY, V66, P602, DOI 10.1212/01.WNL.0000198762.41312.E1; Siemers ER, 2007, CLIN NEUROPHARMACOL, V30, P317, DOI 10.1097/WNF.0b013e31805b7660; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sommer B, 1998, MOL PSYCHIATR, V3, P284, DOI 10.1038/sj.mp.4000397; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Van Dooren T, 2006, AM J PATHOL, V168, P245, DOI 10.2353/ajpath.2006.050752; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2007, NEURON, V54, P671, DOI 10.1016/j.neuron.2007.05.018; Velliquette RA, 2005, J NEUROSCI, V25, P10874, DOI 10.1523/JNEUROSCI.2350-05.2005; Wang YH, 2009, J ASIAN NAT PROD RES, V11, P604, DOI 10.1080/10286020902843152; Williams P, 2011, NAT PROD REP, V28, P48, DOI 10.1039/c0np00027b; Wong GT, 2004, J BIOL CHEM, V279, P12876, DOI 10.1074/jbc.M311652200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Yin F, 2012, CNS NEUROL DISORD-DR; Yin F, 2010, BIOL PHARM BULL, V33, P1841, DOI 10.1248/bpb.33.1841; Yin F, 2010, ACTA PHARMACOL SIN, V31, P540, DOI 10.1038/aps.2010.28; Zhang C, 2010, J ALZHEIMERS DIS, V22, P683, DOI 10.3233/JAD-2010-100816; Zhang X, 2012, NEUROSCIENCE, V220, P191, DOI 10.1016/j.neuroscience.2012.06.027; Zhang ZG, 2008, MOL ENDOCRINOL, V22, P186, DOI 10.1210/me.2007-0119; Zhao HF, 2009, BRAIN RES, V1256, P111, DOI 10.1016/j.brainres.2008.12.031; Zhu W., 2007, HUBEI MED SCH CHINES, V5, P4	72	19	23	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 5	2013	8	3							e58181	10.1371/journal.pone.0058181	http://dx.doi.org/10.1371/journal.pone.0058181			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	099RC	23472157	gold, Green Published, Green Submitted			2023-01-03	WOS:000315637900103
J	Wei, HF; Huang, J; Yang, J; Zhang, XJ; Lin, LW; Xue, ES; Chen, ZK				Wei, Hongfen; Huang, Jing; Yang, Jing; Zhang, Xiujuan; Lin, Liwu; Xue, Ensheng; Chen, Zhikui			Ultrasound Exposure Improves the Targeted Therapy Effects of Galactosylated Docetaxel Nanoparticles on Hepatocellular Carcinoma Xenografts	PLOS ONE			English	Article							ASIALOGLYCOPROTEIN RECEPTOR; IN-VIVO; MOLECULAR-WEIGHT; GENE-TRANSFER; CANCER; LIPOSOMES; DELIVERY; CELLS; PROLIFERATION; INHIBITION	Purpose: The distribution of targeted nanoparticles in tumor tissue is affected by a combination of various factors such as the physicochemical properties of the nanoparticles, tumor hemoperfusion and tumor vascular permeability. In this study, the impact of the biological effects of ultrasound on nanoparticle targeting to liver carcinoma was explored. Methods: The copolymer MePEG-PLGA was used to prepare the galactosylated docetaxel nanoparticles (GDN), and the physical and chemical properties as well as the acute toxicity were then assayed. The impact of ultrasound exposure (UE) on tumor hemoperfusion was observed by contrast-enhanced ultrasonography (CEUS), and the distribution of docetaxel in tumors and liver were detected by high performance liquid chromatography (HPLC). In the GDN combined with UE treatment group, the mice were injected intravenously with GDN, followed by ultrasound exposure on the human hepatocellular carcinoma xenografts. Twenty-eight days post-administration, the tumor growth inhibition rate was calculated, and the expression of Survivin and Ki67 in tumor tissues were determined by immunohistochemistry assay and quantitative real-time PCR. Results: The mean size of prepared liver-targeting nanoparticles GDN was 209.3 nm, and the encapsulation efficiency was 72.28%. The median lethal dose of GDN was detected as 219.5 mg/kg which was about four times higher than that of docetaxel. After ultrasound exposure, the tumor peak - base intensity difference value, examined by CEUS, increased significantly. The drug content in the tumor was 1.96 times higher than in the GDN treated control. In vivo, GDN intravenous injection combined with ultrasound exposure therapy achieved the best anti-tumor effect with a tumor growth inhibition rate of 74.2%, and the expression of Survivin and Ki67 were significantly decreased as well. Conclusion: Ultrasound exposure can improve targeting nanoparticles accumulation in the tumor, and achieve a synergism antitumor effect on the hepatocellular carcinoma xenografts.	[Wei, Hongfen; Zhang, Xiujuan; Lin, Liwu; Xue, Ensheng; Chen, Zhikui] Fujian Med Univ, Affiliated Union Hosp, Dept Ultrasonog, Fuzhou, Peoples R China; [Wei, Hongfen] Zhejiang Univ, Affiliated Sir Run Run Shaw Hosp, Dept Ultrasonog, Hangzhou 310003, Zhejiang, Peoples R China; [Huang, Jing] Peoples Hosp Zhuhai City, Dept Ultrasonog, Zhuhai, Peoples R China; [Yang, Jing] Fujian Med Univ, Affiliated Union Hosp, Dept Pharm, Fuzhou, Peoples R China	Fujian Medical University; Zhejiang University; Fujian Medical University	Chen, ZK (corresponding author), Fujian Med Univ, Affiliated Union Hosp, Dept Ultrasonog, Fuzhou, Peoples R China.	jimchen2003@163.com			Key Laboratory Fund at the Affiliated Union Hospital, Fujian Medical University; Medical Innovation Foundation by Fujian Provincial Department of Health [2012-CXB-15]	Key Laboratory Fund at the Affiliated Union Hospital, Fujian Medical University; Medical Innovation Foundation by Fujian Provincial Department of Health	This research was financially supported in part by the Key Laboratory Fund at the Affiliated Union Hospital, Fujian Medical University and the Medical Innovation Foundation Grant provided by Fujian Provincial Department of Health (2012-CXB-15). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arii S, 2000, HEPATOLOGY, V32, P1224, DOI 10.1053/jhep.2000.20456; Bergh J, 2012, J CLIN ONCOL, V30, P921, DOI 10.1200/JCO.2011.35.7376; Braun JR, 1996, J BIOL CHEM, V271, P21160, DOI 10.1074/jbc.271.35.21160; Chen ZK, 2012, MED ONCOL, V29, P62, DOI 10.1007/s12032-010-9762-2; Dong L, 2008, J BIOMED MATER RES A, V84A, P777, DOI 10.1002/jbm.a.31328; Fang Chao, 2006, Yaoxue Xuebao, V41, P305; Gan HK, 2012, CANC RES; Guhagarkar SA, 2010, INT J PHARMACEUT, V401, P113, DOI 10.1016/j.ijpharm.2010.09.012; Jeong YI, 2005, INT J PHARMACEUT, V296, P151, DOI 10.1016/j.ijpharm.2005.02.027; Kawakami S, 1998, BIOCHEM BIOPH RES CO, V252, P78, DOI 10.1006/bbrc.1998.9602; Lee SH, 2011, ISLETS, V3, P358, DOI 10.4161/isl.3.6.17923; Lentacker I, 2010, J CONTROL RELEASE, V148, pE113, DOI 10.1016/j.jconrel.2010.07.085; Li LL, 2010, ACS NANO, V4, P6874, DOI 10.1021/nn100918a; Lin F, 2012, CELL PROLIFERAT, V45, P207, DOI 10.1111/j.1365-2184.2012.00812.x; Managit C, 2005, J PHARM SCI-US, V94, P2266, DOI 10.1002/jps.20443; Negishi Y, 2010, MOL PHARMACEUT, V7, P217, DOI 10.1021/mp900214s; Ning YX, 2012, ONCOL REP, V27, P1857, DOI 10.3892/or.2012.1739; Niu G, 2012, J CONTROL RELEASE, V161, P18, DOI 10.1016/j.jconrel.2012.04.043; Oeffinger BE, 2004, ULTRASONICS, V42, P343, DOI 10.1016/j.ultras.2003.11.011; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peng DJ, 2007, CANCER GENE THER, V14, P66, DOI 10.1038/sj.cgt.7700985; Pouleau HB, 2012, INT J ONCOL, V40, P923, DOI 10.3892/ijo.2011.1260; Preusser M, 2012, HISTOPATHOLOGY, V60, P885, DOI 10.1111/j.1365-2559.2011.04134.x; Rottenberg S, 2012, CANCER RES, V72, P2350, DOI 10.1158/0008-5472.CAN-11-4201; Suzuki R, 2010, J CONTROL RELEASE, V142, P245, DOI 10.1016/j.jconrel.2009.10.027; Takayasu K, 2006, GASTROENTEROLOGY, V131, P461, DOI 10.1053/j.gastro.2006.05.021; Thaci B, 2012, CANCER GENE THER, V19, P431, DOI 10.1038/cgt.2012.21; van Zuylen L, 2001, INVEST NEW DRUG, V19, P125, DOI 10.1023/A:1010618632738; Xu ZH, 2009, BIOMATERIALS, V30, P226, DOI 10.1016/j.biomaterials.2008.09.014; Yata Y, 2010, HEPATOL RES, V40, P304, DOI 10.1111/j.1872-034X.2009.00598.x; Zhang Y, 2007, J CONTROL RELEASE, V117, P281, DOI 10.1016/j.jconrel.2006.11.006; Zheng WY, 2011, DRUG DISCOV THER, V5, P293, DOI 10.5582/ddt.2011.v5.6.293	32	9	9	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 1	2013	8	3							e58133	10.1371/journal.pone.0058133	http://dx.doi.org/10.1371/journal.pone.0058133			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	103EI	23469265	Green Published, gold, Green Submitted			2023-01-03	WOS:000315897100062
J	Lin, HJ; Weng, SF; Yang, CM; Wu, MP				Lin, Huey-Juan; Weng, Shih-Feng; Yang, Chun-Ming; Wu, Ming-Ping			Risk of Hospitalization for Acute Cardiovascular Events among Subjects with Lower Urinary Tract Symptoms: A Nationwide Population-Based Study	PLOS ONE			English	Article							QUALITY-OF-LIFE; OVERACTIVE BLADDER; ERECTILE DYSFUNCTION; NERVOUS-SYSTEM; HEALTH-CARE; INCONTINENCE; PREVALENCE; BURDEN; MEN	Background and Purpose: Lower urinary tract symptoms (LUTS) have been reported to be associated with metabolic syndrome and may predispose subjects to cardiovascular disease. The magnitude of the impact on the medical care remains to be elucidated. Based on a population-based claims dataset in Taiwan, we explored the association between LUTS and the risk of subsequent hospitalization for acute cardiovascular events. Materials and Methods: Among a representative sample of one million subjects from nationwide health insurance enrollees, subjects with codes of LUTS in service claims and without previous cardiovascular diseases including stroke were compared with age-and sex-matched non-LUTS subjects in subsequent hospitalization for acute coronary syndrome or stroke from the recruited date (between 2001-2004) to 2009. The risk of outcomes was assessed with Kaplan-Meier curves and the impact of LUTS was estimated with Poison regression analysis and Cox proportional hazards models. Results: We included 4,553 LUTS subjects and 22,765 matched non-LUTS subjects, with a mean age of 47 years and 43% of men. Hypertension, diabetes, and hyperlipidemia were more prevalent in the LUTS group. The incidence rate of the composite endpoint was significantly higher in the LUTS group than in the non-LUTS group (5.4/1000 vs. 4.0/1000 person-years). The difference mainly derived from stroke rather than acute coronary syndrome. After adjusting for age, sex, diabetes, hypertension, and hyperlipidemia in multivariable analysis, LUTS remained a significant predictor (hazard ratio, 1.29; 95% confidence incidence, 1.06-1.50). Conclusion: Subjects free of cardiovascular disease and presenting with LUTS are at risk of subsequent hospitalization for acute cardiovascular events, mainly stroke. The information might prompt practitioners encountering such patients to undergo appropriate diagnostic and preventive measures.	[Lin, Huey-Juan; Yang, Chun-Ming] Chi Mei Med Ctr, Dept Neurol, Tainan, Taiwan; [Weng, Shih-Feng; Wu, Ming-Ping] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Wu, Ming-Ping] Chi Mei Med Ctr, Dept Obstet & Gynecol, Div Urogynecol, Tainan, Taiwan; [Lin, Huey-Juan] Chia Nan Univ Pharm & Sci, Dept Cosmet Sci, Tainan, Taiwan; [Wu, Ming-Ping] Chia Nan Univ Pharm & Sci, Ctr Gen Educ, Tainan, Taiwan; [Weng, Shih-Feng] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan	Chi Mei Hospital; Chi Mei Hospital; Chi Mei Hospital; Chia Nan University of Pharmacy & Science; Chia Nan University of Pharmacy & Science; Chia Nan University of Pharmacy & Science	Wu, MP (corresponding author), Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.	mpwu@mail.chimei.org.tw		Weng, Shih-Feng/0000-0001-8684-3487	Chi Mei Medical Center	Chi Mei Medical Center	The study was funded by Chi Mei Medical Center (http://www.chimei.org.tw/main/cmh_department/54220/english/2012/index.html). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson KE, 2010, BJU INT, V106, P268, DOI 10.1111/j.1464-410X.2009.09073.x; Asche CV, 2012, BJU INT, V109, P572, DOI 10.1111/j.1464-410X.2011.10436.x; Baumhakel M, 2007, INT J CLIN PRACT, V61, P361, DOI 10.1111/j.1742-1241.2006.01274.x; Bouwman II, 2009, EUR J GEN PRACT, V15, P128, DOI 10.3109/13814780903329536; Coyne KS, 2009, BJU INT, V103, P4, DOI 10.1111/j.1464-410X.2009.08371.x; Glavind K, 2011, INT UROGYNECOL J, V22, P907, DOI 10.1007/s00192-011-1411-6; Hubeaux K, 2011, NEUROUROL URODYNAM, V30, P1467, DOI 10.1002/nau.21154; Irwin DE, 2006, EUR UROL, V50, P1306, DOI 10.1016/j.eururo.2006.09.019; Karatas OF, 2010, INT J CARDIOL, V144, P452, DOI 10.1016/j.ijcard.2009.03.099; Kirby MG, 2010, NEUROUROL URODYNAM, V29, P1360, DOI 10.1002/nau.20892; Lukacz ES, 2011, INT J CLIN PRACT, V65, P1026, DOI 10.1111/j.1742-1241.2011.02763.x; Malmsten UGH, 2010, EUR UROL, V58, P149, DOI 10.1016/j.eururo.2010.03.014; McVary KT, 2011, J UROLOGY, V185, P1793, DOI 10.1016/j.juro.2011.01.074; Parthasarathy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030969; Penson DF, 2011, J UROLOGY, V186, P2316, DOI 10.1016/j.juro.2011.07.067; Wehrberger C, 2011, UROLOGY, V78, P1063, DOI 10.1016/j.urology.2011.05.065; Wu MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057825; Wu MP, 2013, UROLOGY, V81, P61, DOI 10.1016/j.urology.2012.08.033; Zhang XW, 2011, UROL INT, V86, P173, DOI 10.1159/000321895	19	62	66	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2013	8	6							e66661	10.1371/journal.pone.0066661	http://dx.doi.org/10.1371/journal.pone.0066661			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163FW	23826095	Green Published, gold, Green Submitted			2023-01-03	WOS:000320322400114
J	Miyasaki, Y; Rabenstein, JD; Rhea, J; Crouch, ML; Mocek, UM; Kittell, PE; Morgan, MA; Nichols, WS; Van Benschoten, MM; Hardy, WD; Liu, GY				Miyasaki, Yoko; Rabenstein, John D.; Rhea, Joshua; Crouch, Marie-Laure; Mocek, Ulla M.; Kittell, Patricia Emmett; Morgan, Margie A.; Nichols, Wesley Stephen; Van Benschoten, M. M.; Hardy, William David; Liu, George Y.			Isolation and Characterization of Antimicrobial Compounds in Plant Extracts against Multidrug-Resistant Acinetobacter baumannii	PLOS ONE			English	Article							INFECTIONS; PLATE	The number of fully active antibiotic options that treat nosocomial infections due to multidrug-resistant Acinetobacter baumannii (A. baumannii) is extremely limited. Magnolia officinalis, Mahonia bealei, Rabdosia rubescens, Rosa rugosa, Rubus chingii, Scutellaria baicalensis, and Terminalia chebula plant extracts were previously shown to have growth inhibitory activity against a multidrug-resistant clinical strain of A. baumannii. In this study, the compounds responsible for their antimicrobial activity were identified by fractionating each plant extract using high performance liquid chromatography, and determining the antimicrobial activity of each fraction against A. baumannii. The chemical structures of the fractions inhibiting >40% of the bacterial growth were elucidated by liquid chromatography/mass spectrometry analysis and nuclear magnetic resonance spectroscopy. The six most active compounds were identified as: ellagic acid in Rosa rugosa; norwogonin in Scutellaria baicalensis; and chebulagic acid, chebulinic acid, corilagin, and terchebulin in Terminalia chebula. The most potent compound was identified as norwogonin with a minimum inhibitory concentration of 128 mg/mL, and minimum bactericidal concentration of 256 mg/mL against clinically relevant strains of A. baumannii. Combination studies of norwogonin with ten anti-Gram negative bacterial agents demonstrated that norwogonin did not enhance the antimicrobial activity of the synthetic antibiotics chosen for this study. In conclusion, of all identified antimicrobial compounds, norwogonin was the most potent against multidrug-resistant A. baumannii strains. Further studies are warranted to ascertain the prophylactic and therapeutic potential of norwogonin for infections due to multidrug-resistant A. baumannii.	[Miyasaki, Yoko; Hardy, William David] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Rabenstein, John D.; Rhea, Joshua; Crouch, Marie-Laure; Mocek, Ulla M.] Albany Mol Res Inc, Bothell Res Ctr, Bothell, WA USA; [Kittell, Patricia Emmett] Cedars Sinai Med Ctr, Dept Patient Financial Serv, Los Angeles, CA 90048 USA; [Morgan, Margie A.; Nichols, Wesley Stephen] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Van Benschoten, M. M.] MM Van Benschoten OMD MA CA & Associates, Canoga Pk, CA USA; [Liu, George Y.] Cedars Sinai Med Ctr, Dept Pediat, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Miyasaki, Y (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.	yoko.miyasaki@cshs.org	Hardy, W. David/AHD-8960-2022	Rabenstein, John/0000-0002-9702-6586	Cedars-Sinai Medical Center in Los Angeles, California, USA; Cedars-Sinai Medical Center	Cedars-Sinai Medical Center in Los Angeles, California, USA; Cedars-Sinai Medical Center	This research study was funded by Cedars-Sinai Medical Center in Los Angeles, California, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have the following interests. Dr. M.M. Van Benschoten is a self-employed community-based, private practitioner of oriental medicine. The title of his practice is M. M. Van Benschoten, O.M.D., M.A., C.A. and Associates. As an experienced oriental medicine practitioner, Dr. Van Benschoten helped conceive the experiments conducted in this study and assisted with obtaining the original plant extracts used in the study. For these services, he received consultation fee of $ 3,500 from Cedars-Sinai Medical Center. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.	Carroll P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009823; Chan BCL, 2011, J ETHNOPHARMACOL, V137, P767, DOI 10.1016/j.jep.2011.06.039; Chusri S, 2009, J ANTIMICROB CHEMOTH, V64, P1203, DOI 10.1093/jac/dkp381; *CLIN LAB STAND I, 2006, METH ANT DIL DISK SU, P16; Clinical and Laboratory Standards Institute, 2009, PERF STAND ANT SUSC, p[46, 100]; Cowan MM, 1999, CLIN MICROBIOL REV, V12, P564, DOI 10.1128/CMR.12.4.564; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; Huang H, 2010, PLANTA MED, V76, P76, DOI 10.1055/s-0029-1185943; Huang H, 2009, FITOTERAPIA, V80, P448, DOI 10.1016/j.fitote.2009.06.004; Jones WP, 2010, NATURAL PRODUCT ISOL, P323; Karageorgopoulos DE, 2008, LANCET INFECT DIS, V8, P751, DOI 10.1016/S1473-3099(08)70279-2; Krueger WA, 2002, AM J RESP CRIT CARE, V166, P1029, DOI 10.1164/rccm.2105141; Lu YJ, 2011, J AGR FOOD CHEM, V59, P10934, DOI 10.1021/jf202741x; Mann CM, 1998, J APPL MICROBIOL, V84, P538, DOI 10.1046/j.1365-2672.1998.00379.x; Miyasaki Y, 2012, FEMS MICROBIOL LETT, V328, P26, DOI 10.1111/j.1574-6968.2011.02480.x; Miyasaki Y, 2010, PHYTOTHER RES, V24, P1202, DOI 10.1002/ptr.3113; Munoz-Price LS, 2008, NEW ENGL J MED, V358, P1271, DOI 10.1056/NEJMra070741; Osterburg A, 2009, CLIN MICROBIOL INFEC, V15, P341, DOI 10.1111/j.1469-0691.2009.02710.x; Palomino JC, 2002, ANTIMICROB AGENTS CH, V46, P2720, DOI 10.1128/AAC.46.8.2720-2722.2002; Perez F, 2007, ANTIMICROB AGENTS CH, V51, P3471, DOI 10.1128/AAC.01464-06; SCALBERT A, 1991, PHYTOCHEMISTRY, V30, P3875, DOI 10.1016/0031-9422(91)83426-L; Smith CF, 1999, J FOOD PROTECT, V62, P1404, DOI 10.4315/0362-028X-62.12.1404; Sukumaran S, 2011, ASIAN PAC J TROP MED, V4, P735, DOI 10.1016/S1995-7645(11)60183-1; Urban C, 2003, CLIN INFECT DIS, V36, P1268, DOI 10.1086/374847; Wu Jing, 2008, Zhong Yao Cai, V31, P707	25	72	79	2	42	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2013	8	4							e61594	10.1371/journal.pone.0061594	http://dx.doi.org/10.1371/journal.pone.0061594			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JR	23630600	Green Published, Green Submitted, gold			2023-01-03	WOS:000317911500050
J	Tsai, HH; Lin, HW; Lu, YH; Chen, YL; Mahady, GB				Tsai, Hsin-Hui; Lin, Hsiang-Wen; Lu, Ying-Hung; Chen, Yi-Ling; Mahady, Gail B.			A Review of Potential Harmful Interactions between Anticoagulant/Antiplatelet Agents and Chinese Herbal Medicines	PLOS ONE			English	Article							ST-JOHNS-WORT; PRODUCT-DRUG INTERACTIONS; IN-VIVO ASSESSMENT; ALTERNATIVE MEDICINE; PRESCRIPTION MEDICATIONS; DIETARY-SUPPLEMENTS; HEALTHY-SUBJECTS; GINKGO-BILOBA; PHARMACOKINETIC INTERACTIONS; NUTRITIONAL SUPPLEMENTS	Background: The risks attributed to drug-herb interactions, even when known, are often ignored or underestimated, especially for those involving anti-clotting drugs and Chinese medicines. The aim of this study was to structurally search and evaluate the existing evidence-based data associated with potential drug interactions between anticoagulant/antiplatelet drugs and Chinese herbal medicines (CHMs) and evaluate the documented mechanisms, consequences, and/or severity of interactions. Methodology and Findings: Information related to anticoagulant/antiplatelet drug-CHM interactions was retrieved from eight interaction-based textbooks, four web resources and available primary biomedical literature. The primary literature searches were conducted in English and/or Chinese from January 2000 through December 2011 using the secondary databases (e.g., PubMed, Airiti Library, China Journal full-text database). The search terms included the corresponding medical subject headings and key words. Herbs or natural products not used as a single entity CHM or in Chinese Medicinal Prescriptions were excluded from further review. The corresponding mechanisms and severity ratings of interactions were retrieved using MicroMedex (R), Lexicomp (R) and Natural Medicines Comprehensive Database (R). Finally, we found 90 single entity CHMs contributed to 306 documented drug-CHM interactions. A total of 194 (63.4%) interactions were verified for its evidence describing possible mechanisms and severity. Of them, 155 interactions (79.9%) were attributable to pharmacodynamic interactions, and almost all were rated as moderate to severe interactions. The major consequences of these interactions were increased bleeding risks due to the additive anticoagulant or antiplatelet effects of the CHMs, specifically danshen, dong quai, ginger, ginkgo, licorice, and turmeric. Conclusions/Significance: Conventional anticoagulants and antiplatelet drugs were documented to have harmful interactions with some commonly used single entity CHMs. For those patients who are taking conventional anti-clotting medications with CHMs for cardiovascular or cerebrovascular diseases, the potential risks of increased bleeding due to drug-CHM interactions should not be ignored.	[Tsai, Hsin-Hui; Lin, Hsiang-Wen; Lu, Ying-Hung; Chen, Yi-Ling] China Med Univ, Coll Pharm, Sch Pharm, Taichung, Taiwan; [Tsai, Hsin-Hui; Lin, Hsiang-Wen; Lu, Ying-Hung; Chen, Yi-Ling] China Med Univ, Coll Pharm, Grad Inst, Taichung, Taiwan; [Tsai, Hsin-Hui; Lin, Hsiang-Wen] China Med Univ Hosp, Dept Pharm, Taichung, Taiwan; [Lin, Hsiang-Wen] Univ Illinois, Coll Pharm, Dept Pharm Adm, Chicago, IL USA; [Mahady, Gail B.] Univ Illinois, Coll Pharm, Dept Pharm Practice, PAHO WHO Collaborating Ctr Tradit Med, Chicago, IL USA	China Medical University Taiwan; China Medical University Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lin, HW (corresponding author), China Med Univ, Coll Pharm, Sch Pharm, Taichung, Taiwan.	hsiangwl@mail.cmu.edu.tw	Chen, Yi/HIR-2608-2022	Tsai, Hsiu Ting/0000-0003-1137-9274	Committee on Chinese medicine and Pharmacy, Department of Health, Executive Yuan, Taiwan, R.O.C. [CCMP99-RD-016]; National Science Council [NSC 99-2320-B-039 -031 -MY3]	Committee on Chinese medicine and Pharmacy, Department of Health, Executive Yuan, Taiwan, R.O.C.; National Science Council(Ministry of Science and Technology, Taiwan)	This study was fully supported by the Committee on Chinese medicine and Pharmacy, Department of Health, Executive Yuan, Taiwan, R.O.C. ( grant number: CCMP99-RD-016) and partially supported by National Science Council (grant number: NSC 99-2320-B-039 -031 -MY3). Those founders have no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Abarca Jacob, 2004, J Am Pharm Assoc (2003), V44, P136, DOI 10.1331/154434504773062582; Abdul MIM, 2010, BRIT J CLIN PHARMACO, V69, P508, DOI 10.1111/j.1365-2125.2010.03620.x; Al Faraj S, 2005, ANN TROP MED PARASIT, V99, P219, DOI 10.1179/136485905X17434; Alherbish A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019623; Awang Dennis V C, 2002, J Cardiovasc Nurs, V16, P64; Blalock SJ, 2009, ALTERN THER HEALTH M, V15, P26; Bone KM, 2008, MOL NUTR FOOD RES, V52, P764, DOI 10.1002/mnfr.200700098; Borrelli F, 2009, AAPS J, V11, P710, DOI 10.1208/s12248-009-9146-8; Brazier Nicole C, 2003, Am J Ther, V10, P163, DOI 10.1097/00045391-200305000-00003; Bressler R, 2005, GERIATRICS, V60, P32; Bressler R, 2005, GERIATRICS, V60, P16; Bressler R, 2005, GERIATRICS, V60, P21; Bressler R, 2005, GERIATRICS-US, V60, P30; Bush TM, 2007, ALTERN THER HEALTH M, V13, P30; Butterweck V, 2008, CLIN PHARMACOKINET, V47, P383, DOI 10.2165/00003088-200847060-00003; Canter PH, 2004, DRUG AGING, V21, P597, DOI 10.2165/00002512-200421090-00004; Cassileth BR, 2003, HERB DRUG INTERACTIO; Chan ALF, 2011, J ALTERN COMPLEM MED, V17, P513, DOI 10.1089/acm.2010.0295; Chan E, 2010, CURR OPIN DRUG DISC, V13, P50; Chan HT, 2011, J CARDIOVASC PHARM, V58, P87, DOI 10.1097/FJC.0b013e31821cd888; Chang HC, 2003, CHINESE MED HERBS PR; Chang LC, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-170; Charrois TL, 2007, ANN PHARMACOTHER, V41, P1124, DOI 10.1345/aph.1H463; Chavez ML, 2006, LIFE SCI, V78, P2146, DOI 10.1016/j.lfs.2005.12.009; Chen FN, 2008, J INT CHIN W MED, V10, P25; Chen FP, 2011, FAMILY MED PRIMARY M, V26, P168; Chen J., 2007, CHIN J CLIN PHARM TH, V12, P1348; Choi YH, 2011, ARCH PHARM RES, V34, P1843, DOI 10.1007/s12272-011-1106-z; Clauson KA, 2008, ALTERN THER HEALTH M, V14, P36; Clauson KA, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-42; Cohen PA, 2010, CARDIOVASC THER, V28, P246, DOI 10.1111/j.1755-5922.2010.00193.x; Colalto C, 2010, PHARMACOL RES, V62, P207, DOI 10.1016/j.phrs.2010.04.001; Committee on Chinese Medicine and Pharmacy, 2004, TAIW HERB PHARM; Committee on Chinese Medicine and Pharmacy Department of Health Executive Yuan, ABSTR YB; Coxeter PD, 2004, CURR MED CHEM, V11, P1513, DOI 10.2174/0929867043365198; De Smet PAGM, 2008, CURR DRUG METAB, V9, P1055, DOI 10.2174/138920008786927730; Department of Health Executive Yuan R.O.C. (TAIWAN), DEP HLTH GOV RES B; Dergal JM, 2002, DRUG AGING, V19, P879, DOI 10.2165/00002512-200219110-00005; Di Carlo G, 2001, TRENDS PHARMACOL SCI, V22, P292, DOI 10.1016/S0165-6147(00)01716-8; Di YM, 2008, CURR PHARM DESIGN, V14, P1723, DOI 10.2174/138161208784746798; Dunn Steven P., 2011, Cardiovascular & Hematological Agents in Medicinal Chemistry, V9, P231; Ernst E, 2000, EUR J CLIN PHARMACOL, V56, P523, DOI 10.1007/s002280000194; Ernst E, 2004, PHARMACOEPIDEM DR S, V13, P767, DOI 10.1002/pds.1014; Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; Fugh-Berman A, 2001, BRIT J CLIN PHARMACO, V52, P587, DOI 10.1046/j.0306-5251.2001.01469.x; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; Gardiner P, 2008, AM FAM PHYSICIAN, V77, P73; Goldman RD, 2008, J PEDIATR-US, V152, P521, DOI 10.1016/j.jpeds.2007.09.026; Greenblatt DJ, 2005, J CLIN PHARMACOL, V45, P127, DOI 10.1177/0091270004271404; Greeson JM, 2001, PSYCHOPHARMACOLOGY, V153, P402, DOI 10.1007/s002130000625; Haller CA, 2006, CLIN TOXICOL, V44, P605, DOI 10.1080/15563650600795545; Holbrook AM, 2005, ARCH INTERN MED, V165, P1095, DOI 10.1001/archinte.165.10.1095; Holcomb SS, 2009, NURSE PRACT, V34, P21, DOI 10.1097/01.NPR.0000350567.61353.2b; Hsieh SC, 2008, PHARMACOEPIDEM DR S, V17, P609, DOI 10.1002/pds.1611; Hu ZP, 2005, DRUGS, V65, P1239, DOI 10.2165/00003495-200565090-00005; Huang SM, 2004, J CLIN PHARMACOL, V44, P559, DOI 10.1177/0091270004265367; Izzo AA, 2001, DRUGS, V61, P2163, DOI 10.2165/00003495-200161150-00002; Izzo AA, 2005, FUND CLIN PHARMACOL, V19, P1, DOI 10.1111/j.1472-8206.2004.00301.x; Izzo AA, 2005, INT J CARDIOL, V98, P1, DOI 10.1016/j.ijcard.2003.06.039; Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000; Javed F, 2008, J LARYNGOL OTOL, V122, P116, DOI 10.1017/S0022215107000011; Jennes F, 2007, HERB TOXICITIES DRUG; Jiang XM, 2004, BRIT J CLIN PHARMACO, V57, P592, DOI 10.1111/j.1365-2125.2003.02051.x; Jiang XM, 2006, J CLIN PHARMACOL, V46, P1370, DOI 10.1177/0091270006292124; Ko Richard J, 2004, J Chin Med Assoc, V67, P109; Kuhn Merrily A, 2002, Crit Care Nurse, V22, P22; Kuo YF, 2006, J PHARM PHARMACOL, V58, P521, DOI 10.1211/jpp.58.4.0012; Lai D, 2007, FAM PRACT, V24, P56, DOI 10.1093/fampra/cml058; Lai JN, 2010, YB CHINESE MED PHARM, V28, P291; Lai YC, 2007, CHUNG SHAN MED J, V18, P343; Lee GBW, 2004, FAM PRACT, V21, P654, DOI 10.1093/fampra/cmh613; Lexicomp, 2012, LEX INT ONL; Li JY, 2008, J TAIWAN PHARM, V24, P135; Li YH, 2010, J ETHNOPHARMACOL, V128, P623, DOI 10.1016/j.jep.2010.02.003; Lim MK, 2005, COMPLEMENT THER MED, V13, P16, DOI 10.1016/j.ctim.2004.11.002; Lin JJ, 2003, SHOW CHWAN MED J, V4, P1; Madabushi R, 2006, EUR J CLIN PHARMACOL, V62, P225, DOI 10.1007/s00228-006-0096-0; Mahady GB, 2001, BOT DIETARY SUPPLEME, V1; Makino T, 2002, J ETHNOPHARMACOL, V82, P35, DOI 10.1016/S0378-8741(02)00175-7; Mao XQ, 2007, CHIN J CLIN PHARM TH, V12, P728; Markowitz J S, 2001, Psychopharmacol Bull, V35, P53; McFadden Roger, 2011, Nurs Stand, V25, P65; Mills E, 2005, THER DRUG MONIT, V27, P549, DOI 10.1097/01.ftd.0000170880.95267.90; Mousa SA, 2010, METHODS MOL BIOL, V663, P229, DOI 10.1007/978-1-60761-803-4_9; National Center for Complementary and Alternative Medicine, 2010, TRAD CHIN MED INTR; National Center for Complementary and Alternative Medicine, HERBS GLANC; Natural Medicines Comprehensive Database, NAT PROD DRUG INT CH; Norred CL, 2001, ALTERN THER HEALTH M, V7, P58; Nutescu E, 2011, J THROMB THROMBOLYS, V31, P326, DOI 10.1007/s11239-011-0561-1; Nutescu EA, 2006, EXPERT OPIN DRUG SAF, V5, P433, DOI 10.1517/14740338.5.3.433; *OFF DIET SUPPL, DIET SUPPL FACT SHEE; Ohnishi Noriaki, 2004, Keio Journal of Medicine, V53, P137, DOI 10.2302/kjm.53.137; Pal D, 2006, LIFE SCI, V78, P2131, DOI 10.1016/j.lfs.2005.12.010; Peng B, 2010, WORLD SCI TECHNOLOGY, DOI [10.3969/j.issn.1674-3849.2010.02.024, DOI 10.3969/J.ISSN.1674-3849.2010.02.024]; Philp RB, 2004, HERBAL DRUG INTERACT; Poppenga RH, 2002, CLIN TECH SMALL AN P, V17, P6, DOI 10.1053/svms.2002.27785; Rochelle TL, 2010, BRIT J HEALTH PSYCH, V15, P715, DOI 10.1348/135910709X479195; Rossler W, 2007, PSYCHOL MED, V37, P73, DOI 10.1017/S0033291706008841; Rogers EA, 2001, ACAD EMERG MED, V8, P932, DOI 10.1111/j.1553-2712.2001.tb01157.x; Samuels N, 2005, THROMB HAEMOSTASIS, V93, P3, DOI 10.1160/TH04-05-0285; Saw Jun Tze, 2006, Complement Ther Clin Pract, V12, P236, DOI 10.1016/j.ctcp.2006.06.002; Segal R, 2006, CAN MED ASSOC J, V174, P1281, DOI 10.1503/cmaj.051191; Shalansky S, 2007, PHARMACOTHERAPY, V27, P1237, DOI 10.1592/phco.27.9.1237; Singh YN, 2005, J ETHNOPHARMACOL, V100, P108, DOI 10.1016/j.jep.2005.05.014; Skalli S, 2007, THER DRUG MONIT, V29, P679, DOI 10.1097/FTD.0b013e31815c17f6; Stargrove M.B., 2008, HERB NUTR DRUG INTER; State Administration of Traditional Chinese Medicine, 1999, CHIN MAT MED 11; Su DJ, 2011, J HEALTH CARE POOR U, V22, P296, DOI 10.1353/hpu.2011.0002; Su G, 2010, YONSEI MED J, V51, P793, DOI 10.3349/ymj.2010.51.5.793; Suchard JR, 2004, EUR J EMERG MED, V11, P193, DOI 10.1097/01.mej.0000134721.72356.f7; Tachjian A, 2010, J AM COLL CARDIOL, V55, P515, DOI 10.1016/j.jacc.2009.07.074; Tatro D.S., 2011, DRUG INTERACTION FAC; Tirona RG, 2006, BRIT J CLIN PHARMACO, V61, P677, DOI 10.1111/j.1365-2125.2006.02684.x; Tomlinson B, 2008, MOL NUTR FOOD RES, V52, P799, DOI 10.1002/mnfr.200700454; Tsai CH, 2009, TAIPEI J CHINESE MED, V15, P98; Tsai HH, 2013, EUR J CLIN PHARMACOL, V69, P629, DOI 10.1007/s00228-012-1359-6; Ueng Yune-Fang, 2004, Current Pharmacogenomics, V2, P209, DOI 10.2174/1570160043377646; Ulbricht C, 2008, CURR DRUG METAB, V9, P1063, DOI 10.2174/138920008786927785; Ulbricht C., 2009, NATURAL STANDARD HER; Venkataramanan R, 2006, LIFE SCI, V78, P2105, DOI 10.1016/j.lfs.2005.12.021; Wang TY, 2011, J LONG TERM CARE, V15, P24; Wang YY, 2003, J TAIWAN PHARM, V19, P5; Whitten DL, 2006, BRIT J CLIN PHARMACO, V62, P512, DOI 10.1111/j.1365-2125.2006.02755.x; Williamson E., 2009, STOCKLEYS HERBAL MED; Williamson Elizabeth M, 2005, Expert Opin Drug Saf, V4, P355, DOI 10.1517/14740338.4.2.355; Williamson EM, 2003, DRUG SAFETY, V26, P1075, DOI 10.2165/00002018-200326150-00002; Wittkowsky AK, 2008, J THROMB THROMBOLYS, V25, P72, DOI 10.1007/s11239-007-0110-0; Woodward KN, 2005, HUM EXP TOXICOL, V24, P219, DOI 10.1191/0960327105ht529oa; World Health Organization, 2008, 10 LEAD CAUS DEATH B; Wu WWP, 2010, PHYTOMEDICINE, V17, P219, DOI 10.1016/j.phymed.2009.05.005; Xu GL, 2009, PHYTOTHER RES, V23, P1721, DOI 10.1002/ptr.2819; Yamashita H, 2002, COMPLEMENT THER MED, V10, P84, DOI 10.1054/ctim.2002.0519; Yang XX, 2006, CURR PHARM DESIGN, V12, P4649, DOI 10.2174/138161206779010440; Yeh GY, 2006, AM J CARDIOL, V98, P673, DOI 10.1016/j.amjcard.2006.03.051; Yuan CS, 2004, ANN INTERN MED, V141, P23, DOI 10.7326/0003-4819-141-1-200407060-00011; Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630; Zhou SF, 2003, DRUG METAB REV, V35, P35, DOI 10.1081/DMR-120018248; Zhou SF, 2004, J PSYCHOPHARMACOL, V18, P262, DOI 10.1177/0269881104042632; Zhou SF, 2007, DRUG DISCOV TODAY, V12, P664, DOI 10.1016/j.drudis.2007.06.004; Zhu Yan-feng, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P318, DOI 10.3736/jcim20120311	141	130	134	0	55	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 9	2013	8	5							e64255	10.1371/journal.pone.0064255	http://dx.doi.org/10.1371/journal.pone.0064255			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	155HD	23671711	Green Published, Green Submitted, gold			2023-01-03	WOS:000319737700069
J	Ghosh, A; Sarkar, S; Mandal, AK; Das, N				Ghosh, Aparajita; Sarkar, Sibani; Mandal, Ardhendu K.; Das, Nirmalendu			Neuroprotective Role of Nanoencapsulated Quercetin in Combating Ischemia-Reperfusion Induced Neuronal Damage in Young and Aged Rats	PLOS ONE			English	Article							DRUG-DELIVERY; NITRIC-OXIDE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; BRAIN; DEATH; FLAVONOIDS; NANOPARTICLES; ANTIOXIDANTS; MEMBRANE	Cerebral stroke is the leading cause of death and permanent disability among elderly people. In both humans and animals, cerebral ischemia damages the nerve cells in vulnerable regions of the brain, viz., hippocampus, cerebral cortex, cerebellum, and hypothalamus. The present study was conducted to evaluate the therapeutic efficacy of nanoencapsulated quercetin (QC) in combating ischemia-reperfusion-induced neuronal damage in young and aged Swiss Albino rats. Cerebral ischemia was induced by occlusion of the common carotid arteries of both young and aged rats followed by reperfusion. Nanoencapsulated quercetin (2.7 mg/kg b wt) was administered to both groups of animals via oral gavage two hours prior to ischemic insults as well as post-operation till day 3. Cerebral ischemia and 30 min consecutive reperfusion caused a substantial increase in lipid peroxidation, decreased antioxidant enzyme activities and tissue osmolality in different brain regions of both groups of animals. It also decreased mitochondrial membrane microviscosity and increased reactive oxygen species (ROS) generation in different brain regions of young and aged rats. Among the brain regions studied, the hippocampus appeared to be the worst affected region showing increased upregulation of iNOS and caspase-3 activity with decreased neuronal count in the CA1 and CA3 subfields of both young and aged rats. Furthermore, three days of continuous reperfusion after ischemia caused massive damage to neuronal cells. However, it was observed that oral treatment of nanoencapsulated quercetin (2.7 mg/kg b wt) resulted in downregulation of iNOS and caspase-3 activities and improved neuronal count in the hippocampal subfields even 3 days after reperfusion. Moreover, the nanoformulation imparted a significant level of protection in the antioxidant status in different brain regions, thus contributing to a better understanding of the given pathophysiological processes causing ischemic neuronal damage.	[Ghosh, Aparajita; Sarkar, Sibani; Mandal, Ardhendu K.; Das, Nirmalendu] Indian Inst Chem Biol, Biomembrane Div, Kolkata, W Bengal, India; [Ghosh, Aparajita] Bose Inst, Div Mol Med, Kolkata, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Department of Science & Technology (India); Bose Institute	Das, N (corresponding author), Indian Inst Chem Biol, Biomembrane Div, Kolkata, W Bengal, India.	dasnirmalendu@hotmail.com	; Jabgunde, Amit/I-8155-2018; Ghosh, Sougata/GOH-0726-2022; Mandal, Ardhendu Kumar/R-3694-2018; Pardesi, Karishma/D-5827-2012; Ghosh, Sougata/C-6409-2018	Dhavale, Dilip/0000-0001-8221-6347; Jabgunde, Amit/0000-0002-9324-8552; Jagtap, Soham/0000-0002-8687-7326; Ghosh, Sougata/0000-0001-8631-0357; Mandal, Ardhendu Kumar/0000-0001-8336-1220; Shinde, Vaishali/0000-0001-8800-7247; Patil, Ajay B./0000-0003-0509-4926; Pardesi, Karishma/0000-0001-7535-6317; Ghosh, Sougata/0000-0003-0077-1318	Indian Council of Medical Research (ICMR), Government of India [58/17/2003-BMS]; Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi	Indian Council of Medical Research (ICMR), Government of India(Indian Council of Medical Research (ICMR)); Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi(Council of Scientific & Industrial Research (CSIR) - India)	This work was supported by the Indian Council of Medical Research (ICMR), Adhoc Project number 58/17/2003-BMS, Government of India, and the Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABE K, 1995, STROKE, V26, P1478, DOI 10.1161/01.STR.26.8.1478; Aebi H, 1984, Methods Enzymol, V105, P121; Almeida A, 1999, BRAIN RES, V816, P580, DOI 10.1016/S0006-8993(98)01240-2; Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20; Batandier C, 2002, J CELL MOL MED, V6, P175, DOI 10.1111/j.1582-4934.2002.tb00185.x; BORS W, 1990, METHOD ENZYMOL, V186, P343; Brouns R, 2009, CLIN NEUROL NEUROSUR, V111, P483, DOI 10.1016/j.clineuro.2009.04.001; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Changtam C, 2010, EUR J MED CHEM, V45, P941, DOI 10.1016/j.ejmech.2009.11.035; Chen J, 1997, J NEUROCHEM, V69, P232; Chrissobolis S, 2008, TRENDS MOL MED, V14, P495, DOI 10.1016/j.molmed.2008.09.003; DAVIES DC, 1992, ACTA NEUROPATHOL, V83, P510, DOI 10.1007/BF00310028; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; DogruAbbasoglu S, 1997, MECH AGEING DEV, V98, P177, DOI 10.1016/S0047-6374(97)00082-1; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; GINSBERG MD, 1994, ANN NEUROL, V36, P553, DOI 10.1002/ana.410360402; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Hariharan S, 2006, PHARM RES-DORDR, V23, P184, DOI 10.1007/s11095-005-8418-y; Harry GJ, 2003, NEUROTOXICOLOGY, V24, P343, DOI 10.1016/S0161-813X(03)00039-1; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; HAVSTEEN B, 1983, BIOCHEM PHARMACOL, V32, P1141, DOI 10.1016/0006-2952(83)90262-9; HORN M, 1992, ACTA NEUROPATHOL, V85, P79, DOI 10.1007/BF00304636; ISSA AM, 1990, J NEUROSCI, V10, P3247; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kong LD, 2000, CELL MOL LIFE SCI, V57, P500, DOI 10.1007/PL00000710; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Lee H, 2004, J NEUROSCI RES, V77, P892, DOI 10.1002/jnr.20193; Lee JC, 2003, EXP CELL RES, V291, P386, DOI 10.1016/S0014-4827(03)00410-5; Lockman PR, 2002, DRUG DEV IND PHARM, V28, P1, DOI 10.1081/DDC-120001481; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1975, P NATL ACAD SCI USA, V72, P1184, DOI 10.1073/pnas.72.3.1184; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; McCracken E, 2000, J CEREBR BLOOD F MET, V20, P1529, DOI 10.1097/00004647-200011000-00002; MEANEY MJ, 1988, SCIENCE, V239, P766, DOI 10.1126/science.3340858; Moghimi SM, 2001, PHARMACOL REV, V53, P283; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Olivier Jean-Christophe, 2005, NeuroRx, V2, P108, DOI 10.1007/BF03206647; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RAPOPORT SI, 1978, J THEOR BIOL, V74, P439, DOI 10.1016/0022-5193(78)90224-2; RECKNAGEL RO, 1984, METHOD ENZYMOL, V105, P331; Rodriguez RJ, 2001, FOOD CHEM TOXICOL, V39, P437, DOI 10.1016/S0278-6915(00)00159-9; Ruozi B, 2007, TALANTA, V73, P12, DOI 10.1016/j.talanta.2007.03.031; Sarkar A, 1995, CANCER BIOCHEM BIOPH, V15, P111; Sarkar S, 2002, J DRUG TARGET, V10, P573, DOI 10.1080/106118021000072681; Silva GA, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S4; Squire L.R., 2002, NEUROPSYCHOLOGY MEMO; Taylor CP, 1999, J NEUROSCI, V19, P619; Vergoni AV, 2009, NANOMED-NANOTECHNOL, V5, P369, DOI 10.1016/j.nano.2009.02.005; Xia Y, 1996, P NATL ACAD SCI USA, V93, P6770, DOI 10.1073/pnas.93.13.6770; Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507	52	114	119	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2013	8	4							e57735	10.1371/journal.pone.0057735	http://dx.doi.org/10.1371/journal.pone.0057735			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130JA	24367520	gold, Green Published, Green Submitted			2023-01-03	WOS:000317909500001
J	Blatteau, JE; Brubakk, AO; Gempp, E; Castagna, O; Risso, JJ; Vallee, N				Blatteau, Jean-Eric; Brubakk, Alf O.; Gempp, Emmanuel; Castagna, Olivier; Risso, Jean-Jacques; Vallee, Nicolas			Sidenafil Pre-Treatment Promotes Decompression Sickness in Rats	PLOS ONE			English	Article							BUBBLE FORMATION; NITRIC-OXIDE; SILDENAFIL; DIVE; PEROXYNITRITE; ACTIVATION; DAMAGE; PDE5	Vascular bubble formation after decompression contributes to endothelial injuries which form the basis for the development of decompression sickness (DCS). Nitric oxide (NO) is a powerful vasodilator that contributes to vessel homeostasis. It has been shown that NO-releasing agent may reduce bubble formation and prevent serious decompression sickness. The use of sildenafil, a well-known, phosphodiesterase-5 blocker, which act by potentiating the vasodilatory effect on smooth muscle relaxation, has never been studied in DCS. The purpose of the present study was to evaluate the clinical effects of sildenafil pre-treatment on DCS in a rat model. 67 rats were subjected to a simulated dive at 90 msw for 45 min before staged decompression. The experimental group received 10 mg/kg of sildenafil one hour before exposure (n = 35) while controls were not treated (n = 32). Clinical assessment took place over a period of 30 min after surfacing. At the end, blood samples were collected for blood cells counts and the level of circulating bubbles in the right cavities was quantified. There were significantly more manifestations of DCS in the sildenafil group than in the controls (34.3% vs 6.25%, respectively, p = 0.012). Platelet count was more reduced in treated rats than in controls (-21.7% vs -7%, respectively, p = 0.029), whereas bubble grades did not differ between groups. We concluded that pre-treatment with sildenafil promotes the onset and severity of neurological DCS. When considering the use of phosphodiesterase-5 blockers in the context of diving, careful discussion with physician should be recommended.	[Blatteau, Jean-Eric; Castagna, Olivier; Risso, Jean-Jacques; Vallee, Nicolas] Inst Rech Biomed Armees, Dept Environm Operat Environm Extremes, Equipe Residante Rech Subaquat Operat, Toulon, France; [Brubakk, Alf O.] Norwegian Univ Sci & Technol, Med Technol Ctr, Fac Med, Dept Physiol & Biomed Engn, N-7034 Trondheim, Norway; [Castagna, Olivier] Univ Toulon & Var, Lab Motricite Humaine Educ Sport & Sante, Equipe Accueil 6309, Toulon, France; [Gempp, Emmanuel] HIA St Anne, Serv Med Hyperbare & Expertise Plonge, Toulon, France	Norwegian University of Science & Technology (NTNU); Universite de Toulon; Hospital Instruction Of Armees Sainte-Anne	Blatteau, JE (corresponding author), Inst Rech Biomed Armees, Dept Environm Operat Environm Extremes, Equipe Residante Rech Subaquat Operat, Toulon, France.	je.blatteau@infonie.fr						AHN HS, 1991, ELECTRON LETT, V27, P191, DOI 10.1049/el:19910123; Barnett CF, 2006, VASC HEALTH RISK MAN, V2, P411, DOI 10.2147/vhrm.2006.2.4.411; BERGHAGE TE, 1979, UNDERSEA BIOMED RES, V6, P1; Bert P, 1878, BAROMETRIC PRESSURE; Blatteau JE, 2006, AVIAT SPACE ENVIR MD, V77, P1068; Blatteau JE, 2011, NEUROCRIT CARE, V15, P120, DOI 10.1007/s12028-010-9370-1; Blatteau JE, 2008, AVIAT SPACE ENVIR MD, V79, P1100, DOI 10.3357/ASEM.2377.2008; Byoun HS, 2010, J KOREAN NEUROSURG S, V47, P210, DOI 10.3340/jkns.2010.47.3.210; Demchenko IT, 2009, J APPL PHYSIOL, V106, P1234, DOI 10.1152/japplphysiol.91407.2008; Dujic Z, 2006, MED SCI SPORT EXER, V38, P1432, DOI 10.1249/01.mss.0000228936.78916.23; Francis T. J. R., 2003, BENNETT ELLIOTTS PHY, P530; Gempp E, 2010, RES SPORTS MED, V18, P205, DOI 10.1080/15438627.2010.490189; GIRY PBL, 1977, UNDERSEA BIOMED RES, V4, P147; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Gopal VK, 2001, EUR J BIOCHEM, V268, P3304, DOI 10.1046/j.1432-1327.2001.02233.x; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hurlimann D, 2002, EUR HEART J SUPPL, V4, pA1, DOI 10.1016/S1520-765X(02)90067-2; Kotera J, 2000, J HISTOCHEM CYTOCHEM, V48, P685, DOI 10.1177/002215540004800512; LABORIT. H., 1961, AGRESSOLOGIE, V2, P229; Li L, 2007, BRAIN RES, V1132, P185, DOI 10.1016/j.brainres.2006.10.098; Lin CS, 2006, CURR PHARM DESIGN, V12, P3439, DOI 10.2174/138161206778343064; Mollerlokken A, 2006, J APPL PHYSIOL, V101, P1541, DOI 10.1152/japplphysiol.01191.2005; Montcalm-Smith EA, 2008, AVIAT SPACE ENVIR MD, V79, P7, DOI 10.3357/ASEM.2071.2008; Nishi R. Y., 2003, BENNETT ELLIOTTS PHY, P501; Nossum V, 1999, UNDERSEA HYPERBAR M, V26, P1; Nyquist PA, 2004, AVIAT SPACE ENVIR MD, V 75, P211; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Padma-Nathan H, 1998, INT J CLIN PRACT, V52, P375; Phillips BG, 2000, CIRCULATION, V102, P3068; PHILP R B, 1974, Undersea Biomedical Research, V1, P117; Pontier JM, 2008, AVIAT SPACE ENVIR MD, V79, P1096, DOI 10.3357/ASEM.2352.2008; Sawatzky KD, 1991, THESIS YORK U TORONT; Takizawa Shunya, 2003, J Stroke Cerebrovasc Dis, V12, P196, DOI 10.1016/S1052-3057(03)00074-0; THORSEN T, 1987, UNDERSEA BIOMED RES, V14, P45; Wisloff U, 2004, J PHYSIOL-LONDON, V555, P825, DOI 10.1113/jphysiol.2003.055467; Wisloff U, 2003, J PHYSIOL-LONDON, V546, P577, DOI 10.1113/jphysiol.2002.030338; Zhang L, 2005, STROKE, V36, P847, DOI 10.1161/01.STR.0000158923.19956.73	37	20	23	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2013	8	4							e60639	10.1371/journal.pone.0060639	http://dx.doi.org/10.1371/journal.pone.0060639			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	130FG	23844058	gold, Green Published, Green Submitted			2023-01-03	WOS:000317898000044
J	Lee, JK; So, KA; Piyathilake, CJ; Kim, MK				Lee, Jae Kwan; So, Kyeong A.; Piyathilake, Chandrika J.; Kim, Mi Kyung			Mild Obesity, Physical Activity, Calorie Intake, and the Risks of Cervical Intraepithelial Neoplasia and Cervical Cancer	PLOS ONE			English	Article							BODY-MASS INDEX; POSTMENOPAUSAL BREAST-CANCER; NIH-AARP DIET; OVARIAN-CANCER; WOMEN; ASSOCIATION; PROSTATE; IMPACT; COHORT; EPIDEMIOLOGY	Objective: We investigated whether obesity, physical activity, and calorie intake are associated with the risks of cervical intraepithelial neoplasia (CIN) and cervical cancer. Methods: We enrolled 1125 women (age, 18-65 years) into a human papillomavirus cohort study established from 2006 to 2012. Multinomial logistic regression models were used to estimate crude and multivariate odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs), and to assess whether body mass index (BMI), height, weight, total calorie intake, and physical activity were associated with the risks of CIN and cervical cancer. Results: Cervical cancer risk was positively associated with BMI and inversely associated with physical activity. When compared with women with a normal BMI (18.5-23 kg/m(2)), the multivariate ORs (95% CIs) for those overweight (23-25 kg/m(2)) and mild obesity (>= 25 kg/m(2)) were 1.25 (0.79-2.00) and 1.70 (1.10-2.63), respectively. When compared with women with the lowest tertile of physical activity (<38.5 MET-hours/week), the ORs (95% CIs) for cervical cancer were 0.95 (0.61-1.48) and 0.61 (0.38-0.98) for women with medium physical activity (38.5-71.9 MET-hours/week) and those with high physical activity (72 MET-hours/week), respectively (p for linear trend = 0.03). The CIN2/3 risk was inversely associated with physical activity after adjustment for confounders. Compared with women with low physical activity (< 38.5 MET-hours/week), the ORs (95% CIs) for CIN2/3 were 0.64 (0.40-1.01) and 0.58 (0.36-0.93) for the medium and high physical activity groups, respectively (p for linear trend = 0.02). Total calorie intake was not statistically associated with the risks of CIN and cervical cancer after adjustment for confounders. Conclusion: Our results indicate that in addition to screening for and treatment of CIN, recommendations on the maintenance of an appropriate BMI with an emphasis on physical activity could be an important preventive strategy against the development of cervical cancer.	[Lee, Jae Kwan; So, Kyeong A.] Korea Univ, Coll Med, Dept Obstet & Gynecol, Seoul 136705, South Korea; [Piyathilake, Chandrika J.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA; [Kim, Mi Kyung] Natl Canc Ctr, Canc Epidemiol Branch, Goyang, South Korea	Korea University; Korea University Medicine (KU Medicine); University of Alabama System; University of Alabama Birmingham; National Cancer Center - Korea (NCC)	Kim, MK (corresponding author), Natl Canc Ctr, Canc Epidemiol Branch, Goyang, South Korea.	alrud@ncc.re.kr	Kang, Moonkyu/AAR-8974-2021; Auger, Cyril/N-4702-2016; Oak, Min-Ho/AAE-7405-2020	Kang, Moonkyu/0000-0002-2039-4866; LEE, Jae Kwan/0000-0003-3101-6403	Korea National Cancer Center [NCC-1110320, NCC-1310361]	Korea National Cancer Center	This study was supported by a grant-in-aid from the Korea National Cancer Center (grant no. NCC-1110320, NCC-1310361). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Aldrich T, 2010, J MIDWIFERY WOM HEAL, V55, P344, DOI 10.1016/j.jmwh.2009.10.001; [Anonymous], 2002, WEIGHT CONTR PHYS AC; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/S0140-6736(03)15268-3; Brown Pamela, 2002, W V Med J, V98, P271; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Castellsague Xavier, 2003, J Natl Cancer Inst Monogr, P20; Castle Philip E, 2003, J Natl Cancer Inst Monogr, P29; Chang SC, 2006, CANCER EPIDEM BIOMAR, V15, P334, DOI 10.1158/1055-9965.EPI-05-0479; Choo V, 2002, LANCET, V360, P235, DOI 10.1016/S0140-6736(02)09512-0; Deurenberg-Yap M, 2001, INT J OBESITY, V25, P1554, DOI 10.1038/sj.ijo.0801739; Gierach GL, 2009, INT J CANCER, V124, P2139, DOI 10.1002/ijc.24059; Hwang JH, 2010, INT J GYNECOL CANCER, V20, P398, DOI 10.1111/IGC.0b013e3181d02ff2; Hwang JH, 2010, CANCER CAUSE CONTROL, V21, P51, DOI 10.1007/s10552-009-9433-9; Inoue M, 2008, AM J EPIDEMIOL, V168, P391, DOI 10.1093/aje/kwn146; James PT, 2001, OBES RES, V9, p228S, DOI 10.1038/oby.2001.123; Kim YO, 2009, BRIT J NUTR, V101, P1218, DOI 10.1017/S0007114508061497; Ko GTC, 1999, INT J OBESITY, V23, P1136, DOI 10.1038/sj.ijo.0801043; Korea Health Industry Development Institute Ministry of Health and Welfare, 2000, DEV NUTR DAT REC PRO; Lacey JV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-84; Lacey JV, 2003, CANCER-AM CANCER SOC, V98, P814, DOI 10.1002/cncr.11567; Lane Geoffrey, 2008, Menopause Int, V14, P33, DOI 10.1258/mi.2007.007036; Lee GJ, 2005, J KOREAN MED SCI, V20, P267, DOI 10.3346/jkms.2005.20.2.267; Lundqvist E, 2007, INT J CANCER, V121, P810, DOI 10.1002/ijc.22746; Maruthur NM, 2009, OBESITY, V17, P375, DOI 10.1038/oby.2008.480; Mitchell RS, 2008, AM J PREV MED, V35, P127, DOI 10.1016/j.amepre.2008.03.031; Modesitt SC, 2005, OBSTET GYNECOL SURV, V60, P683, DOI 10.1097/01.ogx.0000180866.62409.01; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Patil V, 2006, Indian J Public Health, V50, P38; Pereira M A, 1997, Med Sci Sports Exerc, V29, pS1; Peters TM, 2009, CANCER EPIDEM BIOMAR, V18, P289, DOI 10.1158/1055-9965.EPI-08-0768; PRENTICE RL, 1979, BIOMETRIKA, V66, P403, DOI 10.1093/biomet/66.3.403; Rajkumar T, 2003, BRIT J CANCER, V88, P1388, DOI 10.1038/sj.bjc.6600902; Regional Office for the Western Pacific/World Health Organization International Obesity TaskForce/International Association for the Study of Obesity, 2000, AS PAC PERSP RED OB; Rieck G, 2006, BEST PRACT RES CL OB, V20, P227, DOI 10.1016/j.bpobgyn.2005.10.010; SALLIS JF, 1985, AM J EPIDEMIOL, V121, P91, DOI 10.1093/oxfordjournals.aje.a113987; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; SCHILL W, 1993, BIOMETRIKA, V80, P339, DOI 10.1093/biomet/80.2.339; Schouten LJ, 2008, CANCER EPIDEM BIOMAR, V17, P902, DOI 10.1158/1055-9965.EPI-07-2524; Schouten LJ, 2004, JNCI-J NATL CANCER I, V96, P1635, DOI 10.1093/jnci/djh291; SHEPHARD RJ, 1995, CAN J APPL PHYSIOL, V20, P1, DOI 10.1139/h95-001; Song SH, 2008, GYNECOL ONCOL, V108, P543, DOI 10.1016/j.ygyno.2007.11.006; Song YM, 2004, STROKE, V35, P831, DOI 10.1161/01.STR.0000119386.22691.1C; Stefanescu B I, 2007, Rev Med Chir Soc Med Nat Iasi, V111, P155; Stein CJ, 2004, BRIT J CANCER, V90, P299, DOI 10.1038/sj.bjc.6601509; Tong SY, 2010, CANCER CAUSE CONTROL, V21, P23, DOI 10.1007/s10552-009-9430-z; TORNBERG SA, 1994, BRIT J CANCER, V69, P358, DOI 10.1038/bjc.1994.65; Ulmer H, 2012, GYNECOL ONCOL, V125, P330, DOI 10.1016/j.ygyno.2012.01.052; van Gils CH, 2009, CANCER EPIDEM BIOMAR, V18, P377, DOI 10.1158/1055-9965.EPI-08-0823; Velthuis MJ, 2009, MENOPAUSE, V16, P777, DOI [10.1097/GME.0b013e318197122a, 10.1097/gme.0b013e318197122a]; WANG SS, 2003, J NATL CANC I MONOGR, V31, P35, DOI DOI 10.1093/OXFORDJOURNALS.JNCIMONOGRAPHS.A003480; WHO, 2004, LANCET, V363, P902; Wolin KY, 2009, BRIT J CANCER, V100, P611, DOI 10.1038/sj.bjc.6604917; Wolk A, 2001, CANCER CAUSE CONTROL, V12, P13, DOI 10.1023/A:1008995217664; World Cancer Research Fund & American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P; World Health Organization, 2000, INT ASS STUD OB INT; Yajnik C S, 2002, Obes Rev, V3, P217, DOI 10.1046/j.1467-789X.2002.00072.x; Yoo K Y, 1997, J Epidemiol, V7, P117; Zhou BF, 2002, BIOMED ENVIRON SCI, V15, P83	60	41	42	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2013	8	6							e66555	10.1371/journal.pone.0066555	http://dx.doi.org/10.1371/journal.pone.0066555			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	163FW	23755196	Green Submitted, Green Published, gold			2023-01-03	WOS:000320322400111
J	Richter, L; Neumann, G; Oung, S; Schweikard, A; Trillenberg, P				Richter, Lars; Neumann, Gunnar; Oung, Stephen; Schweikard, Achim; Trillenberg, Peter			Optimal Coil Orientation for Transcranial Magnetic Stimulation	PLOS ONE			English	Article							MOTOR CORTEX; BRAIN-STIMULATION; ACTIVATION; AREA; LOCALIZATION; THRESHOLD; COLUMN; PULSE; TMS	We study the impact of coil orientation on the motor threshold (MT) and present an optimal coil orientation for stimulation of the foot. The result can be compared to results of models that predict this orientation from electrodynamic properties of the media in the skull and from orientations of cells, respectively. We used a robotized TMS system for precise coil placement and recorded motor-evoked potentials with surface electrodes on the abductor hallucis muscle of the right foot in 8 healthy control subjects. First, we performed a hot-spot search in standard (lateral) orientation and then rotated the coil in steps of 10 degrees or 20 degrees. At each step we estimated the MT. For navigated stimulation and for correlation with the underlying anatomy a structural MRI scan was obtained. Optimal coil orientation was 33.1 +/- 18.3 degrees anteriorly in relation to the standard lateral orientation. In this orientation the threshold was 54 +/- 18% in units of maximum stimulator output. There was a significant difference of 8.0 +/- 5.9% between the MTs at optimal and at standard orientation. The optimal coil orientations were significantly correlated with the direction perpendicular to the postcentral gyrus (r=0.78). Robotized TMS facilitates sufficiently precise coil positioning and orientation to study even small variations of the MT with coil orientation. The deviations from standard orientation are more closely matched by models based on field propagation in media than by models based on orientations of pyramidal cells.	[Richter, Lars] Med Univ Lubeck, Inst Robot & Cognit Syst, D-23538 Lubeck, Germany; [Richter, Lars; Oung, Stephen; Schweikard, Achim] Med Univ Lubeck, Grad Sch Comp Med & Life Sci, D-23538 Lubeck, Germany; [Neumann, Gunnar; Trillenberg, Peter] Univ Hosp Schleswig Holstein, Dept Neurol, Lubeck, Germany	University of Lubeck; University of Lubeck; University of Kiel; Schleswig Holstein University Hospital	Richter, L (corresponding author), Med Univ Lubeck, Inst Robot & Cognit Syst, D-23538 Lubeck, Germany.	richter@rob.uni-luebeck.de		Arif, Mohammad/0000-0002-5887-2050; Ochoa-Corona, Francisco/0000-0002-4112-8209	Graduate School for Computing in Medicine and Life Sciences; Germany's Excellence Initiative [DFG GSC 235/1]	Graduate School for Computing in Medicine and Life Sciences; Germany's Excellence Initiative	This work was partially supported by the Graduate School for Computing in Medicine and Life Sciences funded by Germany's Excellence Initiative [DFG GSC 235/1]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.	Allison T, 1996, EVOKED POTENTIAL, V100, P126, DOI 10.1016/0013-4694(95)00226-X; Awiszus F, 2003, SUPPL CLIN NEUROPHYS, V56, P13; Awiszus F, 2011, BRAIN STIMUL, V4, P58, DOI 10.1016/j.brs.2010.09.004; Balslev D, 2007, J NEUROSCI METH, V162, P309, DOI 10.1016/j.jneumeth.2007.01.021; BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Brockhardt, 2011, TMS MOTOR THRESHOLD; Cauda F, 2011, HUM BRAIN MAPP, V32, P1566, DOI 10.1002/hbm.21132; Cohen J., 2013, STAT POWER ANAL BEHA; DAVEY NJ, 1994, J PHYSIOL-LONDON, V477, P223, DOI 10.1113/jphysiol.1994.sp020186; Fox PT, 2004, HUM BRAIN MAPP, V22, P1, DOI 10.1002/hbm.20006; Geyer S, 1996, NATURE, V382, P805, DOI 10.1038/382805a0; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P250, DOI 10.1016/S1388-2457(00)00513-7; Kocak M, 2009, RADIOLOGY, V251, P485, DOI 10.1148/radiol.2512080231; Langguth B, 2010, NEUROPHYSIOL CLIN, V40, P45, DOI 10.1016/j.neucli.2009.03.001; Matthaus L, 2006, STUD HEALTH TECHNOL, V119, P373; Matthaus L, 2008, THESIS U LUBECK; MILLS KR, 1992, ELECTROEN CLIN NEURO, V85, P17, DOI 10.1016/0168-5597(92)90096-T; Mishory A, 2004, J ECT, V20, P160, DOI 10.1097/00124509-200409000-00007; Niyazov DM, 2005, CLIN NEUROPHYSIOL, V116, P1601, DOI 10.1016/j.clinph.2005.02.028; Oberlaender M, 2012, CEREB CORTEX, V22, P2375, DOI 10.1093/cercor/bhr317; Opitz A, 2011, NEUROIMAGE, V58, P849, DOI 10.1016/j.neuroimage.2011.06.069; PASCUALLEONE A, 1994, ELECTROEN CLIN NEURO, V93, P42, DOI 10.1016/0168-5597(94)90090-6; PENTLAND A, 1980, PERCEPT PSYCHOPHYS, V28, P377, DOI 10.3758/BF03204398; Qazi AA, 2009, NEUROIMAGE, V47, pT98, DOI 10.1016/j.neuroimage.2008.06.034; Richter L, 2012, BRAIN STIMUL, P1; Richter L, 2011, INT J MED ROBOT COMP, V7, P414, DOI 10.1002/rcs.411; Ruohonen J, 2010, NEUROPHYSIOL CLIN, V40, P7, DOI 10.1016/j.neucli.2010.01.006; Ruohonen J, 1999, EEG CL N SU, P30; Ruohonen J, 1998, THESIS HELSINKI U TE; Sakai K, 1997, EXP BRAIN RES, V113, P24, DOI 10.1007/BF02454139; Siebner HR, 2009, BRAIN STIMUL, V2, P58, DOI 10.1016/j.brs.2008.11.002; Sommer M, 2006, CLIN NEUROPHYSIOL, V117, P838, DOI 10.1016/j.clinph.2005.10.029; TERAO Y, 1994, ACTA NEUROL SCAND, V89, P378; Terao Y, 1998, EXP BRAIN RES, V121, P145, DOI 10.1007/s002210050446; Terao Y, 2000, BRAIN RES, V859, P137, DOI 10.1016/S0006-8993(00)01975-2; Thielscher A, 2011, NEUROIMAGE, V54, P234, DOI 10.1016/j.neuroimage.2010.07.061; Trillenberg P, 2011, KLIN NEUROPHYSIOL, V42, pP280, DOI [10.1055/s-0031-1272727, DOI 10.1055/S-0031-1272727]; Wagner T, 2012, ANNU REV BIOMED ENG, V9, P527; WERHAHN KJ, 1994, ELECTROEN CLIN NEURO, V93, P138, DOI 10.1016/0168-5597(94)90077-9; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141; Zarkowski P, 2006, CLIN EEG NEUROSCI, V37, P247, DOI 10.1177/155005940603700316	43	59	59	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2013	8	4							e60358	10.1371/journal.pone.0060358	http://dx.doi.org/10.1371/journal.pone.0060358			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	123JA	23593200	Green Submitted, gold, Green Published			2023-01-03	WOS:000317383200006
J	Sugihara, M; Odagiri, F; Suzuki, T; Murayama, T; Nakazato, Y; Unuma, K; Yoshida, K; Daida, H; Sakurai, T; Morimoto, S; Kurebayashi, N				Sugihara, Masami; Odagiri, Fuminori; Suzuki, Takeshi; Murayama, Takashi; Nakazato, Yuji; Unuma, Kana; Yoshida, Ken-ichi; Daida, Hiroyuki; Sakurai, Takashi; Morimoto, Sachio; Kurebayashi, Nagomi			Usefulness of Running Wheel for Detection of Congestive Heart Failure in Dilated Cardiomyopathy Mouse Model	PLOS ONE			English	Article							CHAIN ISOFORM EXPRESSION; KNOCKOUT MICE; TROPONIN MUTATION; NATURAL-HISTORY; EXERCISE; HYPERACTIVITY; DYSFUNCTION; PHENOTYPE	Background: Inherited dilated cardiomyopathy (DCM) is a progressive disease that often results in death from congestive heart failure (CHF) or sudden cardiac death (SCD). Mouse models with human DCM mutation are useful to investigate the developmental mechanisms of CHF and SCD, but knowledge of the severity of CHF in live mice is necessary. We aimed to diagnose CHF in live DCM model mice by measuring voluntary exercise using a running wheel and to determine causes of death in these mice. Methodology/Principal Findings: A knock-in mouse with a mutation in cardiac troponin T (Delta K210) (DCM mouse), which results in frequent death with a t(1/2) of 70 to 90 days, was used as a DCM model. Until 2 months of age, average wheel-running activity was similar between wild-type and DCM mice (approximately 7 km/day). At approximately 3 months, some DCM mice demonstrated low running activity (LO: <1 km/day) while others maintained high running activity (HI: >5 km/day). In the LO group, the lung weight/body weight ratio was much higher than that in the other groups, and the lungs were infiltrated with hemosiderin-loaded alveolar macrophages. Furthermore, echocardiography showed more severe ventricular dilation and a lower ejection fraction, whereas Electrocardiography (ECG) revealed QRS widening. There were two patterns in the time courses of running activity before death in DCM mice: deaths with maintained activity and deaths with decreased activity. Conclusions/Significance: Our results indicate that DCM mice with low running activity developed severe CHF and that running wheels are useful for detection of CHF in mouse models. We found that approximately half of Delta K210 DCM mice die suddenly before onset of CHF, whereas others develop CHF, deteriorate within 10 to 20 days, and die.	[Sugihara, Masami; Odagiri, Fuminori; Suzuki, Takeshi; Murayama, Takashi; Sakurai, Takashi; Kurebayashi, Nagomi] Juntendo Univ, Dept Cellular & Mol Pharmacol, Grad Sch Med, Tokyo, Japan; [Sugihara, Masami; Odagiri, Fuminori; Suzuki, Takeshi; Nakazato, Yuji; Daida, Hiroyuki] Juntendo Univ, Dept Cardiovasc Med, Grad Sch Med, Tokyo, Japan; [Unuma, Kana] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Sect Forens Med, Tokyo, Japan; [Unuma, Kana; Yoshida, Ken-ichi] Univ Tokyo, Dept Forens Med, Grad Sch Med, Tokyo, Japan; [Morimoto, Sachio] Kyushu Univ, Dept Clin Pharmacol, Fac Med Sci, Fukuoka 812, Japan	Juntendo University; Juntendo University; Tokyo Medical & Dental University (TMDU); University of Tokyo; Kyushu University	Kurebayashi, N (corresponding author), Juntendo Univ, Dept Cellular & Mol Pharmacol, Grad Sch Med, Tokyo, Japan.	nagomik@juntendo.ac.jp		Morimoto, Sachio/0000-0001-9171-3636	Ministry of Education, Culture, Sports, Science and Technology of Japan [23136514]; MEXT-Supported Program for the Strategic Research Foundation at Private Universities; Vehicle Racing Commemorative Foundation; Institute of Seizon and Life Sciences	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT-Supported Program for the Strategic Research Foundation at Private Universities(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Vehicle Racing Commemorative Foundation; Institute of Seizon and Life Sciences	This work was supported by a Grant-in Aid (# 23136514), a "High Technology Research Center'' Project for Private Universities: matching fund subsidy from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2011-2015. The authors also thank the Vehicle Racing Commemorative Foundation and the Institute of Seizon and Life Sciences for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brum PC, 2002, AM J PHYSIOL-HEART C, V283, pH1838, DOI 10.1152/ajpheart.01063.2001; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; Du CK, 2007, CIRC RES, V101, P185, DOI 10.1161/CIRCRESAHA.106.146670; Goehringer C, 2009, CARDIOVASC RES, V82, P404, DOI 10.1093/cvr/cvp061; Hayek S, 2011, CARDIOVASC THER, V29, P362, DOI 10.1111/j.1755-5922.2010.00152.x; Jefferies JL, 2010, LANCET, V375, P752, DOI 10.1016/S0140-6736(09)62023-7; Jing XF, 1998, ARCH PATHOL LAB MED, V122, P94; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; Kuwahara K, 2003, EMBO J, V22, P6310, DOI 10.1093/emboj/cdg601; Lakdawala NK, 2010, J AM COLL CARDIOL, V55, P320, DOI 10.1016/j.jacc.2009.11.017; Lerman I, 2002, J APPL PHYSIOL, V92, P2245, DOI 10.1152/japplphysiol.01045.2001; Libby P., 2011, BRAUNWALDS HEART DIS, V8th; LOMPRE AM, 1979, NATURE, V282, P105, DOI 10.1038/282105a0; Luedde M, 2010, CARDIOVASC RES, V86, P452, DOI 10.1093/cvr/cvq009; Lygate CA, 2009, J MOL CELL CARDIOL, V46, P93, DOI 10.1016/j.yjmcc.2008.09.710; Medeiros A, 2008, J APPL PHYSIOL, V104, P103, DOI 10.1152/japplphysiol.00493.2007; Millane T, 2000, BRIT MED J, V320, P559, DOI 10.1136/bmj.320.7234.559; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Morimoto S, 2002, P NATL ACAD SCI USA, V99, P913, DOI 10.1073/pnas.022628899; Morimoto S, 2008, CARDIOVASC RES, V77, P659, DOI 10.1093/cvr/cvm084; Ojaimi C, 2005, AM J PHYSIOL-HEART C, V289, pH1399, DOI 10.1152/ajpheart.00170.2005; Okutucu S, 2010, CARDIOL J, V17, P219; Rundell VLM, 2004, AM J PHYSIOL-HEART C, V287, pH408, DOI 10.1152/ajpheart.00049.2004; Shende P, 2011, CIRCULATION, V123, P1073, DOI 10.1161/CIRCULATIONAHA.110.977066; Suzuki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035353; Unuma K, 2010, CIRC J, V74, P2693, DOI 10.1253/circj.CJ-10-0529; Wang TJ, 2003, CIRCULATION, V108, P977, DOI 10.1161/01.CIR.0000085166.44904.79; Wang YY, 2010, CARDIOVASC RES, V87, P636, DOI 10.1093/cvr/cvq133; Watanabe T, 2008, J AM COLL CARDIOL, V52, P779, DOI 10.1016/j.jacc.2008.06.003; Watson PA, 2007, AM J PHYSIOL-HEART C, V293, pH246, DOI 10.1152/ajpheart.00734.2006; Zhan DY, 2009, CARDIOVASC RES, V84, P64, DOI 10.1093/cvr/cvp168	32	70	74	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2013	8	1							e55514	10.1371/journal.pone.0055514	http://dx.doi.org/10.1371/journal.pone.0055514			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	085JH	23585901	Green Submitted, Green Published, gold			2023-01-03	WOS:000314610600117
J	Lee, JO; Auger, C; Park, DH; Kang, M; Oak, MH; Kim, KR; Schini-Kerth, VB				Lee, Jung-Ok; Auger, Cyril; Park, Dong Hyun; Kang, Moonkyu; Oak, Min-Ho; Kim, Kyoung Rak; Schini-Kerth, Valerie B.			An Ethanolic Extract of Lindera obtusiloba Stems, YJP-14, Improves Endothelial Dysfunction, Metabolic Parameters and Physical Performance in Diabetic db/db Mice	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; II-INDUCED HYPERTENSION; OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; VASCULAR REACTIVITY; PIOGLITAZONE; PREVALENCE; CELLS; RISK; RATS	Lindera obtusiloba is a medicinal herb traditionally used in Asia for improvement of blood circulation, treatment of inflammation, and prevention of liver damage. A previous study has shown that an ethanolic extract of Lindera obtusiloba stems (LOE) has vasoprotective and antihypertensive effects. The possibility that Lindera obtusiloba improves endothelial function and metabolic parameters in type 2 diabetes mellitus (T2DM) remains to be examined. Therefore, the aim of the present study was to determine the potential of LOE to prevent the development of an endothelial dysfunction, and improve metabolic parameters including hyperglycemia, albuminuria and physical exercise capacity in db/db mice, an experimental model of T2DM. The effect of LOE (100 mg/kg/day by gavage for 8 weeks) on these parameters was compared to that of an oral antidiabetic drug, pioglitazone (30 mg/kg/day by gavage). Reduced blood glucose level, body weight and albumin-creatinine ratio were observed in the group receiving LOE compared to the control db/db group. The LOE treatment improved endothelium-dependent relaxations, abolished endothelium-dependent contractions to acetylcholine in the aorta, and normalized the increased vascular oxidative stress and expression of NADPH oxidase, cyclooxygenases, angiotensin II, angiotensin type 1 receptors and peroxynitrite and the decreased expression of endothelial NO synthase in db/db mice. The angiotensin-converting enzyme (ACE) activity was reduced in the LOE group compared to that in the control db/db group. LOE also inhibited the activity of purified ACE, COX-1 and COX-2 in a dose-dependent manner. In addition, LOE improved physical exercise capacity. Thus, the present findings indicate that LOE has a beneficial effect on the vascular system in db/db mice by improving endothelium-dependent relaxations and vascular oxidative stress most likely by normalizing the angiotensin system, and also on metabolic parameters, and these effects are associated with an enhanced physical exercise capacity.	[Lee, Jung-Ok; Auger, Cyril; Schini-Kerth, Valerie B.] Univ Strasbourg, CNRS, Fac Pharm, Lab Biophoton & Pharmacol,UMR 7213, Illkirch Graffenstaden, France; [Lee, Jung-Ok; Kang, Moonkyu; Kim, Kyoung Rak] Hanwha Pharma Co Ltd, Ctr Res & Dev, Chunchon, South Korea; [Park, Dong Hyun] YangJi Chem, Res Ctr, Suwon, South Korea; [Oak, Min-Ho] Mokpo Natl Univ, Coll Pharm, Muan, Jeonam, South Korea	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Mokpo National University	Schini-Kerth, VB (corresponding author), Univ Strasbourg, CNRS, Fac Pharm, Lab Biophoton & Pharmacol,UMR 7213, Illkirch Graffenstaden, France.	valerie.schini-kerth@unistra.fr	Kang, Moonkyu/AAR-8974-2021; Auger, Cyril/N-4702-2016; Oak, Min-Ho/AAE-7405-2020	Kang, Moonkyu/0000-0002-2039-4866; LEE, Jae Kwan/0000-0003-3101-6403	The Ministry of Knowledge Economy, Republic of Korea, under the Leading Industry Development for Gangwon Economic Region (LIDGER) program [70007579]; Hanwha Pharma. Co., Ltd; Hanwha Pharma. Co., Ltd, Chuncheon, Republic of Korea	The Ministry of Knowledge Economy, Republic of Korea, under the Leading Industry Development for Gangwon Economic Region (LIDGER) program(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea); Hanwha Pharma. Co., Ltd; Hanwha Pharma. Co., Ltd, Chuncheon, Republic of Korea	The study was supported, in part, by The Ministry of Knowledge Economy, Republic of Korea, under the Leading Industry Development for Gangwon Economic Region (LIDGER) program (number 70007579), and by Hanwha Pharma. Co., Ltd. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Jung-Ok Lee, Moonkyu Kang and Kyoung Rak Kim are all employees of Hanwha Pharma. Co., Ltd, Chuncheon, Republic of Korea, whose company provided funding toward this study. Dong Hyun Park is an employee of YangJi Chemicals, Suwon, Republic of Korea, which is a daughter company of Hanwha. Hanwha has filed a European and US patent on YJP14 and endothelial dysfunction. The Korean FDA have approved further clinical studies regarding YJP-14 and endothelial dysfunction in diabetes. At present there are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.	Ajay M, 2006, VASC PHARMACOL, V45, P127, DOI 10.1016/j.vph.2006.05.001; Alhaider AA, 2011, CHEM-BIOL INTERACT, V192, P233, DOI 10.1016/j.cbi.2011.03.014; Bakker W, 2009, CELL TISSUE RES, V335, P165, DOI 10.1007/s00441-008-0685-6; Balletshofer BM, 2000, CIRCULATION, V101, P1780, DOI 10.1161/01.CIR.101.15.1780; Capellini VK, 2010, CURR VASC PHARMACOL, V8, P526; CHANG KC, 1993, J PHARMACOL EXP THER, V266, P992; Chen WG, 2010, BIOCHEMISTRY-US, V49, P3129, DOI 10.1021/bi9016632; Cohen RA, 2010, J CARDIOVASC PHARM, V55, P308, DOI 10.1097/FJC.0b013e3181d89670; Ding H, 2010, PFLUG ARCH EUR J PHY, V459, P977, DOI 10.1007/s00424-010-0807-3; Dunstan DW, 2002, DIABETES CARE, V25, P829, DOI 10.2337/diacare.25.5.829; Feletou M, 2010, CURR HYPERTENS REP, V12, P267, DOI 10.1007/s11906-010-0118-2; Fowler M.J., 2008, CLIN DIABETES, V26, P77, DOI [10.2337/diaclin.26.2.77, DOI 10.2337/DIACLIN.26.2.77]; Freise C, 2010, J NUTR BIOCHEM, V21, P1170, DOI 10.1016/j.jnutbio.2009.09.013; Gao L, 2009, CARDIOVASC RES, V82, P9, DOI 10.1093/cvr/cvp031; Grundy SM, 1999, CIRCULATION, V100, P1134, DOI 10.1161/01.CIR.100.10.1134; Hartge Martin M, 2007, Diab Vasc Dis Res, V4, P84; Heitzer T, 2001, CIRCULATION, V104, P2673, DOI 10.1161/hc4601.099485; Henry RMA, 2004, ATHEROSCLEROSIS, V174, P49, DOI 10.1016/j.atherosclerosis.2004.01.002; Idris-Khodja N, 2012, N-S ARCH PHARMACOL, V385, P749, DOI 10.1007/s00210-012-0749-8; Ihm SH, 2009, ATHEROSCLEROSIS, V206, P47, DOI 10.1016/j.atherosclerosis.2009.01.036; Jimenez R, 2007, FREE RADICAL BIO MED, V43, P462, DOI 10.1016/j.freeradbiomed.2007.05.007; Johnson DK, 2002, ENDOTHELIUM-J ENDOTH, V9, P191, DOI 10.1080/10623320213638; Junker N, 2005, CANCER SCI, V96, P183, DOI 10.1111/j.1349-7006.2005.00026.x; Kanda Y, 2010, AM J PHYSIOL-ENDOC M, V298, pE278, DOI 10.1152/ajpendo.00388.2009; Kusunoki M, 2011, EUR J PHARMACOL, V668, P486, DOI 10.1016/j.ejphar.2011.07.030; Lee JO, 2011, N-S ARCH PHARMACOL, V383, P635, DOI 10.1007/s00210-011-0643-9; Lewis TV, 1999, J AM COLL CARDIOL, V33, P805, DOI 10.1016/S0735-1097(98)00667-6; Liang W, 2008, J PHYSIOL SCI, V58, P405, DOI 10.2170/physiolsci.RP012808; Lim YK, 2002, ATHEROSCLEROSIS, V160, P311, DOI 10.1016/S0021-9150(01)00576-7; Mohan S, 2008, LAB INVEST, V88, P515, DOI 10.1038/labinvest.2008.23; Musicki B, 2010, J SEX MED, V7, P3023, DOI 10.1111/j.1743-6109.2010.01880.x; Nichols GA, 2001, DIABETES CARE, V24, P1614, DOI 10.2337/diacare.24.9.1614; ODriscoll G, 1997, J CLIN INVEST, V100, P678, DOI 10.1172/JCI119580; Okudan N, 2011, J MED FOOD, V14, P1298, DOI 10.1089/jmf.2010.0030; Ota H, 2010, ARTERIOSCL THROM VAS, V30, P2205, DOI 10.1161/ATVBAHA.110.210500; Park JH, 2011, J BIOCHEM MOL TOXIC, V25, P238, DOI 10.1002/jbt.20381; Park Y, 2008, AM J PHYSIOL-HEART C, V295, pH1982, DOI 10.1152/ajpheart.01261.2007; Plutzky J, 2011, AM J CARDIOL, V108, p25B, DOI 10.1016/j.amjcard.2011.03.014; Regensteiner JG, 2003, VASC MED, V8, P169, DOI 10.1191/1358863x03vm489oa; Sallam N, 2011, N-S ARCH PHARMACOL, V383, P483, DOI 10.1007/s00210-011-0614-1; Sarr M, 2006, CARDIOVASC RES, V71, P794, DOI 10.1016/j.cardiores.2006.05.022; Savage S, 1996, DIABETES CARE, V19, P1243, DOI 10.2337/diacare.19.11.1243; Schalkwijk CG, 2005, CLIN SCI, V109, P143, DOI 10.1042/CS20050025; Schmidt TS, 2007, CLIN SCI, V113, P47, DOI 10.1042/CS20070108; Selvin E, 2004, CIRCULATION, V110, P738, DOI 10.1161/01.CIR.0000137913.26087.F0; Senador D, 2009, EXP PHYSIOL, V94, P648, DOI 10.1113/expphysiol.2008.046474; Sharma A, 2012, INT J VASC MED, V2012, DOI 10.1155/2012/750126; Smith SR, 2005, METABOLISM, V54, P24, DOI 10.1016/j.metabol.2004.07.008; Sowers JR, 2001, HYPERTENSION, V37, P1053, DOI 10.1161/01.HYP.37.4.1053; Sridulyakul P, 2006, CLIN HEMORHEOL MICRO, V34, P315; Stapleton PA, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-54; Thompson D, 2001, Obes Rev, V2, P189, DOI 10.1046/j.1467-789x.2001.00037.x; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Title LM, 2000, J AM COLL CARDIOL, V36, P758, DOI 10.1016/S0735-1097(00)00809-3; Urso C, 2011, MINERVA MED, V102, P59; W.H. Organization, 1999, DEFINITION DIAGNOSIS; Wang XR, 2011, AM J PHYSIOL-ENDOC M, V300, pE1135, DOI 10.1152/ajpendo.00001.2011; Wong WT, 2010, ANTIOXID REDOX SIGN, V13, P757, DOI 10.1089/ars.2009.2831; Ying CJ, 2003, HYPERTENS RES, V26, P823, DOI 10.1291/hypres.26.823; Yook C., 1997, COLORED MED PLANTS K, P588; Zanetti M, 2010, EXP GERONTOL, V45, P848, DOI 10.1016/j.exger.2010.07.002; Zhang HR, 2010, AM J PHYSIOL-HEART C, V299, pH985, DOI 10.1152/ajpheart.00489.2010; Zhang SL, 2007, PEDIATR NEPHROL, V22, P813, DOI 10.1007/s00467-007-0444-z; Zheng Z, 2011, DIABETES	64	41	42	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2013	8	6							e65227	10.1371/journal.pone.0065227	http://dx.doi.org/10.1371/journal.pone.0065227			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	157CD	23755196	Green Published, Green Submitted, gold			2023-01-03	WOS:000319872300059
J	Li, SH; Arguelles, L; Jiang, F; Chen, WJ; Jin, XM; Yan, CH; Tian, Y; Hong, XM; Qian, C; Zhang, J; Wang, XB; Shen, XM				Li, Shenghui; Arguelles, Lester; Jiang, Fan; Chen, Wenjuan; Jin, Xingming; Yan, Chonghuai; Tian, Ying; Hong, Xiumei; Qian, Ceng; Zhang, Jun; Wang, Xiaobin; Shen, Xiaoming			Sleep, School Performance, and a School-Based Intervention among School-Aged Children: A Sleep Series Study in China	PLOS ONE			English	Article							DAYTIME SLEEPINESS; ACADEMIC-PERFORMANCE; RISK-FACTORS; DURATION; DISTURBANCES; ADOLESCENTS; PREVALENCE; DISRUPTION; DISORDERS; CHILDHOOD	Background: Sufficient sleep during childhood is essential to ensure a transition into a healthy adulthood. However, chronic sleep loss continues to increase worldwide. In this context, it is imperative to make sleep a high-priority and take action to promote sleep health among children. The present series of studies aimed to shed light on sleep patterns, on the longitudinal association of sleep with school performance, and on practical intervention strategy for Chinese school-aged children. Methods and Findings: A serial sleep researches, including a national cross-sectional survey, a prospective cohort study, and a school-based sleep intervention, were conducted in China from November 2005 through December 2009. The national cross-sectional survey was conducted in 8 cities and a random sample of 20,778 children aged 9.0 +/- 1.61 years participated in the survey. The five-year prospective cohort study included 612 children aged 6.8 +/- 0.31 years. The comparative cross-sectional study (baseline: n = 525, aged 10.80 +/- 0.41; post-intervention follow-up: n = 553, aged 10.81 +/- 0.33) was undertaken in 6 primary schools in Shanghai. A battery of parent and teacher reported questionnaires were used to collect information on children's sleep behaviors, school performance, and sociodemographic characteristics. The mean sleep duration was 9.35 +/- 0.77 hours. The prevalence of daytime sleepiness was 64.4% (sometimes: 37.50%; frequently: 26.94%). Daytime sleepiness was significantly associated with impaired attention, learning motivation, and particularly, academic achievement. By contrast, short sleep duration only related to impaired academic achievement. After delaying school start time 30 minutes and 60 minutes, respectively, sleep duration correspondingly increased by 15.6 minutes and 22.8 minutes, respectively. Moreover, intervention significantly improved the sleep duration and daytime sleepiness. Conclusions: Insufficient sleep and daytime sleepiness commonly existed and positively associated with the impairment of school performance, especially academic achievement, among Chinese school-aged children. The effectiveness of delaying school staring time emphasized the benefits of optimal school schedule regulation to children's sleep health.	[Li, Shenghui; Yan, Chonghuai; Zhang, Jun] Shanghai Jiao Tong Univ, MOE Shanghai Key Lab Childrens Environm Hlth, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China; [Li, Shenghui; Tian, Ying; Qian, Ceng] Shanghai Jiao Tong Univ, Sch Publ Hlth, Shanghai 200030, Peoples R China; [Arguelles, Lester; Hong, Xiumei; Wang, Xiaobin] Northwestern Univ, Feinberg Sch Med, Mary Ann & J Milburn Smith Child Hlth Res Program, Chicago, IL 60611 USA; [Arguelles, Lester; Hong, Xiumei; Wang, Xiaobin] Childrens Mem Hosp, Chicago, IL 60614 USA; [Arguelles, Lester; Hong, Xiumei; Wang, Xiaobin] Childrens Mem Res Ctr, Chicago, IL USA; [Jiang, Fan; Chen, Wenjuan; Jin, Xingming] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Sch Med, Shanghai 200030, Peoples R China; [Wang, Xiaobin; Shen, Xiaoming] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Ctr Childhood Origins Dis, Baltimore, MD USA	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Shanghai Jiao Tong University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Li, SH (corresponding author), Shanghai Jiao Tong Univ, MOE Shanghai Key Lab Childrens Environm Hlth, Sch Med, Xinhua Hosp, Shanghai 200030, Peoples R China.	Lsh9907@163.com; Shenxm9907@126.com	Jiang, Fan/AHA-6297-2022; Jiang, Fan/AGX-9052-2022; CHEN, Haiyong/G-6787-2014; Devreese, Bart/B-2011-2009	Jiang, Fan/0000-0003-0634-101X; Anthony, Arguelles Arias/0000-0003-4359-733X; Fickers, Patrick/0000-0002-2600-5833; CHEN, Haiyong/0000-0002-4889-2752; Devreese, Bart/0000-0002-9764-2581	MOE - Shanghai Key Laboratory of Children's Environmental Health [06DZ22024]; Key Discipline in Public Health of Shanghai Municipal Education Commission; National Natural Science Foundation of China [81072314, 30700670, 81172685]; Innovation Program of Shanghai Municipal Education Commission [13YZ034]; New Bairenjihua in Shanghai Jiaotong University School of Medicine; Shanghai public health academic leader project [GWDTR201222]	MOE - Shanghai Key Laboratory of Children's Environmental Health; Key Discipline in Public Health of Shanghai Municipal Education Commission; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); New Bairenjihua in Shanghai Jiaotong University School of Medicine; Shanghai public health academic leader project	This study was funded by Grants from MOE - Shanghai Key Laboratory of Children's Environmental Health (06DZ22024), the Key Discipline in Public Health of Shanghai Municipal Education Commission, National Natural Science Foundation of China (81072314, 30700670, 81172685), Innovation Program of Shanghai Municipal Education Commission (13YZ034), 2009 New Bairenjihua in Shanghai Jiaotong University School of Medicine, and 2012 Shanghai public health academic leader project (GWDTR201222). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altevogt B.M., 2006, SLEEP DISORDERS SLEE; Beebe DW, 2010, J ADOLESCENT HEALTH, V47, P523, DOI 10.1016/j.jadohealth.2010.03.005; Bruni O, 2006, SLEEP MED, V7, P43, DOI 10.1016/j.sleep.2005.09.003; Calhoun SL, 2011, SLEEP, V34, P503, DOI 10.1093/sleep/34.4.503; Clinkinbeard SS, 2011, J YOUTH ADOLESCENCE, V40, P916, DOI 10.1007/s10964-010-9594-6; Curcio G, 2006, SLEEP MED REV, V10, P323, DOI 10.1016/j.smrv.2005.11.001; Dewald JF, 2010, SLEEP MED REV, V14, P179, DOI 10.1016/j.smrv.2009.10.004; Dexter Donn, 2003, WMJ, V102, P44; Gaina A, 2007, J PEDIATR-US, V151, P518, DOI 10.1016/j.jpeds.2007.04.036; Grandner MA, 2012, SLEEP MED REV, V16, P199, DOI 10.1016/j.smrv.2012.02.001; Gruber R, 2010, SLEEP MED, V11, P289, DOI 10.1016/j.sleep.2009.09.007; Heussler HS, 2005, MED J AUSTRALIA, V182, P484, DOI 10.5694/j.1326-5377.2005.tb06793.x; Holley S, 2010, BEHAV SLEEP MED, V8, P16, DOI 10.1080/15402000903425462; Iglowstein I, 2003, PEDIATRICS, V111, P302, DOI 10.1542/peds.111.2.302; Institute of M. Sleep disorders sleep deprivation, 2006, UNM PUBL HLTH PROBL; Jiang Fan, 2002, Zhonghua Yi Xue Za Zhi, V82, P736; Kerkhof GA, 2010, PROG BRAIN RES, V185, P1, DOI 10.1016/B978-0-444-53702-7.00001-4; Leproult R, 2010, ENDOCR DEV, V17, P11, DOI 10.1159/000262524; Li Sheng-hui, 2007, Zhonghua Er Ke Za Zhi, V45, P176; Li SH, 2007, SLEEP, V30, P361, DOI 10.1093/sleep/30.3.361; Li SH, 2010, SLEEP MED, V11, P907, DOI 10.1016/j.sleep.2010.03.018; Li YC, 2008, SLEEP MED, V9, P142, DOI 10.1016/j.sleep.2007.01.018; Liu XC, 2005, PEDIATRICS, V115, P241, DOI 10.1542/peds.2004-0815F; Matricciani L, 2012, SLEEP MED REV, V16, P203, DOI 10.1016/j.smrv.2011.03.005; Matricciani L, 2011, SLEEP, V34, P651, DOI 10.1093/sleep/34.5.651; Matricciani LA, 2012, PEDIATRICS, V129, P548, DOI 10.1542/peds.2011-2039; Mindell JA, 2003, CLIN GUIDE PEDIAT SL; Mindell JA, 2011, SLEEP MED, V12, P203, DOI 10.1016/j.sleep.2011.01.003; Nieuwenhuis ILC, 2011, BEHAV BRAIN RES, V218, P325, DOI 10.1016/j.bbr.2010.12.009; Nixon GM, 2008, SLEEP, V31, P71, DOI 10.1093/sleep/31.1.71; O'Brien LM, 2009, CHILD ADOL PSYCH CL, V18, P813, DOI 10.1016/j.chc.2009.04.008; Owens JA, 2000, SLEEP, V23, P1043; Owens JA, 2010, ARCH PEDIAT ADOL MED, V164, P608, DOI 10.1001/archpediatrics.2010.96; Perez-Chada D, 2007, SLEEP, V30, P1698, DOI 10.1093/sleep/30.12.1698; Ravid S, 2009, DEV NEUROPSYCHOL, V34, P574, DOI 10.1080/87565640903133533; Ravikiran SR, 2011, INDIAN PEDIATR, V48, P221, DOI 10.1007/s13312-011-0049-2; Seegers V, 2011, AM J EPIDEMIOL, V173, P621, DOI 10.1093/aje/kwq389; Spruyt K, 2005, J SLEEP RES, V14, P163, DOI 10.1111/j.1365-2869.2005.00458.x; Spruyt K, 2011, PEDIATRICS, V127, pE345, DOI 10.1542/peds.2010-0497; Teufel J. A., 2007, American Journal of Health Studies, V22, P10; Wolfson Amy R, 2007, Behav Sleep Med, V5, P194; Yang J., 2007, CHINA J SCH DOCTOR, V21, P379	42	150	156	5	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2013	8	7							e67928	10.1371/journal.pone.0067928	http://dx.doi.org/10.1371/journal.pone.0067928			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	182SU	24349428	Green Published, gold, Green Submitted			2023-01-03	WOS:000321765300017
J	Yang, DY; Baumgartner, RN; Slattery, ML; Wang, CX; Giuliano, AR; Murtaugh, MA; Risendal, BC; Byers, T; Baumgartner, KB				Yang, Dongyan; Baumgartner, Richard N.; Slattery, Martha L.; Wang, Chenxi; Giuliano, Anna R.; Murtaugh, Maureen A.; Risendal, Betsy C.; Byers, Tim; Baumgartner, Kathy B.			Dietary Intake of Folate, B-Vitamins and Methionine and Breast Cancer Risk among Hispanic and Non-Hispanic White Women	PLOS ONE			English	Article							ONE-CARBON METABOLISM; SOUTHWESTERN UNITED-STATES; ESTROGEN-RECEPTOR STATUS; MTHFR POLYMORPHISMS; BODY-SIZE; POSTMENOPAUSAL WOMEN; GENE POLYMORPHISMS; COLON-CANCER; ALCOHOL; NUTRIENTS	Background: Low dietary folate intake is associated with several neoplasias, but reports are inconsistent for breast cancer. Additionally, the association of folate with breast cancer estrogen receptor (ER) status is not well established. Objective: To determine if dietary intakes of folate, B-vitamins (B-2, B-6, B-12) and methionine are associated with breast cancer risk and ER status in Hispanic, and non-Hispanic White women in the southwestern US. Materials and Methods: Primary breast cancer cases (n = 2,325) in the 4-Corners region (Arizona, Colorado, New Mexico and Utah), diagnosed between October 1999 and May 2004, were identified through state cancer registries. Controls (n = 2,525) were frequency-matched by ethnicity and age (+/- 5 years). Dietary intake, physical activity and other exposures were assessed using in-person interviews. Risk was assessed through multivariable and multinomial logistic regression with adjustment for relevant covariates. Result: While there was no overall association with breast cancer, the highest quartile of folate intake was marginally inversely associated with ER- breast cancer (Odds Ratio (OR) = 0.50, 95% CI 0.25-1.00, p for trend = 0.07). Vitamin B-12 intake was inversely associated with breast cancer also (OR = 0.73, 95% CI 0.53-1.00, p for trend = 0.06), particularly for the highest quartile of ER+ breast cancer (OR = 0.67, 95% CI 0.46-0.99, p for trend = 0.06), among NHW women (OR = 0.49, 95% CI 0.29-0.81, p for trend = 0.01) and invasive breast cancer (OR = 0.63; 95% CI: 0.42, 0.93, P-trend = 0.01). Methionine intake was also inversely associated with ER+ breast cancer (OR for 4th quartile = 0.83, 95% CI 0.66-1.03, p for trend = 0.04), primarily among Hispanic women (OR = 0.71, 95% CI 0.47-1.06, and P for trend = 0.02). Conclusion: Higher intake of folate is marginally associated with a lower risk for ER- breast cancer, and higher intakes of vitamin B-12 and methionine are marginally associated with a lower risk of ER+ breast cancer.	[Yang, Dongyan; Baumgartner, Richard N.; Wang, Chenxi; Baumgartner, Kathy B.] Univ Louisville, Sch Publ Hlth & Informat Sci, Dept Epidemiol & Populat Hlth, Louisville, KY 40292 USA; [Slattery, Martha L.; Murtaugh, Maureen A.] Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; [Giuliano, Anna R.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Risendal, Betsy C.; Byers, Tim] Univ Colorado, Sch Publ Hlth, Denver, CO 80202 USA	University of Louisville; Utah System of Higher Education; University of Utah; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Colorado School of Public Health; University of Colorado System; University of Colorado Denver	Yang, DY (corresponding author), Univ Louisville, Sch Publ Hlth & Informat Sci, Dept Epidemiol & Populat Hlth, Louisville, KY 40292 USA.	d0yang01@louisville.edu	peng, yu/GXW-2071-2022; Wang, Wei Eric/AAE-9504-2022; Wang, Wei Eric/AFE-0795-2022; Lv, Yuanjie/AER-0767-2022; Murtaugh, Maureen/AAN-6225-2020	Murtaugh, Maureen/0000-0001-5281-0302	National Cancer Institute [CA 078682, CA 078762, CA078552, CA078802, N01-PC-67000]; Utah Cancer Registry; State of Utah Department of Health	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Utah Cancer Registry; State of Utah Department of Health	This research was supported by the grants from the National Cancer Institute (CA 078682, CA 078762, CA078552, and CA078802). This research also was supported by the Utah Cancer Registry, which is funded by Contract #N01-PC-67000 from the National Cancer Institute, and with additional support from the State of Utah Department of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Baumgartner Kathy B., 2002, Ethnicity & Disease, V12, P460; Buechley RW, 1976, GEN USEFUL ETHNIC SE; Chen J, 2005, CANCER RES, V65, P1606, DOI 10.1158/0008-5472.CAN-04-2630; Cho EY, 2007, CANCER EPIDEM BIOMAR, V16, P2787, DOI 10.1158/1055-9965.EPI-07-0683; Choumenkovitch SF, 2002, J NUTR, V132, P2792, DOI 10.1093/jn/132.9.2792; Curtin K, 2007, CARCINOGENESIS, V28, P1672, DOI 10.1093/carcin/bgm089; DuBose Katrina D, 2007, J Phys Act Health, V4, P343; Durnitrescu RG, 2005, ALCOHOL, V35, P213, DOI 10.1016/j.alcohol.2005.04.005; ELLEDGE RM, 1994, J NATL CANCER I, V86, P705, DOI 10.1093/jnci/86.9.705; Ericson U, 2007, AM J CLIN NUTR, V86, P434, DOI 10.1093/ajcn/86.2.434; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; Hines LM, 2008, CANCER EPIDEM BIOMAR, V17, P2700, DOI 10.1158/1055-9965.EPI-08-0504; HOWARD CA, 1983, AM J EPIDEMIOL, V117, P27, DOI 10.1093/oxfordjournals.aje.a113512; Institute of Medicine, 1998, DIET REF INT THIAM R, P1; Jatoi I, 2007, J CLIN ONCOL, V25, P1683, DOI 10.1200/JCO.2006.09.2106; JEWELL N. P., 2004, STAT EPIDEMIOLOGY; Kabat GC, 2008, BRIT J CANCER, V99, P816, DOI 10.1038/sj.bjc.6604540; Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511; Kim YI, 2006, NUTR REV, V64, P468, DOI 10.1301/nr.2006.oct.468-475; Koutros S, 2008, AM J EPIDEMIOL, V167, P287, DOI 10.1093/aje/kwm307; Lajous M, 2006, CANCER EPIDEM BIOMAR, V15, P443, DOI 10.1158/1055-9965.EPI-05-0532; Lajous M, 2006, CANCER CAUSE CONTROL, V17, P1209, DOI 10.1007/s10552-006-0053-3; Larsson SC, 2007, JNCI-J NATL CANCER I, V99, P64, DOI 10.1093/jnci/djk006; Levi F, 2001, INT J CANCER, V91, P260, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1041&gt;3.3.CO;2-R; Lewis SJ, 2006, JNCI-J NATL CANCER I, V98, P1607, DOI 10.1093/jnci/djj440; Lin J, 2008, AM J CLIN NUTR, V87, P734, DOI 10.1093/ajcn/87.3.734; Liu Kiang, 1994, Ethnicity and Disease, V4, P15; Maruti SS, 2009, AM J CLIN NUTR, V89, P624, DOI 10.3945/ajcn.2008.26568; Mason JB, 2005, ALCOHOL, V35, P235, DOI 10.1016/j.alcohol.2005.03.012; Moore CE, 2005, J NUTR, V135, P2478, DOI 10.1093/jn/135.10.2478; Murtaugh MA, 2008, AM J CLIN NUTR, V87, P978, DOI 10.1093/ajcn/87.4.978; Murtaugh MA, 2007, J AM DIET ASSOC, V107, P1311, DOI 10.1016/j.jada.2007.05.008; Murtaugh MA, 2007, CANCER CAUSE CONTROL, V18, P153, DOI 10.1007/s10552-006-0099-2; Negri E, 2000, J NATL CANCER I, V92, P1270, DOI 10.1093/jnci/92.15.1270-a; Osborne CK, 1991, BREAST DIS, P301; Prinz-Langenohl R, 2001, EUR J NUTR, V40, P98, DOI 10.1007/PL00007387; Risendal B, 2008, CANC CAUSES CONTROL; Rogers A, 2004, AM J EPIDEMIOL, V160, P85, DOI 10.1093/aje/kwh176; Rohan TE, 2000, J NATL CANCER I, V92, P266, DOI 10.1093/jnci/92.3.266; Rollison DE, 2008, AM J EPIDEMIOL, V167, P447, DOI 10.1093/aje/kwm322; Satia-Abouta J, 2003, CANCER EPIDEM BIOMAR, V12, P747; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Sellers TA, 2002, CANCER EPIDEM BIOMAR, V11, P1104; Shen HB, 2003, CANCER EPIDEM BIOMAR, V12, P980; Shrubsole MJ, 2011, AM J EPIDEMIOL, V173, P1171, DOI 10.1093/aje/kwq491; Shrubsole MJ, 2004, CANCER EPIDEM BIOMAR, V13, P190, DOI 10.1158/1055-9965.EPI-03-0273; Shrubsole MJ, 2001, CANCER RES, V61, P7136; Slattery ML, 2007, BREAST CANCER RES TR, V104, P197, DOI 10.1007/s10549-006-9403-9; Slattery ML, 2008, BREAST CANCER RES TR, V109, P101, DOI 10.1007/s10549-007-9629-1; Slattery ML, 2008, OBESITY, V16, P339, DOI 10.1038/oby.2007.44; Slattery ML, 2007, BREAST CANCER RES TR, V105, P327, DOI 10.1007/s10549-006-9453-z; Slattery ML, 2007, ANN EPIDEMIOL, V17, P342, DOI 10.1016/j.annepidem.2006.10.017; Slattery ML, 2007, CANCER EPIDEM BIOMAR, V16, P747, DOI 10.1158/1055-9965.EPI-06-0667; Slattery ML, 2007, BREAST CANCER RES TR, V102, P85, DOI 10.1007/s10549-006-9292-y; SLATTERY ML, 1994, J AM DIET ASSOC, V94, P761, DOI 10.1016/0002-8223(94)91944-5; Slattery ML, 2005, CANCER CAUSE CONTROL, V16, P1147, DOI 10.1007/s10552-005-0318-2; STANFORD JL, 1989, AM J PUBLIC HEALTH, V79, P71, DOI 10.2105/AJPH.79.1.71; Steffen AD, 2008, CANCER EPIDEM BIOMAR, V17, P447, DOI 10.1158/1055-9965.EPI-07-2576; Stevens VL, 2010, AM J CLIN NUTR, V91, P1708, DOI 10.3945/ajcn.2009.28553; Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895, DOI 10.1093/ajcn/83.4.895; Suitor CW, 2000, J AM DIET ASSOC, V100, P88, DOI 10.1016/S0002-8223(00)00027-4; Suzuki T, 2008, CARCINOGENESIS, V29, P356, DOI 10.1093/carcin/bgm295; Sweeney C, 2008, CANCER CAUSE CONTROL, V19, P391, DOI 10.1007/s10552-007-9098-1; Sweeney C, 2007, AM J EPIDEMIOL, V166, P1210, DOI 10.1093/aje/kwm192; Sweeney C, 2007, CANCER EPIDEM BIOMAR, V16, P142, DOI 10.1158/1055-9965.EPI-06-0706; Ulrich CM, 2006, NUTRIENT-GENE INTERACTIONS IN CANCER, P75, DOI 10.1201/9781420004847.ch5; Ulrich CM, 2007, AM J CLIN NUTR, V86, P271, DOI 10.1093/ajcn/86.2.271; Wang C, 2008, BREAST CANC RES TREA; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1998, NUTR EPIDEMIOLOGY; Word DL, 1996, 13 US BUR CENS POP D, P1; Zhang SM, 2005, CANCER EPIDEM BIOMAR, V14, P2004, DOI 10.1158/1055-9965.EPI-05-0083; Zhang SM, 1999, JAMA-J AM MED ASSOC, V281, P1632, DOI 10.1001/jama.281.17.1632; Zhu KM, 1998, CANCER CAUSE CONTROL, V9, P615, DOI 10.1023/A:1008819210777	78	223	230	3	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2013	8	2							e54495	10.1371/journal.pone.0054495	http://dx.doi.org/10.1371/journal.pone.0054495			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	092DU	23408942	Green Published, gold, Green Submitted			2023-01-03	WOS:000315100000006
J	Liu, XQ; Zhou, CL; Li, YJ; Ji, Y; Xu, GP; Wang, XT; Yan, JL				Liu, Xiaoqi; Zhou, Changlong; Li, Yanjing; Ji, Ye; Xu, Gongping; Wang, Xintao; Yan, Jinglong			SDF-1 Promotes Endochondral Bone Repair during Fracture Healing at the Traumatic Brain Injury Condition	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; HEAD-INJURY; ENHANCED OSTEOGENESIS; IN-VITRO; MYOCARDIAL-INFARCTION; MARROW; GROWTH; MIGRATION; MODEL; RATS	Purposes: The objective of this study was to investigate the role of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, on bone healing and whether SDF-1 contributes to accelerating bone repair in traumatic brain injury (TBI)/fracture model. Materials and Methods: Real-time polymerase chain reaction and immunohistochemical analysis were used to detect the expression of SDF-1 during the repair of femoral bone in TBI/fracture model. The TBI/fracture model was treated with anti-SDF-1 neutralizing antibody or AMD3100, an antagonist for CXCR4, and evaluated by histomorphometry. In vitro and in vivo migration assays were used to evaluate the functional effect of SDF-1 on primary mesenchymal stem cells. Results: The expression of SDF1 and CXCR4 messenger RNA was increased during the bone healing in TBI/fracture model but was less increased in fracture only model. High expression of SDF-1 protein was observed in the surrounding tissue of the damaged bone. Treated with anti-SDF-1 antibody or AMD3100 could inhibit new bone formation. SDF-1 increased mesenchymal stem cell chemotaxis in vitro in a dose-dependent manner. The in vivo migration study demonstrated that mesenchymal stem cells recruited by SDF-1 participate in endochondral bone repair. Conclusion: The SDF-1/CXCR4 axis plays a crucial role in the accelerating fracture healing under the condition of TBI and contributes to endochondral bone repair.	[Liu, Xiaoqi; Zhou, Changlong; Li, Yanjing; Ji, Ye; Xu, Gongping; Wang, Xintao; Yan, Jinglong] Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin, Peoples R China	Harbin Medical University	Yan, JL (corresponding author), Harbin Med Univ, Affiliated Hosp 1, Dept Orthoped Surg, Harbin, Peoples R China.	yanjlhyd@hotmail.com		John, Ciny/0000-0003-3688-0751; Liu, Geoffrey/0000-0002-2603-7296	National Natural Science Foundation of China [100334]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The National Natural Science Foundation of China (100334) (http://www.nsfc.gov.cn/Portal0/default152.htm). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301-620x.86b6.14176; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Castano-Izquierdo H, 2007, J BIOMED MATER RES A, V82A, P129, DOI 10.1002/jbm.a.31082; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Guo ZK, 2006, STEM CELLS, V24, P992, DOI 10.1634/stemcells.2005-0224; HaraIrie F, 1996, BONE, V18, P29, DOI 10.1016/8756-3282(95)00425-4; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003; Khare G N, 1995, Indian J Med Sci, V49, P281; Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283; Kucia M, 2004, BLOOD CELL MOL DIS, V32, P52, DOI 10.1016/j.bcmd.2003.09.025; Liu XQ, 2012, BIOTECHNOL LETT, V34, P387, DOI 10.1007/s10529-011-0757-7; Ma J, 2005, BASIC RES CARDIOL, V100, P217, DOI 10.1007/s00395-005-0521-z; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mori T, 2004, MOL CANCER THER, V3, P29; Otfinowski Janusz, 1993, Patologia Polska, V44, P133; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Sordi V, 2005, BLOOD, V106, P419, DOI 10.1182/blood-2004-09-3507; SPENCER RF, 1990, S AFR J SURG, V28, P51; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109; Thevenot PT, 2010, BIOMATERIALS, V31, P3997, DOI 10.1016/j.biomaterials.2010.01.144; Tiyapatanaputi P, 2004, J ORTHOP RES, V22, P1254, DOI 10.1016/j.orthres.2004.03.017; Togel F, 2005, KIDNEY INT, V67, P1772, DOI 10.1111/j.1523-1755.2005.00275.x; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; Wieczorek G, 2003, CELL TISSUE RES, V311, P227, DOI 10.1007/s00441-002-0671-3; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Zhang G, 2007, TISSUE ENG, V13, P2063, DOI 10.1089/ten.2006.0013	35	100	110	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 22	2013	8	1							e54077	10.1371/journal.pone.0054077	http://dx.doi.org/10.1371/journal.pone.0054077			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	077HS	24130878	Green Published, gold, Green Submitted			2023-01-03	WOS:000314019100041
J	Yang, DZ; Wang, W; Li, LP; Peng, YL; Chen, P; Huang, HY; Guo, YL; Xia, XW; Wang, YY; Wang, HY; Wang, WE; Zeng, CY				Yang, Dezhong; Wang, Wei; Li, Liangpeng; Peng, Yulan; Chen, Peng; Huang, Haiyun; Guo, Yanli; Xia, Xuewei; Wang, Yuanyuan; Wang, Hongyong; Wang, Wei Eric; Zeng, Chunyu			The Relative Contribution of Paracine Effect versus Direct Differentiation on Adipose-Derived Stem Cell Transplantation Mediated Cardiac Repair	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; FUNCTIONAL IMPROVEMENT; REGENERATIVE MEDICINE; PARACRINE MECHANISMS; CONDITIONED MEDIUM; STROMAL CELLS; IN-VITRO; HEART; THERAPY; DISEASE	Background: Recent studies have demonstrated that transplantation of adipose-derived stem cell (ADSC) can improve cardiac function in animal models of myocardial infarction (MI). However, the mechanisms underlying the beneficial effect are not fully understood. In this study, we characterized the paracrine effect of transplanted ADSC and investigated its relative importance versus direct differentiation in ADSC transplantation mediated cardiac repair. Methodology/Principal Findings: MI was experimentally induced in mice by ligation of the left anterior descending coronary artery. Either human ADSC, conditioned medium (CM) collected from the same amount of ADSC or control medium was injected into the peri-infarct region immediately after MI. Compared with the control group, both ADSC and ADSC-CM significantly reduced myocardial infarct size and improved cardiac function. The therapeutic efficacy of ADSC was moderately superior to ADSC-CM. ADSC-CM significantly reduced cardiomyocyte apoptosis in the infarct border zone, to a similar degree with ADSC treatment. ADSC enhanced angiogenesis in the infarct border zone, but to a stronger degree than that seen in the ADSC-CM treatment. ADSC was able to differentiate to endothelial cell and smooth muscle cell in post-MI heart; these ADSC-derived vascular cells amount to about 9% of the enhanced angiogenesis. No cardiomyocyte differentiated from ADSC was found. Conclusions: ADSC-CM is sufficient to improve cardiac function of infarcted hearts. The therapeutic function of ADSC transplantation is mainly induced by paracrine-mediated cardioprotection and angiogenesis, while ADSC differentiation contributes a minor benefit by being involved in angiogenesis. Highlights 1 ADSC-CM is sufficient to exert a therapeutic potential. 2. ADSC was able to differentiate to vascular cells but not cardiomyocyte. 3. ADSC derived vascular cells amount to about 9% of the enhanced angiogenesis. 4. Paracrine effect is the major mechanism of ADSC therapeutic function for MI.	[Yang, Dezhong; Wang, Wei; Li, Liangpeng; Peng, Yulan; Chen, Peng; Xia, Xuewei; Wang, Hongyong; Wang, Wei Eric; Zeng, Chunyu] Third Mil Med Univ, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China; [Huang, Haiyun; Guo, Yanli] Third Mil Med Univ, Southwest Hosp, Dept Ultrasonog, Chongqing, Peoples R China; [Wang, Yuanyuan] Third Mil Med Univ, Daping Hosp, Dept Plast Surg, Chongqing, Peoples R China	Army Medical University; Army Medical University; Army Medical University	Wang, WE (corresponding author), Third Mil Med Univ, Daping Hosp, Dept Cardiol, Chongqing, Peoples R China.	wangw28@gmail.com; cyzeng1@hotmail.com	peng, yu/GXW-2071-2022; Wang, Wei Eric/AAE-9504-2022; Wang, Wei Eric/AFE-0795-2022; Lv, Yuanjie/AER-0767-2022; Murtaugh, Maureen/AAN-6225-2020	Murtaugh, Maureen/0000-0001-5281-0302	National Natural Science Foundation of China [31130029, 81100111, 30925018]; Natural Science Foundation Project of CQ CSTC (CSTC) [2009BA5044]; National Basic Research Program of China (973 Program) [2008CB517308, 2012CB517801]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of CQ CSTC (CSTC)(Natural Science Foundation Project of CQ CSTC); National Basic Research Program of China (973 Program)(National Basic Research Program of China)	This study was supported by the grants from the National Natural Science Foundation of China (31130029, 81100111, 30925018), Natural Science Foundation Project of CQ CSTC (CSTC, 2009BA5044), and National Basic Research Program of China (973 Program, 2008CB517308, 2012CB517801). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai XW, 2010, EUR HEART J, V31, P489, DOI 10.1093/eurheartj/ehp568; Bayes-Genis A, 2010, J MOL CELL CARDIOL, V49, P771, DOI 10.1016/j.yjmcc.2010.08.010; Bergmann O, 2009, SCIENCE, V324, P98, DOI 10.1126/science.1164680; Biancone L, 2012, NEPHROL DIAL TRANSPL, V27, P3037, DOI 10.1093/ndt/gfs168; Chacko SM, 2010, AM J PHYSIOL-CELL PH, V299, pC1562, DOI 10.1152/ajpcell.00221.2010; Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682; Cho YJ, 2012, J NEUROSCI RES, V90, P1794, DOI 10.1002/jnr.23063; Christoffels V, 2011, NATURE, V474, P585, DOI 10.1038/474585a; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Deuse T, 2009, CIRCULATION, V120, pS247, DOI 10.1161/CIRCULATIONAHA.108.843680; Deveza L, 2013, STEM CELLS DEV, V22, P483, DOI 10.1089/scd.2012.0201; Egashira Y, 2012, BRAIN RES, V1461, P87, DOI 10.1016/j.brainres.2012.04.033; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Kubo H, 2008, CIRCULATION, V118, P649, DOI 10.1161/CIRCULATIONAHA.107.761031; Li TS, 2012, J AM COLL CARDIOL, V59, P942, DOI 10.1016/j.jacc.2011.11.029; Li XH, 2007, J MOL CELL CARDIOL, V42, P295, DOI 10.1016/j.yjmcc.2006.07.002; Li YX, 2011, CIRCULATION, V123, P866, DOI 10.1161/CIRCULATIONAHA.110.947531; Madonna R, 2009, ARTERIOSCL THROM VAS, V29, P1723, DOI 10.1161/ATVBAHA.109.187179; Mazo M, 2008, EUR J HEART FAIL, V10, P454, DOI 10.1016/j.ejheart.2008.03.017; Miranville A, 2004, CIRCULATION, V110, P349, DOI 10.1161/01.CIR.0000135466.16823.D0; Mirotsou M, 2011, J MOL CELL CARDIOL, V50, P280, DOI 10.1016/j.yjmcc.2010.08.005; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Planat-Benard V, 2004, CIRC RES, V94, P223, DOI 10.1161/01.RES.0000109792.43271.47; Ramkisoensing AA, 2012, STEM CELLS, V30, P1236, DOI 10.1002/stem.1086; Ratajczak MZ, 2012, LEUKEMIA, V26, P1166, DOI 10.1038/leu.2011.389; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Sanchez PL, 2010, EUR HEART J, V31, P394, DOI 10.1093/eurheartj/ehp403; Segers VFM, 2008, NATURE, V451, P937, DOI 10.1038/nature06800; Son NH, 2010, J CLIN INVEST, V120, P3443, DOI 10.1172/JCI40905; Tang JM, 2011, CARDIOVASC RES, V91, P402, DOI 10.1093/cvr/cvr053; Tongers J, 2011, EUR HEART J, V32, P1197, DOI 10.1093/eurheartj/ehr018; Valina C, 2007, EUR HEART J, V28, P2667, DOI 10.1093/eurheartj/ehm426; van Poll D, 2008, HEPATOLOGY, V47, P1634, DOI 10.1002/hep.22236; Wang L, 2009, AM J PHYSIOL-HEART C, V297, pH1020, DOI 10.1152/ajpheart.01082.2008; Wang XH, 2009, CIRCULATION, V120, pS238, DOI 10.1161/CIRCULATIONAHA.109.885236; Williams AR, 2011, CIRC RES, V109, P923, DOI 10.1161/CIRCRESAHA.111.243147; Xiong DZ, 2010, J MOL CELL CARDIOL, V48, P211, DOI 10.1016/j.yjmcc.2009.07.003; Yang JJ, 2012, TOHOKU J EXP MED, V226, P231, DOI 10.1620/tjem.226.231; Zhang HY, 2010, CIRC RES, V107, P800, DOI 10.1161/CIRCRESAHA.110.219220	40	223	230	3	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e59020	10.1371/journal.pone.0059020	http://dx.doi.org/10.1371/journal.pone.0059020			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	125SR	23408942	Green Published, gold, Green Submitted			2023-01-03	WOS:000317562100066
J	Jiang, FS; Li, WP; Huang, YF; Chen, YT; Jin, B; Chen, NP; Ding, ZS; Ding, XH				Jiang, Fusheng; Li, Weiping; Huang, Yanfen; Chen, Yitao; Jin, Bo; Chen, Nipi; Ding, Zhishan; Ding, Xinghong			Antioxidant, Antityrosinase and Antitumor Activity Comparison: The Potential Utilization of Fibrous Root Part of Bletilla striata (Thunb.) Reichb.f.	PLOS ONE			English	Article							PHENOLIC-COMPOUNDS; TYROSINASES; PREVENTION; EXTRACTS; SEQUENCE; ORCHIDS; AGENTS; PLANT	This study was carried out to evaluate the utilization probability of the fibrous root part (FRP) of Bletilla striata, which was usually discarded and harvesting pseudobulb part (PSP). The chemical composition, total phenolic content, DPPH radical scavenging activity, Ferric-reducing antioxidant power and tyrosinase inhibition activity were compared between FRP and PSP. Antioxidant and pro-oxidant effect as well as antitumor effect of the extract of FRP and PSP were analyzed by in vitro cell system as well. Thin layer chromatography and high performance liquid chromatography analysis indicated that the chemical compositions in the two parts were similar, but the content in FRP was much higher than PSP. Meanwhile, the FRP extracts showed higher phenolic content, stronger DPPH scavenging activity, Ferric-reducing antioxidant capacity and tyrosinase inhibition activity. Sub-fraction analysis revealed that the distribution characteristic of phenolic components and other active constituents in FRP and PSP were consistent, and mainly deposited in chloroform and acetoacetate fractions. Especially, the chloroform sub-fraction (sch) of FRP showed extraordinary DPPH scavenging activity and tyrosinase inhibition activity, with IC50 0.848 mg/L and 4.3 mg/L, respectively. Besides, tyrosinase inhibition activity was even stronger than the positive compound arbutin (31.8 mg/L). Moreover, In vitro cell system analysis confirmed that FRP extract exerts comparable activity with PSP, especially, the sub-fraction sch of FRP showed better antioxidant activity at low dosage and stronger per-oxidant activity at high dosage, and both sch of FRP and PSP can dose-dependent induce HepG2 cells apoptosis, which implied tumor therapeutic effect. Considering that an additional 0.3 kg FRP would be obtained when producing 1.0 kg PSP, our work demonstrated that FRP is very potential to be used together with PSP.	[Jiang, Fusheng; Huang, Yanfen; Chen, Yitao; Jin, Bo; Chen, Nipi; Ding, Zhishan] Zhejiang Chinese Med Univ, Inst Biotechnol, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China; [Li, Weiping] Zhejiang Chinese Med Univ, Dept Med Chem, Coll Pharmaceut Sci, Hangzhou, Zhejiang, Peoples R China; [Ding, Xinghong] Zhejiang Chinese Med Univ, Anal & Testing Ctr, Hangzhou, Zhejiang, Peoples R China	Zhejiang Chinese Medical University; Zhejiang Chinese Medical University; Zhejiang Chinese Medical University	Ding, XH (corresponding author), Zhejiang Chinese Med Univ, Anal & Testing Ctr, Hangzhou, Zhejiang, Peoples R China.	xinghongding@163.com	li, wj/HGD-7322-2022; 黎, 伟/GXM-4040-2022; Sinnaeve, Davy/F-2293-2013; Rokni-Zadeh, Hassan/B-8098-2008	Sinnaeve, Davy/0000-0003-2556-5895; Madder, Annemieke/0000-0003-0179-7608; De Vleeschouwer, Matthias/0000-0001-6889-1928; Rozenski, Jef/0000-0001-9624-5536; Rokni-Zadeh, Hassan/0000-0001-5503-0344; Dai, Haibin/0000-0002-5768-2714; Martins, Jose/0000-0001-7350-2253	Public Welfare Technology Research Projects of Zhejiang Province [2011C22047]; New-Shoot Talented Man Plan Project of Zhejiang Province [2010R4100581/4CE2011R4100191/4CE2012R410038]	Public Welfare Technology Research Projects of Zhejiang Province; New-Shoot Talented Man Plan Project of Zhejiang Province	This research was supported by the Public Welfare Technology Research Projects of Zhejiang Province (No. 2011C22047, http://www.zjkjt.gov.cn/) and New-Shoot Talented Man Plan Project of Zhejiang Province (No. 2010R4100581/4CE2011R4100191/4CE2012R410038, http://www.zjkjt.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047; Canadanovic-Brunet JM, 2009, INT J FOOD SCI TECH, V44, P269, DOI 10.1111/j.1365-2621.2007.01680.x; Claus H, 2006, SYST APPL MICROBIOL, V29, P3, DOI 10.1016/j.syapm.2005.07.012; Ding ZS, 2008, MOLECULES, V13, P220, DOI 10.3390/molecules13020220; Duan XW, 2007, MOLECULES, V12, P759, DOI 10.3390/12040759; Gan RY, 2010, J MED PLANTS RES, V4, P2438; Kaji H, 2009, J CLIN PHARM THER, V34, P197, DOI 10.1111/j.1365-2710.2008.00993.x; Kong JM, 2003, ACTA PHARMACOL SIN, V24, P7; Lei TC, 1999, CHINESE TRADITIONAL, V30, P336; Liang QY, 2006, J GUANGXI MED U, V23, P36; Lin SQ, 1994, THESIS NATL CHENG KU; Luo Y, 2010, J BIOMED MATER RES A, V94A, P193, DOI 10.1002/jbm.a.32711; Maisuthisakul P, 2009, FOOD CHEM, V117, P332, DOI 10.1016/j.foodchem.2009.04.010; Mao XL, 2011, CENTRAL S PHARM, V9, P604; MARTINEZ MV, 1995, TRENDS FOOD SCI TECH, V6, P195, DOI 10.1016/S0924-2244(00)89054-8; Marxen K, 2007, SENSORS-BASEL, V7, P2080, DOI 10.3390/s7102080; Morita H, 2005, BIOORG MED CHEM LETT, V15, P1051, DOI 10.1016/j.bmcl.2004.12.026; Pasciu V, 2010, TOXICOL SCI, V114, P101, DOI 10.1093/toxsci/kfp301; Gutierrez RMP, 2010, J MED PLANTS RES, V4, P592; PONNAZHAGAN S, 1994, J INVEST DERMATOL, V102, P744, DOI 10.1111/1523-1747.ep12376924; [黄海云 Rui Haiyun], 2003, [南京师大学报. 自然科学版, Journal of Nanjing Normal University. Natural Science], V26, P94; Shi J, 2009, THESIS HAINAN U HAIN; SLINKARD K, 1977, AM J ENOL VITICULT, V28, P49; Smit N, 2009, INT J MOL SCI, V10, P5326, DOI 10.3390/ijms10125326; Sun DF, 2006, CHINESE WILD PLANT R, V25, P34; Sun F, 2007, J DALIAN I LIGHT IND, V26, P97; TAKAGI S, 1983, PHYTOCHEMISTRY, V22, P1011, DOI 10.1016/0031-9422(83)85044-4; VanGelder CWG, 1997, PHYTOCHEMISTRY, V45, P1309, DOI 10.1016/S0031-9422(97)00186-6; VIDENSEK N, 1990, J NAT PROD, V53, P1609, DOI 10.1021/np50072a039; Wang CM, 2006, BIOTECHNOL LETT, V28, P539, DOI 10.1007/s10529-006-0011-x; Wazir D, 2011, J PLANT BIOCHEM BIOT, V20, P234, DOI 10.1007/s13562-011-0051-8; Wojdylo A, 2007, FOOD CHEM, V105, P940, DOI 10.1016/j.foodchem.2007.04.038; Yang Y, 2009, ASIA PACIFIC TRADITI, V5, P23; Zhang HH, 2010, FREE RADICAL BIO MED, V49, P2010, DOI 10.1016/j.freeradbiomed.2010.09.031; Zhu JY, 2011, THESIS FUJIAN U TRAD	35	73	82	5	87	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 28	2013	8	2							e58004	10.1371/journal.pone.0058004	http://dx.doi.org/10.1371/journal.pone.0058004			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	098DA	24098758	gold, Green Published, Green Submitted			2023-01-03	WOS:000315524900220
J	Zhang, XY; Sun, Q; Shan, M; Niu, M; Liu, T; Xia, BS; Liang, XS; Wei, W; Sun, SS; Zhang, YX; Liu, XS; Song, QB; Yang, YM; Ma, YY; Liu, Y; Yang, L; Ren, YL; Zhang, GQ; Pang, D				Zhang, Xianyu; Sun, Qian; Shan, Ming; Niu, Ming; Liu, Tong; Xia, Bingshu; Liang, Xiaoshuan; Wei, Wei; Sun, Shanshan; Zhang, Youxue; Liu, Xiaolong Sean; Song, Qingbin; Yang, Yanmei; Ma, Yuyan; Liu, Yang; Yang, Long; Ren, Yanlv; Zhang, Guoqiang; Pang, Da			Promoter Hypermethylation of ARID1A Gene Is Responsible for Its Low mRNA Expression in Many Invasive Breast Cancers	PLOS ONE			English	Article							CLEAR-CELL CARCINOMA; SOMATIC MUTATIONS; SWI/SNF COMPLEXES; PROTEIN P270; EPIGENETICS; COMPONENT	ARID1A (AT-rich interactive domain 1A) has recently been identified as a tumor suppressor gene. Its mRNA expression is significantly low in many breast cancers; this is often associated with more aggressive phenotypes. However, the underlying molecular mechanism for its low expression has not been fully understood. This study was undertaken to evaluate the contribution of gene copy number variation, mutations, promoter methylation and histone modification to ARID1A's low expression. 38 pairs of breast invasive ductal carcinomas and their normal breast tissue counterparts from the same patients were randomly selected for gene expression and copy number variation detection. Promoter methylation and histone modification levels were evaluated by MeDIP-qPCR and ChIP-qPCR, respectively. PCR product Sanger sequencing was carried out to detect the exon mutation rate. Twenty-two out of 38 invasive ductal carcinomas in the study (57.9%) revealed ARID1A mRNA low expression by realtime RT-PCR. The relative promoter methylation level was, significantly higher in ARID1A mRNA low expression group compared with its high expression group (p<0.001). In the low expression group, nineteen out of 22 invasive ductal carcinomas (86.4%) exhibited ARID1A promoter hypermthylation. In addition, the promoter hypermethylation was accompanied with repressive histone modification (H3K27Me3). Although five out of 38 invasive ductal carcinomas (13.2%) exhibited loss of ARID1A gene copy number by realtime PCR and nine exon novel mutations are seen from eight out of 33 invasive ductal carcinomas (24.2%), there was no statistically significant difference in both ARID1A mRNA low and high expression groups (p = 0.25, and p = 0.68, respectively). We demonstrate that promoter hypermethylation was the main culprit for ARID1A mRNA low expression in invasive ductal carcinomas. The influence of mutation and copy number variation on the expression were statistically insignificant at mRNA level, and were, therefore, not considered the main causes for ARID1A mRNA low expression in invasive breast cancer.	[Zhang, Xianyu; Sun, Qian; Shan, Ming; Niu, Ming; Liu, Tong; Xia, Bingshu; Liang, Xiaoshuan; Wei, Wei; Sun, Shanshan; Zhang, Youxue; Ren, Yanlv; Zhang, Guoqiang; Pang, Da] Harbin Med Univ, Dept Breast Surg, Affiliated Hosp 3, Harbin, Heilongjiang, Peoples R China; [Liu, Xiaolong Sean] Harbin Med Univ, Dept Pathol, Affiliated Hosp 3, Harbin, Heilongjiang, Peoples R China; [Song, Qingbin] Mt Sinai Sch Med, Dept Med, New York, NY USA; [Yang, Yanmei; Ma, Yuyan; Pang, Da] Heilongjiang Inst Canc Res, Key Lab, Harbin, Heilongjiang, Peoples R China; [Yang, Long] Life Technol Corp, ICFC Custom Serv, Beijing, Peoples R China	Harbin Medical University; Harbin Medical University; Icahn School of Medicine at Mount Sinai; Thermo Fisher Scientific	Pang, D (corresponding author), Harbin Med Univ, Dept Breast Surg, Affiliated Hosp 3, Harbin, Heilongjiang, Peoples R China.	pangda@ems.hrbmu.edu.cn	Zhang, Guo-Qiang/AAG-6817-2019; Liu, Wei/N-4465-2017	Zhang, Guo-Qiang/0000-0001-6439-019X; LIU, TONG/0000-0001-9234-1328; Liu, Wei/0000-0001-9819-3178; Wu, Chongming/0000-0003-2898-370X	National Natural Science Foundation of China [81172498/H1622]; Harbin Science and Technology bureau [2011RFXYS056]; Postgraduate Innovation Research Fund of Heilongjiang Province [YJSCX2011-332-HLJ]; Research initiation Fund of the Third Affiliated Hospital of Harbin Medical University [JJ2010-24]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Harbin Science and Technology bureau; Postgraduate Innovation Research Fund of Heilongjiang Province; Research initiation Fund of the Third Affiliated Hospital of Harbin Medical University	This work was supported by National Natural Science Foundation of China (81172498/H1622), Harbin Science and Technology bureau (2011RFXYS056), Postgraduate Innovation Research Fund of Heilongjiang Province (YJSCX2011-332-HLJ) and Research initiation Fund of the Third Affiliated Hospital of Harbin Medical University (JJ2010-24). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cornen S., 2012, ONCOGENE; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Katagiri A, 2012, MODERN PATHOL, V25, P282, DOI 10.1038/modpathol.2011.161; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nagl NG, 2005, CANCER RES, V65, P9236, DOI 10.1158/0008-5472.CAN-05-1225; Nagl NG, 2007, EMBO J, V26, P752, DOI 10.1038/sj.emboj.7601541; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24; Wang XM, 2004, INT J CANCER, V112, P636, DOI 10.1002/ijc.20450; Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Zhang XY, 2012, CANCER EPIDEMIOL, V36, P288, DOI 10.1016/j.canep.2011.07.006	21	714	735	4	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2013	8	1							e53931	10.1371/journal.pone.0053931	http://dx.doi.org/10.1371/journal.pone.0053931			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	076FX	23613974	Green Published, Green Submitted, gold			2023-01-03	WOS:000313943000021
J	Chen, JY; Tang, YA; Li, WS; Chiou, YC; Shieh, JM; Wang, YC				Chen, Jia-Yang; Tang, Yen-An; Li, Wen-Shan; Chiou, Yu-Ching; Shieh, Jiunn-Min; Wang, Yi-Ching			A Synthetic Podophyllotoxin Derivative Exerts Anti-Cancer Effects by Inducing Mitotic Arrest and Pro-Apoptotic ER Stress in Lung Cancer Preclinical Models	PLOS ONE			English	Article							ANTIMITOTIC ACTIVITY; NATURAL-PRODUCTS; BINDING AGENTS; DRUG DISCOVERY; RESISTANCE; TUBULIN; MITOSIS; MICROTUBULES; EXPRESSION; KINASES	Some potent chemotherapy drugs including tubulin-binding agents had been developed from nature plants, such as podophyllotoxin and paclitaxel. However, poor cytotoxic selectivity, serious side-effects, and limited effectiveness are still the major concerns in their therapeutic application. We developed a fully synthetic podophyllotoxin derivative named Ching001 and investigated its anti-tumor growth effects and mechanisms in lung cancer preclinical models. Ching001 showed a selective cytotoxicity to different lung cancer cell lines but not to normal lung cells. Ching001 inhibited the polymerization of microtubule resulting in mitotic arrest as evident by the accumulation of mitosis-related proteins, survivin and aurora B, thereby leading to DNA damage and apoptosis. Ching001 also activated pro-apoptotic ER stress signaling pathway. Intraperitoneal injection of 2 mg/kg Ching001 significantly inhibited the tumor growth of A549 xenograft, while injection of 0.2 mg/kg Ching001 decreased the lung colonization ability of A549 cells in experimental metastasis assay. These anti-tumor growth and lung colonization inhibition effects were stronger than those of paclitaxel treatment at the same dosage. The xenograft tumor tissue stains further confirmed that Ching001 induced mitosis arrest and tumor apoptosis. In addition, the hematology and biochemistry tests of blood samples as well as tissue examinations indicated that Ching001 treatment did not show apparent organ toxicities in tested animals. We provided preclinical evidence that novel synthetic microtubule inhibitor Ching001, which can trigger DNA damage and apoptosis by inducing mitotic arrest and ER stress, is a potential anti-cancer compound for further drug development.	[Chen, Jia-Yang; Tang, Yen-An; Wang, Yi-Ching] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 70101, Taiwan; [Li, Wen-Shan; Chiou, Yu-Ching] Acad Sinica, Inst Chem, Taipei 115, Taiwan; [Chiou, Yu-Ching] Natl Taiwan Normal Univ, Dept Chem, Taipei, Taiwan; [Shieh, Jiunn-Min] Chi Mei Med Ctr, Dept Internal Med, Div Chest Med, Tainan, Taiwan; [Shieh, Jiunn-Min] Chia Nan Univ Pharm & Sci, Ctr Gen Educ, Tainan, Taiwan; [Wang, Yi-Ching] Natl Cheng Kung Univ, Dept Pharmacol, Tainan, Taiwan	National Cheng Kung University; Academia Sinica - Taiwan; National Taiwan Normal University; Chi Mei Hospital; Chia Nan University of Pharmacy & Science; National Cheng Kung University	Shieh, JM (corresponding author), Chi Mei Med Ctr, Dept Internal Med, Div Chest Med, Tainan, Taiwan.	shieh225@ms29.hinet.net; ycw5798@mail.ncku.edu.tw	CHEN, JIA-YANG/M-8413-2014; Li, Wen-Shan/F-1972-2015; Wang, Yi-Ching/J-8702-2019; Peng, Hongquan/AAI-6239-2021; Chen, Jianping/C-4225-2009	CHEN, JIA-YANG/0000-0001-9159-7591; Li, Wen-Shan/0000-0002-8359-4582; Wang, Yi-Ching/0000-0002-7694-2067; Chen, Hui/0000-0002-0048-0193; Peng, Hongquan/0000-0003-4893-7903; Chen, Jianping/0000-0001-6494-5271; Li, Wei/0000-0002-9991-7892	Chi Mei Medical Center, Taiwan [CMNCKU10107]; National Science Council, Taiwan [NSC 101-2325-B-006-008]	Chi Mei Medical Center, Taiwan; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported in part by grants CMNCKU10107 from the Chi Mei Medical Center, Taiwan (JMS) and NSC 101-2325-B-006-008 from the National Science Council, Taiwan (YCW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bicknell AA, 2007, J CELL BIOL, V177, P1017, DOI 10.1083/jcb.200702101; Bohlin L, 1996, DRUG DISCOV TODAY, V1, P343, DOI 10.1016/1359-6446(96)10028-3; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chang JY, 2004, MOL PHARMACOL, V65, P77, DOI 10.1124/mol.65.1.77; Chen JJW, 2001, CANCER RES, V61, P5223; Cragg GM, 1998, MED RES REV, V18, P315, DOI 10.1002/(SICI)1098-1128(199809)18:5<315::AID-MED3>3.0.CO;2-W; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Desbene Stephanie, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P71, DOI 10.2174/1568011023354353; Domingo-Sananes MR, 2011, PHILOS T R SOC B, V366, P3584, DOI 10.1098/rstb.2011.0087; Dumontet C, 2010, NAT REV DRUG DISCOV, V9, P790, DOI 10.1038/nrd3253; Felix CA, 1998, BBA-GENE STRUCT EXPR, V1400, P233, DOI 10.1016/S0167-4781(98)00139-0; Fojo T, 2007, ANN ONCOL, V18, pV3, DOI 10.1093/annonc/mdm172; Imbert TF, 1998, BIOCHIMIE, V80, P207, DOI 10.1016/S0300-9084(98)80004-7; Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803; Kawanobe T, 2012, BIOCHEM BIOPH RES CO, V418, P736, DOI 10.1016/j.bbrc.2012.01.090; Komericki P, 2011, SEX TRANSM DIS, V38, P216, DOI 10.1097/OLQ.0b013e3181f68ebb; Kuo CC, 2004, CANCER RES, V64, P4621, DOI 10.1158/0008-5472.CAN-03-3474; Lara PN, 2009, J CLIN ONCOL, V27, P2530, DOI 10.1200/JCO.2008.20.1061; Liu EH, 2009, MINI-REV MED CHEM, V9, P1547, DOI 10.2174/138955709790361520; Lv M, 2011, MINI-REV MED CHEM, V11, P901, DOI 10.2174/138955711796575461; Mano M, 2006, CANCER TREAT REV, V32, P106, DOI 10.1016/j.ctrv.2005.12.008; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; PEDERSENBJERGAARD J, 1992, LEUKEMIA RES, V16, P61, DOI 10.1016/0145-2126(92)90102-D; SACKETT DL, 1993, PHARMACOL THERAPEUT, V59, P163, DOI 10.1016/0163-7258(93)90044-E; Schonbrunn E, 1999, J STRUCT BIOL, V128, P211, DOI 10.1006/jsbi.1999.4183; Shore GC, 2011, CURR OPIN CELL BIOL, V23, P143, DOI 10.1016/j.ceb.2010.11.003; Tapia C, 2006, AM J SURG PATHOL, V30, P83, DOI 10.1097/01.pas.0000183572.94140.43; Wall ME, 1998, MED RES REV, V18, P299	29	265	274	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2013	8	4							e62082	10.1371/journal.pone.0062082	http://dx.doi.org/10.1371/journal.pone.0062082			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	146GG	23874985	gold, Green Published, Green Submitted			2023-01-03	WOS:000319077300026
